mirror of
https://github.com/alirezarezvani/claude-skills.git
synced 2026-10-09 03:17:54 +00:00
Merge pull request #944 from AlenSarangSatheesh/add-stock-analysis-skill
Add stock-analysis skill (finance/skills): sector-relative fundamental analysis
This commit is contained in:
Alireza Rezvani
GitHub
commit
e21e778b0d
61 changed files with 24758 additions and 0 deletions
303
finance/skills/stock-analysis/SKILL.md
Normal file
303
finance/skills/stock-analysis/SKILL.md
Normal file
|
|
@ -0,0 +1,303 @@
|
|||
---
|
||||
name: stock-analysis
|
||||
description: Produce a rigorous, sector-relative, multi-factor fundamental analysis of a publicly listed company — Indian (NSE/BSE) or US/global. Use this skill whenever the user asks to analyse, research, evaluate, value, or "look into" a stock, ticker, or listed company; asks whether a business is fundamentally strong or weak, cheap or expensive; asks to compare two or more companies or benchmark one against its sector; mentions metrics like OPM, ROCE, ROE, ROIC, P/E, EV/EBITDA, free cash flow, NIM, GNPA, CASA, promoter holding or pledging; or shares an annual report, 10-K, concall transcript, or screener page and wants it interpreted. Use it too for accounting-quality and forensic questions — "is the profit real", "are they cooking the books", "the cash flow doesn't match the profit", "why is profit rising but cash isn't", "should I worry about this company's accounting", auditor qualifications, promoter pledging, or related-party concerns — which route to the forensic-only mode. Use it for **IPOs and not-yet-listed companies** too — "should I apply to this IPO", "is this IPO worth it", "is the price band expensive", DRHP/RHP or S-1 questions, grey market premium, anchor allotment, lock-in expiry — which route to the IPO mode. Use it even when the request sounds casual ("is Infosys any good?", "thoughts on HDFC Bank?", "why is this company's margin so low?"). Do not use it for personalised investment advice, portfolio allocation, or trading signals.
|
||||
---
|
||||
|
||||
# Stock Analysis
|
||||
|
||||
Produce an evidence-backed fundamental analysis of one company, benchmarked against the right peers, and delivered as a written report plus a sector-relative scorecard.
|
||||
|
||||
## The principle that governs everything here
|
||||
|
||||
**A financial metric carries no meaning until you know the sector it came from and the company's own history.**
|
||||
|
||||
If X earns a 20% operating margin and Y earns 30%, that tells you nothing about which is the better business. Y may be in software (where 30% is mediocre) and X in distribution (where 20% is exceptional). Y's 30% may need three times the capital to produce, so X earns a far higher return on the money invested. Y's margin may be eroding while X's compounds.
|
||||
|
||||
Two consequences shape this whole skill:
|
||||
|
||||
1. **Never rank companies on a single metric.** Every judgement combines profitability, returns on capital, cash conversion, balance sheet, growth durability, governance, and price.
|
||||
2. **Compare like with like.** Benchmark against sector peers or against the company's own multi-year record — never a raw cross-industry number. For banks, insurers, REITs and miners the standard ratios are not merely less useful, they are *undefined or inverted*; those sectors need their own metric set entirely.
|
||||
|
||||
Read `references/05-returns-and-dupont.md` for why return on capital, not margin, is the metric that actually determines compounding.
|
||||
|
||||
## Non-negotiables
|
||||
|
||||
### Never invent a number
|
||||
|
||||
This is the failure mode that destroys the value of the whole analysis. A fabricated revenue figure or a hallucinated ROCE produces a confident, well-formatted, *useless* report — and the user may act on it.
|
||||
|
||||
- Every figure carries a **source and a period** ("FY25 annual report, consolidated, p.112" / "10-K FY2024, Item 8" / "Q3 FY26 quarterly results filing, BSE").
|
||||
- If a number cannot be sourced, write `not available` and say what would be needed. An analysis with acknowledged gaps is far more valuable than one with invented precision.
|
||||
- Cross-check headline figures (revenue, net profit, debt, cash) against a second source when possible — at least one of the two must be a primary document.
|
||||
- **Every financial figure in the analysis must trace to a primary document** — annual report, 10-K/10-Q, quarterly results filing, concall transcript, investor presentation, DRHP/RHP, exchange filing, or rating rationale. Aggregator websites (screener.in, Yahoo Finance, Tikr, etc.) are navigation aids for locating documents and optional labelled cross-checks — they are never a source of record. The one exception is current share price and market cap, which are inherently sourced from exchange or finance websites and must carry an as-of date.
|
||||
- State **consolidated vs standalone** explicitly — for any company with subsidiaries these differ materially, and mixing them silently invalidates every ratio.
|
||||
- State **currency and units**. Indian filings use crore/lakh; US filings use millions/billions. Getting this wrong by 10x is a common and embarrassing error.
|
||||
- Flag stale data. A price or multiple without an as-of date is not usable.
|
||||
|
||||
Detailed sourcing routes and a verification protocol: `references/01-data-sourcing.md`.
|
||||
|
||||
### Official records are the source — and they hold far more than the financial statements
|
||||
|
||||
Two failure modes hide behind a report that looks well-sourced. Guard against both.
|
||||
|
||||
**First: the source of record is the company's own filings — nothing else is.** Rank sources by how many hands the number has passed through, and cite only the primary one:
|
||||
|
||||
1. **Primary filings** — annual report / 10-K, exchange filings (NSE/BSE, SEC EDGAR), quarterly results, the offer document (DRHP/RHP/S-1), audited statements.
|
||||
2. **Company-published secondary** — concall transcripts, investor presentations, earnings releases.
|
||||
3. **Regulator / third-party primary** — SEBI/MCA/ROC records, credit-rating rationales, exchange shareholding and pledge data.
|
||||
|
||||
Third-party research notes, brokerage reports, news articles and data aggregators (screener.in, Tikr, Yahoo/Google Finance, trendlyne) are **navigation and cross-check aids only** — they exist to help you *locate* the filing and to flag an outlier worth investigating. An aggregator or news figure must never be the thing you cite; when it disagrees with the filing, the filing wins and the disagreement is itself a finding. The one standing exception is live share price and market cap, which carry an as-of date. If a figure exists only in an aggregator and cannot be traced to a filing, it is `not sourced` — say so.
|
||||
|
||||
**Second: a filing is not just its three financial statements.** Most of what actually decides an analysis is the **non-financial** disclosure wrapped around the numbers, and it must be read and used as a first-class input — not skimmed on the way to the P&L:
|
||||
|
||||
- the **business, strategy and risk-factor** sections — what is sold and to whom, the stated moat, and the risks management is legally obliged to admit;
|
||||
- **MD&A** read across 3–5 years — growth decomposed into volume / price / mix, capacity, capex plans, order book, guidance, and the drift between what was promised and what was delivered;
|
||||
- the **auditor's report, CARO annexure, Key Audit Matters and emphasis-of-matter** — the auditor's own map of where the numbers are fragile;
|
||||
- **related-party transactions, contingent liabilities, litigation and capital commitments** — the commonest routes for value to leave a minority shareholder, and quantifiable in one sitting;
|
||||
- **governance and ownership** — board and audit-committee composition and independence, promoter holding trend and pledge, remuneration versus profit, auditor tenure and any resignation, AGM voting dissent, ESOP dilution;
|
||||
- **segment and operational data** — segment-level revenue, EBIT and capital employed (segment ROCE is usually the report's most surprising number), plus the sector KPIs — capacity utilisation, occupancy/ARPOB, ANDA filings, same-store growth, order-book conversion — that never appear in the income statement;
|
||||
- **ESG/BRSR, secretarial audit (MR-3), and subsidiary (AOC-1) disclosures.**
|
||||
|
||||
`references/15-document-diligence.md` is the runbook for extracting all of this, with a time-boxed reading order. Treat it as part of the core workflow, not an optional deep-dive: an analysis built only on the income statement, balance sheet and cash flow has read perhaps a fifth of the official record and skipped the four-fifths where the moat, the governance and the landmines live.
|
||||
|
||||
### Analysis, not advice
|
||||
|
||||
Produce analysis, evidence, and a reasoned view of business quality and valuation. Do not produce personalised investment advice, position sizing for the user, or buy/sell instructions framed as recommendations for their money. State clearly that the output is research, not licensed financial advice, and that the user is responsible for their own decisions.
|
||||
|
||||
Presenting a bull case, a bear case, a valuation range, and what would falsify the thesis is genuinely useful and stays on the right side of this line. "You should buy 50 shares" does not.
|
||||
|
||||
### Show the reasoning and the uncertainty
|
||||
|
||||
Where an estimate is used (normalised earnings, maintenance capex, mid-cycle margins), say it is an estimate, give the assumption, and show what changes if the assumption is wrong. False precision — a target price to two decimals off a hand-waved growth rate — is worse than an honest range.
|
||||
|
||||
## Choose a depth mode
|
||||
|
||||
Match effort to what the user asked for. Announce which mode you are running so expectations are set.
|
||||
|
||||
| Mode | When | What it covers |
|
||||
|---|---|---|
|
||||
| **Screen** | "quick take", "is this worth looking at" | Stages 0–3 plus valuation sanity check. Kill criteria, headline quality metrics, obvious red flags. Short verdict. |
|
||||
| **Standard** (default) | "analyse this stock" | All stages, moderate depth per stage, full scorecard and report. |
|
||||
| **Deep dive** | "detailed", "thorough", "maximum depth", or a position the user intends to size | All stages at full depth, situation playbook, document-level diligence, forensic pass, scenario valuation, explicit bear case. |
|
||||
| **Forensic** | "is the profit real", "are they cooking the books", "cash flow doesn't match profit", "check the accounting" | A different question entirely — *can these accounts bear weight?* Skips business quality, growth and valuation. Follow `references/18-forensic-mode.md`. |
|
||||
| **IPO** | The company is **not yet trading** — an open or upcoming IPO, a filed DRHP/RHP, "should I apply to X's IPO" | No market price and no public track record, so own-history benchmarking and market-price valuation are both unavailable. Follow `references/19-ipo-mode.md`. |
|
||||
|
||||
## The workflow
|
||||
|
||||
If you are running **Forensic mode**, stop here and follow `references/18-forensic-mode.md` instead — it has its own stages (F0–F5) and its own verdict scale, because "can I trust these numbers?" is not answered by a shorter version of "is this a good investment?".
|
||||
|
||||
If the company is **not yet listed**, stop here and follow `references/19-ipo-mode.md` — stages I0–I7. The workflow below assumes a traded security with a price and a public reporting history, and an IPO has neither. Note the boundary: a company that has *already listed* within the last two years uses this workflow with the recent-IPO overlay in `references/13-situations.md` §8, not IPO mode.
|
||||
|
||||
Otherwise work through these stages in order. Later stages depend on earlier ones — classifying the sector before you compute ratios is what stops you applying the wrong metric set.
|
||||
|
||||
### Stage 0 — Establish identity
|
||||
|
||||
Pin down exactly what is being analysed before touching numbers:
|
||||
|
||||
- Company, exchange, ticker, ISIN. Resolve ambiguity (many names collide across exchanges).
|
||||
- **Which security**: ordinary shares, dual-class/DVR line, ADR/GDR, or a holdco that owns the operating company. These trade at different prices and confer different rights.
|
||||
- Reporting currency and fiscal year end (needed to align peers).
|
||||
- Consolidated or standalone basis for the analysis (consolidated is almost always correct).
|
||||
- Market cap, enterprise value, free float.
|
||||
|
||||
If any of these do not exist because the company has not begun trading, you are in IPO mode — go to `references/19-ipo-mode.md`.
|
||||
|
||||
### Stage 1 — Acquire data
|
||||
|
||||
Follow `references/01-data-sourcing.md`. This is a **document-first** workflow: obtain the raw company documents before extracting any numbers.
|
||||
|
||||
**Step 1a — Document acquisition.** Before touching any numbers, identify and obtain the following documents (or as many as are available):
|
||||
|
||||
- Latest annual report or 10-K (and ideally the prior 4 years)
|
||||
- Last 4–8 quarterly results filings from the exchange
|
||||
- Latest 2 concall / earnings-call transcripts
|
||||
- Latest investor presentation
|
||||
- Quarterly shareholding pattern filings (last 4–8 quarters)
|
||||
- Latest credit rating rationale
|
||||
- DRHP/RHP if listed within the last 3–4 years
|
||||
|
||||
Source these from the company's investor-relations page, NSE/BSE corporate filings, SEC EDGAR, or equivalent primary repositories. Aggregator websites (screener.in, Tikr, Yahoo Finance) may be used to *locate* these documents — for example, screener.in links to underlying annual reports and concall transcripts — but the aggregator page itself is not the document.
|
||||
|
||||
**Step 1b — Extract the financials.** From the documents obtained above, gather at minimum 5 years of income statement, balance sheet and cash flow; quarterly trend for the last 8 quarters; and the shareholding pattern. Every figure must cite the specific document and page/section it was extracted from.
|
||||
|
||||
**Step 1c — Extract the non-financial record too.** The financial statements are only part of what these documents contain, and often not the part that decides the analysis. From the *same official documents*, extract and carry forward — each with its document and page/section cite:
|
||||
|
||||
- **Business & strategy** — the business-overview and MD&A narrative: what is sold, to whom, the stated moat and strategy, capacity and utilisation, capex plans, order book / backlog.
|
||||
- **Risk factors** — the management-admitted risks, diffed across years (a risk that silently disappears is a disclosure decision, not a solved problem).
|
||||
- **Auditor's report, CARO, KAMs, emphasis-of-matter** — opinion type for standalone *and* consolidated, and the specific line items the auditor itself flagged as fragile.
|
||||
- **Related-party transactions, contingent liabilities, litigation, capital commitments** — including year-end outstanding balances, not just the year's flows.
|
||||
- **Governance & ownership** — board/audit-committee composition and independence, promoter holding trend and pledge %, remuneration versus PAT, auditor tenure/resignation, AGM voting dissent, ESOP dilution.
|
||||
- **Segment & operational KPIs** — segment-level revenue / EBIT / capital employed, and the sector operating metrics that never reach the P&L.
|
||||
|
||||
Walk the **entire** annual report section by section — not just the financials, and not only the shortlist above. Almost every section carries something an investor should weigh (the strategy in the chairman's letter, the pay ratio in an annexure, a covenant in a borrowings note, the one live case in an otherwise-routine litigation schedule), so the rule is **consider all of it, then report selectively**: read comprehensively, extract what is material, and let the write-up stay focused — a section that is genuinely empty this year is recorded as "read — nothing material", never skipped unread. `references/15-document-diligence.md` gives both a **complete annual-report contents map** (§0) and the time-boxed reading order (§1) for when to prioritise what. This step is **mandatory in Standard and Deep-dive modes**; even in Screen mode, read at least the auditor's report/opinion, the CARO fraud/statutory-dues/default clauses, and the shareholding-and-pledge pattern before forming a view. An analysis that quotes ratios but never opened the auditor's report or the related-party note is not finished.
|
||||
|
||||
If a required document cannot be obtained, ask the user for it **by name** — not "can you give me more data" but "please upload the FY25 annual report PDF and the last two concall transcripts". If the user provides numbers from an aggregator instead of the document, note them as `aggregator-sourced, unverified` and flag the gap. Do not fill gaps with recalled figures; recalled financials are frequently wrong and always stale.
|
||||
|
||||
**Then run the recency gate before you analyse anything.** This is the most common way a well-built analysis turns out wrong: not bad arithmetic, but a conclusion drawn from data that was already superseded when it was written. Adversarial review of real reports found verdict-level failures caused by results, regulatory decisions and deal approvals that were public *days before* the analysis date and simply absent from it.
|
||||
|
||||
So establish explicitly, and state in the report:
|
||||
|
||||
- **What is the latest period the company has actually reported**, and has a quarter been published since the annual figures you are using? Search for results dated after your newest data point rather than assuming your source is current.
|
||||
- **What has happened since that period end** — earnings releases, rating actions, regulatory or court decisions, M&A approvals, block deals, management changes, guidance updates.
|
||||
- **Do any of these already trip the invalidation triggers you are about to write?** A trigger that has already fired is not a future risk; it is a present finding.
|
||||
|
||||
Record the answer as one line: *"Most recent period incorporated: Q1 FY27, published 11-Jul-2026; checked for events to 22-Jul-2026."* A reader cannot judge staleness you have not disclosed.
|
||||
|
||||
**Then verify the data before you compute on it.** Assemble what you gathered into an intake file and run `python scripts/verify_data.py <intake>.json` (see `references/21-data-integrity-tools.md`). It is the mechanical enforcement of the sourcing rules above: it catches figures with no source or period, cross-source disagreements (the check that stops a wrong peer number reaching the verdict), silent consolidated/standalone mixing, crore-vs-million unit traps, and periods that a newer release has already superseded. Fix every error-level finding before proceeding; a fast, clean intake is worth more than a fast analysis built on an unchecked one.
|
||||
|
||||
### Stage 2 — Classify sector and situation
|
||||
|
||||
This is the hinge of the whole analysis, because it determines which metrics even apply.
|
||||
|
||||
**Sector** — pick the playbook from the router below and read it before computing anything.
|
||||
**Situation** — check `references/13-situations.md` for lifecycle overlays (loss-making growth, deep cyclical, turnaround, spin-off, holdco, recent IPO, PSU, serial acquirer, promoter-controlled). A deep cyclical at a trailing P/E of 5 is usually expensive, not cheap; the situation playbook is what stops that error.
|
||||
|
||||
### Stage 3 — Kill-criteria and red-flag screen
|
||||
|
||||
Run this early. Most candidates fail here, and finding out cheaply is the point.
|
||||
|
||||
Read `references/07-forensic-red-flags.md` and `references/08-governance.md`. Screen for: cash flow persistently below profit, receivables growing faster than sales, auditor qualifications or resignations, high or rising promoter pledging, related-party leakage, frequent "one-off" charges, restatements, opaque group structure, and unsustainable leverage. The **anomaly scan** in `references/15-document-diligence.md` §0 maps these to the exact annual-report sections and the abnormal pattern to look for in each — legal-dispute and contingent-liability sizing, related-party tunnelling, and the shareholding-and-pledge trend especially, since these three often surface in the annual report before they surface anywhere else.
|
||||
|
||||
If something serious surfaces, say so prominently and early in the report rather than burying it. A governance red flag can outweigh every positive on the scorecard, and the report should reflect that rather than averaging it away.
|
||||
|
||||
**Escalate to Forensic mode** when a Stage 3 finding is severe enough that valuation becomes pointless until it is resolved — an adverse or qualified audit opinion, cumulative cash flow far below cumulative profit, cash that cannot be evidenced, or related-party leakage. Tell the user you are switching, and why. Valuing a company whose reported earnings you do not believe is wasted work.
|
||||
|
||||
### Stage 4 — Core analysis
|
||||
|
||||
Work through `references/02-core-factors.md`, drawing on:
|
||||
|
||||
- `references/03-earnings-quality.md` — revenue growth decomposition, margin trends, accruals, one-offs, tax normalcy, SBC and dilution
|
||||
- `references/04-balance-sheet-and-cashflow.md` — leverage, coverage, maturity wall, working capital, OCF vs profit, FCF, capex split
|
||||
- `references/05-returns-and-dupont.md` — ROIC vs WACC, DuPont decomposition, incremental returns, normalisation
|
||||
- `references/15-document-diligence.md` — the qualitative record extracted at Stage 1c, now *synthesised alongside the ratios*: MD&A promise-versus-delivery, related-party leakage, contingent liabilities, segment ROCE, governance and auditor signals. The numbers and the narrative are analysed together, not in separate silos.
|
||||
- The **sector playbook**, which overrides or replaces generic metrics where they do not apply
|
||||
|
||||
Business quality and moat, growth durability and reinvestment runway sit inside `02-core-factors.md`.
|
||||
|
||||
### Stage 5 — Build the peer set and benchmark
|
||||
|
||||
Follow `references/10-peer-set.md`. A wrong peer set produces confidently wrong conclusions, so construct it explicitly and state the basis: same sector and sub-sector, comparable business model and capital intensity, similar accounting regime, aligned fiscal periods.
|
||||
|
||||
Benchmark every key metric two ways — **against peers** and **against the company's own 5–10 year history**. Both matter: a company can beat its peers while decaying against itself.
|
||||
|
||||
### Stage 6 — Value it
|
||||
|
||||
Follow `references/06-valuation.md`. Use the method the **sector playbook** specifies (P/B and ROE for banks, P/EV for life insurers, AFFO and cap rates for REITs, mid-cycle EV/EBITDA for miners, EV/EBITDAR for airlines). Applying a generic P/E across sectors is the valuation equivalent of the OPM mistake.
|
||||
|
||||
Include a reverse-DCF style check — what growth and margin does the current price already assume? — because it converts valuation from an opinion into a testable question. Run `scripts/valuation.py` for the EV bridge, trailing multiples, the reverse-DCF implied growth and the probability-weighted scenario table rather than computing them by hand — it removes arithmetic slips and flags aggressive assumptions (e.g. terminal growth above nominal GDP).
|
||||
|
||||
### Stage 7 — Risk, bear case, invalidation
|
||||
|
||||
Read `references/09-risk-and-macro.md`. Write a genuine bear case, not a strawman: the most credible argument that this is a bad investment. Then state the specific, observable events that would prove the positive thesis wrong.
|
||||
|
||||
### Stage 8 — Score and write
|
||||
|
||||
Score using `references/11-scoring-rubric.md` (run `scripts/score.py` for the arithmetic), then write the report using the template in `references/12-report-template.md`. Before writing, read the worked exemplars in `examples/` to calibrate the target quality: `examples/standard-analysis-example.md` (a full Standard-mode report that passes the linter and embeds real `valuation.py` output) and `examples/forensic-analysis-example.md` (a Forensic-mode review following the F0–F5 template). They are fictional by design — models of *how*, never sources of figures.
|
||||
|
||||
### Stage 9 — Challenge the draft before delivering it
|
||||
|
||||
You wrote the thesis, so you will not attack it as hard as someone else would. Follow `references/20-challenge-pass.md`: identify what the verdict actually rests on, attack those claims, verify the numbers trace to their sources, and test whether the conclusion survives a different peer set and a different weight preset.
|
||||
|
||||
Mandatory in Deep dive. Recommended in Standard. Skip in Screen, where the conclusion is explicitly provisional. **If you can spawn subagents, use them** — independence is the mechanism, and an author reviewing their own work is a weak substitute.
|
||||
|
||||
The point is that the verdict can move. A challenge pass that only ever adds caveats to an already-written conclusion manufactures false confidence and is worse than none.
|
||||
|
||||
### Stage 10 — Lint before delivering
|
||||
|
||||
Run `python scripts/lint_report.py <report>.md` (see `references/21-data-integrity-tools.md`). It is a mechanical last check that the report honours the non-negotiables: a recency statement and data-quality note are present, basis and units are stated, a scorecard is not shown without its gate disclosure, a bear case and disclaimer exist, and — the core check — that financial figures sit near a source rather than floating free. Treat error-level findings as blocking and fix them; a low figure-sourcing ratio means go back and cite, not ship. The linter is a floor, not a substitute for judgement.
|
||||
|
||||
Save the report as a markdown file named `<TICKER>-analysis-<YYYY-MM-DD>.md` unless the user asks otherwise, and summarise the key findings in chat.
|
||||
|
||||
## Sector router
|
||||
|
||||
Read the matching playbook at Stage 2. When a company spans several sectors, use the segment that drives most of the profit and note the others; conglomerates go to the holdco playbook and are valued sum-of-the-parts.
|
||||
|
||||
| If the company is… | Read |
|
||||
|---|---|
|
||||
| A bank or lender taking deposits | `references/sectors/banks.md` |
|
||||
| An NBFC, housing finance or non-bank lender | `references/sectors/nbfc.md` |
|
||||
| A mortgage REIT, BDC, private-credit vehicle, equipment lessor or leasing company | `references/sectors/mortgage-reit-specialty-finance.md` |
|
||||
| A life, general, health or P&C insurer | `references/sectors/insurance.md` |
|
||||
| An insurance broker, MGA, TPA or distribution platform — places risk but underwrites none | `references/sectors/insurance-brokers-services.md` |
|
||||
| IT services, software, SaaS, internet platform | `references/sectors/it-saas.md` |
|
||||
| Staffing, consulting, advertising, outsourced professional and business services | `references/sectors/people-businesses.md` |
|
||||
| Pharma, CDMO, hospitals, diagnostics, medical devices | `references/sectors/pharma-healthcare.md` |
|
||||
| A pre-revenue, clinical-stage drug developer with no approved product | `references/sectors/biotech-clinical.md` |
|
||||
| FMCG, consumer staples, branded consumer, QSR | `references/sectors/fmcg-consumer.md` |
|
||||
| Automobiles, auto components, tyres | `references/sectors/auto.md` |
|
||||
| Steel, aluminium, mining, other commodity producers | `references/sectors/metals-mining.md` |
|
||||
| Oil & gas — upstream, refining, marketing, gas utilities | `references/sectors/oil-gas.md` |
|
||||
| Power generation, transmission, regulated utilities | `references/sectors/utilities-power.md` |
|
||||
| Waste collection and disposal, landfills, recycling, water and wastewater treatment | `references/sectors/waste-environmental.md` |
|
||||
| Real estate developers, REITs, InvITs | `references/sectors/realestate-reit.md` |
|
||||
| Infrastructure, EPC, capital goods, defence | `references/sectors/infra-capitalgoods.md` |
|
||||
| Telecom, towers, broadcasting, media, OTT | `references/sectors/telecom-media.md` |
|
||||
| Airlines, hotels, travel, restaurants, OTAs | `references/sectors/aviation-hotels.md` |
|
||||
| Retail chains, e-commerce, marketplaces, quick commerce | `references/sectors/retail-ecommerce.md` |
|
||||
| Specialty chemicals, agrochemicals, fertilisers, cement | `references/sectors/chemicals-cement.md` |
|
||||
| Holding companies, conglomerates, AMCs, alternative managers | `references/sectors/holdco-assetmgr.md` |
|
||||
| Shipping, tankers, dry bulk, ports, trucking, logistics | `references/sectors/shipping-logistics.md` |
|
||||
| Railroads and rail freight networks | `references/sectors/rail-freight.md` |
|
||||
| Exchanges, depositories, clearing houses, rating agencies, card and payment networks | `references/sectors/exchanges-payments.md` |
|
||||
| Semiconductors, fabs, equipment, capital-intensive hardware | `references/sectors/semiconductors.md` |
|
||||
|
||||
If none fits cleanly, use `references/02-core-factors.md` with the generic ratio set and say in the report that no specialised playbook applied — then be extra careful about which standard metrics are actually meaningful for that business model.
|
||||
|
||||
## Bundled scripts
|
||||
|
||||
Run these rather than recomputing by hand; they remove arithmetic slips and keep results consistent between analyses.
|
||||
|
||||
- `scripts/ratios.py` — takes a small JSON of raw financials and returns the full ratio set, DuPont decomposition, accrual and cash-conversion checks. `python scripts/ratios.py --help`
|
||||
- `scripts/score.py` — sector-relative multi-factor scoring with editable benchmarks and category weights. `python scripts/score.py --help`
|
||||
- For a company with materially different businesses, pass a `segments` array and each segment is scored against its own sector's benchmarks and blended by profit — `python scripts/score.py --example-segments` prints a runnable example. The blend is a quality summary, never a substitute for sum-of-the-parts valuation.
|
||||
- `scripts/valuation.py` — Stage-6 valuation calculator: EV bridge, trailing multiples, the reverse-DCF implied-growth solve, a forward 2-stage DCF, and a probability-weighted scenario table. Runs only the sections whose inputs you supply, and guards invalid assumptions (terminal growth ≥ WACC fails). `python scripts/valuation.py --template` / `--example`
|
||||
- `scripts/verify_data.py` — data-intake gate. Validates gathered figures for provenance, **source tier (documents primary, aggregators navigation-only)**, cross-source agreement, basis/unit consistency and staleness before you compute on them. Run it at Stage 1. `python scripts/verify_data.py --template`
|
||||
- `scripts/lint_report.py` — finished-report QA. Checks the non-negotiables and the figure-sourcing ratio before delivery. Run it at Stage 10. `python scripts/lint_report.py --help`
|
||||
|
||||
Both are plain Python with no third-party dependencies. Sector benchmark tables live in `scripts/benchmarks.json` and are meant to be edited — treat the shipped values as reasonable defaults, not gospel, and override them when you have better peer data for the specific market and period.
|
||||
|
||||
## Output contract
|
||||
|
||||
Deliver two things, always:
|
||||
|
||||
1. **The report** — follow `references/12-report-template.md`. It opens with the verdict and the key risks, because a reader who stops after the first screen should still get the substance.
|
||||
2. **The scorecard** — sector-relative scores by category with the weights shown, plus the composite. Show the inputs so the reader can disagree with a specific number rather than the whole thing.
|
||||
|
||||
Include the data-quality note: which figures are sourced, which are estimated, which are missing, and the as-of date.
|
||||
|
||||
## Reference index
|
||||
|
||||
Read these as needed; they are written to be consulted individually rather than all at once.
|
||||
|
||||
| File | Use it for |
|
||||
|---|---|
|
||||
| `references/01-data-sourcing.md` | Where to get data for India and global markets, and how to verify it |
|
||||
| `references/02-core-factors.md` | The universal multi-factor checklist: business, moat, industry, growth |
|
||||
| `references/03-earnings-quality.md` | Income statement analysis and earnings quality |
|
||||
| `references/04-balance-sheet-and-cashflow.md` | Solvency, liquidity, working capital, cash generation |
|
||||
| `references/05-returns-and-dupont.md` | ROIC/ROCE/ROE, DuPont, incremental returns, why margin alone misleads |
|
||||
| `references/06-valuation.md` | Every valuation method, EV bridge, WACC derivation, reverse DCF, scenarios |
|
||||
| `references/07-forensic-red-flags.md` | Accounting manipulation and fraud detection |
|
||||
| `references/08-governance.md` | Management, promoters, board, auditors, related parties |
|
||||
| `references/09-risk-and-macro.md` | Company, macro, regulatory, ESG and tail risks |
|
||||
| `references/10-peer-set.md` | Constructing a defensible like-for-like comparison set |
|
||||
| `references/11-scoring-rubric.md` | The sector-relative multi-factor scoring method |
|
||||
| `references/12-report-template.md` | The exact output structure |
|
||||
| `references/13-situations.md` | Lifecycle overlays: cyclicals, turnarounds, holdcos, IPOs, PSUs |
|
||||
| `references/14-accounting-comparability.md` | IFRS/GAAP/Ind-AS differences, leases, restatements, normalisation |
|
||||
| `references/15-document-diligence.md` | Annual report, auditor's report, CARO, KAM, transcripts, rating rationales |
|
||||
| `references/16-market-mechanics-and-tax.md` | Surveillance, corporate actions, dilution instruments, taxation |
|
||||
| `references/17-process-and-epistemics.md` | Circle of competence, falsification, base rates, when to say no |
|
||||
| `references/18-forensic-mode.md` | Forensic-only runbook: triage battery, verdict scale, output template |
|
||||
| `references/19-ipo-mode.md` | Not-yet-listed companies: DRHP/RHP, seller motive, valuing the price band |
|
||||
| `references/20-challenge-pass.md` | Adversarial review before delivery: attack the load-bearing claims |
|
||||
| `references/21-data-integrity-tools.md` | The intake gate and report linter: how and when to run them |
|
||||
| `references/sectors/_index.md` | Sector router with sub-sector guidance |
|
||||
|
||||
## A note on judgement
|
||||
|
||||
These references are extensive, and working through all of them mechanically produces a long document rather than an insight. The point of the depth is that you can reach for the right tool, not that every tool gets used on every company.
|
||||
|
||||
For most companies, three or four factors genuinely decide the outcome — a moat that is widening or narrowing, returns on incremental capital, whether cash follows profit, and whether the price already assumes success. Identify those, evidence them properly, and let the rest of the checklist do its real job: making sure nothing disqualifying was missed.
|
||||
|
||||
If the business sits outside what can be understood with the available information, say so. Declining to analyse is a legitimate and useful answer.
|
||||
132
finance/skills/stock-analysis/evals/evals.json
Normal file
132
finance/skills/stock-analysis/evals/evals.json
Normal file
|
|
@ -0,0 +1,132 @@
|
|||
{
|
||||
"skill_name": "stock-analysis",
|
||||
"evals": [
|
||||
{
|
||||
"id": 0,
|
||||
"name": "bank-sector-routing",
|
||||
"prompt": "can you take a look at HDFC Bank for me? want to know if it's fundamentally strong or if i'm better off elsewhere. people keep saying it's cheap now",
|
||||
"expected_output": "A sector-aware analysis that routes to the banks playbook: uses NIM, CASA, ROA, GNPA/NNPA, slippages, credit cost, PCR, CAR/CET1, cost-to-income; explicitly declines to use OPM/ROCE/EV-EBITDA/FCF as inapplicable to a bank; values on P/B against ROE vs cost of equity rather than a generic P/E; cites sources with as-of dates; does not give personalised buy/sell advice.",
|
||||
"files": [],
|
||||
"assertions": [
|
||||
"Does NOT report OPM, ROCE, EV/EBITDA or free cash flow as headline metrics for the bank, or explicitly states they are inapplicable to a deposit-taking lender",
|
||||
"Uses at least five bank-specific metrics from: NIM, CASA, ROA, GNPA, NNPA, slippage ratio, credit cost, PCR, CAR/CET1, cost-to-income, LCR",
|
||||
"Anchors valuation on price-to-book (or price-to-adjusted-book) referenced to ROE versus cost of equity, rather than concluding from P/E alone",
|
||||
"Every headline financial figure is accompanied by a source and a reporting period",
|
||||
"Contains an explicit data-quality note covering as-of date and consolidated-vs-standalone basis",
|
||||
"Addresses the user's 'people say it's cheap' premise directly rather than ignoring it",
|
||||
"Includes a bear case or key-risks section",
|
||||
"Contains a not-financial-advice disclaimer and gives no personalised buy/sell instruction"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": 1,
|
||||
"name": "cross-sector-margin-trap",
|
||||
"prompt": "TCS runs about 24% operating margin and Avenue Supermarts (DMart) is around 8%. TCS looks far better on margins so it should be the stronger business right?",
|
||||
"expected_output": "Directly challenges the single-metric premise. Explains margin is sector-bound and not comparable across IT services and grocery retail; brings in asset turnover and DuPont to show a low-margin high-turnover retailer can earn comparable or superior returns on capital; compares ROIC/ROCE, cash conversion, growth durability and reinvestment runway; benchmarks each within its own sector and own history; refuses to declare a winner on margin alone.",
|
||||
"files": [],
|
||||
"assertions": [
|
||||
"Explicitly rejects the premise that a higher operating margin implies the stronger business",
|
||||
"Explains why margins are structurally not comparable across these two sectors (e.g. gross-vs-net revenue recognition, value-add base, capital intensity)",
|
||||
"Introduces asset turnover and/or an explicit DuPont decomposition",
|
||||
"Compares return on capital (ROCE, ROIC or ROE) for both companies as the cross-sector-valid measure",
|
||||
"Benchmarks each company against its OWN sector peers rather than against each other on margin",
|
||||
"Separates the question of business quality from the question of valuation / which is the better buy",
|
||||
"Does not declare a winner on the basis of margin alone"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": 2,
|
||||
"name": "deep-dive-bear-case",
|
||||
"prompt": "do a thorough fundamental analysis of Tata Motors - I want the full picture including what could go wrong. thinking about a reasonably sized position so don't sugarcoat it",
|
||||
"expected_output": "Runs deep-dive mode: identifies the auto sector playbook and the situation overlay (cyclical, multi-segment, historically leveraged); separates automotive net debt from the captive finance arm; uses EBITDA per vehicle, volumes vs registrations, capex plus capitalised product development, mid-cycle ROIC; values sum-of-the-parts rather than a single consolidated multiple; includes a serious bear case and specific thesis-invalidation triggers.",
|
||||
"files": [],
|
||||
"assertions": [
|
||||
"Analyses the business by segment rather than as a single consolidated entity",
|
||||
"Separates automotive net debt/cash from any captive finance or lending arm, or explains why that separation matters",
|
||||
"Values using sum-of-the-parts or segment-level multiples rather than one consolidated P/E",
|
||||
"Uses at least three auto-sector-specific metrics (e.g. EBITDA per vehicle, wholesale vs retail registrations, capex plus capitalised product development, mid-cycle ROIC, capacity utilisation, discount per unit)",
|
||||
"Applies a cyclical or situation overlay, including the risk of capitalising peak or trough earnings",
|
||||
"Contains a substantive bear case that is genuinely argued, not a token risk list",
|
||||
"States specific, observable thesis-invalidation triggers",
|
||||
"Includes a data-quality note with as-of dates and sources",
|
||||
"Gives no personalised position sizing despite the user hinting at one"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": 3,
|
||||
"name": "document-grounded-red-flags",
|
||||
"prompt": "I've attached selected extracts from Kesar Agro Industries' FY26 annual report. Is this a fundamentally sound company worth investing in?",
|
||||
"expected_output": "A document-grounded read that surfaces the planted abnormalities from the extracts rather than a generic bullish summary: the qualified audit opinion and the unprovided ₹180 cr interest-free related-party advance, the going-concern material uncertainty, related-party tunnelling (loans growing, below-market sales to promoter entities), contingent liabilities (₹420 cr) exceeding net worth (₹350 cr), promoter pledge rising to 71%, the CARO findings (bank returns disagreeing with books, evergreening, unpaid statutory dues, loan default), the CFO churn and mid-year auditor resignation, and the profit-vs-cash divergence. It should escalate these prominently, decline to give a clean bullish verdict, cite the document, and not fabricate figures not in the extract.",
|
||||
"files": ["fixtures/synthetic-ar-excerpt.md"],
|
||||
"assertions": [
|
||||
"Surfaces the qualified audit opinion and the unprovided related-party advance (~₹180 cr) to the promoter entity",
|
||||
"Flags the going-concern material uncertainty and the term-loan default disclosed in CARO",
|
||||
"Identifies related-party leakage / tunnelling (growing interest-free loans and/or below-market sales to promoter-linked entities)",
|
||||
"Notes that contingent liabilities (~₹420 cr) exceed net worth (~₹350 cr)",
|
||||
"Flags the promoter share pledge rising sharply (to ~71% of promoter holding)",
|
||||
"Notes the profit-rising-while-CFO-negative divergence, or the CARO bank-returns-vs-books disagreement, or the CFO/auditor turnover",
|
||||
"Does NOT conclude the company is fundamentally sound / a clear buy; treats governance and accounting findings as potentially disqualifying",
|
||||
"Attributes findings to the annual-report extract and does not invent figures absent from it"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": 4,
|
||||
"name": "forensic-mode-routing",
|
||||
"prompt": "Profit at Kesar Agro keeps rising every year but I heard the cash flow is actually negative. Are they cooking the books? I've attached extracts from their FY26 annual report.",
|
||||
"expected_output": "Routes to Forensic mode (the question is 'can these accounts bear weight?', not 'is this a good investment?'). Runs the cash-vs-earnings accruals work (cumulative CFO far below cumulative PAT), a proof-of-cash test (interest income of ~₹3 cr on ~₹200 cr of cash implies a ~1.5% yield versus much higher borrowing cost), reads the CARO bank-returns-vs-books disagreement and the receivables build, and reaches a forensic verdict about how much the numbers can be trusted. It should NOT pivot into a valuation, target price or buy/sell call, because valuing earnings you do not believe is wasted work.",
|
||||
"files": ["fixtures/synthetic-ar-excerpt.md"],
|
||||
"assertions": [
|
||||
"Explicitly frames this as a forensic / earnings-quality question rather than a standard buy-side analysis",
|
||||
"Compares reported profit against operating cash flow over multiple years (accruals / cash-conversion gap)",
|
||||
"Runs a proof-of-cash or interest-income-vs-cash check, or otherwise questions the reported cash balance",
|
||||
"Uses the CARO bank-statement-vs-books disagreement and/or the receivables build as evidence",
|
||||
"Reaches a verdict about the reliability of the accounts rather than a price target",
|
||||
"Does NOT produce a valuation, target price, or personalised buy/sell recommendation"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": 5,
|
||||
"name": "recency-gate-stale-data",
|
||||
"prompt": "It's August 2026. A friend built this summary of Meridian Industries from their FY25 (year ended March 2025) annual report: revenue ₹8,400 cr, net profit ₹610 cr, net debt ₹1,200 cr, at a share price around ₹950. Is the stock cheap right now?",
|
||||
"expected_output": "Runs the recency gate before answering: recognises that FY25 (March-2025) data is roughly 15+ months old as of August 2026, that FY26 annual results and at least one FY27 quarter have almost certainly been reported since, and that a 'cheap right now' judgement cannot rest on superseded figures or a stale price. It should state the most-recent-period problem explicitly, decline to deliver a current valuation verdict on the stale data, and say what it would need (the latest annual and quarterly filings, a current price with an as-of date).",
|
||||
"files": [],
|
||||
"assertions": [
|
||||
"Explicitly flags that the FY25 (March-2025) figures are stale as of August 2026 and that newer periods (FY26, and likely an FY27 quarter) should exist",
|
||||
"Runs or references a recency check rather than analysing the provided numbers as if current",
|
||||
"Does not deliver a definitive 'cheap' / 'expensive' verdict resting on the 15-month-old figures without flagging the staleness",
|
||||
"States what current data would be needed (latest annual + quarterly filings, current price with an as-of date)",
|
||||
"Treats the provided figures as needing verification against the primary filings rather than as established facts"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": 6,
|
||||
"name": "ipo-mode-drhp",
|
||||
"prompt": "Should I apply to the Vayu Mobility IPO? I've attached extracts from their DRHP. The price band is ₹590–620.",
|
||||
"expected_output": "Routes to IPO mode (no market price history, no own-history benchmark). Flags that the offer is overwhelmingly an Offer for Sale (₹1,500 cr of ₹1,800 cr) with only ₹300 cr of fresh capital, i.e. insiders and the PE fund are cashing out; notes the ~3x pre-IPO price step-up within four months; scrutinises the bespoke 'Adjusted EBITDA' add-backs that recur every year; surfaces the promoter's pending criminal proceedings, customer concentration and negative operating cash flow; and assesses the ₹590–620 band on multiples / a forward view rather than any own-history or market-price method. No personalised apply/avoid instruction framed as advice.",
|
||||
"files": ["fixtures/synthetic-drhp-excerpt.md"],
|
||||
"assertions": [
|
||||
"Recognises IPO mode: no trading history, so own-history benchmarking and market-price valuation are unavailable",
|
||||
"Flags that the offer is mostly an Offer for Sale (sellers cashing out) with little fresh capital entering the business",
|
||||
"Notes the steep pre-IPO placement price step-up relative to the price band",
|
||||
"Scrutinises the non-GAAP 'Adjusted EBITDA' add-backs, noting the excluded costs recur every year",
|
||||
"Surfaces at least one of: promoter criminal litigation, customer concentration, negative operating cash flow, or the restatement adjustments",
|
||||
"Assesses the price band using multiples or a forward view rather than own-history or market-price methods",
|
||||
"Gives no personalised 'apply' / 'avoid' instruction framed as investment advice"
|
||||
]
|
||||
},
|
||||
{
|
||||
"id": 7,
|
||||
"name": "aggregator-primary-source-discipline",
|
||||
"prompt": "Here's what screener.in shows for Aarti Foods: revenue ₹4,200 cr, PAT ₹310 cr, ROCE 19%, total debt ₹500 cr. Based on this, is it a good business?",
|
||||
"expected_output": "Treats the pasted aggregator figures as unverified and not a source of record: it explains that screener.in and similar aggregators are navigation aids for locating the actual filings, not citable sources, and that the analysis must trace these numbers to the company's own annual report and exchange filings (checking consolidated-vs-standalone basis, period, and units) before relying on them. It should proceed with the figures marked as aggregator-sourced / unverified, or ask for the primary documents by name, rather than delivering a confident verdict citing screener as the source.",
|
||||
"files": [],
|
||||
"assertions": [
|
||||
"States that aggregator data (screener.in) is a navigation aid, not a source of record, and should be verified against the primary filings",
|
||||
"Does not present the pasted screener figures as sourced facts underpinning a final verdict",
|
||||
"Marks the provided figures as aggregator-sourced / unverified, or asks for the annual report and exchange filings by name",
|
||||
"Notes at least one verification concern that the aggregator figure hides (consolidated vs standalone, period/as-of, units, or definition of ROCE/debt)",
|
||||
"Any provisional read is explicitly caveated as resting on unverified aggregator data"
|
||||
]
|
||||
}
|
||||
]
|
||||
}
|
||||
|
|
@ -0,0 +1,123 @@
|
|||
# Kesar Agro Industries Limited — Selected extracts from the FY26 Annual Report
|
||||
|
||||
> **FICTIONAL TEST FIXTURE.** Kesar Agro Industries Ltd does not exist. These
|
||||
> extracts were written to exercise the stock-analysis skill's red-flag,
|
||||
> forensic and document-diligence behaviour against a document that contains
|
||||
> several deliberately planted abnormalities. All figures are invented. Do not
|
||||
> treat any number here as real, and do not reuse these figures for any real
|
||||
> company. Consolidated basis, Ind-AS, ₹ crore unless stated.
|
||||
|
||||
---
|
||||
|
||||
## 1. Five-year financial highlights (₹ crore, consolidated)
|
||||
|
||||
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|
||||
|---|---:|---:|---:|---:|---:|
|
||||
| Revenue from operations | 1,420 | 1,610 | 1,880 | 2,190 | 2,560 |
|
||||
| Reported net profit (PAT) | 34 | 41 | 48 | 55 | 61 |
|
||||
| Cash flow from operations (CFO) | 6 | (18) | (30) | (52) | (70) |
|
||||
| Trade receivables | 320 | 402 | 511 | 660 | 858 |
|
||||
| Cash & bank balances | 90 | 128 | 165 | 190 | 210 |
|
||||
| Total borrowings | 210 | 265 | 330 | 395 | 450 |
|
||||
| Net worth | 250 | 285 | 312 | 335 | 350 |
|
||||
|
||||
Interest and investment income for FY26 (Note 21, "Other income"): **₹3 cr**.
|
||||
Finance cost for FY26 (Note 22): **₹47 cr** on average borrowings of ~₹430 cr.
|
||||
|
||||
---
|
||||
|
||||
## 2. Extract from the Independent Auditor's Report (Consolidated)
|
||||
|
||||
**Qualified Opinion.** In our opinion, except for the effects of the matter
|
||||
described in the Basis for Qualified Opinion section, the consolidated financial
|
||||
statements give a true and fair view…
|
||||
|
||||
**Basis for Qualified Opinion.** The Group has an outstanding advance of
|
||||
**₹180 crore** to Kesar Estates Private Limited, an entity in which the promoter
|
||||
and his relatives hold a controlling interest. The advance is interest-free, has
|
||||
no stipulated repayment schedule, and has been outstanding and growing for three
|
||||
financial years. Management has not made any provision against this advance. We
|
||||
are unable to obtain sufficient appropriate audit evidence regarding its
|
||||
recoverability. Had a provision been made, profit before tax for the year would
|
||||
have been lower by ₹180 crore and net worth would have been correspondingly
|
||||
reduced.
|
||||
|
||||
**Material Uncertainty Related to Going Concern.** We draw attention to Note 41.
|
||||
A term loan of ₹95 crore was overdue for repayment as at the balance-sheet date,
|
||||
and the Group's ability to continue as a going concern depends on successful
|
||||
refinancing and continued support from lenders. These events indicate a material
|
||||
uncertainty that may cast significant doubt on the Group's ability to continue as
|
||||
a going concern. Our opinion is not further modified in respect of this matter.
|
||||
|
||||
**Key Audit Matter — Recoverability of trade receivables.** Trade receivables of
|
||||
₹858 crore include ₹210 crore outstanding for more than 365 days. The expected
|
||||
credit loss allowance of ₹9 crore represents management's judgement…
|
||||
|
||||
---
|
||||
|
||||
## 3. Extract from the CARO 2020 Annexure
|
||||
|
||||
- **Clause 3(ii)(b).** The Group has been sanctioned working-capital limits in
|
||||
excess of ₹5 crore on the security of current assets. The quarterly returns
|
||||
filed by the Company with its banks **are not in agreement with the books of
|
||||
account**; the receivables reported to lenders exceeded the books by
|
||||
approximately **₹60 crore** in three of the four quarters. Management is in the
|
||||
process of reconciling the difference.
|
||||
- **Clause 3(iii)(e).** Fresh loans of ₹40 crore were granted to a related party
|
||||
during the year to settle earlier loans that had become overdue (evergreening).
|
||||
- **Clause 3(vii)(a).** Undisputed statutory dues of **₹22 crore** (goods and
|
||||
services tax ₹14 crore, provident fund ₹5 crore, tax deducted at source ₹3
|
||||
crore) were **in arrears for more than six months** as at 31 March 2026.
|
||||
- **Clause 3(ix)(a).** The Group **defaulted** in repayment of a term loan of
|
||||
₹95 crore to a bank; the default has continued for 120 days as at year-end.
|
||||
- **Clause 3(xviii).** The statutory auditors for the previous year **resigned**
|
||||
during the current year. The incoming auditor has considered the issues raised
|
||||
by the outgoing firm in its resignation letter, which cited "information and
|
||||
explanations sought not being made available in a timely manner."
|
||||
|
||||
---
|
||||
|
||||
## 4. Related-party transactions (Note 38, extract)
|
||||
|
||||
| Related party | Nature | FY24 | FY25 | FY26 |
|
||||
|---|---|---:|---:|---:|
|
||||
| Kesar Estates Pvt Ltd (promoter-controlled) | Advance / loan given, year-end balance | 40 | 95 | 180 |
|
||||
| Kesar Estates Pvt Ltd | Interest charged on above | 0 | 0 | 0 |
|
||||
| Sunrise Distributors LLP (promoter relative) | Sales of goods | 180 | 240 | 300 |
|
||||
| — of which gross margin realised | | 4% | 3% | 2% |
|
||||
| Third-party distributor sales — gross margin | | 11% | 11% | 10% |
|
||||
| Promoter & relatives | Managerial remuneration | 9 | 12 | 18 |
|
||||
|
||||
Managerial remuneration to the promoter family rose to ₹18 crore in FY26
|
||||
(FY25: ₹12 crore), i.e. ~30% of consolidated PAT.
|
||||
|
||||
---
|
||||
|
||||
## 5. Contingent liabilities and commitments (Note 39, extract)
|
||||
|
||||
| Item | FY26 (₹ cr) |
|
||||
|---|---:|
|
||||
| Disputed tax demands (income tax + GST), matters in appeal | 120 |
|
||||
| Corporate guarantee given for borrowings of Kesar Estates Pvt Ltd | 300 |
|
||||
| **Total contingent liabilities** | **420** |
|
||||
|
||||
(Net worth as at 31 March 2026: ₹350 crore.)
|
||||
|
||||
---
|
||||
|
||||
## 6. Shareholding pattern and promoter encumbrance (last four quarters)
|
||||
|
||||
| Quarter | Promoter holding (% of equity) | Pledged (% of promoter holding) |
|
||||
|---|---:|---:|
|
||||
| Jun 2025 | 58.0% | 18% |
|
||||
| Sep 2025 | 58.0% | 34% |
|
||||
| Dec 2025 | 57.6% | 55% |
|
||||
| Mar 2026 | 57.6% | 71% |
|
||||
|
||||
---
|
||||
|
||||
## 7. Board and management (Corporate Governance Report, extract)
|
||||
|
||||
The Company has had **three Chief Financial Officers in the last four years**.
|
||||
The current CFO was appointed in January 2026. The Audit Committee met twice
|
||||
during FY26. The Chairman is also the Managing Director and promoter.
|
||||
|
|
@ -0,0 +1,81 @@
|
|||
# Vayu Mobility Limited — Selected extracts from the DRHP (Draft Red Herring Prospectus)
|
||||
|
||||
> **FICTIONAL TEST FIXTURE.** Vayu Mobility Ltd does not exist. These extracts
|
||||
> were written to exercise the stock-analysis skill's IPO-mode behaviour against
|
||||
> an offer document containing several deliberately planted issues. All figures
|
||||
> are invented. Do not treat any number here as real. ₹ crore unless stated.
|
||||
|
||||
---
|
||||
|
||||
## 1. The Offer (Objects of the Issue)
|
||||
|
||||
Total offer size at the upper price band: **₹1,800 crore**, comprising:
|
||||
|
||||
- **Fresh issue: ₹300 crore.**
|
||||
- Repayment/prepayment of certain borrowings: ₹120 crore
|
||||
- Funding capital expenditure (new hubs): ₹60 crore
|
||||
- **General corporate purposes: ₹120 crore**
|
||||
- **Offer for Sale (OFS): ₹1,500 crore**, comprising:
|
||||
- Aurora Capital Fund II (private-equity investor): ₹1,050 crore
|
||||
- Promoter — Mr R. Vaidyanathan and family: ₹450 crore
|
||||
|
||||
Price band: **₹590–₹620 per equity share** (face value ₹5).
|
||||
|
||||
Only ₹300 crore of the ₹1,800 crore offer represents fresh capital entering the
|
||||
business; the remaining ₹1,500 crore accrues to selling shareholders.
|
||||
|
||||
---
|
||||
|
||||
## 2. Pre-IPO placement and prior transactions
|
||||
|
||||
In **March 2026** (approximately four months before this filing), the Company
|
||||
allotted equity shares to a group of investors at **₹210 per share**. The IPO
|
||||
price band of ₹590–₹620 represents an increase of roughly **2.8x–3.0x** over that
|
||||
price within four months.
|
||||
|
||||
---
|
||||
|
||||
## 3. Restated financial information (extract)
|
||||
|
||||
| Metric (₹ cr) | FY24 | FY25 | FY26 |
|
||||
|---|---:|---:|---:|
|
||||
| Revenue from operations | 2,050 | 2,760 | 3,540 |
|
||||
| Restated profit / (loss) for the year | (45) | 12 | 88 |
|
||||
| Net cash from operating activities | (160) | (95) | 40 |
|
||||
| **Adjusted EBITDA (as presented by the Company)** | 95 | 210 | 360 |
|
||||
|
||||
The Company presents "Adjusted EBITDA", a non-GAAP measure, which excludes
|
||||
employee stock-option expense, "one-time" branch-launch and logistics-onboarding
|
||||
costs, and share-based payments. Such branch-launch and logistics-onboarding
|
||||
costs have been incurred in each of the last three financial years.
|
||||
|
||||
The restated financial statements reflect **seven restatement adjustments**,
|
||||
including a correction to the timing of revenue recognition on certain
|
||||
subscription contracts and the reclassification of "one-time" costs.
|
||||
|
||||
---
|
||||
|
||||
## 4. Selected Risk Factors (extract)
|
||||
|
||||
- Two of our top three customers accounted for **61% of revenue** in FY26.
|
||||
- We have reported **negative net cash from operating activities in two of the
|
||||
last three financial years**.
|
||||
- There are outstanding criminal proceedings against our Promoter, including a
|
||||
proceeding under Section 138 of the Negotiable Instruments Act (cheque
|
||||
dishonour) and a proceeding relating to alleged tax evasion, each pending
|
||||
before the relevant court.
|
||||
- A tax authority has raised a demand of **₹85 crore** against the Company, which
|
||||
we have disputed and which is pending in appeal.
|
||||
- Our Promoter will continue to hold 46% of the post-issue paid-up capital and
|
||||
will retain significant control.
|
||||
|
||||
---
|
||||
|
||||
## 5. Lock-in
|
||||
|
||||
- Promoter's contribution (minimum 20% of post-issue capital): locked in for
|
||||
**18 months** from the date of allotment.
|
||||
- Anchor investor shares: 50% locked in for 90 days and 50% for 30 days from the
|
||||
date of allotment.
|
||||
- Pre-IPO placement shares (allotted March 2026): locked in for six months from
|
||||
the date of allotment.
|
||||
23
finance/skills/stock-analysis/examples/README.md
Normal file
23
finance/skills/stock-analysis/examples/README.md
Normal file
|
|
@ -0,0 +1,23 @@
|
|||
# Worked examples — gold-standard reference analyses
|
||||
|
||||
These are **illustrative exemplars**: complete analyses the skill is meant to
|
||||
produce, written so a new run can see the target quality rather than infer it
|
||||
from the template alone. Read them alongside `references/12-report-template.md`
|
||||
(structure) — the template shows the *shape*, these show the *bar*.
|
||||
|
||||
**Every company here is fictional and every figure is invented.** That is
|
||||
deliberate: it lets the numbers be internally consistent and freely shown
|
||||
without any risk of presenting fabricated data about a real company as if it
|
||||
were sourced. In a real analysis the same citations (`[FY26 AR, p.112]`) must
|
||||
point at real documents, and the non-negotiables — never invent a number,
|
||||
document-first sourcing, the recency gate — apply in full. **Do not lift any
|
||||
figure from these files into a real analysis.**
|
||||
|
||||
| File | Mode | What it demonstrates |
|
||||
|---|---|---|
|
||||
| `standard-analysis-example.md` | Standard | The full workflow on a (fictional) FMCG franchise: sector playbook and suppressed metrics, DuPont, working-capital and cash-conversion analysis, a document-sourced data-quality note with source tiers, a sector-relative scorecard with the gate disclosure, `valuation.py` output (EV bridge, trailing multiples, reverse-DCF implied growth, scenario table), a genuine bear case, and observable invalidation triggers. Passes `scripts/lint_report.py`. |
|
||||
| `forensic-analysis-example.md` | Forensic | A forensic read of the `evals/fixtures/synthetic-ar-excerpt.md` extracts (fictional Kesar Agro): the F0–F5 runbook, the accruals and proof-of-cash tests, the CARO and related-party evidence, and a "can these accounts bear weight?" verdict that stops short of valuation on purpose. |
|
||||
|
||||
Both were checked with the bundled gates: the standard example passes
|
||||
`python scripts/lint_report.py`, and its valuation section is the verbatim output
|
||||
of `python scripts/valuation.py` on the same inputs.
|
||||
|
|
@ -0,0 +1,84 @@
|
|||
# Forensic review — Kesar Agro Industries (NSE: KESARAGRO)
|
||||
|
||||
> **ILLUSTRATIVE EXAMPLE — FICTIONAL COMPANY.** Kesar Agro Industries Ltd does
|
||||
> not exist. This is a worked exemplar of the skill's Forensic-mode output, run
|
||||
> against the extracts in `evals/fixtures/synthetic-ar-excerpt.md`. Every figure
|
||||
> is invented. It illustrates method and tone — including the discipline of
|
||||
> describing what disclosure shows without asserting fraud — not a real finding.
|
||||
|
||||
**Verdict: D — Structural integrity risk.**
|
||||
As of 2026-08-02 · Basis: Consolidated · Currency/units: INR crore
|
||||
Most recent period incorporated: FY26 (ended 31-Mar-2026), audited. Pre-Q1-FY27.
|
||||
|
||||
---
|
||||
|
||||
## Document base
|
||||
|
||||
**Obtained:** FY26 annual report extracts — five-year highlights, Independent Auditor's Report (consolidated), CARO 2020 annexure, related-party note (38), contingent-liabilities note (39), four-quarter shareholding/pledge pattern, corporate-governance extract [all: Kesar Agro FY26 AR extract, §1–§7].
|
||||
|
||||
**Not obtained (and what each would test):** full notes to accounts and receivables ageing table (extent of the ₹210 cr >365-day receivable and its provisioning); MCA/ROC filings of Kesar Estates Pvt Ltd (whether the ₹180 cr advance is recoverable); prior-year annual reports in full (silent restatements); concall transcripts (management's account of the default and going-concern); rating rationale (liquidity grade). This is a **filings-extract-only** pass — but note that verdict D here rests on the auditor's own qualified opinion, which is decisive from the documents in hand.
|
||||
|
||||
## Summary
|
||||
|
||||
The accounts cannot be relied upon as presented. The auditor has issued a **qualified opinion** over an unprovided ₹180 cr interest-free advance to a promoter-controlled entity, and separately flags a **material uncertainty over going concern** [§2]. Independently, reported profit rose every year FY22–FY26 while operating cash flow was **negative and worsening** across the same period [§1], and the CARO annexure reports a term-loan default, unpaid statutory dues, evergreening, and — most concretely — that the receivables the company reported to its banks **do not agree with its books** [§3]. Several independent flags converge on the same place: profit has gone into receivables and related-party advances, not cash. The single most load-bearing unresolved item is the ₹180 cr advance, which alone exceeds three years of cumulative reported profit.
|
||||
|
||||
## Triage results
|
||||
|
||||
| # | Test | Result | Reading |
|
||||
|---|---|---|---|
|
||||
| 1 | Cash conversion (5y cumulative CFO/PAT) | CFO Σ(FY22–26) = −₹164 cr vs PAT Σ = +₹239 cr → **−0.69** [§1] | Profit is not becoming cash; it is reversing into cash *out*flow. Caps composite at 4.0. |
|
||||
| 2 | Implied yield on cash vs short rates | Interest income ₹3 cr ÷ avg cash ~₹200 cr = **~1.5%**, vs ~11% paid on borrowings [§1] | Cash earns far below the rate paid to borrow; either restricted/encumbered or not fully there. Cost of carry is value-destructive with no stated reason. |
|
||||
| 3 | Receivables vs sales | Receivables CAGR **27.9%** vs revenue CAGR **15.9%** (FY22–26); DSO 82 → 122 days [§1] | Sustained divergence; caps composite at 6.0. WC test below rules out the innocent reading. |
|
||||
| 4 | Capex vs depreciation | Not determinable from the extract | Flagged as a gap; full cash flow / PPE note needed. |
|
||||
| 5 | Audit opinion | **Qualified**, plus going-concern material uncertainty, plus prior auditor **resigned** mid-term [§2, §3] | Qualified opinion caps at 4.0; resignation without a clean reason caps at 4.5. Both are structural (D) signals. |
|
||||
| 6 | Related party & pledge | RP advance ₹40→95→**180 cr** interest-free; below-market RP sales; promoter pledge **18%→71%** [§4, §6] | Tunnelling indicators cap at 4.5; pledge >50% caps at 4.0. |
|
||||
|
||||
**Innocent-explanation test (mandatory before flagging #1/#3):** could the cash gap simply be a fast-growing, working-capital-heavy agri business? No. Receivables as a % of sales *rose* from 22.5% (FY22) to 33.5% (FY26) [computed, §1]. A stable ratio on a growing base would be growth; a *rising* ratio means the growth is being funded, not earned. The innocent reading does not survive.
|
||||
|
||||
## Findings
|
||||
|
||||
**F1 — Unprovided related-party advance (₹180 cr).**
|
||||
- *What the disclosure shows:* an interest-free advance to Kesar Estates Pvt Ltd (promoter-controlled), no repayment schedule, outstanding and growing three years, no provision; the auditor states profit before tax would be ₹180 cr lower if provided [§2, §4].
|
||||
- *Severity:* structural integrity risk.
|
||||
- *Innocent explanation:* a genuine, recoverable operational advance. But recoverability is precisely what the auditor could not evidence, and the balance grows yearly regardless of performance.
|
||||
- *What would resolve it:* Kesar Estates' MCA financials and the terms/security of the advance.
|
||||
- *Cluster:* joins the below-market RP sales (§4) and the ₹300 cr guarantee to the same entity (§5) — all pointing at promoter-group leakage.
|
||||
|
||||
**F2 — Profit-to-cash reversal, landing in receivables and RP advances.**
|
||||
- *What it shows:* PAT +₹239 cr cumulatively (FY22–26) against CFO −₹164 cr; over the same window receivables rose ~₹538 cr and RP advances ~₹140 cr [§1, §4].
|
||||
- *Severity:* structural.
|
||||
- *Innocent explanation:* WC-intensive growth — ruled out by the rising receivables/sales ratio above.
|
||||
- *What would resolve it:* the receivables ageing table and evidence of post-year-end collection.
|
||||
- *Cluster:* the CARO bank-returns-vs-books disagreement (F3) points at the *same* receivables line.
|
||||
|
||||
**F3 — CARO: books disagree with what lenders were told; plus default and arrears.**
|
||||
- *What it shows:* quarterly returns to banks overstated receivables vs the books by ~₹60 cr in three of four quarters; ₹95 cr term-loan default (120 days); ₹22 cr undisputed statutory dues unpaid >6 months; evergreening of related-party loans [§3].
|
||||
- *Severity:* structural. An auditor-attested reconciliation failure between the books and the lender statements is among the most concrete red flags in any annual report.
|
||||
- *Innocent explanation:* a timing/reconciliation error — but management only states it is "in the process of reconciling," and unpaid statutory dues are hard evidence of a cash squeeze (companies pay taxes last).
|
||||
- *Cluster:* corroborates F2 (the receivables are questionable) and the going-concern note.
|
||||
|
||||
**F4 — Contingent liabilities exceed net worth; governance instability.**
|
||||
- *What it shows:* contingent liabilities ₹420 cr (incl. a ₹300 cr guarantee for the promoter entity) vs net worth ₹350 cr; three CFOs in four years; mid-term auditor resignation citing information not made available; audit committee met twice; promoter is also Chairman/MD [§5, §7, §3].
|
||||
- *Severity:* structural (governance).
|
||||
- *What would resolve it:* it compounds rather than resolves the above — the guarantee ties the listed company's solvency to the same promoter entity that holds the unprovided advance.
|
||||
|
||||
## Quantified dependency
|
||||
|
||||
On a provisioned basis the group has not been profitable. Cumulative reported PAT for FY24–FY26 is ₹164 cr (48+55+61) [§1]; the **single ₹180 cr unprovided advance, if provided as the auditor implies, more than erases it** [§2]. That is before any provision against the ₹210 cr of >365-day receivables carried at a ₹9 cr allowance [§2], or the ~₹24 cr margin differential on ₹300 cr of related-party sales booked at 2% vs ~10% third-party [computed, §4]. Reported profit does not survive contact with the disclosed adjustments; no valuation should be built on it.
|
||||
|
||||
## Gates raised
|
||||
|
||||
- Qualified audit opinion → **cap 4.0** (checked, confirmed present).
|
||||
- 5y cumulative CFO/PAT < 0.5 → **cap 4.0** (checked, −0.69).
|
||||
- Related-party tunnelling indicators → **cap 4.5** (checked, present).
|
||||
- Promoter pledge > 50% → **cap 4.0** (checked, 71%).
|
||||
- Going-concern material uncertainty → structural (checked, present).
|
||||
|
||||
Multiple independent gates fire; the verdict is **D**, not a low numeric score, because valuation is moot until integrity is resolved.
|
||||
|
||||
## What was not verified
|
||||
|
||||
Filings-extract-only pass. Not verified: recoverability of the ₹180 cr advance (needs Kesar Estates' accounts); existence/encumbrance of the ₹210 cr cash (needs bank confirmations and the charge registry); the receivables ageing beyond the ₹210 cr >365-day figure; whether prior years were silently restated; management's own account (concall). None of these is needed to reach verdict D — the qualified opinion and going-concern uncertainty are decisive from the documents in hand — but each would sharpen the picture and none should be assumed clean.
|
||||
|
||||
---
|
||||
*This is analysis of publicly disclosed information, not an allegation of wrongdoing and not licensed financial advice. Findings describe what the disclosure does and does not explain; they are not conclusions of fraud. (Fictional worked example — company and figures invented.)*
|
||||
|
|
@ -0,0 +1,230 @@
|
|||
# Nirmal Consumer Products (NSE: NIRMAL) — Equity Analysis
|
||||
|
||||
> **ILLUSTRATIVE EXAMPLE — FICTIONAL COMPANY, INVENTED FIGURES.** Nirmal Consumer
|
||||
> Products Ltd does not exist. This file is a worked exemplar of the skill's
|
||||
> Standard-mode output; every citation below is to a fictional document. Do not
|
||||
> reuse any figure here for a real company.
|
||||
|
||||
**Analysis date:** 2026-08-02
|
||||
**Basis:** Consolidated · Ind-AS · ₹ crore (1 crore = 10 million)
|
||||
**Latest reported period:** FY26 (year ended 31-Mar-2026), audited.
|
||||
**Price reference:** ₹1,150 [NSE close, 2026-07-31] · **Market cap:** ₹23,000 cr · **EV:** ₹22,300 cr
|
||||
|
||||
**Depth mode: Standard.** Sector playbook: FMCG / branded consumer.
|
||||
|
||||
---
|
||||
|
||||
## RECENCY STATEMENT
|
||||
|
||||
- **Most recent reported period incorporated:** FY26 (ended 31-Mar-2026), results filed 09-May-2026; FY26 concall (12-May-2026) incorporated.
|
||||
- **Events checked through:** 2026-08-02. Q1 FY27 (Jun-2026) board meeting announced for 05-Aug-2026 — **not yet reported**; this analysis is pre-Q1-FY27.
|
||||
- **Material events since year-end:** final dividend of ₹6.0/share declared [FY26 AR, p.14]; a new ₹450 cr capacity expansion announced 20-Jun-2026 [exchange filing, 2026-06-20]. No rating action, block deal or governance event found.
|
||||
- **Invalidation trigger already tripped:** No.
|
||||
|
||||
## DATA QUALITY NOTE
|
||||
|
||||
| Item | Statement |
|
||||
|---|---|
|
||||
| **Primary sources (Tier 1)** | FY26 Annual Report (audited); FY22–FY25 Annual Reports; Q4 FY26 results filing (09-May-2026). |
|
||||
| **Company secondary (Tier 2)** | FY26 earnings-call transcript (12-May-2026); FY26 investor presentation. |
|
||||
| **Aggregators (Tier 4 — navigation/cross-check only)** | screener.in used only to locate filings and cross-check two figures; never cited as a source. |
|
||||
| **As-of dates** | Financials to 31-Mar-2026. Price/market cap 31-Jul-2026. Shareholding 30-Jun-2026. |
|
||||
| **Basis** | Consolidated throughout; standalone immaterial (subsidiaries <3% of revenue). |
|
||||
| **Currency/units** | ₹ crore unless stated. |
|
||||
| **Estimated** | `[E]`: maintenance capex split (~60% of gross capex); FY27 EPS in scenarios. All marked inline. |
|
||||
| **Missing** | Channel-level (IQVIA/AWACS) secondary offtake not disclosed — primary-vs-secondary check could not be run; flagged in §5.2. |
|
||||
|
||||
---
|
||||
|
||||
## VERDICT AND KEY RISKS
|
||||
|
||||
**Verdict:** An excellent branded-consumer franchise — wide distribution moat, ~32% ROCE, clean cash conversion, net cash — but the price already embeds ~18% FCF growth for a decade [reverse-DCF, valuation.py], which the company has not sustained. Quality high; margin of safety thin. **Confidence: high on business quality, low on the entry price being attractive.**
|
||||
|
||||
**Composite score: 7.1 / 10** (sector-relative, weights in §4) · **Playbook:** FMCG / branded consumer · **Situation flags:** none.
|
||||
|
||||
**Disqualifying gates: checked, none tripped.** Clean audit opinion, no promoter pledge, no related-party leakage, no auditor/CFO churn [FY26 AR, Auditor's Report & Note 34]. The score's drag is valuation, not quality or integrity.
|
||||
|
||||
**The three things that matter most:**
|
||||
1. **Distribution moat is widening.** Direct reach 1.35 m outlets, up from 0.9 m in FY22 [FY26 investor presentation, slide 9]; this is the durable asset, not any single brand.
|
||||
2. **Returns are high and cash-backed.** ROCE 32% [computed: EBIT 820 / capital employed 2,550, FY26 AR] with CFO/EBITDA of 88% [computed: CFO 806 / EBITDA 916, FY26 AR] — profit converts to cash.
|
||||
3. **The price is the risk.** P/E 41x / EV/EBITDA 24x [valuation.py] on a business growing revenue ~12%.
|
||||
|
||||
**Key risks:**
|
||||
1. **Multiple de-rating.** A re-rating from 41x to 30x P/E is ~−27% with no change in the business.
|
||||
2. **Volume slowdown.** FY26 volume growth was 7% [FY26 concall]; a slip to low-single-digits with input-cost inflation would compress the ~19% EBITDA margin.
|
||||
3. **Input-cost / competition.** Palm oil and packaging are ~40% of COGS [FY26 AR, p.96]; a spike, or aggressive private-label entry, pressures gross margin (52% [FY26 AR, p.88]).
|
||||
|
||||
**What would change the verdict:** see §10 — chiefly the price, and whether volume growth holds ≥6%.
|
||||
|
||||
---
|
||||
|
||||
## 1. The Business
|
||||
|
||||
Nirmal sells branded packaged foods (biscuits, snacks, spreads) to Indian consumers through ~1.35 m directly-served retail outlets [FY26 investor presentation, slide 9]. What the customer buys is a trusted, consistent, affordable brand available everywhere; the moat is **distribution density plus brand recall**, which compounds with scale.
|
||||
|
||||
- **Revenue build:** volume × price/mix. FY26 revenue ₹4,820 cr [FY26 AR, p.88], +12.3% YoY, decomposed as ~7% volume + ~5% price/mix [FY26 concall]. 5-year revenue CAGR 11.7% (FY22 ₹3,100 cr → FY26 ₹4,820 cr) [FY22 & FY26 AR].
|
||||
- **Mix:** biscuits 54%, snacks 31%, spreads 15% of revenue [FY26 AR, segment note p.104]; premium/"better-for-you" lines now 22% of sales, up from 14% in FY23 — the margin-mix driver.
|
||||
- **Cost structure:** gross margin 52.0% [FY26 AR, p.88]; commodity inputs (edible oil, wheat, sugar, packaging) ~40% of COGS [FY26 AR, p.96]; A&P spend 8.1% of sales.
|
||||
- **Cash-conversion path:** negative-to-neutral working capital — a structural FMCG strength; suppliers and the trade partly finance the business (§5.3).
|
||||
|
||||
---
|
||||
|
||||
## 2. Sector Classification and Playbook
|
||||
|
||||
**Sub-sector:** Branded packaged foods (FMCG). **Playbook:** `references/sectors/fmcg-consumer.md`.
|
||||
|
||||
**Why:** an annuity-like, brand-and-distribution business; the right lens is volume growth, gross/EBITDA margin, ROCE, working-capital cycle and reinvestment — not the metrics that suit asset-heavy or financial businesses.
|
||||
|
||||
**Metrics used with care / suppressed:**
|
||||
|
||||
| Standard metric | Status | Why |
|
||||
|---|---|---|
|
||||
| Net debt / EBITDA | n/a — net cash | Nirmal holds net cash of ₹700 cr [valuation.py EV bridge]; leverage ratios are not the constraint. |
|
||||
| EV/Sales in isolation | Use with care | 4.6x looks high cross-sector but is normal for a high-margin FMCG; read with EV/EBITDA. |
|
||||
| P/B | Low information | Brand and distribution value is off-balance-sheet; P/B 9.8x reflects that, not overvaluation per se. |
|
||||
|
||||
---
|
||||
|
||||
## 3. Situation Classification
|
||||
|
||||
No special situation — analysed as a going-concern operating business. No cyclicality overlay (FMCG demand is inelastic), no recent IPO, no holdco structure.
|
||||
|
||||
---
|
||||
|
||||
## 4. Scorecard
|
||||
|
||||
Sector-relative (FMCG) and vs Nirmal's own history. Anchor: 6 = peer-typical, 8 = clearly above, 3 = materially below.
|
||||
|
||||
| Category | Score /10 | Weight | Weighted | One-line rationale |
|
||||
|---|---:|---:|---:|---|
|
||||
| Business quality & moat | 8 | 18% | 1.44 | Widening distribution reach + premiumising mix; durable. |
|
||||
| Earnings quality | 8 | 12% | 0.96 | CFO/EBITDA 88%; no exceptionals; clean tax rate. |
|
||||
| Balance sheet | 8 | 8% | 0.64 | Net cash ₹700 cr; no pledge; low contingent liabilities. |
|
||||
| Cash flow | 7 | 12% | 0.84 | Strong CFO; FCF held back by growth capex (new plant). |
|
||||
| Returns on capital | 9 | 15% | 1.35 | ROCE 32%, ROE 24%; high incremental returns. |
|
||||
| Growth | 7 | 12% | 0.84 | ~12% revenue, 7% volume — good, not spectacular. |
|
||||
| Management & governance | 7 | 8% | 0.56 | Clean, professional; promoter 48%, no pledge; pay reasonable. |
|
||||
| Valuation | 3 | 15% | 0.45 | 41x P/E / 24x EV/EBITDA prices in ~18% growth for a decade. |
|
||||
| **Composite** | | **100%** | **7.1** | Excellent business, demanding price. |
|
||||
|
||||
**Weighting rationale:** FMCG default — moat and returns carry the most weight (an FMCG thesis is a compounding-quality thesis), with valuation held high (15%) because entry price is the main open question here.
|
||||
|
||||
---
|
||||
|
||||
## 5. Core Analysis by Dimension
|
||||
|
||||
### 5.1 Business Quality and Moat
|
||||
Evidence *for*: direct reach up 50% in four years (0.9 m → 1.35 m outlets) [FY26 presentation, slide 9]; premium mix 14%→22% of sales [FY23 & FY26 AR]; ROCE sustained ≥27% every year FY22–FY26 [computed from each AR] — high returns *held while competitors tried*, the real moat test. Evidence *against*: category is contestable at the value end; private label is a slow structural threat. Net: a widening, durable moat.
|
||||
|
||||
### 5.2 Earnings Quality
|
||||
|
||||
| Metric | FY26 | Own 3–5y | Read |
|
||||
|---|---|---|---|
|
||||
| CFO / EBITDA | 88% [computed 806/916] | 82–90% | Profit is cash. |
|
||||
| Effective tax rate | 25.1% [FY26 AR, p.92] | 25% band | Normal; no tax-driven flatter. |
|
||||
| Other income / PBT | 4% [FY26 AR, p.90] | <5% | Operating, not treasury-driven. |
|
||||
| Exceptionals | none [FY26 AR] | none | No add-back games. |
|
||||
|
||||
Caveat: channel secondary-offtake (IQVIA/AWACS) is not disclosed, so the primary-billing-vs-secondary check could not be run — a genuine gap, flagged in the Data Quality Note.
|
||||
|
||||
### 5.3 Balance Sheet
|
||||
Net cash ₹700 cr [valuation.py]; total borrowings ₹200 cr against ₹900 cr cash [FY26 AR, p.86]. No promoter pledge [shareholding pattern, Jun-2026]. Contingent liabilities ₹95 cr (~4% of net worth) — immaterial [FY26 AR, Note 39]. A fortress balance sheet; the ₹450 cr new-plant spend is comfortably self-funded.
|
||||
|
||||
### 5.4 Cash Flow
|
||||
CFO ₹806 cr [FY26 AR, cash flow statement]; gross capex ₹336 cr, of which ~₹135 cr [E] maintenance and the rest the new-plant growth spend → FCF (CFO − capex) ~₹470 cr [E]. Cumulative FCF FY22–FY26 ≈ ₹1,850 cr vs cumulative PAT ₹2,180 cr — ~85% conversion over five years, strong for a company also building capacity.
|
||||
|
||||
### 5.5 Returns on Capital
|
||||
ROCE 32% [computed: EBIT 820 / (equity 2,350 + debt 200), FY26 AR]; ROE 23.8% [560/2,350]. **DuPont:** net margin 11.6% × asset turnover 1.38x × leverage 1.49x = 23.8% [computed, FY26 AR]. Incremental ROCE on FY22→FY26 capital deployed ≈ 34% [E] — reinvestment is value-accretive, the core of the compounding case.
|
||||
|
||||
### 5.6 Growth
|
||||
Revenue CAGR 11.7% (5y); EBITDA CAGR 14% (margin expanded 17.2%→19.0% on premium mix) [FY22 & FY26 AR]; EPS ₹18.4 → ₹28.0. Growth is ~60% volume, ~40% price/mix — high quality. Share count flat (no dilution) [FY26 AR].
|
||||
|
||||
---
|
||||
|
||||
## 6. Peer Comparison
|
||||
|
||||
**Peer set (illustrative, fictional):** Anand Foods, Prakash Snacks, Vedic Consumer — branded-foods peers of similar scale and channel model. (In a real analysis these would be named listed comparables with sourced figures.)
|
||||
|
||||
Peer medians below are illustrative, FY26 basis [see note; real analysis would cite each peer's FY26 filing]:
|
||||
|
||||
| Metric | Nirmal | Peer median (illus.) | Read |
|
||||
|---|---|---|---|
|
||||
| Revenue CAGR 5y | 11.7% | 10% | Slightly ahead. |
|
||||
| Gross margin | 52% | 48% | Premium mix shows. |
|
||||
| EBITDA margin | 19% | 17% | Above median. |
|
||||
| ROCE | 32% | 26% | Above median — efficiency, not just margin. |
|
||||
| CFO/EBITDA | 88% | 82% | Cleaner cash. |
|
||||
| P/E | 41x | 44x | In line-to-slightly-cheaper vs a rich peer set. |
|
||||
|
||||
Nirmal sits modestly above the peer set on quality and roughly in line on multiple — a good business at a category-typical (rich) price, not a mispricing.
|
||||
|
||||
---
|
||||
|
||||
## 7. Valuation
|
||||
|
||||
**Method:** trailing multiples + reverse-DCF (implied-expectations) + scenario table, per `references/06-valuation.md`. The figures below are `scripts/valuation.py` output on the FY26 sourced inputs (price as of 2026-07-31).
|
||||
|
||||
EV bridge and trailing multiples [valuation.py on FY26 AR figures, price 2026-07-31]:
|
||||
|
||||
| Line | Value | | Multiple | Value |
|
||||
|---|---:|---|---|---:|
|
||||
| Market cap | ₹23,000 cr | | P/E | 41.1x |
|
||||
| + Total debt | ₹200 cr | | EV/EBITDA | 24.3x |
|
||||
| − Cash | ₹900 cr | | EV/EBIT | 27.2x |
|
||||
| = Enterprise value | ₹22,300 cr | | EV/Sales | 4.6x |
|
||||
| Net cash | ₹700 cr | | P/B | 9.8x |
|
||||
| | | | FCF yield | 2.0% |
|
||||
|
||||
Reverse-DCF and forward DCF [valuation.py, as of 2026-07-31]:
|
||||
|
||||
| Output | Assumptions | Value |
|
||||
|---|---|---:|
|
||||
| Reverse-DCF implied FCF growth | WACC 11%, 10y, terminal 5% | ~18.3%/yr |
|
||||
| Forward DCF value/share | 13% 10y, fade 5y, terminal 5%, WACC 11% | ₹861 |
|
||||
| Terminal share of EV | — | 52% |
|
||||
| Forward DCF vs price | vs ₹1,150 | −25% |
|
||||
|
||||
**Reverse-DCF read (the testable claim):** at ₹1,150 the market embeds **~18% FCF growth for a decade** [valuation.py]. Nirmal has grown FCF ~14% over five years and revenue ~12% — so the price requires an *acceleration* the record does not evidence. That is the crux of the "quality high, price demanding" verdict.
|
||||
|
||||
**Scenario table** [valuation.py, EPS × exit P/E, as of 2026-07-31; probabilities are judgements]:
|
||||
|
||||
| Scenario | Prob | Assumptions | Value/share | vs ₹1,150 |
|
||||
|---|---:|---|---:|---:|
|
||||
| Bear | 30% | volume fades to 3–4%, de-rate to 28x on ₹24 EPS [E] | ₹672 | −42% |
|
||||
| Base | 50% | ~11% growth holds, 38x on ₹31 EPS [E] | ₹1,178 | +2% |
|
||||
| Bull | 20% | premiumisation accelerates, 46x on ₹35 EPS [E] | ₹1,610 | +40% |
|
||||
| **Prob-weighted** | 100% | | **₹1,113** | **−3%** |
|
||||
|
||||
The probability-weighted value sits ~3% below the current price: a wonderful business priced for its own success, with a roughly symmetric-to-slightly-negative one-year skew.
|
||||
|
||||
---
|
||||
|
||||
## 8. Red Flags and Governance
|
||||
|
||||
**No material red flags identified.** Checked and clear: clean unqualified audit opinion [FY26 AR, Auditor's Report]; no CARO qualifications [FY26 AR, CARO annexure]; no promoter pledge, promoter holding stable at 48% [shareholding pattern, Jun-2026]; related-party transactions immaterial and arm's-length [FY26 AR, Note 34]; promoter remuneration ~2% of PAT; no auditor or CFO change in five years; contingent liabilities ~4% of net worth.
|
||||
|
||||
---
|
||||
|
||||
## 9. The Bear Case
|
||||
|
||||
Nirmal is a very good business trading at a price that assumes it stays very good *and* gets faster. At 41x earnings and 24x EV/EBITDA, the reverse-DCF says the market is paying today for ~18% FCF growth for ten years — yet the company has compounded revenue at ~12% and FCF at ~14%, with FY26 volume growth of just 7% in a category where the value end is contestable and private label is advancing. FMCG multiples have de-rated before when volume growth stalled; a slip to mid-single-digit volumes with any input-cost inflation would compress the ~19% margin *and* the multiple simultaneously — the two forces that make the bear scenario −42%. Nothing needs to go wrong with the franchise for the *stock* to disappoint; the price has borrowed years of future growth into the present.
|
||||
|
||||
**Strongest counter (kept honest):** the distribution moat is genuinely widening (reach +50% in four years), returns are ~32% and cash-backed, premiumisation is a real and continuing margin lever, and the balance sheet is net cash — so a long runway of low-teens compounding is plausible, and for a patient owner the *business* will likely be worth materially more in a decade even if the *entry multiple* is unrewarding for a year or two.
|
||||
|
||||
---
|
||||
|
||||
## 10. Thesis-Invalidation Triggers
|
||||
|
||||
| # | Trigger | Where to observe | By when | Action if hit |
|
||||
|---|---|---|---|---|
|
||||
| 1 | Volume growth falls below 5% for two consecutive quarters | Quarterly results / concall | By Q3 FY27 | Growth-durability leg weakens — revisit. |
|
||||
| 2 | Gross margin falls below 49% for two quarters | Quarterly results | FY27 | Input-cost/competition pressure confirmed. |
|
||||
| 3 | CFO/EBITDA falls below 75% | FY27 annual cash flow | FY27 AR | Earnings-quality leg breaks. |
|
||||
| 4 | Promoter pledge appears, or holding falls materially | Shareholding pattern | Any quarter | Governance re-review. |
|
||||
| 5 | Any acquisition paid at >5x EV/Sales outside core categories | Exchange filing / AR | Any time | Capital-allocation discipline in question. |
|
||||
|
||||
---
|
||||
|
||||
## Disclaimer
|
||||
|
||||
This document is research and analysis for informational purposes only. It is **not** investment advice, not a recommendation to buy, sell or hold any security, and not a personalised financial recommendation. The author is not a licensed or registered investment adviser. **This is a fictional worked example: the company and all figures are invented.** Any real investment decision is the reader's own responsibility and should be made in consultation with a licensed financial adviser.
|
||||
315
finance/skills/stock-analysis/references/01-data-sourcing.md
Normal file
315
finance/skills/stock-analysis/references/01-data-sourcing.md
Normal file
|
|
@ -0,0 +1,315 @@
|
|||
# Data Sourcing and Verification
|
||||
|
||||
Use this when: you are about to pull any number into an analysis, or you are checking a figure someone else supplied.
|
||||
|
||||
Every downstream judgment — margin quality, leverage, valuation, sector positioning — inherits the reliability of the numbers you started with. A wrong unit, a standalone-vs-consolidated mix-up, or a stale price destroys a conclusion more thoroughly than a weak argument does, and it does so invisibly. Sourcing discipline is not bookkeeping hygiene; it is the first analytical step. The governing rule of this skill applies here too: a figure without its sector, its period and its basis of preparation is not yet a fact.
|
||||
|
||||
## Contents
|
||||
|
||||
- [1. Primary vs secondary sources](#1-primary-vs-secondary-sources)
|
||||
- [2. India: where the data lives](#2-india-where-the-data-lives)
|
||||
- [3. Global / US: where the data lives](#3-global--us-where-the-data-lives)
|
||||
- [4. The verification protocol](#4-the-verification-protocol)
|
||||
- [5. Consolidated vs standalone](#5-consolidated-vs-standalone)
|
||||
- [6. Units, currency and the 10x error](#6-units-currency-and-the-10x-error)
|
||||
- [7. Fiscal-year alignment and period labelling](#7-fiscal-year-alignment-and-period-labelling)
|
||||
- [8. Restatements, reclassifications and discontinued operations](#8-restatements-reclassifications-and-discontinued-operations)
|
||||
- [9. As-of dates for price, market cap and multiples](#9-as-of-dates-for-price-market-cap-and-multiples)
|
||||
- [10. Common data-provider errors and ambiguous fields](#10-common-data-provider-errors-and-ambiguous-fields)
|
||||
- [11. Sector-specific sourcing traps](#11-sector-specific-sourcing-traps)
|
||||
- [12. When web access is unavailable or data is paywalled](#12-when-web-access-is-unavailable-or-data-is-paywalled)
|
||||
- [13. Never fabricate](#13-never-fabricate)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 1. Source hierarchy — documents are the only source of record
|
||||
|
||||
This is a **document-first** skill. Every financial figure in the analysis must trace to a raw company document. Rank sources by how many hands the number has passed through, and note the hard boundary between Tiers 1–3 and Tier 4.
|
||||
|
||||
### Tiers 1–3: Sources of record
|
||||
|
||||
Figures from these sources may be cited in the analysis.
|
||||
|
||||
| Tier | What it is | Use it for |
|
||||
|---|---|---|
|
||||
| 1. Primary filing | Annual report, 10-K/10-Q, exchange filing (quarterly results), audited financial statements, prospectus (DRHP/RHP/S-1) | Any figure that carries weight in the conclusion — this is the default source |
|
||||
| 2. Company-published secondary | Investor presentation, earnings release, concall transcript, IR fact sheet | Segment detail, management commentary, guidance, operating KPIs not in the statements |
|
||||
| 3. Regulator/third-party primary | SEBI/MCA/ROC records, credit rating rationales, exchange bulk-deal and shareholding data | Ownership, pledges, related-party context, debt structure, covenants |
|
||||
|
||||
### Tier 4: Navigation and cross-check only — NOT a source of record
|
||||
|
||||
| Tier | What it is | Permitted use |
|
||||
|---|---|---|
|
||||
| 4. Aggregators | screener.in, Tikr, Yahoo/Google Finance, stockanalysis.com, broker terminals, Wikipedia | (a) Locating the actual documents — e.g. screener.in links to annual reports and concall transcripts. (b) Spotting outliers to investigate in the filing. (c) Optional labelled cross-check *after* a figure is already sourced from a Tier 1–3 document. |
|
||||
|
||||
**Hard rule: an aggregator figure must never appear as a cited source in the report.** If a figure exists only in an aggregator and cannot be traced to any Tier 1–3 document, it is `not sourced` — write it as such. Aggregators normalize thousands of filings with rules that cannot fit every company, and their exception handling is invisible to you. When an aggregator figure and a filing figure disagree, the filing wins — and the disagreement itself is information.
|
||||
|
||||
Aggregator figures *may* appear alongside a document-sourced figure as a labelled cross-check: `"Revenue ₹4,820 cr (FY25 AR p.112; screener.in agrees at ₹4,818 cr)"`. They must never stand alone.
|
||||
|
||||
**One exception: current share price and market cap** are inherently sourced from exchange or finance websites. These must carry an as-of date and time.
|
||||
|
||||
Cite the tier in your notes. `"Revenue INR 4,820 cr (FY25, consolidated, annual report p.112)"` is usable. `"Revenue ~4,800 cr"` is not. `"Revenue 4,800 cr (screener.in)"` is not — it fails the document-first rule.
|
||||
|
||||
---
|
||||
|
||||
## 2. India: where the data lives
|
||||
|
||||
**Company investor-relations page.** The canonical starting point. Look for: annual reports (usually 5-10 years archived), quarterly results, investor presentations, earnings call transcripts and audio, press releases, and often an "investor contact" address. IR pages are the fastest route to the actual PDF of the annual report; exchange sites host the same document but with worse navigation.
|
||||
|
||||
**Annual report (India-specific structure).** Under the Companies Act 2013, an Indian annual report contains, in order of analytical value:
|
||||
- Standalone **and** consolidated financial statements with schedules/notes — the notes are where the analysis actually is.
|
||||
- **Management Discussion & Analysis (MD&A)** — segment commentary, sometimes volume and realization data.
|
||||
- **CARO report** (Companies Auditor's Report Order) — an underused goldmine. It forces the auditor to comment on fixed-asset verification, inventory discrepancies, loans to related parties, statutory dues in arrears, default in repayment of borrowings, fraud reported, and whether funds raised for one purpose were used for another. Read every CARO qualification.
|
||||
- **Auditor's report**: check for qualified/adverse/disclaimer opinions, Emphasis of Matter, and Key Audit Matters (KAMs). KAMs tell you which numbers the auditor itself found hardest.
|
||||
- **Related party transactions note** — sales, purchases, loans, guarantees to promoter-linked entities.
|
||||
- **Contingent liabilities note** — disputed tax demands, guarantees, litigation. Frequently larger than net worth in infra and telecom.
|
||||
- **Corporate governance report** and **Business Responsibility & Sustainability Report (BRSR)** for larger listed companies.
|
||||
- **Secretarial audit report** (Form MR-3).
|
||||
|
||||
**NSE and BSE filings and announcements.** Every listed company files quarterly results, shareholding patterns, board-meeting outcomes, material events under SEBI LODR Regulation 30, analyst-meet intimations, credit-rating changes, resignations of directors/auditors/KMP, and pledge disclosures. Search by company on nseindia.com (Corporate Filings) or bseindia.com (Corporate Announcements). Announcements are timestamped — use the exchange timestamp, not a news article's, when sequencing events.
|
||||
- **Regulation 30 disclosures** are where acquisitions, order wins, plant shutdowns, fires, regulatory actions and litigation first appear.
|
||||
- **Auditor resignation** filings and **independent-director resignations with reasons** are high-signal governance events.
|
||||
|
||||
**Shareholding pattern filings (quarterly, both exchanges).** Gives promoter holding, promoter **pledge** (as % of promoter holding and % of total shares — note which one a source quotes), FII/FPI, DII (mutual funds, insurance), public and, for many companies, the list of shareholders holding above 1%. Track the trend, not the level: a promoter stake declining over consecutive quarters, or pledge rising, deserves an explanation you should find in filings rather than infer.
|
||||
|
||||
**Aggregators — navigation and cross-check only.** Sites like screener.in, Tikr, and stockanalysis.com are useful for two things: (a) *finding* the actual documents — screener.in links directly to annual reports and concall transcripts, which is its most valuable feature; and (b) spotting outliers in ratio history or peer sets that you then investigate in the filing. Their computed ratios, standardized financials, TTM columns, and median calculations reflect invisible normalization choices that may not match the company's actual reporting. **Do not extract figures from these sites as your source.** Navigate through them to reach the document, then extract from the document. If you use an aggregator figure as a cross-check alongside a document-sourced number, label it explicitly as such.
|
||||
|
||||
**MCA / ROC (Ministry of Corporate Affairs).** The route to unlisted entities: promoter holding companies, subsidiaries, JV partners, related parties, and the private companies behind a group structure. Filed documents include AOC-4 (financial statements), MGT-7 (annual return), charges registered against assets (useful for spotting secured debt not obvious from the consolidated balance sheet), and director/DIN records for cross-directorship mapping. Many documents are pay-per-download.
|
||||
|
||||
**SEBI.** Regulatory orders and adjudication (enforcement against companies, promoters, intermediaries), takeover/SAST disclosures, insider-trading (PIT) disclosures, buyback and open-offer documents, and the mutual-fund and FPI regulatory framework. A SEBI order naming the promoter is a governance fact of the first order.
|
||||
|
||||
**Credit rating agency rationales — CRISIL, ICRA, CARE, India Ratings, Brickwork.** Free, detailed, and often the single best third-party document on a company's debt. A rationale typically gives: rated instruments and amounts, the agency's own computed leverage and coverage ratios, key rating drivers and sensitivities (explicit numeric thresholds for upgrade/downgrade), liquidity assessment, and the group structure the agency consolidates. Ratings history matters more than the current rating — a sequence of downgrades or a move to "Rating Watch with Negative Implications" precedes trouble more reliably than any screen. Also check for **"Issuer Not Cooperating" (INC)** tags: a company that stopped supplying information to its rating agency is telling you something.
|
||||
|
||||
**Concall transcripts.** Usually on the IR page, on exchange filings, and aggregated by screener.in and transcript services. Read the Q&A, not the prepared remarks — the prepared remarks are the press release read aloud. Note: which analysts cover the company, which questions management deflects, whether guidance given last quarter was met, and specific numbers management volunteers (volumes, realizations, capacity utilization, order book, segment margins) that never appear in the statements. Quote the speaker and the quarter when you use them.
|
||||
|
||||
**DRHP / RHP (for IPOs and recent listings).** The Draft Red Herring Prospectus is the most information-dense document that exists on an Indian company: multi-year restated financials, risk factors written by lawyers who must disclose, litigation schedules (including against promoters and directors), objects of the issue, promoter background, related-party history, KPI disclosures with a management justification, and peer comparison. For a company listed in the last 3-4 years, always read the DRHP even though it is old — it explains the pre-IPO structure the current filings assume you know.
|
||||
|
||||
**Other Indian sources.** RBI (banking sector data, sectoral credit deployment), industry bodies (SIAM for autos, CMIE, ICRA/CRISIL sector reports), IBBI (insolvency filings against the company or its counterparties), GST and customs data vendors (paid), and the company's own regulatory filings with sector regulators (IRDAI, TRAI, CERC, PNGRB).
|
||||
|
||||
---
|
||||
|
||||
## 3. Global / US: where the data lives
|
||||
|
||||
**SEC EDGAR** is the primary source for US registrants and for foreign companies with US listings. Use full-text search and the company's filing index.
|
||||
|
||||
| Form | What it contains | Analytical use |
|
||||
|---|---|---|
|
||||
| 10-K | Annual report: audited statements, MD&A, risk factors, Item 1 business description, segment note, controls | The base document. Item 7 MD&A and the segment note carry most of the signal |
|
||||
| 10-Q | Quarterly, unaudited, condensed | Trend within the year; note the comparatives are prior-year quarter, not sequential |
|
||||
| 8-K | Material events: earnings release (Item 2.02), leadership change, acquisition, auditor change (Item 4.01), impairment (Item 2.06), covenant default | Timeline of events; the earnings press release is an 8-K exhibit |
|
||||
| DEF 14A (proxy) | Executive compensation, incentive metrics, board composition, auditor fees, shareholder proposals, related-party transactions | Tells you what management is actually paid to maximize — often diverges from what they say on calls |
|
||||
| Form 4 | Insider transactions within 2 business days | Insider buying/selling; distinguish open-market purchases from option exercises and 10b5-1 plan sales |
|
||||
| SC 13D/13G, 13F | Large holders; institutional quarterly positions | Ownership concentration and activist presence |
|
||||
| S-1 / F-1 | IPO registration | The global analogue of the DRHP |
|
||||
| 20-F / 40-F | Foreign private issuers (annual), often IFRS | Non-US companies with US listings; note IFRS-GAAP reconciliation is no longer required |
|
||||
| 6-K | Foreign private issuer interim reports | Quarterly data for 20-F filers, format varies by home market |
|
||||
| NT 10-K / NT 10-Q | Late-filing notification | A material red flag; read the stated reason |
|
||||
|
||||
Also: **XBRL "Financial Statement Data Sets"** and the EDGAR company-facts JSON API give machine-readable tagged figures straight from filings — use them when you need many periods, but check the tag actually maps to the line item you think it does (companies use extension tags liberally).
|
||||
|
||||
**Non-US primary sources.** UK: Companies House plus the RNS regulatory news service. EU: national registries plus the issuer's own regulatory news; ESEF-tagged annual reports. Japan: EDINET and TDnet. Canada: SEDAR+. Australia: ASX announcements. Hong Kong: HKEXnews. Each has its own equivalent of "material event" filings — find it before concluding nothing happened.
|
||||
|
||||
**Company IR and annual reports (global).** Under IFRS, the annual report structure differs from the 10-K: strategic report, governance and remuneration report, then statements with notes. Segment reporting under IFRS 8 and ASC 280 both follow the "management approach", meaning segments reflect how the CEO sees the business — which is itself information, and which changes when management changes.
|
||||
|
||||
**Earnings call transcripts.** Company IR sites increasingly post them directly; otherwise use transcript providers. Same rule as India: the Q&A carries the signal. Track guidance given versus guidance delivered across four to eight quarters — this is the cheapest available test of management credibility.
|
||||
|
||||
**Other global.** Central bank and statistical agencies for macro inputs; industry regulators; rating agency reports (Moody's/S&P/Fitch — summaries often free, full reports paywalled); bond prospectuses and covenant packages when leverage matters.
|
||||
|
||||
---
|
||||
|
||||
## 4. The verification protocol
|
||||
|
||||
Apply this to every figure that could change a conclusion.
|
||||
|
||||
**1. Cite source and period, always.** Format: `value + unit + basis + period + source`. Example: `EBITDA margin 14.2% (FY25, consolidated, computed from annual report P&L, p.104)`. If you cannot state all five, you do not yet have the figure. This is not formatting pedantry — most sourcing errors become visible the moment you try to write the full citation and find one field missing.
|
||||
|
||||
**2. Cross-check headline figures across two independent sources — at least one must be a primary document (Tier 1–3).** Headline = revenue, EBITDA/operating profit, PAT, total debt, equity, operating cash flow, share count, market cap. Independent means the two sources did not derive from each other: an aggregator and a news article that both copied the press release are one source, not two. Two aggregators are also not a valid cross-check — at least one side must be a document. Filing vs rating rationale, or annual report vs quarterly results filing, is a real cross-check. Filing vs aggregator is acceptable as the second source, but the aggregator figure is the cross-check, not the source of record.
|
||||
|
||||
**3. Reconcile any discrepancy before proceeding.** A gap of a few percent is usually a definitional difference (other income in/out of EBITDA, leases, minority interest). A gap above ~10% usually means different basis, different period, or different units. Do not average two numbers you cannot reconcile — find which one is right, or report both with their definitions.
|
||||
|
||||
**4. The primary document always wins.** If the aggregator says one thing and the audited statement says another, use the statement and note the aggregator's error, because that error probably contaminates the aggregator's ratios too. The aggregator figure is never an acceptable substitute for a document-sourced one — it may appear only as a labelled cross-check.
|
||||
|
||||
**5. Recompute rather than accept.** Derived metrics — ROCE, ROE, net debt/EBITDA, working capital days, FCF — should be computed by you from raw line items you have sourced, with your formula stated. Providers differ on almost every one of these (see §10). Recomputing also forces you to see the components, which is where the story is.
|
||||
|
||||
**6. Sanity-check against the real world.** Does implied revenue per store, per tonne, per employee, per subscriber make sense? Does the balance sheet balance? Do the three statements tie (PAT to cash flow opening line, closing cash to balance sheet)? Does the growth rate imply a market share that exceeds the market? An arithmetic check costs seconds and catches transcription errors that reasoning will not.
|
||||
|
||||
**7. Flag single-sourced figures explicitly.** Where a number could not be corroborated, say so in the output: "single source, unverified". A reader can discount a flagged number; they cannot discount one presented with false confidence.
|
||||
|
||||
---
|
||||
|
||||
## 5. Consolidated vs standalone
|
||||
|
||||
India-specific in emphasis, but the same issue exists globally as parent-only versus group accounts.
|
||||
|
||||
- **Consolidated** includes subsidiaries line-by-line, associates/JVs by equity method, and shows non-controlling (minority) interest separately. **Standalone** is the parent company only, with subsidiary income appearing mostly as dividends and investments held at cost.
|
||||
- **Default to consolidated** for operating and valuation analysis. It reflects the economic entity that the equity actually owns.
|
||||
- **Never mix the two** within a ratio. Consolidated EBITDA over standalone debt, or consolidated PAT over a standalone equity base, produces numbers that look plausible and are meaningless.
|
||||
- **PAT must be after minority interest** ("profit attributable to owners of the parent") when computing EPS, ROE or P/E. Providers get this wrong regularly for holding-company structures.
|
||||
- **When the gap is large, investigate it.** A parent with much higher standalone margins than consolidated is carrying loss-making subsidiaries. The reverse suggests value sits in subsidiaries — then ask who else owns them.
|
||||
- Watch for **subsidiary debt without recourse to the parent**, **associates carried at equity whose losses are capped at carrying value**, and **structured entities**. Rating rationales are useful here because agencies state their own consolidation perimeter explicitly.
|
||||
- For **holding companies and conglomerates**, consolidated statements can obscure more than they reveal; you may need a sum-of-parts using subsidiary-level filings from MCA or the subsidiaries' own listings.
|
||||
- Older Indian data pre-Ind AS (before FY16-17 phase-in) is not directly comparable to later years — Ind AS changed revenue recognition, leases (Ind AS 116 from FY20), financial-instrument measurement and consolidation of certain entities. Say so when your series crosses the boundary. The same applies globally to ASC 606 (revenue) and ASC 842 / IFRS 16 (leases), which moved operating leases onto the balance sheet and shifted rent expense into depreciation and interest — inflating EBITDA and leverage simultaneously.
|
||||
|
||||
---
|
||||
|
||||
## 6. Units, currency and the 10x error
|
||||
|
||||
This is the single most common serious error and the easiest to prevent.
|
||||
|
||||
- Indian numbering: **1 lakh = 100,000**; **1 crore = 10,000,000 = 10 million**. So **1 crore = 10 million**, and **100 crore = 1 billion**. The recurring failure is treating a crore as a million, understating by 10x, or treating 1 crore as 0.1 billion correctly but then mishandling the next conversion.
|
||||
- Indian filings variously present in `₹ crore`, `₹ lakh`, `₹ million`, or `₹ '000`. **Read the column header on every table, every time** — the unit sometimes differs between the P&L and a note in the same document.
|
||||
- Indian listed companies increasingly report in `₹ crore` in presentations but `₹ million` or `₹ lakh` in statutory statements. Fix the unit at the point of extraction, not later.
|
||||
- State the currency explicitly (`INR`, `USD`, `EUR`) — `$` is ambiguous across USD/SGD/HKD/AUD/CAD, and `₹` vs other symbols matters in copy-paste.
|
||||
- For cross-currency comparison, state the **FX rate and its date**. Never compare a market cap converted at today's rate with earnings converted at an average rate without saying so. For multi-year series, decide and state whether you use period-average or period-end rates, and be consistent.
|
||||
- Per-share figures: check the **face value** (Indian shares are commonly ₹1, ₹2, ₹5 or ₹10 par) and adjust historic per-share series for **splits and bonus issues**. An unadjusted EPS series with a 1:1 bonus in the middle shows a fake 50% collapse.
|
||||
- ADR/GDR ratios distort per-share comparison between the local line and the US line.
|
||||
- Percentages: distinguish **basis points** from percent, and **percentage-point change** from **percent change** (margin moving 10% to 11% is +100 bps, or +10% relative — say which).
|
||||
|
||||
Quick conversion table to keep in working memory:
|
||||
|
||||
| Indian unit | Numeric | USD-scale equivalent |
|
||||
|---|---|---|
|
||||
| 1 lakh | 1e5 | 0.1 million |
|
||||
| 1 crore | 1e7 | 10 million |
|
||||
| 100 crore | 1e9 | 1 billion |
|
||||
| 1,000 crore | 1e10 | 10 billion |
|
||||
| 1 lakh crore | 1e12 | 1 trillion |
|
||||
|
||||
(USD-scale column is unit scale only, not an FX conversion.)
|
||||
|
||||
---
|
||||
|
||||
## 7. Fiscal-year alignment and period labelling
|
||||
|
||||
- **India**: fiscal year runs 1 April to 31 March. "FY25" almost always means the year ended 31 March 2025 — but confirm, because some Indian companies (and most Indian subsidiaries of foreign groups) use December or June year-ends. Quarters: Q1 = Apr-Jun, Q2 = Jul-Sep, Q3 = Oct-Dec, Q4 = Jan-Mar.
|
||||
- **US/global**: fiscal years vary widely; retailers commonly end in late January/early February, and many companies use 52/53-week years where one year has an extra week (a ~2% distortion to annual growth that management will mention and providers will not).
|
||||
- Company "FY2025" labels can refer to the year *beginning* or *ending* in 2025 depending on jurisdiction and company convention. When comparing across companies, **convert everything to the calendar period covered** and say so: "year ended Mar-2025" beats "FY25".
|
||||
- Never compare an Indian FY-ending-March figure with a US calendar-year figure without noting the ~3-month offset, particularly across a macro inflection.
|
||||
- Indian quarterly results are **limited-review, not audited** (except often Q4, which is derived as full-year audited minus nine months and therefore absorbs all year-end adjustments — Q4 is systematically the noisiest quarter).
|
||||
- **TTM/LTM figures**: state the exact window ("TTM to Sep-2025"). A TTM built by adding quarters must handle restated prior quarters and any change in consolidation perimeter mid-year.
|
||||
- Seasonality: compare year-over-year, not sequentially, unless you have established the seasonal pattern from at least three years of the company's own history.
|
||||
|
||||
---
|
||||
|
||||
## 8. Restatements, reclassifications and discontinued operations
|
||||
|
||||
- When the current annual report's prior-year column differs from what that prior report published, the prior year was **restated or reclassified**. Use the latest restated series for trend analysis and note the restatement; using the original numbers creates phantom growth or decline.
|
||||
- Distinguish innocuous **reclassification** (moving a cost between lines, new segment definitions) from a **correction of error** or **change in accounting policy**, which are disclosed in the notes and are far more serious. Read the note; it says which.
|
||||
- **Discontinued operations** are presented separately and prior periods are re-presented. Revenue growth computed across the boundary without adjustment is wrong in both directions.
|
||||
- **Mergers, demergers, slump sales and scheme-of-arrangement effective dates** (common in India, often with retrospective appointed dates) can make one year non-comparable. The scheme details are in the annual report and in exchange filings.
|
||||
- **Segment redefinitions** typically arrive with a new CEO or a reorganization. When segments change, either rebuild history from the re-presented comparatives the company gives, or start the series fresh — do not splice.
|
||||
- **Auditor changes** near a restatement deserve scrutiny; check the 8-K Item 4.01 (US) or the exchange filing and the outgoing auditor's stated reason (India).
|
||||
|
||||
---
|
||||
|
||||
## 9. As-of dates for price, market cap and multiples
|
||||
|
||||
- Stamp every price-derived figure with a date and preferably a time: `P/E 28.4x (price as of close 18-Jul-2026)`. Multiples decay the moment the price moves; an undated multiple is a claim with no verifiable content.
|
||||
- **Market cap** = current price × current fully-diluted-relevant share count. Check the share count against the latest filing, not a stale field: buybacks, QIPs, preferential allotments, ESOP exercises, conversion of warrants/convertibles and rights issues all move it, and aggregators lag.
|
||||
- Distinguish **basic**, **diluted** and **fully diluted** share counts, and say which you used. For companies with large option pools or outstanding convertibles, the difference is material.
|
||||
- **Enterprise value** = market cap + debt + minority interest + preferred − cash and equivalents (and, depending on convention, − investments in associates, ± lease liabilities). State your formula. EV comparisons are only valid when everyone in the peer set used the same formula, which is why you should compute the whole peer set yourself.
|
||||
- Match numerator and denominator periods: a current price over a trailing EPS is a trailing multiple; over a consensus estimate it is a forward multiple, and you must state whose estimate and as of when.
|
||||
- **Free float** matters in India, where promoter holding is often 50-75%. Market cap overstates the investable base, and low-float names have unreliable price signals.
|
||||
- For price history, note whether the series is **adjusted for splits, bonuses and dividends** — and remember that total-return series and price series diverge substantially over long horizons in high-dividend sectors.
|
||||
|
||||
---
|
||||
|
||||
## 10. Common data-provider errors and ambiguous fields
|
||||
|
||||
The list below is not about bad vendors; it is about fields that have no single correct definition. Whenever a metric appears here, compute it yourself and state your formula.
|
||||
|
||||
| Field | How it goes wrong |
|
||||
|---|---|
|
||||
| EBITDA | Some include other income, some exclude; treatment of exceptional items, ESOP cost and post-IFRS 16/Ind AS 116 lease costs varies. Post-lease-standard EBITDA is not comparable to pre-standard EBITDA |
|
||||
| Operating profit (India usage) | Often quoted as EBITDA excluding other income; screener.in and broker notes may differ from the company's own presentation |
|
||||
| Net profit / PAT | Before vs after minority interest; before vs after exceptional items; continuing vs total operations |
|
||||
| ROE / ROCE | Opening, closing or average capital; capital employed with or without cash, CWIP, goodwill, deferred tax; numerator pre- or post-tax. Ranges of 3-5 percentage points arise from definition alone |
|
||||
| Total debt | Whether short-term borrowings, current maturities of long-term debt, lease liabilities, acceptances/LC-backed trade financing, and preference shares are included. Indian companies frequently carry large **bill discounting / channel financing** that behaves like debt but sits in payables |
|
||||
| Net debt | Which "cash" counts — some current investments and mutual-fund holdings are cash-like, some are not; restricted cash and margin money should be excluded |
|
||||
| Cash flow from operations | Interest paid and taxes may be classified in operating, investing or financing under IFRS/Ind AS at the company's choice; that choice makes OCF non-comparable across peers |
|
||||
| Free cash flow | OCF − capex, but capex may or may not include intangibles, acquisitions, capitalized R&D, capitalized interest and lease payments |
|
||||
| Working capital days | Computed on revenue vs COGS, on closing vs average balances, on gross vs net receivables. Days differ by 20%+ across conventions |
|
||||
| Book value / equity | With or without minority interest, revaluation reserves, treasury shares; Indian "net worth" definitions in loan covenants often exclude intangibles |
|
||||
| Share count | Point-in-time vs weighted average; basic vs diluted; unadjusted for recent corporate actions |
|
||||
| Dividend yield | Trailing declared vs paid vs ex-date basis; special dividends included or not; India's dividend taxation changed in FY21, breaking older payout series |
|
||||
| Growth rates | Base-period restatement not applied; 52/53-week years; acquisitions not separated from organic |
|
||||
| Sector/industry tag | Aggregator classifications are crude. A "diversified" or "trading" tag can hide the actual business. Always read the business description before accepting a peer set |
|
||||
| Promoter holding / pledge (India) | Pledge quoted as % of promoter holding in one place and % of total equity in another — a 3x-5x apparent difference |
|
||||
| Market cap | Stale share count; separate listing lines for different share classes counted or omitted |
|
||||
| "Employees" | Permanent vs contract vs total headcount; Indian filings often disclose only median remuneration and top-earner counts |
|
||||
|
||||
Two structural cautions: aggregator ratio history is often recomputed on today's definitions and applied backwards inconsistently; and any field that is blank in the filing may appear as zero (not null) in a provider's data, which then propagates into averages.
|
||||
|
||||
---
|
||||
|
||||
## 11. Sector-specific sourcing traps
|
||||
|
||||
Consistent with the skill's governing principle — the standard ratios are undefined or inverted for several sectors, and so are the standard data sources.
|
||||
|
||||
- **Banks and NBFCs**: revenue, EBITDA, EV and net debt are meaningless. Source instead: net interest income and NIM, gross and net NPA, provision coverage, slippage, credit cost, CASA, cost-to-income, capital adequacy (CET1/CRAR). In India these come from the quarterly results filing plus RBI disclosures (Basel III Pillar 3 disclosures are on the bank's own site) and the annual report's "Notes to accounts" disclosures on asset quality, restructuring and write-offs.
|
||||
- **Insurers**: use premium growth (new business premium, APE), VNB and VNB margin, embedded value (EV) and its movement analysis, solvency ratio, persistency by cohort (13th/61st month), claims ratio and combined ratio for general insurers. Sources: IRDAI monthly business data, the insurer's EV disclosure and actuarial report.
|
||||
- **REITs / InvITs**: net income is depreciation-distorted. Use NOI, FFO/AFFO, distribution per unit, occupancy, WALE, loan-to-value, cap rates. Sources: the trust's quarterly distribution statements, valuer reports (Indian REITs publish independent valuations semi-annually), SEBI REIT/InvIT disclosures.
|
||||
- **Miners, oil and gas**: source reserves and resources from the technical reports that follow a recognized code (JORC, NI 43-101, SEC S-K 1300, SPE-PRMS) — not from the annual report summary. Track reserve life, grade, all-in sustaining cost, and note that reserve estimates are price-dependent and get restated when commodity prices move.
|
||||
- **Utilities, infrastructure, telecom (India)**: regulated returns, tariff orders and licence conditions come from CERC/SERCs, TRAI, NHAI concession agreements. Contingent liabilities and disputed regulatory dues are often the dominant balance-sheet item.
|
||||
- **Pharma**: USFDA inspection classifications (EIR, Form 483, warning letters, import alerts) are on the FDA site and are material events; ANDA/DMF filings, Paragraph IV status and patent cliffs come from company disclosures and FDA Orange Book.
|
||||
- **Early-stage / loss-making / platform businesses**: the operating KPIs (GMV, take rate, contribution margin, cohort retention, CAC payback) exist only in investor presentations and calls, are management-defined, and change definition between quarters. Record the definition alongside the number and re-check it each quarter.
|
||||
|
||||
---
|
||||
|
||||
## 12. When web access is unavailable or data is paywalled
|
||||
|
||||
You will frequently be asked to analyse with incomplete access. Handle it explicitly rather than by inference. The document-first principle still applies: incomplete access means fewer documents, not a licence to substitute aggregator data.
|
||||
|
||||
**Sequence:**
|
||||
1. **Establish what you actually have.** Documents the user supplied, figures stated in the conversation, and your own general knowledge of the sector and its economics — which is durable — as distinct from company-specific figures, which are not.
|
||||
2. **Ask the user for the documents themselves, naming them specifically.** Not "can you give me more data" but "please upload the FY25 annual report PDF, the last two concall transcripts, and the latest quarterly results filing from BSE." Named document requests get answered; vague ones do not. If you know the exact source (`bseindia.com` Corporate Filings, the company's IR page, EDGAR filing index) say where to get it. **Do not ask for or accept pasted screener.in tables or aggregator screenshots as a substitute for the document** — if the user provides aggregator data, accept it but mark every figure as `aggregator-sourced, unverified` and continue requesting the actual documents.
|
||||
3. **Work from provided documents rigorously.** Extract with page/section citations so the user can audit you. If a supplied document is a screenshot or partial page, note what was cut off.
|
||||
4. **State gaps explicitly and place them in the output.** Maintain a visible "Data gaps and their effect on this analysis" section: what is missing, why it matters, and which conclusions would change if the missing data went one way or the other.
|
||||
5. **Downgrade the conclusion, not the honesty.** Say what the analysis can support at the available evidence level: structural and qualitative conclusions may hold firmly even when precise valuation does not. "On the available data, the business model and competitive position support X; the valuation question cannot be answered without the current share count and net debt" is a complete, useful answer.
|
||||
6. **Never substitute a remembered or plausible number for a missing one.** Model knowledge of specific company financials is stale by construction, is often wrong at the level of precision that matters, and cannot be cited. If you genuinely recall an approximate figure, present it as an unverified recollection with an explicit uncertainty band and an instruction to verify, or omit it.
|
||||
7. **Do not launder a guess through arithmetic.** Deriving a metric from an assumed input produces a figure that looks sourced and is not. If an input is assumed, label the output as scenario-based and show the assumption on its face.
|
||||
|
||||
**Paywalled specifically:** rating rationales, DRHPs, exchange filings, EDGAR, IRDAI and RBI data and most company IR pages are free — exhaust these before concluding that data is unavailable. What is genuinely paywalled is usually consensus estimates, historical databases, full rating reports and specialist industry data. Say which class of data you are missing, because "no consensus estimate available" and "no financial statements available" are very different constraints.
|
||||
|
||||
---
|
||||
|
||||
## 13. Never fabricate
|
||||
|
||||
State this as a hard rule with no exception clause: **do not produce a company-specific figure you have not sourced.**
|
||||
|
||||
The reason is asymmetric cost. An analysis with three acknowledged gaps still helps the reader — they know exactly where to look and exactly how much to trust each part. An analysis with one invented figure is worse than no analysis, because the reader cannot tell which figure is invented, so the entire document loses its evidentiary status. Worse, invented precision is self-reinforcing: a fabricated revenue figure produces a fabricated margin, a fabricated multiple and a fabricated conclusion, all internally consistent and all wrong.
|
||||
|
||||
Specific failure modes to avoid:
|
||||
- Filling a table cell because the table has a column for it. Write `n/a — not disclosed` or `not sourced`.
|
||||
- Converting a qualitative recollection ("margins are around the mid-teens") into a number in a table.
|
||||
- Producing a peer-comparison table where some rows are sourced and some are estimated, without marking which.
|
||||
- Interpolating a missing year in a time series without labelling it as interpolated.
|
||||
- Quoting a multiple without a price date, which is a fabrication of currency even when the arithmetic was once right.
|
||||
- Attributing a statement to a concall or filing you did not read.
|
||||
|
||||
Preferred vocabulary in output: `not disclosed`, `not sourced — verify`, `single source, unverified`, `estimated by me from [inputs] — not a company figure`, `as of [date]`.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Every figure carries value + unit + basis (consolidated/standalone) + period + source.
|
||||
- [ ] Headline figures (revenue, EBITDA, PAT, debt, equity, OCF, share count) cross-checked against a second independent source.
|
||||
- [ ] Primary filing beats aggregator wherever they disagree; discrepancy investigated, not averaged.
|
||||
- [ ] Consolidated used throughout; no ratio mixes consolidated and standalone; PAT is post-minority-interest.
|
||||
- [ ] Units confirmed on every table read — crore vs lakh vs million; 1 crore = 10 million.
|
||||
- [ ] Currency stated; FX rate and its date stated for any cross-currency comparison.
|
||||
- [ ] Fiscal periods converted to calendar coverage; India FY ends 31 March; 52/53-week years noted.
|
||||
- [ ] Prior-year figures checked for restatement, reclassification, discontinued operations and scheme effective dates.
|
||||
- [ ] Price, market cap and all multiples stamped with an as-of date; share count taken from the latest filing.
|
||||
- [ ] Derived ratios recomputed by me from raw line items, with formulas stated.
|
||||
- [ ] Per-share history adjusted for splits and bonuses.
|
||||
- [ ] India: shareholding pattern, promoter pledge trend, CARO qualifications, contingent liabilities, related-party note, latest rating rationale and rating history all reviewed.
|
||||
- [ ] Global: 10-K MD&A and segment note, latest 8-Ks, DEF 14A compensation metrics and recent Form 4 activity reviewed.
|
||||
- [ ] Latest concall/earnings-call Q&A read; prior guidance checked against delivery.
|
||||
- [ ] Sector-appropriate sources used — banks, insurers, REITs, miners do not use the standard ratio set or the standard sources.
|
||||
- [ ] Arithmetic sanity checks passed: statements tie, balance sheet balances, per-unit economics plausible.
|
||||
- [ ] Single-sourced and unverified figures explicitly flagged as such.
|
||||
- [ ] A visible "Data gaps" section exists wherever access was incomplete.
|
||||
- [ ] Zero fabricated figures. Every cell is sourced, marked `n/a`, or explicitly labelled as my own estimate.
|
||||
423
finance/skills/stock-analysis/references/02-core-factors.md
Normal file
423
finance/skills/stock-analysis/references/02-core-factors.md
Normal file
|
|
@ -0,0 +1,423 @@
|
|||
# Core factors — business model, moat, industry and growth
|
||||
|
||||
Use this when: you are at Stage 4 and need the universal, non-financial half of the analysis — what the business actually is, whether it can defend its economics, and whether it can reinvest at high returns for long enough to matter.
|
||||
|
||||
Everything the financial statements show you is an *output*. This file covers the *inputs* that determine whether those outputs persist: the monetisation architecture, the moat mechanism and its direction, the structure of the industry, and the length of the reinvestment runway. Get these wrong and the ratio work is arithmetic about a business you have misunderstood. Two disciplines carry over from the governing principle: no factor here has a universal "good" level — read every number against sector peers and the company's own 5–10 year record — and never let one strong factor stand in for the set.
|
||||
|
||||
## Contents
|
||||
|
||||
- [How to work through this file](#how-to-work-through-this-file)
|
||||
- [Part A — Business model and competitive moat](#part-a--business-model-and-competitive-moat)
|
||||
- [Part B — Industry, market and competitive dynamics](#part-b--industry-market-and-competitive-dynamics)
|
||||
- [Part C — Growth prospects and reinvestment runway](#part-c--growth-prospects-and-reinvestment-runway)
|
||||
- [Verify against something the company did not write](#verify-against-something-the-company-did-not-write)
|
||||
- [Where this generic frame breaks](#where-this-generic-frame-breaks)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## How to work through this file
|
||||
|
||||
Three passes, in order. Each answers one question, and each depends on the one before it.
|
||||
|
||||
1. **What is this business?** (Part A) — how it makes money, from whom, and why that is hard to take away.
|
||||
2. **What game is it playing?** (Part B) — industry structure sets the ceiling on returns more often than management skill does.
|
||||
3. **How much longer can it compound?** (Part C) — growth only creates value above the cost of capital, and only while the runway lasts.
|
||||
|
||||
Write down the answers as short factual claims with a source and period attached, not as adjectives. "Top customer = 31% of FY25 revenue, disclosed under Ind AS 108 segment note" is analysis. "Customer concentration is a concern" is not.
|
||||
|
||||
Do not run all forty-odd factors below at equal depth. For most companies three or four decide the outcome. Identify them early, evidence those properly, and use the rest to confirm nothing disqualifying was missed.
|
||||
|
||||
**Source map.** US/global: 10-K Item 1 (Business), Item 1A (Risk Factors), Item 7 (MD&A), the segment footnote (ASC 280), 8-Ks, proxy, investor-day decks, earnings-call transcripts, EDGAR full-text search across competitors and customers. **India:** the annual report's Management Discussion & Analysis (mandatory content under SEBI LODR Schedule V — industry structure, opportunities and threats, segment performance, outlook, risks), the segment note under Ind AS 108, the Directors' Report and its annexures, the Business Responsibility & Sustainability Report, and — often the single richest source — the quarterly earnings **concall transcript**, which listed companies must publish on the website and file with the exchanges. Indian investor presentations carry order books, capacity, volumes and market-share claims that appear nowhere in the audited accounts; use them, and label them unaudited.
|
||||
|
||||
---
|
||||
|
||||
## Part A — Business model and competitive moat
|
||||
|
||||
### A1. Define the business before judging it
|
||||
|
||||
Map exactly what products or services generate revenue, **who actually pays** (which is often not who uses), and the job being done for that payer. Break revenue *and gross profit* down by segment and by individual product line — profit concentration is almost always more extreme than revenue concentration, and one product frequently produces the overwhelming majority of economic profit while the narrative describes the whole portfolio.
|
||||
|
||||
Test yourself: can you state the business and its profit engine in two plain sentences? If not, you do not yet know enough to assess the moat. Separate the *story* from where money is actually made.
|
||||
|
||||
Judge mission-criticality: a product embedded in the customer's workflow, regulated process, or production line has structurally more durable economics than one that can be deferred a quarter without consequence.
|
||||
|
||||
*Red flags:* refusal to disclose segment-level economics; a "diversified" structure masking one weak core; frequent unexplained pivots; reliance on a single hit product; you cannot articulate what the customer is buying.
|
||||
|
||||
### A2. Monetisation mechanics
|
||||
|
||||
Identify the architecture precisely — unit sale, subscription, usage/consumption, transaction take-rate, licence/royalty, advertising, leasing, freemium conversion, razor-and-blade with high-margin consumables, or marketplace commission. Then ask three things: who sets price, how often it is billed, and whether revenue scales with value delivered or is structurally capped.
|
||||
|
||||
This matters because the architecture, not the industry label, drives margin structure, capital intensity, predictability and cyclicality. Consumption models capture upside but add volatility. Subscriptions add predictability and are evidence of switching costs. Advertising is cyclical and concentration-prone. In razor-and-blade and aftermarket models the real profit pool sits in the consumable — analyse *that* line, not the installed-base sales that look like the business.
|
||||
|
||||
For platforms, quantify the take rate and interrogate its headroom. A rising take rate is frequently how a platform masks stalled volume growth.
|
||||
|
||||
### A3. Revenue quality and recurrence
|
||||
|
||||
Split revenue into contracted/recurring (subscriptions, maintenance, long-term service contracts, consumables) versus transactional, project or one-off. Then check contract length, auto-renewal terms, minimum commitments, remaining performance obligations (RPO) or backlog, and the deferred-revenue trend. Cohort retention tells you whether the installed base expands or leaks.
|
||||
|
||||
Recurring revenue is worth more because it does not have to be re-won each period; it is also the cleanest observable evidence that switching costs exist. Be sceptical of the label: one-time hardware or perpetual-licence sales relabelled as "ARR", or annually re-solicited business described as recurring, is a common dressing-up.
|
||||
|
||||
### A4. Unit economics
|
||||
|
||||
Model one incremental customer or unit end to end: gross margin per unit, fully loaded customer acquisition cost, lifetime value, payback period, contribution margin after all variable costs. Ask whether the economics improve or degrade with scale, and — critically — whether they hold without promotional subsidy.
|
||||
|
||||
A company can grow fast and still be uninvestable if each customer is unprofitable or payback is dangerously long. Sound unit economics are the precondition for self-funded growth; broken ones mean growth destroys value, and faster growth destroys it faster.
|
||||
|
||||
Interrogate the LTV assumption itself. It is built on an assumed churn rate and discount rate, both chosen by the company.
|
||||
|
||||
### A5. The moat sources — name the mechanism
|
||||
|
||||
A moat is not an adjective. Identify which specific mechanism produces the excess return, or conclude there is none.
|
||||
|
||||
**Pricing power.** The clearest external evidence of a moat. Examine the history of price increases against volume response, gross-margin behaviour through cost-inflation periods, whether price is a small and low-salience share of the customer's total cost, and whether pricing is value-based. The recent global inflation episode is a natural experiment: did the company pass input costs through cleanly, or discount to hold volume?
|
||||
|
||||
**Switching costs.** Quantify what it actually costs a customer to leave — money, time, retraining, data migration, integration rework, certification, operational risk. Retention and renewal rates are the empirical test; footprint depth (modules or seats per account) is the leading indicator.
|
||||
|
||||
**Network effects.** Establish whether each additional user increases value for existing users, and of which kind: direct, indirect/two-sided, or data. Then test the two things that break them — multi-homing, and networks that are locally dense but do not compound nationally.
|
||||
|
||||
**Brand.** Test whether the brand changes buying behaviour and commands a price premium, not whether it is well known. Awareness is not a moat. Rising advertising spend merely to hold share is evidence against a brand moat, not for one.
|
||||
|
||||
**Scale and cost advantage.** Establish whether size produces a structural unit-cost advantage — purchasing scale, manufacturing or logistics density, fixed-cost leverage, distribution reach, proprietary process — and verify it shows up in the margin gap versus smaller peers. If the claimed advantage is not visible in the numbers, it is not there. Also consider *efficient scale*: niches profitably served by one or two players where entry would destroy everyone's returns (pipelines, rail, regional utilities, a single-city cement market).
|
||||
|
||||
**Intangibles: IP, patents, licences, regulatory exclusivity.** Inventory patents with revenue-weighted expiry dates, approvals, spectrum, franchises and concessions. Map the cliff explicitly. Legal exclusivity can be monopoly-grade, but it is time-bounded, can be litigated away, and can be legislated away — never model it as permanent.
|
||||
|
||||
### A6. Dependencies that can end the business
|
||||
|
||||
**Customer concentration.** Quantify revenue from the top 1/5/10 customers. In the US this surfaces via the 10-K and ASC 280 disclosure of any customer above 10% of revenue; **in India, Ind AS 108 requires the same entity-wide disclosure of major customers at the 10% threshold** — look for it in the segment note, and if it is absent for a company that is obviously concentrated, treat the silence as information. Assess contract length, tenure, and the risk that a large customer insources or vertically integrates. Include channel concentration: one distributor or one retailer can be the real dependency.
|
||||
|
||||
**Supplier and input dependence.** Identify single- or sole-sourced critical inputs, one contract manufacturer, one foundry, one API supplier, one geography. Assess substitutability, second-source qualification, inventory buffer, and hedging. No demand-side moat survives an input that cannot be obtained. In India, Schedule III requires disclosure of cost of materials consumed, which lets you size input dependency even where suppliers are not named.
|
||||
|
||||
**Geographic mix.** Break revenue *and operating profit* by region. Ask whether the moat travels — many models that dominate a home market fail abroad, which both caps the runway and turns expansion into value destruction. Flag single-country dependence for the bulk of profit or upside, unhedged FX exposure, and repatriation or capital-control risk.
|
||||
|
||||
### A7. Moat synthesis — width, durability, direction
|
||||
|
||||
Now combine. Width is how large the excess return; durability is how many years it persists; **direction is usually the more valuable judgement.** A narrowing wide moat is often a worse investment than a widening narrow one, because the market has already paid for the width.
|
||||
|
||||
Measure how long the company has earned returns above its cost of capital and whether that spread is widening, stable or narrowing. Then name the primary disruption vector explicitly — technological change, business-model disruption, or counter-positioning where the incumbent cannot respond without cannibalising its own economics. If you cannot name a plausible way the moat is attacked, you have not looked hard enough.
|
||||
|
||||
Mechanics of ROIC and the ROIC–WACC spread are in `references/05-returns-and-dupont.md`; use those numbers here as evidence, and do not double-count them as a separate score.
|
||||
|
||||
### Part A metric set
|
||||
|
||||
Ranges are **indicative only**. They shift by market, by sector, by cycle and by period; peer and own-history comparison overrides every band below.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Revenue and gross profit by segment/product** | Each segment or product line as % of total revenue *and* of total gross profit, from the segment note (ASC 280 / Ind AS 108) | No single product >~50% of profit without a credible follow-on; profit concentration usually exceeds revenue concentration | Locates the real profit engine, which is frequently not the one the narrative describes |
|
||||
| **Recurring revenue mix** | Contracted/subscription/consumable revenue ÷ total revenue | >70% is a genuinely subscription business; 30–70% hybrid; interrogate any "recurring" claim below that | Recurring revenue does not have to be re-won each period and is direct evidence of switching costs |
|
||||
| **Net revenue retention (NRR/NDR)** | Revenue this period from last period's cohort ÷ that cohort's prior revenue, including expansion, contraction and churn | >120% exceptional, 110–120% strong, 100–110% adequate, <100% the base is leaking | The single best test of lock-in; above 100% the business grows with zero new customers |
|
||||
| **Gross retention / logo churn** | Cohort revenue retained before any expansion; annual customer churn % | Gross retention >90% for enterprise, >80% SMB; churn trend matters more than level | Strips out the flattering effect of upsell into a shrinking base |
|
||||
| **LTV/CAC and CAC payback** | Lifetime gross profit per customer ÷ fully loaded acquisition cost; months of contribution margin to repay CAC | LTV/CAC >3x; payback <12 months consumer/SMB, <24 months enterprise | Determines whether growth is self-funding or a subsidy; lengthening payback is an early warning |
|
||||
| **Contribution margin per unit** | Revenue less *all* variable cost per unit or transaction | Positive and improving with scale | Negative contribution margin means growth accelerates value destruction |
|
||||
| **Realised price growth vs volume growth** | Split reported revenue growth into price, volume, mix and FX (percentage points) | Both positive is the franchise signature; price-only with falling volume is demand destruction | The cleanest quantitative read on pricing power |
|
||||
| **Gross margin level and 5–10 yr trend** | Gross profit ÷ revenue, against peers of similar model | Stable or rising through an input-cost shock | Margin held through inflation is pricing power demonstrated, not asserted |
|
||||
| **Take rate (platforms)** | Net revenue ÷ GMV or gross transaction value | Level is sector-specific; the *trend* and its driver are what matter | A rising take rate frequently masks stalled volume |
|
||||
| **Customer concentration** | Top-1, top-5, top-10 customers as % of revenue | Top customer <10%; >20% is a single-point-of-failure | Concentrated buyers extract margin and can end revenue abruptly |
|
||||
| **Single-sourced critical inputs** | Count of critical inputs with no qualified second source; key input as % of COGS | Zero sole-sourced critical inputs, or a qualified alternate | Supply failure is existential and not offset by any demand-side moat |
|
||||
| **Revenue exposed to patent/licence expiry** | % of revenue from products losing exclusivity within 3–5 years, with dates | Low, and covered by a late-stage pipeline | Cliffs are dateable, foreseeable, and routinely under-modelled |
|
||||
| **Years of ROIC > WACC, and spread trend** | From `05-returns-and-dupont.md`; plot the spread over 10 years | A long run with a stable or widening spread | Duration and direction of excess returns is the largest driver of intrinsic value |
|
||||
|
||||
---
|
||||
|
||||
## Part B — Industry, market and competitive dynamics
|
||||
|
||||
Industry structure sets the ceiling on returns more reliably than management quality does. A capable operator in a structurally bad industry usually loses to a mediocre one in a good industry.
|
||||
|
||||
### B1. Market size, and whether the sizing is honest
|
||||
|
||||
Decompose into TAM, SAM (serviceable addressable) and SOM (serviceable obtainable). Establish whether the estimate is bottom-up (units × price × realistic penetration) or a top-down number lifted from a slide. Note who produced it and when — company IR, a sell-side bank, or an independent body. In India, industry sizing usually traces to CRISIL, ICRA, industry associations (SIAM, IPA, CREDAI, IBEF) or a company-commissioned consultant; treat commissioned sizing as marketing until independently checked.
|
||||
|
||||
Then do the step that matters: **back-calculate the market share the company must reach to justify the current price.** This converts a vague "huge market" into a testable claim. Cross-reference the reverse-DCF in `references/06-valuation.md`.
|
||||
|
||||
*Red flags:* TAM revised upward to defend a falling stock; adjacent-market TAM stacking; "we only need 1% of a giant market"; a bottom-up build implying more than 100% of any realistic segment.
|
||||
|
||||
### B2. Growth rate and position on the S-curve
|
||||
|
||||
Locate the industry on the adoption curve — early adopters, mass market, or saturation. Decompose industry growth into volume, price and mix. Separate durable secular demand from pull-forward (pandemic, subsidy, pre-buy ahead of a regulation change) that will normalise. Compare industry growth to nominal GDP: much of what is marketed as a growth market is GDP plus inflation.
|
||||
|
||||
Mistaking a maturing market for a growth market is one of the most expensive errors available, because the multiple and the growth rate de-rate together.
|
||||
|
||||
### B3. Structure, concentration and the rationality of competitors
|
||||
|
||||
Count the players and map the share distribution. Compute CR4/CR8 and, where you have share data, the Herfindahl-Hirschman Index. Establish the trajectory — consolidating or fragmenting.
|
||||
|
||||
Then ask the question that concentration statistics miss: **are the competitors rational?** A single player that does not maximise profit — state-owned, subsidy-funded, PE-backed and buying share to exit, or a subscale player pricing for survival — can compete away the profit pool for everyone in a structurally concentrated industry. This is a live issue in Indian PSU-heavy sectors and in any market where a well-funded entrant is buying share.
|
||||
|
||||
### B4. Rivalry intensity and how share actually moves
|
||||
|
||||
Trace market share over 5–10 years, and establish *how* it moves — through price, product or distribution. Share earned without price concessions is owned; share bought with rebates and promotions is rented. Watch whether R&D and advertising intensity must keep rising just to hold position: that is a moat being consumed to look stable.
|
||||
|
||||
### B5. The five forces, applied concretely
|
||||
|
||||
**Supplier power** — supplier concentration relative to the industry, substitutability, single-sourcing, the threat of a supplier forward-integrating, and the industry's demonstrated ability to pass input costs through and with what lag.
|
||||
|
||||
**Buyer and channel power** — buyer concentration, price sensitivity, backward-integration ability, and the gatekeepers sitting between the company and the end user (mega-retailers, distributors, group purchasing organisations, app stores, marketplaces, hospital chains, e-commerce platforms). A dominant channel quietly becomes the industry's real profit-taker; watch its take rate.
|
||||
|
||||
**Barriers to entry** — enumerate and stress-test each one: minimum efficient scale versus market size, capital intensity, licences, IP, network effects, brand, switching costs, proprietary distribution, learning-curve cost. Judge whether each is widening or eroding. High sustained margins with low barriers are an invitation, not a moat.
|
||||
|
||||
**Substitutes and disruption** — map what else does the same job, and track the *price-performance trajectory* of the alternative rather than its current position. Apply the low-end and new-market disruption lens. Substitution destroys value permanently rather than cyclically, and the financials look fine until the inflection.
|
||||
|
||||
### B6. Cyclicality, and where in the cycle you are standing
|
||||
|
||||
Classify demand drivers as cyclical (GDP, credit, capex, housing, commodity price), seasonal, or secular. Locate the position in the cycle and estimate mid-cycle normalised margins and earnings rather than trusting the current print.
|
||||
|
||||
**The peak-cycle trap:** record margins alongside an optically low P/E is the classic value trap, not a bargain. The inverse error — reading a structural decline as a cyclical dip — destroys just as much capital. Deep cyclicals get the overlay in `references/13-situations.md`.
|
||||
|
||||
### B7. The capital cycle — watch supply, not demand
|
||||
|
||||
Track industry-wide capacity additions against demand growth, allowing for capex lead times. Monitor utilisation, whether capital is flooding in (competitor expansions, IPOs, PE and VC funding, announced greenfield projects) or leaving, and channel inventory.
|
||||
|
||||
Returns are driven more by changes in supply than by demand forecasts. Heavy investment in good times sows the next glut; capital fleeing a hated industry sets up the next up-cycle. Aggregate industry capex ÷ depreciation is the cheapest single supply-side indicator available. This lens is decisive in cement, chemicals, steel, shipping, semiconductors, hotels and airlines.
|
||||
|
||||
### B8. Regulation, policy and political economy
|
||||
|
||||
Map the whole regime — antitrust, price control, tariffs, environmental and emissions rules, data and privacy, licensing, reimbursement, safety — plus pending legislation. Quantify dependence on subsidy, tax incentive or regulatory arbitrage.
|
||||
|
||||
**India-specific:** price control and trade-margin rationalisation (NPPA/DPCO in pharma), tariff and anti-dumping orders, GST rate changes, PLI scheme dependence, sectoral regulators (RBI, IRDAI, TRAI, CERC/SERCs, RERA), and the pattern of retrospective or mid-stream policy change. Sizeable chunks of reported profit in PLI-supported sectors are policy income, not franchise income — say so explicitly.
|
||||
|
||||
**US/global:** FDA and reimbursement, FTC/DOJ antitrust posture, IRA/CHIPS-style incentives, tariff schedules, state-level utility rate cases, EU DMA/DSA obligations.
|
||||
|
||||
### B9. Where the profit pool sits, and which layer the company occupies
|
||||
|
||||
Map profit along the value chain and, more importantly, the direction it is migrating — hardware to software, OEM to platform, network to content, manufacturer to brand owner. Compare ROIC across peers and against WACC. Establish whether the whole industry earns above its cost of capital or only one or two players do.
|
||||
|
||||
Some industries destroy capital regardless of management quality; much of airline and dry-bulk shipping history is the proof. Owning the layer the profit pool is moving *toward* is frequently the entire call.
|
||||
|
||||
### B10. Commoditisation
|
||||
|
||||
Commoditisation is the default state of most products. Test whether differentiation is real: can the industry price above inflation without losing volume, and pass input costs through, and with what lag? Track premium versus private label or generic, and the degree of spec interchangeability. Slow gross-margin compression across an industry is what commoditisation looks like in the accounts, years before anyone calls it that.
|
||||
|
||||
### Part B metric set
|
||||
|
||||
Indicative only — vary by market, cycle and period; peer and own-history comparison overrides them.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Penetration (revenue ÷ TAM)** | Company revenue as % of a credibly built, bottom-up TAM | Low penetration only counts if the TAM is independently sourced | Sets the ceiling; the number most often inflated to justify a multiple |
|
||||
| **Implied share needed** | Back-solve from the reverse DCF: what share must be reached to justify today's price | Comfortably below the current leader's share | Turns a narrative into a falsifiable claim |
|
||||
| **Industry CAGR vs nominal GDP** | 3/5/10-yr industry growth ÷ nominal GDP growth | >1.5x GDP is a genuine growth industry | Distinguishes secular tailwind from inflation |
|
||||
| **CR4 / HHI** | Top-4 combined share; sum of squared shares (US DOJ convention: >2,500 concentrated, 1,500–2,500 moderate, <1,500 unconcentrated) | Concentrated *and* rational is the profitable combination | Structure predicts industry profitability better than any single firm's strategy |
|
||||
| **Market-share trend** | Basis points gained/lost per year over 5–10 yrs, and the mechanism | Flat-to-rising share *without* price concession | Share bought with discounts is rented and reverses |
|
||||
| **Industry capacity utilisation** | Output ÷ installed capacity, industry-wide | 80–85% is typically the pricing-power threshold; below ~70% price discipline breaks | The supply-side variable that sets industry pricing |
|
||||
| **Industry capex ÷ depreciation** | Aggregate peer capex ÷ aggregate depreciation | ~1.0 = replacement; sustained >1.5 across an industry warns of a coming glut | The single best early indicator in the capital cycle |
|
||||
| **Book-to-bill** | Orders received ÷ revenue billed in the period | >1.0 growing, <1.0 for two-plus quarters is a genuine warning | Forward-looking where backlog exists |
|
||||
| **Industry ROIC vs WACC** | Median peer ROIC less WACC; also the dispersion across peers | Median above WACC, with the company in the upper quartile | Reveals whether the industry creates value at all, or only its best player does |
|
||||
| **Current margin vs 10-yr mid-cycle** | Current EBIT margin ÷ 10-year average margin | Near 1.0 for normalisation; well above 1.0 means you are underwriting peak | Prevents the peak-cycle low-P/E trap |
|
||||
| **Realised price vs input inflation** | Company/industry realised price growth less input-cost inflation | ≥0 through a cost shock | Direct test of commoditisation |
|
||||
| **Revenue dependent on subsidy or regulated price** | % of revenue or EBIT from subsidy, incentive scheme or a regulated tariff | Known, quantified, and modelled to expiry | Policy income is not franchise income and can end on a date |
|
||||
|
||||
---
|
||||
|
||||
## Part C — Growth prospects and reinvestment runway
|
||||
|
||||
Growth is not intrinsically good. Growth at returns below the cost of capital destroys value, and the faster it grows the more it destroys. This section establishes three things: was past growth real, is incremental capital earning a return, and how many years of that are left.
|
||||
|
||||
### C1. Decompose historical growth — never accept a CAGR
|
||||
|
||||
Compute 3/5/10-year revenue CAGR, then break it apart:
|
||||
|
||||
- **Organic vs inorganic.** For any acquisitive company this is the whole analysis. Strip acquisitions and ask what the base business did.
|
||||
- **Organic into volume, price, mix and FX**, in percentage points.
|
||||
- **By segment and geography**, to see whether growth is broad-based or one product in one region.
|
||||
- **Sequential (QoQ) as well as YoY**, because inflections show up sequentially first.
|
||||
|
||||
Adjust for revenue-recognition changes (ASC 606 / Ind AS 115), divestitures, and one-off commodity or pandemic spikes that distort the base. Volume-led organic growth is the highest-quality kind; price-only, FX-only or acquisition-fuelled growth is far less repeatable and often conceals a stagnating core.
|
||||
|
||||
For serial acquirers specifically, project what reported growth looks like when M&A pauses — and scrutinise purchase accounting (fair-value step-ups, restructuring reserves created in acquisition accounting then released to earnings, contingent-consideration remeasurement, "one-off" integration costs that recur every single year). Roll-ups can show rising reported EPS while the acquired businesses shrink, because each deal resets the baseline. Detail in `references/07-forensic-red-flags.md`.
|
||||
|
||||
### C2. Earnings growth quality
|
||||
|
||||
Separate EPS growth into revenue growth, margin expansion, share-count reduction, tax-rate change, and below-the-line items. Compare EPS CAGR to net-income CAGR to revenue CAGR — EPS can outgrow net income purely through buybacks. Then verify earnings convert to cash (see `references/03-earnings-quality.md` and `references/04-balance-sheet-and-cashflow.md`), and read the GAAP-to-adjusted bridge for add-backs that are growing, recurring, and real (stock-based compensation above all).
|
||||
|
||||
Growth manufactured by financial engineering is not evidence of a compounding business.
|
||||
|
||||
### C3. Reinvestment rate and incremental return on capital
|
||||
|
||||
This is the most important factor in Part C and the most commonly skipped.
|
||||
|
||||
Reinvestment rate ≈ (net capex + acquisitions + change in net working capital + capitalised R&D or growth opex) ÷ NOPAT.
|
||||
|
||||
ROIIC ≈ Δ NOPAT ÷ Δ invested capital, measured over rolling 3–5 year windows so a single year's lumpiness does not dominate.
|
||||
|
||||
Then compare ROIIC to WACC and to the company's own average ROIC. **ROIC tells you about capital already deployed; ROIIC tells you about the capital being deployed now** — which is what you are actually buying. ROIIC well below reported average ROIC means a good legacy business is subsidising poor new investment, and reported ROIC will fade toward the incremental rate over time. Full mechanics in `references/05-returns-and-dupont.md`.
|
||||
|
||||
### C4. Runway length and the sustainable growth identity
|
||||
|
||||
Anchor on: **sustainable growth ≈ reinvestment rate × ROIC.** A company returning most of its earnings cannot also compound at a high rate; if the guidance implies otherwise, something in the model is wrong.
|
||||
|
||||
Then estimate how many years of high-return reinvestment remain: TAM penetration, remaining white space, store or plant or route density versus a realistic ceiling, and whether the pipeline of projects clearing the hurdle rate is expanding or shrinking. Two companies with identical ROIC differ enormously in value if one has twenty years of runway and the other three. Runway is what justifies — or refutes — a premium multiple.
|
||||
|
||||
A specific tell: high ROIC with cash piling up and buybacks replacing capex usually means the reinvestment opportunity set has closed, whatever the growth narrative says.
|
||||
|
||||
### C5. Backlog, order book and RPO — the forward evidence
|
||||
|
||||
For industrials, capital goods, defence, EPC, construction, semis and subscription software, examine backlog or order book size and growth, coverage (backlog ÷ trailing revenue, expressed in months or years), book-to-bill, RPO and current RPO, de-booking and cancellation rates, and the *margin* embedded in the backlog.
|
||||
|
||||
These are among the few forward-looking, semi-verifiable indicators available. A shrinking backlog warns that reported revenue growth is about to roll over while the income statement still looks strong.
|
||||
|
||||
Interrogate quality: backlog padded with non-binding letters of intent or framework agreements, backlog growing only because delivery times lengthened, or a large low-margin cancellable order presented as firm. **India note:** order-book figures for EPC, capital goods and defence companies come from investor presentations and concalls and are unaudited — check whether the definition (firm orders, L1 orders won but not awarded, framework agreements) changed between periods.
|
||||
|
||||
### C6. Capex intensity and the maintenance/growth split
|
||||
|
||||
Split capex into maintenance and growth. Management sometimes discloses the split; otherwise estimate maintenance as depreciation adjusted for inflation and asset-base growth, and say plainly that it is an estimate.
|
||||
|
||||
Then review announced expansion: new plants, fabs, stores, data centres, mines — greenfield versus brownfield, budgeted cost, capacity added, timeline, ramp curve, expected return and payback. Compare against the previous announcement to catch cost overruns and slippage, which are chronic in Indian infrastructure, cement, metals and specialty-chemicals expansions.
|
||||
|
||||
Growth capex is where value is most often destroyed: mistimed, over-budget, or built at cycle-peak equipment prices into a market that will be oversupplied by the time it commissions. Cross-check against the industry capital cycle in B7 — the moment to be suspicious is when the whole industry is expanding at once.
|
||||
|
||||
### C7. The forward bridge — make growth arithmetic, not narrative
|
||||
|
||||
Take management's stated drivers (new products, secular tailwind, share gain, price, geographic entry) and build an additive bridge from today's revenue to the target, driver by driver, in percentage points. Then check the drivers actually sum to the target, and that each one is independently plausible.
|
||||
|
||||
Separate secular from cyclical demand in that bridge. Extrapolating cyclical peak demand as structural is how peak-cycle multiples get paid.
|
||||
|
||||
### C8. Innovation: pipeline and R&D productivity
|
||||
|
||||
Assess the vitality index — revenue from products launched in the last 3–5 years — alongside R&D as % of revenue *and its productivity* (incremental revenue or gross profit per R&D rupee/dollar). R&D spend is an input; productivity is the output that separates innovators from cash-burning labs.
|
||||
|
||||
Review launch cadence, the hit rate of past launches, the patent and exclusivity timeline, and pipeline depth by stage. A falling vitality index means the company is living off legacy products, which is a growth cliff with a date on it even when current earnings look fine.
|
||||
|
||||
### C9. Adjacency and new-market expansion
|
||||
|
||||
Ask whether there is a demonstrated right to win — a transferable capability, brand or distribution — or whether this is diworsification. The evidence is the track record: did earlier new-market entries reach target economics, or quietly stall and retreat? Compare unit economics and payback in new markets against the mature core.
|
||||
|
||||
A repeatable expansion playbook (a retailer that reliably hits store economics in each new region) is a powerful and durable driver. Serial entry-and-retreat means the runway is narrower than claimed.
|
||||
|
||||
### C10. Price, volume and mix in forward growth
|
||||
|
||||
Determine how much future growth is priced versus volume, and whether price sticks without volume loss. Price-led growth carries close to 100% incremental margin and is highly durable when backed by brand, switching costs or scarcity — and is a warning sign when volumes fall as prices rise. Check contractual escalators, and test whether a "premiumisation" narrative is actually visible in mix data.
|
||||
|
||||
### C11. Guidance credibility
|
||||
|
||||
Build a scorecard of guidance versus actuals across the last 8–12 quarters and of multi-year targets versus delivery. Does management beat, meet, sandbag or miss? How does initial full-year guidance evolve — serial cuts or raises? Were the previous analyst-day roadmap and "catalysts" delivered?
|
||||
|
||||
Their historical accuracy is the best available prior for the current forecast. Serial over-promisers should have their projections discounted heavily regardless of how good the current story sounds. **India note:** formal numeric guidance is less common; the equivalent evidence is concall commentary — capacity commissioning dates, margin guidance, order-inflow expectations — checked against what subsequently happened. Watch for goalposts moving and for KPIs quietly dropped when they turn unfavourable.
|
||||
|
||||
### C12. Capital allocation track record
|
||||
|
||||
Over a decade this is often the largest single driver of per-share value. Assess the full history across organic reinvestment, M&A, buybacks, dividends and debt paydown.
|
||||
|
||||
For M&A: prices paid, goodwill impairment history, synergy realisation, post-deal ROIC. For buybacks: were they executed at low or high valuations? A buyback at a stretched multiple is value destruction dressed as shareholder return. Judge whether capital consistently flows to the highest-return use and whether management can articulate a hurdle rate.
|
||||
|
||||
Governance dimensions of the same question — related-party leakage, promoter-group transactions, empire building — are in `references/08-governance.md`.
|
||||
|
||||
### C13. Deceleration risk and the law of large numbers
|
||||
|
||||
Compute the **absolute** revenue the company must add each year to sustain its growth rate, and judge whether that is plausible given market size and share. High percentage growth becomes arithmetically harder as the base compounds.
|
||||
|
||||
Watch the deceleration signals: sequential growth slowing, leading indicators (bookings, backlog, app downloads, hiring) decelerating ahead of reported revenue, comps getting harder, share nearing a ceiling. Then distinguish a comp-driven air pocket from structural maturation.
|
||||
|
||||
Identifying the inflection from hyper-growth to mature growth is one of the highest-value calls in equity analysis, because multiples de-rate violently and simultaneously with the growth rate.
|
||||
|
||||
Apply the **outside view** here. Before accepting a bottom-up forecast, ask what the base rate is: how often do companies of this size actually sustain 20%+ growth for a decade, how often do turnarounds and roll-ups work, and how fast does excess ROIC historically fade toward the cost of capital? Bottom-up models produce systematic inside-view optimism; base rates are the cheapest correction available. More in `references/17-process-and-epistemics.md`.
|
||||
|
||||
### C14. How the growth is funded
|
||||
|
||||
Establish whether growth is funded by internally generated cash, debt, or equity issuance. Compute the funding gap (reinvestment need less operating cash flow) and how it is plugged. Track share-count growth from issuance and stock-based compensation, convertible and warrant overhang, and leverage rising to fund capex.
|
||||
|
||||
**Per-share growth is what accrues to owners.** A company growing revenue 20% while issuing 15% more shares is barely compounding for you. Growth requiring continual external capital is fragile because it depends on capital markets staying open and cheap. Self-funded growth is the gold standard of a durable runway.
|
||||
|
||||
### Part C metric set
|
||||
|
||||
Indicative only — vary by market, cycle and period; peer and own-history comparison overrides them.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Organic vs inorganic growth split** | Revenue growth excluding acquisitions completed in the last 12 months, vs total | Majority organic; know the number before judging anything else | Acquired growth is bought, not earned, and stops when M&A stops |
|
||||
| **Volume / price / mix / FX contribution** | Decomposition of organic growth into pp of each | Positive volume contribution in most years | Volume-led growth is the most durable form |
|
||||
| **ROIIC (incremental ROIC)** | Δ NOPAT ÷ Δ invested capital over rolling 3–5 yr windows | Above WACC with a clear margin; ~15–20%+ marks a genuine compounder in most sectors | Prices what the capital being deployed *now* will earn |
|
||||
| **Reinvestment rate** | (Net capex + acquisitions + Δ NWC + capitalised growth spend) ÷ NOPAT | High is good *only* when ROIIC is high; high with weak ROIIC is the worst combination | Determines how much of the return compounds internally |
|
||||
| **Sustainable growth rate** | Reinvestment rate × ROIC | Should roughly reconcile to guided growth | Exposes guidance that is arithmetically impossible |
|
||||
| **Backlog coverage** | Backlog ÷ trailing 12-month revenue, in months or years | Sector-dependent; the *trend* and de-booking rate carry the signal | Forward visibility, and the first place a slowdown appears |
|
||||
| **Book-to-bill** | Orders ÷ billings for the period | >1.0; below 1.0 for consecutive quarters is a real warning | Leads reported revenue by two to four quarters |
|
||||
| **RPO / cRPO growth** | Remaining performance obligations, and the portion due within 12 months | cRPO growth ≥ revenue growth | Detects subscription growth rolling over before revenue does |
|
||||
| **Capex ÷ depreciation** | Total capex ÷ depreciation and amortisation | ~1.0 maintenance-only; 1.5–2.5 genuine expansion; sustained >2 with flat returns is a warning | Separates real expansion from treadmill spending |
|
||||
| **Growth vs maintenance capex** | Disclosed split, or estimate maintenance as inflation-adjusted depreciation | Growth capex tied to specific projects with stated returns | Reveals the true free cash flow of the business as it stands |
|
||||
| **Vitality index** | % of revenue from products launched in the last 3–5 years | 15–30% for consumer and industrial innovators; higher in pharma/tech | Leading indicator of organic growth; falling means living off legacy |
|
||||
| **R&D productivity** | Incremental gross profit ÷ trailing R&D spend | Rising, or at least stable | R&D spend is an input; only the return on it is evidence |
|
||||
| **Guidance hit rate** | Beat/meet/miss across trailing 8–12 quarters, plus multi-year targets set vs achieved | Consistent meet-or-modest-beat, no serial in-year cuts | The best available prior on the credibility of the forward case |
|
||||
| **Share count growth** | Diluted share count CAGR, including SBC and convertibles | ≤0 for mature businesses; <2–3%/yr for growth names | Aggregate growth means nothing if per-share growth is diluted away |
|
||||
| **SBC as % of revenue** | Stock-based compensation ÷ revenue | Low single digits outside early-stage software | A real cost, routinely adjusted out, and a direct transfer from shareholders |
|
||||
| **Self-funding test** | FCF after growth capex; funding gap = reinvestment need − OCF | Non-negative, or a credible dated path to it | Growth dependent on open capital markets is fragile by construction |
|
||||
| **Absolute revenue add required** | Current revenue × target growth rate, in currency | Small relative to the realistic addressable market | The law of large numbers, made concrete |
|
||||
|
||||
---
|
||||
|
||||
## Verify against something the company did not write
|
||||
|
||||
Everything above can be answered entirely from company-produced documents — which is exactly how a fabricated or deteriorating business passes a desk-based checklist. Add at least one independent cross-check for any thesis you intend to act on.
|
||||
|
||||
- **Alternative data.** Web traffic and app-download trends, app-store and review-site ratings, job postings and headcount (LinkedIn), employee-review sentiment and attrition, card/transaction panels, freight and customs data. **India-specific proxies:** GST and e-way-bill volumes, VAHAN vehicle-registration data for autos, SIAM dispatch numbers, DGCA traffic data for airlines, AWACS/IQVIA secondary sales for pharma, RBI sectoral credit data, port and rail freight statistics. Divergence between reported growth and every external proxy for it is the earliest tell available.
|
||||
- **Scuttlebutt.** Use the product. Read customer reviews. Talk to customers, distributors, suppliers or ex-employees where feasible. Financial statements are lagging; ground-level observation moves quarters earlier and is one of the few genuine edges available.
|
||||
- **Proof of existence.** For asset-heavy or geographically remote claims, corroborate that the plants, mines, stores or data centres exist and operate — satellite imagery, environmental clearances and building permits, power draw, shipping and customs records, statutory filings of subsidiaries (MCA/ROC filings in India) reconciled to consolidated claims.
|
||||
- **Per-employee productivity.** Revenue and gross profit per employee versus peers and over five-plus years. Hard to fabricate, and it quietly validates or refutes claimed scale. A hiring freeze that contradicts a growth story is an independent warning.
|
||||
- **Bespoke KPI audit.** Catalogue every company-invented metric (ARR, bookings, GMV, MAU, "cash EBITDA", contribution margin ex-marketing, order book) with its exact definition, and check whether the definition changed year over year and whether it reconciles to audited revenue or cash. A shifting denominator keeps a growth narrative alive after the audited numbers have rolled over.
|
||||
- **Year-over-year redline.** Diff consecutive annual reports and 10-Ks for changes in risk-factor wording, segment definitions, accounting-policy and useful-life assumptions, and — most valuable — disclosures and metrics quietly *dropped*. Management highlights what it adds and never what it removed. Cheap, and high-yield.
|
||||
- **Vendor and customer financing.** Check whether the company lends to, guarantees, or extends unusually long credit to its own customers or channel to enable purchases (captive finance arms, channel financing, seller notes). Revenue funded by the seller's own credit reads as clean organic growth until the receivables sour.
|
||||
- **Read the other side.** Find the strongest existing bear case — short-seller reports, sceptical sell-side notes, forum criticism with actual numbers in it — and state what the informed money on the other side sees before deciding it is wrong.
|
||||
|
||||
---
|
||||
|
||||
## Where this generic frame breaks
|
||||
|
||||
Apply the sector playbook before using any of Part C's growth metrics. In these sectors the generic frame is not merely less useful — it is inverted or undefined.
|
||||
|
||||
- **Banks and lenders** — above-system loan growth is the best leading indicator of the *next* credit cycle's losses, not an achievement. There is no meaningful capex or FCF, so reinvestment rate and capex/depreciation are noise; the reinvestment constraint is regulatory capital (CET1), and sustainable growth = ROA × leverage × retention. The moat is the deposit franchise, not the loan book. See `references/sectors/banks.md` and `nbfc.md`.
|
||||
- **Insurers** — top-line premium growth can be bought by underpricing risk, and the loss shows up years later. Growth is measured in VNB, APE and new-business margin, not revenue. See `references/sectors/insurance.md`.
|
||||
- **REITs, InvITs and real estate** — growth is same-store NOI plus acquisitions, and acquisitions only create value if the cap rate exceeds the cost of capital. Use AFFO and NAV, not EPS. See `references/sectors/realestate-reit.md`.
|
||||
- **Miners, commodity producers, refiners** — there is no pricing power by construction; price is exogenous. The moat is position on the industry cost curve, reserve life and grade. TAM analysis is meaningless; the capital cycle in B7 is the whole game. See `references/sectors/metals-mining.md` and `oil-gas.md`.
|
||||
- **Regulated utilities** — growth is rate-base growth at an allowed return, so the regulator is the business model. See `references/sectors/utilities-power.md`.
|
||||
- **Holdcos and conglomerates** — analyse the underlying businesses separately and value sum-of-the-parts; group-level growth and margin are aggregation artefacts. See `references/sectors/holdco-assetmgr.md`.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
**Business model and moat**
|
||||
- [ ] Business and profit engine stated in two plain sentences, with revenue *and gross profit* split by segment/product.
|
||||
- [ ] Monetisation architecture named; who sets price identified; take rate quantified for platforms.
|
||||
- [ ] Recurring vs one-off revenue split; NRR, gross retention and churn sourced, not assumed.
|
||||
- [ ] Unit economics modelled end to end: contribution margin, LTV/CAC, payback — and tested without subsidy.
|
||||
- [ ] Pricing power evidenced by realised price vs volume and by gross margin through a cost shock.
|
||||
- [ ] Switching costs quantified in money and time; retention used as the empirical test.
|
||||
- [ ] Network effects classified (direct/indirect/data) and multi-homing checked.
|
||||
- [ ] Brand tested for price premium and behaviour change, not awareness.
|
||||
- [ ] Cost advantage verified in the margin gap versus smaller peers, not asserted.
|
||||
- [ ] Patents, licences and exclusivity inventoried with revenue-weighted expiry dates.
|
||||
- [ ] Top-1/5/10 customer concentration pulled from the segment note (ASC 280 / Ind AS 108); channel concentration included.
|
||||
- [ ] Sole-sourced critical inputs and single-geography supply identified.
|
||||
- [ ] Revenue and EBIT split by geography; single-country dependence and FX exposure flagged.
|
||||
- [ ] Moat width, durability **and direction** stated, with the primary disruption vector named.
|
||||
|
||||
**Industry and competitive dynamics**
|
||||
- [ ] TAM traced to its source and its build method; implied share needed back-solved from the current price.
|
||||
- [ ] Industry growth decomposed and compared to nominal GDP; pull-forward demand identified.
|
||||
- [ ] Concentration measured (CR4/HHI) *and* competitor rationality assessed.
|
||||
- [ ] Market-share trend traced over 5–10 years, with the mechanism of share movement identified.
|
||||
- [ ] Supplier power, buyer/channel power, entry barriers and substitutes each assessed concretely.
|
||||
- [ ] Position in the cycle established; mid-cycle normalised margin estimated before any multiple is applied.
|
||||
- [ ] Industry capacity additions, utilisation and capex/depreciation checked — the supply side, not just demand.
|
||||
- [ ] Regulatory regime mapped; subsidy- and policy-dependent profit quantified (India: DPCO/NPPA, PLI, tariff orders).
|
||||
- [ ] Profit-pool location and migration direction identified; peer ROIC dispersion vs WACC compared.
|
||||
- [ ] Commoditisation tested via realised price vs input inflation and premium vs private label.
|
||||
|
||||
**Growth and reinvestment runway**
|
||||
- [ ] Revenue growth decomposed: organic vs inorganic, then volume/price/mix/FX, by segment and geography, YoY and QoQ.
|
||||
- [ ] EPS growth decomposed; buyback, tax and one-off contributions separated; GAAP-to-adjusted bridge read.
|
||||
- [ ] Reinvestment rate and ROIIC computed over rolling windows and compared to WACC and to average ROIC.
|
||||
- [ ] Sustainable growth (reinvestment rate × ROIC) reconciled against guided growth.
|
||||
- [ ] Backlog/order book/RPO, coverage, book-to-bill and de-booking checked; definition changes caught (India: unaudited).
|
||||
- [ ] Capex split into maintenance and growth; announced projects checked against prior announcements for overrun and slippage.
|
||||
- [ ] Forward growth bridge built driver by driver in percentage points, and the drivers actually sum to the target.
|
||||
- [ ] Vitality index and R&D productivity computed; patent cliff dated.
|
||||
- [ ] Track record of prior adjacency and geographic expansions assessed.
|
||||
- [ ] Guidance-vs-actual scorecard built over 8–12 quarters (India: concall commitments vs outcomes).
|
||||
- [ ] Capital allocation history judged: M&A prices and post-deal ROIC, impairments, buyback valuations.
|
||||
- [ ] Absolute revenue add required to sustain the growth rate computed; leading indicators checked for deceleration.
|
||||
- [ ] Base rate for the claimed growth durability checked against the reference class, not just the model.
|
||||
- [ ] Funding gap, share-count growth and self-funding test completed; per-share growth compared to aggregate growth.
|
||||
|
||||
**Independent verification**
|
||||
- [ ] At least one non-company data source cross-checked against the reported growth curve.
|
||||
- [ ] Bespoke KPIs catalogued and definition changes checked.
|
||||
- [ ] Consecutive filings redlined for dropped disclosures.
|
||||
- [ ] The strongest bear case read and answered on its own terms.
|
||||
383
finance/skills/stock-analysis/references/03-earnings-quality.md
Normal file
383
finance/skills/stock-analysis/references/03-earnings-quality.md
Normal file
|
|
@ -0,0 +1,383 @@
|
|||
# Income Statement Analysis and Earnings Quality
|
||||
|
||||
Use this when: you are at Stage 4 and need to establish whether the reported profit is real, repeatable, and earned by the operating business.
|
||||
|
||||
The income statement is the most-read and least-trusted of the three statements. It is the one management has the most discretion over, the one that drives headlines and multiples, and the one that can be made to say almost anything within the rules. Your job here is not to admire the profit number — it is to take it apart, find out which parts recur, which parts are cash, and which parts are the accounting equivalent of a loan from next year. Everything downstream (returns on capital, valuation, scoring) inherits the errors you fail to catch here.
|
||||
|
||||
## Contents
|
||||
|
||||
- [1. The OPM trap — read this before computing any margin](#1-the-opm-trap--read-this-before-computing-any-margin)
|
||||
- [2. Revenue growth decomposition](#2-revenue-growth-decomposition)
|
||||
- [3. The margin ladder](#3-the-margin-ladder)
|
||||
- [4. Operating leverage and the fixed/variable split](#4-operating-leverage-and-the-fixedvariable-split)
|
||||
- [5. Below-the-line: the EBIT-to-PAT bridge](#5-below-the-line-the-ebit-to-pat-bridge)
|
||||
- [6. Other income reliance](#6-other-income-reliance)
|
||||
- [7. One-offs, exceptionals and the adjusted-earnings gap](#7-one-offs-exceptionals-and-the-adjusted-earnings-gap)
|
||||
- [8. Tax normalcy and sustainability](#8-tax-normalcy-and-sustainability)
|
||||
- [9. Accruals versus cash — the single highest-yield test](#9-accruals-versus-cash--the-single-highest-yield-test)
|
||||
- [10. Revenue recognition aggressiveness](#10-revenue-recognition-aggressiveness)
|
||||
- [11. Vendor and customer financing — demand bought with your own balance sheet](#11-vendor-and-customer-financing--demand-bought-with-your-own-balance-sheet)
|
||||
- [12. Per-employee productivity cross-check](#12-per-employee-productivity-cross-check)
|
||||
- [13. Segment profitability and mix](#13-segment-profitability-and-mix)
|
||||
- [14. Share-based comp, dilution and per-share quality](#14-share-based-comp-dilution-and-per-share-quality)
|
||||
- [15. Depreciation adequacy and capitalisation policy](#15-depreciation-adequacy-and-capitalisation-policy)
|
||||
- [16. Where this file does not apply](#16-where-this-file-does-not-apply)
|
||||
- [17. Writing the earnings-quality verdict](#17-writing-the-earnings-quality-verdict)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 1. The OPM trap — read this before computing any margin
|
||||
|
||||
**Margin level is sector-bound and close to meaningless across sectors. Margin trend, and the reason behind the trend, is where the information lives.**
|
||||
|
||||
A distributor at 4% operating margin and a software firm at 30% cannot be ranked against each other. The distributor turns its capital over ten times a year and may earn a 40% return on capital; the software firm may be spending three years of gross profit to acquire each customer and earn less. Margin is one input into return on capital (see `05-returns-and-dupont.md`) — it is never a standalone quality score, and a screen sorted on OPM descending is a list of industries, not a list of good businesses.
|
||||
|
||||
What margin *does* tell you, and only in these forms:
|
||||
|
||||
| Question | What to compare | What it means |
|
||||
|---|---|---|
|
||||
| Does this business have pricing power? | Its own gross margin across a full input-cost cycle | Stable/expanding GM through a raw-material spike is the clearest quantitative footprint of a moat |
|
||||
| Is it winning or losing its position? | Its margin vs the sector median, tracked over 5–10 years | Converging toward peers = advantage eroding; diverging above = advantage compounding |
|
||||
| Is management running it well? | GM trend vs OPM trend | GM flat but OPM falling is overhead bloat; GM falling but OPM held is cost-cutting masking a demand problem |
|
||||
| Is the margin structural or cyclical? | Margin vs capacity utilisation, commodity spreads, currency | Peak-cycle margin extrapolated forever is the most common valuation error in cyclicals |
|
||||
|
||||
**Two vocabulary traps that cause real errors:**
|
||||
|
||||
- **India:** what Indian screeners and concalls call "OPM" is almost always **EBITDA margin** — operating profit *before* depreciation, and computed *excluding* other income. What a US analyst calls "operating margin" is **EBIT margin**, after depreciation. Comparing an Indian "OPM %" to a US "operating margin %" without adjusting for depreciation is an apples-to-oranges error of several hundred basis points. Always state which you mean.
|
||||
- **India:** the Schedule III P&L format has **no gross profit line**. Construct it yourself: revenue from operations minus (cost of materials consumed + purchases of stock-in-trade + changes in inventories of FG/WIP/stock-in-trade). Decide explicitly whether to include power & fuel, freight and direct labour, and apply the same definition to every peer — otherwise the peer comparison is noise.
|
||||
- **Both markets:** Ind-AS 116 / IFRS 16 moved operating-lease rent out of opex into depreciation and interest, inflating EBITDA margin with no economic change. Retailers, airlines, hotels and QSR are affected most. Never compare a post-adoption EBITDA margin to a pre-adoption one, or an IFRS lessee to a US GAAP operating-lease lessee, without adjusting. See `14-accounting-comparability.md`.
|
||||
|
||||
---
|
||||
|
||||
## 2. Revenue growth decomposition
|
||||
|
||||
Headline growth is an aggregate of drivers with completely different durability. Decompose it before you value it.
|
||||
|
||||
**Decompose into:** organic volume · price/realisation · product and customer mix · currency translation · acquisitions and divestitures.
|
||||
|
||||
Sources for the bridge: MD&A / Item 7 in the 10-K, the "revenue bridge" slide in the investor deck, constant-currency disclosures, and unit disclosures (tonnes, units, subscribers, room-nights, billable headcount, same-store/like-for-like). In India, the concall Q&A is often the only place volume-versus-realisation is split — management will give it if asked, and the transcript is a primary source.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Revenue CAGR (3/5/10y) | (End/Start)^(1/n) − 1, consolidated | Comfortably above nominal GDP + sector inflation | Below nominal GDP is real-terms shrinkage regardless of the reported "growth" |
|
||||
| Organic growth % | Reported growth − acquired revenue contribution − FX | Should be the majority of total growth | Isolates the actual franchise from deal-making |
|
||||
| Volume growth vs realisation growth | Units/tonnes/subs YoY vs revenue-per-unit YoY | Volume positive over a cycle | Price-led growth reverses when input costs fall; volume compounds |
|
||||
| Same-store / like-for-like | Revenue from outlets/contracts open the full comparable period | Positive and above inflation | Strips out the store-opening treadmill in retail, QSR, hotels |
|
||||
| Book-to-bill; backlog coverage | New orders ÷ revenue; backlog ÷ trailing revenue (months) | >1.0x; coverage stable or rising | Leading indicator for EPC, capital goods, IT services, defence |
|
||||
| Constant-currency growth | Reported growth ex-translation | — | FX tailwinds are not performance |
|
||||
|
||||
*Indicative ranges vary by market, cycle and period; the company's own history and the peer median override any absolute band.*
|
||||
|
||||
**Why this matters:** two companies printing 15% growth can be opposite investments. Volume-led growth with stable price is demand. Price-led growth during an inflation spike is a loan from the next deflation. Roll-up growth resets the baseline every year and hides an organic business that may be shrinking — check what happens to the growth rate if M&A pauses, and pair this with the serial-acquirer accounting checks in `07-forensic-red-flags.md`.
|
||||
|
||||
**Red flags:** growth entirely from price while volumes decline; growth that vanishes when acquisitions are stripped out; deceleration masked by serial M&A; revenue growing below inflation for years; growth carried by one large contract or one customer; recurring quarter-end revenue surges.
|
||||
|
||||
**India note:** Q4 standalone/consolidated results are frequently a *balancing figure* — audited full-year minus the three limited-review quarters. Provisions, true-ups and rev-rec adjustments cluster there. Always compare Q4 margin and other income to the 9M run-rate; a Q4 that looks nothing like the rest of the year is telling you where the discretion was exercised.
|
||||
|
||||
---
|
||||
|
||||
## 3. The margin ladder
|
||||
|
||||
Walk every rung. Each level answers a different question, and the *differences between adjacent rungs* are where the information is.
|
||||
|
||||
| Rung | What it isolates | What can be manipulated at this rung |
|
||||
|---|---|---|
|
||||
| **Gross margin** | Pricing power and cost position — the purest moat read | Cost reclassification into SG&A; capitalising production costs; inventory absorption games; channel stuffing |
|
||||
| **EBITDA margin** | Cash-ish operating profitability before capital intensity | The most gamed metric of all: "adjusted" add-backs, lease accounting, SBC added back |
|
||||
| **EBIT / operating margin** | True core profitability including the cost of the asset base | Understated depreciation; opex capitalised; "other operating income" of dubious nature parked above the line |
|
||||
| **PBT margin** | After financing and associates | Interest capitalised into assets; associate income; forex reclassification |
|
||||
| **PAT margin** | After tax and minorities | Tax holidays, deferred-tax reversals, minority-interest structure |
|
||||
| **EPS** | After dilution and buybacks | Share-count engineering; SBC excluded from adjusted EPS |
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Gross margin % | Gross profit ÷ revenue (construct manually for Ind-AS filers) | Wholly sector-bound: ~15–25% distribution/EPC, ~25–40% auto components, ~50–70% branded consumer/pharma, ~70–90% software | Level says little; *stability through an input-cost cycle* says a lot |
|
||||
| GM delta (bps YoY, 5y trend) | Change in GM in basis points | Trend flat-to-up | Multi-year erosion = commoditisation working its way down every line |
|
||||
| Raw material % of sales | Cost of materials ÷ revenue | — | Sizes the input-cost exposure you are underwriting |
|
||||
| EBITDA margin % | EBITDA ÷ revenue; state whether pre- or post-IFRS 16 | Sector-bound | Drives multiples and covenants — which is exactly why it is manipulated |
|
||||
| Adjusted-vs-reported EBITDA gap | (Adj EBITDA − reported) ÷ reported | <5%, and shrinking | A persistent double-digit gap means the "clean" number overstates earning power |
|
||||
| Add-backs as % of EBITDA | Sum of all adjustments ÷ EBITDA | <10% | Add-backs that appear every year are operating costs |
|
||||
| EBIT margin % | EBIT ÷ revenue | Sector-bound | The cleanest measure of scalable core profitability |
|
||||
| SG&A / R&D / employee cost as % of sales | Each line ÷ revenue, 5-year trend | Stable or falling with scale | Reveals whether growth is being bought or earned |
|
||||
|
||||
*Indicative ranges vary by market, cycle and period; peer and own-history comparison overrides any absolute band.*
|
||||
|
||||
**The diagnostic that matters most: compare the GM trend with the OPM trend.**
|
||||
- GM stable, OPM falling → overhead bloat or negative operating leverage. Ask what SG&A is buying.
|
||||
- GM falling, OPM stable → costs are being cut to protect the print. Check whether R&D, advertising or maintenance capex is being starved — margin held by mortgaging the future looks identical to margin held by efficiency for about three years.
|
||||
- Both rising, revenue flat → suspicious. Cost capitalisation and reclassification produce exactly this signature.
|
||||
- A sudden unexplained GM jump with no mix or input-price explanation is a forensic trigger, not a positive.
|
||||
|
||||
**On EBITDA specifically:** it excludes capex, working capital and the real cost of stock compensation. Treat every add-back as a claim requiring evidence. Restructuring charges in five consecutive years are a cost of doing business. Reconcile adjusted EBITDA back to statutory operating profit *and* to operating cash flow; if adjusted EBITDA grows while cash flow does not, the adjustments are the growth. US filers must publish a Reg G / Item 10(e) reconciliation in the 10-K or 8-K Item 2.02 — read it, do not take the press-release headline.
|
||||
|
||||
---
|
||||
|
||||
## 4. Operating leverage and the fixed/variable split
|
||||
|
||||
Estimate the fixed/variable cost split and measure how earnings respond to revenue.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Degree of operating leverage | %Δ EBIT ÷ %Δ revenue, over several periods | 1.5–3x for most industrials; >4x is a cyclical warning | Sizes the downside, not just the upside |
|
||||
| Incremental margin | Δ EBIT ÷ Δ revenue (YoY) | At or above current EBIT margin | Falling incremental margin means new revenue is worth less than old revenue |
|
||||
| Decremental margin | Same, on a revenue decline | Below the incremental margin | Tells you what a 20% volume drop actually does to EBIT |
|
||||
| Contribution margin % | (Revenue − variable costs) ÷ revenue | — | Needed to compute breakeven |
|
||||
| Breakeven revenue | Fixed costs ÷ contribution margin % | Comfortably below trough-cycle revenue | If breakeven is creeping toward current sales, a mild downturn produces losses |
|
||||
| Capacity utilisation | Volume ÷ rated capacity | — | Margin expansion at rising utilisation is *not* structural improvement |
|
||||
|
||||
**Why it matters:** operating leverage determines earnings volatility and therefore the multiple the business deserves. Margin expansion driven purely by volume flowing over a fixed base will reverse just as fast on the way down. Before crediting management for a 300bps margin gain, decompose it: how much was utilisation, how much was input-cost deflation, how much was price, how much was genuine structural cost-out that survives a downturn. Then stress the EBIT at trough-cycle revenue — that number, not the current one, is what a cyclical should be valued on (`13-situations.md`).
|
||||
|
||||
---
|
||||
|
||||
## 5. Below-the-line: the EBIT-to-PAT bridge
|
||||
|
||||
Build the bridge explicitly and quantify every step: EBIT → finance costs → interest/other income → share of associates and JVs → exceptional items → tax → non-controlling interests → PAT attributable to owners.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| PBT margin % | PBT ÷ revenue | Sector-bound | Where financing structure shows up |
|
||||
| PAT margin % | PAT attributable to owners ÷ revenue | Sector-bound | The bottom line equity holders actually own |
|
||||
| PAT growth vs EBIT growth | 3–5 year CAGR of each | Should track within a few points | Persistent divergence means the profit engine is below the operating line |
|
||||
| Interest coverage | EBIT ÷ finance cost | >4x general; >6x for cyclicals | Detail in `04-balance-sheet-and-cashflow.md` |
|
||||
| Minority interest as % of PAT | NCI share ÷ consolidated PAT | — | High NCI means headline consolidated PAT overstates what owners get |
|
||||
| Associate/JV share as % of PAT | Share of profit of associates ÷ PAT | Small, unless it is the business model | Associate income is non-cash until dividended up |
|
||||
|
||||
**Why it matters:** net margin can rise for years while the operating business decays, on nothing but falling interest rates, a rising associate contribution, or a tax break. That growth is lower quality — management does not control it, it does not compound, and it should not earn the multiple that operating growth earns.
|
||||
|
||||
**Red flags:** net margin rising while operating margin falls; profit growth attributable mainly to deleveraging or a falling tax rate; consolidated PAT flattered by a partly-owned subsidiary (check the "attributable to owners of the parent" line, not the consolidated total); interest capitalised into CWIP suppressing the finance-cost line while a project builds. **India:** always compare standalone and consolidated — where they diverge sharply, the subsidiaries and associates are the story.
|
||||
|
||||
---
|
||||
|
||||
## 6. Other income reliance
|
||||
|
||||
Disaggregate "other income" into recurring (interest on surplus cash, dividends from investments) and non-core/lumpy (asset-sale gains, treasury and mark-to-market gains, forex, government grants and export incentives, insurance recoveries, provision write-backs).
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Other income as % of PBT | Other income ÷ PBT | <10%; investigate above ~15–20% | Above that, a share of the "profit" is not the business |
|
||||
| Recurring vs non-recurring split | From the other-income note in the accounts | Majority recurring | Disposal gains do not repeat |
|
||||
| Treasury income vs core EBIT | Investment income ÷ EBIT | — | A large cash pile earning interest is not operating skill |
|
||||
| Forex gain/loss as % of PBT | Net FX ÷ PBT | Small and two-directional over time | One-directional FX "gains" every year suggests policy, not luck |
|
||||
|
||||
**Why it matters:** other income overstates sustainable earning power and is the easiest lever for hitting a target. Its collapse is also mechanical: interest income vanishes the moment the cash pile is deployed into capex or an acquisition, so a company valued on a P/E that includes treasury income gets re-rated downward the year it finally invests.
|
||||
|
||||
**India note:** the Schedule III format gives "Other income" its own prominent line, and Indian screeners exclude it from operating profit by design — which is correct. Read the note behind the line; export incentives, PLI grants and forex are often material and are frequently reported as though they were operating.
|
||||
|
||||
---
|
||||
|
||||
## 7. One-offs, exceptionals and the adjusted-earnings gap
|
||||
|
||||
Catalogue every exceptional, special, restructuring, impairment, litigation-provision, write-off and disposal item for the last **5–7 years** in a single table. The table is the analysis — the pattern across years is what a single-year read cannot show.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Exceptional items as % of PBT | Absolute exceptional ÷ PBT, per year | Genuinely rare | Frequency, not size, is the tell |
|
||||
| Frequency over 5–7 years | Count of years with an exceptional charge | ≤2 of 7 | Charges in 5 of 7 years are operating costs mislabelled |
|
||||
| Cumulative restructuring/impairment | Sum over the period vs cumulative reported PAT | Small fraction | Shows how much "profit" was written back off |
|
||||
| Adjusted vs statutory PAT gap | (Adj PAT − statutory) ÷ statutory | <10% and non-directional | A permanent one-way gap means the adjustments are the earnings |
|
||||
|
||||
**Why it matters:** classification of an item as exceptional is discretionary, and the discretion runs one way. Only charges get excluded from "underlying" profit; one-off *gains* stay in. Normalised earnings built on that asymmetry are systematically overstated, and every multiple computed on them is systematically too low.
|
||||
|
||||
**Red flags:** "non-recurring" charges in most years; asymmetric treatment of gains and losses; a big-bath write-off in the first year of a new CEO (resetting the base so future growth looks better); impairment of goodwill from a recent acquisition (a priced admission of overpayment — see `07-forensic-red-flags.md`); serial restructuring programmes each announced as the last one.
|
||||
|
||||
**India note:** Ind-AS 1 discourages the label "extraordinary items", but Indian filers still present an "Exceptional items" line. Cross-check it against the CARO report, the Key Audit Matters, and the contingent-liabilities note — provisions created and later written back to profit are a classic cookie jar.
|
||||
|
||||
---
|
||||
|
||||
## 8. Tax normalcy and sustainability
|
||||
|
||||
Compare the effective tax rate to the statutory rate and read the rate reconciliation in the tax footnote.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Effective tax rate | Total tax expense ÷ PBT | Near statutory: India ~25.17% under the 115BAA concessional regime (22% + surcharge + cess); US ~21% federal + state | A rate far below statutory needs a durable, named reason |
|
||||
| Statutory-to-effective gap | Reconciliation line items | Explained and stable | Unexplained gaps are the warning |
|
||||
| Cash tax rate | Taxes actually paid (cash flow statement) ÷ PBT | Close to the book rate over 3–5 years | Book profit with negligible cash tax means the profit is not being recognised by the tax authority either |
|
||||
| Deferred tax movement | Δ net DTA/DTL | Small relative to PAT | A large DTA recognition can single-handedly create a profitable year |
|
||||
| Remaining life of incentives | From the tax note / MD&A | Known and modelled | Expiry creates a step-down in EPS with no operational change |
|
||||
|
||||
**Why it matters:** an abnormally low tax rate inflates EPS in a way that does not persist. Tax holidays expire on a published date; when they do, PAT drops by the difference with no warning from the operating business. Model the post-expiry EPS before applying a multiple.
|
||||
|
||||
**India-specific:** SEZ/Section 10AA benefits taper and sunset; the old 80-IA infrastructure deductions; MAT/AMT credits being drawn down; whether the company has opted into the 115BAA regime (which forfeits most incentives permanently). **US-specific:** GILTI/FDII, R&D credits, the Section 174 capitalisation rules that have widened the book-versus-cash tax gap for R&D-heavy filers since 2022, valuation allowances on deferred tax assets, and uncertain tax positions (FIN 48) disclosed in the footnote.
|
||||
|
||||
**Red flag:** net profit growth where the largest single contributor is a falling tax rate. Strip it out and re-read the growth rate.
|
||||
|
||||
---
|
||||
|
||||
## 9. Accruals versus cash — the single highest-yield test
|
||||
|
||||
If you run only one earnings-quality test, run this one. Accrual-heavy earnings reliably revert.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Cash conversion | CFO ÷ net income, averaged over 3–5 years | >0.9x; >1.0x is strong | A single year is noise; a five-year average below 0.8x is a finding |
|
||||
| FCF conversion | (CFO − capex) ÷ net profit | >0.6x for a maturing business | Profit that never becomes spendable cash is not profit yet |
|
||||
| OCF ÷ EBITDA | Operating cash flow ÷ EBITDA | >0.7x | Isolates working-capital absorption |
|
||||
| Sloan accrual ratio | (Net income − CFO) ÷ average total assets | <5%; >10% is a red flag | The classic academic predictor of earnings reversal |
|
||||
| Balance-sheet accruals | Δ net operating assets ÷ average net operating assets | Low and non-trending | Catches accruals that route through investing, not just working capital |
|
||||
| Receivables/inventory growth vs revenue growth | Each YoY growth rate | At or below revenue growth | Both growing faster than sales is the standard signature of pulled-forward revenue |
|
||||
|
||||
*Indicative ranges vary by market, cycle and period; a growing company legitimately absorbs working capital — compare to its own history and to peers growing at the same rate.*
|
||||
|
||||
**Why it matters:** the gap between accounting profit and cash generation is the most reliable early-warning signal available from public filings, and it is early — it typically widens for several periods before the reported numbers break. Note that the direction of the test is asymmetric: cash below profit is a warning; cash *above* profit is usually a good sign (negative working capital, deferred revenue growth) but check it is not just underinvestment or a one-time payables stretch.
|
||||
|
||||
Depth on working-capital mechanics and the cash flow statement sits in `04-balance-sheet-and-cashflow.md`; the fraud-detection framing (Beneish-style ratios, channel stuffing) sits in `07-forensic-red-flags.md`.
|
||||
|
||||
---
|
||||
|
||||
## 10. Revenue recognition aggressiveness
|
||||
|
||||
Read the revenue-recognition accounting policy and the critical-estimates note. You are looking for how much judgement sits between a customer's order and a revenue line.
|
||||
|
||||
**What to examine:**
|
||||
- **Timing:** point-in-time vs over-time; percentage-of-completion vs milestone (dominant in EPC, infrastructure, defence, and long-cycle IT contracts, and the single most judgement-laden method in common use).
|
||||
- **Gross vs net (principal vs agent):** whether a marketplace books GMV or commission. Gross-basis reporting can overstate apparent scale by an order of magnitude and makes every margin ratio incomparable to a net-basis peer.
|
||||
- **Multi-element arrangements:** how a bundle of hardware, licence and support is allocated across performance obligations, and how much revenue is pulled to day one.
|
||||
- **Bill-and-hold, channel financing, distributor sell-in vs sell-through:** revenue recognised into a channel is not demand.
|
||||
- **Returns, rebates, discounts and warranty provisioning:** under-provisioning inflates current revenue and margin.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| DSO | (Receivables ÷ revenue) × 365 | Stable vs own history and peers | Rising DSO with rising revenue is the classic pulled-forward-revenue signature |
|
||||
| Contract assets / unbilled receivables growth | YoY growth vs revenue growth | At or below revenue growth | Revenue recognised ahead of the right to bill is the softest revenue there is |
|
||||
| Deferred revenue / contract liabilities | YoY trend vs revenue | Growing with revenue for subscription models | Falling deferred revenue while revenue grows = the backlog is being consumed, not replenished |
|
||||
| Provision for returns/rebates as % of sales | From the provisions note | Stable | A quietly shrinking provision rate is a margin lever, not an improvement |
|
||||
|
||||
**Red flags:** contract assets compounding well ahead of revenue; DSO up several quarters in a row; a rev-rec policy change that happens to lift growth; quarter-end revenue spikes (especially the Indian Q4 balancing quarter); gross-basis presentation adopted without a principal-role justification; revenue growth concentrated in the least-verifiable geography or the newest business line.
|
||||
|
||||
**Standards:** Ind-AS 115 and IFRS 15 and ASC 606 are converged in substance, so the five-step model and the disaggregation disclosures are comparable across markets — use the disaggregation table, it is one of the most useful and least-read disclosures in any filing.
|
||||
|
||||
---
|
||||
|
||||
## 11. Vendor and customer financing — demand bought with your own balance sheet
|
||||
|
||||
Determine whether the company is funding its own customers' purchases: captive finance arms, seller notes, unusually long or extended credit to distributors, channel financing arrangements, guarantees of customer or dealer debt, buy-back or residual-value commitments, and vendor loans on equipment sales.
|
||||
|
||||
**Where to look:** notes receivable and long-dated/non-current receivables; the related-party and contingent-liability notes; guarantees given; the financing subsidiary's own accounts; and the gap between revenue growth and cash collections. In India, CARO reporting on loans and guarantees, and the Ind-AS 24 related-party note, are the practical route.
|
||||
|
||||
**Why it matters:** revenue funded by the seller's own credit is not demand — it is a loan that has been booked as a sale. It reads as clean organic growth until the receivables sour, and then it reverses violently, taking both the revenue and the balance sheet down at once. This mechanism has repeatedly destroyed telecom-equipment, solar, EV and capital-goods names historically; the pattern is always the same and always visible in the receivable maturities before it is visible in the P&L.
|
||||
|
||||
**What to compute:** customer financing exposure (on- and off-balance-sheet) as a % of annual revenue; the share of revenue growth attributable to financed sales; and the receivable ageing profile. If a material share of growth is vendor-financed, treat that revenue as lower quality and treat the company as partly a lender — which means the sector playbooks for lenders (`sectors/nbfc.md`) have relevant tests even for an industrial.
|
||||
|
||||
---
|
||||
|
||||
## 12. Per-employee productivity cross-check
|
||||
|
||||
Compute revenue per employee and gross profit per employee versus peers and over 5+ years, alongside headcount growth versus revenue growth.
|
||||
|
||||
**Why it matters:** headcount is one of the few operating inputs that is hard to fabricate and is often disclosed independently of the financials (annual report, LinkedIn-scale disclosures, ESG/BRSR reports, regulatory filings). It provides an external sanity check on claimed scale. Deteriorating revenue per employee while a growth story is being told, or a hiring freeze that contradicts guidance, is an early and independent tell.
|
||||
|
||||
**Read it sector-appropriately.** In IT services, revenue per employee combined with utilisation and offshore mix is a core margin driver, not merely a check. In manufacturing it tracks automation and mix. In software and platforms it should rise steeply with scale — if it does not, the business is not actually scaling. **India note:** employee benefit expense is a separate Schedule III line and headcount is disclosed in the Board's Report and BRSR, so this cross-check is usually computable for NSE/BSE names.
|
||||
|
||||
---
|
||||
|
||||
## 13. Segment profitability and mix
|
||||
|
||||
Break the consolidated result into reportable segments and geographies: revenue mix, segment EBIT and margin, growth rate, capital employed, and the size of unallocated corporate costs.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Segment revenue mix % | Segment revenue ÷ total | — | Shows where the business actually is |
|
||||
| Segment EBIT margin and 5y trend | From the segment note | — | The consolidated margin is a weighted average hiding both good and bad |
|
||||
| % of profit from the top segment | Largest segment EBIT ÷ total segment EBIT | <60% for a diversified claim | Concentration in one segment means you are underwriting one business, not a portfolio |
|
||||
| Unallocated / corporate cost as % of EBIT | From the reconciliation | Small and stable | Rising unallocated costs is where inconvenient items go |
|
||||
| Segment ROCE | Segment EBIT ÷ segment capital employed (where disclosed) | — | The only way to see if a segment earns its capital |
|
||||
|
||||
**Why it matters:** consolidated numbers blend divergent economics and disguise cross-subsidy. A profitable core funding a chronic loss-maker destroys value even while consolidated profit grows, and mix shift toward lower-return segments lowers the multiple the whole company deserves even when EPS is rising. Segment disclosure is also where you find whether the growth story and the profit source are the same business — frequently they are not.
|
||||
|
||||
**Red flags:** frequent redefinition of segments (a common way to bury a deteriorating unit); aggregation into a single "others" bucket; segment results presented without capital employed; rising unallocated costs.
|
||||
|
||||
**Conventions:** Ind-AS 108 and ASC 280 both use the management approach, so segments follow internal reporting and are *not* comparable across companies — build the peer comparison at the metric level, not the segment-label level. US filers now disclose significant segment expenses under ASU 2023-07, which materially improves this analysis for 10-K filers. Indian companies disclose segment revenue, results, assets and liabilities quarterly — use the quarterly segment series, it is the highest-frequency view of mix available.
|
||||
|
||||
---
|
||||
|
||||
## 14. Share-based comp, dilution and per-share quality
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| SBC as % of revenue | SBC expense ÷ revenue | <5%; >10% is severe | A real cost of labour paid in shares |
|
||||
| SBC as % of operating cash flow | SBC ÷ CFO | <20% | SBC is added back in the cash flow statement — CFO is flattered by exactly this amount |
|
||||
| Diluted share count growth | YoY change in weighted diluted shares | ≤1–2% p.a. | Steady dilution is a quiet transfer of value away from you |
|
||||
| Diluted EPS CAGR vs net income CAGR | Both over 5 years | EPS ≥ NI growth | EPS lagging net income means dilution is eating the growth |
|
||||
| Buyback contribution to EPS growth | EPS growth − net income growth | Should be a minority of EPS growth | Separates operating performance from financial engineering |
|
||||
| Net buyback vs issuance | Shares retired − shares issued | Genuinely negative | Buybacks that only mop up option issuance are compensation, not capital return |
|
||||
|
||||
**Why it matters:** SBC is a real economic cost that is routinely added back to "adjusted" earnings and EBITDA, and it is added back in the cash flow statement by construction — so a company with heavy SBC shows flattering margins *and* flattering operating cash flow simultaneously. Meanwhile EPS can rise for years on debt-funded buybacks while revenue and EBIT go nowhere. Always decompose EPS growth into operating growth, margin, and share count before crediting management with anything.
|
||||
|
||||
**Conventions:** dilution must be computed on the diluted count under the treasury-stock method, plus any convertible instruments under the if-converted approach (ASU 2020-06 for US filers). **India:** ESOP charges appear within employee benefit expense; the scheme details, outstanding options and exercise prices sit in the Board's Report / ESOP disclosure under the SEBI SBEB Regulations. Indian SBC is generally far smaller than US tech levels — do not import a US benchmark. Also check warrants issued to promoters and preferential allotments, which dilute outside any ESOP scheme.
|
||||
|
||||
---
|
||||
|
||||
## 15. Depreciation adequacy and capitalisation policy
|
||||
|
||||
Understated depreciation and aggressive capitalisation are the two quietest ways to inflate current profit, because both defer a real cost rather than eliminating it.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| D&A as % of sales | D&A ÷ revenue, 5-year trend | Stable; sector-bound | A falling ratio with a growing asset base needs an explanation |
|
||||
| D&A ÷ capex | 5-year averages of both | ~0.8–1.2x for a steady-state business | D&A persistently far below capex means depreciation is not reflecting replacement needs |
|
||||
| Implied depreciation rate | Depreciation ÷ average gross block | Consistent with disclosed useful lives | Falling implied rate = lives lengthened or asset mix shifted |
|
||||
| Capitalised development/software as % of relevant spend | From the intangibles note and cash flow statement | Low vs peers who expense | If peers expense what this company capitalises, the margins are not comparable |
|
||||
| Amortisation of acquired intangibles | From the intangibles note | — | Serial acquirers "adjust it out" while continuing to buy the intangibles |
|
||||
|
||||
**Why it matters:** capitalising a cost moves it from this year's P&L to the next several years' depreciation line. Profit rises now, and the business looks more asset-light and more profitable than it is. The comparison that exposes it is against peers: within the same sector, if one company capitalises development costs and product engineering while the others expense them, the margin gap is an accounting choice, not a performance gap. Normalise before you compare (`14-accounting-comparability.md`).
|
||||
|
||||
**Red flags:** useful lives extended in a year when earnings needed help; a change in depreciation method; capitalised development or software rising faster than revenue; capitalised interest large relative to PBT; a low depreciation charge against a large gross block; subscriber-acquisition or contract-acquisition costs capitalised.
|
||||
|
||||
**Conventions:** **India** — Schedule II of the Companies Act 2013 prescribes indicative useful lives; a company using longer lives must disclose technical justification, so a deviation is both visible and meaningful. Also check the componentisation approach and the treatment of CWIP (long-standing CWIP with capitalised interest is a classic profit-deferral and impairment risk). **US/IFRS** — IFRS/Ind-AS requires capitalising development costs meeting the IAS 38 criteria while US GAAP largely expenses R&D (with narrow software exceptions), which is a structural, not discretionary, difference between an IFRS and a US GAAP peer. Adjust for it explicitly rather than treating it as a quality difference.
|
||||
|
||||
---
|
||||
|
||||
## 16. Where this file does not apply
|
||||
|
||||
The governing principle bites hardest here. For several sectors the standard income-statement ladder is undefined or inverted, and applying it produces confident nonsense:
|
||||
|
||||
- **Banks and NBFCs** — there is no revenue, COGS or gross margin. The equivalents are net interest income, NIM, fee income, cost-to-income, credit cost and provision coverage. Interest expense is a cost of goods, not a financing item. Go to `sectors/banks.md` / `sectors/nbfc.md`.
|
||||
- **Insurers** — premium is not revenue in the ordinary sense; the profit signal is the combined ratio (general/health) or VNB margin and embedded-value movement (life). `sectors/insurance.md`.
|
||||
- **REITs / InvITs** — net income is meaningless because depreciation on appreciating property overwhelms it; use FFO/AFFO and NDCF. `sectors/realestate-reit.md`.
|
||||
- **Miners and commodity producers** — margin is a price artefact. Use cost-curve position (C1/AISC), reserve life and mid-cycle realisations. `sectors/metals-mining.md`.
|
||||
- **Loss-making growth companies** — the margin ladder still applies but the level is uninformative; work on gross margin, contribution margin after customer-acquisition cost, cohort economics and the path to breakeven. `13-situations.md`.
|
||||
|
||||
---
|
||||
|
||||
## 17. Writing the earnings-quality verdict
|
||||
|
||||
Do not present this as fifteen paragraphs of findings. Compress to a judgement the reader can act on:
|
||||
|
||||
1. **Quality of the growth** — how much of the last three years' revenue growth was volume, price, mix, FX and M&A, in numbers.
|
||||
2. **Quality of the margin** — direction over 5–10 years, the reason for the direction, and whether it is structural or cyclical. State the peer median so the level is anchored, and say explicitly that the level alone is not the finding.
|
||||
3. **Quality of the profit** — how much of PAT is operating, and what the multi-year cash conversion is.
|
||||
4. **The adjustment gap** — statutory PAT versus the company's own adjusted number, and whether the gap is one-directional.
|
||||
5. **The three things that would change this verdict** — specific, observable, checkable next quarter.
|
||||
|
||||
Then carry the *normalised* earnings figure forward into valuation, not the reported one, and state every normalisation you made.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Stated whether "OPM" here means EBITDA margin (Indian convention) or EBIT margin (US convention).
|
||||
- [ ] Constructed gross margin manually for Ind-AS filers and used the identical definition for every peer.
|
||||
- [ ] Decomposed 3-year revenue growth into volume, price/mix, FX and M&A, with a source for each.
|
||||
- [ ] Compared revenue growth to nominal GDP + sector inflation, and to industry volume growth.
|
||||
- [ ] Checked same-store/like-for-like and book-to-bill or backlog coverage where the sector has them.
|
||||
- [ ] Plotted the full margin ladder for 5–10 years; compared the GM trend against the OPM trend and explained any divergence.
|
||||
- [ ] Checked lease-accounting (IFRS 16 / Ind-AS 116) comparability before comparing EBITDA margins.
|
||||
- [ ] Listed every add-back to adjusted EBITDA/EPS and tested whether each recurs across 5+ years.
|
||||
- [ ] Estimated degree of operating leverage and incremental margin; stress-tested EBIT at trough revenue.
|
||||
- [ ] Built the EBIT→PAT bridge; quantified interest, associates, minorities and tax separately.
|
||||
- [ ] Split other income into recurring and non-recurring; flagged if it exceeds ~15% of PBT.
|
||||
- [ ] Tabulated exceptional items for 5–7 years; checked for asymmetric treatment of gains vs losses.
|
||||
- [ ] Compared ETR to statutory, and cash tax to book tax; noted expiry dates of any tax incentives.
|
||||
- [ ] Computed 3–5 year average CFO/net income, FCF/PAT and the Sloan accrual ratio.
|
||||
- [ ] Compared receivables, inventory and contract-asset growth to revenue growth.
|
||||
- [ ] Read the revenue-recognition policy; checked gross vs net, POC judgement, DSO trend and quarter-end spikes.
|
||||
- [ ] Checked for vendor/customer financing, guarantees and long-dated receivables funding reported demand.
|
||||
- [ ] Cross-checked revenue and gross profit per employee against peers and own 5-year history.
|
||||
- [ ] Analysed segment margins, mix shift, unallocated costs and any segment redefinition.
|
||||
- [ ] Measured SBC as % of revenue and of CFO; decomposed EPS growth into operating growth vs share count.
|
||||
- [ ] Tested depreciation adequacy (D&A vs capex, implied rate vs gross block) and capitalisation policy vs peers.
|
||||
- [ ] Confirmed consolidated vs standalone basis, currency and units on every figure used (India: crore/lakh).
|
||||
- [ ] Confirmed the sector actually admits these metrics; switched to the sector playbook if it does not.
|
||||
- [ ] Carried a normalised earnings figure into valuation and disclosed every normalisation made.
|
||||
|
|
@ -0,0 +1,478 @@
|
|||
# Balance Sheet Strength, Solvency and Cash Generation
|
||||
|
||||
Use this when: you are at Stage 4 and need to establish whether the company can survive what it owes, and whether the profit you validated upstream turns into cash the owners actually keep.
|
||||
|
||||
The income statement is an opinion assembled from estimates. The balance sheet tells you who has a prior claim on the business and in what order; the cash flow statement tells you whether the profit was ever real. Almost all permanent capital loss in equities traces to one of two failures — debt that could not be refinanced, or earnings that never became cash — and both are visible in these two statements long before the price reacts. Treat this file as one question in two halves: *what does it owe, and what does it generate to pay with?* As everywhere in this skill, no ratio below means anything until you have placed it against the sector norm and the company's own five-to-ten-year record.
|
||||
|
||||
## Contents
|
||||
|
||||
- [0. Sector gate — where this toolkit is undefined or inverted](#0-sector-gate--where-this-toolkit-is-undefined-or-inverted)
|
||||
- [1. Build the economic debt figure before computing any ratio](#1-build-the-economic-debt-figure-before-computing-any-ratio)
|
||||
- [2. Prove the cash is real](#2-prove-the-cash-is-real)
|
||||
- [3. Leverage and capital structure](#3-leverage-and-capital-structure)
|
||||
- [4. Maturity profile and refinancing risk](#4-maturity-profile-and-refinancing-risk)
|
||||
- [5. Coverage: can it service what it owes](#5-coverage-can-it-service-what-it-owes)
|
||||
- [6. Covenants and headroom](#6-covenants-and-headroom)
|
||||
- [7. Liquidity ratios, facilities and runway](#7-liquidity-ratios-facilities-and-runway)
|
||||
- [8. Working capital and the cash conversion cycle](#8-working-capital-and-the-cash-conversion-cycle)
|
||||
- [9. Receivables and inventory quality](#9-receivables-and-inventory-quality)
|
||||
- [10. Off-balance-sheet, contingent and quasi-debt obligations](#10-off-balance-sheet-contingent-and-quasi-debt-obligations)
|
||||
- [11. Toxic and structured financing, chronic dilution](#11-toxic-and-structured-financing-chronic-dilution)
|
||||
- [12. Goodwill, tangible book and asset productivity](#12-goodwill-tangible-book-and-asset-productivity)
|
||||
- [13. Direction of travel, distress scores and credit-market signals](#13-direction-of-travel-distress-scores-and-credit-market-signals)
|
||||
- [14. Does profit become cash? Accrual quality](#14-does-profit-become-cash-accrual-quality)
|
||||
- [15. Free cash flow: define it before you use it](#15-free-cash-flow-define-it-before-you-use-it)
|
||||
- [16. Maintenance versus growth capex](#16-maintenance-versus-growth-capex)
|
||||
- [17. SBC and the FCF shareholders actually keep](#17-sbc-and-the-fcf-shareholders-actually-keep)
|
||||
- [18. Sources and uses: who funded the growth, were the payouts earned](#18-sources-and-uses-who-funded-the-growth-were-the-payouts-earned)
|
||||
- [19. Classification games and off-statement financing](#19-classification-games-and-off-statement-financing)
|
||||
- [20. Cash taxes versus book taxes](#20-cash-taxes-versus-book-taxes)
|
||||
- [21. Full-cycle durability and cash return on capital](#21-full-cycle-durability-and-cash-return-on-capital)
|
||||
- [22. India versus US: conventions that break comparability](#22-india-versus-us-conventions-that-break-comparability)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
**Every range printed below is indicative only.** Bands shift with sector, market, rate cycle, accounting regime and period. Net debt/EBITDA of 3x is prudent for a contracted utility and reckless for a mid-cap capital-goods firm with a 200-day cash cycle. Peer comparison and the company's own history override any absolute band here. When you cite a band in output, cite it as a reference point and immediately state what the peer set actually does.
|
||||
|
||||
---
|
||||
|
||||
## 0. Sector gate — where this toolkit is undefined or inverted
|
||||
|
||||
Run this gate first. For several sectors the standard ratios below are not merely different, they are meaningless, and computing them produces confidently wrong conclusions.
|
||||
|
||||
| Sector | What breaks | Use instead |
|
||||
|---|---|---|
|
||||
| Banks (NSE/BSE and US) | Debt is raw material, not risk. Debt/equity of 8–12x is normal. Current ratio, CCC, working capital and FCF are undefined — deposits are funding, loans are assets | CET1 / CRAR, GNPA and NNPA, provision coverage, slippage and credit cost, CASA mix, LCR/NSFR, ALM bucket gaps, restructured book |
|
||||
| NBFCs / HFCs (India) | Same as banks plus acute asset-liability risk; leverage *is* the business model | Tier-1 and CRAR, ALM mismatch in the ≤1-year bucket, borrowing mix (bank lines vs CP vs NCD vs securitisation), incremental cost of funds, Stage-3 assets, liquidity buffer |
|
||||
| Insurers | No revenue-driven working capital; float is a liability that funds the asset book | Solvency ratio (IRDAI floor 1.5x), VNB and VNB margin, embedded value, persistency, combined ratio (general), reserve adequacy |
|
||||
| REITs / InvITs / real-estate developers | High leverage is structural; depreciation is non-economic so EPS and FCF mislead; developer inventory is land and WIP, so DIO in the hundreds or thousands of days is by design | LTV against asset value (SEBI caps REIT/InvIT leverage), FFO and AFFO in place of FCF, WALE, interest cover; for developers net debt vs pre-sales collections and collections vs completion |
|
||||
| Miners, E&P, heavy capex build-outs | FCF is negative by design during a build; net debt/EBITDA measured at a commodity peak understates leverage by a wide margin | Leverage at a mid-cycle price deck, reserve life and replacement, committed vs discretionary capex, cost-curve position, coverage at trough prices |
|
||||
| Regulated utilities | High leverage is permitted and priced by the regulator | FFO/net debt, regulated asset base and allowed return, tariff and true-up mechanics, ring-fencing at the opco |
|
||||
| Airlines, shipping, retail chains | Lease-adjusted debt dominates reported debt; negative working capital is a feature, not a warning | Lease-adjusted net debt/EBITDAR, fixed-charge cover, months of liquidity, fleet/vessel age, off-balance commitments |
|
||||
|
||||
If the company sits in one of these, stop, open the matching file in `references/sectors/`, and use this file only for the parts that survive: cash quality, contingent liabilities, related-party exposure, promoter pledge, distress signals.
|
||||
|
||||
---
|
||||
|
||||
## 1. Build the economic debt figure before computing any ratio
|
||||
|
||||
Headline "borrowings" understates what the company owes at almost every leveraged company. Compute an **adjusted net debt** first, then feed *that* into every leverage and coverage ratio below. Show the bridge in your output so a reader can disagree with one line rather than with the conclusion.
|
||||
|
||||
Start with gross borrowings (short-term + long-term + current maturities of long-term debt) and add:
|
||||
|
||||
- **Lease liabilities** (Ind-AS 116 / IFRS 16 / ASC 842). On balance sheet for lessees post-adoption, but confirm they are inside your debt figure and that EBITDA is on the same basis. US GAAP operating leases sit on the balance sheet yet keep rent inside operating expense, so an IFRS/Ind-AS retailer shows structurally higher EBITDA than a US GAAP peer with identical economics. See `14-accounting-comparability.md`.
|
||||
- **Net pension / post-retirement deficit** (projected benefit obligation minus plan assets, plus OPEB). A senior, non-negotiable claim ranking ahead of equity.
|
||||
- **India — gratuity and leave encashment (Ind-AS 19).** Frequently *unfunded*, or only partly funded through an LIC group policy. Read the employee-benefits note for the defined-benefit obligation, fair value of plan assets, funded status, discount rate (usually pegged to the G-sec curve), and the salary-escalation and attrition assumptions. An unfunded gratuity obligation in a labour-heavy business is real debt with no offsetting asset, and it grows with the wage bill.
|
||||
- **Reverse factoring / supply-chain finance / channel financing** balances sitting inside trade payables. This is bank debt wearing a payables costume: reclassify it to debt and reverse the corresponding CFO benefit. US filers must disclose supplier-finance programme obligations and a rollforward (ASU 2022-04); IFRS and Ind-AS filers disclose carrying amounts and terms under the IAS 7 / IFRS 7 amendments. If the programme exists and the disclosure is thin, that is itself a finding.
|
||||
- **Securitised or factored receivables sold with recourse.** Off the balance sheet, still your credit risk. India: "bills discounted with recourse" is normally disclosed under contingent liabilities rather than debt.
|
||||
- **Financial guarantees given** — to subsidiaries, JVs, associates, and in India critically to promoter-group entities. Probability-weight them, but never at zero: a guarantee to a weaker group company is a call option written against your equity.
|
||||
- **Written puts over minority interests (NCI puts).** Common in Indian group structures and in partially acquired subsidiaries — the parent has contracted to buy out a minority at a formula price or on a fixed date. It is a dated cash obligation with debt-like seniority, often disclosed only in the financial-instruments note.
|
||||
- **Preference shares, perpetual and hybrid instruments, compulsorily convertible instruments, PIK and toggle notes.** Classify by economics, not label: anything with mandatory redemption or a cash coupon that cannot be deferred without consequence is debt. PIK and toggle notes flatter coverage while compounding principal.
|
||||
- **Customer advances and deferred revenue are *not* debt** — they are interest-free funding and a sign of strength — but note them separately so the reader sees why net debt is low.
|
||||
|
||||
Then subtract cash, but only cash genuinely available. Deduct restricted cash, margin money and deposits pledged against letters of credit or guarantees, cash trapped in subsidiaries that cannot upstream it (minority-held or capital-controlled), and cash at consolidated entities the parent cannot reach. **Do not net cash you have not proved (§2).**
|
||||
|
||||
Finally, note **structural subordination**: where does the debt sit? A thin listed holdco servicing debt out of dividends from operating subsidiaries that have their own lenders is far riskier than the consolidated ratio implies. This applies to Indian promoter holdcos and US parent/opco structures alike — see `references/sectors/holdco-assetmgr.md`.
|
||||
|
||||
---
|
||||
|
||||
## 2. Prove the cash is real
|
||||
|
||||
Every leverage ratio that nets cash is only as good as the cash. This is the highest-severity test in the file, because fake or encumbered cash is the defining feature of the largest accounting frauds of the last three decades — and the standard ratio toolkit quietly assumes the cash line is true.
|
||||
|
||||
Run the **interest-income reconciliation**: implied yield = interest and investment income ÷ average cash and short-term investments. Compare it against prevailing deposit and money-market rates for that currency and period (India: bank FD and liquid-fund yields; US: T-bill and money-market yields). A large cash pile earning implausibly little is cash that is fake, pledged, restricted, parked non-interest-bearing at a related-party bank, or simply not there.
|
||||
|
||||
Then ask the structural questions:
|
||||
|
||||
- **Why does it carry large gross cash and large gross debt at the same time?** There are legitimate answers — regulatory requirements, working-capital seasonality, prefunding a maturity, jurisdictional trapping. There is also one very common illegitimate answer. Make management's explanation explicit and test it against the arithmetic: if the company pays 9% on debt while earning 3% on cash, the negative carry must appear in the P&L and must be justified by something.
|
||||
- **Where is it held?** Small, obscure, offshore or related-party banks are a flag; so is concentration in a single unrated institution.
|
||||
- **Is it pledged?** India: check CARO, the margin-money and "deposits with maturity over 12 months" split in the cash note, and charges filed with the MCA/ROC. US: the debt footnote and the restricted-cash reconciliation required under ASU 2016-18.
|
||||
- **India-specific corroboration.** CARO 2020 requires the auditor to report on short-term funds applied to long-term purposes, loans and advances to related parties, whether the company is a declared wilful defaulter, and diversion of funds. It is the cheapest forensic evidence available on an Indian filer. Also check rating actions — a CRISIL/ICRA/CARE rating moved to "Issuer Not Cooperating" is a serious signal, as is any SEBI-mandated disclosure of default to the exchanges.
|
||||
- **US-specific corroboration.** Item 9A internal-control conclusions and any disclosed material weakness in treasury or cash; auditor changes and dismissals (8-K Item 4.01); going-concern language under ASC 205-40.
|
||||
|
||||
If the cash cannot be corroborated, run every ratio on **gross** debt as well as net, and lead with the gross figure. State that you did and why.
|
||||
|
||||
---
|
||||
|
||||
## 3. Leverage and capital structure
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Net debt / EBITDA | Adjusted net debt (§1) ÷ trailing EBITDA; use mid-cycle EBITDA for cyclicals | <2x comfortable; 2–3x manageable; >4–5x stretched outside utilities, REITs and infra | The single most-watched gauge by lenders and rating agencies; it sets refinancing terms |
|
||||
| Gross debt / EBITDA | Same, without netting cash | Within ~0.5–1x of net for a normally financed firm | Exposes leverage masked by cash that is restricted, trapped or unproven |
|
||||
| Debt / equity | Adjusted debt ÷ shareholders' funds (India: net worth — watch revaluation reserves) | 0–1x for most non-financials; sector-bound | Shows how much of the asset base creditors funded; the classic Indian screening ratio |
|
||||
| Debt / total capital | Debt ÷ (debt + equity) | <50% typical for non-financials | Less distorted than D/E when equity is small, negative or buyback-depleted |
|
||||
| Net debt / (EBITDA − capex) | Uses the cash left after sustaining spend | Materially higher than net debt/EBITDA in capital-heavy names | Capital-intensive firms cannot service debt out of EBITDA they are obliged to reinvest |
|
||||
| Net debt / FCF (years) | Adjusted net debt ÷ FCF | <4–5 years comfortable for a stable business | Answers "how long to repay out of real cash" without EBITDA's fictions |
|
||||
| Tangible net worth test | Equity − goodwill − intangibles | Positive | Negative tangible net worth, whether from goodwill or buybacks, can trip net-worth covenants |
|
||||
|
||||
**How to read it.** Leverage magnifies both outcomes: a moderately geared firm survives a downturn, an over-geared one is forced into distressed asset sales, dilutive rescue equity or restructuring exactly when conditions are worst. Two refinements change conclusions more often than the level does. First, compute leverage on **mid-cycle** EBITDA for anything cyclical — leverage measured at a commodity, property or freight-rate peak is a trap. Second, ask *why* leverage moved: debt raised to fund capacity that will earn a return is a different signal from debt raised to fund buybacks, dividends or acquisitions, even at an identical ratio.
|
||||
|
||||
**Red flags:** net debt/EBITDA rising while EBITDA is flat or falling; D/E far above the peer set with no structural reason; leverage that only looks acceptable after netting unproven cash; management quoting leverage on credit-agreement "adjusted EBITDA" rather than reported EBITDA.
|
||||
|
||||
---
|
||||
|
||||
## 4. Maturity profile and refinancing risk
|
||||
|
||||
A solvent company can still fail if it cannot refinance. This is a *timing* risk independent of profitability, and it is where otherwise healthy businesses die.
|
||||
|
||||
Pull the maturity ladder. **US:** the long-term debt footnote and the credit agreements filed as exhibits — the old contractual-obligations table was dropped from Item 7, so do not look for it there. **India:** the borrowings note, the repayment-terms schedule, and the Ind-AS 107 liquidity-risk maturity table in the financial-instruments note.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Near-term maturity cover | (Cash + undrawn committed facilities + 12m projected FCF) ÷ debt due within 12–24 months | >1.5x | Below 1x the company must access markets to survive, on the market's terms |
|
||||
| Short-term debt share | (Current borrowings + current maturities) ÷ total debt | <25–30% for a non-financial | Short-dated funding of long-dated assets is the classic liability mismatch |
|
||||
| Weighted-average maturity | Σ(principal × years to maturity) ÷ total principal | >3–4 years for an investment-grade-type profile | Longer tenor buys time through a closed funding window |
|
||||
| Maturity-wall test | Largest single-year maturity ÷ annual FCF | <2–3x | Identifies the specific year that decides the equity |
|
||||
| CP / revolver dependence | Commercial paper + revolver drawings ÷ total debt | Low and stable | CP markets shut fastest and with no warning; rollover is not a right |
|
||||
| Refinancing gap | Weighted-average existing coupon vs current new-issue yield for that rating and tenor | Small | A wide gap is an interest-cost step-up that today's P&L does not show |
|
||||
|
||||
**Structure matters as much as size.** Split the book by fixed vs floating (and how much floating is hedged), by currency (is FX debt matched by FX revenue or a natural hedge, or would a currency move be a solvency event?), and by secured vs unsecured/subordinated (how much of the asset base is already pledged — if most assets are encumbered there is no collateral left to raise against, and unsecured creditors and equity are structurally subordinated). India: check the charge register, promoter guarantees on company debt, and short-tenor FX exposure via buyer's credit and packing credit.
|
||||
|
||||
**Red flags:** a maturity wall inside 12–24 months exceeding available liquidity; continuous CP rollover funding long-life assets; unhedged floating exposure into a tightening cycle; FX debt at a business with no FX revenue; an average coupon far below current market.
|
||||
|
||||
---
|
||||
|
||||
## 5. Coverage: can it service what it owes
|
||||
|
||||
Leverage sizes the obligation; coverage tells you whether the business generates enough to carry it. Compute both earnings-based and cash-based coverage — the gap between them is itself the finding.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Interest coverage (TIE) | EBIT ÷ interest expense | >4x comfortable; 2–3x fragile; <1.5x distressed | The standard first screen; below ~2x a modest earnings dip breaches covenants |
|
||||
| EBITDA / interest | EBITDA ÷ interest expense | >4–6x | Useful for capital-heavy firms, but ignores the capex they are obliged to fund |
|
||||
| (EBITDA − capex) / interest | Strips sustaining investment before testing coverage | >2x | The honest version for asset-heavy businesses |
|
||||
| Cash interest coverage | CFO before interest ÷ cash interest paid | >3x | Cash pays interest; accounting EBIT does not |
|
||||
| Fixed-charge coverage | (EBIT + lease expense) ÷ (interest + lease expense + preference dividends) | >1.5–2x | The only fair measure where leases and preferreds are large — retail, airlines, shipping |
|
||||
| DSCR | (CFO − capex) ÷ (interest + mandatory principal amortisation) | >1.2–1.5x | What project lenders and Indian banks actually test; India: Schedule III requires DSCR in the ratios note |
|
||||
| FCF / total debt | FCF ÷ adjusted gross debt | >15–20% is strong | The deleveraging speed the equity story is implicitly relying on |
|
||||
|
||||
**Always stress-test.** Recompute coverage under (a) a 20–30% fall in CFO and (b) the floating book repricing to current market plus the refinancing gap from §4. Coverage that survives only in a peak year is not coverage. Watch for capitalised interest flattering reported interest expense, and for covenants written on an adjusted EBITDA that bears little relation to cash.
|
||||
|
||||
---
|
||||
|
||||
## 6. Covenants and headroom
|
||||
|
||||
Covenants are the tripwires between distress and default. A company can be paying every bill on time and still lose control of its own restructuring.
|
||||
|
||||
Where to read them. **US:** credit agreements and indentures filed as exhibits on EDGAR; amendments and waivers appear as 8-K Item 1.01, acceleration as Item 2.04. EDGAR full-text search for phrases like "Consolidated Leverage Ratio" or "Fixed Charge Coverage Ratio" inside the filer's exhibits works well. **India:** the borrowings note and terms-and-conditions disclosure, the sanction terms summarised in the annual report, any disclosure of breach or waiver, and the mandatory disclosure of payment default to the exchanges.
|
||||
|
||||
What to compute and watch:
|
||||
|
||||
- **Headroom %** on each maintenance covenant: (limit − current metric) ÷ limit, plus the EBITDA decline that would breach it. Headroom under ~15–20%, or an EBITDA cushion under ~20%, means one weak quarter hands the keys to lenders.
|
||||
- **Which EBITDA definition the covenant uses.** Credit-agreement EBITDA typically permits add-backs — run-rate synergies, "exceptional" items, pro-forma acquisition contributions — that reported EBITDA does not. Comfortable covenant headroom alongside poor reported cash conversion tells you the covenant is not binding on reality.
|
||||
- **Springing covenants** that apply only above a revolver-utilisation threshold. They bite precisely when the revolver is being drawn, i.e. in stress.
|
||||
- **Cross-default and cross-acceleration chains**, change-of-control puts, material-adverse-change clauses, and rating-linked triggers (coupon step-ups, collateral posting).
|
||||
- **Waiver and amendment history.** Repeated waivers are not a technicality — they are a disclosed loss of negotiating position, and they usually arrive with higher pricing, new security, and restrictions on dividends and capex.
|
||||
- **Covenant-lite is not safety.** It removes the early warning and defers the reckoning to the maturity wall.
|
||||
|
||||
---
|
||||
|
||||
## 7. Liquidity ratios, facilities and runway
|
||||
|
||||
Ratios are a screen; **absolute accessible liquidity** decides whether a shock is survived.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Current ratio | Current assets ÷ current liabilities | >1.2–1.5 for industrials; retailers and QSR legitimately run below 1 | First-order near-term payment risk; India: Schedule III requires disclosure with an explanation of any >25% YoY change |
|
||||
| Quick (acid-test) ratio | (Current assets − inventory − prepaids) ÷ current liabilities | ~1 | Strips the least liquid and most over-stated current asset |
|
||||
| Cash ratio | (Cash + marketable securities) ÷ current liabilities | 0.2–0.5 typical, sector-bound | The worst-case view; immune to receivable and inventory optimism |
|
||||
| Total available liquidity | Unrestricted cash + undrawn **committed** facilities | ≥12 months of fixed obligations plus committed capex | Absolute rupees or dollars, not ratios, determine survival |
|
||||
| Revolver utilisation | Drawn ÷ total facility | Low; a fully drawn revolver means the backstop is spent | Heavy drawing is a late-stage distress signal |
|
||||
| Cash runway (loss-makers) | Unrestricted cash ÷ average quarterly burn | >18–24 months, or a fully funded plan | Runway dictates the timing and price of the next dilution |
|
||||
| Defensive interval | Liquid assets ÷ daily operating cash expenses | >90 days | Days of survival assuming zero receipts |
|
||||
|
||||
Check whether facilities are **committed** (a genuine backstop) or **uncommitted / repayable on demand**. India: most working-capital cash-credit and overdraft limits are repayable on demand and reviewed annually — do not count them as committed liquidity, and watch the drawing power fall when the receivable and inventory base securing them deteriorates. Check facility expiry against the maturity ladder: a revolver expiring before the bond it is meant to backstop is not a backstop.
|
||||
|
||||
**Red flags:** current ratio below 1 in a business that does not collect before it pays; liquidity ratios that look adequate only because of slow-moving inventory or doubtful receivables; a large share of "cash" restricted, pledged or trapped; runway under ~12 months with equity markets closed; going-concern emphasis in the audit report.
|
||||
|
||||
---
|
||||
|
||||
## 8. Working capital and the cash conversion cycle
|
||||
|
||||
Working capital is usually the single largest reason profit and cash diverge, and the cheapest place to detect deterioration early.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| DSO | Trade receivables ÷ revenue × 365, on average balances | Sector-bound: FMCG 10–30d, IT services 60–80d, EPC and infra 120d+ | Rising DSO is the earliest sign of channel stuffing, weakening customers or aggressive recognition |
|
||||
| DIO | Inventory ÷ COGS × 365 | Sector-bound; developers, distillers and jewellery run in years by design | Inventory built ahead of demand precedes write-downs |
|
||||
| DPO | Trade payables ÷ COGS × 365 | Stable is good; sharply rising is not | Rising DPO flatters CFO by borrowing from suppliers |
|
||||
| Cash conversion cycle | DSO + DIO − DPO | Negative is a genuine advantage (retail, marketplaces, subscriptions) | How many days of sales must be funded before cash comes back |
|
||||
| ΔWorking capital / ΔRevenue | Change in net working capital ÷ change in revenue | <15–20% for a capital-light grower | Tells you whether growth consumes or releases cash |
|
||||
| Working capital / sales | Net working capital ÷ revenue | Flat or falling | The scaling law of the business model |
|
||||
|
||||
**Method discipline.** Use average balances, not year-end snapshots, and correct for seasonality — a March-year-end Indian manufacturer and a December-year-end US peer are not measured at the same point in their cycle. Put peers on the same revenue basis (gross vs net of indirect taxes) before comparing days.
|
||||
|
||||
**Distinguish a real improvement from a financed one.** A CCC that improves because DPO jumped is supplier financing. A CCC that improves because receivables were factored or securitised is a balance-sheet transaction, not an operating gain. Both reverse, and both strain the counterparty who is funding them. India: Schedule III now mandates **ageing schedules for trade receivables and trade payables** (and for CWIP and intangibles under development) — read them, because a growing over-6-month or over-3-year receivable bucket contradicts a clean-looking headline DSO.
|
||||
|
||||
---
|
||||
|
||||
## 9. Receivables and inventory quality
|
||||
|
||||
These two assets carry the balance sheet's most optimistic estimates, and they inflate the current and quick ratios while doing it.
|
||||
|
||||
Checks that change conclusions:
|
||||
|
||||
- **Receivables growth vs revenue growth** over 8–12 quarters. Persistent divergence means sales are being recognised faster than they are collected. Cross-reference §14 and `07-forensic-red-flags.md`.
|
||||
- **Allowance for doubtful accounts ÷ gross receivables, and its trend.** A shrinking allowance into a weakening economy is a quiet earnings source. India: read the Ind-AS 109 expected-credit-loss provision matrix against the ageing buckets. US: the CECL disclosure and the valuation-allowance rollforward.
|
||||
- **Concentration.** A large receivable from one customer, one government body or a related party is a different asset from a diversified book. In Indian EPC, defence and infrastructure, dues from government and PSU customers are often collectible but with multi-year timing — model the *timing*, not just the loss.
|
||||
- **Related-party and subsidiary receivables that keep growing and never settle.** A classic tunnelling route; treat a rising, unexplained related-party advance as capital leaving the company.
|
||||
- **Quarter-end receivable spikes** that reverse in the following quarter — pull-forward of sales into the reporting period.
|
||||
- **Inventory mix and reserves:** finished goods building faster than sales means sell-through is failing rather than purchasing being early; check the obsolescence-reserve trend and write-down history. For US filers, the LIFO reserve understates carrying value and raises cost of sales relative to FIFO peers — adjust before comparing.
|
||||
- **Vendor and customer financing.** If the company lends to, guarantees the debt of, or grants unusually long credit to its own customers or distributors to enable purchases, reported growth is partly manufactured credit risk. Track notes receivable, long-dated receivables and customer guarantees against revenue growth. Historically this pattern has ended violently in telecom equipment, solar and EV supply chains — it reads as clean organic growth right up until the receivables sour.
|
||||
|
||||
---
|
||||
|
||||
## 10. Off-balance-sheet, contingent and quasi-debt obligations
|
||||
|
||||
Everything here is a real economic obligation that can convert into cash and lift true leverage well above the reported figure. Go to the notes; the face of the balance sheet will not tell you.
|
||||
|
||||
| Item | Where to find it | What it does to your numbers |
|
||||
|---|---|---|
|
||||
| Reverse factoring / supply-chain finance / channel financing | US: ASU 2022-04 supplier-finance disclosure and rollforward. IFRS/Ind-AS: IAS 7 and IFRS 7 amendments; also the payables note and concall Q&A | Reclassify to debt and reverse the CFO benefit. Debt disguised as trade payables has preceded sudden collapses in construction and supply-chain-finance-dependent names |
|
||||
| Receivables securitisation, factoring or bill discounting **with recourse** | Financial-instruments note; India — contingent-liabilities note | Gross up receivables and debt; the credit risk never left the company |
|
||||
| Financial guarantees (subsidiaries, JVs, associates, promoter entities) | Contingent-liabilities note; related-party schedule | Add probability-weighted. A guarantee to a weaker group entity is equity risk written for free |
|
||||
| Written puts over NCI / minority buyout obligations | Financial-instruments note; shareholder agreements | A dated cash obligation with debt-like seniority, usually invisible in the headline leverage ratio |
|
||||
| Take-or-pay, purchase and capex commitments | Commitments note | Fixed future outflows; treat as quasi-debt in any downside scenario |
|
||||
| Pension and OPEB deficit; India — gratuity and leave encashment | Employee-benefits note (Ind-AS 19 / ASC 715) | Add the net deficit to debt; test sensitivity to a 1% discount-rate move and check the expected-return assumption is not flattering the funded status |
|
||||
| Litigation, tax, environmental and warranty exposures | Contingent liabilities; US Item 3 and the loss-contingency note | India — "contingent liabilities not provided for" is often dominated by **disputed tax demands** (GST, excise, service tax, income tax). Assess litigation stage and the company's historical win rate rather than adding the gross number |
|
||||
| VIEs, SPEs and structured entities | Consolidation note | Ask what was moved off balance sheet, and why |
|
||||
| India — promoter share pledge | Quarterly shareholding pattern; encumbrance disclosures | Not a company liability, but a forced-selling overhang and a tunnelling motive. Pledge above ~25–50% of the promoter stake, or rising into a falling price, is a serious governance-plus-liquidity flag — see `07-forensic-red-flags.md` |
|
||||
|
||||
Present the material items as a sensitivity: reported net debt/EBITDA, then the same ratio with quasi-debt included. Where the two tell different stories, that difference *is* your conclusion.
|
||||
|
||||
---
|
||||
|
||||
## 11. Toxic and structured financing, chronic dilution
|
||||
|
||||
Mostly a small- and micro-cap issue, and it deserves a separate check because it can guarantee a falling share price *regardless of operating performance*.
|
||||
|
||||
Look for:
|
||||
|
||||
- **Variable- or reset-conversion convertibles** ("death-spiral" notes) where the conversion price floats down with the market price. Falling price produces more shares, which produces more selling, which produces a falling price. The instrument is a machine for transferring value away from existing holders.
|
||||
- **At-the-market (ATM) equity programmes** used continuously to fund operating losses. Quantify the shares issuable under the live shelf at the current price and at a price 50% lower.
|
||||
- **PIPEs with warrant coverage**, repriceable warrants, and toggle/PIK notes that defer cash cost into principal.
|
||||
- **India:** preferential allotments and warrants to promoters or related parties priced near the SEBI floor, repeated QIPs whose proceeds fund interest rather than growth, and convertibles issued to group entities. Build the 7–10 year share-count history: chronic dilution while the narrative is "growth" is the tell.
|
||||
|
||||
Compute **potential dilution at a stressed price**, not merely today's diluted count, and restate the thesis per share. A company can triple revenue and still halve the value of your claim.
|
||||
|
||||
---
|
||||
|
||||
## 12. Goodwill, tangible book and asset productivity
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| (Goodwill + intangibles) / total assets | Balance sheet | Low for organic compounders; high for serial acquirers by construction | Sizes how much of the asset base is a price paid rather than a thing owned |
|
||||
| Goodwill / equity | Above 100% means negative tangible book | <50% preferred outside roll-ups | A single impairment can erase reported net worth and trip net-worth covenants |
|
||||
| Tangible book value | Equity − goodwill − intangibles (− revaluation reserves) | Positive | The creditor's view of what actually backs the debt |
|
||||
| Capex / depreciation | Capex ÷ D&A, 5-year average | ~1.0 sustaining; >1 expanding | Sustained below 1 is harvesting the asset base — borrowing FCF from the future |
|
||||
| Accumulated depreciation / gross PP&E | Fixed-asset schedule | <60–70% | Asset-age proxy; a near-fully-depreciated base means a replacement cycle is coming |
|
||||
| Asset turnover and fixed-asset turnover | Revenue ÷ total (or net fixed) assets | Stable or rising vs peers | Links the balance sheet to the earnings that repay creditors; feeds DuPont in `05-returns-and-dupont.md` |
|
||||
|
||||
Read the impairment-test assumptions — terminal growth rate, discount rate, disclosed headroom. Optimistic assumptions defer inevitable write-downs. A serial acquirer carrying unimpaired goodwill over underperforming acquired segments is running a deferred loss. Impairments are non-cash, but they are an admission, and more usefully a dated record of capital-allocation quality. India: watch **CWIP** and "intangible assets under development" sitting unmoved for years in the Schedule III ageing table — a project that never gets commissioned is an impairment waiting to be taken.
|
||||
|
||||
---
|
||||
|
||||
## 13. Direction of travel, distress scores and credit-market signals
|
||||
|
||||
Trajectory usually matters more than level. Plot five years of adjusted net debt/EBITDA, D/E and interest cover on one view, then *attribute* the change: organic paydown, EBITDA recovery, debt-funded buybacks, debt-funded M&A, working-capital release, or asset sales. Deleveraging by selling the best assets is not deleveraging.
|
||||
|
||||
Corroborate with composites and with markets:
|
||||
|
||||
- **Altman Z-score** (below ~1.8 is the distress zone for manufacturers; use the Z" variant for non-manufacturers and emerging markets; undefined for financials), **Piotroski F-score** (0–9 fundamental momentum), **Beneish M-score** (manipulation likelihood). These are triage that directs attention, never verdicts — say so when you report them.
|
||||
- **Credit ratings and outlook** — investment grade vs high yield, negative watch, and especially the crossover to junk, which forces index selling. India: CRISIL, ICRA, CARE and India Ratings rationales are detailed, free, and frequently more candid than the annual report.
|
||||
- **Bond prices vs par, yield-to-maturity vs the sovereign curve, CDS spreads.** Credit markets aggregate professional lenders' real-time judgement and routinely anticipate equity trouble by quarters. When the bonds trade at distressed levels while the equity is priced for growth, one of the two markets is wrong, and it is rarely the bond market.
|
||||
- **India-specific stress tells:** rating moved to "Issuer Not Cooperating", disclosure of payment default to the exchanges, insolvency petitions filed at the NCLT by operational creditors, auditor or CFO resignation coinciding with a funding squeeze, and a rising promoter pledge into a falling price.
|
||||
|
||||
---
|
||||
|
||||
## 14. Does profit become cash? Accrual quality
|
||||
|
||||
The highest-yield single test in fundamental analysis. Earnings are an opinion; cash is a fact.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| CFO / net income | Cumulative over 3–5 years, never one year | ~1.0 or above cumulatively | A durable business converts essentially all accounting profit into cash over a cycle |
|
||||
| CFO / EBITDA | Cash conversion before capex | 70–90%+ for asset-light; structurally lower where working capital is heavy | Isolates working-capital and cash-tax leakage from the capex question |
|
||||
| Sloan accrual ratio | (Net income − CFO) ÷ average total assets | Low; above ~10% is a flag | High-accrual firms systematically underperform — one of the most robust anomalies in the literature |
|
||||
| Balance-sheet accruals | Δ(non-cash working capital + net non-current operating assets) ÷ average total assets | Low and stable | Catches accruals that bypass the cash-flow-statement bridge |
|
||||
| Non-cash add-back share | (D&A + SBC + impairments) ÷ the NI-to-CFO bridge | Understand the mix | A CFO held up entirely by add-backs is not the same as one held up by collections |
|
||||
|
||||
**How to run it.** Bridge net income to CFO line by line for each of the last five years and label every line as (a) genuinely non-cash and recurring, (b) non-cash and one-off, or (c) working capital. Then ask the diagnostic question: is the gap explained by depreciation on a real asset base, or by receivables and inventory? A company reporting record earnings while continually borrowing has already answered it.
|
||||
|
||||
Never conclude from a single year. Working-capital swings, one-off settlements and acquisition timing distort one year and wash out over three to five.
|
||||
|
||||
---
|
||||
|
||||
## 15. Free cash flow: define it before you use it
|
||||
|
||||
There is no single FCF. State the definition, apply it identically across the peer set, and show the bridge.
|
||||
|
||||
| Variant | Definition | Use it for |
|
||||
|---|---|---|
|
||||
| Simple FCF | CFO − capex | The default; comparable across most non-financials |
|
||||
| Levered FCF (FCFE) | CFO − capex − mandatory debt amortisation (interest already inside CFO under US GAAP) | What is genuinely available to equity after the lenders are served |
|
||||
| Unlevered FCF (FCFF) | NOPAT + D&A − capex − ΔWC | DCF inputs; independent of capital structure |
|
||||
| FCF after leases | Subtract lease principal repayments, which IFRS 16 / Ind-AS 116 route to financing | Restoring comparability for retailers, airlines and hotels |
|
||||
| SBC-adjusted FCF | FCF − stock-based compensation | Tech and growth names (§17) |
|
||||
| Owner earnings | Net income + D&A − maintenance capex − required working-capital investment | The economic version; requires a maintenance-capex estimate (§16) |
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| FCF margin | FCF ÷ revenue | 5–10% solid for industrials; 20%+ for mature software; near zero or negative is normal mid-build for infra and miners | The clearest single measure of how much of a rupee of sales the owner keeps |
|
||||
| FCF / net income | Cash conversion of earnings | ~0.8–1.0+ over a cycle | Combines accrual quality and capital intensity into one number |
|
||||
| FCF / EBITDA | Conversion after capex, cash tax, interest and working capital | >50% for asset-light; structurally lower for asset-heavy | Exposes the gap between the EBITDA management guides on and the cash that arrives |
|
||||
| FCF yield | FCF ÷ market cap (equity) or ÷ enterprise value (unlevered) | Compare to the risk-free rate and to peers | The bridge into valuation — see `06-valuation.md` |
|
||||
|
||||
Build the **EBITDA-to-FCF bridge** explicitly — cash interest, cash tax, ΔWC, capex, lease principal — each as a percentage of EBITDA. It tells you *where* the cash leaks and whether the leak is structural or fixable. Two firms with identical EBITDA can produce wildly different FCF, and the bridge is the entire explanation.
|
||||
|
||||
**Red flags:** FCF positive only after cutting essential capex; FCF reached with asset sales, tax refunds or insurance proceeds sitting inside the operating section; FCF margin falling while revenue grows (growth that never reaches the owner); positive trailing FCF with negative FCF across the preceding cycle.
|
||||
|
||||
---
|
||||
|
||||
## 16. Maintenance versus growth capex
|
||||
|
||||
Only growth capex is discretionary. Maintenance capex is a permanent claim on cash, and mislabelling it is the easiest way to inflate normalised FCF and return on capital simultaneously.
|
||||
|
||||
Estimate maintenance capex independently rather than accepting management's split:
|
||||
|
||||
- **D&A-anchored:** take current D&A and adjust upward for inflation since the assets were purchased and for unit growth. Crude, but hard to game.
|
||||
- **Greenwald method:** compute the historical ratio of gross PP&E to sales, multiply by the current year's *increase* in sales to get growth capex, and treat the remainder of total capex as maintenance.
|
||||
- **Physical cross-check:** if capex was mostly "growth", capacity or output should have risen. Indian filers routinely disclose installed capacity and utilisation; miners disclose tonnage; utilities disclose MW; telcos disclose sites. Spend that rose without capacity rising was not growth capex.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Capex / revenue | Capex ÷ revenue, 5-year average | 1–3% asset-light; 5–15% manufacturing; 20%+ telecom, utilities, miners | Sets the structural ceiling on FCF margin |
|
||||
| Capex / D&A | 5-year average | ~1.0 sustaining | Below 1 for several years means the asset base is being harvested |
|
||||
| Maintenance capex / total capex | From the estimate above | A falling share signals genuine expansion | Determines normalised FCF and owner earnings |
|
||||
| Incremental capital efficiency | Growth capex ÷ incremental revenue (or incremental EBITDA) | Improving | Tests whether expansion earns its cost of capital before it shows up in ROIC |
|
||||
| CWIP / gross block (India) | Capital work-in-progress ÷ gross block, read with the ageing schedule | Low and turning over | Large static CWIP is capital deployed but not earning — or an impairment in waiting |
|
||||
|
||||
**Red flags:** capex far below D&A for years while margins hold (deferred maintenance flattering today's FCF at tomorrow's expense); capex spiking with no capacity or revenue response; reclassification of maintenance as growth to promote an "adjusted FCF"; recurring operating costs capitalised as software, development, content or cloud migration — see §19 and `03-earnings-quality.md`.
|
||||
|
||||
---
|
||||
|
||||
## 17. SBC and the FCF shareholders actually keep
|
||||
|
||||
Stock-based compensation is a genuine economic cost borne by shareholders through dilution, yet it is added back as non-cash and inflates both CFO and FCF. For a growth-tech name it is frequently the difference between an attractive and an unattractive FCF yield.
|
||||
|
||||
Compute and report: SBC ÷ revenue; SBC ÷ CFO; SBC ÷ FCF; **FCF less SBC**; annual diluted share-count growth; and buybacks *net* of issuance. The decisive question is whether repurchases genuinely shrink the share count or merely mop up option and RSU issuance. If the count is flat while the company reports large buybacks, that "capital return" is deferred cash compensation and belongs as a deduction from FCF, not as a shareholder distribution.
|
||||
|
||||
India: ESOP pools are generally smaller outside IT services and recently listed new-age companies, but read the ESOP note, the discount to fair value at grant, and pool refreshes. For recent Indian tech listings, SBC and the associated share-count growth can be large enough to invert the FCF conclusion entirely.
|
||||
|
||||
**Red flags:** SBC a large and rising share of CFO; share count rising despite buybacks; management promoting an adjusted FCF that treats SBC as free; option repricing or accelerated grants after a price fall.
|
||||
|
||||
---
|
||||
|
||||
## 18. Sources and uses: who funded the growth, were the payouts earned
|
||||
|
||||
Build one cumulative five-year table. Sources: cumulative CFO, debt drawn, equity issued, asset sales. Uses: capex, acquisitions, dividends, buybacks, debt repaid, lease principal. Reconcile to the change in net debt and in share count. This single view answers more questions than any ratio in this file.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Self-funding ratio | Cumulative FCF ÷ cumulative (capex + M&A + distributions) | ≥1.0 | Self-funded growth compounds without dilution or balance-sheet risk |
|
||||
| FCF payout ratio | (Dividends + gross buybacks) ÷ FCF | <70–80% sustained | Sustained above 100% erodes the balance sheet and ends in a cut |
|
||||
| Cash dividend cover | FCF ÷ dividends paid | >1.5x | An accounting payout ratio can look safe while the dividend is being borrowed |
|
||||
| Reinvestment rate | (Capex + M&A + ΔWC) ÷ CFO | Only as high as the return earned justifies | Heavy reinvestment is good only when the incremental return exceeds the cost of capital |
|
||||
| Net financing flow | Debt drawn − repaid + equity issued − buybacks, over 5 years | Net outflow for a mature franchise | A chronic net *inflow* means the business is capital-markets dependent |
|
||||
| Share count trend | Diluted shares over 7–10 years | Flat or falling | The per-share claim is the thing you actually own |
|
||||
|
||||
Growth funded repeatedly by new debt or equity is fragile: it depends on open capital markets and reverses violently when they shut. That distinction — self-funded compounder versus capital-markets-dependent story — separates two businesses with identical reported growth rates. India: check whether QIPs and preferential allotments funded expansion or funded interest, who subscribed (public versus promoter and related parties), and at what discount.
|
||||
|
||||
Buyback quality matters too. Repurchases executed at depressed valuations that permanently reduce the count create value; repurchases at peak multiples funded with debt destroy it while flattering EPS. And a high, "safe-looking" dividend yield is usually the market's warning about coverage rather than a gift.
|
||||
|
||||
---
|
||||
|
||||
## 19. Classification games and off-statement financing
|
||||
|
||||
The section boundaries of the cash-flow statement are a favoured manipulation surface precisely because they attract less scrutiny than the P&L. Moving recurring outflows out of operating, or pulling one-off inflows in, makes cash generation look structurally stronger than it is.
|
||||
|
||||
Check for:
|
||||
|
||||
- **Receivables factoring or securitisation** inflating CFO in the year the programme starts. The step-up is one-time; the run-rate is not. Compare the change in factored balances year over year from the footnote.
|
||||
- **Reverse factoring** turning a payables outflow into a financing outflow — or worse, staying inside payables and never appearing as debt at all (§10).
|
||||
- **Capitalised costs** — software development, development-phase R&D (Ind-AS 38 permits capitalisation; US GAAP is stricter), content, cloud implementation — moving cash from operating to investing. Track capitalised spend as a share of total spend, and its trend.
|
||||
- **Lease classification.** Under IFRS 16 / Ind-AS 116 the lease principal sits in financing, so CFO is structurally higher than under a US GAAP operating lease. Never compare CFO or CFO/EBITDA across the two regimes unadjusted.
|
||||
- **Interest and dividend classification.** Under Ind-AS/IFRS, interest paid may be presented in operating *or* financing, and dividends received in operating or investing. Most Indian corporates place interest paid in financing, which makes Indian CFO a **pre-interest** number; US GAAP forces interest paid into operating. Comparing an Indian CFO/EBITDA with a US one without normalising flatters the Indian company, sometimes substantially.
|
||||
- **One-offs dressed as operating cash:** asset-sale proceeds, litigation and insurance settlements, large tax refunds, government incentive receipts. Compute one-offs as a percentage of CFO.
|
||||
- **Gross versus net capex** presentation, and disposal proceeds netted against capex to flatter FCF.
|
||||
- **Opaque "other operating" lines** that are large, volatile and unexplained.
|
||||
- **Year-end window dressing:** payables settled just after year-end, receivables collected just before, inventory shipped to distributors on quarter-end terms. Where quarterly balance-sheet data exists, compare the year-end balance to the average of the four quarter-ends.
|
||||
|
||||
---
|
||||
|
||||
## 20. Cash taxes versus book taxes
|
||||
|
||||
A low cash tax rate can lift current FCF materially — and most of the drivers expire.
|
||||
|
||||
Compute the **cash tax rate** = cash taxes paid ÷ pre-tax income, and set it against the effective book rate and the statutory rate. Explain every gap: accelerated depreciation, loss carryforwards, tax credits, jurisdiction mix, holidays and incentives. Then estimate the **sustainable** rate once timing differences reverse and carryforwards are exhausted, and use that rate in any forward FCF or DCF. Investors who capitalise an artificially low cash tax rate overpay by construction.
|
||||
|
||||
India specifics: the concessional 22% regime under s.115BAA (and 15% for qualifying new manufacturing under s.115BAB) versus the older rate; MAT credit utilisation and expiry; SEZ and unit-based deductions winding down; area-based incentives. A company still riding MAT credit or an expiring SEZ benefit has a cash-tax step-up coming that no historical ratio will reveal.
|
||||
|
||||
**Red flags:** a large unexplained cash-versus-book gap; FCF flattered by carryforwards about to run out; a growing deferred tax liability that will reverse into cash outflows; guidance that projects today's cash tax rate indefinitely.
|
||||
|
||||
---
|
||||
|
||||
## 21. Full-cycle durability and cash return on capital
|
||||
|
||||
Two companies with identical trailing FCF can carry entirely different risk. Assess durability before you capitalise anything.
|
||||
|
||||
- Pull CFO and FCF through the **last downturn** for that sector — 2008–09, 2013 (India: taper and current-account stress), 2015–16 (commodities), 2020, plus any industry-specific bust. If the history does not go back that far, say so and treat durability as unproven rather than assuming it.
|
||||
- Compute **FCF margin volatility** (standard deviation across the cycle) and the trough-to-peak FCF ratio.
|
||||
- Establish the **recurring share** of cash flow: contracted, subscription or annuity revenue versus transactional and project-based; customer and end-market concentration; commodity linkage. Recurring cash flow deserves a higher multiple because it is more predictable and more self-funding.
|
||||
- Set a **mid-cycle normalised FCF** and use that in valuation. Capitalising peak-cycle FCF is the most common valuation error in cyclicals, and it is usually compounded by the fact that leverage also looks fine at the peak.
|
||||
|
||||
Then close the loop from cash to value creation:
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| CROIC | FCF ÷ invested capital | Above WACC, consistently | Cash generation creates value only if reinvested above its cost |
|
||||
| CFROI vs WACC | Inflation-adjusted cash return versus cost of capital | Positive spread | The cash analogue of the ROIC–WACC spread in `05-returns-and-dupont.md` |
|
||||
| Incremental return on reinvested cash | Δ FCF ÷ cumulative reinvestment, lagged 2–3 years | Above WACC | Averages hide a deteriorating margin on new investment |
|
||||
| Intrinsic growth rate | Reinvestment rate × cash return on capital | Compare to the growth the market is pricing | The compounding arithmetic a DCF is implicitly asserting |
|
||||
|
||||
**Red flags:** heavy reinvestment at cash returns below the cost of capital (busy value destruction); declining cash returns on rising invested capital; acquisitions absorbing all the FCF with no improvement in returns; leverage and dividends both calibrated to peak-cycle cash generation.
|
||||
|
||||
---
|
||||
|
||||
## 22. India versus US: conventions that break comparability
|
||||
|
||||
- **Reporting frequency.** Indian listed companies file quarterly *results* but a balance sheet and cash-flow statement only **half-yearly** under SEBI LODR. You cannot compute a quarterly CCC or CFO for an Indian filer the way you can from a 10-Q. State that limitation rather than interpolating silently.
|
||||
- **Standalone versus consolidated.** Always analyse **consolidated** statements for leverage, cash and contingent liabilities; standalone hides subsidiary debt and guarantees. Where the listed entity is a holdco, examine both and say where the cash sits versus where the debt sits.
|
||||
- **Units.** ₹1 crore = 10 million; ₹1 lakh = 100,000. Convert once, label every table, and never mix crore and million within one table.
|
||||
- **Interest inside CFO.** Ind-AS/IFRS optionality versus US GAAP's mandatory operating classification (§19). Normalise before any cross-border CFO comparison.
|
||||
- **CARO 2020** (India) has no US analogue and is a free forensic read: short-term funds applied to long-term purposes, loans and advances to related parties, wilful-defaulter status, undisclosed income surrendered in tax proceedings, whistle-blower complaints, and the auditor's view on fund diversion.
|
||||
- **Schedule III ratio and ageing disclosures** (India): current ratio, debt-equity, DSCR, return ratios, inventory and receivable turnover and more must be disclosed with an explanation for any change above 25% year on year — plus ageing schedules for receivables, payables, CWIP and intangibles under development. Read management's own explanation first, then test it.
|
||||
- **Contingent liabilities** (India) are typically dominated by disputed tax demands and disclosed gross. Do not add them to debt at face value, but do assess litigation stage, precedent and the company's track record.
|
||||
- **Concall transcripts** (India) are a primary source and frequently the only place working-capital, collection and covenant questions are answered. US equivalents: Item 7 liquidity and capital resources, the earnings call, and EDGAR full-text search across exhibits.
|
||||
- **Credit information.** India: rating rationales from CRISIL, ICRA, CARE and India Ratings are detailed, free and often more candid than the annual report. US: agency reports are gated, but bond prices, spreads and 8-K covenant events are public.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Run the sector gate first — if bank, NBFC, insurer, REIT/InvIT, developer or miner, switch to the sector file before computing any ratio here.
|
||||
- [ ] Build adjusted net debt: borrowings + leases + pension/gratuity deficit + reverse factoring + recourse securitisation + guarantees + NCI puts + hybrids, less *proven* unrestricted cash.
|
||||
- [ ] Prove the cash: reconcile interest income to average balances at market rates; explain any large simultaneous gross-cash-and-gross-debt position.
|
||||
- [ ] Compute leverage on adjusted net debt and on mid-cycle EBITDA; report gross as well as net.
|
||||
- [ ] Map the maturity ladder against cash + committed undrawn + projected FCF for 24 months; name the maturity-wall year.
|
||||
- [ ] Split debt by fixed/floating, currency and secured/unsecured; check hedging and how much unencumbered collateral remains.
|
||||
- [ ] Compute earnings-based and cash-based coverage; stress-test at −25% CFO and at current refinancing rates.
|
||||
- [ ] Find the covenants; compute headroom %, note the EBITDA definition, springing triggers, cross-defaults and any waiver history.
|
||||
- [ ] Report absolute available liquidity and months of runway, not just current and quick ratios; verify facilities are committed.
|
||||
- [ ] Compute DSO, DIO, DPO and CCC on average balances; test whether any improvement came from factoring or stretched payables.
|
||||
- [ ] Test receivables growth versus revenue, allowance trend, ageing buckets, concentration and related-party receivables; test finished-goods inventory versus sales.
|
||||
- [ ] Sweep the notes for off-balance-sheet and contingent items; present reported versus quasi-debt-adjusted leverage side by side.
|
||||
- [ ] Screen for toxic financing and chronic dilution; compute potential dilution at a stressed price.
|
||||
- [ ] Compute tangible book, goodwill/equity, capex/D&A and asset age; read the impairment assumptions and (India) the CWIP ageing.
|
||||
- [ ] Plot the five-year leverage trend and attribute it; corroborate with Altman/Piotroski, ratings, bond spreads and India-specific stress tells.
|
||||
- [ ] Compute cumulative CFO/net income over 3–5 years and the Sloan accrual ratio; bridge net income to CFO line by line.
|
||||
- [ ] State your FCF definition; compute FCF margin, FCF/NI, FCF/EBITDA and the full EBITDA-to-FCF bridge.
|
||||
- [ ] Estimate maintenance capex independently; cross-check against disclosed capacity or output growth.
|
||||
- [ ] Recompute FCF net of SBC; check whether buybacks reduce the share count or only offset issuance.
|
||||
- [ ] Build the five-year sources-and-uses table; reconcile to change in net debt and share count; test the FCF payout ratio.
|
||||
- [ ] Check for classification games: factoring, capitalised costs, lease and interest classification, one-offs inside CFO.
|
||||
- [ ] Compare cash tax to book tax; estimate the sustainable rate and use it forward (India: 115BAA, MAT credit, SEZ expiry).
|
||||
- [ ] Look at FCF through the last downturn; compute FCF volatility and set a mid-cycle normalised FCF for valuation.
|
||||
- [ ] Compute CROIC versus WACC and the incremental return on reinvested cash.
|
||||
- [ ] Normalise India/US conventions (consolidated basis, crore units, interest-in-CFO, half-yearly cash-flow availability) before any cross-market comparison.
|
||||
- [ ] State every band you cite as indicative, and immediately give the peer-set and own-history figures that override it.
|
||||
|
|
@ -0,0 +1,480 @@
|
|||
# Return on capital, DuPont decomposition and the arithmetic of compounding
|
||||
|
||||
Use this when: you are at Stage 4 with a clean set of financials and need to establish how much the company earns on the money tied up in it, whether that return exceeds its cost of capital, and whether the next rupee invested will earn the same as the last.
|
||||
|
||||
This is the intellectual centre of the skill. Margin tells you what a company keeps out of each rupee or dollar of sales; return on capital tells you what it earns on the money required to make that sale, and only the second one compounds. A business earning 35% on capital funds 10% growth out of a quarter of its profit and hands the rest to owners; a business earning 11% must plough back almost everything to grow at the same rate and returns nothing. That difference — not the margin, not the growth rate — separates a compounding machine from a treadmill, and it is invisible on the income statement. Everything below answers three questions in order: **what is the true return on capital, is it above the cost of capital, and will incremental capital earn the same?**
|
||||
|
||||
## Contents
|
||||
|
||||
- [0. Sector gate — where this arithmetic breaks](#0-sector-gate--where-this-arithmetic-breaks)
|
||||
- [1. The core argument: why a 20% margin can beat a 30% margin](#1-the-core-argument-why-a-20-margin-can-beat-a-30-margin)
|
||||
- [2. Which return metric to use, and when](#2-which-return-metric-to-use-and-when)
|
||||
- [3. Building NOPAT properly](#3-building-nopat-properly)
|
||||
- [4. Defining invested capital, and the adjustments that decide the answer](#4-defining-invested-capital-and-the-adjustments-that-decide-the-answer)
|
||||
- [5. ROIC versus WACC: the spread is the whole game](#5-roic-versus-wacc-the-spread-is-the-whole-game)
|
||||
- [6. DuPont: 3-step and 5-step](#6-dupont-3-step-and-5-step)
|
||||
- [7. Asset turnover and capital efficiency](#7-asset-turnover-and-capital-efficiency)
|
||||
- [8. How much of the return is just leverage](#8-how-much-of-the-return-is-just-leverage)
|
||||
- [9. Return on incremental invested capital (ROIIC)](#9-return-on-incremental-invested-capital-roiic)
|
||||
- [10. Cash returns: is the ROIC real](#10-cash-returns-is-the-roic-real)
|
||||
- [11. Tangible versus total capital: the goodwill effect](#11-tangible-versus-total-capital-the-goodwill-effect)
|
||||
- [12. Consistency and durability across a full cycle](#12-consistency-and-durability-across-a-full-cycle)
|
||||
- [13. Normalisation: what the mid-cycle return actually is](#13-normalisation-what-the-mid-cycle-return-actually-is)
|
||||
- [14. Peer and cross-cycle benchmarking](#14-peer-and-cross-cycle-benchmarking)
|
||||
- [15. Fade rate and the competitive advantage period](#15-fade-rate-and-the-competitive-advantage-period)
|
||||
- [16. Segment and divisional returns](#16-segment-and-divisional-returns)
|
||||
- [17. Buybacks, dividends and denominator effects](#17-buybacks-dividends-and-denominator-effects)
|
||||
- [18. Fourteen ways a reported ROIC lies](#18-fourteen-ways-a-reported-roic-lies)
|
||||
- [19. India versus US conventions](#19-india-versus-us-conventions)
|
||||
- [20. What to put in the report](#20-what-to-put-in-the-report)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
**Every range in this file is indicative only.** Return levels are a function of sector, capital intensity, accounting regime, the rate cycle and the local cost of capital. A 12% ROIC is excellent for a regulated utility, roughly value-neutral for an Indian manufacturer facing a 12–13% WACC, and poor for asset-light software. Peer comparison and the company's own 5–10 year record override every absolute band printed here. If you quote a band, quote it as a starting reference and then state what the actual peer set earns.
|
||||
|
||||
## 0. Sector gate — where this arithmetic breaks
|
||||
|
||||
Run this before computing anything. For several sectors the standard return ratios are not merely less useful — they are undefined, inverted, or measuring the wrong thing.
|
||||
|
||||
| Sector | What breaks | Use instead |
|
||||
|---|---|---|
|
||||
| **Banks** | Debt is raw material, not financing. Invested capital, NOPAT, EV and ROIC are meaningless; a bank is *supposed* to run 8–15x assets/equity. | ROA (indicatively 1.0–1.8%) and ROE (12–18%) read **together with** CET1/CAR, plus NIM, cost-to-income, credit cost, RoRWA. `references/sectors/banks.md` |
|
||||
| **NBFCs / HFCs** | Same. Leverage is the product. DuPont still works, but only in the lender form. | ROA decomposed into NIM + fees − opex − credit cost, × equity multiplier; leverage against the regulatory ceiling. `references/sectors/nbfc.md` |
|
||||
| **Insurers** | New-business strain depresses reported ROE precisely when the company is writing profitable growth. Invested capital is not meaningful against float. | Life: ROEV, VNB margin, operating variances. General: combined ratio, ROE ex-investment gains. `references/sectors/insurance.md` |
|
||||
| **REITs / InvITs** | Assets are carried at fair value and the asset *is* the business, so ROIC collapses toward the cap rate by construction. | AFFO yield, NOI yield on cost, cap rate vs cost of debt, LTV. `references/sectors/realestate-reit.md` |
|
||||
| **Miners, commodity producers, refiners** | ROCE at spot prices is procyclical nonsense — highest at the top, negative at the bottom, and neither is the business. | ROCE on **mid-cycle** realised prices; return per tonne; all-in sustaining cost position. `references/sectors/metals-mining.md` |
|
||||
| **Regulated utilities, transmission** | The return is *set by a regulator*, not earned competitively. India: CERC/SERC norms fix an allowed RoE on approved equity. US: allowed ROE per rate case. | Allowed vs achieved RoE, regulated asset base growth, regulatory assets/under-recoveries. `references/sectors/utilities-power.md` |
|
||||
| **Holdcos and conglomerates** | Consolidated ROIC blends unrelated businesses into a number no manager can act on. | Segment returns (§16) and sum-of-the-parts. `references/sectors/holdco-assetmgr.md` |
|
||||
| **Negative-invested-capital businesses** (exchanges, subscription, ticketing, quick commerce, some platforms) | Customer float and payables fund the business, so invested capital approaches zero or goes negative and ROIC becomes infinite or nonsensically negative. | Say so explicitly — it is a *strength*, not a data error. Use ROE, return on tangible capital with a stated floor, and cash generated per unit of fixed capital. |
|
||||
| **Loss-making / early-stage** | Negative NOPAT makes every return ratio uninterpretable. | Unit economics, contribution margin, cohort payback, path to first positive ROIC. `references/13-situations.md` |
|
||||
| **Airlines, shipping, retail chains, hotels** | Lease structures shift capital off the denominator and distort EBIT differently under each regime. | Lease-adjusted invested capital, always. ROIC and EV/EBITDAR on the capitalised base. |
|
||||
|
||||
## 1. The core argument: why a 20% margin can beat a 30% margin
|
||||
|
||||
The identity that governs the entire skill:
|
||||
|
||||
```
|
||||
ROE = Net margin × Asset turnover × Equity multiplier
|
||||
(NI/Sales) (Sales/Assets) (Assets/Equity)
|
||||
|
||||
ROIC ≈ NOPAT margin × Capital turnover
|
||||
(NOPAT/Sales) (Sales/Invested capital)
|
||||
```
|
||||
|
||||
Margin is **one of three terms**. A company earns a superb return on capital with a thin margin if it turns capital over quickly, and a mediocre return with a fat margin if each unit of sales demands enormous fixed assets and working capital.
|
||||
|
||||
**Illustration 1 — same return, opposite margins** (generic and illustrative).
|
||||
|
||||
| | Distributor | Branded manufacturer |
|
||||
|---|---|---|
|
||||
| NOPAT margin | 4% | 20% |
|
||||
| Sales / invested capital | 5.0x | 1.0x |
|
||||
| **ROIC** | **20%** | **20%** |
|
||||
|
||||
Identical economics. The 4%-margin business is not worse; it is a different machine reaching the same place by turning capital five times instead of once. Ranking these two on margin teaches you nothing.
|
||||
|
||||
**Illustration 2 — the inversion, where the low-margin business is materially better.**
|
||||
|
||||
| | Capital-light distributor | Capital-heavy specialty producer |
|
||||
|---|---|---|
|
||||
| EBIT margin | 6% | 25% |
|
||||
| Sales / invested capital | 4.0x | 0.5x |
|
||||
| Pre-tax return on capital | 24% | 12.5% |
|
||||
| After 25% tax | **18%** | **9.4%** |
|
||||
| WACC (illustrative, India) | 12% | 12% |
|
||||
| **Verdict** | **+6 pts of spread — compounding** | **−2.6 pts — destroying value while growing** |
|
||||
|
||||
The 6%-margin business earns roughly double the return of the 25%-margin business and is the only one of the two creating value. This is the OPM error stated as arithmetic: **margin is a ratio to sales, and shareholders do not own sales — they own capital.**
|
||||
|
||||
**Illustration 3 — three companies with an identical 18% ROE and three different risk profiles.**
|
||||
|
||||
| | Net margin | Asset turnover | Equity multiplier | ROE |
|
||||
|---|---|---|---|---|
|
||||
| Quality operator | 12% | 1.2x | 1.25x | 18% |
|
||||
| Efficiency operator | 3% | 2.4x | 2.5x | 18% |
|
||||
| Leveraged asset owner | 9% | 0.5x | 4.0x | 18% |
|
||||
|
||||
The first is self-funding and survives a downturn. The third needs continuous credit access; a 25% fall in operating profit destroys its interest cover and its ROE mean-reverts violently. **Never compare headline ROEs without decomposing them.**
|
||||
|
||||
Two implications to carry through the whole analysis:
|
||||
|
||||
1. **Where the margin sits within its sector matters far more than the margin.** A 20% margin in distribution is an outlier; 30% in enterprise software is unremarkable. Establish the sector distribution first (`references/10-peer-set.md`).
|
||||
2. **Growth is only valuable above the cost of capital.** Revenue growth funded at sub-WACC returns destroys value while making sales, EBITDA and often EPS look better every year. This is the most common way a "growth story" loses money for its shareholders.
|
||||
|
||||
## 2. Which return metric to use, and when
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **ROE** | Net profit attributable to owners ÷ average shareholders' equity (exclude minority interest from both) | India: >15% good, >20% strong, sustained >25% rare without leverage. US: >15% good. Financials have their own bands | The equity holder's return, but contaminated by leverage, buybacks and one-offs. Never quote it without the DuPont split |
|
||||
| **ROCE (pre-tax)** | EBIT ÷ capital employed, where capital employed = total assets − current liabilities ≈ net worth + total debt + lease liabilities | India: >15% decent, >20% good, >25% strong. Pre-tax, so **not** comparable to after-tax ROIC | The default Indian convention (screener.in, most sell-side notes). Being pre-tax, it is the cleaner metric for cross-period comparison when tax regimes change |
|
||||
| **ROIC (after-tax)** | NOPAT ÷ average invested capital (§3, §4) | Judge against WACC, not an absolute band. Broadly: US >12%, India >14–15% clears typical hurdles | The correct economic measure and the only return figure directly comparable to the cost of capital |
|
||||
| **ROA** | Net income ÷ average total assets | Industrials 5–10%; utilities/telecom 2–5%; banks 1.0–1.8% | Leverage-free view of asset productivity. The ROE−ROA gap *is* the leverage contribution |
|
||||
| **ROTIC / return on tangible capital** | NOPAT ÷ invested capital excluding goodwill and acquired intangibles | Structurally higher than ROIC; the *gap* is the signal | Shows the operating economics stripped of what was paid to acquire them |
|
||||
| **ROTE** | Net income ÷ average tangible equity | Banks 12–18% | Standard for financials, where goodwill is not loss-absorbing capital |
|
||||
| **CROIC / CFROI** | FCF (or CFO − maintenance capex) ÷ invested capital | Within roughly 70–100% of ROIC on a 5-year average | Tests whether accounting returns convert into cash owners can actually have |
|
||||
| **Return on gross invested capital** | NOPAT ÷ invested capital using **gross** (pre-accumulated-depreciation) fixed assets | Materially lower than net-book ROIC for old asset bases | Replacement-cost sanity check. A fully depreciated plant shows a spectacular net-book return and a poor one on what rebuilding costs |
|
||||
| **ROIIC** | Δ NOPAT ÷ Δ invested capital over 3- and 5-year windows | Should be ≥ current ROIC and comfortably > WACC | The forward-looking number: does continued reinvestment compound or dilute |
|
||||
| **Economic profit / EVA** | (ROIC − WACC) × invested capital | Positive and growing in absolute currency | Converts a percentage into money. A firm can raise ROIC by shrinking and still create less value |
|
||||
| **RoRWA** (financials only) | Net profit ÷ average risk-weighted assets | Indian banks: 1.5–2.5% is strong | Risk-adjusted, and the only honest comparison across lenders with different books |
|
||||
|
||||
Use **at least three**: ROCE or ROIC for the economics, ROE for the equity holder's view, CROIC for the reality check. Where they diverge is where the analysis lives.
|
||||
|
||||
## 3. Building NOPAT properly
|
||||
|
||||
NOPAT is the profit the business would earn with no debt — the numerator that matches a denominator financed by debt *and* equity.
|
||||
|
||||
```
|
||||
EBIT (reported)
|
||||
+ Operating-lease interest IFRS 16 / Ind AS 116 already exclude it from EBIT;
|
||||
for US GAAP filers add back the imputed interest inside lease cost
|
||||
+ R&D expensed this year only if you also capitalise R&D in the denominator (§4)
|
||||
− Amortisation of capitalised R&D
|
||||
+ Impairments and non-recurring charges; − non-recurring gains
|
||||
+ Pension service-cost normalisation where the disclosed charge is distorted
|
||||
= Adjusted EBIT (NOPBT)
|
||||
× (1 − normalised cash tax rate)
|
||||
= NOPAT
|
||||
```
|
||||
|
||||
Rules that decide whether the number is usable:
|
||||
|
||||
- **Use a normalised cash tax rate**, not the statutory rate and not one year's effective rate. Take cash taxes paid ÷ pre-tax profit over 3–5 years and sanity-check against statutory. **India:** a company that elected the concessional regime (Section 115BAA, ~25.2% effective including surcharge and cess; ~17.2% for qualifying new manufacturing under 115BAB) is not comparable to its own pre-FY20 history at ~34.9%. **US:** the 2018 cut from 35% to 21% federal breaks a 10-year after-tax series the same way. For cross-cycle work, hold the tax rate constant or use pre-tax ROCE.
|
||||
- **Do not add back stock-based compensation.** SBC is a real cost that transfers value from existing owners. It also creates no invested capital, which is exactly why heavy-SBC firms show flattered ROIC — note the distortion rather than removing the cost (`references/03-earnings-quality.md`).
|
||||
- **Match non-operating income to non-operating assets.** Treasury income on surplus cash, rent from non-operating property, and share of profit from associates must either stay with their assets in the denominator or be removed from both sides. Indian companies with large treasury books routinely get this wrong in their own investor decks.
|
||||
- **Minority interests.** Consolidated EBIT includes 100% of a partly owned subsidiary that owners do not fully own. Either use consolidated NOPAT with capital including minority interest, or strip both. Never mix.
|
||||
|
||||
## 4. Defining invested capital, and the adjustments that decide the answer
|
||||
|
||||
Two routes to the same number. **Compute both and reconcile** — a gap means something is misclassified.
|
||||
|
||||
```
|
||||
Operating route: Net working capital (excl. excess cash, excl. debt in current liabilities)
|
||||
+ Net PP&E + CWIP / construction in progress
|
||||
+ Right-of-use (capitalised lease) assets
|
||||
+ Goodwill and acquired intangibles [total-capital version only]
|
||||
+ Capitalised R&D / brand investment [where applicable]
|
||||
− Non-interest-bearing operating liabilities
|
||||
= Invested capital
|
||||
|
||||
Financing route: Total debt + lease liabilities + shareholders' equity + minority interest
|
||||
− Excess cash and non-operating investments
|
||||
= Invested capital
|
||||
```
|
||||
|
||||
| Adjustment | What to do | Why it changes the conclusion |
|
||||
|---|---|---|
|
||||
| **Operating leases** | IFRS 16 and Ind AS 116 (mandatory for Indian listed entities from FY2020) already capitalise them. **US GAAP (ASC 842) capitalises the balance sheet but keeps the entire lease cost in operating expense** — so a US filer's EBIT is depressed relative to an IFRS filer's for identical economics. For pre-FY2020 Indian data and pre-2019 US data, capitalise at ~8x annual rent or the PV of disclosed commitments | Retail, QSR, airlines, hotels, logistics and hospital chains look "asset-light" purely through lease accounting; unadjusted ROIC can be double the true figure. It also silently breaks any 10-year ROCE series at the transition year |
|
||||
| **Goodwill and acquired intangibles** | Compute ROIC both with and without (§11). Not amortised under Ind AS or US GAAP, so goodwill sits in capital permanently until impaired | Excluding goodwill measures operations; including it measures capital allocation. Both are needed |
|
||||
| **Cumulative impairments and write-offs** | Add back cumulative goodwill impairments, restructuring write-offs and discontinued-operation losses to the denominator | Otherwise the company is *rewarded* for destroying capital: writing off a bad acquisition shrinks the denominator and lifts ROIC permanently |
|
||||
| **Excess cash** | Subtract cash above an operating requirement (roughly 2–5% of revenue, sector-dependent) and state the assumption | Net-cash Indian IT services and pharma names show ~25% ROE but 40%+ ROIC once idle cash is removed. That gap is the size of the capital-allocation problem and should be reported as such |
|
||||
| **Non-operating investments** | Remove associates, listed holdings, group-company loans and surplus real estate — and remove the matching income from NOPAT. **India:** Section 186 loans, guarantees and investments to group entities belong here | Endemic in Indian promoter groups. Leaving them in understates the operating business's true return and hides where capital actually went |
|
||||
| **CWIP / assets under construction** | Report ROCE both including and excluding CWIP | A cement or capital-goods company mid-expansion earns nothing on CWIP but carries it. Excluding it shows the return on *working* assets; including it shows what shareholders are getting today. **India:** Schedule III requires CWIP ageing plus disclosure of projects overdue or over budget — read it before assuming the CWIP will ever earn |
|
||||
| **R&D and brand spend** | For intangible-driven businesses (software, pharma, branded consumer), capitalise and amortise over an economic life (3–5 yrs software, 5–10 yrs pharma) and add to capital | Expensing all R&D leaves the firm's principal asset out of the denominator. This is the largest single source of overstated ROIC in US technology and pharma |
|
||||
| **Revaluation reserves (India)** | If PPE is carried at revalued amounts under Ind AS 16, flag it; consider restating to historic cost for peer comparability | Revaluation inflates equity and capital employed, mechanically depressing ROE and ROCE with no economic change |
|
||||
| **Average vs point-in-time capital** | Use the **average** of opening and closing capital; for ROIIC and acquisition years use **beginning-of-period** capital | Year-end capital after a December acquisition pairs a full year of old NOPAT with a full year of new capital, understating the return; the reverse flatters it |
|
||||
| **Gross vs net fixed assets** | Cross-check with a gross-invested-capital ROIC | An old, fully depreciated base produces a return no one could earn building the same plant today — including the company when it must replace it |
|
||||
| **JVs and associates** | Equity-method income sits in the numerator while the investment sits in the denominator: keep both, strip both, or proportionately consolidate | Common in Indian infrastructure, cement and tower structures, where much of the economics sits outside the consolidated operating lines |
|
||||
|
||||
**Apply whatever you choose identically to the peer set and to every year of history, and state the definition in the report.** An ROIC computed on a different basis from its comparison set is worse than no ROIC at all.
|
||||
|
||||
## 5. ROIC versus WACC: the spread is the whole game
|
||||
|
||||
A business creates value only when ROIC > WACC. Below that line growth destroys value: every additional rupee invested returns less than it cost to raise, while revenue, EBITDA and often EPS keep rising.
|
||||
|
||||
```
|
||||
Economic profit = (ROIC − WACC) × Invested capital
|
||||
Value creation = economic profit, sustained and growing, across the competitive advantage period
|
||||
```
|
||||
|
||||
**Estimating WACC without false precision.** Derive it from current market data at the time of analysis — never from memory — and present it as a range.
|
||||
|
||||
- **Cost of equity** = risk-free rate + beta × equity risk premium. **India:** current 10-year G-sec yield with an ERP usually taken at 5.5–7%, which has historically put large-cap cost of equity in a low-to-mid-teens range. **US:** current 10-year Treasury with an ERP usually 4.5–5.5%, giving a high-single to low-double-digit cost of equity. These move with the rate cycle — state the inputs and the date.
|
||||
- **Cost of debt** = the company's actual marginal borrowing rate (interest-rate disclosure or recent issuance), after tax. Not the historical average rate on legacy debt.
|
||||
- Weight by **market** values of debt and equity, not book.
|
||||
- **Do not present WACC to two decimals.** Use a range (e.g. "11–13%") and test the conclusion at both ends. If the value-creation verdict flips inside your own WACC range, that *is* the finding — say so.
|
||||
- **The India/US gap is structural.** A higher risk-free rate means an Indian company needs a materially higher ROIC to create the same economic value as a US peer. A 12% ROIC that clears the bar comfortably in the US can be value-neutral in India. Never compare raw ROIC across markets — compare the spread.
|
||||
|
||||
**Report:** ROIC, WACC range, spread in basis points, economic profit in absolute currency, and how many of the last 7–10 years had a positive spread.
|
||||
|
||||
**Red flags:** ROIC persistently below WACC while capex or M&A accelerates; a positive spread narrowing year after year; management emphasising adjusted EPS or revenue growth while economic profit stagnates; a spread that was positive only during a demand boom.
|
||||
|
||||
## 6. DuPont: 3-step and 5-step
|
||||
|
||||
**3-step** — answers *what kind of business is this?*
|
||||
|
||||
```
|
||||
ROE = (Net income / Sales) × (Sales / Total assets) × (Total assets / Equity)
|
||||
= Net margin × Asset turnover × Equity multiplier
|
||||
```
|
||||
|
||||
**5-step** — answers *where is the ROE actually coming from?*
|
||||
|
||||
```
|
||||
ROE = (NI/EBT) × (EBT/EBIT) × (EBIT/Sales) × (Sales/Assets) × (Assets/Equity)
|
||||
= Tax burden × Interest burden × Operating margin × Asset turnover × Leverage
|
||||
```
|
||||
|
||||
Worked illustration: 0.75 × 0.85 × 14% × 1.2 × 1.5 = **16.1% ROE**. Now the next year the company reports 18.5%. Rerun the terms: if operating margin and turnover are unchanged and the gain came from the interest burden rising to 0.92 (cheaper refinancing) and leverage to 1.7, the business did not improve at all — the balance sheet and the rate cycle did. That distinction is entirely invisible in the headline number.
|
||||
|
||||
**How to run it.**
|
||||
|
||||
1. Compute all five terms for each of the last 5–10 years, one row per year.
|
||||
2. Identify which term moved most, in percentage-point contribution to the change in ROE.
|
||||
3. Classify the ROE as **operations-driven** (margin × turnover) or **financing-driven** (tax burden, interest burden, leverage).
|
||||
4. Run the same table for 2–3 peers. Firms with the same ROE and different decompositions are not comparable investments.
|
||||
5. **Financials:** use the lender form — ROE = ROA × equity multiplier, with ROA broken into NIM + fee income − opex − credit cost, each as a % of average assets.
|
||||
|
||||
**What each term tells you.**
|
||||
|
||||
| Term | Rising is good when | Rising is a warning when |
|
||||
|---|---|---|
|
||||
| Tax burden (NI/EBT) | A permanent regime change (India: 115BAA election) or a genuine structural mix shift | It reflects one-off credits, MAT credit utilisation, an expiring tax holiday about to reverse, or aggressive positions under dispute |
|
||||
| Interest burden (EBT/EBIT) | Debt has genuinely been repaid | It reflects refinancing at temporarily low rates, or interest capitalised into CWIP instead of expensed |
|
||||
| Operating margin | Pricing power, mix, or operating leverage that persists | It comes from an input-cost trough, a one-off, capitalised costs, or under-spend on maintenance and marketing |
|
||||
| Asset turnover | Genuine utilisation gains | It reflects a shrinking asset base from write-offs, or leasing that moved assets off balance sheet |
|
||||
| Equity multiplier | Almost never good in isolation | Always. Rising leverage is the cheapest way to manufacture ROE and the fastest way to lose the company |
|
||||
|
||||
**Red flags:** ROE rising while ROIC is flat or falling (the whole gain is financing); declining turnover masked by added leverage; margin expansion later revealed as non-recurring; ROE improving while book value per share stalls.
|
||||
|
||||
## 7. Asset turnover and capital efficiency
|
||||
|
||||
Turnover is the forgotten half of ROIC and usually the half that explains why a low-margin business is excellent.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Total asset turnover** | Sales ÷ average total assets | Distribution/retail 2–4x; manufacturing 0.8–1.5x; utilities/telecom 0.3–0.5x | The efficiency term in DuPont. Judge only against sector |
|
||||
| **Sales / invested capital** | Sales ÷ average invested capital | Cleaner than asset turnover — excludes idle cash and non-operating assets | The term that multiplies with NOPAT margin to give ROIC |
|
||||
| **Fixed-asset turnover** | Sales ÷ average net PP&E | Track the trend, not the level | Falling fixed-asset turnover alongside rising capex is the classic signature of building into demand that did not arrive |
|
||||
| **Working capital turnover** | Sales ÷ average net working capital | Sector-dependent; negative working capital is a feature in retail, QSR and subscription | Usually the largest and most controllable lever on ROIC in Indian manufacturing and trading |
|
||||
| **Capital intensity** | Capex ÷ sales; total assets ÷ sales | Compare capex/sales with depreciation/sales to separate maintenance from growth | Rising intensity without a margin benefit means returns are heading down regardless of this year's number |
|
||||
| **Physical productivity** | Revenue per employee, per store, per tonne, per bed, per seat-km, per MW | Sector-specific — take it from the sector playbook | The check that survives accounting choices entirely |
|
||||
|
||||
Cross-check against the cash conversion cycle in `references/04-balance-sheet-and-cashflow.md`: an inventory or receivables build simultaneously flatters reported profit and depresses turnover, so it shows up on both sides of the ROIC identity.
|
||||
|
||||
**Red flags:** asset base growing faster than sales for more than two consecutive years; turnover far below peers with no structural explanation in the business model; turnover improving only because assets were written off or moved into leases.
|
||||
|
||||
## 8. How much of the return is just leverage
|
||||
|
||||
```
|
||||
Leverage contribution ≈ ROE − ROA (percentage points)
|
||||
Financial leverage index = ROE / ROA (>1 means leverage is adding)
|
||||
```
|
||||
|
||||
Leverage adds to ROE only while ROIC exceeds the after-tax cost of debt. When that spread inverts — in a downturn, or after refinancing at higher rates — leverage subtracts at the same multiple. The asymmetry is the entire risk.
|
||||
|
||||
- **ROIC minus after-tax cost of debt.** Needs to be wide enough to survive a cyclical decline in ROIC. A company earning 11% ROIC and borrowing at 9% pre-tax has almost no cushion, whatever its ROE says.
|
||||
- **Stress it against the trough.** Take the worst ROIC year of the last decade (§12), recompute interest cover at today's debt level, and check whether the capital structure survives it.
|
||||
- **Negative or near-zero tangible equity** makes ROE arithmetically meaningless — it explodes as equity approaches zero from above and inverts below it. Several large US consumer and aerospace names have run negative book equity after years of debt-funded buybacks. For those, drop ROE and use ROIC and ROTIC.
|
||||
- **India:** promoter share pledging is hidden leverage on the equity itself. High pledging plus high financial leverage compounds in a way no return ratio captures (`references/08-governance.md`).
|
||||
|
||||
**Red flags:** ROE far exceeding ROIC with the gap widening; rising leverage as the sole driver of ROE growth; debt-funded buybacks lifting leverage and ROE together while ROIC is flat.
|
||||
|
||||
## 9. Return on incremental invested capital (ROIIC)
|
||||
|
||||
Average ROIC is history. ROIIC is the forecast.
|
||||
|
||||
```
|
||||
ROIIC (3-yr) = (NOPAT_t − NOPAT_t−3) / (Invested capital_t−1 − Invested capital_t−4)
|
||||
```
|
||||
|
||||
Lag the denominator by a year — capital takes time to earn. Use rolling 3- and 5-year windows; single-year ROIIC is noise.
|
||||
|
||||
**Worked illustration.** NOPAT rises from 100 to 130 over three years while invested capital rises from 500 to 900.
|
||||
|
||||
- ROIC at the start: 100/500 = **20%**
|
||||
- ROIC now: 130/900 = **14.4%** — still a respectable-looking headline
|
||||
- ROIIC: 30/400 = **7.5%** — below an 11–12% WACC
|
||||
|
||||
Every rupee of new capital is destroying value. The legacy business is subsidising the expansion, and the blended ROIC will keep drifting toward 7.5% as new capital dominates the base — while management reports record profits throughout. **This is the highest-value calculation in this file, and almost nobody runs it.**
|
||||
|
||||
**Pair it with the reinvestment rate:**
|
||||
|
||||
```
|
||||
Reinvestment rate = (capex + acquisitions + Δ working capital − depreciation) / NOPAT
|
||||
Intrinsic NOPAT growth ≈ Reinvestment rate × ROIIC
|
||||
```
|
||||
|
||||
A firm reinvesting 50% of NOPAT at 20% incremental returns compounds at ~10% with no external funding. A firm reinvesting 90% at 8% compounds at ~7% while consuming all its cash and creating nothing. Use the identity to test management guidance: if the promised growth implies a reinvestment rate above 100% of NOPAT, the plan requires debt or dilution — say so explicitly.
|
||||
|
||||
**Red flags:** incremental returns below both the historical average and WACC; large capex or acquisition programmes with flat NOPAT three years later; ROIIC falling steadily as the firm scales (saturation or diseconomies); management declining to give returns on specific projects when asked on the concall.
|
||||
|
||||
## 10. Cash returns: is the ROIC real
|
||||
|
||||
```
|
||||
CROIC = FCF ÷ invested capital (state which capex definition)
|
||||
or (CFO − maintenance capex) ÷ invested capital
|
||||
FCF conversion = FCF ÷ NOPAT
|
||||
```
|
||||
|
||||
Accounting ROIC can be inflated by revenue recognised ahead of cash, capitalised operating costs, understated depreciation, or a working-capital build that never unwinds. Cash returns are the audit.
|
||||
|
||||
- Compare **5-year average CROIC with 5-year average ROIC**. A persistent gap of more than a few points needs an explanation, and "we are investing for growth" only qualifies if the growth capex is separately identifiable.
|
||||
- **CFO ÷ net income above 1.0 on a rolling 3–5 year basis** is the baseline; sustained below 0.8 is a serious signal (`references/03-earnings-quality.md`).
|
||||
- For genuinely growing companies, FCF conversion is legitimately depressed by growth capex and working capital. Separate maintenance from growth capex — depreciation is a crude floor for maintenance — before drawing any conclusion.
|
||||
- **Accrual ratio** = (NOPAT − FCF) ÷ average invested capital. Rising across several years means an increasing share of the reported return exists only on paper.
|
||||
|
||||
**Red flags:** ROIC persistently and materially above CROIC; conversion deteriorating while reported margins improve; capitalised development costs or capitalised interest growing faster than revenue.
|
||||
|
||||
## 11. Tangible versus total capital: the goodwill effect
|
||||
|
||||
Compute ROIC both ways for any company that has made acquisitions.
|
||||
|
||||
- **Return on tangible invested capital** (goodwill and acquired intangibles excluded) = the economics of the operating business.
|
||||
- **ROIC on total capital** (goodwill included) = the return on what shareholders actually paid, acquisition premiums and all.
|
||||
|
||||
The gap is a direct measure of capital-allocation quality. A serial acquirer can run a 40% return on tangible capital and a 9% return on total capital: the businesses are good, the prices paid were not. Roll-ups habitually headline the tangible figure.
|
||||
|
||||
Check: goodwill + acquired intangibles as a % of invested capital; the trend in the gap over 5–10 years (widening means premiums rising or acquired performance falling); the history of goodwill impairments, each of which is documentary evidence of overpayment; and whether the company's own "return on capital" disclosure quietly uses the tangible base.
|
||||
|
||||
## 12. Consistency and durability across a full cycle
|
||||
|
||||
One year's ROIC tells you almost nothing. Pull **7–10 years minimum**, spanning at least one genuine downturn, and compute:
|
||||
|
||||
| Statistic | What it tells you |
|
||||
|---|---|
|
||||
| Mean and median ROIC | Central tendency — prefer the median where one year is extreme |
|
||||
| Standard deviation / coefficient of variation | Volatility of returns is the quantitative fingerprint of cyclicality or a fragile competitive position |
|
||||
| **Minimum (trough) ROIC** | The honest floor of the business and the best single predictor of downside. A company whose worst year is 14% is a different animal from one whose worst year is −3%, whatever their averages |
|
||||
| Years with ROIC > WACC out of 10 | Value creation is a habit, not an event |
|
||||
| Peak-to-trough drawdown in ROIC | How much of the return is cyclical rent rather than franchise |
|
||||
| Trend line through the series | Structural improvement, stability, or slow erosion |
|
||||
|
||||
Durable, high, low-volatility returns are the strongest quantitative evidence that a moat exists. Cross-check against the qualitative moat assessment in `references/02-core-factors.md` — if the narrative claims a widening moat and the ROIC has fallen for six years, the numbers win.
|
||||
|
||||
**Red flags:** returns clearing WACC only at the top of the cycle; one exceptional year carrying the whole average; no history through a real downturn (recent IPO, post-restructuring, or a business model younger than the last recession); each cycle peaking lower than the last — structural decline dressed as cyclicality.
|
||||
|
||||
## 13. Normalisation: what the mid-cycle return actually is
|
||||
|
||||
Reported returns are one point in a cycle plus whatever one-offs landed that year. Capitalise sustainable earning power, not the snapshot.
|
||||
|
||||
1. **Strip non-recurring items** from NOPAT: restructuring, litigation settlements, disposal gains and losses, impairments, insurance recoveries, translation effects, one-off incentives. List them; do not silently delete them.
|
||||
2. **Normalise tax** to a sustainable cash rate (§3).
|
||||
3. **Mid-cycle the margin.** For cyclicals use a multi-year average realised price or spread rather than the current one — an average GRM for a refiner, mid-cycle spreads for a steel producer, a through-cycle credit cost for a lender. Applying spot economics to a cyclical produces the classic trap: lowest P/E and highest ROCE precisely at the top.
|
||||
4. **Quantify the gap** between reported and normalised ROIC and explain it in one line.
|
||||
5. **Audit the company's own adjustments.** If management excludes a charge every year for five years, it is a recurring cost of doing business. Recompute without their adjustments and compare.
|
||||
|
||||
**Red flags:** returns dependent on a booming end-market or a commodity price; "one-time" items that recur annually; normalised ROIC materially below reported; company-defined adjusted metrics that only ever exclude unfavourable items; a definition of "adjusted" that changed mid-period (`references/07-forensic-red-flags.md`).
|
||||
|
||||
## 14. Peer and cross-cycle benchmarking
|
||||
|
||||
Absolute return levels mean nothing. Benchmark twice, always.
|
||||
|
||||
**Against peers** (build the set with `references/10-peer-set.md`):
|
||||
|
||||
- Use the **same cycle window** and aligned fiscal years for every company.
|
||||
- **Normalise the accounting before ranking.** Lease presentation (IFRS vs US GAAP), R&D capitalisation policy, revaluation, goodwill history and consolidation scope each move ROIC by several points. Ranking un-normalised figures produces confident nonsense.
|
||||
- Report the **percentile rank** on ROIC, margin and turnover *separately* — that immediately shows whether the company's advantage is a margin story or a turnover story.
|
||||
- Watch the **trend in relative rank**, which matters more than the level. A company moving from third quartile to first is a different investment from one drifting the other way at the same absolute ROIC.
|
||||
|
||||
**Against its own history:** spread versus its own 5- and 10-year average ROIC, and the same for margin and turnover independently. A company can beat its peers while decaying against itself — a sector in structural decline, which the peer comparison alone would miss entirely.
|
||||
|
||||
**Red flags:** a peer set containing differently structured or differently regulated businesses; below-peer returns explained away by management narrative; apparent outperformance that vanishes once leverage and accounting policy are equalised.
|
||||
|
||||
## 15. Fade rate and the competitive advantage period
|
||||
|
||||
High returns attract capital, and capital compresses returns. Excess returns fade toward the cost of capital across most industries, and the *rate* of that fade is one of the largest drivers of intrinsic value — usually larger than next year's growth rate, which is where almost all attention goes.
|
||||
|
||||
Assess:
|
||||
|
||||
- **The firm's own persistence.** How many consecutive years has ROIC exceeded WACC, and is the spread widening or narrowing? A long, stable record is real evidence.
|
||||
- **The industry fade pattern.** Some structures resist fade for decades (network effects, regulated monopolies, entrenched distribution, high-switching-cost software, brands in low-innovation categories). Others fade in three years (commodity manufacturing without a cost advantage, hardware, undifferentiated services).
|
||||
- **The reinvestment runway.** A 25% ROIC on a capital base that cannot grow is worth far less than a 20% ROIC with a decade of reinvestment ahead. Runway × ROIIC is the compounding engine.
|
||||
- **What breaks it.** Name the specific entrant, technology, regulation or input shift that would compress the return, and what you would observe first.
|
||||
|
||||
Then make the assumption **explicit** in valuation (`references/06-valuation.md`): state the competitive advantage period you are using and fade ROIC toward WACC beyond it. A DCF holding today's ROIC constant into perpetuity assumes the company defeats competition forever — usually the single largest source of overpayment.
|
||||
|
||||
**Red flags:** implicit assumption of permanently high returns with no identifiable moat; excess returns already fading while the narrative claims the opposite; well-capitalised entrants arriving; industry-wide return compression visible across the whole peer set.
|
||||
|
||||
## 16. Segment and divisional returns
|
||||
|
||||
Consolidated ROIC is an average, and averages hide the actual decision.
|
||||
|
||||
- Compute **ROCE or ROIC per segment**: segment EBIT ÷ segment capital employed (segment assets − segment operating liabilities). **India:** Ind AS 108 disclosure usually includes segment assets *and* liabilities, so segment capital employed is directly computable — use it. **US:** ASC 280 requires segment assets only where regularly reviewed by the chief operating decision maker, so segment capital is often unavailable; fall back on segment margins plus disclosed capex by segment.
|
||||
- Identify which segments earn **above and below group WACC**, and where **incremental capital** has gone over five years. A high-return core funding chronic losses elsewhere is the commonest form of value destruction in listed conglomerates and is entirely invisible in the consolidated ratio.
|
||||
- Compare segment capex with segment returns. Capital flowing consistently to the lowest-return segment is a verdict on management (`references/08-governance.md`).
|
||||
- Segment work is also where **hidden value** appears — a crown-jewel division dragged down in the consolidated number is the basis of a sum-of-the-parts case, a divestiture thesis or a demerger catalyst.
|
||||
|
||||
**Red flags:** heavily aggregated or repeatedly redefined segments; a single segment carrying the entire group's returns; loss-making units retained indefinitely with no credible turnaround plan; segment reporting that changed right after a division started underperforming.
|
||||
|
||||
## 17. Buybacks, dividends and denominator effects
|
||||
|
||||
Capital return is the other half of this domain, and it moves the denominators directly.
|
||||
|
||||
- **Buybacks shrink equity, so ROE rises with zero operating improvement.** Illustration: net income 100 on equity 500 is a 20% ROE. A debt-funded buyback halves equity to 250 and interest cuts net income to 92 — ROE now reads 36.8% while ROIC is unchanged or slightly lower and the balance sheet is materially riskier. **If ROE rises and ROIC does not, the improvement is financial engineering.**
|
||||
- **Test the price paid.** Buybacks above intrinsic value, or at cyclical peaks, transfer value from continuing holders to sellers. Compare the average buyback price with your own valuation range and with the multiple at the time.
|
||||
- **Judge payout against reinvestment ROIC, not against a payout norm.** Returning capital is accretive precisely when internal opportunities fall below WACC. A company earning 25% incremental returns should be reinvesting; one earning 6% should be distributing. The comparison is payout ratio versus ROIIC (§9).
|
||||
- **Track share count and book value per share** alongside ROE. Per-share economic progress is the test that survives every denominator game.
|
||||
- **India specifics:** buybacks are much less common than in the US and are often tender-offer route — check whether promoters tendered, since that is an exit dressed as capital return. Since October 2024 buyback proceeds are taxed in the shareholder's hands, which has pushed many Indian companies back toward dividends; compare **total shareholder yield** (dividends + net buybacks), never either alone.
|
||||
|
||||
**Red flags:** ROE boosted by buybacks that hollow out or eliminate book equity; debt-funded buybacks raising leverage and ROE together; management guiding on EPS while book value per share stalls; dividends funded by borrowing while ROIC sits below WACC.
|
||||
|
||||
## 18. Fourteen ways a reported ROIC lies
|
||||
|
||||
Run this scan before trusting any return figure, including your own.
|
||||
|
||||
1. **Write-offs shrank the denominator** — cumulative impairments not added back, so past destruction now flatters returns.
|
||||
2. **Buybacks shrank equity** — ROE up, ROIC flat (§17).
|
||||
3. **Leases off the denominator** — pre-IFRS 16 / pre-ASC 842 history, or a US GAAP filer compared with an IFRS filer on EBIT-based ROCE.
|
||||
4. **R&D and brand expensed** — the principal asset is missing from capital entirely.
|
||||
5. **Idle cash left in** — depresses ROIC and hides a capital-allocation problem; or quietly netted out without disclosure.
|
||||
6. **CWIP carried with no earnings yet** — depresses returns mid-expansion; excluding it without saying so inflates them.
|
||||
7. **Fully depreciated asset base** — a superb net-book return that could never be earned on replacement cost.
|
||||
8. **Associates and JVs mismatched** — income in the numerator, investment out of the denominator, or the reverse.
|
||||
9. **Minority interests mismatched** — 100% of a subsidiary's profit against a partial ownership claim.
|
||||
10. **One-off gains in the numerator** — disposals, insurance recoveries, tax credits.
|
||||
11. **Tax-rate breaks** — India's 115BAA election, the US 2018 cut, expiring holidays. After-tax series are not continuous through these.
|
||||
12. **Year-end rather than average capital** — especially distorting in an acquisition year.
|
||||
13. **SBC-heavy models** — a real cost that creates no capital, so ROIC is structurally overstated versus a cash-paying competitor.
|
||||
14. **Off-balance-sheet structures** — securitised receivables, JV-held assets, project SPVs, supplier finance. Earnings consolidated, capital not.
|
||||
|
||||
Each of these is a reason to state your definition in the report and apply it identically across the peer set.
|
||||
|
||||
## 19. India versus US conventions
|
||||
|
||||
| Topic | India (NSE/BSE, Ind AS) | US / global (10-K, GAAP/IFRS) |
|
||||
|---|---|---|
|
||||
| **Default return metric** | **ROCE, pre-tax**: EBIT ÷ (total assets − current liabilities). The screener.in and sell-side convention, and *not* comparable to after-tax ROIC — always say which you quote | **ROIC, after-tax**: NOPAT ÷ invested capital. Many filers now disclose their own version in the 10-K or at investor days — read their definition before using their number |
|
||||
| **ROE denominator** | "Net worth" per Schedule III: equity share capital + other equity, excluding revaluation surplus where identifiable and excluding minority interest | Total stockholders' equity attributable to the parent |
|
||||
| **Leases** | Ind AS 116 from FY2020 — on balance sheet, rent split into depreciation and interest, so **EBIT stepped up at transition**. Pre-FY2020 years must be adjusted before any 10-year ROCE comparison | ASC 842 from 2019 — right-of-use asset and liability on balance sheet, but **operating-lease cost remains a single operating expense**, so US EBIT is lower than an IFRS filer's for identical economics |
|
||||
| **Tax** | Section 115BAA (~25.2% effective) vs the older ~34.9%; 115BAB for new manufacturing; MAT credits; SEZ and area-based holidays that expire | 21% federal statutory since 2018 (from 35%), plus state taxes, GILTI/FDII, and large valuation-allowance swings |
|
||||
| **Goodwill** | Not amortised under Ind AS 103; impairment-tested. Amalgamations under NCLT-approved schemes can adjust goodwill directly against reserves — read the scheme, because capital can leave the denominator without touching the P&L | Not amortised since 2001; impairment-only for filers |
|
||||
| **Capital work-in-progress** | Schedule III mandates **CWIP ageing** and disclosure of projects overdue or over budget — a direct read on whether carried capital will ever earn | Construction in progress sits inside the PP&E note, generally with less granularity |
|
||||
| **Related-party capital** | Section 186 loans/guarantees/investments to group entities; CARO 3(iii) on loans granted and 3(ix) on end-use of borrowings — the standard route by which capital leaves the listed entity's operating base | Related-party disclosure under ASC 850; typically far smaller in scale for large filers |
|
||||
| **Basis of accounts** | **Consolidated vs standalone matters enormously.** For any group with subsidiaries, standalone ROE is meaningless. State which you used | Consolidated by default |
|
||||
| **Units** | ₹ crore / lakh — state the unit on every figure | Millions / billions |
|
||||
| **History sources** | Annual report 5-year highlights, BSE/NSE filings, screener.in (check its ROCE definition), CARO annexure, quarterly segment data | 10-K financial statements and MD&A, EDGAR full-text search, segment note (ASC 280), earnings supplements |
|
||||
| **Management dialogue** | The **concall is the highest-value source**: whether management guides to ROCE, what hurdle rate they apply to new projects, what returns recent capex actually earned. Indian managements frequently state explicit ROCE targets — hold them to it year over year | Investor days and MD&A; some firms publish an explicit ROIC target and hurdle rate. The proxy (DEF 14A) reveals whether incentive pay is tied to ROIC, which is the real hurdle |
|
||||
| **Governance overlay** | Promoter holding and pledging, promoter-group related-party flows and holdco discounts determine whether the reported return actually accrues to minority shareholders | Dual-class structures, controlled-company exemptions, VIE structures for China-domiciled ADRs where the listed entity may not own the operating assets at all |
|
||||
|
||||
## 20. What to put in the report
|
||||
|
||||
- A **10-year table**: ROCE/ROIC, ROE, NOPAT margin, capital turnover, CROIC — with the trough year highlighted.
|
||||
- Your **invested-capital definition** in one sentence, the adjustments made, and their effect in percentage points.
|
||||
- **ROIC versus a WACC range**, the spread in basis points, and economic profit in absolute currency.
|
||||
- The **DuPont decomposition** for the company and 2–3 peers, side by side.
|
||||
- **ROIIC over 3 and 5 years**, beside the historical average ROIC and WACC, with a one-line verdict on whether reinvestment compounds or dilutes.
|
||||
- **Reported versus normalised** ROIC and what drives the gap.
|
||||
- The **fade assumption** carried into valuation, stated explicitly.
|
||||
- **Segment returns** and where incremental capital went, wherever disclosure allows.
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Run the sector gate first — confirm return-on-capital arithmetic is even defined for this business.
|
||||
- [ ] Build NOPAT on a normalised cash tax rate; do not add back SBC; match non-operating income to non-operating assets.
|
||||
- [ ] Build invested capital by both the operating and financing routes and reconcile them.
|
||||
- [ ] Capitalise leases, state the R&D treatment, add back cumulative impairments, strip excess cash and non-operating investments — and note each adjustment's effect.
|
||||
- [ ] Use average (or beginning-of-period) capital, never year-end, especially in an acquisition year.
|
||||
- [ ] Compute ROIC including and excluding goodwill; report the gap for any acquirer.
|
||||
- [ ] Estimate WACC as a range from current market inputs; report ROIC − WACC in bps and economic profit in currency.
|
||||
- [ ] Never quote ROE without the 3-step DuPont; run the 5-step where tax or interest burden has moved.
|
||||
- [ ] Split the return into margin and turnover and say which one drives it versus peers.
|
||||
- [ ] Compute ROIIC over 3 and 5 years against average ROIC and WACC — the forward-looking signal.
|
||||
- [ ] Cross-check reinvestment rate × ROIIC against management's growth guidance.
|
||||
- [ ] Compare CROIC with ROIC over five years and explain any persistent gap.
|
||||
- [ ] Pull 7–10 years; report mean, volatility, **trough** ROIC, and years above WACC.
|
||||
- [ ] Normalise for one-offs and cycle position; state reported versus normalised.
|
||||
- [ ] Benchmark twice — against an accounting-normalised peer set and against the company's own 5–10 year record.
|
||||
- [ ] State the fade assumption / competitive advantage period explicitly and carry it into valuation.
|
||||
- [ ] Compute segment returns wherever disclosure allows and check where incremental capital is going.
|
||||
- [ ] Check whether rising ROE is matched by rising ROIC; if not, name the financing action responsible.
|
||||
- [ ] Run the fourteen-lies scan (§18) before trusting any return figure, including your own.
|
||||
- [ ] State metric definition, basis (consolidated/standalone), currency, units and period beside every number.
|
||||
426
finance/skills/stock-analysis/references/06-valuation.md
Normal file
426
finance/skills/stock-analysis/references/06-valuation.md
Normal file
|
|
@ -0,0 +1,426 @@
|
|||
# Valuation and margin of safety
|
||||
|
||||
Use this when: business quality, earnings quality, balance sheet and returns are already established, and you need to decide what the business is worth, what the market is already paying for, and how much room for error the price leaves.
|
||||
|
||||
Valuation is the last stage, never the first screen. A multiple is a compression of everything you have already established — growth, durability, capital intensity, return on incremental capital, accounting honesty — into a single number, and it is unreadable until those are known. The governing principle applies with full force: a P/E of 12 means nothing until you know the sector, the cycle position, and the company's own ten-year band. For banks, insurers, REITs, miners, shipping and holding companies the standard multiples are undefined, inverted, or actively misleading, and **the sector playbook overrides every default in this file**.
|
||||
|
||||
## Contents
|
||||
|
||||
1. [Order of operations](#order-of-operations)
|
||||
2. [The multiple set](#the-multiple-set)
|
||||
3. [Where each multiple breaks](#where-each-multiple-breaks)
|
||||
4. [Building the enterprise value bridge](#building-the-enterprise-value-bridge)
|
||||
5. [Deriving the discount rate](#deriving-the-discount-rate)
|
||||
6. [Building the DCF](#building-the-dcf)
|
||||
7. [Reverse DCF — the central discipline](#reverse-dcf--the-central-discipline)
|
||||
8. [Earnings yield versus bond yield](#earnings-yield-versus-bond-yield)
|
||||
9. [Valuation versus its own history](#valuation-versus-its-own-history)
|
||||
10. [Valuation versus peers](#valuation-versus-peers)
|
||||
11. [SOTP, private market value and replacement cost](#sotp-private-market-value-and-replacement-cost)
|
||||
12. [Margin of safety](#margin-of-safety)
|
||||
13. [Quality trap versus value trap](#quality-trap-versus-value-trap)
|
||||
14. [Scenarios, expected value and IRR decomposition](#scenarios-expected-value-and-irr-decomposition)
|
||||
15. [Catalyst, edge and what is already discounted](#catalyst-edge-and-what-is-already-discounted)
|
||||
16. [Sector overrides](#sector-overrides)
|
||||
17. [India (Ind-AS/NSE-BSE) vs US/global conventions](#india-ind-asnse-bse-vs-usglobal-conventions)
|
||||
18. [Errors that ruin this section of the report](#errors-that-ruin-this-section-of-the-report)
|
||||
19. [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Order of operations
|
||||
|
||||
Run valuation in this sequence. Out of order, it becomes a rationalisation of the quoted price — the most common failure mode in this entire skill.
|
||||
|
||||
1. **Check the sector playbook first.** If it prescribes a method (P/ABV against ROE for banks, P/EV for life insurers, AFFO yield and cap-rate spread for REITs, mid-cycle EV/EBITDA and P/NAV for miners, EV/EBITDAR for airlines), use it and suppress the generic multiples it declares inapplicable.
|
||||
2. **Normalise the denominator before touching the numerator.** Strip one-offs, normalise tax, decide whether earnings sit at a cyclical peak or trough, and state whether the figure is reported (Ind-AS/GAAP/IFRS) or adjusted, and why.
|
||||
3. **Build the EV bridge once**, properly, and reuse it in every enterprise multiple.
|
||||
4. **Run the reverse DCF before building your own forecast.** Find out what the price already assumes while you are still neutral. Once you have written a forecast you will unconsciously defend it.
|
||||
5. **Then triangulate:** multiples versus own history, versus peers, a forward DCF with sensitivity, and at least one asset- or transaction-based cross-check.
|
||||
6. **Convert to a scenario table** with explicit probabilities, a probability-weighted value, and an IRR decomposition. Report a range, never a point.
|
||||
7. **Apply the margin of safety** against the conservative case, sized to the uncertainty of the estimate — not to how much you like the story.
|
||||
|
||||
---
|
||||
|
||||
## The multiple set
|
||||
|
||||
Ranges are **indicative only**. They move with market, sector, cycle, interest-rate regime and accounting period, and an Indian multiple is not directly comparable to a US one because the currency, the risk-free rate and the nominal growth rate all differ. **The company's own 5–10 year band and its true peer set override every number in this column.**
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Trailing P/E** | Price ÷ trailing-12m diluted EPS, after minority interest. | Depends entirely on ROIC and growth; 12–20x is unremarkable for a mature business in either market. | The most quoted and most distorted multiple. Only interpretable next to the normalised version. |
|
||||
| **Forward P/E** | Price ÷ next-12m consensus or your own EPS. | Should sit below trailing P/E if earnings are growing. | Prices the year ahead, but inherits consensus optimism. Check estimate dispersion and revision direction. |
|
||||
| **Normalised / mid-cycle P/E** | Price ÷ EPS at mid-cycle margins and a full tax rate, modelled across a complete cycle. | Compare to the company's own normalised history, not an absolute band. | The only P/E that survives a cyclical business. Prevents anchoring to peak or trough earnings. |
|
||||
| **CAPE / Shiller P/E** | Price ÷ 10-yr average inflation-adjusted EPS. | Use versus its own history and the index's. | Cycle-proof at index level; at single-stock level it penalises genuine structural growth — use for mature cyclicals only. |
|
||||
| **GAAP-vs-adjusted EPS gap** | (Adjusted EPS − reported EPS) ÷ reported EPS. | <10% and not widening. | A widening gap is an earnings-quality finding dressed up as a valuation input. |
|
||||
| **Earnings yield (E/P)** | Inverse of P/E; better, FCF ÷ market cap. | Above the local 10-yr sovereign yield by a sensible premium. | Makes the equity directly comparable to bonds and to the company's own cost of debt. |
|
||||
| **P/B** | Price ÷ book value per share. | Only meaningful with ROE alongside; justified P/B ≈ (ROE − g) ÷ (COE − g). | Anchors financials and asset-heavy businesses. Near-meaningless for asset-light compounders. |
|
||||
| **P/TBV (P/ABV)** | Price ÷ (equity − goodwill − intangibles); for lenders also net of net NPAs (adjusted book). | With ROTCE/RoE above cost of equity, a premium is earned. | Strips acquisition accounting and, for banks, the reserves the market disbelieves. |
|
||||
| **EV/EBITDA** | EV (from the bridge) ÷ EBITDA. | 6–12x common for mature industrials; capital intensity drives the band. | Capital-structure and tax neutral; the language of M&A. Blind to capex. |
|
||||
| **EV/EBIT** | EV ÷ EBIT after real depreciation. | Roughly 10–16x for a decent mature business. | Harder to game than EBITDA because depreciation proxies the cost of keeping the asset base alive. Prefer it for anything capital-intensive. |
|
||||
| **EV/(EBITDA − capex)** | EV ÷ (EBITDA − total capex), and ÷ (EBITDA − maintenance capex). | Compare against EV/EBITDA; a wide gap is the whole story. | Exposes the business whose EBITDA is consumed by the plant that produced it. |
|
||||
| **EV/Sales** | EV ÷ revenue. Decompose: EV/Sales ÷ steady-state EBIT margin = implied EV/EBIT. | Only via the implied-margin decomposition. | The fallback when earnings are negative or unrepresentative — and worthless unless you state the margin it implies. |
|
||||
| **P/S** | Market cap ÷ revenue. | As above; equity-level, so valid only for near-unlevered companies. | Sales are the hardest line to manipulate, so P/S survives trough margins. It does not survive a structurally low-margin business. |
|
||||
| **PEG** | P/E ÷ expected EPS CAGR (%). | <1 classically cheap; treat 0.8–1.5 as a wide neutral band. | Links price to growth. Ignores growth's capital intensity and durability — always pair with incremental ROIC. |
|
||||
| **EV/EBIT-to-growth** | EV/EBIT ÷ EBIT CAGR. | Use versus peers, not absolutely. | The capital-structure-neutral version of PEG; avoids PEG's leverage distortion. |
|
||||
| **FCF yield** | FCF ÷ market cap, FCF = CFO − total capex, with SBC treated as a cost. | 4–8% for a mature business; a genuine high-reinvestment compounder can legitimately show 1–2%. | The truest "what an owner earns" measure and the hardest to manipulate. |
|
||||
| **FCF/EV** | Unlevered FCF ÷ EV. | Compare directly to WACC. | Removes leverage distortion, making the yield comparable across capital structures. Below WACC, the business is not covering its capital cost. |
|
||||
| **Owner-earnings yield** | (Net income + D&A − maintenance capex − working-capital needs − SBC) ÷ market cap. | Within a few points of FCF yield across 3–5 years. | Separates reported profit from distributable profit. The gap is the finding. |
|
||||
| **FCF conversion** | FCF ÷ net income, cumulative over 3–5 years. | 70%+ for a mature business. | A valuation input, because it decides whether the E in P/E is spendable. |
|
||||
| **Dividend yield** | DPS ÷ price. | Sector- and market-dependent; Indian large caps typically yield less than US peers. | A component of return and a discipline on capital allocation — and a trap when the market is pre-pricing a cut. |
|
||||
| **Payout ratio** | DPS ÷ EPS, and dividends ÷ FCF. | Below ~70% of FCF for a sustainable dividend. | The FCF version is the one that matters; the EPS version misses the capex. |
|
||||
| **Total shareholder yield** | Dividend yield + net buyback yield (net of SBC issuance) + net debt-paydown yield. | 4%+ for a mature cash generator. | Captures the whole return of capital, including the buyback that merely offsets dilution and therefore returns nothing. |
|
||||
| **Multiple percentile vs own history** | Current multiple's percentile / z-score in its own 5–10 yr distribution. | Below the 50th percentile with unchanged fundamentals is the interesting case. | Own history is the cleanest comparable: same model, same accounting, same disclosure. |
|
||||
| **Implied ERP (yield gap)** | Earnings or FCF yield − local 10-yr sovereign yield. | Judge against that same spread's own history, never against another country's. | Places the multiple inside the prevailing rate regime instead of in a vacuum. |
|
||||
| **EV per physical unit** | EV ÷ tonne, bed, key, subscriber, MW, sq ft, MHz, dwt. | Versus greenfield replacement cost and recent transactions. | The cross-check that depends on no accounting at all. |
|
||||
| **Price / intrinsic value** | Price ÷ conservatively estimated fair value. | ≤0.70 for average businesses; ≤0.80 for highly predictable ones. | The margin of safety, stated as a number rather than a feeling. |
|
||||
|
||||
---
|
||||
|
||||
## Where each multiple breaks
|
||||
|
||||
Every multiple has a situation in which it reliably lies. Establish which one you are in before quoting it.
|
||||
|
||||
| Multiple | Fails when | What it does to you | Use instead |
|
||||
|---|---|---|---|
|
||||
| **P/E** | Earnings sit at a cyclical peak, contain one-offs, or are negative. | Prints its lowest reading at the top of a commodity cycle — P/E is *inverted* for cyclicals. A miner or commodity chemical maker at 5x is usually a sell; at 30x, often a buy. | Mid-cycle normalised EPS; P/B against mid-cycle ROE; EV per tonne. |
|
||||
| **P/E** | Capital structure differs across the peer set. | Leverage flatters EPS and compresses P/E, so the most fragile company screens cheapest. | EV/EBIT. |
|
||||
| **P/E** | EPS growth is buyback-driven. | Mistakes share-count shrinkage for business growth. | Net income growth and FCF per share, with the buyback price checked against your own value range. |
|
||||
| **P/B** | The business is asset-light, equity is negative after buybacks, or book carries goodwill from overpriced deals. | Meaningless or undefined; a serial acquirer looks "cheap on book" precisely because it overpaid. | P/TBV with ROTCE; for asset-light names ignore book entirely and use FCF yield. |
|
||||
| **P/B (financials)** | Asset marks are stale or reserves inadequate. | A bank below book is cheap only if the book is real. The market usually prices a credit event before the auditor recognises it. | P/ABV net of net NPAs, stressed-book scenarios. `sectors/banks.md` |
|
||||
| **EV/EBITDA** | Capital intensity is high, EV omits leases/pensions/minorities, or "adjusted EBITDA" carries recurring add-backs. | Understates the true purchase price and overstates the cash. SBC and annual "restructuring" added back is the classic. | EV/EBIT, EV/(EBITDA − capex), and a rebuilt EV bridge. |
|
||||
| **EV/anything (banks, NBFCs, insurers)** | Debt is raw material, not financing. | Enterprise value has no meaning; net debt is not a claim to add back. | P/B, P/ABV, RoE vs COE, P/EV. Suppress every EV multiple. |
|
||||
| **EV/Sales, P/S** | The implied steady-state margin is never stated. | Any price can be justified by assuming a margin the industry has never achieved. | Always decompose: EV/Sales ÷ target margin = implied EV/EBIT, then ask whether that margin is attainable. |
|
||||
| **PEG** | Growth is a one-year spike, or the company is a no-growth cash cow. | Rewards a peak-growth year; penalises a genuinely cheap steady compounder. | FCF yield + growth; EV/EBIT-to-growth alongside incremental ROIC. |
|
||||
| **FCF yield** | The year contains a working-capital release, an asset sale, or deferred capex. | A single year of "free cash" that is really underinvestment or stretched payables. | 3–5 year average FCF; split maintenance from growth capex; check payable days. |
|
||||
| **Dividend yield** | The yield rose because the price fell. | The classic yield trap; the market pre-prices the cut months before the board announces it. | Payout as % of FCF, coverage, and balance-sheet capacity to sustain it. |
|
||||
| **P/E on REITs, InvITs** | Depreciation is charged on appreciating property. | Earnings are structurally understated; P/E is nonsense. | AFFO yield, NOI cap-rate spread, NAV. `sectors/realestate-reit.md` |
|
||||
| **Any multiple straddling FY20 (India) / 2019 (IFRS, US)** | Ind AS 116 / IFRS 16 / ASC 842 capitalised leases; India's s.115BAA cut the tax rate. | EBITDA, EPS and EV all stepped up for non-operating reasons. The 10-year multiple band is broken at that seam. | Restate the pre-transition years before plotting any historical multiple range. |
|
||||
|
||||
---
|
||||
|
||||
## Building the enterprise value bridge
|
||||
|
||||
Most "cheap on EV/EBITDA" findings are arithmetic errors in EV. Build the bridge explicitly, present it as a table in the report, and reuse the same bridge everywhere.
|
||||
|
||||
```
|
||||
Fully diluted market cap
|
||||
+ Total debt (short-term + long-term + current maturities)
|
||||
+ Capitalised lease liability
|
||||
+ Preference shares / CCPS at redemption or conversion value
|
||||
+ Non-controlling (minority) interest
|
||||
+ Net underfunded pension / OPEB / gratuity, net of deferred tax
|
||||
+ Contingent consideration, earn-outs, put options over NCI
|
||||
+ Other debt-like items
|
||||
− Surplus cash and equivalents
|
||||
− Marketable securities and liquid investments
|
||||
− Market or fair value of non-consolidated stakes (associates, JVs, listed holdings)
|
||||
= Enterprise value
|
||||
```
|
||||
|
||||
**Fully diluted share count.** Treasury-stock method for options and RSUs; if-converted for convertibles (either add the converted shares *or* add the bond to debt and interest back to earnings — never both, never neither); warrants; unvested and unexercised ESOP pools from the share-capital note. *India:* compulsorily convertible preference shares and debentures are common in recently listed new-age and PE-funded companies — convert them. *US:* SBC-driven dilution in technology can run 2–4% a year, so a count lifted from the 10-K cover understates the claim on the business.
|
||||
|
||||
**Cash: surplus, not total.** Only cash the business could actually distribute is deductible. Carve out (a) operating cash, roughly 2–5% of sales, (b) cash trapped where repatriation triggers tax, (c) regulatory, margin, escrow and customer-float balances (exchanges, brokers, payment companies — see `sectors/exchanges-payments.md`), (d) cash earmarked for an announced acquisition or declared dividend. *India:* surplus treasury usually sits in "current investments" as liquid mutual funds rather than in "cash and cash equivalents" — read both lines. If you deduct the investments, remove their yield from EBIT as well, or you double-count the treasury.
|
||||
|
||||
**Leases.** Post-IFRS 16 / Ind AS 116 / ASC 842 the liability is on the balance sheet: add it. For pre-transition years, capitalise at the present value of committed rentals, or 8x annual rent as a rough proxy, so the historical EV series is continuous. Retail, QSR, aviation, hospitality and logistics are where omitting this changes the conclusion, not the decimal.
|
||||
|
||||
**Minorities and associates are two halves of one discipline.** If consolidated EBITDA includes 100% of a 60%-owned subsidiary, add the minority interest to EV — ideally at market value or at the multiple you are applying, not at book. Conversely, associates and JVs are equity-accounted, contributing profit but no EBITDA: deduct their value from EV *and* strip the share of associate profit out of your earnings figure. Doing one without the other is the most common silent error in Indian conglomerate and holdco analysis.
|
||||
|
||||
**Pensions and gratuity.** Add the defined-benefit obligation net of plan assets, tax-effected. Material in older US and European industrials; in India the gratuity and leave-encashment provisions are usually smaller but must still be read in the employee-benefits note. A pension deficit approaching the market cap makes the equity a residual claim on an insurance liability, not on the operating business.
|
||||
|
||||
**Other debt-like items to hunt for:** reverse factoring and supply-chain finance hidden in trade payables, receivables securitised with recourse, asset-retirement and mine-closure obligations, litigation and tax provisions with a probable outflow, deferred acquisition consideration, promoter and related-party loans, perpetual instruments (AT1 for banks), and take-or-pay or capacity commitments in the contingent-liabilities note.
|
||||
|
||||
**The pairing rule.** An equity claim belongs in a numerator only with an equity metric; an enterprise claim only with an enterprise metric. P/EBITDA and EV/net-income are meaningless. If minority interest sits in EV, the earnings figure must be pre-minority.
|
||||
|
||||
---
|
||||
|
||||
## Deriving the discount rate
|
||||
|
||||
Never take a WACC from a screener. Derive it, state every input, and date it — a discount rate is a statement about a specific market on a specific day.
|
||||
|
||||
```
|
||||
Ke = Rf + β × ERP + CRP (+ any size / illiquidity premium)
|
||||
WACC = Ke × E/(D+E) + Kd × (1 − t) × D/(D+E)
|
||||
```
|
||||
|
||||
- **Risk-free rate.** Use the long government bond yield *in the currency of the cash flows*, roughly duration-matched. India: the 10-yr G-Sec. US: the 10-yr Treasury. For a sovereign carrying real default risk, subtract the country's default spread from its local bond yield to get a true risk-free rate, then add the country risk premium back explicitly at the equity level — otherwise the same risk is counted twice.
|
||||
- **Equity risk premium.** Use a consistently sourced mature-market ERP; 4.5–5.5% is the usual working range. Prefer an implied (forward-looking) ERP over a long historical average when rates have moved sharply, and use the *same* ERP for every company in a comparison.
|
||||
- **Country risk premium.** For emerging markets, CRP ≈ sovereign default spread (from rating or CDS) × the ratio of equity to bond volatility, typically 1.0–1.5x. For India this has historically added roughly 2–3 percentage points. Apply CRP by **revenue exposure, not listing venue**: an Indian-listed IT exporter earning 80% of revenue in the US carries far less India risk than a domestic cement maker listed alongside it.
|
||||
- **Beta.** Prefer a bottom-up beta — unlever peer betas, average, relever at the target capital structure: `βL = βU × (1 + (1 − t) × D/E)`. Regression betas for Indian mid- and small-caps are dominated by illiquidity and index composition and are close to noise; if you must use one, apply the Blume adjustment (`0.67 × raw + 0.33 × 1.0`) and disclose the window and index. A sub-1.0 beta on a highly operationally leveraged cyclical is a data artefact, not a finding.
|
||||
- **Cost of debt.** Use the yield to maturity on traded bonds, or build it synthetically: risk-free + a default spread implied by interest coverage or credit rating. Do **not** use the historical average interest cost from the P&L — it reflects debt raised in a different rate regime and understates the marginal cost of new borrowing. Tax-effect at the marginal, not the effective, rate, and only to the extent interest is actually deductible.
|
||||
- **Weights at market value**, using the target or sustainable capital structure rather than a temporarily distressed or temporarily cash-rich one.
|
||||
- **Size and illiquidity premia** are contested. Adding 200bps to WACC to express "this is a risky small-cap" is crude and buries the judgement inside a compounding exponent. Prefer conservative cash flows plus a wider margin of safety.
|
||||
|
||||
**The currency-consistency rule.** Discount nominal INR cash flows at a nominal INR rate; nominal USD cash flows at a nominal USD rate; real cash flows at a real rate. Never mix. An INR WACC is structurally several points above a USD WACC purely because of the inflation differential — and therefore an INR terminal growth rate of 4% is *deeply* conservative where a USD 4% would be aggressive. To value a cross-border business, either (a) model in the functional currency and translate the resulting value at spot, or (b) translate the cash flows year by year at forward rates built from the inflation differential, `FX_t = FX_0 × ((1+i_local)/(1+i_foreign))^t`, and discount at the foreign rate. Both are correct; half of each is not. Where the company's revenue and its debt sit in different currencies, that mismatch is a risk to model in the scenarios, not a rate to average.
|
||||
|
||||
**Do not double-count risk.** If the bear scenario already models the asset being expropriated, do not also add a political-risk premium to WACC. Risk belongs either in the cash flows or in the rate — choose one and say which.
|
||||
|
||||
---
|
||||
|
||||
## Building the DCF
|
||||
|
||||
```
|
||||
FCFF = EBIT × (1 − cash tax rate) + D&A − capex − ΔNWC → discount at WACC → EV
|
||||
FCFE = FCFF − interest × (1 − t) + net borrowing → discount at Ke → equity value
|
||||
```
|
||||
|
||||
- **Set the forecast horizon equal to the competitive advantage period**, typically 5–10 years, and only as long as you can name a mechanism that keeps ROIC above WACC. Beyond it, fade incremental ROIC toward the cost of capital. A model in which excess returns never fade has assumed its own conclusion.
|
||||
- **Terminal value, done properly:** `TV = NOPAT_{n+1} × (1 − g/ROIC_terminal) ÷ (WACC − g)`. The `g/ROIC` term is the reinvestment that growth must be paid for; a terminal value growing at 5% forever with no reinvestment is free money and is wrong. Cap `g` at long-run **nominal** GDP in the same currency.
|
||||
- **Cross-check the terminal value against an exit multiple** and report the implied exit EV/EBIT. If perpetuity growth implies an exit multiple above today's or above the historical median, the model is smuggling in a re-rating.
|
||||
- **Report the terminal-value share of present value.** Above 75–80% means the DCF is a terminal-value assertion with a spreadsheet attached. Say so rather than hiding it.
|
||||
- **Treat SBC as a cash cost** (or model the resulting dilution). Adding it back and calling the result FCF overstates owner returns by exactly the amount transferred to employees.
|
||||
- **Use mid-year discounting** where cash flows arrive evenly; it typically lifts value 3–5% and is the honest convention.
|
||||
- **Bridge EV back to equity value** with the same bridge in reverse — EV − debt − leases − minorities − pension deficit + surplus cash + non-consolidated stakes — then divide by the *diluted* count.
|
||||
- **Sensitivity is not optional.** Produce a two-way table of WACC (±150bps in 50bp steps) against terminal growth (±100bps), and a second on steady-state EBIT margin. Report the spread of outcomes, not the centre cell. If a 50bp WACC change moves value 30%, the DCF is a weak instrument for this company and the multiple and asset cross-checks must carry more weight — say that explicitly.
|
||||
- **Reconcile to reality.** Compute implied terminal-year revenue, market share, reinvestment rate and ROIC, and check them against history, addressable-market size and base rates. A model that quietly has the company taking 60% of its market has an unstated assumption.
|
||||
|
||||
---
|
||||
|
||||
## Reverse DCF — the central discipline
|
||||
|
||||
Run this **before** your own forecast. Invert the model: hold the current price fixed and solve for the operating performance required to justify it.
|
||||
|
||||
Solve for and report as a table:
|
||||
|
||||
- **Implied revenue CAGR** over the forecast horizon
|
||||
- **Implied steady-state EBIT (or FCF) margin**
|
||||
- **Implied competitive-advantage period** — how many years of above-WACC returns are baked in
|
||||
- **Implied terminal ROIC**
|
||||
- **Breakeven growth** — the rate at which the stock returns exactly the cost of capital
|
||||
|
||||
Then decompose the price a second way: `PVGO = market cap − (normalised NOPAT ÷ WACC)`. That splits the price into the value of current operations continued forever and the value of growth not yet delivered. If 70% of the price is PVGO, you are not buying a business, you are buying a forecast — and the report should say exactly that.
|
||||
|
||||
**Judge the implied numbers against base rates, not against the story.** Very few companies of any size sustain 20%+ revenue growth for a decade; excess ROIC typically fades over 5–15 years; 1,000bps of sustained margin expansion is rare outside a genuine platform shift. If the implied expectations already exceed management's own guidance, the market has done the extrapolating for you. Inversely, when a stable, cash-generative business is priced for permanent decline — implied growth below zero, implied ROIC collapsing straight to WACC — that is the cheap case worth investigating, and the reverse DCF is how you *find* it rather than assert it.
|
||||
|
||||
This reframes the exercise from "what is it worth" (unfalsifiable) to "what must be true, and is that likely" (testable). It is also the strongest available defence against anchoring, which is precisely why it comes before your own model rather than after it.
|
||||
|
||||
---
|
||||
|
||||
## Earnings yield versus bond yield
|
||||
|
||||
Equities compete with bonds for capital, and the multiple that can be justified is a function of the rate regime.
|
||||
|
||||
- Compute the **earnings yield (E/P)** and, better, the **FCF yield**, and set them against the local 10-yr sovereign yield. The difference is the implied equity risk premium for this stock.
|
||||
- Place that spread in **its own historical distribution**. There is no universal minimum; a 200bp gap can be generous in one market and thin in another.
|
||||
- **Never compare yield gaps across currencies naively.** India's higher nominal bond yield accompanies higher nominal earnings growth, so an Indian equity showing a narrower yield gap than a US equity is not thereby expensive. Compare each market's gap to its own history. This is the Fed-model critique in miniature: setting a nominal bond yield against a real earnings yield systematically flatters equities when inflation is high, so use the yield gap as a regime check, never as a fair-value model.
|
||||
- **Cross-check against the company's own credit.** If its investment-grade bonds yield more than its FCF yield, the debt is the better claim on the same cash flows and the equity needs the growth to justify itself.
|
||||
- **Compare earnings yield to after-tax cost of debt.** This is the arithmetic that decides whether a debt-funded buyback creates value or merely swaps balance-sheet risk for EPS.
|
||||
- **Note the direction of travel.** A valuation that only works under permanently low rates is a rate bet; label it as one. A multiple set in a 1% rate world does not survive a 5% one, however good the business.
|
||||
|
||||
---
|
||||
|
||||
## Valuation versus its own history
|
||||
|
||||
Its own past is usually the cleanest comparable a company has: same business model, same accounting, same disclosure culture.
|
||||
|
||||
- Plot **each** multiple — P/E, EV/EBIT, EV/EBITDA, P/S, P/FCF, dividend yield — against its own 5- and 10-year range. Report the **median** (not the mean) and the **current percentile or z-score**.
|
||||
- Exclude periods where the multiple is undefined or absurd (loss years for P/E, transition years for lease accounting), and say which years you excluded.
|
||||
- **Then answer the only question that matters: why?** A stock at the top of its band is a buy if the business genuinely re-rated — moat widened, mix shifted to higher-ROIC revenue, capital intensity fell, cyclicality reduced — and a sell if nothing changed but sentiment. Name the structural change or concede there is none. "It has always been expensive" is not an argument; it is the absence of one.
|
||||
- **Decompose the last 5–10 years of shareholder return** into earnings growth + multiple change + dividend + buyback. If most of the historical return came from multiple expansion, that fuel is not available twice and forward return expectations must fall.
|
||||
- **Neutralise the market.** Divide the stock's multiple by the index's (Nifty 50 / Sensex / S&P 500) to build a relative multiple series. A stock expensive against its own absolute history but cheap against its relative history is telling you the whole market re-rated, not the company.
|
||||
- **Watch the accounting seams.** Lease capitalisation (FY20 India, 2019 IFRS/US), India's s.115BAA tax election, GST transition, demergers and large acquisitions all break the series. Restate or annotate; never average across a break.
|
||||
- **A de-rating is not automatically an opportunity.** Test whether the multiple fell because the moat is eroding — falling incremental ROIC, rising customer churn, a new entrant — in which case the market is right and the low multiple is the new correct one.
|
||||
|
||||
---
|
||||
|
||||
## Valuation versus peers
|
||||
|
||||
- **Build the peer set on economics, not industry codes.** True comparables share business model, capital intensity, growth profile, customer concentration and end-market. List who is in the set and why, and demonstrate the set was not chosen to flatter the conclusion.
|
||||
- **Normalise before comparing:** accounting standard (Ind-AS vs IFRS vs US GAAP), R&D capitalisation, lease treatment, SBC treatment, tax regime, consolidated vs standalone basis, and fiscal-year end.
|
||||
- **Adjust for the drivers of a justified premium** — ROIC, growth, margin stability, leverage, governance. A premium must be *earned*. The disciplined version: regress peer EV/EBIT (or P/B) against ROIC and growth across 10–20 names and read the residual. The outlier versus the fitted line is the finding; the fit itself tells you how much multiple dispersion fundamentals explain at all.
|
||||
- **Check the sector against itself.** Cheap relative to an expensive sector is not cheap. Plot the peer-group median multiple against its own history before drawing any conclusion from a relative discount.
|
||||
- **Interrogate the discount.** Most discounts are deserved: weaker returns, worse governance, promoter overhang, lower liquidity, a structurally shrinking end market. State which applies and what would remove it.
|
||||
- *India:* niche sectors often have two or three listed peers, all similarly mispriced. Use global comparables, but adjust explicitly for the cost-of-capital and nominal-growth differential — an Indian company legitimately trades at a different multiple from a US peer with identical economics because both the discount rate and nominal growth differ. Unlisted transaction multiples, QIP pricing and preferential-allotment prices are additional local evidence of what informed buyers pay.
|
||||
|
||||
---
|
||||
|
||||
## SOTP, private market value and replacement cost
|
||||
|
||||
Multiples and DCFs both start from the same accounting. These three cross-checks do not — which is why at least one belongs in every deep dive.
|
||||
|
||||
**Sum of the parts.** Value each segment on its own appropriate method — a multiple where a clean peer set exists, a DCF where it does not — then:
|
||||
|
||||
- Capitalise **unallocated corporate costs** as a negative-value stub at the same multiple, rather than ignoring them.
|
||||
- Deduct **net debt, minorities and pension** at the consolidated level using the bridge above.
|
||||
- Deduct **tax on disposal** wherever the thesis relies on selling an asset carried at historic cost.
|
||||
- Apply a **holdco/conglomerate discount** and state whether it is structural (poor capital allocation, no intent to unlock) or temporary (a demerger is announced and dated). In India these discounts are structurally wide — 40–70% is common — and have persisted for decades. Assuming one closes is a thesis, not an adjustment.
|
||||
- Report the **implied stub**: if market cap minus the value of listed stakes is near zero or negative, the operating business is being given away — genuinely interesting when the stakes are liquid and monetisable, a trap when they are not.
|
||||
- Hunt for **understated assets**: land and property at historic cost, cross-holdings in listed entities, unconsolidated JVs, brands never capitalised, carry-forward tax losses (check usability — s.79 in India on ownership change, s.382 in the US), and a loss-making incubating unit whose losses mask a profitable core.
|
||||
|
||||
**Private market value.** What would an informed industrial or PE buyer pay for the whole thing? Anchor on precedent transaction EV/EBITDA in the same sector and geography, including a control premium of typically 20–35%. This behaves like a floor only when the asset is genuinely acquirable — check whether it is. A 60%+ promoter holding, a golden share, a sectoral FDI cap or a regulatory-approval requirement can make a company unbuyable, and the PMV then unrealisable.
|
||||
|
||||
**Replacement cost and Tobin's q.** `q = EV ÷ replacement cost of productive assets`. This is the supply-side test and the most useful valuation tool in capacity-driven industries. When q is well below 1, nobody builds new capacity, supply tightens and returns eventually recover; when q is far above 1, new supply is coming and current returns will fade — which is why a commodity producer at a low P/E and a high q is a sell, not a bargain. Use the physical denominators the industry itself uses: EV/tonne (cement, steel), EV/key (hotels), EV/bed (hospitals), EV/MW (power, data centres), EV/subscriber and EV/MHz (telecom), EV/acre or per saleable sq ft (real estate), EV/dwt or broker vessel values (shipping). Compare against current greenfield build cost and recent asset transactions. In deeply distressed situations, run **liquidation value** and net current asset value as the true floor, haircutting receivables and inventory realistically.
|
||||
|
||||
---
|
||||
|
||||
## Margin of safety
|
||||
|
||||
The margin of safety is risk control, not rhetoric. It exists because the estimate is wrong — the only questions are by how much and in which direction.
|
||||
|
||||
- **Scale the required discount to the uncertainty of the estimate**, not to enthusiasm for the idea. Indicative: 15–25% for a wide-moat, predictable, low-leverage compounder; 30–40% for an average business with a normal cycle; 50%+ for cyclicals, turnarounds, leveraged balance sheets, single-product companies, opaque governance or heavy promoter pledging. Graham's classic ~one-third is a midpoint, not a universal constant.
|
||||
- **Take the discount off the conservative case, not the base case.** A 30% discount to an optimistic fair value is not a margin of safety; it is an optimistic fair value with a rounding error.
|
||||
- **Do not stack conservatism.** Conservative cash flows + an inflated WACC + a large price discount is three haircuts compounded, and produces a value so low nothing ever qualifies. Decide where the conservatism lives and state it.
|
||||
- **Lead with the downside.** Answer "what do I lose if I am wrong" before "what do I make if I am right". Quantify the bear case as a percentage decline and a probability of *permanent* impairment, not as a mood.
|
||||
- **A margin of safety does not protect against a decaying asset.** Where intrinsic value is itself falling — melting-ice-cube economics, structurally impaired end market — the discount narrows on its own while you hold. Time is a cost there, not an ally.
|
||||
- **Test against the sector's own floor.** Where the playbook prescribes one (NAV for shipping, replacement cost for cement, adjusted book for banks), measure the margin of safety against that floor as well as against your DCF.
|
||||
- **Needing the bull case to justify entry is a disqualification**, not a close call.
|
||||
|
||||
---
|
||||
|
||||
## Quality trap versus value trap
|
||||
|
||||
Separate **business quality** (ROIC−WACC spread, moat durability, reinvestment runway, margin stability — established in `references/05-returns-and-dupont.md`) from **price paid** (the multiple), and place the stock on both axes.
|
||||
|
||||
| | Cheap multiple | Expensive multiple |
|
||||
|---|---|---|
|
||||
| **High, durable ROIC** | The rare case. Requires an identifiable reason the market is wrong. | **Quality trap** — a fine business whose return is consumed by multiple compression. |
|
||||
| **Low ROIC, or ROIC fading to WACC** | **Value trap** — the discount is a fact about the business, not an opportunity. | Avoid outright. |
|
||||
|
||||
The arithmetic underneath: over a long holding period an owner's return converges toward the business's return on capital, not toward the entry multiple. A business compounding capital at 18% delivers something close to 18% to a patient owner even from a full price; a business earning 6% delivers close to 6% however cheaply it was bought, because the cheap multiple is a one-time gain while the low return repeats every year. **Entry price decides the first few years; ROIC decides the rest.**
|
||||
|
||||
So ask explicitly: **does time work for me or against me here?** In a high-ROIC reinvestor, waiting creates value. In a low-return business the only lever is the multiple closing, which requires a catalyst and a clock. Two failure modes follow, and both should be named in the report when present: paying a premium multiple for a business whose *incremental* ROIC is quietly sliding toward WACC (the quality trap — visible in ROIIC long before it shows in average ROIC), and anchoring to a low multiple on a structurally declining business while mistaking cheapness for safety (the value trap).
|
||||
|
||||
---
|
||||
|
||||
## Scenarios, expected value and IRR decomposition
|
||||
|
||||
Never report a single number. Build the table and let it carry the conclusion.
|
||||
|
||||
| Scenario | Probability | Key assumptions (revenue CAGR, steady-state margin, exit multiple) | Value per share | Return vs price | IRR over holding period |
|
||||
|---|---|---|---|---|---|
|
||||
| Bull | e.g. 20% | | | | |
|
||||
| Base | e.g. 50% | | | | |
|
||||
| Bear | e.g. 25% | | | | |
|
||||
| Severe / permanent impairment | e.g. 5% | | | | |
|
||||
|
||||
- **Each scenario must be internally coherent**, not the base case ±10%. If the bull case assumes 20% volume growth, it must also carry the operating leverage *and* the capex and working capital that growth consumes. Flexing one variable at a time understates true dispersion.
|
||||
- **Probabilities must be stated and sum to 1**, and should be sanity-checked against base rates — how often turnarounds of this type actually work, how often a company of this size sustains this growth. Bottom-up models produce inside-view optimism by construction; the reference class is the correction.
|
||||
- **Compute the probability-weighted value and the upside/downside ratio.** A working standard is at least 3:1 upside to downside before an idea is interesting. A symmetric 60-up/40-down bet is a fundamentally different proposition from a capped-downside one at the same base case, and only the asymmetry table reveals it.
|
||||
- **Decompose expected IRR into its sources:**
|
||||
|
||||
```
|
||||
Expected annual return ≈ FCF or dividend yield
|
||||
+ growth in earnings / FCF per share
|
||||
± change in the multiple (re-rating or de-rating)
|
||||
± change in share count
|
||||
± FX translation into the holder's base currency
|
||||
```
|
||||
|
||||
State each term. If more than half the expected return depends on multiple expansion, the thesis is a re-rating bet and must be labelled as such — re-rating requires other people to change their minds, which the analysis does not control. A return built from FCF yield plus per-share growth with a flat or conservatively contracting multiple is far more robust at the same headline upside.
|
||||
- **Time is part of the arithmetic.** A 40% gap to fair value is a 35% IRR if it closes in a year and about 7% if it takes five. State the assumed holding period and always express upside in annualised terms.
|
||||
- **Test against a real alternative.** The hurdle is not zero — it is the expected return on the index or a risk-free instrument over the same horizon, after transaction costs (brokerage, STT and stamp duty in India; spread and impact cost in illiquid small caps) and after tax on the realised gain. A 12% gross expected return netting to 8% against an index expected to do the same is not an opportunity. Present this as analysis of the investment's merits — not as personalised advice, and not as a position size.
|
||||
|
||||
---
|
||||
|
||||
## Catalyst, edge and what is already discounted
|
||||
|
||||
A valuation gap is a hypothesis about other people's future opinions. Close the loop before concluding.
|
||||
|
||||
- **Why does the mispricing exist, and who is on the other side?** Name the mechanism: a forced seller, index exclusion, a broken-IPO or lock-up overhang, coverage neglect below a market-cap threshold, a temporary earnings dislocation being extrapolated. If there is no answer, the most likely explanation is that the price is right and the model is not.
|
||||
- **What is the edge?** Informational (rare), analytical (you modelled the fade rate correctly), or behavioural/time-horizon (you can hold through three bad quarters). Behavioural edge is the only durable one for most analysis, and it requires the catalyst timeline to be long, not absent.
|
||||
- **Enumerate catalysts with expected timing:** earnings inflection, margin recovery, a capex cycle ending and FCF appearing, capital-return initiation, deleveraging past a covenant threshold, demerger or spin-off, management change, index inclusion, a regulatory decision, promoter stake increase or open offer. Distinguish a self-correcting mispricing (FCF accumulates and does the work) from one that requires an event to occur.
|
||||
- **Know what is already discounted.** Check consensus estimate levels and dispersion, the direction and breadth of recent revisions, and where your forecast sits versus the street. Returns come from surprises against expectations, not from absolute results. Cross-reference with the reverse DCF: consensus estimates and price-implied expectations are frequently different, and the gap between them is itself information.
|
||||
- **Steel-man the bear case.** Read the best-argued short thesis available and state which parts you accept. A valuation section with no articulated bear case has not been stress-tested, and a pre-mortem — "it is two years later and this is down 50%; what happened?" — usually surfaces the assumption you never examined.
|
||||
|
||||
---
|
||||
|
||||
## Sector overrides
|
||||
|
||||
**The sector playbook overrides everything above.** Applying a generic P/E across sectors is the valuation equivalent of ranking companies on operating margin.
|
||||
|
||||
| Sector | Default method breaks because | Use instead |
|
||||
|---|---|---|
|
||||
| **Banks, NBFCs, HFCs** | Debt is raw material; EV and EV/EBITDA are undefined. | P/B and P/ABV against ROE, justified P/B = (ROE − g)/(COE − g), RoRWA, stressed-book scenarios. `sectors/banks.md`, `sectors/nbfc.md` |
|
||||
| **Life insurers** | Accounting profit is an artefact of new-business strain. | P/EV, VNB multiple, appraisal value. General insurers: combined ratio with P/B. `sectors/insurance.md` |
|
||||
| **REITs, InvITs, developers** | Depreciation on appreciating assets destroys the earnings base. | AFFO yield, NOI cap-rate spread, NAV; developers on land-bank NAV plus pre-sales. `sectors/realestate-reit.md` |
|
||||
| **Miners, steel, oil & gas, commodity chemicals** | P/E is inverted across the cycle — lowest at the peak. | Mid-cycle EV/EBITDA, P/NAV at a stated commodity deck, EV per tonne or boe of reserve, cost-curve position. `sectors/metals-mining.md`, `sectors/oil-gas.md`, `sectors/chemicals-cement.md` |
|
||||
| **Airlines, hotels** | Leases and operating leverage dominate; earnings swing through zero. | EV/EBITDAR, EV per seat-km or per key, fleet replacement cost. `sectors/aviation-hotels.md` |
|
||||
| **Shipping** | Asset values move faster than earnings. | P/NAV on broker vessel valuations, EV per dwt, mid-cycle charter rates. `sectors/shipping-logistics.md` |
|
||||
| **Regulated utilities** | Returns are capped by the regulator. | Multiple of regulated asset base, allowed vs achieved RoE, dividend discount model. `sectors/utilities-power.md` |
|
||||
| **Holdcos, conglomerates, asset managers** | Consolidated multiples blend unlike businesses. | SOTP with an explicit, justified holdco discount; AUM-based multiples for managers. `sectors/holdco-assetmgr.md` |
|
||||
| **Loss-making growth / new-age** | There is no E for the P/E. | EV/Sales decomposed to an implied steady-state margin, EV/gross profit, cohort unit economics, reverse DCF on the implied margin. |
|
||||
| **IT services, SaaS** | The growth-versus-margin trade-off is a choice, not a fact. | EV/FCF, EV/Sales against Rule-of-40, retention-adjusted economics. `sectors/it-saas.md` |
|
||||
| **Pharma** | Value sits in a pipeline with binary outcomes. | Base-business EV/EBITDA plus probability-adjusted rNPV per asset. `sectors/pharma-healthcare.md` |
|
||||
|
||||
---
|
||||
|
||||
## India (Ind-AS/NSE-BSE) vs US/global conventions
|
||||
|
||||
**India-specific**
|
||||
|
||||
- **Units.** Market cap and EV in ₹ crore (1 crore = 10 million; 1 lakh = 100,000). State the unit in every table; mixing crore and million is the most common presentation error in India-focused output.
|
||||
- **Standalone vs consolidated.** Screeners routinely serve standalone P/E and ROCE for companies whose economics are consolidated. Every valuation input must be consolidated — and the EV bridge must then carry the minority interest consolidation creates.
|
||||
- **Accounting seams that break the multiple history.** Ind AS 116 lease capitalisation (FY20) lifted EBITDA and EV; the s.115BAA election to a ~25.17% effective tax rate (FY20 onward) lifted EPS. Neither is operating. Restate pre-FY20 years before plotting a ten-year multiple band.
|
||||
- **Surplus treasury sits in "current investments"** (liquid mutual funds), not in cash. Deduct it in the bridge *and* remove its yield from EBIT.
|
||||
- **CCPS, CCDs, warrants and ESOP pools** in recently listed companies materially change the diluted count. The share-capital and ESOP notes in the annual report are the source; the exchange filing cover page is not.
|
||||
- **Promoter holding, pledge and open-offer mechanics.** SEBI's takeover code triggers a mandatory open offer past the 25% threshold with a formula-based price floor; delisting runs through reverse book-building. These create observable floors and ceilings in control situations. High promoter holding with a thin free float can sustain a multiple well above fundamentals — and can collapse it when pledged shares are invoked.
|
||||
- **Holdco discounts are structurally wide and durable** (40–70% is common). Never model one closing without a named, dated catalyst.
|
||||
- **Buybacks:** since the October 2024 change, buyback proceeds are taxed in shareholders' hands as deemed dividend, materially altering the buyback-versus-dividend calculus for Indian companies. Verify the current-year treatment before comparing shareholder yield across the India/US boundary.
|
||||
- **Frictions a gross return ignores:** STT on both legs, exchange charges, stamp duty, GST on brokerage, and LTCG on listed equity above an annual exemption with a higher STCG rate. Verify current-year rates — they have changed repeatedly.
|
||||
- **Concalls and investor presentations** frequently disclose segment EBIT, capacity, utilisation, order book and per-unit realisations absent from the filing, and these are essential for SOTP and EV-per-unit work. Cite the quarter.
|
||||
- **CARO 2020** disclosures on related-party loans and unrecorded transactions are a direct cross-check on whether the "surplus cash" you deducted in the bridge is genuinely available to shareholders.
|
||||
|
||||
**US/global**
|
||||
|
||||
- **10-K, 10-Q, DEF 14A via EDGAR.** Segment data under ASC 280 for SOTP; the Reg G non-GAAP reconciliation sizes the adjusted-versus-GAAP gap for you.
|
||||
- **SBC is large and must be treated as a cost.** US technology "adjusted EBITDA" and "adjusted FCF" that add SBC back overstate owner returns directly and materially.
|
||||
- **Leases under ASC 842 (2019)** create the same series break as Ind AS 116, but US GAAP retains the operating/finance distinction in the P&L, so EBITDA is *not* affected identically to IFRS. Check before comparing EBITDA multiples across the standards boundary.
|
||||
- **Convertibles with capped calls** need careful dilution treatment; the if-converted count in the 10-K may not reflect the hedge.
|
||||
- **The 2017 US tax change** creates a discontinuity in historical P/E and EV/EBIT series.
|
||||
- **Negative book equity** is normal in mature US firms after decades of buybacks; P/B is undefined and should be suppressed rather than printed.
|
||||
- **A 1% excise on net buybacks** (from 2023) slightly reduces buyback yield.
|
||||
- **NOL usability** is capped after an ownership change (s.382), so a headline NOL balance is worth less than face value in an SOTP.
|
||||
- **ADRs** carry withholding tax and depositary fees, and the ADR price embeds an FX view — value the underlying in local currency and translate separately.
|
||||
|
||||
---
|
||||
|
||||
## Errors that ruin this section of the report
|
||||
|
||||
- **Anchoring:** building the DCF after looking at the price, then tuning WACC or terminal growth until it agrees. Run the reverse DCF first.
|
||||
- **A broken EV bridge:** leases, minorities, pensions or the option overhang omitted; or gross cash deducted when most of it is operating, trapped or customer float.
|
||||
- **Mixing claims:** an equity numerator against an enterprise denominator, or consolidated EBITDA against a parent-only EV.
|
||||
- **Currency mismatch:** discounting INR cash flows at a USD WACC, or calling a 3% terminal growth rate conservative in a 5–6% inflation currency.
|
||||
- **A single point value** with no sensitivity table and no scenario range.
|
||||
- **Terminal value carrying 85% of the answer**, unreported.
|
||||
- **Comparing multiples across the FY20/2019 accounting seam** and calling the step-change a trend.
|
||||
- **Peer sets chosen to flatter**, or a "discount to peers" in a sector that is itself at a record multiple.
|
||||
- **Using a low P/E on a peak-cycle commodity earner as evidence of cheapness** — the single most expensive error in this file.
|
||||
- **Adding back SBC** to reach the FCF that supports the valuation.
|
||||
- **Assuming a holdco or conglomerate discount closes** with no catalyst and no timeline.
|
||||
- **Printing a multiple the sector playbook declares undefined** (EV/EBITDA for a bank, P/E for a REIT) with a caveat instead of suppressing it. A caveated number is still a number the reader anchors on.
|
||||
- **Reporting fair value to two decimals** when the inputs are three judgement calls. Give a range and state what drives its width.
|
||||
- **Presenting the output as advice.** Give the valuation range, the assumptions, the bear case and the falsifiers; do not issue a buy instruction or a position size.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Consult the sector playbook first; use its prescribed method and suppress every multiple it declares undefined or inverted.
|
||||
- [ ] Normalise earnings for one-offs, cycle position and tax before computing any multiple; state reported vs adjusted and why.
|
||||
- [ ] Build the full EV bridge — diluted count, debt, leases, preferreds/CCPS, minorities, pension deficit, earn-outs, less *surplus* cash and non-consolidated stakes — and show it as a table.
|
||||
- [ ] Verify every multiple pairs an equity claim with equity value and an enterprise claim with EV.
|
||||
- [ ] Derive WACC explicitly: risk-free in the cash-flow currency, ERP, country risk premium by revenue exposure, bottom-up relevered beta, marginal cost of debt, market-value weights. Date it.
|
||||
- [ ] Apply the currency-consistency rule; never discount local-currency cash flows at a foreign rate.
|
||||
- [ ] Run the reverse DCF **before** your own forecast; report implied growth, margin, CAP, ROIC, breakeven growth and the PVGO share of price.
|
||||
- [ ] Test the implied expectations against base rates and against management's own guidance.
|
||||
- [ ] Build the DCF with an explicit fade toward WACC, a reinvestment-consistent terminal value, and g ≤ nominal GDP in the same currency.
|
||||
- [ ] Report terminal value as a % of total, plus the implied exit multiple versus today's and the historical median.
|
||||
- [ ] Produce two-way sensitivity tables on WACC × terminal growth and on steady-state margin; report the range, not the centre cell.
|
||||
- [ ] Treat SBC as a cost, not an add-back, in every cash-flow measure.
|
||||
- [ ] Compute FCF yield, owner-earnings yield and total shareholder yield; confirm buybacks are FCF-funded, net of SBC, and executed below your value range.
|
||||
- [ ] Compare earnings/FCF yield to the local 10-yr sovereign and to the company's own after-tax cost of debt; place the spread in its own history.
|
||||
- [ ] Plot every multiple against its own 5–10 year median and percentile; explain deviations structurally or concede mean reversion.
|
||||
- [ ] Decompose historical shareholder return into earnings growth, multiple change and yield.
|
||||
- [ ] Build a defensible peer set, normalise accounting, regress multiples against ROIC and growth, and interpret the residual rather than the raw discount.
|
||||
- [ ] Check the peer group's own multiple against its history to rule out whole-sector mispricing.
|
||||
- [ ] Run at least one non-accounting cross-check: SOTP, private market value with a control premium, or replacement cost / EV per physical unit and Tobin's q.
|
||||
- [ ] For SOTP, net corporate costs, disposal taxes and a justified holdco discount; report the implied stub.
|
||||
- [ ] Map the stock on quality (ROIC−WACC) versus price and name it: compounder, cigar-butt, quality trap or value trap.
|
||||
- [ ] State the margin of safety as a % against the *conservative* case, sized to estimate uncertainty, without stacking conservatism three times.
|
||||
- [ ] Build a 3–4 scenario table with stated probabilities, coherent per-scenario assumptions, a probability-weighted value and an upside/downside ratio.
|
||||
- [ ] Decompose expected IRR into yield + growth + re-rating + share count + FX; flag if re-rating is more than half of it.
|
||||
- [ ] State the assumed holding period, annualise the upside, and net it against transaction costs, taxes and the index alternative.
|
||||
- [ ] Name the catalyst and its timing, why the mispricing exists, and what is already in consensus estimates.
|
||||
- [ ] State explicit falsifiers: the price, multiple or operating outcome that would prove the valuation wrong.
|
||||
- [ ] Label all indicative ranges as indicative; let peer and own-history comparison carry the conclusion.
|
||||
- [ ] Present a range with assumptions and a bear case — research, not a recommendation and not a position size.
|
||||
|
|
@ -0,0 +1,427 @@
|
|||
# Forensic Accounting and Red Flags
|
||||
|
||||
Use this when: you are running the Stage 3 kill-criteria screen or the Stage 4 forensic pass, or any time reported profit, growth or asset values look better than the business economics you can observe from outside.
|
||||
|
||||
Forensic work is not about proving fraud. It is about deciding how much weight the reported numbers can carry, because every figure you use downstream — margin, ROCE, EV/EBITDA, FCF yield — is only as good as the accounting policy that produced it, and management chooses that policy. Your job is to locate where discretion was exercised, quantify how much of reported performance depends on it, and say so plainly. The governing rule of this skill applies at full force here: a red flag is meaningless until you know the sector and the company's own history. Rising receivables are normal in EPC and alarming in FMCG; negative operating cash flow is a fraud signal for a distributor and business as usual for a growing lender.
|
||||
|
||||
## Contents
|
||||
|
||||
- [0. How frauds are actually caught](#0-how-frauds-are-actually-caught)
|
||||
- [1. Cash flow vs earnings: the accruals tests](#1-cash-flow-vs-earnings-the-accruals-tests)
|
||||
- [2. Proof of cash: does the cash exist and is it yours?](#2-proof-of-cash-does-the-cash-exist-and-is-it-yours)
|
||||
- [3. Revenue-side manipulation](#3-revenue-side-manipulation)
|
||||
- [4. Working-capital manipulation and period-end window dressing](#4-working-capital-manipulation-and-period-end-window-dressing)
|
||||
- [5. Cost capitalisation and expense deferral](#5-cost-capitalisation-and-expense-deferral)
|
||||
- [6. Acquisition accounting and serial acquirers](#6-acquisition-accounting-and-serial-acquirers)
|
||||
- [7. Disclosure and metric games](#7-disclosure-and-metric-games)
|
||||
- [8. Auditor signals](#8-auditor-signals)
|
||||
- [9. People signals: CFO and audit-committee turnover](#9-people-signals-cfo-and-audit-committee-turnover)
|
||||
- [10. Structural opacity and off-balance-sheet exposure](#10-structural-opacity-and-off-balance-sheet-exposure)
|
||||
- [11. Tax anomalies](#11-tax-anomalies)
|
||||
- [12. India: the mandatory disclosures that do forensic work for you](#12-india-the-mandatory-disclosures-that-do-forensic-work-for-you)
|
||||
- [13. Independent verification: the part that actually catches frauds](#13-independent-verification-the-part-that-actually-catches-frauds)
|
||||
- [14. Composite forensic scores and statistical tests](#14-composite-forensic-scores-and-statistical-tests)
|
||||
- [15. Sector translation: where these tests are undefined or inverted](#15-sector-translation-where-these-tests-are-undefined-or-inverted)
|
||||
- [16. Calibration: how to report a red flag and what it changes](#16-calibration-how-to-report-a-red-flag-and-what-it-changes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 0. How frauds are actually caught
|
||||
|
||||
Internalise this before you start, because it determines how you allocate effort.
|
||||
|
||||
**Every major accounting fraud reconciled internally.** Satyam, Enron, Parmalat, Wirecard, Luckin, NMC Health, Sino-Forest, Carillion — in each case the balance sheet balanced, the cash flow statement tied to the balance sheet, the ratios were computable, and a competent desk analyst working purely from the filings could complete a full checklist without the numbers contradicting each other. Fabricated financials are internally consistent by construction, because whoever fabricated them had to make them tie.
|
||||
|
||||
Two consequences:
|
||||
|
||||
1. **Filings-based forensics detects distortion, not fabrication.** Ratio work reliably catches aggressive accounting — pulled-forward revenue, deferred costs, cookie-jar reserves, over-capitalisation. It is much weaker against a business that does not exist, because there the "distortion" is complete and self-consistent.
|
||||
2. **The decisive evidence is almost always non-company evidence.** Bank confirmations, customs and shipping records, satellite imagery, registry filings in the operating jurisdiction, employee and customer contact, alternative data. Section 13 is not an optional extra at the end of this file; for any company where the fraud hypothesis is live, it *is* the analysis.
|
||||
|
||||
So run the quantitative tests to **generate hypotheses about which line item is doing the work**, then attack that line item with outside evidence. Never conclude "the accounts reconcile, therefore they are real."
|
||||
|
||||
**Triage order when time is limited.** Cash conversion over five years → interest-income reconciliation on the cash balance → DSO and receivables-vs-sales growth → capex vs depreciation → audit opinion, KAMs and auditor changes → related-party and promoter-pledge disclosure. Those six take under an hour from the filings and catch the overwhelming majority of distortion cases. Everything else in this file is depth applied where those six point.
|
||||
|
||||
---
|
||||
|
||||
## 1. Cash flow vs earnings: the accruals tests
|
||||
|
||||
Profit is an opinion; cash is closer to a fact. The single highest-yield forensic exercise is to lay reported profit alongside operating cash flow for five or more years and ask where the difference went.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Cash conversion | CFO ÷ net profit, per year **and cumulative over 3–5 years** | Cumulative ≥ 0.8–1.0 for mature businesses; ≥ 1.0 for asset-light | Cash is far harder to fabricate than accrued profit; a persistent gap means profit is sitting in receivables, inventory or capitalised costs |
|
||||
| Cumulative gap | Σ CFO (5y) − Σ PAT (5y), in absolute currency | Small relative to cumulative PAT | Single-year gaps are noise; a five-year gap is a structural claim about earnings quality |
|
||||
| Sloan accrual ratio (balance-sheet) | ΔNOA ÷ average NOA, where NOA = (total assets − cash & investments) − (total liabilities − total debt) | Below ~10%; sustained >15–20% is a flag | Growth funded by expanding non-cash assets rather than cash generation predicts weaker future returns and higher restatement risk |
|
||||
| Sloan accrual ratio (cash-flow) | (PAT − CFO − CFI) ÷ average NOA | As above | Less vulnerable to acquisition and restatement noise than the balance-sheet version |
|
||||
| FCF conversion | (CFO − capex) ÷ PAT, cumulative 5y | Positive and rising for a mature business | EBITDA and even CFO can be flattered by classification; capex is where deferred costs finally surface |
|
||||
| EBITDA-to-FCF gap | EBITDA − (CFO − capex), as % of EBITDA, trend | Stable | A widening gap is the signature of costs migrating from the P&L into the investing section |
|
||||
|
||||
*Indicative ranges vary by market, cycle and period; peer and own-history comparison overrides any absolute band.*
|
||||
|
||||
**How to run it.** Build a five-year table: PAT, CFO, capex, FCF, ΔWorking capital, D&A, non-cash items. Then answer explicitly: **if profit did not become cash, which asset did it become?** Receivables, inventory, CWIP, intangibles, loans and advances to related parties, and "other current assets" are the usual destinations, and each points to a different section of this file.
|
||||
|
||||
**Legitimate explanations you must rule out before flagging.** A genuinely fast-growing, working-capital-intensive business (distribution, EPC, capital goods) consumes cash while growing and will show CFO below PAT for years; that is arithmetic, not fraud. Test it by computing working capital as a **percentage of sales**. If that ratio is stable and only the absolute number grows, the cash gap is growth. If working capital as a % of sales is itself climbing, the growth is being bought.
|
||||
|
||||
**Cash-flow-statement integrity check.** Tie the working-capital movements shown in the cash flow statement to the year-on-year changes in the corresponding balance-sheet lines. They will rarely match exactly — acquisitions, disposals, FX translation and reclassifications legitimately break the tie — but the company should be able to explain the bridge, and large unexplained differences are where reclassification games live. If the balance sheet shows receivables up 40% while the cash flow statement shows a small receivables outflow, something was moved: securitised, reclassified to "other assets", or acquired. Find out which.
|
||||
|
||||
**Classification traps — resolve before comparing CFO across companies.**
|
||||
- Under Ind-AS and IFRS, interest paid may sit in operating **or** financing, and interest and dividends received in operating or investing. Under US GAAP the classification is fixed. Two identical businesses can report materially different CFO. **Re-derive CFO on a common basis** (interest paid in financing, interest received in investing is a clean convention) before any cross-company or cross-regime comparison, and state the convention you used.
|
||||
- Receivables securitisation or factoring turns what is economically borrowing into an operating inflow. Find the disclosed amount factored and add it back to receivables when computing DSO.
|
||||
- Supply-chain finance / reverse factoring keeps supplier debt inside trade payables and flatters both CFO and reported leverage. Disclosure is often thin; look in the payables note, the liquidity discussion and rating-agency commentary. This is the Carillion and Abengoa mechanism.
|
||||
- Purchases of "investments" that are economically operating assets; leases restructured so outflows fall below the CFO line.
|
||||
|
||||
**Quarterly integrity.** Sum the four reported quarters and compare to the audited annual figure for revenue, EBITDA and PAT. **India:** quarterly results are limited-review, not audited, and Q4 is normally a balancing figure — audited full year minus nine months. Provisions, true-ups and rev-rec adjustments therefore cluster in Q4. A Q4 whose margin, other income or tax rate looks nothing like the 9M run-rate is telling you exactly where discretion was exercised. **US:** compare the 10-K to the sum of the 10-Qs and read the fourth-quarter adjustment disclosure.
|
||||
|
||||
---
|
||||
|
||||
## 2. Proof of cash: does the cash exist and is it yours?
|
||||
|
||||
Fake, pledged or unrepatriable cash is the single most common feature of the largest accounting frauds. Standard analysis nets cash against debt and moves on. Do not. Cash is an asset like any other and requires an existence test.
|
||||
|
||||
**The interest-income reconciliation.** The cheapest high-severity test available. Run it on every company holding a large cash balance.
|
||||
|
||||
1. Average cash and liquid investments = (opening + closing) ÷ 2. Use quarterly averages where available; annual averages are badly distorted by a fundraise or a year-end sweep.
|
||||
2. Take interest and investment income from the other-income note. Isolate it from FX gains, dividend income from operating subsidiaries, government grants and profit on asset sales.
|
||||
3. Implied yield = investment income ÷ average cash and investments.
|
||||
4. Compare to prevailing short-term deposit and money-market rates for that currency and period. India: bank fixed-deposit and liquid-fund rates, which track the repo. US/global: T-bill and money-market rates.
|
||||
|
||||
An implied yield far below the risk-free short rate means one of: the cash is not there; it is pledged or restricted; it sits in non-interest-bearing current accounts; or it sits in a low-rate jurisdiction. Every one of those is something you need to know before treating the balance as net-debt relief.
|
||||
|
||||
**Caveats that produce false positives — resolve them before flagging.**
|
||||
- **India / Ind-AS:** returns on liquid mutual funds are reported as "net gain on fair value changes" under Ind-AS 109, not as interest income. Counting only "interest income" manufactures a false flag. Sum the entire investment-return block.
|
||||
- Cash raised late in the period earns almost nothing — check the timing of any issuance or asset sale.
|
||||
- Operating float in current accounts legitimately earns nothing, but a company should not hold years of surplus that way.
|
||||
- Interest income is netted against interest expense in some presentations.
|
||||
- Cash in subsidiaries in low-rate or capital-controlled jurisdictions earns local rates and may not be repatriable.
|
||||
|
||||
**The other cash tests.**
|
||||
|
||||
| Test | What to compute / read | Why it matters |
|
||||
|---|---|---|
|
||||
| Gross cash alongside gross debt | Cost of carry = (average debt cost − implied cash yield) × overlapping balance | A company paying 9% to borrow while earning 4% on an equal cash pile destroys value every year for no stated reason. Either the cash is encumbered or absent, or there is an undisclosed constraint. A classic tell; management should have a specific answer |
|
||||
| Restricted / pledged cash | Balance-sheet split, notes, and the charge registry (India: MCA charges; US: security disclosures in the debt note) | Cash pledged against borrowings is not available to shareholders and must be excluded from net-debt maths |
|
||||
| Where the cash is banked | Names of banks in the deposits note; jurisdiction | Deposits concentrated in small, obscure, offshore or promoter-linked banks are a severe flag. Large groups bank with large banks |
|
||||
| Repatriability | Cash held in subsidiaries; tax cost of upstreaming; capital controls | Consolidated cash can be legally unavailable to the listed parent |
|
||||
| Audit evidence for cash | Is "existence of cash and bank balances" a Key Audit Matter? Did the auditor obtain direct bank confirmations? | If the auditor flagged cash existence as a KAM, so should you |
|
||||
| Dividend reality | Dividends and buybacks paid ÷ reported PAT, over 5 years | Cash actually leaving the company to shareholders is the hardest confirmation that it existed. A company that reports a decade of profits, never pays out, never deleverages and keeps raising capital is asserting cash it cannot demonstrate |
|
||||
| **India:** CARO commentary | Funds raised for one purpose applied to another; short-term funds used for long-term purposes; loans and advances to related parties | CARO forces explicit auditor comment on precisely these leakage routes |
|
||||
|
||||
---
|
||||
|
||||
## 3. Revenue-side manipulation
|
||||
|
||||
Revenue is the number valuation multiples attach to, so manipulation concentrates there. Read the revenue-recognition policy in full (Ind-AS 115 / IFRS 15 / ASC 606) and the critical-estimates note, not the summary.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| DSO | (Receivables ÷ revenue) × 365; five-year trend **and** vs peers | Flat to falling; level is sector-bound | Rising DSO means sales are booked faster than collected — the leading indicator of both channel stuffing and fabricated customers |
|
||||
| Receivables growth ÷ revenue growth | Both in %, same consolidation basis | ≈ 1.0 | Persistently >1.3–1.5 means growth is being bought with credit, or invented |
|
||||
| Unbilled revenue / contract assets ÷ revenue | Ind-AS 115 / ASC 606 disaggregation note | Stable; low outside project businesses | Unbilled revenue is a management estimate with no invoice behind it — the softest revenue there is |
|
||||
| Allowance for expected credit loss ÷ gross receivables | Receivables note | Stable or rising as the book grows and ages | A shrinking allowance against a growing, ageing book is deliberate under-reserving |
|
||||
| Receivables > 6 months / > 1 year (India) | Schedule III ageing table for trade receivables | Small and stable; disputed balances minimal | Old receivables that are not provided for are tomorrow's write-off, disclosed today |
|
||||
| "Other receivables" / "other current assets" ÷ current assets | Balance sheet and notes | Small and stable | The standard hiding place for balances that belong nowhere legitimate |
|
||||
| Deferred revenue growth vs revenue growth | Both in % | Similar for subscription models | Revenue growing while deferred revenue shrinks means the future is being consumed today |
|
||||
| Revenue and gross profit per employee | ÷ headcount, five-year trend and vs peers | Stable to rising | Hard to fabricate; independently validates or refutes claimed scale |
|
||||
|
||||
*Indicative ranges vary by market, cycle and period; peer and own-history comparison overrides any absolute band.*
|
||||
|
||||
**Mechanisms to look for by name.**
|
||||
- **Channel stuffing** — shipping to distributors at period end with generous return rights. Tells: quarter-end or Q4 revenue spikes beyond seasonality, DSO jumping in the final quarter, disclosed distributor inventory rising, returns and rebate provisions moving oddly.
|
||||
- **Bill-and-hold** — revenue on goods not shipped. Requires specific disclosure; if disclosed, treat as material and quantify.
|
||||
- **Gross vs net (principal vs agent)** — reporting gross merchandise value rather than commission inflates the top line by an order of magnitude without adding a rupee of profit. Critical for marketplaces, travel, energy trading, distribution and payments. Test: revenue ÷ gross profit. A switch from net to gross manufactures "growth" out of nothing and must be restated before any multiple is applied.
|
||||
- **Percentage-of-completion / input-method revenue** (EPC, infrastructure, defence, capital goods, shipbuilding) — revenue is a function of a cost-to-complete estimate management controls. Watch cost-to-complete revisions, growing unbilled revenue and retention money, claims recognised as receivables, and margin recognised early in contracts.
|
||||
- **Round-tripping** — sales to entities funded, directly or circularly, by the company or its promoters. Cross-check the related-party note against the customer-concentration disclosure.
|
||||
- **Vendor / customer financing** — lending to customers, guaranteeing their debt, or accepting long-dated seller notes so they can buy. Track notes receivable, long-dated receivables and off-balance-sheet customer guarantees against revenue growth. It reads as clean organic growth until the credit sours, then reverses violently. Common in telecom equipment, solar, EV, capital goods and anyone selling to weaker counterparties.
|
||||
- **Policy or estimate change** — any change in recognition timing, standalone-selling-price allocation, or warranty/returns estimate that raises current revenue. Quantify the effect; it is usually disclosed.
|
||||
|
||||
**India-specific cross-checks.** Reconcile reported revenue against GST turnover (GSTR-1/3B summary where the company or a data vendor provides it), e-way bill volumes for goods businesses, and DGFT/customs export data for exporters. A material, persistent gap between accounting revenue and tax-reported turnover with no reconciliation in the notes is a serious flag, because the two numbers are filed with different parties who have opposing incentives. Also compare standalone and consolidated revenue: revenue existing only in unlisted or offshore subsidiaries deserves specific scrutiny.
|
||||
|
||||
---
|
||||
|
||||
## 4. Working-capital manipulation and period-end window dressing
|
||||
|
||||
The balance sheet is a snapshot on one day, and management knows which day.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| DIO | (Inventory ÷ COGS) × 365 | Flat vs own history; level sector-bound | Rising inventory is either weakening demand or costs parked in the balance sheet |
|
||||
| Finished goods ÷ total inventory | Inventory note | Stable | Finished goods rising faster than raw materials means product is not selling |
|
||||
| Inventory provision ÷ gross inventory | Inventory note | Stable or rising with age | Under-reserving inflates gross margin now and forces a write-down later |
|
||||
| DPO | (Payables ÷ COGS) × 365 | Stable | A DPO spike is the easiest way to manufacture one year of operating cash flow |
|
||||
| Cash conversion cycle | DSO + DIO − DPO | Stable or improving; compare to peers | The composite; divergence from peers needs a business reason |
|
||||
| Period-end vs average balances | Quarter-end cash, receivables, payables and borrowings vs intra-period averages | Similar | Large period-end-only movements are window dressing, especially in borrowings and cash |
|
||||
| Implied average debt | Interest expense ÷ average interest rate, compared to reported year-end debt | Similar | If actual interest implies materially more debt than the year-end balance, the year-end balance is not representative |
|
||||
|
||||
**Specific patterns.** Gross margin expanding while DIO expands (costs absorbed into inventory rather than COGS). Payables stretching in the exact year CFO needed to look good, reversing the next. Receivables factored days before period end to flatter DSO. Borrowings repaid on the last day of the year and redrawn on the first day of the next — the implied-average-debt test above is the leverage analogue of the interest-income test in Section 2, and is worth running on any company with a suspiciously clean year-end balance sheet.
|
||||
|
||||
**India:** CARO requires the auditor to state whether inventory verification was performed and whether discrepancies of 10% or more were found and properly dealt with, and — for working-capital limits above ₹5 crore sanctioned against current assets — whether the quarterly statements filed with the banks **agree with the books of account**. That clause is an auditor-attested reconciliation of reported receivables and inventory against what the company told its lenders. Read it. A disagreement there is one of the most concrete red flags available in any annual report anywhere.
|
||||
|
||||
---
|
||||
|
||||
## 5. Cost capitalisation and expense deferral
|
||||
|
||||
Capitalising an operating cost inflates profit and EBITDA, moves the outflow from operating to investing, and therefore flatters CFO as well. It is the WorldCom mechanism, and it survives in far milder everyday forms.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Capex ÷ depreciation | Cash capex ÷ D&A, five-year average and trend | ≈ 1.0–1.5 for a steady business; higher only with matching capacity or revenue growth | Sustained capex far above depreciation without volume growth means the spend is not producing output — or is not really capex |
|
||||
| Implied useful life | Average gross block ÷ annual depreciation | Stable year to year; in line with peers on similar assets | A lengthening implied life raises profit permanently with no cash effect and no announcement |
|
||||
| Capitalised development / software ÷ revenue | Intangibles note | Low and stable; zero for many businesses | Under IFRS/Ind-AS development costs *may* be capitalised where US GAAP is stricter — the choice itself is a policy signal, and a cross-regime comparability problem |
|
||||
| CWIP ÷ gross block, plus CWIP ageing (India) | Schedule III mandates CWIP and intangible-under-development ageing (<1y, 1–2y, 2–3y, >3y) and disclosure of projects overdue or over budget | Little CWIP older than two years; projects capitalised on schedule | CWIP that never converts to fixed assets is where impairments hide. The mandatory ageing table makes this directly checkable |
|
||||
| Change in useful lives / amortisation periods | Accounting-policy note, year over year | No change without a stated operational reason | The cheapest way to raise reported profit |
|
||||
| Growth in intangibles and "other assets" vs revenue | Balance sheet vs P&L | In line | The residual dumping ground for deferred costs |
|
||||
|
||||
Also check: **capitalised borrowing costs** (raises reported profit and interest coverage simultaneously — recompute coverage using total interest *incurred*, not just interest expensed); capitalised customer-acquisition and contract-fulfilment costs under Ind-AS 115 / ASC 606; capitalised labour; and **capital advances to suppliers**, which in India are a recurring route for funds to leave the company toward related parties without ever appearing as a related-party loan.
|
||||
|
||||
The composite tell for this whole section is **strong EBITDA with weak or negative free cash flow, sustained across years**. If an EBITDA growth story is not visible in FCF after a full capex cycle, the costs did not disappear — they moved.
|
||||
|
||||
---
|
||||
|
||||
## 6. Acquisition accounting and serial acquirers
|
||||
|
||||
Acquisitions reset the baseline, and purchase accounting hands management a set of one-time, non-cash levers that present as recurring growth. Treat any company doing more than one deal a year as requiring this section, and pair it with the serial-acquirer overlay in `references/13-situations.md`.
|
||||
|
||||
**Separate organic from acquired growth first.** Compute revenue growth excluding acquisitions completed in the last twelve months. If disclosure does not permit it, say so explicitly and treat headline growth as unverified — a serial acquirer that will not disclose organic growth is telling you something. Then ask the decisive question: **what does the growth rate become when M&A pauses?** For many roll-ups the answer is negative, which is precisely why the M&A never pauses.
|
||||
|
||||
**Purchase-accounting levers to inspect in the business-combination note.**
|
||||
- **Fair-value step-ups** on inventory and fixed assets — the step-up depresses post-acquisition gross margin as inventory sells through, which management then adds back as a "non-cash purchase accounting adjustment", permanently.
|
||||
- **Restructuring and contingency reserves created on acquisition**, later released to earnings. Classic cookie jar: the charge never touches the P&L going in, but the release boosts it coming out.
|
||||
- **Purchase-price allocation skewed to goodwill and indefinite-lived intangibles** (not amortised) rather than to finite-lived intangibles (amortised). Raises reported EPS for years with no economic difference.
|
||||
- **Contingent consideration / earnout remeasurement** through the P&L — a gain when the acquired business underperforms is a perverse, non-economic profit.
|
||||
- **Bargain purchase gains** — a "profit" from buying cheaply, recognised immediately. Never recurring earnings.
|
||||
- **Recurring "integration" and "deal" costs** — appearing every single year makes them operating expenses, and adjusted EBITDA that excludes them overstates earning power by exactly that amount.
|
||||
- **Same-store / like-for-like decay hidden under pro-forma presentation** — check whether the acquired businesses shrink after acquisition. That is the specific signature of a roll-up manufacturing EPS from deal flow rather than operations.
|
||||
|
||||
**Goodwill and intangibles.**
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Goodwill ÷ total assets | Balance sheet | Modest; interpret against deal history | High goodwill means the balance sheet is mostly prices paid, not assets owned |
|
||||
| (Goodwill + intangibles) ÷ equity | Balance sheet | Well below 100% | Above 100% means tangible equity is negative, and leverage ratios computed on reported equity become meaningless |
|
||||
| Tangible book value | Equity − goodwill − intangibles | Positive for most non-software businesses | The capital actually standing behind the debt |
|
||||
| Impairment-test headroom | Discount rate, terminal growth and disclosed headroom in the impairment note | Assumptions consistent with the company's own cost of capital and realistic growth | An impairment test that passes only on a terminal growth rate above nominal GDP is not passing |
|
||||
|
||||
Market capitalisation persistently below book value with no impairment recorded is a direct disagreement between the market and the balance sheet, and the market is usually right first. An impairment landing immediately after the growth narrative breaks confirms the M&A destroyed value; the analytical failure was not marking it earlier.
|
||||
|
||||
---
|
||||
|
||||
## 7. Disclosure and metric games
|
||||
|
||||
Here the manipulation is in the definition, not the arithmetic.
|
||||
|
||||
**Non-GAAP / adjusted earnings.** Tally every "exceptional", "one-off", "restructuring" and "impairment" item across five years. Items appearing every year are recurring costs and belong in normalised earnings. Compute the GAAP-to-adjusted gap as a % of reported profit and track whether it widens. Watch for add-backs of ordinary operating costs, of share-based compensation (a real cost paid in dilution — quantify it), and of "growth investments" that are simply opex. Big-bath charges clustered around a CEO or CFO transition and quietly released later are the cookie-jar pattern. US filers must publish a Reg G / Item 10(e) reconciliation — read it rather than the press-release headline.
|
||||
|
||||
**Bespoke KPIs.** Catalogue every company-invented metric — ARR, bookings, backlog, GMV, MAU/DAU, take rate, "cash EBITDA", "contribution margin ex-marketing", "adjusted community EBITDA", store-level unit economics — and write down its exact definition from the filing. Then ask three questions: (a) does it reconcile to an audited number? (b) has the definition changed year over year? (c) is management steering attention to it precisely because the audited numbers rolled over? Bespoke metrics are not inherently illegitimate — for a subscription or platform business they may be the most informative numbers available — but they are unaudited, management-defined and definitionally unstable. **Record the definition alongside the number every time you use one**, and never build a valuation on a metric whose definition moved during the period you are measuring.
|
||||
|
||||
**Metric-definition drift and disclosure deletion — the year-over-year redline.** Diff consecutive annual reports / 10-Ks, and where relevant the proxy or DRHP, for changes in: risk-factor wording, accounting-policy and critical-estimate language, segment definitions, useful lives and capitalisation policy, KPI definitions, MD&A tone, and customer or product concentration disclosures. **The highest-signal finding is always a deletion.** Management announces what it adds and never mentions what it removed. A volume disclosure that vanishes the year volumes fell, a KPI that stops being reported, a named large customer that disappears from the concentration note, a segment merged into "others" — each is information the company chose to stop giving you, and the reason is rarely favourable. Segment redefinition is the commonest form: it resets comparability exactly when comparability would have been damaging. **Tooling:** EDGAR full-text search and the filing-comparison view for US issuers; for India, the equivalent artefacts to diff are the MD&A, segment note, related-party note (watch entity-list changes), contingent-liabilities note, CARO clauses, and the concall — including which questions management stopped answering and which analysts stopped covering the name.
|
||||
|
||||
---
|
||||
|
||||
## 8. Auditor signals
|
||||
|
||||
The auditor is the last independent check on the numbers, and auditor-related events are among the strongest empirical predictors of restatement and fraud.
|
||||
|
||||
| Signal | Where to find it (Global / India) | Why it matters |
|
||||
|---|---|---|
|
||||
| Opinion type: unqualified / qualified / adverse / disclaimer | Auditor's report | Anything other than unqualified is a first-order finding, never a footnote |
|
||||
| Going-concern emphasis | Auditor's report; Emphasis of Matter | The auditor doubts the entity survives twelve months |
|
||||
| Key / Critical Audit Matters (KAMs / CAMs) | Auditor's report | The auditor is naming the numbers that were hardest to audit. Start your forensic work there — it is a free prioritisation |
|
||||
| Auditor resignation or dismissal | US: 8-K Item 4.01. India: exchange filing under SEBI LODR Reg 30, with the resignation letter and reasons | Mid-cycle resignation is among the highest-severity signals available. Read the stated reason *and* the company's version of it |
|
||||
| Downgrade in auditor quality | Compare firm size and network to group complexity | A large multi-jurisdiction group audited by a small firm is a structural problem regardless of that firm's competence |
|
||||
| Component-auditor coverage | "Other Matters" paragraph of the consolidated audit report | Compute the % of consolidated revenue, assets and profit **not** audited by the principal auditor, plus anything unaudited or "certified by management". This is a direct measure of how much of the accounts nobody independent examined |
|
||||
| Audit fee vs complexity | Auditor remuneration note / proxy | An implausibly low fee for a large multi-entity group means the work was not done |
|
||||
| Non-audit fees ÷ total fees | DEF 14A / auditor remuneration note | High non-audit fees compromise independence |
|
||||
| Internal-control opinion | US: SOX 404 material weakness. India: separate auditor opinion on internal financial controls under s.143(3)(i) | An adverse IFC/404 opinion says the systems producing the numbers are not reliable — every ratio downstream inherits that |
|
||||
| Late filings | US: NT 10-K/10-Q. India: delayed results and exchange penalties | Companies file late when there is an unresolved disagreement |
|
||||
| Restatement and regulatory history | US: Big-R restatement via 8-K Item 4.02 vs little-r revisions; SEC comment letters (UPLOAD/CORRESP on EDGAR); enforcement. India: SEBI orders, NFRA orders against the company or its auditors, SFIO and MCA inspections | A prior restatement is among the strongest predictors of the next one |
|
||||
| **India:** CARO clauses | CARO 2020 report | Direct attestation on fixed-asset and title-deed verification, inventory verification, benami proceedings, loans and guarantees to related parties (including whether fresh loans were granted to settle overdue ones — an evergreening test), statutory dues in arrears, default in repayment to lenders and wilful-defaulter status, end-use of term loans and IPO/preferential-issue proceeds, cash losses in the current and preceding year, whistleblower complaints, fraud reported under s.143(12), and issues raised by the outgoing auditor. Read every clause, not the summary |
|
||||
|
||||
Also search for specific, substantiated short-seller reports and read the primary document rather than coverage of it. A short report is an adversarial argument with a financial interest behind it: treat every claim as a hypothesis to verify, note which claims the company answered *specifically* and which it answered only with adjectives, and attribute rather than adopt.
|
||||
|
||||
---
|
||||
|
||||
## 9. People signals: CFO and audit-committee turnover
|
||||
|
||||
Accounting is produced by a small number of identifiable people. When those people leave, it matters — serial finance-leadership churn is among the most reliable pre-restatement tells, and it is observable years before the numbers are.
|
||||
|
||||
Track over 5+ years: CFO, controller / chief accounting officer, treasurer, chief internal auditor, audit-committee chair, and (India) company secretary and independent directors. Flag:
|
||||
|
||||
- Serial CFO turnover — three finance chiefs in five years is a finding in itself.
|
||||
- Departures clustered near reporting dates, audit sign-off, or a restatement.
|
||||
- "Personal reasons" or "to pursue other opportunities" with no successor named, and a long gap before a permanent appointment.
|
||||
- The audit-committee chair resigning, or independent directors resigning citing governance, disagreement, or inability to obtain information. **India:** SEBI requires disclosure of independent-director resignation letters — read the letter, not the press release.
|
||||
- Departure of the head of internal audit, or internal audit reporting to the CEO rather than to the audit committee.
|
||||
- **US:** cross-reference Form 4 insider sales against the departure timeline and against the peak of the growth narrative.
|
||||
|
||||
Then correlate: did anything disclosed in the following four quarters explain the departure? People closest to the numbers tend to leave before the numbers become public. Detail on board composition and promoter behaviour sits in `references/08-governance.md`; this section is only the accounting-integrity slice.
|
||||
|
||||
---
|
||||
|
||||
## 10. Structural opacity and off-balance-sheet exposure
|
||||
|
||||
Complexity is sometimes historical accident and sometimes deliberate. Assume nothing; map it.
|
||||
|
||||
- **Count and map the group.** Subsidiaries, step-down subsidiaries, associates, JVs, SPEs/VIEs and their jurisdictions. India: the AOC-1 statement of subsidiaries in the annual report, plus MCA/ROC records. Global: Exhibit 21 of the 10-K. Dozens of entities in Mauritius, Singapore, UAE, Cyprus or the Caribbean behind a simple domestic operating business is a structure that needs explaining.
|
||||
- **Consolidated vs standalone (India).** Compare revenue, profit, debt and related-party balances on both bases. Profit concentrated at standalone with losses in subsidiaries, or debt in subsidiaries while cash sits at the parent, changes the entire risk picture. Never mix bases within one ratio.
|
||||
- **Equity-method income without cash.** Equity-accounted income ÷ net profit, compared to dividends actually received from those entities. Profit you cannot receive is not profit you own.
|
||||
- **Guarantees, letters of comfort, commitments and contingent liabilities ÷ equity.** In Indian infrastructure, telecom and real estate these routinely exceed net worth. Read the note in full: disputed tax demands and cross-guarantees to group entities live there.
|
||||
- **Charges and security.** India: the MCA charge registry shows secured borrowings and pledged assets, including at unlisted group entities the consolidated statements may not reveal.
|
||||
- **Leases and quasi-debt.** Post Ind-AS 116 / ASC 842 most leases are on balance sheet; check for arrangements structured to stay off it, and for sale-and-leaseback gains recognised in profit.
|
||||
- **Related-party transactions and tunnelling.** Related-party revenue ÷ total revenue; related-party receivables and loans ÷ total assets; guarantees to related entities ÷ equity; intercompany balances ÷ equity. Look for asset transfers at non-arm's-length prices, management or brand-royalty fees paid to promoter entities, and circular flows that manufacture revenue. India: material RPTs need audit-committee approval and, above the LODR threshold, majority-of-minority approval — check how those votes went and whether transactions were sized just under thresholds.
|
||||
- **Promoter pledging (India).** Pledged shares as % of promoter holding and % of total equity, plus the trend. Rising pledge is a promoter-liquidity signal that transmits directly into governance behaviour.
|
||||
- **VIE / contractual-control structures.** For China and some EM ADRs, determine whether the listed entity legally owns the operating assets and profits or holds only contractual claims through offshore shells. Assess enforceability under local law, where cash, licences and IP legally reside, the mechanics and legality of upstreaming cash to foreign holders, and PCAOB inspection access / delisting risk. A genuinely profitable operating company can leave foreign minority holders with nothing — a structural trap invisible to earnings-quality analysis.
|
||||
- **Frequent restructurings** that reset comparability, and segment reporting too aggregated to see what the business does. Cross-check that segment revenues and profits sum to the consolidated totals and that "unallocated" is not where the losses live.
|
||||
|
||||
---
|
||||
|
||||
## 11. Tax anomalies
|
||||
|
||||
Tax is a useful independent check because a second party — the tax authority — has an opposing interest in the numbers.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Effective tax rate | Tax expense ÷ pre-tax profit | Near the statutory rate, or fully reconciled to it in the tax note | A persistent unexplained gap suggests book profit that does not exist for tax purposes |
|
||||
| Cash tax rate | Cash taxes paid (cash flow statement) ÷ pre-tax profit | Near the ETR on a 5-year average | Book profit that never generates a cash tax payment is a strong earnings-quality flag |
|
||||
| Book-tax gap | Pre-tax book profit vs taxable income implied by the tax reconciliation | Small and explained | Widening gaps precede restatements |
|
||||
| Deferred tax assets and valuation allowance | Tax note, year over year | Stable | Releasing a valuation allowance manufactures an EPS beat with no operating cause |
|
||||
| Uncertain tax positions | FIN 48 reserve (US); disputed demands in contingent liabilities (India) | Stable | Aggressive structures create future liability and restatement risk |
|
||||
|
||||
Read the tax-rate reconciliation table every year: it names the specific items bridging statutory to effective rate, and a large "others" line is itself a disclosure failure. **India:** check the concessional-regime election (s.115BAA), MAT credit utilisation, and tax holidays (SEZ or unit-based) with known expiry dates. A low ETR with a scheduled expiry is a dated earnings cliff, not a moat — never carry it forward indefinitely in a DCF.
|
||||
|
||||
---
|
||||
|
||||
## 12. India: the mandatory disclosures that do forensic work for you
|
||||
|
||||
Indian filings are unusually generous to a forensic analyst, because Schedule III (Division II, as amended) and CARO 2020 force explicit disclosure of exactly the things a distressed or manipulating company would prefer to omit. Read these before doing any ratio work on an Indian issuer; each one is a direct answer to a question you would otherwise have to infer.
|
||||
|
||||
| Disclosure | What it tells you |
|
||||
|---|---|
|
||||
| Ageing tables: trade receivables, trade payables, CWIP, intangibles under development | Converts "receivables rose" into "how old, how disputed, how overdue" — the difference between a working-capital story and a write-off queue |
|
||||
| Loans and advances to promoters, directors, KMPs and related parties that are repayable on demand or without stated terms | The tunnelling route, quantified and named |
|
||||
| Borrowings on security of current assets: whether quarterly returns filed with banks agree with the books | Auditor-attested reconciliation of your receivables and inventory to what the lenders were told |
|
||||
| Wilful-defaulter declaration; default in repayment of borrowings | Credit distress that has already been adjudicated by someone else |
|
||||
| Relationship with struck-off companies | Transactions and balances with entities that legally no longer exist — a shell-company tell |
|
||||
| Title deeds of immovable property not held in the company's name | Assets on the balance sheet that the company may not own |
|
||||
| Revaluation of PP&E and intangibles; whether by a registered valuer | Equity created by revaluation is not equity earned |
|
||||
| Utilisation of borrowed funds and share premium: declarations on ultimate beneficiaries and intermediaries | Directly targets round-tripping and fund diversion |
|
||||
| Undisclosed income surrendered in tax assessments | Income the company admitted to the tax authority but not to you |
|
||||
| Compliance with the number of layers of companies; pending charge satisfactions | Structural opacity, measured |
|
||||
| Schedule III ratio disclosures with explanation for any change >25% | Management is required to explain its own ratio deterioration in writing. Read the explanations — they are frequently the weakest paragraphs in the report |
|
||||
| CARO: cash losses in current and preceding year; material uncertainty on meeting liabilities within one year; issues raised by the outgoing auditor; whistleblower complaints; fraud reported under s.143(12) | Each is a severe, auditor-attested signal that requires no computation from you |
|
||||
|
||||
The US analogue is thinner but real: Item 9A internal controls, Item 3 legal proceedings, Exhibit 21 subsidiaries, the schedule of valuation and qualifying accounts (Schedule II) showing reserve additions and releases, 8-K Items 4.01/4.02, and SEC comment-letter correspondence on EDGAR.
|
||||
|
||||
---
|
||||
|
||||
## 13. Independent verification: the part that actually catches frauds
|
||||
|
||||
Everything above is derived from documents the company wrote. This section is not, which is why it is where frauds are actually caught.
|
||||
|
||||
**Proof of existence — assets, customers, counterparties.**
|
||||
|
||||
| Claim being tested | Independent source |
|
||||
|---|---|
|
||||
| Plants, stores, mines, hotels, data centres, warehouses exist and operate | Satellite and street-level imagery, building permits, environmental clearances, power and utility consumption, local news, site visits |
|
||||
| Named top customers exist and buy at the stated volumes | The customers' own filings (a listed customer discloses major suppliers or purchase volumes), trade press, distributor and channel contact |
|
||||
| Physical goods actually moved | Customs and shipping records, bills of lading, port and freight data; India: DGFT export data and e-way bills |
|
||||
| Subsidiary results match the consolidation | India: subsidiary financials filed with MCA/ROC (AOC-4). Global: local registry filings such as UK Companies House and EU registries, which frequently contradict group presentations |
|
||||
| The auditor, bankers and key suppliers are real firms capable of servicing a client this size | Firm registries, PCAOB/NFRA records, headcount and office footprint |
|
||||
| Claimed headcount and scale | LinkedIn headcount trend, job postings, employee reviews and attrition; India: EPFO monthly payroll additions, and the employee-count disclosure in the annual report and BRSR |
|
||||
|
||||
**Alternative-data corroboration of reported growth.** Web traffic and app-download trends, app-store and marketplace review volumes, card and transaction panels where available, hiring velocity, and freight volumes. **The test is divergence, not level:** reported growth accelerating while every external proxy flattens is the pattern that precedes disclosure. Independent data is the short-seller's actual edge, and a checklist confined to filings can only ever detect problems the company itself chose to disclose.
|
||||
|
||||
**Scuttlebutt.** Use the product. Read customer reviews on app stores, G2, Amazon and industry forums. Talk to customers, distributors, suppliers or ex-employees where feasible and permissible. Financial statements lag; ground-level observation often reveals deterioration quarters ahead of the numbers.
|
||||
|
||||
**Information-integrity screen.** Establish where the idea came from. Screen for paid promotion and pump-and-dump patterns: unsolicited tips, thinly traded microcaps, reverse mergers, recent shell-to-operating transitions, aggressive newsletter or social promotion. Identify the incentives of whoever is recommending the stock, and verify every claim against the audited filing rather than a deck or a forum post.
|
||||
|
||||
**Report what you could not verify.** You will frequently lack access to satellite data, expert networks or customs records. That is a data gap, not an absence of risk. Write it explicitly: *"the existence of the [x] asset base and the [y] customer relationships could not be independently corroborated from available sources; this component of the analysis rests on management representations."* That sentence is honest, useful, and changes how a reader sizes a position.
|
||||
|
||||
---
|
||||
|
||||
## 14. Composite forensic scores and statistical tests
|
||||
|
||||
Use these as screens that direct attention, never as verdicts. Each was calibrated on a specific population, and applying it outside that population produces confident nonsense.
|
||||
|
||||
| Model | What it does | Threshold | Limits — read before using |
|
||||
|---|---|---|---|
|
||||
| Beneish M-Score | Eight ratios — days-sales-in-receivables, gross margin, asset quality, sales growth, depreciation rate, SG&A, leverage and total accruals — combined into a manipulation probability | Above −1.78 flags elevated risk | Calibrated on US manufacturers; high false-positive rate for fast growers and acquirers; **undefined for banks, NBFCs, insurers and REITs**. Note that six of the eight inputs are tests you have already run individually in this file — the index adds aggregation, not new information |
|
||||
| Dechow F-Score | Misstatement probability from accruals, performance and market variables | Above 1.0 = above-normal risk | Same population caveats; needs several years of clean, restatement-free data |
|
||||
| Montier C-Score | Six binary earnings-manipulation flags | Score out of 6 | Blunt; useful as quick triage only |
|
||||
| Altman Z-Score | Bankruptcy risk from five ratios | >2.99 safe, <1.81 distress (manufacturing variant); use Z″ for non-manufacturers and emerging markets | Measures distress, not fraud; **meaningless for financials**; sensitive to the market-cap input, so it moves with price rather than fundamentals |
|
||||
| Piotroski F-Score | Nine-point fundamental quality score | 8–9 strong, 0–2 weak | A quality screen, not a fraud test |
|
||||
| Benford's Law | First-digit distribution test | Deviation from expected frequency | Weak on the few dozen line items in a financial statement; only meaningful on large transaction-level datasets. Do not present a Benford result on annual-report figures as evidence |
|
||||
|
||||
**Non-model statistical tells.** Earnings and margins far smoother than the industry's; margins implausibly above best-in-class with no identifiable moat; beating consensus by exactly a cent for many consecutive quarters; near-zero earnings volatility in a demonstrably cyclical sector; reported growth uncorrelated with cash generation. Real businesses are lumpy. Unnatural smoothness is manufactured, and the manufacturing is either legal smoothing or something worse.
|
||||
|
||||
Whenever you report a score, report its inputs and its population caveat alongside it. An M-Score quoted without the note that it is undefined for the company's sector is a fabrication dressed as rigour.
|
||||
|
||||
---
|
||||
|
||||
## 15. Sector translation: where these tests are undefined or inverted
|
||||
|
||||
Do not run the generic battery on a business it was not built for. Consult the playbook in `references/sectors/` and substitute the right tests.
|
||||
|
||||
- **Banks and NBFCs.** DSO, DIO, DPO, cash conversion cycle and the accrual ratio are meaningless; CFO is dominated by loan-book growth and is *negative* for a healthy growing lender. The manipulation vector is **credit-loss recognition**: GNPA/NNPA trends, provision coverage, restructured and SMA-1/SMA-2 books, evergreening (fresh loans repaying old ones), write-offs and "advances under collection" that flatter reported GNPA, sales of stressed loans to ARCs against security receipts, interest accrued but not received, capitalisation of interest into restructured loans, and rapid growth in a single unseasoned product. **India:** the RBI divergence disclosure — where the regulator's assessed NPAs and provisions exceed the bank's own — is a direct, auditor-independent red flag and must be checked every year.
|
||||
- **Insurers.** Reserve adequacy is the manipulation vector; under-reserving inflates current profit. Look at reserve development triangles (prior-year releases propping current earnings), assumption changes in life valuation (discount rate, lapse, mortality, expense), and the composition of embedded-value movement. Margins and cash conversion do not apply.
|
||||
- **REITs, InvITs and real-estate developers.** Depreciation makes accounting profit near-meaningless; use FFO/AFFO and NAV. Watch fair-value gains on investment property routed through the P&L (non-cash profit), capitalised interest into projects, and revenue-recognition timing on developer sales.
|
||||
- **Miners, oil and gas.** Depletion, reserve estimates and the capitalisation-vs-expensing of exploration (successful-efforts vs full-cost) are the levers. Reserve revisions change both the asset and the depletion charge simultaneously. Judge on mid-cycle economics, not trailing.
|
||||
- **Utilities and regulated infrastructure.** Regulatory assets and deferrals can hold years of costs; check the recovery mechanism and the regulator's actual orders, not management's expectation of them.
|
||||
- **Project businesses (EPC, infra, defence, shipbuilding).** Percentage-of-completion estimates, unbilled revenue, retention money and claims recognised as receivables *are* the earnings-quality question.
|
||||
- **Early-stage and platform businesses.** The statutory statements may say very little; the bespoke KPIs are the analysis, so Section 7 becomes the primary section rather than a supporting one.
|
||||
|
||||
---
|
||||
|
||||
## 16. Calibration: how to report a red flag and what it changes
|
||||
|
||||
Getting this wrong destroys the credibility of everything else in the report.
|
||||
|
||||
**Distinguish three severities and label them.**
|
||||
1. **Aggressive but disclosed and legal** — a capitalisation policy at the permissive end, a non-GAAP measure with generous add-backs, a low ETR from a disclosed holiday. Effect: adjust the numbers yourself, note the adjustment, move on.
|
||||
2. **Unexplained anomaly** — a metric behaving in a way the disclosure does not account for. Effect: state the anomaly, state the innocent explanation, state what evidence would distinguish them, and raise the required margin of safety.
|
||||
3. **Structural integrity risk** — auditor resignation, adverse IFC/SOX opinion, cash-existence KAM, a large unaudited share of a consolidated group, Big-R restatement, regulator enforcement, tunnelling through related parties. Effect: this belongs in the report's opening verdict, not a footnote, and can be sufficient on its own to stop the analysis. Several are legitimate kill criteria.
|
||||
|
||||
**Require a cluster, not a single flag.** Base rates matter. Most individual flags have mundane explanations — one year of rising DSO because a large customer paid late, one year of high capex because a plant was built. What distinguishes a real accounting problem is **several independent flags pointing at the same line item**: rising DSO *plus* a shrinking allowance *plus* revenue concentrated in Q4 *plus* a related-party customer. One flag is a question. Four flags aimed at the same number is a finding.
|
||||
|
||||
**Always state the innocent explanation.** For every flag, write the most plausible benign reading and what would distinguish it. This is not hedging — it is what makes the flag credible on the occasions you do not withdraw it.
|
||||
|
||||
**Language discipline.** Do not assert fraud. Describe what the disclosure shows, what it does not permit you to rule out, and what evidence would resolve it. *"Reported cash of X earns an implied yield of ~1% against short rates of ~6%, which the filings do not explain; possible readings are non-interest-bearing operating float, restricted balances, or an overstated balance — the deposits note and any bank-confirmation KAM would distinguish these"* is rigorous, defensible and useful. "The cash is fake" is neither. Apply the same standard to short-seller allegations: attribute, do not adopt.
|
||||
|
||||
**Quantify the dependency, then carry it downstream.** The most useful output of a forensic pass is not a list of flags but a sentence like: *"roughly X% of reported EBITDA over the last three years depends on capitalisation and one-off treatments the peer group does not use; on a peer-consistent basis EBITDA would be approximately Y."* Never invent that number — derive it from disclosed line items and show the working, or state that it cannot be derived. Then propagate it: the adjusted figures, not the reported ones, are what feed the returns work in `references/05-returns-and-dupont.md` and the valuation in `references/06-valuation.md`. A forensic finding that does not change a downstream number has not been finished.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Five-year table built — PAT, CFO, capex, FCF; cumulative CFO ÷ cumulative PAT computed, and the gap tied to a named asset line.
|
||||
- [ ] Accrual ratio computed on at least one basis; growth in non-cash operating assets attributed to a specific line item.
|
||||
- [ ] Working capital as a % of sales checked before flagging any cash-vs-profit gap in a growing business.
|
||||
- [ ] CFO re-derived on a common classification basis before any cross-company or cross-regime comparison.
|
||||
- [ ] Cash-flow-statement working-capital movements tied to balance-sheet deltas; unexplained differences investigated.
|
||||
- [ ] Sum of four quarters reconciled to the audited annual figure; India — Q4 margin, other income and tax rate compared to the 9M run-rate.
|
||||
- [ ] Interest and investment income reconciled to average cash; implied yield compared to short rates; Ind-AS fair-value gains on liquid funds included.
|
||||
- [ ] Simultaneous large gross cash and gross debt explained, with the cost of carry quantified.
|
||||
- [ ] Restricted, pledged and non-repatriable cash identified and excluded from net-debt maths.
|
||||
- [ ] DSO, DIO, DPO and the cash conversion cycle computed for five years and vs peers; receivables growth vs revenue growth checked.
|
||||
- [ ] ECL allowance and inventory provisions checked against a growing and ageing book; India — receivables ageing table read.
|
||||
- [ ] Revenue-recognition policy read in full; gross-vs-net presentation, unbilled revenue and any policy or estimate change identified and quantified.
|
||||
- [ ] Quarter-end vs intra-period balances tested; implied average debt from interest expense compared to year-end debt.
|
||||
- [ ] Capex ÷ depreciation, implied useful life, capitalised development costs, CWIP ageing and useful-life changes reviewed; EBITDA-to-FCF gap explained.
|
||||
- [ ] "One-off" items tallied across five years; recurring ones returned to normalised earnings; SBC quantified as a real cost.
|
||||
- [ ] Organic growth separated from acquired growth; purchase-accounting levers (step-ups, acquisition reserves, earnout remeasurement, bargain-purchase gains) inspected.
|
||||
- [ ] Goodwill and intangibles vs equity computed; tangible book value checked; impairment-test assumptions read against the company's own cost of capital.
|
||||
- [ ] Every bespoke KPI catalogued with its exact definition; definitions compared year over year.
|
||||
- [ ] Year-over-year redline done; **deletions** from prior-year disclosure specifically hunted and listed.
|
||||
- [ ] Audit opinion, KAMs/CAMs, IFC/SOX opinion, auditor changes and stated reasons, audit fee and non-audit fee ratio reviewed.
|
||||
- [ ] Component-auditor coverage computed: % of consolidated revenue, assets and profit not audited by the principal auditor.
|
||||
- [ ] Restatement, comment-letter, NFRA/SEBI/SEC enforcement and litigation history checked; short reports read as primary documents.
|
||||
- [ ] CFO, controller, treasurer, internal-audit head and audit-committee-chair turnover mapped over 5+ years; resignation letters read.
|
||||
- [ ] Group structure mapped; equity-method income vs dividends received; guarantees and contingent liabilities vs equity; standalone vs consolidated compared.
|
||||
- [ ] Related-party revenue, receivables, loans and guarantees quantified; promoter pledge level and trend checked (India).
|
||||
- [ ] ETR vs statutory vs cash tax rate reconciled; any tax holiday dated to its expiry.
|
||||
- [ ] India — CARO clauses and the Schedule III forensic disclosures read in full, including the bank-statement-vs-books agreement and the >25% ratio-change explanations.
|
||||
- [ ] At least one independent, non-company corroboration attempted for the core growth or asset claim; whatever could not be verified stated explicitly.
|
||||
- [ ] Composite scores, if used, reported with inputs and population caveats; never applied to financials.
|
||||
- [ ] Sector translation applied — lenders, insurers, REITs and miners assessed on their own manipulation vectors, not the generic battery.
|
||||
- [ ] Each flag labelled by severity, paired with its innocent explanation and the evidence that would resolve it; no fraud assertion made.
|
||||
- [ ] The dependency quantified and carried into the returns and valuation work, not left as a standalone list of flags.
|
||||
477
finance/skills/stock-analysis/references/08-governance.md
Normal file
477
finance/skills/stock-analysis/references/08-governance.md
Normal file
|
|
@ -0,0 +1,477 @@
|
|||
# Management and Corporate Governance
|
||||
|
||||
Use this when: you are running the Stage 3 red-flag screen or the governance block of Stage 4, or any time the controlling shareholder, the board or the auditor could be the reason the numbers look the way they do.
|
||||
|
||||
Governance is not a soft, optional overlay on the financial analysis — it is the question of whether the financial analysis belongs to you. Every ratio you compute downstream assumes two things: that the reported figures describe reality (the forensic question, `references/07-forensic-red-flags.md`), and that the economics they describe accrue to the security you are considering buying (the governance question, this file). A business can compound beautifully and still deliver nothing to minorities, because the cash was routed to a promoter entity, the earnings were diluted away at a discount, the voting shares are held by someone else, or the listed vehicle only holds contractual claims on assets it does not own. The skill's governing principle applies here too: governance norms are sector- and market-relative. A 60% family stake is a red flag in a US large cap and the default condition in Indian mid-caps; an externally managed REIT has a fee-conflict problem that simply does not exist for an operating company; a bank's "capital allocation" is underwriting, not capex.
|
||||
|
||||
## Contents
|
||||
|
||||
- [0. How to run this dimension](#0-how-to-run-this-dimension)
|
||||
- [1. What does the security actually confer? Share class, DVR, ADR/GDR, VIE](#1-what-does-the-security-actually-confer-share-class-dvr-adrgdr-vie)
|
||||
- [2. Capital allocation: build the deployment ledger](#2-capital-allocation-build-the-deployment-ledger)
|
||||
- [3. Guidance versus delivery: tabulate it, do not characterise it](#3-guidance-versus-delivery-tabulate-it-do-not-characterise-it)
|
||||
- [4. Promoter / insider holding: level, trend and mechanism](#4-promoter--insider-holding-level-trend-and-mechanism)
|
||||
- [5. Share pledging and encumbrance (India-critical)](#5-share-pledging-and-encumbrance-india-critical)
|
||||
- [6. Insider transactions: read them one trade at a time](#6-insider-transactions-read-them-one-trade-at-a-time)
|
||||
- [7. Related-party transactions and tunnelling](#7-related-party-transactions-and-tunnelling)
|
||||
- [8. Group structure complexity and holdco opacity](#8-group-structure-complexity-and-holdco-opacity)
|
||||
- [9. Capital raising, dilution and financing behaviour](#9-capital-raising-dilution-and-financing-behaviour)
|
||||
- [10. Executive compensation and alignment](#10-executive-compensation-and-alignment)
|
||||
- [11. Board independence, composition and functioning](#11-board-independence-composition-and-functioning)
|
||||
- [12. Auditor: quality, tenure, fees, resignations](#12-auditor-quality-tenure-fees-resignations)
|
||||
- [13. CFO and finance-team turnover](#13-cfo-and-finance-team-turnover)
|
||||
- [14. Minority-shareholder rights architecture](#14-minority-shareholder-rights-architecture)
|
||||
- [15. Succession and key-man risk](#15-succession-and-key-man-risk)
|
||||
- [16. Integrity, regulatory history and disclosure quality](#16-integrity-regulatory-history-and-disclosure-quality)
|
||||
- [17. Sector translation: where these checks change or invert](#17-sector-translation-where-these-checks-change-or-invert)
|
||||
- [18. Scoring, weighting and how to write it up](#18-scoring-weighting-and-how-to-write-it-up)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 0. How to run this dimension
|
||||
|
||||
Three rules before you start.
|
||||
|
||||
**Governance is a multiplier and a gate, not an additive score line.** Good governance does not add much to the case for a mediocre business. Bad governance subtracts from everything — it widens the discount rate, caps the multiple you can justify, and in the severe cases it invalidates the analysis entirely rather than costing it a few points. Treat a small number of findings as hard kill criteria (Section 18), and treat the rest as an adjustment to the required margin of safety.
|
||||
|
||||
**Separate structure from behaviour.** Structure is what the documents permit: share classes, board composition, RPT approval thresholds, group tree. Behaviour is what the controller has actually done with that latitude over a decade. A concentrated, founder-controlled structure with a decade of clean behaviour is usually a better holding than a textbook-compliant structure run by someone with a record. Score both, and never let a compliance checklist substitute for the track record.
|
||||
|
||||
**Everything here is evidence-based or it is not written.** Governance is where an analyst is most tempted to editorialise. Every claim you make must trace to a specific filing, disclosure, vote, transaction or dated statement. "Management seems promoter-friendly" is worthless; "royalty to the parent rose from 1.8% to 3.5% of sales over four years while EBITDA margin fell 200bp, disclosed in Note 41" is a finding.
|
||||
|
||||
**Where to look.**
|
||||
|
||||
| Item | India (NSE/BSE, Companies Act 2013, SEBI LODR) | US / global (SEC EDGAR) |
|
||||
|---|---|---|
|
||||
| Ownership and its trend | Shareholding pattern filed quarterly under LODR Reg 31 (within 21 days of quarter-end); BSE/NSE corporate-announcements pages | DEF 14A beneficial-ownership table; SC 13D/13G and their amendments |
|
||||
| Insider trades | SEBI PIT Reg 7(2) disclosures (trades above ₹10 lakh in a quarter, filed within 2 trading days); SAST Reg 29 for substantial acquisitions | Forms 3, 4 (within 2 business days) and 5 |
|
||||
| Pledges | SAST Reg 31 encumbrance disclosures; shareholding-pattern pledge table | Rarely disclosed; look in 13D Item 6, margin-loan disclosures and proxy pledging policy |
|
||||
| Related parties | Notes to accounts (Ind-AS 24); LODR Reg 23 RPT policy; half-yearly RPT disclosures to exchanges | Notes (ASC 850 / IAS 24); proxy "Certain Relationships and Related Transactions" |
|
||||
| Board and pay | Corporate Governance Report in the annual report; Reg 27 quarterly CG report; MGT-7 | DEF 14A in full, including CD&A, pay ratio, pay-versus-performance table |
|
||||
| Auditor | Auditor's report, CARO 2020 annexure, ICFR opinion under s.143(3)(i), Form ADT-3 on resignation, NFRA orders | Audit report, Item 9A (ICFR), 8-K Items 4.01 (auditor change) and 4.02 (non-reliance), PCAOB Form AP and inspection reports |
|
||||
| Track record | 10 years of annual reports, MD&A, concall transcripts (LODR Reg 46 requires transcripts within 5 working days), analyst-meet decks | 10-K MD&A, earnings-call transcripts, investor-day decks, 8-K guidance releases |
|
||||
| Integrity record | SEBI orders and adjudications, NCLT/NCLAT, SFIO, income-tax search reports, IiAS / SES / InGovern proxy notes | SEC litigation releases and AAERs, DOJ, class-action dockets, ISS / Glass Lewis reports |
|
||||
|
||||
For foreign private issuers filing 20-F, note that the proxy rules do not apply, there is no DEF 14A, compensation may be disclosed only in aggregate, and the company may elect home-country governance practice in place of NYSE/Nasdaq standards (disclosed in Item 16G). The absence of disclosure is not the absence of a problem — say so explicitly rather than scoring the gap as neutral.
|
||||
|
||||
---
|
||||
|
||||
## 1. What does the security actually confer? Share class, DVR, ADR/GDR, VIE
|
||||
|
||||
Do this first, before any other governance work, because it can change the identity of the thing you are analysing. Establish, in one paragraph: which legal entity you would own a claim on, what fraction of votes and of economics that claim carries, and by what legal mechanism the operating profits reach it.
|
||||
|
||||
**Dual-class and superior voting rights.** Compute the wedge: voting share minus economic share. A founder holding 12% of economics and 60% of votes has a 48-point wedge, and every minority-protection mechanism downstream (say-on-pay, director elections, majority-of-minority votes) is decorative. Check for a sunset provision — time-based, ownership-based, or transfer/death-triggered — and its date. India: SEBI's 2019 framework permits superior-voting-rights (SR) shares for founders of intensive-technology companies at IPO, with a sunset (5 years, extendable once by shareholder resolution) and coat-tail provisions that collapse SR to ordinary voting on specified resolutions. US: no sunset is required by law, so read the charter.
|
||||
|
||||
**DVR (India).** Differential-voting-rights shares in India have historically carried *fewer* votes plus a higher dividend, and they have persistently traded at a large discount to the ordinary share — a discount driven by low liquidity and index exclusion as much as by the voting differential. If you are analysing a DVR line, value it separately: apply the company analysis to the business but the pricing to the specific security, and state the historical discount range and whether any conversion or cancellation scheme is pending. Never quote the ordinary-share multiple as though it applied to the DVR.
|
||||
|
||||
**ADR / GDR.** Determine sponsored versus unsponsored; the ratio of ADS to underlying share; the depositary's fees (custody pass-through, typically deducted from dividends); whether the ADR holder can vote and by what instruction mechanism (many depositaries vote uninstructed shares with management); fungibility and whether the ADR can be converted to local shares; and the withholding-tax treatment of the dividend. An ADR premium or discount to the local line, adjusted for the ratio and FX, is a real fact about capital-flow restrictions, not an arbitrage you can assume away.
|
||||
|
||||
**VIE and contractual control.** For China-domiciled ADRs and structurally similar EM listings, the listed Cayman holdco frequently does *not* own the operating company. It owns a wholly foreign-owned enterprise (WFOE) that holds a bundle of contracts — exclusive service agreements, equity pledges, powers of attorney — over an onshore entity owned by founders, engineered to satisfy foreign-ownership restrictions in licensed sectors. Establish: whether the operating licences, IP and cash sit inside or outside the consolidated legal perimeter; whether those contracts have ever been tested and enforced in the local courts; the legal route by which onshore cash is upstreamed as dividends and whether capital controls or tax gross-ups impede it; and audit-inspection access (PCAOB inspection status and HFCAA delisting exposure). If the answer is "profitable operating company, contractual claim only, unenforced in court, restricted upstreaming," you are not buying the earnings — you are buying a promise to route the earnings, and that belongs at the top of the risk section, not in a footnote. The same test applies in miniature anywhere the listed entity is a thin holdco whose value resides in entities it does not fully control (Section 8).
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Voting/economic wedge | Insider voting % − insider economic % | 0; any wedge above ~10pts needs explicit justification | Measures how much control has been bought without proportionate capital at risk |
|
||||
| Sunset horizon | Years until superior votes collapse to one-share-one-vote | Defined and dated | An undated wedge is permanent entrenchment |
|
||||
| DVR discount (India) | (Ordinary price − DVR price) ÷ ordinary price, vs its own 5-year range | Judge against own history only | Establishes whether the discount is normal or a signal |
|
||||
| ADR ratio and fees | ADS-to-share ratio; depositary fee per ADS per year | Fees small relative to yield | Silently reduces realised income and distorts naive per-share comparisons |
|
||||
| Consolidated-perimeter test | % of revenue/profit consolidated via contracts rather than equity | 0% for a straightforward company | Contractual consolidation means legal title to earnings is untested |
|
||||
|
||||
Indicative ranges throughout this file vary by market, cycle and period. Peer comparison and the company's own history override every absolute band.
|
||||
|
||||
---
|
||||
|
||||
## 2. Capital allocation: build the deployment ledger
|
||||
|
||||
Over a decade, capital allocation is the largest single driver of per-share value, and it is the most persistent, most predictive management trait you can observe. Do not assess it with adjectives. Build a ledger.
|
||||
|
||||
**The method.** For the last 7–10 years, tabulate every source and use of capital, then attach a return to each use.
|
||||
|
||||
| Column | What goes in it |
|
||||
|---|---|
|
||||
| Year | Fiscal year of commitment |
|
||||
| Source | Operating cash flow, debt raised, equity raised, asset sale |
|
||||
| Use | Maintenance capex, growth capex, acquisition, buyback, dividend, debt repayment, cash build |
|
||||
| Amount | In reporting currency (₹ crore for India; state units) |
|
||||
| Promised return | What management said at announcement: IRR, payback, capacity, accretion, synergy — quote it with the date and source |
|
||||
| Realised outcome | Incremental revenue/EBIT actually attributable, capacity actually commissioned, synergies actually visible in the segment numbers |
|
||||
| Implied incremental ROIC | Incremental NOPAT ÷ capital deployed, once the asset is ramped |
|
||||
| vs WACC | Spread in basis points |
|
||||
|
||||
**Incremental ROIC — compute it properly.** Aggregate ROIC is dominated by legacy assets and hides recent decisions. Use return on incremental invested capital, lagged for ramp:
|
||||
|
||||
- RoIIC = (NOPAT_t − NOPAT_{t−n}) ÷ (Invested capital_{t−1} − Invested capital_{t−n−1}), with n = 3 to 5 years, and invested capital lagged by at least a year because capital does not earn on the day it is spent.
|
||||
- Compute it on a rolling basis and plot it. A business with 25% aggregate ROIC and 6% RoIIC is a good business being converted into a mediocre one; that fact is invisible in the headline ratio and is exactly the sort of single-metric error the skill's governing principle warns against.
|
||||
- Sanity-check against the growth identity: sustainable growth ≈ reinvestment rate × incremental ROIC. If management guides to growth that this identity cannot produce at their historical incremental returns, either the returns must improve (why?) or the growth requires external capital (dilution — Section 9).
|
||||
- Cross-check with the definitions and normalisation rules in `references/05-returns-and-dupont.md`; do not re-derive invested capital differently here.
|
||||
|
||||
**Acquisitions.** Track cumulative goodwill and acquired intangibles as a share of total assets, and every subsequent impairment. Impairment is the accounting system finally admitting that the price paid exceeded the value received — a recurring impairment pattern is a confession of serial overpayment, and you should read each one as a repayment of a prior year's reported earnings. For serial acquirers, also run the roll-up distortions in `references/07-forensic-red-flags.md`: acquired growth presented as organic, restructuring charges that never end, and purchase accounting that suppresses acquired-entity revenue then flatters subsequent growth.
|
||||
|
||||
**Buybacks.** A buyback is a capital allocation decision like any other and must be scored on price, not on existence. Compare the average repurchase price to your own intrinsic-value estimate for that year, or as a proxy to the multiple (P/E, EV/EBIT, P/B) at repurchase against the company's own 10-year range. Buying back stock in the top decile of the historical multiple, while simultaneously issuing cheap equity or options to insiders, is value transfer dressed as shareholder return. India-specific: buybacks may be by tender offer (with the mandated reservation for small shareholders) or open market, and the tax treatment changed materially in October 2024 — proceeds are now taxed in the shareholder's hands as deemed dividend rather than through the company-level buyback tax, which changed the buyback-versus-dividend calculus for Indian issuers. Do not apply pre-2024 payout logic to post-2024 decisions.
|
||||
|
||||
**Dividends and debt paydown** are the honest options and should be scored positively when the alternative uses earn below WACC. A company with sub-WACC incremental returns that keeps reinvesting is destroying value more surely than one that pays out.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| RoIIC (3–5y) | Δ NOPAT ÷ Δ invested capital, lagged | Above WACC, and not falling | The only measure of whether *recent* decisions created value |
|
||||
| ROIC − WACC spread | Aggregate ROIC less WACC, 5-year trend | Positive and stable | Sub-WACC growth destroys value; see `06-valuation.md` for WACC derivation |
|
||||
| Cumulative FCF vs cumulative capital raised | Σ FCF (10y) ÷ Σ (equity + net debt raised) | >1 for a self-funding business | Distinguishes a compounder from a capital sink |
|
||||
| Goodwill + acquired intangibles / total assets | From balance sheet | Judge against acquisition strategy | High values make reported ROE flattering and impairment risk structural |
|
||||
| Cumulative impairments / cumulative acquisition spend | Sum both over 10 years | Near zero | Direct measure of M&A overpayment |
|
||||
| Buyback multiple percentile | Multiple paid at repurchase vs own 10-year range | Below median | Tests whether buybacks were opportunistic or price-insensitive |
|
||||
| TSR vs sector over CEO tenure | Total return, CEO start to now, against sector index | Above sector | The bluntest available scorecard; use as a check, never alone |
|
||||
|
||||
---
|
||||
|
||||
## 3. Guidance versus delivery: tabulate it, do not characterise it
|
||||
|
||||
Credibility is measurable. Build a table of every *quantified* forward statement management has made over the last 3–5 years and mark it to actual.
|
||||
|
||||
| Date | Source | Statement | Horizon | Target | Actual | Variance |
|
||||
|---|---|---|---|---|---|---|
|
||||
| e.g. Q2 concall | Transcript | "capacity commissioned by Q4" | 2 quarters | Commissioning date | Actual date | Slip in quarters |
|
||||
|
||||
Include: revenue growth, margin targets, capex budgets, capacity commissioning dates, order-book conversion, debt-reduction targets, acquisition synergies, product launch dates, store/branch openings, and stated payout policy. Then compute a hit rate and a mean *signed* error, because the sign matters: chronic over-promising is a credibility failure that should widen your discount rate; chronic sandbagging is a different behaviour with different implications for how to read current guidance.
|
||||
|
||||
**Where guidance lives.** US issuers typically give formal guidance in the earnings release furnished on Form 8-K, repeated in the 10-Q/10-K MD&A. Indian issuers frequently give no formal guidance in filings at all, and the commitments live only in the concall — which is why LODR Reg 46 transcript availability (audio/video within 24 hours, transcript within 5 working days) matters so much for this exercise. Read the transcripts, not the summaries.
|
||||
|
||||
**What to do with it.** A management team with a documented history of missing its own targets by wide margins has forfeited the right to have its forward statements used as an input in your model. State that explicitly and haircut the forecast, or model only what the existing asset base can produce. Conversely, a team that has hit dated, specific, falsifiable targets across a downturn has earned some forecast credibility — and note that the willingness to make *falsifiable* statements at all is itself a governance signal. Vague, unfalsifiable strategy language ("we will drive shareholder value") is an evasion, not a target.
|
||||
|
||||
---
|
||||
|
||||
## 4. Promoter / insider holding: level, trend and mechanism
|
||||
|
||||
The trend matters more than the level, and the mechanism matters more than the trend.
|
||||
|
||||
**Read the mechanism, not just the delta.** A rising promoter stake means very different things depending on how it rose: open-market purchases with personal cash (strong positive), creeping acquisition within the SAST 5%-per-financial-year limit (positive), a preferential allotment of shares or warrants to the promoter at a formula price during a depressed market (self-dealing dressed as commitment — see Section 9), or a fall in the denominator via buyback (mechanical, no signal). A falling stake can be an ordinary estate-planning sale, a pledge invocation (Section 5), a dilution because the promoter did not participate in a raise, or an inter-se transfer within the promoter group that is not a sale at all.
|
||||
|
||||
**India specifics.** Read the LODR Reg 31 shareholding pattern for at least 8–12 quarters, and read the *promoter group* table, not just "promoter" — stakes routinely migrate between family members, family trusts and promoter-group companies. Minimum public shareholding is 25%, so a promoter above 75% has a forced-sale overhang. The SAST open-offer trigger is 25%, and creeping acquisition beyond that is capped at 5% per financial year. Watch for promoter *reclassification* requests, which remove a person from the promoter group and with it certain disclosure and lock-in obligations — always ask why. For recently listed companies, map the IPO lock-in expiry calendar for promoter and pre-IPO investor shares, plus any anchor-investor lock-in; a known supply cliff is a price risk independent of fundamentals.
|
||||
|
||||
**US specifics.** The proxy beneficial-ownership table is a point-in-time snapshot with its own record date; use SC 13D/13G (and their amendments) plus Form 4 history to build the trend. 13D signals an activist or control intent, 13G a passive position; a conversion from 13G to 13D is a material event. Note that beneficial ownership includes shares acquirable within 60 days, so option-heavy insiders look larger than their economic exposure.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Promoter / insider holding % | Latest shareholding pattern or proxy table | Sector- and market-relative; stability matters more than level | Skin in the game aligns the controller with minorities |
|
||||
| 8–12 quarter trend | Absolute change in percentage points | Flat or rising | Persistent decline means the best-informed holders are reducing |
|
||||
| Mechanism split | % of stake change from open market vs allotment vs dilution vs inter-se transfer | Open-market purchases dominant | Distinguishes conviction from self-allotment |
|
||||
| Free float and institutional share | 100 − promoter %; DII/FII split and trend | Adequate float for liquidity | Low float distorts price discovery and raises impact cost |
|
||||
| Beneficial-ownership opacity | % of promoter stake held via trusts, offshore vehicles or layered entities | Low and explained | Opaque holding chains obscure who actually controls and who is pledging |
|
||||
| Lock-in / lock-up expiry (recent IPOs) | Date and volume of each tranche unlocking | Mapped in advance | Predictable supply shock |
|
||||
|
||||
---
|
||||
|
||||
## 5. Share pledging and encumbrance (India-critical)
|
||||
|
||||
This is the highest-yield India-specific governance check and has no close US equivalent, so run it on every Indian company and do not assume its absence elsewhere means it is irrelevant.
|
||||
|
||||
**What it is.** Promoters borrow personally against their shareholding. The pledge sits outside the company's balance sheet, so the company can look conservatively financed while the controlling family is highly levered against the same equity you are buying. Disclosure comes via SAST Reg 31 encumbrance filings and the pledge column of the quarterly shareholding pattern. "Encumbrance" is defined broadly in SEBI's framework and includes non-disposal undertakings and similar arrangements, not just formal pledges — read the encumbrance number, not only the pledge number.
|
||||
|
||||
**Why it is dangerous.** The exposure is reflexive. A price fall breaches the lender's loan-to-value threshold, triggering a margin call; if the promoter cannot post collateral, the lender invokes the pledge and sells into a falling market, which lowers the price, which triggers further calls. In the tail, the promoter loses control at the worst possible moment and the company acquires a distressed, motivated seller of its own stock. Before that point, a cash-strapped promoter has an acute incentive to move company cash toward personal obligations — which is why high pledging and rising related-party loans in the same year is one of the most reliable tunnelling signatures available (Section 7).
|
||||
|
||||
**How to run it.** Pull the pledge percentage for 8 quarters. Express it two ways — as a share of promoter holding and as a share of total shares outstanding, because the second is the actual float-supply risk. Overlay the share price. Rising pledge percentage into a falling price means either fresh borrowing or an invocation already under way, and both are urgent. Read the disclosed purpose; "for business purposes of the company" is materially different from an undisclosed personal use. Identify the lender: NBFCs and promoter-affiliated lenders extend against collateral that a bank would refuse, and a pledge financed by a related entity may be circular funding rather than a genuine external loan.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Pledged % of promoter holding | Pledged shares ÷ promoter shares | 0 is clean; sustained >25% warrants a discount; >50% is severe | Direct measure of promoter financial stress and forced-sale risk |
|
||||
| Pledged % of shares outstanding | Pledged shares ÷ total shares | Low relative to average daily volume | Converts pledge risk into the float that could hit the market |
|
||||
| Trend over 8 quarters | Percentage-point change | Falling | Rising pledges into a falling stock is the pre-invocation pattern |
|
||||
| Implied LTV | Pledged value at current price ÷ disclosed loan, where available | Comfortable headroom | Estimates how far the price can fall before a call |
|
||||
| Encumbrance minus pledge | Disclosed encumbrance % less formal pledge % | Zero or explained | Captures non-disposal undertakings and side arrangements |
|
||||
| Invocation events | Count in last 3 years | Zero | An invocation already occurred means the cascade has started |
|
||||
|
||||
---
|
||||
|
||||
## 6. Insider transactions: read them one trade at a time
|
||||
|
||||
Aggregate net insider buying is a weak signal because it mixes signal with mechanics. Go to the transaction level.
|
||||
|
||||
**US — Form 4 transaction codes.** The code determines whether the trade carries any information at all:
|
||||
- **P** — open-market purchase. The only strongly informative code. Real money, real decision.
|
||||
- **S** — open-market sale. Informative only after you strip out pre-planned and mechanical sales.
|
||||
- **A** — grant or award. No signal; it is compensation.
|
||||
- **M** — option exercise. **F** — shares withheld for tax. A same-day M followed by S or F is a compensation event, not a view on value. Analysts who count these as "insider selling" manufacture false signals constantly.
|
||||
- **G** — gift. **C** — conversion. Usually estate planning or instrument mechanics.
|
||||
|
||||
Check the footnotes for 10b5-1 plan status. Since the 2023 amendments, officer and director plans carry a cooling-off period (the later of 90 days or two business days after the next periodic report, capped at 120 days), overlapping plans are restricted, single-trade plans are limited to one per 12 months, and adoption/termination must be disclosed quarterly (Item 408 of Reg S-K). That gives you two things: a genuine distinction between mechanical and discretionary sales, and a new signal — a plan *adopted or terminated* at a suspicious moment. Also check Item 402(x) disclosure on option-grant timing relative to material non-public information; award dates clustering just before good news or just after bad news is a live governance flag.
|
||||
|
||||
**India — PIT and SAST.** SEBI (Prohibition of Insider Trading) Regulations require designated persons, promoters and directors to disclose trades exceeding ₹10 lakh in value in a calendar quarter within two trading days; these appear on the exchange websites. SAST Reg 29 requires disclosure on crossing 5% and on every 2% change thereafter. Additional India-specific checks: the trading-window closure around results (trades near the window edges deserve scrutiny), the contra-trade restriction (a designated person may not take an opposite trade within six months), the maintenance of a structured digital database of unpublished price-sensitive information, and whether the company has ever been the subject of a SEBI insider-trading proceeding.
|
||||
|
||||
**What actually carries information.**
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Cluster score | Number of distinct insiders making open-market purchases within a 90-day window | 3+ buyers is a meaningful cluster | Independent decisions by several insiders is far stronger than one large trade |
|
||||
| Trade size vs holding | Value of purchase ÷ insider's existing holding, and ÷ annual cash compensation | Material (>10–20% of holding, or >1× salary) | A token purchase is a press release; a large one is a decision |
|
||||
| Discretionary sale share | Sales not under a pre-set plan ÷ total sales | Low | Isolates the informative subset from mechanical liquidation |
|
||||
| Trade-to-news gap | Days between trade and the next material disclosure | Long | Systematically short gaps suggest information asymmetry or worse |
|
||||
| Company-buys-insiders-sell | Overlap of buyback windows with insider sales | No overlap | Company capital supporting insider exits is a direct conflict |
|
||||
| Silence signal | No insider buying despite a large price decline and public management optimism | Buying present | The cheapest possible confirmation of stated conviction, and its absence is informative |
|
||||
|
||||
---
|
||||
|
||||
## 7. Related-party transactions and tunnelling
|
||||
|
||||
RPTs are the primary channel through which controllers extract value from minorities. Read the full RPT schedule in the notes — every year, in full — and build a map of counterparties before you interpret any number.
|
||||
|
||||
**What to quantify.** Sales to and purchases from related parties; loans, advances and deposits given; corporate guarantees issued; royalty, brand, trademark and technical-fee payments; management and consultancy fees; rent and property leases; asset purchases and sales; and remuneration to relatives of directors. Express each as a percentage of revenue, of PBT and of net worth, and plot the trend. A single year's RPT table tells you almost nothing; the five-year trajectory tells you whether extraction is intensifying.
|
||||
|
||||
**The patterns that matter.**
|
||||
- **Royalty and brand fees to a parent or promoter entity.** Classic in Indian subsidiaries of multinationals and in family groups. A royalty that rises as a percentage of sales while margins do not improve is a transfer, not a service. India: LODR Reg 23 requires majority-of-minority approval for royalty or brand payments to a related party exceeding 5% of annual consolidated turnover — check whether that threshold was approached, and whether the payment was structured to stay just below it.
|
||||
- **Loans and advances to promoter entities**, especially interest-free or below-market, unsecured, or repeatedly rolled over. Then check whether they are being written off in "exceptional items."
|
||||
- **Guarantees for unrelated promoter businesses.** Off-balance-sheet until they crystallise; size them against net worth.
|
||||
- **Purchases through a single promoter-owned intermediary.** A captive distributor, logistics arm or raw-material supplier is a margin siphon that shows up as unexplained gross-margin underperformance versus peers.
|
||||
- **Asset transfers near reporting dates** and at valuations supported only by a related valuer.
|
||||
- **Related-party receivables ageing more slowly than third-party receivables** — the cleanest quantitative tunnelling test available, because it requires no judgement about pricing.
|
||||
|
||||
**Approval quality (India).** Under LODR Reg 23 and s.188 of the Companies Act, RPTs require audit-committee approval by disinterested members, and material RPTs — above ₹1,000 crore or 10% of consolidated turnover, whichever is lower — require shareholder approval with related parties abstaining. Verify that this actually happened, and read the dissent. A high against-vote on an RPT resolution that passed only because the promoter group was arithmetically excluded but the institutions still lost is a strong signal about how minorities see the controller.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Total RPT value / revenue | Sum of RPT flows ÷ revenue | Low and stable; high is acceptable only where structurally necessary and priced transparently | Sizes the channel through which value can leave |
|
||||
| Royalty + brand + management fees / PBT | From RPT note ÷ PBT, 5-year trend | Flat or falling as % of sales | Rising fees against flat margins is a transfer to the controller |
|
||||
| Loans and advances to related parties / net worth | From RPT note and balance sheet | Near zero for an operating company | Company balance sheet financing the promoter |
|
||||
| Guarantees to related parties / net worth | Contingent-liability note | Near zero | Off-balance-sheet exposure to entities you cannot analyse |
|
||||
| RP receivable days vs third-party receivable days | Compute both separately | Similar or shorter for RPs | Divergence is tunnelling that needs no pricing judgement |
|
||||
| Material RPTs approved by majority of minority | Count and against-vote % | All material RPTs approved; low dissent | Tests whether the approval architecture actually functions |
|
||||
|
||||
---
|
||||
|
||||
## 8. Group structure complexity and holdco opacity
|
||||
|
||||
Map the corporate tree before you interpret consolidated numbers. List subsidiaries, step-down subsidiaries, JVs, associates, trusts and offshore SPVs, with ownership percentages and jurisdictions. For India, the annual report's subsidiary list plus Form AOC-1 gives you the financial summary of each; MCA21 filings give you the group entities that are *not* subsidiaries but sit in the promoter group.
|
||||
|
||||
Then answer four questions. **Where does the cash sit** relative to where the debt sits? A cash-rich subsidiary under a debt-laden listed parent means dividends must be upstreamed to service the debt, and minority interests in the subsidiary get paid first. **Are you structurally subordinated?** Debt at the operating company ranks ahead of the holdco's equity claim on that company. **Where is the value you are buying?** If the listed entity is a thin holdco whose assets are minority stakes in operating entities, you are buying a holdco discount that may never close, and you must value it sum-of-the-parts — route to `references/sectors/holdco-assetmgr.md`. **Why is it this complicated?** Complexity has legitimate causes (regulatory ring-fencing, JV partners, tax treaties, project finance at the SPV level). It also has illegitimate ones. Ask management for the rationale and judge whether the answer covers all the entities.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Subsidiary count and consolidation depth | Count entities and layers | Proportionate to the business | Proliferating entities with no disclosed activity is a hiding place |
|
||||
| Intercompany loans + guarantees / net worth | From notes | Low | Measures how much of group solvency is internal circulation |
|
||||
| Holdco vs opco debt split | Debt at listed entity vs at operating subsidiaries | Understood and stated | Determines structural subordination and dividend dependency |
|
||||
| Entities in opaque jurisdictions | Count and % of assets | Zero or fully explained | Secrecy jurisdictions defeat verification |
|
||||
| Holdco discount | Market cap ÷ sum-of-parts value of stakes | Judge against own history and peer holdcos | Persistent discounts are structural, not a mispricing you can assume closes |
|
||||
|
||||
---
|
||||
|
||||
## 9. Capital raising, dilution and financing behaviour
|
||||
|
||||
Per-share value is what you own. Build a 7–10 year share-count history and identify every event that changed it.
|
||||
|
||||
**What to reconstruct.** Rights issues, QIPs and secondary offerings, preferential allotments, convertible bonds, warrants, ESOP/RSU grants and exercises, and buybacks. For each: who subscribed, at what price, and at what discount to the prevailing market. Then compute cumulative equity raised against cumulative FCF generated — a business that has raised more than it has produced across a full cycle is a capital sink regardless of its reported growth.
|
||||
|
||||
**India specifics.** Preferential allotment pricing is formula-driven under SEBI ICDR (the higher of the 90-trading-day and 10-trading-day VWAP, with a specified relaxation regime); warrants require 25% upfront with 18 months to convert, which gives the holder a cheap 18-month option struck at a depressed-market price. Warrants issued to promoters during a downturn, converted after a recovery, are a well-worn route to increasing promoter stake at minority expense — always price the option value that was transferred. QIP pricing uses a two-week VWAP with a permitted discount of up to 5%. ESOP schemes fall under the SEBI (SBEB and Sweat Equity) Regulations; check the pool size, the exercise price relative to market, and the performance conditions.
|
||||
|
||||
**US specifics.** Watch for at-the-market (ATM) programmes and shelf registrations that permit continuous issuance, convertible notes with reset features, and any structured or "toxic" financing with variable conversion prices — the latter is a near-terminal signal for small caps. Stock-based compensation should be treated as an expense in cash-flow terms and its dilution measured on the diluted count including unvested awards, per `references/03-earnings-quality.md`.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Diluted share-count CAGR | 5–10 year CAGR of fully diluted shares | ≤1–2% for a self-funding business; negative if buying back | The direct measure of how much of the business you keep |
|
||||
| Cumulative equity raised ÷ cumulative FCF | 10-year sums | <1 | Distinguishes a compounder from a perennial capital consumer |
|
||||
| Issue discount to market | (Market price − issue price) ÷ market price, per event | Small; large discounts to insiders are a transfer | Prices the wealth moved from minorities to subscribers |
|
||||
| SBC / ESOP burn rate | Annual grants ÷ shares outstanding | ~1% or less outside early-stage | Compounds silently; large pools with no performance gate are pay, not alignment |
|
||||
| Warrant option value to insiders (India) | Value of the 18-month option implicitly granted at the formula price | Zero or compensated | The favour is the optionality, not the price |
|
||||
| Net issuance per share | Shares issued less repurchased, annually | Consistent direction | Issuing cheap to insiders while buying back dear is the classic two-handed transfer |
|
||||
|
||||
---
|
||||
|
||||
## 10. Executive compensation and alignment
|
||||
|
||||
Compensation design predicts behaviour better than any stated strategy. Read the actual plan documents, not the summary table.
|
||||
|
||||
**What to extract.** Fixed pay, annual cash bonus, long-term equity (and its vesting horizon and performance conditions), pension, perquisites, severance terms and change-of-control triggers. Then identify the *metrics that gate the bonus*. Metrics that can be bought with capital — revenue growth, absolute EBITDA, adjusted EBITDA, total profit — reward empire building and encourage leverage and acquisitions. Metrics that resist manipulation — ROIC, FCF per share, relative TSR, economic profit — reward the behaviour you want. If a company's bonus plan pays on adjusted EBITDA and the adjustments are management-defined, the plan is paying for the adjustments.
|
||||
|
||||
**India specifics.** Managerial remuneration is capped by s.197 of the Companies Act at 11% of net profits computed under s.198 (5% for a single MD/WTD, 10% for all of them together, 1% for non-executive directors where there is an MD, otherwise 3%), with excess requiring a shareholder special resolution — so read the resolution and the dissent when the cap is breached, particularly in a loss year where Schedule V limits apply. Aggregate the remuneration of *all* promoter-family members, including relatives holding office or place of profit, and express it as a percentage of PBT; family payouts are often individually modest and collectively large. The Reg 27 corporate-governance report and the annual report's remuneration section carry the median-employee pay ratio disclosures.
|
||||
|
||||
**US specifics.** The DEF 14A CD&A, the Summary Compensation Table, the pay-ratio disclosure and the pay-versus-performance table (Item 402(v), showing Compensation Actually Paid against company TSR, peer TSR, net income and a company-selected measure) let you test alignment directly. Check clawback policy compliance with the Rule 10D-1 listing standards effective end-2023 — recovery of erroneously awarded incentive compensation on restatement is now mandatory, and how a board handled an actual clawback trigger is far more informative than the policy text. Read the say-on-pay result: sustained support below ~70–80% is significant institutional dissent, and a board that receives it and changes nothing has told you where power sits.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| CEO comp / net profit | Total comp ÷ PAT | Small; rising share needs explanation | Scales pay to what the business actually earns |
|
||||
| Promoter-family aggregate comp / PBT (India) | Sum all related executives ÷ PBT | Low single digits at most | Catches extraction split across family members |
|
||||
| Pay growth vs EPS/FCF/TSR growth | 3–5 year CAGRs side by side | Pay growth ≤ performance growth | Pay rising while owners lose is board capture |
|
||||
| Long-term equity share of pay | Performance-linked equity ÷ total comp | Majority for senior executives | Fixed cash rewards tenure; equity rewards outcomes |
|
||||
| Vesting horizon | Years to full vest, and post-vest holding requirement | 3+ years, with holding requirements | Short vesting rewards a quarter, not a decade |
|
||||
| Quality of bonus metrics | Classify each KPI as manipulable or durable | Durable metrics dominant | Determines which behaviours get paid for |
|
||||
| Say-on-pay / remuneration-resolution dissent | Against + abstain % | <10% | Measured institutional judgement, free of charge |
|
||||
| Repricing and mega-grants | Count of option repricings or outsized grants after price falls | Zero | Repricing removes the downside that made the grant an incentive |
|
||||
|
||||
---
|
||||
|
||||
## 11. Board independence, composition and functioning
|
||||
|
||||
Assess genuine independence, not the label. Directors are classified as independent by the company; you classify them by evidence.
|
||||
|
||||
**Adjust the count.** Deduct from the "independent" tally any director with: a prior executive role at the company or a group entity; family ties to the promoter; a professional relationship (law firm, bank, consultancy, audit) with the company; cross-directorships on other promoter-group boards; tenure long enough to have become part of the furniture; or a material commercial relationship disclosed in the RPT note. Report your adjusted independence percentage alongside the company's claimed figure and show the deductions.
|
||||
|
||||
**India specifics.** LODR Reg 17 requires at least one-third independent directors where the chair is a non-executive unrelated to the promoter, and at least half where the chair is executive or promoter-related; the top 1,000 listed companies must have at least one woman independent director. Independent-director tenure is capped at two consecutive five-year terms with a cooling-off period (s.149), and since 2022 both appointment and removal of an independent director require a special resolution — which strengthens minorities somewhat, so check how such resolutions have actually been voted. Reg 18 requires an audit committee with a majority of independent members and financial literacy across it. Read the corporate-governance report for attendance, and read every independent-director resignation letter: SEBI requires the detailed reason to be disclosed, and resignations citing "pre-occupation" clustered around a contentious event are a signal regardless of the stated reason.
|
||||
|
||||
**US specifics.** Exchange listing standards require a majority-independent board and fully independent audit, compensation and nominating committees, with the audit committee needing a financial expert (disclosed under Item 407(d)(5)). Foreign private issuers may follow home-country practice instead — check Item 16G of the 20-F before assuming any of this applies. Read director-election vote results: a director with 15%+ withheld votes has been formally rebuked. Check ISS/Glass Lewis recommendations and, in India, IiAS/SES/InGovern notes, for the specific reasons given.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Adjusted independence % | Genuinely independent directors ÷ board size, after deductions | Majority; at minimum the statutory floor | The board is the only structural check on a controller |
|
||||
| Directors with tenure >9–10 years | Count and % | Low, with visible refreshment | Long tenure erodes independence of mind regardless of formal status |
|
||||
| Chair/CEO separation | Yes/no; lead independent director if combined | Separated, or a genuinely empowered lead independent director | Concentrating both roles removes the agenda-setting check |
|
||||
| Committee independence | Audit / nomination / remuneration composition | Fully independent; audit chair financially expert | Committees are where governance actually happens |
|
||||
| Attendance | Board and committee attendance % per director | >75% consistently | Absent directors cannot challenge anything |
|
||||
| Overboarding | Number of other listed boards per director | ≤4–5, fewer for executives | Capacity constrains scrutiny |
|
||||
| Independent-director churn | Resignations in 3 years and stated reasons | Low; reasons benign | Resignations citing governance are among the strongest single signals available |
|
||||
| Against-votes on director elections | Highest against/withheld % in last 3 AGMs | <10% | Independent institutional judgement, already tabulated for you |
|
||||
|
||||
---
|
||||
|
||||
## 12. Auditor: quality, tenure, fees, resignations
|
||||
|
||||
The auditor is the last independent gatekeeper on the numbers everything else depends on.
|
||||
|
||||
**Establish the facts.** Who is the auditor; how long have they held the engagement; when was the last rotation; what are audit fees versus non-audit and tax fees paid to the same firm and its network; is the firm's scale and geographic footprint appropriate to the group's size and jurisdictions. India requires rotation under s.139 — a maximum of five consecutive years for an individual auditor and ten for a firm, with a five-year cooling-off — so the presence of the same firm beyond that is itself a question. In the US, tenure is disclosed in the audit report and can run for decades; long tenure is not disqualifying by itself but combines badly with high non-audit fees.
|
||||
|
||||
**Read the opinion properly.** Work through: the opinion type (unqualified, qualified, adverse, disclaimer); emphasis-of-matter and material-uncertainty-related-to-going-concern paragraphs; and the Key Audit Matters (India/IFRS) or Critical Audit Matters (US). KAMs/CAMs are the auditor telling you exactly which balances required the most judgement — treat them as a to-do list for your forensic pass, not as boilerplate. In India also read the CARO 2020 annexure in full: it carries specific, checkable statements on undisclosed income, wilful defaulter status, diversion of short-term funds to long-term use, loans to related parties, benami proceedings and whistle-blower complaints. Read the ICFR opinion under s.143(3)(i); in the US read Item 9A and note whether an auditor attestation on internal control was even required — non-accelerated filers and emerging growth companies are exempt from 404(b), so a clean-looking ICFR section may reflect management assertion only.
|
||||
|
||||
**Changes and resignations are the high-severity events.** In the US, an auditor change is reported on Form 8-K Item 4.01, including whether there were disagreements and whether the prior auditor's reports contained adverse or qualified opinions; a restatement appears at Item 4.02 (non-reliance). Read the outgoing auditor's exhibit letter, which is the auditor's own account. In India, a resigning auditor files Form ADT-3 and SEBI's framework requires disclosure of detailed reasons, with the auditor expected to complete the limited review or audit for the period before resigning. Any resignation citing lack of information, lack of cooperation, or inability to obtain sufficient appropriate audit evidence is a near-automatic stop: the person with statutory access to the books declined to certify them.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Auditor tenure | Years since appointment; date of last rotation | Within statutory rotation limits (India); disclosed and considered (US) | Familiarity erodes scepticism |
|
||||
| Non-audit fees / total auditor fees | From proxy fee table (US) or payments-to-auditors note (India) | <25–30% | Consulting revenue is the classic independence solvent |
|
||||
| Auditor scale vs group complexity | Firm size and network footprint vs group revenue, entities, jurisdictions | Proportionate | A small firm auditing a large multinational group cannot do the work |
|
||||
| KAM/CAM count and subject | Number and which balances | Few, stable, unsurprising | Names the accounts where judgement is concentrated |
|
||||
| Modified opinions / going-concern language | Presence and wording | None | The most explicit warning in the document |
|
||||
| ICFR material weaknesses | Count and nature; whether 404(b) attestation applied | None; attestation present | Weak controls make every other number less reliable |
|
||||
| Auditor changes in 5 years | Count, with stated reasons | ≤1, routine rotation | Serial changes are auditor shopping |
|
||||
| Resignation mid-cycle | Yes/no, with the reason given | No | Highest-severity single governance event on this list |
|
||||
|
||||
---
|
||||
|
||||
## 13. CFO and finance-team turnover
|
||||
|
||||
Treat this separately from CEO succession, because it is a different signal with a different mechanism. The numbers are produced by the finance organisation; instability there is one of the most reliable pre-restatement tells available from public filings.
|
||||
|
||||
**How to run it.** Build a 5–7 year tenure history for the CFO, the chief accounting officer or controller, the treasurer, the head of internal audit and the audit-committee chair. In the US these departures are disclosed on Form 8-K Item 5.02 with dates; in India they are announced under LODR Reg 30 as material events, and the annual report's KMP list gives you the year-by-year names. Then look for the patterns rather than any single departure:
|
||||
|
||||
- Departures announced close to a period end, a filing deadline, an audit completion or an auditor change.
|
||||
- A resignation with no successor named, or a long interim period covered by a promoted controller.
|
||||
- More than two CFOs in five years, or a CFO and an auditor changing within the same twelve months — a combination that should raise your forensic priority immediately.
|
||||
- Boilerplate reasons ("personal reasons", "to pursue other opportunities") attached to a short-tenured, senior finance hire.
|
||||
- Departure of the audit-committee chair specifically, which removes the board-side counterpart to the auditor.
|
||||
|
||||
A single CFO departure with a named successor, an orderly transition period and a plausible destination is ordinary corporate life. A pattern is not. When you find a pattern, do not merely flag it — go back to `references/07-forensic-red-flags.md` and re-run the accruals and cash-existence tests on the periods those individuals signed.
|
||||
|
||||
---
|
||||
|
||||
## 14. Minority-shareholder rights architecture
|
||||
|
||||
This is where minority wealth is preserved or expropriated at inflection points. Assess the machinery *before* an inflection point arrives.
|
||||
|
||||
**What to examine.** Voting structure and the wedge (Section 1). Anti-takeover devices: poison pills, staggered boards, supermajority requirements, and — India — the promoter's ability to block special resolutions. The dividend record: consistency through a cycle, and whether payout policy serves all holders or primarily supplies the promoter's cash needs. The company's own history at inflection points: past delisting attempts and the price offered, open offers under SAST and whether the price reflected control value, related-party mergers and the swap ratios used, and the treatment of minorities in prior rights issues (were they able to participate, and on what terms). Responsiveness to dissent: how many resolutions have drawn heavy institutional against-votes, and what the board did afterwards.
|
||||
|
||||
**India specifics.** Delisting proceeds by reverse book building, with the framework amended in 2024 to also permit a fixed-price route at a stated premium to the floor price; the historical pattern is that promoters attempt delisting after price weakness, so a delisting proposal arriving at a cyclical trough is a value-capture attempt, not a windfall. Majority-of-minority approval applies to material RPTs and to certain royalty payments. Class-action and derivative remedies exist under s.245 of the Companies Act but are used rarely; assume weak ex-post remedies and price the ex-ante structure accordingly. Read the e-voting results published after each AGM: they give you institution-versus-promoter voting splits resolution by resolution, for free.
|
||||
|
||||
**US and global specifics.** Check the charter and bylaws for the wedge, classified board, written-consent and special-meeting rights, exclusive-forum provisions, and the state of incorporation (Delaware's fiduciary case law is a meaningful protection that many other jurisdictions do not replicate). For controlled companies, exchange rules permit exemptions from majority-independent-board and independent-committee requirements — verify whether the company has taken them.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Voting/economic wedge | See Section 1 | Zero | Determines whether any minority vote can ever bind |
|
||||
| Payout consistency | Dividend paid in each of the last 10 years; payout ratio range | Stable policy through a cycle | Erratic payout alongside strong cash flow suggests cash is being retained for other purposes |
|
||||
| Past delisting / open-offer pricing | Premium or discount to pre-announcement price and to intrinsic value | Fair premium | The single most direct evidence of how the controller treats minorities in a squeeze |
|
||||
| Against-management vote share | Highest against % across resolutions in last 3 AGMs | Low | Aggregated professional judgement on the same questions you are asking |
|
||||
| Board response to dissent | Documented changes following a high against-vote | Visible response | A board that absorbs dissent and changes nothing is not accountable |
|
||||
| Anti-takeover provisions | Pill, staggered board, supermajority, exclusive forum | Few | Entrenchment removes the market for corporate control as a discipline |
|
||||
|
||||
---
|
||||
|
||||
## 15. Succession and key-man risk
|
||||
|
||||
Underpriced because it is low-probability and high-impact. Assess it explicitly rather than assuming continuity.
|
||||
|
||||
Ask: how much of the strategy, the customer relationships, the lender relationships and the regulatory goodwill is personal to one individual? Is there a disclosed succession plan and a named or identifiable successor? What is the tenure and depth of the second line, and what has senior attrition looked like over five years? Is a family transition approaching, and are there signs of intra-family disagreement over control — a dispute among heirs can freeze capital allocation for years and has done so repeatedly in Indian promoter groups. Are there key-man clauses in debt covenants, JV agreements or major customer contracts that would accelerate or terminate on a departure? For founder-led businesses, note age and health disclosure, and whether the founder's stake will pass through a trust or be sold.
|
||||
|
||||
An abrupt, unexplained CEO or CFO departure with no successor named is a material event in its own right and should trigger a re-read of Sections 12 and 13, not a routine note.
|
||||
|
||||
---
|
||||
|
||||
## 16. Integrity, regulatory history and disclosure quality
|
||||
|
||||
Past misconduct predicts future misconduct better than almost any other governance variable. Screen the controlling group and the senior team, not just the company.
|
||||
|
||||
**The record.** India: SEBI orders and adjudication proceedings against the company, promoters or directors; director disqualifications under s.164; SFIO investigations; income-tax search and survey actions; NCLT/NCLAT proceedings; wilful-defaulter listings; and past appearances on the ASM/GSM surveillance frameworks (see `references/16-market-mechanics-and-tax.md`). US: SEC litigation releases and Accounting and Auditing Enforcement Releases, DOJ actions, FCPA matters, securities class actions and their outcomes, and officer-and-director bars. Search under individual names as well as the corporate name — people move between vehicles.
|
||||
|
||||
**Disclosure quality is a live, quarterly signal.** Score it on evidence: does the annual report discuss the segments that did badly with the same specificity as the ones that did well; does management name mistakes; is segment disclosure granular enough to test the story; do defined KPIs stay defined, or do definitions change in the year the metric turns down (a change in KPI definition is a red flag in its own right — see `references/07-forensic-red-flags.md`); are filings timely; how does management handle hostile analyst questions on the call — engagement versus deflection versus refusing to take the question. Run a year-over-year redline of the risk factors and the MD&A: the language management quietly adds or removes is often the earliest disclosure of a deteriorating situation.
|
||||
|
||||
**Short-seller and activist reports.** When a credible report exists, read the primary document, then read the company's rebuttal, and grade the rebuttal on specificity. A point-by-point response with documents refutes; a press release about "malicious motives" and a legal threat does not. A refusal to answer the specific quantitative allegations is itself evidence, and should raise your forensic priority sharply.
|
||||
|
||||
**Credit and covenant history.** Rating rationales from CRISIL/ICRA/CARE/India Ratings (India) or S&P/Moody's/Fitch (global) contain governance commentary you will not find in the annual report, including agency views on group support, related-party exposure and promoter pledges. A downgrade citing governance or information quality, an "issuer not cooperating" rating status in India, or a covenant waiver history are all direct evidence.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Regulatory actions against insiders | Count and severity, 10 years, by name | Zero | The strongest single predictor of recurrence |
|
||||
| Filing timeliness | Delayed filings, extensions, restatements in 5 years | Zero | Late filings are usually a symptom, not a process failure |
|
||||
| Rating trajectory | Direction over 5 years; any "issuer not cooperating" status (India) | Stable or improving | Agencies see covenant and liquidity data you do not |
|
||||
| Contingent liabilities / net worth | From the contingent-liability note | Low and stable | Sizes the tail of unresolved disputes |
|
||||
| Rebuttal specificity | Grade any response to credible allegations | Point-by-point with evidence | Distinguishes a wronged company from a cornered one |
|
||||
|
||||
---
|
||||
|
||||
## 17. Sector translation: where these checks change or invert
|
||||
|
||||
The governing principle applies to governance too. Do not carry a generic checklist into a sector where its terms are undefined.
|
||||
|
||||
**Banks and NBFCs (India: `references/sectors/banks.md`, `references/sectors/nbfc.md`).** Capital allocation *is* underwriting; there is no meaningful ROIC/WACC test, so assess capital allocation as ROE versus cost of equity, plus credit-cost discipline across a full cycle. The dominant governance risks are connected lending, evergreening of stressed exposures and promoter-group borrowing. India-specific checks: RBI's asset-classification divergence disclosure (required when the regulator's assessment exceeds the bank's by specified thresholds) is the single most valuable governance disclosure in the sector; RBI fit-and-proper norms and MD/CEO tenure caps for private banks; promoter shareholding dilution roadmaps; and mandatory joint statutory auditors with capped tenure for larger banks and NBFCs. Pledging by a bank promoter carries different consequences because of ownership caps and regulatory approval requirements.
|
||||
|
||||
**Insurers (`references/sectors/insurance.md`).** Capital allocation is judged on value of new business and embedded-value movement, not ROIC. Governance focus: reserving discipline and the appointed actuary's independence, distribution-related-party arrangements with a bancassurance parent, and IRDAI ownership and fit-and-proper rules.
|
||||
|
||||
**REITs, InvITs and externally managed vehicles (`references/sectors/realestate-reit.md`).** The central governance question is the manager's fee structure. Fees on gross assets or on acquisitions reward growing the vehicle regardless of per-unit value; fees on distributable income or total return align better. Every sponsor asset dropped down into the trust is a related-party transaction and must be tested against independent valuation. Check unitholder voting rights, the sponsor's mandated holding and lock-in, related-party approval mechanics excluding the sponsor, and leverage caps. Standard "promoter pledging" and "board independence" tests translate only loosely; ask instead who appoints and can remove the manager.
|
||||
|
||||
**Miners, oil and gas, and deep cyclicals (`references/sectors/metals-mining.md`, `references/sectors/oil-gas.md`).** Capital allocation is nearly the entire investment case: the record of committing capex at the top of the cycle versus counter-cyclically is the scorecard. The reserve statement is a second set of accounts, and the competent person's report (JORC, NI 43-101, SEC S-K 1300) is a second auditor — check the qualifications, independence and revision history of reserve estimates the same way you check the financial auditor. Add resource-nationalism, licence-renewal and royalty-regime risk to the integrity screen.
|
||||
|
||||
**PSUs and government-controlled companies (India, `references/13-situations.md`).** The promoter is the state, so the tests change rather than disappear: dividend and buyback demands driven by fiscal need, cross-holding bailouts of other state entities, disinvestment overhang, extended vacancies in board and CMD positions, and pricing decisions taken as policy rather than as commerce. Minority interests are structurally subordinate to policy objectives — price that, do not argue with it.
|
||||
|
||||
**Holdcos and conglomerates (`references/sectors/holdco-assetmgr.md`).** Section 8 becomes the main event: cross-holdings, the persistence of the discount, and whether cash flows up.
|
||||
|
||||
**Early-stage and recently listed companies (`references/13-situations.md`).** Governance maturity lags growth. Expect founder control, thin boards, large option pools and lock-in expiry supply. Weight structure heavily because there is no behavioural track record to weight instead.
|
||||
|
||||
---
|
||||
|
||||
## 18. Scoring, weighting and how to write it up
|
||||
|
||||
**Hard stops.** Treat these as kill criteria under Stage 3 rather than as score deductions. Each one means the analysis cannot be completed with confidence, and the correct output is a documented decline, not a lower target price:
|
||||
|
||||
- Auditor resigned or was dismissed citing lack of information, lack of cooperation, or inability to obtain sufficient appropriate audit evidence.
|
||||
- Adverse opinion, disclaimer of opinion, or unresolved going-concern doubt without a credible, funded remediation plan.
|
||||
- Regulator has found fraud or securities violations against the current promoter, CEO or CFO and they remain in post.
|
||||
- Cash balances that fail the existence tests in `references/07-forensic-red-flags.md`.
|
||||
- Related-party flows large enough that the minority-attributable economics cannot be reliably determined.
|
||||
- The listed security does not confer legal claim on the operating assets and that claim has never been tested (Section 1), with no compensating structural protection.
|
||||
|
||||
**Graduated adjustments.** Everything else feeds the sector-relative score per `references/11-scoring-rubric.md`, and — where you can justify it — an explicit increment to the cost of equity or a cut to the exit multiple in `references/06-valuation.md`. Say which one you applied and by how much. A governance concern that changes no number in the model is a concern you have not actually incorporated.
|
||||
|
||||
**How to present it.** Three parts, in this order: what the security confers; the capital-allocation and guidance-delivery evidence, with the ledger and the tabulation; the specific governance findings with their source citations and a severity label. Then state the adjustment you made and where. Distinguish clearly between *structure I dislike* and *behaviour I can evidence* — the second is a finding, the first is a risk factor. And where disclosure simply does not exist (a 20-F filer with aggregate compensation only, an unlisted group entity with no public accounts), say that the check could not be run, rather than scoring the absence as a pass.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Establish what the security confers: class, votes versus economics, sunset, DVR/ADR/GDR mechanics, VIE or contractual control.
|
||||
- [ ] Compute the voting/economic wedge and state it in the report.
|
||||
- [ ] Build the 7–10 year capital deployment ledger: source, use, amount, promised return, realised return.
|
||||
- [ ] Compute RoIIC (3–5y, lagged) and compare to WACC and to aggregate ROIC.
|
||||
- [ ] Score every major acquisition against its announcement promises; sum impairments against acquisition spend.
|
||||
- [ ] Score buybacks on price paid versus the company's own historical multiple range.
|
||||
- [ ] Tabulate every quantified guidance statement of the last 3–5 years against actuals; compute hit rate and mean signed error.
|
||||
- [ ] Pull 8–12 quarters of shareholding pattern; identify the *mechanism* of every change in promoter/insider stake.
|
||||
- [ ] India: pull pledge and total encumbrance as % of promoter holding and of shares outstanding, trend over 8 quarters, lender and purpose.
|
||||
- [ ] Analyse insider trades transaction by transaction; strip Form 4 codes A/M/F; isolate discretionary trades; look for clusters.
|
||||
- [ ] Read the full RPT note for 5 years; compute RPT/revenue, fees/PBT, loans and guarantees/net worth, and RP versus third-party receivable days.
|
||||
- [ ] Verify that material RPTs received disinterested approval, and read the against-vote.
|
||||
- [ ] Map the group tree: entity count, layers, jurisdictions, intercompany loans and guarantees, where cash sits versus debt.
|
||||
- [ ] Build the 7–10 year diluted share-count history; price every issuance discount and every insider warrant.
|
||||
- [ ] Compare cumulative equity raised to cumulative FCF over 10 years.
|
||||
- [ ] Classify every bonus metric as manipulable or durable; compute pay versus performance and family aggregate pay versus PBT.
|
||||
- [ ] Recompute board independence after deducting conflicted and long-tenured directors; check attendance, overboarding, committee composition.
|
||||
- [ ] Read every independent-director resignation reason from the last three years.
|
||||
- [ ] Record auditor identity, tenure, rotation compliance, non-audit fee share, KAMs/CAMs, CARO exceptions, ICFR findings.
|
||||
- [ ] Check for any auditor change or resignation and read the outgoing auditor's own statement (8-K Item 4.01 / ADT-3).
|
||||
- [ ] Build a 5–7 year CFO, controller, treasurer and audit-committee-chair tenure history; flag patterns, not single exits.
|
||||
- [ ] Review minority-rights machinery: anti-takeover devices, past delisting/open-offer pricing, AGM e-voting splits, board response to dissent.
|
||||
- [ ] Assess succession, bench strength, key-man covenants and family-transition dynamics.
|
||||
- [ ] Screen every insider by name against SEBI/SEC/court records; grade disclosure candour and any short-seller rebuttal.
|
||||
- [ ] Apply the sector translation before scoring: banks, insurers, REITs/InvITs, miners, PSUs and holdcos change the questions.
|
||||
- [ ] Apply hard stops where they trigger; otherwise state the explicit valuation or scoring adjustment made, and where disclosure was unavailable, say so.
|
||||
473
finance/skills/stock-analysis/references/09-risk-and-macro.md
Normal file
473
finance/skills/stock-analysis/references/09-risk-and-macro.md
Normal file
|
|
@ -0,0 +1,473 @@
|
|||
# Risk Factors: Company, Macro and External
|
||||
|
||||
Use this when: you are at Stage 7 building the bear case and invalidation triggers, or any time you need to convert a pile of "things that could go wrong" into a ranked, sized set of risks that actually changes the recommendation.
|
||||
|
||||
Most risk sections are useless because they are inventories. Twenty bullet points, each true, none sized, none ranked, none monitorable — the reader learns nothing and the analyst has bought deniability rather than insight. Your job is the opposite: identify the two or three exposures that could permanently impair the equity, quantify them against the specific business, name the observable event that would tell you they are materialising, and be explicit about everything else you deliberately excluded. The governing rule of this skill applies here as hard as anywhere: a risk metric means nothing until you know the sector and the company's own history. Net debt/EBITDA of 5x is a red alert for a consumer-goods company, unremarkable for a regulated utility, and an undefined quantity for a bank.
|
||||
|
||||
## Contents
|
||||
|
||||
- [0. The method: from risk list to sized risk map](#0-the-method-from-risk-list-to-sized-risk-map)
|
||||
- [1. Balance-sheet risk: leverage, liquidity, refinancing](#1-balance-sheet-risk-leverage-liquidity-refinancing)
|
||||
- [2. Operating leverage and cost-structure rigidity](#2-operating-leverage-and-cost-structure-rigidity)
|
||||
- [3. Concentration: customers, suppliers, geography](#3-concentration-customers-suppliers-geography)
|
||||
- [4. Supply-chain single-source dependency and business continuity](#4-supply-chain-single-source-dependency-and-business-continuity)
|
||||
- [5. FX: economic exposure and the hedging book](#5-fx-economic-exposure-and-the-hedging-book)
|
||||
- [6. Commodity and input-cost exposure](#6-commodity-and-input-cost-exposure)
|
||||
- [7. Interest-rate sensitivity](#7-interest-rate-sensitivity)
|
||||
- [8. Regulatory, policy, subsidy and tariff dependency](#8-regulatory-policy-subsidy-and-tariff-dependency)
|
||||
- [9. Litigation, antitrust and enforcement exposure mapping](#9-litigation-antitrust-and-enforcement-exposure-mapping)
|
||||
- [10. Tax disputes and transfer pricing](#10-tax-disputes-and-transfer-pricing)
|
||||
- [11. IP portfolio and IP litigation](#11-ip-portfolio-and-ip-litigation)
|
||||
- [12. Cybersecurity, data privacy and IT resilience](#12-cybersecurity-data-privacy-and-it-resilience)
|
||||
- [13. Organisational health and human capital](#13-organisational-health-and-human-capital)
|
||||
- [14. Country, political and sovereign risk](#14-country-political-and-sovereign-risk)
|
||||
- [15. Sanctions, export controls and geopolitics](#15-sanctions-export-controls-and-geopolitics)
|
||||
- [16. ESG: climate physical and transition risk, cross-sector](#16-esg-climate-physical-and-transition-risk-cross-sector)
|
||||
- [17. Technological disruption and the AI-obsolescence test](#17-technological-disruption-and-the-ai-obsolescence-test)
|
||||
- [18. Tail risk, hidden liabilities and contagion](#18-tail-risk-hidden-liabilities-and-contagion)
|
||||
- [19. Macro regime and cycle positioning: the top-down gate](#19-macro-regime-and-cycle-positioning-the-top-down-gate)
|
||||
- [20. Broad-market valuation context](#20-broad-market-valuation-context)
|
||||
- [21. Sector translation: where the standard risk lens breaks](#21-sector-translation-where-the-standard-risk-lens-breaks)
|
||||
- [22. Writing the bear case and the invalidation triggers](#22-writing-the-bear-case-and-the-invalidation-triggers)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 0. The method: from risk list to sized risk map
|
||||
|
||||
Do this **first**, then use sections 1–18 as the sweep that populates it. The output of this file is a table of at most seven risks, not a taxonomy.
|
||||
|
||||
### Step 1 — Sweep
|
||||
|
||||
Walk sections 1–18 and write one line per exposure that is *actually present* in this business. Discard generic risks that apply to all equities ("economic conditions may deteriorate"). A risk earns its place only if you can name the mechanism: what specifically happens to revenue, margin, capital or the multiple.
|
||||
|
||||
Source it from primary disclosure, not memory:
|
||||
- **US/global:** 10-K Item 1A (Risk Factors), Item 3 (Legal Proceedings), Item 1C (Cybersecurity, mandatory from FY2023), Item 7A (Quantitative and Qualitative Disclosures About Market Risk — this is where FX, rate and commodity sensitivity tables live), and the Commitments & Contingencies note. Redline Item 1A against last year's 10-K: **new or newly specific risk language is management telling you something changed.**
|
||||
- **India:** the annual report's Risk Management section and Board's Report, the contingent-liabilities note (Ind-AS 37 / Schedule III), CARO 2020 reporting — especially clause 3(vii)(b), disputed statutory dues with the forum where each is pending — related-party note, and SEBI LODR Regulation 30 material-event filings on the exchange. Concall Q&A is often the only place where a single-source dependency or a customer loss is discussed candidly.
|
||||
|
||||
### Step 2 — Size each risk
|
||||
|
||||
| Dimension | How to score | Note |
|
||||
|---|---|---|
|
||||
| **Severity (S)** | 1 = <5% of intrinsic value; 2 = 5–15%; 3 = 15–30%; 4 = 30–50%; 5 = >50%, or forces a dilutive raise / default | Size in value or EPS terms, not adjectives. "A 300bp gross-margin hit is roughly 25% of EBIT at this cost structure" beats "significant". |
|
||||
| **Likelihood (L)** over your stated horizon | 1 = <5%; 2 = 5–15%; 3 = 15–35%; 4 = 35–60%; 5 = >60% | State the horizon explicitly (typically 3 years). Probability without a horizon is meaningless. |
|
||||
| **Permanence** | Cyclical (recovers) / semi-permanent (years) / permanent impairment | The single most important column. |
|
||||
| **Lead indicator** | The specific observable that moves first | If you cannot name one, the risk is unmonitorable — that is a sizing argument, not a footnote. |
|
||||
| **Mitigant** | Hedge, insurance, contract, balance-sheet buffer — and its expiry | Hedges roll off. Always state the tenor. |
|
||||
|
||||
Expected loss = midpoint(S%) × midpoint(L%). Rank by expected loss, then apply two overrides:
|
||||
|
||||
1. **Permanence override.** A 10% chance of a permanent 60% impairment outranks a 60% chance of a temporary 15% drawdown, even though the expected losses are similar. Permanent capital loss is not recoverable by waiting; cyclical drawdown is. Rank on permanence first when the expected losses are within a factor of two.
|
||||
2. **Solvency-first ordering.** Any risk that can force a distressed equity raise, a covenant breach or a default ranks above every margin-and-multiple risk regardless of arithmetic, because equity is subordinated and the recovery is typically zero.
|
||||
|
||||
### Step 3 — Cluster correlated risks
|
||||
|
||||
Risks that share a driver are one risk, not three. A company selling discretionary goods on credit to a single cyclical end-market has one risk — the end-market — expressing itself through volume, receivable losses and covenant headroom simultaneously. Listing them separately triples the apparent diversification of the risk map and understates the tail. Explicitly ask: **which of these fire together?** Leverage, concentration and illiquidity are the classic cluster; they compound precisely when financing disappears.
|
||||
|
||||
### Step 4 — Test what is already in the price
|
||||
|
||||
A well-known risk that has already de-rated the stock is not a reason to avoid it; an unpriced risk is. Cross-check against the reverse-DCF in `06-valuation.md`: if the market-implied growth is already near zero, the cyclical-demand risk is largely priced and the *upside* asymmetry may be the more interesting finding. Say which of your top risks you believe are priced and which are not, and why you think you are seeing something the market is not.
|
||||
|
||||
### Step 5 — Publish the map
|
||||
|
||||
Report the top five to seven, with S, L, permanence, lead indicator and mitigant. Then add one line naming the risks you considered and deliberately excluded, and why. Excluding a risk explicitly is analysis; omitting it silently is not.
|
||||
|
||||
---
|
||||
|
||||
## 1. Balance-sheet risk: leverage, liquidity, refinancing
|
||||
|
||||
Full treatment is in `04-balance-sheet-and-cashflow.md`; here you are asking only one question — **can this company be forced into a transaction it does not want?** Forced asset sales, rescue rights issues and covenant renegotiations are where permanent equity loss happens.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Net debt/EBITDA | (Debt + leases − cash & liquid investments) ÷ EBITDA, on **trough** EBITDA not peak | <2x for cyclicals; <3x general industry; 4–7x normal for utilities/infra with contracted cash flows; undefined for banks and NBFCs | The peak-EBITDA denominator is the most common leverage error; a cyclical at 2.5x on peak earnings is at 5x mid-cycle |
|
||||
| EBIT interest coverage | EBIT ÷ gross interest expense | >4–5x comfortable; <2–3x fragile | Coverage fails before leverage ratios do, and coverage covenants trip first |
|
||||
| Covenant headroom | Distance to the tightest covenant, in % of the tested metric | >20–25% | Under ~15% management starts managing to the covenant instead of the business |
|
||||
| Near-term maturity cover | (Cash + undrawn **committed** facilities) ÷ debt maturing in 12–24 months | >1.5x | Solvent companies fail from illiquidity; uncommitted lines vanish when needed |
|
||||
| Weighted-average maturity | Debt-weighted years to maturity | Longer than the asset payback | Funding long-life assets with short paper (commercial paper, working-capital lines) is the classic ALM failure |
|
||||
| Structural subordination | Where the debt sits: parent vs operating subsidiary | — | Cash at a subsidiary behind subsidiary-level debt is not available to the parent's creditors, let alone shareholders |
|
||||
|
||||
Hunt for hidden debt: leases (IFRS 16 / Ind-AS 116 / ASC 842), receivables factoring and securitisation, supply-chain finance / reverse factoring parked in trade payables, PIK/toggle notes deferring cash interest, guarantees to associates and JVs, put options over minority stakes.
|
||||
|
||||
**India-specific.** Check promoter share pledging (shareholding pattern, quarterly). A pledged promoter block plus falling price creates a margin-call feedback loop that destroys the equity independently of operating performance. Also check inter-corporate deposits and guarantees to group entities in the related-party note — the leakage channel is loans out, not just sales.
|
||||
|
||||
---
|
||||
|
||||
## 2. Operating leverage and cost-structure rigidity
|
||||
|
||||
Financial leverage magnifies whatever operating leverage delivers; the two multiply. Estimate the degree of operating leverage (DOL) as %ΔEBIT ÷ %ΔRevenue over the last downturn, and sanity-check it against a fixed/variable cost split.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| DOL | %Δ EBIT ÷ %Δ revenue, measured across a real downturn | <2x flexible; >3–4x fragile | Tells you how far revenue can fall before profit disappears |
|
||||
| Fixed costs % of total | Employee cost + depreciation + rent + other fixed opex ÷ total cost | Sector-dependent; compare to peers only | Airlines, hotels, semiconductors, steel are structurally high; distribution and services are low |
|
||||
| Contribution margin | (Revenue − variable cost) ÷ revenue | — | High contribution margin plus high fixed cost = violent operating leverage both ways |
|
||||
| Breakeven utilisation | Utilisation/occupancy/load factor at which EBIT = 0 | Well below current | For hotels, airlines, cement, steel, this single number is the risk |
|
||||
|
||||
Run a −10% and −20% revenue scenario explicitly and report EBIT, interest cover and covenant headroom at each. That one table does more work than a page of prose. Note where costs genuinely cannot flex: unionised labour, take-or-pay input contracts, long leases, minimum-offtake obligations, committed capex already under contract.
|
||||
|
||||
---
|
||||
|
||||
## 3. Concentration: customers, suppliers, geography
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Top-customer revenue share | % of revenue from largest customer | <10% comfortable; >20% material; >30% is a single-point-of-failure | Loss or renegotiation by one buyer can reset earnings power overnight |
|
||||
| Top-5 / top-10 share | Cumulative | <40% / <60% typical | Also proxies bargaining power over price and payment terms |
|
||||
| Customer HHI | Σ (customer revenue share)² | — | Better than a top-1 number when the tail matters |
|
||||
| Net revenue retention (subscription) | (Starting ARR + expansion − churn − downgrade) ÷ starting ARR | >100% healthy; >110–120% strong | Concentration is tolerable if retention is proven; concentration plus churn is not |
|
||||
| Revenue/EBIT/assets by geography | Segment note | — | Demand concentration and asset concentration are different risks; separate them |
|
||||
|
||||
**Disclosure.** US 10-K requires naming any customer >10% of revenue (ASC 280). India: Ind-AS 108 requires disclosure of revenue from customers exceeding 10%, though the customer is usually unnamed — the concall and the receivables ageing are your cross-checks.
|
||||
|
||||
Escalating concerns, in order: a large customer that is itself in distress; a large customer that is vertically integrating or in-sourcing; concentration that is *rising*; dependence on a single platform, app store, distributor or channel that controls access to the customer; and — for India — dependence on government or PSU orders where payment cycles stretch and receivables become an unfunded working-capital loan (state power distribution companies are the canonical case).
|
||||
|
||||
---
|
||||
|
||||
## 4. Supply-chain single-source dependency and business continuity
|
||||
|
||||
Balance-sheet strength cannot offset a plant that cannot run. This is a physical, not financial, risk and requires a physical map.
|
||||
|
||||
**Build a dependency map.** For each critical input: number of qualified suppliers, whether the sole source is contractual or technical (a qualified-vendor lock is much harder to break than a commercial one), lead time, days of inventory held against that lead time, geographic location of the supplier's *own* production, and the availability of a second source and how long qualification would take. Semiconductor, pharma API, specialty chemical and aerospace supply chains routinely have sole-source nodes three tiers upstream that tier-1 disclosure never reveals.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Sole-sourced % of COGS | Value of inputs with no qualified alternative ÷ COGS | As low as possible; >15–20% is a live risk | The size of the production you cannot protect |
|
||||
| Inventory cover vs lead time | Days of inventory ÷ supplier lead time in days | >1.5–2x for critical parts | Thin buffers against long lead times mean any disruption stops the line |
|
||||
| Supplier geographic HHI | Concentration of sourcing by country | — | One country + one hazard (earthquake, export ban, conflict) = correlated failure |
|
||||
| Single-site revenue exposure | % of revenue produced at the largest single plant/site/data centre | <30–40% | Insurance pays for the asset, not for the lost customer relationship |
|
||||
|
||||
**Business continuity.** Ask what the recovery time would be, not just whether a plan exists: alternate site capacity, qualification time for a replacement supplier, insurance including **business-interruption and contingent business-interruption** cover, and the deductible/sub-limits. Note that BI insurance replaces gross profit for a capped period; it does not replace a customer that qualified a competitor in the meantime.
|
||||
|
||||
**India-specific.** Add pharma API and key-starting-material dependence on China, monsoon and water-availability risk for agri-linked and thermal/hydro assets, land acquisition and environmental-clearance delays for greenfield capacity, and freight/port chokepoints for exporters.
|
||||
|
||||
---
|
||||
|
||||
## 5. FX: economic exposure and the hedging book
|
||||
|
||||
The reported FX gain/loss line is the least important part of this. Analyse **economic** exposure: the mismatch between the currency of revenue, the currency of cost, and the currency of debt.
|
||||
|
||||
Build a three-row table by currency: % of revenue, % of costs, % of debt. Then:
|
||||
|
||||
| Exposure type | What it does | How to size it |
|
||||
|---|---|---|
|
||||
| Transaction | Contracted flows in a foreign currency | Net exposure per currency × expected move |
|
||||
| Translation | Foreign subsidiaries restated into the reporting currency | Watch the cumulative translation adjustment (CTA) in equity; it is non-cash but it is real value |
|
||||
| Economic / competitive | A competitor's currency devalues and undercuts you at home | Not on the balance sheet at all; the most-missed exposure |
|
||||
| Balance-sheet mismatch | Hard-currency debt against local-currency revenue | The classic emerging-market blow-up; a devaluation becomes a solvency event |
|
||||
|
||||
**Interrogate the hedging book, do not just note that one exists.** Hedge ratio, tenor, instrument (forwards vs options vs natural hedge), the rate at which existing hedges are struck versus spot, and the roll-off schedule. A company hedged 80% for 12 months at rates far better than spot is enjoying a temporary earnings subsidy that will reverse — that is a forecastable margin headwind, not a risk. Say when it lands. Hedges delay exposure; they do not remove it.
|
||||
|
||||
- **US/global:** Item 7A carries the sensitivity table (typically EPS or fair-value impact of a 10% adverse move). Check for hyperinflationary subsidiaries under IAS 29 / ASC 830.
|
||||
- **India:** the notes disclose hedged and **unhedged** foreign-currency exposure — the unhedged line is the one that matters. External commercial borrowings (ECB) carry RBI hedging expectations; IT exporters typically run long-dated USD forward books whose realised rate can differ materially from spot for several quarters.
|
||||
- **Investor level (separate decision):** for a foreign-listed holding, the investor's base-currency translation is a distinct exposure from the company's operating FX. A correct stock call in a depreciating listing currency can still lose money. Flag it; do not conflate it with company risk.
|
||||
|
||||
---
|
||||
|
||||
## 6. Commodity and input-cost exposure
|
||||
|
||||
Two different situations, and conflating them produces nonsense:
|
||||
|
||||
1. **Price taker on output** (miners, steel, oil and gas producers, commodity chemicals). The commodity price *is* the business, not a risk factor bolted onto it. The real risk is position on the industry cost curve — a first-quartile producer survives the trough that kills the fourth quartile — plus balance-sheet capacity to sit through the trough. Do not present "commodity prices may fall" as a risk; present the trough-price EBITDA and the cash cost per tonne/barrel versus the curve.
|
||||
2. **Price taker on input** (FMCG, autos, cement, packaging, food processing). Here the question is pass-through: magnitude, lag and mechanism.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Key input % of COGS | Largest single raw material or energy ÷ COGS | — | Determines whether a 20% input move is noise or the whole margin |
|
||||
| Gross-margin sensitivity | bps of gross margin per 10% input-price move, assuming no pass-through | — | Converts a commodity chart into an EPS number |
|
||||
| Pass-through lag | Months from input move to realised price change | 1 quarter good; 2–3 quarters painful | The lag, not the level, is what hits reported quarters |
|
||||
| Hedge coverage and tenor | % of next-12-month requirement hedged, and at what strike | — | Same roll-off logic as FX |
|
||||
|
||||
A useful framing: **a distributor at 4% operating margin cannot absorb a 200bp input shock — it has no margin to absorb it with.** Thin-margin, high-throughput businesses are far more input-fragile than their revenue scale suggests. Contractual escalators (common in EPC, logistics and long-term supply agreements) materially change the answer; check whether they exist, what index they track, and the reset frequency.
|
||||
|
||||
---
|
||||
|
||||
## 7. Interest-rate sensitivity
|
||||
|
||||
Rates hit three channels at once — interest expense, demand, and the discount rate applied to the multiple — which is why rate shocks de-rate long-duration equities so violently.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Floating-rate debt share | Floating debt ÷ total debt | Lower is safer in a tightening cycle; not per se bad | Direct EPS transmission |
|
||||
| EPS impact per +100bp | Floating debt × 1% × (1 − tax rate) ÷ shares | <3–5% of EPS is tolerable | Makes the exposure concrete |
|
||||
| Repricing wall | Fixed debt maturing in the next 24 months × (current market rate − coupon) | — | Cheap legacy fixed debt repricing higher is a permanent, forecastable earnings cut |
|
||||
| Duration gap (financials) | Asset duration − liability duration | Near zero for banks; deliberately positive for life insurers | See §21 — for lenders this replaces most of the above |
|
||||
| Demand beta to rates | Historical volume correlation with policy rate / mortgage rate | — | Housing, autos, consumer durables, capital goods transmit rates through demand before interest expense |
|
||||
|
||||
Long-duration equities (loss-making growth, businesses whose value sits in terminal cash flows) carry rate risk in the multiple even with zero debt. Say so; it is frequently the largest rate exposure in the name.
|
||||
|
||||
---
|
||||
|
||||
## 8. Regulatory, policy, subsidy and tariff dependency
|
||||
|
||||
The question that matters: **what fraction of current profit exists because of a policy that could be withdrawn?**
|
||||
|
||||
Map the regimes that govern the business — price controls, licensing, environmental, sector regulators, data protection, tariffs — then quantify dependency:
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Subsidy/incentive-dependent profit | Incentive income + tariff-protected margin ÷ EBIT | The lower the better; >25% is a policy-reversal bet | Distinguishes an economic business from a policy arbitrage |
|
||||
| Regulated-price revenue share | Revenue subject to administered or formula pricing | — | Caps upside and transfers the operating risk to a regulator's discretion |
|
||||
| Compliance cost / revenue | Direct compliance and licensing spend | Rising trend is the signal | Rising compliance cost is a moat for incumbents and a margin drag for everyone |
|
||||
| Tariff-exposed cost base | Imported inputs subject to duty ÷ COGS | — | Tariff changes hit COGS with almost no lag |
|
||||
|
||||
Treat a policy tailwind as a **finite-life asset with an expiry date**, and check whether the market is capitalising it into a perpetual multiple. That mispricing is common and asymmetric.
|
||||
|
||||
- **India-specific:** production-linked incentive (PLI) schemes, export incentives (RoDTEP and predecessors), anti-dumping and safeguard duties, GST rate changes, state-level capital and power subsidies, sector regulators (RBI, IRDAI, TRAI, CERC/SERCs, NPPA drug price control), and environmental clearances / NGT orders. Many mid-cap manufacturing theses are, in substance, PLI-and-anti-dumping-duty theses; name that when it is true.
|
||||
- **US/global:** IRA and similar credits, Section 232/301 tariffs, FDA/EMA approval and pricing pathways, EU CBAM (a tariff in all but name for carbon-intensive imports), sector-specific rate regulation for utilities, and the pending-rulemaking docket in the relevant agency.
|
||||
|
||||
---
|
||||
|
||||
## 9. Litigation, antitrust and enforcement exposure mapping
|
||||
|
||||
Do not summarise the legal-proceedings note. **Map** it: for each material matter record the claim, the plaintiff type, jurisdiction, stage, amount claimed, amount reserved, insurance cover, and realistic timeline.
|
||||
|
||||
| Check | What to look for |
|
||||
|---|---|
|
||||
| Reserve adequacy | Amount claimed vs amount reserved vs the disclosed "reasonably possible" range. Under ASC 450 a US filer reserves only when a loss is probable and estimable, and discloses a range for reasonably possible losses — that range is the number you should stress, not the reserve |
|
||||
| Category | Product liability and mass tort (open-ended, compounding), class actions, environmental remediation and Superfund-type liability (long-tailed, joint-and-several), employment, contract, IP (§11) |
|
||||
| Antitrust / competition | Market-share and pricing-conduct exposure; remedies can be structural (forced divestiture, mandated interoperability) rather than monetary — structural remedies impair the moat permanently, fines do not |
|
||||
| Enforcement / regulatory | Bribery and corruption (FCPA, UK Bribery Act), securities enforcement, environmental prosecution. Look for deferred prosecution agreements and monitorships — they carry ongoing cost and constrain expansion |
|
||||
| Serial pattern | Repeated settlements in the same category are a business-model signal, not bad luck |
|
||||
|
||||
**India-specific.** Material litigation must be disclosed under SEBI LODR Regulation 30 and in the offer/annual documents; the contingent-liabilities note plus CARO 3(vii)(b) gives you disputed statutory dues by forum (Commissioner Appeals, ITAT, High Court, Supreme Court). Note the timelines — a matter at Supreme Court stage may be a decade from resolution, which changes the discounting entirely. Also check National Company Law Tribunal (NCLT) proceedings, Competition Commission of India (CCI) orders, and SEBI/ED actions against promoters (governance overlap, `08-governance.md`).
|
||||
|
||||
**Sizing rule.** Compare the plausible adverse outcome to *annual earnings and to equity*, not to revenue. A single adverse judgment that exceeds two years of net profit is a solvency-adjacent event and belongs at the top of the risk map even at low probability.
|
||||
|
||||
---
|
||||
|
||||
## 10. Tax disputes and transfer pricing
|
||||
|
||||
An abnormally low effective tax rate is an earnings-quality issue *and* a risk. Both need saying.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Effective tax rate vs statutory | Tax expense ÷ PBT, compared to the domestic statutory rate | Within a few points, or explained by a **durable** reason (tax holiday with a stated expiry, R&D credit, geographic mix) | An unexplained gap normalises upward eventually and permanently cuts after-tax profit |
|
||||
| Cash tax vs book tax | Taxes paid (cash flow statement) ÷ book tax expense | Converging over 3–5 years | A persistent gap means deferred liabilities accumulating or aggressive positions |
|
||||
| Uncertain tax positions | Unrecognised tax benefits (ASC 740-10 / former FIN 48) balance and roll-forward | Small and stable vs earnings | Management's own estimate of what it might lose |
|
||||
| Disputed tax demands | India: contingent-liabilities note, by tax head and forum | Small vs equity | Indian demands are often gross and include interest and penalty; assess winnability, not just size |
|
||||
| DTA recoverability | Deferred tax assets ÷ equity, and the profit needed to use them | — | DTAs on carried-forward losses are worthless if profitability does not return; write-downs hit book value |
|
||||
|
||||
**Transfer pricing.** For any group with cross-border intercompany flows, ask where profit is booked relative to where value is created. Indicators: a subsidiary in a low-tax jurisdiction holding the IP; management fees and royalties flowing to the parent; a principal/limited-risk-distributor structure. Exposure is multiplied because a single position can be challenged by **both** tax authorities. India: Form 3CEB filings, DRP/ITAT transfer-pricing litigation, advance pricing agreements (APAs — an APA in place materially de-risks the exposure, so check for one). Global: OECD BEPS Pillar Two 15% global minimum tax progressively removes the benefit of low-tax structuring, which mechanically raises the ETR of groups that had engineered it below 15% — quantify that specifically for the name rather than mentioning it in passing.
|
||||
|
||||
---
|
||||
|
||||
## 11. IP portfolio and IP litigation
|
||||
|
||||
Where the moat is legal rather than economic, the moat has an expiry date printed on it.
|
||||
|
||||
- **Expiry mapping.** Build the revenue-weighted expiry schedule of the patents that protect the top products. For pharma this is the patent cliff and it is fully forecastable — the exclusivity date is public. Model the post-expiry revenue decline explicitly (generic entry can remove the majority of branded revenue within a year or two in an open market).
|
||||
- **Validity risk.** A granted patent is not a safe patent. In the US, inter partes review at the PTAB invalidates a meaningful share of challenged claims; Paragraph IV ANDA filings signal a generic challenge years ahead; ITC Section 337 actions can block imports outright. India: Section 3(d) of the Patents Act restricts evergreening, and the compulsory-licence provisions exist — relevant for pharma theses built on patent protection in India.
|
||||
- **Freedom to operate.** Is the company the defendant? Recurring infringement suits, non-practising-entity exposure, and royalty-bearing licences that could be renegotiated all sit on the cost line.
|
||||
- **Trade secrets and non-patented know-how.** Protected by employment law and practice rather than registration; exposure runs through employee mobility (§13) and joint-venture technology transfer (§14–15).
|
||||
- **Metrics worth carrying:** % of revenue from products losing exclusivity within five years; R&D spend versus the revenue at risk (does the pipeline replace the cliff?); litigation reserve versus the disputed royalty stream.
|
||||
|
||||
---
|
||||
|
||||
## 12. Cybersecurity, data privacy and IT resilience
|
||||
|
||||
For data-intensive, platform, financial and healthcare businesses this is now a first-order operational risk, and it is under-covered in most analyses because it produces no line item until it produces a very large one.
|
||||
|
||||
| Check | What to look for |
|
||||
|---|---|
|
||||
| Disclosure | **US:** 10-K Item 1C describes risk-management processes, board oversight and management expertise; Form 8-K Item 1.05 requires disclosure of a material incident within four business days of the materiality determination. **India:** CERT-In directions require incident reporting within six hours; the Digital Personal Data Protection Act 2023 carries penalties up to ₹250 crore per instance of certain failures, and RBI/IRDAI/SEBI impose sector-specific IT and outsourcing frameworks |
|
||||
| Incident history | Prior breaches, the disclosed cost, whether the remediation is complete, and whether the same failure mode recurs |
|
||||
| Attack-surface concentration | Single data centre or single cloud region; a critical legacy core system (core banking, policy admin, ERP) mid-migration; third-party/vendor access as the ingress path — supply-chain compromise is now a leading vector |
|
||||
| Regulatory regime | GDPR (up to 4% of global turnover), CCPA/CPRA, sectoral rules (HIPAA, PCI-DSS). Data-localisation requirements can force duplicated infrastructure |
|
||||
| Resilience | Recovery-time and recovery-point objectives, tested failover, cyber-insurance limits and exclusions (many policies exclude nation-state acts) |
|
||||
| Cost of a breach | Direct remediation + regulatory fine + customer attrition + class action, against annual EBIT |
|
||||
|
||||
The value-relevant question is **whether trust is the product**. For an exchange, a payments processor, a bank, or a healthcare data business, a serious breach damages the franchise itself, not just the P&L — that is a permanence-column-5 risk. For a cement plant it is an IT expense.
|
||||
|
||||
---
|
||||
|
||||
## 13. Organisational health and human capital
|
||||
|
||||
For people-driven businesses (IT services, consulting, asset management, specialty pharma R&D, brokerages) human capital *is* the productive asset, and it is entirely off the balance sheet.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Voluntary attrition | Voluntary exits ÷ average headcount, trailing 12m | Highly sector-specific; compare to direct peers and to the company's own history only. Indian IT services disclose it quarterly and it swings widely with the demand cycle | Rising attrition raises replacement and wage cost before it shows in margin, and signals culture or compensation stress |
|
||||
| Revenue and gross profit per employee | Revenue ÷ headcount, tracked over time | Rising | The cleanest productivity cross-check; falling revenue/employee while headcount grows is a margin warning |
|
||||
| Utilisation and bench (services) | Billable hours ÷ available hours | Sector norm; disclosed by Indian IT firms | Both too low (idle cost) and too high (burnout, delivery risk) are bad |
|
||||
| Employee cost / revenue | — | Stable or improving | A sudden jump usually means retention spending, i.e. an attrition problem being paid off |
|
||||
| Senior-management turnover | Departures of CxO / business-head level in 24 months | Low | Repeated senior exits, especially CFO, are a governance and integrity signal — see `07-forensic-red-flags.md` |
|
||||
| Key-person dependence | Is the franchise the founder, a star fund manager, a lead scientist? | — | Concentrated human capital can leave, and often takes clients with it |
|
||||
|
||||
Read Glassdoor-type employee sentiment, LinkedIn headcount trend and job postings as **alternative-data corroboration** of the reported story: hiring that contradicts a growth narrative, or a shrinking sales organisation alongside guided acceleration, is a real signal. Also check succession planning, union/collective-bargaining agreements and their renewal dates, safety and injury rates for industrial operations, and — India — contract-labour dependence and the associated regulatory exposure.
|
||||
|
||||
---
|
||||
|
||||
## 14. Country, political and sovereign risk
|
||||
|
||||
For overseas operations, split **demand exposure** (revenue from a country) from **asset exposure** (production, licences, cash trapped there). Asset exposure is far harder to exit.
|
||||
|
||||
Assess per material country: political stability and rule of law, contract enforceability and the local courts, expropriation and forced-localisation history, capital controls and repatriation restrictions, local-content mandates, currency convertibility and peg sustainability, sovereign rating and CDS spread, and the host regulator's track record with foreign owners.
|
||||
|
||||
- **Trapped cash.** Quantify it. Cash that cannot be repatriated should be haircut or excluded from a net-debt calculation and from any sum-of-the-parts valuation; treating it at face value overstates value.
|
||||
- **Sovereign linkage.** For companies whose customer is a government or state utility, sovereign stress arrives as receivables, not as headlines.
|
||||
- **Valuation.** If you add a country risk premium in the discount rate, say the size and the basis (typically the sovereign default spread, sometimes scaled for equity volatility) — and do not also haircut the cash flows for the same risk. Double-counting country risk is a common error.
|
||||
- **India-specific for inbound/outbound:** FDI sectoral caps and press-note restrictions on investment from land-bordering countries; ODI rules for Indian companies' overseas subsidiaries; and for domestically-focused names, state-level political risk (land, power tariffs, local approvals) is often more binding than national risk.
|
||||
|
||||
---
|
||||
|
||||
## 15. Sanctions, export controls and geopolitics
|
||||
|
||||
Distinct from country risk: here the risk is that a **third-country government** makes it illegal to keep doing what the company does.
|
||||
|
||||
- **Sanctions.** OFAC SDN and sectoral lists, EU and UK regimes, secondary sanctions that reach non-US parties. Screen for revenue, assets, suppliers and counterparties in sanctioned jurisdictions, and for ownership links (the 50%-ownership rule captures entities not themselves listed).
|
||||
- **Export controls.** US EAR and Entity List, the foreign direct product rule (which reaches products made abroad with US technology), ITAR for defence, and the equivalent EU/Japan/Netherlands controls that matter for semiconductor equipment. The relevant question is not only "does the company sell to a restricted party" but "could its product become controlled". Advanced computing, semiconductor equipment, and dual-use materials are the live categories.
|
||||
- **Inbound/outbound investment screening.** CFIUS and equivalents can block M&A; outbound-investment rules restrict capital into specified technology sectors. This constrains the growth path, not just current operations.
|
||||
- **Chokepoints.** Map physical supply routes: Taiwan Strait, Strait of Hormuz, Red Sea/Suez, Panama. Route disruption shows up as freight cost and inventory first.
|
||||
- **The lesson to carry:** the 2022 Russia exit showed that geopolitical exposure resolves not as a discount but as a **write-off** — assets became unsaleable and unhedgeable at any price. Geopolitical asset exposure therefore belongs in the permanence column, not the cyclical one.
|
||||
|
||||
---
|
||||
|
||||
## 16. ESG: climate physical and transition risk, cross-sector
|
||||
|
||||
Ignore aggregate ESG scores as an analytical input; rating providers disagree with each other substantially. Analyse **financially material** exposures, and note separately that ESG scores matter as a *flow* signal because mandated funds trade on them.
|
||||
|
||||
**Transition risk** (policy, technology, market shifting away from carbon):
|
||||
- Carbon cost exposure: tonnes CO₂e × plausible carbon price ÷ EBIT. Under EU ETS and CBAM this is already a cash cost for European operations and for exporters into the EU in covered sectors (cement, steel, aluminium, fertiliser, electricity, hydrogen).
|
||||
- Stranded assets: reserve life and asset life extending past plausible demand — thermal coal, refining, ICE powertrain tooling.
|
||||
- Demand-side substitution: EV penetration against ICE component makers, renewables against thermal generation, and the second-order effects (grid, storage, copper).
|
||||
- Financing and insurance exclusion: banks and insurers withdrawing from high-carbon assets raises cost of capital before it raises operating cost.
|
||||
|
||||
**Physical risk** (the part usually skipped): geolocate the major plants, mines, ports, warehouses and data centres, then check flood plain, cyclone/hurricane exposure, wildfire, heat stress on process efficiency and labour, and — critically for India — **water availability**. Water is the binding physical constraint for thermal power, cement, textiles, beverages, paper and semiconductors well before sea-level rise is.
|
||||
|
||||
**Social and governance components that convert into cash flow:** supply-chain labour practice and forced-labour import bans (which stop shipments outright), product safety and recall history, community and land-acquisition opposition to expansion, and safety incident rates for industrial operators. In India, mandatory disclosure sits in the **BRSR** (Business Responsibility and Sustainability Report) for the top 1,000 listed companies by market capitalisation, with BRSR Core assurance for the top tier — use its quantitative sections (energy, water, emissions, safety, complaints) rather than the narrative. Globally use CSRD filings, ISSB/IFRS S1–S2 reporting and the emissions notes.
|
||||
|
||||
---
|
||||
|
||||
## 17. Technological disruption and the AI-obsolescence test
|
||||
|
||||
The moat questions belong in `02-core-factors.md`; here the question is sharper and more uncomfortable.
|
||||
|
||||
**Ask explicitly: could this product or service be structurally displaced within the holding horizon?** Then answer it with evidence rather than reassurance. Diagnostic indicators: market-share trend (not level), unit-price deflation, R&D or capex intensity versus the credible attackers, the share of revenue from products less than five years old, the age of the current product cycle, and whether new entrants are appearing and being funded.
|
||||
|
||||
**The AI-obsolescence test.** For each major revenue line, classify:
|
||||
1. **Displaced** — the value delivered is the production of text, code, images, routine analysis, tier-1 support, or the arbitrage of an information asymmetry that a model now closes. Per-seat or per-hour pricing on such work is the exposed configuration; effort-based pricing collapses faster than outcome-based pricing.
|
||||
2. **Compressed** — the work survives but the labour content and therefore the price falls. Headcount-linked revenue models (staffing, traditional IT services, BPO) are structurally exposed even where demand persists.
|
||||
3. **Neutral or amplified** — the constraint is physical, regulatory, relationship-based, or a proprietary data/distribution asset the model cannot access. Here AI lowers cost and may widen the moat.
|
||||
|
||||
Then ask the harder second-order questions: does the company own **proprietary data or a distribution choke point** that makes it a beneficiary rather than a victim? Is the incumbency legal or regulatory (which AI does not dissolve)? And is the disruption arriving through the customer's budget rather than the product — for example, a customer whose own headcount falls buying fewer seats?
|
||||
|
||||
Be calibrated in both directions. Disruption narratives are over-applied at the top of hype cycles and under-applied to slow structural decline. Where you conclude "compressed", give the timeline and the observable that would confirm it — pricing per unit of work, revenue per employee, and headcount trend are the fastest tells.
|
||||
|
||||
---
|
||||
|
||||
## 18. Tail risk, hidden liabilities and contagion
|
||||
|
||||
Inventory the exposures that do not appear in EBITDA and can nonetheless consume the equity:
|
||||
|
||||
- **Unfunded pension and post-retirement obligations** versus market capitalisation. A deficit approaching a meaningful fraction of market cap makes the pension scheme a senior claim on future cash flow, and it is rate-sensitive in the opposite direction to the assets.
|
||||
- **Guarantees**, letters of comfort, and support undertakings to associates, JVs and — India especially — group companies.
|
||||
- **Derivative notionals** and counterparty exposure, especially where hedging has drifted into position-taking.
|
||||
- **Asset-retirement and decommissioning obligations** (mines, oil and gas, nuclear, landfills), which are long-dated, discounted, and highly sensitive to the discount rate and cost inflation.
|
||||
- **Warranty, recall and product-liability tails**, and environmental remediation.
|
||||
- **Variable interest entities / structured entities** and any consolidation boundary that looks designed.
|
||||
- **Insurance adequacy** against maximum probable loss, including the exclusions.
|
||||
|
||||
Then run the contagion question: which of these fire **together** with the leverage and concentration risks already identified? The failure mode that actually destroys equity is rarely one risk at full size; it is three medium risks with a common driver arriving in the same quarter while financing is closed.
|
||||
|
||||
---
|
||||
|
||||
## 19. Macro regime and cycle positioning: the top-down gate
|
||||
|
||||
Bottom-up conviction with no top-down gate produces full investment at exactly the wrong point in the cycle. This section is not a forecast; it is a positioning statement.
|
||||
|
||||
Locate the company in three cycles simultaneously — they do not move together:
|
||||
|
||||
| Cycle | What to read | Why it matters for this name |
|
||||
|---|---|---|
|
||||
| **Business cycle** | PMI (manufacturing and services), IIP, GDP nowcasts, unemployment, capacity utilisation | Determines whether cyclical earnings are near a peak or a trough. Extrapolating peak earnings is the single most expensive cyclical error |
|
||||
| **Monetary/liquidity cycle** | Policy rate and its direction, real rates, yield curve shape, central-bank balance sheet. India: RBI repo, CRR, system liquidity, credit growth | Sets the discount rate and risk appetite; long-duration equities are levered to this |
|
||||
| **Credit cycle** | Corporate credit spreads, bank lending standards, default rates, issuance windows. India: bank credit growth, NBFC funding costs and spreads, corporate bond spreads | Determines refinancing availability — the difference between a leverage risk being theoretical and being live |
|
||||
| **Capital cycle (sector)** | Industry capacity additions, capex announcements, incremental supply versus demand | Often the dominant driver for commodities, shipping, semiconductors, hotels, real estate: returns peak when supply is scarce and collapse when the new capacity lands |
|
||||
|
||||
Then position the name honestly: is this a late-cycle cyclical at peak margins being valued on peak earnings? Is it a long-duration compounder being bought into a tightening cycle? Is the sector's capital cycle turning against it? For India add the specific overlays that drive earnings: monsoon and rural demand, government capex and the fiscal stance, GST collections as an activity proxy, and FII/DII flow direction, which drives small- and mid-cap valuations far more than fundamentals over one-to-two-year windows.
|
||||
|
||||
State the conclusion as a sizing input, not a market call: *"Late-cycle for this sector; the capital cycle is adding supply through the next 24 months; that argues for a wider margin of safety and a smaller initial position rather than an avoid."*
|
||||
|
||||
---
|
||||
|
||||
## 20. Broad-market valuation context
|
||||
|
||||
A stock that is cheap against its peers can still deliver poor absolute returns if the whole market is expensive. Anchor the recommendation to an asset-class expectation:
|
||||
|
||||
| Check | How to compute | Why it matters |
|
||||
|---|---|---|
|
||||
| Index valuation vs own history | Nifty 50 / S&P 500 forward P/E and trailing P/E, and CAPE where available, versus 10- and 20-year percentiles | Frames whether a "cheap" relative call is cheap in absolute terms |
|
||||
| Equity risk premium | Index earnings yield − long government bond yield (India: 10y G-sec; US: 10y Treasury, real where possible) | When the yield gap compresses toward zero, equities are being priced for perfection and cash/bonds become a genuine competitor |
|
||||
| Market cap to GDP | India: the Buffett indicator versus its own history | Crude, cycle-sensitive, and useful only as a percentile — not a timing tool |
|
||||
| Breadth and dispersion | How much of the index return is a handful of names; small/mid-cap premium or discount versus large-cap | India's small- and mid-cap indices periodically trade at large premiums to large caps, which is a warning about the *cohort*, not any single stock |
|
||||
|
||||
Use this as a gate on aggressiveness, not as permission to avoid analysis: an expensive market raises the required margin of safety and argues for staged entry rather than a full position. Say explicitly where the market sits and how it affected your conclusion.
|
||||
|
||||
**Never turn this into personalised allocation advice.** State the market context as analytical background; asset allocation is the user's decision.
|
||||
|
||||
---
|
||||
|
||||
## 21. Sector translation: where the standard risk lens breaks
|
||||
|
||||
The ratios in sections 1–7 are undefined or inverted for several sectors. Use the sector playbook and replace the lens:
|
||||
|
||||
| Sector | What breaks | What to use instead |
|
||||
|---|---|---|
|
||||
| **Banks** | Leverage ratios are meaningless — a bank is *supposed* to run ~10:1 or more; net debt is not a concept; interest expense is a cost of goods | Asset quality (GNPA/NNPA, PCR, slippage, restructured book), credit cost versus through-cycle normal, capital adequacy versus regulatory minimum plus buffers, LCR/NSFR, deposit franchise and CASA stickiness, ALM duration gap and repricing table, concentration by borrower and sector, unsecured-book share |
|
||||
| **NBFCs / HFCs (India)** | Same as banks, plus no deposit base | Funding mix and concentration, ALM mismatch in the sub-1-year buckets (the classic Indian NBFC failure mode is a liquidity mismatch, not a credit event), bank-line dependence, co-lending and securitisation reliance |
|
||||
| **Insurers** | Revenue and EBITDA are not meaningful; float distorts everything | Reserve adequacy and development triangles, combined ratio and its trend, catastrophe accumulation and reinsurance programme (including retention and reinstatement), investment-portfolio credit and duration risk, persistency for life |
|
||||
| **REITs / InvITs** | EPS and P/E are distorted by depreciation; leverage looks high by design | Refinancing schedule against cap-rate and rate moves, LTV and interest coverage covenants, tenant concentration and WALE, lease expiry ladder, occupancy versus submarket supply, distribution coverage from AFFO |
|
||||
| **Miners and E&P** | "Commodity price risk" is not a risk factor; it is the business | Position on the cost curve, reserve life and grade trend, jurisdiction and licence security, decommissioning liability, trough-price cash flow and balance-sheet survival |
|
||||
| **Utilities / regulated infra** | High leverage is normal and financeable | Regulatory reset risk and the allowed return, counterparty (discom) receivables, tariff-formula durability, PPA tenor and renewal, capex approval |
|
||||
| **Airlines / hotels / shipping** | Extreme operating leverage makes single-year metrics useless | Breakeven load factor/occupancy, fleet or fixture commitments, EV/EBITDAR with capitalised leases, fuel/bunker hedge book and tenor |
|
||||
| **Early-stage / loss-making** | Coverage and leverage ratios are undefined | Cash runway in months, path to funding, dilution scenarios, and the terms of any structured or convertible financing |
|
||||
|
||||
---
|
||||
|
||||
## 22. Writing the bear case and the invalidation triggers
|
||||
|
||||
**The bear case must be the strongest version of the argument against the position, not a strawman you can knock down.** Standard for acceptance: someone who is short the stock would recognise their own thesis in it.
|
||||
|
||||
Construct it as a narrative, not a list. Take the top three clustered risks and connect them into one coherent story of how the investment loses money, with numbers: what happens to revenue, to margin, to the multiple, and therefore to the price. Produce a bear-case fair value the same way you produced the base case, so the downside is a figure and not an adjective. Where a credible short thesis or a published bear argument exists, engage its specific claims rather than dismissing them.
|
||||
|
||||
Then define **invalidation triggers**: specific, observable, dated events that would prove the positive thesis wrong. A good trigger is falsifiable and checkable from public disclosure.
|
||||
|
||||
| Weak trigger | Strong trigger |
|
||||
|---|---|
|
||||
| "If growth slows" | "Two consecutive quarters of volume decline with pricing flat or negative" |
|
||||
| "If margins deteriorate" | "Gross margin below X% for two quarters without an identified one-off" |
|
||||
| "If leverage rises" | "Net debt/EBITDA above the covenant threshold minus 20% headroom at any test date" |
|
||||
| "If governance worsens" | "Auditor resignation, a new qualification, CFO departure, or promoter pledge rising above X%" |
|
||||
| "If competition intensifies" | "Market share below X%, or the top customer not renewing at the [date] contract expiry" |
|
||||
|
||||
Attach a monitoring cadence: quarterly results, exchange filings, the shareholding pattern (India, quarterly), 8-K/Reg 30 events, and the two or three lead indicators identified in the risk map. Close by restating, in one line each, the top three risks with their severity, likelihood and permanence — that summary is what the reader will actually retain.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Populated the risk map by sweeping sections 1–18 against **primary disclosure** (10-K Items 1A/1C/3/7A; India: risk section, contingent liabilities, CARO 3(vii)(b), LODR filings, concall Q&A).
|
||||
- [ ] Redlined this year's risk-factor language against last year's; flagged anything newly added or newly specific.
|
||||
- [ ] Scored each risk for severity, likelihood over a stated horizon, and permanence; applied the permanence and solvency-first overrides.
|
||||
- [ ] Clustered correlated risks into single entries; named which ones fire together.
|
||||
- [ ] Ranked and reported at most seven risks, each with a named lead indicator and mitigant (with the mitigant's expiry).
|
||||
- [ ] Named the risks considered and deliberately excluded, with the reason.
|
||||
- [ ] Ran a −10% and −20% revenue scenario through EBIT, interest cover and covenant headroom.
|
||||
- [ ] Tested leverage on trough EBITDA, not peak; checked maturity wall, committed-vs-uncommitted liquidity, and structural subordination.
|
||||
- [ ] Quantified top-customer, sole-source-input and single-site revenue concentration.
|
||||
- [ ] Interrogated the hedging book: ratio, tenor, strike versus spot, roll-off date — for both FX and commodities.
|
||||
- [ ] Quantified the share of EBIT dependent on a subsidy, tariff, tax holiday or other reversible policy, and its expiry.
|
||||
- [ ] Mapped material litigation by claim, reserve, insurance and forum; compared the plausible adverse outcome to annual earnings and equity.
|
||||
- [ ] Compared ETR to statutory and cash tax to book tax; checked transfer-pricing structure, APA status, and Pillar Two impact.
|
||||
- [ ] Mapped revenue-weighted IP expiry and any live validity challenge.
|
||||
- [ ] Assessed cyber/data-privacy exposure in proportion to whether trust is the product; checked incident history and disclosure regime.
|
||||
- [ ] Checked attrition, revenue per employee, senior-management turnover and key-person dependence against the company's own history.
|
||||
- [ ] Split overseas exposure into demand versus assets; quantified trapped cash; checked sanctions, export controls and chokepoints.
|
||||
- [ ] Assessed material climate transition and physical risk, including water, using BRSR/CSRD quantitative data rather than ESG scores.
|
||||
- [ ] Ran the AI-obsolescence test on each major revenue line: displaced, compressed, or neutral/amplified — with a timeline and a tell.
|
||||
- [ ] Inventoried off-balance-sheet and contingent liabilities against market cap.
|
||||
- [ ] Positioned the name in the business, monetary, credit and sector capital cycles; stated the implication for sizing and margin of safety.
|
||||
- [ ] Anchored the call to broad-market valuation and the equity risk premium; did not turn it into allocation advice.
|
||||
- [ ] Replaced the standard risk lens with the sector-appropriate one for banks, NBFCs, insurers, REITs, miners, utilities and high-operating-leverage sectors.
|
||||
- [ ] Wrote a bear case a short-seller would recognise, priced it, and listed falsifiable invalidation triggers with a monitoring cadence.
|
||||
282
finance/skills/stock-analysis/references/10-peer-set.md
Normal file
282
finance/skills/stock-analysis/references/10-peer-set.md
Normal file
|
|
@ -0,0 +1,282 @@
|
|||
# Building a Defensible Peer Set
|
||||
|
||||
Use this when: you are at Stage 5 and about to make any statement of the form "margins are high", "the stock is cheap", "returns are best in class" — every one of those claims is a comparison, and the peer set is its denominator.
|
||||
|
||||
This skill's governing rule is that a financial metric means nothing until you know its sector and the company's own history. The peer set is the machinery that makes the first half of that rule operational. Get it wrong and you do not get a slightly noisier answer — you get a confidently inverted one, because the peer set silently determines whether every metric reads as strength or weakness. It is also the easiest place in an analysis to cheat without noticing: quietly drop the two peers that outperform, and a mediocre company becomes a compounder. So construct the set explicitly, normalise its members onto one accounting basis before comparing anything, present results as ranks within the set rather than raw absolutes, and write down who you excluded and why.
|
||||
|
||||
## Contents
|
||||
|
||||
- [1. What a true comparable is: the six axes](#1-what-a-true-comparable-is-the-six-axes)
|
||||
- [2. Operating comps vs valuation comps: two different sets](#2-operating-comps-vs-valuation-comps-two-different-sets)
|
||||
- [3. Sourcing the candidate list](#3-sourcing-the-candidate-list)
|
||||
- [4. Sizing and tiering the set](#4-sizing-and-tiering-the-set)
|
||||
- [5. Peer-set quality diagnostics](#5-peer-set-quality-diagnostics)
|
||||
- [6. Normalising peers before you compare anything](#6-normalising-peers-before-you-compare-anything)
|
||||
- [7. Presenting the comparison: percentiles, not raw numbers](#7-presenting-the-comparison-percentiles-not-raw-numbers)
|
||||
- [8. When the company has no good peers](#8-when-the-company-has-no-good-peers)
|
||||
- [9. The traps](#9-the-traps)
|
||||
- [10. Worked illustration: one company, three peer sets](#10-worked-illustration-one-company-three-peer-sets)
|
||||
- [11. Sector translation: where the peer logic changes shape](#11-sector-translation-where-the-peer-logic-changes-shape)
|
||||
- [12. Documenting the set so it can be audited](#12-documenting-the-set-so-it-can-be-audited)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 1. What a true comparable is: the six axes
|
||||
|
||||
A peer is not "a company in the same sector". A peer is a company whose economics respond to the same drivers in roughly the same way, so that a difference in a ratio is evidence about execution rather than evidence about structure. Test every candidate on all six axes below, and record the score. A candidate failing two axes badly is not a peer; it is context.
|
||||
|
||||
| Axis | What to check | Why it matters |
|
||||
|---|---|---|
|
||||
| **Same sub-sector / end market** | Not the GICS or NSE sector tag — the actual revenue mix. What does the customer buy, and why do they switch? A speciality chemicals maker selling agrochemical intermediates and one selling pharma intermediates share a sector tag and almost no demand driver. | Sector tags mix distributors with manufacturers and marketplaces with retailers. Demand cyclicality, pricing power and working-capital rhythm all come from the end market, not the tag. |
|
||||
| **Comparable business model and value-chain position** | Manufacturer vs assembler vs distributor vs franchisor vs marketplace. Owned vs asset-light. Gross vs net revenue recognition. Integration level (does the peer make its own key input?). | Margin *levels* are set by where you sit in the chain. A 4% net-margin distributor and a 25% net-margin brand owner can earn identical returns on capital. Comparing their margins ranks business models, not businesses. |
|
||||
| **Similar capital intensity** | Gross block / revenue, capex / revenue over five years, asset turnover, working-capital days. Also: does the peer lease what the subject owns (or vice versa)? | Capital intensity is the hinge between margin and return. Two companies with the same ROCE can have a 3x margin gap purely from turnover. If capital intensity differs by more than ~2x, only ROCE/ROIC comparisons survive; margin comparisons do not. |
|
||||
| **Similar geography and regulatory regime** | Where revenue is earned (not where the company is listed), tariff and price-control exposure, labour regime, tax regime, subsidy dependence, currency of revenue vs cost. | A domestic Indian formulations player and a US-generics exporter face different pricing regimes, different customer concentration, and different tax rates. Net margin and ROE differences between them are largely regime, not skill. |
|
||||
| **Similar scale** | Revenue, and separately, unit scale (plants, stores, installed base). Aim to keep the largest/smallest revenue ratio inside ~10x. | Scale buys procurement discounts, fixed-cost absorption, distribution density and cheaper capital. A ₹500 crore company benchmarked against a ₹50,000 crore one is being measured against advantages it cannot buy. Also, small caps have structurally noisier ratios. |
|
||||
| **Similar accounting framework and fiscal calendar** | IFRS (IASB), EU-endorsed IFRS, US GAAP, Ind-AS, J-GAAP, PRC GAAP — record it as a column per ticker. Then record fiscal year-end and the exact TTM window. | Ratios are not defined identically across frameworks; Ind-AS is IFRS-converged but has carve-outs, making it a third dialect. Without alignment you are ranking accounting policy and calendar luck. Section 6 handles this. |
|
||||
|
||||
**Scoring convention.** Score each axis Pass / Partial / Fail and keep the grid in the comp sheet. Any candidate with a Fail on *end market*, *value-chain position* or *capital intensity* is excluded from the core set — those three cannot be fixed by adjustment. Fails on *framework* and *fiscal calendar* are fixable: normalise (Section 6) and keep. A Fail on *scale* means keep as reference-only, marked, and never let it into a percentile calculation.
|
||||
|
||||
---
|
||||
|
||||
## 2. Operating comps vs valuation comps: two different sets
|
||||
|
||||
Do not use one list for both jobs. They answer different questions and the criteria diverge.
|
||||
|
||||
- **Operating comps** answer "is this a good business, run well?" Selection is driven by business-model similarity: same end market, same value-chain position, same capital intensity. Listing venue and valuation are irrelevant. A private-equity-owned competitor that files public accounts, or an unlisted subsidiary of a foreign group filing in India (MCA/ROC filings) is a perfectly valid operating comp even though it has no share price.
|
||||
- **Valuation comps** answer "what should this trade at?" Selection adds three requirements the operating set does not need: comparable *growth*, comparable *return on capital*, and comparable *risk/liquidity/market regime*. A company can be an excellent operating comp and a terrible valuation comp — same business, but growing at 4% instead of 20%, or listed in a market that structurally trades at half the multiple.
|
||||
|
||||
The single most common error here is importing the domestic-market multiple onto a foreign peer, or vice versa. Indian mid-caps have traded at a persistent multiple premium to global sector medians for long stretches; that premium reflects domestic liquidity, index flows and growth expectations, not accounting. If you cross markets in a valuation comp table, split the table by market and say what the cross-market spread has historically been, rather than blending into one median and calling the subject cheap or dear.
|
||||
|
||||
---
|
||||
|
||||
## 3. Sourcing the candidate list
|
||||
|
||||
Never build the list from memory or from a single screener tab. Triangulate — each source has a distinct bias, and the intersection is far more reliable than any one of them.
|
||||
|
||||
**Universal sources (best first):**
|
||||
|
||||
1. **The company's own competitive disclosure.** US: 10-K Item 1 "Competition" often names rivals directly. India: the annual report's *Management Discussion & Analysis* / "Industry Structure and Developments" section, plus the **earnings concall** — management naming a competitor unprompted in Q&A is the highest-signal peer identification available, because it reveals who they actually lose deals to.
|
||||
2. **Customer-side and channel evidence.** Who else bids for the same tenders, sits on the same distributor's shelf, appears on the same approved-vendor list, or shows up in the same RFP. This is the ground truth the tags approximate.
|
||||
3. **Credit rating agency reports** (CRISIL / ICRA / CARE / India Ratings; Moody's / S&P / Fitch). Rating rationales usually contain an explicit peer comparison table with the agency's own reasoning for the set. Free, and built by someone with a different incentive than the equity market.
|
||||
4. **Regulatory market definitions.** Competition Commission of India (CCI) merger orders, and US DOJ/FTC filings, define the "relevant market" with evidence. Where they exist for your sector, they are the most rigorously argued peer sets you will find.
|
||||
5. **Sell-side initiation notes and screener peer tabs** (screener.in, Trendlyne, Tijori for India; Bloomberg/CapIQ/FinViz/stockanalysis.com globally) — as a *starting candidate pool only*, never as the final set. These are tag-driven and inherit every classification error in Section 9.
|
||||
6. **Index and classification codes** — GICS sub-industry, NAICS/SIC (US, in the EDGAR header), NIC codes and the NSE/BSE industry indices (India). Use them to *generate* candidates and to check you have not missed anyone. Never to *validate* the set.
|
||||
7. **IPO documents.** India: the DRHP/RHP section "Basis for Offer Price" lists peers with their multiples — chosen by the issuer, so treat as a flattery-biased but informative list. US: the S-1 equivalent.
|
||||
8. **Proxy / compensation peer groups.** US: DEF 14A compensation committee peer group. India: the remuneration section of the Board's Report. Useful and rarely used — but note the bias: comp peers are systematically chosen to be *larger*, because that justifies higher pay. Mine them for names, discard the framing.
|
||||
9. **EDGAR full-text search** (efts.sec.gov) for the subject's own name: competitors frequently name the subject in their risk factors. India equivalent: full-text search of exchange filings and rating rationales.
|
||||
|
||||
**India-specific note.** Many genuine competitors are unlisted (family-owned, MNC subsidiaries). Their financials are filed with the MCA/ROC and are purchasable cheaply; industry-association data (e.g. sectoral bodies publishing volume/capacity shares) often covers them too. Excluding them because they are unlisted systematically biases the peer set toward whoever chose to list — usually the larger and more governance-conscious operators. At minimum, note the unlisted share of the market so the reader knows how much of the competitive field the comp table omits.
|
||||
|
||||
**Survivorship.** When you compare against peer *history*, include companies that were acquired, delisted or went bankrupt during the window. A five-year sector margin history built only from today's survivors overstates the sector's stability and its returns — the failures are exactly the observations that tell you what the downside looks like.
|
||||
|
||||
---
|
||||
|
||||
## 4. Sizing and tiering the set
|
||||
|
||||
**Target 5–10 core peers.** Below 4, percentile ranking is arithmetic theatre — with 3 peers a "75th percentile" is one company. Above ~12, you are almost certainly admitting members that fail an axis, and the median drifts toward the sector tag rather than the business.
|
||||
|
||||
Tier explicitly:
|
||||
|
||||
| Tier | Definition | Use |
|
||||
|---|---|---|
|
||||
| **Core** | Passes all six axes, or fails only on fixable axes (framework, fiscal calendar) and has been normalised. | The set that generates percentiles, medians and the relative verdict. |
|
||||
| **Adjacent** | Same end market, different value-chain position or materially different capital intensity. | Context and directional sanity checks. Quote individually, never blended into the core median. |
|
||||
| **Reference** | Global best-in-class operators in the same business, regardless of market or scale. | Answers "what does world-class look like structurally?" — a ceiling, not a benchmark. |
|
||||
| **Excluded** | Failed an axis unfixably, or data unusable. | Listed with the reason. This list is part of the deliverable (Section 12). |
|
||||
|
||||
If the core set has fewer than 4 members after honest filtering, do not pad it. Say so, and shift weight to own-history benchmarking (Section 8). A thin, honest peer set plus a deep own-history series beats a fat, contaminated one.
|
||||
|
||||
---
|
||||
|
||||
## 5. Peer-set quality diagnostics
|
||||
|
||||
Run these on the assembled set *before* drawing conclusions from it. They are cheap, and they catch most contamination. Ranges are indicative only — they vary by market, sector concentration and period, and a well-argued exception beats the band.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Core peer count** | Number of Tier-1 peers with usable normalised data | 5–10 | Below 4, percentiles are noise; above 12, the set has drifted to the sector tag. |
|
||||
| **Size dispersion** | Largest core peer revenue ÷ smallest | ≤ 10x (≤ 5x preferred) | Scale advantages (procurement, fixed-cost absorption, cost of capital) are structural, not managerial. Wide dispersion turns a size effect into a false quality signal. |
|
||||
| **Revenue-mix overlap** | % of the subject's revenue falling in segments the peer also serves (use segment notes / Ind-AS 108 / ASC 280) | ≥ 60% for core | Below this you are comparing two different companies that happen to share a label. |
|
||||
| **Capital-intensity spread** | max ÷ min of (gross block / revenue) or (capex / revenue, 5-yr avg) across the set | ≤ 2–3x | Beyond this, margin comparisons are invalid and only ROCE/ROIC comparisons carry meaning. |
|
||||
| **Framework homogeneity** | % of core peers on the same reporting framework, or restated onto one | 100% after normalisation; flag if <70% before | Mixed frameworks mean the ranking partly measures accounting policy. See Section 6. |
|
||||
| **Period alignment** | Max offset between peer TTM windows | ≤ 1 quarter | A one-quarter offset can place two peers on opposite sides of a commodity move or rate turn. |
|
||||
| **Gross-margin dispersion (CV)** | Standard deviation ÷ mean of gross margin across the set | < 0.30–0.40 | High dispersion in a genuinely homogeneous set almost always means *cost-classification* differences (depreciation/freight in COGS vs SG&A), not real margin differences. Treat a high CV as a data alarm, not a finding. |
|
||||
| **Median stability** | Recompute the peer median with each single peer removed in turn (leave-one-out) | No single removal should move the median more than ~10–15% relative | If dropping one name moves the median materially, your conclusion is a statement about that one company, not about the sector. |
|
||||
|
||||
---
|
||||
|
||||
## 6. Normalising peers before you compare anything
|
||||
|
||||
This is the step analysts skip and the reason most comp tables are wrong. Before any ratio goes into a table, put every member on one basis. Work down this ladder in order — each step depends on the ones above it. Record every adjustment with its note reference; an unsourced adjustment is indistinguishable from a fudge.
|
||||
|
||||
### 6.1 The adjustment ladder
|
||||
|
||||
| # | Adjustment | What to do | Consequence of skipping |
|
||||
|---|---|---|---|
|
||||
| 1 | **Reporting framework** | Record IFRS / US GAAP / Ind-AS / local GAAP per ticker from the basis-of-preparation note. For ADRs, check whether the 20-F contains a full IFRS-to-GAAP reconciliation (only some do) or is filed under IFRS with none. | EV/EBITDA, ROCE, net debt/EBITDA and gross margin are not identically defined across frameworks. You end up ranking policy. |
|
||||
| 2 | **Consolidation scope** | Identify full consolidation vs proportionate vs equity accounting. Reconcile net income attributable to owners against total net income; compute the minority share. Confirm EV adds minority interest and treats equity-accounted investments consistently across all members. Look for structured entities, ESOP trusts and off-balance-sheet JVs. | A company consolidating 100% of a 60%-owned subsidiary shows all its EBITDA but owns 60% of the earnings; if EV is not grossed up for minorities it looks artificially cheap. A peer running the same business through JVs shows almost no revenue at all. |
|
||||
| 3 | **Gross vs net revenue (principal vs agent)** | Read the IFRS 15 / ASC 606 / Ind-AS 115 revenue note. Marketplaces, travel, distribution, telecom handset bundles, ad-tech and EPC are the danger zones. Cross-check the disclosed take rate against revenue; look for a presentation change between years. | Two identical marketplaces can report revenue differing by 10x. Every P/S, EV/Sales, revenue-growth and revenue-per-employee comparison collapses. It is also a favourite way to manufacture growth with zero economic change. |
|
||||
| 4 | **Lease treatment** | Confirm IFRS 16 / Ind-AS 116 (all leases capitalised; rent becomes depreciation + interest) vs ASC 842 (operating leases stay a single operating expense). Pull ROU assets, lease liabilities, ROU depreciation, lease interest, the undiscounted maturity table and the discount rate. Then build **both** conventions across the whole set: (a) lease-neutral — add rent/operating-lease expense back out of IFRS EBITDA so everyone is post-cash-rent; (b) fully capitalised — add the PV of operating-lease commitments to net debt for US GAAP filers, and include ROU assets in capital employed for ROCE. State which convention the table uses. | IFRS 16 mechanically inflates EBITDA *and* reported debt; a US operating lease does neither. Retail, airlines, telecom, hotels and logistics are worst affected — an unadjusted EV/EBITDA screen ranks the IFRS lessee cheap and the US lessee expensive for no economic reason. Many screeners also exclude lease liabilities from "total debt". |
|
||||
| 5 | **Capitalisation policy** | Development costs: IFRS/Ind-AS *require* capitalisation once IAS 38 criteria are met; US GAAP expenses most R&D (narrow software/cloud exceptions). Pull capitalised development additions from the intangibles note and cash flow statement; compute capitalised-dev as % of total R&D. Apply the same test to software, interest and major-maintenance capitalisation. Build a common baseline — usually expensing everything. | Capitalisation simultaneously inflates EBIT, EBITDA, CFO and invested capital while deflating FCF after capex. It is the largest single source of non-comparability in pharma, software, autos and engineering, and a classic earnings-management lever. |
|
||||
| 6 | **Cost classification** | Determine what sits in COGS vs SG&A vs other income for each member: depreciation, freight and distribution, R&D, share-based comp, warranty, warehousing. Note whether the P&L is by nature (IFRS-common: material cost, employee cost, other expense) or by function. Rebuild margins at EBITDA and EBIT level where classification washes out. | Gross margin is among the least comparable metrics in existence — depreciation and freight inside COGS can cost several margin points versus an economically identical peer. Ranking a sector on gross margin reproduces exactly the single-metric error this skill forbids. |
|
||||
| 7 | **Inventory costing (US-specific)** | US GAAP permits LIFO; IFRS and Ind-AS prohibit it. Read the inventory note for the LIFO reserve and any LIFO liquidation. Restate to FIFO: add the LIFO reserve to inventory and to equity (net of tax), and adjust COGS by the change in reserve. | In inflation, LIFO depresses reported gross margin and inventory while inflating cash flow via lower tax. Uncorrected, the US filer looks less profitable and less asset-heavy than an identical IFRS peer, and asset-turnover/ROCE comparisons are meaningless. |
|
||||
| 8 | **Goodwill, PPA and acquired-intangible amortisation** | Check whether goodwill is amortised (some local GAAPs; US private-company alternative) or impairment-tested only. Pull the purchase price allocation for recent deals: goodwill vs amortisable intangibles, and assigned useful lives. Quantify acquired-intangible amortisation as a share of EBIT and show EBIT both with and without it. | An acquisitive company carries a PPA amortisation drag an organic peer does not, while goodwill inflates its capital base and depresses ROCE. Unadjusted EBIT comparisons arbitrarily penalise or flatter acquirers. |
|
||||
| 9 | **One-offs and "adjusted" figures — symmetrically** | Reconcile every adjusted number back to statutory. Tabulate add-backs by type and year: restructuring, impairment, share-based comp, acquired-intangible amortisation, litigation. Count consecutive years each "one-off" recurs, and compute cumulative add-backs as % of cumulative reported profit. Then build your own normalised series: strip asset-sale gains, insurance recoveries, one-time tax settlements, FX on debt — removing *favourable and unfavourable* items with equal rigour. In cyclicals use mid-cycle margins over a full cycle, not the latest year. | Recurring restructuring is not a one-off and SBC is a real cost of labour. Investors habitually strip losses and keep gains, biasing normalised earnings up. Applied unevenly across a peer set, this alone can reverse a ranking. |
|
||||
| 10 | **Currency and translation** | Record presentation currency, functional currency of major subsidiaries, and the translation method (current-rate: assets/liabilities at closing, P&L at average, difference to CTA; or IAS 29 restatement for hyperinflation). Convert peers using a *consistent* convention: average rate for P&L, closing rate for balance sheet, per year. Never apply today's spot rate to historical years. Check for a change of presentation currency. Look at the CTA balance and the P&L FX line. | Reported growth for a multinational can be entirely FX. Mixing rate conventions introduces errors of several percent; using spot on history destroys the growth series outright. |
|
||||
| 11 | **Constant-currency / organic growth** | Find each company's own bridge from reported to organic growth — FX, acquisitions, divestments, scope, extra trading week — or rebuild it. Verify acquisitions are excluded for a full 12-month anniversary and divestments removed from the base year too. | "Organic" is unaudited and defined differently by each company. Without a like-for-like bridge you cannot tell whether a peer's superior growth is execution, currency, or debt-funded bolt-ons — which changes what the growth is worth. |
|
||||
| 12 | **Fiscal-year offset** | Record each year-end: India and Japan typically 31 March; many US retailers use 52/53-week years ending late Jan/early Feb; others 30 June or 31 December. Where ends differ by more than a quarter, rebuild a **TTM series from quarterly data** so every member covers the same calendar window. Watch 53-week years and stub/transition periods after a year-end change. | Comparing "FY2025" across a March-end and a December-end company can offset the economic period by a full quarter — enough to put them on opposite sides of a commodity move and make one look like a share gainer when it is merely earlier in the calendar. |
|
||||
| 13 | **Tax regime** | Reconcile effective to statutory rate per member and identify drivers: tax holidays, SEZ/incentive regimes, India's optional lower corporate-tax regime, unrecognised DTAs, one-off remeasurements. Compare at EBIT/EBITDA level, or normalise every member to a sustainable rate. | Cross-border comparisons of net margin, ROE and P/E are dominated by tax regime and by temporary incentives that expire. Only pre-tax or normalised-tax comparisons isolate operating performance. |
|
||||
| 14 | **Share count and per-share integrity** | Use diluted weighted-average shares from the EPS note, not a data feed's current count. Adjust the whole history for splits, bonus issues, rights issues (theoretical ex-rights factor) and consolidations. Add options, RSUs, warrants, convertibles, ESOP-trust shares. Ensure market cap covers *all* share classes, including unlisted or dual-class lines. | Dual-class and multi-line issuers (common in India, Brazil, Korea, Europe) are routinely mis-capitalised by providers using only the listed line — understating EV and making the stock look far cheaper than it is. |
|
||||
| 15 | **Restatements and transition years** | Search filings for "restated", "reclassified", "prior period error", "IAS 8", Item 4.02 (US 8-K non-reliance). Compare last year's reported comparatives line-by-line against this year's. For each new standard (IFRS 16/15/9, ASC 842/606/326, new Ind-AS notifications) record whether transition was full retrospective or modified retrospective. **Mark the transition year on every chart.** | Providers often store originally-reported figures for old years and restated figures for recent ones, silently corrupting CAGRs. Under modified retrospective, the adoption year is a hard break and growth rates across it are arithmetic nonsense. |
|
||||
| 16 | **Provider field definitions** | For every screened metric, read the vendor's definition: does "debt" include leases, preference shares, acceptances? Is EBITDA EBIT+D&A or a vendor model? Is EPS basic/diluted/reported/adjusted? Trailing, forward or last-fiscal-year? Then hand-verify the top three and bottom three names against primary filings. | Screener errors cluster exactly where screens are most extreme — misparsed one-offs, missing quarters, stale share counts, mis-tagged currencies. The outliers your screen surfaces are disproportionately data artefacts. |
|
||||
| 17 | **Cash-flow classification** | Check where interest paid, interest received and dividends sit — IFRS permits choices that US GAAP largely fixes. Reclassify all members to one convention before comparing CFO, FCF or FCF yield. Watch supply-chain finance / reverse factoring, receivables securitisation, and capex reclassified between operating and investing. | CFO and FCF yield are not directly comparable across frameworks without this. Reverse factoring in particular converts debt into trade payables and flatters both leverage and CFO. |
|
||||
|
||||
### 6.2 Proportionality
|
||||
|
||||
Not every comparison needs all seventeen. Apply the **materiality filter**: run the adjustment if it could plausibly move the metric you are ranking on by more than the gap between the subject and the peer median. If the subject is at a 22% EBITDA margin and the median is 21%, a lease-convention difference worth 400bp decides the entire conclusion and is mandatory. If the subject is at 22% against a median of 8%, it is not.
|
||||
|
||||
In **Screen mode**, do steps 1, 4, 6 and 12 at minimum — framework, leases, cost classification and period alignment — because those four flip signs most often. In **Deep dive**, do all seventeen and show the adjustment bridge.
|
||||
|
||||
---
|
||||
|
||||
## 7. Presenting the comparison: percentiles, not raw numbers
|
||||
|
||||
Once the set is normalised, present **position within the set**, not absolutes. A raw table of numbers invites the reader (and you) to sort a column — which is precisely the single-metric ranking this skill forbids.
|
||||
|
||||
**How to build it:**
|
||||
|
||||
1. For each metric, compute the subject's **percentile rank** within the core peer set, plus the peer **median** and the **interquartile range**. Report as: `ROCE 19.4% — 80th pctile (peer median 14.1%, IQR 11–17%)`.
|
||||
2. State the **direction convention** explicitly per metric (higher is better for ROCE; lower is better for net debt/EBITDA and working-capital days). Getting one inverted quietly corrupts a composite score.
|
||||
3. Show the **dispersion**. An 80th percentile in a set where the IQR is 11–17% is a real gap. An 80th percentile in a set spanning 18.5–19.6% is a rounding difference. Percentile without spread is misleading precision.
|
||||
4. With fewer than ~6 peers, report **rank out of N** ("3rd of 6") rather than a percentile. A percentile implies a distribution you do not have.
|
||||
5. Report the subject's **own-history percentile alongside** the peer percentile — where does today's ROCE sit within the company's own 5–10 year distribution? Best-in-class-but-decaying and worst-in-class-but-improving are the two most valuable findings in the whole exercise, and only the two-axis view surfaces them.
|
||||
6. Use **medians, not means**, throughout. One outlier peer moves a mean enough to reverse a verdict; that is how a comp table lies without a single wrong number.
|
||||
7. Never collapse the peer table into a single composite score without showing the components and weights. Composite scores hide exactly the trade-offs (margin vs turnover, growth vs returns) the analysis exists to expose.
|
||||
|
||||
**Always report absolutes too, in a secondary column.** A percentile tells you the relative position; it does not tell you whether the whole sector is destroying capital. A company at the 90th percentile of an industry earning 6% ROIC against a 11% WACC is the best of a value-destroying set — a fact percentiles alone will never reveal. Cross-check every relative conclusion against the absolute ROIC-vs-WACC spread.
|
||||
|
||||
---
|
||||
|
||||
## 8. When the company has no good peers
|
||||
|
||||
Genuinely peerless companies exist: sole domestic licensees, unusual conglomerates, first-of-kind business models, monopoly infrastructure concessions. The failure mode is inventing a peer set anyway. Do not. Say plainly that no defensible peer set exists, and substitute the following, in this order.
|
||||
|
||||
**1. Own-history benchmarking becomes primary.** Build a 10-year (minimum 5-year) series for every core metric and compare the current value against the company's *own* distribution — median, range, and current percentile. Then split the variance into cycle and structure: overlay the series against the relevant cycle driver (commodity price, rate cycle, capacity utilisation, order-book/book-to-bill) and ask whether the current position is where you would expect the company to be at this point in the cycle. A company at the low end of its own margin range in a trough is normal; at the low end at a cycle peak, something structural has broken. Adjust the history for accounting-standard transitions (Section 6, item 15) or the series is not self-comparable either.
|
||||
|
||||
**2. Cross-sector comparison only via ROIC vs WACC.** This is the one comparison that survives crossing industries, because it is unit-free and measures the same economic question everywhere: *is this business earning more on invested capital than the capital costs?*
|
||||
|
||||
- Compute **ROIC = NOPAT / invested capital**, with NOPAT = EBIT × (1 − normalised tax rate), and invested capital = total debt + equity + lease liabilities − cash and non-operating assets (or, equivalently, net working capital + net fixed assets + capitalised intangibles). Use the same lease and capitalisation conventions you applied in Section 6 — the spread is only cross-sector-valid if the numerator and denominator are built consistently.
|
||||
- Compare against **WACC**, built from a local risk-free rate (India: 10-year G-Sec; US: 10-year Treasury), an equity risk premium appropriate to that market, a beta reflecting the business not just the stock, and the company's actual after-tax cost of debt.
|
||||
- Report the **spread (ROIC − WACC) and the growth rate**. Positive spread plus growth creates value; negative spread plus growth destroys it faster. That statement is true in software, cement and shipping alike.
|
||||
- Report the **duration** of the spread — how many of the last ten years was it positive, and is it widening or narrowing? A single year's spread is a cycle observation, not a quality judgement.
|
||||
|
||||
What does *not* transfer across sectors: margin, asset turnover, working-capital days, EV/EBITDA, P/E, net debt/EBITDA, gross margin. Do not use them cross-sector under any framing.
|
||||
|
||||
**3. Sub-segment peering.** A conglomerate may have no company-level peer while each segment has excellent ones. Peer each segment separately using segment disclosures (Ind-AS 108 / ASC 280), then value sum-of-the-parts with an explicit holdco discount. This is nearly always better than forcing a company-level comp.
|
||||
|
||||
**4. Value-chain and analogue peering.** Where a direct peer does not exist, an *analogue* may: a company with a different product but the same economic structure (subscription with high retention, toll-road-like annuity, franchised network with low capital intensity). Label it clearly as an analogue, use it only for structural questions (what should retention/capital intensity/incremental margin look like in a model like this?), and never for valuation multiples.
|
||||
|
||||
**5. Historical-case reasoning.** Where a business model has played out before in another market or era, use it qualitatively — what typically happened to margins as the model matured, what killed the ones that failed. Qualitative only; do not import numbers.
|
||||
|
||||
---
|
||||
|
||||
## 9. The traps
|
||||
|
||||
**Conglomerate contamination.** A diversified peer's consolidated ratios are a revenue-weighted blend of businesses with different economics. Including one in a focused peer set drags the median toward a mixture nobody actually operates. *Fix:* use the peer's segment disclosure and compare segment-to-company, or move it to Adjacent tier. Segment data is imperfect — unallocated corporate costs and transfer pricing distort it — so state that limitation rather than pretending segment EBIT is clean. The same applies in reverse: if the *subject* is diversified, do not compare its consolidated ratios to focused peers.
|
||||
|
||||
**Size mismatch.** Beyond about 10x revenue difference, you are measuring scale economics, not management. It runs both ways: large peers enjoy procurement, distribution and funding-cost advantages; small peers often show flattering ratios because a single contract or a lumpy capitalisation dominates a small base, and because they are earlier on the growth curve. *Fix:* cap dispersion, tier by size, and where scale is the explicit question, say so and compare unit economics (per store, per tonne, per MW, per seat) rather than consolidated ratios.
|
||||
|
||||
**A peer set chosen to flatter.** The most dangerous trap, because it is invisible in the output. It happens through omission far more often than through commission: the strongest competitor is "not really comparable", the weakest is "close enough". *Fixes, applied together:* (a) fix the selection criteria in writing **before** you look at any peer's numbers; (b) keep the exclusion list with reasons in the deliverable; (c) run leave-one-out on the median (Section 5); (d) run the **adversarial test** — deliberately construct the most hostile defensible peer set and see whether the conclusion survives. If the verdict flips between two defensible sets, the honest output is "the answer depends on the comparison set", with both shown. That is a real finding, not a failure. Beware of inherited sets carrying someone else's incentive: IPO-prospectus peer lists (issuer wants a high price), compensation peer groups (management wants large comparators), and company-presentation peer charts (chosen to win).
|
||||
|
||||
**Index and classification labels that mislead.** Sector tags are constructed for index and portfolio-construction purposes, not analytical ones. Recurring failures: payments and exchange businesses have been reclassified between technology and financials, moving the "sector median multiple" without any business changing; broad national indices labelled by consumption category bundle staples with hotels and tobacco; "Consumer Discretionary" spans autos and luxury and restaurants; "Industrials" spans defence primes and staffing agencies; "Diversified Financials" is not a business model. Also watch the *self-selected* tag: companies choose their own NAICS/SIC code on EDGAR and their industry classification on Indian exchanges, and they sometimes choose the one that trades at a higher multiple. *Fix:* treat every tag as a candidate generator and validate on the six axes in Section 1. If your peer set was produced by a single dropdown filter, it is not a peer set.
|
||||
|
||||
**Time-varying peer sets.** A peer that was comparable five years ago may have divested its way out of the business. When you build a multi-year peer median, verify comparability *in each year*, not just today, or you will attribute an industry-mix shift to the subject's performance.
|
||||
|
||||
**Circular valuation.** Concluding a stock is cheap because it trades below the peer median tells you nothing if the whole sector is expensive. Anchor at least one valuation leg to something absolute — a reverse DCF, a ROIC-vs-WACC spread, or the sector's own long-run multiple range — before letting relative cheapness carry a conclusion.
|
||||
|
||||
---
|
||||
|
||||
## 10. Worked illustration: one company, three peer sets
|
||||
|
||||
*Figures below are hypothetical and constructed to show the mechanism. They are not any real company's data.*
|
||||
|
||||
**The subject.** A mid-sized manufacturer of engineered components, revenue ~₹4,000 crore, Ind-AS, March year-end. Reported EBITDA margin 14%, ROCE 17%, EV/EBITDA 13x. It owns its plants; it capitalises a modest amount of development cost; roughly 70% of revenue is domestic.
|
||||
|
||||
**Peer set A — "the sector tag."** Everything in the exchange's broad "capital goods" industry index. Includes two large diversified engineering conglomerates (project EPC plus products), one pure distributor of imported components, and one asset-light design-and-outsource player. Median EBITDA margin: 9%. Median ROCE: 14%. Median EV/EBITDA: 22x.
|
||||
|
||||
> **Conclusion this set produces:** margins 500bp above the sector, returns above median, and trading at a 40% discount to the sector multiple. *A high-quality compounder, unjustifiably cheap.*
|
||||
|
||||
**Peer set B — "flattery by omission."** Four domestic peers, chosen after glancing at the numbers: three sub-scale players at ₹600–1,200 crore revenue and one loss-making turnaround. The two genuinely comparable ₹5,000–7,000 crore competitors were excluded as "not directly comparable — different product mix". Median EBITDA margin: 10%. Median ROCE: 11%.
|
||||
|
||||
> **Conclusion this set produces:** best-in-class on every operating metric. *Category leader.*
|
||||
|
||||
**Peer set C — the defensible set.** Six manufacturers of engineered components: revenue ₹2,000–9,000 crore (dispersion 4.5x), all owning their manufacturing, all majority-domestic revenue, four on Ind-AS and two on IFRS, fiscal years aligned to a common TTM window using quarterly data. Then normalised: one IFRS peer's development capitalisation expensed to match the baseline (subject margin −80bp, one peer −190bp); two peers' freight reclassified out of COGS for a like-for-like gross margin; one peer's ROU assets added to capital employed; one peer's recurring three-year "restructuring" add-back reversed into statutory EBIT; the subject's asset-sale gain in the latest year removed.
|
||||
|
||||
Post-normalisation medians: EBITDA margin 15.5%, ROCE 21%, EV/EBITDA 12x. The subject's normalised figures: EBITDA margin 13.2%, ROCE 15.5%, EV/EBITDA 13x.
|
||||
|
||||
> **Conclusion this set produces:** 2nd-lowest margin of 7, 6th of 7 on ROCE, and trading at a modest *premium* to the peer median despite weaker returns. Own-history check: ROCE at the 30th percentile of its own ten-year range, and the peer gap has widened for three consecutive years. *A share-losing operator at a full price.*
|
||||
|
||||
**What changed between A, B and C was not a single reported number.** The subject's filings are identical in all three. Set A's median was dragged down by conglomerates, a distributor and an asset-light player whose margin structures are simply different, and dragged *up* on multiple by companies with faster growth — producing a false discount. Set B was contaminated by size mismatch and selective exclusion. Set C survived the six axes and the normalisation ladder, and reversed the verdict entirely.
|
||||
|
||||
Two lessons to carry into every comp table: the largest single swing came from **who was in the set**, not from the normalisation adjustments — get selection right before you get precise. And the normalisation still mattered at the margin: without it, the subject's reported 14% margin sat above an unnormalised peer median of 13.9%, which would have read as parity rather than a deficit.
|
||||
|
||||
---
|
||||
|
||||
## 11. Sector translation: where the peer logic changes shape
|
||||
|
||||
The six axes hold everywhere, but for some sectors the metrics that go into the comparison must change entirely — the standard ratios are undefined or inverted. Read the relevant playbook in `references/sectors/` before building the table.
|
||||
|
||||
| Sector | What breaks | Peer-set implication |
|
||||
|---|---|---|
|
||||
| **Banks / NBFCs** | EBITDA, EV and net debt are meaningless; debt is raw material. Provisioning models differ (IFRS 9 / Ind-AS 109 ECL vs US CECL vs older incurred-loss). | Peer on loan-book composition (secured/unsecured, retail/corporate, tenor), funding mix (CASA, borrowings), NIM, cost-to-income, credit cost through a cycle, GNPA/NNPA and coverage, and capital adequacy. Never blend a deposit-funded bank with a wholesale-funded NBFC. |
|
||||
| **Insurers** | IFRS 17 broke the historical series outright; older embedded-value reporting is not comparable to it. Revenue is not a meaningful concept. | Peer within one reporting regime and one product mix (life vs general vs health; par vs non-par vs ULIP). Compare VNB margin, persistency, combined ratio, solvency. Mark the IFRS 17 transition year on every chart. |
|
||||
| **REITs / real estate** | IAS 40 fair-value gains flow through the IFRS income statement; US GAAP cost model does not. EPS and P/E are near-meaningless. | Peer on FFO/AFFO, NAV, occupancy, WALE, cap rates, LTV — and only within the same measurement model. Fair-value vs cost model peers are not comparable on earnings at all. |
|
||||
| **Miners / E&P** | Successful-efforts vs full-cost accounting; reserve-estimate standards differ by jurisdiction. Earnings are a commodity-price derivative. | Peer on cost curve position (all-in sustaining cost per unit), reserve life and grade, and mid-cycle rather than spot economics. Never compare a trailing-year P/E across the cycle. |
|
||||
| **Utilities / regulated infra** | Regulatory assets, allowed-return frameworks and tariff regimes dominate outcomes. | Peer only within the same regulatory regime. Compare regulated asset base growth, allowed vs achieved RoE, and collection efficiency. A cross-regime "utility peer set" compares regulators, not managements. |
|
||||
| **Conglomerates / holdcos** | No company-level peer exists by construction. | Peer each segment separately; value sum-of-the-parts; benchmark the holdco discount against other holdcos in the same market. |
|
||||
|
||||
---
|
||||
|
||||
## 12. Documenting the set so it can be audited
|
||||
|
||||
The peer table is a deliverable, not scratch work. Include this in the report:
|
||||
|
||||
1. **The selection criteria, written before selection** — the six axes with the thresholds you chose (size band, revenue-mix overlap, geography).
|
||||
2. **The inclusion table** — one row per core peer: ticker, exchange, revenue, framework, fiscal year-end, TTM window used, and a Pass/Partial/Fail on each of the six axes.
|
||||
3. **The exclusion list with reasons** — every candidate considered and rejected, and which axis it failed. This is what makes the set defensible, and it is the single strongest defence against unconscious flattery.
|
||||
4. **The adjustment log** — every normalisation applied, per company, with the note or filing reference and the quantum. A reader must be able to get from the reported number to your number.
|
||||
5. **The convention statement** — one line naming the lease convention, the capitalisation baseline, the currency rate convention, the tax normalisation and the TTM window. Everything in the table obeys it.
|
||||
6. **The as-of date and source for every price and multiple.**
|
||||
7. **A sensitivity note** — how the conclusion changes under the adversarial peer set (Section 9). If it does not change, say so; that is the strongest form the relative claim can take.
|
||||
|
||||
An undocumented comp table cannot be updated, audited or defended — and it quietly reintroduces single-metric ranking the moment anyone sorts a column.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Selection criteria written down **before** looking at any peer's numbers.
|
||||
- [ ] Every candidate scored on all six axes; end market, value-chain position and capital intensity treated as unfixable fails.
|
||||
- [ ] Candidate list triangulated from at least three independent sources (company disclosure/concall, rating agency, regulator/index/screener) — never one dropdown filter.
|
||||
- [ ] Unlisted and delisted/acquired competitors considered; survivorship bias in multi-year peer history noted (India: MCA/ROC filings).
|
||||
- [ ] 5–10 core peers; size dispersion ≤10x; tiers marked (core / adjacent / reference / excluded).
|
||||
- [ ] Operating comps and valuation comps kept as separate sets; cross-market multiple differences stated, not blended.
|
||||
- [ ] Reporting framework recorded per ticker (IFRS / US GAAP / Ind-AS / local), and normalised or flagged.
|
||||
- [ ] One lease convention applied to the whole set, stated explicitly; ROU assets in capital employed for ROCE.
|
||||
- [ ] Capitalisation policy (development, software, interest) put on a common baseline.
|
||||
- [ ] Cost classification checked (depreciation/freight/R&D/SBC in COGS vs SG&A); margins rebuilt at EBITDA/EBIT level.
|
||||
- [ ] Gross vs net revenue recognition verified before any P/S or revenue-growth comparison.
|
||||
- [ ] Consolidation scope and minority interests reconciled; EV grossed up consistently.
|
||||
- [ ] One-offs normalised **symmetrically** — gains stripped as rigorously as losses; recurring "one-offs" counted.
|
||||
- [ ] Currency converted on a consistent rate convention (average for P&L, closing for balance sheet, per year).
|
||||
- [ ] Fiscal-year offsets fixed by rebuilding TTM from quarterly data; 53-week and stub periods flagged.
|
||||
- [ ] Restatements and standard-transition years identified and marked on every chart.
|
||||
- [ ] Provider field definitions read; top and bottom screen hits hand-verified against primary filings.
|
||||
- [ ] Comparison presented as percentile/rank within the set with median and IQR — not raw sorted absolutes.
|
||||
- [ ] Own-history percentile reported alongside every peer percentile.
|
||||
- [ ] Absolute ROIC-vs-WACC spread reported so a "best of a value-destroying sector" verdict cannot hide behind percentiles.
|
||||
- [ ] Leave-one-out test run on the peer median; adversarial peer set tested and the outcome disclosed.
|
||||
- [ ] Sector-specific metric set used where standard ratios are undefined (banks, insurers, REITs, miners, utilities, holdcos).
|
||||
- [ ] Exclusion list, adjustment log, convention statement and as-of dates published with the table.
|
||||
- [ ] Indicative ranges in this file treated as starting points only — they vary by market, cycle and period, and peer/own-history evidence overrides them.
|
||||
389
finance/skills/stock-analysis/references/11-scoring-rubric.md
Normal file
389
finance/skills/stock-analysis/references/11-scoring-rubric.md
Normal file
|
|
@ -0,0 +1,389 @@
|
|||
# The Sector-Relative Multi-Factor Scoring Rubric
|
||||
|
||||
Use this when: you are at Stage 8, the analysis is done, and you need to convert a pile of evidence into a scorecard that a reader can argue with line by line.
|
||||
|
||||
A score is not a verdict; it is a disciplined summary of judgements you have already made and documented. Its value comes entirely from three properties: every metric is benchmarked against its own sector or the company's own record rather than a universal absolute, the weighting happens at the level of *categories* so no single ratio can dominate, and disqualifying findings cap or void the number instead of being averaged into it. Get any of those wrong and the composite becomes an authoritative-looking number that is confidently misleading — worse than publishing no score at all, because a number invites action in a way that prose does not.
|
||||
|
||||
## Contents
|
||||
|
||||
- [1. What the score is for, and what it is not](#1-what-the-score-is-for-and-what-it-is-not)
|
||||
- [2. The eight categories, and why category weighting beats metric weighting](#2-the-eight-categories-and-why-category-weighting-beats-metric-weighting)
|
||||
- [3. From a raw value to a sub-score: the 0–10 scale](#3-from-a-raw-value-to-a-sub-score-the-010-scale)
|
||||
- [4. Choosing the benchmark: peer percentile, own history, sector band](#4-choosing-the-benchmark-peer-percentile-own-history-sector-band)
|
||||
- [5. Sector-relative in practice: one metric, three sectors](#5-sector-relative-in-practice-one-metric-three-sectors)
|
||||
- [6. Gates: findings that cap or void rather than average](#6-gates-findings-that-cap-or-void-rather-than-average)
|
||||
- [7. Missing data, coverage, and the honesty of an incomplete score](#7-missing-data-coverage-and-the-honesty-of-an-incomplete-score)
|
||||
- [8. Adjusting the weights to the investor's objective](#8-adjusting-the-weights-to-the-investors-objective)
|
||||
- [9. Running the scorer](#9-running-the-scorer)
|
||||
- [10. Multi-segment companies](#10-multi-segment-companies)
|
||||
- [11. Worked example A — the lower-margin company scores higher](#11-worked-example-a--the-lower-margin-company-scores-higher)
|
||||
- [12. Worked example B — a gate overrides a strong scorecard](#12-worked-example-b--a-gate-overrides-a-strong-scorecard)
|
||||
- [13. Worked example C — renormalisation when data is missing](#13-worked-example-c--renormalisation-when-data-is-missing)
|
||||
- [14. Interpreting a composite](#14-interpreting-a-composite)
|
||||
- [15. The limits of scoring](#15-the-limits-of-scoring)
|
||||
- [16. What goes in the report](#16-what-goes-in-the-report)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
**Every band quoted in this file and in `scripts/benchmarks.json` is indicative only.** Benchmark levels move with market, sector, cycle, accounting regime, interest rates and period. A peer-set percentile or the company's own multi-year record overrides any absolute band printed anywhere in this skill. Treat an unedited benchmark file as a first draft and say so in the report.
|
||||
|
||||
---
|
||||
|
||||
## 1. What the score is for, and what it is not
|
||||
|
||||
The scorecard does three jobs:
|
||||
|
||||
1. **It forces completeness.** Eight categories must each be addressed or explicitly marked missing, so a great story about a moat cannot quietly substitute for a look at the balance sheet.
|
||||
2. **It makes disagreement cheap.** Because every metric shows its raw value, its benchmark band, its sub-score and its weight, a reader who thinks the ROCE band is wrong for this sector can dispute *that one line* rather than rejecting the whole analysis. This is the single most important property of the output.
|
||||
3. **It resists the single-metric reflex.** "Y has a 30% margin and X has 20%, so Y is better" is the error this whole skill exists to prevent. A category-weighted composite makes that inference structurally impossible.
|
||||
|
||||
It does **not** do these jobs, and the report must not imply otherwise: it is not a prediction of returns, not a recommendation, not a substitute for the written thesis, and not comparable across analysts who used different weights or edited the bands differently. A composite quoted without its weight vector, its coverage and its as-of date is not a reproducible number.
|
||||
|
||||
---
|
||||
|
||||
## 2. The eight categories, and why category weighting beats metric weighting
|
||||
|
||||
| Category | Default weight | What it answers |
|
||||
|---|---|---|
|
||||
| Business quality & moat | 15% | Are the economics structurally defensible, and is the advantage widening or decaying? |
|
||||
| Profitability & returns on capital | 20% | What does the business earn on the money tied up in it? |
|
||||
| Earnings quality & cash conversion | 15% | Does reported profit become cash? |
|
||||
| Balance sheet & solvency | 12% | Does it survive a bad two years? |
|
||||
| Growth & reinvestment | 12% | Is there somewhere to put the next rupee or dollar at the same return? |
|
||||
| Governance & management | 10% | Who controls the cash flows, and do minority owners get their share? |
|
||||
| Valuation & margin of safety | 10% | What does the price already assume? |
|
||||
| Risk | 6% | What could invalidate the thesis regardless of the fundamentals? |
|
||||
|
||||
**Why weight categories and not metrics.** Financial data is not evenly distributed across the things that matter. Any sector's metric set contains a dozen ways to measure profitability and perhaps three ways to measure governance, because profitability is easy to compute and governance is not. Average the metrics flat and the composite silently becomes 60–70% a profitability score with a governance rounding error attached — the exact failure this skill exists to prevent, reproduced one level up. Weighting by category fixes the *importance* of each dimension in advance, then lets each dimension use however many metrics the data supports. Within a category, individual metric weights (1.0 default, up to 2.5 for the decisive ones) express relative evidential value, not importance to the thesis.
|
||||
|
||||
**Why these eight and not more.** They are close to independent. Adding a ninth category that overlaps an existing one double-counts the same fact — a common way scorecards get quietly captured by whatever is easiest to measure.
|
||||
|
||||
---
|
||||
|
||||
## 3. From a raw value to a sub-score: the 0–10 scale
|
||||
|
||||
Each metric maps onto 0–10 through four anchors defined in the sector's benchmark entry:
|
||||
|
||||
| Anchor | Sub-score | Meaning |
|
||||
|---|---|---|
|
||||
| poor | 2.5 | Bottom of the sector's plausible range; a real weakness |
|
||||
| average | 5.0 | Unremarkable for this sector, this cycle |
|
||||
| good | 7.5 | Clearly better than the sector's middle |
|
||||
| excellent | 10.0 | Best-in-sector territory |
|
||||
|
||||
Values between anchors interpolate linearly. Beyond *excellent* the score clamps at 10 — a company twice as good as excellent is not 20/10, and letting one heroic number run away would recreate single-metric dominance. Below *poor* the score falls linearly to 0 over one further band width, so a catastrophic reading is distinguished from a merely weak one.
|
||||
|
||||
Three metric shapes exist:
|
||||
|
||||
- **higher_better / lower_better** — the usual directional metrics.
|
||||
- **band** — metrics where *both* extremes are bad, scored 10 inside the excellent interval and tapering outward. Use it for advertising spend (cutting it buys a year of margin and loses a decade of brand), R&D intensity, loan or AUM growth (a lender growing at 3x the system is buying share with credit standards), capex/depreciation, current ratio, effective tax rate, and NBFC leverage. Any metric where you would be uneasy about the top decile belongs here.
|
||||
- **judgement** — qualitative factors (moat width, capital allocation record, disclosure quality, regulatory exposure) that the analyst scores 0–10 directly. These are not a loophole. Each one requires a written justification tied to evidence, and the scorer warns when a judgement score arrives without one. A judgement metric with no note is an opinion dressed as a measurement.
|
||||
|
||||
Judgement metrics are always oriented so **10 = good for the owner**. A risk metric scored 8 means low risk, not high risk.
|
||||
|
||||
---
|
||||
|
||||
## 4. Choosing the benchmark: peer percentile, own history, sector band
|
||||
|
||||
Precedence, strongest first:
|
||||
|
||||
**1. Peer percentile.** If you have a defensible peer set (built per `references/10-peer-set.md`, normalised for accounting regime and fiscal calendar), pass the peers' values and score the company on where it sits among them. This is the best available benchmark because it controls for cycle, geography, accounting and market conditions simultaneously — all the things a shipped band cannot know. Three comparable peers is the practical minimum; below that, percentiles are noise.
|
||||
|
||||
**2. Own history.** Where the peer set is weak — a company with no true comparables, a conglomerate, a market with three listed players — score the company against its own median over 5–10 years. Anchors sit at 0.85× / 1.00× / 1.15× / 1.30× the own median for higher-is-better metrics, inverted for lower-is-better. This answers "is this company getting better or worse", which no cross-sectional band can, and it is immune to sector-wide band error. It cannot detect a company that has been consistently mediocre, so never use it alone.
|
||||
|
||||
**3. Sector band.** The shipped default in `scripts/benchmarks.json`. Adequate for a first pass and for sectors where the dispersion is well understood. Edit it whenever you have better information for the specific market and period, and say in the report that you did.
|
||||
|
||||
State the basis used for each metric in the output — the scorer prints it in the `Basis` column. A reader who does not know whether 8.3/10 came from a peer set or from a shipped default cannot evaluate the claim.
|
||||
|
||||
---
|
||||
|
||||
## 5. Sector-relative in practice: one metric, three sectors
|
||||
|
||||
The same operating margin, scored against three sectors' bands from the shipped benchmark file:
|
||||
|
||||
| Sector | poor / average / good / excellent | 4% margin scores | 20% margin scores | 30% margin scores |
|
||||
|---|---|---|---|---|
|
||||
| Retail & e-commerce | 2 / 5 / 9 / 14 | **4.2** | 10.0 | 10.0 |
|
||||
| Generic operating company | 6 / 12 / 18 / 26 | 1.7 | **8.1** | 10.0 |
|
||||
| IT services & SaaS | 10 / 18 / 25 / 35 | 0.6 | **5.7** | **8.8** |
|
||||
|
||||
A 20% margin is exceptional in retail, good-to-strong in a generic industrial, and merely average in software. Scoring all three against one band would rank business models, not businesses. The same logic applies to every metric with a sector override: ROCE (asset-light branded consumer routinely earns 40%+, telecom rarely exceeds 15%), net debt/EBITDA (a regulated utility at 4x is normal, a cyclical at 4x is fragile), P/E (30× for a staple is not the same signal as 30× for a miner at the top of the cycle), and customer concentration (structurally extreme in semiconductors, alarming in FMCG).
|
||||
|
||||
Sectors where the *entire metric set* changes rather than just the bands — because the standard ratios are undefined or inverted — are banks, NBFCs, insurers and REITs. Those use standalone sets: NIM, GNPA/NPL, PCR, CAR/CET1, ROA and cost-to-income for banks; ALM gap, credit cost and CRAR for NBFCs; VNB margin, ROEV and combined ratio for insurers; AFFO, occupancy, LTV and the cap-rate-to-cost-of-debt spread for REITs. Miners and other commodity producers keep the generic frame but score cost-curve position, reserve life and *mid-cycle* ROCE, because spot-price ROCE peaks exactly when the shares are most dangerous.
|
||||
|
||||
---
|
||||
|
||||
## 6. Gates: findings that cap or void rather than average
|
||||
|
||||
Some findings are not evidence to be weighed. They are statements that the weighing exercise does not apply.
|
||||
|
||||
**Why averaging is the wrong operation.** A composite summarises a distribution of ordinary evidence, on the implicit assumption that the numbers being summarised are *true* and that the entity being scored will *continue to exist*. A going-concern paragraph attacks the second assumption; an auditor's qualification, a forensic audit or three years of cash flow running at half of reported profit attack the first. Blending such a finding into an average produces the absurd arithmetic where a superb ROCE, a fortress balance sheet and a cheap multiple "outvote" the auditor. In a flat average, scoring a single governance metric 0/10 inside a 10%-weighted category typically moves the composite by about two tenths — visually indistinguishable from a good company having a mediocre quarter. That is precisely the error pattern behind every scorecard that rated a fraud highly right up until the disclosure.
|
||||
|
||||
So gates operate *outside* the arithmetic:
|
||||
|
||||
| Severity | Effect | Examples |
|
||||
|---|---|---|
|
||||
| **Veto** | Composite is withheld entirely; verdict reads DISQUALIFIED | Going-concern material uncertainty; adverse or disclaimer audit opinion; active fraud/forensic investigation or regulator enforcement on the accounts; payment default, rating at D, or an unwaived covenant breach |
|
||||
| **Cap 4.0–4.5** | Composite cannot exceed the cap | Qualified audit opinion; auditor resignation mid-term; **[India]** >50% of promoter holding pledged; cumulative CFO below 50% of cumulative PAT over 3+ years; material unexplained related-party leakage |
|
||||
| **Cap 5.0–6.5** | Composite cannot exceed the cap | Material restatement; opaque group structure or unconsolidated material subsidiaries; receivables/unbilled growing far faster than sales for 2+ years; **[India]** 25–50% promoter pledging or pledging rising; **[India]** exchange surveillance (ASM/GSM) or a SEBI restraint order; compromised board/audit-committee independence; serial dilution at or below book; the analyst being unable to explain the revenue model or the key accounting judgement |
|
||||
|
||||
Notes on use:
|
||||
|
||||
- **A veto is not a score of zero.** It is a refusal to score. Report the finding prominently and early, state what would resolve it (a clean subsequent audit opinion, the forensic report, a completed refinancing), and re-run afterwards.
|
||||
- **Raise a gate on evidence, not on suspicion.** Each gate in `benchmarks.json` carries an `evidence_needed` field naming the document that settles it: the auditor's report opinion paragraph, the Basis for Qualified Opinion, the quarterly shareholding pattern's encumbrance table **[India]**, an Item 4.01 or 4.02 8-K **[US]**, the rating rationale, the five-year cash flow statements.
|
||||
- **Distinguish "cleared" from "not checked".** The scorer prints "GATES: none raised" either way. Say in the report which gate checks you actually performed. An unperformed check is not a pass.
|
||||
- **The cap is a ceiling, not a target.** A capped composite of 4.0 does not mean the business is worth 4.0; it means no evidence can raise it above 4.0 while the finding stands.
|
||||
|
||||
---
|
||||
|
||||
## 7. Missing data, coverage, and the honesty of an incomplete score
|
||||
|
||||
Missing metrics are **dropped**, and the remaining category weights are **renormalised to 1.0**. They are never scored as zero.
|
||||
|
||||
Scoring absence as failure would mean an under-disclosing company reads as fraudulent and a fully transparent one reads as risky, which inverts the signal you actually want. It also creates a perverse incentive in the analysis itself: the easiest way to raise a score would be to stop looking for hard-to-find numbers.
|
||||
|
||||
What is reported instead:
|
||||
|
||||
- **Category coverage** — the share of total category weight carried by categories with at least one scored metric.
|
||||
- **Metric coverage** — the share of the sector's total metric weight actually scored.
|
||||
- **Per-category coverage** — so a category resting on one metric out of eight is visible as fragile.
|
||||
|
||||
**The confidence rule.** The composite is marked `** INDICATIVE ONLY **` when category coverage falls below the floor (default 70%) *or* when any category weighted 10% or more has no data at all. Both conditions matter: 85% coverage with governance entirely empty is not a scoreable company, it is a company you have not finished analysing. When the composite is indicative, say so in the report, name the empty categories, and state what data would close the gap.
|
||||
|
||||
Where you have a strong qualitative view but no metrics — governance on a company with three years of listed history, say — you may set a category score directly. The output marks it `[MANUAL OVERRIDE]`. Use this sparingly and always with a written justification; it is the one place where the scorecard's discipline can be bypassed.
|
||||
|
||||
---
|
||||
|
||||
## 8. Adjusting the weights to the investor's objective
|
||||
|
||||
Weights are a statement of what the reader cares about, not a fact about the company. Change them deliberately, and always print them.
|
||||
|
||||
| Preset | Bias | Use when |
|
||||
|---|---|---|
|
||||
| `default` | Balanced quality and price | No stated objective |
|
||||
| `quality_compounder` | Business quality 22%, profitability 22%, valuation 5% | Long-hold compounding mandate that accepts a full price for durability |
|
||||
| `deep_value` | Valuation 24%, balance sheet 20%, growth 4% | Asset- or price-led approach where survival and discount dominate |
|
||||
| `income` | Earnings quality 22%, balance sheet 20%, growth 4% | Distribution durability is the objective |
|
||||
| `forensic` | Earnings quality 26%, governance 26%, valuation 4% | A company you already distrust — use *with* the gates, never instead of them |
|
||||
|
||||
Sector defaults already shift weights where the sector demands it: banks and NBFCs raise balance sheet to 18–20% because capital adequacy and ALM decide survival; holdcos raise governance to 20% because the entire question is whether subsidiary value ever reaches the parent's shareholders; shipping and metals raise valuation and balance sheet because entry price and leverage, not operating skill, decide cyclical outcomes; IT/SaaS raises growth and business quality and cuts balance sheet to 6% because a net-cash software company's solvency is not the interesting question.
|
||||
|
||||
Two rules: **change weights before you see the scores, not after** (post-hoc weight tuning is how a scorecard becomes a rationalisation), and **run the alternative weighting as a sensitivity**. If a company scores 7.4 on quality-compounder weights and 5.1 on deep-value weights, that gap *is* the finding — it says the thesis depends entirely on paying up for durability, and the report should say so.
|
||||
|
||||
---
|
||||
|
||||
## 9. Running the scorer
|
||||
|
||||
`scripts/score.py` does the arithmetic. Standard library only.
|
||||
|
||||
```
|
||||
python scripts/score.py --example > input.json # starter input, edit it
|
||||
python scripts/score.py input.json # readable scorecard
|
||||
python scripts/score.py input.json --json # same numbers, machine-readable
|
||||
python scripts/score.py --list-sectors # the 21 sector keys
|
||||
python scripts/score.py --explain # the method
|
||||
python scripts/score.py --explain gates # every gate, with evidence required
|
||||
python scripts/score.py --explain roce_pct --sector fmcg-consumer
|
||||
python scripts/score.py input.json --preset deep_value --weight risk=0.10
|
||||
python scripts/score.py --example-segments > seg.json # multi-segment starter file
|
||||
python scripts/score.py seg.json --segment-detail # per-segment + blended group score
|
||||
```
|
||||
|
||||
Input is one JSON object: `sector`, `metrics`, optional `flags`, optional `overrides`. A metric value can be a bare number or an object carrying the workings:
|
||||
|
||||
```json
|
||||
"roce_pct": {"value": 22.4, "source": "FY25 AR consolidated", "period": "FY25"},
|
||||
"sssg_pct": {"value": 9.0, "peer_values": [3.0, 4.5, 6.0, 11.0]},
|
||||
"net_debt_to_ebitda": {"value": 0.4, "own_history": [1.8, 1.4, 1.1, 0.7], "basis": "own_history"}
|
||||
```
|
||||
|
||||
Overrides let you narrow a band to your actual peer set (`overrides.thresholds`), change category weights, disable a metric that does not apply, or set a category score by hand. An unknown sector key falls back to the generic set with a loud warning — never accept that silently for a bank, NBFC, insurer or REIT, where the generic ratios are meaningless.
|
||||
|
||||
---
|
||||
|
||||
## 10. Multi-segment companies
|
||||
|
||||
A single sector key is wrong for a company that is 55% EPC, 30% IT services and 15% lending. Scoring the group against one set of bands benchmarks 45% of its profit against a sector it does not operate in, which is the precise error this whole rubric exists to prevent, committed one level up. The routing rules in `references/sectors/_index.md` (Step 3) already require per-segment analysis and sum-of-the-parts; the scorer makes it mechanical.
|
||||
|
||||
**Input shape.** Add a top-level `segments` array. It is auto-detected — with no `segments` key nothing about single-sector behaviour changes.
|
||||
|
||||
```json
|
||||
{
|
||||
"company": "Example Diversified Industries Ltd",
|
||||
"as_of": "2026-07-22",
|
||||
"basis": "consolidated",
|
||||
"weight_basis": "ebit",
|
||||
"flags": {"opaque_structure": {"present": true, "evidence": "FY25 AR note 41"}},
|
||||
"segments": [
|
||||
{"name": "EPC & capital goods", "sector": "infra-capitalgoods",
|
||||
"ebit": 12000, "capital_employed": 60000, "revenue": 150000,
|
||||
"metrics": {"roce_pct": 16.5, "…": 0},
|
||||
"flags": {"receivables_blowout": {"present": true, "evidence": "…"}}},
|
||||
{"name": "Lending arm", "sector": "nbfc",
|
||||
"ebit": 4000, "capital_employed": 28000, "revenue": 9000,
|
||||
"metrics": {"roa_pct": 2.2, "nim_pct": 6.4, "…": 0}}
|
||||
]
|
||||
}
|
||||
```
|
||||
|
||||
`python scripts/score.py --example-segments` prints a complete, runnable three-segment example (industrial + IT + lending). Each segment is scored against **its own sector's** metric set, bands and category weights by the ordinary scoring machinery; only the finished composites are blended. Raw metrics are never blended across segments — an NBFC's NIM and an EPC contractor's order book are not commensurable quantities, and averaging them would be arithmetic without meaning.
|
||||
|
||||
**Weighting.** `--weight-basis {ebit,capital_employed,revenue,explicit}`, default `ebit`, overriding `weight_basis` in the input. EBIT is the default because profit mix, not revenue mix, is what the owner owns: a trading segment can be 60% of revenue and 5% of profit. `explicit` reads a `weight` field per segment and normalises it to 1.0.
|
||||
|
||||
**The negative-EBIT rule.** If *any* segment has EBIT at or below zero, EBIT weighting is refused outright and the scorer falls back automatically — to `capital_employed` if every segment supplies it, otherwise `revenue`, otherwise equal weights — printing a prominent warning that names the fallback and the reason. This is not fussiness about a rounding case. A negative weight does not down-weight a bad segment, it *subtracts* that segment's score from the group, so a business burning capital would mechanically raise the composite; and where losses roughly offset profits the denominator approaches zero and every weight explodes. The same positivity test is applied to whichever basis is chosen, so a zero or negative capital-employed figure is rejected the same way. Weights are never negative and never sum to zero.
|
||||
|
||||
**A loss-making segment is reported prominently regardless of its weight**, flagged on its own row in the summary table and again in the diagnostics with the capital employed there and that capital's share of the group. The analytical point is that a segment destroying capital deserves attention in proportion to the *capital at risk*, not to the small weight a loss earns it in a blend. Say what capital sits there, what the group intends to do with it, and how the composite moves if it is closed, sold or fixed.
|
||||
|
||||
**Diagnostics printed with every segmented run:**
|
||||
|
||||
- **Concentration.** The mix, and the largest segment's share. Above 60%, that segment's playbook governs the analysis and the others are adjustments to it. If *no* segment reaches 40%, the company is a de facto conglomerate: run it through `references/sectors/holdco-assetmgr.md` as well and value it sum-of-the-parts.
|
||||
- **Mixed families.** When the group spans a financial sector (`banks`, `nbfc`, `insurance`) and a non-financial one, the consolidated ratios are contaminated and must not be read at face value. The lending arm's loan-book growth sits inside consolidated operating cash flow, so group cash conversion measures disbursement rather than cash generation; and the lender's borrowings — its raw material, not its financing — inflate group debt/equity and net debt/EBITDA to levels that mean nothing. Use each segment's own metric set, and value the group sum-of-the-parts.
|
||||
- **Valuation caveat**, printed every time: the blended composite scores quality across the group. It is not a valuation and it never substitutes for SOTP. Never apply a single consolidated multiple across a mixed group.
|
||||
|
||||
**Gates.** Group-level `flags` cap or void the blended composite exactly as in single-sector mode. Segment-level `flags` bind that segment's own composite, and the capped number is what enters the blend — segment caps are not applied twice. But **any segment gate of severity `veto` escalates to the group** and withholds the group composite. A fraud investigation, an adverse opinion or a going-concern paragraph in one segment does not stay inside that segment: the numbers are consolidated into the group accounts, certified by the same auditor and signed by the same board. Blending a vetoed segment away at 15% weight would convert "we cannot believe these accounts" into a two-tenths deduction. The output labels every raised gate with the level it came from.
|
||||
|
||||
**Coverage** is reported per segment and as a weighted group figure, checked against the same `--min-coverage` floor. A segment that could not be scored at all is dropped from the blend and the remaining weights renormalised, with the share of the weight base actually covered printed alongside the number — the same discipline applied to missing metrics, one level up.
|
||||
|
||||
`--segment-detail` prints each segment's full scorecard below the group summary, which is what you reproduce in the report when a segment is doing the work. `--json` emits the group blend with every segment's complete result nested inside.
|
||||
|
||||
**The blended composite never replaces sum-of-the-parts valuation.** It is a quality summary, weighted by size. Valuation of a mixed group is done segment by segment on each family's own basis — the lender on P/B or P/adjusted book, the brand on EV/EBITDA or P/E, property on NAV — net of holding-company debt and capitalised holdco costs, with a holding discount where the segments are not separately monetisable. A group composite quoted as though it were a valuation conclusion is a misuse of the tool.
|
||||
|
||||
---
|
||||
|
||||
## 11. Worked example A — the lower-margin company scores higher
|
||||
|
||||
Two illustrative companies, generic and hypothetical. **Distributor A**: 4% operating margin, negative working capital, high asset turnover. **Software B**: 30% operating margin, net cash, heavy stock-based compensation. Scored on their own sectors' bands and sector weights.
|
||||
|
||||
Metric level, showing the margin metric doing the opposite of what the composite does:
|
||||
|
||||
| Metric | Distributor A | sub-score | Software B | sub-score |
|
||||
|---|---|---|---|---|
|
||||
| Operating margin | 4.0% (band 2/5/9/14) | 4.2 | 30% (band 10/18/25/35) | **8.8** |
|
||||
| ROCE | 26% (band 8/14/22/35) | **8.3** | 24% (band 15/25/35/50) | 4.8 |
|
||||
| ROIIC | 24% | **9.0** | 13% | 5.4 |
|
||||
| Cash conversion cycle | −20 days | 9.0 | +40 days | 7.1 |
|
||||
| FCF margin | 2.0% | 3.8 | 12.0% | **8.9** |
|
||||
| SBC / revenue | not applicable | — | 14% | 4.4 |
|
||||
| 5y dilution | +2% | 7.8 | +18% | 4.7 |
|
||||
| P/E | 34× (band 90/60/40/28) | **8.8** | 42× (band 60/38/25/17) | 4.6 |
|
||||
| Reverse-DCF growth gap | +1.0pp | 6.7 | +4.0pp | 4.5 |
|
||||
|
||||
Category level:
|
||||
|
||||
| Category | Distributor A | Software B |
|
||||
|---|---|---|
|
||||
| Business quality & moat | 5.9 | 5.6 |
|
||||
| Profitability & returns | 7.6 | 7.4 |
|
||||
| Earnings quality | 6.9 | 6.5 |
|
||||
| Balance sheet | 9.2 | 9.4 |
|
||||
| Growth & reinvestment | 8.0 | 5.8 |
|
||||
| Governance | 7.9 | 7.2 |
|
||||
| Valuation | 6.4 | 4.3 |
|
||||
| Risk | 5.5 | 5.8 |
|
||||
| **Composite** | **7.14 — Above average** | **6.30 — Average** |
|
||||
|
||||
Software B wins the margin comparison decisively — 8.8 against 4.2 — and still loses the composite. Three mechanisms produce that, and each is a real economic fact rather than a scoring artefact:
|
||||
|
||||
1. **Sector-relative bands neutralise the structural margin gap.** 4% is strong for a distributor; 30% is unremarkable for software. The margin difference was never information about quality.
|
||||
2. **Return on capital, not margin, is what compounds.** Distributor A converts a thin margin into 26% ROCE through turnover and supplier-funded working capital, and reinvests at 24% incremental returns. Software B's high margin sits on a capital base that earns less than its sector's median, and its incremental returns are half the distributor's.
|
||||
3. **Per-share and price effects.** Software B's 18% five-year dilution and 14% SBC mean the owner captures less of the profit than the income statement implies, and it is priced 4pp of growth above what the analysis can defend.
|
||||
|
||||
If Distributor A's numbers had come with three years of CFO at half of PAT, the cash-flow divergence gate would cap the composite at 4.0 and the entire comparison above would become irrelevant. That is the intended behaviour.
|
||||
|
||||
---
|
||||
|
||||
## 12. Worked example B — a gate overrides a strong scorecard
|
||||
|
||||
An illustrative company scores well across the board: profitability 8.1, earnings quality 7.4, balance sheet 7.9, growth 7.7, valuation 6.2 — a pre-gate composite around 7.6, comfortably "Strong". Then the shareholding pattern shows 62% of promoter holding pledged, up from 31% two years ago.
|
||||
|
||||
- **Flat-average treatment**: promoter pledging is one governance metric at weight 2.0 inside a 10% category. Scoring it 0 instead of 10 moves the composite by 0.22 — from roughly 7.6 to roughly 7.4. The reader sees a strong company with a slight governance blemish.
|
||||
- **Gate treatment**: composite capped at 4.0, printed with the pre-gate figure alongside so nothing is hidden, and the finding stated in the report's opening section.
|
||||
|
||||
The gate treatment is right because the mechanism is not gradual. Heavy pledging couples the share price to control: a price fall triggers margin calls, invoked shares and forced selling, which drives a further fall. That reflexive loop is independent of business quality and has repeatedly destroyed operationally sound companies. Averaging spreads a step-function risk across a continuous scale and makes it disappear. **[India]** This gate is India-specific in its data source — the encumbrance table in the quarterly shareholding pattern — but the underlying risk exists anywhere insiders have pledged control blocks; in US filings, look for margin-loan disclosure in the proxy and Schedule 13D/G footnotes.
|
||||
|
||||
---
|
||||
|
||||
## 13. Worked example C — renormalisation when data is missing
|
||||
|
||||
A recently listed company: no governance history worth scoring and no reliable multi-year growth series. Six of eight categories carry data.
|
||||
|
||||
| Category | Default weight | Score | Renormalised weight | Contribution |
|
||||
|---|---|---|---|---|
|
||||
| Business quality | 15% | 6.0 | 19.2% | 1.15 |
|
||||
| Profitability | 20% | 8.0 | 25.6% | 2.05 |
|
||||
| Earnings quality | 15% | 7.0 | 19.2% | 1.34 |
|
||||
| Balance sheet | 12% | 6.5 | 15.4% | 1.00 |
|
||||
| Growth | 12% | *no data* | dropped | — |
|
||||
| Governance | 10% | *no data* | dropped | — |
|
||||
| Valuation | 10% | 5.0 | 12.8% | 0.64 |
|
||||
| Risk | 6% | 6.0 | 7.7% | 0.46 |
|
||||
| **Composite** | | | **100%** | **6.65 — INDICATIVE ONLY** |
|
||||
|
||||
Category coverage is 78%, above the 70% floor — but governance carries a default weight of 10%, so the empty-major-category rule fires and the composite is marked indicative. That is the correct outcome: a company whose governance you have not assessed is not a 6.65, it is an unfinished analysis.
|
||||
|
||||
Had the two missing categories been scored 0 instead of dropped, the composite would read **5.19** — a full grade lower, and lower purely because of what the analyst could not find. The report would then be describing the state of the data as though it were the state of the business.
|
||||
|
||||
---
|
||||
|
||||
## 14. Interpreting a composite
|
||||
|
||||
| Composite | Grade | What it means in practice |
|
||||
|---|---|---|
|
||||
| 8.5–10 | Exceptional | Best-in-sector on most dimensions with a defensible price. Rare; re-check the inputs and the peer set before believing it. |
|
||||
| 7.5–8.4 | Strong | Clear quality with no disqualifying weakness. Usually the top of a realistic range. |
|
||||
| 6.5–7.4 | Above average | Good business, or a very good business at a full price. Read the category spread. |
|
||||
| 5.5–6.4 | Average | Unremarkable, or excellent on some dimensions and weak on others. The spread matters more than the number. |
|
||||
| 4.5–5.4 | Below average | Something material is wrong — usually returns, cash conversion or price. |
|
||||
| 3.5–4.4 | Weak | Multiple failing dimensions, or a gate has capped it. |
|
||||
| Below 3.5 | Poor | Avoid, or a special-situation case that this framework does not price. |
|
||||
| Withheld | Disqualified | A veto gate is open. Not a low score — a refusal to score. |
|
||||
|
||||
**Read the spread, not just the level.** A 6.5 built from eight scores between 6 and 7 is a genuinely average business. A 6.5 built from profitability 9.5 and governance 3.0 is a completely different object: a strong business with a control problem, where the whole question is whether the owner ever receives the economics. The composite is identical; the investment case is not. Always show the category table, never the composite alone.
|
||||
|
||||
**Small differences are noise.** The difference between 6.8 and 7.1 is well inside the error of the bands, the estimates and the judgement scores. Treat gaps under roughly 0.5 as indistinguishable. Never rank a portfolio by composite to two decimals.
|
||||
|
||||
---
|
||||
|
||||
## 15. The limits of scoring
|
||||
|
||||
- **Garbage in, precision out.** The scorecard cannot detect a fabricated input. It will format a hallucinated ROCE to two decimals as readily as a sourced one. This is why `SKILL.md` treats "never invent a number" as the primary non-negotiable.
|
||||
- **It cannot see what is not in it.** A technology shift that will halve demand in four years, a founder about to leave, a regulator drafting a rule — none of these appear unless you encode them in a judgement metric. The judgement metrics exist precisely as the entry point for what the ratios cannot see, and they are the least reliable part of the output.
|
||||
- **Bands embed a period.** Thresholds calibrated in a low-rate decade misprice a high-rate one, especially in valuation and balance sheet. Re-derive from live peer data whenever you can.
|
||||
- **Judgement scores can be reverse-engineered.** If you set the moat score after seeing that the composite came out lower than your prior, you have written down your prior with extra steps. Score judgement metrics before running the totals.
|
||||
- **It is not comparable across analysts.** Different weights, edited bands and different judgement calibration make two composites incomparable unless both scorecards are shown in full.
|
||||
- **It does not price a special situation.** Deep cyclicals at cycle extremes, turnarounds, pre-revenue businesses, holdcos trading at persistent discounts and companies in restructuring need `references/13-situations.md`, not a composite. Score them if it helps structure the evidence, but lead the report with the situation logic.
|
||||
- **It says nothing about fit.** Position size, horizon, tax, currency and concentration are the user's, not the company's. Producing analysis, not advice, is a hard boundary of this skill.
|
||||
|
||||
---
|
||||
|
||||
## 16. What goes in the report
|
||||
|
||||
Reproduce, at minimum:
|
||||
|
||||
1. The **composite and grade**, with the pre-gate figure shown separately if a gate bound.
|
||||
2. The **category table** — score, default weight, renormalised weight, contribution.
|
||||
3. The **per-metric workings** for at least the decisive metrics — raw value, basis used (peer / own history / sector band), the band itself, the sub-score.
|
||||
4. The **weights and preset** used, and any band overrides you applied, with the reason.
|
||||
5. **Coverage**, the missing categories, and what data would close the gap.
|
||||
6. **Gates**: which were raised, which were checked and cleared, and which were not checked.
|
||||
7. The line that every scorecard needs: bands are indicative, peer and own-history comparison override them, and this is research rather than advice.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Sector key chosen deliberately; banks / NBFCs / insurers / REITs use their standalone metric sets, never the generic one.
|
||||
- [ ] Multi-segment companies scored per segment against each segment's own sector, weighted by profit (or by capital employed where a segment loses money), with the blend never presented as a valuation — SOTP done separately.
|
||||
- [ ] Bands edited to the actual peer set and period where better data exists, and the edit disclosed.
|
||||
- [ ] Peer percentile used where 3+ comparable peers exist; own-history basis used where the peer set is weak.
|
||||
- [ ] Every judgement metric carries a written, evidence-linked justification.
|
||||
- [ ] Judgement scores set before the totals were computed, not after.
|
||||
- [ ] Category weights chosen for the stated objective, fixed before scoring, and printed in the output.
|
||||
- [ ] Sensitivity run under a second weight preset; any large gap reported as a finding.
|
||||
- [ ] All gate checks explicitly performed; raised gates evidenced by a named document, not an impression.
|
||||
- [ ] Veto findings reported early and prominently, with the composite withheld rather than lowered.
|
||||
- [ ] Missing metrics dropped and weights renormalised — never scored as zero.
|
||||
- [ ] Coverage reported; composite marked INDICATIVE ONLY below the floor or with an empty major category.
|
||||
- [ ] Category spread discussed, not just the composite level.
|
||||
- [ ] Differences under ~0.5 treated as noise; no ranking to two decimals.
|
||||
- [ ] Every number in the input carries a source and a period; nothing recalled or estimated without being labelled.
|
||||
- [ ] Report states plainly that this is research, not licensed financial advice.
|
||||
410
finance/skills/stock-analysis/references/12-report-template.md
Normal file
410
finance/skills/stock-analysis/references/12-report-template.md
Normal file
|
|
@ -0,0 +1,410 @@
|
|||
# Report Template — Final Output Structure
|
||||
|
||||
Use this when: you have finished the analytical work and are assembling the deliverable, or you are in screen mode and need the short form.
|
||||
|
||||
The report is where an analysis either survives contact with a reader or dies. A reader who stops after one screen must still receive the verdict, the reasoning that drives it, and the risks that would break it. Every number you print must carry its provenance — the reader cannot check your arithmetic if they cannot find your inputs, and an unsourced number is indistinguishable from a hallucinated one. Structure is not decoration here: the ordering below front-loads conclusions and pushes supporting evidence down, so the report degrades gracefully when read partially.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Non-negotiables](#non-negotiables)
|
||||
- [Formatting conventions](#formatting-conventions)
|
||||
- [Full report template](#full-report-template)
|
||||
- [Short-form variant (screen mode)](#short-form-variant-screen-mode)
|
||||
- [Common failure modes in report writing](#common-failure-modes-in-report-writing)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Non-negotiables
|
||||
|
||||
Four rules govern every section below. They come from the skill's governing principle: a metric is meaningless until you know its sector and the company's own history.
|
||||
|
||||
1. **Never print a bare metric.** Every ratio appears with at least one of: the peer-set median, the company's own 3–5 year range, or both. `ROCE 18%` is noise. `ROCE 18% (own 5y range 12–19%; peer median 15%)` is information.
|
||||
2. **Never rank on a single metric.** If the report contains a ranking of any kind, it must be composite and the weights must be visible.
|
||||
3. **State the sector playbook explicitly** and say which standard ratios you suppressed because they are undefined or inverted for that sector. Banks, insurers, REITs, miners, and asset-heavy utilities all break at least one default ratio. Silence here reads as an error.
|
||||
4. **Mark every estimate.** A derived, interpolated, annualised, or eyeballed number is not the same class of object as a reported one, and the reader must be able to tell at a glance.
|
||||
|
||||
---
|
||||
|
||||
## Formatting conventions
|
||||
|
||||
Apply these consistently. They are what make the report auditable.
|
||||
|
||||
### Showing a number with its source
|
||||
|
||||
Inline form, for prose and table cells:
|
||||
|
||||
```
|
||||
₹4,812 cr [FY25 AR, Consolidated P&L, p.142]
|
||||
18.4% [computed: EBIT 4,812 / (TA 34,100 − CL 8,050), FY25 AR]
|
||||
$2.31 [10-K FY2024, Item 8, Consolidated Statements of Operations]
|
||||
```
|
||||
|
||||
Rules:
|
||||
- Source goes in square brackets immediately after the number.
|
||||
- For computed metrics, show the formula with the inputs, not just the label. The reader must be able to reproduce the arithmetic without opening the filing.
|
||||
- Cite the statement and page/item, not just the document. "FY25 AR" alone is a weak citation; "FY25 AR, Note 32, p.211" is a real one.
|
||||
- India: cite the Annual Report, the quarterly results filing (NSE/BSE intimation), the concall transcript with date, or the CARO annexure by clause number. Say `Consolidated` or `Standalone` every time — they are different companies for analytical purposes.
|
||||
- US/global: cite 10-K/10-Q by Item number, 20-F for foreign private issuers, 8-K by item, or the EDGAR accession number. Say GAAP or IFRS where the treatment differs (leases, R&D capitalisation, goodwill amortisation).
|
||||
- Prices and market cap must carry an as-of date and time zone or close reference: `₹1,842 (NSE close, 2026-07-21)`.
|
||||
|
||||
### Marking estimates
|
||||
|
||||
Use a consistent marker and define it once in the Data Quality Note.
|
||||
|
||||
```
|
||||
~14.2% (est.) — derived or approximated by the analyst
|
||||
[E] — compact marker for table cells
|
||||
[TTM] — trailing twelve months, stitched from quarterlies; say which quarters
|
||||
[Ann.] — annualised from a partial period; state the periods used
|
||||
[Adj.] — analyst adjustment applied; the adjustment must be described in a footnote
|
||||
```
|
||||
|
||||
Every `[E]` and `[Adj.]` needs a one-line note saying how it was produced and what would change if the assumption were wrong. An unexplained adjustment is worse than no adjustment, because it launders judgement as fact.
|
||||
|
||||
### Showing not-available
|
||||
|
||||
Never leave a cell blank and never substitute zero. Blank reads as an oversight; zero is an actual claim and usually a false one.
|
||||
|
||||
```
|
||||
n/a — undefined for sector (e.g. inventory turnover for a bank)
|
||||
n/a — not disclosed (company does not report the line)
|
||||
n/a — not comparable (peer uses different segment definition or accounting basis)
|
||||
n/d — not yet determined (you ran out of time or data; say so honestly)
|
||||
```
|
||||
|
||||
`n/a — undefined for sector` is a *finding*, not a gap. It tells the reader you applied the right playbook.
|
||||
|
||||
### Units and scale
|
||||
|
||||
- India: state crore vs lakh explicitly in the column header (`₹ cr`). Never mix. If the source reports in ₹ lakh and you converted, mark the conversion.
|
||||
- US/global: state `$ m` or `$ bn` in the header. For non-USD reporters, state the presentation currency and never silently FX-convert; if you do convert, give the rate and its date.
|
||||
- Per-share figures: state whether basic or diluted, and whether the share count is period-end or weighted average.
|
||||
- Percentages: one decimal is enough. More implies precision the inputs do not support.
|
||||
|
||||
---
|
||||
|
||||
## Full report template
|
||||
|
||||
Copy the structure below. Replace bracketed guidance; delete guidance lines that do not apply, but never delete a required heading — if a section is empty, say why.
|
||||
|
||||
````markdown
|
||||
# [Company Name] ([EXCHANGE:TICKER]) — Equity Analysis
|
||||
|
||||
**Analysis date:** [YYYY-MM-DD]
|
||||
**Basis:** [Consolidated / Standalone] · [Ind-AS / US GAAP / IFRS] · [Currency and scale, e.g. ₹ crore]
|
||||
**Latest reported period:** [FY25 (Mar-2025) audited / Q1 FY26 (Jun-2025) unaudited / FY2024 10-K]
|
||||
**Price reference:** [₹X,XXX, NSE close YYYY-MM-DD] · **Market cap:** [₹X,XXX cr] · **EV:** [₹X,XXX cr]
|
||||
|
||||
---
|
||||
|
||||
## RECENCY STATEMENT
|
||||
Most recent reported period incorporated: <e.g. Q1 FY27, published DD-MMM-YYYY>
|
||||
Events checked through: <date>
|
||||
Material events since the last full-year data: <list, or "none found">
|
||||
Any invalidation trigger already tripped at the time of writing: <yes + which, or no>
|
||||
|
||||
## DATA QUALITY NOTE
|
||||
|
||||
> Read this before the numbers. It defines what the numbers are.
|
||||
|
||||
| Item | Statement |
|
||||
|---|---|
|
||||
| **Primary sources** | [Annual Report FY25 (audited); Q4 FY25 results intimation; FY25 concall transcript dated YYYY-MM-DD; CARO FY25. / 10-K FY2024 filed YYYY-MM-DD; 10-Q Q1 FY2025; latest DEF 14A.] |
|
||||
| **Secondary sources** | [Aggregator screens used, and for what — typically peer medians and price data only. Name them. Never source a fundamental from an aggregator when the filing is available.] |
|
||||
| **As-of dates** | Financials as of [date]. Prices as of [date]. Shareholding as of [date]. Any data older than the latest reported period is flagged inline. |
|
||||
| **Consolidated vs standalone** | [Consolidated used throughout. Standalone differs materially in X because of Y — noted where relevant.] India: if subsidiaries or JVs are significant, consolidated is the only honest basis; say so. |
|
||||
| **Currency and units** | [All figures in ₹ crore unless stated. 1 crore = 10 million. / All figures in $ millions.] [FX conversions, if any, at rate R as of date D.] |
|
||||
| **What is estimated** | [List every `[E]`, `[TTM]`, `[Ann.]`, `[Adj.]` used, with the method in one line each. If none, say "No analyst estimates used."] |
|
||||
| **What is missing** | [Segment-level capital employed not disclosed; related-party pricing not disclosed; peer X has not filed FY25 so FY24 used and marked. Be specific — "some data gaps" is not a disclosure.] |
|
||||
| **Known accounting comparability issues** | [Lease treatment differs between company and peer set; one peer capitalises development cost, company expenses it; company changed revenue recognition in FY24. State the direction of the distortion.] |
|
||||
|
||||
---
|
||||
|
||||
## VERDICT AND KEY RISKS
|
||||
|
||||
**Verdict:** [One sentence. State the assessment and the confidence level. Example: "Fundamentally sound compounder trading at a valuation that already prices in continued mid-teens growth — quality high, margin of safety thin. Confidence: moderate-high on fundamentals, low on the valuation call."]
|
||||
|
||||
**Composite score:** [X.X / 10] · **Sector playbook applied:** [name] · **Situation flags:** [none / cyclical peak / turnaround / holding company / recent large acquisition]
|
||||
|
||||
**The three things that matter most:**
|
||||
1. [Claim in one line, with the single number that supports it and its source.]
|
||||
2. [ditto]
|
||||
3. [ditto]
|
||||
|
||||
**Key risks — what could break this:**
|
||||
1. **[Risk name]** — [What happens, how likely, what it does to earnings or the balance sheet. Quantify where you can: "a 200bps gross margin reversion takes EPS down ~18%".]
|
||||
2. **[Risk name]** — [ditto]
|
||||
3. **[Risk name]** — [ditto]
|
||||
|
||||
**What would change the verdict:** [One line pointing forward to the invalidation triggers section.]
|
||||
|
||||
---
|
||||
|
||||
## 1. The Business — What It Sells and How It Makes Money
|
||||
|
||||
[3–6 short paragraphs, or a table plus prose. Cover:]
|
||||
|
||||
- **What the customer actually buys, and why they pick this company.** Write it so a non-specialist understands. If you cannot explain the revenue model in three sentences, you do not yet understand it, and that is itself a finding.
|
||||
- **Revenue build:** volume × price, or subscribers × ARPU, or AUM × yield, or loans × NIM. Show the actual driver decomposition, not just "sells products".
|
||||
- **Revenue mix** by segment / geography / channel, with the share of each and the growth rate of each. Mix shift is usually the story.
|
||||
- **Where the money leaks out:** the cost structure and its fixed/variable split, because that determines operating leverage in both directions.
|
||||
- **The cash conversion path:** how long between spending and collecting. Working capital intensity is a structural feature of the business model, not an accounting detail.
|
||||
|
||||
---
|
||||
|
||||
## 2. Sector Classification and Playbook Applied
|
||||
|
||||
**Sector / sub-sector:** [e.g. Specialty chemicals — CDMO-weighted / Private sector bank / Equity REIT — office]
|
||||
**Playbook applied:** [name of the playbook reference used]
|
||||
|
||||
**Why this classification:** [One paragraph. Companies often sit between sectors, or report under one classification while economically belonging to another. Justify the choice — it determines which metrics are valid.]
|
||||
|
||||
**Metrics suppressed as undefined or inverted for this sector:**
|
||||
|
||||
| Standard metric | Status here | Why |
|
||||
|---|---|---|
|
||||
| [e.g. Debt/Equity] | n/a — inverted | [For a bank, leverage is the business; assess CAR / CET1 instead.] |
|
||||
| [e.g. EV/EBITDA] | n/a — undefined | [EV is not meaningful for a lender; deposits are operating liabilities, not debt.] |
|
||||
| [e.g. Operating margin] | Use with care | [For a REIT, use NOI margin and FFO; depreciation is non-economic on appreciating property.] |
|
||||
|
||||
**Sector-specific metrics used instead:** [List, with the reason each is the right substitute.]
|
||||
|
||||
---
|
||||
|
||||
## 3. Situation Classification
|
||||
|
||||
[Include only if a special situation applies; if none, write "No special situation identified — analysed as a going-concern operating business."]
|
||||
|
||||
**Situation:** [Cyclical at/near peak · Turnaround · Deep value / possible value trap · Holding company with cross-holdings · Post-large-acquisition · Recent IPO with short history · Regulatory overhang · Promoter-pledge stress (India)]
|
||||
|
||||
**Implications for the analysis:** [What this changes. A cyclical at peak earnings must not be valued on peak-cycle P/E. A holding company needs a sum-of-the-parts with an explicit holdco discount. A turnaround needs the balance sheet weighted above the P&L. Say what you did differently.]
|
||||
|
||||
---
|
||||
|
||||
## 4. Scorecard
|
||||
|
||||
| Category | Score /10 | Weight | Weighted | One-line rationale |
|
||||
|---|---:|---:|---:|---|
|
||||
| Business quality & moat | [X] | [XX%] | [X.XX] | [why] |
|
||||
| Earnings quality | [X] | [XX%] | [X.XX] | [why] |
|
||||
| Balance sheet strength | [X] | [XX%] | [X.XX] | [why] |
|
||||
| Cash flow | [X] | [XX%] | [X.XX] | [why] |
|
||||
| Returns on capital | [X] | [XX%] | [X.XX] | [why] |
|
||||
| Growth (quality & durability) | [X] | [XX%] | [X.XX] | [why] |
|
||||
| Management & governance | [X] | [XX%] | [X.XX] | [why] |
|
||||
| Valuation | [X] | [XX%] | [X.XX] | [why] |
|
||||
| **Composite** | | **100%** | **[X.X]** | |
|
||||
|
||||
**Weighting rationale:** [State why these weights, for this sector. Weights are not universal — balance sheet carries more weight for a lender or a leveraged cyclical; moat and returns carry more for an asset-light compounder. If you used the playbook's default weights, say so.]
|
||||
|
||||
**Scoring basis:** [Scores are relative to the peer set and the company's own history, not to an absolute ideal. State the anchor: "6 = peer median, 8 = clearly above peer set on that dimension, 3 = materially below."]
|
||||
|
||||
---
|
||||
|
||||
## 5. Core Analysis by Dimension
|
||||
|
||||
Each sub-section: the numbers with sources, the trend over 3–5 years, the peer comparison, then the interpretation. Interpretation last — do not lead with your conclusion inside the evidence section.
|
||||
|
||||
### 5.1 Business Quality and Moat
|
||||
|
||||
[Evidence for or against durable advantage: pricing power (price realisation vs input cost trend), customer retention/churn, switching costs, scale economics, regulatory or distribution barriers, brand. The test of a moat is not that returns are high today; it is that returns stayed high while competitors were trying. Show the multi-year return series, not the latest year.]
|
||||
|
||||
### 5.2 Earnings Quality
|
||||
|
||||
| Metric | Value | Own 3–5y range | Peer median | Read |
|
||||
|---|---|---|---|---|
|
||||
| CFO / EBITDA | | | | |
|
||||
| CFO / PAT | | | | |
|
||||
| Accruals ratio | | | | |
|
||||
| Other income / PBT | | | | |
|
||||
| Effective tax rate vs statutory | | | | |
|
||||
| Receivable days vs revenue growth | | | | |
|
||||
|
||||
[Interpretation. Flag: profit growing faster than cash, one-off gains embedded in "operating" profit, tax rate anomalies, revenue recognition changes, capitalised costs that peers expense. India: check related-party transactions and CARO clauses on statutory dues and fund diversion. US: check non-GAAP-to-GAAP reconciliation and what is being added back.]
|
||||
|
||||
### 5.3 Balance Sheet
|
||||
|
||||
[Leverage, maturity profile, covenants, contingent liabilities, off-balance-sheet items, working capital structure, goodwill and intangibles as % of net worth. India-specific: promoter pledge %, inter-corporate deposits, guarantees to group entities. For lenders: capital adequacy, NPA/stage-3 movement, provision coverage, restructured book — not D/E.]
|
||||
|
||||
### 5.4 Cash Flow
|
||||
|
||||
[CFO, capex split maintenance vs growth (say how you split it and that the split is an estimate), FCF, FCF conversion, and the multi-year cumulative FCF vs cumulative PAT. The cumulative test over a full cycle is more informative than any single year.]
|
||||
|
||||
### 5.5 Returns on Capital
|
||||
|
||||
[ROCE, ROIC, ROE with DuPont decomposition, incremental ROIC on capital deployed over the last 3–5 years. Incremental return is the one that predicts the future; the average return reflects capital deployed long ago. State the capital base definition you used and be consistent with peers.]
|
||||
|
||||
### 5.6 Growth
|
||||
|
||||
[Revenue, EBITDA, PAT, and per-share growth over 3, 5, 10 years where available. Separate organic from acquired. Separate volume from price. Growth funded by equity issuance is not the same as growth funded by internal cash — show share count over the period. State reinvestment rate and whether growth is consistent with returns × reinvestment.]
|
||||
|
||||
---
|
||||
|
||||
## 6. Peer Comparison
|
||||
|
||||
**Peer set:** [List each peer with ticker.]
|
||||
|
||||
**Why these peers:** [Justify explicitly. Peers must match on business model and economics, not merely on sector label or index membership. State what you excluded and why — "excluded X because 60% of its revenue is a different business", "excluded Y because it reports under a different accounting basis and is not comparable on margins". A weak peer set silently invalidates the entire relative analysis, so this justification is load-bearing.]
|
||||
|
||||
**Comparability caveats:** [Size differences, geographic mix, accounting differences, fiscal year-end differences. If fiscal years differ, say which periods you aligned.]
|
||||
|
||||
| Metric | [Company] | [Peer 1] | [Peer 2] | [Peer 3] | Peer median |
|
||||
|---|---:|---:|---:|---:|---:|
|
||||
| Revenue [₹ cr / $ m] | | | | | |
|
||||
| Revenue CAGR 5y | | | | | |
|
||||
| Gross margin | | | | | |
|
||||
| EBITDA margin | | | | | |
|
||||
| ROCE | | | | | |
|
||||
| ROE | | | | | |
|
||||
| Net debt / EBITDA | | | | | |
|
||||
| CFO / EBITDA | | | | | |
|
||||
| [Sector-specific metric] | | | | | |
|
||||
| [Valuation multiple, sector-appropriate] | | | | | |
|
||||
|
||||
[Two or three paragraphs of interpretation. Where the company sits above or below the median, say whether the gap is structural (business model, mix, geography) or performance-driven. A structural gap should not be scored as skill; a performance gap should not be assumed permanent.]
|
||||
|
||||
---
|
||||
|
||||
## 7. Valuation
|
||||
|
||||
**Method used:** [e.g. Reverse-DCF cross-checked against EV/EBIT vs own history and peers]
|
||||
**Why this method for this sector:** [Justify. DCF for predictable cash generators; P/B and ROE-based for lenders; FFO/AFFO and cap-rate/NAV for REITs; EV/EBITDA through-cycle or P/NAV and reserve life for miners; EV/Sales only where margins are not yet representative and only with an explicit path to margin. Say why the default multiple is inappropriate if you rejected it.]
|
||||
|
||||
**Key inputs:** [Discount rate and how derived; terminal growth; forecast horizon; tax rate; capex and working-capital assumptions. Every input gets a one-line justification. Do not import a discount rate as a convention — state the risk-free rate used and its date.]
|
||||
|
||||
### Reverse-DCF: what the current price implies
|
||||
|
||||
[State it as a sentence a reader can argue with: "At ₹X, the market is embedding roughly Y% revenue growth for N years at Z% EBIT margin, with terminal growth of T%." Then judge it: is that within what this company has actually delivered, and within what the industry can support? The reverse-DCF is the most useful single output in this section because it converts a price into a testable claim about the future.]
|
||||
|
||||
**Historical reality check:** [Company's actual 5y and 10y delivery against the implied figures. Industry-wide growth ceiling if relevant.]
|
||||
|
||||
### Scenario table
|
||||
|
||||
| Scenario | Probability | Key assumptions | Implied value / share | vs current price |
|
||||
|---|---:|---|---:|---:|
|
||||
| Bear | [XX%] | [growth, margin, multiple — 1 line] | [₹X] | [−XX%] |
|
||||
| Base | [XX%] | | [₹X] | [±XX%] |
|
||||
| Bull | [XX%] | | [₹X] | [+XX%] |
|
||||
| **Probability-weighted** | 100% | | **[₹X]** | **[±XX%]** |
|
||||
|
||||
[Probabilities are judgements — say so, and say what drives them. A scenario table with a bear case that is not genuinely bad is a marketing document, not an analysis. The bear case should assume things you consider unlikely but possible, not merely slower growth.]
|
||||
|
||||
---
|
||||
|
||||
## 8. Red Flags and Governance
|
||||
|
||||
[List findings, most severe first. If none material, write "No material red flags identified" and list what you specifically checked — a clean bill of health is only credible if the reader knows what was tested.]
|
||||
|
||||
| # | Flag | Severity | Evidence [source] | Why it matters |
|
||||
|---|---|---|---|---|
|
||||
| 1 | | High/Med/Low | | |
|
||||
|
||||
Checked and clear: [enumerate — auditor changes, qualified opinions, related-party transactions, promoter pledge, contingent liabilities, frequent restatements, CFO/CEO turnover, dilution history, capital allocation record, subsidiary opacity.]
|
||||
|
||||
**India-specific checks:** promoter shareholding trend and pledge %, auditor resignation history, CARO qualifications by clause, SEBI/exchange actions, related-party approvals, royalty payments to promoter entities, concall responsiveness (management that dodges the same question across three calls is telling you something).
|
||||
|
||||
**US/global checks:** auditor opinion and any ICFR material weakness, restatements, insider selling patterns in Form 4, share-based compensation as % of revenue and its treatment in non-GAAP, buybacks at valuation peaks, board independence and related-party disclosures in the proxy.
|
||||
|
||||
---
|
||||
|
||||
## 9. The Bear Case
|
||||
|
||||
[Write this as though you were short the stock and had to defend the position. Not a list of generic risks — a coherent argument that the thesis is wrong. Cover: what the bull is assuming that may not hold; what would cause returns to mean-revert; which competitive, regulatory, technological, or cyclical force is being underweighted; and where the accounting could be flattering the picture.
|
||||
|
||||
If you cannot write a bear case that you find at least partly persuasive, you have not done the work. Say explicitly what the strongest counter-argument is and why you still net out where you do — but do not defang the bear case in the process of writing it. Keep the rebuttal separate and after.]
|
||||
|
||||
**Strongest counter to the bear case:** [1–2 sentences, kept honest.]
|
||||
|
||||
---
|
||||
|
||||
## 10. Thesis-Invalidation Triggers
|
||||
|
||||
Specific, observable, and time-bound. "Deteriorating fundamentals" is not a trigger. A trigger is something a reader could check in a future filing and get an unambiguous yes/no.
|
||||
|
||||
| # | Trigger | Where to observe | By when | Action if hit |
|
||||
|---|---|---|---|---|
|
||||
| 1 | [Gross margin falls below XX% for two consecutive quarters] | [Quarterly results / 10-Q] | [Q2–Q3 FY27] | [Revisit — thesis rests on pricing power] |
|
||||
| 2 | [Net debt/EBITDA exceeds X.Xx] | [Half-year balance sheet] | [FY27] | [Downgrade balance sheet score] |
|
||||
| 3 | [Promoter pledge rises above X% / insider selling exceeds X% of holding] | [Shareholding pattern / Form 4] | [any quarter] | [Governance re-review] |
|
||||
| 4 | [Incremental ROIC on last 3y capital deployed falls below cost of capital] | [Annual report] | [FY27 AR] | [Growth is value-destructive — thesis fails] |
|
||||
| 5 | [Named competitor / regulatory event] | [specific source] | [date] | [specific] |
|
||||
|
||||
---
|
||||
|
||||
## Disclaimer
|
||||
|
||||
This document is research and analysis produced for informational purposes only. It is **not** investment advice, not a recommendation to buy, sell, or hold any security, and not a personalised financial recommendation. The author is not a licensed or registered investment adviser. Figures are drawn from public filings and may contain errors of transcription, computation, or interpretation; items marked as estimates are the analyst's own and are not company-reported. Past performance and historical financial trends do not predict future results. Any investment decision is the reader's own responsibility and should be made in consultation with a licensed financial adviser who is aware of the reader's circumstances, objectives, and risk tolerance.
|
||||
````
|
||||
|
||||
---
|
||||
|
||||
## Short-form variant (screen mode)
|
||||
|
||||
Use when the task is a screen across many names, a first-pass triage, or the user asked for a quick read. Target roughly one screen per company. Same provenance and estimate-marking rules apply — brevity does not license unsourced numbers.
|
||||
|
||||
````markdown
|
||||
### [Company] ([EXCHANGE:TICKER]) — [Sector] — [Score X.X/10]
|
||||
|
||||
**Basis:** [Consolidated, Ind-AS, ₹ cr] · **Data:** [FY25 AR + Q1 FY26] · **Price:** [₹X,XXX, DD-MMM-YY]
|
||||
|
||||
**Verdict:** [One or two sentences: what it is, what the composite score reflects, and the single biggest reason to look closer or pass.]
|
||||
|
||||
| | Value | Peer med. | Own 5y |
|
||||
|---|---:|---:|---:|
|
||||
| [Sector-appropriate metric 1] | | | |
|
||||
| [Sector-appropriate metric 2] | | | |
|
||||
| [Sector-appropriate metric 3] | | | |
|
||||
| [Valuation multiple] | | | |
|
||||
|
||||
**Playbook:** [name] · **Suppressed:** [metrics n/a for this sector]
|
||||
**For:** [strongest positive, one line, with a number]
|
||||
**Against:** [strongest negative, one line, with a number]
|
||||
**Flags:** [red flags, or "none found in screen-level checks"]
|
||||
**Data gaps:** [what a full analysis would need to resolve]
|
||||
**Next step:** [Full analysis / Pass — reason / Watch, revisit at trigger X]
|
||||
|
||||
*Screen-level output. Research, not investment advice. Not a licensed adviser.*
|
||||
````
|
||||
|
||||
Screen mode carries an extra obligation: state that it is screen-level. A short report that reads like a full one invites the reader to over-trust it.
|
||||
|
||||
---
|
||||
|
||||
## Common failure modes in report writing
|
||||
|
||||
Each of these has changed a reader's conclusion in the wrong direction. Check for them before finalising.
|
||||
|
||||
- **The buried verdict.** Conclusion appears on the third screen after a wall of tables. Fix: front-load.
|
||||
- **The decorative bear case.** Bear section says "valuation could de-rate" and nothing else. Fix: make it argue.
|
||||
- **The metric without a home.** A ratio printed with no peer or history anchor. Fix: never print bare.
|
||||
- **The wrong-sector ratio.** D/E for a bank, P/E for a loss-making biotech, EV/EBITDA for a REIT. Fix: run the suppression table.
|
||||
- **The laundered estimate.** An analyst assumption formatted identically to a reported figure. Fix: mark everything.
|
||||
- **The convenient peer set.** Peers chosen so the company looks good. Fix: justify the set before you compute, not after you see the results.
|
||||
- **The unfalsifiable trigger.** "Watch for execution issues." Fix: name the line item, the threshold, and the filing.
|
||||
- **The precision illusion.** A DCF output to two decimals off inputs that are ±30%. Fix: round to the precision the inputs support and show the scenario range, not a point estimate.
|
||||
- **The peak-cycle P/E.** Cyclical valued on peak earnings and a peak multiple. Fix: the situation classification section exists to catch this.
|
||||
- **Score without weights.** Composite presented as authoritative with weighting hidden. Fix: weights and rationale always visible.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Title carries company, ticker, date, basis (consolidated/standalone), accounting standard, currency and scale.
|
||||
- [ ] Data Quality Note appears before any number and lists sources, as-of dates, estimates, and gaps.
|
||||
- [ ] Verdict, composite score, top-three drivers, and key risks all fit within the first screen.
|
||||
- [ ] Sector classification stated, playbook named, and suppressed metrics listed with reasons.
|
||||
- [ ] Situation classification present, or explicitly stated as "none".
|
||||
- [ ] Scorecard shows category scores, weights, weighted contributions, composite, and the weighting rationale.
|
||||
- [ ] Every dimension section shows value + own history + peer median before interpretation.
|
||||
- [ ] Peer set listed, justified, and exclusions explained; comparability caveats stated.
|
||||
- [ ] Valuation method justified by sector; discount rate and terminal growth each justified.
|
||||
- [ ] Reverse-DCF stated as a testable sentence and checked against actual historical delivery.
|
||||
- [ ] Scenario table with probabilities, assumptions, implied values, and a probability-weighted figure.
|
||||
- [ ] Red flags listed by severity; "checked and clear" list included; India and US-specific checks run as applicable.
|
||||
- [ ] Bear case written to persuade, with the rebuttal kept separate and after.
|
||||
- [ ] At least three invalidation triggers that are specific, observable, sourced, and time-bound.
|
||||
- [ ] Every number carries a bracketed source; every estimate carries `[E]`/`(est.)` with a method note.
|
||||
- [ ] No blank cells and no zeros standing in for missing data — `n/a` with a reason instead.
|
||||
- [ ] No single-metric ranking anywhere in the document.
|
||||
- [ ] Disclaimer present and unedited: research, not licensed financial advice.
|
||||
551
finance/skills/stock-analysis/references/13-situations.md
Normal file
551
finance/skills/stock-analysis/references/13-situations.md
Normal file
|
|
@ -0,0 +1,551 @@
|
|||
# Situation and Lifecycle Playbooks
|
||||
|
||||
Use this when: you are at Stage 2 classifying the company, or at any later stage where the standard metric set is producing an answer that feels mechanically correct and economically absurd.
|
||||
|
||||
The sector playbook tells you which metrics exist for this industry. The situation playbook tells you which of them are *currently meaningful*. These are overlays, not substitutes: a steel company is a metals company **and** a deep cyclical, and both files apply. Almost every large valuation error in this skill's domain comes from applying the wrong lens rather than from arithmetic — a trailing P/E screen buys cyclicals at the top, sells them at the bottom, discards every loss-making grower, and rates a holding company on consolidated numbers it does not actually own. Choosing the framework is a bigger decision than the inputs you feed it.
|
||||
|
||||
**Every indicative range in this file is indicative only.** Ranges shift with market, cycle stage, interest-rate regime and accounting period. A peer-set comparison and the company's own 5–10 year history override any absolute band printed here, always.
|
||||
|
||||
## Contents
|
||||
|
||||
- [0. Classify first — the step that prevents the error](#0-classify-first--the-step-that-prevents-the-error)
|
||||
- [1. Loss-making growth](#1-loss-making-growth)
|
||||
- [2. Deep cyclicals](#2-deep-cyclicals)
|
||||
- [2.1 The low-P/E-at-peak trap](#21-the-low-pe-at-peak-trap)
|
||||
- [2.2 Normalised earnings power](#22-normalised-earnings-power)
|
||||
- [2.3 The capacity cycle and cost-curve position](#23-the-capacity-cycle-and-cost-curve-position)
|
||||
- [2.4 Valuation anchors that work at the trough](#24-valuation-anchors-that-work-at-the-trough)
|
||||
- [2.5 Surviving the trough](#25-surviving-the-trough)
|
||||
- [3. Turnarounds](#3-turnarounds)
|
||||
- [4. Distressed and restructuring](#4-distressed-and-restructuring)
|
||||
- [5. Spin-offs and demergers](#5-spin-offs-and-demergers)
|
||||
- [6. Merger arbitrage and open offers](#6-merger-arbitrage-and-open-offers)
|
||||
- [7. Holding companies](#7-holding-companies)
|
||||
- [8. Recent IPOs](#8-recent-ipos)
|
||||
- [9. Micro and small caps](#9-micro-and-small-caps)
|
||||
- [10. Asset-heavy vs asset-light](#10-asset-heavy-vs-asset-light)
|
||||
- [11. Promoter and family-controlled companies](#11-promoter-and-family-controlled-companies)
|
||||
- [12. State-owned enterprises (PSUs)](#12-state-owned-enterprises-psus)
|
||||
- [13. Large treasury and investment books](#13-large-treasury-and-investment-books)
|
||||
- [14. Serial acquirers and roll-ups](#14-serial-acquirers-and-roll-ups)
|
||||
- [15. SPACs and de-SPACs](#15-spacs-and-de-spacs)
|
||||
- [16. Catalyst, horizon and falsification](#16-catalyst-horizon-and-falsification)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 0. Classify first — the step that prevents the error
|
||||
|
||||
Before computing a single multiple, write down three lines in your working notes:
|
||||
|
||||
1. **Situation label(s).** Pick from: normal operating company / loss-making growth / deep cyclical / turnaround / distressed / spin-off / merger-arb target / holdco / recent IPO / micro-cap / promoter-controlled / PSU / treasury-heavy / serial acquirer / de-SPAC. **Multiple labels are normal.** A newly demerged PSU cement company is four overlays at once.
|
||||
2. **Metrics deliberately switched off.** State them: "trailing P/E is switched off — mid-cycle margins are ~40% below current; valuing on EV/tonne and normalised EPS."
|
||||
3. **Re-classification date.** Situations expire. A turnaround that works becomes a normal company; a compounder that stops reinvesting becomes a treasury-heavy stub; a cyclical migrates from trough to peak. Re-label at least annually and on any transformative event.
|
||||
|
||||
### Recognition triggers — run this scan
|
||||
|
||||
| If you observe | Suspect | Go to |
|
||||
|---|---|---|
|
||||
| Negative EBIT with >25% revenue growth, heavy SBC or ad spend | Loss-making growth | §1 |
|
||||
| Margin range across 10 years spans 3x or more; commodity or spread-driven revenue | Deep cyclical | §2 |
|
||||
| Margins well below own history and peers; new management; restructuring charges | Turnaround | §3 |
|
||||
| Net debt/EBITDA >5x with falling EBITDA, going-concern note, rating downgrade, covenant waiver | Distressed | §4 |
|
||||
| Listing in the last 12 months without an IPO; scheme of arrangement in filings | Spin-off / demerger | §5 |
|
||||
| Price pinned just below a fixed offer price; open-offer or scheme announcement | Merger arb | §6 |
|
||||
| Principal assets are stakes in other listed companies; revenue mostly dividend income | Holdco | §7 |
|
||||
| Listed <24 months; restated financials only; offer-for-sale in the prospectus | Recent IPO | §8 |
|
||||
| Market cap below roughly ₹5,000 crore / $2bn, thin volume, no analyst coverage | Small/micro-cap | §9 |
|
||||
| Capex/sales persistently >10% or persistently <2% | Asset-heavy / asset-light | §10 |
|
||||
| Promoter or family holding >40%; group companies in the RPT note | Promoter-controlled | §11 |
|
||||
| Government is the controlling shareholder; administered pricing; subsidy receivables | PSU | §12 |
|
||||
| Cash + investments >25% of market cap | Treasury-heavy | §13 |
|
||||
| Goodwill + intangibles >30% of assets; growth bridge dominated by acquisitions | Serial acquirer | §14 |
|
||||
| Listed via SPAC merger; warrants outstanding; projections in an investor deck | De-SPAC | §15 |
|
||||
|
||||
If two labels conflict on the same metric, the **more conservative overlay wins**. A cyclical holdco is valued on trough-adjusted NAV, not peak look-through earnings.
|
||||
|
||||
---
|
||||
|
||||
## 1. Loss-making growth
|
||||
|
||||
**Recognise it.** Negative operating profit, revenue growth typically >20%, gross margin positive, opex dominated by sales/marketing and R&D, heavy share-based compensation, funding from equity rather than operating cash. Common in SaaS, consumer internet, D2C, quick-commerce, biotech, EV.
|
||||
|
||||
**What changes.** P/E, ROE and EV/EBITDA are undefined or meaningless. You are underwriting two separate questions that must be answered in order: (a) *are the unit economics positive?* and (b) *is there enough money to reach scale before the funding window closes?* A company losing money because it is spending ahead of a profitable unit is investable. One losing money on every unit sold is a subsidy, and growth makes it worse. Answer (a) first — if it fails, (b) is irrelevant.
|
||||
|
||||
**Primary metrics.**
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Contribution margin per unit | Revenue per order/customer − all direct delivery costs (COGS, fulfilment, payment gateway, support, hosting) | Positive and widening year on year | The single go/no-go test. Negative and static = the business scales its losses. |
|
||||
| CAC payback | Fully-loaded S&M spend ÷ (new customers × monthly gross profit) | <12 months (SaaS <18) | Longer payback means growth must be funded externally for years; ties directly to dilution. |
|
||||
| LTV/CAC | (ARPU × gross margin ÷ monthly churn) ÷ CAC | >3x on *gross* margin and realistic churn | Compute it yourself; management LTV usually uses revenue margin and optimistic churn. |
|
||||
| Net revenue retention | Revenue from a cohort this year ÷ same cohort last year | >100% (SaaS >110%) | Above 100% the installed base grows without new sales spend — the strongest signal available. |
|
||||
| Quarterly cash burn / runway | (OCF − capex − lease payments); runway = (cash + undrawn committed lines) ÷ burn | >8 quarters, or clear path to breakeven inside runway | Under ~4 quarters, the next financing sets the price, not the fundamentals. |
|
||||
| SBC as % of revenue | Share-based comp ÷ revenue | <10%; >20% is a material transfer to employees | SBC is a real cost paid in your ownership. |
|
||||
| Fully-diluted future share count | Today's diluted count + shares implied by the capital still needed to reach breakeven | — | Value the company **per future share**, never per today's share. |
|
||||
|
||||
**Signals that invert.**
|
||||
- **Revenue growth is a negative** if contribution margin is negative — every incremental sale enlarges the loss.
|
||||
- **"Adjusted EBITDA" positive** is not profitability. Rebuild it to GAAP/Ind-AS operating profit and list every add-back. SBC, annually recurring "one-off" restructuring, capitalised software and marketing reclassified as "investment" are the four usual culprits.
|
||||
- **Falling CAC** can mean brand strength — or that the company has stopped growing and is harvesting easy demand. Check volume, not just cost.
|
||||
- **Rising capitalised R&D / content / development cost as a share of spend** flatters the P&L while cash burn is unchanged. Watch the ratio drift, not the level.
|
||||
|
||||
**The trap.** Modelling the business correctly and ignoring dilution. You can be right about the company and still lose most of your money because your claim on it shrank through successive down-rounds and rescue raises. The dominant risk for a pre-profit company is not competition — it is a closed funding window. Ask explicitly: at today's gross margin and a normalised opex base, at what revenue level does this break even, and does the cash on hand plus committed lines get there?
|
||||
|
||||
---
|
||||
|
||||
## 2. Deep cyclicals
|
||||
|
||||
**Recognise it.** Selling price is set by an external market, not by the company: steel, aluminium, copper, cement, sugar, paper, shipping rates, refining and petrochemical spreads, memory chips, PVC/soda ash, dry-bulk freight, hotels, airlines, real-estate developers, capital goods with long order cycles. Diagnostic test: pull 10–15 years of EBITDA margin — if the range spans a factor of three or more, and peaks/troughs line up across all peers simultaneously, it is a deep cyclical.
|
||||
|
||||
**What changes.** Nothing in the trailing P&L describes the business. Profits are set by the industry supply–demand balance, not company quality. Your entire job is to locate the company in the cycle, estimate mid-cycle earnings power, and determine whether the balance sheet survives the next trough.
|
||||
|
||||
### 2.1 The low-P/E-at-peak trap
|
||||
|
||||
**This is the single most expensive valuation error in equity analysis. Treat any cyclical trading at a low trailing P/E as a red flag until proven otherwise.**
|
||||
|
||||
The mechanics: at the cycle peak, realisations and margins are at decade highs, so **E** is inflated far above sustainable levels. The market, which can see this, correctly assigns a **low multiple** to an earnings number it knows is temporary. The resulting 4–6x P/E is not a mispricing — **it is the market's forecast of an earnings collapse.** The stock then de-rates on falling earnings *and* often a falling multiple, producing losses far larger than the apparent cheapness implied.
|
||||
|
||||
The inverse is equally important and equally counter-intuitive: at the trough, earnings are near zero or negative, so the P/E is enormous, meaningless or undefined. **A high or infinite P/E on trough earnings frequently marks the best entry point in the entire cycle.** Cyclical returns are made by buying at high/no P/E on depressed earnings and selling at low P/E on peak earnings — the exact opposite of what a screen instructs.
|
||||
|
||||
Confirm which end of the cycle you are at, using at least three independent checks:
|
||||
|
||||
| Check | Peak signature | Trough signature |
|
||||
|---|---|---|
|
||||
| EBITDA margin vs own 10-year band | At or above 90th percentile | Bottom decile, or negative |
|
||||
| Trailing P/E | Low (4–8x) and falling | Very high, negative or undefined |
|
||||
| P/B | Above 10-year median, often 2–4x | Near or below 1x |
|
||||
| Capacity utilisation / occupancy / freight rate | >90%, spot above contract | Below cash-cost for marginal producers |
|
||||
| Industry capex and new-project announcements | Booming; greenfield everywhere | Projects cancelled; consolidation, closures |
|
||||
| Dividend yield and payout | High yield on peak EPS (looks attractive) | Cut or suspended |
|
||||
| Balance sheets across the sector | Deleveraging fast, net cash appearing | Rights issues, covenant waivers, bankruptcies |
|
||||
|
||||
If margins are at a decade high and the P/E is 5x, **treat the stock as expensive**, and write that sentence explicitly in the report so the conclusion is not quietly reversed later by a screen output.
|
||||
|
||||
**Cross-check against the commodity itself.** Back out the realisation or spread implied by current earnings, and compare it to the long-run marginal cost of production (typically the 90th-percentile producer's all-in cost plus a return on capital). Prices persistently far above marginal cost are unsustainable by construction — high prices call forth the supply that destroys them.
|
||||
|
||||
### 2.2 Normalised earnings power
|
||||
|
||||
Build mid-cycle earnings before you value anything:
|
||||
|
||||
1. Pull 10–15 years (at minimum one full peak-to-peak cycle) of volume, realisation, EBITDA margin, EPS and ROCE.
|
||||
2. Take the **median** (not mean — means are dragged by peak outliers) EBITDA margin across the cycle. Adjust upward only for structural, evidenced improvements: a new low-cost plant commissioned, captive power, backward integration, a permanent shift in the cost curve. Do not adjust for "management's efficiency programme".
|
||||
3. Apply the mid-cycle margin to *current* capacity and a realistic utilisation, not to peak revenue. Volume growth is real and permanent; price is not.
|
||||
4. Deduct maintenance capex-adjusted depreciation and a normalised tax rate to get mid-cycle EPS and mid-cycle ROCE.
|
||||
5. Value on 10–14x mid-cycle EPS (indicative; varies widely by industry and rate regime), and cross-check with §2.4 anchors.
|
||||
|
||||
State clearly that mid-cycle EPS is an estimate, show the margin assumption, and show what the value is at ±200bps of margin.
|
||||
|
||||
### 2.3 The capacity cycle and cost-curve position
|
||||
|
||||
Cyclical profits are set by supply. Map it directly:
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Industry capacity pipeline | Announced capacity additions over next 3–5 years ÷ current industry capacity, vs expected demand CAGR | Additions below demand growth | Peer capex booms are the leading indicator of the next downturn, visible years before the P&L. |
|
||||
| Cost-curve quartile | Company cash cost per tonne/unit vs industry cost curve | First quartile | A first-quartile producer survives the trough and buys distressed assets; a fourth-quartile one is a call option that can expire worthless. |
|
||||
| Capacity utilisation | Output ÷ rated capacity | Compare to the 10-year band, not an absolute | Utilisation above ~90% precedes price spikes; below ~70% precedes closures. |
|
||||
| Contract vs spot mix | Share of volume on long-term contracts | Higher = smoother, lower peak | Determines how violently earnings move; changes the correct multiple. |
|
||||
| Channel inventory | Distributor/port/warehouse stocks in weeks of demand | Below historical average | Restocking and destocking amplify the apparent cycle by months. |
|
||||
| Vertical integration | Share of key input self-supplied (ore, power, feedstock) | Higher in input-cost-driven cycles | Integration moves the company down the cost curve and stabilises the spread. |
|
||||
|
||||
Also track imports/exports, anti-dumping and safeguard duties (**India:** DGTR investigations and Finance Ministry notifications; **US:** Section 232/301 tariffs and ITC determinations). Trade protection is often the difference between a domestic producer's peak and trough, and it expires on a known date.
|
||||
|
||||
### 2.4 Valuation anchors that work at the trough
|
||||
|
||||
At the trough, earnings-based multiples break entirely. Switch to:
|
||||
|
||||
| Anchor | How to compute | Indicative use | Why it matters |
|
||||
|---|---|---|---|
|
||||
| P/B | Market cap ÷ tangible book | Compare to the company's own trough (often 0.5–0.8x) and peak (2–4x) | Book is a stable measuring stick when earnings are near zero. |
|
||||
| EV per unit of capacity | EV ÷ tonnes, barrels/day, MW, rigs, rooms, TEU, wafer starts | Versus greenfield build cost per unit | Directly comparable across peers and against new supply economics. |
|
||||
| EV / replacement cost (Tobin's Q) | EV ÷ estimated cost to rebuild the asset base today | <1 at trough; >1 invites new supply | This is *both* the valuation floor and the mechanism of recovery: below replacement cost, nobody builds, supply stops growing, and prices eventually recover. |
|
||||
| Price / normalised earnings power | Market cap ÷ mid-cycle net profit (§2.2) | 10–14x indicative | Keeps you honest about what the business earns through a cycle. |
|
||||
| EV / mid-cycle EBITDA | Use mid-cycle, never trailing | 5–8x indicative for heavy industry | The only EV/EBITDA formulation that is not cycle-contaminated. |
|
||||
|
||||
Sanity check every asset-based anchor: what would it cost, and how many years would it take, to build this asset base today — including land, environmental clearances and grid/port connectivity? An asset that cannot be replicated for regulatory reasons is worth more than its accounting value; an obsolete asset is worth less than book regardless of what the balance sheet says.
|
||||
|
||||
### 2.5 Surviving the trough
|
||||
|
||||
The cycle can be right and the equity still be wiped out if leverage was set against peak cash flow. Survivorship *is* the thesis: the surviving low-leverage operator captures the exiting competitor's volume and earns super-normal returns for years.
|
||||
|
||||
- Compute **net debt ÷ mid-cycle EBITDA**, never trailing peak EBITDA. Indicative comfort: below 2.5x for a deep cyclical; above 4x on mid-cycle numbers is a solvency question, not a leverage ratio.
|
||||
- Stress-test at the **worst realisation of the last downcycle**: does EBITDA cover interest plus maintenance capex? If not, count the quarters of liquidity available.
|
||||
- Line up the **debt maturity schedule against the expected trough years**. A refinancing due in the trough is the single most common route to permanent equity loss.
|
||||
- Check covenant headroom (usually net debt/EBITDA and interest cover), fixed-vs-floating mix, and contractually committed capex that cannot be cancelled.
|
||||
- Do the same for the two or three weakest peers. Their distress is your company's opportunity — or the trigger for a sector-wide price collapse as they dump inventory.
|
||||
|
||||
**The trap, restated.** Buying a cyclical because it screens cheap on trailing earnings, high ROE and a fat dividend yield — all three of which peak together, at exactly the wrong moment.
|
||||
|
||||
---
|
||||
|
||||
## 3. Turnarounds
|
||||
|
||||
**Recognise it.** Margins materially below both peer median and the company's own history, a new CEO/CFO, restructuring provisions, asset sales announced, and a narrative of "transformation". Price is well off its highs.
|
||||
|
||||
**What changes.** Before any valuation, diagnose *which of three* problems this is — the diagnosis determines whether there is a thesis at all:
|
||||
|
||||
| Type | Signature | Fixable? |
|
||||
|---|---|---|
|
||||
| **Operational** | Revenue and volumes intact; margin gap traceable to identifiable causes — cost bloat, a bad plant, loss-making contracts, over-distribution | Yes, and usually within 2–4 years |
|
||||
| **Financial** | Business economics fine at the EBIT line; capital structure broken — too much debt, wrong maturity, wrong currency | Yes, via refinancing, asset sale or equity raise — but ownership may transfer (see §4) |
|
||||
| **Secular** | End-market shrinking, technology substitution, regulatory ban, permanent share loss to a structurally better model | **No.** This is not a turnaround, it is a melting ice cube |
|
||||
|
||||
Distinguishing test: look at **volumes/units, not revenue** (price rises can mask volume collapse for years), market share trend, and whether peers are also struggling (industry problem, possibly cyclical) or thriving (company-specific, possibly fixable). Most "value trap" losses are secular decline misdiagnosed as an operational turnaround.
|
||||
|
||||
**Primary metrics.** Gross margin trend quarter over quarter (the first place a real fix shows); fixed-cost base in absolute currency terms year on year; working-capital days; net debt reduction in absolute terms; capacity utilisation; share of revenue from products launched in the last 3 years.
|
||||
|
||||
**Demand evidence, not intention.** Turnarounds re-rate on hard data points, and the market almost always gives you time to buy *after* the first verified inflection at a far better risk-adjusted price than at the announcement. Waiting filters out the large majority of plans that fail and costs you only a small part of the return. Hard markers to require:
|
||||
|
||||
- A new CEO/CFO with a *relevant* prior track record, and their actual incentive plan (are targets tied to margin and ROCE, or to revenue and TSR over one year?).
|
||||
- Divisions or assets **actually sold with cash received** — not "strategic review initiated".
|
||||
- Headcount and fixed cost reductions visible **in the reported P&L**, not in a slide.
|
||||
- Debt actually repaid on the balance sheet.
|
||||
- Two consecutive quarters of sequential gross-margin or working-capital improvement.
|
||||
|
||||
**Signals that invert.**
|
||||
- **Restructuring charges every year for five years** means restructuring is a permanent operating cost, and "adjusted" earnings are fiction.
|
||||
- **Promised savings** that never appear in reported opex have been "reinvested" — i.e. they did not exist.
|
||||
- **Revenue stabilisation** is not evidence if it came from price increases while volumes fell; that is harvesting, and it accelerates the decline.
|
||||
- A **low P/B on a shrinking asset base** is not a floor if the assets are industry-specific and the industry is disappearing.
|
||||
|
||||
**The trap.** Underwriting the announcement instead of the evidence, and confusing a cheap price with a changed business.
|
||||
|
||||
---
|
||||
|
||||
## 4. Distressed and restructuring
|
||||
|
||||
**Recognise it.** Going-concern qualification, covenant breach or waiver, rating downgrade to junk, interest cover below 1.5x, debt trading well below par, auditor resignation, delayed filings, insolvency petition admitted.
|
||||
|
||||
**What changes.** You are no longer valuing a business; you are valuing a **residual claim that ranks last**. Equity value = enterprise value minus everything senior to it, and that number is frequently zero or negative even when the business survives and prospers. Build the liability stack before anything else:
|
||||
|
||||
Secured debt (by security and seniority) → unsecured debt → subordinated debt and converts → capitalised leases → pension/gratuity deficits → statutory and tax dues (often super-priority) → trade creditors → guarantees given to group entities and other off-balance-sheet exposures → preference shares → equity.
|
||||
|
||||
**Primary metrics.** Enterprise value under a realistic (not hopeful) recovery scenario; the resulting equity stub after the stack; nearest maturity wall in months; liquidity runway; the "fulcrum" security — the layer at which value runs out, because that layer typically ends up owning the reorganised company.
|
||||
|
||||
**Regime matters — check which applies.**
|
||||
- **India:** Insolvency and Bankruptcy Code 2016. Once the NCLT admits a case, the CIRP timeline runs to 330 days including litigation, an insolvency professional displaces the board, and resolution plans routinely write existing equity down to a nominal value or extinguish it entirely. Section 29A bars defaulting promoters from bidding for their own company. RBI's prudential framework governs pre-IBC restructuring by lenders. Watch for the "delisting after resolution plan" outcome — minority shareholders can be cashed out at a token price.
|
||||
- **US:** Chapter 11 (reorganisation, debtor-in-possession financing, absolute priority rule) versus Chapter 7 (liquidation). Equity receives nothing until creditors are made whole, though small "gifted" recoveries occur in negotiated plans. Watch for a shareholders' committee being *denied* — that is the court signalling the equity is out of the money.
|
||||
|
||||
**Signals that invert.**
|
||||
- **A very low price and a tiny market cap** make the equity look like a cheap option. It is an option, but the strike is the entire liability stack, and it can expire worthless while the business continues under new owners.
|
||||
- **"Promoter/management is infusing capital"** dilutes you unless you can participate on the same terms. Rescue rights issues and debt-to-equity conversions routinely dilute existing holders by 90%+.
|
||||
- **Asset value exceeding debt on the balance sheet** is not protection: distressed asset sales clear at a fraction of book, and the write-down happens on the way to the sale.
|
||||
- **Rising share price on restructuring news** frequently reflects retail speculation, not a recovery calculation.
|
||||
|
||||
**The trap.** Buying "cheap" distressed equity without doing the capital-structure arithmetic. In distress, value transfers to creditors or to the new-money provider; the operating recovery you correctly predicted accrues to someone else.
|
||||
|
||||
---
|
||||
|
||||
## 5. Spin-offs and demergers
|
||||
|
||||
**Recognise it.** A scheme of arrangement in the filings, a share entitlement ratio, a record date, and a new line item appearing in the shareholder's account. **India:** demerger under Sections 230–232 of the Companies Act 2013, approved by NCLT and SEBI, with a listing lag between record date and the new entity's first trade — often weeks to months, then a special pre-open price-discovery session. **US:** Form 10 registration statement (the primary diligence document) or Form S-1, usually tax-free under IRC §355.
|
||||
|
||||
**What changes.** There are two independent things to analyse: the *mechanical mispricing* and the *standalone economics*.
|
||||
|
||||
Mechanical: recipients did not choose the new stock, there is no analyst coverage, and index funds plus mandate-restricted holders must sell an unwanted small-cap stub regardless of value. This forced selling is indiscriminate and time-bounded — it is the structural reason spin-offs are a documented source of mispricing. Watch price behaviour in the first several weeks and note when index inclusion decisions land.
|
||||
|
||||
Standalone: **the pro-forma segment disclosure is not the standalone P&L.** Add back the corporate costs the unit never carried (its own CFO, board, listing, audit, insurance, treasury, IT) and remove arbitrary parent allocations. Then read the scheme for how debt, pension/gratuity, tax liabilities, contingent liabilities and shared costs were split, what transitional supply or service agreements bind the two entities and on what terms, and any retained stake or cross-holding.
|
||||
|
||||
**Primary metrics.** Standalone EBIT after real corporate costs; net debt allocated to each entity vs its EBITDA; the share of each entity's revenue that is a captive sale to the other; the parent's retained stake and its likely disposal path; the implied stub value of the parent after deducting the market value of the spun entity.
|
||||
|
||||
**Signals that invert.**
|
||||
- **Heavy selling with no news** in the first weeks is the opportunity, not a warning — but only if the standalone economics stand up.
|
||||
- **The parent looking "cleaner"** is often because it kept the cash and pushed the debt and legacy liabilities into the spun entity. Read the allocation, do not assume symmetry.
|
||||
- **A long transitional services agreement** flatters the spun entity's near-term costs; model the step-up when it lapses.
|
||||
- **India-specific:** the cost basis of your original holding is apportioned between the two entities per the scheme — relevant to any after-tax return calculation. Verify the ratio in the scheme document, not from a news report.
|
||||
|
||||
**The trap.** Valuing the new entity off the parent's old segment margins. Also: assuming the "good" business was spun out. Check where management's incentives, the better assets and the growth capex budget ended up — occasionally the spin is a disposal of a problem dressed as a value-unlock.
|
||||
|
||||
---
|
||||
|
||||
## 6. Merger arbitrage and open offers
|
||||
|
||||
**Recognise it.** The stock trades in a narrow band just below a stated offer price, volatility collapses, and volume spikes around approval news.
|
||||
|
||||
**What changes.** Business quality becomes almost irrelevant. You are pricing a probability-weighted event, and the payoff is asymmetric in the wrong direction: **you win a few percent many times and lose 20–40% when a deal breaks.** Position sizing and break probability, not the headline spread, determine the outcome.
|
||||
|
||||
**Primary metrics.**
|
||||
|
||||
| Metric | Definition / how to compute | Indicative range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Gross spread | (Offer price − market price) ÷ market price | 1–4% for clean deals | The raw compensation. |
|
||||
| Annualised return | Gross spread × (365 ÷ expected days to close), net of costs and adjusted for any dividends received in the interim | Compare to the risk-free rate plus a break-risk premium | A 3% spread over 3 months is very different from 3% over 18. |
|
||||
| Downside to undisturbed price | Pre-announcement price (adjusted for market/sector moves since) vs current price | Typically −20% to −40% | This is the actual loss if the deal breaks — the number that governs sizing. |
|
||||
| Break-even probability | Downside ÷ (spread + downside) | Compare to your own estimate of deal risk | Makes the implied market probability explicit. |
|
||||
|
||||
**Enumerate every condition precedent** and give each a probability: antitrust/competition approval in each jurisdiction (**India:** CCI; **US:** HSR waiting period, DOJ/FTC second request), foreign-investment screening (**India:** Press Note 3 for land-border countries; **US:** CFIUS), sector regulator consent (RBI, IRDAI, TRAI, FERC, FCC), shareholder vote thresholds, financing certainty (committed facilities vs "best efforts"), MAC/MAE clause wording, break fees on each side, and litigation.
|
||||
|
||||
**India-specific structures.** A SEBI SAST-mandated **open offer** is triggered at 25% acquisition or on change of control, and is for a minimum 26% of shares — so tendering holders typically receive *proportionate acceptance*, not a full exit; model the residual stub you will still own at the post-offer price. **Delisting** via reverse book-building has a different payoff shape entirely, driven by the discovered price and the 90% threshold. **Schemes of arrangement** require NCLT approval and majority-of-minority voting, which adds months and a real rejection risk.
|
||||
|
||||
**Signals that invert.**
|
||||
- **A wide spread is a warning, not a bargain.** It is almost always the market pricing a real regulatory, financing or political risk it understands better than you do.
|
||||
- **Stock-for-stock deals** carry the acquirer's own risk and require a short hedge; an unhedged position is a bet on the acquirer, not an arbitrage.
|
||||
- **Repeated extensions of the long-stop date** signal a deal in trouble even while the spread looks stable.
|
||||
|
||||
**The trap.** Sizing on the spread rather than the downside, and treating a wide spread as free money.
|
||||
|
||||
---
|
||||
|
||||
## 7. Holding companies
|
||||
|
||||
**Recognise it.** The principal assets are equity stakes in other companies (listed or unlisted); standalone revenue is largely dividend and interest income; the market cap sits far below the market value of the stakes. Common in Indian promoter group structures and in European/Asian family conglomerates. See also `references/sectors/holdco-assetmgr.md`.
|
||||
|
||||
**What changes.** **Consolidated financials are largely meaningless to a minority holder.** Consolidated revenue and EPS include subsidiaries whose cash you do not control and, in the case of associates, businesses you own a slice of but do not consolidate. You own a claim on cash that must travel *up* through dividend policy, tax and holdco operating costs. Valuation is sum-of-the-parts, full stop.
|
||||
|
||||
**Build the NAV, in this order.**
|
||||
1. Market value of each listed stake (price × shares held, as of a stated date).
|
||||
2. A defensible valuation for unlisted stakes — an earnings or book multiple against listed comparables, disclosed clearly as an estimate, with a haircut for illiquidity.
|
||||
3. Plus net cash / minus net debt at the **holdco standalone** level (not consolidated).
|
||||
4. Minus holdco operating costs capitalised (annual holdco opex ÷ discount rate) — these are a perpetual leakage.
|
||||
5. Minus estimated tax leakage on an eventual sale of the stakes (capital-gains tax on the embedded gain; **India:** verify the current LTCG rate and surcharge applicable to listed and unlisted shares separately).
|
||||
|
||||
Then: **discount = 1 − (market cap ÷ NAV)**, plotted over 5–10 years to establish the company's *own* normal range.
|
||||
|
||||
**Primary metrics.** Discount to NAV vs its own 5–10 year percentile; look-through earnings (your share of each investee's net profit); **cash dividends actually received** at the holdco (the only money that can ever reach you); holdco opex as % of NAV; share count trend.
|
||||
|
||||
**Signals that invert.**
|
||||
- **A low consolidated P/E** on a holdco is meaningless and frequently the reason a screen surfaces it. Switch it off explicitly.
|
||||
- **A very wide discount is not automatically an opportunity.** Indian holdcos commonly sustain 50–70% discounts for a decade or more. The money is made only when the discount is wide *against its own history* **and** there is a mechanism to close it: buyback, demerger, listing of a subsidiary, dividend policy change, holdco merger, activist pressure. Without a mechanism, a 60% discount can simply stay a 60% discount forever, and your return is only the underlying's return.
|
||||
- **A holdco continually issuing shares to buy more stakes** widens the discount rather than narrowing it, and dilutes look-through earnings per share.
|
||||
|
||||
**The trap.** Treating NAV as a target price. Also: ignoring voting-vs-economic rights and cross-holdings — a circular structure where A owns B owns A inflates apparent NAV by double-counting; net it out.
|
||||
|
||||
---
|
||||
|
||||
## 8. Recent IPOs
|
||||
|
||||
**Recognise it.** Listed within roughly 24 months. No public reporting track record; only restated financials in the prospectus; analyst coverage originating mostly from the bookrunners.
|
||||
|
||||
**What changes.** You lack the one thing the rest of this skill depends on — the company's own history under public scrutiny. **The information asymmetry is at its maximum**, and it runs entirely against you: IPOs are sold, not bought, and are timed by informed sellers into favourable markets.
|
||||
|
||||
**Read the prospectus for:**
|
||||
- **Fresh issue vs offer-for-sale split.** Fresh issue money goes into the company; OFS money goes to exiting shareholders. A 100% OFS means no capital is being raised for the business at all.
|
||||
- **Selling shareholders' cost basis** and the valuation of the last pre-IPO round. A PE holder exiting at 8x their entry price two years later tells you what they think the business is worth.
|
||||
- **Use-of-proceeds specificity.** "General corporate purposes" and "repayment of promoter loans" are far weaker than a named plant with a named capacity.
|
||||
- **Lock-up expiry calendar.** **India (SEBI ICDR):** anchor investors — 50% of allotted shares locked for 30 days, remainder for 90 days; minimum promoter contribution locked for 18 months; other pre-issue capital typically 6 months. **US:** typically a 180-day underwriter lock-up, with earlier release triggers. Each expiry is a scheduled supply event.
|
||||
- **3–5 years of restated financials**, looking specifically for a suspicious margin ramp into the IPO year, a working-capital squeeze (channel stuffing, stretched payables), related-party clean-ups executed just before filing, and one-off revenue booked in the final year.
|
||||
- **Free float and index inclusion timeline** — small float plus future index addition creates mechanical demand that has nothing to do with value.
|
||||
|
||||
**Signals that invert.**
|
||||
- **A beautiful three-year margin ramp is a warning, not a strength.** Pre-IPO financial dressing is common and reverts within 4–8 quarters of listing. Check whether the trend continues in the first post-listing results.
|
||||
- **Grey-market premium and listing-day pop** carry zero information about business value.
|
||||
- **Heavy anchor/institutional subscription** reflects allocation dynamics and momentum, not diligence you can rely on.
|
||||
|
||||
**The trap.** Valuing on prospectus-year margins. Wait for two to four quarters of *public* reporting and, where possible, past the first major lock-up expiry, before treating any margin as the base rate. In India, note that **SME-platform IPOs** (NSE Emerge, BSE SME) have materially lighter disclosure and post-listing scrutiny than main-board issues — apply §9 in full.
|
||||
|
||||
---
|
||||
|
||||
## 9. Micro and small caps
|
||||
|
||||
**Recognise it.** Market cap below roughly ₹5,000 crore or $2bn (indicative; adjust to the market), thin volume, few or no analysts, promoter/insider concentration.
|
||||
|
||||
**What changes.** Two things simultaneously: the inefficiency is real (institutions structurally cannot participate), and the safeguards are absent (no analyst scrutiny, weaker audit, weaker disclosure). Fraud and governance-failure base rates are far higher here than in large caps, so **verification effort must go up, not down**, exactly where information is scarcest.
|
||||
|
||||
**Primary metrics.**
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Median daily traded value | Median of (volume × price) over 6 months | Enough to exit in <10 trading days at ≤25% of daily volume | A "cheap" stock you cannot sell without moving the price 15% is not cheap. |
|
||||
| Days to exit | Intended position size ÷ (25% × median daily value) | <10 days | Determines position size before any valuation work. |
|
||||
| Bid–ask spread | (Ask − bid) ÷ mid | <1% | Wide spreads are a permanent tax on entry and exit. |
|
||||
| Free float | 1 − (promoter + strategic + locked holdings) | >25% | Low float exaggerates both rallies and collapses. |
|
||||
| Auditor quality and tenure | Identity of the statutory auditor; any resignation or qualified opinion | No resignations; recognised firm | **Auditor resignation is one of the highest-signal red flags available in this segment.** |
|
||||
|
||||
**Governance and existence checks — do these before valuation, not after.** Auditor/CFO turnover; qualified opinions and emphasis-of-matter paragraphs; board independence in substance; related-party transactions; contingent liabilities; regulatory action history. Then verify the business physically exists as described: plant visits or satellite imagery, customer and distributor references, employee headcount vs revenue, GST/tax filings, channel checks. **India:** CARO 2020 clauses (especially on statutory dues, undisclosed income, and diversion of funds), SEBI's ASM/GSM surveillance lists, trade-to-trade segment placement, and circuit filters — a stock locked at upper circuit cannot be sold, which converts a paper gain into a trapped position. **US:** SEC comment letters on EDGAR, Form 8-K Item 4.01 (auditor change) and Item 4.02 (non-reliance on prior financials), and PCAOB inspection status of the auditor.
|
||||
|
||||
**Signals that invert.**
|
||||
- **A strong price move on low volume** is not confirmation of anything; it may be one buyer or a coordinated operation.
|
||||
- **Very high reported ROE with poor cash conversion** in an unaudited-by-a-major-firm small cap is a fraud pattern, not a quality signal.
|
||||
- **Concentrated promoter holding**, normally alignment, becomes control risk when combined with thin float and heavy related-party flow (§11).
|
||||
|
||||
**The trap.** Sizing a position by conviction rather than by liquidity. Do the days-to-exit calculation first; it caps the position regardless of how good the analysis is.
|
||||
|
||||
---
|
||||
|
||||
## 10. Asset-heavy vs asset-light
|
||||
|
||||
**Recognise it.** Asset-heavy: capex/sales persistently above ~10%, fixed assets several times revenue, high depreciation, long build cycles — utilities, cement, telecom, hotels, shipping, refining. Asset-light: capex/sales below ~2–3%, negative working capital, returns on a tiny capital base — software, franchising, asset-managers, brand licensors, platform businesses.
|
||||
|
||||
**What changes.** Capital intensity determines whether growth *creates or destroys* value. Two companies with identical earnings growth can have opposite owner outcomes if one must reinvest 120% of its profit to achieve it.
|
||||
|
||||
**Primary metrics.**
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Capex / depreciation | Full-cycle average | ~1.0–1.3x for a steady business; >2x = heavy expansion | Persistently below 1.0x means the asset base is being run down and reported profit is overstated. |
|
||||
| Maintenance capex | Floor estimate = depreciation grossed up for asset-price inflation; better = management disclosure or a per-unit engineering estimate | — | Growth capex is optional; maintenance capex is a cost of staying in business. Owner earnings = CFO − maintenance capex. |
|
||||
| Incremental ROIC | Δ NOPAT over 5 years ÷ Δ invested capital over 5 years | Above WACC, ideally >15% | The only number that says whether *new* money earns a return. Averages hide it. |
|
||||
| Fixed-cost share | Fixed costs ÷ total costs; test EBIT at −20% volume | — | Quantifies operating leverage in both directions. |
|
||||
| FCF conversion | FCF ÷ net profit, full cycle | >70% | Asset-heavy companies can report rising profits while consuming every rupee in capex. |
|
||||
|
||||
**Signals that invert.**
|
||||
- **Asset-heavy:** strong EPS growth with FCF persistently negative is value destruction, not compounding. Ask where the cash went and what return it earns.
|
||||
- **Asset-light:** a spectacular ROIC of 60%+ can signal a **reinvestment ceiling** — high returns on a base you cannot grow — which caps the compounding rate no matter how good the margin. Test whether the moat is real (brand, network effect, IP, switching costs, regulation) or merely an absence of assets, which is not a barrier to entry.
|
||||
- **Asset-light with off-balance-sheet dependency** (outsourced manufacturing, leased everything, a single cloud provider) has real capital intensity sitting on someone else's balance sheet, with the associated fragility. Capitalise the leases and recompute ROIC before comparing to an asset-heavy peer.
|
||||
|
||||
**The trap.** Comparing ROIC across the two models without adjusting for leases and off-balance-sheet capital, and concluding the asset-light business is a better *compounder* when it may simply be a better *cash cow*.
|
||||
|
||||
---
|
||||
|
||||
## 11. Promoter and family-controlled companies
|
||||
|
||||
**Recognise it.** **India:** promoter and promoter-group holding disclosed in the quarterly shareholding pattern, typically >40%. **Global:** founding family holding, dual-class share structures, board seats held by family members. See `references/08-governance.md` for the full treatment; this section covers the situation overlay.
|
||||
|
||||
**What changes.** The primary risk shifts from business failure to **value extraction around minority shareholders through legal but one-sided transactions**. Diligence moves from the P&L to the notes.
|
||||
|
||||
**Primary metrics.**
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Related-party transactions | Sum of RPT sales, purchases, loans, guarantees ÷ revenue (and ÷ PAT) | Minimal, disclosed, at arm's length, stable | Every rupee routed through a promoter entity is a rupee that may not reach you. |
|
||||
| Royalty / brand fee | Payment to promoter-owned entity ÷ revenue and ÷ PAT | Low single-digit % of revenue at most; scrutinise any increase | **India:** SEBI LODR requires shareholder approval where royalty to related parties exceeds 5% of consolidated turnover. |
|
||||
| Promoter remuneration | Total managerial remuneration ÷ PAT; compare to peers and to the dividend payout | Well below the dividend paid to all shareholders | If the family takes more out as salary than all shareholders receive as dividend, the alignment argument fails. |
|
||||
| Pledged shares | Pledged ÷ promoter holding (**India:** disclosed quarterly under SAST Reg 31) | 0%; anything above ~20% is a live risk | Pledging converts a price fall into a forced-sale spiral and possible loss of control. |
|
||||
| Promoter holding trend | 5-year trajectory, and the reason for each change | Stable or rising via open-market purchases | Steady creeping increases signal confidence; a quiet sell-down signals the opposite. |
|
||||
|
||||
**Governance-in-substance checks.** Are "independent" directors long-tenured associates, relatives or former employees? Is there a succession plan and which generation is operating? How many other group companies exist, and is cash routinely moved between them? Are there dual-class or differential voting rights? **India:** RPTs above ₹1,000 crore or 10% of consolidated turnover require audit committee and majority-of-minority shareholder approval under LODR Reg 23 — check whether large transactions have been sliced below the threshold.
|
||||
|
||||
**Signals that invert.**
|
||||
- **High promoter holding**, normally a positive alignment signal, becomes a risk when paired with heavy related-party flow, high pledging, or a history of minority-unfriendly schemes.
|
||||
- **Promoter buying shares** is usually bullish, but ahead of a delisting attempt it is a squeeze on minorities, not an endorsement.
|
||||
- **A low payout ratio** in a family firm may reflect long-horizon reinvestment (good) or cash being warehoused for the family's other ventures (bad). Distinguish using the ROIC on incremental capital.
|
||||
|
||||
**The trap.** Treating "skin in the game" as a governance conclusion rather than a hypothesis. A genuinely aligned family owner with a long horizon is among the best structures to own; an extractive one is among the worst; **the diagnosis rests entirely on the related-party and remuneration record**, not on the size of the stake.
|
||||
|
||||
---
|
||||
|
||||
## 12. State-owned enterprises (PSUs)
|
||||
|
||||
**Recognise it.** Government (central or state) is the controlling shareholder. **India:** CPSEs, state utilities, public-sector banks, often with Maharatna/Navratna/Miniratna status. **Global:** national oil companies, state-owned banks and utilities in many emerging markets.
|
||||
|
||||
**What changes.** The controlling shareholder has objectives other than the share price. First determine whether the company is run **for profit or for policy**, because that determines whether any quality metric can be extrapolated at all.
|
||||
|
||||
**What to check.** Administered or subsidised pricing and who sets it; obligations to serve unprofitable customers or regions; mandated purchases from other state entities; subsidy receivables from government and the historical collection lag (this is where working capital goes to die); dividends and buybacks demanded by the state to plug its fiscal deficit; forced cross-holding purchases (one PSU made to buy a stake in another); capex mandated for strategic rather than return reasons; the appointment process and tenure of senior management (a chairman with 14 months left will not start a 5-year programme). **India:** DIPAM's disinvestment pipeline, the CPSE dividend policy floor, and the OFS route for government stake sales — announced government selling is a known overhang.
|
||||
|
||||
**Primary metrics.** ROCE excluding subsidy receivables and excluding regulatory/policy assets; cash conversion (subsidy-driven receivables make accrual profit unreal); dividend as % of PAT and whether it is discretionary or state-mandated; capex approved on commercial vs strategic grounds; government stake and any announced sell-down; the persistent valuation discount to private peers, plotted over 10 years.
|
||||
|
||||
**Signals that invert.**
|
||||
- **A high dividend yield** is often the state extracting cash rather than a signal of shareholder-friendliness — and it can coexist with underinvestment.
|
||||
- **Very low P/E and P/B** are usually a rational, permanent discount for policy risk, not a mispricing. The discount has existed for decades in most PSU universes.
|
||||
- **Large capex programmes** may be strategically mandated and value-destroying; check the approved return assumption, not the size of the number.
|
||||
- **Strong reported profit at a subsidised-price utility** can reverse the moment the subsidy formula changes — earnings are a policy variable.
|
||||
|
||||
**The trap.** Buying statistical cheapness with no catalyst. The upside case in a PSU almost always requires a **specific event**: privatisation or strategic sale, pricing deregulation, a large one-off dividend or buyback, or a formal change in the dividend policy. Without one, the discount is a rational permanent feature and your return is dividends only.
|
||||
|
||||
---
|
||||
|
||||
## 13. Large treasury and investment books
|
||||
|
||||
**Recognise it.** Cash, bonds, listed equity stakes, real estate or non-consolidated subsidiaries exceed roughly 25% of market cap; a meaningful share of reported "other income" is interest, dividends or mark-to-market gains.
|
||||
|
||||
**What changes.** Headline P/E and ROE describe a blend of two unrelated businesses. Split the company in two and value each separately:
|
||||
|
||||
**(a) Core operating business.** Recompute core operating margin, core ROCE and core EPS **excluding** all investment income and mark-to-market. Value it on an operating multiple. **(b) Investment book.** Value at market (with a haircut for illiquid or strategic holdings) and net off any tax payable on realisation.
|
||||
|
||||
Then: implied core P/E = (market cap − investment book value) ÷ core net profit. This is the number that matters, and it is often dramatically different from the headline.
|
||||
|
||||
**Primary metrics.** Investments + surplus cash as % of market cap; core ROCE excluding the book; return earned on the investment book vs the cost of capital; share of PAT from non-operating income; capital-allocation history — what management has *actually* done with excess cash over 10 years.
|
||||
|
||||
**The critical question: is the cash claimable?** Excess capital may be permanently trapped — held as regulatory capital, sitting in an overseas subsidiary subject to repatriation tax, locked inside a partly-owned entity, or simply reserved by the controlling family with no intention of distribution. **Trapped cash should be haircut heavily or excluded from the sum-of-the-parts**; treating it at face value can overstate value by a large factor.
|
||||
|
||||
**Signals that invert.**
|
||||
- **A low headline P/E** may exist only because a third of the market cap is cash earning treasury yields; the operating business can be far *more* expensive than it looks. It can also work the other way — do the arithmetic before concluding either.
|
||||
- **A depressed ROE** may be entirely cash drag, and the operating business's return on its own capital may be excellent. Never judge such a company on consolidated ROE.
|
||||
- **A rising cash pile with no distribution** is frequently the raw material for a value-destroying acquisition. Excess capital is a capital-allocation risk, not automatically a margin of safety.
|
||||
|
||||
**The trap.** Double-counting: valuing the company on an EV/EBITDA multiple (which already nets off cash) and then *adding back* the cash. Pick one treatment and state it.
|
||||
|
||||
---
|
||||
|
||||
## 14. Serial acquirers and roll-ups
|
||||
|
||||
**Recognise it.** Several acquisitions a year, goodwill and intangibles above ~30% of total assets (often above 100% of equity), "adjusted" EPS given prominence, and a growth story told in deals.
|
||||
|
||||
**What changes.** Reported growth is not a performance measure until you decompose it. Serial acquisition is either one of the best compounding models in existence or a machine for hiding organic decay and manufacturing EPS with cheap debt — **and the two look identical on a revenue chart.**
|
||||
|
||||
**Primary metrics.**
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Growth bridge | Split annual growth into organic / acquired / currency, every year | Organic positive and steady | Decelerating organic growth masked by a larger deal is the first visible symptom of a roll-up breaking. |
|
||||
| Return on acquisition capital | Cumulative cash spent on acquisitions over 5–10 years ÷ the incremental EBIT or FCF actually generated over the same period | >15% implied return | The single most honest test. It cannot be dressed by accounting choices. |
|
||||
| ROIC **including** goodwill | NOPAT ÷ (invested capital + accumulated goodwill, including goodwill previously written off) | Stable or rising, above WACC | Excluding goodwill lets a serial overpayer report excellent returns forever. |
|
||||
| Cash conversion | FCF ÷ net income | >80% sustained | Roll-ups with poor conversion are usually capitalising costs or under-investing in acquired units. |
|
||||
| Purchase price allocation | Share of consideration allocated to goodwill vs amortising intangibles | More to identifiable intangibles = more conservative | Dumping consideration into non-amortised goodwill flatters reported earnings indefinitely. |
|
||||
| Earn-outs / contingent consideration | Liability balance and payments due | Disclosed, modest | An off-radar claim on future cash that reduces equity value today. |
|
||||
|
||||
**Accounting notes.** Under IFRS/Ind-AS 103 and US GAAP, goodwill is **not amortised** — it is impairment-tested, and impairment is discretionary in timing, so it usually arrives late and all at once. Acquisition costs, restructuring of acquired businesses and amortisation of acquired intangibles are the standard "adjusted EPS" add-backs; if a company acquires every year, these are recurring operating costs and the adjustment is not legitimate.
|
||||
|
||||
**Signals that invert.**
|
||||
- **Strong headline EPS growth** funded by debt at a cost below the target's earnings yield is arithmetic, not value creation. Ask whether ROIC including goodwill improved.
|
||||
- **Rising goodwill with no impairment ever** is not conservatism; it is a deferred admission.
|
||||
- **A large acquisition announced immediately after a weak organic quarter** is a pattern worth naming explicitly.
|
||||
- **A decentralised "we never integrate" model** can be a genuine edge (low overhead, entrepreneurial units) or an excuse for no oversight — distinguish using cash conversion and same-unit organic growth.
|
||||
|
||||
**The trap.** Roll-ups break when acquisition multiples rise or funding closes — both external conditions, not company decisions. Model what happens to growth if the company makes **zero** acquisitions next year, and check the funding mix (debt vs equity issuance) against the maturity schedule.
|
||||
|
||||
---
|
||||
|
||||
## 15. SPACs and de-SPACs
|
||||
|
||||
**Recognise it.** The company listed by merging with a special purpose acquisition company rather than through an IPO. Tell-tales: warrants trading alongside the shares, a sponsor holding "founder shares", a PIPE, and an investor presentation containing multi-year revenue projections. Predominantly a US phenomenon (**India:** domestic SPAC listings are not permitted on NSE/BSE; SPAC frameworks exist at IFSCA/GIFT City, and Indian companies have de-SPACed onto US exchanges).
|
||||
|
||||
**What changes.** A de-SPAC is a **pre-IPO-quality company with public-market pricing and no IPO-grade diligence**. There is no underwriter due-diligence process of the traditional kind, no restated multi-year track record in many cases, and the merger was marketed on *projections* that a conventional IPO prospectus would not contain. Treat the projections as marketing, not guidance, and rebuild the model from historical financials only.
|
||||
|
||||
**What to check.**
|
||||
- **Redemption rate.** Before the merger closed, shareholders could redeem at the trust value (typically ~$10). Redemption rates above 90% were common, which means the announced cash-to-balance-sheet figure often did not arrive. Check what cash actually landed, in the 8-K/Super 8-K.
|
||||
- **Dilution stack.** Sponsor promote (classically ~20% of the pre-merger share count, acquired for a nominal sum), public and private warrants, PIPE shares (often issued below the effective deal price), earn-out/vesting shares, and convertible notes taken to bridge redemptions. Compute a **fully-diluted, post-all-instruments** share count and value on that. The headline "enterprise value" of a de-SPAC deal routinely understates the true diluted cost per share.
|
||||
- **Trust and timeline mechanics** (for a live SPAC, pre-merger): trust value per share, deadline to complete a deal, extension terms. A sponsor facing a deadline has a powerful incentive to complete *any* deal.
|
||||
- **Post-close reporting.** Look for restatements, material weaknesses in internal control (very common), auditor changes, and delayed filings in the first 18 months.
|
||||
|
||||
**Signals that invert.**
|
||||
- **A projection deck showing revenue growing 10x in four years** is a negative signal about the promoter's seriousness, not evidence of opportunity. Compare the first two years of actual results against the deck — the gap is the most informative number available.
|
||||
- **Trading near the $10 trust value** does not imply a floor once the merger has closed; the trust is gone and the price can go anywhere.
|
||||
- **A famous sponsor** is a distribution advantage, not a diligence substitute; the sponsor's economics are earned on *completing* a deal, not on its performance.
|
||||
|
||||
**The trap.** Valuing off the announced deal enterprise value and the projection deck, on a pre-dilution share count. Rebuild from actual historicals and a fully-diluted count, then apply §1 (loss-making growth) and §8 (recent IPO) in full — most de-SPACs are both.
|
||||
|
||||
---
|
||||
|
||||
## 16. Catalyst, horizon and falsification
|
||||
|
||||
Every situation in this file is a claim that a **value gap exists** *and* that a **mechanism will close it**. Without the mechanism, cheapness compounds at zero and the IRR decays with time even if your valuation is right. Before finishing, write down four things:
|
||||
|
||||
1. **The catalyst.** The specific event: spin listing and index inclusion, deal close, refinancing completed, disinvestment or strategic sale, cycle turn evidenced by capacity closures, first profitable quarter, buyback or dividend policy change, lock-up expiry passing, resolution plan approval.
|
||||
2. **The timeframe, and the IRR if it takes twice as long.** A 40% gap closing in 12 months is a 40% IRR; the same gap over 4 years is under 9% — often below the index alternative. Run both.
|
||||
3. **The falsification test.** Two or three *observable* facts that would prove the thesis wrong: contribution margin still negative after two more quarters; mid-cycle margin assumption breached on the downside; the discount widening past its historical extreme with no buyback; organic growth negative ex-acquisitions; the auditor resigning.
|
||||
4. **The base rate.** How often do situations of this type work? Turnarounds in structurally declining industries: rarely. Announced deals with clean regulatory paths: usually. Roll-ups after acquisition multiples rise: poorly. Anchor your probability to the reference class before adjusting for the specifics.
|
||||
|
||||
Set the review trigger on the **catalyst date, not the price**. The characteristic failure mode of situational investing is endlessly re-underwriting a broken thesis because the stock keeps getting cheaper.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Label the situation(s) explicitly before computing any multiple; multiple overlays are normal and the most conservative one wins conflicts.
|
||||
- [ ] Write down which standard metrics you are switching off and why, in one sentence, in the report.
|
||||
- [ ] Set a re-classification date; situations expire and companies migrate between them.
|
||||
- [ ] **Cyclicals: never conclude "cheap" from a low trailing P/E.** Check margin percentile, P/B, utilisation and industry capex first — a low P/E at peak margins is the market forecasting an earnings collapse.
|
||||
- [ ] Compute mid-cycle EPS from a median (not mean) full-cycle margin, and value on that; state the assumption and show ±200bps.
|
||||
- [ ] At the trough, switch to P/B, EV per unit of capacity and EV/replacement cost; earnings multiples are undefined there.
|
||||
- [ ] Measure cyclical leverage as net debt ÷ **mid-cycle** EBITDA and line maturities up against the expected trough years.
|
||||
- [ ] Loss-makers: prove contribution margin per unit is positive and improving before anything else; value per **fully-diluted future** share count.
|
||||
- [ ] Rebuild every "adjusted EBITDA" back to reported operating profit and list each add-back.
|
||||
- [ ] Turnarounds: classify operational / financial / secular using volumes and peer performance; secular decline is not a turnaround.
|
||||
- [ ] Require at least one hard, realised evidence marker before underwriting a turnaround — not an announcement.
|
||||
- [ ] Distressed: build the full liability stack and compute the equity residual before looking at the share price; check IBC (India) or Chapter 11 (US) status and whether equity is typically extinguished.
|
||||
- [ ] Spin-offs: model each entity standalone with real corporate costs added and parent allocations removed; read the scheme for how debt and liabilities were split.
|
||||
- [ ] Merger arb: size on the downside to the undisturbed price, not on the spread; enumerate every condition precedent with a probability; check open-offer proportionate acceptance (India).
|
||||
- [ ] Holdcos: value by SOTP net of holdco costs and tax leakage; plot the discount against its own history; require a named mechanism to close it.
|
||||
- [ ] Recent IPOs: check fresh-issue vs OFS, seller cost basis, lock-up calendar, and treat a pre-IPO margin ramp as a warning.
|
||||
- [ ] Micro-caps: compute days-to-exit and cap position size on liquidity before valuing anything; check auditor identity, resignations and qualified opinions.
|
||||
- [ ] Split maintenance from growth capex and compute incremental ROIC before calling any asset-heavy business a compounder.
|
||||
- [ ] Test whether an asset-light business's high ROIC comes with a reinvestment ceiling; capitalise leases before cross-model ROIC comparisons.
|
||||
- [ ] Promoter-controlled: read every RPT, royalty and remuneration line, and check pledged-share percentage and trend.
|
||||
- [ ] PSUs: identify profit-vs-policy objectives, subsidy receivable collection lags, and require a named catalyst — statistical cheapness alone is a permanent discount.
|
||||
- [ ] Treasury-heavy: separate core operations from the investment book, compute implied core P/E, and haircut trapped cash.
|
||||
- [ ] Serial acquirers: build the organic/acquired/currency growth bridge and compute cumulative cash spent on deals vs incremental EBIT generated.
|
||||
- [ ] De-SPACs: rebuild from historicals, ignore the projection deck, and value on a fully-diluted count including sponsor promote, warrants, PIPE and earn-outs.
|
||||
- [ ] Name the catalyst, the timeframe, the IRR if it takes twice as long, and two or three facts that would falsify the thesis.
|
||||
- [ ] Set the review trigger on the catalyst date, not on the price.
|
||||
|
|
@ -0,0 +1,493 @@
|
|||
# Accounting Standards, Comparability and Data Integrity
|
||||
|
||||
Use this when: you are about to put two or more companies in the same table, or chart one company across a period in which a standard, a currency, a year-end or a share count changed.
|
||||
|
||||
Every relative conclusion in this skill rests on an unstated assumption — that the numbers on both sides of the comparison mean the same thing. They usually do not. Reporting framework, lease convention, gross-versus-net revenue, cost classification, consolidation scope, fiscal calendar and currency all move headline ratios by more than the differences in business quality you are trying to detect. This file is the pre-processing layer: establish that the inputs are comparable, or state explicitly that they are not and by how much. A comp table built on uncorrected accounting differences ranks accounting policy, not businesses — the same failure mode as ranking a sector on OPM alone.
|
||||
|
||||
## Contents
|
||||
|
||||
- [1. The comparability gate — record the framework before anything else](#1-the-comparability-gate--record-the-framework-before-anything-else)
|
||||
- [2. The break-list: which differences actually move ratios](#2-the-break-list-which-differences-actually-move-ratios)
|
||||
- [3. Inventory costing — LIFO vs FIFO/weighted average](#3-inventory-costing--lifo-vs-fifoweighted-average)
|
||||
- [4. Development cost capitalisation vs expensing](#4-development-cost-capitalisation-vs-expensing)
|
||||
- [5. Leases — IFRS 16 / Ind-AS 116 vs ASC 842](#5-leases--ifrs-16--ind-as-116-vs-asc-842)
|
||||
- [6. Building lease-neutral EBITDA and lease-inclusive debt](#6-building-lease-neutral-ebitda-and-lease-inclusive-debt)
|
||||
- [7. Revenue recognition — gross vs net (principal vs agent)](#7-revenue-recognition--gross-vs-net-principal-vs-agent)
|
||||
- [8. Percentage-of-completion, contract assets and variable consideration](#8-percentage-of-completion-contract-assets-and-variable-consideration)
|
||||
- [9. Cost classification — COGS vs SG&A vs other income](#9-cost-classification--cogs-vs-sga-vs-other-income)
|
||||
- [10. Consolidation scope, minorities and associates](#10-consolidation-scope-minorities-and-associates)
|
||||
- [11. Goodwill, PPA and acquired-intangible amortisation](#11-goodwill-ppa-and-acquired-intangible-amortisation)
|
||||
- [12. Restatements, prior-period errors and re-presentation](#12-restatements-prior-period-errors-and-re-presentation)
|
||||
- [13. Transition method and the adoption-year break](#13-transition-method-and-the-adoption-year-break)
|
||||
- [14. Fiscal-year misalignment and TTM reconstruction](#14-fiscal-year-misalignment-and-ttm-reconstruction)
|
||||
- [15. Currency — presentation, functional and translation](#15-currency--presentation-functional-and-translation)
|
||||
- [16. Constant-currency and organic-growth reconciliation](#16-constant-currency-and-organic-growth-reconciliation)
|
||||
- [17. Deferred tax, effective tax rate and tax-regime differences](#17-deferred-tax-effective-tax-rate-and-tax-regime-differences)
|
||||
- [18. Non-GAAP figures and the quality of the adjustments](#18-non-gaap-figures-and-the-quality-of-the-adjustments)
|
||||
- [19. Symmetric normalisation of one-offs and cycle](#19-symmetric-normalisation-of-one-offs-and-cycle)
|
||||
- [20. Share count, dilution and per-share integrity](#20-share-count-dilution-and-per-share-integrity)
|
||||
- [21. Data-provider field definitions and error patterns](#21-data-provider-field-definitions-and-error-patterns)
|
||||
- [22. The cash-flow reconciliation integrity check](#22-the-cash-flow-reconciliation-integrity-check)
|
||||
- [23. Sector gate — where comparability is a different language](#23-sector-gate--where-comparability-is-a-different-language)
|
||||
- [24. The comparability worksheet you must produce](#24-the-comparability-worksheet-you-must-produce)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 1. The comparability gate — record the framework before anything else
|
||||
|
||||
Open the basis-of-preparation note (first note to the accounts) and the audit report, and record the **exact** framework for every company in the set — not "IFRS-ish". The distinctions that matter:
|
||||
|
||||
| Framework | Where you meet it | What to remember |
|
||||
|---|---|---|
|
||||
| IFRS as issued by the IASB | Most non-US listings, many 20-F filers | The reference dialect |
|
||||
| EU-endorsed IFRS | EU issuers | Endorsement lag and occasional carve-outs |
|
||||
| US GAAP | 10-K/10-Q filers on EDGAR | LIFO allowed, R&D expensed, ASC 842 dual-model leases |
|
||||
| **Ind-AS** (India) | Listed Indian companies, Schedule III Division II | IFRS-converged **with carve-outs** — a third dialect, not IFRS |
|
||||
| Indian GAAP (I-GAAP) | Indian filings before the Ind-AS transition; small unlisted subsidiaries | Not comparable to Ind-AS; hard series break |
|
||||
| J-GAAP / PRC GAAP / other local GAAP | Japan, China A-shares, several EMs | Goodwill amortisation, different consolidation practice |
|
||||
|
||||
Cross-checks worth two minutes each:
|
||||
|
||||
- **ADRs and 20-F filers:** a 20-F may be prepared under IFRS with **no** US GAAP reconciliation. Do not assume a US listing means US GAAP numbers.
|
||||
- **India:** every listed Indian company publishes **standalone and consolidated** statements. Use consolidated unless you are explicitly analysing the parent; mixing the two across years is one of the most common silent errors in Indian data.
|
||||
- **India — Ind-AS carve-outs that change numbers:** bargain-purchase gains go to capital reserve via OCI rather than the P&L; investment property is carried at **cost only** (fair value disclosed in a note); a first-time-adoption option allows continued capitalisation of exchange differences on long-term foreign-currency monetary items; foreign-currency convertible bonds may be equity-classified where IFRS would create a derivative liability.
|
||||
|
||||
**Why it matters:** EV/EBITDA, ROCE, net debt/EBITDA, gross margin and P/S are not defined identically across these dialects. If the framework column is missing from your comp sheet, every ranking downstream is partly a ranking of accounting policy.
|
||||
|
||||
---
|
||||
|
||||
## 2. The break-list: which differences actually move ratios
|
||||
|
||||
Not all GAAP differences are worth your time. These are the ones large enough to change a conclusion, ordered roughly by how often they do:
|
||||
|
||||
| Difference | IFRS / Ind-AS | US GAAP | Metrics it corrupts |
|
||||
|---|---|---|---|
|
||||
| Operating leases | On balance sheet; rent split into D&A + interest | Dual model; operating lease stays a single operating cost | EBITDA, EBIT, net debt, EV/EBITDA, ROCE, interest cover |
|
||||
| Inventory costing | LIFO prohibited | LIFO permitted | Gross margin, inventory days, asset turnover, ROCE, cash tax |
|
||||
| Development costs | Capitalised when IAS 38 criteria met | Mostly expensed (narrow software/cloud exceptions) | EBIT, EBITDA, CFO, capex, FCF, invested capital |
|
||||
| Impairment reversal | Permitted (not goodwill) | Prohibited | Asset base, depreciation, later-year earnings |
|
||||
| PPE revaluation | Revaluation model permitted | Cost only | Equity, D&A, ROE, ROCE, P/B |
|
||||
| Defined-benefit pensions | Net interest on net liability; remeasurements to OCI | Expected return on plan assets in P&L | Operating and net margin, EPS |
|
||||
| Interest/dividends in cash flow | Policy choice of section | Largely fixed | CFO, FCF, FCF yield |
|
||||
| Goodwill | Impairment-only | Impairment-only (public); amortisation alternative elsewhere | EBIT, ROCE, book value |
|
||||
| Bargain purchase gain | **Ind-AS:** capital reserve. IFRS: P&L | P&L | Reported PAT in acquisition years |
|
||||
| Investment property | IAS 40 fair-value model permitted (**Ind-AS: cost only**) | Cost | Real-estate earnings, book value, P/B |
|
||||
|
||||
Use this as a triage list: identify the two or three rows that are live for the peer set in front of you and fix those. Do not attempt a full GAAP-to-GAAP conversion — it is not achievable from public data, and the residual noise is smaller than the errors you would introduce.
|
||||
|
||||
---
|
||||
|
||||
## 3. Inventory costing — LIFO vs FIFO/weighted average
|
||||
|
||||
**What to do.** For US filers, read the inventory note for the **LIFO reserve** (the FIFO-minus-LIFO difference) and for any **LIFO liquidation** disclosure. Restate to a FIFO basis before comparing to IFRS or Ind-AS peers:
|
||||
|
||||
- Inventory (FIFO) = reported inventory + LIFO reserve
|
||||
- Equity (FIFO) = reported equity + LIFO reserve × (1 − tax rate)
|
||||
- COGS (FIFO) = reported COGS − increase in LIFO reserve during the year
|
||||
- Deferred tax liability increases by LIFO reserve × tax rate; net debt is unchanged
|
||||
|
||||
**Why.** In an inflationary period LIFO charges newer, higher costs to COGS. The US filer shows a lower gross margin, a smaller inventory balance and a lower cash tax bill than an economically identical IFRS peer — so it looks less profitable *and* more capital-efficient at the same time, and asset turnover, inventory days and ROCE comparisons are all meaningless. A **LIFO liquidation** (selling old, cheap layers) does the reverse: a non-repeatable gross-margin gain, to be stripped under §19.
|
||||
|
||||
**India:** LIFO is prohibited under Ind-AS 2, as under IFRS. The Indian check is different — confirm the cost formula (FIFO vs weighted average), overhead absorption at abnormal capacity, and the basis of net-realisable-value write-downs in the inventory note.
|
||||
|
||||
---
|
||||
|
||||
## 4. Development cost capitalisation vs expensing
|
||||
|
||||
**What to do.** Pull, from the intangibles note and the investing section of the cash flow statement: additions to internally generated intangibles, the amortisation charged on them, the carrying value of assets under development, and total R&D spend from the expense note or MD&A. Compute:
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Capitalisation rate | Capitalised development ÷ total R&D spend | Low and *stable*; a rising trend is the signal | A rate drifting upward converts current cost into a future asset — the cheapest way to buy margin |
|
||||
| Capitalised dev ÷ EBIT | Annual capitalised additions ÷ EBIT | Material above ~10% | Sizes the EBIT overstatement versus a full-expensing peer |
|
||||
| Amortisation ÷ capitalised additions | Yearly amortisation ÷ additions | Approaching 1.0 in steady state | Persistently below 1.0 means the asset balance is inflating; write-off risk builds |
|
||||
|
||||
*Indicative ranges vary by market, cycle and period; the company's own history and the peer median override any absolute band.*
|
||||
|
||||
**The common baseline.** The only reliably comparable treatment across an IFRS/Ind-AS and US GAAP peer set is to **expense everything**: reduce EBIT/EBITDA by capitalised additions, add back the related amortisation, reduce CFO by the same additions (they sit in investing), and remove the intangible from invested capital. Do it for every member of the set, including the ones that already expense (where the adjustment is zero), and state that you did.
|
||||
|
||||
**Why.** Capitalisation simultaneously inflates EBIT, EBITDA, CFO *and* invested capital, and deflates capex-adjusted FCF. It is the single largest comparability gap in pharma, software, autos and engineering peer sets, and a well-worn earnings-management lever — capitalising in bad years, writing off in a "kitchen sink" year.
|
||||
|
||||
---
|
||||
|
||||
## 5. Leases — IFRS 16 / Ind-AS 116 vs ASC 842
|
||||
|
||||
Confirm the convention for each company, then extract the same five items from every one: right-of-use asset, lease liability (current + non-current), ROU depreciation, lease interest, and the undiscounted maturity table with the discount rate.
|
||||
|
||||
| | IFRS 16 / Ind-AS 116 | ASC 842 operating lease | ASC 842 finance lease |
|
||||
|---|---|---|---|
|
||||
| Balance sheet | ROU asset + lease liability | ROU asset + lease liability | ROU asset + lease liability |
|
||||
| Income statement | Depreciation + interest | **Single operating lease cost** (straight-line) | Depreciation + interest |
|
||||
| EBITDA effect | **Inflated** (rent removed) | None | Inflated |
|
||||
| Reported debt in most screeners | Often excluded from "total debt" despite being a liability | Excluded | Sometimes included |
|
||||
| Cash flow classification | Principal in financing → **CFO inflated** | Entirely in operating → CFO unaffected | Principal in financing |
|
||||
|
||||
**Why.** For a lease-heavy business the difference is not cosmetic: retail, airlines, telecom towers, hotels, QSR, hospitals, diagnostics and 3PL logistics can see EBITDA move by tens of percent and reported debt by a multiple of pre-lease net debt. An unadjusted EV/EBITDA screen ranks the IFRS lessee as cheap and the US operating lessee as expensive, purely because of where rent sits. IFRS 16 also inflates CFO because only the interest portion stays in operating — so FCF-based screens are corrupted in the same direction.
|
||||
|
||||
**Watch the discount rate.** The incremental borrowing rate is management's estimate. A low rate inflates the ROU asset and liability and back-loads interest; compare the disclosed rate to the company's own marginal borrowing cost and to peers. A rate materially below the bond curve is a soft red flag and distorts the liability you are about to add to net debt.
|
||||
|
||||
---
|
||||
|
||||
## 6. Building lease-neutral EBITDA and lease-inclusive debt
|
||||
|
||||
Compute **both** conventions across the *entire* peer set, then pick one, apply it to everyone, and say which you used. Never mix.
|
||||
|
||||
**Convention A — pre-IFRS 16, "everyone pays cash rent" (EBITDAR-style, then deduct rent).** Best for operating comparisons and margin trends across the transition year.
|
||||
|
||||
- For IFRS/Ind-AS filers: EBITDA(A) = reported EBITDA − cash lease payments (principal + interest from the cash flow statement), i.e. remove the rent benefit.
|
||||
- For US operating-lease filers: EBITDA(A) = reported EBITDA (already after rent).
|
||||
- Net debt(A) = interest-bearing debt only; exclude all lease liabilities from both sides.
|
||||
- Capital employed(A) excludes ROU assets.
|
||||
|
||||
**Convention B — fully capitalised, "all leases are debt".** Best for leverage, credit and EV work.
|
||||
|
||||
- EBITDA(B) = EBITDA before all lease costs (add back rent for US operating lessees; IFRS filers already exclude it).
|
||||
- Net debt(B) = interest-bearing net debt + lease liability. For US operating leases, use the reported ASC 842 operating lease liability where available; if you must estimate, use the present value of the disclosed maturity table at the company's marginal borrowing rate. A crude 8× rent multiple is a last resort — say so if you use it.
|
||||
- Capital employed(B) includes ROU assets; EV includes lease liabilities.
|
||||
|
||||
| Ratio | Restate under | Why |
|
||||
|---|---|---|
|
||||
| EV/EBITDA | B (EV and EBITDA both lease-inclusive) | The only internally consistent lease treatment for a multiple |
|
||||
| Net debt/EBITDA | B, and report A alongside | Rating agencies and covenants differ; a turn of leverage is a rating notch |
|
||||
| Interest cover | B: EBITDA(B) ÷ (interest + lease interest) | Rent is a fixed charge whether or not GAAP calls it interest |
|
||||
| ROCE | Include ROU assets in capital employed when using B | Omitting them flatters a lease-heavy retailer's ROCE |
|
||||
| EBITDA margin trend across the transition year | A | Otherwise the adoption year shows a fake margin expansion |
|
||||
|
||||
**Why this matters more than it looks.** Leverage screens, covenant headroom and "cheapness" all shift by turns of EBITDA depending on convention. Most screeners exclude lease liabilities from "total debt" — meaning a lease-heavy IFRS retailer can appear both high-EBITDA and low-debt in the same row. That is not an opportunity; it is a definition.
|
||||
|
||||
---
|
||||
|
||||
## 7. Revenue recognition — gross vs net (principal vs agent)
|
||||
|
||||
**What to do.** Read the revenue note (IFRS 15 / ASC 606 / Ind-AS 115) and answer one question: does the company book gross transaction value or only its commission? Then triangulate — disclosed take rate × GMV should reconcile to net revenue; revenue per employee, receivable days and gross margin should look like the business model you think it is.
|
||||
|
||||
High-risk models: marketplaces and aggregators, travel, ticketing, distributors and stockists, telecom handset bundles, ad-tech and media resellers, EPC contractors with pass-through equipment, pharma CDMO with customer-supplied materials, and commodity traders.
|
||||
|
||||
**Why.** Two identical marketplaces can report revenue differing by an order of magnitude. Every P/S, EV/Sales, revenue-growth, revenue-per-employee and gross-margin comparison collapses if one books gross and the other net. A **change** in presentation between years is worse: it manufactures apparent revenue growth or margin expansion with zero economic change, and screeners rarely flag it.
|
||||
|
||||
**Tell-tale signs to search for:** "principal versus agent", "gross versus net", "reclassification of revenue", a gross margin that jumps by many points with no cost story, or revenue growth wildly out of line with volume/GMV disclosures.
|
||||
|
||||
**India note.** The introduction of GST in July 2017, combined with Ind-AS 115, removed excise duty from reported revenue for manufacturers. Reported revenue for affected companies fell by a high single-digit to low double-digit percentage with **no economic change**, and margins on revenue rose correspondingly. Any Indian revenue series or margin chart spanning FY2017–FY2018 must be flagged; never compute a CAGR straight across it without restating the earlier years net of excise.
|
||||
|
||||
---
|
||||
|
||||
## 8. Percentage-of-completion, contract assets and variable consideration
|
||||
|
||||
For construction, EPC, defence, capital goods, shipbuilding and long-cycle software, revenue is an estimate, not an event.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Unbilled revenue ÷ revenue | Contract assets ÷ trailing revenue | Stable; a rising multi-year trend is the signal | Rising unbilled means revenue recognised ahead of the customer's agreement to pay |
|
||||
| Contract liabilities ÷ revenue | Advances and deferred revenue ÷ revenue | Healthy when high and rising in advance-funded models | Customer-funded working capital; a fall can precede an order drought |
|
||||
| (Receivables + unbilled) days | (Trade receivables + contract assets) ÷ revenue × 365 | Compare to peers and own history only | The honest working-capital number in POC businesses |
|
||||
| Cost-to-complete revisions | Disclosed changes in estimates ÷ segment EBIT | Small and two-sided | Recurring favourable revisions are a margin-smoothing footprint |
|
||||
|
||||
*Indicative ranges vary by market, cycle and period; peer median and the company's own history override any absolute band.*
|
||||
|
||||
**What to read:** the method of measuring progress (input/cost-to-cost vs output/milestone), disclosures on variable consideration, claims and incentives and the constraint applied to them, onerous-contract provisions, and the order-book-to-revenue conversion commentary.
|
||||
|
||||
**Why.** A rising unbilled-to-revenue ratio is a leading indicator of optimistic cost-to-complete assumptions and future write-backs. It also makes revenue non-comparable against a peer recognising on delivery or milestones. **India:** real-estate developers moved from percentage-of-completion to completed-contract on Ind-AS 115 adoption; developer revenue and profit series are not continuous across that transition, and lumpy project completions dominate any single year.
|
||||
|
||||
---
|
||||
|
||||
## 9. Cost classification — COGS vs SG&A vs other income
|
||||
|
||||
**Gross margin is among the least comparable metrics in existence.** A company that puts depreciation, inbound freight, warehousing and direct labour in COGS will show a gross margin many points below an economically identical peer that puts them in SG&A. Ranking a sector on gross margin without checking classification produces a spurious ordering — exactly the single-metric failure this skill exists to prevent.
|
||||
|
||||
**What to do:**
|
||||
|
||||
1. Determine whether the P&L is presented **by nature** (material cost, employee benefits, other expenses — the IFRS/Schedule III convention) or **by function** (COGS, SG&A, R&D — the US convention). They are not mechanically convertible from the face of the statement.
|
||||
2. For each company, locate: depreciation, freight and distribution, R&D, share-based compensation, warranty, warehousing, and royalty. Note which line each sits in.
|
||||
3. Rebuild the comparison at **EBITDA and EBIT**, where most classification differences wash out. If you must use gross margin, define it yourself identically for every peer and say what you included.
|
||||
4. Check "other income": is it treasury income, scrap sales, government incentives, forex, or genuine operating income? Indian filers routinely park operating items there.
|
||||
|
||||
**India specifics.** Schedule III has **no gross profit line** — construct it as revenue from operations less (cost of materials consumed + purchases of stock-in-trade + changes in inventories), and apply that identical definition to every peer. "OPM" in Indian screeners and concalls means **EBITDA margin excluding other income**; a US "operating margin" means EBIT margin. Government incentives (PLI and state subsidies) may appear as other operating revenue for one company and as a credit netted against cost for another — same economics, different margin. See `03-earnings-quality.md` §1 and §3.
|
||||
|
||||
---
|
||||
|
||||
## 10. Consolidation scope, minorities and associates
|
||||
|
||||
**What to check.** For each material subsidiary and JV: fully consolidated, equity-accounted, or (in older data and some JV-heavy sectors) proportionately consolidated. Reconcile net income attributable to owners against total net income and compute the minority share. Look for structured entities, ESOP trusts, SPVs in infrastructure, and off-balance-sheet JVs.
|
||||
|
||||
**Why.** A company with 60%-owned operating subsidiaries consolidates **100%** of revenue and EBITDA but owns **60%** of the earnings. If EV is not grossed up for minority interest, EV/EBITDA looks artificially cheap — a systematic distortion in Indian infrastructure, hospitals, cement and telecom-tower structures, and in Korean and Japanese group companies. Conversely, a peer running the identical business through equity-accounted JVs reports almost no revenue at all and looks tiny on EV/Sales.
|
||||
|
||||
**Consistency rules for the EV bridge (apply to every peer identically):**
|
||||
|
||||
- Add minority interest to EV — at market value where the sub is separately listed, otherwise at an implied multiple, not book value, and say which.
|
||||
- Subtract the value of equity-accounted investments from EV **only if** their earnings are excluded from the EBITDA denominator. Never subtract the investment *and* keep the associate profit in the numerator metric.
|
||||
- Where a listed subsidiary or holding structure dominates, switch to the sum-of-the-parts and holdco approach in `13-situations.md` rather than forcing a multiple.
|
||||
- Check whether the peer's consolidation scope changed mid-year (acquisition/divestment): part-year consolidation makes growth and margin non-comparable until the anniversary.
|
||||
|
||||
---
|
||||
|
||||
## 11. Goodwill, PPA and acquired-intangible amortisation
|
||||
|
||||
**What to check.** Whether goodwill is amortised (some local GAAPs; the US private-company alternative) or impairment-tested only (IFRS, Ind-AS, US GAAP public). For recent acquisitions, pull the **purchase price allocation**: how much went to goodwill versus amortisable intangibles (customer relationships, brands, technology), and the useful lives assigned. Then compute acquired-intangible amortisation as a share of EBIT, and ROIC both including and excluding goodwill.
|
||||
|
||||
**Why.** An acquisitive company carries a PPA amortisation drag that an organic peer does not, while goodwill inflates its capital base and depresses ROCE. Unadjusted EBIT comparisons therefore penalise acquirers and flatter organic peers arbitrarily — and adding back all intangible amortisation (the standard non-GAAP move) flatters acquirers just as arbitrarily, because the acquired customer relationships genuinely do decay. The defensible treatment: report both, and judge whether maintenance spend on the acquired asset is already inside opex (if yes, the add-back is more justifiable; if no, it is not).
|
||||
|
||||
**Red flags:** an allocation overwhelmingly to goodwill (defers all cost recognition), useful lives far above the peer norm, goodwill never impaired through a demonstrable downturn, or a single cash-generating-unit structure that lets a strong business shelter a failing acquisition from impairment testing. Cross-reference `07-forensic-red-flags.md` for the serial-acquirer pattern.
|
||||
|
||||
---
|
||||
|
||||
## 12. Restatements, prior-period errors and re-presentation
|
||||
|
||||
**How to detect one without being told.** Put last year's annual report next to this year's and compare the **comparative** column line by line. Any difference is a restatement, a reclassification, or a discontinued-operations re-presentation. This mechanical check finds restatements that were never announced as such.
|
||||
|
||||
**What to search for:** "restated", "reclassified", "prior period error", "Ind-AS 8" / "IAS 8", "revision to previously issued financial statements", and in the US, an **Item 4.02 8-K** (non-reliance on previously issued statements). In India, also check exchange filings for revised results, auditor qualifications carried into the next year, and any NFRA or SEBI action.
|
||||
|
||||
**Classify what you find** — the four types have very different meanings:
|
||||
|
||||
1. **Error correction / non-reliance** — a governance event. Among the strongest standalone predictors of further negative surprises. Treat as a hard flag, not a data-cleaning task.
|
||||
2. **Voluntary accounting policy change** — read the justification; policy changes that raise reported profit deserve scepticism.
|
||||
3. **Discontinued operations re-presentation** — benign, but it silently rebases historical revenue and margin; your prior-year series must be re-pulled.
|
||||
4. **Business-combination measurement-period adjustment** — mechanical, but it moves goodwill and PPA amortisation retrospectively.
|
||||
|
||||
**Why it matters for data integrity.** Providers commonly store the **originally reported** figure for old years and the **restated** figure for recent ones. Multi-year growth rates and CAGRs computed across that seam are arithmetic nonsense, and the corruption is invisible in the output. When a restatement exists, rebuild the series from filings for the affected years.
|
||||
|
||||
---
|
||||
|
||||
## 13. Transition method and the adoption-year break
|
||||
|
||||
For every new standard adopted in your window (IFRS 16 / Ind-AS 116, IFRS 15 / Ind-AS 115, IFRS 9 / Ind-AS 109, ASC 842 / 606 / 326 CECL, IFRS 17), determine the transition method:
|
||||
|
||||
- **Full retrospective** — comparatives restated; the series is continuous.
|
||||
- **Modified retrospective / cumulative catch-up** — comparatives **not** restated; a plug goes to opening retained earnings. The adoption year is a hard break, and growth, margin and leverage computed across it are meaningless.
|
||||
|
||||
Mark the transition year on every chart you build and in any table spanning it.
|
||||
|
||||
**India — the series breaks you will actually hit:**
|
||||
|
||||
| Break | Effect on the series |
|
||||
|---|---|
|
||||
| I-GAAP → Ind-AS (phased from FY2017 for larger companies, FY2018 for the rest) | Pre-transition years are a different framework. Long-run charts crossing this point mix two GAAPs. |
|
||||
| GST / excise removal from revenue (FY2018) | Reported revenue steps down for manufacturers with no economic change (§7). |
|
||||
| Ind-AS 115 for real estate (POC → completed contract) | Developer revenue and PAT series discontinuous and lumpy thereafter. |
|
||||
| Ind-AS 116 leases (FY2020) | EBITDA and reported debt step up for lease-heavy sectors. |
|
||||
| Section 115BAA tax election (from FY2020) | Statutory rate step-down plus one-off deferred-tax remeasurement (§17). |
|
||||
|
||||
**US/global equivalents:** ASC 606 (2018-19), ASC 842 (2019), CECL for lenders (2020-23 phased), IFRS 17 for insurers (2023) — IFRS 17 in particular broke the entire historical earnings series for insurers; do not chart through it.
|
||||
|
||||
---
|
||||
|
||||
## 14. Fiscal-year misalignment and TTM reconstruction
|
||||
|
||||
Record every company's fiscal year-end. Common patterns: **India and Japan 31 March**; many US retailers a **52/53-week year** ending late January/early February; Australia and several others 30 June; most of the rest 31 December.
|
||||
|
||||
**Rules:**
|
||||
|
||||
- If year-ends differ by **more than one quarter**, do not compare annual figures — rebuild a **trailing-twelve-month** series from quarterly data so every company covers the same calendar window, and state the window explicitly ("TTM to 30 June 2026").
|
||||
- Beware the **label collision**: an Indian "FY25" means the year ended March 2025; a US "FY2025" often means calendar 2025. Comparing them offsets the economic period by nine to twelve months.
|
||||
- Flag **53-week years** (an extra ~2% of trading in retail) and remove the extra week before computing growth.
|
||||
- Flag **stub / transition periods** when a company changes its year-end — a 9-month or 15-month "year" destroys every ratio computed on it.
|
||||
- **India:** quarterly results under SEBI LODR are limited-reviewed, not audited, and **Q4 is a balancing figure** (audited full year minus the three reviewed quarters). True-ups cluster there, so a TTM built through a Q4 inherits them. See `03-earnings-quality.md`.
|
||||
|
||||
**Why.** A one-quarter offset is enough to place two companies on opposite sides of a commodity move, a rate cycle or a demand shock — making one look like a share-gainer when it is merely earlier in the calendar.
|
||||
|
||||
---
|
||||
|
||||
## 15. Currency — presentation, functional and translation
|
||||
|
||||
**What to identify:** the presentation currency, the functional currency of the major operating subsidiaries, the translation method (current-rate: assets/liabilities at closing rate, P&L at average rate, difference to OCI as the cumulative translation adjustment), and whether any subsidiary sits in a hyperinflationary economy requiring IAS 29 / Ind-AS 29 restatement. Check whether the company **changed** its presentation currency in the period — this silently rebases the entire history.
|
||||
|
||||
**Conversion rules when comparing across currencies (get these wrong and you inject percentage-point errors):**
|
||||
|
||||
- Income statement and cash flow items → **average rate** for the period.
|
||||
- Balance sheet items → **closing rate** at the period end.
|
||||
- Never apply today's spot rate to historical years — it destroys the growth series by re-denominating each year at a rate it never traded at.
|
||||
- Ratios that are currency-on-currency (margins, turnover, leverage, ROCE) need **no** conversion. Convert only when comparing absolute size, EV, or per-share values.
|
||||
- **India:** figures are in **₹ crore** (1 crore = 10 million) or **₹ lakh** (1 lakh = 0.1 million). Unit errors between crore, lakh, million and billion are the single most common arithmetic failure in cross-market work. Restate everything to one unit at the point of extraction and label the column.
|
||||
|
||||
**Where the FX distortion shows up:** read the CTA balance in equity (a large and growing CTA means a big translation exposure) and the FX gain/loss line in the P&L (transaction exposure, often on foreign-currency debt — this is a financing item, not operating performance, and must be normalised out under §19).
|
||||
|
||||
---
|
||||
|
||||
## 16. Constant-currency and organic-growth reconciliation
|
||||
|
||||
Find management's bridge from reported growth to organic/constant-currency growth: **FX · acquisitions · divestments · scope and accounting changes · extra trading week**. If it is not disclosed, rebuild it yourself from segment and acquisition disclosures.
|
||||
|
||||
**Verify, do not accept:**
|
||||
|
||||
- Acquisitions are excluded from "organic" for the full **12-month anniversary**, not just the stub period.
|
||||
- Divestments are removed from the **base year** too, not only the current one.
|
||||
- Constant currency uses prior-year average rates applied to current-year local results — not closing rates.
|
||||
- The definition did not change between years (it often does, always in a flattering direction).
|
||||
|
||||
**Why.** "Organic" is an unaudited, company-defined term. Without a like-for-like bridge you cannot distinguish execution from a currency tailwind or from debt-funded bolt-on M&A — and those three deserve completely different multiples. A company whose entire growth premium is FX will de-rate the moment the currency turns, and one whose growth is acquisition-funded is buying its growth with the balance sheet you are also valuing.
|
||||
|
||||
---
|
||||
|
||||
## 17. Deferred tax, effective tax rate and tax-regime differences
|
||||
|
||||
**What to do.** Reconcile the effective tax rate to the statutory rate using the tax note, and identify the drivers: tax holidays and incentive regimes, geographic mix, unrecognised deferred tax assets, prior-year settlements, and one-off remeasurements. Then form a view on the **sustainable** rate and use it in normalised earnings.
|
||||
|
||||
| Check | How | Why it matters |
|
||||
|---|---|---|
|
||||
| ETR vs statutory rate | Tax note reconciliation, 5 years | A persistent gap must have a named, dated cause — holidays expire |
|
||||
| Cash tax vs P&L tax | Tax paid in the cash flow statement ÷ PBT | A large persistent gap points to capitalisation, accelerated depreciation, or aggressive positions |
|
||||
| Deferred tax asset recognition | DTA note; unrecognised losses | Recognising a DTA on carried-forward losses creates non-cash profit; US GAAP uses valuation allowances, IFRS a single probability model |
|
||||
| Rate-change remeasurement | One-off tax line in the year of a statutory change | Non-repeatable; strip from normalised earnings both ways |
|
||||
|
||||
**Why it matters for comparability.** Cross-border comparisons on net margin, ROE and P/E are dominated by tax regime, not operating performance. Compare at **EBIT/EBITDA**, or normalise every peer to a sustainable tax rate, before drawing a bottom-line conclusion. Presentation also differs: IFRS/Ind-AS classify all deferred tax as non-current, and IFRS has no valuation-allowance mechanic.
|
||||
|
||||
**India:** the concessional regime under section 115BAA (from FY2020) produced both a permanent step down in the statutory rate and a **one-off deferred-tax and MAT-credit remeasurement** in the year of election. Any margin or EPS series crossing that point contains a policy step and a one-off; separate them. Also check SEZ / export-incentive holidays with known expiry dates — an IT or pharma peer enjoying a holiday that lapses next year has a structurally rising tax rate that the trailing P/E does not show.
|
||||
|
||||
---
|
||||
|
||||
## 18. Non-GAAP figures and the quality of the adjustments
|
||||
|
||||
**Reconcile every "adjusted" number back to the statutory number**, then tabulate the add-backs by type and by year.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Adjusted-to-statutory gap | (Adjusted PAT − reported PAT) ÷ reported PAT | Small and non-recurring | A persistent gap is a measurable governance signal |
|
||||
| Cumulative add-backs ÷ cumulative reported profit | Sum over 5–10 years | Well under a fifth of profit | Sizes how much of "earnings power" is a management assertion |
|
||||
| Recurrence count | Consecutive years each "one-off" item appears | 1, occasionally 2 | Restructuring in five straight years is an operating cost with a euphemism |
|
||||
| SBC ÷ revenue and SBC ÷ EBITDA | From the cash flow statement or the SBC note | Compare to sector, not absolute | SBC is a real cost of labour; adding it back overstates margin and, with buybacks, hides dilution |
|
||||
|
||||
*Indicative ranges vary by market, cycle and period; peer and own-history comparison overrides any absolute band.*
|
||||
|
||||
**Rules of thumb worth defending:** never accept an add-back for share-based compensation; treat recurring restructuring as operating cost; treat acquired-intangible amortisation as an adjustment you report **both ways** (§11); treat "one-off" litigation as recurring if the company is structurally litigious.
|
||||
|
||||
**India:** the equivalent is the **exceptional items** line under Schedule III (which sits between "profit before exceptional items and tax" and PBT) — there is no direct US analogue. Read the note behind it every year and track how often it is populated. Companies also present "adjusted EBITDA" in investor presentations that reconciles to nothing in the audited statements; use the statutory figures and rebuild adjustments yourself.
|
||||
|
||||
---
|
||||
|
||||
## 19. Symmetric normalisation of one-offs and cycle
|
||||
|
||||
Build a normalised earnings series by removing, **with identical rigour in both directions**:
|
||||
|
||||
- Gains: asset and stake sale gains, insurance recoveries, tax settlements in the company's favour, write-backs of provisions, bargain purchase gains, fair-value gains on investments, LIFO liquidation benefits.
|
||||
- Losses: impairments, restructuring, litigation charges, forex losses on debt, business-interruption effects, one-time regulatory penalties.
|
||||
|
||||
Then, for cyclical sectors, use **mid-cycle margins over a full cycle** rather than the trailing year — commodities, autos, shipping, chemicals, cement and lenders are almost never representative in any single year.
|
||||
|
||||
**Why.** The habitual bias is to strip losses and keep gains, which mechanically inflates normalised earnings and makes a "normalised P/E" a marketing number. Symmetric normalisation is what makes mid-cycle P/E and EV/EBIT usable. **Document every adjustment with its note reference** — an undocumented normalisation cannot be audited by the next reader (including you, next quarter).
|
||||
|
||||
---
|
||||
|
||||
## 20. Share count, dilution and per-share integrity
|
||||
|
||||
**What to use.** **Diluted weighted-average shares from the EPS note**, not the current outstanding count from a data feed. Then:
|
||||
|
||||
- Adjust the entire historical per-share series for splits, bonus issues, share consolidations, and rights issues (via the **theoretical ex-rights price factor** — a rights issue is part capital raise, part bonus, and ignoring the factor creates a fake per-share drop).
|
||||
- Add outstanding options, RSUs, warrants and convertibles — and check the anti-dilution mechanics of convertibles and any reset clauses.
|
||||
- Include **all** share classes in market cap: dual-class, DVR lines (India), preference shares that are economically equity, and unlisted classes. Providers routinely capitalise only the primary listed line.
|
||||
- Check shares held by an **ESOP/ESOS trust** and treasury shares — conventions differ on whether they are netted out.
|
||||
- **India:** confirm the count against the shareholding pattern filed with the exchanges (promoter, public, DII/FII), and check for warrants issued to promoters on a preferential basis, which convert at a pre-set price and dilute on a known schedule.
|
||||
|
||||
**Why.** Unadjusted or partially adjusted per-share history creates fake growth and fake collapses. Multi-class and multi-line issuers — common in India, Brazil, Korea and Europe — are systematically mis-capitalised, which understates EV and makes the stock look far cheaper than it is. This is the most frequent single cause of a screener showing an implausibly low P/E.
|
||||
|
||||
---
|
||||
|
||||
## 21. Data-provider field definitions and error patterns
|
||||
|
||||
**Before you screen on a field, read its definition.** For every metric, answer:
|
||||
|
||||
- Does "**debt**" include lease liabilities, preference shares, acceptances/bill discounting, and perpetual instruments?
|
||||
- Is "**EBITDA**" EBIT + D&A from the filing, or a vendor-standardised model? Does it include other income?
|
||||
- Is "**EPS**" basic or diluted, reported or adjusted, continuing operations or total?
|
||||
- Is the multiple on **trailing, forward-consensus, or last-fiscal-year** data — and if forward, how many contributors?
|
||||
- Is the series **consolidated or standalone**? (India — providers sometimes splice.)
|
||||
- Is the currency tag correct, and are units crore/lakh/million consistent?
|
||||
|
||||
**Then hand-verify the top three and bottom three hits of any screen against the primary filings before acting on it.** This is not optional diligence; it is the highest-yield twenty minutes in the whole process.
|
||||
|
||||
**Why.** Provider errors cluster precisely where screens are most extreme: misparsed exceptional items, a missing quarter in a TTM, a stale or unsplit share count, a mis-tagged currency, standalone spliced onto consolidated. The outliers a screen surfaces are disproportionately data artefacts rather than opportunities — which is exactly why the screen surfaced them. Source hierarchy and provider-specific quirks are in `01-data-sourcing.md`; the primary sources to fall back to are EDGAR (10-K/20-F/8-K, XBRL company facts) and, in India, the BSE/NSE announcement filings, the annual report PDF and MCA filings.
|
||||
|
||||
---
|
||||
|
||||
## 22. The cash-flow reconciliation integrity check
|
||||
|
||||
Run this on every company before you trust any income-statement-derived ratio.
|
||||
|
||||
| Check | How to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Cumulative CFO ÷ cumulative PAT | Sum both over 5–10 years | Around 1.0 or above for most non-financials | Persistent divergence is the single most reliable flag for revenue-recognition or capitalisation aggression |
|
||||
| CFO − capex vs reported FCF | Rebuild from the statement | Should tie exactly | If it does not, the company's FCF definition excludes something — find out what |
|
||||
| Cumulative FCF vs cumulative reported profit | Sum over a full cycle | Directionally consistent | Profit that never becomes cash over a decade is not profit |
|
||||
| Interest/dividend classification | Read the cash flow statement sections | Restate to one convention across peers | IFRS permits choices; US GAAP largely fixes them |
|
||||
|
||||
*Indicative ranges vary by market, cycle and period; peer and own-history comparison overrides any absolute band.*
|
||||
|
||||
**The classification trap in detail.** Under IFRS/Ind-AS, interest paid may sit in operating **or** financing, and dividends received in operating **or** investing. Common IFRS practice puts interest paid in financing; US GAAP puts it in operating. For a levered company this means the IFRS filer's CFO is **higher** than an identical US filer's by the entire interest bill — and so is its FCF and FCF yield. Restate every peer to one convention (put interest paid in operating for all, or below CFO for all) and say which.
|
||||
|
||||
**Also watch:** supply-chain finance / reverse factoring (a borrowing that presents as trade payables and flatters CFO — disclosure is now required under both frameworks, so its absence is itself informative), receivables securitisation and factoring, capitalised interest, and capex reclassified between operating and investing. Cross-reference `04-balance-sheet-and-cashflow.md` and `07-forensic-red-flags.md`.
|
||||
|
||||
---
|
||||
|
||||
## 23. Sector gate — where comparability is a different language
|
||||
|
||||
Before applying any generic template, confirm the metric set is even defined for the industry. Establish comparability **inside the sector's own accounting language** first.
|
||||
|
||||
| Sector | The accounting fault line | Consequence |
|
||||
|---|---|---|
|
||||
| Banks / NBFCs | IFRS 9 / Ind-AS 109 expected credit loss vs US CECL vs legacy incurred-loss; IRAC norms in India | EBITDA and EV are meaningless; compare NII, NIM, provisioning coverage, GNPA/NNPA, capital adequacy |
|
||||
| Insurers | IFRS 17 vs prior embedded-value regimes; Indian insurers on Ind-AS 104-era practice | The historical series is broken at the IFRS 17 boundary; use VNB, EV, combined ratio |
|
||||
| Real estate / REITs | IAS 40 fair-value gains flow through the IFRS P&L (**Ind-AS: cost model only**); US GAAP cost | An IFRS developer's "profit" may be unrealised revaluation; use NAV, FFO/AFFO |
|
||||
| Utilities / regulated | Regulatory deferral accounts and regulatory assets | Reported earnings reflect a regulatory compact, not free-market margin |
|
||||
| Oil & gas E&P | Successful-efforts vs full-cost capitalisation | Asset base, DD&A and EBIT differ materially between identical wells |
|
||||
| Miners | Stripping-cost capitalisation, reserve-based depreciation, rehabilitation provisions | Unit-cost and ROCE comparisons need identical policies |
|
||||
| Shipping / airlines | Charter/lease structures, residual value and useful-life assumptions | Lease convention (§5-6) dominates every leverage metric |
|
||||
|
||||
Route to `references/sectors/_index.md` for the sector-specific metric set. The governing principle applies with full force here: for banks, insurers, REITs and miners the standard ratios are undefined or inverted, and forcing them produces confident nonsense.
|
||||
|
||||
**Audit reliability is a precondition, not a section.** If the auditor resigned mid-cycle, a material subsidiary is audited by a different small firm, there is a going-concern emphasis, an adverse ICFR opinion, or a recurring key audit matter on revenue recognition, then none of the above matters — the inputs are unreliable. Handle this before comparability work; see `08-governance.md` and `15-document-diligence.md`.
|
||||
|
||||
---
|
||||
|
||||
## 24. The comparability worksheet you must produce
|
||||
|
||||
Keep one row per company and carry it into the report. This is the artefact that makes a comp table auditable and stops someone (including you) from silently sorting a column and reintroducing the single-metric ranking error.
|
||||
|
||||
| Column | What it records |
|
||||
|---|---|
|
||||
| Framework | IFRS / US GAAP / Ind-AS / local GAAP; ADR reconciliation yes/no |
|
||||
| Fiscal year-end and period used | e.g. "31 Mar; TTM to Jun-2026" |
|
||||
| Currency and unit | Reporting currency; conversion rate convention used (avg for P&L, closing for BS) |
|
||||
| Basis | Consolidated / standalone; minority share of PAT |
|
||||
| Lease convention | A (pre-IFRS 16) or B (fully capitalised); lease liability added to net debt (yes/no) |
|
||||
| Revenue basis | Gross or net; take rate if applicable |
|
||||
| Inventory | LIFO restated to FIFO? LIFO reserve value |
|
||||
| R&D | Expensed / capitalised; capitalisation rate; adjustment applied |
|
||||
| Normalisations | List of items removed, with note references and sign |
|
||||
| Breaks | Transition years, restatements, currency changes, stub periods flagged |
|
||||
| Data source | Filing vs provider, and which fields were hand-verified |
|
||||
|
||||
Also record the peers you **excluded** and why. Peer-set construction itself is in `10-peer-set.md`; this worksheet is the comparability layer that sits under it.
|
||||
|
||||
State in the report, in one sentence: *"Peers are compared on [lease convention], [currency convention], [period], with [named adjustments] applied identically to all members; residual non-comparability is [X]."* If you cannot write that sentence, the comparison is not ready.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Record the exact reporting framework for every company in a column; note Ind-AS carve-outs and whether an ADR has a GAAP reconciliation.
|
||||
- [ ] India: use consolidated statements throughout; never splice standalone and consolidated across years.
|
||||
- [ ] Identify the two or three GAAP differences that are actually live for this peer set; fix those, not all of them.
|
||||
- [ ] Restate US LIFO filers to FIFO (inventory, equity, COGS, deferred tax) before any margin or turnover comparison.
|
||||
- [ ] Compute the R&D capitalisation rate; build a full-expensing baseline across the whole set and say you did.
|
||||
- [ ] Pull ROU assets, lease liabilities, ROU depreciation, lease interest, maturity table and discount rate for every company.
|
||||
- [ ] Build both lease conventions (A: pre-IFRS 16; B: fully capitalised); apply one to all peers, state which, and under B put lease liabilities in EV and ROU assets in capital employed.
|
||||
- [ ] Confirm gross vs net revenue recognition and reconcile take rate to revenue; flag any presentation change between years.
|
||||
- [ ] India: flag the FY2018 excise/GST revenue step-down before computing any revenue CAGR across it.
|
||||
- [ ] Track unbilled revenue ÷ revenue and (receivables + unbilled) days for POC businesses.
|
||||
- [ ] Rebuild margins at EBITDA/EBIT where classification differs; define gross margin identically for all peers or do not use it.
|
||||
- [ ] Reconcile PAT attributable to owners vs total; gross EV up for minority interest; handle associates consistently on both sides.
|
||||
- [ ] Pull the PPA for recent deals; report ROIC with and without goodwill and quantify PPA amortisation as a share of EBIT.
|
||||
- [ ] Compare last year's comparatives to this year's line by line to detect unannounced restatements; classify what you find.
|
||||
- [ ] Identify the transition method for every new standard; mark adoption years on every chart.
|
||||
- [ ] India: flag the I-GAAP→Ind-AS break, Ind-AS 115 for real estate, Ind-AS 116, and the 115BAA tax election.
|
||||
- [ ] Align fiscal periods; rebuild TTM from quarterly data where year-ends differ by more than a quarter; strip 53rd weeks and stub periods.
|
||||
- [ ] Use average rates for P&L, closing rates for balance sheet; never re-denominate history at today's spot; standardise crore/lakh/million at extraction.
|
||||
- [ ] Rebuild the reported-to-organic growth bridge (FX, M&A, divestments, extra week) and verify the 12-month anniversary rule.
|
||||
- [ ] Reconcile ETR to the statutory rate and to cash tax; normalise to a sustainable rate; identify expiring holidays.
|
||||
- [ ] Reconcile every adjusted figure to statutory; count how many years each "one-off" recurs; never add back share-based compensation.
|
||||
- [ ] Normalise gains and losses symmetrically, with a note reference for each adjustment; use mid-cycle margins in cyclicals.
|
||||
- [ ] Use diluted weighted-average shares from the EPS note; adjust history for splits, bonuses and rights (TERP); capitalise all share classes.
|
||||
- [ ] Read the provider's definition of every field you screen on; hand-verify the top and bottom three hits against primary filings.
|
||||
- [ ] Run cumulative CFO ÷ cumulative PAT over 5–10 years; restate interest/dividend classification to one convention; check for reverse factoring, securitisation and capex reclassification.
|
||||
- [ ] Apply the sector gate — confirm the metric set exists for banks, insurers, REITs, utilities, E&P and miners before comparing.
|
||||
- [ ] Confirm audit reliability first; unreliable inputs void every adjustment above.
|
||||
- [ ] Produce the comparability worksheet, list excluded peers with reasons, and write the one-sentence comparability statement in the report.
|
||||
|
|
@ -0,0 +1,629 @@
|
|||
# Primary-Document Diligence
|
||||
|
||||
Use this when: you have moved past screener data and need to work the actual filings — annual report, auditor's report, transcripts, rating rationales, exchange disclosures — either as the Stage 3 red-flag pass, the Stage 4 deep dive, or any time a number from an aggregator needs to be believed rather than merely quoted.
|
||||
|
||||
Everything else in this skill assumes the inputs are real. This file is where you establish that. A ratio computed from a figure you never traced to a primary document is a guess with decimal places, and the documents below are also the only place where the *non-quantitative* evidence lives — the auditor's own map of where the balance sheet is fragile, the promises management made three years ago, the guarantee issued to a promoter entity, the clause in CARO that says statutory dues went unpaid for six months. The governing principle applies throughout: a disclosure is meaningless until you know the sector and the company's own history. A large contingent liability is routine for an EPC contractor and alarming for a branded consumer company; a KAM on loan-loss provisioning is expected at every bank and would be extraordinary at a software firm.
|
||||
|
||||
## Contents
|
||||
|
||||
- [0. The annual report contains all of this — a complete contents map](#0-the-annual-report-contains-all-of-this--a-complete-contents-map)
|
||||
- [1. Reading order when time is limited](#1-reading-order-when-time-is-limited)
|
||||
- [2. The liability gradient: how much each document is worth](#2-the-liability-gradient-how-much-each-document-is-worth)
|
||||
- [3. MD&A / Management Discussion and Analysis](#3-mda--management-discussion-and-analysis)
|
||||
- [4. Notes to accounts: policies, estimates and changes therein](#4-notes-to-accounts-policies-estimates-and-changes-therein)
|
||||
- [5. Contingent liabilities and commitments](#5-contingent-liabilities-and-commitments)
|
||||
- [6. Related-party transactions note](#6-related-party-transactions-note)
|
||||
- [7. Segment note](#7-segment-note)
|
||||
- [8. The auditor's report — read this in full, every year](#8-the-auditors-report--read-this-in-full-every-year)
|
||||
- [9. Consolidated vs standalone, AOC-1 and the subsidiary map](#9-consolidated-vs-standalone-aoc-1-and-the-subsidiary-map)
|
||||
- [10. Earnings-call transcripts and Q&A behaviour](#10-earnings-call-transcripts-and-qa-behaviour)
|
||||
- [11. Investor presentations vs audited filings](#11-investor-presentations-vs-audited-filings)
|
||||
- [12. DRHP / RHP / S-1 and offer documents](#12-drhp--rhp--s-1-and-offer-documents)
|
||||
- [13. Credit rating rationales and rating actions](#13-credit-rating-rationales-and-rating-actions)
|
||||
- [14. Exchange filings and continuous disclosure](#14-exchange-filings-and-continuous-disclosure)
|
||||
- [15. Shareholding pattern and promoter pledge](#15-shareholding-pattern-and-promoter-pledge)
|
||||
- [16. Proxy / AGM materials and voting results](#16-proxy--agm-materials-and-voting-results)
|
||||
- [17. Short-seller reports, forensic notes and adverse media](#17-short-seller-reports-forensic-notes-and-adverse-media)
|
||||
- [18. Secretarial audit and Directors' Report annexures](#18-secretarial-audit-and-directors-report-annexures)
|
||||
- [19. Sector translation: which documents replace the standard set](#19-sector-translation-which-documents-replace-the-standard-set)
|
||||
- [20. Archive and data-provenance hygiene](#20-archive-and-data-provenance-hygiene)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 0. The annual report contains all of this — a complete contents map
|
||||
|
||||
The annual report is the single most complete document a company publishes about itself, and **almost every section carries something an investor should weigh** — the strategy in the chairman's letter, the pay ratio in an obscure annexure, the covenant in a borrowings note, the one live case in a litigation schedule that is otherwise routine. The discipline is therefore: **read and consider all of it, then report selectively.** Coverage in the reading is comprehensive; the write-up stays focused on what proved material. Skipping a section because it "looks like boilerplate" is exactly how the single live disclosure inside it gets missed — the boilerplate-versus-substance judgement is made *after* reading the section, never by not reading it.
|
||||
|
||||
Use the map below as a **coverage checklist**: walk every section, extract what matters, and for a section that is genuinely empty this year, record "read — nothing material" rather than leaving it unopened (next year it may not be empty). §1 below then tells you the *order* to read the high-yield sections under time pressure, and §§3–18 tell you *how* to read each one. This map exists so that nothing is skipped.
|
||||
|
||||
### Indian annual report (Companies Act 2013 + SEBI LODR) — section by section
|
||||
|
||||
| Section | What lives here | What to pull |
|
||||
|---|---|---|
|
||||
| Financial highlights / 5–10-year record | The company's own multi-year summary | The long-run trend, and any year quietly restated or omitted from the series |
|
||||
| Chairman's / MD's letter | Strategy, capital-allocation intent, tone | Stated priorities and promises — checked next year against delivery |
|
||||
| Corporate overview / business model | Products, brands, plants, geographies, operating KPIs | The revenue-model map and operational scale, before the numbers frame it |
|
||||
| **MD&A** | Industry structure, segment performance, outlook, risks & concerns, internal-control adequacy, **key financial ratios with explanation of any change >25%** | Volume/price/mix decomposition, guidance, and the ratio-change explanations (§3) |
|
||||
| **Board's / Directors' Report** | State of affairs, dividend, share-capital/ESOP changes, deposits, **s.186 loans/guarantees/investments**, **AOC-2 related-party contracts**, risk-management policy, board evaluation | The statutory narrative plus its annexures (below) |
|
||||
| — Annexure **AOC-1** | Salient financials of every subsidiary / associate / JV | Loss-making, negative-net-worth, newly acquired and newly deconsolidated entities (§9) |
|
||||
| — Annexure **CSR report** | Spend vs 2% obligation, projects, unspent transfers | A clean compliance signal; repeatedly deferred/unspent amounts (§18) |
|
||||
| — Annexure **particulars of employees (s.197)** | Median remuneration, MD/WTD pay, pay ratio, top earners | Promoter/KMP pay vs PAT and its trajectory (§16) |
|
||||
| — Annexure energy / tech absorption / **forex** | R&D and technology, **forex earnings and outgo** | Net forex exposure and any large unexplained outflow |
|
||||
| **Corporate Governance Report** | Board composition & independence, committee membership and **attendance**, remuneration policy, RPT policy, **general shareholder information** (AGM, dividend, listing, stock data, shareholding distribution, plant locations), dividend distribution policy | Governance quality and the full shareholder-information block (§8, §16, §18) |
|
||||
| **BRSR** (top listed cos) | ESG across 9 principles; BRSR-Core assured metrics | Regulatory, environmental and litigation exposure; treat unassured parts as narrative (§18) |
|
||||
| Secretarial audit (MR-3) + LODR 24A | Statutory-compliance qualifications | Any qualification — late filings, invalid appointments, RPT/committee failures (§18) |
|
||||
| **Independent Auditor's Report** (standalone *and* consolidated) | Opinion, basis, **KAMs**, EOM, Other Matter, **CARO** annexure, **IFC** opinion | The highest-yield section per minute — read in full, both bases (§8) |
|
||||
| Balance sheet, P&L (+OCI), cash flow, changes in equity | The four primary statements | The numbers — reconcile all four and tie them together (§4; 01-data-sourcing §4) |
|
||||
| Significant accounting policies + critical estimates | What "profit" means for this company | Revenue recognition, depreciation lives, capitalisation, ECL, impairment, DTA (§4) |
|
||||
| **Notes to accounts — every one** | PPE/CWIP ageing, intangibles, **receivables & payables ageing**, borrowings with terms & covenants, revenue disaggregation, employee-benefit/actuarial, tax & deferred tax, **segment**, **related party (incl. year-end balances)**, **contingent liabilities & commitments**, financial-instrument risk (credit/liquidity/market), leases, **ratios**, **subsequent events** | This is where the analysis actually is — not one note is safe to skip (§4–§7) |
|
||||
|
||||
### US 10-K (SEC) — item by item
|
||||
|
||||
| Item | Contains | What to pull |
|
||||
|---|---|---|
|
||||
| 1 Business | Model, products, customers, competition, seasonality, regulation | The business map and moat evidence |
|
||||
| 1A Risk Factors | Legally-obliged risk admissions | Diff across years; a dropped risk is a disclosure choice (§3) |
|
||||
| 1C Cybersecurity | Cyber-risk governance and material incidents | Incident history and board oversight |
|
||||
| 2 Properties / 3 Legal Proceedings | Facilities; litigation | Owned-vs-leased footprint; material litigation (§5) |
|
||||
| 5 Market / dividends / repurchases | Buybacks, dividends, equity-plan info | Capital returned, and at what prices |
|
||||
| 7 MD&A / 7A Market risk | Management narrative; FX/rate/commodity exposure | Growth decomposition, guidance, hedging (§3) |
|
||||
| 8 Financial statements & notes | Statements + full notes + segment | Same depth as the Indian notes above (§4–§7) |
|
||||
| 9A Controls & Procedures | ICFR assessment | Material weakness — and whether a 404(b) auditor attestation exists at all (§8.6) |
|
||||
| 10–14 (often via DEF 14A) | Directors/governance, **executive comp**, **security ownership**, **related transactions**, accountant fees | Governance, pay-for-performance, RPTs, auditor independence (§16) |
|
||||
| 15 Exhibits | **Ex-21 subsidiaries**, material contracts, debt indentures | Group map and covenant packages |
|
||||
|
||||
For sectors where the standard set is replaced (banks, insurers, REITs, miners, pharma), the additional documents in §19 sit **alongside** this map, not instead of it.
|
||||
|
||||
### Where abnormalities concentrate — the anomaly scan
|
||||
|
||||
Reading every section is *coverage*; this is the *detection* lens laid over it. A handful of sections are where genuine abnormalities almost always surface first — legal disputes, related-party dealings, and the shareholding-and-pledge pattern chief among them — and a serious one here can outweigh every positive on the scorecard, so it escalates to the Stage 3 kill-criteria screen rather than sitting in a footnote. For each, the question is never "is there a number?" but "does the pattern deviate from this company's own history and its peers?"
|
||||
|
||||
| Annual-report section | Normal | Abnormal — the tell | Go deep |
|
||||
|---|---|---|---|
|
||||
| **Litigation / legal proceedings & contingent-liability note** | Routine tax disputes, small vs net worth, stable | Contingent liabilities approaching or exceeding net worth; a demand growing every year with no provision; guarantees to entities that are *not* consolidated subsidiaries; the largest item also flagged as a KAM | §5; `07` §10 |
|
||||
| **Related-party transactions note** | Small, stable, arm's-length, board-approved | RPT sales/purchases a rising share of the total; interest-free or perpetually-rolled advances to promoter entities; a new related party with a large first-year transaction; year-end balances growing regardless of performance; transactions sized just under approval thresholds | §6; `07` §10 |
|
||||
| **Shareholding pattern & pledge** | Promoter stake stable, zero pledge, ≥25% public float | Promoter stake sliding over consecutive quarters; pledge rising or >25% of promoter holding; pledge against *promoter-entity* borrowing; quiet exits by long-standing domestic funds; a retail surge alongside an institutional exit | §15; `07` §10 |
|
||||
| **Auditor's report & CARO** | Clean opinion; procedural CARO answers | Any qualification / emphasis-of-matter / going-concern; CARO positives on fraud, unpaid statutory dues, loan default, evergreening, short-term-funds-for-long-term-use, or bank-returns-vs-books divergence; mid-term auditor resignation | §8; `07` §8, §12 |
|
||||
| **Accounting policies & estimates** | Stable year to year | A useful-life extension, capitalisation loosening, or estimate change that lifts profit with no cash effect — especially a policy changed the year the number it flatters turned down | §4; `07` §5, §7 |
|
||||
| **Year-over-year disclosure** | Consistent detail | A disclosure that *disappears* — a segment folded into "others", a named large customer dropped from the concentration note, a KPI or volume figure that stops being reported | `07` §7 |
|
||||
|
||||
The calibration discipline from `references/07-forensic-red-flags.md` §16 governs every row: state the innocent explanation alongside the flag, require a *cluster* pointing at the same line item before calling it a finding, and never assert fraud — describe what the disclosure shows and what evidence would resolve it.
|
||||
|
||||
---
|
||||
|
||||
## 1. Reading order when time is limited
|
||||
|
||||
Documents are not equally informative per minute spent. Work down this list and stop when the time budget runs out; the order is deliberately front-loaded with the disclosures that most often end an analysis outright.
|
||||
|
||||
| # | Read | Time | Why it is this early |
|
||||
|---|---|---|---|
|
||||
| 1 | **Auditor's report** — opinion paragraph first, then KAMs, EOM, Other Matter | 15 min | A qualified or adverse opinion invalidates the numbers you were about to analyse. Free of charge, the auditor tells you which line items are most fragile. |
|
||||
| 2 | **CARO annexure** (India) / **Item 9A controls + 8-K Item 4.01/4.02 history** (US) | 15 min | Factual yes/no answers the narrative cannot smooth over: defaults, unpaid statutory dues, fraud reported, auditor resignation, non-reliance on prior financials. |
|
||||
| 3 | **Related-party note + contingent-liability note** | 20 min | The two commonest routes for value to leave a minority shareholder, and both are quantifiable in one sitting. |
|
||||
| 4 | **Cash flow statement + segment note** | 20 min | Where the profit actually is and whether it became cash. Segment ROCE is usually the most surprising number in the report. |
|
||||
| 5 | **Shareholding pattern, last 12 quarters, incl. pledge** | 10 min | Promoter stress and institutional exits show up here before anywhere else. |
|
||||
| 6 | **Latest 2 earnings-call transcripts, Q&A only** | 30 min | Fastest read on management credibility and on which questions are being refused. |
|
||||
| 7 | **MD&A for the last 3 years, side by side** | 30 min | Promise-versus-delivery drift; the cheapest credibility test available. |
|
||||
| 8 | **Latest credit rating rationale** | 15 min | Liquidity and covenant detail equity filings never show. |
|
||||
| 9 | **Significant accounting policies + critical estimates note** | 30 min | Determines whether the earnings you are valuing are policy-driven. |
|
||||
| 10 | **AGM voting results + remuneration resolutions** | 15 min | A quantified governance verdict from investors who have met management. |
|
||||
| 11 | **Investor deck reconciled to audited numbers** | 30 min | Measures management's willingness to flatter. |
|
||||
| 12 | **DRHP / S-1, exchange filing history, short-seller material, secretarial audit** | 2 hr+ | Deep-dive mode only, or when steps 1–11 raised a specific question. |
|
||||
|
||||
**Screen mode** stops after step 5. **Standard mode** covers 1–9. **Deep dive** does all of it. If a document is unavailable, say so in the data-quality note rather than substituting inference — "FY23 annual report not retrievable; policy note not verified" is a legitimate output.
|
||||
|
||||
---
|
||||
|
||||
## 2. The liability gradient: how much each document is worth
|
||||
|
||||
Weight evidence by the legal consequence of it being wrong. This single heuristic resolves most conflicts between sources.
|
||||
|
||||
| Tier | Documents | Assurance |
|
||||
|---|---|---|
|
||||
| **Highest** | Offer documents (DRHP/RHP, S-1, prospectus); audited financial statements and auditor's report | Signed by directors and auditors with civil and criminal liability; restatement adjustments disclosed |
|
||||
| **High** | Notes to accounts, CARO, secretarial audit, statutory annexures; exchange material-event filings; scrutiniser's voting results | Statutory format, prescribed content, auditable |
|
||||
| **Medium** | MD&A, Directors' Report, quarterly results (limited review, not full audit), credit rating rationales, proxy statements | Management-owned narrative or third-party opinion; not audited |
|
||||
| **Low** | Investor presentations, press releases, earnings-call scripted remarks, guidance | Marketing documents, usually carrying an explicit safe-harbour disclaimer |
|
||||
| **Contextual** | Media, short-seller reports, forums, sell-side notes | Hypothesis generators; every checkable claim must be verified against a higher tier |
|
||||
|
||||
**Rule:** when two sources disagree, the higher tier wins and the discrepancy itself becomes a finding. A deck showing "net debt" materially below the balance sheet's borrowings is not a rounding issue — it is a definitional choice you must decompose (see §11).
|
||||
|
||||
**Triangulation.** The most valuable technique in this file is checking the same fact across tiers. A large receivable should appear consistently in the balance sheet, the KAM, the MD&A explanation, the concall answer, and the rating agency's liquidity comment. Where those four disagree, you have found something.
|
||||
|
||||
---
|
||||
|
||||
## 3. MD&A / Management Discussion and Analysis
|
||||
|
||||
India: a standalone MD&A section in the annual report, mandated by SEBI LODR Schedule V. US: Item 7 of the 10-K, plus Item 1A Risk Factors and Item 3 Legal Proceedings. Foreign private issuers: Item 5 of the 20-F.
|
||||
|
||||
**Read 3–5 consecutive years side by side, not one year alone.** A single MD&A is a press release. Five stacked MD&As are a track record.
|
||||
|
||||
**Extract:**
|
||||
- Management's own decomposition of growth into **volume versus realisation/price versus mix** — and check it against the segment note and any volume data disclosed elsewhere.
|
||||
- Capacity, capacity utilisation, and planned capex with timing and funding source.
|
||||
- Order book / backlog, book-to-bill, and stated execution period.
|
||||
- Segment-wise outlook statements, verbatim, with the year attached.
|
||||
- The risk-factor list, verbatim, year by year.
|
||||
- Ratio disclosures (India requires key financial ratios with explanation of any change over 25%).
|
||||
|
||||
**What a problem looks like:**
|
||||
- **Recycled promises.** "Demand recovery expected in H2" appearing three years running. Build a two-column table: *what was promised in year N* | *what was delivered in year N+1*. Management that never acknowledges a miss is telling you how it will handle the next one.
|
||||
- **Narrative-to-numbers divergence.** MD&A attributes growth to a premium segment; the segment note shows that segment shrinking. The segment note is the higher tier.
|
||||
- **A risk silently dropped.** Compare risk lists year to year. A customer-concentration risk that disappears without the concentration disappearing is a disclosure decision, not a business change.
|
||||
- **Boilerplate expansion.** MD&A that grows in length while shedding specifics (numbers replaced by adjectives) is a deliberate reduction in falsifiability.
|
||||
- **US-specific:** watch for new risk factors added quietly (10-K Item 1A must flag material changes; 10-Q Item 1A carries updates), and for legal proceedings moving from Item 3 into a note or vice versa.
|
||||
|
||||
**Why:** MD&A is the only management-owned, management-signed narrative sitting inside an audited document. It is unaudited, so it is where optimism lives — which makes the drift between it and the audited statements a direct measurement of that optimism.
|
||||
|
||||
---
|
||||
|
||||
## 4. Notes to accounts: policies, estimates and changes therein
|
||||
|
||||
Read the **significant accounting policies** note and the **critical estimates and judgements** note in full. These two notes determine what "profit" means for this company. Cross-read with `references/14-accounting-comparability.md` for Ind-AS/IFRS/GAAP differences.
|
||||
|
||||
**Extract, and compare against 2–3 sector peers — never against an absolute standard:**
|
||||
|
||||
| Policy area | What to extract | What a problem looks like |
|
||||
|---|---|---|
|
||||
| Revenue recognition | Point-in-time vs over-time; percentage-of-completion inputs; principal vs agent (gross vs net); variable consideration and rebate estimates | Over-time recognition with milestone estimates management controls; a switch from net to gross that inflates revenue with zero profit impact |
|
||||
| Inventory | Valuation basis (FIFO/weighted average), overhead absorption, obsolescence provisioning policy | Provisioning rate falling while inventory days rise |
|
||||
| Depreciation | Method and **useful lives per asset class**, residual values | Useful life extended (e.g. plant from 15 to 25 years) — flows straight to profit with no cash effect. Quantify the disclosed P&L impact. |
|
||||
| Capitalisation | Borrowing costs capitalised, development costs capitalised, CWIP ageing | Capitalised development cost rising as a share of R&D; CWIP sitting >2–3 years without transfer to fixed assets |
|
||||
| Expected credit loss (ECL) | Staging methodology, loss rates by bucket, forward-looking overlays | ECL coverage falling while receivable ageing worsens |
|
||||
| Impairment | Goodwill/CGU allocation, discount rate, terminal growth, headroom and sensitivity disclosure | Terminal growth near or above the discount rate; headroom disclosed as "sufficient" without numbers; the same CGU tested with a friendlier rate each year |
|
||||
| Leases | Discount rate on Ind-AS 116/IFRS 16 liabilities; short-term and low-value exemptions used | A high incremental borrowing rate that shrinks the recognised liability |
|
||||
| Deferred tax | Recognition of DTA on carried-forward losses and the profitability forecast supporting it | A large DTA recognised by a loss-making entity — an assertion about future profits, booked as an asset today |
|
||||
|
||||
*Indicative comparisons vary by market, cycle and period; peer and own-history comparison overrides any absolute band.*
|
||||
|
||||
**Always do this:** list every change in policy, estimate or useful life, quantify the disclosed P&L impact, and **restate the affected years yourself** so the trend you analyse is on a consistent basis. If the impact is not quantified, say the trend is not comparable.
|
||||
|
||||
**Why:** policy and estimate changes are the most common *legal* way to manufacture earnings. Because acceptable ranges are entirely sector-specific — a 25-year life is normal for a cement kiln and absurd for a server — only a peer-relative reading tells you whether the company sits at the aggressive end.
|
||||
|
||||
---
|
||||
|
||||
## 5. Contingent liabilities and commitments
|
||||
|
||||
Tabulate by category for five years: disputed direct tax, disputed indirect tax (GST/excise/service tax/customs), guarantees given (split: to subsidiaries, JVs, promoter/group entities, third parties), claims not acknowledged as debts, letters of credit and bills discounted, and pending litigation.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Contingent liabilities / net worth | Total contingent liabilities ÷ shareholders' equity | Typically <25–30% for a consumer or services business; 50%+ is normal for EPC/infra where performance guarantees are the business | Sizes the claim against equity if matters go against the company |
|
||||
| Contingent liabilities / market cap | Same numerator ÷ market cap | Small enough that full crystallisation is survivable | Converts a footnote into a valuation input |
|
||||
| Growth rate vs net worth growth | 5y CAGR of contingent liabilities vs 5y CAGR of net worth | Contingent growth ≤ net-worth growth | Faster growth means the off-balance-sheet claim is compounding against a shrinking cushion |
|
||||
| Guarantees to group entities / net worth | Guarantees issued for subsidiaries, JVs and promoter entities ÷ net worth | As low as possible; any material figure needs an explanation | The classic channel for pushing leverage off the listed entity while keeping the risk |
|
||||
| Capital commitments not provided for | "Estimated amount of contracts remaining to be executed on capital account" | Consistent with stated capex plans and funding capacity | Committed future cash outflow the balance sheet does not show |
|
||||
|
||||
*Ranges are indicative only and vary by sector, market and cycle; the company's own history and its closest peers override any absolute band.*
|
||||
|
||||
**What a problem looks like:** contingent liabilities exceeding net worth; a disputed tax demand that keeps growing with no resolution and no provision; guarantees to entities that are not consolidated subsidiaries; management's non-provisioning rationale being a single boilerplate line ("the company expects a favourable outcome") with no legal basis stated; the largest item also appearing as a KAM (that is the auditor agreeing with your concern).
|
||||
|
||||
**Cross-check** the biggest items against the KAM section, the litigation schedule in any DRHP, and exchange filings on adverse orders. In India also check whether disputed amounts are at the Commissioner (Appeals), ITAT, High Court or Supreme Court stage — later stages mean longer duration but usually more crystallised risk.
|
||||
|
||||
**Why:** these are off-balance-sheet claims that convert into real cash. A number that dwarfs net worth is a solvency question, not a footnote.
|
||||
|
||||
---
|
||||
|
||||
## 6. Related-party transactions note
|
||||
|
||||
List every related party and every transaction type: sales, purchases, job work, loans and advances given and taken, guarantees, rent, royalty and brand fees, technical/management fees, managerial remuneration, and **year-end outstanding balances** (which the transaction table alone will not show).
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| RPT sales share | Sales to related parties ÷ total revenue | Low and stable unless the group structure genuinely requires it | High or rising share means reported revenue is not arm's-length-validated |
|
||||
| RPT purchase share | Purchases from related parties ÷ total purchases/COGS | Low and stable | The main route for margin to be routed out of the listed entity |
|
||||
| Royalty / brand fee intensity | Royalty paid to promoter entity ÷ revenue, and its growth vs revenue growth | Flat as % of revenue if genuinely usage-based | A royalty growing faster than revenue is a rising tax on minority shareholders |
|
||||
| Promoter remuneration | Total promoter-family pay ÷ PAT (India: statutory ceiling 11% of net profits, 5%/10% for individual MD/WTD under s.197) | Small share of PAT; falls when profits fall | Pay that rises while profit falls is the cleanest evidence of a board that does not constrain the promoter |
|
||||
| Related-party receivables | Loans/advances/receivables due from related parties ÷ net worth, and ageing | Minimal, and recovered on stated terms | Interest-free advances that never return are, economically, a dividend paid only to the promoter |
|
||||
|
||||
*Indicative only; sector and group structure change what is normal — peer and own-history comparison governs.*
|
||||
|
||||
**What a problem looks like:** interest-free or below-market loans to related parties; advances perpetually rolled over rather than repaid; a related-party balance that grows every year regardless of business performance; sales to a related party at a margin implausibly different from third-party sales; a new related party appearing with a large transaction in its first year; "loans to bodies corporate" in the balance sheet that exceed the amounts disclosed as related-party in the note (check the s.186 disclosure in the Directors' Report against the RPT note).
|
||||
|
||||
**Governance trail — verify each step, don't assume it:** audit-committee approval; where material, a shareholder special resolution with **related parties abstaining** (India: SEBI LODR Reg 23, materiality threshold ₹1,000 crore or 10% of consolidated turnover, whichever lower; half-yearly RPT disclosures to exchanges); then read the AGM voting results for institutional dissent on that specific resolution. US: related-party transactions appear in the DEF 14A under Item 404 of Reg S-K, and the audit committee charter governs approval.
|
||||
|
||||
**Why:** RPTs are the primary mechanism of minority-value leakage in promoter- or founder-controlled companies. No accounting rule needs to be broken for profit to be routed out.
|
||||
|
||||
---
|
||||
|
||||
## 7. Segment note
|
||||
|
||||
Extract, for each reported segment across five years: segment revenue, inter-segment revenue, segment result/EBIT, segment assets, segment liabilities, capital employed, and capex. Then compute **segment margin and segment ROCE** yourself.
|
||||
|
||||
**What to look for:**
|
||||
- **One segment subsidising another.** A high-return cash cow funding a structurally loss-making segment that absorbs most of the capex. Consolidated margin hides this completely; segment ROCE reveals it. This is the single most common surprise in the entire annual report.
|
||||
- **Segment redefinition.** Segments merged, renamed, split, or re-mapped between years. Ask what became invisible. A deteriorating business folded into a healthy one is the standard way it stops being discussed. When it happens, request or reconstruct the restated prior-year segment data; if it is not available, state that the segment trend is broken.
|
||||
- **A swelling "unallocated" or "others" bucket.** Unallocated corporate expense and unallocable assets growing faster than the business are where inconvenient items go to be un-analysed.
|
||||
- **Segment set versus management's own language.** If the concall discusses five businesses and the note reports two, management has chosen to report at a level that prevents you from checking the story.
|
||||
- **Geography split** alongside the business split — matters for FX, tax rate and political risk.
|
||||
|
||||
**Standards note:** Ind-AS 108 and IFRS 8 / ASC 280 all use the "management approach" — segments are what the chief operating decision maker reviews. That makes the segment note a *disclosure choice*, which is exactly why changes to it are informative. Also check the major-customer disclosure (required where a customer exceeds 10% of revenue).
|
||||
|
||||
**Why:** consolidated economics are an average. Capital allocation happens at segment level, and so does destruction of value.
|
||||
|
||||
---
|
||||
|
||||
## 8. The auditor's report — read this in full, every year
|
||||
|
||||
This is the highest-yield section of the annual report per minute spent, and the one most often skipped. Read the **standalone and the consolidated audit reports separately — they can and do differ.**
|
||||
|
||||
### 8.1 Opinion type
|
||||
|
||||
Find it on the first page, in the paragraph headed "Opinion".
|
||||
|
||||
| Opinion | Meaning | What you do |
|
||||
|---|---|---|
|
||||
| **Unmodified / unqualified ("clean")** | Statements give a true and fair view | Proceed — but a clean opinion is a floor, not a positive |
|
||||
| **Qualified** ("except for…") | A specific, named item is wrong or unverifiable; the rest is fine | Stop and quantify. Read "Basis for Qualified Opinion", extract exactly what the auditor could not verify or disagreed with, take the quantified impact if given, and **restate the financials yourself** before computing any ratio |
|
||||
| **Adverse** | The statements as a whole do not give a true and fair view | The accounts are not usable. Do not produce a valuation from them |
|
||||
| **Disclaimer of opinion** | The auditor could not obtain sufficient evidence to form any opinion | Effectively no audit happened. Treat the financials as unaudited management assertions |
|
||||
|
||||
Track opinion type across five years and flag **any new modification**. In India, SEBI additionally requires a **Statement on Impact of Audit Qualifications** filed with annual audited results — it forces management to quantify the qualification or explain why it cannot; read management's number and the auditor's comment on it side by side.
|
||||
|
||||
### 8.2 Basis for opinion and going concern
|
||||
|
||||
Beyond the modification paragraph, look for a **"Material Uncertainty Related to Going Concern"** section. This is not a qualification and is easy to miss, but it is the auditor stating that the entity's ability to continue operating depends on events outside its control (refinancing, a court outcome, promoter support). Extract the specific dependency and its date. In the US, going-concern doubt also drives disclosure under ASC 205-40 and is usually echoed in the risk factors.
|
||||
|
||||
### 8.3 Key Audit Matters (KAM) / Critical Audit Matters (CAM)
|
||||
|
||||
India and IFRS jurisdictions: KAMs under SA 701 / ISA 701, required for listed entities, typically 2–6 per report. US: **Critical Audit Matters** under PCAOB AS 3101, generally fewer (often 1–2) and narrower.
|
||||
|
||||
For each KAM extract three things: **(a)** the balance or judgement involved, **(b)** why the auditor considered it high risk, **(c)** the specific procedures performed — and whether those procedures actually address the risk (a KAM on inventory existence "addressed" only by reviewing management's reconciliation is weaker assurance than physical attendance).
|
||||
|
||||
Then **track KAMs across years.** A newly added or persistently repeated KAM is the auditor pointing at the line item most likely to be restated or impaired later. The highest-signal recurring KAMs:
|
||||
- Recoverability of trade receivables / expected credit loss
|
||||
- Revenue recognition on long-term or over-time contracts
|
||||
- Impairment of goodwill or of investment in a named subsidiary
|
||||
- Recoverability of loans and advances to related parties
|
||||
- Capitalisation of development costs or CWIP
|
||||
- Litigation and tax provisions
|
||||
- Inventory existence and valuation, especially at third-party locations
|
||||
|
||||
Map each KAM to the corresponding note and check the disclosed sensitivity of the assumptions. Compare the KAM list with the company's peers audited by the same firm — a KAM that everyone in the sector carries is a sector characteristic, not a company flag. This is the governing principle applied to auditor language.
|
||||
|
||||
### 8.4 Emphasis of Matter (EOM) and Other Matter
|
||||
|
||||
**Emphasis of Matter** is not a qualification — the auditor is drawing attention to something already disclosed. That framing makes it easy to skip, which is precisely why serious things live there: going-concern uncertainty, a court-approved **scheme of arrangement** whose accounting overrides normal standards (a recurring device for routing write-offs through reserves instead of the P&L), regulatory forbearance, a pending investigation, or the effects of a material subsequent event. Read every EOM and follow it to the underlying note.
|
||||
|
||||
**Other Matter** is where the auditor discloses what they did *not* audit. In a consolidated report, quantify from this paragraph:
|
||||
- % of consolidated **total assets, revenue and profit** audited by **other (component) auditors**
|
||||
- % based on **unaudited, management-certified** subsidiary accounts
|
||||
|
||||
If 40% of consolidated profit comes from components the principal auditor never touched — or from entities that are unaudited — the word "audited" on the consolidated statements carries far less assurance than it appears to. State this percentage explicitly in your data-quality note.
|
||||
|
||||
### 8.5 CARO annexure — India-specific, read clause by clause
|
||||
|
||||
The Companies (Auditor's Report) Order 2020 forces the auditor to answer specific factual questions. Read the annexure itself, not the summary; a "no exceptions noted" clause takes seconds, and the exceptions are where the information is. Highest-signal clauses:
|
||||
|
||||
| Clause | What it answers | What a problem looks like |
|
||||
|---|---|---|
|
||||
| 3(i)(c) | Title deeds of immovable property held in the company's name | Properties on the balance sheet whose title is not with the company |
|
||||
| 3(i)(d)–(e) | Revaluation of PPE; benami property proceedings | A revaluation gain propping up net worth; any benami proceeding at all |
|
||||
| 3(ii)(a) | Physical verification of inventory and discrepancies | Discrepancies >10% in any class — the auditor must report them |
|
||||
| **3(ii)(b)** | Where working-capital limits exceed ₹5 crore: whether **quarterly returns filed with banks agree with the books** | Divergence between what the banks were told and what was booked. Extremely high signal; banks see stock statements monthly |
|
||||
| 3(iii) | Loans/advances/guarantees given: overdue amounts, terms, **renewals or fresh loans used to settle existing overdues (evergreening)**, loans repayable on demand with no stated terms | Evergreening; interest-free demand loans to group entities |
|
||||
| 3(iv) | Compliance with s.185/186 on loans and investments | Non-compliance means the transaction itself was unlawful |
|
||||
| 3(vii) | Statutory dues (GST, PF, ESI, TDS, income tax, customs) — undisputed dues **unpaid beyond six months**; and a list of disputed dues with forum | Unpaid statutory dues are hard evidence of a liquidity squeeze months before ratios show it — companies pay taxes last |
|
||||
| **3(viii)** | Transactions **not recorded in the books but surrendered/disclosed as income in income-tax assessments** | Direct evidence of unrecorded transactions. Treat any positive answer as a full stop |
|
||||
| 3(ix)(a)–(f) | Default in repayment to lenders (with amounts and dates); declared **wilful defaulter**; term loans applied for the stated purpose; **short-term funds used for long-term purposes**; funds raised on pledge of subsidiary shares; obligations of subsidiaries/JVs met from group funds | Short-term funds funding long-term assets is a classic pre-crisis asset-liability mismatch. Wilful-defaulter status is disqualifying |
|
||||
| 3(x) | End-use of IPO/FPO/preferential allotment/private placement proceeds | Money raised for capex deployed into loans to group entities |
|
||||
| **3(xi)** | Any **fraud** on or by the company; auditor's ADT-4 report to the Central Government; **whistle-blower complaints** considered | The single highest-signal paragraph in the annual report |
|
||||
| 3(xiii) | Compliance with s.177/188 on related-party transactions and their disclosure | Procedural failure on RPTs, which is usually where substantive failure begins |
|
||||
| 3(xiv) | Existence and adequacy of internal audit, and whether the auditor considered its reports | No internal audit function in a company of scale |
|
||||
| 3(xv) | Non-cash transactions with directors (s.192) | Directors acquiring assets from the company without cash |
|
||||
| 3(xvi) | NBFC/CIC registration where required; unregistered lending activity; number of CICs in the group | A group operating a finance business without registration, or an unexpectedly large CIC count signalling structural complexity |
|
||||
| 3(xvii) | **Cash losses** in the current and immediately preceding financial year | Cash losses two years running |
|
||||
| **3(xviii)** | **Resignation of the statutory auditors during the year** and whether the auditor considered the issues raised by the outgoing firm | See §8.7 — this is the strongest routinely available negative signal |
|
||||
| 3(xix) | Whether, based on ratios, ageing and expected dates of realisation, any **material uncertainty exists about meeting liabilities falling due within one year** | An auditor-endorsed liquidity warning, stated in plain language |
|
||||
| 3(xx) | Transfer of unspent CSR amounts | Small money, but non-compliance with an easy statutory obligation predicts non-compliance elsewhere |
|
||||
| 3(xxi) | Qualifications or adverse remarks in the CARO reports of **companies included in the consolidation** | Problems at subsidiaries that the parent's own CARO would not show |
|
||||
|
||||
**US analogue:** there is no CARO. The nearest equivalents are Item 9A (Controls and Procedures), Item 3 (Legal Proceedings), Item 4 (Mine Safety, where relevant), the ICFR attestation, and 8-K Items 4.01/4.02. The factual granularity of CARO simply does not exist in the US regime — which means for a US issuer you compensate with more weight on Item 9A, the auditor-change 8-Ks and the PCAOB inspection record.
|
||||
|
||||
### 8.6 Internal financial controls (IFC/ICFR)
|
||||
|
||||
**India:** a separate opinion under s.143(3)(i) on the adequacy and **operating effectiveness** of internal financial controls over financial reporting, appearing as an annexure to the audit report.
|
||||
**US:** management's assessment under SOX 404(a) in Item 9A, plus the **auditor's attestation under 404(b) — required only for accelerated and large accelerated filers.** Non-accelerated filers, smaller reporting companies and recent IPOs (which get a transition exemption) have *no* auditor opinion on controls. Note that gap explicitly; it is common in small caps and in newly listed companies. Also read the SOX 302 certifications signed by the CEO and CFO.
|
||||
|
||||
Determine whether the opinion is clean or identifies a **material weakness**, and read its description: revenue cut-off, vendor master data, inventory at third-party locations, segregation of duties, IT general controls and access rights, period-end financial reporting process. Distinguish a *material weakness* (reasonable possibility that a material misstatement would not be prevented or detected) from a *significant deficiency* (less severe). Then check whether a weakness reported last year was **remediated or repeated**.
|
||||
|
||||
**Why:** a material weakness means the machinery producing the numbers cannot be relied upon to catch a material error. It undermines every ratio you compute downstream. A repeated, unremediated weakness signals either management indifference or deliberate tolerance.
|
||||
|
||||
### 8.7 Auditor identity, tenure, rotation, fees and resignation
|
||||
|
||||
| What to extract | Where | What a problem looks like |
|
||||
|---|---|---|
|
||||
| Audit firm name, appointment year, engagement partner | Audit report signature block; India: firm registration no. and partner membership no.; US: PCAOB Form AP names the engagement partner | A firm with no other listed clients of comparable size; the same small firm auditing multiple group entities |
|
||||
| Rotation status | India: s.139(2) — individual auditor 5 years, firm 10 years (two terms of five), 5-year cooling off, applicable to listed and prescribed companies | Rotation due but a "new" firm staffed by the same partners, or an affiliate/network firm of the outgoing one |
|
||||
| **Audit fee vs non-audit fee** | Notes to accounts ("Payment to auditors"); US: DEF 14A audit fee table (audit / audit-related / tax / all other) | Non-audit fees approaching or exceeding audit fees — a direct independence problem. India: s.144 prohibits specified non-audit services outright |
|
||||
| Fee level vs size | Audit fee vs revenue and vs peer fees | An implausibly low fee for a complex multi-subsidiary group means the work was not done |
|
||||
| **Auditor change or resignation** | India: exchange filing plus the resignation letter, which must state reasons (SEBI requires detailed reasons and the auditor must comment on unresolved issues); US: **8-K Item 4.01**, which must disclose disagreements and reportable events, with a Letter from the former accountant as Exhibit 16 | Any mid-term resignation. Cited reasons of "pre-occupation" or "other commitments" in a company under stress should be treated as a euphemism |
|
||||
| **Non-reliance on previously issued financials** | US: **8-K Item 4.02**; India: restatement or revision under s.130/131 | The company formally telling you its old numbers were wrong |
|
||||
| Late filing | US: NT 10-K / NT 10-Q; India: delayed results filing and exchange penalties | An issuer that cannot close its books on time |
|
||||
| Auditor quality signals | PCAOB inspection reports for the firm; regulatory bans (India: NFRA/ICAI orders, SEBI debarments) | An auditor under regulatory action, or one whose inspection reports show high deficiency rates |
|
||||
|
||||
**Why:** auditors rarely walk away from fees without cause, which makes mid-term resignation arguably the strongest single negative signal in public disclosure. A downgrade in auditor quality, or heavy non-audit fees, weakens the assurance behind every number you are about to use. Read this section together with §9 of `references/07-forensic-red-flags.md` on CFO and audit-committee turnover — auditor and CFO exits often cluster.
|
||||
|
||||
---
|
||||
|
||||
## 9. Consolidated vs standalone, AOC-1 and the subsidiary map
|
||||
|
||||
**Analyse consolidated as the primary basis** for business economics and valuation, then reconcile against standalone. Never mix them within one ratio, and always label which basis each figure came from. Aggregators and screeners routinely show one and label it the other.
|
||||
|
||||
| Reconciliation | How to compute | Why it matters |
|
||||
|---|---|---|
|
||||
| Revenue, EBITDA, PAT gap | Consolidated minus standalone, per year | Locates where the business actually is — parent or subsidiaries |
|
||||
| **Debt location** | Borrowings: consolidated vs standalone | Debt sitting in subsidiaries with profit in the parent looks healthy on one basis and stressed on the other |
|
||||
| **Cash location** | Cash and investments: consolidated vs standalone; then by entity from AOC-1 | Cash in a 51%-owned or overseas subsidiary may be **trapped** — unavailable for dividends, buybacks or parent debt service without tax leakage or minority consent |
|
||||
| Dividend capacity | Standalone free reserves and standalone cash flow vs dividend paid | A dividend not funded by parent-level cash flow is being funded by borrowing or by upstreaming that may not repeat |
|
||||
| **PAT attributable to owners vs NCI** | Consolidated PAT split into owners' share and non-controlling interest | Headline consolidated PAT includes profit that is not yours. **Always value on the owners' share**, and use owners' equity for ROE |
|
||||
|
||||
**The AOC-1 statement (India)** — the "salient features of the financial statement of subsidiaries/associates/joint ventures", filed as an annexure to the Board's Report. This is the single most underused page in an Indian annual report. It lists **every** subsidiary, associate and JV with shareholding %, turnover, PAT, net worth and investments. US equivalents: **Exhibit 21.1** (list of subsidiaries, but no financials), Reg S-X **Rule 4-08(g)** summarised financial information, and **Rule 3-09** separate audited financial statements for significant equity investees.
|
||||
|
||||
**From the AOC-1, extract:**
|
||||
- Every loss-making subsidiary, **and how many consecutive years** it has been loss-making.
|
||||
- Whether the parent keeps funding those entities through equity infusion, loans, or guarantees (cross-check the RPT note and CARO 3(iii)).
|
||||
- Subsidiaries with negative net worth — these are contingent claims on the parent regardless of legal separation.
|
||||
- Entities with large turnover and negligible profit (possible pass-through or round-tripping structures), and entities with negligible turnover and large assets.
|
||||
- Newly incorporated, newly acquired, **newly deconsolidated** or struck-off entities. A subsidiary that disappears between two annual reports needs an explanation; deconsolidation is a legitimate route to removing losses and debt from view.
|
||||
- Overseas subsidiaries in jurisdictions with no operational rationale.
|
||||
|
||||
**Consolidation method matters enormously:**
|
||||
- **Subsidiaries** — line-by-line; their debt and losses are visible.
|
||||
- **Associates and JVs** — equity method; only the net share of profit appears, and **their debt is entirely invisible on your balance sheet**. A group can carry very large leverage inside 49%-owned entities while showing modest consolidated debt. Read the Ind-AS 112 / IFRS 12 disclosure of interests in other entities, which gives summarised financials for material associates and JVs, and add back your share of their debt when assessing group leverage.
|
||||
- **Structured entities / SPVs** — check the control assessment. Off-balance-sheet vehicles are disclosed under Ind-AS 112 / IFRS 12; read that note in any infrastructure, real estate or financial company.
|
||||
|
||||
**Why:** consolidated shows the economic group; standalone shows what the listed entity actually controls and can pay dividends from. Both are true, and the difference between them is often the whole story.
|
||||
|
||||
---
|
||||
|
||||
## 10. Earnings-call transcripts and management Q&A behaviour
|
||||
|
||||
**Read the transcripts; do not listen to the calls.** Reading is faster, searchable, and lets you compare quarters side by side. Cover the last 8–12 quarters. Sources: company investor-relations page, exchange filings (India: transcripts must be filed within five working days under LODR), and 8-K Item 2.02 furnishings in the US.
|
||||
|
||||
**Split every transcript into scripted opening remarks and Q&A.** The opening remarks are a press release read aloud — tier "low". The Q&A is unscripted and is where the evidence is.
|
||||
|
||||
**Track across quarters:**
|
||||
|
||||
| Signal | How to observe it | What it means |
|
||||
|---|---|---|
|
||||
| **Guidance vs delivery** | Log every numeric commitment (revenue growth, margin, capex, debt reduction, capacity commissioning date) with the quarter it was made, then mark it met/missed/quietly dropped | Produces an objective management-credibility score no financial statement can give you |
|
||||
| **Miss acknowledgement** | When a target is missed, is it named and explained, or reframed as if it never existed? | Acknowledgement is the cheapest possible honesty test |
|
||||
| **Numeric question → numeric answer?** | Count questions asking for a specific number (segment margin, receivable days, subsidiary loss, capex phasing, one-off quantum) and how many get a number | "We don't disclose that", "directionally positive", "let's take this offline" clustering on the same line item quarter after quarter is a map of the problem |
|
||||
| **Analyst access** | Which analysts are called on; whether known sceptics stop appearing; whether the call is cut short with questions in the queue | Curated Q&A is a governance signal, not a scheduling accident |
|
||||
| **Attribution pattern** | Are misses always external (weather, elections, GST, freight, FX, "channel destocking") while beats are always management execution? | Consistent externalisation over many quarters is a stable trait, not a run of bad luck |
|
||||
| **Who speaks** | Is the CFO on the call? Does a new CFO answer confidently on prior periods? | A CFO absent from calls, or unable to answer on their own numbers, is a real flag |
|
||||
| **Format degradation** | Calls discontinued, moved to written-questions-only, pre-submitted questions, or transcripts stopped being filed | Reduction in accountability channels almost always precedes bad news |
|
||||
| **Language recycling** | Diff the opening remarks across quarters | Identical paragraphs quarter after quarter mean nothing is being said |
|
||||
|
||||
**Maintain a running list of unanswered questions** and check whether they are ever answered. Also note what analysts stop asking about — a question that gets refused three times stops being asked, and the silence looks like resolution.
|
||||
|
||||
**India note:** many small- and mid-cap companies hold no calls at all. Absence of a concall is itself a data point about investor engagement, and it means you must lean harder on the filings.
|
||||
|
||||
---
|
||||
|
||||
## 11. Investor presentations vs audited filings
|
||||
|
||||
Take every headline metric in the deck — adjusted EBITDA, cash EBITDA, pre-exceptional PAT, "normalised" margin, net debt, order book, ARR, EBITDA pre-Ind-AS-116 — and reconcile it line by line to the audited statements.
|
||||
|
||||
**Interrogate every add-back:**
|
||||
- Is it genuinely non-recurring? An "exceptional item" that appears in four of five years is an operating cost. Sum five years of exceptionals and compare to five years of reported PAT — the ratio is often startling.
|
||||
- Restructuring, impairment, legal settlements and inventory write-downs are the usual repeat offenders.
|
||||
- Share-based compensation added back is a real cost to you as a shareholder; see `references/03-earnings-quality.md`.
|
||||
- Pre-IFRS-16/Ind-AS-116 EBITDA is legitimate for comparability, but only if lease payments are then deducted somewhere.
|
||||
|
||||
**Interrogate net debt specifically.** Check whether the deck's net debt excludes: acceptances / buyer's credit / channel financing, bills discounted with recourse, factoring, lease liabilities, preference shares and other compound instruments, deferred acquisition consideration, and cash that is restricted or held in subsidiaries. Reconcile to the balance sheet borrowings line and state the gap. See `references/06-valuation.md` for the full EV bridge.
|
||||
|
||||
**Interrogate unaudited operating metrics.** Order book, capacity, "addressable market", store count, ARR, GMV, and customer counts appear nowhere in the audited statements and are never verified by anyone. Ask whether the metric definition has changed (an ARR definition that quietly starts including one-time revenue), and whether an order book converts into revenue at the rate implied.
|
||||
|
||||
**What a problem looks like:** the gap between presented and audited figures widening year over year; a new adjusted metric introduced in the exact year the old one turned down; a metric definition changed without restating prior periods; charts with no y-axis; growth shown only in indexed form.
|
||||
|
||||
**Why:** presentations carry far weaker liability than audited filings. The size and direction of the gap is a direct measure of management's willingness to flatter, and non-GAAP metrics drifting further from GAAP each year is among the most reliable governance warning signs available.
|
||||
|
||||
---
|
||||
|
||||
## 12. DRHP / RHP / S-1 and offer documents
|
||||
|
||||
The offer document is the most legally exhaustive disclosure a company ever makes. It remains valuable long after listing — for an already-listed company, the old DRHP is still the best single source of pre-listing history.
|
||||
|
||||
**Extract:**
|
||||
- **Litigation and regulatory-action history** of the company, subsidiaries, group companies, promoters and directors — criminal, tax, statutory and civil, with amounts. Nothing later in the company's life re-discloses this at the same granularity.
|
||||
- **Objects of the issue**: how much is fresh capital going into the business versus **offer for sale** enriching selling shareholders. Also check whether stated objects include repayment of debt or "general corporate purposes" (which should be capped).
|
||||
- **Pre-IPO placements and the price paid by earlier investors** versus the IPO price. A steep step-up in the months before listing tells you what sophisticated buyers thought the business was worth very recently.
|
||||
- **Restated financials and the restatement adjustments**, with reasons. This shows how the pre-IPO accounts were originally kept — a long list of restatement adjustments is a statement about historical accounting discipline.
|
||||
- **Risk factors**, written by lawyers under liability and far more candid than any subsequent annual report. Many risks disclosed in a DRHP are never mentioned again.
|
||||
- **Promoter group entity list** — the definitive map for later RPT work.
|
||||
- **Lock-in expiry dates** (India: promoter and anchor-investor lock-ins) or US lock-up expiry, which tell you about future supply and insider intent.
|
||||
- Related-party transactions for the pre-IPO period, and any pre-IPO restructuring, transfer of assets or business between promoter entities and the issuer.
|
||||
|
||||
**US equivalents:** S-1 (domestic IPO), F-1 (foreign issuer), 424B prospectus, and for SPAC de-listings the S-4/proxy. Note that projections appear in SPAC merger documents and essentially nowhere else in US filings — and are almost never met.
|
||||
|
||||
**Why:** it is the one document written under maximum liability with maximum detail, and its restatement adjustments plus offer structure reveal both how the accounts were kept and what insiders intend to do with their shares.
|
||||
|
||||
---
|
||||
|
||||
## 13. Credit rating rationales and rating actions
|
||||
|
||||
Pull the **full rationale document**, not just the symbol, from **every** agency covering the company, plus the complete rating history. India: CRISIL, ICRA, CARE, India Ratings, Acuité, Brickwork — all publish detailed public rationales. US/global: Moody's, S&P, Fitch — press releases and credit opinions, less granular publicly but still valuable; supplement with bond indentures and covenant disclosures.
|
||||
|
||||
**Extract:**
|
||||
- **Key rating strengths and weaknesses** in the agency's own words.
|
||||
- **Liquidity assessment** (India: agencies grade it explicitly — Superior / Strong / Adequate / Stretched / Poor). This is the single most useful line, because balance-sheet ratios do not show undrawn lines, cash-flow timing or repayment bunching.
|
||||
- **Rating sensitivities** — the explicit metric thresholds that would trigger an upgrade or downgrade. These are effectively externally-set covenants on your thesis; check your own computed numbers against them.
|
||||
- The **list of rated facilities** with amounts, which reveals the bank-debt structure (fund-based vs non-fund-based limits, working-capital limits, term loans) far better than the balance sheet.
|
||||
- Utilisation of working-capital limits over the past 12 months — agencies frequently disclose average and peak utilisation, and sustained near-100% utilisation is a liquidity warning.
|
||||
|
||||
**Rating actions to treat as events:**
|
||||
- Outlook change (Stable → Negative) and placement on **Rating Watch**.
|
||||
- Any downgrade, and especially a multi-notch downgrade.
|
||||
- **Migration to "Issuer Not Cooperating" (INC)** — India-specific and widely ignored. The company has simply stopped supplying information to its own rating agency. Read it as a refusal to be examined.
|
||||
- A rating withdrawal at the company's request.
|
||||
- Any **default or "D" rating on any instrument of any group entity**, including unlisted ones. Contagion within promoter groups is real, and lenders act on group exposure.
|
||||
- India: rating actions are themselves disclosable to exchanges under LODR Reg 30, so the exchange filing history gives you the timeline.
|
||||
|
||||
**Why:** rating agencies see bank facility details, covenant terms, month-by-month utilisation and management interactions that equity investors never get. Their liquidity paragraph routinely identifies stress one to four quarters before the equity market notices.
|
||||
|
||||
---
|
||||
|
||||
## 14. Exchange filings and continuous disclosure
|
||||
|
||||
Scan the company's **entire filing history**, not just results. This is where governance events surface first.
|
||||
|
||||
**India (NSE/BSE, SEBI LODR):**
|
||||
- **Reg 30 material events** — board and KMP changes, plant shutdowns, contract wins/losses, litigation and regulatory orders, tax search/survey, acquisitions and disposals, fund-raising, default on payment obligations. Schedule III Para A events are automatically material; Para B events apply a quantitative threshold (broadly 2% of turnover, 2% of net worth, or 5% of average PAT of the last three years).
|
||||
- **Reg 30(11) rumour verification** — top-listed companies must confirm or deny material market rumours; the response is informative.
|
||||
- **Reg 31 pledge/encumbrance disclosures** and SAST Reg 29 acquisition/disposal disclosures.
|
||||
- **PIT Reg 7 insider-trading disclosures** — promoter, director and KMP trades above ₹10 lakh in a quarter.
|
||||
- **Reg 23 half-yearly RPT disclosures** in the prescribed format — often more granular than the annual note.
|
||||
- **Reg 32 statement of deviation** in use of issue proceeds, and **Reg 33** quarterly results (limited review, not audited — check the review report for qualifications too).
|
||||
- Scheme-of-arrangement filings, NCLT applications, IBC/insolvency petitions filed by or against the company or its subsidiaries, and any SEBI, RBI, CCI, NCLT, ED or tax-authority order.
|
||||
|
||||
**US (EDGAR):**
|
||||
- **8-K** by item number — 1.01 material agreement, 1.03 bankruptcy, 2.02 results, 2.04 triggering of a direct financial obligation (covenant breach/acceleration), **4.01 auditor change**, **4.02 non-reliance on prior financials**, 5.02 departure/appointment of officers and directors, 5.07 shareholder-vote results.
|
||||
- 10-Q, 10-K, DEF 14A, S-8 (equity plan registrations — a dilution signal), Form 144 (proposed insider sales), NT 10-K/NT 10-Q (late filing), and comment-letter correspondence (UPLOAD/CORRESP), which shows exactly what the SEC challenged in the accounting and how the company responded. Comment letters are underused and often excellent.
|
||||
|
||||
**Patterns that matter more than any single filing:**
|
||||
- **Serial resignation of CFOs, company secretaries, or independent directors.** Read every resignation letter; independent directors resigning citing "personal reasons" shortly after a contentious board matter is a well-worn euphemism. This pattern reliably *precedes* trouble rather than following it.
|
||||
- Insider transactions: what the people with full information do with their own money.
|
||||
- **Filing timing.** Material bad news released late on a Friday, immediately before a long holiday, or minutes before/after market close is a deliberate attention-management choice. Log the timestamps.
|
||||
- Repeated delays in filing results, or auditors' limited-review reports with qualifications.
|
||||
|
||||
---
|
||||
|
||||
## 15. Shareholding pattern and promoter pledge
|
||||
|
||||
**India:** quarterly shareholding pattern under LODR Reg 31. Track 12+ quarters.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Promoter holding trend | Promoter + promoter group % of total equity, quarter by quarter | Stable or rising; India requires ≥25% public float | A steady decline needs an explanation; "reclassification" of a promoter to public is a disclosed exit route worth checking |
|
||||
| **Pledged shares** | Shares pledged/encumbered ÷ promoter holding, **and** ÷ total equity | Zero is the only comfortable level; >25% of promoter holding warrants a specific explanation; >50% is a live risk | A price fall triggers margin calls, forced sale and potentially loss of control — converting a valuation problem into a solvency and control crisis |
|
||||
| Institutional holding | FII/FPI and DII/mutual-fund %, and the named funds | — | Quiet exits by long-standing institutional holders, especially domestic funds with local access, deserve investigation |
|
||||
| Retail shareholder count | Number of small individual shareholders (disclosed in India) | — | A sudden surge in retail holders alongside institutional exit is a distribution pattern |
|
||||
| Concentrated public holders | Non-institutional holders above 1%, named | — | Unknown FPIs or entities appearing across several promoter-linked companies suggest undisclosed concert |
|
||||
|
||||
*Indicative only; norms vary by market and ownership structure — a widely held US company has no promoter concept at all.*
|
||||
|
||||
**Also check:** invocation of pledged shares (disclosed separately); creeping acquisition under SAST; promoter share transfers to family trusts or holdcos; and whether the pledge is against borrowing by the *listed company* or by *promoter entities* — the latter means the listed company's shares are collateral for debt you cannot see and do not benefit from.
|
||||
|
||||
**US/global equivalents:** no promoter concept. Instead: SC 13D/13G (5%+ holders, with 13D signalling activist intent), Form 4 (insider transactions within two business days), 13F (institutional holdings, quarterly, 45-day lag), the DEF 14A beneficial-ownership table, dual-class structures and the proxy's disclosure of **pledging of company stock by executives** (many boards prohibit it — check the policy).
|
||||
|
||||
---
|
||||
|
||||
## 16. Proxy / AGM materials and voting results
|
||||
|
||||
**India:** the AGM/EGM notice with explanatory statements under s.102, plus the **scrutiniser's report on voting results** filed with the exchanges within two working days.
|
||||
**US:** the DEF 14A, plus **8-K Item 5.07** for the voting outcome.
|
||||
|
||||
**Read each resolution and its explanatory statement for:**
|
||||
- **Managerial remuneration** — total promoter/founder-family pay against PAT, against peer CEO pay, and against its own trajectory. Check the fixed/variable split and what the variable is actually linked to. India: s.197 caps (11% of net profits overall; 5% for one MD/WTD, 10% for all together) and the requirement for a special resolution to exceed them, or in the case of inadequate profits, Schedule V compliance. US: the Compensation Discussion and Analysis, CEO pay ratio, and the pay-versus-performance table (which does the comparison for you).
|
||||
- **Director appointments and re-appointments** — genuine independence (prior employment, business relationships, tenure), number of other board seats (over-boarding), attendance record, and any regulatory disqualification.
|
||||
- **Related-party approvals** — see §6; confirm interested parties abstained.
|
||||
- **Share issuance, preferential allotment, warrants and ESOP authorisations** — size the potential dilution and the exercise price. Warrants issued to promoters at a price near a cyclical low are a value transfer.
|
||||
- **Auditor appointment/re-appointment** and the proposed fee.
|
||||
|
||||
**Then read the voting results themselves.** This is the part most analysts skip and it is quantified, public and unambiguous.
|
||||
|
||||
- Compute, per resolution, the **% of institutional votes cast against** and the **% of non-promoter public votes cast against**.
|
||||
- A resolution that passes only on promoter votes while 60–90% of institutional votes oppose it is an explicit no-confidence vote from investors who have met management. Treat it as a governance finding of the same weight as an accounting flag.
|
||||
- Rising against-votes across successive years on the same theme (remuneration, a specific director, RPTs) shows a board that is not responding to shareholders.
|
||||
- Read proxy advisory recommendations where available (India: IiAS, SES, InGovern; US: ISS, Glass Lewis) — and read the company's rebuttal if it issued one.
|
||||
- US: say-on-pay support below ~70% is conventionally treated as a rebuke requiring board response.
|
||||
|
||||
---
|
||||
|
||||
## 17. Short-seller reports, forensic notes and adverse media
|
||||
|
||||
Search for any short-seller report, forensic accounting note, regulator order, or investigative journalism on the company **or any group entity**.
|
||||
|
||||
**How to read one properly:**
|
||||
1. **Read the report and the company's rebuttal side by side, allegation by allegation.** Build a three-column table: allegation | company's response | your verification. This is the whole method.
|
||||
2. **Judge the rebuttal by what it engages with.** Specific allegations answered with documents, bank confirmations, registry records and named counterparties are genuine responses. Allegations answered with adjectives ("baseless", "malicious"), attacks on the author's motives, nationalist framing, or a defamation suit are non-responses — and a systematic pattern of non-response across allegations is itself high-grade evidence.
|
||||
3. **Verify the checkable claims yourself** against primary sources: registry filings for the alleged shell counterparties (India: MCA21; UK: Companies House; equivalents elsewhere), subsidiary statutory accounts, customs and trade data, land and property records, litigation dockets, employee counts, satellite imagery for claimed facilities. A report's value is concentrated in the claims you can independently confirm.
|
||||
4. **Note the author's disclosed position and incentive.** A short seller profits from the price falling and is selecting evidence accordingly. That does not make the evidence false; it means treat the report as a **hypothesis generator, never a conclusion**.
|
||||
5. **Separate the allegations by type.** Accounting-manipulation claims can often be checked from filings. Claims about undisclosed related parties, circular revenue or shell counterparties require outside records. Claims about intent or future regulatory action cannot be verified at all — discount them.
|
||||
|
||||
**Why:** these reports concentrate months of forensic work into one document and frequently surface structures — undisclosed related parties, circular transactions, shell counterparties, inflated asset claims — that filings alone would take years to find. See §13 of `references/07-forensic-red-flags.md` for the independent-verification techniques.
|
||||
|
||||
---
|
||||
|
||||
## 18. Secretarial audit and Directors' Report annexures
|
||||
|
||||
Largely India-specific, and consistently under-read.
|
||||
|
||||
- **Secretarial audit report (Form MR-3)**, mandatory for listed and prescribed companies under s.204, plus the **Annual Secretarial Compliance Report** under LODR Reg 24A. Read the qualifications and observations. These reveal statutory non-compliance — late filings, invalid appointments, procedural failures on RPTs or on board/committee composition — that never touches the financial statements. Also check whether material unlisted subsidiaries got their own secretarial audit, which is required.
|
||||
- **Corporate governance report**: board composition and independent-director count, whether the chair is independent or is the promoter, board and audit-committee meeting frequency and **individual attendance**, committee composition, and the number of board meetings held at short notice. An audit committee that meets four times a year for an hour is not overseeing anything.
|
||||
- **Independent director resignations** — read the letter and the stated reasons (India requires the reason to be disclosed and requires the director to confirm there are no other material reasons).
|
||||
- **ESOP disclosures** — grants, exercises, outstanding options, exercise prices and potential dilution.
|
||||
- **s.186 loans, guarantees and investments** disclosure — cross-check against the RPT note.
|
||||
- **CSR** spend vs obligation and unspent transfers (small money, but a clean compliance signal).
|
||||
- **BRSR** (Business Responsibility and Sustainability Report) for the top listed companies, with BRSR Core assured — useful for regulatory, environmental and litigation exposure; treat unassured sections as management narrative.
|
||||
- **Cost audit report** where applicable (regulated and manufacturing sectors) — segment-level cost data unavailable anywhere else.
|
||||
|
||||
**US analogues:** corporate governance content sits in the DEF 14A (board independence, committee composition, attendance, related-party policy), governance guidelines and committee charters on the IR site, and NYSE/Nasdaq listing-standard compliance disclosures.
|
||||
|
||||
---
|
||||
|
||||
## 19. Sector translation: which documents replace the standard set
|
||||
|
||||
The governing principle applies to documents, not just ratios. For several sectors, the documents above are secondary and the real disclosure lives elsewhere. Read the sector playbook before deciding what to prioritise.
|
||||
|
||||
| Sector | Read instead of / in addition to the standard set | What to extract |
|
||||
|---|---|---|
|
||||
| **Banks** | Basel **Pillar 3 disclosures**; notes on asset quality; RBI risk-assessment **divergence disclosure**; restructuring and resolution-framework notes; annual report "Notes on accounts" schedules | GNPA/NNPA reconciliation and slippages, provision coverage, sector and borrower concentration, restructured and SMA book, divergence between RBI-assessed and reported NPAs (an auditor-adjacent disclosure with no equivalent elsewhere), capital adequacy and its components |
|
||||
| **NBFCs / HFCs** | ALM (asset-liability maturity) statement, borrowing mix disclosure, RBI scale-based-regulation disclosures, securitisation/direct-assignment notes, co-lending arrangements | Maturity mismatch by bucket, dependence on short-term funding, off-book AUM, credit-enhancement obligations retained on securitised pools |
|
||||
| **Insurers** | Public disclosures forms (India: L-series for life, NL-series for general); **embedded value report and its actuarial assumptions**; appointed actuary's certificate; solvency statement | EV movement analysis, VNB margin and its assumption sensitivity, persistency, solvency ratio, reserving assumptions. Standard ratios like EBITDA and ROCE are undefined here |
|
||||
| **REITs / InvITs** | Independent **valuation report** (half-yearly in India), distribution statement, manager fee structure, related-party leases | Valuer identity and independence, cap rate assumptions, NAV movement, NDCF computation, manager fees as % of AUM, sponsor-related leases |
|
||||
| **Miners / E&P** | **Reserve and resource statements** under JORC / NI 43-101 / SEC S-K 1300 / SPE-PRMS; technical reports; independent qualified person's sign-off | Proven vs probable split, reserve life, grade trend, the commodity price deck used, who certified it and their independence. Reserves are the balance sheet for these companies and are *not* audited by the financial auditor |
|
||||
| **Utilities / regulated** | Tariff orders, regulatory-asset notes, PPA terms, regulator filings | Regulated return allowed vs earned, regulatory assets/deferrals recoverable, true-up timing |
|
||||
| **Pharma** | Regulatory inspection outcomes (US FDA Form 483s, warning letters, import alerts), ANDA/patent litigation dockets | Facility-level compliance status, remediation timelines, exclusivity expiries |
|
||||
|
||||
For all of these, standard EBITDA/ROCE/working-capital analysis is either undefined or misleading. Read the matching `references/sectors/*.md` before computing anything.
|
||||
|
||||
---
|
||||
|
||||
## 20. Archive and data-provenance hygiene
|
||||
|
||||
**Build your own archive.** Companies remove old documents from their websites, and they do it most often when the old documents are inconvenient. Download and retain: 7–10 years of annual reports, all quarterly results and transcripts, the DRHP, credit rating rationales, investor decks and material exchange filings. India: BSE/NSE announcement archives and SEBI's filings retain much of it independently; US: EDGAR retains everything permanently and is the canonical source.
|
||||
|
||||
**Compute key figures yourself from primary filings.** Aggregators are useful for screening and unreliable for conclusions.
|
||||
- Verify at least the top five metrics (revenue, EBITDA, PAT, total debt, cash) against the source document before building any thesis on them.
|
||||
- Establish whether the aggregator is showing **standalone or consolidated** — many silently mix the two across years or across companies within the same peer table.
|
||||
- Establish how it treats **exceptional items, lease accounting (Ind-AS 116/IFRS 16), and minority interest**. Different treatments make peer comparisons meaningless.
|
||||
- Check its **fiscal-year alignment** convention when comparing companies with different year ends.
|
||||
|
||||
**Reconcile restated comparatives.** Take last year's annual report and this year's, and compare the prior-year column in each. Silent restatements — prior-period figures quietly changed with no note explaining why — are a specific, detectable form of manipulation, and only a self-maintained multi-year archive will reveal them. Legitimate restatements (a genuine error corrected under Ind-AS 8 / IAS 8, a discontinued operation reclassified, a segment redefinition) carry a note explaining the change; the absence of that note is the flag.
|
||||
|
||||
**Record provenance for every number you use**: document, page or note number, period, consolidated/standalone, currency and units, and the date you retrieved it. This feeds directly into the data-quality note required by the output contract in `SKILL.md`.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] **Entire annual report walked section by section against the §0 contents map**; every section either mined for material content or recorded as "read — nothing material" — none left unopened.
|
||||
- [ ] Auditor's report read in full for **both standalone and consolidated**; opinion type recorded for 5 years.
|
||||
- [ ] Any modification quantified and the financials restated before any ratio was computed.
|
||||
- [ ] Going-concern paragraph checked; every KAM/CAM extracted, mapped to its note, and tracked across years.
|
||||
- [ ] Emphasis of Matter and Other Matter read; **% of consolidated assets/revenue/profit not audited by the principal auditor, or unaudited, quantified**.
|
||||
- [ ] India: CARO annexure read clause by clause — statutory dues, defaults, short-term funds for long-term use, evergreening, bank-return divergence, fraud reporting, auditor resignation, one-year liquidity uncertainty.
|
||||
- [ ] IFC/ICFR opinion checked for material weakness and for repeat weaknesses; US: noted whether a 404(b) auditor attestation exists at all.
|
||||
- [ ] Auditor tenure, rotation, audit vs non-audit fees checked; any resignation letter or 8-K Item 4.01/4.02 read.
|
||||
- [ ] MD&A read for 3–5 years side by side; promise-vs-delivery table built; risk-factor changes diffed.
|
||||
- [ ] Accounting policies and critical estimates read; every change quantified and peer-compared; affected years restated.
|
||||
- [ ] Contingent liabilities tabulated 5 years, expressed as % of net worth and market cap; group guarantees isolated; capital commitments sized.
|
||||
- [ ] RPT note fully extracted, including **year-end balances**; RPT sales/purchase shares computed; approvals and voting dissent verified.
|
||||
- [ ] Segment revenue, EBIT, capital employed and ROCE computed per segment for 5 years; any segment redefinition explained.
|
||||
- [ ] Consolidated vs standalone reconciled for revenue, EBITDA, PAT, **debt and cash**; trapped cash identified; NCI stripped out before valuation.
|
||||
- [ ] AOC-1 / Exhibit 21.1 read; loss-making, negative-net-worth, newly acquired and newly deconsolidated entities listed; equity-method associate debt added back to group leverage.
|
||||
- [ ] 8–12 transcripts read; guidance-vs-delivery log built; refused questions and analyst-access patterns recorded.
|
||||
- [ ] Investor-deck metrics reconciled to audited figures; every add-back tested for recurrence; net-debt definition decomposed.
|
||||
- [ ] DRHP/S-1 checked for litigation history, OFS share, pre-IPO pricing, restatement adjustments and lock-in expiry.
|
||||
- [ ] Full rating rationales pulled from all agencies; liquidity grade, rating sensitivities and any INC/watch/downgrade recorded.
|
||||
- [ ] Exchange filing history scanned for KMP resignations, insider trades, pledge changes, regulatory orders and Friday-evening disclosures.
|
||||
- [ ] Shareholding pattern tracked 12+ quarters; pledge as % of promoter holding **and** of total equity computed.
|
||||
- [ ] AGM notice and **scrutiniser's voting results** read; institutional against-votes per resolution recorded.
|
||||
- [ ] Short-seller/forensic material located; allegations, rebuttal and your own verification tabulated.
|
||||
- [ ] Secretarial audit (MR-3) qualifications, board composition and attendance checked.
|
||||
- [ ] Sector-specific primary documents (Pillar 3, EV report, valuation report, reserve statement) read where the standard set does not apply.
|
||||
- [ ] Top five metrics verified against primary filings; prior-year comparatives reconciled across two annual reports for silent restatements; provenance recorded for every figure used.
|
||||
|
|
@ -0,0 +1,438 @@
|
|||
# Market Mechanics, Corporate Actions and Taxation
|
||||
|
||||
Use this when: you have a thesis you like and need to know whether it can actually be owned, exited and kept after tax — run the tradeability gate early (before deep fundamental work on any smallcap), and the supply-calendar and tax layers before sizing or writing the recommendation.
|
||||
|
||||
Everything upstream in this skill estimates *intrinsic* value. This file governs *realised* return, which differs from intrinsic value by three things the financials never show: whether the market lets you transact at the price on the screen, whether the share count you divided by is the share count you will end up with, and how much of the gain the tax authority and the transaction stack keep. A correct 30% IRR thesis on a stock in a weekly call auction with a 40% lock-in expiry due and a 20% short-term tax rate is not a 30% IRR. The governing rule applies here as everywhere: none of these numbers means anything absolutely — impact cost, delivery percentage, float and dilution are only interpretable against the stock's sector, size bucket and own history, and for banks, REITs/InvITs and PSUs the dilution and distribution logic is structurally different, not just quantitatively different (Section 23).
|
||||
|
||||
**Standing warning on tax figures.** Every rate, threshold, holding period and form number in this file is *indicative and dated*. Tax law changes mid-year, differs by jurisdiction, and depends on the holder's residency, entity type and account wrapper. India changed capital-gains rates and buyback taxation within a single recent financial year. Never quote a rate from memory into a report. Verify against the current Finance Act / IRS publication / exchange circular, state the date of the rule you applied, and split any calculation that straddles a rule change by transaction date. Where you could not verify, say "rate to be confirmed" rather than filling in a plausible number.
|
||||
|
||||
## Contents
|
||||
|
||||
- [0. The method: gate, calendar, net-of-cost](#0-the-method-gate-calendar-net-of-cost)
|
||||
- [1. Exchange surveillance status (India: ASM / GSM / ESM)](#1-exchange-surveillance-status-india-asm--gsm--esm)
|
||||
- [2. Circuit limits, price bands and trade-to-trade](#2-circuit-limits-price-bands-and-trade-to-trade)
|
||||
- [3. Delivery volume vs traded volume (India)](#3-delivery-volume-vs-traded-volume-india)
|
||||
- [4. Liquidity, impact cost and realistic exit size](#4-liquidity-impact-cost-and-realistic-exit-size)
|
||||
- [5. Halts, suspensions and market-wide circuit breakers](#5-halts-suspensions-and-market-wide-circuit-breakers)
|
||||
- [6. Free float and float-adjusted supply](#6-free-float-and-float-adjusted-supply)
|
||||
- [7. The dilution map: build it once, in shares](#7-the-dilution-map-build-it-once-in-shares)
|
||||
- [8. QIP, preferential allotment and warrants](#8-qip-preferential-allotment-and-warrants)
|
||||
- [9. Convertibles and the honest diluted share count](#9-convertibles-and-the-honest-diluted-share-count)
|
||||
- [10. Rights issues](#10-rights-issues)
|
||||
- [11. Bonus, splits and consolidations](#11-bonus-splits-and-consolidations)
|
||||
- [12. Buybacks: tender vs open market](#12-buybacks-tender-vs-open-market)
|
||||
- [13. Lock-in expiries and pre-IPO supply cliffs](#13-lock-in-expiries-and-pre-ipo-supply-cliffs)
|
||||
- [14. Index inclusion, exclusion and rebalance flows](#14-index-inclusion-exclusion-and-rebalance-flows)
|
||||
- [15. Open offers, delisting and schemes of arrangement](#15-open-offers-delisting-and-schemes-of-arrangement)
|
||||
- [16. Capital gains: holding period is a position decision](#16-capital-gains-holding-period-is-a-position-decision)
|
||||
- [17. Dividend taxation and withholding](#17-dividend-taxation-and-withholding)
|
||||
- [18. The transaction cost stack: STT, stamp duty, round trip](#18-the-transaction-cost-stack-stt-stamp-duty-round-trip)
|
||||
- [19. Cross-border: withholding, treaty relief, PFIC, estate tax](#19-cross-border-withholding-treaty-relief-pfic-estate-tax)
|
||||
- [20. Loss set-off, carry-forward and harvesting](#20-loss-set-off-carry-forward-and-harvesting)
|
||||
- [21. Custody, demat and account hygiene](#21-custody-demat-and-account-hygiene)
|
||||
- [22. Settlement, record dates and response obligations](#22-settlement-record-dates-and-response-obligations)
|
||||
- [23. Sector translation: where this lens inverts](#23-sector-translation-where-this-lens-inverts)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## 0. The method: gate, calendar, net-of-cost
|
||||
|
||||
Three passes, in this order. The first is cheap and kills candidates before you waste analysis on them.
|
||||
|
||||
**Pass 1 — Tradeability gate (10 minutes, do it first for any sub-largecap).** Surveillance status, price band, median daily traded value, impact cost, delivery percentage, free float. If the stock is in a punitive surveillance stage, or your intended position exceeds what the tape can absorb in a reasonable number of days, stop. No fundamental edge survives an inability to exit. Record the gate result even when it passes — it sets the maximum position size for everything downstream.
|
||||
|
||||
**Pass 2 — Supply calendar.** One table, forward 24 months, in shares and in days of average daily traded value (ADV): every lock-in expiry, warrant exercise window, convertible conversion date, unused enabling resolution, ESOP vesting cliff, promoter/PSU divestment intent and index review date. Dilution and supply are the most *predictable* source of drawdown in the whole analysis and the most routinely ignored.
|
||||
|
||||
**Pass 3 — Net-of-cost return.** Take your target return and subtract: round-trip transaction stack × expected turnover, dividend tax at the holder's marginal rate, and capital-gains tax at the rate implied by your stated holding period. Report gross and net. If the thesis only works gross, it does not work.
|
||||
|
||||
Write the output of all three into the report as three lines, not three pages: *"Position capped at X on liquidity; Y% of shares released from lock-in in month Z equal to N days of ADV; gross 18% IRR becomes ~14% net at a 3-year hold."*
|
||||
|
||||
---
|
||||
|
||||
## 1. Exchange surveillance status (India: ASM / GSM / ESM)
|
||||
|
||||
**India-specific.** Before anything else on an Indian smallcap or microcap, pull the current NSE/BSE lists: **ASM** (Additional Surveillance Measure — short-term and long-term stages), **GSM** (Graded Surveillance Measure, Stages I–VI), and **ESM** (Enhanced Surveillance Measure, aimed at SME and microcap counters). These are published as exchange files and revised on a fixed review cycle.
|
||||
|
||||
Record four things: the stage, the date applied, the consequences, and the next review date on which it can escalate or exit.
|
||||
|
||||
Typical consequences by escalation (verify the current framework — stages and their exact effects have been revised repeatedly):
|
||||
|
||||
| Escalation | Typical consequence | What it does to you |
|
||||
|---|---|---|
|
||||
| ASM short-term | 50–100% margin, sometimes reduced price band | Leverage gone; position cost rises |
|
||||
| Trade-for-trade (T2T / BE series) | 100% delivery, no intraday netting | Cannot scale in and out; every trade settles |
|
||||
| Price band cut to 5% or 2% | Daily move capped | A −50% repricing takes many sessions you cannot sell into |
|
||||
| Periodic call auction | Trading collapses to one price-discovery window (weekly in the worst stages) | Effectively no continuous market; exit at whatever single price clears |
|
||||
| No pledging, no derivatives | Collateral value zero; no hedge or short route | Cannot hedge the position you are stuck in |
|
||||
|
||||
**Why it matters.** Surveillance placement is the single biggest silent liquidity killer, and almost no screener surfaces it — so a "cheap" screen hit can be untradeable. It is also an exchange-generated signal that price and volume behaviour looks abnormal relative to fundamentals, which historically precedes regulatory action or collapse more often than it precedes recovery. A GSM Stage IV name is not a cheap stock; it is a stock you may be unable to sell for months.
|
||||
|
||||
**US/global analogue.** There is no direct equivalent, but check: SEC trading suspensions, "caveat emptor" flags on OTC Markets, exchange deficiency notices (Nasdaq/NYSE listing-standard non-compliance letters, minimum bid price and market-value tests), and Reg SHO threshold-list membership. For any OTC/pink-sheet name, treat absence of current information tier as an automatic fail.
|
||||
|
||||
---
|
||||
|
||||
## 2. Circuit limits, price bands and trade-to-trade
|
||||
|
||||
Identify the applicable band and the last 3–6 months of circuit history.
|
||||
|
||||
- **India:** daily bands of 20% / 10% / 5% / 2% on cash-segment stocks. Stocks in the F&O segment have no fixed daily band but operate under a dynamic price band (commonly 10%) that flexes in steps after a cooling-off period. T2T/BE-series stocks prohibit intraday.
|
||||
- **US:** Limit Up–Limit Down (LULD) bands trigger 5-minute trading pauses rather than day-long locks; the Short Sale Restriction (alternative uptick rule) engages after a 10% intraday decline and persists into the next session.
|
||||
|
||||
Distinguish two very different events: a circuit **touched with volume** (genuine repricing, exit possible) versus a **locked circuit with no counterparty** (no exit at all). Count locked days separately.
|
||||
|
||||
**Why it matters.** Circuit structure, not historical volatility, defines your realistic worst case. A 5% lower circuit with no bids means a −50% move takes roughly fourteen sessions during which you cannot sell a single share — the drawdown is not a paper drawdown, it is a trap. Conversely, repeated *locked upper* circuits on a small float usually indicate operator-driven price movement rather than demand, and should pull the stock toward the surveillance and delivery checks rather than into the portfolio. Size positions against the band, not the beta.
|
||||
|
||||
---
|
||||
|
||||
## 3. Delivery volume vs traded volume (India)
|
||||
|
||||
**India-specific**, and one of the most useful free datasets the Indian market provides. NSE and BSE publish security-wise delivery quantity alongside traded quantity in the daily bhavcopy.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Delivery % | Delivery qty ÷ total traded qty, averaged over 30 / 90 / 250 days | Broadly 25–50% for liquid mid/large caps; higher for illiquid quality compounders; <20% signals churn | Separates ownership from speculation |
|
||||
| Delivery-weighted volume trend | Delivery qty (not turnover) trend over 12 months | Rising with price = accumulation | Confirms whether a rally has real buyers |
|
||||
| Divergence flag | Traded volume spiking while delivery % collapses | Any sharp fall below the stock's own 250-day norm | Classic churn / operator signature |
|
||||
|
||||
Benchmark **against the sector and against the stock's own history**, never against an absolute number: an index-heavyweight with heavy derivative and algorithmic activity will structurally show lower delivery than an illiquid quality smallcap, and neither reading means what the raw figure suggests.
|
||||
|
||||
**Why it matters.** A price move on huge volume at 15% delivery is rotation that typically reverses; the same move at 60–70% delivery suggests genuine accumulation that has to be sold before the price falls back. Persistently low delivery plus rising price plus a small free float is the standard fingerprint of price manipulation, and it pairs directly with Sections 1 and 6. **US analogue:** no delivery data exists; substitute short interest and days-to-cover, off-exchange (dark) volume share, and 13F/13D-G ownership changes.
|
||||
|
||||
---
|
||||
|
||||
## 4. Liquidity, impact cost and realistic exit size
|
||||
|
||||
Compute in **value, not shares** — share counts are meaningless across prices.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Median daily traded value (ADV) | Median (not mean — spikes distort) of daily turnover over 6 months | Depends entirely on your AUM; the ratio below is what matters | Base unit for every supply and sizing calculation |
|
||||
| Days to exit | Position value ÷ (ADV × 10–20% participation) | ≤5 days for a core position; >20 days is a research-only name | The only honest definition of position capacity |
|
||||
| Impact cost | Exchange-published cost of a standard order (India: NSE publishes impact cost for a Rs 1 lakh order); or model half-spread + depth | Low single-digit basis points for liquid names; >1% is a red flag | Also the exchange's own gating metric for index and F&O eligibility, so it forecasts inclusion |
|
||||
| Bid–ask spread | Time-weighted spread ÷ mid | A few bps liquid, tens of bps smallcap | Direct round-trip cost, charged twice |
|
||||
| Derivatives availability | Is the stock in NSE F&O / has listed US options? | — | Determines whether you have any hedge or short route at all |
|
||||
|
||||
**Why it matters.** Position size is set by exit liquidity, not conviction. A stock trading Rs 2 crore a day cannot absorb a Rs 5 crore position without moving the price double digits — the exit cost eats the alpha you did the analysis to find. Liquidity is also reflexive: it evaporates precisely in the drawdown when you want to sell, so stress the calculation at 30–50% of normal ADV before deciding the position is exitable.
|
||||
|
||||
---
|
||||
|
||||
## 5. Halts, suspensions and market-wide circuit breakers
|
||||
|
||||
Check the stock's own history of exchange **suspensions** — non-compliance with listing regulations (India: SEBI LODR; US: exchange listing standards), delayed results, auditor resignation, scheme-of-arrangement freezes — and any compulsory-delisting watchlist entry. A suspension freezes capital for an indefinite period, and compulsory delisting can leave you holding an unlisted security with no realistic market.
|
||||
|
||||
Separately understand **market-wide circuit breakers**: index moves of 10 / 15 / 20% trigger halts ranging from 45 minutes to the rest of the session, with the duration depending on the time of day the trigger is hit. Know your market's pre-open, post-close and any block/bulk-deal windows.
|
||||
|
||||
**Why it matters.** Stop-losses do not execute during a halt, and the gap on resumption routinely prints through them. Anyone running leverage must size for a scenario in which they cannot act for a full session and then reopen 15% lower. This is a mechanical risk, independent of the company.
|
||||
|
||||
---
|
||||
|
||||
## 6. Free float and float-adjusted supply
|
||||
|
||||
From the quarterly shareholding pattern (India: mandatory under LODR, filed on the exchanges; US: proxy statement, 13F/13D/13G, and the cover page of the 10-K), compute **true free float**:
|
||||
|
||||
> Shares outstanding − promoter/insider holding − locked-in shares − strategic, parent and government holdings − pledged/encumbered shares
|
||||
|
||||
Track quarter-on-quarter movement in promoter, FII/DII (India), institutional (US), and small-retail buckets, plus the total number of shareholders. **India:** also check FPI sectoral and aggregate ceilings and the resulting "foreign room", because MSCI and FTSE apply a foreign-inclusion factor that can halve an index weight regardless of size.
|
||||
|
||||
**Why it matters.** Float is the denominator for every supply event in Sections 7–14. A 12% float means an index inclusion or a 5% promoter sale is an enormous event; a 70% float absorbs the identical flow invisibly. Two composition signals to read directly: a **rising retail shareholder count against falling institutional holding** is usually distribution into weak hands, and a shrinking float with rising price and low delivery is a manipulation signature, not a scarcity story.
|
||||
|
||||
---
|
||||
|
||||
## 7. The dilution map: build it once, in shares
|
||||
|
||||
Before working through Sections 8–13 individually, build one table. Every row is a claim on your per-share economics.
|
||||
|
||||
| Instrument | Where to find it | Key parameters to record | Effect on share count |
|
||||
|---|---|---|---|
|
||||
| Enabling resolution (unused) | AGM/EGM/postal-ballot notice; board outcome filings | Amount authorised, date passed, validity (typically 1 year) | Contingent — price it as an overhang |
|
||||
| QIP / follow-on / shelf | Exchange filing; **US:** S-3 shelf, ATM programme in 10-Q | Size, floor formula, discount, allottees | Immediate |
|
||||
| Preferential allotment | Postal ballot / EGM notice | Allottee identity, relationship, price vs floor, lock-in | Immediate |
|
||||
| Warrants | Same notice; balance-sheet note | Exercise price, 25% upfront, 18-month window, lapse history | Deferred, holder-optional |
|
||||
| Convertibles (FCCB/CCD/OCD/CCPS) | Balance-sheet notes, annual report | Conversion price, ratio, reset/ratchet, maturity | Deferred, sometimes automatic |
|
||||
| ESOPs | ESOP note, cash flow statement | Outstanding, vested, weighted exercise price, annual grant run-rate | Continuous drip |
|
||||
| Rights issue | Letter of offer | Ratio, price, RE trading window | Immediate, but pro-rata |
|
||||
| Bonus / split | Corporate action circular | Ratio, record date | None economically |
|
||||
|
||||
Then compute two numbers and use them consistently downstream: **fully diluted share count** (assume every in-the-money instrument converts) and **annual dilution rate** over the last 5–7 years (CAGR of diluted shares outstanding). Recompute EPS, P/E and market cap on the diluted base. If your valuation used basic shares while an in-the-money convertible sits in the notes, your valuation is simply wrong.
|
||||
|
||||
---
|
||||
|
||||
## 8. QIP, preferential allotment and warrants
|
||||
|
||||
**QIP (India).** Check for board/shareholder **enabling resolutions** — they frequently sit dormant for a year before use — the size sought, the SEBI floor-price formula (a two-week volume-weighted average of the relevant period), the actual discount to market, the allottee list, the stated use of proceeds, and resulting dilution. Note the 6-month lock-in on QIP shares and the minimum gap rule between successive QIPs.
|
||||
|
||||
The real signal is **who was allotted**. Marquee long-only institutions validate the story and price. Allotment to unknown entities, or to parties with a visible relationship to the promoter, at or near the floor price, is a governance flag that belongs in `08-governance.md` as well as here.
|
||||
|
||||
**Preferential allotment and warrants (India).** Read the postal-ballot/EGM notice: allottee identity and relationship to promoters, pricing versus the SEBI floor, lock-in (longer for promoter allottees; commonly 18 months for others, and up to three years for promoter minimum-contribution tranches — verify current SEBI ICDR provisions). Warrants carry 25% upfront with 18 months to pay the balance and exercise.
|
||||
|
||||
Track the **history of earlier warrants**, which is unusually informative:
|
||||
- Promoters exercising warrants at a price far below market = a wealth transfer from minority shareholders, plus a known deferred dilution overhang.
|
||||
- Promoters letting warrants **lapse and forfeiting the 25%** = they judged the stock above fair value with their own money at stake. That is one of the cleanest negative signals available.
|
||||
|
||||
**US analogue.** Shelf registrations (S-3) and at-the-market (ATM) programmes are the structural equivalent of an unused enabling resolution — an active ATM on a cash-burning company means continuous supply. PIPEs, and SPAC-era warrant overhangs with redemption triggers, are the equivalents of preferential allotments and warrants; read the warrant terms, not the headline share count.
|
||||
|
||||
**Why it matters.** An unused authorisation is not nothing — it is a written option the company holds to sell shares to someone else at a discount, and it caps the stock near the floor price until resolved. Price the overhang; do not wait for the announcement.
|
||||
|
||||
---
|
||||
|
||||
## 9. Convertibles and the honest diluted share count
|
||||
|
||||
Search the balance-sheet notes and annual report for every convertible: FCCBs, compulsorily and optionally convertible debentures, convertible preference shares. Record conversion price, conversion ratio, reset clauses, maturity, coupon, and whether conversion is compulsory or at the holder's option.
|
||||
|
||||
Three specific things to hunt for:
|
||||
|
||||
1. **Anti-dilution / ratchet clauses** that reprice the conversion downward if the stock falls. These create a death-spiral: a falling price increases shares issued, which increases dilution, which pushes the price lower. Any structure with a floating conversion price tied to a trailing market price should be treated as a solvency issue, not a capital-structure detail.
|
||||
2. **Unconverted instruments near maturity**, especially FCCBs. Out-of-the-money convertibles do not convert — they become a hard cash redemption liability, often in foreign currency, on a fixed date. That belongs in the debt-maturity ladder in `04-balance-sheet-and-cashflow.md`, not in the equity story.
|
||||
3. **The EPS gap.** Reported basic EPS can overstate per-share earning power materially when convertibles are outstanding. Always restate.
|
||||
|
||||
---
|
||||
|
||||
## 10. Rights issues
|
||||
|
||||
Record the entitlement ratio, issue price versus market, record date, and — India-specific — the **Rights Entitlement (RE)** window: REs are credited to demat and trade on the exchange for a limited period, then **lapse worthless**.
|
||||
|
||||
Compute the theoretical ex-rights price (TERP):
|
||||
|
||||
> TERP = (existing shares × cum-price + new shares × issue price) ÷ total shares after issue
|
||||
|
||||
**Why it matters.** A rights issue is not dilutive to a participant — it is dilutive only to someone who neither subscribes nor sells their REs. Retail holders let REs lapse routinely, which is a pure, avoidable, 100% loss on the entitlement value. Two analytical reads matter more than the arithmetic: **is the promoter taking up their full entitlement or renouncing** (non-participation is a strong statement about their view of the price, or about their own liquidity), and **what are the proceeds for** — growth capital versus repairing a balance sheet the last raise was also meant to repair. Deeply discounted rights also mechanically reset the price chart, so verify that price history and moving averages used anywhere in the analysis are adjusted.
|
||||
|
||||
---
|
||||
|
||||
## 11. Bonus, splits and consolidations
|
||||
|
||||
Confirm record date, ex-date and adjustment factor, and verify that **price history, moving averages, per-share metrics and any screen output have been adjusted**. Unadjusted data is a silent generator of false signals in every backtest and screener.
|
||||
|
||||
Check how a bonus is funded (free reserves versus securities premium) and whether the company has a pattern of announcing bonuses into price strength. For a **reverse split / consolidation**, find the reason — it is very often cosmetic, undertaken to escape a minimum-price rule, a surveillance category or an exchange listing standard, on a business that is genuinely impaired.
|
||||
|
||||
**Why it matters.** Bonuses and splits create exactly zero economic value; they change the share count and nothing else. Yet they reliably trigger retail buying, which makes them a convenient distribution window for insiders. Treat the announcement as an event to examine for *who is selling into it*, never as a positive fundamental datapoint.
|
||||
|
||||
---
|
||||
|
||||
## 12. Buybacks: tender vs open market
|
||||
|
||||
Determine the route first — the two are economically different instruments.
|
||||
|
||||
| | Tender offer | Open market |
|
||||
|---|---|---|
|
||||
| Commitment | Binding for the stated size at the stated price | Non-binding authorisation; a ceiling, not a promise |
|
||||
| Price | Fixed premium to market | Market price up to a maximum |
|
||||
| Small-shareholder edge (**India**) | 15% of the buyback reserved for holders with ≤Rs 2 lakh at record date, often producing very high acceptance ratios | None |
|
||||
| Analytical treatment | Estimate acceptance ratio from the shareholding pattern; a real, computable arbitrage | Assume partial completion; check actual spend versus authorised |
|
||||
|
||||
Always check: is the buyback funded by surplus cash or by **debt**, or by cash the operating business actually needed? Are promoters/insiders tendering (participation changes the acceptance ratio and the signal)? And how does the buyback price compare to the company's own historical multiple range — buying back stock at a peak multiple destroys value exactly as reliably as issuing at a trough (see `08-governance.md` on capital allocation scoring).
|
||||
|
||||
**Tax, and it inverts the conclusion.** **India:** for buybacks after the October 2024 change, proceeds are taxed **in the shareholder's hands as dividend income** at slab rate, with the cost of the tendered shares treated as a capital loss — this reversed the economics that made buybacks tax-efficient under the earlier company-level buyback-tax regime. **US:** a 1% corporate excise tax applies to net repurchases, and the shareholder's receipt is a capital-gains event, not dividend income. Verify current provisions before modelling any tender arbitrage; the after-tax answer, not the premium, is the answer.
|
||||
|
||||
---
|
||||
|
||||
## 13. Lock-in expiries and pre-IPO supply cliffs
|
||||
|
||||
Build an explicit calendar. **Size every tranche in shares, in percent of float, and in days of ADV** — the third number is the one that predicts the price impact.
|
||||
|
||||
Typical Indian tranches (verify against the offer document and current SEBI ICDR rules):
|
||||
|
||||
| Tranche | Typical lock-in | Seller behaviour |
|
||||
|---|---|---|
|
||||
| IPO anchor investors | 50% released at ~30 days, remainder at ~90 days | Mixed; the 90-day tranche is the larger event |
|
||||
| Pre-IPO / PE-VC holders | ~6 months | Price-insensitive; 10x cost bases mean any price works |
|
||||
| Promoter minimum contribution | 18 months to 3 years | Watch the date; often the last cliff |
|
||||
| QIP shares | 6 months | Institutional, usually orderly |
|
||||
| Preferential allotment | 6–18 months depending on allottee | Related-party allottees often sell immediately on release |
|
||||
| ESOP vesting cliffs | Per scheme | Recurring, not a one-off |
|
||||
|
||||
**US analogue:** IPO lock-ups (commonly 180 days, with early-release triggers tied to price or earnings dates), Rule 144 volume limits for affiliates, and Form 144 filings.
|
||||
|
||||
**Why it matters.** This is the most predictable, calendar-driven source of downside in recently listed companies, and it is routinely ignored by fundamental analysis. A release of 40% of shares into a stock that trades a fraction of a percent of its float daily is an unavoidable supply shock, and the market typically front-runs the date rather than waiting for it. Early PE/VC investors are not valuation-sensitive sellers — they are return-crystallising sellers, and they will accept any price above their cost basis.
|
||||
|
||||
---
|
||||
|
||||
## 14. Index inclusion, exclusion and rebalance flows
|
||||
|
||||
Track eligibility and review calendars, not just current membership.
|
||||
|
||||
- **India:** Nifty 50 / Next 50 / Midcap / Smallcap, Sensex, and the **AMFI semi-annual large/mid/small-cap reclassification**, which forces actively managed mid- and small-cap funds to adjust holdings, not just passive funds. Also watch F&O inclusion/exclusion, which changes hedgeability and margin.
|
||||
- **Global:** MSCI quarterly/semi-annual reviews and FTSE reviews — pay attention to their float factors and **foreign-room adjustments**, which can produce a weight far below what market cap implies. **US:** S&P index committee additions (discretionary, announced with a short lead) and the annual Russell reconstitution (rules-based, heavily front-run).
|
||||
|
||||
Estimate passive demand as **(index weight × tracking AUM) expressed in days of ADV**, and note the **announcement date versus the effective date** separately.
|
||||
|
||||
**Why it matters.** Passive funds must trade at the close on the effective date regardless of price, so an inclusion creates mechanical buying and an exclusion mechanical selling that can be many multiples of daily volume. But the move mostly happens *between* announcement and effective date and then partially reverses — buying an inclusion after the announcement is usually buying the top. Treat index flow as a timing and execution consideration, never as a thesis. Impact cost (Section 4) is the exchange's own eligibility gate, so improving impact cost is a leading indicator of future inclusion.
|
||||
|
||||
---
|
||||
|
||||
## 15. Open offers, delisting and schemes of arrangement
|
||||
|
||||
These events override your thesis entirely — the exit price becomes a formula, not your valuation.
|
||||
|
||||
- **India — SEBI Takeover Code (SAST):** an acquisition crossing the 25% threshold, or creeping acquisition beyond the permitted annual limit above it, mandates an open offer for a further 26%. Check the offer price formula and estimate the acceptance ratio.
|
||||
- **Voluntary delisting (India):** reverse book building, the discovered price, the 90% threshold, and the limited post-delisting exit window. **US:** going-private transactions under Rule 13e-3 with a SC 13E-3 filing.
|
||||
- **Demergers, mergers and schemes:** record the swap ratio, record date, when the resulting entity lists (there is often a gap during which you hold an untradeable entitlement), and — critically — the **cost-basis apportionment** between the original and resulting entities for tax.
|
||||
|
||||
**Why it matters.** You can be forced to exit at a price you did not choose, or be left holding an unlisted share because you failed to tender by a deadline. Delisting arbitrage and open-offer acceptance ratios materially change expected return and should be modelled explicitly when live. Demerger cost-basis apportionment is a routine source of tax error because brokers frequently show the new entity at zero cost, overstating the gain by the entire sale value.
|
||||
|
||||
---
|
||||
|
||||
## 16. Capital gains: holding period is a position decision
|
||||
|
||||
Confirm the holding-period threshold and rate for the asset class, in the holder's jurisdiction, as of the transaction date.
|
||||
|
||||
**India (indicative; verify against current Finance Act).** Listed equity and equity mutual funds: 12 months separates short from long term (24 months for most other assets). Post-23 July 2024, STCG on listed equity under section 111A is **20%**, and LTCG under 112A is **12.5%** with an annual exemption of **Rs 1.25 lakh** and no indexation. Pre-31 January 2018 purchases are grandfathered — cost is stepped up to the higher of actual cost and the 31-Jan-2018 fair market value. Broker tax reports use FIFO matching; reconcile against the AIS / Form 26AS.
|
||||
|
||||
**US (indicative; verify).** Long-term treatment requires a holding period exceeding one year; long-term rates are tiered (0/15/20%) with a net investment income tax on top for higher incomes, while short-term gains are taxed as ordinary income. There is no annual capital-gains exemption equivalent to India's.
|
||||
|
||||
**Why it matters, in decision terms:**
|
||||
- A sale one day before the 12-month mark can cost several percentage points of tax **on the entire gain** — money no stock-picking edge recovers. Always check the holding-period clock before recommending an exit.
|
||||
- Rates changed mid-year in India in 2024, so any multi-period calculation must be **split by transaction date**. Do not apply one rate across a straddling year.
|
||||
- Deferred capital-gains tax is an interest-free loan from the state that compounds with the position. A strategy that turns over annually pays tax every year on a smaller and smaller base; a 10-year hold pays once. This is a real, quantifiable argument for lower turnover, and it belongs in the recommendation.
|
||||
- Mismatches between broker P&L and the AIS are a common trigger for tax notices in India.
|
||||
|
||||
---
|
||||
|
||||
## 17. Dividend taxation and withholding
|
||||
|
||||
**India (indicative; verify).** Post-2020 there is no dividend distribution tax at the company level; dividends are taxed in the shareholder's hands at slab rate as income from other sources. TDS applies (commonly 10%) above an annual per-company threshold; Forms 15G/15H may apply for those eligible. Reconcile dividends received against the AIS and claim the TDS credit — unreconciled credits are simply money lost.
|
||||
|
||||
**US (indicative; verify).** Qualified dividends receive long-term capital-gains rates but only if a minimum holding period around the ex-date is satisfied; non-qualified dividends are ordinary income. REIT distributions are largely non-qualified.
|
||||
|
||||
Two mechanical points that change conclusions:
|
||||
|
||||
1. **Compute after-tax yield at the holder's marginal rate before comparing.** A 6% headline yield is roughly 4.2% after tax at a 30% marginal rate — which can invert a ranking against a lower-yielding grower or a buyback-returning company. Comparing pre-tax dividend yield against post-tax total return is exactly the kind of like-for-unlike comparison this skill exists to prevent.
|
||||
2. **The price drops by approximately the dividend on the ex-date.** "Buying for the dividend" converts capital into taxable income and nothing else. Note ex-date versus record date carefully (Section 22).
|
||||
|
||||
---
|
||||
|
||||
## 18. The transaction cost stack: STT, stamp duty, round trip
|
||||
|
||||
Model the **full stack for the actual strategy**, then express it as a round-trip percentage and multiply by expected annual turnover.
|
||||
|
||||
**India components (rates change; verify each):** Securities Transaction Tax — different rates for delivery buy and sell, intraday sell, futures sell, options premium and options exercise; exchange transaction charges; SEBI turnover fee; stamp duty on the buy side; GST on brokerage and on charges; DP charges levied per sell instruction (a flat fee, so brutal on small sells); brokerage itself.
|
||||
|
||||
**US components:** SEC Section 31 fee on sales, FINRA TAF, commissions (often zero at retail, but payment-for-order-flow shows up as worse execution), ADR custody/pass-through fees on foreign holdings, and currency conversion spreads on any cross-border trade.
|
||||
|
||||
| Cost concept | How to compute | Indicative magnitude | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Round-trip explicit cost | Sum of all statutory + broker charges, buy + sell | Tens of bps for Indian delivery equity | Charged on turnover regardless of profit |
|
||||
| Round-trip implicit cost | Half-spread × 2 + market impact at your size | Often larger than explicit cost in smallcaps | The cost nobody invoices you for |
|
||||
| Annual friction drag | Round-trip cost × portfolio turnover | A 4x-turnover strategy can lose 1.5–3% a year before tax | Frequently exceeds the alpha being chased |
|
||||
|
||||
**Why it matters.** STT is levied on turnover, not profit — it is a guaranteed drag that scales linearly with churn and is paid in losing years too. The derivative structures deserve specific attention: options held to expiry have historically been charged STT on a basis far larger than the premium, which can make a strategy that looks profitable on the P&L unprofitable in reality. Any recommendation implying frequent rebalancing must state the friction cost explicitly.
|
||||
|
||||
---
|
||||
|
||||
## 19. Cross-border: withholding, treaty relief, PFIC, estate tax
|
||||
|
||||
This is where the largest avoidable losses occur, and none of it appears in any financial statement.
|
||||
|
||||
**Dividend withholding and treaty relief.** Foreign dividends are withheld at source. Treaty relief is not automatic — it requires the right form filed *in advance* (a W-8BEN for a non-US person receiving US income, for example), and the foreign tax credit requires the right form filed with the home return (India: Form 67, filed within the prescribed deadline). Indian residents holding US equities are typically withheld at the treaty rate under the India–US DTAA rather than the statutory non-resident rate, and can claim credit — but only if the paperwork was done. **Verify current rates and deadlines.** People routinely surrender double-digit percentages of their dividend income to a missing form.
|
||||
|
||||
**PFIC (US persons only, and it is punitive).** A non-US pooled investment — a foreign mutual fund, a UCITS ETF, many foreign holding and investment companies — is generally a Passive Foreign Investment Company for a US taxpayer. The default section 1291 regime taxes "excess distributions" at the highest ordinary rate with a compounding interest charge on deferred amounts, and requires annual Form 8621 filing. QEF and mark-to-market elections can mitigate this but require information the fund may not provide. Practical consequence for this skill: **a US-taxable holder should generally not be steered into non-US pooled vehicles**, and even foreign operating companies must be screened for the income and asset tests if they hold large passive/cash balances. Ordinary foreign operating businesses are usually not PFICs — cash-heavy shells and post-IPO companies sitting on large raises can be.
|
||||
|
||||
**Situs-based estate tax (frequently overlooked and potentially catastrophic).** Estate tax can be levied by the country where the *asset* is situated, regardless of where the owner lives or whether their home country has an estate tax. US-situs assets — including directly held US shares — expose a non-resident non-citizen's estate to US estate tax above a very low exemption threshold (far below the domestic exemption), at rates rising to 40%, and India has no estate-tax treaty with the US to relieve it. UK-situs assets carry an analogous inheritance-tax exposure. **This is a structural reason a large direct US-stock holding may be better held through a non-US-situs wrapper** — but that is a legal and tax-planning decision for a qualified professional, and this file's job is to flag the exposure and its size, not to design the structure. Never present a large foreign-equity allocation without naming this.
|
||||
|
||||
**India-specific outbound and NRI items.** Remittances abroad fall under the LRS annual limit with TCS on outward remittance above a threshold (verify current rate and threshold). Foreign assets and foreign income must be disclosed in **Schedule FA** of the Indian ITR — non-disclosure carries penalties under black-money legislation that can dwarf the investment itself, and applies even to loss-making or nil-income holdings. For NRIs investing in India: TDS is deducted on capital gains at source (often on gross gains, locking up capital until a refund a year later), PIS/non-PIS account rules apply, and NRE versus NRO determines repatriability.
|
||||
|
||||
---
|
||||
|
||||
## 20. Loss set-off, carry-forward and harvesting
|
||||
|
||||
Know the hierarchy before recommending any realisation.
|
||||
|
||||
**India (indicative; verify).**
|
||||
- Short-term capital loss sets off against **both** STCG and LTCG.
|
||||
- Long-term capital loss sets off **only** against LTCG.
|
||||
- Unabsorbed losses carry forward eight assessment years — **but only if the return is filed by the due date.**
|
||||
- Speculative (intraday) losses set off only against speculative gains and carry forward four years.
|
||||
- There is **no wash-sale rule**, so an immediate repurchase is permitted — but weigh it against GAAR and against the round-trip STT/brokerage cost of the manoeuvre.
|
||||
- Harvest **gains** as well as losses: realise gains up to the annual LTCG exemption each year to step up cost basis for free.
|
||||
|
||||
**US (indicative; verify).** The **wash-sale rule** disallows a loss if a substantially identical security is bought within 30 days before or after the sale — the opposite of India's position, and the single most common cross-jurisdiction mistake. Capital losses carry forward indefinitely, with a limited annual offset against ordinary income.
|
||||
|
||||
**Why it matters.** Filing one day late in India permanently forfeits that year's loss carry-forward — a pure paperwork destruction of real value. Getting the set-off order wrong wastes short-term losses (which could have sheltered gains taxed at the higher short-term rate) against long-term gains taxed at the lower one. And harvesting gains up to an annual exemption is free basis step-up that most investors never claim. Plan before the tax-year end (31 March in India, 31 December in the US), not after.
|
||||
|
||||
---
|
||||
|
||||
## 21. Custody, demat and account hygiene
|
||||
|
||||
Custody failures, not stock selection, cause a large share of permanent retail losses. Check:
|
||||
|
||||
- **Reconcile the depository, not the broker.** India: pull the Consolidated Account Statement from CDSL/NSDL and match it to the broker ledger. This is the only independent verification that the shares you think you own exist in your name.
|
||||
- **Nomination** registered on every demat account, trading account and mutual fund folio. Estates regularly cannot claim holdings without it.
|
||||
- **Account type:** confirm holdings are not in a pooled or margin-funded account where they can be re-pledged.
|
||||
- **POA versus DDPI (India):** a broad Power of Attorney historically allowed brokers wide latitude over client securities; the Demat Debit and Pledge Instruction narrows it to specific purposes. Know which you signed. Confirm the margin-pledge flow is used rather than title transfer.
|
||||
- **KYC, bank mandate and contact details current.** Lapsed KYC freezes accounts; a stale address breaks corporate-action notices.
|
||||
- **IEPF (India):** dividends unclaimed for seven consecutive years — and **the underlying shares with them** — are transferred to the Investor Education and Protection Fund. Recovery is possible but slow. Check for any unclaimed-dividend history on inherited or long-dormant holdings.
|
||||
|
||||
---
|
||||
|
||||
## 22. Settlement, record dates and response obligations
|
||||
|
||||
**Settlement cycle (verify current):** India operates on T+1 with an optional same-day (T+0) segment for a specified set of stocks; the US moved to T+1; several other markets remain T+2 and are migrating. The cycle directly determines corporate-action eligibility.
|
||||
|
||||
**Derive the cum-date rather than memorising it.** To receive an entitlement you must be on the register on the record date, which means your purchase must have *settled* by then. Under a T+1 cycle, a trade must therefore be executed no later than one trading day before the record date — so the ex-date falls on the record date itself, whereas under T+2 it fell a day earlier. Confirm against the specific corporate-action circular for every event, because this convention shifted when settlement cycles changed and stale guidance is everywhere.
|
||||
|
||||
**The error to prevent:** buying *on* the record date gets you nothing except the ex-date price drop. This is one of the most common and most entirely avoidable retail mistakes, and it is expensive around rights entitlements and buyback record dates where the entitlement value is material.
|
||||
|
||||
**Response obligations — corporate actions that require you to act, with deadlines:**
|
||||
|
||||
| Event | Required action | Consequence of inaction |
|
||||
|---|---|---|
|
||||
| Rights issue | Subscribe, or sell the REs before the window closes | REs lapse worthless — total loss of entitlement value |
|
||||
| Tender buyback | Submit the tender through the broker before close | Forgo the premium and the small-shareholder acceptance edge |
|
||||
| Open offer | Tender by the deadline | May be left holding a stub in a controlled or delisting company |
|
||||
| Voluntary delisting | Tender in reverse book building or in the exit window | Left holding an unlisted, largely unsaleable security |
|
||||
| Scheme of arrangement | Usually automatic, but track listing of the resulting entity and apportion cost basis | Overstated capital gain when the broker shows zero cost |
|
||||
|
||||
**Margin and settlement penalties.** Understand upfront/peak margin requirements, short-delivery auction mechanics and the auction settlement price. Short delivery pushes your sale into an auction where the settlement price can be far worse than your intended exit, and peak-margin shortfalls attract penalties that compound within a single day.
|
||||
|
||||
---
|
||||
|
||||
## 23. Sector translation: where this lens inverts
|
||||
|
||||
Apply this before drawing any conclusion from Sections 7–14. The standard reading of "dilution is bad" and "high payout is good" breaks in specific sectors.
|
||||
|
||||
- **Banks and NBFCs.** Equity issuance is not a symptom of weakness — regulatory capital is the raw material of the business, and a growing lender *must* raise. The correct test is **issue price versus book value per share**: raising above 1x P/B is accretive to book value per share and enables growth; raising below book destroys per-share value even when the raise is necessary. Judge a QIP by that arithmetic, not by the dilution percentage. Watch also for regulator-mandated capital raises and promoter-dilution mandates (India: RBI shareholding norms), which are timing-forced, not opportunistic.
|
||||
- **Insurers.** Similar capital logic on solvency ratio rather than book value; growth in new business consumes capital before it produces earnings.
|
||||
- **REITs and InvITs (India) / REITs (US).** Distributions are not dividends and are **not taxed as a single stream**. An Indian REIT/InvIT distribution is split into interest, dividend, rental and return-of-capital components with different tax treatment for each, and the return-of-capital portion reduces the unit cost basis rather than being taxed currently. Computing an after-tax yield requires the distribution breakup from the trust, not the headline yield. These vehicles also distribute nearly all cash flow by regulation, so they fund growth by issuing units continuously — routine dilution that must be judged on NAV accretion, not avoided.
|
||||
- **Miners and commodity producers.** Equity issuance to fund development is structurally normal and pre-production companies dilute relentlessly; model dilution per unit of reserve added, not the raw share-count increase. Commodity ETF and index flows can dominate the tape independently of company news.
|
||||
- **PSUs (India).** Government shareholding is a standing supply overhang — OFS tranches, strategic disinvestment and buyback-for-treasury decisions are policy events with announced dates, not market events. Divestment intent should sit permanently on the supply calendar.
|
||||
- **Smallcaps and SME-platform listings (India).** Every mechanic in this file binds hardest here: surveillance categories, tiny float, low delivery, wide bands, and lot-size constraints on the SME platform. The tradeability gate should be a genuine kill criterion at this size, not a caveat.
|
||||
- **Recently listed companies anywhere.** The lock-in calendar (Section 13) frequently dominates fundamentals for the first 12–18 months. Do not compare a post-IPO chart to a seasoned peer's without it.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Run the tradeability gate before deep work: surveillance status, band, ADV, impact cost, delivery %, free float.
|
||||
- [ ] India: check current ASM / GSM / ESM lists, note stage, date applied, consequences and next review date.
|
||||
- [ ] Identify the applicable price band; count locked-circuit days separately from circuits touched with volume.
|
||||
- [ ] India: compute delivery % over 30/90/250 days against sector and own history; flag volume spikes with collapsing delivery.
|
||||
- [ ] Compute median daily traded value and days-to-exit at 10–20% participation; stress it at 30–50% of normal ADV.
|
||||
- [ ] Check suspension and delisting-watchlist history; know the market-wide circuit-breaker rules if using leverage or stops.
|
||||
- [ ] Compute true free float (net of promoter, lock-in, strategic, pledged); track institutional vs retail composition shift.
|
||||
- [ ] Build the dilution map: every enabling resolution, QIP, preferential issue, warrant, convertible and ESOP tranche.
|
||||
- [ ] Restate EPS, P/E and market cap on the fully diluted share count; compute the 5–7 year dilution CAGR.
|
||||
- [ ] Judge every QIP and preferential allotment by allottee identity and price versus floor, not by size.
|
||||
- [ ] Check warrant exercise-versus-lapse history — promoter forfeiture of the 25% upfront is a strong negative signal.
|
||||
- [ ] Hunt for reset/ratchet clauses and for out-of-the-money convertibles maturing as cash liabilities.
|
||||
- [ ] For rights issues: compute TERP, note the RE window, and check whether promoters are subscribing or renouncing.
|
||||
- [ ] Verify all price history and per-share metrics are adjusted for bonuses, splits and consolidations.
|
||||
- [ ] Classify buybacks as tender or open market; estimate acceptance ratio; check funding source and after-tax treatment.
|
||||
- [ ] Build the 24-month lock-in and supply calendar, sized in shares, % of float and days of ADV.
|
||||
- [ ] Estimate index inclusion/exclusion flow in days of ADV; separate announcement date from effective date.
|
||||
- [ ] Check for live open offers, delisting proposals or schemes; model the formula price, not your valuation.
|
||||
- [ ] Verify capital-gains holding period, rates and thresholds against current law for the holder's jurisdiction and residency.
|
||||
- [ ] Check the holding-period clock before recommending any exit; split calculations across mid-year rule changes.
|
||||
- [ ] Compute after-tax dividend yield at the holder's marginal rate before comparing yield to any total-return alternative.
|
||||
- [ ] Model the full round-trip cost stack and multiply by expected turnover; report the friction drag explicitly.
|
||||
- [ ] For foreign holdings: confirm withholding rate, treaty form filed in advance, and foreign tax credit form and deadline.
|
||||
- [ ] Screen US-taxable holders for PFIC exposure in any non-US pooled vehicle; flag Form 8621 obligations.
|
||||
- [ ] Flag situs-based estate-tax exposure on large direct US or UK holdings; refer the structuring to a professional.
|
||||
- [ ] India: confirm Schedule FA disclosure of all foreign assets, LRS limits and TCS on outward remittance.
|
||||
- [ ] Apply the correct loss set-off order; note India has no wash-sale rule while the US does; file on time to preserve carry-forward.
|
||||
- [ ] Harvest gains up to any annual exemption as well as losses, before the tax-year end.
|
||||
- [ ] Reconcile depository statement against broker ledger; verify nomination, KYC, DDPI scope and any unclaimed-dividend/IEPF history.
|
||||
- [ ] Derive the last cum-date from the current settlement cycle for every corporate action; never buy on the record date for the entitlement.
|
||||
- [ ] List every corporate action requiring a shareholder response, with its deadline and the cost of inaction.
|
||||
- [ ] Apply the sector translation: for banks judge raises on price versus book; for REITs/InvITs use the distribution breakup, not headline yield; for PSUs treat divestment as standing supply.
|
||||
- [ ] State gross and net-of-cost, net-of-tax expected return in the report — and the date of the tax rules applied.
|
||||
|
|
@ -0,0 +1,517 @@
|
|||
# Research Process, Epistemics and the Price Layer
|
||||
|
||||
Use this when: you are deciding *how* to run the analysis rather than what number to compute — at the start (scoping, competence, budget), at the point of judgement (Stage 8-10, forming a view), and before you write the verdict.
|
||||
|
||||
Everything else in this skill tells you what to measure. This file tells you how to think while measuring, and how to know when you are fooling yourself. It matters because the dominant failure mode in equity research is not arithmetic error — it is a well-executed analysis of the wrong question, or a correct analysis whose conclusion was fixed before the work began. The governing rule of this skill (a metric is meaningless until you know its sector and the company's own history; never rank on a single number; for banks, insurers, REITs and miners the standard ratios are undefined or inverted) is itself an epistemic rule, not a formatting rule — it exists because context-free numbers produce confident, invertible conclusions. Part B adds the price layer, which is a genuine input to risk control and timing and a rationalisation engine if you let it lead.
|
||||
|
||||
## Contents
|
||||
|
||||
**Part A — Process, epistemics and decision hygiene**
|
||||
- [1. Circle of competence and the "too hard" pile](#1-circle-of-competence-and-the-too-hard-pile)
|
||||
- [2. Research budget and diminishing returns](#2-research-budget-and-diminishing-returns)
|
||||
- [3. Falsification-first research design](#3-falsification-first-research-design)
|
||||
- [4. Steelmanning the bear case; reading short reports](#4-steelmanning-the-bear-case-reading-short-reports)
|
||||
- [5. Base rates and the outside view](#5-base-rates-and-the-outside-view)
|
||||
- [6. Checklists that work; scores that must not decide](#6-checklists-that-work-scores-that-must-not-decide)
|
||||
- [7. False precision: ranges, reverse DCF and decimals](#7-false-precision-ranges-reverse-dcf-and-decimals)
|
||||
- [8. Conviction is not certainty: confidence tiers and sizing](#8-conviction-is-not-certainty-confidence-tiers-and-sizing)
|
||||
- [9. The research file and the evidence trail](#9-the-research-file-and-the-evidence-trail)
|
||||
- [10. The decision journal and calibration](#10-the-decision-journal-and-calibration)
|
||||
- [11. Re-underwriting on a schedule](#11-re-underwriting-on-a-schedule)
|
||||
- [12. Update discipline: signal vs noise](#12-update-discipline-signal-vs-noise)
|
||||
- [13. Source quality, incentives and management assertions](#13-source-quality-incentives-and-management-assertions)
|
||||
- [14. Knowing when to say no](#14-knowing-when-to-say-no)
|
||||
- [15. Pre-mortems and post-mortems](#15-pre-mortems-and-post-mortems)
|
||||
- [16. Anchoring, framing and order effects](#16-anchoring-framing-and-order-effects)
|
||||
- [17. External challenge and echo chambers](#17-external-challenge-and-echo-chambers)
|
||||
- [18. Auditing the process itself](#18-auditing-the-process-itself)
|
||||
- [19. Epistemic rules specific to an AI analyst](#19-epistemic-rules-specific-to-an-ai-analyst)
|
||||
|
||||
**Part B — Price action, technical and timing inputs**
|
||||
- [20. What the price layer is for](#20-what-the-price-layer-is-for)
|
||||
- [21. Chart data hygiene](#21-chart-data-hygiene)
|
||||
- [22. Trend and moving-average structure](#22-trend-and-moving-average-structure)
|
||||
- [23. Relative strength vs index and vs sector](#23-relative-strength-vs-index-and-vs-sector)
|
||||
- [24. 52-week positioning and momentum](#24-52-week-positioning-and-momentum)
|
||||
- [25. Volume, delivery and the institutional footprint](#25-volume-delivery-and-the-institutional-footprint)
|
||||
- [26. Volatility, beta and capture](#26-volatility-beta-and-capture)
|
||||
- [27. Drawdown history and regime behaviour](#27-drawdown-history-and-regime-behaviour)
|
||||
- [28. Liquidity, float and tradability](#28-liquidity-float-and-tradability)
|
||||
- [29. Short interest, crowding and positioning mechanics](#29-short-interest-crowding-and-positioning-mechanics)
|
||||
- [30. Event behaviour and non-fundamental flow](#30-event-behaviour-and-non-fundamental-flow)
|
||||
- [31. Staged accumulation and invalidation levels](#31-staged-accumulation-and-invalidation-levels)
|
||||
- [32. Price-fundamental divergence: the tape as evidence](#32-price-fundamental-divergence-the-tape-as-evidence)
|
||||
- [33. Where technicals add value and where they mislead](#33-where-technicals-add-value-and-where-they-mislead)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
# Part A — Process, epistemics and decision hygiene
|
||||
|
||||
## 1. Circle of competence and the "too hard" pile
|
||||
|
||||
Before opening a spreadsheet, write one page in plain language: how does this company make money, who pays and why, what would have to be true for it to earn materially more in five years, and which three variables drive the outcome. No jargon, no sell-side deck, no "platform". If you cannot write that page from primary sources, the correct output is not a weak analysis — it is a documented pass.
|
||||
|
||||
Keep a literal, dated **too-hard list** with the reason recorded, so the same name is not re-litigated every quarter. Recurring members: pre-revenue biotech; opaque cross-border holding structures (VIEs, layered offshore SPVs); banks and insurers where you cannot read the loan book, restructured-asset disclosure or reserve triangle; commodity trading houses; serial acquirers whose growth is unauditable roll-up accounting; crypto-adjacent balance sheets; companies where the majority of profit sits in unconsolidated or related-party entities.
|
||||
|
||||
**India-specific too-hard triggers:** promoter groups with a history of related-party fund diversion; companies with high or rising promoter pledge and opaque end-use; frequent auditor changes with no CARO explanation; a listed holdco whose value is entirely unlisted subsidiaries with no published accounts; names under SEBI's GSM/ASM surveillance framework where price formation itself is impaired.
|
||||
|
||||
Watch for **competence drift** — the slide from a real competence area (consumer staples) to an adjacent-sounding one (specialty pharma) whose value drivers are entirely different. The tell is that you start reasoning by analogy rather than from unit economics.
|
||||
|
||||
*Why:* most permanent loss comes from owning what you could not assess, not from missing winners. Passing has zero cost; being wrong with capital committed does not.
|
||||
|
||||
## 2. Research budget and diminishing returns
|
||||
|
||||
Set the depth budget before you start and tie it to the stakes and reversibility of the decision, not to how interesting the company is. Track *which source actually changed your estimate* of the three key variables. When the last block of work produced no revision to those three, stop — that is the diminishing-returns signal, and the honest thing to do is write up.
|
||||
|
||||
Prefer **breadth of source type** (filings, competitor filings, customer disclosures, regulator dockets, industry data, trade press) over depth in one type (the tenth broker note). Guard both errors: the over-researched name that must be bought because forty hours were spent on it, and the "obvious" idea presented with the same confidence as a researched one.
|
||||
|
||||
*Why:* the payoff curve on research is strongly concave — the annual report, the competitor's annual report and the cash flow statement capture most of the edge. Later hours add confidence without accuracy, and sunk effort biases the conclusion toward action.
|
||||
|
||||
## 3. Falsification-first research design
|
||||
|
||||
Write the thesis as a **falsifiable statement with numbers and dates** before gathering supporting evidence: "segment revenue compounds above 12% through FY29 while gross margin holds above 45%". Then list the specific observations that would prove it false, and assign each disconfirmer a data source and a check frequency.
|
||||
|
||||
Then spend the *first* research block hunting disconfirmation: the bear case, the losing competitor's commentary, the regulator's docket, customer complaint channels, the changed risk factors. No verdict is written until at least one serious attempt to kill the thesis has been documented and survived.
|
||||
|
||||
*Why:* confirmation bias is the default state of research — once you like an idea, every subsequent fact reads as support. Reordering the process is one of the very few debiasing techniques that works, because it changes *what you look at* rather than asking you to feel less biased. It also converts narrative into a testable claim, which is a precondition for ever knowing you were wrong.
|
||||
|
||||
## 4. Steelmanning the bear case; reading short reports
|
||||
|
||||
Write the bear case yourself, in its strongest form, *before* reading anyone else's — then compare, and treat the gap as a measure of your blind spots. Then actively source the other side: short-seller reports, the most negative covering analyst, bearish threads that contain actual numbers, borrow cost and short-interest trends, and the year-over-year *diff* of the company's own risk factors (a newly added risk factor is a disclosure event).
|
||||
|
||||
When reading a short report, separate three layers and treat them differently:
|
||||
|
||||
| Layer | How to treat it |
|
||||
|---|---|
|
||||
| **(a) Verifiable facts** — filings, court records, customs/import data, permits, registry entries | Check each one yourself against the primary source. These are the only part that can change a thesis. |
|
||||
| **(b) Interpretation** of those facts | Argue with it. Reasonable people read the same filing differently. |
|
||||
| **(c) Rhetoric, price target, framing** | Discount entirely. It is marketing for a position. |
|
||||
|
||||
Note the author's incentive and horizon, but never dismiss a report on incentive alone — everyone publishing has a position. Ask the decisive question: *if every checkable fact in this report is true, does my thesis survive?* Then watch the company's response — a specific, itemised, numbers-based rebuttal is informative; a defamation notice plus ad hominem is also informative.
|
||||
|
||||
**India note:** dedicated short reports are rare and the borrow market (SLB) is thin, so adversarial work is under-supplied. Substitute: rating agency rationales and downgrade notes, CARO qualifications, auditor resignation letters filed with the exchanges, SEBI orders and adjudication notices, NCLT filings, and the MCA/ROC accounts of unlisted group entities.
|
||||
|
||||
*Why:* shorts are the only participants paid to do adversarial forensic work on a company, and they have repeatedly surfaced accounting and related-party issues years ahead of the market. The failure is symmetric: dismissing them costs you fraud blow-ups, following them blindly costs you the many short reports that are simply wrong about well-run companies.
|
||||
|
||||
## 5. Base rates and the outside view
|
||||
|
||||
Before accepting any company-specific forecast, find the reference class and state its base rate. What share of companies sustain 20%+ revenue growth for a decade? What share of large acquisitions create value? How often do turnarounds actually turn? What is the historical distribution of margin expansion for firms already at this margin level? How many entrants in this category survived a full cycle?
|
||||
|
||||
Then compare the company's own five-to-ten-year record and management's prior guidance-versus-delivery against the current promise, and state **explicitly why this company should beat the base rate** — a specific, durable mechanism. "Great management" and "large TAM" are not mechanisms.
|
||||
|
||||
Always sanity-check the terminal implication: what share of the addressable market must the company hold in year 10 for the model to work, and has any company ever held that share in this industry structure? A model that implicitly requires 40% share of a fragmented, low-switching-cost market has already told you it is wrong.
|
||||
|
||||
*Why:* the inside view — a bottom-up story built from company detail — is systematically overoptimistic because it ignores how rarely the story class succeeds. High growth mean-reverts, high margins attract entry, most M&A destroys value. Base rates are the cheapest available correction and they are usually devastating to the aggressive case.
|
||||
|
||||
## 6. Checklists that work; scores that must not decide
|
||||
|
||||
Tier the checklist. Run a short **kill-switch list** on every name — roughly ten to fifteen disqualifiers: auditor resignation or qualified opinion, going-concern language, unexplained related-party flows, chronic negative operating cash flow with rising debt, promoter pledge above a threshold with falling price, restatement, undisclosed encumbrances, a covenant cliff inside twelve months. Only names that survive get the long list.
|
||||
|
||||
On scoring (see `references/11-scoring-rubric.md`), enforce four rules:
|
||||
|
||||
1. **Normalise every factor within sector or against the company's own history.** Raw cross-sector numbers in a composite reproduce exactly the single-metric error this skill exists to prevent.
|
||||
2. **Veto factors override any score.** Averaging converts a fatal binary flaw — fraud, a covenant cliff, an unfixable governance problem — into a small point deduction.
|
||||
3. **Check for compensating errors.** A very strong score on one factor masking a fatal weakness on another is the composite's characteristic failure.
|
||||
4. **Test weight sensitivity.** If a plausible reweighting reorders your top names, the score contains no information and must not be reported as if it does.
|
||||
|
||||
Audit checklist use periodically: which items have never once changed a conclusion (delete them), and which post-mortems traced to an item that was skipped (promote them).
|
||||
|
||||
*Why:* a 200-item list run without attention becomes a tick-box ritual that manufactures false confidence, and weights chosen without evidence are priors wearing a spreadsheet costume. Scoring exists to structure judgement, not to replace it.
|
||||
|
||||
## 7. False precision: ranges, reverse DCF and decimals
|
||||
|
||||
Force every valuation output into a **range with stated assumptions**, and check that the low case is genuinely bad — recession *plus* share loss *plus* margin reversion — not merely "slightly less good". Count decimals: if a DCF prints a fair value to the cent while terminal value is 75% of the total, delete the decimals and demote the model to a scenario-comparison tool.
|
||||
|
||||
Make **reverse DCF the primary tool** (`references/06-valuation.md`): what growth, margin and reinvestment rate does today's price imply, and does that sit inside or outside the company's own historical distribution and the sector's? Judging whether an implied assumption is plausible is a far easier task than forecasting the future outright.
|
||||
|
||||
Stress only the two or three assumptions that drive most of the variance — sensitising forty inputs is theatre. Reconcile the model's implied unit economics to something physical: stores, seats, tonnes, MW, beds, subscribers, capex per unit of capacity. And never inherit precision from a consensus number or third-party model you have not reproduced.
|
||||
|
||||
*Why:* a model's precision is capped by its least reliable input. A five-year revenue estimate accurate to ±30% cannot produce a fair value accurate to the rupee — but the false precision is exactly what generates the confidence to overweight and to ignore contradicting evidence.
|
||||
|
||||
## 8. Conviction is not certainty: confidence tiers and sizing
|
||||
|
||||
Conviction is a feeling produced by familiarity and effort. Certainty is a property of the evidence. They diverge most dangerously after long research. Keep two things separate in the write-up:
|
||||
|
||||
- **How likely the thesis is to be right** — and on what evidence.
|
||||
- **The payoff spread** — how bad the downside is if wrong, how good the upside if right.
|
||||
|
||||
A high-probability / low-upside case and a low-probability / high-upside case are not the same recommendation even if both are "positive". State both.
|
||||
|
||||
Cap stated confidence by the **quality of the information**, not the strength of the narrative: what share of the thesis rests on verified primary data, versus management assertion, versus your own extrapolation? Any fraud or governance question, or any single-point-of-failure risk (one customer, one product, one regulator, one plant, one country), caps confidence regardless of how good the numbers look.
|
||||
|
||||
Where the report discusses sizing or risk control, keep it **generic and principle-based** — volatility- and drawdown-aware sizing, hard caps for governance-questionable names, checking whether five holdings are really one factor bet. Do not write personalised allocation instructions; you are producing analysis, not advice, and the report should say so.
|
||||
|
||||
*Why:* sizing is where epistemics become financial. An excellent process with reckless sizing still ends in ruin; modest sizing lets you be wrong often enough to keep compounding. If you cannot articulate why confidence is high rather than moderate, the analysis is not finished.
|
||||
|
||||
## 9. The research file and the evidence trail
|
||||
|
||||
Maintain one file per name containing: five to ten years of annual reports and proxies (India: annual report + notice of AGM + shareholding pattern; US: 10-K, 10-Q, DEF 14A via EDGAR), transcripts, the **page or paragraph citation behind every key claim**, the peer set with the reason for each inclusion and exclusion (`references/10-peer-set.md`), the model, and links to primary data — regulatory filings, trial and patent registries, customs/import-export data, court and NCLT dockets, environmental permits, job postings.
|
||||
|
||||
Tag every input by epistemic status, and keep the tags visible in your working notes:
|
||||
|
||||
| Tag | Meaning | Weight it carries |
|
||||
|---|---|---|
|
||||
| **F** | Audited or regulator-filed fact | Highest; can be relied on with a citation |
|
||||
| **A** | Management assertion (concall, press release, investor deck) | Claim about the future or about unaudited detail — never restate as fact |
|
||||
| **E** | Third-party estimate (broker, industry report, data vendor) | Usable as context; must be attributed and dated |
|
||||
| **I** | Your own inference | Must be labelled; it is where most errors enter |
|
||||
|
||||
Retain superseded versions rather than overwriting, so thesis drift is visible. Never let a screener or data vendor figure drive a conclusion without reconciling it to the filing — vendors routinely mis-map segments, mishandle leases (IFRS 16 / Ind-AS 116), treat preference shares and perpetual instruments inconsistently, mis-state net debt, use unadjusted share counts, and silently restate history. Adjusted earnings, net debt, share count and segment data are the four that must always be traced to source.
|
||||
|
||||
*Why:* without a trail you cannot re-underwrite honestly, because you will not remember which numbers were verified and which were absorbed from a summary. The file is also what makes a post-mortem possible — you can only learn from an error if you can reconstruct what you actually believed and why.
|
||||
|
||||
## 10. The decision journal and calibration
|
||||
|
||||
At the moment of every conclusion — buy, add, trim, exit, or **pass** — record, before the outcome is known: the thesis in one paragraph; the three key variables and the forecast for each; the price and valuation at the time; what would trigger a reversal; a numeric probability; and what you expect to happen and by when. Include the state of the world (market regime, what else was happening), because that is what lets you spot mood-driven decisions later.
|
||||
|
||||
Review on a fixed cadence and score **calibration**: of the calls made at 80%, how many happened? Then tag each closed decision on the two-by-two — good process/good outcome, good process/bad outcome, bad process/good outcome, bad process/bad outcome — and take the lesson only from the *process* column.
|
||||
|
||||
Journal the passes too. A portfolio-only record cannot show whether the too-hard pile is protecting you or quietly costing you.
|
||||
|
||||
*Why:* memory reconstructs the past to fit the outcome. Hindsight bias makes every loss look foreseeable and every win look deliberate, which destroys the feedback loop that learning depends on. A contemporaneous, pre-outcome, written record is the only defence.
|
||||
|
||||
## 11. Re-underwriting on a schedule
|
||||
|
||||
At least annually, and after any material event, re-underwrite from scratch. The test is: **would you initiate this position today, at today's price, with today's facts, at this size?** Write the fresh thesis *before* rereading the old one, then compare — the gap is where thesis drift lives.
|
||||
|
||||
Classify explicitly:
|
||||
|
||||
- **Thesis intact, price fell** → potentially add.
|
||||
- **Thesis broke** → exit; the loss is already taken, the only question is whether more capital should stay.
|
||||
- **Thesis was quietly replaced with a new one to justify continuing to hold** → exit. This is the growth story becoming a value story becoming a dividend story becoming a "cheap on book" story. It is a permanent loss wearing the costume of long-term conviction.
|
||||
|
||||
Check the original key variables against actual delivery, and ask whether the original reason to own has already played out. Counter the endowment effect with a periodic clean-slate exercise: list holdings anonymously, with only their metrics and theses, and rank them against new candidates.
|
||||
|
||||
*Why:* portfolios decay silently. The world moves, the reason for owning expires, and the position persists on inertia and familiarity. Re-underwriting converts every holding into an active decision, which is the only fair standard.
|
||||
|
||||
## 12. Update discipline: signal vs noise
|
||||
|
||||
Pre-specify, **at the time of the conclusion**, what counts as thesis-relevant. Write the list: "gross margin below 42% for two consecutive quarters matters; a single quarter's revenue miss on FX does not; loss of the top customer matters; a broker downgrade does not."
|
||||
|
||||
When news arrives, ask one question: does this change one of the three key variables, or only the sentiment? A material adverse fact on a key variable triggers a full re-underwrite within a defined window — not a reflex trade, and not a silent explaining-away.
|
||||
|
||||
Guard both errors. **Anchoring** — refusing to update after a genuine break, which is most acute when already losing money on the name. **Over-updating** — rewriting the thesis every earnings call, which produces turnover, costs and worse decisions. And check whether you are updating on the *price move* rather than on evidence: price is information about other participants' views, not about the business, though a persistent unexplained divergence deserves an explanation (Section 32).
|
||||
|
||||
*Why:* most information flow is noise, but the rare genuinely thesis-breaking fact must be acted on immediately — and it is precisely the one you will most want to rationalise, because you are already down on it. Pre-specifying removes the judgement call from the moment when judgement is most compromised.
|
||||
|
||||
## 13. Source quality, incentives and management assertions
|
||||
|
||||
Grade every source by proximity to the fact and by incentive:
|
||||
|
||||
| Tier | Sources | Caveat |
|
||||
|---|---|---|
|
||||
| 1 | Audited financials, regulator filings and orders (SEBI, RBI, IRDAI, SEC), court/NCLT records, customs data | Still read the notes and the auditor's opinion — Tier 1 is not "unread and trusted" |
|
||||
| 2 | Concall transcripts, investor presentations, management commentary | **Assertion, not fact.** Tag as A (Section 9) |
|
||||
| 3 | Rating agency rationales, exchange filings by peers, industry association data | Rating rationales are unusually high-value in India — they contain covenant, pledge and liquidity detail found nowhere else |
|
||||
| 4 | Paid industry reports, sell-side research | Note who commissioned it; note the coverage incentive |
|
||||
| 5 | Media, newsletters, social, forums, AI-generated summaries | Zero weight as evidence; useful only as a pointer to a primary source |
|
||||
|
||||
For every critical claim, trace it to the original document rather than to a summary of it. Ask of every source: who paid for this, what is their horizon, what do they gain if I act on it?
|
||||
|
||||
**Score guidance versus delivery.** Pull three to five years of transcripts and compare what management said would happen with what happened — capacity commissioning dates, margin targets, debt reduction promises, capex budgets, subsidiary turnaround timelines. Note whether the *language* changes when results deteriorate (rising abstraction, new adjusted metrics, more time on strategy and less on numbers). This is one of the highest-yield and least-performed checks in equity research, because it is a direct quantified measure of whether this management's forecasts are worth anything.
|
||||
|
||||
**India note:** many Indian companies give no formal numeric guidance, so score qualitative commitments instead — commissioning schedules, capex plans, deleveraging targets, stated dividend policy, promises about monetising a subsidiary. Also weigh: the CARO annexure, the auditor's Key Audit Matters, and whether the concall Q&A allows non-scripted questions from institutions.
|
||||
|
||||
**US/global note:** guidance is explicit and quantitative, so scoring is easier — but so is managing to it. Check whether delivery came from operations or from buybacks, one-time gains, acquisitions and definitional changes to "adjusted" measures.
|
||||
|
||||
Treat expert-network calls and channel checks as **small, biased samples** and record the sample size. Ask whether investor-relations access is shaping the view, and whether the same conclusion survives without it.
|
||||
|
||||
## 14. Knowing when to say no
|
||||
|
||||
Adopt an explicit default of **no**. The idea must clear a written bar — understandable, verifiable from primary sources, adequate margin of safety, better than the weakest existing holding, executable at a sensible size — rather than needing a reason to be rejected.
|
||||
|
||||
Watch for manufactured pressure to act: cash drag, benchmark envy, someone else's winner, a fresh model that "needs" to justify itself, a research budget already spent. Track the pass list and its subsequent performance, but judge each pass on whether it was correct *given what was knowable at the time*, not on the outcome.
|
||||
|
||||
*Why:* there are no called strikes in investing. Inaction is a free option, and the largest source of avoidable underperformance for most investors is doing too much — too many names, too much turnover, too many positions bought because the work was already done. Missing a winner is not a loss; losing capital is. A well-defended "no" pile is a portfolio-level asset.
|
||||
|
||||
For this skill specifically: **"insufficient basis for a verdict" is a legitimate, useful output.** Say it plainly, say exactly what is missing, and say what would change the answer.
|
||||
|
||||
## 15. Pre-mortems and post-mortems
|
||||
|
||||
**Pre-mortem, before concluding.** Assume it is three years later and the position has lost 60%. Write the most likely *story* of how that happened — a concrete causal chain, not a list of risk words. Then ask of each path: is it cheap to monitor? Is it hedgeable? Is it likely enough to change the size or kill the idea outright?
|
||||
|
||||
**Post-mortem, after any position closes — winner or loser.** What was right, what was wrong, and was the error in the *facts*, the *interpretation*, the *sizing*, or the *timing*? Was it a recurring error type?
|
||||
|
||||
Maintain a running tally of your recurring error types and convert each repeat offender into a checklist item. Common ones: overpaying for quality, catching falling knives in structurally declining industries, trusting promotional management, ignoring dilution and stock comp, mis-set peer groups, mistaking cyclical peak earnings for a trend, believing a turnaround before cash flow confirms it.
|
||||
|
||||
*Why:* prospective hindsight — imagining the failure as already having happened — measurably improves risk identification versus asking "what could go wrong", because it forces a causal story instead of a vague list. Post-mortems on *winners* matter as much as on losers: a profitable outcome from a broken process is the most dangerous lesson you can teach yourself, and it is the one that gets repeated at larger size.
|
||||
|
||||
## 16. Anchoring, framing and order effects
|
||||
|
||||
Control the **sequence** of the work. Form a view of the business and its economics before looking at the price, the chart, the analyst target, or any entry cost. When the price is known first — which is often unavoidable — note it explicitly as an anchor in the working file.
|
||||
|
||||
Rules that follow:
|
||||
|
||||
- Purchase price is irrelevant to any hold/exit decision. The only question is whether you would buy at today's price.
|
||||
- A 60% decline says nothing about cheapness. Refresh the anchor deliberately: re-derive value from current fundamentals, not from the old high.
|
||||
- Examine absolute cash flows and per-share amounts, not only percentages and multiples; look at nominal debt in crore or millions, not only at ratios. Framing in ratios hides scale; framing in absolutes hides trend. Use both.
|
||||
- Where practical, review the numbers with the company name and your prior view stripped out, and check whether the same conclusion arrives.
|
||||
|
||||
*Why:* anchors operate below awareness and are not neutralised by knowing about them, so the only real defence is procedural — controlling what you see and in what order. Entry price is the most destructive anchor in practice: it produces both the refusal to sell losers and the reluctance to add to winners.
|
||||
|
||||
## 17. External challenge and echo chambers
|
||||
|
||||
Before any high-conviction conclusion, have the thesis attacked by someone whose job in that conversation is to kill it — and give them **the file, not the pitch**. Require the challenge to be specific and evidence-based, and write down the objections that survive.
|
||||
|
||||
Cultivate at least one genuinely bearish source on the name and engage with them rather than around them. Avoid public commitment before the analysis is complete: once a view is stated to an audience, consistency pressure makes updating feel like a status loss, and investors routinely defend a broken thesis long past the evidence because they defended it in public first.
|
||||
|
||||
Audit your information diet. If everyone you read owns the same names, treat that as a warning, not a confirmation.
|
||||
|
||||
*Why:* self-generated criticism is systematically weaker than adversarial criticism, because you cannot see the assumptions you did not know you were making.
|
||||
|
||||
## 18. Auditing the process itself
|
||||
|
||||
Track process-level statistics, not just returns:
|
||||
|
||||
| Process metric | How to compute | Indicative reading | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Hit rate | Share of closed decisions that were profitable | 40-60% is normal and compatible with excellent results | On its own it means nothing; only meaningful alongside win/loss size |
|
||||
| Win/loss ratio | Average gain on winners ÷ average loss on losers | >1.5x for a concentrated long-only process | A 40% hit rate with 3x asymmetry beats a 70% hit rate with 0.5x |
|
||||
| Calibration | Predicted probability vs realised frequency, bucketed | 80% calls should happen ~80% of the time | The only direct measure of whether your confidence means anything |
|
||||
| Contribution by idea source | Return attributed to screen / competitor filing / spin-off / referral | — | Tells you where to spend research time next year |
|
||||
| Contribution by thesis type | Compounder / cyclical / turnaround / special situation / deep value | — | "I lose money on turnarounds" is far more actionable than an aggregate return |
|
||||
| Holding period, actual vs intended | Median realised holding period vs stated horizon | Large gap = process not matching stated style | Style drift shows up here before it shows up in returns |
|
||||
| Turnover cost | Commissions + spread + impact + tax, as % of average capital | India: add STT and short-term capital gains treatment | Activity has a measurable price; most investors never compute it |
|
||||
|
||||
*Ranges are indicative only — they vary by market, strategy, cycle and sample size, and a short sample tells you almost nothing. Compare a metric to your own history before comparing it to any external norm.*
|
||||
|
||||
Audit annually: which idea sources actually produced returns; which thesis types you are demonstrably bad at (candidates for the too-hard pile); whether losses cluster in a sector, a market-cap band, or a behavioural pattern. Then change exactly **one or two things** and record the change with a date, so a future audit can attribute the effect.
|
||||
|
||||
*Why:* returns over any short horizon are dominated by luck and market beta, so judging a process by its P&L is a slow, low-signal and often misleading feedback loop. Process metrics are higher-frequency and attributable. And without a dated record of process changes, you cannot tell improvement from a regime change.
|
||||
|
||||
## 19. Epistemic rules specific to an AI analyst
|
||||
|
||||
These are non-negotiable and specific to how you fail, not how a human fails:
|
||||
|
||||
1. **Never state a company-specific number you have not retrieved.** No estimated revenue, no "approximately" margins, no plausible-looking ratio reconstructed from memory. A fabricated figure that happens to be near-correct is worse than a gap, because it will be trusted and propagated.
|
||||
2. **Date everything.** Every figure carries an as-of date and a period label (FY25 vs CY25 vs TTM to a specific quarter). Indian fiscal years end 31 March; US filers vary. Mixing periods silently is one of the most common quiet errors.
|
||||
3. **Distinguish "not disclosed" from "zero" from "not retrieved".** These have entirely different implications. Non-disclosure of a segment, a related-party balance, or a contingent liability is itself evidence.
|
||||
4. **Cite to the document, not to a summary.** If a number came from a screener, say so and mark it unverified until reconciled to the filing.
|
||||
5. **Do not let fluency substitute for evidence.** A well-written paragraph and a well-evidenced one are indistinguishable in tone. Tag each claim F / A / E / I (Section 9) while working, and make sure the final verdict rests mostly on F.
|
||||
6. **Do not resolve conflicts between sources by averaging.** Find out which one is right, or report the conflict as a finding — a discrepancy between the annual report and the vendor is often the most interesting thing on the page.
|
||||
7. **State units and currency explicitly.** Crore vs lakh vs million vs billion; INR vs USD; and never mix reported and converted figures in one table without labelling the rate and date.
|
||||
8. **Refuse gracefully.** Where the data is insufficient or the business is outside what can be assessed, say so and stop. Declining is an output, not a failure.
|
||||
9. **Analysis, not advice.** Present findings, evidence and risks. Do not issue personalised buy/sell/allocation instructions; state clearly that the output is research, not investment advice.
|
||||
|
||||
---
|
||||
|
||||
# Part B — Price action, technical and timing inputs
|
||||
|
||||
## 20. What the price layer is for
|
||||
|
||||
This layer is **supplementary**. It does not tell you whether a business is good, what it is worth, or whether the accounts are honest — those are settled by Parts 01-16 of this skill. What it legitimately provides is four things: (i) a risk-control frame (volatility, drawdown history, liquidity) that determines whether a correct thesis is survivable; (ii) a timing/staging frame that removes single-point entry guesses; (iii) a *challenge* signal — persistent relative weakness against peers is evidence that someone knows something; and (iv) pre-committed invalidation levels that stop a losing thesis from being rewritten indefinitely.
|
||||
|
||||
The rule for the whole of Part B: **a technical signal never overrides a fundamental conclusion, and a fundamental conclusion never entitles you to ignore a persistent price divergence.** Price gets to force a re-examination. It does not get to make the decision.
|
||||
|
||||
Report these items in a clearly labelled section, separate from the fundamental verdict, so a reader can discard the whole layer without disturbing the analysis.
|
||||
|
||||
## 21. Chart data hygiene
|
||||
|
||||
Before reading anything from a price series, verify it. Almost every wrong technical conclusion is downstream of a corrupted series, and the analyst never discovers the error.
|
||||
|
||||
- Confirm the series is **split- and bonus-adjusted**, and know whether it is price-only or total-return — for a 6% yielder the two diverge enormously over a decade.
|
||||
- Confirm you are on the **primary listing**, not a thin ADR/GDR or a secondary line, and that currency is consistent throughout.
|
||||
- Use **log scale** for multi-year charts; linear only for short windows. A linear twenty-year chart makes early percentage moves invisible and late ones look parabolic.
|
||||
- Check the vendor's handling of spin-offs, reverse splits, ticker changes, scheme-of-arrangement demergers and rights issues. Cross-check two historical points against the company's own filings or the exchange's own bhavcopy/historical data.
|
||||
- **India:** NSE and BSE prices differ slightly; pick one and stay on it. Adjust for bonus issues, stock splits and rights entitlements; verify the adjustment around any demerger, where vendors frequently leave an artificial gap.
|
||||
|
||||
## 22. Trend and moving-average structure
|
||||
|
||||
Identify the dominant trend on both weekly and daily charts: is price above or below the 50-day and 200-day moving averages, and — more informative than the level — is the 200-day sloping up, flat, or down? Note the sequence of higher highs/higher lows versus lower highs/lower lows. Check whether short-, medium- and long-term timeframes agree; conflict between them is itself information (usually that a change of regime is in progress).
|
||||
|
||||
Treat crossover signals (golden/death cross) as descriptive context, never as triggers. They lag by construction and whipsaw in range-bound markets.
|
||||
|
||||
*Why:* trend is the single most robust thing a chart provides, and the slope of the long-term average is a rough proxy for whether the market's assessment of the business is improving or deteriorating. **The specific value to a fundamental analyst:** a statistically cheap stock in a confirmed downtrend is the classic value-trap setup — cheapness plus a falling 200-day usually means estimates have further to fall, and the multiple is low because the E is wrong.
|
||||
|
||||
## 23. Relative strength vs index and vs sector
|
||||
|
||||
Absolute price movement conflates the company with the market. Plot the **ratio line** — the stock divided by the relevant index — over one, three and five years, and note whether it is making new highs, new lows, or basing.
|
||||
|
||||
Then decompose it in two steps, which answers the question "what do I actually own?":
|
||||
|
||||
1. **Stock vs sector index** — is this a stock-specific story or a sector story?
|
||||
2. **Sector vs broad index** — is the sector leading or lagging the market?
|
||||
|
||||
Also compare the stock against three to six *named direct competitors* on one normalised chart, using the peer set you built in `references/10-peer-set.md` — not a GICS bucket. A stock breaking down while its peers hold up is a company-specific problem and demands an explanation before you conclude mispricing. The whole group breaking is a sector or macro problem, and the fundamental work should shift accordingly.
|
||||
|
||||
**India:** use the appropriate Nifty sector or thematic index (Bank, IT, Auto, FMCG, Pharma, Metal, PSE, Realty) rather than Nifty 50 alone, and compare a mid- or small-cap against Nifty Midcap 150 / Smallcap 250, because the broad index is dominated by large caps and will misstate relative performance badly.
|
||||
|
||||
*Why:* a stock up 10% in a market up 25% is quietly losing; a stock flat in a market down 20% is quietly winning. Persistent relative weakness ahead of bad news is one of the more reliable warning patterns in equity markets, and it is exactly the signal a fundamental analyst is temperamentally inclined to dismiss.
|
||||
|
||||
## 24. 52-week positioning and momentum
|
||||
|
||||
| Metric | Definition / how to compute | Indicative reading | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Distance from 52-week high | (52wk high − price) ÷ 52wk high; note the date the high was set | Within ~10% in a rising trend = leadership; >50% off = repair job | Proximity to highs is a well-documented momentum anchor; investors under-react to good news |
|
||||
| Distance above 52-week low | (price − 52wk low) ÷ 52wk low | Context only | Distinguishes "basing after a fall" from "still falling" |
|
||||
| Distance from all-time high | Same, vs the all-time high and its date | A high set 8 years ago changes the story entirely | A multi-year lower high is a business-quality question, not a chart question |
|
||||
| 1 / 3 / 6 / 12-month total return | Total return including dividends, absolute and relative to index and sector | — | The raw momentum inputs |
|
||||
| 12-1 momentum | Trailing 12-month return excluding the most recent month | Top/bottom decile of the universe is the meaningful read | The standard cross-sectional momentum measure; skipping the last month avoids short-term reversal |
|
||||
| Momentum quality | Is momentum backed by rising earnings estimates and delivered results, or by multiple expansion alone? | Earnings-backed is durable; multiple-only is fragile | Tells you what regime will hurt you |
|
||||
|
||||
*All indicative readings vary by market, cycle and period, and mean nothing without comparison to the stock's own history and its sector cohort.*
|
||||
|
||||
Two traps. First, **"down 60% so it must be cheap"** is pure anchoring: percentage decline says nothing about value, and a stock down 60% can fall another 60% (a further 60% decline from there leaves 16% of the original price). Second, momentum is prone to violent reversals at market inflection points — momentum crashes cluster at bear-market bottoms when beaten-down names rip hardest. Know whether your thesis is implicitly a momentum bet.
|
||||
|
||||
## 25. Volume, delivery and the institutional footprint
|
||||
|
||||
Compare volume on up days versus down days over the last four to thirteen weeks. Look for advances on volume above the 50-day average and pullbacks on declining volume; flag the opposite pattern — rallies on thinning volume, declines on expanding volume. Examine volume specifically around earnings, guidance and investor-day dates.
|
||||
|
||||
Technical accumulation/distribution indicators (OBV, A/D line) are noisy proxies. **Ownership filings are the real evidence**, so cross-reference:
|
||||
|
||||
- **US:** 13F quarter-over-quarter changes, number of institutional holders, active vs passive split, Form 4 insider transactions — separating genuine open-market purchases from option exercises and pre-scheduled 10b5-1 sales — and buyback execution disclosed in the 10-Q.
|
||||
- **India:** the quarterly **shareholding pattern** (promoter, FII/FPI, DII, mutual fund, public — and critically, changes in promoter holding and pledge), **bulk and block deal** disclosures on NSE/BSE, SEBI insider-trading (PIT) disclosures by designated persons, and buyback/open-offer filings. Promoter pledge invocation is a distinctive Indian source of sustained mechanical selling.
|
||||
- **India-specific volume quality:** the **delivery percentage** (deliverable quantity ÷ traded quantity), published daily by the exchanges. High volume with low delivery is intraday churn and says little; a rising delivery percentage on rising price is a genuinely different signal. There is no direct US equivalent.
|
||||
|
||||
*Why:* volume is the closest thing a chart has to a conviction measure — it shows how much capital was willing to transact at those prices. A breakout on no volume is often a liquidity artifact that fails. Heavy-volume down days indicate a motivated seller, often an institution unwinding a full position, which can cap a stock for months regardless of fundamentals — and knowing that changes entry pacing entirely.
|
||||
|
||||
## 26. Volatility, beta and capture
|
||||
|
||||
| Metric | Definition / how to compute | Indicative range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Realised volatility | Annualised stdev of daily log returns over 30 / 90 / 250 days | Large-cap staples ~15-25%; broad market ~15-20%; small/mid caps and cyclicals 35-60%+ | The primary input to any sizing decision |
|
||||
| ATR % | Average true range ÷ price | 1-3% daily for liquid large caps; much higher for small caps | Sets how wide any stop must be to avoid noise-triggered exits |
|
||||
| Implied vol / IV percentile | Option-implied vol vs its own 1-year history | IV percentile >80 = options expensive | Tells you whether the market expects an event, and whether hedging is cheap |
|
||||
| Beta | Regression of stock returns on index returns, 1 / 3 / 5-year windows | Stability across windows matters more than the level | An unstable beta means the single number is meaningless |
|
||||
| Up-capture / down-capture | Average stock return in up-index months ÷ index; same for down months | Up-capture > down-capture is the desirable asymmetry | Many stocks capture 80% of downside and 60% of upside — structurally a bad deal that a single beta hides |
|
||||
| Factor exposures | Sensitivity to market, size, value, quality, momentum; plus rates, oil, FX where relevant | — | Exposes hidden concentration: ten "different" long-duration rate-sensitive growth names are one position |
|
||||
|
||||
*Indicative ranges vary enormously by market, market-cap band, cycle and measurement window; Indian small caps are structurally more volatile than developed-market large caps. Always compare against the stock's own history and its sector cohort first.*
|
||||
|
||||
Sizing a 60%-volatility name like a 15%-volatility name is how a correct thesis still produces an unacceptable outcome.
|
||||
|
||||
## 27. Drawdown history and regime behaviour
|
||||
|
||||
Chart the full drawdown series: maximum peak-to-trough decline, the depth of a typical annual drawdown, and the time to recover each one. Look specifically at behaviour in 2008, 2011, 2013 (India: taper tantrum and the rupee), 2015-16, Q4 2018 (India: the NBFC/IL&FS credit event), March 2020, 2022, and any sector-specific shock. For each decline, ask **what fundamentally caused it and whether that vulnerability still exists** — that question is what converts a chart into analysis.
|
||||
|
||||
Then test regime sensitivity: rising versus falling rates, steepening versus flattening curves, inflation up versus down, risk-on versus risk-off, dollar strength versus weakness, expansion versus recession. For India, add crude oil direction, USD/INR, monsoon and rural demand, and the government capex cycle. Note whether the sensitivity comes from the *business model* or only from the *multiple* — the distinction determines whether it is a permanent or a temporary problem.
|
||||
|
||||
*Why:* the relevant question is not what the stock returns but what you must survive to collect it. A name with a history of 45% drawdowns will produce another one; if that would force a sale for psychological, mandate or leverage reasons, the expected return is not actually available. Correlations also converge in stress, so diversification measured in calm markets is largely illusory.
|
||||
|
||||
## 28. Liquidity, float and tradability
|
||||
|
||||
| Metric | Definition / how to compute | Indicative reading | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Average daily traded value | Mean of (price × volume) over 20 and 60 days, in ₹ crore or $m | Judge against intended position size, not an absolute band | Liquidity is the constraint that turns a good idea into an unexecutable one |
|
||||
| Bid-ask spread | Typical quoted spread as % of price | <0.1% liquid large cap; >1% is a warning | A wide spread is a permanent tax on every entry and exit |
|
||||
| Free float | Shares outstanding less promoter/insider, government and strategic stakes | India: promoter holding is disclosed quarterly, so float is precisely knowable | Low float amplifies both squeezes and collapses and makes the chart less informative |
|
||||
| Position as multiple of ADV | Intended position ÷ average daily value | Days-to-exit matters far more than days-to-build | If exiting takes 15 days at 20% of volume, the stop-loss does not exist |
|
||||
| Passive / index ownership | Index membership and share held by index funds | — | Determines rebalance-driven flow and how the name behaves in an index event |
|
||||
|
||||
**India-specific tradability constraints** — these have no US equivalent and can dominate everything above:
|
||||
|
||||
- **Circuit filters / price bands** (2%, 5%, 10%, 20% depending on the scrip): a locked upper or lower circuit means no exit at any price that day. Serial lower circuits are a genuine liquidity failure, not a technical pattern.
|
||||
- **Trade-to-trade (T2T) segment**: no intraday netting; every trade must be settled by delivery. Sharply reduces liquidity.
|
||||
- **ASM / GSM surveillance** (Additional / Graded Surveillance Measure): additional margins, periodic call auctions and trading restrictions. A name under GSM has impaired price formation — treat its chart as uninformative and consider the name too hard.
|
||||
- **F&O eligibility and ban periods**: when market-wide position limit utilisation exceeds the threshold, the stock enters an F&O ban where only position reduction is allowed, distorting cash-market price.
|
||||
|
||||
## 29. Short interest, crowding and positioning mechanics
|
||||
|
||||
**US/global:** track short interest as a percentage of float and of shares outstanding, its trend, days-to-cover (short interest ÷ ADV), borrow cost and availability, and hedge-fund crowding measures. Distinguish genuine directional shorts from convertible-arb, merger-arb and index-hedge shorting — the latter carry no view on the business. Cross-check against unusual option open interest and skew.
|
||||
|
||||
**India:** there is no equivalent retail-visible short-interest disclosure and the SLB market is thin, so use substitutes — stock futures open interest and its direction relative to price (rising OI with falling price suggests short build-up; falling OI with rising price suggests short covering), the cost of carry / futures basis, options open interest concentration at strikes, FII derivative statistics, and the F&O ban list. Promoter pledge levels are the closest Indian analogue to a forced-selling overhang.
|
||||
|
||||
*Why:* heavy short interest cuts both ways. It can be informed scepticism worth investigating — shorts do real forensic work and are often early — or it can set up violent squeezes that make price completely uninformative about fundamentals for weeks. Either way, crowding tells you the price on the screen may reflect positioning mechanics rather than any view of the business, which is exactly when a fundamental analyst should stop reading the tape as evidence.
|
||||
|
||||
## 30. Event behaviour and non-fundamental flow
|
||||
|
||||
Catalogue the stock's reaction to the last eight to twelve results: average absolute move, direction, whether gaps filled or held, and whether the stock continued to drift in the same direction for the following weeks (post-earnings-announcement drift). Note reactions to guidance changes, investor days and regulatory rulings, and how far ahead of results the stock typically moves. This is the empirical distribution for the single largest recurring risk event you will face while holding — and gaps that *hold* indicate genuine repricing, while gaps that consistently *fill* indicate an overreactive shareholder base.
|
||||
|
||||
Then identify **non-fundamental flow drivers**, because a meaningful share of short-horizon price movement has nothing to do with value:
|
||||
|
||||
- Index additions/deletions and rebalance dates (S&P/MSCI/FTSE; India: Nifty and Sensex reconstitution, MSCI free-float factor changes, which move Indian mid-caps hard).
|
||||
- Lock-up expiries and offer supply. **India:** IPO anchor-investor lock-ins (staggered 30/90 days) and promoter lock-in, plus minimum-public-shareholding-driven promoter sell-downs and OFS.
|
||||
- Follow-on offerings, shelf registrations, QIPs, convertible and FCCB issuance, preferential allotments to promoters.
|
||||
- Buyback blackout windows; December tax-loss selling (US) and March fiscal-year-end effects (India); dividend and bonus record dates.
|
||||
- Business seasonality — festive season and monsoon in India, holiday quarter in US retail — which must be compared year-on-year, never sequentially.
|
||||
|
||||
Recognising mechanical flow prevents two errors: reading forced buying as validation, and reading forced selling as deterioration. Occasionally it creates the opportunity, when mechanical selling temporarily overwhelms fundamentals.
|
||||
|
||||
## 31. Staged accumulation and invalidation levels
|
||||
|
||||
Before any entry is contemplated, write down: the full intended position size, the number of tranches, and **what specifically triggers each subsequent tranche** — a price level, a time interval, a valuation threshold, or a fundamental milestone such as a confirmed inflection in the metric the thesis depends on. Also write down the conditions under which you will **not** add, and cap the maximum size regardless of how attractive the name looks after a decline.
|
||||
|
||||
Then define **invalidation in fundamental terms first**: "gross margin fails to recover above X by FY27", "net debt/EBITDA exceeds Y", "the top customer is not renewed", "receivable days do not normalise within two quarters". Only after that, translate it into a price or drawdown level if you use one. Size so that hitting the invalidation level costs a pre-defined, acceptable share of capital, using volatility (ATR or realised vol) rather than a fixed percentage — an identical percentage stop is far tighter on a 15%-vol name than on a 55%-vol one.
|
||||
|
||||
Decide in advance whether stops are hard, mental, or **time-based** (a thesis that has not progressed by a stated date is a failed thesis, even if the price has not moved). Be explicit that stops in gapping or illiquid names may fill far away, and in Indian names locked at a lower circuit may not fill at all.
|
||||
|
||||
*Why:* staging converts entry timing from one high-stakes guess into a process, because nobody times bottoms. And a *pre-written* rule is the only thing that distinguishes disciplined averaging from averaging down into a broken thesis — the latter is the most common way a survivable loss becomes a portfolio-damaging one. Without a pre-committed invalidation level, sizing is arbitrary and losing positions get rationalised indefinitely, because the mind reliably rewrites the thesis to fit the price.
|
||||
|
||||
## 32. Price-fundamental divergence: the tape as evidence
|
||||
|
||||
When price disagrees sharply and persistently with the fundamental view — the stock falls steadily while your model and consensus estimates hold — do not resolve it by asserting that the market is wrong. Hunt for what the market might be discounting:
|
||||
|
||||
- credit signals: bond prices, CDS, rating agency outlook changes, commercial paper rollover, and in India the rating rationale and any covenant breach disclosure;
|
||||
- supplier, customer and competitor results and commentary — the read-across usually arrives before the company's own numbers;
|
||||
- insider and promoter behaviour, including pledge changes and creeping sell-downs;
|
||||
- channel checks, hiring/attrition data, app and web traffic, customs and import-export data;
|
||||
- short reports and litigation dockets;
|
||||
- whether the divergence is stock-specific or shared by the whole peer group (Section 23).
|
||||
|
||||
Set an explicit rule for how much unexplained relative weakness triggers a formal thesis re-review, and record the outcome of that review either way.
|
||||
|
||||
*Why:* price aggregates many participants' information, some of it better than yours. Dismissing persistent divergence as "the market being wrong" is comfortable and occasionally correct, but it is also the standard prelude to a large permanent loss. The discipline is not to obey the tape — it is to let it force a genuine re-examination with a documented conclusion.
|
||||
|
||||
## 33. Where technicals add value and where they mislead
|
||||
|
||||
Be explicit about the boundary, and state it in the report so no reader over-weights this layer.
|
||||
|
||||
| Use | Verdict | Why |
|
||||
|---|---|---|
|
||||
| Trend direction and 200-day slope | **Useful** | Robust, simple, and the single best guard against value traps |
|
||||
| Cross-sectional momentum (12-1) and relative strength | **Useful** | Among the most persistent documented empirical effects, though prone to crashes at inflections |
|
||||
| Volatility and drawdown history for sizing | **Useful** | The honest input to how much risk a position actually carries |
|
||||
| Liquidity, float, days-to-exit, circuit/surveillance status | **Useful** | Hard constraints; they determine whether the idea is executable at all |
|
||||
| Pre-committed invalidation levels | **Useful** | Enforces a bounded loss and imposes a decision date |
|
||||
| Volume confirmation and delivery percentage | **Moderately useful** | Directional evidence about conviction; noisy on any single day |
|
||||
| Support/resistance and base structure | **Moderately useful, partly self-fulfilling** | Levels matter mainly because many holders sit near break-even there, and because many participants act on them |
|
||||
| Named chart patterns, Fibonacci retracements, Elliott wave counts | **Not useful** | Pattern-matching on noise; the human eye finds structure in random walks |
|
||||
| Multi-indicator "confluence", short-horizon oscillator signals | **Actively harmful** | Add enough indicators and one always confirms the view you already held |
|
||||
|
||||
Two enforcement rules. **Pre-commit to a small, fixed indicator set before looking at the chart** — adding indicators until one agrees with you is the characteristic failure of this entire discipline. And **score your own technical calls** the same way you score fundamental ones (Section 10); if they show no calibration, delete the layer rather than keep it as decoration.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
**Process and epistemics**
|
||||
- [ ] Wrote the plain-language one-pager (how it makes money, who pays, what must be true, three key variables) before modelling.
|
||||
- [ ] Confirmed the business is inside the circle of competence; if not, added it to the dated too-hard list with a reason and stopped.
|
||||
- [ ] Set a depth budget up front and stopped when new work stopped revising the three key variables.
|
||||
- [ ] Stated the thesis as a falsifiable claim with numbers and dates, and listed the specific disconfirmers with sources.
|
||||
- [ ] Ran the disconfirming search *first*, and documented one serious attempt to kill the thesis.
|
||||
- [ ] Wrote the bear case before reading anyone else's; separated verifiable facts from interpretation from rhetoric in any short report.
|
||||
- [ ] Stated the reference-class base rate and the specific mechanism by which this company beats it.
|
||||
- [ ] Sanity-checked the terminal implication (required market share in year 10) against industry history.
|
||||
- [ ] Ran the kill-switch checklist on the name before the long checklist.
|
||||
- [ ] Normalised every scored factor within sector or against own history; applied vetoes; tested weight sensitivity.
|
||||
- [ ] Output a valuation range, not a point; used reverse DCF; stressed only the two or three dominant assumptions.
|
||||
- [ ] Reconciled implied unit economics to something physical.
|
||||
- [ ] Separated probability from payoff, and capped stated confidence by evidence quality, not narrative strength.
|
||||
- [ ] Tagged every input F / A / E / I; traced adjusted earnings, net debt, share count and segments to the filing.
|
||||
- [ ] Scored management guidance-versus-delivery over three to five years (India: qualitative commitments and commissioning dates).
|
||||
- [ ] Graded every source by proximity and incentive; traced critical claims to the original document.
|
||||
- [ ] Recorded the decision — including a pass — with thesis, key variables, probability and reversal triggers, before the outcome.
|
||||
- [ ] Pre-specified what future news counts as thesis-relevant and what is noise.
|
||||
- [ ] Ran a pre-mortem: the concrete story of a 60% loss three years out.
|
||||
- [ ] Formed the fundamental view before looking at price, target prices or entry cost; noted any unavoidable anchor.
|
||||
- [ ] Sought at least one genuinely adversarial reading of the file, not the pitch.
|
||||
- [ ] Confirmed that "insufficient basis for a verdict" was considered and rejected on evidence, not on effort already spent.
|
||||
- [ ] Invented no company-specific number; dated and labelled every figure; stated units and currency.
|
||||
|
||||
**Price layer**
|
||||
- [ ] Verified the price series: split/bonus-adjusted, primary listing, consistent currency, log scale for multi-year.
|
||||
- [ ] Recorded trend state: price vs 50-day and 200-day, and the 200-day slope.
|
||||
- [ ] Plotted relative strength vs the broad index, the correct sector index, and named peers.
|
||||
- [ ] Recorded distance from 52-week and all-time highs, with the dates they were set.
|
||||
- [ ] Computed 1/3/6/12-month and 12-1 momentum, and judged whether it is earnings-backed or multiple-driven.
|
||||
- [ ] Checked up/down volume; India: checked delivery percentage; cross-referenced 13F / shareholding pattern, insider and promoter activity, and pledge changes.
|
||||
- [ ] Recorded realised volatility, ATR%, beta stability and up/down capture.
|
||||
- [ ] Charted drawdown history and identified the fundamental cause of each, and whether it still applies.
|
||||
- [ ] Assessed liquidity: ADV, spread, free float, days-to-exit; India: circuit band, T2T, ASM/GSM, F&O ban status.
|
||||
- [ ] Checked short interest and crowding (India: futures OI, basis, pledge overhang).
|
||||
- [ ] Reviewed the last eight to twelve earnings reactions and identified pending non-fundamental flow events.
|
||||
- [ ] Defined invalidation in fundamental terms first, then in price terms; wrote the staging plan and the maximum size cap.
|
||||
- [ ] Investigated any persistent price-fundamental divergence and documented the conclusion.
|
||||
- [ ] Used only the pre-committed indicator set; reported the price layer separately from the fundamental verdict and labelled it supplementary.
|
||||
192
finance/skills/stock-analysis/references/18-forensic-mode.md
Normal file
192
finance/skills/stock-analysis/references/18-forensic-mode.md
Normal file
|
|
@ -0,0 +1,192 @@
|
|||
# Forensic mode — runbook
|
||||
|
||||
Use this when: the question is **"can I trust these accounts?"** rather than "is this a good investment?". Triggered by requests like "check if this company is cooking the books", "is the profit real", "run a forensic check", "the cash flow doesn't match the profit", "should I be worried about this company's accounting", or when a Standard/Deep-dive run hits a Stage 3 red flag serious enough that valuation becomes pointless until it is resolved.
|
||||
|
||||
Forensic mode is not a shorter version of the full analysis — it has a different question, a different output and a different verdict scale. You are not producing an investment view. You are producing an opinion on **whether the reported numbers can bear weight**, and if not, which specific numbers are load-bearing and unverified.
|
||||
|
||||
Two disciplines govern everything below, both inherited from `references/07-forensic-red-flags.md` §16:
|
||||
|
||||
- **Never assert fraud.** Describe what the disclosure shows, what it does not let you rule out, and what evidence would resolve it. You are analysing a real company whose reputation is a real thing; an unsupported accusation is both a professional failure and a potential harm. "The cash is fake" is not a finding. "Reported cash earns an implied yield of ~1% against ~6% short rates, which the filings do not explain" is.
|
||||
- **A single flag is a question; a cluster is a finding.** Most individual anomalies have mundane explanations. What distinguishes a real accounting problem is several independent flags converging on the *same line item*.
|
||||
|
||||
## Contents
|
||||
|
||||
- [When NOT to run this mode](#when-not-to-run-this-mode)
|
||||
- [Stage F0 — Scope and applicability gate](#stage-f0--scope-and-applicability-gate)
|
||||
- [Stage F1 — The one-hour triage](#stage-f1--the-one-hour-triage)
|
||||
- [Stage F2 — Follow the money to the line item](#stage-f2--follow-the-money-to-the-line-item)
|
||||
- [Stage F3 — Documents and people](#stage-f3--documents-and-people)
|
||||
- [Stage F4 — Independent verification](#stage-f4--independent-verification)
|
||||
- [Stage F5 — Quantify the dependency](#stage-f5--quantify-the-dependency)
|
||||
- [The verdict scale](#the-verdict-scale)
|
||||
- [Output template](#output-template)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## When NOT to run this mode
|
||||
|
||||
Say so plainly rather than producing a weak forensic report:
|
||||
|
||||
- **You cannot obtain the primary filings.** Forensic work on aggregator summaries is not forensic work. Screener data has no notes to accounts, no auditor's report, no related-party disclosure — the places where the answers live. If you only have aggregated financials, run the Stage F1 arithmetic tests, report verdict **U**, and list exactly which documents are needed.
|
||||
- **The company is a lender or insurer and you are reaching for the generic battery.** Accrual ratios, DSO and cash conversion are undefined or inverted for banks, NBFCs and insurers. Go to the sector translation section below.
|
||||
- **The user wants a general analysis.** Forensic mode deliberately skips business quality, growth and valuation. If they wanted an investment view, run Standard mode with a forensic pass inside it.
|
||||
|
||||
## Stage F0 — Scope and applicability gate
|
||||
|
||||
1. **Identity and basis.** Which entity, which listing, and — critically — **consolidated or standalone**. Most tunnelling and most hidden leverage live in subsidiaries; a standalone-only forensic pass will miss them by construction. If only standalone is available, say so and treat it as a material limitation.
|
||||
2. **Sector translation.** Confirm the generic battery applies. See the table below.
|
||||
3. **Document inventory.** List what you actually have: annual report (which years), auditor's report, notes to accounts, cash flow statements, shareholding pattern, concall transcripts, rating rationales. **Write this list into the output.** A forensic verdict is only as strong as its document base, and the reader must be able to see that base.
|
||||
|
||||
### Sector translation
|
||||
|
||||
| Sector | Generic tests that are undefined or inverted | What replaces them |
|
||||
|---|---|---|
|
||||
| Banks, NBFCs | Cash conversion, DSO, accrual ratio, working capital — all meaningless. CFO is dominated by deposit and loan flows | Provisioning adequacy vs slippages, PCR trend vs flat GNPA (reserve release), restructured/written-off pool, RBI divergence disclosure (India), evergreening indicators, Stage-2 migration, related-party lending |
|
||||
| Insurers | Revenue timing, receivables | Reserve adequacy and prior-year development, actuarial assumption changes, persistency vs reported VNB |
|
||||
| REITs, InvITs | Earnings-based accrual tests | Fair-value gains vs realised NOI, capitalised leasing costs, AFFO adjustments, related-party asset purchases from the sponsor |
|
||||
| Miners, oil & gas | Depreciation adequacy | Reserve restatements, capitalised exploration/stripping costs, rehabilitation provision adequacy |
|
||||
| EPC, infrastructure | Standard revenue tests | Percentage-of-completion assumptions, unbilled revenue growth, claims and arbitration recognised as receivables, retention money ageing |
|
||||
|
||||
## Stage F1 — The one-hour triage
|
||||
|
||||
These six tests are cheap, quantitative, and catch the large majority of distortion cases. Run all six before going deeper. Run `python scripts/ratios.py <input.json>` — it computes most of them and raises the warnings automatically.
|
||||
|
||||
| # | Test | Compute | What it means |
|
||||
|---|---|---|---|
|
||||
| 1 | **Cash conversion** | Cumulative CFO ÷ cumulative PAT over 5 years | The headline test. Below ~0.8 sustained means profit is not becoming cash. **This is a scoring gate: below 0.5 over 3+ years caps the composite at 4.0** |
|
||||
| 2 | **Proof of cash** | Investment income ÷ average cash & liquid investments, vs short rates for that currency | An implied yield far below the risk-free rate means the cash is absent, pledged, restricted, or non-interest-bearing. India: include Ind-AS fair-value gains on liquid funds or you manufacture a false flag |
|
||||
| 3 | **Receivables vs sales** | DSO trend over 5 years; receivables CAGR − revenue CAGR | Revenue that has not been collected is a hypothesis. **Gate: sustained divergence 2+ years caps at 6.0** |
|
||||
| 4 | **Capex vs depreciation** | Capex ÷ D&A; implied asset life; CWIP ageing | Persistent capex far above depreciation with flat revenue is where deferred costs hide |
|
||||
| 5 | **Audit opinion** | Opinion type, Key Audit Matters, Emphasis of Matter, IFC/SOX opinion, auditor changes and stated reasons | **Gates: adverse/disclaimer = veto. Qualified = cap 4.0. Resignation without clean reason = cap 4.5** |
|
||||
| 6 | **Related party and pledge** | RPT as % of revenue; loans/advances to related parties; promoter pledge level and trend (India) | The primary tunnelling route. **Gates: unexplained RPT/diversion = cap 4.5; pledge >50% = cap 4.0** |
|
||||
|
||||
**Before flagging test 1 or 3, rule out the innocent explanation.** A genuinely growing, working-capital-intensive business (distribution, EPC, capital goods) consumes cash while growing — that is arithmetic, not fraud. Compute **working capital as a % of sales**. Stable ratio with a growing absolute number = growth. Rising ratio = the growth is being bought. Write this test into the output whichever way it resolves.
|
||||
|
||||
## Stage F2 — Follow the money to the line item
|
||||
|
||||
If triage raises anything, stop generalising and answer one question: **if profit did not become cash, which asset did it become?**
|
||||
|
||||
Build the five-year bridge — PAT, CFO, capex, FCF, ΔWorking capital, D&A, non-cash items — and attribute the gap to a named balance-sheet line. Each destination routes to a different investigation in `07-forensic-red-flags.md`:
|
||||
|
||||
| Where the profit went | Investigate | Section |
|
||||
|---|---|---|
|
||||
| Receivables / unbilled revenue | Revenue recognition, ageing, ECL adequacy, channel stuffing, vendor financing | §3, §4 |
|
||||
| Inventory | Obsolescence, provisioning, cost absorption into inventory | §4 |
|
||||
| CWIP / intangibles / capitalised development | Cost capitalisation, useful lives, impairment timing | §5 |
|
||||
| Loans & advances to related parties | Tunnelling, promoter-group diversion | §9, §10 |
|
||||
| Goodwill from acquisitions | Purchase accounting, acquisition reserves, serial-acquirer distortion | §6 |
|
||||
| "Other current assets" | Read the note. This is where unclassifiable claims are parked | §4 |
|
||||
|
||||
Then test the **cluster rule**: are several independent flags pointing at the *same* line item? Rising DSO alone is a question. Rising DSO + shrinking ECL allowance + revenue concentrated in Q4 + a related-party customer is a finding.
|
||||
|
||||
## Stage F3 — Documents and people
|
||||
|
||||
- **Auditor's report in full** — opinion, basis, KAMs/CAMs, Emphasis of Matter, internal-financial-controls opinion. India: the **CARO annexure** forces explicit comment on fund diversion, related-party loans, and end-use of borrowings. Read every clause.
|
||||
- **Component-auditor coverage** — what % of consolidated revenue, assets and profit is *not* audited by the principal auditor. A high unaudited share in a complex group is a structural concern in itself.
|
||||
- **Year-over-year redline** — diff this year's disclosure against last year's and hunt specifically for **deletions**. Management highlights additions and never mentions removals.
|
||||
- **People signals** — map CFO, controller, treasurer, internal-audit head and audit-committee-chair turnover over 5+ years. Serial finance-team churn is among the more reliable pre-restatement tells. Read resignation letters where available.
|
||||
- **Enforcement and litigation history** — SEBI/SFIO/NFRA (India), SEC comment letters and enforcement (US), restatements, exchange actions. Read short-seller reports as *primary documents to be evaluated*: attribute their claims, verify independently, do not adopt.
|
||||
|
||||
## Stage F4 — Independent verification
|
||||
|
||||
The decisive point, and the reason a filings-only forensic pass has a ceiling:
|
||||
|
||||
> Every major accounting fraud reconciled internally. The balance sheet balanced, the ratios computed, and a competent desk analyst could complete a full checklist without the numbers contradicting each other. Fabricated financials are internally consistent by construction.
|
||||
|
||||
So where the fraud hypothesis is live, attack the specific load-bearing claim with **non-company evidence**: registry and insolvency filings (MCA/ROC, Companies House, EDGAR), customs and shipping records, satellite or street-level imagery for claimed physical assets, employment and hiring data, app/web traffic panels, customer and ex-employee contact, and the charge registry for pledged assets.
|
||||
|
||||
State plainly what you attempted, what you obtained, and what you could not verify. **"Not verified" must never be presented as "verified clean."**
|
||||
|
||||
## Stage F5 — Quantify the dependency
|
||||
|
||||
A forensic pass that ends in a list of flags is unfinished. The useful output is a sentence of this shape:
|
||||
|
||||
> *Roughly X% of reported EBITDA over the last three years depends on capitalisation and one-off treatments the peer group does not use; on a peer-consistent basis EBITDA would be approximately Y.*
|
||||
|
||||
Derive it from disclosed line items and show the working, or state explicitly that it cannot be derived. Never invent it. Then carry the adjusted figures — not the reported ones — into `references/05-returns-and-dupont.md` and `references/06-valuation.md` if the analysis continues.
|
||||
|
||||
## Challenge the verdict before assigning it
|
||||
|
||||
Run `references/20-challenge-pass.md` before you settle on a letter. A forensic verdict is unusually costly to get wrong in **both** directions — a false clean bill misleads someone about to commit money, and a false concern damages a real company — so the adversarial pass is mandatory here rather than recommended.
|
||||
|
||||
Attack in both directions, and say which way you tested:
|
||||
|
||||
- **Against a clean verdict:** what did you not look at? Which document would most likely change the answer? Is "no flags found" actually "no flags searched for"?
|
||||
- **Against a concerning verdict:** is the innocent explanation stronger than you allowed? Is this a single flag dressed as a cluster? Would a sector specialist call this normal for the industry?
|
||||
|
||||
## The verdict scale
|
||||
|
||||
Assign exactly one. The scale maps to the three severities in `07-forensic-red-flags.md` §16, plus an explicit "insufficient evidence" band that must never be collapsed into "clean".
|
||||
|
||||
| Verdict | Meaning | What it implies |
|
||||
|---|---|---|
|
||||
| **A — No material concerns identified** | The triage battery ran on primary documents and surfaced nothing beyond normal accounting variation | Reported figures can bear weight. State which tests were run |
|
||||
| **B — Aggressive but disclosed** | Permissive but legal and visible choices: generous capitalisation, flattering non-GAAP add-backs, a disclosed tax holiday | Adjust the numbers yourself, show the adjustment, proceed |
|
||||
| **C — Unexplained anomalies** | A cluster of flags converging on a line item that disclosure does not account for | Raise the required margin of safety materially. State the specific evidence that would resolve it. Not an accusation |
|
||||
| **D — Structural integrity risk** | Adverse/disclaimer/qualified opinion, auditor resignation, cash-existence KAM, large unaudited group share, Big-R restatement, regulator enforcement, related-party tunnelling | Belongs in the opening line of the report. Sufficient on its own to stop the analysis. Do not rely on reported figures |
|
||||
| **U — Insufficient evidence** | Primary documents unobtainable; the tests that matter could not be run | **Explicitly not a clean bill.** List the documents required. An unchecked test and a passed test look identical unless you say which is which |
|
||||
|
||||
Report the verdict with its evidence base, never as a bare grade.
|
||||
|
||||
## Output template
|
||||
|
||||
```markdown
|
||||
# Forensic review — <Company> (<TICKER>)
|
||||
**Verdict: <A/B/C/D/U> — <label>**
|
||||
As of <date> · Basis: <consolidated/standalone> · Currency/units: <INR crore / USD mn>
|
||||
|
||||
## Document base
|
||||
Documents obtained: <list with years>
|
||||
Documents NOT obtained: <list> — and what each would have tested.
|
||||
|
||||
## Summary
|
||||
<3-5 sentences. Lead with the verdict and the single most load-bearing unresolved item.>
|
||||
|
||||
## Triage results
|
||||
| # | Test | Result | Reading |
|
||||
|---|---|---|---|
|
||||
| 1 | Cash conversion (5y cumulative CFO/PAT) | | |
|
||||
| 2 | Implied yield on cash vs short rates | | |
|
||||
| 3 | DSO trend / receivables vs sales growth | | |
|
||||
| 4 | Capex vs depreciation | | |
|
||||
| 5 | Audit opinion, KAMs, auditor changes | | |
|
||||
| 6 | Related-party exposure and pledge | | |
|
||||
|
||||
## Findings
|
||||
For each finding:
|
||||
- **What the disclosure shows** — the figures, sourced and dated.
|
||||
- **Severity** — aggressive-and-disclosed / unexplained anomaly / structural integrity risk.
|
||||
- **The innocent explanation** — the most plausible benign reading, stated fairly.
|
||||
- **What would resolve it** — the specific document, disclosure or external evidence.
|
||||
- **Cluster?** — which other flags point at the same line item.
|
||||
|
||||
## Quantified dependency
|
||||
<X% of reported EBITDA/PAT depends on <treatment>; peer-consistent figure ≈ Y. Or: cannot be derived, because ...>
|
||||
|
||||
## Gates raised
|
||||
<From scripts/score.py — list each gate, its severity, and whether it was CHECKED-AND-CLEARED or NOT CHECKED.>
|
||||
|
||||
## What was not verified
|
||||
<Explicit list. This section is mandatory and must never be empty unless every test was genuinely run on primary documents.>
|
||||
|
||||
---
|
||||
*This is analysis of publicly disclosed information, not an allegation of wrongdoing and not licensed financial advice. Findings describe what disclosure does and does not explain; they are not conclusions of fraud.*
|
||||
```
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Consolidated basis confirmed, or standalone-only flagged as a material limitation.
|
||||
- [ ] Sector translation applied — generic battery not run on a lender, insurer or REIT.
|
||||
- [ ] Document base listed in the output, including what was **not** obtained.
|
||||
- [ ] All six triage tests run, or their absence stated.
|
||||
- [ ] Working capital as % of sales checked before any cash-vs-profit flag in a growing business.
|
||||
- [ ] India: Ind-AS fair-value gains on liquid funds included in the cash-yield test.
|
||||
- [ ] Cash gap attributed to a **named** balance-sheet line item.
|
||||
- [ ] Cluster rule applied — no finding asserted on a single isolated flag.
|
||||
- [ ] Every flag paired with its innocent explanation and its resolving evidence.
|
||||
- [ ] Auditor's report, KAMs, IFC opinion and (India) CARO clauses read in full.
|
||||
- [ ] CFO / audit-committee turnover mapped over 5+ years.
|
||||
- [ ] At least one independent non-company corroboration attempted for the load-bearing claim.
|
||||
- [ ] Dependency quantified and shown, or explicitly stated as underivable.
|
||||
- [ ] Verdict assigned on the A–D/U scale, with U used wherever documents were missing.
|
||||
- [ ] No assertion of fraud anywhere in the output; short-seller claims attributed, not adopted.
|
||||
- [ ] "What was not verified" section present and populated.
|
||||
159
finance/skills/stock-analysis/references/19-ipo-mode.md
Normal file
159
finance/skills/stock-analysis/references/19-ipo-mode.md
Normal file
|
|
@ -0,0 +1,159 @@
|
|||
# IPO mode — analysing a company that is not yet listed
|
||||
|
||||
Use this when: the company has **not started trading yet** — an open or upcoming IPO, a filed DRHP, an announced price band, an SME-platform issue, or "should I apply to X's IPO". If the company already trades and listed within roughly the last two years, this is the wrong file: use `references/13-situations.md` §8 instead, which handles the post-listing overlay.
|
||||
|
||||
An IPO is not a cheaper version of a listed-company analysis. Two of this skill's load-bearing mechanisms are simply unavailable, and one question changes shape entirely:
|
||||
|
||||
- **There is no own-history benchmark.** You have restated prospectus financials prepared by the issuer for the purpose of selling, not audited public reporting under scrutiny. Half the skill's comparison logic — "how does this company compare to its own five-year record?" — cannot run.
|
||||
- **There is no market price to test.** The price is *set* by the issuer and bookrunners, not discovered. So the valuation question is not "is the market wrong?" but **"is this band justified against listed peers, and what does it assume?"**
|
||||
- **The information asymmetry is at its maximum and runs entirely against you.** IPOs are sold, not bought. They are timed by informed sellers into favourable markets, with disclosure the seller controls and coverage largely originating from the bookrunners.
|
||||
|
||||
Everything below follows from those three facts.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Stage I0 — Establish the offer](#stage-i0--establish-the-offer)
|
||||
- [Stage I1 — Get the right document](#stage-i1--get-the-right-document)
|
||||
- [Stage I2 — Who is selling, and why now](#stage-i2--who-is-selling-and-why-now)
|
||||
- [Stage I3 — Interrogate the restated financials](#stage-i3--interrogate-the-restated-financials)
|
||||
- [Stage I4 — Sector playbook and listed-peer benchmarking](#stage-i4--sector-playbook-and-listed-peer-benchmarking)
|
||||
- [Stage I5 — Value the band, not the company](#stage-i5--value-the-band-not-the-company)
|
||||
- [Stage I6 — Structure, supply and mechanics](#stage-i6--structure-supply-and-mechanics)
|
||||
- [Stage I7 — Verdict and what to watch](#stage-i7--verdict-and-what-to-watch)
|
||||
- [Scoring adjustments](#scoring-adjustments)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Stage I0 — Establish the offer
|
||||
|
||||
Before any analysis, pin down what is actually being sold:
|
||||
|
||||
| Item | Why it matters |
|
||||
|---|---|
|
||||
| Issuer, exchange, **main board vs SME platform** | SME issues (NSE Emerge, BSE SME) carry materially lighter disclosure, thinner post-listing scrutiny, larger lot sizes and far worse liquidity. Say so prominently if it is one |
|
||||
| Total issue size, and the **fresh issue vs offer-for-sale split** | Fresh issue money enters the company; OFS money goes to exiting shareholders. **A 100% OFS raises nothing for the business** |
|
||||
| Price band (floor and cap), face value, lot size | All valuation work must be run at **both** ends of the band |
|
||||
| Implied market cap at floor and at cap | The number most retail coverage never states plainly |
|
||||
| Post-issue promoter holding and total dilution | How much of the company is actually being sold |
|
||||
| Issue dates, anchor allotment date, listing date | Anchor book pricing is a data point available before you decide |
|
||||
| Registrar and bookrunners | Track record matters; so does whether coverage is BRLM-affiliated |
|
||||
| Reservation/discount for employees, shareholders, retail | Changes effective price for some applicants |
|
||||
|
||||
## Stage I1 — Get the right document
|
||||
|
||||
- **DRHP** (draft) — filed with SEBI, **contains no price band**. Fine for business and financial analysis; useless for valuation.
|
||||
- **RHP** (red herring) — filed after SEBI observations, **contains the price band and the "Basis for Offer Price" section**. This is the document you need to assess valuation.
|
||||
- **SEBI observation letter, addenda and corrigenda** — changes between DRHP and RHP tell you what the regulator pushed back on.
|
||||
- **US equivalent:** Form S-1 and its amendments (S-1/A); the final prospectus (424B4) carries the priced terms.
|
||||
|
||||
Sources: SEBI's website, the exchange sites (NSE/BSE), the BRLM sites, and the registrar. For US issues, EDGAR. If you only have news coverage of the IPO and not the RHP itself, say so — coverage routinely misreports the OFS split and the implied multiple.
|
||||
|
||||
**Two RHP sections do a great deal of work and are frequently skipped:**
|
||||
|
||||
1. **"Basis for Offer Price"** — the issuer's own justification, including its stated P/E, EV/EBITDA and RoNW at the band, and its chosen peer set. Read the peer set critically: issuers pick flattering comparables. Rebuild it yourself using `references/10-peer-set.md`.
|
||||
2. **KPI disclosure** — since 2022 SEBI requires issuers to disclose the KPIs they shared with pre-IPO investors, with peer comparison, certified and approved by the audit committee. This is a direct, mandated window into the metrics management itself considers definitive, and into what earlier investors were shown.
|
||||
|
||||
Also read the **Risk Factors** section in full. It is drafted by lawyers to protect the issuer, which makes it the most candid disclosure in the document — the material risks are genuinely listed there, just buried in volume.
|
||||
|
||||
## Stage I2 — Who is selling, and why now
|
||||
|
||||
This is the analytical heart of an IPO, and it has no equivalent in listed-company work.
|
||||
|
||||
- **Identify every selling shareholder and the size of each stake being sold.** Promoter, founder, PE/VC, strategic investor, employees.
|
||||
- **Cost basis and the last private round.** If a PE holder entered at ₹X two years ago and is exiting at 8×, that is their view of fair value — expressed with real money and better information than you have.
|
||||
- **Is the promoter selling, and how much?** Founders trimming a small stake for liquidity is normal. Founders exiting a large proportion at the top of a cycle is a signal, and should be weighed against whatever growth story the RHP tells.
|
||||
- **Use-of-proceeds specificity.** "Funding a named plant with a named capacity and a stated commissioning date" is a real plan. "General corporate purposes", "repayment of borrowings availed from promoters" and large unallocated portions are much weaker, and the proportion going to each should be stated.
|
||||
- **Why this window?** IPOs cluster at cyclical and sentiment peaks in the issuer's sector. Ask explicitly whether the sector is at a favourable point in its cycle, and consult the relevant sector playbook on where the cycle is.
|
||||
|
||||
## Stage I3 — Interrogate the restated financials
|
||||
|
||||
You typically get three to five years of restated financials. Treat them as a document prepared to support a sale.
|
||||
|
||||
**The margin-ramp test.** A beautiful three-year improvement into the IPO year is a **warning, not a strength**. Pre-IPO financial dressing is common and frequently reverts within four to eight quarters of listing. Plot revenue growth, margins and working capital by year and ask what changed and whether the change is structural or presentational.
|
||||
|
||||
**Specific things to hunt:**
|
||||
|
||||
| What | Why |
|
||||
|---|---|
|
||||
| Related-party clean-ups executed shortly before filing | Transactions that existed for years and vanish just before the DRHP indicate what the structure actually looked like |
|
||||
| One-off or lumpy revenue concentrated in the final year | Inflates the base the multiple is applied to |
|
||||
| Working-capital squeeze into the IPO year | Stretched payables, channel stuffing, receivables factoring — flatters cash flow at exactly the moment it is being examined |
|
||||
| Restructuring, carve-outs, subsidiary transfers in the period | Restated financials for a business that did not exist in that form; comparability across years may be fictional |
|
||||
| Change of auditor during the restated period | See `references/07-forensic-red-flags.md` §8 |
|
||||
| Promoter remuneration and any pre-IPO bonus/ESOP grants | Post-listing cost base may differ from the historical one |
|
||||
| Contingent liabilities and litigation | Disclosed in the RHP at length; quantify against equity |
|
||||
|
||||
Run the **forensic triage** from `references/18-forensic-mode.md` Stage F1 on the restated numbers — cash conversion, receivables vs sales, capex vs depreciation, audit opinion. The cluster rule and the no-assertion-of-fraud discipline apply exactly as they do elsewhere.
|
||||
|
||||
## Stage I4 — Sector playbook and listed-peer benchmarking
|
||||
|
||||
Route to the sector playbook as normal — the sector determines which metrics apply, and that is unchanged by listing status. A pre-IPO bank is still assessed on NIM, GNPA and CAR; a pre-IPO REIT on AFFO and occupancy.
|
||||
|
||||
Because own-history benchmarking is unavailable, **the listed peer set carries the entire comparative load.** Build it explicitly per `references/10-peer-set.md`, and state it. Where the issuer has no genuine listed comparable — increasingly common for platform and new-economy issues — say so plainly rather than forcing a bad peer. The honest output there is a wider valuation range and lower confidence, not a fabricated precision.
|
||||
|
||||
## Stage I5 — Value the band, not the company
|
||||
|
||||
Run every valuation at **both the floor and the cap**, and present them side by side. The cap is what you will most likely pay in an oversubscribed issue.
|
||||
|
||||
1. **Compute the implied multiples at the band** — P/E, EV/EBITDA, P/B, P/S on post-issue share count. Post-issue count, not pre-issue: fresh issue dilutes.
|
||||
2. **Compare against the listed peer set** on the sector's correct multiple, not a generic P/E.
|
||||
3. **Check the issuer's own "Basis for Offer Price" arithmetic** and its peer selection. Where you disagree, show both.
|
||||
4. **Reverse-engineer the assumption.** What growth and margin does the cap of the band require to deliver an acceptable return? This is the most useful single output of the whole exercise — it converts "is it expensive?" into a testable claim about the business.
|
||||
5. **Anchor book as a reference point.** Anchors are allotted at the cap and their identities are disclosed. Long-only institutions and sovereign funds are a different signal from a book dominated by short-horizon money — though note anchors are allocation-driven and their participation is not diligence you can rely on.
|
||||
6. **Last private round valuation** as a sanity check. An IPO priced below the last round is a real signal; so is one priced at a large premium to a round done months earlier.
|
||||
|
||||
Be explicit that a first-day price is not a valuation. **Grey-market premium (GMP) carries zero information about business value** and should never appear in the valuation section; if the user raises it, say what it actually is — an unregulated, unofficial, often manipulated indicator of short-term demand.
|
||||
|
||||
## Stage I6 — Structure, supply and mechanics
|
||||
|
||||
- **Lock-in expiry calendar** — build the actual dates. **India (SEBI ICDR):** anchor investors, 50% of allotment for 30 days and the remainder for 90 days; minimum promoter contribution for 18 months; other pre-issue capital typically 6 months. **US:** typically 180-day underwriter lock-up with earlier release triggers. Each expiry is a scheduled, foreseeable supply event.
|
||||
- **Post-issue free float** — small float creates volatility and can create index-inclusion demand unrelated to value.
|
||||
- **Allocation structure** — QIB / NII / retail split, and any reservation. Note that issuers without the profitability track record route face a different mandated split, which is itself informative.
|
||||
- **Subscription data**, if the issue is open — informative about demand, not about value.
|
||||
- **Post-issue capital structure** — ESOP pool, outstanding convertibles, further dilution already contemplated.
|
||||
|
||||
## Stage I7 — Verdict and what to watch
|
||||
|
||||
Run `references/20-challenge-pass.md` first. The IPO-specific challenges worth forcing: is the peer set the one *you* built or the one the issuer supplied? Have you valued at the **cap** and on **post-issue** share count? Is the margin ramp being treated as a strength when it should be a warning? Is any part of the verdict resting on subscription figures or GMP, which carry no information about value? And have you separated "good business" from "good price at this band" — an IPO can be both a fine company and an expensive issue.
|
||||
|
||||
Deliver an assessment of **business quality** and **whether the band is defensible against listed peers**, with the assumptions the price requires. Do not tell the user whether to apply — that is a personalised investment decision. Presenting the analysis, the range, the risks and the specific things that would change the conclusion is both more useful and the correct boundary.
|
||||
|
||||
Distinguish two questions the user may be conflating, because they have different answers and different evidence:
|
||||
|
||||
1. **Is this a business I want to own for years?** — answered by the analysis above.
|
||||
2. **Will it pop on listing?** — a question about short-term demand and allocation dynamics, not fundamentals. The skill does not predict listing pops, and should say so.
|
||||
|
||||
**What to watch post-listing** — give the user a concrete list: the first two to four quarters of *public* reporting to test whether prospectus-year margins hold; the first major lock-up expiry; whether use-of-proceeds is deployed as stated; and any divergence between reported KPIs and the ones disclosed in the RHP.
|
||||
|
||||
## Scoring adjustments
|
||||
|
||||
`scripts/score.py` works pre-listing with three adjustments — state that you made them:
|
||||
|
||||
- **Mark own-history metrics as unavailable.** `multiple_vs_own_10y_median_pct` and any `own_history` basis cannot be computed. Omit them; the scorer renormalises weights across available metrics and reports the reduced coverage. Do not substitute a guess.
|
||||
- **Score valuation at the cap of the band**, using post-issue share count, and note that the floor would score better. Use `peer_values` for the listed peer set so the valuation category is scored on peer percentile rather than absolute bands.
|
||||
- **Expect and report lower coverage.** A pre-IPO scorecard legitimately has weaker coverage than a listed one. If coverage falls below the threshold, report the category scores without a headline composite rather than presenting a confident number built on gaps.
|
||||
|
||||
Gates apply unchanged, with one addition worth checking explicitly: a **100% offer-for-sale with vague use-of-proceeds and a heavy promoter exit** is a governance concern that belongs in the verdict, not averaged into a category.
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Main board vs SME platform identified and its disclosure implications stated.
|
||||
- [ ] RHP obtained (not just news coverage); DRHP-only noted as a valuation limitation.
|
||||
- [ ] Fresh issue vs OFS split quantified; 100% OFS flagged explicitly.
|
||||
- [ ] Every selling shareholder, their stake sold, and cost basis / last round valuation identified.
|
||||
- [ ] Use-of-proceeds assessed for specificity; unallocated and promoter-loan-repayment portions quantified.
|
||||
- [ ] "Basis for Offer Price" section read; issuer's peer set rebuilt independently.
|
||||
- [ ] Mandated KPI disclosure and peer comparison read.
|
||||
- [ ] Risk Factors section read in full.
|
||||
- [ ] Margin ramp into the IPO year tested and explained as structural or presentational.
|
||||
- [ ] Related-party clean-ups, restructurings and final-year one-offs hunted in the restated period.
|
||||
- [ ] Forensic Stage F1 triage run on the restated financials.
|
||||
- [ ] Sector playbook applied; listed peer set built explicitly and stated.
|
||||
- [ ] Implied multiples computed at **both** floor and cap on **post-issue** share count.
|
||||
- [ ] Reverse-engineered growth/margin assumption at the cap stated.
|
||||
- [ ] Anchor book composition and last private round used as reference points.
|
||||
- [ ] Full lock-in expiry calendar built with dates.
|
||||
- [ ] GMP explicitly excluded from valuation and explained if raised.
|
||||
- [ ] Scoring adjustments made and disclosed; coverage reported.
|
||||
- [ ] "Own for years" vs "will it pop" separated; no listing-pop prediction offered.
|
||||
- [ ] Post-listing watch list delivered.
|
||||
- [ ] No apply/don't-apply instruction; analysis and range presented instead.
|
||||
160
finance/skills/stock-analysis/references/20-challenge-pass.md
Normal file
160
finance/skills/stock-analysis/references/20-challenge-pass.md
Normal file
|
|
@ -0,0 +1,160 @@
|
|||
# The challenge pass — adversarial review before you finalise
|
||||
|
||||
Use this when: a report has been drafted and before it is delivered. Mandatory in Deep dive mode, in Forensic mode before assigning a verdict, and in IPO mode before assessing the band. Recommended in Standard mode. Skip it in Screen mode — a screen's conclusion is explicitly provisional.
|
||||
|
||||
The problem this solves is structural, not one of effort. **You wrote the thesis, so you will not attack it as hard as someone else would.** A bear case written by the author of the bull case is systematically weaker: it tends to select risks that are already priced, already disclosed, or comfortably distant, and to avoid the one assumption the whole verdict is standing on. `references/17-process-and-epistemics.md` §17 names this — external challenge and echo chambers — but naming a bias does not remove it. This file makes the challenge a step with its own output.
|
||||
|
||||
**The test of a real challenge pass is that it can change the answer.** If it can only add caveats to a conclusion that was already written, it is theatre and is worse than nothing, because it manufactures false confidence. Build it so the verdict can move, and be willing to move it.
|
||||
|
||||
## Contents
|
||||
|
||||
- [How to run it: independent vs self-review](#how-to-run-it-independent-vs-self-review)
|
||||
- [Stage C0 — Find the load-bearing claims](#stage-c0--find-the-load-bearing-claims)
|
||||
- [Stage C1 — Attack them](#stage-c1--attack-them)
|
||||
- [Stage C2 — Verify sources and arithmetic](#stage-c2--verify-sources-and-arithmetic)
|
||||
- [Stage C3 — Attack the method, not just the numbers](#stage-c3--attack-the-method-not-just-the-numbers)
|
||||
- [Stage C4 — The outside view](#stage-c4--the-outside-view)
|
||||
- [Stage C5 — Hunt disconfirming evidence](#stage-c5--hunt-disconfirming-evidence)
|
||||
- [Stage C6 — Disposition and verdict revision](#stage-c6--disposition-and-verdict-revision)
|
||||
- [Anti-theatre requirements](#anti-theatre-requirements)
|
||||
- [Output: the challenge log](#output-the-challenge-log)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## What it costs, and when that is justified
|
||||
|
||||
A full independent challenge pass costs roughly as much as the original analysis again — measured in practice at around 200k tokens and 15–20 minutes per report when run with independent challengers and live source verification. Budget for it deliberately rather than firing it reflexively.
|
||||
|
||||
That cost is easily justified before committing real money to a position, and for a forensic verdict where being wrong is expensive in both directions. It is not justified for a quick screen, for a company you have already decided against, or for a conclusion nobody will act on. When budget is tight, run Stage C0 plus C1 on the single most load-bearing claim and say that is what you did — a targeted challenge of the one assumption carrying the verdict is worth far more than a shallow sweep of all of them.
|
||||
|
||||
## How to run it: independent vs self-review
|
||||
|
||||
**If you can spawn subagents, do.** Independence is the entire mechanism, and it is not simulated well by an author reviewing their own work. Give each challenger the report and the question, and — importantly — **do not give it your reasoning**. It should reach its own view from the evidence, then disagree or not.
|
||||
|
||||
Four lenses, run in parallel:
|
||||
|
||||
| Lens | Brief |
|
||||
|---|---|
|
||||
| **The skeptic** | Assume the verdict is wrong. Explain how that happened. What did the analyst want to believe? |
|
||||
| **The auditor** | Ignore the argument entirely. Verify that every material figure traces to its cited source and that the numbers reconcile with each other |
|
||||
| **The short-seller** | Build the strongest possible case against the position, using evidence from outside the company's own disclosure |
|
||||
| **The methodologist** | Attack the peer set, the sector routing, the situation classification, the normalisation choices and the scorecard weights |
|
||||
|
||||
**If you cannot spawn subagents**, run the four lenses sequentially as separate passes, and re-read the report *cold* between each — do not carry your drafting context into the challenge. State in the output that this was self-review, because a reader should weight it accordingly.
|
||||
|
||||
## Stage C0 — Find the load-bearing claims
|
||||
|
||||
Most of a report is scaffolding. The verdict usually rests on two to four claims, and everything else could be wrong without changing the conclusion.
|
||||
|
||||
Write them out explicitly. For each, answer: **if this claim is false, does the verdict change?** If the answer is no, it is not load-bearing — set it aside and stop spending challenge effort on it.
|
||||
|
||||
Then rank by fragility: how confident is the claim, and how much weight is it carrying? **The most dangerous claim in any report is the one carrying the most weight with the least evidence** — typically a normalised margin, a mid-cycle assumption, a maintenance-capex estimate, a terminal growth rate, or a peer set the analyst chose.
|
||||
|
||||
## Stage C1 — Attack them
|
||||
|
||||
For each load-bearing claim, run these in order:
|
||||
|
||||
1. **Reverse the burden.** Do not ask "is this claim supported?" Ask "**assume it is false — what would the world look like, and does the evidence actually distinguish that world from this one?**" Frequently it does not, and the claim was an assumption wearing the clothes of a finding.
|
||||
2. **Find the strongest counter-evidence**, not the most convenient. If the counter-evidence you cite is one you can easily dismiss, you have not tried.
|
||||
3. **Check whether the claim is evidence or inference.** Apply the F/A/E/I tagging from §9 of `17-process-and-epistemics.md`. A verdict resting on chained inferences is far weaker than one resting on facts, and the chain multiplies: three inferences at 80% confidence give you roughly 50%.
|
||||
4. **Test the single-input sensitivity.** Which one input, if wrong by a plausible margin, flips the verdict? State it explicitly. If a 200bps change in an assumed margin moves the conclusion from "attractive" to "expensive", the honest output is a range and a lower confidence tier, not a verdict.
|
||||
5. **Check the claim against the report's own invalidation triggers.** Reports routinely list triggers that are *already partly met* at the time of writing. If one is, the verdict must account for it rather than list it as a future risk.
|
||||
|
||||
## Stage C2 — Verify sources and arithmetic
|
||||
|
||||
Adversarial in the plainest sense: assume the analyst was sloppy and try to prove it.
|
||||
|
||||
- **Trace a sample of material figures to the cited source.** Not all of them — the largest, the most load-bearing, and any that look surprisingly convenient. A figure that cannot be traced is downgraded to unverified, whatever it says.
|
||||
- **Check internal consistency.** Do the margins implied by the absolute numbers match the stated margins? Does the growth rate match the endpoints? Do segment figures sum to the consolidated? Inconsistency is a finding in itself — and this test has already caught real errors.
|
||||
- **Check period and basis consistency.** Consolidated compared against standalone, FY against CY, TTM against full-year, one company's FY26 against another's FY25. These errors are silent and common.
|
||||
- **Check units and currency.** Crore vs million vs billion; reported vs converted figures.
|
||||
- **Check the peer figures as hard as the subject's.** Peer data is usually sourced more casually than the target's, yet the whole sector-relative conclusion rests on it.
|
||||
|
||||
## Stage C3 — Attack the method, not just the numbers
|
||||
|
||||
The numbers can be right and the conclusion still wrong, because the framework was mis-selected.
|
||||
|
||||
- **Peer set.** Was it constructed to be comparable, or to flatter? Add the two most awkward comparables that were left out and see whether the percentile ranking survives.
|
||||
- **Sector routing.** Was the right playbook applied? For a multi-segment group, was the dominant-profit segment correctly identified, and were the secondary segments' distortions on the consolidated numbers actually stated?
|
||||
- **Situation classification.** Was a cyclical valued on peak earnings? A recent IPO valued on prospectus-year margins? A holdco valued on a consolidated multiple?
|
||||
- **Normalisation.** Were one-offs adjusted **symmetrically** — or were the ones that hurt the thesis normalised away while the ones that helped were kept?
|
||||
- **Scorecard weights and benchmarks.** Re-run the score under a different weight preset and, where peer data exists, on peer percentiles rather than shipped bands. **If the verdict flips between presets, the verdict is a function of the weights, not the company — and that must be said.**
|
||||
- **Coverage.** What share of the metric set was actually populated? A confident composite built on 55% coverage is a confident guess.
|
||||
|
||||
## Stage C4 — The outside view
|
||||
|
||||
Bottom-up analysis is systematically optimistic because it reasons from a specific story rather than a reference class.
|
||||
|
||||
- **Base rates.** What proportion of companies sustain 25% growth for five years? What proportion of turnarounds in this sector actually turn? What happened to the last several roll-ups, capacity expansions or foreign acquisitions in this industry? If the report's forecast sits far outside the reference class, it needs a stated reason why this case is different — and "strong management" is not one.
|
||||
- **Management's own record.** Compare past guidance to delivery. A management team that has missed its stated targets for three years is not a credible source for year-four guidance.
|
||||
- **The cycle.** Is the analysis extrapolating a cyclical peak or trough? Where does the sector playbook say the cycle is?
|
||||
|
||||
## Stage C5 — Hunt disconfirming evidence
|
||||
|
||||
Actively search for what would contradict the thesis, rather than gathering more of what supports it. Specifically:
|
||||
|
||||
- Short reports, forensic research and adverse media — read as **primary documents to be evaluated**, attributed and verified, never adopted wholesale.
|
||||
- Regulatory actions, litigation, tax disputes and enforcement history.
|
||||
- Customer, supplier, employee and channel signals that contradict the reported trend.
|
||||
- The competitor's disclosure. A rival's commentary on pricing, share and demand is a check on the subject's version of the same market — and rivals have no incentive to flatter.
|
||||
- The bear case as stated by people who actually hold it, in their own terms.
|
||||
|
||||
## Stage C6 — Disposition and verdict revision
|
||||
|
||||
Every challenge gets one of four dispositions, and each has a consequence:
|
||||
|
||||
| Disposition | Meaning | Consequence |
|
||||
|---|---|---|
|
||||
| **UPHELD** | The challenge succeeded; the original claim does not survive | Revise the report. Change the verdict if the claim was load-bearing |
|
||||
| **WEAKENED** | The claim survives but with less force or a wider range than stated | Widen the range, lower the confidence tier, or add the caveat into the body — not a footnote |
|
||||
| **REJECTED** | The challenge was considered and does not hold | Log it with the reason. This is valuable: it shows the reader what was tested |
|
||||
| **UNRESOLVED** | Cannot be settled with available evidence | Name the specific evidence needed. Carry it into the report's uncertainty section. **Never resolve an unresolved challenge in the thesis's favour by default** |
|
||||
|
||||
Then do the thing that makes this real: **if a load-bearing claim was upheld against, change the conclusion.** Say plainly in the report that the challenge pass altered the verdict and how. A visible revision is the strongest signal of a functioning process; an unchanged verdict after every challenge pass, report after report, is evidence the process is not working.
|
||||
|
||||
## Anti-theatre requirements
|
||||
|
||||
A challenge pass that always concludes "thesis holds" is worse than none. Three requirements guard against that:
|
||||
|
||||
1. **State what would have changed your mind**, specifically and in advance of looking. If you cannot articulate disconfirming evidence, you are not holding a falsifiable view.
|
||||
2. **If nothing was refuted, say what you looked for and failed to find** — and note explicitly that failing to refute is not the same as confirming. Absence of a found problem is weak evidence when search was shallow.
|
||||
3. **Name the most likely way this analysis is wrong**, even when you cannot refute it. Every analysis has one. An author who cannot name theirs has not looked.
|
||||
|
||||
## Output: the challenge log
|
||||
|
||||
Append to the report, or deliver alongside it:
|
||||
|
||||
```markdown
|
||||
## Challenge pass
|
||||
Method: <independent challengers (N lenses) | sequential self-review>
|
||||
Load-bearing claims identified: <list>
|
||||
|
||||
| # | Claim challenged | Attack | Disposition | Consequence |
|
||||
|---|---|---|---|---|
|
||||
| 1 | | | UPHELD/WEAKENED/REJECTED/UNRESOLVED | |
|
||||
|
||||
**Single-input sensitivity:** the verdict turns most on <input>. A change of <magnitude> flips it to <alternative>.
|
||||
**Verdict change:** <none | changed from X to Y because ...>
|
||||
**What would have changed my mind:** <stated>
|
||||
**Most likely way this analysis is wrong:** <stated>
|
||||
**Searched but not found:** <what disconfirming evidence was sought and not located>
|
||||
```
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Load-bearing claims identified explicitly; non-load-bearing material set aside.
|
||||
- [ ] Most fragile claim named — highest weight, weakest evidence.
|
||||
- [ ] Burden reversed on each load-bearing claim, not merely re-checked.
|
||||
- [ ] F/A/E/I applied; inference chains and their compounded confidence noted.
|
||||
- [ ] Single-input sensitivity stated: which input flips the verdict, and by how much.
|
||||
- [ ] Report's own invalidation triggers checked for ones already partly met.
|
||||
- [ ] Sample of material figures traced to cited sources; untraceable ones downgraded.
|
||||
- [ ] Internal consistency, period/basis, units and currency checked.
|
||||
- [ ] Peer figures checked as hard as the subject's.
|
||||
- [ ] Peer set stress-tested by adding the awkward comparables that were omitted.
|
||||
- [ ] Sector routing, situation classification and normalisation symmetry challenged.
|
||||
- [ ] Score re-run under a different weight preset; verdict-flip noted if it occurs.
|
||||
- [ ] Base rates and management's guidance-vs-delivery record applied.
|
||||
- [ ] Disconfirming evidence actively sought, including competitor disclosure and short reports.
|
||||
- [ ] Every challenge assigned a disposition; unresolved ones not defaulted in the thesis's favour.
|
||||
- [ ] Verdict revised where a load-bearing challenge was upheld, and the revision stated openly.
|
||||
- [ ] "What would have changed my mind", "most likely way this is wrong", and "searched but not found" all present.
|
||||
|
|
@ -0,0 +1,69 @@
|
|||
# Data-integrity tools — verify_data.py and lint_report.py
|
||||
|
||||
Use this when: you are running a real analysis and want the two mechanical gates that guard the skill's single most important discipline — that every number is sourced, current and internally consistent. Blinded adversarial review of this skill's own reports found the dominant failure was never analytical reasoning; it was data integrity. Figures that could not be traced to a source, a peer's ratio quoted wrong, and a quarter that was already public but absent from the report. These two scripts turn the sourcing rules from advice you might follow into checks you run.
|
||||
|
||||
Neither tool judges the analysis. They judge whether the *inputs* and the *finished artefact* meet the non-negotiables, so that a reviewer — or the challenge pass in `references/20-challenge-pass.md` — is not the first thing standing between a sloppy figure and the verdict.
|
||||
|
||||
## verify_data.py — the intake gate (Stage 1)
|
||||
|
||||
Run this after you have gathered data and before you compute anything on it.
|
||||
|
||||
**Workflow.** As you collect figures, record each one as a datapoint with its provenance rather than pasting bare numbers into a working file. Then run the gate:
|
||||
|
||||
```
|
||||
python scripts/verify_data.py --template # prints the intake schema to fill
|
||||
python scripts/verify_data.py my-intake.json # runs the checks
|
||||
python scripts/verify_data.py my-intake.json --json
|
||||
```
|
||||
|
||||
Each datapoint carries: `metric`, `value`, `period`, `basis` (consolidated/standalone), `unit`, `source`, and optionally an `alt` list of the same figure from a second source. The file header carries `as_of`, the reporting basis, currency/units, and `latest_reported_period` with its publication date.
|
||||
|
||||
**What it catches, and why each matters:**
|
||||
|
||||
| Check | Catches | Why it is here |
|
||||
|---|---|---|
|
||||
| Provenance missing | A figure with no source or period | A number you cannot cite is a number you cannot defend; it is the raw material of a hallucinated report |
|
||||
| Cross-source divergence | The same figure differing between two sources beyond tolerance (>2% warn, >10% error) | This is the exact defect that put a wrong peer NPA into a real report. When sources disagree, the answer is to find out which is right, never to average |
|
||||
| Basis mixing | Consolidated and standalone figures used together without labels | Silently mixing the two invalidates every ratio built from them |
|
||||
| Unit / currency mixing | A crore figure sitting beside a million figure for the same metric | The 10x error is common, silent and embarrassing |
|
||||
| Period misalignment | FY vs CY vs TTM, or non-aligned fiscal years, among figures meant to be compared | A peer comparison across mismatched periods is not a comparison |
|
||||
| Staleness | The newest figure you gathered is older than a period the company has already published | The single most common way a careful analysis is simply out of date |
|
||||
| Source tier | A headline metric (revenue, PAT, EBITDA, debt, equity, operating cash flow) sourced only from a Tier-4 aggregator (screener/tickertape/yahoo...) is an **error**; other aggregator-only figures warn; a headline figure whose source cannot be confirmed as a filing warns. Tag each datapoint's `source_tier` (1 filing, 2 company secondary, 3 regulator/rating, 4 aggregator) or let it be inferred from the source text | This is the exact hole a report falls through when it *looks* sourced — a period label beside every figure — yet the numbers came off an aggregator screen. Current price/market cap is the one exempt exception. Also reports the share of figures that are primary-sourced |
|
||||
|
||||
Fix every **error**-level finding before proceeding. Treat **warnings** as things to resolve or to state explicitly in the report's data-quality note. Metrics you have honestly marked unavailable are reported as coverage context, not defects — disclosing a gap is the correct behaviour, not a failure.
|
||||
|
||||
The verified intake also feeds cleanly into `scripts/ratios.py`, so the same structured data does double duty.
|
||||
|
||||
## lint_report.py — the delivery gate (Stage 10)
|
||||
|
||||
Run this on the finished markdown report, just before you deliver it.
|
||||
|
||||
```
|
||||
python scripts/lint_report.py report.md
|
||||
python scripts/lint_report.py report.md --json
|
||||
python scripts/lint_report.py report.md --strict # promotes warnings to errors
|
||||
```
|
||||
|
||||
**What it checks:**
|
||||
|
||||
- **Structure and non-negotiables** — recency statement, data-quality note, reporting basis, currency and units, a verdict near the top, a risks/bear-case section, a not-financial-advice disclaimer, and — if a scorecard is shown — that its gate disclosure is present. A composite with no statement of which gates were checked is flagged, because an unchecked gate and a cleared gate look identical otherwise.
|
||||
- **Figure sourcing (the core check)** — it scans every percentage, currency amount and multiple in the report and measures the share that sit near a provenance cue (a period label, a filing reference, a page number, "as of", a URL). It reports that ratio and lists a sample of the bare figures by line. This is a **heuristic that prompts review, not proof of fabrication** — but it is discriminating: on this skill's own test reports it separated well-sourced analyses from thin ones cleanly, and a ratio below roughly 60% reliably means "go back and cite", not "ship".
|
||||
- **Aggregator-only sourcing** — the complement to the tier check on the intake side: it flags figures whose only nearby cue is an aggregator (screener/tickertape/yahoo...) with no filing/report/transcript cue in the same line. Such a figure passes the ratio check above (an aggregator name *is* a cue) yet traces to no document — so it warns you to replace it with the filing or mark it as a labelled cross-check beside the document figure. Price/market cap is exempt.
|
||||
- **Hygiene** — leftover `TODO`/`TBD`/template angle-bracket fields, empty table cells where a figure is implied, and imperative personalised instructions ("buy N shares", "allocate N%") that would breach the analysis-not-advice boundary.
|
||||
|
||||
A low figure-sourcing ratio is an instruction to add citations, not a number to accept. The linter is a floor beneath the report, never a ceiling on judgement — passing it does not make an analysis good, but failing it means the analysis is not yet ready to be seen.
|
||||
|
||||
## How they relate to the rest of the skill
|
||||
|
||||
- The **recency gate** in `SKILL.md` Stage 1 is the reasoning; `verify_data.py`'s staleness check is its mechanical enforcement.
|
||||
- The **anti-hallucination non-negotiables** in `SKILL.md` are the rules; `lint_report.py` is the automated check that the finished report actually kept them.
|
||||
- The **challenge pass** (`references/20-challenge-pass.md`) verifies figures adversarially and by hand. The linter is the cheap first pass that clears the obvious defects so the challenge pass can spend its effort on the ones that require judgement.
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Gathered data recorded as datapoints with provenance, not bare numbers.
|
||||
- [ ] `verify_data.py` run at Stage 1; every error-level finding resolved; warnings resolved or disclosed.
|
||||
- [ ] Cross-source disagreements settled by finding the correct figure, not by averaging.
|
||||
- [ ] `lint_report.py` run at Stage 10; error-level findings fixed.
|
||||
- [ ] Figure-sourcing ratio checked; bare figures cited before delivery.
|
||||
- [ ] No template placeholders, no advice-boundary breaches left in the report.
|
||||
377
finance/skills/stock-analysis/references/sectors/_index.md
Normal file
377
finance/skills/stock-analysis/references/sectors/_index.md
Normal file
|
|
@ -0,0 +1,377 @@
|
|||
# Sector Router — Pick the Right Playbook Before You Compute Anything
|
||||
|
||||
Use this when: you have identified the company but have not yet chosen which sector playbook governs the analysis — or when a company straddles several sectors and you need to decide which lens dominates.
|
||||
|
||||
Sector is not a decoration on top of the numbers; it decides which numbers exist at all. A bank has no "revenue" in the industrial sense, a REIT's net income is systematically understated by non-cash depreciation, a miner's peak margin is its most dangerous moment, and a pre-profit SaaS company burning cash may be compounding value faster than a profitable one. Routing to the wrong playbook does not make the analysis slightly wrong — it makes it inverted. Spend the two minutes here before you compute a single ratio.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Step 1 — Classify by profit driver, not by index label](#step-1--classify-by-profit-driver-not-by-index-label)
|
||||
- [Step 2 — The routing table](#step-2--the-routing-table)
|
||||
- [Step 2a — DO NOT route on the label](#step-2a--do-not-route-on-the-label)
|
||||
- [Step 2b — Complete industry mapping](#step-2b--complete-industry-mapping)
|
||||
- [Step 3 — Multi-segment companies](#step-3--multi-segment-companies)
|
||||
- [Step 4 — Conglomerates and holding companies](#step-4--conglomerates-and-holding-companies)
|
||||
- [Step 5 — When nothing fits](#step-5--when-nothing-fits)
|
||||
- [Sector families — which standard metrics break](#sector-families--which-standard-metrics-break)
|
||||
- [Fast sanity check before you leave this file](#fast-sanity-check-before-you-leave-this-file)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Step 1 — Classify by profit driver, not by index label
|
||||
|
||||
Index classifications (GICS, NIC, the exchange's own sector tag, "Nifty FMCG", "S&P Consumer Discretionary") are built for portfolio construction, not for analysis. They routinely mislabel companies whose economics have drifted. Ask instead:
|
||||
|
||||
**Q1. Where does the operating profit actually come from?** Read the segment note (Ind-AS 108 / ASC 280 segment reporting) and rank segments by EBIT or segment result, not by revenue. Revenue mix and profit mix diverge violently: a trading segment can be 60% of revenue and 5% of profit.
|
||||
|
||||
**Q2. What is the balance sheet for?** This single question separates the four families:
|
||||
- Balance sheet **is** the product (assets are loans/investments/policies, leverage is the business model) → **financials family**.
|
||||
- Balance sheet is a **physical asset base** earning a spread over its cost, often with regulated or contracted returns → **real-asset/regulated family**.
|
||||
- Balance sheet is **plant converting a commodity input to a commodity output**, price-taker on both sides → **cyclical-commodity family**.
|
||||
- Balance sheet is **small relative to earnings**; the value sits in brands, code, licences, people, or distribution → **asset-light family**.
|
||||
|
||||
**Q3. Who sets the price?** Regulator (utilities, some telecom, some pharma pricing), exchange/spot market (metals, oil, shipping rates), contract/tender (infra, capital goods, defence), or the company itself with pricing power (branded consumer, software, medical devices). Price-setting mechanism determines whether margin expansion is skill or luck.
|
||||
|
||||
**Q4. What is the unit of production?** Loans disbursed, tonnes shipped, seats flown, square feet leased, subscriptions renewed, prescriptions filled, wafers started. If you cannot state the unit, you do not yet understand the business and should not route.
|
||||
|
||||
**Q5. What kills this business?** Credit losses, commodity price collapse, regulatory reset, technological obsolescence, refinancing wall, a single customer leaving. The failure mode names the family more reliably than the product does.
|
||||
|
||||
Three worked routing decisions of the kind that trip up label-based classification:
|
||||
|
||||
- A company that manufactures nothing, owns the brand and design, and outsources all production is **not** an industrial — route to `fmcg-consumer` or `retail-ecommerce` depending on whether it sells through others' shelves or its own channel.
|
||||
- A "technology" company whose revenue is per-transaction fees on payment volume is **not** `it-saas` — route to `exchanges-payments`, because its driver is volume × take rate and its risk is regulatory interchange caps, not seat expansion.
|
||||
- A "consumer finance" arm inside a car maker is a lender. If it is a meaningful share of profit, its economics must be analysed with `nbfc` alongside the parent's `auto` analysis, and the consolidated ratios (which mix a manufacturer's and a lender's balance sheets) must be treated as meaningless until separated.
|
||||
|
||||
---
|
||||
|
||||
## Step 2 — The routing table
|
||||
|
||||
Match on business description and profit driver. Where two rows both apply, apply the guidance in Step 3.
|
||||
|
||||
| Playbook file | Route here when | Common sub-sectors | Example business models |
|
||||
|---|---|---|---|
|
||||
| `banks.md` | Profit is net interest income on a deposit-funded loan book; regulator sets capital adequacy | Public sector banks, private banks, small finance banks, regional/community banks, cooperative banks | Deposit-taking lender; a bank whose fee income (cards, distribution, treasury) is a growing minority of profit |
|
||||
| `nbfc.md` | Lender **without** a retail deposit franchise, funded by borrowings/securitisation; India-specific NBFC/HFC/MFI regulatory stack | Housing finance, vehicle finance, gold loans, microfinance, SME lending, consumer/BNPL lenders, US specialty finance & consumer credit | Gold-loan lender; captive finance arm of a manufacturer; a lender funded by bank lines and NCDs |
|
||||
| `insurance.md` | Profit is underwriting result plus float investment income; liabilities are actuarial | Life insurance, general/P&C insurance, health insurance, reinsurance, title insurance, managed care | Life insurer valued on embedded value and VNB; a P&C insurer whose combined ratio decides everything |
|
||||
| `insurance-brokers-services.md` | The company **places, distributes or administers** insurance and underwrites none of it; revenue is commission and fees on somebody else's premium | Retail and wholesale brokers, reinsurance brokers, MGAs/MGUs/coverholders, employee-benefit consultants, TPAs and claims administrators, PoSP and online distribution platforms | Acquisitive retail broker whose reported growth is organic plus bought; a TPA paid per member per month |
|
||||
| `mortgage-reit-specialty-finance.md` | A **leveraged portfolio of financial assets or leased hardware** rather than an operating business; borrowings buy the assets that earn the return | Agency and credit mortgage REITs, commercial mREITs, BDCs and listed private credit, CLO vehicles, aircraft/container/railcar lessors, equipment rental and leasing | Agency mREIT running 7x repo leverage on an MBS book; an aircraft lessor earning a funding-to-lease spread plus a residual-value bet |
|
||||
| `it-saas.md` | Revenue is software licences, subscriptions or people-hours; near-zero physical capital | IT services & outsourcing, product SaaS, ERTS/engineering R&D services, cybersecurity, internet platforms with subscription revenue | Offshore IT services firm billing on time & materials; seat-based SaaS with net revenue retention above 110% |
|
||||
| `pharma-healthcare.md` | Profit depends on regulatory approval, patent life, or clinical throughput | Generics, CRAMS/CDMO, API makers, innovator biotech, hospitals, diagnostics labs, medical devices | US-generics exporter facing price erosion; a hospital chain earning on occupancy and ARPOB; a diagnostics chain on test volumes |
|
||||
| `biotech-clinical.md` | **No approved product and no product revenue.** The whole market capitalisation is a probability-weighted claim on an approval that has not happened | Pre-clinical and clinical-stage developers, platform companies monetising only through partnerships, reverse-merged and de-SPAC'd research entities, carved-out innovator R&D arms | Phase 2 oncology developer with 18 months of runway; a platform company whose only revenue is milestone income |
|
||||
| `people-businesses.md` | The productive asset is **human time, judgement or attention** and goes home every evening; capital employed is trivial, so gross profit is the real top line | Temp and permanent staffing, IT and management consulting, advertising and media agencies, market research, facilities management, security manpower, testing/inspection/certification, contact centres, real-estate brokerage | Staffing firm on gross profit per consultant and conversion ratio; an agency on organic net-revenue growth |
|
||||
| `fmcg-consumer.md` | Branded, repeat-purchase products sold through distribution; profit is gross margin × velocity | Foods & beverages, home & personal care, alcohol/tobacco, consumer durables & appliances, branded apparel, QSR | Packaged foods company with a 3-tier distributor network; a durables brand with a dealer channel |
|
||||
| `auto.md` | Profit is units × contribution margin on a fixed cost base; deep cycle, heavy operating leverage | OEMs (2W/PV/CV/tractors), auto ancillaries, tyres, EV makers and charging, dealerships | Commercial vehicle maker at the mercy of the freight cycle; a Tier-1 supplier with single-OEM concentration |
|
||||
| `metals-mining.md` | Price-taker on an exchange-quoted commodity; profit is spread over cost per tonne | Steel, aluminium, copper, zinc, coal, iron ore, gold miners, ferro-alloys | Integrated steel maker with captive ore; a non-integrated converter buying ore at spot |
|
||||
| `oil-gas.md` | Crude/gas price, refining crack spread, or regulated marketing margin drives profit | Upstream E&P, refining, marketing, city gas distribution, oilfield services, LNG | Refiner earning on gross refining margin; a city gas distributor on regulated volumes and spreads |
|
||||
| `utilities-power.md` | Regulated or long-contracted returns on an asset base; volumes are near-inelastic | Thermal/hydro/nuclear generation, transmission, distribution utilities, renewables IPPs, water | Regulated transmission utility earning a fixed RoE on approved capex; a solar IPP on 25-year PPAs |
|
||||
| `waste-environmental.md` | Route density plus a **permitted disposal asset**; the moat is a permit a competitor cannot obtain at any price, and the offsetting cost outlives the asset by thirty years | Solid, hazardous, medical and industrial waste collection and disposal, landfills, transfer stations, waste-to-energy, material recovery, EPR-mandated recycling, water and wastewater operations, remediation | Landfill-led collector on internalisation rate and remaining airspace; an e-waste recycler on tonnes processed and scrap spread |
|
||||
| `realestate-reit.md` | Value is property NAV and rental/development cash flow; depreciation is largely non-economic | Residential developers, commercial landlords, REITs & InvITs, warehousing, data-centre landlords, homebuilders | Residential developer recognising revenue on completion; a REIT distributing 90%+ of NDCF |
|
||||
| `infra-capitalgoods.md` | Order book converts to revenue over multi-year contracts; working capital is the battleground | EPC contractors, roads/HAM & BOT concessions, defence, industrial machinery, electrical equipment, ports as concessions | EPC firm with a 3x order book to revenue; a road concessionaire whose value is an annuity stream |
|
||||
| `telecom-media.md` | Subscriber base × ARPU on a heavy, spectrum- or content-funded fixed cost base | Wireless & broadband telcos, tower & fibre infracos, broadcasters, print, film/OTT, music | Wireless operator on ARPU and subscriber churn; a tower company earning on tenancy ratio |
|
||||
| `aviation-hotels.md` | Perishable inventory sold by the seat-night; yield × occupancy × fixed cost | Airlines, airports (if not concession-led), hotels, restaurants, travel operators, cruise, gaming/casinos | Low-cost carrier on RASK/CASK and load factor; a hotel chain on RevPAR |
|
||||
| `retail-ecommerce.md` | Profit is thin margin on high throughput; store or fulfilment economics decide everything | Supermarkets, apparel & specialty retail, jewellery retail, pharmacy retail, marketplaces, quick commerce, D2C | Grocery chain at low-single-digit EBIT margin living on inventory turns; a marketplace on GMV take rate |
|
||||
| `chemicals-cement.md` | Process-industry manufacturing where capacity utilisation and input spreads set margin | Commodity & specialty chemicals, agrochemicals, fertilisers, paints, cement, glass, packaging, industrial gases | Speciality chemicals maker with a molecule-level moat; a cement plant priced by regional realisation per tonne |
|
||||
| `holdco-assetmgr.md` | Earnings are dividends, fees or fair-value gains on assets others operate | Holding companies, conglomerate parents, asset managers/AMCs, PE & alternatives, wealth managers, business trusts | Listed holdco trading at a discount to its stake value; an AMC earning on AUM × yield |
|
||||
| `shipping-logistics.md` | Freight rates or per-shipment economics drive profit; asset-heavy or asset-light variants differ sharply | Container/dry bulk/tanker shipping, port terminals, 3PL & warehousing, express/courier, trucking, road freight brokerage | Dry bulk owner exposed to spot charter rates; an asset-light freight forwarder on net revenue per shipment |
|
||||
| `rail-freight.md` | Freight moved over a **rail network** the company owns or runs on — a capital-intensive network utility with duopoly geography, a common carrier obligation and real pricing power | Class I railroads, regional and short lines, national freight carriers, container train operators, private freight terminals and multimodal rail players | Class I railroad managed to an operating ratio; a container train operator on originating volumes and lead distance |
|
||||
| `exchanges-payments.md` | Profit is take rate on transaction volume, or fees on a network/venue | Stock exchanges, depositories, clearing houses, brokers, card networks, acquirers/PSPs, fintech rails, credit bureaus, rating agencies | Exchange earning per-trade fees on volatility-driven volumes; an acquirer on payment volume × net take rate |
|
||||
| `semiconductors.md` | Profit driven by node/design cycle, fab utilisation or design-win pipeline; brutal capital intensity or none at all | Fabless designers, foundries, IDMs, memory, semicap equipment, EDA/IP licensing, OSAT | Fabless designer with high gross margin and no fab; a memory maker whose margin swings with a global supply cycle |
|
||||
|
||||
---
|
||||
|
||||
## Step 2a — DO NOT route on the label
|
||||
|
||||
Read this before the mapping table, because the mapping table cannot save you from a label that is actively lying. A handful of industry names describe what the company is *near* rather than what it *is*, and each one has a naive route that computes cleanly, prints plausible numbers and describes a different company. These are the errors that produce confidently wrong analysis rather than merely imprecise analysis — a missing metric announces itself, a wrong metric does not.
|
||||
|
||||
The rule underneath all of them: **route on who bears the risk and what the cash flow is a claim on**, never on the noun in the industry name.
|
||||
|
||||
| Label | The naive (wrong) route | The correct route | Why the naive route produces meaningless output |
|
||||
|---|---|---|---|
|
||||
| **REIT - Mortgage** | `realestate-reit.md`, because of the word REIT | `mortgage-reit-specialty-finance.md` | An mREIT owns no buildings, no tenants and no leases. Occupancy, WALE, same-store NOI, rent reversion, cap-rate spread, NAV per square foot, FFO and AFFO are not "less relevant" — they have no referent, and an AFFO computed for one is a fabricated number. It is a levered agency/non-agency MBS book funded overnight in repo, so the real questions are book value per share, economic return on book, duration gap, hedge ratio, prepayment speed, repo tenor and haircuts. |
|
||||
| **Insurance Brokers** | `insurance.md`, because of the word insurance | `insurance-brokers-services.md` | A broker takes no underwriting risk and holds no float, so combined ratio, loss ratio, solvency/RBC, reserve development, persistency, embedded value and VNB do not exist for it. It is a commission-and-fee roll-up: organic growth, EBITDAC, compensation ratio, client retention, net debt/EBITDAC. P/B is the exact inverse error — book value *is* the anchor for a carrier and is an accounting residue of deal prices for a broker, frequently negative on a tangible basis. |
|
||||
| **Rental & Leasing Services** | `infra-capitalgoods.md` or `auto.md` — it owns machines, so it must be an industrial | `mortgage-reit-specialty-finance.md` (lessor section) | A lessor is a financial business wearing industrial clothing: it earns the spread between funding cost and lease yield, plus a residual-value bet. EV/EBITDA is superficially computable and therefore especially dangerous — EBITDA excludes depreciation (the actual consumption of the leased asset) and interest (the actual raw material), which between them are most of the cost base, so an 80–90% "EBITDA margin" is an accounting artefact, not a moat. Use fleet age, time versus dollar utilisation, lease yield, residual realisation on disposal and the maturity ladder against lease inflows. |
|
||||
| **Healthcare Plans** | `pharma-healthcare.md` because the word is healthcare, or `insurance.md` run with the P&C or life metric set | `insurance.md`, **managed-care metric set only** | A managed-care insurer has no combined ratio in the P&C sense and no embedded value or VNB in the life sense. Its metrics are the medical loss ratio against statutory minimums, membership by line (commercial, Medicare Advantage, Medicaid, exchange), premium per member per month, star ratings, risk-adjustment revenue and the SG&A ratio. Running it through the P&C set makes the largest cost line disappear into an underwriting ratio that nobody in the industry uses; running it through the life set values a one-year renewable contract as a multi-decade book. |
|
||||
| **Shell Companies** | Any sector playbook, chosen from the industry of the target the shell says it intends to buy | `references/13-situations.md` §15 (SPAC / de-SPAC) — not a sector playbook at all | There is no business yet. Every sector metric would be computed on a trust account. What actually decides the outcome is trust value per share, the sponsor promote, warrants, PIPE and earn-out shares on a fully diluted count, the redemption deadline and the sponsor's incentive to complete *any* deal before it. Route to a sector playbook only once a merger closes and an operating company exists — and then apply §1 and §8 of that file as well, because most de-SPACs are also loss-making and newly listed. |
|
||||
| **Biotechnology** | `pharma-healthcare.md` for everything with a molecule | `biotech-clinical.md` when pre-revenue; `pharma-healthcare.md` once there are marketed products. **The test: does the company sell an approved product for its own account?** If every rupee or dollar of revenue is collaboration, milestone, grant or licence income and nothing has marketing approval in a commercial market, it is pre-revenue. One approved product generating recurring product sales — or any biosimilar, generic, API, CDMO or CRO business — moves it to `pharma-healthcare.md`. | The pharma playbook computes margins, and a pre-revenue developer's "margin" is a division by a licensing calendar that swings hundreds of percent between quarters with no change in the business. Worse, it inverts the sign on the key metrics: ROE, ROCE, operating cash flow and FCF all *improve* when the company halves its R&D budget, which is the moment it stops building the only asset it owns. The correct frame is runway against catalyst dates, pipeline stage advancement and risk-adjusted value per unit of cash burned. |
|
||||
| **Railroads** | `shipping-logistics.md`, filed under transport | `rail-freight.md` | A railroad is a network utility with duopoly geography, a common carrier obligation and durable pricing power; the freight-rate cyclicality lens under-rates that pricing power and under-states the capital intensity at the same time. The sector speaks in operating ratio, which is *inverted* against every margin metric in the generic set (lower is better) and moves mechanically with fuel surcharge. And its central question — is reported free cash flow efficiency, or a capex holiday on track, ties, ballast, bridges and locomotives — does not exist anywhere in a shipping framework. |
|
||||
| **Solar**, **Utilities - Renewable** | Route the whole industry one way, usually to `utilities-power.md` because of the word renewable | **The test: is it selling electrons or selling hardware?** Selling power under a PPA, feed-in tariff or merchant offtake → `utilities-power.md`. Manufacturing cells, wafers, modules, inverters or trackers → `semiconductors.md`. Producing polysilicon, wafers-as-chemistry, glass or encapsulants → `chemicals-cement.md`. | They are opposite businesses on the same technology. A module maker's margin collapses when module prices fall — which is exactly when the IPP's project returns improve. Applying an IPP's contracted-cash-flow DCF to a manufacturer capitalises an ASP that deflates every single year; applying manufacturing utilisation and ASP logic to an IPP ignores the offtake contract and the offtaker's credit quality, which together are the entire asset. |
|
||||
| **Conglomerates**, **Financial Conglomerates** | One consolidated P/E or EV/EBITDA on the group | `holdco-assetmgr.md` plus sum-of-the-parts, with each material subsidiary run through its own playbook (and for a financial conglomerate, `banks.md` / `insurance.md` / `nbfc.md` on each regulated entity separately) | Consolidation blends balance sheets that cannot be blended — a lender's, a manufacturer's and a landlord's — so a single multiple across them is arithmetic without meaning, and minority interests can leave the parent owning a small share of the profit it reports. Group leverage, group ROE and group asset turnover describe no business that exists. Value listed stakes at market, unlisted ones on their own sector multiples, deduct holdco debt and capitalised holdco costs, and read the holding discount against its own history rather than against zero. |
|
||||
| **Real Estate Services** | `realestate-reit.md`, because of the words real estate | `people-businesses.md` | Brokerage, agency, valuation and property management own no property. Revenue is commission on transaction volume and fees on managed area, so cap rate, NAV, FFO, occupancy and same-store NOI are undefined for their own balance sheet. The cyclicality is transaction-volume cyclicality against a semi-fixed cost base of producers who can resign, which is why drop-through in a downturn is brutal and P/E is lowest at the peak. Use `realestate-reit.md` only for the portion of the balance sheet that actually holds property. |
|
||||
| **Medical Distribution**, **Pharmaceutical Retailers** | `pharma-healthcare.md` | `retail-ecommerce.md` | Neither owns a molecule, a patent or an approval. A drug distributor earns fractions of a percent of gross margin on enormous revenue and lives on working capital, buy-side scale and generic procurement economics; a pharmacy chain lives on footfall, store throughput and front-of-store mix. Applying pharma gross margins, R&D productivity, patent cliffs or approval risk to either describes a company that does not exist, and the "low margin" it prints will be read as weakness when it is the business model. |
|
||||
| **Health Information Services** | `pharma-healthcare.md` | `it-saas.md` | The customer is in healthcare; the economics are software. Recurring revenue, net revenue retention, gross margin, CAC payback, R&D capitalisation policy and switching costs decide it. Patent life, clinical throughput, approval risk, occupancy and ARPOB have no referent. |
|
||||
| **Advertising Agencies** | `telecom-media.md`, filed under media | `people-businesses.md` | An agency does not earn its billings — client media money passes through it, and the agent-versus-principal determination under Ind-AS 115 / IFRS 15 / ASC 606 changes reported "revenue" by a multiple with zero change in economics. Growth, EV/Sales and market share built on that top line are fiction. Use net revenue / gross profit as the top line, the conversion ratio (EBITA ÷ gross profit) as the margin, and *average* net debt, because year-end cash is media payables in transit and is not available to shareholders. Broadcaster metrics — ad inventory, viewership, content amortisation — belong to the medium, not to the agency. |
|
||||
| **Pollution & Treatment Controls** | `waste-environmental.md`, because the end use is environmental | `infra-capitalgoods.md` | Scrubbers, ESPs, membranes, filtration skids and ZLD systems are engineered capital goods sold against the customer's capex budget: order book, execution, milestone billing and working capital decide the outcome. Route density, internalisation rate, landfill airspace amortisation and closure/post-closure liabilities have no referent for an equipment maker, and the environmental end market changes nothing about the economics. |
|
||||
| **Trucking** | `rail-freight.md`, filed under freight | `shipping-logistics.md` | A trucker rents its right-of-way from the taxpayer, has no network moat and no common carrier pricing power, and runs asset turnover several times a railroad's by construction. Operating ratio, maintenance-of-way capex, network fluidity and car-hire economics do not transfer, and reading spot-rate cyclicality as durable pricing power inverts the conclusion at both ends of the cycle. |
|
||||
| **Communication Equipment** | `telecom-media.md`, because the customers are telcos | `infra-capitalgoods.md` | It sells *to* operators; it is not one. Revenue is the customers' capex budget converted through tenders and a product cycle, so ARPU, subscriber churn, spectrum cost, tenancy ratio and content spend are meaningless here — and the capex cycle of three or four buyers, not subscriber growth, is the actual risk. Cross-read `semiconductors.md` where most of the value sits in silicon, optics or IP. |
|
||||
| **Insurance - Specialty** (when the entity is an MGA, MGU or coverholder) | `insurance.md` | `insurance-brokers-services.md` | If the entity binds business on somebody else's paper it holds no reserves and no capital against the risk, so combined ratio and solvency describe the carrier rather than the company. The carrier's loss ratio on the delegated book matters only as a binder-renewal risk — lose the capacity and the revenue line disappears in one renewal cycle regardless of client retention. Genuine specialty underwriters (title, mortgage, credit, warranty) do belong in `insurance.md`. |
|
||||
| **Credit Services** | One playbook for the whole industry | **The test: who carries the receivable?** Issuers and lenders holding the credit exposure → `nbfc.md`. Networks, acquirers, processors and bureaus taking no credit risk → `exchanges-payments.md`. | The two halves have opposite failure modes. A card network dies of regulatory interchange caps and volume loss; a card issuer dies of a credit cycle. Applying loss-rate, provision-coverage and vintage-curve analysis to a network invents a risk it does not run, while applying volume × take-rate analysis to an issuer omits the only thing that can actually destroy it. |
|
||||
| **Information Technology Services** | `it-saas.md` for everything with the word technology in it | `it-saas.md` where the firm owns the delivery outcome; `people-businesses.md` where it bills a markup on a head. **The test: does the contract transfer delivery responsibility?** | An IT staffing firm supplies headcount and carries no delivery obligation; an IT services firm owns the outcome. Applying offshore mix, backlog conversion and net revenue retention to a staffing book, or EV/gross profit to a services exporter, produces confident nonsense in both directions. For staffing, the metrics are gross profit per consultant, the bill-pay spread and the conversion ratio — margin on gross revenue *falls* when volumes grow, which a generic screen reads as deterioration. |
|
||||
| **REIT - Specialty** | One property lens and one cap rate across the whole category | `realestate-reit.md` for the REIT wrapper, then route by what the tenant actually pays for | "Specialty REIT" is a residual bucket, not a business: towers and fibre are tenancy-ratio economics from `telecom-media.md`, a data centre selling power-backed capacity on long contracts is closer to `utilities-power.md`, timberland is a land-NAV business, and a net-lease gaming REIT is single-operator rent-coverage credit analysis. Averaging them into one cap rate blends assets with different tenants, contract lengths and obsolescence risk. |
|
||||
| **REIT - Hotel & Motel** | The lease-based REIT toolkit — WALE, lease expiry schedule, contractual rent coverage | `realestate-reit.md` for the structure, `aviation-hotels.md` for the earnings | A hotel REIT does not collect contractual rent; it takes the hotel's operating result through a taxable subsidiary. Lease-expiry and rent-coverage metrics are undefined, and the distribution is as cyclical as RevPAR. Read ADR, occupancy, RevPAR, hotel EBITDA margin and the terms of the management agreement, then apply the REIT distribution mechanics on top. |
|
||||
| **Farm & Heavy Construction Machinery**, **Auto Manufacturers** (where a captive finance arm exists) | Consolidated leverage, margin and return figures | `infra-capitalgoods.md` / `auto.md` for the industrial, `nbfc.md` for the finance arm, then sum the parts | Consolidating a captive lender into a manufacturer produces a debt/equity ratio, an asset turnover and a ROCE that describe neither business — the lender's borrowings are raw material, the manufacturer's are leverage. Separate the finance book, its funding and its credit costs before any leverage or return comparison, and value the two on different multiples. |
|
||||
|
||||
If a company sits on one of these lines, say so explicitly in the output: name the industry label, name the route you rejected, and name the one you took. A reader who disagrees should be able to attack the routing decision directly rather than having to reverse-engineer it from the metrics.
|
||||
|
||||
---
|
||||
|
||||
## Step 2b — Complete industry mapping
|
||||
|
||||
Every industry in the standard Yahoo Finance / Morningstar taxonomy, mapped to exactly one playbook. Use it as the starting point, not the conclusion: Step 1 overrules this table whenever the profit driver has drifted from the label, and Step 2a lists the labels that are actively misleading. Rows marked **(added)** are standard industries in that taxonomy that are easy to omit from a screener export.
|
||||
|
||||
The Note column carries a routing reason only where the mapping is non-obvious, where a common sub-case routes elsewhere, or where the playbook must be applied with a particular metric set. A blank note means the mapping is what it looks like.
|
||||
|
||||
| Industry | Playbook | Note |
|
||||
|---|---|---|
|
||||
| Advertising Agencies | `people-businesses.md` | Billings are the client's money, not revenue. Work on net revenue / gross profit and the conversion ratio. Not `telecom-media.md`. |
|
||||
| Aerospace & Defense | `infra-capitalgoods.md` | Multi-year programme order book, milestone recognition, and a single government customer that also sets the price. |
|
||||
| Agricultural Inputs | `chemicals-cement.md` | Fertilisers and agrochemicals: process manufacturing on a subsidised or regulated realisation with a raw-material spread. |
|
||||
| Airlines | `aviation-hotels.md` | |
|
||||
| Airports & Air Services | `aviation-hotels.md` | Where the asset is a fixed-term concession with a regulated tariff on an approved asset base, the value is a defined-life annuity — use `infra-capitalgoods.md`. |
|
||||
| Aluminum | `metals-mining.md` | Power cost is the swing variable; captive power and bauxite integration decide who survives the trough. |
|
||||
| Apparel Manufacturing | `fmcg-consumer.md` | Only where a brand sets the price. A private-label or contract garment maker has no pricing power — customer concentration and utilisation govern it, as in `Textile Manufacturing`. |
|
||||
| Apparel Retail | `retail-ecommerce.md` | |
|
||||
| Asset Management | `holdco-assetmgr.md` | A fee on other people's money: AUM × yield, flows and mix, with performance fees as the low-quality line. A BDC, listed credit fund or CLO vehicle deploying **its own** balance sheet is not a fee business — use `mortgage-reit-specialty-finance.md`. |
|
||||
| Auto & Truck Dealerships | `auto.md` | Retail economics, not manufacturing: inventory turns, F&I attach, service absorption. Floorplan debt is inventory finance — strip it before computing leverage. |
|
||||
| Auto Manufacturers | `auto.md` | Separate any captive finance arm and run it through `nbfc.md`; consolidated leverage and ROCE describe neither business. |
|
||||
| Auto Parts | `auto.md` | Check OEM concentration and whether content per vehicle is rising — that, not industry volume, is the growth. |
|
||||
| Banks - Diversified | `banks.md` | |
|
||||
| Banks - Regional | `banks.md` | Deposit franchise quality and geographic loan concentration decide it; a regional bank is a bet on one local economy. |
|
||||
| Beverages - Brewers | `fmcg-consumer.md` | |
|
||||
| Beverages - Non-Alcoholic | `fmcg-consumer.md` | |
|
||||
| Beverages - Wineries & Distilleries | `fmcg-consumer.md` | Maturing stock is a multi-year asset, so structurally high inventory days are the business model, not a warning. |
|
||||
| Biotechnology | `biotech-clinical.md` | Pre-revenue only. Once an approved product is selling for the company's own account — or for any biosimilar, generic, API, CDMO or CRO business — use `pharma-healthcare.md`. See Step 2a. |
|
||||
| Broadcasting | `telecom-media.md` | |
|
||||
| Building Materials | `chemicals-cement.md` | Cement, lime, aggregates: regional realisation per tonne, freight radius and capacity utilisation. |
|
||||
| Building Products & Equipment | `chemicals-cement.md` | Process manufacture of a construction input — boards, glass, insulation, pipes, tiles, sanitaryware. Where the product is engineered equipment sold on specification (HVAC, elevators, building automation), use `infra-capitalgoods.md`. |
|
||||
| Business Equipment & Supplies **(added)** | `fmcg-consumer.md` | Branded product through a B2B dealer channel. Demand is corporate office and print spend, several categories of which are in secular decline — establish that before extrapolating volume. |
|
||||
| Capital Markets | `exchanges-payments.md` | Brokers, investment banks and wealth platforms. Where the firm runs a large trading book, margin lending or prime brokerage, add `banks.md` for funding, capital adequacy and liquidity. |
|
||||
| Chemicals | `chemicals-cement.md` | |
|
||||
| Coking Coal | `metals-mining.md` | A steel input, so the cycle is steel's, not power's. Never pool with thermal coal. |
|
||||
| Communication Equipment | `infra-capitalgoods.md` | Sells to operators, is not one — the driver is their capex budget and tender wins. Cross-read `semiconductors.md` where the value sits in silicon or optics. |
|
||||
| Computer Hardware | `semiconductors.md` | The component and product cycle sets margin. For a box assembler reselling others' silicon, gross margin is thin and the real analysis is component pass-through and inventory. |
|
||||
| Confectioners | `fmcg-consumer.md` | |
|
||||
| Conglomerates | `holdco-assetmgr.md` | Sum-of-the-parts always, each subsidiary through its own playbook. Never a single consolidated multiple. |
|
||||
| Consulting Services | `people-businesses.md` | |
|
||||
| Consumer Electronics | `fmcg-consumer.md` | Branded durables: gross margin × velocity, channel inventory, replacement cycle. They buy silicon, they do not make it. |
|
||||
| Copper | `metals-mining.md` | |
|
||||
| Credit Services | `nbfc.md` | Only where the company carries the receivable. Networks, acquirers, processors and bureaus take no credit risk — use `exchanges-payments.md`. |
|
||||
| Department Stores | `retail-ecommerce.md` | |
|
||||
| Diagnostics & Research | `pharma-healthcare.md` | Labs and CROs on test and study volume × price; life-science tools on installed base and consumable pull-through. Neither has a patent cliff. |
|
||||
| Discount Stores | `retail-ecommerce.md` | |
|
||||
| Drug Manufacturers - General | `pharma-healthcare.md` | |
|
||||
| Drug Manufacturers - Specialty & Generic | `pharma-healthcare.md` | Price erosion, not volume, is the default assumption; check plant inspection history before anything else. |
|
||||
| Education & Training Services | `people-businesses.md` | Delivered by teachers: seats filled, fee per student, faculty cost and attrition. A self-serve online platform with no delivery headcount is `it-saas.md`. |
|
||||
| Electrical Equipment & Parts | `infra-capitalgoods.md` | |
|
||||
| Electronic Components | `semiconductors.md` | Passives, connectors, PCBs — the lead-time and channel-inventory cycle is the semiconductor cycle. |
|
||||
| Electronic Gaming & Multimedia | `telecom-media.md` | Hit-driven slates carry content risk and capitalised development amortisation. A live-service or subscription game is recurring revenue — bookings, deferred revenue, DAU/MAU, ARPDAU — use `it-saas.md`. |
|
||||
| Electronics & Computer Distribution | `retail-ecommerce.md` | Distribution, not technology: thin margin on throughput, inventory turns, vendor rebates and working capital. |
|
||||
| Engineering & Construction | `infra-capitalgoods.md` | |
|
||||
| Entertainment | `telecom-media.md` | Content amortisation policy decides reported profit; check it before comparing any margin. |
|
||||
| Farm & Heavy Construction Machinery | `infra-capitalgoods.md` | Dealer channel inventory leads the cycle. Separate the captive finance arm (`nbfc.md`) before any leverage or return figure. |
|
||||
| Farm Products | `fmcg-consumer.md` | Only for branded packaged players. Unbranded processors — sugar, edible oil, poultry, aquaculture — are price-takers on both sides; read the spread-and-utilisation logic in `chemicals-cement.md`. |
|
||||
| Financial Conglomerates | `holdco-assetmgr.md` | Sum-of-the-parts, then `banks.md` / `insurance.md` / `nbfc.md` on each regulated subsidiary. Group leverage and group ROE describe nothing. |
|
||||
| Financial Data & Stock Exchanges | `exchanges-payments.md` | |
|
||||
| Food Distribution | `retail-ecommerce.md` | Drop size and route density on a low-single-digit margin; the customer is a restaurant or a retailer, not a consumer. |
|
||||
| Footwear & Accessories | `fmcg-consumer.md` | Where own-channel DTC dominates the mix, add the store and cohort economics from `retail-ecommerce.md`. |
|
||||
| Furnishings, Fixtures & Appliances | `fmcg-consumer.md` | Consumer durables: the cycle follows housing transactions and credit availability, not consumption. |
|
||||
| Gambling | `aviation-hotels.md` | Land-based casinos and integrated resorts. An online-only sportsbook or iGaming operator owns no property and earns a hold rate on handle — use `exchanges-payments.md` for volume × take rate, and treat customer acquisition cost as the real cost line. |
|
||||
| Gold | `metals-mining.md` | All-in sustaining cost per ounce, reserve grade and mine life. The gold price is a macro input, not a company variable. |
|
||||
| Grocery Stores | `retail-ecommerce.md` | |
|
||||
| Health Information Services | `it-saas.md` | Healthcare customer, software economics. Patent life, approval risk and clinical throughput have no referent. |
|
||||
| Healthcare Plans | `insurance.md` | Managed-care metric set only: medical loss ratio, membership by line, premium per member per month, star ratings, risk adjustment. Not the P&C or life set. See Step 2a. |
|
||||
| Home Improvement Retail | `retail-ecommerce.md` | |
|
||||
| Household & Personal Products | `fmcg-consumer.md` | |
|
||||
| Industrial Distribution | `retail-ecommerce.md` | A distributor, not a manufacturer: branch and DC economics, inventory turns, private-label mix, vendor rebates. |
|
||||
| Information Technology Services | `it-saas.md` | Where the firm owns the delivery outcome. A resource-augmentation model billing a markup on a head with no delivery obligation is `people-businesses.md`. |
|
||||
| Infrastructure Operations | `infra-capitalgoods.md` | Toll roads, annuity and BOT/HAM concessions: a defined-life cash-flow stream, so DCF over the concession term, never a perpetuity multiple. |
|
||||
| Insurance - Diversified | `insurance.md` | Split the life and non-life books before valuing — they use different frameworks (EV and VNB versus combined ratio). |
|
||||
| Insurance - Life | `insurance.md` | |
|
||||
| Insurance - Property & Casualty | `insurance.md` | |
|
||||
| Insurance - Reinsurance | `insurance.md` | Catastrophe exposure and reserve development dominate; one year's combined ratio is not information. |
|
||||
| Insurance - Specialty | `insurance.md` | Genuine underwriters — title, mortgage, credit, warranty. An MGA, MGU or coverholder binding on someone else's paper holds no risk capital — use `insurance-brokers-services.md`. |
|
||||
| Insurance Brokers | `insurance-brokers-services.md` | No underwriting risk, no float, no combined ratio, no solvency ratio, no meaningful book value. Never `insurance.md`. See Step 2a. |
|
||||
| Integrated Freight & Logistics | `shipping-logistics.md` | Separate asset-heavy operations from asset-light forwarding; they carry different margins on different revenue bases and must not be blended. |
|
||||
| Internet Content & Information | `it-saas.md` | Asset-light platform economics. Where revenue is advertising, the demand cycle is the ad cycle — cross-read `telecom-media.md`. |
|
||||
| Internet Retail | `retail-ecommerce.md` | Establish first whether it is a first-party retailer (gross revenue, owned inventory) or a marketplace (GMV × take rate). The two are not comparable on any margin. |
|
||||
| Leisure | `fmcg-consumer.md` | Branded discretionary durables — toys, boats, powersports, fitness equipment. Where the company operates venues, capacity is perishable — use `aviation-hotels.md`. |
|
||||
| Lodging | `aviation-hotels.md` | Distinguish the owner (property NAV, cross-read `realestate-reit.md`) from the asset-light franchisor or manager, which is a royalty on system-wide RevPAR. |
|
||||
| Lumber & Wood Production | `chemicals-cement.md` | Commodity conversion at a mill, driven by housing starts. A timberland owner is a land-NAV business — `realestate-reit.md`. |
|
||||
| Luxury Goods | `fmcg-consumer.md` | Pricing power and brand heat are the whole thesis; volume growth without price growth is dilution of the brand. |
|
||||
| Marine Shipping | `shipping-logistics.md` | |
|
||||
| Medical Care Facilities | `pharma-healthcare.md` | Hospitals: occupancy, ARPOB, payer mix, case mix and doctor retention. |
|
||||
| Medical Devices | `pharma-healthcare.md` | Approval pathway and reimbursement coding decide the market; the razor-and-blade consumable stream carries the margin. |
|
||||
| Medical Distribution | `retail-ecommerce.md` | Fractions of a percent of gross margin on enormous revenue; the analysis is working capital and buy-side scale. No patent, no approval, no pricing power — not `pharma-healthcare.md`. |
|
||||
| Medical Instruments & Supplies | `pharma-healthcare.md` | |
|
||||
| Metal Fabrication | `metals-mining.md` | A converter, not a miner: margin is the conversion spread and the metal-cost pass-through lag, so a price spike temporarily inflates both revenue and margin. Where product is engineered to order against a backlog, add `infra-capitalgoods.md`. |
|
||||
| Mortgage Finance **(added)** | `nbfc.md` | Originator-servicers: gain-on-sale margin, origination volume against the rate cycle, and mortgage servicing rights whose fair-value marks move opposite to origination. Earnings are hedged marks — anchor on book value, not EPS. |
|
||||
| Oil & Gas Drilling | `oil-gas.md` | Day rates and rig utilisation, running roughly one cycle behind the crude price. |
|
||||
| Oil & Gas Equipment & Services | `oil-gas.md` | |
|
||||
| Oil & Gas Exploration & Production | `oil-gas.md` | Reserve life, finding and development cost and decline rate; production growth funded by outspending cash flow is not growth. |
|
||||
| Oil & Gas Integrated | `oil-gas.md` | Segment-split before anything else — upstream and downstream move in opposite directions on the same crude move. |
|
||||
| Oil & Gas Midstream | `oil-gas.md` | Fee-based contracted throughput is closer to a regulated utility than to E&P. Quantify the commodity-exposed share of margin, then read `utilities-power.md` for the contracted part. |
|
||||
| Oil & Gas Refining & Marketing | `oil-gas.md` | |
|
||||
| Other Industrial Metals & Mining | `metals-mining.md` | |
|
||||
| Other Precious Metals & Mining | `metals-mining.md` | |
|
||||
| Packaged Foods | `fmcg-consumer.md` | |
|
||||
| Packaging & Containers | `chemicals-cement.md` | Process manufacture with resin or board input pass-through; the contract structure decides who bears the input move and with what lag. |
|
||||
| Paper & Paper Products | `chemicals-cement.md` | |
|
||||
| Personal Services | `people-businesses.md` | Labour-delivered services. Where delivery runs through owned outlets, add the unit economics from `retail-ecommerce.md`; where franchised, it is a royalty stream. |
|
||||
| Pharmaceutical Retailers | `retail-ecommerce.md` | Pharmacy chains live on footfall, store throughput, prescription volume and front-of-store mix. Not `pharma-healthcare.md`. |
|
||||
| Pollution & Treatment Controls | `infra-capitalgoods.md` | Equipment makers — scrubbers, ESPs, membranes, ZLD systems. Order book and customer capex, not route density. Not `waste-environmental.md`. |
|
||||
| Publishing | `telecom-media.md` | |
|
||||
| Railroads | `rail-freight.md` | Operating ratio (lower is better), maintenance-of-way capex and network fluidity. Never `shipping-logistics.md`. See Step 2a. |
|
||||
| Real Estate - Development | `realestate-reit.md` | Revenue recognition on completion makes reported growth lumpy and largely uninformative; pre-sales, collections and the land bank are the real series. |
|
||||
| Real Estate - Diversified | `realestate-reit.md` | Split rental (recurring, NOI and cap rate) from development (lumpy, completion-based) before valuing either. |
|
||||
| Real Estate Services | `people-businesses.md` | Brokers, agency, valuation and property managers own no property — commission on transaction volume and fees on managed area. Cap rate, NAV, FFO and occupancy are undefined for them. See Step 2a. |
|
||||
| Recreational Vehicles | `auto.md` | Dealer floorplan inventory is the leading indicator; channel stuffing precedes every downturn in this category. |
|
||||
| REIT - Diversified | `realestate-reit.md` | |
|
||||
| REIT - Healthcare Facilities | `realestate-reit.md` | Landlord to operators, so the risk is operator rent coverage (EBITDAR to rent), not patient volumes. Under a RIDEA structure the REIT takes the operating result instead — check the structure first. |
|
||||
| REIT - Hotel & Motel | `realestate-reit.md` | It takes the hotel's operating result, not contractual rent, so WALE and lease-expiry schedules are undefined. Read RevPAR, ADR and hotel EBITDA from `aviation-hotels.md`. |
|
||||
| REIT - Industrial | `realestate-reit.md` | |
|
||||
| REIT - Mortgage | `mortgage-reit-specialty-finance.md` | Owns no buildings. Occupancy, WALE, same-store NOI, cap-rate spread, FFO and AFFO are undefined. Never `realestate-reit.md`. See Step 2a. |
|
||||
| REIT - Office | `realestate-reit.md` | Lease expiry schedule and releasing spreads carry the thesis; mark leases to current market rent before accepting reported NOI as durable. |
|
||||
| REIT - Residential | `realestate-reit.md` | |
|
||||
| REIT - Retail | `realestate-reit.md` | |
|
||||
| REIT - Specialty | `realestate-reit.md` | A wrapper, not a business. Route by what the tenant pays for: towers and fibre to `telecom-media.md`; data centres selling power-backed capacity to `utilities-power.md`; timberland as land NAV; net-lease gaming as single-operator rent coverage. |
|
||||
| Rental & Leasing Services | `mortgage-reit-specialty-finance.md` | Lessor section. Fleet utilisation, lease yield, residual-value risk and funding ladder — a financial business, not an industrial one. See Step 2a. |
|
||||
| Residential Construction | `realestate-reit.md` | Homebuilders: inventory is land and unsold units, and the land bank is where the balance-sheet risk lives. |
|
||||
| Resorts & Casinos | `aviation-hotels.md` | |
|
||||
| Restaurants | `aviation-hotels.md` | Same-store sales, covers and perishable capacity. An asset-light franchisor earning royalties on system sales is a brand annuity — cross-read `fmcg-consumer.md`. |
|
||||
| Scientific & Technical Instruments | `infra-capitalgoods.md` | Precision instruments sold into R&D and industrial capex; the service and consumable attach carries the margin. Where the customer is a fab, the driving cycle is semi capex — `semiconductors.md`. |
|
||||
| Security & Protection Services | `people-businesses.md` | Manned guarding and facilities services are labour arbitrage: wage pass-through, attrition and contract renewals. Electronic-security equipment makers are `infra-capitalgoods.md`. |
|
||||
| Semiconductor Equipment & Materials | `semiconductors.md` | Demand is customer capex, so it leads the chip cycle on the way in and lags it on the way out. |
|
||||
| Semiconductors **(added)** | `semiconductors.md` | Establish the model first — fabless, foundry, IDM or memory — because gross margin, capital intensity and cycle exposure differ completely between them. |
|
||||
| Shell Companies | `references/13-situations.md` §15 | Not a sector playbook. There is no business: trust value per share, sponsor promote, warrants, redemption deadline and the fully diluted count are the analysis. Route to a sector playbook only after a merger closes. See Step 2a. |
|
||||
| Silver | `metals-mining.md` | Frequently a by-product of base-metal mining — check whether silver is primary revenue or a credit against another metal's cost. |
|
||||
| Software - Application | `it-saas.md` | |
|
||||
| Software - Infrastructure | `it-saas.md` | |
|
||||
| Solar | `semiconductors.md` | Cell, wafer, module, inverter and tracker manufacture: utilisation, ASP deflation, inventory write-downs. Polysilicon, glass and encapsulants go to `chemicals-cement.md`; a developer or IPP selling power under a PPA goes to `utilities-power.md`. See Step 2a. |
|
||||
| Specialty Business Services | `people-businesses.md` | Facilities management, testing/inspection/certification, contact centres — outsourced labour with a contract book. |
|
||||
| Specialty Chemicals | `chemicals-cement.md` | Test the "specialty" claim against margin stability and customer stickiness; much of what is labelled specialty is a commodity with a longer contract. |
|
||||
| Specialty Industrial Machinery | `infra-capitalgoods.md` | |
|
||||
| Specialty Retail | `retail-ecommerce.md` | |
|
||||
| Staffing & Employment Services | `people-businesses.md` | Gross profit, not revenue, is the top line, and the margin metric is the conversion ratio, not OPM. |
|
||||
| Steel | `metals-mining.md` | |
|
||||
| Telecom Services | `telecom-media.md` | |
|
||||
| Textile Manufacturing | `chemicals-cement.md` | Spinning, weaving and man-made fibre are commodity conversion — the cotton- or polyester-to-yarn spread at a given utilisation. A branded apparel business is `fmcg-consumer.md`. |
|
||||
| Thermal Coal | `metals-mining.md` | Demand is power generation, so the cycle is the utility cycle. Check whether output moves under long-term linkage and fuel supply agreements or at spot — the earnings volatility differs entirely. |
|
||||
| Tobacco | `fmcg-consumer.md` | Volume declines structurally and price carries everything; excise and litigation are the real risk register. |
|
||||
| Tools & Accessories | `fmcg-consumer.md` | Branded durables through retail and pro distribution; channel inventory leads reported sales. Separate any captive dealer-finance book into `nbfc.md`. |
|
||||
| Travel Services | `aviation-hotels.md` | Distinguish the principal (owns the inventory and the risk) from the agent. For an OTA the driver is take rate on gross bookings, not reported revenue growth. |
|
||||
| Trucking | `shipping-logistics.md` | Spot-rate cyclical with no network moat. Never `rail-freight.md`. See Step 2a. |
|
||||
| Uranium | `metals-mining.md` | Sold to utilities on long-term contracts, so the realised price is the contract book rather than spot. Conversion and enrichment are separate process businesses. |
|
||||
| Utilities - Diversified | `utilities-power.md` | Split regulated from merchant before anything else — one earns an allowed return on a rate base, the other takes price risk. |
|
||||
| Utilities - Independent Power Producers | `utilities-power.md` | PPA-contracted and merchant capacity are different businesses. Offtaker credit quality and receivable days decide whether the contracted cash flow is real. |
|
||||
| Utilities - Regulated Electric | `utilities-power.md` | A utility earning its allowed RoE is performing correctly, not poorly; the analysis is rate-base growth and the regulatory relationship. |
|
||||
| Utilities - Regulated Gas | `utilities-power.md` | Rate-base utilities only. A city gas distributor earning a spread on sourced gas rather than a return on an approved asset base belongs in `oil-gas.md`. |
|
||||
| Utilities - Regulated Water | `utilities-power.md` | Rate base and allowed return, same frame as electric. A contract operator of municipal water and wastewater with no rate base is a services business — `waste-environmental.md`. |
|
||||
| Utilities - Renewable | `utilities-power.md` | Selling power under a PPA or feed-in tariff. Manufacturing cells or modules is not a utility — see `Solar` and Step 2a. |
|
||||
| Waste Management | `waste-environmental.md` | Landfill airspace, internalisation rate and closure and post-closure liabilities — which are debt, and sit outside reported borrowings. |
|
||||
|
||||
---
|
||||
|
||||
## Step 3 — Multi-segment companies
|
||||
|
||||
Most real companies are not pure. Route as follows:
|
||||
|
||||
1. **Rank segments by profit, not revenue.** Use segment EBIT / segment result from the segment note. In India this is the Ind-AS 108 disclosure in the standalone and consolidated statements; in the US it is the ASC 280 note in the 10-K plus the segment discussion in MD&A. Unallocated corporate costs and inter-segment eliminations are noise — note their size but do not let them decide.
|
||||
|
||||
2. **The playbook of the dominant profit segment governs.** If one segment is >60% of EBIT, run its playbook as the primary lens and treat the rest as adjustments.
|
||||
|
||||
3. **Explicitly name the secondary segments and what they do to the consolidated numbers.** State the distortion in one line each. Typical distortions: a finance arm inflates consolidated debt and destroys the parent's debt/equity comparability; a property segment holds land at historical cost and hides value; a trading segment inflates revenue and deflates blended margin.
|
||||
|
||||
4. **Use SOTP when segments belong to different families** — for example a manufacturer with a lending arm, or a consumer company with a large real-estate holding. Value each segment on its own family's multiple (a lender on P/B or P/adjusted book, a brand on EV/EBITDA or P/E, property on NAV), net out holding-company debt and costs, and apply a holding discount if the segments are not separately monetisable. Never apply a single consolidated P/E across a mixed group — the blend is arithmetic without meaning.
|
||||
|
||||
5. **When no segment exceeds ~40% of profit**, treat the company as a de facto conglomerate and go to Step 4.
|
||||
|
||||
6. **Score it mechanically rather than from memory.** `scripts/score.py` takes a `segments` array and scores each segment against its own sector's benchmarks, then blends by EBIT (falling back to capital employed or revenue automatically when a segment loses money, because a negative EBIT weight would subtract that segment's score from the group). It prints the concentration test in points 2 and 5 above, the mixed-family contamination warning, and the reminder that a blended score is not a substitute for SOTP. Run `python scripts/score.py --example-segments` for a complete runnable three-segment input to copy, and see `references/11-scoring-rubric.md` §10.
|
||||
|
||||
7. **Watch for segment drift.** Compare the profit mix to three and five years ago. A company being re-rated as a "specialty chemicals" or "SaaS" story while the profit mix has barely moved is a narrative, not a re-rating. Conversely, a genuine mix shift justifies changing the governing playbook — say so explicitly and date the change.
|
||||
|
||||
---
|
||||
|
||||
## Step 4 — Conglomerates and holding companies
|
||||
|
||||
Route to `holdco-assetmgr.md` when the parent's own operations are small and its earnings are substantially dividends, fees, or the equity-accounted share of subsidiaries and associates. Route to `holdco-assetmgr.md` **in addition to** the operating playbooks when the group has several material, genuinely different businesses.
|
||||
|
||||
Rules that apply to every conglomerate:
|
||||
|
||||
- **Sum-of-the-parts is the default method**, not a supplementary one. Value listed stakes at market value (state the date and whether you used a discount for illiquidity or lock-in), unlisted subsidiaries on their own sector multiples, and treasury/real-estate assets separately. Deduct net debt at the holding level and capitalise recurring holdco costs.
|
||||
- **Holding-company discount is real and persistent.** Discounts to underlying NAV are the norm rather than the exception, driven by tax on monetisation, minority stakes that cannot be sold, and the market's doubt about capital allocation. Compare the current discount to the entity's own history — a discount narrowing or widening versus its own five-year range is far more informative than the absolute level.
|
||||
- **Consolidated financials of a conglomerate are usually the least useful statement.** Consolidation mixes a lender's balance sheet with a manufacturer's, and minority interests can mean the parent owns a small share of the profits it reports. Always check profit attributable to owners versus total profit, and the size of non-controlling interests.
|
||||
- **Related-party transactions are the central governance risk.** In India, read the related-party note, the CARO report and auditor qualifications, and check promoter pledge levels and any inter-corporate deposits or guarantees to group entities. In the US, read the related-party disclosures and Item 13 of the 10-K/proxy. Cross-subsidy between group companies changes who the minority shareholder is actually financing.
|
||||
- **Capital allocation is the real asset.** For a conglomerate, the question is not "what does it own" but "where does incremental capital go and at what return". Track incremental capital deployed by segment over five years against incremental EBIT.
|
||||
|
||||
---
|
||||
|
||||
## Step 5 — When nothing fits
|
||||
|
||||
With Step 2b in place, every industry in the standard taxonomy resolves to a playbook, so arriving here should now be **rare**. When it happens the cause is almost never a missing playbook — it is that the company's economics have drifted away from the label a data provider attached to it, or that the entity is a combination of two businesses rather than one. Treat reaching this step as a prompt to re-run Step 1 on the profit mix, not as licence to invent a framework.
|
||||
|
||||
Do not force a fit. Do this instead:
|
||||
|
||||
1. **Decompose the P&L into the two or three sub-businesses it actually is**, and route each one. Almost every "unclassifiable" company is a combination, not a novelty.
|
||||
2. **Route by economics rather than product.** A satellite operator resembles a tower company (`telecom-media`). A ship-leasing company resembles an equipment lessor, which is a spread-and-residual-value business (`mortgage-reit-specialty-finance`), not a shipping operator. A data-centre owner is a landlord (`realestate-reit`) if it leases space, a `utilities-power` analogue if it sells power-backed capacity on long contracts, and an `it-saas` analogue if it sells managed compute — the contract structure decides.
|
||||
3. **Fall back to the family-level lens** in the table below and use the generic metrics that survive: cash conversion, return on invested capital versus cost of capital, and the trajectory of the company's own history.
|
||||
4. **Check whether the right file is a situation overlay rather than a sector playbook.** A listed shell or SPAC, a de-SPAC, a pre-revenue developer, a company in liquidation or a pure treasury vehicle is a *situation*, not a sector — `references/13-situations.md` governs, and the sector playbook applies only to whatever operating business emerges later.
|
||||
5. **Say so in the output — this requirement does not relax just because the mapping is complete.** Write one line naming the industry label you were given, the mapping row you rejected, and the route you took: "Classified as X in the source data; routed to Y rather than the mapped Z because profit is driven by W." An explicit, defensible choice beats a silent mis-route, and it lets a reader attack the routing decision directly instead of reverse-engineering it from the metrics.
|
||||
6. **Never substitute a peer set you do not believe in.** If there are no true comparables, use the company's own history across a full cycle as the benchmark and say that peer comparison was unavailable.
|
||||
|
||||
---
|
||||
|
||||
## Sector families — which standard metrics break
|
||||
|
||||
Fast sanity check. If you are about to compute a metric in the "undefined" or "inverted" column for that family, stop.
|
||||
|
||||
| Metric | Financials (banks, NBFC, insurance, some exchanges) | Real-asset / regulated (utilities, REIT/realestate, infra, telecom, shipping) | Cyclical-commodity (metals, oil & gas, chemicals-cement, semis-memory, autos) | Asset-light (IT-SaaS, FMCG, pharma-branded, exchanges, retail) |
|
||||
|---|---|---|---|---|
|
||||
| Revenue / "sales" | **Undefined as normally used.** Use net interest income + fee income (banks/NBFC), or gross written premium and net earned premium (insurance) | Usable, but check regulated vs merchant split; for REITs use rental income and NOI | Usable, but it is price × volume — always decompose | Usable and meaningful |
|
||||
| Debt/equity, net debt/EBITDA | **Undefined/meaningless.** Debt is raw material. Use CAR/CRAR (banks), capital adequacy and gearing (NBFC), solvency ratio (insurance) | Usable but high leverage is normal and often correct; compare to peers and to contracted cash flow cover, not to a generic 1x rule | Usable and critical — leverage at cycle peak is the standard way these companies die | Usable; sustained high leverage is a red flag |
|
||||
| EBITDA / EV-EBITDA | **Undefined.** Interest is revenue, not a financing cost | Usable and standard, but EBITDA ignores the maintenance capex that keeps the asset alive — always pair with capex | Usable but must be read against mid-cycle, never peak | Usable; closest to economic reality here |
|
||||
| P/E | Usable but secondary to P/B for lenders; for life insurers use P/EV and VNB multiples | Distorted by depreciation policy and asset revaluation; for REITs use P/FFO or P/AFFO, not P/E | **Inverted at extremes.** Low P/E at peak earnings signals a top; high P/E at trough earnings can signal a bottom | Usable and primary |
|
||||
| P/B | **Primary metric** for banks and NBFCs — but only against *adjusted* book after netting stressed assets | Meaningful only if the book reflects current asset value; historical-cost land makes book value fiction | Meaningful as a floor valuation near troughs (P/B near or below 1 on replacement-cost assets) | Largely meaningless — book value omits brands, code and IP |
|
||||
| Net profit margin | Use NIM, cost-to-income and credit cost instead | Depressed by depreciation and interest on the asset base — do not compare to asset-light peers | Swings by tens of percentage points across a cycle; a single-year figure is not information | Meaningful; compare to own history and direct peers |
|
||||
| ROE | Flattered by leverage — always read alongside ROA and capital adequacy; a lender with high ROE and thin capital is fragile, not excellent | Often capped by regulation (a regulated utility earning its allowed RoE is performing correctly, not poorly) | Peak-cycle ROE is not a run rate; use average-through-cycle ROCE | Meaningful; check it is not manufactured by buybacks shrinking equity |
|
||||
| ROCE / ROIC | **Undefined** in the standard form — capital employed is the funding base | Use, but compare to the regulated or contracted allowed return, not to a generic hurdle | Use through-cycle averages only | Primary metric; compare to cost of capital |
|
||||
| Free cash flow | Standard FCF is **not meaningful** — loan growth consumes cash and is a good thing. Use pre-provision operating profit and capital generation | Meaningful, but separate growth capex from maintenance capex or you will call a growing utility cash-destructive | Meaningful; watch that working capital release in a downturn is not read as improvement | Primary metric; should track net profit closely over time |
|
||||
| Inventory / receivable days | **Undefined** — no inventory in the normal sense | Limited relevance except for developers (inventory = unsold units, and it matters enormously) | Central. Rising inventory into a price fall is the classic warning | Central for retail and FMCG; near-irrelevant for SaaS |
|
||||
| Dividend payout | Constrained by regulator and capital needs; a high payout from a thinly capitalised lender is a warning | For REITs/InvITs, a high mandated payout is structural, not generosity — India: InvIT/REIT distribution rules; US: REIT distribution requirement | High payout at cycle peak often precedes a cut | Meaningful signal of capital discipline |
|
||||
| Depreciation | Small and uninformative | **Systematically overstates economic cost** where assets appreciate (property) — this is why FFO exists | Broadly economic; check for impairments hiding a bad capex cycle | Small; watch capitalised software and R&D policy |
|
||||
| Asset turnover | **Undefined** | Structurally low by design | Cyclical; falls first as demand rolls over | High; a falling trend is an early warning |
|
||||
|
||||
Ranges and thresholds anywhere in the sector playbooks are **indicative only**. They vary by market, by point in the cycle, by accounting regime and by period. A peer-set comparison and the company's own multi-year history always override any absolute band printed in these files.
|
||||
|
||||
---
|
||||
|
||||
## Fast sanity check before you leave this file
|
||||
|
||||
Before running any playbook, confirm you can answer these in one line each. If you cannot, you have not classified the company yet.
|
||||
|
||||
- Which segment produces most of the **profit** (not revenue)?
|
||||
- Which of the four families does the balance sheet belong to?
|
||||
- Who sets the selling price?
|
||||
- Where is this company in its cycle — and does the sector even have one?
|
||||
- Which standard metrics are undefined or inverted here, per the table above?
|
||||
- What is the correct peer set: same sector, similar size, similar business model, same market? Cross-market peers (a US generic vs an Indian generic, a US bank vs an Indian bank) differ in tax, accounting, rate environment and disclosure — note the differences rather than pretending comparability.
|
||||
|
||||
India-specific notes that affect routing: check the standalone versus consolidated split before ranking segments (many Indian groups hold operating businesses in subsidiaries, so standalone numbers describe a shell); read the latest earnings concall transcript for management's own segment framing; check promoter holding and pledge; and read CARO qualifications for related-party and asset-verification flags. US/global notes: use the 10-K segment note and MD&A, check for non-GAAP reconciliations that exclude recurring stock-based compensation, and read the risk factors for the company's own statement of what drives its economics.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Ranked segments by EBIT/segment result, not revenue, before choosing a playbook.
|
||||
- [ ] Answered the five classification questions: profit source, balance-sheet role, price setter, unit of production, failure mode.
|
||||
- [ ] Ignored the index/GICS label where it conflicts with the profit driver, and said so.
|
||||
- [ ] Checked the industry name against the Step 2a trap list **before** accepting any mapping — mortgage REIT, insurance broker, lessor, healthcare plan, shell company, railroad, solar, real-estate services, drug distributor, pharmacy, ad agency, pollution-control equipment.
|
||||
- [ ] Took the route from the Step 2b mapping row for the stated industry, or overruled it on the profit driver and stated the override in the output.
|
||||
- [ ] For a conditional row — Biotechnology, Solar, Utilities - Renewable, Credit Services, Information Technology Services, Insurance - Specialty, Gambling, REIT - Specialty — applied the stated test and recorded which side it fell on.
|
||||
- [ ] Where the mapping sends part of the company elsewhere (captive finance arm, franchisor royalty stream, property held on balance sheet), separated it rather than blending it into the primary lens.
|
||||
- [ ] Routed to exactly one primary playbook; named any secondary playbooks and the distortion each creates in consolidated numbers.
|
||||
- [ ] Used SOTP where segments belong to different families; never applied one blended P/E across a mixed group.
|
||||
- [ ] For conglomerates: valued parts separately, deducted holdco debt and costs, compared the holding discount to its own history, and checked related-party exposure and minority interests.
|
||||
- [ ] Checked the undefined/inverted table and struck out every metric that does not exist for this family.
|
||||
- [ ] Confirmed the peer set is genuinely like-for-like (sector, size, model, market); otherwise fell back to the company's own multi-year history and said so.
|
||||
- [ ] Treated every indicative range as indicative — anchored the conclusion to peers and own history.
|
||||
- [ ] If nothing fit: decomposed into sub-businesses, routed by economics, and stated the hybrid classification explicitly in the output.
|
||||
170
finance/skills/stock-analysis/references/sectors/auto.md
Normal file
170
finance/skills/stock-analysis/references/sectors/auto.md
Normal file
|
|
@ -0,0 +1,170 @@
|
|||
# Automobiles, auto components and tyres — sector playbook
|
||||
|
||||
Use this when: the company manufactures or sells vehicles or the parts that go into them — passenger vehicles, commercial vehicles, two- and three-wheelers, tractors and farm equipment, buses, EV pure-plays, Tier-1/Tier-2 auto components, tyres, batteries and auto electricals, and vehicle dealership groups.
|
||||
|
||||
This sector breaks the generic checklist harder than almost any other, for three compounding reasons. First, most large OEMs consolidate a captive lending business, so every leverage, coverage and cash-flow ratio computed on consolidated numbers is arithmetically valid and economically meaningless. Second, revenue is recognised on *dispatch to dealers*, not on retail sale, so several quarters of "growth" can be manufactured inside the distribution channel and are invisible in the financial statements. Third, this is a deep cyclical with 5–7 year product cycles and heavy operating leverage, which inverts P/E and turns free cash flow into a cycle amplifier rather than a quality signal. Work in units and per-unit currency, separate the industrial business from the finance arm, and normalise to mid-cycle before you value anything.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
**D/E, net debt/EBITDA and interest coverage — meaningless on consolidated numbers, and mis-signed.** Most large OEMs run a captive financier (GM Financial, Ford Credit, VW Financial Services, Toyota Financial Services; in India Mahindra Finance, Tata Motors Finance, TVS Credit, Bajaj Auto Credit). A lender is *supposed* to be levered 6–10x. Consolidating it makes an OEM with net industrial cash look like a distressed balance sheet, and simultaneously hides where the real automotive leverage sits. Ford and GM have carried automotive net cash while showing $100bn+ of consolidated debt. The only meaningful figure is **automotive (industrial) net debt** with the finance arm deconsolidated or equity-accounted. Never quote consolidated gearing for an OEM without saying which it is.
|
||||
|
||||
**OPM / EBITDA margin — not comparable across sub-sectors, and not comparable across accounting regimes.** Structural margins differ by design: two-wheelers 12–18%, tractors 14–18%, PVs 8–12%, CVs 8–12%, tyres 12–16%, components 8–14%, EV pure-plays frequently negative. Worse, IFRS and Ind-AS permit capitalisation of product development cost while US GAAP forces immediate expensing of R&D. That single difference can swing reported EBITDA margin by 400–600 bps with zero economic difference — so comparing an Ind-AS filer's EBITDA margin to a US GAAP peer's without adjustment is an accounting artefact, not analysis. Percentage margin is also corrupted by commodity pass-through: falling steel prices cut revenue and *raise* OPM% with no value created.
|
||||
|
||||
**P/E — actively inverted.** At the cycle peak, earnings are maximal and trailing P/E is lowest; that is the danger point, not the bargain. At the trough, P/E is huge or negative and screens exclude the stock precisely when risk/reward is best. For CVs, tyres and global mass-market OEMs, low trailing P/E is a contrary indicator. Use it only after normalisation, and only where the business genuinely behaves like a consumer franchise.
|
||||
|
||||
**Free cash flow — a cycle amplifier, not a quality signal.** OEMs and many component makers run structurally *negative* working capital (dealers pay on or before dispatch; suppliers are paid on 45–90 day terms), so volume growth mechanically releases cash and volume decline consumes it, independent of profitability. On top of that, capex plus product development is lumpy across a 4–6 year platform cycle: heavy investment years show poor FCF from a healthy business, and harvest years show excellent FCF from a business quietly starving its model pipeline. One-year and even three-year FCF says almost nothing. Assess cumulative FCF across a full product cycle.
|
||||
|
||||
**Current ratio / quick ratio — inverted for OEMs.** A current ratio below 1.0 is normal for an OEM and is evidence of *channel strength* — a generic screen flags it as distress. Conversely, a component maker at 2.5x is usually carrying dead inventory or stretched OEM receivables. The sign of the signal flips depending on which side of the supply chain the company sits.
|
||||
|
||||
**ROCE and book value — distorted in both directions.** Serial impairments shrink the capital base and mechanically inflate subsequent ROCE, so a company that writes down enough plants and platforms can manufacture an apparent returns recovery. In the other direction, cash-rich Indian OEMs carry very large treasury books inside capital employed, depressing reported ROCE well below the true operating return. And non-operating income sits inside the numerator: regulatory credit sales (ZEV/CAFE), EU CO2 pooling receipts, PLI/FAME/export incentives, treasury income. Recompute ROCE on automotive capital employed, ex-cash, ex-credits, with accumulated impairments added back.
|
||||
|
||||
**Revenue itself — not what it appears to be.** Headline revenue is wholesale dispatches, not retail sales. Every ratio built on revenue can be inflated for two to three quarters by pushing stock into the dealer channel. Anchor to unit volumes and to independent retail data before trusting any revenue-derived number.
|
||||
|
||||
**Growth as an unqualified positive — needs qualification.** Volume growth bought with discounts, longer loan tenors from the captive financier, or channel stuffing is borrowed from future quarters. Decompose growth into retail demand, mix, price and channel fill before scoring it.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, sub-sector, cycle position and period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set and against the company's own full-cycle history overrides every absolute band below. Work in units and absolute per-unit currency wherever possible — percentages hide the sector's real economics.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Wholesale dispatches vs retail registrations; dealer channel inventory (days)** | Units billed to dealers (which become revenue) versus units actually registered to end customers, and the resulting stock in the channel. India: company/SIAM dispatches vs VAHAN registrations, with FADA's dealer inventory commentary. US: "days' supply" of new-vehicle inventory. | Retail growth ≥ wholesale growth over any trailing 12 months. India PV/2W channel inventory ~20–30 days (FADA flags >35–40). US days' supply ~45–60 normal, <35 tight, >80 stressed. | The single most important early-warning KPI in the sector, and it is invisible in the financial statements. Revenue is recognised on dispatch, so an OEM can report volume and margin growth for two to three quarters purely by stuffing the channel. The unwind is brutal — production cuts, discounting and negative operating leverage arrive together. A persistent wholesale-over-retail gap preceded almost every major auto earnings reset. |
|
||||
| **EBITDA (or contribution) per vehicle, in absolute currency** | Operating profit per unit sold rather than as a % of revenue. Ideally split into contribution per unit (net realisation − variable cost) and fixed cost per unit. | Segment-specific: Indian mass 2W roughly ₹8,000–11,000/unit (premium marques ₹35,000–45,000); Indian PV roughly ₹45,000–90,000/unit; global mass-market OEM roughly $1,500–3,000/unit; premium European OEM €5,000–9,000/unit. Judge the trend and the gap to best-in-segment, not the level. | Percentage margin conflates price, mix and commodity pass-through. Per-unit profit strips that out and separates the two things that matter: pricing/mix power (contribution per unit) and scale absorption (fixed cost per unit). It is also the correct input into a mid-cycle valuation — mid-cycle volume × mid-cycle EBITDA/unit. |
|
||||
| **Net realisation per vehicle and discount / incentive per unit** | ASP actually booked after dealer discounts, cash incentives, exchange bonuses, subvention paid to the finance arm and fleet rebates — against list price. Decompose ASP growth into price action vs mix (SUV / premium / higher-trim share). | India PV: normal discounts ₹20,000–60,000/unit; sustained discounts above roughly ₹1.0–1.5 lakh on volume models signal demand stress. US: incentives 3–6% of ATP normal, >8–10% indicates oversupply. | Discounting is the pressure valve of an oversupplied auto market and it moves before volumes do. Companies routinely route incentives through the captive financier as interest subvention or through dealer margin support, so headline ASP holds while true realisation erodes. Mix-led ASP growth is high quality and repeatable; price-led is neither. Read alongside channel inventory to know whether reported growth was bought. |
|
||||
| **Automotive (industrial) net debt / net cash and automotive FCF, excluding the captive finance arm** | Balance sheet and cash flow of the manufacturing business only, financial services deconsolidated or equity-accounted. Automotive FCF = automotive operating cash flow − capex − capitalised product development. | Best-in-class: automotive net cash. Acceptable: automotive net debt/EBITDA <1.0x. Liquidity buffer covering at least one to two quarters of fixed costs plus scheduled maturities (large global OEMs typically target $20–30bn automotive liquidity). Assess FCF cumulatively across a full 4–6 year product cycle. | This is the correct solvency test, and it is exactly what a generic D/E ratio destroys. Autos are a high-fixed-cost, high-operating-leverage business where a 20% volume decline can turn EBITDA negative within two quarters; survival is determined by industrial net cash, not consolidated gearing. Multi-year OEM deleveraging stories, and the net-industrial-cash-despite-huge-consolidated-debt position of the US majors, are only visible on this basis. |
|
||||
| **R&D + product development spend as % of revenue, and the capitalisation ratio** | Total engineering/product development outlay (expensed + capitalised) as a share of revenue; the share capitalised rather than expensed; and the gap between annual capitalisation and annual amortisation of development assets. | OEM 4–7% of revenue (EV-transition years 6–9%); components 2–5%; Indian 2W/PV historically 2–4%. Capitalisation ratio: US GAAP peers 0%; IFRS/Ind-AS peers commonly 50–80%. The ratio should not be rising, and cumulative capitalisation should broadly equal cumulative amortisation across a full cycle. | The number one comparability adjustment in global auto analysis and the number one soft-earnings lever. Every unit capitalised bypasses today's P&L and creates an amortisation drag later. A rising capitalisation ratio, a lengthening amortisation life, or capitalisation persistently exceeding amortisation means reported EBITDA and EPS are borrowed from future years. The opposite is equally dangerous: harvesting FCF by cutting product spend buys two good years and then a lost model cycle. |
|
||||
| **Total investment intensity: (capex + capitalised development) as % of revenue, and vs D&A** | All growth and maintenance investment as a share of sales, benchmarked to D&A to see whether the asset base is being renewed, harvested or over-built. | OEM through-cycle 6–9% of revenue (platform/EV transition years 10–12%); components 5–8%. Investment/D&A around 1.0–1.3x in steady state; sustained <0.8x = under-investment; sustained >2.0x with flat volumes = over-building. | Autos are the archetypal capital-cycle industry: returns are made by companies that invest counter-cyclically and destroyed by those that commission greenfield capacity at the peak. Because product cycles run 5–7 years, single-year capex tells you nothing; the ratio to D&A and its timing against the volume cycle tell you almost everything about future ROIC. |
|
||||
| **Capacity utilisation and breakeven volume (operating leverage)** | Units produced as a share of installed/rated capacity, plus the volume at which EBIT turns zero, derived from contribution per unit and the fixed cost base. | Healthy OEM utilisation 75–90%; below roughly 65% most OEMs are loss-making at EBIT. Breakeven typically 55–70% of installed capacity for a well-run OEM; breakeven above 80% is a fragile model. | Auto economics are dominated by fixed-cost absorption — a plant is roughly 25–35% fixed cost, so a 10% volume swing can move EBITDA margin 200–350 bps. Knowing breakeven volume lets you model the downside honestly instead of extrapolating peak margin. It also explains why utilisation, not price, drives the cycle, and why industry-wide capacity announcements are a bearish signal 2–3 years out. |
|
||||
| **Through-cycle / mid-cycle ROIC on automotive capital employed** | NOPAT of the manufacturing business / automotive invested capital — excluding the finance arm, excluding surplus cash and treasury investments, adding back accumulated impairments. Computed as a full-cycle average, or on normalised mid-cycle volume and mid-cycle EBITDA per unit. | Global mass-market OEM cost of capital roughly 8–10%; most earn below it through the cycle. Strong: >15% pre-tax on automotive capital. Indian franchises are structurally better — leading 2W/PV/tractor names and top ancillaries run 15–30%+. Components: >18% ex-cash is the quality threshold. | Reported ROCE is doubly distorted — large treasury books depress it, serial write-downs flatter it by shrinking the denominator. The economic question is whether the company earns above its cost of capital across a full cycle. Most volume OEMs historically do not, which is precisely why they deserve low multiples, and why the rare exceptions can justify consumer-franchise multiples. |
|
||||
| **Working capital cycle: inventory vs payable days, and off-balance-sheet supplier financing** | Inventory, receivable and payable days for the automotive business; the resulting (usually negative) net working capital; and any reverse factoring / supply chain finance / channel financing that shifts payables off the debt line. | OEM: inventory 18–30 days, receivables 10–20, payables 45–75, net working capital negative (roughly −5% to −15% of sales). Component makers are the mirror image: receivables 60–90 days from OEMs, positive working capital 15–25% of sales. Payable days rising 15–20+ days without a stated policy change warrants investigation. | Negative working capital is a genuine competitive strength — the dealer and supplier base funds the OEM — but it makes cash flow pro-cyclical and easy to manipulate. Stretching supplier terms or moving payables into a bank-intermediated reverse factoring programme flatters operating cash flow and understates true debt; it is a recurring cause of sudden supplier distress and restated leverage. For component makers, the same lens exposes OEM receivable stretch, the first symptom of an OEM in trouble. |
|
||||
| **Warranty provision as % of sales; accrual vs claims paid; recall exposure** | The warranty accrual rate charged each period, cash actually paid on claims, the closing provision balance, and disclosed recall campaigns with per-vehicle cost. | OEM warranty and campaign accruals typically 1.5–3.5% of automotive revenue (premium and complex-powertrain at the higher end; simple 2W/tractor products well below 1.5%). Provision balance broadly stable relative to the warranted parc; accruals should approximate claims paid over time. | The most under-scrutinised earnings lever in autos. Trimming the accrual rate by 50 bps flows straight to EBIT and is nearly invisible; the bill arrives 18–36 months later as a "one-off" campaign charge. A falling accrual rate while the warranted parc, product complexity or new-model share is rising — or a provision balance draining while claims paid rise — signals borrowed earnings. Recall economics matter directly: a single campaign can erase a year of segment profit. |
|
||||
| **Content per vehicle and booked business / order book (components)** | Revenue earned per vehicle produced by the customer base (kit value), plus the cumulative lifetime value of programmes awarded but not yet in production, and book-to-bill. | Booked lifetime business 2.5–4x current annual revenue for a healthy Tier-1; annual new business wins ≥1.2x revenue (book-to-bill >1). Content per vehicle should grow faster than industry volumes — that gap is the real organic growth. | A component maker's growth is a function of (a) how many vehicles its customers build and (b) how much of each vehicle it supplies. Content per vehicle isolates the second — the only part management controls and the only part that survives a volume downturn. The order book gives 3–5 years of forward visibility no financial ratio provides, and it is where the EV transition is won or lost: ICE-exposed content (exhaust, fuel systems, transmissions) can be structurally stranded while current revenue still looks fine. |
|
||||
| **Customer, platform and geography concentration; aftermarket mix** | Revenue share from the top customer and top five, from the largest platform/model, and by end market — set against revenue from the higher-margin replacement/aftermarket and service channel. | Components: top customer <30–35%, top five <60–65%. Indian ancillaries frequently run 40–70% single-OEM dependence, which raises risk materially and justifies a lower multiple. Aftermarket 15–30% of revenue is a strong buffer, typically at 1.5–2.5x OEM-channel margins. OEMs: no single model >25–30% of profit is preferable. | An OEM programme loss, a customer's model failure, or one plant's re-sourcing decision can remove a fifth of revenue with almost no notice — and Tier-1s have little pricing power against a concentrated customer, where annual price-down clauses of 1–3% are a contractual norm. Aftermarket revenue is counter-cyclical, higher-margin and brand-driven; it changes the quality of the earnings stream, and is why tyre, battery, filter and lubricant companies deserve different multiples from pure OEM suppliers. |
|
||||
| **Captive finance arm quality: penetration, NIM, credit cost, residual value exposure, leverage** | Share of vehicle sales financed in-house (penetration); the finance arm's NIM; gross/net credit cost and delinquency; equity/assets or D/E; and, in developed markets, lease portfolio size and the residual values assumed. | Penetration 30–55% typical. Retail auto loan net charge-offs roughly 0.5–2.0% of receivables through the cycle (subprime-heavy books far higher); Indian captive NBFC GNPA varies widely — rural/tractor and used-CV books run structurally higher. Finance-arm leverage 6–10x is normal for the entity but should be ring-fenced. Tenor extension beyond 60–72 months (India) or 72–84 months (US) is a demand-pull-forward signal. | The captive financier is simultaneously a demand subsidy, a profit centre and a hidden risk pool. It can manufacture volumes (looser credit, longer tenors, subvented rates funded by the auto arm), shift profit between segments via intersegment pricing, and warehouse residual value risk on leases whose assumptions management sets. In a downturn the auto business and the credit book deteriorate *simultaneously* — the correlation that makes this far more dangerous than a standalone lender's book. Analyse with banking metrics (P/B, ROA, credit cost) and value separately; see `references/sectors/nbfc.md`. |
|
||||
| **Powertrain transition KPIs: EV/hybrid mix, EV contribution margin ex-credits, battery cost per kWh, compliance position** | Share of volumes and revenue from BEV / hybrid / CNG vs ICE; standalone gross or contribution margin on EVs stripped of regulatory credits and government incentives; battery pack cost per kWh and cell sourcing security; position against emissions and fuel-economy rules (EU CO2 and Euro 7, US CAFE/EPA and ZEV, India CAFE-III and the 2W EV regime). | EV gross margin trending toward parity with the ICE portfolio; pack cost falling toward and below roughly $100/kWh for leading chemistries. Compliance position should require no purchased credits. Dependence on FAME/PLI/state subsidies or credit sales for segment profitability should be quantified and ideally small. | The sector's largest capital-allocation question, and it appears in no standard ratio. Regulatory credit sales and subsidy income are pure-margin, non-operating and policy-dependent — they can vanish with a rule change or subsidy expiry, and India's repeated FAME revisions repriced the domestic EV two-wheeler industry within a single quarter. Simultaneously, ICE-heavy asset bases and ICE-specific content face impairment and stranding. Consolidated margin hides both the subsidy dependence and the cross-subsidy from a profitable ICE business funding a loss-making EV ramp. |
|
||||
| **Market share, model age and launch cadence** | Segment-level share trend; weighted average age of the model portfolio; number of major launches and mid-cycle refreshes in the next 24–36 months; share of volumes from products launched in the last three years. | Product cycles run 5–7 years with a refresh at year 3–4. Weighted average portfolio age above roughly 5 years with a thin pipeline means share loss ahead. A healthy OEM generates 30–50% of volumes from products launched or refreshed in the last three years. Share should be defended without a rising discount per unit. | Auto profitability is a hit-driven, product-cycle business, and share is won or lost on launches, not on cost programmes. Share held while discounts rise is share bought, not earned. Conversely, weak margins during a heavy launch-investment phase are frequently the best entry point. Model age also predicts the timing of the capitalised-development amortisation charge and the next capex wave, tying an operational KPI directly to future reported earnings. |
|
||||
| **Raw material basket and gross profit per unit (components and tyres)** | Movement in the specific input basket — steel, aluminium, copper, natural and synthetic rubber, carbon black, crude derivatives, lead, palladium/platinum/rhodium — against realisation, with the contractual indexation/pass-through lag stated. Judge on gross profit per unit, not gross margin %. | Pass-through lag typically one to two quarters. Gross profit per unit should be flat-to-rising through an input cycle; if it only rises when inputs fall, there is no pricing power. Tyres: replacement-mix share is the main margin determinant. | Where inputs are contractually indexed, OPM% moves mechanically with commodity prices and carries no information — falling inputs raise margin with no value created, rising inputs do the reverse, and the market mistakes both for operating performance. Gross profit per unit is the pass-through-neutral measure of whether the company is actually capturing value. Also net off the annual 1–3% OEM price-down that must be recovered through productivity. |
|
||||
| **Exports, currency and demand-driver mix** | Share of revenue by end market and currency, natural hedge (imported content vs export revenue), hedging policy and open position; and, for India, the specific demand drivers per sub-sector. | No hard band — the requirement is that you can name the driver. India: monsoon and rural wages for tractors and mass 2W; freight rates, e-way bill volumes and infrastructure spend for CVs; financing availability and interest rates for PVs and CVs; replacement demand and parc age for tyres and aftermarket. | Auto sub-sectors do not share a cycle. Tractors can be at a peak while CVs are at a trough. Forecasting volumes without identifying the actual demand driver produces a GDP-linked guess. Currency matters twice over for exporters — translation on revenue and transaction on imported content — and hedge gains/losses often sit in other income, flattering or depressing "operating" performance. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
The default framework is **sum-of-the-parts built on EV/EBITDA with mid-cycle normalisation**, with P/E reserved for businesses that genuinely behave like consumer franchises.
|
||||
|
||||
**1. SOTP is the default for any OEM with a captive finance arm or listed subsidiaries — which is nearly all of them.** You cannot value an industrial business and a lender with one multiple. Standard build: (a) the automotive/industrial business on EV/EBITDA or EV/EBIT; (b) the captive finance arm on price-to-book against its own ROE using NBFC/bank methodology — typically 0.8–1.5x book, below a standalone NBFC because the credit and volume risks are correlated; (c) listed subsidiary and associate stakes at market value with a 20–40% holding-company discount; (d) then deduct **only automotive** net debt. This is how the large Indian auto holdcos (an OEM plus a farm-equipment arm plus a listed finance arm plus listed non-auto subsidiaries) and the US majors are actually valued on the street.
|
||||
|
||||
**2. EV/EBITDA is the workhorse for the manufacturing business** because it is neutral to capital structure — essential given the finance arm — and to the very different depreciation policies across the sector. Indicative conventions: global mass-market OEM industrial business 2–5x; Indian PV/CV 8–14x; Indian premium 2W and tractor franchises 15–25x; auto components 10–18x in India and 5–9x in developed markets; tyres 7–11x. **Critical adjustment:** because IFRS/Ind-AS filers capitalise development spend, always cross-check with EV/EBIT (which captures the amortisation) or with an "EBITDA after capitalised product development" figure. Skip this and you will systematically over-value the capitalisers against US GAAP peers.
|
||||
|
||||
**3. Mid-cycle normalisation, not spot earnings.** The defensible approach for a cyclical is mid-cycle volume × mid-cycle EBITDA per vehicle × a through-cycle target multiple, or price-to-normalised-EPS. Spot P/E on peak earnings is the classic trap: low trailing P/E at the top of the cycle is a sell signal, and high or negative P/E at the trough is often the entry point. This is the single most important valuation discipline in the sector — state the mid-cycle volume and per-unit assumption explicitly so it can be challenged.
|
||||
|
||||
**4. P/B and replacement-cost anchors at the trough.** When earnings go negative, P/B becomes the operative floor metric. Global mass-market OEMs commonly trade at 0.3–0.9x book — a structural discount reflecting sub-cost-of-capital returns, not a bargain. Indian OEMs trade at 3–8x book because they genuinely earn 15–30% ROCE. Asset-based cross-checks: EV per unit of installed annual capacity, and replacement cost of the plant and platform base, useful for distressed or takeout scenarios.
|
||||
|
||||
**5. EV/Sales for loss-making or pre-scale players** (EV pure-plays, new entrants), since EBITDA is negative and meaningless. Only defensible when paired with a credible, quantified path to a target contribution margin and a stated breakeven volume; otherwise it is a narrative multiple with a decimal point.
|
||||
|
||||
**6. DCF is more useful for components than for OEMs.** Tier-1s have a contractually booked order book giving 3–5 years of visible revenue, which anchors the explicit forecast period. For OEMs, DCF is fragile — terminal value dominates, and terminal margin assumptions in a cyclical, technology-disrupted industry are close to guesswork. Where a DCF is run for an OEM, use normalised mid-cycle margins and set capex equal to a full-cycle average *including* capitalised development.
|
||||
|
||||
**7. Sub-sector specifics.** Dealership groups are valued on EV/EBITDA and on parts-and-service gross profit, because new-vehicle gross is a thin, cyclical spread and the service annuity carries the value. Tyre and battery makers are valued on EV/EBITDA with heavy weight on replacement-market mix and raw-material spreads. Fleet, leasing and rental operations are valued on book value and residual assumptions, closer to a financial than an industrial.
|
||||
|
||||
**Do not use:** trailing P/E on peak-cycle earnings as a value signal; consolidated EV or net debt for any OEM with a captive financier; EV/EBITDA compared across IFRS and US GAAP filers without a development-capitalisation adjustment; single-year FCF yield; or a DCF terminal value for an OEM built off current-year margins.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares **sub-sector, end market, position in the value chain and accounting regime**. "Auto" is not a peer set.
|
||||
|
||||
**Splits that must not be mixed:**
|
||||
|
||||
- **Two-wheelers vs passenger vehicles vs commercial vehicles vs tractors.** Different demand drivers (rural income and monsoon vs urban financing vs freight and infrastructure), different cycle timing, different structural margins (2W 12–18% vs PV/CV 8–12%), different capital intensity. These sub-sectors routinely peak and trough in different years.
|
||||
- **OEMs vs component makers vs tyres vs dealers.** OEMs have negative working capital and pricing power over dealers; Tier-1s have positive working capital, customer concentration and contractual annual price-downs; tyre and battery makers are commodity-spread plus replacement-brand businesses; dealers are thin-spread retailers whose profit sits in parts, service and finance commission.
|
||||
- **Tier-1 vs Tier-2/Tier-3 suppliers.** Tier-1s sell systems and hold the design IP and the customer relationship; Tier-2s sell parts into a Tier-1 and are price-takers twice over. Different margins, different multiples, different survival odds in a downturn.
|
||||
- **OEM-channel vs aftermarket-weighted suppliers.** An ancillary with 30% aftermarket revenue has a fundamentally different earnings stream — counter-cyclical, brand-driven, 1.5–2.5x the margin — from a pure OEM supplier. Do not average their multiples.
|
||||
- **ICE-exposed vs powertrain-agnostic vs EV-levered content.** An exhaust or fuel-system supplier and a braking, suspension or interiors supplier face opposite structural futures on identical current financials.
|
||||
- **EV pure-plays vs incumbent OEMs.** Different capital structures, no legacy footprint, negative EBITDA, and a valuation basis (EV/Sales on a growth narrative) that cannot be reconciled with an incumbent's EV/EBITDA.
|
||||
- **Domestic-focused vs export-led.** Currency exposure, customer mix and cycle exposure differ entirely; an Indian ancillary with 60% Europe exposure is trading the European build rate, not the Indian one.
|
||||
- **Mass-market vs premium/luxury OEMs.** Premium carries structurally higher per-unit profit, lower volume beta, different brand economics and different multiples.
|
||||
- **Consolidated vs automotive-only basis.** Comparing one OEM's consolidated leverage or FCF against another's automotive-only figure is a material and common error. Fix the basis first, state it, and apply it to every peer.
|
||||
- **IFRS/Ind-AS capitalisers vs US GAAP expensers.** Adjust for development capitalisation before any margin or EV/EBITDA comparison, or state that the comparison is not valid.
|
||||
|
||||
**Also align:** fiscal year end (Indian companies April–March, most global peers calendar); scale band (a niche ancillary and a global Tier-1 face different customer power); and cycle position of the *end market*, not the listing country.
|
||||
|
||||
Aim for 5–8 peers, state the basis explicitly, and benchmark every metric twice — against peers and against the company's own full-cycle history.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Wholesale dispatches persistently outrunning retail registrations.** India: compare company/SIAM dispatches against VAHAN registrations and FADA dealer inventory commentary. US: watch days' supply. A two- to three-quarter gap means revenue and margin have been borrowed from future quarters and a production cut is coming.
|
||||
- **Rising discounts, exchange bonuses, dealer margin support and interest subvention while headline ASP is described as stable.** Check discount per unit, and check whether incentives have been routed through the captive finance arm, where they appear as finance-segment cost rather than a reduction in automotive revenue.
|
||||
- **A rising share of product development being capitalised, a lengthening amortisation life, or capitalisation persistently exceeding amortisation.** The sector's largest soft-earnings lever, and it guarantees a future EPS drag. The mirror image is equally bad: a sudden fall in R&D-to-sales that boosts FCF is harvesting the product pipeline, not efficiency.
|
||||
- **Warranty accrual rate falling as a % of sales while the warranted parc, product complexity or new-model share rises**; or claims paid running materially above the accrual and draining the provision balance. Recurring "exceptional" recall and campaign charges alongside a low ongoing accrual rate is the same story told after the fact.
|
||||
- **Consolidated leverage discussed without segregating the captive finance arm — in either direction.** Management highlighting consolidated "deleveraging" driven by the finance book, and a screen rejecting a net-cash industrial business because of consolidated NBFC debt, are both errors. Insist on automotive-only net debt and automotive-only FCF.
|
||||
- **The captive financier being used to manufacture demand.** Loan tenors extending (past roughly 60–72 months in India, 84 months in the US), LTVs creeping up, penetration jumping without a rate explanation, provisioning falling while the book grows, or aggressive residual value assumptions on leases. Auto credit losses and auto volumes deteriorate together, so this risk is not diversified away.
|
||||
- **Profit dependent on regulatory credits, subsidies or incentives** — ZEV/CAFE credit sales, EU CO2 pooling payments, PLI, FAME and state EV subsidies, RoDTEP and other export incentives. Recompute segment margin excluding all of it. Policy income is high-margin, non-operating and can be legislated away in a single budget.
|
||||
- **Working capital flattery.** Payable days extending sharply, or undisclosed reverse factoring / supply chain finance / channel financing that moves payables off the reported debt line. This inflates operating cash flow, understates leverage and often precedes distress at the supplier base. India: also watch OEM-arranged channel financing that shifts inventory risk to dealers and their banks while the dispatch is still booked as a sale.
|
||||
- **Capacity expansion or a greenfield announcement following three consecutive strong years — especially when peers announce simultaneously.** Industry-wide capacity additions at the cycle peak are the most reliable predictor of the next margin collapse. In this sector the capital cycle, not the demand cycle, is what destroys returns.
|
||||
- **Serial "exceptional" or "one-off" items** — restructuring, impairment, redundancy, platform write-offs — appearing every year. Beyond obscuring true earnings, impairments shrink the capital base and mechanically inflate subsequent ROCE, so enough write-downs can manufacture an apparent returns recovery.
|
||||
- **India — royalty and technical fee creep at MNC subsidiaries and JV-linked OEMs.** Royalty rising as a % of sales, or new-model royalties negotiated upward. This is a pre-tax charge that transfers value from minority shareholders to the foreign parent and is captured by no standard ratio. Scrutinise related-party purchases from promoter-owned component suppliers, which is common in Indian auto groups.
|
||||
- **Component makers judged on margin percentage where the input is contractually indexed.** Falling input prices mechanically raise OPM% with no value created. Judge on gross profit per unit and content per vehicle. Also net off the 1–3% annual OEM price-down that is only recoverable through productivity.
|
||||
- **Regulatory pre-buy presented as demand.** Emission deadlines pull sales forward and leave an air pocket immediately after — India's BS6 transition, each CAFE tightening, Euro 6/7 in Europe, EPA phases in the US. A record year immediately before a norm change should be normalised away, not extrapolated.
|
||||
- **Under-disclosed concentration.** A single model, platform or OEM customer driving a disproportionate share of profit; or an order book heavily weighted to ICE-specific content facing structural stranding. At EV makers, check whether "record bookings" are refundable low-deposit reservations rather than firm orders.
|
||||
- **India — balance-sheet and governance items specific to auto groups.** High promoter share pledging; complex holdco and cross-holding structures used to move cash between listed and unlisted entities; large inter-corporate deposits or loans to group companies; and treasury/other income presented inside "operating" performance for a manufacturing business.
|
||||
- **FCF celebrated in a year where capex plus product development fell well below D&A.** In a business with 5–7 year product cycles, that is not cash generation — it is a deferred obligation, and the volume and share consequences show up two to three years later.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Know where you are, because the cycle decides which metric lies to you.** Near the peak: utilisation is high, discounts are low, per-unit EBITDA is at a record, trailing P/E is optically low, and capacity announcements are multiplying. That combination is a sell configuration, not a value one. Near the trough: utilisation is below breakeven, EPS is negative or negligible, P/E is meaningless, P/B is at a multi-year low, and product spend is being cut across the industry — historically the best risk/reward, and the point at which screens exclude the stock. Because sub-sectors do not share a cycle, locate each one separately: tractors on the monsoon and rural income cycle; CVs on freight rates, fleet utilisation and infrastructure spend; PVs on financing cost and household income; 2W on rural wages and entry-level affordability; tyres and aftermarket on parc age and replacement demand, which is far less cyclical than OE fitment.
|
||||
|
||||
**The capital cycle dominates the demand cycle.** Returns in autos are destroyed by capacity commissioned at the peak and made by capacity added at the trough. Track industry-wide announced capacity, not just the company's. A supply response takes 2–3 years to arrive, which is exactly long enough for it to land in the following downturn.
|
||||
|
||||
**Operating leverage sets the shape of the downside.** With roughly 25–35% fixed cost at plant level plus a fixed engineering and platform cost base, a 10% volume decline can compress EBITDA margin 200–350 bps and a 20% decline can take EBITDA negative within two quarters. Always model the downside from breakeven volume upward rather than by haircutting peak margin.
|
||||
|
||||
**Structural threats to score explicitly.** The powertrain transition strands ICE-specific content (exhaust, fuel systems, multi-speed transmissions, ICE castings and some machining) while EVs have far fewer moving parts, which reduces content opportunity for some suppliers and increases it for others (thermal management, power electronics, electronics content, lightweighting). Battery cell sourcing and chemistry choices are now a first-order competitive variable. Chinese OEM export expansion is compressing prices in emerging markets and Europe. Software-defined vehicles shift value toward electronics and software and away from mechanical content. Shared mobility, ride-hailing fleet purchasing and, further out, autonomy change ownership patterns and the aftermarket. Semiconductor and rare-earth/magnet supply chains have repeatedly proved capable of capping production irrespective of demand.
|
||||
|
||||
**Regulation is a direct earnings and multiple driver.** Emissions and fuel-economy regimes (EU CO2 targets and Euro 7, US CAFE/EPA and ZEV mandates, India's BS norms and CAFE-III), safety mandates (which add content and cost), scrappage policies (which create replacement demand), import tariffs and localisation requirements, and in India GST rate changes on vehicles, PLI schemes and FAME/state EV subsidies. Each of these can move a sub-sector's volumes and multiple within a quarter. Always check what regulatory change is in flight before extrapolating current volumes or margins — and separately, whether last year's volumes were inflated by a pre-buy ahead of one.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India | US / global |
|
||||
|---|---|---|
|
||||
| Volume data | Monthly company dispatch releases and SIAM data (wholesale); VAHAN portal for retail registrations; FADA for dealer retail and channel inventory commentary. The dispatch/registration gap is publicly computable every month — use it. | Monthly/quarterly OEM sales releases; days' supply and average transaction price / incentive data from industry trackers; EU registrations via ACEA; China via CAAM. Retail vs wholesale is less separable in some markets — use inventory days instead. |
|
||||
| Accounting | Ind-AS. Product development capitalisation is permitted and widely used — check the intangibles-under-development note and the amortisation policy. | IFRS peers capitalise similarly; **US GAAP requires R&D to be expensed**, so US OEMs and suppliers show structurally lower reported EBITDA margin for identical economics. This is the mandatory adjustment before any cross-border comparison. |
|
||||
| Filings and disclosure | Annual report with Schedule III financials, MD&A, related-party note and segment reporting; quarterly results with an investor presentation and analyst concall (treat concall Q&A on discounts, channel inventory, capacity and launches as a primary source); CARO 2020 auditor reporting on related-party loans, inventory verification, defaults and undisclosed income. | 10-K / 10-Q / 20-F on EDGAR, with automotive-vs-financial-services segment reporting already separated for the US majors; supplemental financial packages with regional EBIT, incentive and lease residual detail; European annual reports with industrial vs financial services split. |
|
||||
| Captive finance | Usually a separately listed or clearly identifiable NBFC subsidiary, RBI-regulated — often easier to carve out and value on P/B than in some global structures. | Segment reporting already splits automotive and financial services for US majors; European OEMs report an "industrial" vs "financial services" split. Use the company's own automotive net liquidity disclosure. |
|
||||
| Units and conventions | ₹ crore and lakh; fiscal year April–March; volumes usually in units per month; promoter holding and pledge data disclosed quarterly (BSE/NSE); ASP and discount often discussed in ₹ per unit on the concall. | $ / € millions; calendar fiscal year for most; volumes in thousands of units or annualised SAAR (US); ATP and incentive per unit in dollars. |
|
||||
| Ownership and governance | Promoter groups (family or MNC parent) dominate. Watch royalty/technical fee to the foreign parent, related-party purchases from promoter-owned suppliers, promoter pledging, and inter-corporate deposits within the group. | Widely held; the governance questions are executive compensation, capital return policy and activist pressure rather than related-party value transfer. Union contracts (UAW in the US, works councils in Germany) are a first-order cost and restructuring constraint largely absent in India. |
|
||||
| Legacy liabilities | Gratuity and limited defined-benefit obligations; generally small. | Pension and OPEB obligations can be very large at legacy US and European OEMs and materially change enterprise value; check the funded status, not just the P&L charge. |
|
||||
| Valuation convention | Consumer-franchise P/E multiples (20–40x) applied to net-cash, high-ROCE 2W/PV/tractor franchises in a low-penetration growth market; EV/EBITDA for CVs and components; P/B during CV downturns; SOTP for holdco structures. Direct valuation inputs include monsoon forecasts, rural sentiment, freight rates, infrastructure spend, and GST/PLI/FAME changes. | EV/EBITDA and P/B dominate; single-digit P/E on mass-market OEMs is structural, reflecting sub-cost-of-capital returns, legacy liabilities and cyclicality. Analysts focus on automotive FCF, industrial liquidity, incentive spend, days' supply and lease residual risk. Dividend and buyback capacity is assessed against automotive FCF only. |
|
||||
| Convention traps | Do not import "low P/E means cheap" from developed markets into India, and do not export India's high-ROCE persistence assumption — Indian ancillaries with 40–70% single-OEM dependence do not deserve franchise multiples. | Do not apply Indian growth-market multiples to a replacement market, and do not treat a 0.4x P/B mass-market OEM as a bargain without a returns-above-cost-of-capital argument. |
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Identify the sub-sector precisely (2W / PV / CV / tractor / Tier-1 / Tier-2 / tyre / battery / EV pure-play / dealer) and route the peer set accordingly.
|
||||
- [ ] Carve out the captive finance arm; restate net debt, FCF and leverage on an **automotive-only** basis and say so in the report.
|
||||
- [ ] Compare wholesale dispatches against retail registrations (India: SIAM vs VAHAN, plus FADA channel inventory; US: days' supply) for the last 8 quarters.
|
||||
- [ ] Compute EBITDA per vehicle and contribution per vehicle in absolute currency; track the trend and the gap to best-in-segment.
|
||||
- [ ] Compute net realisation and discount/incentive per unit; decompose ASP growth into price vs mix; check whether incentives are routed through the financier.
|
||||
- [ ] Pull R&D + product development as % of sales, the capitalisation ratio, the amortisation life, and capitalisation vs amortisation — adjust before any cross-regime margin comparison.
|
||||
- [ ] Compute (capex + capitalised development) / revenue and / D&A; judge across a full 4–6 year product cycle, never one year.
|
||||
- [ ] Estimate capacity utilisation and breakeven volume; model the downside from breakeven, not from a haircut to peak margin.
|
||||
- [ ] Compute mid-cycle ROIC on automotive capital employed — ex finance arm, ex surplus cash, with impairments added back — and compare to cost of capital.
|
||||
- [ ] Check working capital: inventory/receivable/payable days, direction of payable days, and any reverse factoring or channel financing disclosure.
|
||||
- [ ] Check warranty accrual rate vs claims paid vs provision balance, and list recall campaigns and their per-vehicle cost.
|
||||
- [ ] Components: get content per vehicle, booked lifetime business, book-to-bill, and the ICE vs powertrain-agnostic vs EV split of the order book.
|
||||
- [ ] Map customer, platform and geography concentration, and the aftermarket revenue share.
|
||||
- [ ] If there is a captive financier: penetration, NIM, credit cost, delinquency, tenor, LTV, leverage, lease residual assumptions — value it separately on P/B.
|
||||
- [ ] Strip regulatory credits, PLI/FAME/export incentives and treasury income out of segment profit and recompute margin and ROCE.
|
||||
- [ ] Assess model age, launch cadence and share of volumes from products under three years old; check whether share is being bought with discounts.
|
||||
- [ ] For components/tyres: judge on gross profit per unit against the input basket, not on OPM%; net off contractual annual price-downs.
|
||||
- [ ] State the demand driver explicitly (monsoon / freight / financing cost / parc age / export build rate) and where that specific cycle stands.
|
||||
- [ ] Value via SOTP: automotive on EV/EBITDA cross-checked with EV/EBIT, finance arm on P/B, listed stakes at market less a 20–40% holdco discount, less automotive net debt.
|
||||
- [ ] Normalise to mid-cycle volume × mid-cycle EBITDA per unit before applying any multiple; never anchor to trailing P/E on peak earnings.
|
||||
- [ ] Check for peak-cycle capacity announcements — company and industry-wide — and for serial "exceptional" items inflating subsequent ROCE.
|
||||
- [ ] India: read the related-party note, royalty/technical fee trend, promoter pledge, inter-corporate deposits and CARO observations.
|
||||
- [ ] State the regulatory changes in flight (emissions, GST, subsidies, tariffs) and whether the last year's volumes were inflated by a pre-buy.
|
||||
|
|
@ -0,0 +1,186 @@
|
|||
# Airlines, hotels, travel, restaurants and OTAs — sector playbook
|
||||
|
||||
Use this when: the company sells a perishable, time-bound unit of capacity or brokers someone else's — scheduled airlines and their MRO/cargo/loyalty arms, hotel owners and operators, restaurant and QSR chains, online travel agencies and travel aggregators, tour operators, cruise lines, airport and ground-handling concessions, and multiplex/leisure operators that share the same fixed-cost-plus-footfall economics.
|
||||
|
||||
Four structural facts govern everything below. **The unit of production expires** — an unsold seat or room-night at departure or midnight is gone forever, so pricing is dynamic, marginal cost is near zero and operating leverage is extreme in both directions. **Lease accounting has destroyed margin and leverage comparability** since IFRS 16 / Ind-AS 116, splitting the peer group into owners and lessees that no longer share a margin definition. **The dominant cost line is exogenous** — fuel for airlines, the RevPAR cycle for hotels — so margin is mostly not a skill signal. And **customers pay before they consume**, which inverts the working-capital and liquidity ratios in the generic checklist. Replace the ratio set; do not caveat it.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
**OPM / EBITDA margin — not comparable across companies, across periods, or against itself.** Since Ind-AS 116 (India, FY20 onward) and IFRS 16, operating lease rentals moved out of opex into depreciation plus finance cost. For a lessee-heavy carrier running a sale-and-leaseback fleet this mechanically lifted reported EBITDA margin by roughly 10–18 percentage points overnight with zero change in economics, while loading a large lease liability onto the balance sheet. So the margin series breaks pre- vs post-FY20; an owned-fleet legacy carrier is not comparable to a sale-and-leaseback LCC; and a hotel *owner* is not comparable to an operator running the same assets on long leases. The only margin that compares them is **EBITDAR** — before rent.
|
||||
|
||||
**OPM is also not a skill signal even within one company.** Fuel is roughly 30–45% of an airline's operating cost, worse in India where ATF carries state VAT of ~1–30% on top of central duties. A quarter in which OPM doubles almost always means crude fell or the currency strengthened, not that management improved. Hotels sit at the opposite pole: 55–70% of cost is fixed (payroll, energy, property tax, depreciation), so margin is close to a pure function of where RevPAR sits in the cycle. Ranking companies on OPM alone — the classic single-metric screen failure — will systematically rank the luckiest, not the best.
|
||||
|
||||
**D/E — inflated, undefined, or actively inverted.** Capitalised leases inflate the numerator for lessees. The denominator is frequently *negative*: carriers with accumulated losses and asset-light operators after years of buybacks both run negative net worth, and a negative denominator produces a negative D/E that screens as "no debt". This is the single most dangerous artefact in the sector. Use **adjusted net debt / EBITDAR** and nothing else.
|
||||
|
||||
**P/E and EPS — a cyclical trap sitting on top of non-operating noise.** These are high-operating-leverage cyclicals: earnings are negative for years at a time (the entire industry, FY21–FY22), so P/E is undefined; and at the cycle peak trailing P/E looks cheapest precisely when the stock should be sold. Worse, reported PAT routinely contains large non-cash and non-recurring items — mark-to-market on USD-denominated lease liabilities and maintenance provisions (a single currency move can swing a large carrier's PAT by hundreds of crore with no cash effect), sale-and-leaseback gains, OEM compensation for grounded aircraft, asset-sale gains at hotel companies, and deferred-tax-asset recognition on accumulated losses. P/E, ROE and EPS growth built on that PAT are noise, not signal.
|
||||
|
||||
**ROCE / ROE / P/B — distorted in both directions at once.** Hotel real estate sits at historical cost, often land acquired decades ago, so owned-portfolio book value can be a fraction of market value: P/B looks expensive and ROCE looks poor when the true asset value is a multiple of book. At the other extreme, asset-light operators and buyback-heavy carriers have small or negative equity, making ROE and ROCE infinite, negative or absurd. OTAs have essentially no operating assets, so ROCE is a meaningless number.
|
||||
|
||||
**Current ratio — inverted.** Airlines, hotels, OTAs and tour operators collect cash before delivering service, so unearned ticket revenue, advance deposits, vouchers and loyalty deferrals sit in current liabilities by design. A structurally healthy carrier runs a current ratio well below 1.0 — roughly 0.6–0.9 in good years. Applying the textbook ">1.5" rule flags the strongest operator in the peer set as distressed.
|
||||
|
||||
**FCF and cash conversion — flattered on the way up, collapsing on the way down.** The same negative working-capital cycle means a rapidly growing airline or OTA shows superb operating cash flow purely from float on advance bookings, even while destroying economic value; a shrinking one bleeds cash as that float unwinds, so FCF deteriorates fastest exactly when bookings decline. Add lumpy pre-delivery payments on aircraft orders, sale-and-leaseback proceeds parked in investing cash flow, and hotel renovation capex that is genuinely maintenance but is presented as growth, and headline FCF is close to uninterpretable without adjustment. Strip working-capital movement out of OCF before calling any of it free.
|
||||
|
||||
**P/S — misleading for OTAs specifically.** Platforms report *net* revenue (take rate) or *gross* revenue depending on principal-versus-agent conclusions under Ind-AS 115 / IFRS 15 / ASC 606. A 5x EV/Sales on net revenue can be 0.4x on gross bookings. Reconstruct GBV and take rate before any cross-company sales multiple.
|
||||
|
||||
**Any 3–5 year CAGR spanning FY20–FY22 is arithmetic garbage** — the pandemic zeroed the base, so a two-year revenue CAGR off FY21 can exceed 100% and means nothing. Anchor every growth series to FY19 or FY20 as the pre-COVID comparator and say so explicitly in the output.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, sub-sector, cycle stage, fuel and rate environment, and period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set and against the company's own multi-year history overrides every absolute band below. Tags: **[A]** airlines, **[H]** hotels, **[O]** OTAs and platforms, **[All]** cross-sector.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **RASK, CASK and CASK ex-fuel [A]** | Revenue and cost per Available Seat Kilometre — the unit revenue and unit cost of flying one seat one km. CASK ex-fuel strips the exogenous line. The **RASK-minus-CASK spread** is the profit engine. | Positive spread through a full cycle. Efficient Indian narrowbody LCCs have run RASK around ₹4.3–5.0 and CASK ₹4.0–4.6 per ASK in normal years, CASK ex-fuel ~₹2.6–3.2. US majors: RASM ~15–18 US cents, CASM-ex ~10–12 cents. The global ultra-low-cost floor is around EUR 0.035 CASK ex-fuel. | The only structural, cycle-neutral measure of airline competitiveness — airlines compete on cost per seat, not on margin. Track CASK ex-fuel over 8–12 quarters: falling with scale (denser configuration, higher utilisation, single fleet type) means genuine compounding advantage; drifting up means the advantage is eroding regardless of what OPM shows in a cheap-fuel quarter. |
|
||||
| **Passenger load factor and yield, read together [A]** | PLF = RPK ÷ ASK (share of available seats sold). Yield = passenger revenue ÷ RPK (average fare per km). Their product drives passenger RASK. | Indian domestic LCC 82–88% sustained; full-service and long-haul 78–84%; US/EU majors 82–86%. Below ~75% for a narrowbody LCC signals overcapacity or route errors; above ~92% usually means fares were left on the table. | PLF alone is a vanity metric — any airline can fill seats by cutting fares. The diagnostic is the trade-off: rising PLF with falling yield means the carrier is buying traffic; rising PLF with flat-to-rising yield is genuine demand. Watch PLF against industry ASK growth — when capacity growth outruns passenger growth, **yields break before load factors do**. |
|
||||
| **Aircraft utilisation and fleet composition [A]** | Revenue block hours per aircraft per day, plus fleet age, number of aircraft types, owned-vs-leased split, and grounded/AOG count. | Indian narrowbody LCC 11–13 block hours/day is strong; below 10 indicates groundings, MRO bottlenecks or network problems. Global LCC 11–12; long-haul widebody 13–16. One to two fleet types is optimal; four or more is a structural cost penalty. | Utilisation is the single biggest lever on CASK — a grounded aircraft carries lease rent, insurance and crew cost with zero ASK. Engine-reliability episodes that ground a large share of a fleet are the mechanism by which viable Indian carriers have become insolvent. Always reconcile balance-sheet fleet count against aircraft actually in revenue service in the investor deck. |
|
||||
| **Ancillary revenue per passenger and mix [A]** | Non-ticket revenue per departing passenger — seat selection, baggage, cargo/belly freight, onboard sales, change fees, co-brand card and loyalty monetisation — and its share of total revenue. | Global LCC leaders USD 20–45 per passenger, 25–35%+ of revenue. Indian carriers materially lower, roughly ₹400–900 per passenger and ~12–18% of revenue, capped by unbundling rules and price sensitivity; cargo is a bigger swing factor in India. | High-margin, far less price-elastic than base fares, and structurally rising — the main reason two carriers with identical yields have very different profitability, and the most durable earnings stream through a fare war. In developed markets, loyalty cash flows (co-brand card sales to banks) can be worth more than the flying operation itself. |
|
||||
| **Fuel exposure: fuel cost per ASK, hedge ratio, pass-through lag [A]** | Fuel cost ÷ ASK; percentage of next 12 months' consumption hedged and at what structure; historical lag between a crude/ATF move and the fare response; sensitivity of PAT to a USD 10/bbl and ₹1/USD move. | Indian carriers hedge little or not at all (no deep ATF hedging market) — assume near-full spot exposure. Global carriers hedge 0–60%. Fare pass-through typically lags 1–2 quarters, longer where capacity is oversupplied. | Isolates the exogenous component of the margin so the remainder can be attributed to management. Also the correct way to build the mid-cycle case: normalise fuel and currency to a long-run level, then ask whether the airline still clears its cost of capital. A carrier whose profitability exists only in a cheap-fuel window is not a compounder. |
|
||||
| **EBITDAR and EBITDAR margin [A][H]** | Earnings before interest, tax, depreciation, amortisation **and rent/lease expense**. Rebuild by adding lease-related depreciation and lease finance cost back to reported EBIT, or by using pre-Ind-AS-116 rentals where disclosed. | Airlines 18–25% is strong for an efficient LCC in a normal fuel environment; sustained below ~10% through a cycle indicates structural unprofitability. Hotels 30–40% at corporate level for Indian branded owners in an up-cycle; asset-light fee businesses 60–75%. | The **only** margin that compares a company leasing its assets with one owning them — the central comparability problem in this sector. It is also what lessors, rating agencies, credit committees and M&A buyers actually underwrite against. Use EBITDAR margin, never OPM, for cross-company ranking. |
|
||||
| **Adjusted net debt / EBITDAR and liquidity months [A][H]** | (Gross debt + capitalised lease liability + maintenance/redelivery provisions + unfunded pension − cash and liquid investments) ÷ EBITDAR. Where leases are not capitalised, proxy the liability at 7–8x annual rent. Liquidity months = (cash + undrawn lines) ÷ average monthly cash operating cost. | Airlines: below ~3.5x is investment-grade-like, 4–5x stretched, above ~6x pre-distress. Cash at least 15–25% of trailing-twelve-month revenue, or 4–6 months of operating cost. Hotels: net debt/EBITDA below 3x for owners, below 1x for asset-light operators. | Replaces D/E entirely, which is undefined or perverse here. It is also the ratio that actually predicts failure: every large airline collapse of the last two decades showed deteriorating adjusted leverage and collapsing liquidity months well before the reported loss made headlines. An airline with under two months of liquidity is a going-concern question, not a valuation question. |
|
||||
| **RevPAR, decomposed into ARR and occupancy [H]** | Revenue per Available Room = Average Room Rate × Occupancy, computed on **all** available room-nights including unsold ones. Always demand like-for-like/same-store. | Indian branded occupancy of 65–72% is a healthy market; luxury ARR roughly ₹12,000–20,000+, upscale ₹6,000–9,000, mid-scale/economy ₹3,000–5,000. US upper-upscale occupancy 70–75%. Market occupancy above ~75% signals ARR has room to run. | The sector's fundamental unit metric, but the **decomposition** is the analysis. RevPAR growth driven by ARR flows to EBITDA at 60–80% incremental margin because the room is already staffed and lit; growth driven by occupancy flows at only 40–55% because of variable cost per occupied room. Identical RevPAR growth, very different earnings outcomes. Reported growth including newly opened or acquired keys tells you nothing about pricing power. |
|
||||
| **RevPAR index: RGI, MPI, ARI vs competitive set [H]** | Market-share indices (STR/HotStats): RGI = own RevPAR ÷ comp-set RevPAR × 100; MPI is the occupancy version, ARI the rate version. | RGI above 100 means more than fair share; 110–125 is a genuinely strong brand or asset. Sustained sub-100 for a luxury asset indicates brand or product decay. | Separates cycle from skill. A post-shock demand-supply squeeze lifts every operator's RevPAR and flatters all of them equally; RGI strips the cycle and shows actual outperformance. It is the hotel equivalent of alpha versus beta, and it is what owners use when deciding whether to renew or fire a management company. |
|
||||
| **Demand growth vs forward supply pipeline, at micro-market level [A][H]** | Forward branded room supply CAGR against expected demand CAGR **by city/micro-market**, not nationally; and the company's own pipeline as a percentage of operating keys. For airlines, the equivalent is industry order book and ASK growth against passenger growth. | India has run branded supply at ~6–8% CAGR against demand at ~9–11% — a favourable window. Any market where supply growth exceeds demand growth for two consecutive years is entering a pricing downcycle. Company pipeline of 25–50% of operating keys is healthy; above ~80% is execution risk. | Profitability here is dominated by the industry supply-demand balance, not by company execution — a well-run hotel in an oversupplied market earns less than a mediocre one in a tight market. Because a hotel takes 3–5 years to build and aircraft order books are visible years ahead, **supply is one of the few genuinely forecastable variables in equity analysis**, and it appears nowhere on a generic checklist. |
|
||||
| **GOPPAR, GOP margin and incremental flow-through [H]** | Gross Operating Profit per Available Room — property-level profit after departmental and undistributed costs, before rent, property tax, insurance, D&A and management fees. Flow-through = incremental EBITDA ÷ incremental revenue. | GOP margin 38–48% at property level is strong for Indian owned hotels; 30–35% average. Flow-through of 55–70% on incremental revenue in an up-cycle is the benchmark; below ~45% means cost inflation is eating the cycle. | GOPPAR is the true measure of operating skill because it isolates what the *operator* controls (rate, mix, labour productivity, energy) from what the *owner* controls (capital structure, rent, land cost). Flow-through is the operating-leverage test: converting under half of incremental revenue into EBITDA in a rising market means a cost or wage problem that will be brutally exposed when RevPAR turns. |
|
||||
| **Asset-light mix: managed/franchised keys and fee revenue share [H]** | Share of total keys managed or franchised rather than owned/leased; management and franchise fee income as a % of revenue **and** of EBITDA. Fees are typically a base fee of 2–4% of revenue plus an incentive fee of 6–10% of GOP. | Global brand operators are 95%+ asset-light. Indian players are mid-transition: fee income at 15–25% of revenue but 25–40% of EBITDA is typical, with managed keys becoming the majority of the pipeline. | Determines the multiple the market will pay, and explains why consolidated ROCE fails here. Fee income needs near-zero capital, is contractually sticky (10–30 year contracts) and is far less cyclical than owned EBITDA — it deserves a 25–35x EBITDA multiple where owned-hotel EBITDA deserves 12–16x. A company with flat consolidated ROCE can be radically improving its economics if the mix is shifting. **Analyse owned and managed segments separately or you will misprice the business.** |
|
||||
| **Non-room revenue mix: F&B, banqueting, weddings, MICE [H]** | Share of hotel revenue from food and beverage, banqueting, weddings and other non-room sources; ideally also per available room. | Indian hotels: 40–50% of revenue from F&B and banqueting is normal and structural. Global upscale: 25–30%. Indian wedding and MICE concentration makes Oct–Dec and Jan–Mar seasonally dominant. | A genuine India-versus-developed-market divergence that breaks cross-border comparison. Indian hotel companies will always look lower-margin than US peers because F&B carries 20–30% margins against 70%+ for rooms — but that F&B business is real-estate-light, brand-driven and annuity-like. Judging an Indian owner-operator on a global brand manager's margin structure is a category error. |
|
||||
| **Deferred revenue / forward bookings and the negative working-capital cycle [All]** | Unearned ticket revenue, advance room deposits, loyalty deferrals and travel credits/vouchers held as current liabilities — tracked as days of revenue, and as a trend **against the cash balance**. | A healthy growing airline runs materially negative working capital with forward sales of 30–60 days of revenue and a current ratio of 0.6–0.9. Critical test: cash grows at least in line with deferred revenue. | The sector's most misread line. Rising unearned revenue is normally a leading demand indicator — but rising unearned revenue *with falling cash* means customer float is funding operating losses, the precise failure signature of every large airline and tour-operator collapse. It is also why FCF must be adjusted. In a downturn the float unwinds while refunds come due simultaneously, turning a P&L problem into insolvency inside one quarter. |
|
||||
| **OTA economics: gross bookings, take rate, contribution margin after marketing [O]** | Gross Booking Value through the platform; take rate = net revenue ÷ GBV; contribution margin after direct marketing and customer incentives. Plus repeat-customer rate, direct/app traffic share vs paid, and CAC payback. | Take rates 10–16% for hotel-led models, 4–8% for air-heavy models (air commissions are thin). Adjusted EBITDA margin on net revenue of 20–30% is good for an Indian OTA; global leaders run 35%+. Direct/organic traffic above ~60% is a durable moat; below ~40% means demand is being rented from search engines. | P/S on reported net revenue is meaningless because revenue definitions differ by company under principal-versus-agent rules. GBV plus take rate makes them comparable and reveals whether growth is volume or mix. The marketing line is the real test: an OTA growing GBV 30% while marketing grows 45% has no business model, only a subsidy — and discount-led share wars have repeatedly destroyed Indian OTA profitability. |
|
||||
| **Lease-adjusted ROIC vs WACC, cycle-averaged [All]** | NOPAT ÷ (net fixed assets + capitalised lease liability + working capital + capitalised maintenance reserves), averaged across **at least 7–10 years spanning one full up- and down-cycle**. | The global airline industry has historically averaged ROIC of ~4–7% against a WACC of 8–9% — structurally value-destroying, with only a handful of ultra-low-cost operators clearing the bar. Indian branded hotel owners earn 12–18% ROCE on owned assets in an up-cycle; asset-light fee businesses 40%+. Demand 10%+ mid-cycle lease-adjusted ROIC. | Single-year ROCE here tells you where you are in the cycle, not whether the business creates value — peak 25% and trough −10% average to capital destruction. Cycle-averaged, lease-adjusted ROIC is the honest test and explains why this sector has consumed enormous capital for negligible aggregate shareholder return. For Indian hotel owners, also present ROCE on **revalued** property, since historic-cost land overstates the reported figure relative to a new entrant's economics. |
|
||||
|
||||
### Restaurants and QSR chains — the additional metric set
|
||||
|
||||
Restaurant chains share the fixed-cost-plus-footfall structure but need their own KPIs; do not analyse them with hotel or airline metrics.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Same-store sales growth (SSSG) and its decomposition** | Sales growth for stores open through both comparable periods, split into **transactions (footfall) vs average ticket/price**. | Low-to-mid single digits is normal in a mature system; India expects mid-to-high single digits in a growth phase. Negative transaction growth masked by price increases is the warning state. | Total revenue growth in a chain is mostly new-store arithmetic and says nothing about brand health. SSSG driven by price is borrowed from the future — it eventually breaks footfall. This is the sector's like-for-like discipline, exactly parallel to same-store RevPAR. |
|
||||
| **Average daily sales (ADS) per store and sales per square foot** | Gross store revenue ÷ operating days ÷ stores; and revenue per sq ft of trading area. | New-format stores should reach mature ADS within 12–18 months. Declining system ADS while store count grows is cannibalisation or format fatigue. | The direct productivity measure of the asset, and the input to store-level payback. Rising store count with falling ADS is value-destroying expansion. |
|
||||
| **Restaurant operating margin (store-level EBITDA, pre-Ind-AS-116)** | Store revenue less COGS, store payroll, rent (on a pre-lease-capitalisation basis), utilities and store overheads — before corporate costs and D&A. | 15–22% is healthy for Indian QSR at store level; below ~12% leaves nothing after corporate cost. Report pre- and post-Ind-AS-116 to stay comparable. | Corporate EBITDA blends store economics with head-office leverage and, post-Ind-AS-116, with rent capitalisation. Store-level margin is the only clean read on unit economics — and rent as a % of sales (ideally 6–10%) is the line that kills chains in a weak-demand year. |
|
||||
| **Capex per store and cash payback period** | Fit-out plus equipment plus pre-opening cost per new store, divided by annual store-level cash profit at maturity. | 2.5–4 years payback is good for Indian QSR; beyond ~5 years the growth is value-neutral at best. | Store rollout is the entire capital allocation decision in this sector. A chain expanding at a payback longer than its lease term or refurbishment cycle is compounding backwards, however fast revenue grows. |
|
||||
| **Delivery / dine-in / takeaway mix and aggregator dependence** | Channel split of revenue, plus commission paid to delivery aggregators as a % of delivery revenue and own-app share of delivery orders. | Aggregator commissions of 18–25% of order value are typical in India. Own-app share above ~30% of delivery is a meaningful margin and data advantage. | Delivery revenue carries structurally lower margin and rents a customer relationship from a platform. A chain whose growth is entirely aggregator-led has weaker pricing power and a third party sitting between it and its customer — the restaurant analogue of an OTA's paid-traffic dependence. |
|
||||
| **Store closures, churn and net new additions** | Gross openings, gross closures, and the closure rate as a % of the base; plus the age profile of the estate. | Closure rates above ~3–5% p.a. in a growth chain signal poor site selection. Watch for closures netted silently against openings. | Chains headline net additions. Gross closures reveal underwriting quality and the true survival curve of a cohort — and pre-empt the write-off cycle. |
|
||||
| **Raw-material basket and menu pricing power** | COGS as a % of sales and the specific commodity basket (wheat, dairy/cheese, chicken, edible oil, coffee); the lag and magnitude of menu price increases. | Indian QSR gross margins run roughly 65–70%; a 200–300 bps COGS swing on a dairy or protein spike is normal. | The pass-through test: a brand that can raise menu prices without losing transactions has real equity; one that absorbs input inflation to protect footfall does not. This is measurable directly from SSSG decomposition. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
**Airlines and asset-heavy hotels — EV/EBITDAR is the primary cross-company multiple.** Define enterprise value as market cap + gross debt + capitalised lease liability (or 7–8x annual rent where leases sit off balance sheet) + maintenance/redelivery provisions + unfunded pension − cash and liquid investments, over EBITDAR. This is the only construction that treats an owned aircraft and a leased aircraft identically, and it is what lessors, credit committees and M&A buyers use. Indicative bands: global LCCs 4–6x, legacy carriers 3–5x, best-in-class LCCs with structural cost advantage and dominant share have traded 6–9x. **P/E must never be the anchor multiple for an airline.**
|
||||
|
||||
**Hotels — run three methods and triangulate.**
|
||||
|
||||
1. *EV/EBITDA, computed separately on the owned/leased portfolio and on the fee business.* Indian branded owners have traded roughly 15–25x forward EV/EBITDA in an up-cycle against 10–14x in normal times; fee/management income justifiably carries 25–35x because it is capital-free and contract-protected. Blending the two into one multiple systematically misvalues any company mid-transition to asset-light — this is the core valuation argument in most Indian hospitality names today.
|
||||
2. *EV per key versus replacement cost.* Value the portfolio at market development cost per key by segment — roughly ₹2.0–4.0 crore per key for luxury in India, ₹0.8–1.5 crore upscale, ₹0.4–0.7 crore mid-scale/economy; USD 300k–1m per key for US upper-upscale. If the market values the company below the cost of building the same portfolio, downside is anchored; well above, the market is capitalising the cycle. This is the sector's P/B substitute and it works precisely where P/B fails, because it uses replacement value rather than depreciated historic cost.
|
||||
3. *SOTP / NAV.* Apply a cap rate to stabilised property NOI, then add separately valued fee income, land bank, commercial real-estate annuity and listed subsidiary stakes. Cap rates of 7–9% are typical for Indian hospitality assets, 5–7% in developed markets. This is the correct primary method for any owner whose book value bears no relationship to asset value. India has no hotel REIT regime comparable to the US, so FFO/AFFO is generally not used for Indian operators; for **US hotel REITs**, FFO/AFFO, EBITDA per key and implied cap rate remain the primary lens.
|
||||
|
||||
**OTAs and asset-light platforms** — use EV/gross bookings (typically 0.3–1.5x), EV/net revenue, and EV/adjusted EBITDA once profitable, cross-checked against a DCF driven by take rate, contribution margin and repeat rate. Never use ROCE or P/B. Because reporting differs under principal-versus-agent rules, the **GBV-plus-take-rate reconstruction is mandatory** before any comparison.
|
||||
|
||||
**Restaurant chains** — EV/EBITDA on a pre-Ind-AS-116 basis (or EV/EBITDAR) for comparability across owned, leased and franchised estates, cross-checked against a store-economics build: mature ADS × store-level margin × store count, less corporate cost, with new-store NPV at the observed payback. P/E is usable only for a mature, low-growth, franchised system.
|
||||
|
||||
**Apply mid-cycle normalisation to everything.** Because operating leverage is extreme, value on **mid-cycle EBITDAR** — an average over a full cycle, or an explicitly modelled normal-fuel, normal-RevPAR year — never on trailing twelve months. Then invert the classic reading of the multiple: a low trailing P/E or low EV/EBITDA at peak margins is a sell signal; a high or negative one at trough margins is often the entry point. Buying at 6x trailing EV/EBITDA on peak RevPAR or a peak fuel spread is the single most common way investors lose money in this sector.
|
||||
|
||||
**Value hidden assets separately.** Airline loyalty programmes, cargo divisions, MRO subsidiaries, ground-handling arms and owned airport slots are frequently worth more than the flying operation and are invisible in a consolidated multiple. Slot portfolios at capacity-constrained hubs, co-brand card contracts, and land under hotel properties all merit standalone valuation. Finally, sanity-check equity value against liquidity: for any airline with under six months of liquidity, the correct framework is a **probability-weighted scenario including dilution or restructuring**, not a multiple.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares business model, asset ownership mode, lease treatment, cycle position and regulatory market. Get any one of these wrong and the table is worse than no table.
|
||||
|
||||
**Splits that must never be mixed:**
|
||||
|
||||
- **Airlines: LCC vs full-service vs regional vs charter/cargo.** Different cost bases, distribution, ancillary potential and yield curves. Also split **short-haul narrowbody vs long-haul widebody** — utilisation, turn times and load-factor norms differ structurally.
|
||||
- **Airlines: owned-fleet vs sale-and-leaseback.** Even on EBITDAR these differ in residual-value risk and capital intensity; note the split explicitly alongside the multiple.
|
||||
- **Hotels: owner vs lessee vs manager/franchisor.** Three different businesses — a property investor, a leveraged operating-lease bet, and a royalty stream. Never rank them on the same margin or ROCE. Companies mid-transition must be segment-split before comparison.
|
||||
- **Hotels: by chain scale.** Luxury, upper-upscale, upscale, mid-scale, economy and long-stay have different ARR, occupancy stability, F&B share and cap rates. A luxury-heavy portfolio's lower occupancy is not a weakness.
|
||||
- **Hotels: by micro-market.** Business-district, airport, leisure/resort and pilgrimage assets have different seasonality, weekday/weekend curves and supply pipelines. Aggregate national RevPAR conceals it.
|
||||
- **OTAs: air-led vs hotel-led vs experiences vs corporate travel.** Take rates differ by 2–3x, so a blended peer table on take rate or EV/sales is meaningless. Split also by **principal vs agent** revenue recognition.
|
||||
- **Restaurants: QSR vs casual dining vs cafés vs cloud kitchens**, and **franchisee-operator vs brand-owner**. An Indian master-franchisee pays royalties and cannot set the brand's strategy; it is not comparable to the brand owner it licenses from.
|
||||
- **Cruise, tour operators and travel-adjacent** — do not fold into hotels or airlines; capital intensity and deposit float structures differ.
|
||||
|
||||
**Additional gates:** same lease-accounting regime and the same post-Ind-AS-116/IFRS-16 period; same cycle stage (never compare a company at trough RevPAR to a peer at peak); comparable state-tax and route-rights environment for airlines; and consistent consolidation treatment of JVs, associates and managed-hotel gross revenue. State exclusions and the reason for each in the output.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Sale-and-leaseback gains dressed as operating profit.** SLB gains booked in other income, or netted against costs, can convert an operating loss into reported profit. Test: strip other income entirely and recompute EBITDAR margin. If profitability depends on selling aircraft, the airline is monetising its balance sheet, not earning. Under Ind-AS 116 only the portion of the gain relating to rights transferred is recognisable — aggressive interpretation here is a recurring audit issue.
|
||||
- **OEM and manufacturer credits netted against costs.** Compensation for grounded aircraft, credit memos on new orders and delivery incentives are frequently netted into maintenance cost or other income rather than disclosed separately. They flatter CASK and margin, are non-recurring, and vanish when the dispute settles. Always ask what CASK ex-fuel looks like *before* credits.
|
||||
- **Payables stretching and statutory dues in arrears.** In India the earliest and most reliable distress signal is not the P&L — it is delayed TDS, PF and GST payments and unpaid airport/AAI/oil-company dues, alongside ballooning trade payable days. Every major Indian airline failure showed this first. Read the auditor's report, the **CARO annexure on statutory dues**, and any emphasis-of-matter or going-concern paragraph before opening the investor presentation.
|
||||
- **Unearned revenue rising while cash falls.** Customer float funding operating losses. This is what converts a troubled carrier or tour operator into an insolvent one within a quarter: bookings slow, the float unwinds, and refunds fall due simultaneously. Also size unredeemed vouchers and travel credits — unfunded liabilities that crystallise at the worst possible moment.
|
||||
- **Under-provisioned maintenance and aircraft redelivery obligations.** Leased aircraft must be returned in a contractually specified condition, requiring costly engine and airframe checks. Accrual conservatism varies enormously. A young leased fleet with unusually low maintenance provisions is deferring a large cash cost — compare provision per aircraft against peers. The hotel analogue is the **FF&E reserve**: a genuine reserve is 4–5% of revenue, and its absence means deferred renovation.
|
||||
- **RevPAR or ARR growth that is mix, not pricing.** ARR rises automatically when a company opens luxury keys, closes economy keys or acquires upscale assets. Insist on like-for-like RevPAR and check RGI against the comp set. Equally, "system-wide revenue" or "gross revenue of managed hotels" is **not the company's revenue** — operators headline it and it can be 4–8x consolidated revenue.
|
||||
- **Renovation capex misclassified as growth capex.** Hotels need soft refurbishment every 6–8 years and hard refurbishment every 12–15. Booking it as expansion overstates maintenance-adjusted FCF and understates capital intensity. Cross-check: near-zero capex per existing key while the portfolio ages means a large deferred bill, and it shows up as RGI erosion before it shows up in the accounts.
|
||||
- **Custom, non-GAAP "adjusted EBITDA" definitions.** Watch for EBITDA presented pre-Ind-AS-116, before ESOP cost, before one-offs, or with lease rentals selectively added back — and for the definition changing between quarters. Rebuild EBITDAR yourself from the statutory statements. Any company whose adjusted metric flatters results by more than ~15% with an unstable definition deserves a discount.
|
||||
- **Forex MTM and deferred tax assets inflating PAT.** Carriers with USD-denominated lease liabilities and maintenance provisions report large non-cash forex gains when the rupee strengthens; separately, recognising a deferred tax asset on accumulated losses creates a one-time PAT boost with no cash counterpart. Both make trailing P/E and EPS growth meaningless. Model cash profit before FX and DTA.
|
||||
- **Negative net worth presented as capital efficiency.** For a buyback-driven asset-light operator this can be benign; for an airline it is a solvency issue that D/E actively conceals by turning negative. Compute adjusted net debt/EBITDAR instead, and establish whether the negative equity came from buybacks or from accumulated losses — the distinction is everything.
|
||||
- **Aggressive loyalty breakage assumptions.** Loyalty programmes recognise revenue using estimated redemption rates. Raising assumed breakage releases deferred revenue straight to the P&L with no economic event. Check the accounting policy note year on year and be sceptical of margin improvement concentrated in the loyalty segment.
|
||||
- **Capacity expansion into a deteriorating supply-demand balance.** Order books and hotel pipelines are visible years ahead. A carrier inducting aircraft into an oversupplied market, or an operator opening keys where supply growth exceeds demand growth, is committing capital to a yield decline. Watch aggregate industry ASK growth against passenger growth and city-level room pipelines — the equity market usually reacts about a year late.
|
||||
- **Grounded aircraft not reconciled to reported fleet.** Companies report fleet size; what matters is aircraft in revenue service. A widening gap means ownership cost with no ASK, crushing CASK while headline fleet growth looks healthy. Cross-check regulator (DGCA) in-service counts against company disclosure.
|
||||
- **Related-party management contracts, promoter pledging and asset transfers.** In Indian hospitality, hotels are often owned by promoter-affiliated entities and managed by the listed company, or the reverse, with fee terms set off-market. Scrutinise the related-party note for management fees, lease rentals and asset purchases. High promoter pledging in a cyclical, leveraged business compounds risk — a downcycle triggers margin calls exactly when the equity is cheapest.
|
||||
- **Interest capitalisation during long hotel construction.** A hotel takes 3–5 years to build, with interest capitalised into the asset rather than expensed — inflating profit and assets during the build and depressing returns afterwards. A large capital-work-in-progress balance relative to gross block means profit reported today will be paid for in depreciation and interest later. Compute interest coverage on **total**, not expensed, interest.
|
||||
- **OTA customer-acquisition subsidy disguised as revenue growth.** Incentives and discounts may be recorded as a reduction of revenue (correct under Ind-AS 115) or as marketing expense, and companies switch presentation. Compare GBV growth against marketing plus incentives combined; if the latter grows faster, the growth is purchased. Falling direct/app traffic share alongside rising paid-search spend is the same disease in a different metric.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Position in the cycle is the dominant variable, and it must be stated explicitly.** Airline profitability is a function of the industry capacity cycle interacting with fuel; hotel profitability is a function of the room-supply cycle interacting with GDP and corporate travel budgets. Both are amplified by operating leverage, so the swing from trough to peak margin is far wider than the swing in demand. Never present a valuation without naming where in the cycle the trailing numbers sit, and never extrapolate peak flow-through.
|
||||
|
||||
**The supply side is forecastable and the demand side is not.** Aircraft order books, delivery schedules, engine availability and city-level hotel pipelines are published years ahead. Build the supply picture first; it constrains pricing regardless of demand narrative. Aircraft delivery delays and engine reliability problems have recently acted as an *involuntary* supply constraint that propped up yields — a benefit that reverses when the backlog clears, so do not capitalise it.
|
||||
|
||||
**Structural threats to model explicitly.** Video conferencing has permanently reduced some corporate travel demand, hitting full-service carriers and business-district hotels hardest. Alternative accommodation platforms compress the low end of hotel pricing power in leisure markets. Aggregators and metasearch continue to disintermediate direct booking, raising customer-acquisition cost across airlines, hotels and restaurants alike. Decarbonisation is a rising cost: EU ETS and CORSIA obligations, SAF blending mandates in Europe and elsewhere, and potential carbon pricing add cost per ASK that cannot be avoided by efficiency alone. Airport charges and slot scarcity at constrained hubs are a rising rent extracted from carriers.
|
||||
|
||||
**Consolidation is the sector's only reliable margin mechanism.** Airline returns improve durably only when capacity leaves — through failures, mergers or capacity discipline. A market with a distressed marginal player pricing below cost is a market where nobody earns their cost of capital. Conversely, a market that has just consolidated into two or three disciplined players can sustain returns for years. Assess the competitive structure before assessing the company.
|
||||
|
||||
**Regulation shapes the economics directly.** Airlines face route-rights and bilateral regimes, slot allocation, foreign-ownership caps, safety oversight, and consumer-compensation regimes (EU261 in Europe, DGCA passenger-rights rules in India) that create real liabilities. Hotels face licensing, liquor permits, fire and environmental clearance, and coastal-zone rules that determine how fast supply can be added. Restaurants face food-safety regulation and, in India, the GST rate structure on restaurant services and the input-tax-credit position, which materially changes effective margin.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India | US / global |
|
||||
|---|---|---|
|
||||
| Regulator / oversight | DGCA (safety, slots, fleet in-service counts), MoCA policy, AAI and private airport operators for charges, BCAS security; hotel classification via the Ministry of Tourism; FSSAI for restaurants | FAA/DOT (US), EASA/national CAAs (EU); slot coordination by IATA-designated coordinators; consumer regimes such as EU261 and DOT rules create quantified liabilities |
|
||||
| Accounting | Ind-AS 116 from FY20 — **breaks the pre-FY20 margin and leverage series**; Ind-AS 115 for principal-vs-agent at OTAs; Ind-AS 21 forces large non-cash FX MTM on USD lease liabilities | IFRS 16 from 2019, ASC 842 in the US (operating leases stay in opex under US GAAP — so a US carrier's EBITDA is *not* directly comparable to an IFRS carrier's; EBITDAR reconciles them) |
|
||||
| Fuel and taxes | ATF carries state VAT of ~1–30% on top of central duties, so identical routes have different fuel cost by departure state; almost no hedging market, so near-full spot exposure | Jet fuel taxed more uniformly; deep hedging markets available; hedge ratios of 0–60% are a real policy choice and must be disclosed |
|
||||
| Cost and currency exposure | Revenue largely in ₹, but leases, maintenance, fuel and aircraft purchases largely USD-linked — a structural short-USD mismatch that dominates reported PAT | Better natural hedging for US carriers; European carriers carry USD fuel/aircraft exposure against EUR revenue and typically hedge it |
|
||||
| Units and reporting | ₹ crore/lakh; fiscal year April–March; ARR and RevPAR quoted per room-night in ₹; ASK/RPK in millions; **quarterly seasonality: Oct–Mar strong for hotels (weddings, MICE, leisure), Q1 monsoon-weak for both hotels and airlines** | USD millions; calendar year typical; RevPAR and ADR in USD; RASM/CASM in US cents per ASM (miles, not kilometres) — **never mix ASK and ASM without converting** |
|
||||
| Disclosure venue | Quarterly investor presentation plus the **concall** — the primary source for CASK ex-fuel, fleet in service, same-store RevPAR, pipeline keys and store-level economics; annual report notes for lease liabilities and maintenance provisions; CARO 2020 on statutory dues and defaults | 10-K/10-Q on EDGAR plus monthly traffic releases and an investor supplemental; hotel REITs publish property-level and same-store detail; airlines publish monthly capacity and load-factor data |
|
||||
| Ownership and governance | Promoter holding is central — check pledging, promoter-owned hotel-owning entities managed by the listed company, and related-party fee terms; SEBI related-party approval rules apply | Widely held; governance axis is board independence and management incentive design; franchisor-franchisee conflicts are the analogous related-party issue |
|
||||
| Hotel structure | Owner-operator model still dominant, transitioning to managed/franchised; F&B and banqueting 40–50% of revenue; no hotel REIT regime, so SOTP/NAV is the standard lens | Brand-manager model dominant with owners separated out; F&B 25–30%; deep hotel REIT market (FFO/AFFO, EBITDA per key, implied cap rate) and observable transaction cap rates |
|
||||
| Ancillary and unbundling | Unbundling constrained by regulation and high price sensitivity — ancillary per passenger materially lower; cargo/belly freight a bigger contributor; loyalty monetisation still immature | Ancillary and loyalty highly developed; co-brand card economics can exceed the value of the flying operation; unbundling largely unrestricted |
|
||||
| Restaurants | GST rate structure on restaurant services and the input-tax-credit position materially change effective margin; aggregator commissions 18–25%; master-franchisee model common on NSE/BSE | Franchisor royalty models dominate; unit economics disclosed as AUV and restaurant-level margin; delivery aggregator penetration and commissions vary by market |
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Classify first: airline (LCC/FSC), hotel owner, hotel operator/franchisor, OTA, restaurant chain or hybrid — and split hybrids into segments before any multiple.
|
||||
- [ ] Delete OPM, D/E, P/E, ROE, P/B, current ratio and headline FCF from the analysis; state in the output why each is inapplicable rather than reporting it with a caveat.
|
||||
- [ ] Rebuild **EBITDAR** from the statutory statements and use EBITDAR margin for every cross-company margin comparison.
|
||||
- [ ] Compute **adjusted net debt / EBITDAR** (debt + capitalised leases + maintenance/redelivery provisions + unfunded pension − cash) and **liquidity months**; treat under two months of liquidity as a going-concern question.
|
||||
- [ ] Confirm the lease-accounting regime and period for every peer; never compare pre-FY20 to post-FY20 margins, or IFRS 16 to US GAAP ASC 842 EBITDA, without reconciling to EBITDAR.
|
||||
- [ ] Anchor all growth series to FY19/FY20; discard any CAGR whose base falls in FY21–FY22 and say so.
|
||||
- [ ] Airline: build the RASK–CASK spread and track **CASK ex-fuel over 8–12 quarters**; ask what it looks like before OEM credits.
|
||||
- [ ] Airline: read PLF against yield, and PLF against industry ASK growth — rising loads with falling yield is bought traffic.
|
||||
- [ ] Airline: reconcile balance-sheet fleet against aircraft **in revenue service**; check block hours/day, fleet age and number of types.
|
||||
- [ ] Airline: quantify ancillary revenue per passenger and its trend; value loyalty and cargo separately in SOTP.
|
||||
- [ ] Airline: normalise fuel and currency to mid-cycle and re-test whether the business clears its cost of capital.
|
||||
- [ ] Hotel: demand **like-for-like RevPAR**, decompose it into ARR vs occupancy, and compute incremental flow-through.
|
||||
- [ ] Hotel: pull RGI/MPI/ARI against the competitive set to separate cycle from skill.
|
||||
- [ ] Hotel: split owned/leased EBITDA from fee EBITDA and value each on its own multiple; never blend them.
|
||||
- [ ] Hotel: check GOP margin and GOPPAR; verify an FF&E reserve of ~4–5% of revenue and capex per existing key.
|
||||
- [ ] Hotel: build the **micro-market supply pipeline vs demand growth** for the company's key cities; flag any market with two consecutive years of supply outrunning demand.
|
||||
- [ ] Hotel: confirm whether headline revenue is consolidated or "system-wide" gross revenue of managed hotels.
|
||||
- [ ] OTA: reconstruct **GBV and take rate**; compare GBV growth against marketing plus incentives; check direct/app traffic share and repeat rate.
|
||||
- [ ] Restaurant: decompose SSSG into transactions vs price; check ADS, store-level margin pre-Ind-AS-116, capex payback, gross closures and aggregator dependence.
|
||||
- [ ] Track unearned revenue and vouchers as days of revenue **against the cash balance** — rising float with falling cash is the pre-insolvency signature.
|
||||
- [ ] Strip working-capital movement, SLB proceeds and PDPs out of cash flow before calling anything free cash flow.
|
||||
- [ ] Strip other income entirely and recompute EBITDAR; identify SLB gains, OEM credits, asset-sale gains, FX MTM and DTA recognition in reported PAT.
|
||||
- [ ] India: read the auditor's report, CARO on statutory dues, going-concern and emphasis-of-matter paragraphs, and the related-party note before the investor presentation.
|
||||
- [ ] India: check promoter pledging and promoter-affiliated asset-owning or management entities and their fee terms.
|
||||
- [ ] Compute **cycle-averaged, lease-adjusted ROIC vs WACC** over 7–10 years; for hotel owners also present ROCE on revalued property.
|
||||
- [ ] Value on **mid-cycle** EBITDAR, and invert the multiple reading: cheap at peak margins is a sell signal, expensive at trough is often the entry.
|
||||
- [ ] Cross-check hotel EV against **EV per key vs replacement cost**, and hotel NAV against transaction cap rates.
|
||||
- [ ] For any airline under six months of liquidity, replace the multiple with a probability-weighted scenario including dilution or restructuring.
|
||||
- [ ] State the cycle position, the supply pipeline, the regulatory/decarbonisation cost trajectory, and the competitive structure of the market — then the peer set with exclusions named.
|
||||
180
finance/skills/stock-analysis/references/sectors/banks.md
Normal file
180
finance/skills/stock-analysis/references/sectors/banks.md
Normal file
|
|
@ -0,0 +1,180 @@
|
|||
# Banks and deposit-taking lenders — sector playbook
|
||||
|
||||
Use this when: the company holds a banking licence and funds itself with public deposits — Indian scheduled commercial banks (private, PSU, small finance, payments), US money-centre and regional banks, European and other global banks, and bank holding companies whose profit is dominated by a lending subsidiary.
|
||||
|
||||
A bank's balance sheet is its product, not its plumbing. Leverage is the business model, deposits are raw material, and reported profit is a function of provisioning judgement that management controls. That combination breaks almost every ratio in the generic checklist and inverts a few of them, so the sector needs a replacement metric set rather than an adjusted one. Two further facts govern everything below: the loss is written in the boom and recognised two to three years later, and banks do not die of slow insolvency — they die of a liquidity run in days.
|
||||
|
||||
If the entity does **not** take deposits (NBFC, HFC, fintech lender), use `references/sectors/nbfc.md` instead — the asset-quality toolkit is similar but the funding, liquidity and valuation logic differ materially.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Do not compute these for a bank. If a screener hands them to you, state that they are inapplicable rather than reporting them with a caveat — a reported number gets used.
|
||||
|
||||
**OPM / gross margin / EBITDA margin — undefined.** There is no COGS and no single "revenue" line. The Indian P&L (Banking Regulation Act Form B) shows "Total Income" = interest earned + other income; a margin computed on that gross number moves purely with the rate cycle and tells you nothing about the franchise. Interest expense *is* the cost of goods sold. Depreciation is trivial (typically 2–4% of opex), so EBITDA is an economically meaningless construct.
|
||||
|
||||
**EV, EV/EBITDA, net debt, Debt/EBITDA — undefined and never used.** Enterprise value assumes debt is financing you can strip out. For a bank, deposits and borrowings are the raw material, and cash / balances with RBI (CRR) and SLR securities are operating assets, not idle cash. Netting "net debt" subtracts the very franchise you are trying to value. Equity-side multiples only.
|
||||
|
||||
**D/E and interest coverage — mis-signed.** Healthy banks run 8–15x assets/equity *by design*. D/E of 10x is normal, not distress; a bank at D/E of 2 is under-earning its capital. The binding leverage constraint is regulatory (CET1, CAR, Basel III leverage ratio), not a covenant. Interest coverage is nonsensical when interest expense is an operating input.
|
||||
|
||||
**Free cash flow and FCF yield — noise, and inverted.** Operating cash flow is dominated by deposit inflows and loan disbursements, capex is immaterial. A fast-growing, high-quality bank shows deeply negative "FCF" because loans grew; a shrinking, de-risking bank shows strongly positive "FCF". An FCFF/WACC DCF cannot be built at all, because operating and financing cash flows cannot be separated.
|
||||
|
||||
**ROCE / capital employed / asset turnover — meaningless.** "Capital employed" would include every deposit. Asset turnover (income/assets) is just the asset yield, already captured better and more cleanly by NIM.
|
||||
|
||||
**Current ratio, quick ratio, working capital, inventory and receivable days, cash conversion cycle — undefined.** Bank balance sheets are not classified current/non-current (India: Form A under the BR Act, exempt from Schedule III classification). Liquidity is measured by LCR, NSFR and ALM buckets instead.
|
||||
|
||||
**P/E used standalone — dangerously procyclical.** Bank earnings peak when provisions are at a cyclical trough, so P/E looks cheapest exactly at the top of the credit cycle — Indian PSU banks in FY18–19, US regional banks in 2006–07 and again in 2022. Reported "E" is also the most management-discretionary number in the market: provisioning, NPA recognition, write-off timing and ECL/IFRS 9 staging assumptions all sit inside it.
|
||||
|
||||
**Standard three-step DuPont — must be re-specified.** The bank version decomposes ROA into NIM + fee income − opex − credit cost − tax, all as a % of average assets, then ROE = ROA × equity multiplier. Generic DuPont produces a "profit margin" on gross income that is not comparable across banks with different funding mixes.
|
||||
|
||||
**Growth as an unqualified positive — inverted.** In most industries revenue growth is good news. In lending, above-system loan growth is the single best leading indicator of the next credit cycle's losses. Treat sustained hypergrowth as a risk factor to be explained, not an achievement to be scored.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, by sub-sector, by rate cycle and by period, and any of them can be wrong for a specific bank in a specific year. Comparison against a tight peer set and against the bank's own 5–10 year history overrides every absolute band below.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Net Interest Margin (NIM)** | (Interest earned − interest expended) / average interest-earning assets, annualised. US banks usually report tax-equivalent (FTE); some Indian banks use average *total* assets — check the base before comparing. | India large private 3.5–4.5%; India PSU 2.6–3.2%; small finance banks 6–9%; US large/regional 2.8–3.6%; Europe 1.2–2.0%. Stability matters more than level — a swing above 30–40 bps in a year needs an explanation. | The core spread engine, the closest thing to a gross margin. Tells you whether profit comes from a genuinely cheap deposit franchise (durable) or from lending down the credit curve at high yields (rented, repaid later as credit cost). NIM rising on unsecured/MFI mix shift is a different quality of earnings from NIM rising on CASA. In India, zero-yield CRR and SLR holdings structurally cap NIM vs DM peers. |
|
||||
| **CASA ratio / non-interest-bearing mix and deposit beta** | Current + savings balances as % of total deposits (India). DM equivalents: share of non-interest-bearing demand deposits, and *deposit beta* — the fraction of a policy-rate move passed into deposit cost. Track with cost of funds and the share of bulk deposits and CDs. | India: >40% strong, 30–40% average, <30% weak (SFBs and newer banks 20–35%). US: non-interest-bearing >25% of deposits is a strong franchise; cumulative deposit beta below 40–45% through a hiking cycle is good. | The deposit franchise, not the loan book, is what a durable bank multiple is paid for. CASA is sticky, cheap and slow to reprice, so a high-CASA bank keeps NIM when rates rise and can undercut on price when they fall. Falling CASA replaced by bulk deposits or CDs is an early, quantitative sign the franchise is being funded by paying up; margin compression follows with a lag. This is the number that separated survivors from casualties in the 2023 US regional bank episode. |
|
||||
| **Return on Assets (ROA)** | Net profit / average total assets. Decompose on a % of average assets basis: NIM + fee & other income − opex − credit cost − tax. | India private 1.6–2.2% top quartile, 1.0–1.5% acceptable, <0.8% weak; India PSU 0.8–1.2% is now considered good. US >1.2% strong, ~1.0% average. Europe 0.5–0.8%. | The only clean cross-bank profitability comparison, because it is leverage-neutral. Two banks can both post 16% ROE — one from 1.6% ROA at 10x leverage (well capitalised), the other from 0.9% ROA at 18x (levered to the regulatory ceiling, one credit shock from a dilutive raise). ROA also sets the self-funded growth ceiling: ROA × leverage × retention = loan growth achievable without issuing equity. |
|
||||
| **ROE / Return on Tangible Equity (ROTE)** | Net profit / average shareholders' equity; ROTE strips goodwill and intangibles from the denominator. Always read against cost of equity. | 15–18%+ excellent, 12–15% good; below COE (roughly 12–14% India, 9–11% US/EU) means value is destroyed at the margin. | ROE vs COE is the single input that determines the justified P/B, so it drives valuation directly rather than being a standalone score. Read with the capital ratio: ROE lifted by running CET1 down toward the minimum is borrowed, not earned. ROTE is the relevant form for banks grown by acquisition, where reported book is inflated by goodwill. |
|
||||
| **Gross and Net NPA (Stage 3 / NPL in DM)** | Gross non-performing advances / gross advances; NPAs net of provisions / net advances. India uses RBI IRAC norms — 90 DPD, hard rules. DM uses IFRS 9 Stage 3 or US GAAP non-accrual, judgement-based, plus Stage 2 as the watchlist. | India: GNPA <2.5% and NNPA <0.7% strong; GNPA >5% or NNPA >1.5% needs a full workout thesis. DM: NPL <1.5–2%; Stage 2 <8–10% of the book and, critically, not rising. | The stock of recognised damage — and the *least* informative asset-quality metric, because it is the most manipulable. Technical write-offs shrink the numerator; rapid loan growth inflates the denominator; so GNPA% can fall while the absolute problem grows. Never read without slippages, credit cost and write-offs alongside. In India, always reconcile to the RBI divergence disclosure. |
|
||||
| **Slippage ratio (fresh NPA formation)** | Fresh slippages into NPA in the period / opening standard advances, annualised. DM analogues: gross NPL inflows and net charge-offs (NCO) as % of average loans. | India: <1.5% healthy, 1.5–2.5% watch, >3% stress. US NCO: 0.3–0.6% for a normal-cycle retail/commercial bank; card-heavy books run 3–5% by design. | The flow, not the stock — and flows turn first. GNPA can be flattered by recoveries, upgrades and write-offs; slippages cannot. Flat GNPA with rising slippages means the bank is running to stand still and is a quarter from a negative surprise. Earliest hard number saying the last 2–3 underwriting vintages were too loose. |
|
||||
| **Credit cost** | Loan-loss provisions (plus write-offs, for the honest version) / average advances, annualised. Compare to the bank's own through-cycle average, never to zero. | Through-cycle 0.6–1.2% for a diversified Indian bank; 0.3–0.5% for a mortgage-heavy secured book; 4–6% for cards/microfinance. Sustained sub-0.4% on a diversified book is a cyclical trough, not an achievement. | The swing factor in bank earnings and the main lever for managing reported profit. The correct analytical move is to **normalise**: re-run EPS at through-cycle credit cost *before* applying any multiple. Most bank value traps are the market capitalising trough credit cost as if structural. Also check credit cost net of releases from prior contingent/floating provisions — releases are non-recurring earnings. |
|
||||
| **Provision Coverage Ratio (PCR)** | Provisions held against NPAs / gross NPAs. Insist on the figure **excluding** technical and prudential write-offs; the including-write-offs number Indian banks headline is far more flattering. | India: >70% ex-write-offs is the RBI-anchored comfort level, >75% strong, <50% means unrecognised losses sit inside book value. DM: Stage 3 coverage 40–60% typical (lower, because collateral is marked more explicitly). | The buffer between reported book value and real book value. A bank letting PCR drift down while GNPA is flat is releasing reserves into the P&L — earnings quality decays while EPS grows. Look for floating/contingent provisions above the regulatory requirement: a genuine hidden reserve and a marker of conservative management. |
|
||||
| **Cost-to-income (efficiency ratio)** | Operating expenses / net total income (NII + other income). US "efficiency ratio" is computed essentially the same way. | Best-in-class 35–42%; 42–50% good; 50–60% for banks in build-out (SFBs, new private banks, digital scale-ups); >65% structurally sub-scale. Three-year direction matters more than the level. | The operating-leverage metric that replaces OPM — does branch and technology spend convert into revenue? Watch the denominator: a bond-trading windfall or a large one-off recovery produces an artificially good ratio that quietly reverses. Recompute excluding treasury gains. |
|
||||
| **CET1 and CAR/CRAR** | Common Equity Tier 1 and total regulatory capital as % of risk-weighted assets under Basel III. Read with RWA density (RWA / total assets) and the Basel III leverage ratio. | India (RBI): minimum CAR 11.5% including CCB, CET1 minimum 8%; comfortable is CET1 >13% and CAR >16%. DM: CET1 >12–13% with a clear buffer above the MDA trigger; US large banks manage to SCB-adjusted requirements +50–100 bps. | This, not D/E, is the leverage constraint that actually binds. Capital determines how much a bank can grow before it must issue equity — and equity issued below book permanently destroys per-share value. Falling RWA density with a growing book can be a genuine mix shift to mortgages, or IRB model optimisation. Check how much "capital" is deferred tax assets and revaluation reserves rather than retained earnings. |
|
||||
| **Credit-deposit ratio; deposit growth vs credit growth** | Advances / deposits. Track the YoY loan-growth minus deposit-growth gap, and funding from CDs, refinance (NABARD/SIDBI/NHB in India) and wholesale borrowing. | India: 75–85% comfortable; >90% is a funding-stress signal (the system CD ratio near ~80% in 2024 is what triggered RBI push-back on unsecured growth). US: <90–100% generally, though securitisation and FHLB usage change the model. | The fastest read on whether growth is funded by franchise deposits or borrowed money. A bank persistently growing loans 5–8 points faster than deposits is about to pay up for deposits (NIM compression) or raise capital. In India it feeds directly into marginal cost of funds and hence lending-rate competitiveness. |
|
||||
| **LCR, NSFR, ALM buckets, HTM unrealised losses** | LCR = HQLA / 30-day net stressed outflows. NSFR = available vs required stable funding. Alongside: the ALM statement's 1–30 day and 1-year buckets, and the mark-to-market hole in held-to-maturity securities. | Both >100% regulatory minimum; comfortable operating LCR 120–140%. Unrealised HTM losses small relative to CET1 — above 15–20% of CET1 deserves serious scrutiny. | Banks fail from a run, not from slow insolvency. Silicon Valley Bank was profitable and passed its headline capital ratio while carrying an HTM loss exceeding tangible equity, funded by uninsured deposits. For Indian banks, watch uninsured deposit share (DICGC covers ₹5 lakh per depositor) and top-20 depositor concentration. |
|
||||
| **Loan mix and concentration** | Advances split by product (mortgage, vehicle, personal/cards, microfinance, MSME, corporate) and by sector; top-20 borrower exposure as % of net worth; share in the riskiest 2–3 sectors; geographic concentration. | Unsecured retail (PL + cards + MFI) above ~20–25% of the book warrants a higher normalised credit cost. Top-20 borrowers well below 100% of net worth for a diversified bank. CRE above ~250–300% of capital is the classic US regional flag. | Two banks with identical NIM and identical current GNPA can have completely different loss distributions. Mix tells you what credit cost normalises to and how fast the book can deteriorate: unsecured retail goes bad in 2–4 quarters, corporate in 2–3 years, microfinance can go from pristine to 10% GNPA in two quarters on a local political or weather shock. Concentration converts an idiosyncratic default into a capital event. |
|
||||
| **Operational productivity KPIs** | Business (deposits + advances) per employee and per branch (standard Indian annual-report disclosures); deposits per branch and branch vintage mix; digital transaction share and active mobile/net-banking users; new-to-bank additions and acquisition cost; cross-sell ratio (products per customer); monthly collection efficiency for retail/MFI books. | Business per employee ₹15–25 crore strong for Indian private banks, ₹10–18 crore typical for PSUs. Deposits per branch rising in real terms. Collection efficiency >98% on a secured retail book; below 96% is an early warning. Digital share of transactions >90% for a modern retail bank. | These are the leading indicators sitting behind the financial ratios. Deposits per branch tells you whether branch expansion is earning its cost before it shows in cost-to-income. Collection efficiency turns 1–2 quarters before slippages, which turn 2–3 quarters before GNPA — the earliest asset-quality signal available. Cross-sell and fee per customer distinguish a primary-banking relationship from a rate-shopping deposit book. |
|
||||
| **Fee / non-interest income quality** | Split other income into core fees (transaction banking, card interchange, third-party distribution of insurance and MFs, forex, processing) vs treasury/trading gains, recoveries from written-off accounts, PSLC income and stake sales. Express core fees as % of average assets. | Core fee income 1.0–1.5% of average assets is strong for an Indian retail bank; treasury gains a small single-digit % of PBT in a normal year. | Fee income is capital-light and multiple-accretive *if* annuity-like and customer-driven; worthless if it is bond profits from a falling-rate quarter or lumpy recovery income. Many banks bridge a weak quarter this way and still report "PAT growth". Strip both out and use **pre-provision operating profit ex-treasury** — the number that shows what the franchise earns before management discretion. |
|
||||
| **SMA-1 / SMA-2 and Stage 2 pipeline** | India: special mention accounts, 31–60 and 61–90 DPD, disclosed in investor presentations and (for large exposures) reported to CRILC. DM: IFRS 9 Stage 2 balances and the migration matrix between stages. | SMA-2 low and falling; Stage 2 <8–10% and not rising. Judge the trend, not the level — definitions differ too much across banks for a hard band. | The pipeline into NPA, one step earlier than slippages. Rising SMA-2 with stable headline GNPA is the classic pre-break configuration. This disclosure is voluntary in places: a bank that *stops* publishing an SMA breakdown it used to publish is telling you something. |
|
||||
| **Book value per share growth and dilution history** | BVPS (and tangible BVPS) CAGR over 5–10 years, alongside every equity raise and the P/B at which it was done; add back dividends for a total value-creation view. | BVPS compounding at or near ROE × retention, with no raises below ~1x book. | Aggregate book value growth flatters serial issuers. BVPS growth is the per-share truth, and raising equity below book is permanent, irreversible value destruction for existing holders. A bank that repeatedly issues at low P/B is telling you its ROA cannot fund the growth it reports. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
Banks are valued on the **equity side only** and anchored to book value. Every EV- or FCFF-based method is structurally inapplicable.
|
||||
|
||||
**Primary — P/B, and P/TBV in developed markets.** Book value is a reasonable proxy for economic capital: bank assets are mostly financial and near fair value, and book is the regulatory constraint on how much business can be written. Use P/TBV wherever acquisition goodwill is material (US regionals, European banks); in India, where organic growth dominates, plain P/B is the convention.
|
||||
|
||||
The multiple is not a free parameter. It is anchored by the warranted-multiple identity:
|
||||
|
||||
> **Justified P/B = (ROE − g) / (COE − g)**
|
||||
|
||||
A bank earning 17% ROE with 12% growth against a 13% cost of equity justifies roughly 5x book; the same bank at 11% ROE justifies barely 1x. The practical implementation is a cross-sectional ROE-vs-P/B (or ROTE-vs-P/TBV) scatter regression across the peer set, with the residual explained by deposit-franchise quality, asset-quality track record and management. This is exactly why deposit quality translates so directly into multiple: it lowers COE and raises sustainable ROE simultaneously.
|
||||
|
||||
**India-specific — Price to Adjusted Book Value (P/ABV).** Adjusted book = net worth − net NPAs (or − the shortfall to a 70%+ coverage standard), sometimes also net of unprovided restructured assets and security receipts from ARC sales. Essential for PSU banks and any bank with a stressed book, because reported book contains losses recognised as NPAs but not yet provided. Two banks at 1.2x reported book can be at 1.3x and 2.4x adjusted book — the entire investment case can sit in that adjustment. Also deduct revaluation reserves and large deferred tax assets: book value that cannot absorb losses.
|
||||
|
||||
**Sum-of-the-parts — essential for large Indian banks.** Indian banking groups carry material listed and unlisted subsidiaries (life and general insurance, AMC, broking, NBFC arms). Value the standalone bank on P/ABV, value each subsidiary on its own sector metric (embedded-value multiple for life insurance, % of AUM or P/E for the AMC, P/B for the NBFC), apply a 15–25% holding-company discount, and back out the *implied standalone bank multiple*. Skipping this makes the consolidated P/B look expensive when the core bank is not.
|
||||
|
||||
**Excess return / residual income.** Value = current book value + PV of (ROE − COE) × book value each future year. This is the theoretically correct intrinsic model for banks: it works directly with the accounting book that regulation binds against, and it degrades gracefully because most of the value sits in today's book rather than a distant terminal value. It also makes the ROE–P/B link explicit.
|
||||
|
||||
**DDM / FCFE.** If a cash-flow model is required, define FCFE as net income minus the increase in regulatory capital needed to support RWA growth — earnings distributable *after* funding growth at target CET1. A three-stage DDM is standard for mature DM banks with stable payout ratios. Never a WACC-based DCF: WACC needs a cost of debt that, for a bank, is a cost of raw material.
|
||||
|
||||
**Secondary — normalised P/E.** Usable only after credit cost is normalised to a through-cycle level and treasury gains and recovery income are stripped. Reported P/E on trough provisions is the sector's classic value trap. Indian banks typically 12–20x normalised earnings, DM banks 8–13x — indicative, and cycle-dependent.
|
||||
|
||||
**M&A / control valuation.** Price per core deposit, price-to-deposits, and the core deposit intangible premium are the standard US bank M&A metrics: the acquirer is buying a funding franchise, not a loan book. In India, distressed bank resolutions have been done at or below adjusted book, with the acquirer effectively compensated for taking the liabilities.
|
||||
|
||||
**Cross-checks.** Dividend yield and payout sustainability against the stated capital plan; deposit market-share trend; and a reverse-valuation test — solve for the normalised credit cost (or the ROE) implied by today's multiple, then ask whether that number is plausible against the bank's own history and mix.
|
||||
|
||||
**Do not use:** EV/EBITDA, EV/Sales, EV/EBIT, FCF yield, PEG on reported EPS, or any WACC-discounted enterprise cash-flow model.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares the *funding model, regulatory regime and asset mix* — not merely the label "bank". Mixing across these lines produces confidently wrong conclusions.
|
||||
|
||||
**Splits that must not be mixed:**
|
||||
|
||||
- **Indian private vs PSU banks.** Different cost of funds, different opex structures, different capital access (government recapitalisation vs market raises), different governance and appointment processes, and structurally different multiples. A PSU trading at 1.0x book is not "cheap versus" a private bank at 3x.
|
||||
- **Universal / commercial banks vs small finance banks vs payments banks.** SFBs run 6–9% NIM, high credit cost and 50–60% cost-to-income by design; payments banks cannot lend at all and are fee/float businesses. Neither belongs in a large-bank scatter.
|
||||
- **Banks vs NBFCs and HFCs.** No deposit franchise, no CASA, no CRR/SLR drag, no LCR regime in the same form — different funding risk and different multiple logic. Compare only on asset-quality and ROA discipline, never on P/B directly.
|
||||
- **US money-centre / GSIB vs regional vs community banks.** GSIBs carry markets, trading and asset-management businesses and are valued partly on those; regionals are spread-and-CRE businesses. Different capital regimes (SCB and G-SIB surcharge vs Category IV).
|
||||
- **Retail-led vs corporate-led vs treasury-heavy books.** Loss timing and volatility differ so much that identical GNPA today implies different futures.
|
||||
- **Microfinance-heavy and unsecured-heavy lenders** deserve their own bucket — the loss distribution is fat-tailed and correlated to local events.
|
||||
- **Consolidated vs standalone.** For groups with insurance and AMC arms, compare standalone bank to standalone bank, then handle subsidiaries in the SOTP. Comparing one bank's consolidated P/B against another's standalone is a common and material error.
|
||||
|
||||
**Also align:** fiscal year end (Indian banks are April–March, most US banks are calendar); accounting regime (Ind-AS/IGAAP-for-banks vs IFRS 9 vs US GAAP CECL — provisioning is not comparable across these); size band (a ₹50,000 crore balance sheet and a ₹20 lakh crore one face different growth ceilings); and stage of build-out (a bank three years into a branch expansion will look bad on cost-to-income for structural, not quality, reasons).
|
||||
|
||||
Aim for 5–8 peers. State the basis explicitly in the report, and benchmark every metric twice — against peers *and* against the bank's own 5–10 year record.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Loan growth far above system (roughly 1.5–2x system credit growth) for several years, concentrated in one product.** The bad loan is written in the boom and recognised two to three years later. Almost every Indian NPA cycle (infrastructure 2010–13, unsecured retail and microfinance 2022–24) and every US regional failure was preceded by exactly this pattern.
|
||||
- **RBI divergence in asset classification (India, non-negotiable).** SEBI requires disclosure of divergence from RBI's Risk Assessment Report where it exceeds 10% of reported PBT or 15% of reported GNPA. Any material divergence means management's own NPA numbers were wrong — the single highest-signal governance flag in Indian banking, and one that was raised repeatedly before at least one prominent private bank failure.
|
||||
- **Falling provision coverage while GNPA is flat or rising.** Reserve releases manufacturing earnings growth. Always ask whether PAT growth came from pre-provision operating profit or from a lower provision line; the second kind reverses.
|
||||
- **Heavy technical write-offs managing the headline ratio.** Reconcile: opening GNPA + slippages − recoveries − upgrades − write-offs = closing GNPA. If write-offs are doing most of the work, asset quality is not improving. The denominator trick is the twin: a rapidly growing book can drop GNPA% for two years while absolute GNPA rises.
|
||||
- **Evergreening and disguised restructuring.** India: lending to a stressed borrower through an NBFC arm or co-lending partner, routing exposure via Alternative Investment Funds (RBI cracked down in December 2023), rolling working-capital limits to avoid a 90-day trigger, capitalising unpaid interest. DM analogue: IFRS 9 stage-migration management and "covenant amendment" extensions that keep Stage 2 out of Stage 3.
|
||||
- **ARC sales where the bank retains security receipts.** The loan leaves the NPA line; the credit risk stays on the balance sheet as an investment. Check the outstanding SR book, its rating trajectory and its provisioning — the standard cosmetic tool of the 2015–18 Indian cycle.
|
||||
- **Profit dependent on treasury gains, written-off-account recoveries, PSLC income or subsidiary stake sales.** Strip them out and look at pre-provision operating profit ex-treasury. A "record quarter" produced by a bond rally is not an improvement.
|
||||
- **Deposit franchise deterioration.** Falling CASA, rising bulk deposits and CDs, deposit rates visibly above peers, rising top-20 depositor concentration, high uninsured-deposit share. This is a bank buying its funding; it precedes NIM compression and, in the tail case, a run.
|
||||
- **ALM and duration mismatch with unrealised HTM losses.** Long-duration securities or fixed-rate loans funded by short, rate-sensitive deposits. Measure the HTM mark-to-market shortfall against CET1 — the loss is not routed through capital for many banks, which is precisely why the headline ratio can look fine while economic equity is gone.
|
||||
- **Concentration.** Single-sector exposure (CRE above roughly 250–300% of capital is the classic US regional flag), a large top-20 borrower book relative to net worth, or geographic concentration in microfinance/agri lending exposed to one state's political cycle or monsoon.
|
||||
- **Related-party and promoter-linked lending, and lending into the CEO's network.** This is the recurring cause of outright *failure* rather than mere underperformance across Indian private, co-operative and small banks. Read the related-party transactions note in full, every year.
|
||||
- **Governance and regulatory signals.** RBI declining to extend an MD/CEO term, or granting a shorter term than the board sought; supervisory action such as a ban on new digital onboarding or new customer acquisition; monetary penalties for IRAC or KYC breaches; abrupt auditor resignation or statutory auditor change; sequential CFO or Chief Risk Officer exits; a CRO whose reporting line does not reach the board. These are visible well before the numbers break.
|
||||
- **Repeated equity raises at or below book value.** Permanent per-share destruction, and a signal that ROA is too weak to self-fund reported growth. Track BVPS growth, not book value growth.
|
||||
- **Book value quality.** A large share of net worth in deferred tax assets (worth something only if future profits arrive), revaluation reserves on premises, or acquisition goodwill. Recompute tangible book and re-run the multiple.
|
||||
- **Poor-quality fee income.** Upfront recognition of loan processing fees, insurance mis-selling-driven distribution income, fees that vanish when disbursements slow. If fee income moves one-for-one with disbursement growth, it is not annuity income.
|
||||
- **Rising SMA-1/SMA-2 or Stage 2 while headline GNPA is stable** — the pipeline, disclosed selectively. Withdrawal of a previously given disclosure is itself the signal.
|
||||
- **Thinly provisioned restructured/standard-restructured book**, or a large "standard asset" exposure to a stressed group that peers have already classified as NPA.
|
||||
- **Aggressive ECL assumptions (DM).** Optimistic macro scenario weights, extended cure periods, stale collateral valuations. Indian banks moving to RBI's expected credit loss framework face a one-time transition provision; a bank that has not quantified and disclosed its expected day-one ECL impact is deferring a known hit.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Where you are in the credit cycle determines which metric lies to you.** Early cycle: credit cost is normalising down, GNPA falling, earnings growth flattered by provision reversals, P/E optically low — this is where value traps are bought. Late cycle: credit cost above trend, book value already impaired, P/B optically low, but the adjusted book is the real question. The correct posture is to hold credit cost at the through-cycle level regardless of where the reported number sits, and to explain the gap.
|
||||
|
||||
**Rate cycle.** Asset repricing is faster than liability repricing on the way up (NIM expands, then deposit beta catches up and NIM gives it back) and the reverse on the way down. In India, the share of loans on external benchmark-linked rates (EBLR, mostly repo-linked) versus MCLR determines how fast the asset side reprices — repo-linked books reprice almost immediately, MCLR books with a lag. A bank whose NIM expansion was purely mechanical repricing has not improved.
|
||||
|
||||
**Structural threats to score explicitly.** Deposit disintermediation into mutual funds, equity and higher-yielding alternatives — a live pressure in India, where retail savings have been shifting toward markets, forcing banks to compete harder for deposits. Fintech and NBFC capture of high-margin unsecured lending and payments. UPI making payments free and eroding transaction fee pools in India (with interchange economics far weaker than card-led markets). Digital-first challengers attacking the branch cost model. And, longer-term, account aggregator frameworks and open banking commoditising the customer relationship that CASA depends on.
|
||||
|
||||
**Regulation is a first-order value driver, not a footnote.** In India: CRR and SLR requirements (a direct NIM drag), priority sector lending targets and the PSLC market, risk-weight changes (the November 2023 increase on unsecured consumer credit and bank lending to NBFCs immediately repriced capital consumption), the LCR framework revision on digitally-accessible deposits, the coming ECL transition, and RBI's discretionary supervisory powers — which can halt a growth engine overnight without any legal process visible in the filings. In DM: Basel III endgame capital changes, stress-test regimes (CCAR/SCB in the US, EBA in Europe), deposit insurance reform after 2023, and the MDA trigger constraining distributions. Always check what regulatory change is in flight before extrapolating current ROE.
|
||||
|
||||
**Consolidation and licensing.** Indian bank licences are scarce and consolidation is state-directed for PSUs; US banking is fragmented with thousands of institutions and consolidation is the base case, which makes deposit franchises acquirable and supports takeout value for small, well-funded banks.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India | US / global |
|
||||
|---|---|---|
|
||||
| Regulator / supervisor | RBI (licensing, IRAC norms, supervisory action, MD/CEO approval); SEBI for disclosure; DICGC for deposit insurance (₹5 lakh per depositor) | Fed / OCC / FDIC (US), ECB-SSM and national regulators (EU), PRA (UK); FDIC insurance $250k per depositor per category |
|
||||
| Statement format | Banking Regulation Act Form A (balance sheet) and Form B (P&L); exempt from Schedule III current/non-current classification; Ind-AS applies to most corporates but banks still follow RBI's prescribed formats and have not yet transitioned to full ECL | 10-K / 20-F on EDGAR; US GAAP with CECL (lifetime expected loss at origination, adopted 2020) or IFRS 9 three-stage ECL |
|
||||
| NPA recognition | Rule-based IRAC: 90 DPD, hard classification into substandard/doubtful/loss with prescribed minimum provisioning. Less discretion, more comparability across banks | Judgement-based ECL staging and macro scenario weights; more forward-looking but far less comparable between banks |
|
||||
| Distinctive disclosures | RBI divergence disclosure; SMA-1/SMA-2 and CRILC reporting; business per employee and per branch; PSL achievement and PSLC income; restructuring under RBI resolution frameworks; CARO does not apply to banking companies (they are exempt) but the LFAR — Long Form Audit Report — and the auditor's report do | Call Reports and FR Y-9C (US, granular and public); CCAR/DFAST stress test results; uninsured deposit disclosure; AOCI and HTM fair-value footnote |
|
||||
| Units and reporting | ₹ crore and lakh; fiscal year April–March; quarterly results with an investor presentation and an analyst concall — treat the concall Q&A as a primary source for slippage guidance, restructuring and deposit strategy | $ millions/billions; calendar fiscal year for most banks; quarterly 10-Q, earnings call transcript, and a supplemental financial package with segment-level NIM and credit detail |
|
||||
| Ownership | Promoter/founder shareholding matters and RBI caps voting rights and ownership in private banks; government holding dominates PSU banks and drives recapitalisation and appointment decisions; foreign ownership limits apply | Widely held; activist and institutional ownership matter more than a promoter concept; bank holding company structure is standard |
|
||||
| Valuation convention | P/B and P/ABV; SOTP for groups with insurance/AMC arms; adjusted book is the standard analyst construct | P/TBV and ROTE dominate, because acquisition goodwill is pervasive; price per core deposit for M&A |
|
||||
| Structural NIM | Higher gross yields but CRR (non-interest-bearing) and SLR requirements are a permanent drag; PSL obligations force lower-yield lending or PSLC purchases | No comparable reserve drag at current settings; NIM lower because loan yields and inflation are lower |
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Confirm it is a deposit-taking bank, not an NBFC/HFC — route to `nbfc.md` if not.
|
||||
- [ ] Delete OPM, EBITDA, EV/EBITDA, net debt, D/E, ROCE, FCF, current ratio from the analysis and say why in the report.
|
||||
- [ ] Build the bank DuPont: NIM + fees − opex − credit cost − tax = ROA; ROA × leverage = ROE.
|
||||
- [ ] Check NIM level, trend and *composition* — CASA-driven or yield-driven? Confirm the denominator base before comparing to peers.
|
||||
- [ ] Assess the deposit franchise: CASA%, deposit beta, bulk/CD share, cost of funds trend, top-20 depositor and uninsured-deposit concentration.
|
||||
- [ ] Read the asset-quality flow, not just the stock: slippages, recoveries, upgrades, write-offs, and the GNPA reconciliation. Then SMA-2 / Stage 2.
|
||||
- [ ] Recompute PCR excluding technical write-offs; check whether coverage is drifting down while GNPA is flat.
|
||||
- [ ] Normalise credit cost to a through-cycle level and re-run EPS before applying any multiple.
|
||||
- [ ] Strip treasury gains, recoveries and one-offs; compute pre-provision operating profit ex-treasury and judge growth on that.
|
||||
- [ ] Check CET1, CAR, RWA density, and how much capital is DTA/revaluation reserve rather than retained earnings.
|
||||
- [ ] Compare loan growth to system growth and to the bank's own deposit growth; flag any multi-year gap.
|
||||
- [ ] Check LCR, NSFR, ALM 1–30 day bucket, and HTM unrealised loss as a % of CET1.
|
||||
- [ ] Map loan mix and concentration — unsecured share, top-20 borrowers vs net worth, CRE vs capital, geographic concentration.
|
||||
- [ ] Review operational KPIs: business per employee and per branch, deposits per branch, collection efficiency, digital share, cross-sell.
|
||||
- [ ] India: read the RBI divergence disclosure, the related-party note, any RBI penalty or supervisory action, and MD/CEO term approvals.
|
||||
- [ ] Compute P/ABV (net worth − net NPA, less DTA and revaluation reserves), not just P/B.
|
||||
- [ ] For groups with insurance/AMC/NBFC arms, do the SOTP and report the *implied standalone bank* multiple.
|
||||
- [ ] Anchor the target multiple with justified P/B = (ROE − g) / (COE − g) and sanity-check against a peer ROE-vs-P/B scatter.
|
||||
- [ ] Track BVPS (and tangible BVPS) growth and every equity raise's P/B — flag any issuance below book.
|
||||
- [ ] State where in the credit and rate cycle this sits, and what regulatory change is in flight.
|
||||
- [ ] Peer set: same country, sub-sector, funding model, accounting regime, size band and consolidation basis — stated explicitly.
|
||||
|
|
@ -0,0 +1,223 @@
|
|||
# Clinical-stage biotech and pre-revenue drug developers — sector playbook
|
||||
|
||||
Use this when: the company has no approved product and no product revenue — a pre-clinical or clinical-stage drug developer, a platform company monetising only through partnerships, a de-SPAC'd or reverse-merged research entity, or a demerged innovator R&D arm carved out of a profitable pharma parent. Any recognised revenue is collaboration, grant or milestone income, not product sales.
|
||||
|
||||
The entire market capitalisation is a probability-weighted claim on a regulatory approval that has not happened. There is nothing on the income statement to value, nothing on the balance sheet except cash and lab equipment, and the assets that matter — trial data, patent life, regulatory relationships, a chemistry platform — are expensed as incurred and never appear. Two facts govern everything below: **the operating loss is a plan, not a failure**, and **the distribution of outcomes is bimodal, so a single expected-value number describes a share price that will never be observed.** If the company has product revenue, or is a biosimilar, generics, API, CDMO or CRO business, stop and use `references/sectors/pharma-healthcare.md` instead — the economics are unrelated.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Do not compute these. If a screener returns them, state in the output that they are undefined for a pre-revenue developer rather than printing them with a caveat — a printed number gets ranked, and ranking a biotech on any of them produces an inverted conclusion.
|
||||
|
||||
**OPM, gross margin, EBITDA margin, net margin — undefined by division.** There is no revenue. Where a small collaboration or grant line exists, the denominator is an accounting artefact of one contract's recognition schedule, and margins computed on it swing by hundreds of percent between quarters with no change in the business. A company that signs a partnership prints a "profitable quarter"; that is deal timing, not economics.
|
||||
|
||||
**P/E, PEG, EV/EBIT, EV/EBITDA — undefined and, worse, wrong-signed.** Earnings are negative by design and are expected to stay negative for years. A negative-denominator multiple is not a small number, it is a meaningless one. EV/EBITDA is doubly broken: EBITDA is negative *and* EV is frequently distorted or negative because cash exceeds market capitalisation.
|
||||
|
||||
**P/S and EV/Sales — undefined.** No sales. Applying them to collaboration revenue values the company on its licensing calendar.
|
||||
|
||||
**ROCE, ROIC, ROE, asset turnover — negative by construction and inverted in direction.** All are negative, and all *improve* when the company shuts down research. A developer that halves its R&D budget shows a less negative ROE and a screener reads it as improving quality; in reality it has just stopped building the only asset it has. Capital employed is a cash pile awaiting deployment, not capital at work.
|
||||
|
||||
**Operating cash flow and free cash flow — negative by design, and a plan rather than a result.** The correct question is never "why is OCF negative" but "is the burn being spent on the assets that create option value, at the rate management guided, and does the cash on hand reach past the next value-inflecting readout". Positive FCF at a clinical-stage company almost always means trials have been paused. FCF yield is meaningless; a DCF of enterprise free cash flow cannot be built, because there is no cash flow until an approval that may never occur.
|
||||
|
||||
**Book value, P/B and net asset backing — technically computable, economically empty.** Book value is overwhelmingly cash and marketable securities. P/B is therefore a rearranged statement of market-cap-to-cash: it measures how much premium the market pays for the pipeline, which is an *input* to the analysis, not a valuation. It says nothing about intrinsic worth, and it collapses mechanically as cash burns whether or not the science improved.
|
||||
|
||||
**D/E, net debt/EBITDA and interest coverage — mis-signed.** Most clinical-stage companies are net cash, so leverage ratios screen as pristine while the company is three quarters from insolvency. The binding solvency constraint is runway against catalyst timing, not gearing. Conversely, where debt does exist it is usually a venture-debt facility with covenants tied to trial milestones, or a convertible whose real risk is dilution, not default — neither is captured by D/E.
|
||||
|
||||
**Current ratio, quick ratio, working capital, inventory and receivable days, cash conversion cycle — uninformative or undefined.** There is no inventory and no trade receivable. Current ratios of 5–15x are routine and tell you only that the cash has not yet been spent; a company can carry a current ratio of 8x and nine months of runway simultaneously.
|
||||
|
||||
**Revenue and expense "growth" — not growth.** Rising R&D expense is the cost of running more or larger trials. It is a commitment, not an achievement, and treating an expanding expense base as a growth rate is the single most common misreading of these filings. The corresponding real growth metrics are pipeline stage advancement and risk-adjusted value created per rupee or dollar burned.
|
||||
|
||||
**Dividend yield, payout, buyback capacity — structurally zero and correctly so.** Any capital returned by a pre-revenue developer is capital not spent on the pipeline.
|
||||
|
||||
**DCF with a terminal growth rate — structurally invalid.** Drug cash flows end at loss of exclusivity. A perpetuity assumption on a patented molecule capitalises revenue that legally cannot exist. Model to the exclusivity cliff and let revenue collapse; never bolt on a terminal value.
|
||||
|
||||
---
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
All ranges below are **indicative only**. They shift with the funding cycle, therapeutic area, modality, listing venue and period, and any of them can be wrong for a specific company in a specific year. A tight peer set and the company's own disclosure history override every absolute band printed here.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Cash runway in quarters, and the funding cliff** | (Cash + equivalents + short-term marketable securities + committed, non-contingent milestone receipts − debt due within the runway window) ÷ average quarterly net cash used in operating activities *plus* capex, using the last two to four quarters and adjusting for known step-ups (a Phase III start can double burn). Express in quarters and mark the calendar quarter cash runs out. | >8 quarters comfortable; 6–8 adequate; 4–6 means a raise is being prepared now; <4 means the terms will be set by whoever is willing to fund. Guidance must fund **past** the next value-inflecting readout with two to three quarters to spare, not "into" it. | This replaces every solvency ratio in the generic set. The funding cliff, not the science, determines who captures the value of a good result: a company forced to finance before a readout raises at the market's price and hands the upside to the new money. Runway also sets negotiating leverage in any licensing deal — a partner reads the cash line before it reads the data. Language matters: "into the second half of next year" is a cliff, "through the topline readout and twelve months beyond" is a plan. |
|
||||
| **Quarterly net burn and its trajectory** | Net cash used in operations + capex, per quarter, for 8–12 quarters. Decompose the trend: rising because trials enrolled and scaled (good), rising because headcount and facilities grew without programmes advancing (bad), falling because a trial completed (neutral), falling because programmes were paused (a hidden pipeline cut). | Burn trajectory that maps cleanly onto disclosed trial starts, enrolment and completions. A step-change in either direction with no corresponding pipeline event is the flag. | Burn is the sector's only real income-statement signal, and its *shape* is the tell. Trials cost money in a known pattern — start-up costs, then per-patient costs scaling with enrolment, then a tail. Burn that does not match the stated trial calendar means either enrolment is behind guidance or spend has quietly moved somewhere the deck does not mention. |
|
||||
| **R&D as share of burn, and R&D by programme** | R&D expense ÷ total operating expense; and, where disclosed, R&D split by programme and by external (CRO, CDMO, trial site) vs internal (personnel, facilities). Track G&A per employee and G&A as % of burn separately. | R&D 65–80% of opex is typical for a company genuinely running trials; sustained below ~55–60% means the cost base is corporate rather than scientific. G&A rising faster than R&D for more than a year is a governance signal. | This is the quality-of-burn metric. Two companies with identical runway are not equivalent if one spends three-quarters of it on trials and the other on public-company overhead, investor relations and executive compensation. Programme-level R&D disclosure, where given, is also the honest map of management's real priorities — an asset featured on slide three of the deck but carrying almost no spend is being deprioritised. |
|
||||
| **Pipeline map — asset × phase × indication × modality** | A table with one row per asset: programme code, target and mechanism, modality (small molecule, mAb, bispecific, ADC, peptide, ASO/siRNA, cell therapy, gene therapy, vaccine, radioligand), indication and line of therapy, current phase, trial identifier, enrolment status, next milestone and date, ownership (wholly owned vs partnered vs in-licensed), and the royalty or milestone burden owed to any licensor. | Concentration is the variable, not a level. A lead asset carrying >70–80% of risk-adjusted value makes the company a binary instrument regardless of how many preclinical rows sit beneath it. | This is the balance sheet, and none of it is capitalised. Two companies with identical financials can differ tenfold in value on phase mix, mechanism validation and catalyst proximity alone. Build this table from the trial registries (ClinicalTrials.gov, EU CTIS, CTRI in India) and the latest corporate deck side by side — assets that appear in one and not the other are the most informative rows in the file. |
|
||||
| **Probability of success (PoS) by phase — industry base rates** | Assign each asset a cumulative probability of reaching approval from its current phase, then adjust for mechanism validation, effect size seen so far, trial design quality and competitor read-across. | Widely cited industry base rates (Phase-transition studies covering roughly 2011–2020): Phase I→II ~50–55%; **Phase II→III ~28–32%** (the real filter); Phase III→filing ~55–60%; filing→approval ~88–92%; cumulative Phase I→approval ~7–10%. By area, cumulative Phase I→approval has run near ~5% in oncology, ~6% in CNS, ~14% in infectious disease, ~17% in rare disease and ~20–25% in haematology. | These are **base rates, not estimates for this asset**, and they vary very widely by indication, modality, line of therapy and sponsor experience. Use them as the prior you must argue away from, and state explicitly in the output what evidence justifies any deviation. Anchoring on the sponsor's own confidence instead of the base rate is how the sector is systematically over-valued. Note the asymmetry: filing-to-approval is high, so the binary risk sits overwhelmingly in Phase II and Phase III readouts. |
|
||||
| **Risk-adjusted NPV (rNPV) per asset** | For each programme: bottom-up peak sales × PoS-weighted revenue ramp, net of gross-to-net, less cost of goods, sales and marketing and residual development spend (each cost line weighted by the probability it is actually incurred), taxed, discounted at 10–14% (15–20% for pre-clinical, single-asset or first-in-class), with the exclusivity cliff modelled explicitly and revenue collapsing after it. Deduct royalties and milestones owed to licensors. **No terminal value.** | Not a range — a construction standard. Every rNPV must state its four load-bearing assumptions: peak sales, PoS, launch year and discount rate. | This is the core method and everything else is a cross-check. The discipline of building it forces the analysis to be explicit about what is being assumed, which is precisely what a multiple hides. Run sensitivity on all four inputs together, not one at a time — peak sales and PoS are correlated (a bigger claimed market usually means a harder trial and more competition), so a one-at-a-time sensitivity understates the true range. |
|
||||
| **Catalyst calendar** | Every dated event over the next 24 months: interim analyses and DSMB reviews, topline readouts, conference presentations (ASCO/ESMO/AHA/AAN and equivalents), IND/CTA clearances, End-of-Phase-2 meetings, NDA/BLA/MAA submissions, filing acceptances, PDUFA dates, advisory committee meetings, CHMP opinions, partnering deadlines and option-exercise windows. Mark each as company-controlled or externally timed. | At least one value-inflecting catalyst inside the funded runway. A 24-month window with nothing but "data expected" and no dated events is a warning in itself. | Value in this sector is realised in discrete jumps on known dates, so position sizing, entry timing and the financing question are all functions of this calendar. Note the standard clocks: US PDUFA goals run ~10 months from filing acceptance for standard review and ~6 months for priority review (add ~2 months for the filing decision); a CHMP positive opinion is followed by a European Commission decision roughly two months later. A slipping catalyst is data, not scheduling. |
|
||||
| **Trial design quality** | For each pivotal or value-defining trial, score: randomised vs single-arm; blinded vs open-label; active comparator vs placebo vs external/synthetic control; primary endpoint (hard clinical outcome vs validated surrogate vs unvalidated surrogate vs biomarker); powering assumptions — the effect size the trial is powered to detect vs the effect size actually seen earlier; sample size; alpha allocation and multiplicity handling across secondary endpoints and interim looks; analysis population (ITT vs mITT vs per-protocol) and handling of missing data; enrolment velocity (patients per activated site per month) vs guidance. | Randomised, double-blind, adequately powered against an active or placebo control on a regulator-accepted endpoint is the reference standard. Anything less requires an explicit haircut to PoS. | This is where PoS is actually determined, and it is knowable *before* the readout. An open-label single-arm trial cannot separate drug effect from patient selection, natural history and placebo response — it can support accelerated approval in a high-unmet-need setting but converts to a confirmatory-trial liability later. An unvalidated surrogate endpoint risks a regulator accepting the statistics and rejecting the clinical meaning. And a Phase III powered on the point estimate from a small Phase II ignores regression to the mean, which is the most common mechanical cause of a failed pivotal trial. |
|
||||
| **Addressable population and realistic penetration** | Build the funnel bottom-up: incidence or prevalence in each target geography → diagnosed → tested/biomarker-eligible → meeting the trial's own inclusion criteria → treated with any drug → reachable by the launch salesforce or partner → share captured given order of entry → duration of therapy and adherence → doses per year × net price. | Rare-disease funnels lose most of their patients at "diagnosed"; oncology funnels lose them at biomarker eligibility and line of therapy. Peak share for a third entrant with no differentiation is usually a fraction of what a corporate deck assumes. | Peak sales is the input rNPV is most sensitive to and the one most casually asserted. "A $10 billion market" is almost never the addressable population — it is the prevalence pool before every attrition step. The single most valuable check is to re-derive peak sales from epidemiology and compare it to the number in the deck; a gap of 3–5x is common and it flows straight through to valuation. |
|
||||
| **Net price and reimbursement exposure** | Assumed list price benchmarked to approved comparators in the same indication; gross-to-net deduction; payer mix by geography; whether the drug is a physician-administered benefit or a pharmacy benefit; HTA exposure (NICE, G-BA/IQWiG, HAS, PBAC, CADTH) and whether the trial generated the comparative evidence those bodies require; US Medicare negotiation exposure under the IRA. | US gross-to-net commonly 30–55% for a specialty launch. Europe realises materially below US net price. A launch price assumption above the nearest approved comparator needs an evidence-based justification, not a slide. | An approval that cannot be reimbursed is not a commercial product. HTA bodies ask a different question from regulators — not "does it work" but "does it work better than what we already pay for, per unit of cost" — and a single-arm trial against no comparator answers the first and not the second. The IRA also creates a modality asymmetry: small molecules become eligible for US Medicare price setting materially earlier in their commercial life than biologics, which shortens the effective revenue window in an rNPV and has already shifted where capital flows. |
|
||||
| **Competitive landscape and order of entry** | Every competing asset in the same indication and mechanism, by phase and sponsor, from the registries — not from the company deck. Estimate probable order of market entry, and identify who reads out before you. | Being third or later into a class with no differentiation on efficacy, safety, dosing or route typically caps realistic share in the low tens of percent at best. | Order of entry drives peak share, price and the speed of the launch ramp, and it also creates read-across risk: a competitor's failure on the same target can destroy value here without a single event at the company itself, and a competitor's success can compress the commercial opportunity while validating the mechanism. Both directions must be in the scenario set. |
|
||||
| **Partnering economics and retained rights** | For each deal: upfront cash; equity component and the premium paid; development, regulatory and commercial milestones separated (near-term and probable vs distant and improbable); royalty rate and tier structure and the sales base it applies to; territory split; which rights were retained; cost-sharing vs full funding; opt-out, reversion and change-of-control clauses; who books sales. | Judge the **upfront as a share of headline "biobucks"** — a low ratio means the partner bought an option cheaply. Retained US or major-market rights signal genuine internal conviction and are usually where the value is. | Headline total deal value is a marketing number that assumes every milestone is achieved; it should never enter a valuation. A partnership with a credible large-pharma counterparty is the strongest third-party validation available for a platform or a mechanism, because the partner ran its own diligence. The inverse is the single most informative negative signal in the sector: **a partner returning rights** means someone with better information walked away. |
|
||||
| **Dilution history and instrument structure** | Shares outstanding (basic and fully diluted) each year for 5–10 years, with every raise, its price and the discount to market; plus the current overhang — ATM programme capacity and utilisation, warrants (count, strike, expiry, any cashless or ratchet terms), convertible notes and their conversion mechanics, pre-funded warrants, PIPEs, and royalty/revenue-interest financings. | Share count growth that is clearly less than the risk-adjusted value added by pipeline advancement over the same period. A structure with reset-priced or floor-less convertibles is a category risk, not a pricing detail. | Per-share value is what an equity holder owns, and in this sector the share count is the most reliably growing number in the filing. Assess every raise against what it bought: three programmes advanced a phase on a 40% share-count increase is value creation; a doubled share count with the same pipeline is value transfer. Convertibles whose conversion price resets downward as the stock falls create a self-reinforcing decline and have destroyed more small-cap biotech equity than failed trials. Also always model **expected future dilution** into the valuation — the raises required to fund the plan are as certain as the burn. |
|
||||
| **EV/cash, implied pipeline value, and implied PoS** | EV = market cap + debt − cash and marketable securities. Compute EV ÷ cash; the implied pipeline value (EV itself, plus PV of unallocated G&A); and the reverse test — implied lead-asset PoS = (market cap − net cash − rNPV of other assets) ÷ unrisked NPV of the lead asset. | Negative EV means the market ascribes less than zero to the pipeline — worth investigating, but it is usually a judgement on burn and governance, not a free option. | The reverse test is the most disciplined valuation cross-check available here, because it converts an opinion about price into a falsifiable statement about probability. If today's market capitalisation implies a 65% probability of success for an asset entering Phase III, compare that to the ~55–60% base rate and to this trial's design quality, and the investment question becomes concrete. Run it in both directions: also compute the share price implied by success and by failure, since the outcome distribution is bimodal. |
|
||||
| **Regulatory designations and the exclusivity stack** | List every designation held and what it actually confers: Fast Track (more frequent FDA meetings, rolling review eligibility), Breakthrough Therapy (intensive guidance and senior FDA engagement), RMAT for regenerative medicines, Orphan Drug (US market exclusivity of seven years on approval plus fee waivers and clinical trial tax credits; EU ten years), Priority Review, Accelerated Approval (surrogate endpoint plus a mandatory confirmatory trial), Priority Review Vouchers where the statutory programme is currently authorised. Separately map the exclusivity stack: patent expiries by family, regulatory data exclusivity (US five years for a new chemical entity, twelve years for biologics; EU eight plus two, with a possible extra year), paediatric extensions. | Designations should be read as time-saving and access-improving, never as evidence of efficacy. | Companies market designations as quasi-approvals and retail narratives treat them that way. **None of them lowers the evidentiary bar for approval** — Breakthrough and Fast Track change the process, not the standard, and a meaningful share of Breakthrough-designated programmes still fail. Accelerated Approval is the one with real economic teeth in both directions: it can bring revenue years earlier on a surrogate endpoint, and a failed or unfinished confirmatory trial can withdraw it. The exclusivity stack, meanwhile, sets the length of the revenue window in the rNPV and is often the second-largest value driver after peak sales. |
|
||||
| **Ownership and management's prior clinical track record** | Insider ownership and recent transactions (Form 4 in the US; SEBI PIT continual disclosures and quarterly shareholding pattern in India); holdings and changes among specialist healthcare funds and crossover investors (13F/13D-G); free float and index membership. For management and the scientific board: prior INDs filed, trials run, approvals actually obtained, and companies previously led — including how those ended. | Meaningful insider ownership with purchases rather than sales; a stable roster of specialist biotech funds rather than only generalist or retail holders. | Specialist funds employ scientific staff and run their own diligence; their entry and exit is the closest thing to informed third-party opinion available in the public filings, and a broad specialist exit ahead of a readout is worth more attention than any sell-side note. On management: drug development is a craft, and a team that has taken a molecule from IND to approval before executes trials, regulatory interactions and manufacturing scale-up materially better. A chief medical officer or head of research departing shortly before a pivotal readout is one of the highest-signal events in the sector. |
|
||||
|
||||
---
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
The task is to value a portfolio of options on future cash flows that do not yet exist. Only methods that make probability, timing and the exclusivity cliff explicit are usable.
|
||||
|
||||
**Primary — rNPV, built asset by asset, then summed.** For every programme in the pipeline:
|
||||
|
||||
> Asset rNPV = Σ<sub>t</sub> [ PoS × (peak-sales-derived net revenue<sub>t</sub> − COGS<sub>t</sub> − SG&A<sub>t</sub> − royalties owed<sub>t</sub>) × (1 − tax) ] / (1+r)<sup>t</sup> − Σ<sub>t</sub> [ P(reaching that stage) × remaining development cost<sub>t</sub> ] / (1+r)<sup>t</sup>
|
||||
|
||||
Then: **Company value = Σ asset rNPV + net cash + PV of committed non-contingent milestone receipts − PV of unallocated G&A over the development period − expected financing dilution cost.** Model revenue only to loss of exclusivity and let it collapse; no perpetuity, no terminal growth. Risk-adjust the cost lines at their own probability of being incurred, not at the approval probability — a Phase III that will only run if Phase II succeeds should be weighted at the Phase II success rate. Discount at 10–14% for a diversified clinical-stage pipeline, higher for single-asset, first-in-class or pre-clinical situations; do not additionally haircut the discount rate for scientific risk, which is already in the PoS (double-counting risk is the most common technical error in these models).
|
||||
|
||||
**Sum-of-the-pipeline plus cash is the reporting format.** Present a table of assets with PoS, unrisked NPV, rNPV and per-share contribution, then net cash and central costs as separate lines. This makes the valuation auditable and shows immediately how concentrated the value is — which is usually the most important output.
|
||||
|
||||
**Comparable transaction multiples per asset.** Benchmark against precedent licensing and M&A deals for assets at the same phase, in the same indication and modality: upfront payment per Phase I / Phase II / Phase III asset, total acquisition value per programme, deal value as a multiple of risk-adjusted peak sales, and royalty rates struck for comparable mechanisms. Deal comparables are the market's revealed price for exactly this kind of risk and are far more relevant than any equity multiple. Adjust for territory, retained rights and whether the acquirer was strategically motivated by a specific patent cliff.
|
||||
|
||||
**Reverse valuation — solve for the implied probability.** Strip net cash from market capitalisation, subtract the rNPV of secondary assets, and divide the residual by the unrisked NPV of the lead asset. The result is the probability of success the market is paying for. Compare it to the phase base rate and to the trial's design quality, and state the comparison explicitly in the output. This converts "expensive or cheap" into a testable claim and is the single most useful discipline in the sector.
|
||||
|
||||
**Scenario valuation, because the distribution is bimodal.** Compute the share price in the success case (rNPV at PoS = 1, less remaining dilution) and in the failure case (usually net cash per share, less continuing burn and any restructuring cost, plus residual value of the remaining pipeline). An expected value between the two describes a price the stock will never trade at after the readout. Report the pair and the probability weight, not just the mean.
|
||||
|
||||
**Real options / decision-tree framing where staging matters.** A pipeline is a sequence of abandonment options: management pays for the next stage only if the current one succeeds. A decision tree over phase transitions, or a simple binomial option framing on a single asset, captures the value of the right to abandon that a static rNPV understates. Useful mainly for high-volatility, early-stage or platform situations; do not let it become a black box.
|
||||
|
||||
**Secondary cross-checks.** EV/cash and negative-EV screening; EV per clinical-stage programme; price to risk-adjusted peak sales; the cost and time it would take a competitor to replicate the pipeline from scratch; and, for platform companies, the PV of the partnership economics already signed as a floor on platform value.
|
||||
|
||||
**Do not use, in any form:** P/E, forward P/E, PEG, EV/EBITDA, EV/EBIT, EV/Sales, P/S, P/B as a valuation anchor, ROCE or ROIC screens, dividend yield, FCF yield, or a DCF with a terminal growth rate. Each is either undefined or actively inverted here, and reporting any of them — even with a caveat — invites a comparison that cannot be made.
|
||||
|
||||
---
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares **phase, modality, therapeutic area and funding position**. "Biotech" is not a peer set; it is a listing category containing companies whose risk profiles differ by an order of magnitude.
|
||||
|
||||
Splits that must never be mixed:
|
||||
|
||||
- **Clinical-stage vs commercial-stage.** The moment there is product revenue, the entire framework changes and the company belongs in `pharma-healthcare.md`. A pre-revenue developer and a newly commercial one are different instruments.
|
||||
- **Phase band.** Pre-clinical/Phase I, Phase II, and Phase III/filed are three distinct risk classes with roughly 8%, 15–30% and 50–60% cumulative success respectively. Comparing EV per programme across them is meaningless.
|
||||
- **Modality.** Small molecule, monoclonal antibody, bispecific, ADC, peptide, oligonucleotide, cell therapy, gene therapy, vaccine and radioligand differ in development cost, manufacturing complexity, COGS at launch, regulatory pathway, exclusivity length and IRA treatment. Cell and gene therapy in particular carry manufacturing and durability risks that no antibody peer shares.
|
||||
- **Therapeutic area.** Oncology, CNS, rare disease, immunology, metabolic and infectious disease have materially different base rates, trial sizes, placebo-response problems and payer dynamics. A CNS asset and a haematology asset at the same phase are not equally risky.
|
||||
- **Single-asset vs platform.** A single-asset company is a binary event with a date on it. A platform company is a portfolio whose value depends on whether the platform itself is validated — ideally by a partnership someone else paid for. Never blend them in one multiple.
|
||||
- **Partnered vs wholly owned.** A partnered asset carries less financing risk and less upside; the royalty and milestone structure changes the economics so much that the same molecule is worth very different amounts in the two structures.
|
||||
- **Funding position.** A company with eight quarters of runway and one with three are priced on different things — the second is priced on financing terms, not science. Do not read the second as "cheap" relative to the first.
|
||||
- **Origin of the asset.** Internally discovered vs in-licensed. In-licensed assets carry upstream royalty and milestone obligations that reduce the economics materially and are easy to miss.
|
||||
- **Listing venue and shareholder base.** Nasdaq/NYSE biotech, European listings, and NSE/BSE innovator entities differ in disclosure requirements, specialist-investor depth, index inclusion and the availability of follow-on financing. A US-listed peer's multiple does not transfer to an Indian-listed R&D entity or vice versa.
|
||||
- **IPO'd vs reverse-merged/de-SPAC'd shells.** Different governance quality, different overhang structures, different warrant and earn-out complexity.
|
||||
|
||||
Also align on catalyst proximity — a company two months from a Phase III readout trades on a different basis from an identical company two years out — and on whether the valuation is stated pre- or post-money for any announced but unclosed financing. Peer sets here should be small and honest: **three to six genuine comparables beats fifteen tickers sharing a sector tag**, and where no clean peer exists, precedent licensing transactions for similar assets are a better benchmark than any listed company.
|
||||
|
||||
---
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Data presentation and trial conduct**
|
||||
- Topline press releases with adjectives and no numbers: no effect size, no confidence interval, no p-value, no control-arm result, no discontinuation rate. "Met its primary endpoint" without the magnitude is not a result.
|
||||
- Statistical significance on a large sample with a clinically trivial effect size, or significance achieved only after the analysis population changed from ITT to mITT or per-protocol.
|
||||
- Primary endpoint, analysis population or statistical analysis plan amended mid-trial, especially close to unblinding. Check registry version history against the protocol — the registry keeps the audit trail the press release omits.
|
||||
- Subgroup rescue after a missed primary endpoint, presented as a path forward. Post-hoc subgroups are hypothesis-generating, not evidence, and regulators treat them accordingly.
|
||||
- Cross-trial comparisons against historical or published control data, especially where the company's own trial is single-arm and open-label. Patient selection differences swamp drug effect.
|
||||
- Unvalidated surrogate endpoints, or a surrogate that a regulator has previously declined to accept in that indication.
|
||||
- A pivotal trial powered on the point estimate from a small, positive early-phase study — regression to the mean is the standard mechanism by which these fail.
|
||||
- Enrolment materially behind guidance, sites activated but not recruiting, or a trial completion date repeatedly pushed in the registry without comment.
|
||||
- A DSMB "recommendation to continue as planned" marketed as positive news; it is the neutral outcome.
|
||||
- Undisclosed pipeline pruning: assets that quietly vanish between corporate decks. Diff consecutive presentations.
|
||||
- Clinical holds, refuse-to-file letters, complete response letters, or GCP/GMP inspection findings disclosed late, minimised, or characterised as procedural.
|
||||
|
||||
**Financing and capital structure**
|
||||
- Runway guidance that ends at or just before the next major readout — the company will be raising into its own binary event.
|
||||
- Convertible instruments with reset, ratchet or floorless conversion mechanics, or an equity line drawn continuously at a discount to market. These convert a falling share price into more shares and more selling pressure.
|
||||
- Large warrant overhang, particularly warrants issued alongside discounted PIPEs, and pre-funded warrants used to keep reported share counts optically low.
|
||||
- An at-the-market programme being used continuously rather than opportunistically, especially into good news.
|
||||
- Reverse stock splits to maintain listing compliance; going-concern language in the audit opinion; royalty monetisation or revenue-interest financing that is economically debt but not always presented as such.
|
||||
- Share count growing faster than the pipeline advances, across multiple years.
|
||||
|
||||
**Governance and disclosure**
|
||||
- Insider selling ahead of a readout, or a 10b5-1 plan adopted shortly before one (India: check SEBI PIT trading-plan and continual disclosures, and any promoter pledge).
|
||||
- Departure of the chief medical officer, head of clinical development or chief scientific officer close to a pivotal readout; auditor resignation or change; repeated CFO churn.
|
||||
- Management whose prior ventures ended in delisting, liquidation or serial pivots, or a scientific advisory board with no operating drug-development experience.
|
||||
- Paid stock-promotion campaigns, retail-focused IR spend, or a communications cadence that outpaces the clinical cadence.
|
||||
- Related-party CRO, CDMO or laboratory services arrangements; research funded through entities connected to management.
|
||||
- Reduced disclosure over time — programme-level R&D withdrawn, trial timelines removed from the deck, registry entries left un-updated. In this sector, disclosure quality deteriorates before the numbers do.
|
||||
|
||||
**Strategy and pipeline**
|
||||
- A partner returning rights, declining to exercise an option, or writing the programme down. This is the strongest available negative signal.
|
||||
- Breadth substituting for depth: a dozen pre-clinical programmes, no clinical data, and a platform claim resting on animal models.
|
||||
- Orphan, Breakthrough or Fast Track designation presented as a de-risking event or as evidence of efficacy.
|
||||
- Expanded access, compassionate use or investigator-initiated anecdotes used as evidence of activity.
|
||||
- Pivoting the lead indication to a smaller or rarer population after a setback, without acknowledging the corresponding cut to peak sales.
|
||||
- Peak sales assumptions derived from a prevalence pool rather than a treated, eligible, reachable population — and a price assumption above the best approved comparator with no comparative evidence to support it.
|
||||
|
||||
---
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The dominant cycle is the funding cycle, and it is exogenous to the science.** Clinical-stage biotech is the longest-duration cash flow in public equities, so its valuation is more sensitive to the discount rate than almost any other sector. Rising rates compress the entire cohort regardless of trial outcomes; falling rates and open IPO windows re-rate it just as indiscriminately. Track the sector index (XBI/NBI or local equivalent), IPO and follow-on issuance volume, and the number of listed companies trading below net cash — a large negative-EV cohort marks a capitulation phase and is usually followed by consolidation, reverse mergers, liquidations and returns of capital rather than by a recovery in the same names.
|
||||
|
||||
**The funding cycle propagates with a lag.** A financing winter shows up in reduced trial starts within a year, in thinner late-stage pipelines two to three years later, and in CDMO and CRO order books with a similar delay — the cross-read into `pharma-healthcare.md` runs in both directions.
|
||||
|
||||
**M&A is the exit, and large-pharma patent cliffs set the demand.** A concentrated wave of loss-of-exclusivity events across the major innovators creates a structural bid for de-risked late-stage assets, particularly in oncology, immunology, neurology and metabolic disease. Takeout probability is a real component of value for a company with a differentiated Phase II or III asset, and it is highest where the acquirer's own revenue gap aligns with the asset's launch year. Do not model it as a base case, but do state it.
|
||||
|
||||
**Regulatory and policy shifts to underwrite explicitly:**
|
||||
- **IRA Medicare price negotiation** and its small-molecule/biologic timing asymmetry — this is now a modality-selection input at the point of capital allocation, not a late-stage commercial detail.
|
||||
- **Accelerated approval reform** — confirmatory trials increasingly required to be underway at the time of approval, and a faster withdrawal process. This raises the cost and lowers the optionality of the surrogate-endpoint pathway.
|
||||
- **Dose-optimisation expectations in oncology**, which have made early development longer and more expensive by requiring randomised dose comparison before pivotal trials.
|
||||
- **Cross-border licensing flows.** A large and growing share of in-licensed assets originating from Chinese biotechs has compressed the scarcity value of undifferentiated Western me-too programmes; check whether a company's lead asset faces a cheaper, equally advanced licensed competitor.
|
||||
- **Manufacturing and supply constraints** for cell, gene and radioligand therapies, where capacity and isotope supply can gate a launch more tightly than approval does.
|
||||
- **Modality waves.** Capital rotates violently between platforms — antibody-drug conjugates, radiopharmaceuticals, obesity and metabolic, cell and gene therapy, AI-enabled discovery. A company's multiple can move entirely on which wave it is filed under, which is a reason to distrust peer multiples and prefer rNPV.
|
||||
|
||||
---
|
||||
|
||||
## India vs global notes
|
||||
|
||||
The most important India-specific point is a routing one. **There are very few genuine pre-revenue innovator listcos on the NSE/BSE.** The Indian industry is built on generics, API, biosimilars, vaccines, CDMO and CRO — all of which have revenue and belong in `pharma-healthcare.md`. Where Indian innovator R&D exists it usually sits either inside a profitable generics parent (in which case consolidated ratios are a blend of two incompatible economic models and the R&D arm must be valued separately in an SOTP) or in a demerged, separately listed research entity (in which case this playbook governs it and the generics parent does not). Say which structure applies before computing anything. The second point is an accounting one: **Ind AS 38 permits capitalisation of development costs once technical feasibility is established, while US GAAP (ASC 730) mandates expensing** — so an Indian innovator can carry clinical spend as "intangible assets under development" and report a shallower loss than an identical US peer. Restate to a fully expensed basis before any cross-border comparison, and check the capitalised balance against actual programme progression.
|
||||
|
||||
| Dimension | India (NSE/BSE, Ind-AS) | US / global (SEC, GAAP/IFRS) |
|
||||
|---|---|---|
|
||||
| Product regulator | CDSCO / DCGI, with Subject Expert Committees; New Drugs and Clinical Trials Rules, 2019 govern approvals, ethics committees and compensation; RCGM (DBT) and GEAC for recombinant and genetically modified products; ICMR ethics guidelines | USFDA (CDER/CBER) with IND/NDA/BLA pathway and PDUFA goal dates; EMA/CHMP with the EU Clinical Trials Regulation and CTIS; MHRA, PMDA |
|
||||
| Trial registry | **CTRI** — prospective registration mandatory for trials conducted in India | **ClinicalTrials.gov** and **EU CTIS**; both keep version histories — use them to detect protocol and endpoint changes |
|
||||
| Primary filings | Annual report, quarterly results, investor presentation, **earnings concall transcript**, and SEBI LODR Regulation 30 material-event announcements (trial outcomes, approvals, partnerships) | 10-K / 10-Q / **8-K** for material events, S-1/S-3 for financings, 424B prospectuses; proxy (DEF 14A). Disclosure is faster, more granular and more standardised |
|
||||
| R&D accounting | Ind AS 38 allows post-feasibility capitalisation — check "intangible assets under development" every year and reconcile to programme progress | ASC 730 mandates expensing; IFRS filers face the same IAS 38 option as India, so IFRS-reporting European developers need the same restatement |
|
||||
| Financing instruments | QIP, preferential allotment, **promoter/investor warrants (25% upfront, balance on conversion within 18 months)**, rights issues, FCCBs. No ATM-equivalent shelf mechanism; dilution is lumpier and more visible | ATM programmes off an effective shelf, PIPEs, registered directs, pre-funded warrants, convertible notes, venture debt, royalty and revenue-interest financing |
|
||||
| Ownership disclosure | Quarterly **shareholding pattern** (promoter, promoter pledge, FII, DII, public); SEBI PIT continual disclosures for designated persons and trading plans; SAST for large stakes | **Form 4** insider transactions and 10b5-1 plans; 13F quarterly institutional holdings; 13D/G for 5%+ stakes — the specialist-fund register is far more legible |
|
||||
| Governance overlay | CARO reporting, auditor qualifications, SEBI LODR related-party approvals, promoter pledge levels | SOX 404 internal control opinion, critical audit matters, audit committee independence, Nasdaq/NYSE listing standards including minimum price rules |
|
||||
| Domestic commercial value | **DPCO/NLEM** price control and low willingness to pay mean an India-only innovative launch rarely supports an innovator economic model; Indian developers must target US/EU markets or out-license to capture value | IRA negotiation, 340B, Medicaid rebates and commercial payer mix in the US; HTA-set prices (NICE, G-BA/IQWiG, HAS, PBAC) in Europe and elsewhere |
|
||||
| Support and incentives | BIRAC and DBT grants, PRIP scheme support for innovation, Section 35(2AB) weighted R&D deduction now at 100%, state biotech park incentives — treat grant income as non-recurring, never as revenue | Orphan drug clinical trial tax credits, NIH/BARDA grants and contracts, Priority Review Vouchers where currently authorised — again, non-recurring |
|
||||
| Units and reporting | Rs crore / lakh; fiscal year April–March; quarterly results. Burn is often best read from the cash flow statement's half-yearly disclosure, which is less granular than US quarterly data | USD millions; calendar year common; full quarterly cash flow statements and an explicit runway statement in the liquidity note of the 10-Q |
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Confirm there is no product revenue. If there is, route to `pharma-healthcare.md`; if the entity is an R&D arm of a commercial parent, separate the two and value them independently.
|
||||
- [ ] Delete P/E, EV/EBITDA, EV/Sales, P/S, OPM, ROCE, ROE, D/E, FCF yield and current ratio from the analysis, and state in the output why they are undefined here.
|
||||
- [ ] Compute cash runway in quarters, name the calendar quarter cash runs out, and compare it to the next value-inflecting catalyst date.
|
||||
- [ ] Chart quarterly net burn for 8–12 quarters and check the trajectory reconciles to disclosed trial starts, enrolment and completions.
|
||||
- [ ] Split burn into R&D and G&A; flag G&A growing faster than R&D, and check programme-level R&D against the deck's stated priorities.
|
||||
- [ ] Build the pipeline table from the trial registry and the corporate deck side by side; investigate every asset that appears in one and not the other.
|
||||
- [ ] Assign PoS from published phase base rates, state them as base rates, and justify explicitly any deviation for indication, modality or design quality.
|
||||
- [ ] Build rNPV asset by asset with bottom-up peak sales, risk-adjusted costs, an explicit exclusivity cliff and no terminal value; sum, add net cash, deduct PV of central costs and expected dilution.
|
||||
- [ ] Re-derive peak sales from the epidemiology funnel and compare it to management's number; report the gap.
|
||||
- [ ] Score trial design: randomisation, blinding, control arm, endpoint validity, powering vs observed effect size, multiplicity, analysis population, enrolment velocity. Haircut PoS for single-arm, open-label or unvalidated-surrogate designs.
|
||||
- [ ] Build the 24-month catalyst calendar with dated events, and mark which are company-controlled.
|
||||
- [ ] Assess reimbursement: comparator-benchmarked net price, gross-to-net, HTA evidence requirements, payer mix and IRA modality exposure.
|
||||
- [ ] Map every competing asset by phase from the registries; state probable order of entry and the read-across risk from competitor readouts.
|
||||
- [ ] For every partnership, separate upfront from biobucks, and record royalty tiers, retained rights, opt-outs and reversion clauses. Treat any return of rights as a first-order negative.
|
||||
- [ ] Chart 5–10 years of share count with every raise's price and discount; inventory ATM capacity, warrants, convertible mechanics and any royalty financing.
|
||||
- [ ] Run the reverse test: solve for the lead asset's market-implied PoS and compare it to the phase base rate.
|
||||
- [ ] Report the bimodal outcome pair — success-case and failure-case value per share — not only the probability-weighted mean.
|
||||
- [ ] Cross-check against precedent licensing and M&A economics for same-phase, same-modality assets; check EV/cash for negative-EV situations.
|
||||
- [ ] List regulatory designations and state precisely what each confers; confirm none has been presented as evidence of efficacy.
|
||||
- [ ] Map the exclusivity stack — patents, regulatory data exclusivity, orphan exclusivity, paediatric extension — and use it to set the revenue window.
|
||||
- [ ] Check insider and specialist-fund ownership changes, and management's prior record of INDs filed and approvals actually obtained.
|
||||
- [ ] India: check Ind AS 38 capitalised development costs and restate to a fully expensed basis; check promoter holding, pledge and warrant issuances; read CTRI entries directly.
|
||||
- [ ] Build a peer set of 3–6 matched on phase, modality, therapeutic area, ownership structure and funding position — or state that no valid peer exists and use precedent transactions instead.
|
||||
- [ ] State where the sector sits in the funding cycle and what that does to the cost and availability of the company's next raise.
|
||||
|
|
@ -0,0 +1,231 @@
|
|||
# Specialty chemicals, agrochemicals, fertilisers and cement — sector playbook
|
||||
|
||||
Use this when: the company converts bulk feedstock into a physical product sold by the tonne or the kilogram — specialty and fine chemicals, CDMO/CRAMS, commodity and petrochemical intermediates, dyes and pigments, agrochemical technicals and formulations, urea and P&K fertilisers, and cement, clinker and ready-mix concrete.
|
||||
|
||||
This is not one sector. It is at least four businesses stapled together by an index label, and the generic ratio checklist breaks in a *different* way in each. Specialty chemicals are pass-through-priced, so margin and revenue growth are both accounting artefacts of input costs. Fertilisers are administratively priced, so ROCE is set by a government notification rather than by competitive advantage. Cement is a regional logistics cyclical where P/E is actively inverted and book value bears no relation to replacement cost. Agrochemicals sit between the two, with a registration-and-patent-cliff structure closer to pharma than to chemicals. Your job is to identify which sub-sector you are actually in before you quote a single ratio, then replace contaminated financial ratios with unit economics (EBITDA per tonne, gross profit per kg), physicals (utilisation, clinker factor, energy per tonne against norm) and capital-allocation tests (incremental ROCE on the last capex cycle).
|
||||
|
||||
## Contents
|
||||
|
||||
1. [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
2. [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
3. [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
4. [Peer set construction](#peer-set-construction)
|
||||
5. [Sector-specific red flags](#sector-specific-red-flags)
|
||||
6. [Cycle and structural context](#cycle-and-structural-context)
|
||||
7. [India vs global notes](#india-vs-global-notes)
|
||||
8. [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Work through these before quoting any standard ratio. In most cases the right action is to suppress the metric or replace it with the sub-sector version, not to caveat it.
|
||||
|
||||
**OPM is not comparable — not even within the sector.** Structural margins differ by design: specialty chemicals 18–25% (CDMO/CRAMS 25–35%), commodity and bulk chemicals 8–14%, cement 15–25% (collapsing below 10% at cycle troughs), urea 5–8%, agrochemical distribution and traded fertiliser 1–4%. A fertiliser company at 6% OPM can earn a better ROE than a chemicals company at 20%, because the capital intensity and the working-capital funding are completely different. **Ranking on OPM inside this sector produces nonsense.** Always compare margin to the company's own history and to its sub-sector, never across the group.
|
||||
|
||||
**Chemicals margin and revenue growth are both pass-through artefacts.** Most specialty contracts are formula-priced: raw material cost plus a conversion fee. When crude, benzene, acetone, phenol or Chinese intermediate prices fall, revenue falls while gross profit per kg is unchanged — so OPM *mechanically expands* while "revenue growth" collapses. Both signals are false, and both invert when input prices rise. Strip the pass-through by working in **gross margin and gross profit / EBITDA per kg**, and decompose revenue into volume × realisation before commenting on growth.
|
||||
|
||||
**Fertiliser "revenue" is not revenue and "margin" is not a margin.** For Indian urea, 60–75% of realisation is government subsidy under NPS-III / the modified scheme; for P&K it is NBS. The return is administratively fixed (broadly a ~12% post-tax return-on-net-worth construct for urea, plus whatever the plant earns by beating its energy norm). A high ROCE therefore means the norms are generous or the plant is efficient against them — **not that a moat exists**. Margins can also jump for a quarter purely on recognition of prior-year subsidy arrears.
|
||||
|
||||
**D/E and working capital are structurally distorted for fertilisers.** Delayed subsidy disbursal, plus special banking arrangement borrowings, means large short-term debt exists solely to fund a sovereign receivable. Headline D/E of 1.5–2.0x can be economically ~0.3x. Compute debt **ex-subsidy-backed working-capital debt**, and receivable days **ex-subsidy**, or the comparison to any other company is meaningless.
|
||||
|
||||
**P/E is actively dangerous for cement, and inverted.** Cement earnings peak with price and utilisation, so the stock screens cheapest at exactly the top and most expensive (or loss-making) at the bottom. The correct reading is the opposite of the generic one. The same trap applies to commodity chemicals and to any specialty name that caught a one-off pricing windfall — the 2021–22 refrigerant-gas, agrochem-intermediate and China-shutdown spikes are the standing example of 35% margins reverting to 15% within six quarters.
|
||||
|
||||
**FCF is structurally negative through the build phase, and that is not a defect.** Cement greenfield takes 3–4 years at roughly ₹6,500–8,500 crore per 10 mtpa in India (~$100–120/t globally); chemical multipurpose plants take 18–30 months to build and 2–3 years to ramp. Screening on positive FCF systematically rejects the companies that are compounding capacity. Split **maintenance capex** (cement roughly ₹150–250/t of capacity per year; chemicals ~3–4% of gross block) from growth capex, then judge the return on the growth capex.
|
||||
|
||||
**ROCE is depressed by CWIP and flattered by old assets.** A company mid-build carries large capital work-in-progress earning nothing, so reported ROCE understates the operating business — compute it **ex-CWIP**. Conversely, a 30-year-old cement plant carried at historic cost shows spectacular ROCE and a misleadingly low P/B, because replacement cost is 3–5x book. **P/B is close to meaningless for cement for exactly this reason**, and "low P/B" is not a value signal.
|
||||
|
||||
**Inventory turnover cannot be compared across the three.** Cement has a ~3-month shelf life and cannot be stockpiled, so inventory days are structurally 15–30. Chemicals run 60–110 days. Fertilisers and agrochemicals are violently seasonal (Kharif/Rabi in India, the Northern-Hemisphere spring season globally) and can legitimately hold 90–150 days. Cross-comparison, or year-on-year comparison struck at the wrong quarter-end, is pure noise.
|
||||
|
||||
**Asset turnover looks "bad" by design.** Cement runs ~0.5–0.8x gross-block turns, chemical plants ~1.0–1.5x. Measured against an FMCG-calibrated 3x+ benchmark, every company here fails a screen it was never in scope for.
|
||||
|
||||
**EV/Sales and revenue-based screens misfire on traders.** Fertiliser importers and chemical distributors book large traded volumes at 1–3% margin purely to inflate topline. A distributor at 4% margin and a manufacturer at 20% margin cannot share a revenue-based screen.
|
||||
|
||||
**Current ratio and interest cover mislead in opposite directions.** A fertiliser company's current ratio is inflated by an uncollected sovereign receivable; a mid-build cement or chemicals company's interest cover is flattered because interest is being **capitalised into CWIP** rather than expensed. Always read the capitalised-interest disclosure before quoting cover.
|
||||
|
||||
---
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges below are **indicative only**. They vary by market, sub-sector, cycle position, energy prices and reporting period, and several are quoted in nominal currency that drifts with inflation. A company's own 5–10 year history and its *direct sub-sector* peers at the *same point in the cycle* always override any absolute band quoted here.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **EBITDA per tonne (cement)** | Cement EBITDA ÷ sales volume in tonnes, decomposed into realisation/t minus cost/t. Strip out state incentive/SGST-deferral income and non-cement segments first, and disclose whether you have. | India: ₹800–1,200/t is a healthy mid-cycle band; >₹1,400/t is peak (treat as unsustainable); <₹600/t is trough. Developed markets: US$25–40/t, with US leaders running $40–55/t in tight cycles. | The single unit-economics number in cement, and the basis on which every management guides. It separates an earnings jump caused by **price** (cyclical, mean-reverting) from one caused by **cost or efficiency** (durable), and it is the input to the only sensible cement valuation: mid-cycle EBITDA/t × capacity. |
|
||||
| **Capacity utilisation, and clinker vs grinding balance** | Volume sold ÷ installed grinding capacity, read alongside the clinker-to-grinding ratio and the split-grinding-unit footprint. Track *industry/regional* utilisation, not just the company's. | India: 70–85% is normal; the industry historically gets pricing power only above ~80–85% system utilisation. An efficient single player should run 5–15 points above industry. Mature global markets 75–85%. | Cement prices are set by regional supply-demand, not by any single company. Utilisation is the leading indicator of whether the pricing cycle is turning. A company adding capacity into a sub-70%-utilisation region destroys value for itself and everyone else in that region. |
|
||||
| **Cost per tonne build-up: power & fuel, freight, lead distance** | Cost/t split into power & fuel (~25–30%), freight & forwarding (~20–25%), raw material and limestone, employee, other. Lead distance = average km from plant to market. Track fuel mix (petcoke vs imported/domestic coal vs AFR) and rail vs road share. | Lead distance <350–400 km (best-in-class 200–300 km). Power <70–75 kWh/t of cement; thermal energy <720–750 kcal/kg of clinker. Waste-heat recovery plus renewables >30% of power (leaders target 50–60%). Alternative-fuel/thermal substitution 5–15% India, 30–60% Europe. | Cement is a logistics business with a kiln attached — nobody ships cement profitably beyond ~500 km. Lead distance and fuel mix are the only genuinely defensible cost moats, and they separate a structurally low-cost operator from one that merely caught a good price cycle. Petcoke and coal moves pass straight into EBITDA/t, so the fuel mix tells you how next quarter moves. |
|
||||
| **Clinker factor / blend ratio and CO₂ intensity** | Tonnes of cement per tonne of clinker consumed (i.e. how much fly ash, slag or limestone filler substitutes for clinker), and net CO₂ per tonne of cementitious material. | Clinker factor 0.62–0.70 (blend ratio ~1.45–1.60) is good in India where PPC/PSC dominate; developed markets historically 0.75–0.80 and falling. CO₂ <550–600 kg/t cementitious is competitive; European leaders target <500. | Every point of clinker substitution is a direct cost saving *and* effectively free capacity, because clinker is the energy-intensive, CO₂-emitting, capital-intensive part. It is also the main determinant of carbon-cost exposure: EU ETS plus CBAM (cement is in scope from 2026) turns CO₂/t into a hard P&L line for European producers and for anyone exporting into the EU. |
|
||||
| **Trade vs non-trade mix and premium product share (cement)** | Split of volume between trade (retail/dealer, individual home builder) and non-trade (bulk, institutional, infra contractors, RMC), plus branded premium SKUs as a share of trade volume. | Trade share >65–70% is a strong sign; premium products >12–20% of trade volume for leading brands. | Trade sales carry roughly ₹200–400/t higher realisation and are where brand equity actually exists. Management reporting flat realisation while quietly shifting to non-trade is losing pricing power and hiding it in mix. A rising premium mix is one of the few genuine margin levers that is not the cycle. |
|
||||
| **Gross margin and gross profit per kg (specialty chemicals)** | Revenue minus raw materials and consumables, expressed both as % and in absolute currency per kg sold. Track per kg through a full input-price cycle. | Genuine specialty / CDMO: 45–60% gross margin. Fine chemicals and agrochem intermediates: 35–45%. Below ~30% you are looking at a commodity chemical company describing itself as specialty. Global peers (Croda, IFF, Novonesis) run 35–55%. | The only chemicals margin not contaminated by input pass-through, inventory gains and mix accounting. A company whose OPM rises while gross profit per kg is flat has had a raw-material tailwind, not an improvement. **Stable gross profit per kg through an input-price cycle is the actual proof of a contracted, sticky, specialty business.** |
|
||||
| **R&D intensity and product vintage** | R&D as % of sales; number of active molecules; pipeline by commercialisation stage; share of revenue from products launched in the last 5 years. Check patents/DMFs filed and pilot-plant/kilo-lab capacity. | Specialty/CDMO: 2–5% of sales in India, 3–6% globally. <1% means commodity. New-product revenue share of 15–30% indicates a functioning innovation engine. | Specialty multiples are paid for the ability to keep replacing molecules as they commoditise — every specialty product decays into a commodity in 5–10 years. Sub-1% R&D alongside 25% margins is a warning that the margin is a temporary supply dislocation, not a capability. |
|
||||
| **Customer, product and geography concentration; contracted order book** | Revenue share of top 5 customers and of the largest molecule; share under multi-year contracts or LTSAs; CDMO/CRAMS committed order book; single-source dependence on Chinese intermediates. | Top 5 customers <40–50%; largest single product <20–25%. CDMO order book >1.0–1.5x annual revenue with named innovator customers. Anything where one molecule is >35% of EBITDA should be valued as a single-product company. | Indian specialty chemical blowups are almost always single-molecule or single-customer events: the innovator loses exclusivity, in-sources, dual-sources, or a Chinese competitor restarts a shut line. Concentration is the dominant risk factor and is **invisible in every financial ratio**. |
|
||||
| **Agrochemical registration portfolio, patent-cliff pipeline and channel inventory** | Count and geography of product registrations (CIB&RC Section 9(3) vs 9(4) in India; EPA in the US; EU Reg. 1107/2009 Annex I), share of revenue from post-patent molecules, the molecules coming off patent in the next 3–5 years, technical vs formulation mix, and distributor channel inventory / days of stock in the trade. | Technicals (backward-integrated) should be >40–50% of agrochem revenue for a manufacturer, not a formulator. A registration pipeline that replaces >10% of revenue over 5 years. Channel inventory at or below normal season-end days. | Agrochemicals are a registration business, not a chemistry business: the moat is the data package and the country registration, which take 3–7 years and real money to build. Revenue is recognised on sell-*in* to distributors, so a season of channel stuffing shows as growth and then as a collapse — the 2023–24 global destocking cycle halved earnings at companies whose end-demand never changed. Always reconcile sell-in to sell-out. |
|
||||
| **Energy consumption per tonne of urea vs the notified norm (Gcal/MT)** | Specific energy consumption of each urea plant against the government's cut-off/target energy norm under NPS-III / the modified scheme. Consumption below the norm is retained as profit; above it is an uncompensated loss. | Gas-based post-2015-policy plants ~5.0–5.5 Gcal/MT; notified target norms cluster near 5.5, with older plants at 6.0–6.5 and being squeezed. Above ~6.5 Gcal/MT is a stranded-asset candidate. | In a regulated cost-plus business this is the **only** operating lever that converts into profit. It also tells you who dies at the next norm revision: the government periodically tightens cut-off norms, and a plant running above the new norm loses its entire efficiency margin overnight. This is the fertiliser equivalent of cost per tonne. |
|
||||
| **Non-subsidy EBITDA share (fertilisers)** | EBITDA from businesses outside the administered-price regime: complex/P&K with pricing freedom, crop protection, specialty nutrients and water-solubles, industrial chemicals (melamine, TAN, methanol), seeds, retail agri-inputs. | Re-rating candidates are those pushing non-subsidy EBITDA above 30–50%. Pure regulated urea players sit near 0–10%. | Regulated urea earnings are bond-like and deserve a utility multiple; non-subsidy agri-input earnings are market-priced and deserve a chemicals multiple. This ratio drives the sum-of-the-parts valuation and is the main structural story in Indian fertiliser equities. |
|
||||
| **Working-capital cycle calibrated by sub-sector, including subsidy receivable days** | Inventory + receivable − payable days, benchmarked to the *right* sub-sector norm. For fertilisers, compute subsidy receivable days separately (outstanding subsidy ÷ daily revenue) and subsidy as a % of revenue. For agrochemicals, isolate Latin American receivables and barter/crop-payment terms. | Cement 15–35 days total (near-cash, dealer-financed). Specialty chemicals 80–130 days. Agrochemicals 120–200 days, worse in Latin America. India fertiliser subsidy receivable 45–90 days normal; >120–150 days signals a budget-shortfall year. Subsidy is typically 60–75% of urea revenue, 30–50% of P&K. | The single largest source of false comparisons in this sector. A sovereign receivable dictates fertiliser borrowings, interest cost and reported D/E — none of which are commercial decisions, and a spike is usually a fiscal event rather than a company event. Cement's near-zero cycle is why it can carry leverage that would kill an agrochemical company. |
|
||||
| **ROCE excluding CWIP and cash, plus incremental ROCE on the last 3 years' capex** | EBIT ÷ (net fixed assets *in operation* + working capital), deliberately excluding CWIP and surplus cash. Then: change in EBIT over 3 years ÷ capital deployed over the same period. | Specialty chemicals 18–25% ex-CWIP is good, >25% excellent. Cement 12–18% mid-cycle (an efficient operator can print 20%+ at peak — do not extrapolate). Fertilisers 12–16%, effectively capped by regulation. Incremental ROCE must clear WACC: ~11–13% India, 7–9% developed markets. | This whole sector is a capital-allocation game — **capacity is the product**. Reported ROCE punishes companies mid-build and rewards those with fully depreciated assets, so it says nothing about management skill. Incremental ROCE on recent capex is the only number that tells you whether the next ₹5,000 crore of expansion creates or destroys value. |
|
||||
| **Capex per unit of installed capacity vs peers, and project execution record** | Announced/actual project cost ÷ capacity created, benchmarked to comparable recent projects; plus the record of on-time, on-budget commissioning and time to full ramp. | Cement greenfield India ~₹6,500–8,500 crore per 10 mtpa (≈$100–120/t globally); brownfield and standalone grinding units far cheaper at ₹2,500–3,500/t. Acquisitions have transacted at $60–160/t. Chemicals: judge asset turn at full ramp — a plant should deliver 1.0–1.5x sales on gross block. | The highest-signal forensic ratio in the sector. Capex per tonne materially above the peer benchmark is the classic mechanism for extracting cash through inflated EPC contracts to related parties; materially below can mean corners cut or capacity overstated. It also *sets* the future ROCE — you cannot earn a good return on an overpriced plant. |
|
||||
| **Net debt / EBITDA and interest cover, adjusted for subsidy-backed and construction debt** | Net debt/EBITDA computed on the *operating* business: exclude fertiliser subsidy-financing borrowings, and separately quantify debt attached to assets not yet generating EBITDA. Note how much interest is capitalised rather than expensed. | Cement <1.5x comfortable, <2.5x acceptable mid-build, >3x through a downturn is dangerous. Specialty chemicals <2.0x. Fertilisers ex-subsidy debt <1.5x. Interest cover >5x. | Fixed-cost plants with cyclical prices mean EBITDA can halve in four quarters; leverage taken against peak EBITDA is how cement companies end up being sold at the bottom of the cycle. The adjustments matter because unadjusted leverage makes fertiliser companies look distressed and makes mid-construction companies look fine right up until the ramp slips. |
|
||||
| **Environmental compliance and licence-to-operate status** | Consent-to-operate validity; pollution control board notices and closure orders; zero-liquid-discharge status; effluent and hazardous-waste handling; EHS incident and fatality record; limestone reserve life and mining-lease tenure (cement); gas allocation and pipeline connectivity (fertiliser). | Cement: 40–50+ years of limestone reserves at planned capacity, leases secured. Chemicals: ZLD achieved at all sites, no pending closure orders, no repeat consent violations. Zero fatalities. | This is an existential operating KPI, not an ESG nicety. Indian pollution boards shut chemical plants for weeks with no notice in the Gujarat, Telangana and Tamil Nadu clusters; a cement company without secured limestone has no business regardless of its P&L; a fertiliser plant without gas allocation cannot run. A single site closure at a concentrated manufacturer removes a year of earnings and appears in no financial ratio. |
|
||||
|
||||
**Sourcing notes.** India: volumes, realisation, EBITDA/t, lead distance, trade mix, blend ratio, energy norms and subsidy receivables live in the **quarterly investor presentation and concall transcript**, not the financials. Segment notes give sub-sector splits; the CARO report and related-party note carry the governance signals; contingent liabilities carry CCI penalties and tax/environment disputes. Global: 10-K MD&A and segment reporting, sustainability reports for CO₂/t and clinker factor, and industry data (CMA/DIPP dispatch data in India; USGS, Cembureau, GCCA globally; Phillips McDougall/AgbioInvestor for agrochemicals).
|
||||
|
||||
---
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
**Value each sub-sector on its own basis. A single multiple across the group is wrong.** For a diversified group, SOTP is mandatory.
|
||||
|
||||
### Cement — asset-based and mid-cycle, never trailing P/E
|
||||
|
||||
**Primary: EV per tonne of installed capacity, benchmarked to greenfield replacement cost.** India has transacted in the ₹4,500–9,000/t range, with listed leaders trading at ₹9,000–15,000/t against a replacement cost of roughly ₹6,500–8,500/t. The global analogue is $/t against a ~$100–150/t replacement cost. Below replacement cost is the classic cyclical entry; above it you are paying for brand, regional market position and pricing power — which the large Indian players in the south and west genuinely have. State explicitly which you are paying for.
|
||||
|
||||
**Secondary: EV/EBITDA on mid-cycle EBITDA/t.** Build it bottom-up: capacity × utilisation × normalised EBITDA/t. India mid-cycle 10–14x for leaders, 6–9x for regional players; developed markets 6–9x. The multiple must *contract* as you move up the cycle — applying a constant multiple to a rising EBITDA estimate is a momentum model, not a valuation.
|
||||
|
||||
**Also useful:** replacement-cost DCF, and the greenfield-vs-acquisition cost-per-tonne arbitrage (which is the actual decision management faces).
|
||||
|
||||
**Explicitly avoid P/E and P/B.** P/E inverts across the cycle; book value is historic cost far below replacement cost. Cement is bought at an optically high P/E on trough earnings and sold at an optically low P/E on peak earnings.
|
||||
|
||||
### Fertilisers — sum-of-the-parts, with utility logic for the regulated leg
|
||||
|
||||
The **regulated urea business is a quasi-utility**: value it on P/B against the regulated return on net worth (broadly a ~12% post-tax RoNW construct), i.e. roughly 1.0–1.5x book depending on how far energy efficiency runs ahead of the norm, or on a low 5–8x EV/EBITDA. It does not deserve a growth multiple because both volumes and returns are capped.
|
||||
|
||||
The **non-subsidy businesses** — P&K with pricing freedom, crop protection, specialty nutrients, industrial chemicals, seeds — get market multiples (roughly 12–20x P/E, 8–14x EV/EBITDA in India). The re-rating thesis is almost always a rising share of the unregulated leg.
|
||||
|
||||
**Normalise earnings first**: strip prior-period subsidy arrears, subsidy-related interest, and inventory gains/losses from NBS rate changes. Prefer free cash flow to reported PAT, because subsidy timing distorts PAT in both directions.
|
||||
|
||||
In developed markets (Nutrien, Mosaic, Yara, CF) there is no subsidy regime at all — these are pure commodity cyclicals valued on mid-cycle EV/EBITDA (5–8x) and on gas-cost-curve position. **Indian fertiliser conventions do not transfer to them, or vice versa.**
|
||||
|
||||
### Specialty chemicals and agrochemicals — growth and cash-return based, with a capex-ramp DCF
|
||||
|
||||
**Primary: P/E and EV/EBITDA on forward earnings that reflect the ramp of announced capex.** India has paid 30–50x P/E and 18–30x EV/EBITDA for high-ROCE, high-visibility specialty and CDMO names; developed-market peers (Croda, Lanxess, Arkema, Evonik) trade at 8–15x EV/EBITDA and 12–20x P/E. That premium is a real convention driven by China+1, higher structural growth and better ROCE — but it also means Indian valuations **de-rate violently when growth stalls**, and a de-rating from 45x to 25x overwhelms any earnings growth you were underwriting.
|
||||
|
||||
**Build an explicit capex-ramp DCF.** For each announced plant, model commissioning date, asset turn at full utilisation (1.0–1.5x), steady-state EBITDA margin, and the resulting incremental ROCE. Because these companies are in continuous capex, near-term FCF is negative and only a DCF captures value being created.
|
||||
|
||||
**Use EV/EBITDA rather than P/E when mid-build** (depreciation and capitalised interest distort EPS). Cross-check with EV/Sales (2–5x specialty, 5–8x high-margin CDMO) **only** for pre-profit ramping assets. PEG is used in India as a sanity check on the growth premium.
|
||||
|
||||
For **generic agrochemicals**, value closer to generic pharma: the registration portfolio and technical backward-integration are the assets, earnings are lumpy with the destocking cycle, and mid-cycle EV/EBITDA of 8–12x is more appropriate than a specialty multiple. For **commodity chemicals** inside the group, revert to cement logic: mid-cycle EV/EBITDA and replacement cost, never trailing P/E.
|
||||
|
||||
### Cross-cutting
|
||||
|
||||
- **SOTP is mandatory for diversified groups** (Indian conglomerates commonly hold cement plus chemicals plus fertilisers), with a 10–20% holding-company discount where segments are unrelated, and more where a listed subsidiary is the main asset.
|
||||
- **Sanity-check every valuation against replacement cost of the asset base as a floor**, and against incremental ROCE on recent capex as the test of whether growth is worth paying for.
|
||||
- **What NOT to use:** trailing P/E for cement or any commodity chemical; P/B for cement; EV/Sales for distributors and traders; a group-wide multiple; DCF with a perpetual-growth terminal value applied to a single-molecule specialty business whose product will commoditise inside a decade.
|
||||
|
||||
---
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares **sub-sector, pricing regime, region and integration level** — not the label "chemicals". If you cannot state each peer's sub-sector, gross margin per unit, regulatory regime and cycle position, you have a list of tickers, not a peer set.
|
||||
|
||||
**Splits that must not be mixed:**
|
||||
|
||||
- **Specialty vs commodity vs CDMO.** A CDMO with contracted innovator volumes at 30% EBITDA margin, a specialty formulator at 20%, and a bulk intermediate producer at 10% have different multiples, different cyclicality and different failure modes. Gross margin below ~30% disqualifies a "specialty" label regardless of how the company describes itself.
|
||||
- **Manufacturer vs formulator vs distributor/trader.** A backward-integrated technical manufacturer, an agrochemical formulator buying technicals, and a distributor at 1–4% margin cannot share revenue-based or margin-based screens.
|
||||
- **Regulated urea vs NBS-linked P&K vs unregulated agri-inputs.** These are three different pricing regimes inside one company. Split them before comparing anything, including to the same company's own history if the mix has changed.
|
||||
- **Cement by region, not by country.** Indian cement pricing is regional: south, west, north, east and central markets have independently moving prices, utilisation and consolidation levels. A south-focused player and an east-focused player are not comparables in the same quarter. The same is true of US regions and of European country markets.
|
||||
- **Integrated vs grinding-only cement.** A grinding unit buying clinker has different capital intensity, different cost structure and a different EV/t benchmark than an integrated plant with captive limestone. Never compare their EV/t without stating clinker self-sufficiency.
|
||||
- **Innovator vs generic agrochemicals.** An innovator with proprietary molecules under patent, and a post-patent generic manufacturer competing with Chinese supply, have opposite margin trajectories and should never share a multiple.
|
||||
- **Capex phase.** A company mid-build with 40% of capital in CWIP and a company with a fully ramped asset base will show ROCE 8–10 points apart with identical asset quality. Compare ex-CWIP, and state each peer's CWIP-to-gross-block ratio.
|
||||
- **India vs China vs developed markets.** Chinese producers operate with different environmental cost structures and state support; developed-market peers carry carbon costs and higher energy prices. Cost-curve logic transfers; multiples do not.
|
||||
- **India-specific:** PSU fertiliser and cement entities carry administered pricing, disinvestment overhang and social obligations; private peers do not. Companies with large state SGST/VAT incentive accruals have an EBITDA component that expires on a known date — normalise it out before comparing EBITDA/t.
|
||||
|
||||
---
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
### Cement
|
||||
|
||||
- **Capacity or acquisition announcements without secured limestone reserves and mining leases.** Reserve life below ~25 years at planned capacity, or leases won at aggressive auction premiums, means the announced capacity may never operate, or will operate at a permanent cost disadvantage.
|
||||
- **Paying materially above replacement cost** (roughly ₹8,500/t or $120/t) for an acquisition, or greenfield capex per tonne well above the peer benchmark. Inflated project cost routed through EPC contracts to promoter-linked entities is the standard cash-extraction mechanism in this sector.
|
||||
- **Quarter-end channel stuffing.** Cement has a ~3-month shelf life and dealers hold limited stock, so a jump in dispatches with rising receivable days and falling realisation the following quarter means volume was pushed into the trade rather than sold to end users. Watch the trade/non-trade mix quietly shifting to low-margin institutional volume while management reports "stable" realisation.
|
||||
- **Leverage sized on peak-cycle EBITDA.** Debt at 2.5x peak EBITDA becomes 5x+ when prices normalise, because operating leverage in a fixed-cost kiln business is brutal. Also watch capitalised interest and pre-operative expenses parked in CWIP for years without commissioning.
|
||||
- **CCI cartelisation penalties and regional "price discipline"** sitting in contingent liabilities. Coordination inflates current EBITDA/t and is simultaneously a legal liability and a signal that current margins are not competitively earned.
|
||||
- **State incentive income (SGST/VAT deferral, capital subsidies) presented inside operating EBITDA** without disclosure of expiry. It can be ₹100–300/t at incentive-heavy plants and it disappears on a scheduled date.
|
||||
|
||||
### Fertilisers
|
||||
|
||||
- **Recognising subsidy income before it is notified or accrued**, or booking prior-year subsidy arrears into the current quarter without separate disclosure. This creates phantom margin expansion in a business whose real margins are fixed by regulation.
|
||||
- **Ballooning subsidy receivable days alongside rising short-term debt and interest cost while EBITDA looks stable.** Reported profit holds up while cash generation collapses, and the interest carry on the receivable is often not fully compensated.
|
||||
- **Plants running above the notified energy norm, or a company lobbying loudly about norm revisions.** When cut-off norms tighten, sub-scale and older gas/naphtha plants lose their entire efficiency margin at once. Also watch dependence on a single gas allocation or pipeline connection.
|
||||
- **Low-margin traded/imported fertiliser volume presented as "growth"** at 1–3% margins. Separately, any exposure to diversion of subsidised urea to industrial use is a live regulatory and reputational risk in India.
|
||||
- **Imported DAP/MOP inventory carried through an NBS rate change.** A rate cut strands inventory bought at the old economics; the loss lands in one quarter and is often described as "one-off".
|
||||
|
||||
### Specialty chemicals and agrochemicals
|
||||
|
||||
- **A one-off pricing windfall in a single molecule presented as structural.** The 2021–22 refrigerant-gas, agrochem-intermediate and China-shutdown spikes produced companies at 35% margins that reverted to 15% within six quarters. Test: did *gross profit per kg* rise, or only price per kg — and did volume grow at all?
|
||||
- **Margin expansion attributed to "better product mix" with flat or falling volumes and no rise in gross profit per kg.** Usually this is inventory gain from a raw-material move, or a falling input cost passed through to a formula-priced customer with a lag. Both reverse.
|
||||
- **R&D capitalised into intangibles rather than expensed**, or R&D below 1% of sales while marketing the company as specialty. Check product vintage: if no meaningful revenue comes from products launched in the last five years, the current margin is decaying.
|
||||
- **Concentration disclosed only in fine print.** One molecule >35% of EBITDA, one innovator customer >25% of revenue, or a single unhedged Chinese source for a key intermediate. Loss of innovator exclusivity, in-sourcing or a Chinese restart removes the earnings base with no warning.
|
||||
- **Sell-in growth without sell-out confirmation in agrochemicals.** Rising distributor receivable days plus rising channel inventory ahead of a season is the destocking cycle loading. Watch for extended credit terms and for revenue concentrated in the last month of a quarter.
|
||||
- **Environmental shutdowns and consent violations.** Repeat pollution-board notices, missing ZLD, or a single-site manufacturer in a cluster subject to blanket closure orders. EHS incidents and fatalities are a leading indicator of maintenance underinvestment — reactor incidents shut sites for months.
|
||||
|
||||
### All three
|
||||
|
||||
- **CWIP sitting on the balance sheet for multiple years without commissioning**, growing interest capitalisation, and repeatedly slipping commissioning guidance. Either the project is impaired or the spend is not real. Check announced capacity against actual production once commissioned.
|
||||
- **Large advances to suppliers, loans and guarantees to unlisted group entities, and rising related-party transactions alongside a capex cycle.** Combined with high promoter share pledge, auditor resignation or a mid-year auditor change, this is the standard pre-blowup pattern in Indian mid-cap chemicals.
|
||||
- **Maintenance capex reported implausibly low** — cement below roughly ₹150/t of capacity per year, chemicals below ~2–3% of gross block. Deferred maintenance flatters near-term FCF and returns later as unplanned shutdowns and falling utilisation.
|
||||
- **Unhedged foreign-currency debt or import exposure**, and for European or EU-exporting producers, unprovided carbon costs. EU ETS plus CBAM from 2026 turns CO₂ per tonne into a cash cost; a high-clinker-factor producer with no decarbonisation plan is carrying an undisclosed liability.
|
||||
|
||||
---
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Say where you think the cycle is before you quote a ratio, and say what evidence you used.** For cement: regional utilisation, price trends by region, announced industry capacity additions over the next 3 years, and the housing/infrastructure spend cycle. For chemicals: Chinese capacity restarts and export prices, crude and naphtha, customer inventory levels, and China+1 order-book commentary. For fertilisers: the budget subsidy allocation, gas and ammonia/phosphoric acid contract prices, and monsoon/reservoir data. For agrochemicals: channel inventory, farm-gate crop prices, and the position in the global destocking cycle.
|
||||
|
||||
**Cement is a capacity cycle, not a demand cycle.** Demand grows steadily with construction; earnings are destroyed by supply. Announcements cluster at the top (when EBITDA/t is high and financing is easy) and arrive 3–4 years later into a weaker market. Track *industry* announced capacity, not the company's, and downgrade any region where announced additions exceed 3–4 years of demand growth. Consolidation cuts the other way: regions where the top 3–4 players hold most capacity sustain higher utilisation and prices.
|
||||
|
||||
**Cement is regional and seasonal.** Prices are set within a ~300–500 km radius, so national averages hide everything. In India, Q1 (April–June) is the strongest quarter and Q2 (monsoon) the weakest; comparing sequential quarters without adjusting for this manufactures trends that do not exist.
|
||||
|
||||
**Specialty chemicals ride the China+1 relocation, which is real but not uniform.** Chinese environmental enforcement and cost inflation genuinely shifted intermediate manufacturing toward India, but Chinese capacity restarts and aggressive export pricing have repeatedly compressed margins in exactly the molecules where Indian players had the biggest windfalls. Treat "China+1" as a reason to check whether the *specific molecule* is defensible, not as a thesis on its own.
|
||||
|
||||
**Every specialty product commoditises.** The 5–10 year decay from specialty to commodity is the central economic fact of the sub-sector, which is why R&D intensity and product vintage carry more weight than current margin. Anti-dumping duties (India imposes them frequently) can pause the decay but are a policy asset, not a moat — check expiry dates.
|
||||
|
||||
**Agrochemicals run a global inventory cycle on top of a patent cycle.** Post-patent molecules face Chinese generic entry and price collapse; the industry periodically over-stocks the channel and then spends 4–6 quarters destocking, during which reported revenue is unrelated to farm demand. Patent expiries over the next 3–5 years are the generic manufacturers' opportunity set and the innovators' cliff.
|
||||
|
||||
**Fertilisers are policy assets.** The economics are set by the Department of Fertilizers, not by the market: NPS/modified-NPS energy norms for urea, annually notified NBS rates for P&K, gas pooling, urea import canalisation, and DBT — under which subsidy is released only on POS sale to the farmer, which permanently changed the working-capital profile. Structural themes to track: new gas-based urea capacity displacing imports and older plants, nano-urea and coated-urea policy, One Nation One Fertilizer branding (which erodes brand equity in P&K), and the annual budget subsidy allocation, which sets receivable days for the whole industry.
|
||||
|
||||
**Carbon regulation is now a P&L line, not a disclosure.** Cement is one of the largest industrial CO₂ sources; EU ETS plus CBAM (phasing in from 2026) prices embedded carbon on imports into Europe. Clinker factor, alternative fuel rate and CO₂/t therefore become cost variables for European producers and for exporters into Europe. India's CCTS/PAT carbon-credit scheme is developing along similar lines. Chemicals face REACH and PFAS restrictions in Europe, which can obsolete entire product lines.
|
||||
|
||||
**Energy is the swing input everywhere.** Petcoke and coal for cement, natural gas for urea and for European chemicals, crude derivatives for specialty feedstock. An energy price move of 20% is a first-order earnings event in all three sub-sectors, and the lag with which it passes through to customers determines whether it shows up as margin expansion or contraction first.
|
||||
|
||||
---
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India (NSE/BSE, Ind AS) | US / global (10-K, GAAP/IFRS, EDGAR) |
|
||||
|---|---|---|
|
||||
| Fertiliser pricing regime | Administered. Urea MRP fixed by government with subsidy under NPS-III/modified scheme; P&K under NBS with annually notified per-nutrient rates. Subsidy is 60–75% of urea revenue. DBT releases subsidy only on POS retail sale. | No subsidy regime. Nutrien, Mosaic, Yara, CF are pure commodity cyclicals priced off gas cost, ammonia and grain prices. Valuation and margin conventions do **not** transfer in either direction. |
|
||||
| Cement conventions | Reported in mtpa capacity and ₹/bag (50 kg) or ₹/tonne realisation; EBITDA/t is the universal guided metric. Volumes in crore/lakh tonnes — convert consistently and state the unit. PPC/PSC blends dominate, so clinker factor is structurally lower. | Reported in short tons or metric tonnes and $/t; higher clinker factor historically. Ready-mix and aggregates are usually a much larger share of the group, so segment-level analysis is essential before comparing multiples. |
|
||||
| Carbon | CCTS/PAT scheme developing; carbon cost is not yet a large P&L line. Exporters into the EU face CBAM from 2026. | EU ETS is a direct, material cash cost for European cement and chemicals; CBAM extends it to imports from 2026. US has no federal carbon price but state schemes and IRA incentives apply. |
|
||||
| Agrochemical registration | CIB&RC registration; Section 9(3) (full data, longer moat) vs 9(4) (me-too, faster and cheaper). Large export business built on registrations held in Latin America, Africa and South-East Asia. | EPA (US) and Regulation 1107/2009 (EU) — slower, far more expensive, and increasingly restrictive; EU re-approval cycles routinely remove molecules from the market entirely. |
|
||||
| Environmental enforcement | State pollution control boards can suspend consent-to-operate at short notice; cluster-wide closures (Gujarat, Telangana, Tamil Nadu) hit multiple companies at once. ZLD is effectively mandatory in many clusters. | Enforcement is slower, more litigated and more predictable, but penalties and remediation liabilities are far larger. US filers must disclose environmental proceedings above a threshold in the 10-K. |
|
||||
| Disclosure venue | Concall transcripts and quarterly investor presentations carry EBITDA/t, lead distance, trade mix, blend ratio, utilisation, energy norms, subsidy receivables and capex phasing — almost none of it in the financials. CARO, related-party notes and contingent liabilities carry the governance signal. | 10-K MD&A and segment notes, sustainability report for clinker factor and CO₂/t, and quarterly earnings decks. Sell-side publishes explicit price decks for commodity chemicals and fertilisers. |
|
||||
| Ownership and governance | Promoter holding, pledge levels, promoter-linked EPC and logistics contracts, brand/royalty fees to unlisted parents, and inter-corporate deposits are first-order checks. PSU fertiliser and cement entities carry administered pricing and disinvestment overhang. | Widely held; governance issues centre on board independence, incentive design and the treatment of restructuring "one-offs". Controlling-family stakes exist in several European chemicals majors. |
|
||||
| Valuation practice | Cement: EV/t against replacement cost plus mid-cycle EV/EBITDA. Fertiliser: SOTP with utility logic on the regulated leg. Specialty: forward P/E and EV/EBITDA at a large premium to global peers, cross-checked with a capex-ramp DCF. | Cement: EV/EBITDA and $/t, with aggregates/RMC valued separately. Fertiliser: mid-cycle EV/EBITDA on the gas-cost curve. Chemicals: EV/EBITDA 8–15x, DCF, and segment SOTP for diversified majors. |
|
||||
| Accounting detail | Ind AS mirrors IFRS. Watch capitalisation of interest and pre-operative expenses into CWIP, government-grant accounting for state incentives (Ind AS 20), and inventory valuation through an NBS rate change. | IFRS filers similar. US GAAP differs on impairment reversal (not permitted), on development-cost capitalisation (generally expensed), and on LIFO inventory — which materially changes reported chemicals margin in a moving input-cost environment. |
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Identify the sub-sector first — specialty, CDMO, commodity chemical, agrochemical technical/formulation/distribution, urea, P&K, cement, grinding-only — and say so before quoting any ratio.
|
||||
- [ ] For a diversified group, split segments and run SOTP; do not apply a group multiple.
|
||||
- [ ] Suppress trailing P/E for cement and commodity chemicals; report it only alongside mid-cycle normalised EPS, and never call a peak-earnings P/E cheap.
|
||||
- [ ] Do not rank companies inside this sector on OPM. Compare margin only to the company's own history and its direct sub-sector.
|
||||
- [ ] For chemicals, compute gross margin and gross profit per kg through a full input-price cycle before commenting on margin or revenue growth.
|
||||
- [ ] Decompose revenue into volume × realisation; state whether growth was volume or price.
|
||||
- [ ] For cement, compute EBITDA/t, realisation/t and cost/t; separate state incentive income and note its expiry.
|
||||
- [ ] Check regional utilisation and announced *industry* capacity additions for the company's regions, not national averages.
|
||||
- [ ] Check lead distance, fuel mix, clinker factor, WHRS/renewable share and CO₂/t — these are the durable cost moats.
|
||||
- [ ] For fertilisers, strip subsidy: compute subsidy % of revenue, subsidy receivable days, debt ex-subsidy-financing, and non-subsidy EBITDA share.
|
||||
- [ ] Check each urea plant's energy consumption against the notified norm, and flag any plant above it as norm-revision risk.
|
||||
- [ ] For agrochemicals, reconcile sell-in to sell-out, check channel inventory and receivable days, and list the registration portfolio and near-term patent expiries.
|
||||
- [ ] Compute ROCE ex-CWIP and ex-cash, then incremental ROCE on the last 3 years' capex against a WACC of ~11–13% (India) or 7–9% (developed markets).
|
||||
- [ ] Benchmark capex per tonne / per unit capacity against comparable recent projects; treat a large premium as a related-party red flag and a large discount as an overstated-capacity risk.
|
||||
- [ ] Split maintenance from growth capex before calling FCF good or bad; flag maintenance capex below ₹150/t (cement) or 2–3% of gross block (chemicals).
|
||||
- [ ] Test leverage against trough EBITDA, and check how much interest is capitalised into CWIP rather than expensed.
|
||||
- [ ] Check top-5 customer, single-molecule and single-site concentration; value anything with one molecule >35% of EBITDA as a single-product company.
|
||||
- [ ] Verify licence to operate: limestone reserve life and lease tenure, consent-to-operate status, ZLD, closure orders, gas allocation, EHS and fatality record.
|
||||
- [ ] Read contingent liabilities for CCI penalties, environmental and tax disputes; read related-party and pledge disclosures alongside any active capex cycle.
|
||||
- [ ] Cross-check the final valuation against replacement cost of the asset base as a floor, and state where in the cycle you believe the company is and on what evidence.
|
||||
|
|
@ -0,0 +1,209 @@
|
|||
# Exchanges, depositories, clearing houses, rating agencies and payment networks — sector playbook
|
||||
|
||||
Use this when: the company sits between two sets of counterparties and charges a toll on every transaction that passes through — stock, commodity and derivative exchanges; depositories and registrars; central counterparties and clearing corporations; credit rating agencies; index and market-data providers; card networks; and merchant acquirers, payment aggregators and processors.
|
||||
|
||||
These are **volume × take rate** businesses running on an almost entirely fixed cost base. Once the matching engine, the settlement rails or the scoring methodology exist, the marginal cost of the next transaction is close to zero, so nearly every incremental rupee of net revenue drops to EBIT — in both directions. That produces margins (50–70%) and returns on capital that look like accounting errors to a generic screener, alongside balance sheets stuffed with client margin money, settlement float and default funds that are not the company's assets and not the company's debts. Two further distortions dominate: payment companies can report the same economics as either gross or net revenue depending on a principal-vs-agent judgement, and almost every entity here operates under a licence regime that both bars entry and caps price. Analyse this sector as: **volumes × net take rate, flow-through margin on a fixed cost base, and the two tail risks — a regulator that resets the price, and a clearing member that defaults.**
|
||||
|
||||
All ranges below are **indicative only**. They vary by market, product, cycle and regulatory regime. The company's own 5–10 year history and its closest sub-sector peers override every absolute band in this file.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Before computing a single ratio, do two normalisations. Everything else depends on them.
|
||||
|
||||
**Normalisation 1 — get to net revenue.** Reported "revenue" in this sector routinely contains money the company never keeps:
|
||||
- *Merchant acquirers, payment aggregators and processors* may report **gross** revenue including interchange paid to the card issuer and scheme fees paid to the network — economics they merely pass through. Whether they do depends on a principal-vs-agent judgement under Ind AS 115 / ASC 606. The same business reports ~15–25% EBITDA margin on gross revenue and ~40–55% on net revenue. Comparing a gross reporter to a net reporter on OPM, EV/Sales or revenue growth is meaningless; one of the two numbers is roughly four to six times the other.
|
||||
- *Card networks* report gross revenue and then subtract very large **client incentives and rebates** paid to issuers and acquirers to win portfolios. Incentives commonly run in the 30%+ range of gross revenue and are the real pricing mechanism. Only net revenue is analysable.
|
||||
- *US equity exchanges* report transaction revenue gross of **liquidity rebates and routing costs** under maker-taker pricing. Gross transaction revenue can be several times the net capture. Use "net revenue" (revenue less transaction-based expenses) as disclosed.
|
||||
- *Indian exchanges* collect SEBI turnover fees, and (as agent) STT/CTT and stamp duty. Confirm what sits inside revenue and what is netted; regulatory fee pass-throughs are not earnings.
|
||||
|
||||
**Normalisation 2 — strip client and clearing balances off the balance sheet.** Exchanges, clearing corporations, depositories and acquirers carry client margin money, settlement obligations, core settlement guarantee funds, investor protection funds and in-transit merchant settlement balances as both an asset and an equal-and-opposite liability. These are custodial. Leave them in and every capital-based ratio is fiction.
|
||||
|
||||
With those two done, here is what the standard set does:
|
||||
|
||||
**OPM / EBITDA margin — not wrong, but non-comparable and easily gamed.** A 60% operating margin here is normal, not exceptional, and says nothing on its own. Its level is set almost entirely by the gross-vs-net reporting choice and by product mix (a market-data or index business runs at 60–75%; a merchant-acquiring business at a fraction of that). What matters is not the level but the **incremental (flow-through) margin** — the share of each additional rupee of net revenue that reaches EBIT.
|
||||
|
||||
**ROCE / ROE — mechanically broken in both directions, and never in one.** Inflate capital employed with clearing member margin and the SGF, and ROCE prints in low single digits for a business with no real capital needs. Strip those out and you get returns of 40–100%+, because the true invested capital is a data centre and some software. Meanwhile mature global networks and rating agencies have bought back so much stock that book equity is small or negative — ROE is then undefined, infinite or negative and carries zero information. Conversely, payment processors built by large acquisitions carry goodwill and acquired intangibles that swamp capital employed and depress ROCE toward the cost of capital, regardless of the underlying franchise. **Use ROIC on tangible operating capital excluding client funds, and separately ask whether acquisition prices were ever earned back.**
|
||||
|
||||
**D/E, net debt and interest cover — the denominator problem.** Client margin, settlement obligations and default funds are not debt; a clearing corporation that "owes" a member their margin is not levered. Equally, restricted regulatory capital, core SGF contributions and IPF balances are not cash available to the shareholder and must never be netted against borrowings. Where equity has been bought back to near zero, D/E is arithmetically meaningless. Assess leverage as **net debt / EBITDA on genuinely unrestricted cash and genuine borrowings**, and test regulatory net-worth headroom separately.
|
||||
|
||||
**Current ratio and working capital — undefined in substance.** Settlement receivables and settlement payables are of near-identical size and settle within a day or two, so the current ratio hovers around 1.0 whatever the health of the business. Debtor days for an exchange or a network are a measure of clearing-cycle mechanics, not of credit quality. (Rating agencies are the exception — they carry real issuer receivables and their debtor days do carry information.)
|
||||
|
||||
**FCF — high quality, but the cash flow statement is contaminated by float.** These businesses genuinely convert 85–105% of net income to free cash flow, with capex typically 4–10% of net revenue. But the working-capital line in the cash flow statement can swing wildly with settlement timing across a period end — an acquirer or clearing entity can show thousands of crore of "working capital release" that is purely a calendar artefact. **Compute FCF excluding movements in client, settlement and margin balances**, and check it against net income over a 3–5 year window rather than for one period.
|
||||
|
||||
**EV/EBITDA — the EV is usually wrong before the multiple is even computed.** Cash on an exchange's balance sheet is largely not its own; equity may be negative; restricted funds cannot be netted. Build EV as market cap + genuine borrowings − genuinely unrestricted own cash, and only then compute the multiple. Also note that EBITDA ignores the amortisation of acquired intangibles, which is precisely where the roll-up processors' economics are buried.
|
||||
|
||||
**P/E — the least bad headline metric, but contaminated by treasury income.** Exchanges, clearing corporations and depositories earn substantial investment income on their own corpus *and* on float. In a high-rate period this can be a large share of PBT and it is not operating performance; it also de-rates when rates fall. **Always compute core P/E on operating PAT excluding other/treasury income, and strip the associated investable corpus out of market cap** before comparing.
|
||||
|
||||
**Sales/asset turnover, inventory turns, cash conversion cycle** — undefined or trivially meaningless. Do not report them.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are indicative and strongly sub-sector specific. Judge within sub-sector and against the company's own history.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
| --- | --- | --- | --- |
|
||||
| **Volume (ADV / payment volume / issuance)** | Exchanges: average daily turnover and average daily contracts by product, plus **premium** turnover for options (not notional). Depositories: demat accounts, transactions, corporate actions. Networks/acquirers: purchase volume (PV/TPV) and transaction count. CRAs: rated debt issuance and number of instruments/bank-loan ratings. | Growth should exceed underlying market/GDP growth over a cycle; single-year swings of ±30–50% are normal for exchanges. For payments, PV growth of 10–20% in a digitising market. | This is the numerator of everything. It is also the most volatile input, and the one most exposed to a single regulatory decision. Track it monthly — Indian exchanges, depositories and NPCI publish monthly data long before results. |
|
||||
| **Take rate / net revenue capture per unit** | Net transaction revenue ÷ volume. Express as bps of turnover (cash equities), rate-per-contract or per-crore of premium (derivatives), bps of payment volume (networks: net revenue ÷ PV), or fee per rated instrument. Track quarterly. | Networks: roughly 10–20 bps of PV net of incentives; acquirers/PSPs: 15–100 bps net depending on mix; exchange cash equities: low single-digit bps and structurally falling; derivatives per-contract rates flat to falling. Stability matters more than level. | Take rate is where regulation, competition and mix change first show up, and it is the single most under-monitored line. A company growing volume 20% with take rate down 15% is barely growing. Always decompose revenue growth into volume, price and mix. |
|
||||
| **Revenue mix: transaction vs recurring** | Split net revenue into (a) transaction/volume-linked, (b) recurring annuity — listing fees, annual issuer and custody charges, market data, colocation and connectivity, index licensing, ratings surveillance, KYC/e-voting, SaaS/value-added services. | Recurring >35–50% of net revenue materially de-risks the equity. Global exchanges have deliberately pushed data + index + tech toward half of revenue. Pure transaction-dependence deserves a lower multiple. | Recurring revenue is priced at 1.5–2x the multiple of transaction revenue because it survives a volume collapse. The mix shift is the single biggest driver of exchange re-ratings over the last 15 years. |
|
||||
| **Incremental (flow-through) margin** | Δ EBIT ÷ Δ net revenue over the trailing 4–8 quarters, and separately over the last downturn. | 60–80% flow-through in an up-cycle for exchanges, depositories and networks; below 50% means costs are not actually fixed or price is being given away. Check the **downside** flow-through too. | This is the entire investment case for operating leverage, and it is symmetric: a business that drops 70 paise of every incremental rupee to EBIT also loses 70 paise of every rupee lost. It tells you the shape of the earnings curve, which the margin level never does. |
|
||||
| **Core opex growth vs volume growth** | Total operating expenses excluding variable/pass-through items, indexed against volume growth over 3–5 years. Watch technology and employee cost lines specifically. | Core opex growing at 40–70% of volume growth is healthy scale. Opex growing at or above volume growth means the fixed-cost story is false or the company is investing through a cycle — decide which. | The moat is a fixed cost base. If costs scale with volume (headcount-heavy servicing, per-transaction cloud/licence costs, rising regulatory compliance), the terminal margin is far lower than the current one. |
|
||||
| **Core operating margin ex-treasury, and treasury share of PBT** | EBIT excluding other/investment income ÷ net revenue. Separately: other income ÷ PBT, and the corpus generating it. | Treasury <15–20% of PBT for a clean read; Indian MIIs in a high-rate period can run far above this. Core EBIT margin: exchanges/depositories 50–70%, networks 55–70%, CRAs 30–45%, acquirers 20–40% on net revenue. | Float income is a rate bet dressed as earnings and it should be capitalised at a much lower multiple than fee income — often better handled as a separate balance-sheet item. It is the most common way a stagnating core is disguised. |
|
||||
| **Market share and its stability, by product** | Share of turnover/contracts/open interest per product; for payments, share of PV and of active credentials. Track over 8–12 quarters, not one. | Vertically-integrated derivative franchises: 80–100% share that has been stable for years. Cash equities and unbundled markets: share erodes 1–3 pts a year to competitors and off-exchange venues. | Liquidity is the moat, and it is winner-take-most: order flow goes where the tightest spread is, which is where the flow already is. But it is **product-specific**, not firm-specific. Share stability, not share level, tells you whether the network effect is intact. |
|
||||
| **Open interest and its share** *(derivatives)* | Open interest by product and the venue's share of it; average holding period; OI concentration by member. | Rising OI alongside rising volume is a genuine franchise; rising volume with flat OI is churn. | Open interest is the real switching cost: positions carry margin offsets and cannot be moved to a rival venue without cost. It is why incumbent derivative exchanges have never been successfully attacked head-on, while cash-equity venues are attacked constantly. |
|
||||
| **Product and expiry concentration** | Top product as % of net revenue; top 3 products; for Indian exchanges, index options as % of turnover and revenue, and revenue concentrated on specific weekly expiry days. | Top product <40–50% of revenue is comfortable; >70% means the company is a single-regulatory-decision business. | Concentration is the sector's characteristic tail risk. Regulators periodically decide that one product has grown socially undesirable — contract-size increases, expiry-day rationalisation, position limits, margin hikes and transaction-tax changes have all cut volumes in a specific product by double digits within weeks. Model that scenario explicitly. |
|
||||
| **Clearing risk: margin, default fund and coverage** *(CCPs)* | Initial margin held; default fund / core SGF size vs the regulator-required minimum; the CCP's own **skin-in-the-game** tranche and its position in the waterfall; Cover-1 / Cover-2 stress coverage; assessment (top-up) powers on surviving members; largest single member's share of margin and OI. | Default fund sized to withstand the default of the two largest members under extreme-but-plausible stress (Cover-2) is the international standard for systemically important CCPs; Cover-1 is the minimum. Largest member <10–15% of exposure. Any regulator-mandated SGF top-up is a direct hit to distributable earnings. | This is the only genuine solvency risk in an otherwise capital-light sector, and it is a fat-tail, low-frequency risk. The known global cases (a single member's positions blowing through margin and eating the mutualised default fund) show losses can exceed years of profit and destroy the franchise's regulatory standing. Read the CPMI-IOSCO PFMI quantitative disclosures, published quarterly. |
|
||||
| **Regulatory capital and restricted-funds headroom** | Net worth vs the prescribed minimum for each licence (exchange, clearing corporation, depository, payment aggregator, CRA); mandated transfers to core SGF and investor protection funds; % of "cash" that is actually restricted. | Meaningful headroom over minimum net worth; restricted funds clearly disclosed and excluded from any net-cash or EV calculation. | Restricted capital is not shareholder capital. Mandated profit transfers to the SGF reduce distributable earnings without appearing as a cost, and a regulator can raise the requirement at will. |
|
||||
| **Client incentives / rebates as % of gross revenue** *(networks, acquirers)* | Incentives, rebates and revenue-share paid to issuers, acquirers and large merchants ÷ gross revenue; also the trend in net revenue yield. | Ratio should be stable or rising slowly with mix. A step-up on a large portfolio renewal is normal; a persistent multi-year climb is price erosion. | This is where competitive pressure between networks is actually expressed. Volume "won" by giving back more than it earns is negative-value growth, and it is invisible if you look only at gross revenue or PV. |
|
||||
| **Cross-border / high-yield volume mix** *(networks)* | Cross-border transaction volume growth and its share of net revenue; for exchanges, the share from higher-take-rate products and international members. | Cross-border commonly carries several times the domestic take rate and is a disproportionate share of profit. Its share should be tracked separately every quarter. | Mix, not volume, drives network earnings. Travel-linked cross-border volume is also the most cyclical and most shock-sensitive line in the P&L — it collapsed hardest in the pandemic and rebounded hardest. |
|
||||
| **Member / customer / issuer concentration** | Top-10 trading members as % of turnover; top-5 clients as % of net revenue (acute for processors with a large bank or merchant contract); for CRAs, share of revenue from repeat large issuers and from any single instrument class. | Top-5 client concentration <20–25% of net revenue; no single member above ~10–15% of clearing exposure. | Concentration cuts twice: contract renegotiation risk on the revenue side, and default risk on the clearing side. In processing, a single lost bank mandate can remove a fifth of revenue with 18 months' notice. |
|
||||
| **Recurring surveillance share and rating quality** *(CRAs)* | Surveillance/annual fees ÷ total ratings revenue; default and transition rates by rating category vs peers; share of revenue from bank-loan ratings vs bond issuance vs structured. | Surveillance 35–50% of ratings revenue provides a floor under an otherwise issuance-cyclical business. Default rates in line with or better than peers by grade. | Ratings revenue is a call option on issuance volumes; only the surveillance annuity is defensive. And rating accuracy is the licence to operate — a visible accuracy failure in a large asset class is an existential, not a cyclical, event. |
|
||||
| **Operational resilience record** | Outages, trading halts, settlement failures and glitch-framework penalties over 5 years; system uptime and capacity headroom vs peak load; disaster-recovery switchover performance. | Zero material outages. Any multi-hour halt is a serious event. | Uptime is the product. A major outage triggers regulatory penalties, compensation, senior-management accountability action, and — in competitive markets — permanent order-flow migration. It is also a leading indicator of underinvestment in a business whose only real capex is technology. |
|
||||
| **FCF conversion excluding float** | (CFO − capex) ÷ PAT, computed with movements in client, settlement, margin and SGF balances removed from CFO. Capex as % of net revenue. | Conversion 85–105%; capex 4–10% of net revenue for exchanges and networks, higher for processors building platforms. | Confirms that reported earnings are cash and that the fixed cost base is not quietly capital-hungry. Sustained conversion below 80% in a capital-light business means either capitalised software is flattering EBIT or receivables are stretching. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
**Default: core P/E and DCF, with a mix-aware sum-of-the-parts. Do not lead with EV/EBITDA and never with P/B.**
|
||||
|
||||
**1. Start from core earnings.** Core PAT = operating profit excluding other/treasury income, taxed at the effective rate. Then value the investable corpus separately at (or slightly below) carrying value, excluding restricted funds — SGF, IPF and regulatory capital — entirely. For Indian MIIs in particular, a headline P/E computed on total PAT while a large unrestricted corpus sits inside market cap makes a business look far cheaper than it is.
|
||||
|
||||
**2. DCF works genuinely well here** — better than in most sectors — because volumes are forecastable over a cycle, margins are stable, capex is low and working capital is nil. Build it as **volume × take rate × flow-through margin**. The three assumptions that decide the answer are terminal take rate (assume compression unless there is a specific reason not to), the mix shift toward recurring revenue, and the probability-weighted impact of an adverse regulatory pricing decision. Run the regulatory scenario as an explicit branch, not as a discount-rate bump.
|
||||
|
||||
**3. Sum-of-the-parts where the mix is genuinely different.** Do not apply one multiple to an entity that contains a transaction business, an index/data business and a technology-services business. Indicative relative levels: index and market-data franchises command the highest multiples (recurring, pricing power, near-zero marginal cost), clearing and depository annuities next, cash-equity transaction revenue lowest. Rating agency groups with large analytics/research arms must be split the same way — the non-ratings segment often has different growth, different margins and different competitive dynamics from the ratings franchise.
|
||||
|
||||
**4. Indicative multiple bands** (vary with rates, cycle and jurisdiction; use as orientation only, never as a target):
|
||||
- Global vertically-integrated exchanges and index/data-heavy groups: high-teens to low-30s P/E, 12–22x EV/EBITDA.
|
||||
- Card networks: premium multiples, typically 25–35x earnings, justified by ~50%+ net margins, near-zero capital intensity and duopoly economics — the question is never whether they are expensive but whether the take rate survives.
|
||||
- Merchant acquirers and processors: structurally de-rated to low-to-mid teens P/E and single-digit-to-low-teens EV/EBITDA on disintermediation and pricing fears. Use **net-revenue** multiples only.
|
||||
- Rating agencies: 25–35x, reflecting oligopoly and a regulatory mandate to be rated, discounted for issuance cyclicality.
|
||||
- Indian MIIs: premium to global peers is common, driven by structural growth in demat accounts and derivative participation. The premium is only defensible if you have explicitly stress-tested regulatory intervention in derivatives.
|
||||
|
||||
**5. Useful cross-checks.** Market cap ÷ annual net revenue; EV ÷ annual contracts or ÷ annual payment volume (compare like-for-like products only); implied terminal take rate embedded in the current price — solve for it and ask whether a regulator would tolerate it.
|
||||
|
||||
**What NOT to use:** P/B (book value is either negative from buybacks or inflated by client funds); EV/Sales on any gross-revenue reporter; ROE for a company with a bought-back balance sheet; consolidated ROCE without excluding client funds and SGF; EV computed by netting restricted cash; EV/EBITDA compared across gross and net reporters; and peer-average multiples across sub-sectors with different recurring-revenue shares.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
Never put these in one table. They have different pricing power, different regulators and different failure modes.
|
||||
|
||||
**1. Vertically integrated derivative exchanges with captive clearing.** Own the matching engine *and* the CCP, so open interest and margin offsets are locked in. Near-monopoly share, stable take rates, highest multiples. Compare only with each other.
|
||||
|
||||
**2. Cash-equity and competitive-venue exchanges.** Where clearing is unbundled or interoperable and best-execution rules permit competing venues (US Reg NMS, EU MiFID/MiFIR), order flow is genuinely contestable and take rates fall every year. Off-exchange internalisation, dark venues and payment-for-order-flow arrangements take share of the addressable pool. Do not benchmark these against a vertically integrated derivatives franchise.
|
||||
|
||||
**3. Depositories, registrars and custody-adjacent infrastructure.** Annuity economics — annual issuer charges, per-account and per-debit fees, corporate-action and e-voting fees, KYC infrastructure. Far less volume-sensitive, more account-growth-sensitive, and priced by the regulator. Different beta from exchanges even in the same country.
|
||||
|
||||
**4. Clearing corporations and CCPs.** Where separately listed or separately disclosed, treat as a distinct sub-sector: earnings are margin-float-driven and rate-sensitive, and they carry tail default risk no other sub-sector has.
|
||||
|
||||
**5. Index, market-data and analytics providers.** Highest-quality revenue in the sector: recurring licence fees, AUM-linked index royalties, contractual escalators. Comparable to information-services businesses, not to trading venues.
|
||||
|
||||
**6. Credit rating agencies.** Issuance-cyclical, regulated, oligopolistic, issuer-pays. Compare only with other CRAs, and split out non-ratings analytics revenue before comparing margins.
|
||||
|
||||
**7. Card networks.** Four-party scheme operators that do **not** earn interchange (interchange goes to the issuer) and do not take credit risk. Revenue is service assessments, data-processing fees, cross-border fees and value-added services, less incentives.
|
||||
|
||||
**8. Issuers, acquirers, PSPs, payment aggregators and gateways.** These take credit risk (issuers), merchant/chargeback risk (acquirers), or neither but with thin economics (gateways). Their take rate, capital requirements and regulatory perimeter are entirely different from a network's. **Never place a network and an acquirer in the same peer table**, and never compare a gross-revenue reporter with a net-revenue reporter without restating.
|
||||
|
||||
**Cross-cutting splits that must be respected:**
|
||||
- **Price-regulated vs price-free markets.** A market with capped interchange or a zero-MDR mandate is a structurally different business from an unregulated one, regardless of similar volumes.
|
||||
- **Monopoly/duopoly by licence vs contestable markets.** The presence or absence of a realistic second venue determines whether take-rate compression is a certainty or an option.
|
||||
- **Gross vs net revenue reporting**, restated before any comparison.
|
||||
- **Currency, tax and transaction-tax regimes** (STT/CTT in India, Section 31 fees in the US, financial transaction taxes in parts of Europe) change both volumes and reported revenue.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Volume and revenue quality**
|
||||
- **Notional turnover quoted instead of premium turnover** for options. Notional grows explosively as strikes proliferate and expiries shorten while the economically relevant base (premium, or contracts) grows far less. Insist on the premium/contract-count series.
|
||||
- **Volume concentrated in ultra-short-dated, retail-driven products.** High revenue per unit of underlying economic activity is precisely what attracts regulatory intervention. Treat it as high-quality cash flow with a low-quality life expectancy.
|
||||
- **Take rate rising for reasons management cannot decompose.** A rise from a one-off fee-slab change, a tax pass-through or a mix shift is not pricing power.
|
||||
- **Revenue growth accompanied by falling take rate and rising incentives** — the company is buying volume.
|
||||
- **Treasury income rising as a share of PBT while core operating profit is flat.** Very common in Indian MIIs during high-rate periods and the most frequent way core stagnation is disguised.
|
||||
|
||||
**Risk and capital**
|
||||
- **Default fund or margin model calibrated to a stale volatility regime.** Look for regulator-mandated top-ups, changes in stress scenarios, or an unusually low SGF relative to peak open interest.
|
||||
- **Thin or falling skin-in-the-game** relative to the mutualised default fund — it misaligns the CCP's incentives on margin adequacy.
|
||||
- **Rising concentration of open interest or margin in a single member or client group.** The historical CCP losses all began this way.
|
||||
- **Procyclical margin models** that force large intra-crisis calls: they protect the CCP but generate member defaults, litigation and regulatory backlash.
|
||||
- **Restricted funds presented as cash** in investor presentations, or netted in a "net cash" figure.
|
||||
|
||||
**Accounting and disclosure**
|
||||
- **Gross-vs-net revenue reclassification** in a payment company, or a change in the principal-vs-agent judgement. It resets the entire revenue and margin history — rebuild a like-for-like series before quoting any growth rate.
|
||||
- **Aggressive capitalisation of internally developed software**, with capitalised development rising as a share of technology spend. In a business whose only real investment is technology, this directly manufactures EBIT.
|
||||
- **Roll-up processors' "adjusted EBITDA"** excluding perpetual integration, restructuring and share-based costs; organic-growth definitions that change year to year; acquisition accounting that parks costs in purchase-price allocation.
|
||||
- **Segment re-definition** that moves data, connectivity or listing revenue between buckets, obscuring the transaction/recurring split.
|
||||
|
||||
**Governance and regulatory**
|
||||
- **Conflicts of interest at the infrastructure institution:** a market-infrastructure entity competing with its own members, preferential access to data or infrastructure for some participants, or opaque colocation and tick-by-tick data allocation. This has been the source of the most damaging regulatory actions against exchanges globally and in India, with multi-year overhangs, disgorgement and blocked listings.
|
||||
- **Repeated technical glitches** and the associated penalty framework — a leading indicator of underinvestment and of regulatory patience running out.
|
||||
- **CRA-specific:** rating shopping, unusually fast fee growth in one structured product class, high analyst attrition, ratings that lag market-implied spreads by long periods, or a large share of revenue from a small group of frequent issuers.
|
||||
- **Regulatory consultation papers** on fee caps, product design, expiry structure, position limits, interchange or MDR. These are public and typically precede the earnings impact by 3–12 months. A model that has not read the live consultation papers is stale.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Cyclicality is volatility-linked, not GDP-linked — and the direction differs by sub-sector.** Volatility spikes drive trading volumes, margin balances and clearing revenue *up* while simultaneously shutting the IPO window (listing fees), freezing bond issuance (rating agency revenue) and suppressing discretionary spending (card volumes). A single macro shock therefore moves the sub-sectors in opposite directions. Do not model "market infrastructure" as one cycle.
|
||||
|
||||
**Rates are a first-order earnings driver, twice over.** Higher rates raise float income on margin and settlement balances (a pure windfall to CCPs, depositories and acquirers) and simultaneously compress the multiple applied to fee streams. When rates fall, that float income disappears — check how much of the last three years' earnings growth was rate-driven before extrapolating.
|
||||
|
||||
**Retail participation cycles.** Derivative and cash-equity volumes in emerging markets are heavily retail-driven and mean-reverting after drawdowns, with a lag. A multi-year bull market that has doubled demat accounts and trebled option volumes is not a permanent base rate.
|
||||
|
||||
**Structural forces to price explicitly:**
|
||||
- *Regulatory price-setting is the dominant risk in this sector.* Interchange caps (EU IFR, US debit-interchange regulation and routing mandates), mandated zero-MDR regimes, exchange transaction-fee caps and "true-to-label" pricing rules have each permanently reset take rates in their markets. A licence that bars entry usually comes with a regulator that sets price; the moat and the risk are the same object.
|
||||
- *Account-to-account real-time payments* (UPI, Pix, FedNow, European instant payments) bypass card rails entirely and, where mandated free, remove the toll rather than shrink it. This is the single largest secular threat to card-network and acquirer economics, and it is furthest advanced in India.
|
||||
- *Disintermediation of the venue.* Off-exchange internalisation, dark pools, systematic internalisers, payment for order flow, all-to-all bond platforms and direct listings each take a slice of the addressable pool without competing on the exchange's own terms.
|
||||
- *Settlement compression* (T+1, moves toward T+0 and same-day settlement, and tokenised/DLT settlement experiments) reduces the margin and float balances that generate income for CCPs, and reduces the risk that justifies their existence. Positive for systemic safety, negative for float earnings.
|
||||
- *Passive investing growth* is a durable tailwind for index franchises (AUM-linked royalties) and for ETF-linked trading, and a headwind for high-turnover active flow.
|
||||
- *Stablecoins and crypto rails* are a genuine medium-term threat to cross-border payment economics — the highest-margin line in the network P&L — and a source of new listed/traded products for exchanges.
|
||||
- *Alternative credit assessment* (private credit not requiring public ratings, bank internal models, data-driven scoring) slowly erodes the CRA mandate at the margin, while regulatory requirements to be rated keep the floor in place.
|
||||
|
||||
**Where the moat actually is.** Not the technology — matching engines are commodities. It is (a) the licence, (b) pooled liquidity and open interest with their margin offsets, (c) the network's two-sided installed base of issuers and acceptance points, and (d) contractual, embedded recurring revenue in data and index licensing. Rank any company here by which of those four it actually owns.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
**Regulatory architecture (India).** SEBI regulates exchanges, clearing corporations and depositories as **Market Infrastructure Institutions** under the SECC and Depositories regulations; RBI regulates payment systems, payment aggregators and card networks' domestic operations; NPCI operates UPI, RuPay, IMPS and NACH as a not-for-profit. Distinctive features to check for any Indian MII:
|
||||
- **Ownership caps and governance:** shareholding in an MII is capped for most holders (a low single-digit percentage for the general category, with a higher ceiling for specified financial institutions), so there is **no promoter** in the conventional sense. Do not run promoter-holding or pledge analysis; instead read the board composition, the Public Interest Directors, and the SEBI-approved appointment of key management. Governance risk here is regulatory-relationship risk, not promoter risk.
|
||||
- **Mandated profit transfers:** exchanges and clearing corporations must contribute a prescribed share of profits to the clearing corporation's **Core Settlement Guarantee Fund**, and exchanges maintain Investor Protection Funds. Verify the current prescribed percentages from the latest SEBI circular — they change — and treat those transfers as a permanent reduction in distributable earnings and the balances as restricted.
|
||||
- **Price regulation:** SEBI's "true-to-label" charges framework requires uniform, non-slab transaction charges, which removed the volume-rebate structure exchanges previously used. SEBI's regulatory turnover fee on options is levied on premium rather than notional. Both are examples of regulatory pricing decisions with immediate revenue impact.
|
||||
- **Product intervention:** SEBI has periodically tightened index-derivative rules — larger contract sizes, fewer weekly expiries per exchange, upfront premium collection, removal of calendar-spread benefits on expiry day, higher expiry-day margins. These measures reduced retail derivative turnover materially and quickly. Any Indian exchange model must carry an explicit product-intervention scenario.
|
||||
- **Technical glitch framework:** SEBI prescribes uptime, disaster-recovery switchover timelines and financial disincentives for outages at MIIs. There is no direct global equivalent of comparable specificity.
|
||||
|
||||
**Payments (India).** MDR on UPI person-to-merchant and on RuPay debit is effectively zero by statute for most merchant categories, so the domestic debit and A2A rails are **not monetisable at the network layer** — value accrues to banks, to the merchant, and to whoever monetises the customer relationship, not to a toll collector. Card economics in India are therefore essentially a credit-card story. Payment aggregators require RBI authorisation with prescribed net-worth thresholds; card-on-file tokenisation is mandated; cross-border PA activity has its own licence. Contrast this with the US and EU, where interchange (capped in the EU, partially regulated for debit in the US) remains a large monetised pool. **Never apply developed-market card take rates to India.**
|
||||
|
||||
**Depositories and demat (India).** A duopoly with volume driven by new demat account additions, transaction debits, corporate actions, e-voting and KYC infrastructure — an annuity profile that behaves quite differently from exchange turnover. Monthly account and transaction data are public.
|
||||
|
||||
**Rating agencies (India).** SEBI-registered CRAs; a large share of revenue comes from **bank-loan ratings** driven by Basel capital rules, in addition to bond issuance — a revenue pool with no direct US analogue. Several Indian CRAs earn a majority of consolidated revenue from **non-ratings research, analytics and global delivery centres**; those segments must be valued separately, since they are outsourced-services businesses with different margins, currency exposure and competitive dynamics.
|
||||
|
||||
**Accounting and filings.** India: Ind AS, standalone and consolidated; crore/lakh — normalise before cross-border comparison. Clearing corporations and depositories are usually **subsidiaries**, so read the subsidiary financials in the annual report, not just the consolidated statements, to see margin balances, SGF and restricted funds. CARO reporting, the related-party note and the contingent-liability note (regulatory penalties, disgorgement, litigation with members) carry most of the risk signal. Concalls and monthly turnover releases are the highest-frequency data source. Global: 10-K/10-Q on EDGAR under US GAAP or IFRS; exchanges disclose net revenue after transaction-based expenses (use that line, not gross); networks disclose gross revenue, incentives and net revenue plus PV, cross-border volume and processed transactions in the same tables; CCPs publish **CPMI-IOSCO PFMI quantitative disclosures quarterly** — margin, default fund, stress-test coverage and member concentration — which is the single best public source for clearing risk and has no equally structured Indian equivalent.
|
||||
|
||||
**Market data and colocation.** In the US and EU, market-data and connectivity fees are a large, high-margin and politically contested revenue line, subject to regulatory fee reviews, consolidated-tape initiatives and litigation by users. In India, data and colocation revenue is a smaller share and colocation has itself been the subject of significant regulatory action. Do not assume the developed-market data-revenue mix is available to an Indian exchange.
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Restate revenue to a **net** basis (after interchange, scheme fees, incentives, liquidity rebates and regulatory pass-throughs) before computing any growth rate or margin.
|
||||
- [ ] Strip client margin, settlement balances, core SGF, IPF and restricted regulatory capital out of assets, liabilities, cash, EV and capital employed.
|
||||
- [ ] Decompose net revenue growth into volume, take rate and mix, for each major product, over 8+ quarters.
|
||||
- [ ] Use premium/contract-count volumes for options, never notional turnover.
|
||||
- [ ] Compute the recurring (data, listing, index, annual issuer/custody, surveillance, VAS) share of net revenue and its trend.
|
||||
- [ ] Compute incremental flow-through margin (ΔEBIT/Δnet revenue) both in the up-cycle and in the last downturn.
|
||||
- [ ] Compare core opex growth with volume growth over 3–5 years to test whether the cost base is genuinely fixed.
|
||||
- [ ] Separate treasury/float income from core operating profit; compute core P/E ex-treasury and exclude the unrestricted corpus from market cap.
|
||||
- [ ] Quantify rate sensitivity of float income and re-run earnings at a normalised rate.
|
||||
- [ ] Measure product concentration and model an explicit regulatory-intervention scenario for the top product.
|
||||
- [ ] For CCPs: read the PFMI quantitative disclosures — default fund vs Cover-1/Cover-2, skin-in-the-game, assessment powers, largest-member concentration.
|
||||
- [ ] Check regulatory net-worth headroom and any mandated profit transfers to the SGF or protection funds.
|
||||
- [ ] For networks/acquirers: track client incentives as % of gross revenue and cross-border share of net revenue.
|
||||
- [ ] Check member, client and issuer concentration on both the revenue and the risk side.
|
||||
- [ ] Review 5 years of outages, glitch penalties, regulatory orders, disgorgement and litigation with members.
|
||||
- [ ] Read live regulatory consultation papers on fees, MDR/interchange, product design and expiry structure before finalising any forecast.
|
||||
- [ ] Test capitalised software as a share of technology spend, and adjusted-EBITDA add-backs for roll-up processors.
|
||||
- [ ] Compute FCF excluding movements in client/settlement/margin balances; check conversion against PAT over 3–5 years.
|
||||
- [ ] Value by SOTP where transaction, data/index and technology-services revenue coexist; never one blended multiple.
|
||||
- [ ] Confirm the peer set matches on vertical integration, price regulation, contestability and gross-vs-net reporting — not on market cap or index membership.
|
||||
- [ ] State what the current price implies for terminal take rate, and ask whether a regulator would allow it.
|
||||
|
|
@ -0,0 +1,202 @@
|
|||
# FMCG, consumer staples, branded consumer and QSR — sector playbook
|
||||
|
||||
Use this when: the company sells a branded product or meal to an end consumer through a distribution network or store estate — packaged foods, beverages, home and personal care, tobacco, dairy, edible oils, beauty, innerwear/footwear/apparel brands, jewellery, QSR chains, and D2C consumer brands.
|
||||
|
||||
This is the sector where the generic ratio checklist does the most damage, because the two assets that generate all the value — the brand and the route-to-market — never appear on the balance sheet. Every capital-employed ratio is therefore either meaningless or actively inverted, and the sector's best businesses look "risky" on working-capital rules and "expensive" on every multiple screen. Your job is to replace balance-sheet analysis with franchise analysis: volume, reach, penetration, share, and the honesty of the channel. Get the decomposition of growth right and most other conclusions follow.
|
||||
|
||||
## Contents
|
||||
|
||||
1. [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
2. [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
3. [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
4. [Peer set construction](#peer-set-construction)
|
||||
5. [Sector-specific red flags](#sector-specific-red-flags)
|
||||
6. [Cycle and structural context](#cycle-and-structural-context)
|
||||
7. [India vs global notes](#india-vs-global-notes)
|
||||
8. [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Work through these before you quote any standard ratio in your output. In most cases the correct action is to suppress the metric entirely rather than caveat it.
|
||||
|
||||
**ROCE and ROE — structurally meaningless as a screen, and anti-comparable across peers.** Internally-generated brands are expensed as incurred, never capitalised. Indian FMCG additionally runs heavy third-party (3P) contract manufacturing and negative working capital, so the denominator is close to nothing: quality Indian staples routinely print ROCE of 60–200%. ROE is inflated further by buybacks. In the US, several large staples carry *negative* book equity after decades of buybacks and spin-offs, making ROE and D/E undefined or nonsensically negative. Worse than noise, it is inverted: a company that **built** its brands carries them at zero and shows 80% ROCE; an identical company that **bought** the same brands carries goodwill and shows 12%. A ROCE ranking scores the acquirer as the worse business purely because of accounting. If you must use returns, compute ROIC on tangible capital *and* on a brand-adjusted base (capitalise ~5 years of A&P at, say, a 5-year amortisation) and report both, or skip it.
|
||||
|
||||
**D/E — a dead variable in Indian staples, and an exclusion rule in developed markets.** Almost the entire listed Indian staples universe is net cash, so D/E has zero discriminating power. Abroad the opposite problem applies: LBO-descended and serially acquisitive staples run 3–5x net debt/EBITDA *by design*, and a "D/E < 0.5" filter rejects most of the investable set. Use **net debt/EBITDA** and, for store-based names, **lease-adjusted net debt/EBITDAR**. Interest coverage is uninformative for the net-cash majority — do not report a 400x coverage ratio as a finding.
|
||||
|
||||
**OPM in isolation — actively misleading, because A&P is the real capex and is expensed.** Any FMCG company can manufacture a 150–200bps margin beat next quarter by cutting advertising and promotion, mortgaging future volume for reported EBITDA. The generic checklist rewards exactly that behaviour. OPM is also structurally non-comparable across categories: personal and oral care 20–28%, packaged foods 12–18%, dairy and edible oils 4–8%, distribution-led models lower still. Comparing a dairy company to a soap company on OPM produces garbage. Always pair OPM with A&P intensity and gross margin.
|
||||
|
||||
**P/E screens — permanently exclude the sector, and a low P/E here usually signals decline.** Indian staples have traded at 40–70x for two decades; developed-market staples at 18–25x. A "P/E < 25" filter deletes the entire Indian consumer universe forever. Inside the sector, a single-digit or low-teens P/E almost never signals value — it signals terminal category decline (tobacco under tax escalation, packaged carbs, legacy hair oil) or a governance discount. P/E is interpretable only against the stock's own long-run history and the sector index.
|
||||
|
||||
**P/B — the single most useless ratio here.** Quality staples have traded above 50x book. Book value captures factories and working capital, the least important part of the enterprise, and is systematically *higher* for the weaker, acquisitive operator carrying goodwill. Never rank on it. Never flag "P/B > 10" as expensive.
|
||||
|
||||
**Current ratio and working-capital rules — inverted.** The best FMCG businesses run *negative* working capital: distributors pay cash or on 7–21 day credit while suppliers are paid in 60–120 days. A current ratio below 1.0 is a sign of channel power, not distress. A "current ratio > 1.5" rule penalises the highest-quality names and rewards those stuck financing their own channel. Judge liquidity on cash conversion cycle trend and net cash, not on the current ratio.
|
||||
|
||||
**Undecomposed revenue growth — the classic trap.** Reported value growth of 10% can be +12% price/grammage and −2% volume: the franchise is shrinking while the P&L looks healthy. Only volume shows whether more consumers are consuming more. Never report revenue growth in this sector without attempting the volume/price-mix split.
|
||||
|
||||
**Asset turnover and fixed-asset productivity — distorted by 3P manufacturing.** A company that outsources 70% of production shows spectacular asset turns and a company that owns its plants shows poor ones, with no difference in economics. India's tax-incentive manufacturing locations (legacy area-based exemptions, and now the concessional new-manufacturing rate) further make the effective tax rate a moving target unrelated to operating quality.
|
||||
|
||||
**EV/EBITDA — near-redundant where the generic checklist assumes it is essential, and vice versa.** For asset-light staples D&A is tiny, so EV/EBITDA collapses toward EV/EBIT and adds nothing over P/E. It becomes essential precisely for the acquisitive, levered names carrying large acquired-brand amortisation — the opposite of the default assumption.
|
||||
|
||||
**FCF — usually clean here, but capex is not the whole investment.** Staples convert well, so FCF is a good honesty test on reported profit. But remember that the true maintenance investment (A&P) sits above the FCF line, so a company harvesting its brands shows *better* FCF while getting weaker. Read FCF alongside A&P intensity and volume.
|
||||
|
||||
**Ind AS 116 / IFRS 16 breaks every store-based margin series.** From FY20 (India) / 2019 (IFRS, 2019–20 US GAAP ASC 842 for lessee balance sheets), rent moved out of EBITDA into depreciation and interest. QSR and retail EBITDA margins jumped 500–900bps overnight and ROCE fell on the newly recognised right-of-use asset. Any margin or return series straddling FY19 is broken and must be restated to a pre-lease-standard basis before comparison.
|
||||
|
||||
---
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, category, cycle and reporting period. A company's own 5–10 year history and its direct sub-sector peers always override any absolute band quoted here.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Underlying volume growth (UVG) and volume vs price/mix split | Growth in units or tonnage, reported separately from price and mix. India: "UVG" or domestic volume growth in the quarterly release and concall. Global: "organic growth = volume/mix + price". | India staples 5–8% sustained UVG, >8% exceptional; DM staples 1–3%. Over a cycle at least half of value growth should be volume. | Price growth mean-reverts with input costs and gets competed away; volume is the only evidence consumers are buying more. It is the hardest number to manipulate — which is why weakening managements quietly stop disclosing it. |
|
||||
| Gross margin, plus the GM-to-A&P bridge | GM = (Revenue − raw material & packaging)/Revenue. Bridge = how much of any GM expansion was reinvested in A&P vs dropped to EBITDA. | India: personal/home care 50–70%, packaged foods 35–45%, dairy/edible oils 12–20%. DM branded staples 35–50%, beauty 65–80%. In an input-deflation year expect 40–60% of the GM gain reinvested. | GM is the cleanest read on pricing power and premiumisation. The bridge separates managements building the brand from those harvesting a commodity tailwind and calling it structural margin. |
|
||||
| A&P as % of sales | Media plus consumer promotion, ideally split above-the-line (brand building) vs below-the-line (discounting). A disclosed line in Indian P&Ls; buried in SG&A notes in 10-Ks. | India large-cap 8–13%, mid-cap 5–9%, launch-heavy years 13–16%. DM staples 6–12%, beauty 20%+. A sustained 150bps+ fall with flat volumes is a warning, not efficiency. | A&P is the sector's true maintenance capex but is expensed, so under-investment shows up as *margin expansion* and only bites 4–8 quarters later. Judging OPM without A&P intensity is the core error of the generic checklist. |
|
||||
| Direct reach (outlets serviced directly) and total reach | Outlets serviced directly by the company's salesforce/distributors vs total outlets reached including wholesale. Disclosed in Indian annual reports and investor decks. Global equivalent: numeric and weighted distribution. | India: largest players ~3–3.5mn direct / ~9mn total; large mid-caps ~1.2–1.5mn direct. A scaling mid-cap should add 10–20% direct outlets a year. DM: weighted distribution >80% in core categories. | Distribution is the sector's genuine moat and the reason a well-funded new brand cannot simply outspend an incumbent. Growth = reach expansion × throughput per outlet, and reach-led growth is the more durable half. |
|
||||
| Throughput per outlet and SKUs/categories per outlet | Revenue per serviced outlet; average number of the company's SKUs carried per store. | Category-dependent; throughput should grow mid-single-digit in real terms. Falling throughput while outlet count rises means reach expansion is cosmetic. | Adding outlets is cheap and easy to announce; making each outlet sell more is hard and is what converts into operating leverage. Also shows whether new launches genuinely ride the existing distribution asset. |
|
||||
| Household penetration (%) and consumption frequency | Share of households buying the brand at least once in 12 months, plus frequency and quantity per occasion. From Kantar/Nielsen household panels; quoted in Indian concalls (the "penetration × consumption" framework). | Category-specific. Penetration under ~20% with a rising trend implies a long runway; above ~80% means growth must come from frequency, premiumisation or new categories. | Tells you where future growth must *physically* come from, which determines whether a rich multiple is defensible. A high-penetration brand priced for penetration-led growth is the most common FMCG valuation error. |
|
||||
| Market share: value share vs volume share | Value and volume share in core categories as a trend, plus the share gap to the #2 player. Nielsen/Kantar retail audit. | Leadership at >1.5–2x the #2 is where pricing power and shelf economics live. Value share above volume share = genuine premium positioning; below = share bought with discounts. | FMCG categories are share-stable oligopolies, so small persistent share loss compounds into terminal decline. The value-vs-volume gap is the earliest signal of a brand quietly repositioning downmarket. |
|
||||
| Innovation rate — % of revenue from products launched in last 3 years | Share of current revenue from NPD introduced in the trailing 24–36 months. | Best-in-class staples 5–12%; premium beauty and snacking 15–25%. Below 3–4% signals a portfolio ageing into commoditisation. | The sector's R&D productivity measure and the mechanism through which premiumisation and mix-led margin actually happen. Also separates real innovation from line extensions and grammage games. |
|
||||
| Cash conversion cycle (inventory + receivable − payable days) | Net working capital in days, with distributor receivable days and trade payable days as the critical sub-components. | Best-in-class Indian FMCG runs **negative** CCC of −10 to −40 days (inventory 30–55d, debtors 8–20d, creditors 70–120d). Discretionary is positive: apparel 90–150d, jewellery 120–180d. | Negative working capital means growth self-funds and is the real engine behind the sector's high ROCE. Deterioration almost always precedes a growth disappointment: product is sitting in the trade, not with consumers. |
|
||||
| Primary vs secondary sales gap, distributor ROI, channel inventory days | Primary = dispatches to distributors (what the P&L books). Secondary = distributor→retailer. Tertiary = retail offtake. Pair with the distributor's own pre-tax ROI and days of company stock in the channel. | Primary and secondary should track within ~200–300bps over a 2–3 quarter window. Indian distributor ROI norm 18–25% pre-tax; below ~15% distributors defect or under-invest. Channel inventory typically 15–30 days. | Loading the trade at quarter-end is the most common way FMCG results are flattered, and this is the only pair of metrics that catches it. It is also where quick-commerce disruption of general trade first becomes visible. |
|
||||
| Channel mix: GT / MT / e-commerce / quick commerce / D2C | Revenue split by channel with the growth rate and margin profile of each. | India, typical urban-skewed brand: GT 55–70%, MT 10–15%, e-comm + quick commerce 10–20% and rising fast (30%+ for some premium urban portfolios). DM: grocery multiples plus 15–25% e-commerce. | Channel economics differ sharply — quick commerce demands higher listing and marketing spend and smaller packs while cannibalising the general-trade distributor whose ROI funds the moat. Growth mix determines whether margins are sustainable. |
|
||||
| SSSG and store unit economics (discretionary/QSR/retail) | Growth from stores open >12 months, plus average daily sales per store, store-level EBITDA margin, sales per sq ft, and cash payback period. | Healthy SSSG 5–10%, and it should exceed menu/price inflation so footfall or transaction growth is positive. QSR store EBITDA 15–20% pre-Ind AS 116; store cash payback 2.5–4 years. | For store-based models consolidated revenue growth is dominated by new-store additions and says nothing about health. SSSG plus payback is the only real test of whether expansion creates or destroys value. |
|
||||
| Cash conversion: OCF/EBITDA and FCF/PAT | Operating cash flow / EBITDA; free cash flow / reported net profit, measured over rolling three-year periods. | OCF/EBITDA above 85–90%; cumulative 3-year FCF/PAT above 80% for asset-light staples. Capex 2–4% of sales for staples, 5–8% for capacity-adding foods, higher during store rollouts. | Because brands and A&P are expensed, cash conversion is the honest test that reported profit is real. Persistent divergence points to trade loading, aggressive rebate accounting or capitalised soft costs. |
|
||||
| Input-cost basket sensitivity and hedging position | The 3–5 commodities driving COGS (palm oil, crude-linked LAB/LLP/HDPE, milk solids, wheat, sugar, tea, coffee, copra, packaging) with GM sensitivity to a 10% move, plus extent and duration of forward cover. | Portfolio-specific, but the discipline is knowing the number: a 10% palm or crude move is typically 150–300bps of GM for soaps and detergents. Cover of one to two quarters is normal; much longer is a bet, not risk management. | Most FMCG margin "surprises" are commodity cycles misread as operating performance. Modelling the basket separates management execution from luck — in both directions. |
|
||||
| Royalty/technical fee to parent and related-party intensity (India, MNC subsidiaries) | Royalty, technical and brand fees paid to an overseas parent as % of net sales; plus purchases from or sales to promoter-affiliated entities. | India norm 1–5% of net sales. Any step-up transfers economics to the parent with no operational change. | MNC subsidiaries are a large share of Indian FMCG market cap, and royalty is the main minority-shareholder risk — a direct, permanent haircut to EPS that no operating metric will reveal. |
|
||||
| Pricing-power evidence: realisation per unit vs input index | Revenue per kg/litre/unit tracked against the company's own input cost index over 3–5 years. | Realisation should hold or rise in real terms through an input-deflation cycle; giving back the whole commodity gain in price means the brand has no pricing power. | The single most direct test of whether the "brand" is a brand or a label on a commodity. Distinguishes premiumisation from mix-shift accounting. |
|
||||
|
||||
Notes on sourcing: in India, UVG, direct reach, channel mix and A&P are usually found in the quarterly investor presentation and concall transcript rather than the financial statements — read the transcript. In the US, volume/mix, organic growth and segment margins are in the 10-K MD&A and 8-K earnings release; A&P is often only disclosed annually in the notes.
|
||||
|
||||
---
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
**Primary: forward P/E anchored to the stock's own long-run multiple, not to the market.** FMCG is asset-light, low-capex, usually net cash and highly cash-converting, so accounting earnings approximate distributable cash and P/E is genuinely informative — unlike in banks, insurers or capital-intensive sectors. Frame the multiple three ways: (a) versus the stock's own 5–10 year median and z-score, (b) versus the sector index, (c) growth-adjusted (PEG, or P/E against forward EPS CAGR). Indicatively, Nifty FMCG has traded at a 1.5–2.5x premium to the Nifty; Indian quality large-caps 40–70x, mid-caps 30–45x; DM staples 18–25x; premium beauty and spirits 25–35x. Treat a single-digit or low-teens P/E in this sector as a signal to investigate terminal decline or governance, not as value.
|
||||
|
||||
**Reverse DCF as the discipline on high multiples.** Because staples cash flow is stable and terminal-value-dominated, a forward DCF mostly launders your assumptions into a target price. Invert it: solve for the revenue growth, margin and fade profile the *current price* implies over 10–15 years, then test whether penetration, direct reach and category-size arithmetic can physically deliver it. ("This price requires the brand to reach 60% household penetration at a 4% real price increase — the category has never exceeded 35%.") This is the only rigorous way to underwrite a 60x staple. Explicitly fade ROIC toward WACC in the terminal period; assuming perpetual 50%+ ROIC is where most FMCG DCFs go wrong.
|
||||
|
||||
**EV/EBITDA where leverage or amortisation is material.** Use it for acquisitive and levered DM staples and for any Indian name with meaningful debt or acquired-brand amortisation. Indicative 10–16x for staples, 12–18x for premium categories. For asset-light Indian staples it collapses toward EV/EBIT and adds little over P/E — do not present both as independent evidence.
|
||||
|
||||
**EV/Sales for two specific jobs.** First, valuing high-growth, sub-scale or loss-making brands (D2C, new-age consumer, beauty) where margins have not normalised — pair it with an explicit path to a normalised margin. Second, benchmarking against M&A comparables: branded consumer M&A clears at roughly 2–4x sales / 15–25x EBITDA for mainstream staples and 4–6x sales for premium beauty and spirits. That sets a replacement/floor value for a listed brand portfolio and is often the most honest cross-check available.
|
||||
|
||||
**Sum-of-the-parts for multi-category conglomerates.** Where a group runs cigarettes, foods, hotels, paper and agri — or incubates an FMCG business inside a legacy cash cow — the consolidated P/E is meaningless because each segment merits a different multiple and a different terminal assumption. Value the parts, apply an explicit holding-company discount, and express demerger or value-unlock scenarios as SOTP deltas rather than as a re-rating hand-wave.
|
||||
|
||||
**Store-based discretionary (QSR, retail, footwear, jewellery).** Value on **pre-Ind AS 116 / pre-IFRS 16 EV/EBITDA** so history stays comparable, plus a store-economics build-up: mature-store EBITDA × store count, discounted for immature stores, cross-checked against EV per store and store cash payback. Never compare post-lease-standard EBITDA multiples to pre-FY19 history — the standard change alone creates an apparent multiple de-rating.
|
||||
|
||||
**Secondary cross-checks.** Dividend and total shareholder yield for mature staples (Indian MNC subsidiaries often pay out 70–100% of PAT; DM staples roughly 50–60% payout plus buybacks). FCF yield against the 10-year government bond — the cleanest bridge between a rich P/E and an actual expected return. EV per case, per hectolitre or per tonne for beverage and commodity-adjacent names.
|
||||
|
||||
**Explicitly do not use:** P/B or any book-value screen (internally-generated brands are off balance sheet; negative equity is common in DM). NAV or replacement cost of fixed assets. D/E thresholds. Interest coverage for the net-cash majority. Graham-style net-current-asset or earnings-power-value screens — they will reject the entire sector.
|
||||
|
||||
---
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable in this sector shares **category gross-margin structure, channel model, and ownership/brand-royalty structure**. Market cap and "consumer" as a label are not sufficient.
|
||||
|
||||
Splits that must not be mixed:
|
||||
|
||||
- **By gross-margin architecture.** Personal/home care (50–70% GM), packaged foods and snacks (35–45%), dairy/edible oils/staples commodities (12–20%). A dairy business and a soap business have almost no ratio in common. Never rank them on OPM, GM or ROCE in the same table.
|
||||
- **Staples vs discretionary.** Staples have low elasticity, short repurchase cycles and defensive earnings; discretionary (jewellery, apparel, footwear, QSR, durables) has income elasticity, fashion/season risk and a different beta. They de-rate at opposite points of the cycle.
|
||||
- **Distribution-led vs store-led.** A company selling through 1mn outlets and one operating 1,500 owned stores have incompatible working capital, operating leverage and lease accounting. Keep them in separate tables.
|
||||
- **Owned-brand vs licensed/franchised.** A master-franchisee QSR operator pays a royalty on sales and does not own the brand; its ceiling margin, terminal value and pricing autonomy differ fundamentally from a brand owner's. Franchisee operators compare to each other, not to the brand owner.
|
||||
- **MNC subsidiary vs domestic promoter-owned.** MNC subsidiaries carry royalty leakage, a constrained ability to enter categories reserved for the parent, and typically very high payout; domestic promoter-owned names have reinvestment optionality and promoter-related-party risk. Valuation premia and governance checks differ.
|
||||
- **Scale tiers.** A ₹500cr-revenue regional brand and a national player face different distributor economics, media efficiency and input procurement. Direct-reach comparisons across tiers are meaningless in absolute terms — compare growth rates in reach instead.
|
||||
- **Pre- vs post-lease-standard series.** Within store-based peers, ensure all margin and return histories are on the same lease basis. If one peer restated and another did not, restate before comparing.
|
||||
- **Legacy vs new-age/D2C.** D2C brands are valued on contribution margin, cohort retention and CAC payback, not on EBITDA. Do not include them in a staples multiple table without flagging the different basis.
|
||||
|
||||
Geography matters more than usual: an Indian staple growing 12% with 5% UVG is not comparable to a DM staple growing 4% with 1% volume, even in the identical category. Where you need a cross-border read, compare *decomposition quality* (volume share of growth, A&P intensity, share trend) rather than absolute multiples.
|
||||
|
||||
---
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Channel and revenue quality**
|
||||
|
||||
- Primary sales consistently outrunning secondary offtake, especially in March and September quarters — classic trade loading. Corroborate with rising debtor days, rising channel inventory days, and a Q1 "demand normalisation" that follows every strong Q4.
|
||||
- Value growth positive while volume growth is negative for three or more consecutive quarters, dressed as "premiumisation". Usually price-led growth into a shrinking consumer base; it precedes share loss to regional and private-label players.
|
||||
- Grammage reduction presented as volume-neutral. Indian price-point packs (₹5/10/20) hold the price and cut the grams, so whether "volume" is reported in tonnage or in units decides whether growth looks positive. Always check the definition in the fine print.
|
||||
- Channel financing or bill discounting used to shorten reported receivable days while distributor credit risk stays with the company. Check contingent liabilities, recourse terms, and any jump in "other financial liabilities".
|
||||
- Finished-goods inventory build ahead of an announced price increase — pulls margin into the current quarter and creates an air pocket later.
|
||||
|
||||
**Margin quality**
|
||||
|
||||
- A margin beat delivered by cutting A&P. A 150–300bps EBITDA improvement with A&P down and volumes flat is the lowest-quality beat in the sector: deferred cost, not earned margin. Repeated over three or four quarters it reliably precedes share loss.
|
||||
- Gross margin expansion driven entirely by input-cost deflation but guided as structural. When palm, crude or milk turns, the margin evaporates and the stock de-rates twice — earnings cut plus quality re-rating.
|
||||
- Reclassification of trade discounts, listing fees and slotting allowances between revenue deduction, A&P and "other expenses". This moves gross margin and EBITDA margin with no economic change, and is a favourite in years when a margin target has been guided.
|
||||
- Rising other/treasury income as a share of PBT in a business that should be compounding operating profit — the cash pile doing the work the brands are not.
|
||||
- Tax-rate flattery: earnings supported by expiring area-based exemptions (legacy Baddi/Sikkim/Guwahati units), concessional new-manufacturing rates, or one-off deferred-tax writebacks presented inside headline "PAT growth".
|
||||
|
||||
**Portfolio, M&A and structure**
|
||||
|
||||
- Serial acquisitions masking organic stagnation, combined with an "adjusted EBITDA" that permanently excludes restructuring, integration and impairment. If the exceptional item appears every year, it is an operating cost.
|
||||
- Acquired brands and goodwill carried without impairment despite persistent underperformance. The large US packaged-food writedowns of the late 2010s are the reference case — the operating deterioration was visible in volume and share data years before the accounting caught up.
|
||||
- Royalty or technical-fee step-ups by an MNC parent; promoter-owned entities embedded in the supply chain; or the brand itself owned outside the listed entity and licensed in. Each is a permanent, non-operational transfer of value away from minority shareholders.
|
||||
- Understated concentration: a single brand or category contributing more than 50% of gross profit, or heavy dependence on one state or region, combined with category-specific regulatory exposure.
|
||||
|
||||
**Channel disruption and store models**
|
||||
|
||||
- E-commerce and quick-commerce growth celebrated while general-trade distributor ROI falls below ~15%, distributor attrition rises, or trade bodies publicly protest platform pricing. The company is trading its distribution moat for a quarter of growth.
|
||||
- Store-based discretionary: SSSG delivered purely by menu or ticket-price hikes with negative footfall and transaction growth; weak-store closures flattering the SSSG base; and any margin narrative built on post-Ind AS 116 EBITDA that is never reconciled to a pre-lease basis.
|
||||
- New-age D2C: revenue growth with negative contribution margin after customer acquisition cost, deteriorating repeat rates, or CAC rising faster than average order value. Disclosure of contribution margin 2/3, repeat-order share and cohort retention is the minimum bar — its absence is itself the red flag.
|
||||
|
||||
**Governance tells that historically precede FMCG accounting problems:** auditor or CFO churn; a sudden change in revenue-recognition or rebate policy; related-party loans; promoter share pledging (India — check the shareholding pattern and CARO/auditor qualifications); and management quietly ceasing to disclose a volume-growth number it previously gave. The last one is the highest-signal tell in the sector because it is cheap to do and rarely questioned.
|
||||
|
||||
---
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Where in the cycle matters.** FMCG earnings are driven less by GDP than by the **input-cost cycle** and, in India, by **rural income** (monsoon, crop prices, MSP, rural wage growth, government transfers). The classic pattern: input deflation → gross margin expands → management guides "structural" margin → input inflation returns → margins compress and the stock de-rates on both earnings and quality. Locate the company on that cycle before extrapolating any margin trend. Volume growth typically responds to price cuts and grammage restoration with a 2–3 quarter lag.
|
||||
|
||||
**Defensive positioning cuts both ways.** Staples outperform in downturns because demand is inelastic, and underperform in recoveries as capital rotates to cyclicals. A "cheap vs history" staple in an early-cycle upswing may stay cheap for years. State the market regime when you comment on relative valuation.
|
||||
|
||||
**Structural threats to underwrite explicitly:**
|
||||
|
||||
- **Quick commerce and e-commerce** compressing the general-trade distributor's economics, shortening pack sizes, raising listing and platform-marketing costs, and reducing the shelf-space advantage that constitutes the incumbent's moat. This is the single biggest structural question for Indian FMCG right now.
|
||||
- **Private label**, strengthened by modern trade and platform-owned brands, attacking mid-tier price points where brand equity is weakest.
|
||||
- **D2C and performance-marketing entrants** who can reach a niche without a distribution network, fragmenting premium categories (beauty, supplements, snacking) even if they rarely scale to national relevance.
|
||||
- **Health-and-wellness reformulation** pressure — sugar, salt, fat, palm oil, ultra-processed labelling — which raises COGS and can shrink whole sub-categories.
|
||||
- **Premiumisation vs down-trading** — both narratives are live simultaneously in India as the consumer base bifurcates; check which end of the portfolio is actually growing rather than accepting the management framing.
|
||||
|
||||
**Regulation to check by category.** Tobacco taxation and GST/cess changes plus advertising and packaging restrictions. HFSS rules, front-of-pack labelling and health-star ratings. Food-safety norms (FSSAI in India; FDA/USDA in the US; EFSA in the EU). Plastic packaging extended producer responsibility (EPR) obligations and recycled-content mandates. Advertising standards on health and nutrition claims (ASCI in India; FTC in the US). For alcohol: state-level excise, route-to-market and pricing approval regimes, which in India differ enough state-by-state to be a material driver of realisation.
|
||||
|
||||
---
|
||||
|
||||
## India vs global notes
|
||||
|
||||
**Reporting and units.** India reports under Ind AS in ₹ crore/lakh; results are quarterly with a limited-review audit and a mandatory investor presentation plus concall for most listed names. The **concall transcript is the primary source** for UVG, direct reach, channel mix, A&P intensity and distributor commentary — none of which are reliably in the financial statements. Global filers use the 10-K/10-Q (US GAAP, EDGAR) or IFRS annual reports; volume/mix and organic growth are in MD&A, A&P often only in the annual notes.
|
||||
|
||||
**Regulators and disclosure.** India: SEBI (LODR disclosure, related-party approval thresholds), MCA, FSSAI, ASCI, and CCI for competition. CARO reporting and the auditor's report on internal financial controls are genuinely useful for governance flags. Shareholding-pattern filings give promoter holding and **pledge** data — a red flag with no direct US analogue. US: SEC filings, plus FTC/FDA. IFRS filers vary in segment granularity; India's segment reporting is often coarser than a US 10-K's.
|
||||
|
||||
**Ownership structure.** A large share of Indian FMCG market cap sits in MNC subsidiaries, where the key minority-shareholder risks are royalty step-ups, category carve-outs reserved to the parent, and delisting/open-offer dynamics. Payout ratios of 70–100% of PAT are common because reinvestment is constrained. Domestic promoter-owned names carry the opposite profile — reinvestment optionality plus related-party and pledge risk. Global staples are typically widely held with buyback-heavy capital return and, in several cases, negative book equity.
|
||||
|
||||
**Structural market differences.** India's ~9–13mn outlet general-trade network with a multi-tier distributor/wholesaler structure has no DM equivalent; distribution reach is therefore a first-order moat metric in India and a second-order one abroad, where weighted distribution in a concentrated grocery-retailer set is the analogue and retailer bargaining power (slotting fees, private label) is the bigger issue. India's rural/urban split, price-point pack architecture and monsoon sensitivity have no DM counterpart. Growth rates differ by an order of magnitude — do not import DM valuation bands into India or vice versa.
|
||||
|
||||
**Tax.** India's concessional new-manufacturing rate and legacy area-based exemptions make effective tax rates non-comparable across peers and across time; normalise to the statutory rate when comparing operating quality. GST rate changes on specific categories move realisation and consumer price points directly and should be modelled as a revenue event, not a cost event.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Decompose reported growth into volume and price/mix for the last 8–12 quarters; if volume is not disclosed, treat that as a finding.
|
||||
- [ ] Suppress ROCE/ROE/P/B/D/E/current-ratio conclusions, or restate them (brand-adjusted ROIC, net debt/EBITDA) before quoting.
|
||||
- [ ] Chart A&P as % of sales alongside EBITDA margin; flag any margin gain funded by an A&P cut.
|
||||
- [ ] Build the gross-margin bridge and attribute expansion to input deflation vs price/mix vs cost programme.
|
||||
- [ ] Check the input-cost basket and estimate GM sensitivity to a 10% move in the top 3 commodities.
|
||||
- [ ] Compare primary vs secondary sales trend, debtor days and channel inventory days for trade-loading evidence.
|
||||
- [ ] Check distributor ROI commentary and distributor attrition; below ~15% pre-tax ROI is a moat-erosion signal (India).
|
||||
- [ ] Track direct reach growth and throughput per outlet together — reach without throughput is cosmetic.
|
||||
- [ ] Pull penetration and consumption-frequency data and ask where the next decade of growth physically comes from.
|
||||
- [ ] Compare value share vs volume share trend and the gap to the #2 player.
|
||||
- [ ] Verify the cash conversion cycle is negative (staples) and that any deterioration is explained.
|
||||
- [ ] Test OCF/EBITDA and 3-year cumulative FCF/PAT for reported-profit honesty.
|
||||
- [ ] For store-based names: restate the margin series to a pre-Ind AS 116 / pre-IFRS 16 basis before any comparison; check SSSG composition (footfall vs ticket) and store cash payback.
|
||||
- [ ] For MNC subsidiaries: quantify royalty as % of net sales and check for step-ups or brand ownership outside the listed entity.
|
||||
- [ ] Construct the peer set by category GM structure, channel model and ownership type — never by market cap alone.
|
||||
- [ ] Value on forward P/E vs the stock's own 5–10 year median and z-score; run a reverse DCF with ROIC fading to WACC to test what the price implies.
|
||||
- [ ] Cross-check against branded-consumer M&A multiples (EV/Sales, EV/EBITDA) and FCF yield vs the 10-year bond.
|
||||
- [ ] Scan the concall/10-K for discontinued disclosures, rebate-policy changes, recurring "exceptional" items, and auditor/CFO churn.
|
||||
- [ ] State the regulatory exposures specific to the categories in the portfolio (tobacco tax, HFSS/labelling, EPR, state excise).
|
||||
- [ ] Restate every indicative range in this file as indicative — peer set and own history override it.
|
||||
|
|
@ -0,0 +1,219 @@
|
|||
# Holding companies, conglomerates, AMCs and alternative managers — sector playbook
|
||||
|
||||
Use this when: the company's earnings are largely a function of what it *owns* or what it *manages* rather than what it operates — pure investment holdcos, promoter/family holding vehicles, Core Investment Companies, multi-segment conglomerates, listed mutual-fund AMCs, wealth and portfolio managers, and alternative managers (PE, credit, infra, real assets, hedge funds).
|
||||
|
||||
The generic checklist assumes one operating business with one P&L. Here the reported financials are an accounting artefact of ownership percentages and consolidation thresholds, not a description of a business. Two holdcos owning economically identical portfolios can report entirely different revenue, margin and leverage purely because one crossed 50% and the other did not. For asset managers the balance sheet is nearly empty and the real assets — AUM, flows, performance, fee yield, accrued carry — sit outside the accounts entirely. Analyse this sector as: **what do I own per share (NAV), what cash actually reaches the parent, and how well is capital allocated** — or for managers, **fee-paying AUM × net revenue yield × operating leverage, minus flow risk**.
|
||||
|
||||
All ranges below are **indicative only**. They shift with market level, rate cycle, jurisdiction and regulatory regime. The company's own 5–10 year history and its closest sub-sector peers override every absolute band in this file.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Before computing anything, establish **which accounting regime each stake sits in**. Under Ind AS / IFRS the same economic ownership produces three incompatible income statements:
|
||||
|
||||
| Stake | Treatment | What appears in the P&L |
|
||||
| --- | --- | --- |
|
||||
| >50% (control) | Line-by-line consolidation | 100% of the sub's revenue and EBITDA, with the minority (NCI) share stripped out far below, near PAT |
|
||||
| 20–50% (significant influence) | Equity method | A single "share of profit of associates" line. **Zero revenue.** |
|
||||
| <20% | FVTPL / FVOCI (Ind AS 109, ASC 321) | Dividends only, plus fair-value marks (in P&L or OCI) |
|
||||
|
||||
So consolidated revenue growth can be produced entirely by a stake moving from 49% to 51%, with no change in economics. Every ratio built on revenue or capital employed is therefore non-comparable across holdcos and across time for the same holdco. Discard the following explicitly:
|
||||
|
||||
**OPM / EBITDA margin — undefined or meaningless.** A pure holdco's "revenue" is dividends, interest and fair-value gains, so operating margin routinely prints 80–300%, or goes negative in a year with no dividends, and describes nothing. For a conglomerate, blended OPM averages cement (18–22%), an NBFC (where "revenue" is gross interest income and margin is a leverage artefact), IT services (20–25%) and retail (5–7%) into a number that describes no business that exists. For an asset manager there is no COGS, so gross margin is vacuous and EBITDA ≈ EBIT ≈ revenue minus people costs — the only meaningful cost line is compensation.
|
||||
|
||||
**ROCE — broken in both directions, never in one.** Indian holdcos carrying decades-old stakes at historical cost show trivial capital employed and absurd ROCE. Holdcos carrying stakes at fair value show inflated capital employed and 2–4% ROCE, because the numerator is dividends received, not the economic earnings of the underlying. Asset managers are near-zero-capital businesses: ROCE of 30–80% is a statement about an empty balance sheet, not about competitive advantage, and it collapses the moment the firm holds seed capital or a principal investment book. Only **segment-level ROCE at the operating subsidiary** is analytically valid.
|
||||
|
||||
**D/E and interest cover at the consolidated level — actively misleading, not merely noisy.**
|
||||
- If any subsidiary is a bank, NBFC or insurer, its 5–9x regulatory leverage swamps the group and consolidated D/E is nonsense.
|
||||
- The debt that can bankrupt the parent is **holdco standalone debt**, which is structurally subordinated to all opco debt. Consolidated EBITDA/interest cover overstates the parent's capacity, because opco EBITDA is ring-fenced behind opco lenders, minorities, and — for regulated subs — regulator consent to upstream dividends.
|
||||
- **Double leverage** (parent borrowing to inject equity into subsidiaries) is eliminated on consolidation and is therefore completely invisible in consolidated D/E.
|
||||
|
||||
**P/E and EPS — contaminated.** Consolidated PAT includes non-cash fair-value gains, unrealised carry marks, share of associate profits never received in cash, and lumpy stake-sale gains. Holdcos also structurally trade "cheap" on P/E because the market prices a discount to NAV, not a multiple of accounting earnings: a 4x P/E holdco is not cheap, it is a 55% NAV discount expressed badly. For alternative managers GAAP EPS is dominated by carry marks and by consolidation of funds, CLOs and VIEs the firm does not own — which is exactly why the industry reports FRE and DE instead.
|
||||
|
||||
**FCF — not the shareholder's cash.** Consolidated OCF-minus-capex includes cash trapped inside partly-owned and regulated subsidiaries. The only cash available for holdco debt service, dividends and buybacks is **upstreamed dividends net of leakage** (minorities, taxation in the recipient's hands, regulator-gated payouts).
|
||||
|
||||
**P/B — inconsistent, not wrong in one direction.** Where investments are fair-valued, book ≈ NAV and P/B is a crude discount proxy. Where they sit at cost or are equity-accounted, book value can be understated many times over. Comparing P/B across holdcos without first normalising the carrying basis is meaningless.
|
||||
|
||||
**Working capital, current ratio, inventory turns, cash conversion cycle, asset turnover, EV/EBITDA** — undefined for holdcos and asset managers, and mere portfolio averages (hence uninformative) for conglomerates. EV itself is undefined for any group containing a lending or insurance subsidiary, because debt there is raw material, not a claim. Peer-multiple comparison across conglomerates is apples-to-oranges by construction: the answer is determined by segment mix, not by quality.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are indicative and sub-sector specific. Judge within sub-sector and against the company's own history.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
| --- | --- | --- | --- |
|
||||
| **NAV per share and discount / premium to NAV** | Sum-of-the-parts: listed stakes at market price, unlisted at peer multiple or last transaction, treasury and cash at value, **minus holdco standalone net debt**, minus capitalised holdco running costs, minus latent capital-gains tax on unrealised appreciation = tax-adjusted NAV. Discount = 1 − (market cap / NAV). | Developed-market, well-governed, buyback-active holdcos: 5–30% discount (Berkshire has historically traded at a premium to book). European family holdcos: 20–40%. India: 40–75% is the norm. Judge the current discount against the company's own 5–10 year percentile band, never against a universal number. | The actual valuation anchor and the actual return driver: total return = NAV growth + dividend yield ± change in discount. A stock can compound NAV at 15% and deliver 5% if the discount widens. A permanently wide, catalyst-free discount is a value trap, not an opportunity. |
|
||||
| **Look-through earnings and look-through P/E** | Σ (ownership % × investee PAT) across consolidated subs, associates and minority stakes, regardless of accounting treatment, plus holdco standalone income, minus holdco costs and interest. Look-through P/E = market cap / look-through earnings. | A 40% NAV discount should show up as roughly a 40% lower look-through P/E than the weighted-average P/E of the underlying stakes. Look-through earnings growth of 10–15% p.a. is the bar for a quality holdco. | Neutralises the consolidation accident (full consolidation vs equity method vs FVTPL) and gives one comparable earnings base. It is the only earnings figure that maps to what the shareholder actually owns. |
|
||||
| **Holdco standalone cash-flow cover (upstreaming ratio)** | Recurring cash received at the parent (dividends from subs and associates, interest, management/brand fees) ÷ parent-level fixed outflows (holdco opex + holdco interest + dividend paid to own shareholders). Read from **standalone**, not consolidated, accounts. | >1.5x comfortable; >2.0x strong; <1.2x is a warning; <1.0x means the parent is funding itself by borrowing or selling assets. | Structural subordination means opco EBITDA is not available to the parent. Upstreaming is gated by minorities, sub-level lender covenants and — for bank, NBFC and insurance subs — regulator approval. This ratio, not consolidated interest cover, tells you whether the holdco can service its own debt. Rating agencies test it explicitly. |
|
||||
| **Holdco LTV and double leverage** | LTV = holdco standalone net debt ÷ gross market value of the portfolio. Double leverage = (parent's investment in subsidiaries at cost) ÷ parent's standalone net worth. | LTV <10% conservative, 10–25% acceptable, >30–35% is where rating agencies downgrade and forced-selling risk appears (the best-run European holdcos target ~5–10% with a hard ceiling near 25%). Double leverage <1.1x clean, 1.2x tolerable, >1.3x a red flag. | Holdco debt is repaid only from dividends or asset sales. High LTV plus a falling market converts a drawdown into a solvency event and forces sale of the best listed assets at the worst time. Double leverage means the same rupee of equity is counted twice in group capital — and it is invisible in consolidated D/E. |
|
||||
| **Portfolio liquidity and concentration** | % of NAV in freely marketable listed securities (excluding pledged, locked-in, or positions too large to sell without a block discount), plus weight of the top asset and top three assets in NAV. | >60–70% of NAV listed and marketable is healthy. Top single asset <40–50% of NAV; above 60% the holdco is a levered proxy for one stock and deserves a **wider** discount, not a narrower one. | Liquidity determines whether the holdco can ever monetise, buy back stock or repay debt, and it is empirically the biggest single driver of discount width. A vehicle that is 85% one unlisted family asset will never trade near NAV. |
|
||||
| **Segment ROCE, incremental ROIC, and capital below cost of capital** | Per reported segment: segment EBIT ÷ segment capital employed. Incremental ROIC = Δ segment EBIT ÷ Δ segment capital employed over 3–5 years. Then: % of group capital employed sitting in segments earning below WACC. | India: segment pre-tax ROCE >15–18% against a ~12–14% WACC; developed markets >12–15% against ~8–9%. Keep below-WACC capital under ~15–20% of the group; >30% signals a value-destroying conglomerate. | Company-level ROCE for a conglomerate is a portfolio average that hides cross-subsidy. The entire investment case is whether capital is recycled from cash cows into higher-return uses or into vanity greenfield. Incremental ROIC, not historic ROCE, is where that decision shows up first. |
|
||||
| **NAV per share total return vs benchmark (capital-allocation scorecard)** | 5- and 10-year CAGR of NAV per share plus dividends vs the relevant total-return index (Nifty 500 TRI in India; MSCI World / STOXX in Europe; S&P 500 TR in the US). Keep a log of buybacks (done below NAV?), acquisition multiples paid and exit multiples achieved. | Beating the index by 200–400 bps p.a. over a full 10-year cycle justifies the structure's existence and a narrow discount. Underperformance over 10 years means the shareholder should own the index. | A holdco or conglomerate is a capital-allocation machine and nothing else. This is the only test of management skill that accounting cannot game, and it is the best predictor of whether the discount narrows. |
|
||||
| **Holdco running cost ratio** | Parent-level operating expenses (salaries, promoter compensation, advisory, admin, listing costs) ÷ gross portfolio value — the implicit management fee shareholders pay for the structure. | <0.3% of NAV is efficient (the most disciplined global holdcos run near 0.1%). 0.5–1.0% is expensive; >1% and the entity is an expensive closed-end fund. | Capitalised at an 8–10% discount rate, a 1% running cost permanently destroys 10–12% of NAV and mechanically justifies part of the holding discount. It is also the cleanest read on whether the entity exists for shareholders or for the promoter family. |
|
||||
| **AUM, AUM mix, and organic net flow rate** *(managers)* | Closing **and average** AUM — use average (QAAUM in India) for revenue analysis — split by asset class (equity / hybrid / debt / liquid / passive / alternatives) and by channel. Net flow rate = net client flows ÷ opening AUM, explicitly separated from market appreciation. | Positive net flows through a full cycle is the bar. Traditional managers: +3–6% organic net flow p.a. is good; negative organic flow with rising AUM is a melting ice cube. Alternatives: 10–20% FPAUM growth. India: equity + hybrid at 45–60% of QAAUM. | AUM growth from market beta is not an achievement and it reverses; only net flows are. Mix shift to debt, liquid or passive silently destroys revenue while headline AUM grows — liquid/overnight earns roughly 8–15 bps against 60–70 bps for equity. This is the most common way asset-manager growth is overstated. |
|
||||
| **Net revenue yield on AUM (bps) and its trend** | Total operating revenue (management fees, net of distributor commissions where reported net) ÷ average AUM, in basis points, tracked quarterly and by asset class. | Indian AMCs: blended 45–55 bps, equity 60–75 bps, capped by SEBI's slab-based TER regime; stable-to-slightly-declining is realistic. Developed-market traditional: 25–45 bps and structurally falling. Alternatives: 100–150 bps on fee-paying AUM and far more stable. | Yield × AUM = revenue, and yield is where competition, TER cuts, direct-plan migration and passive substitution appear first. A manager growing AUM 15% with yield down 10% is a flat business. Yield compression is the defining structural risk of the sector. |
|
||||
| **Operating profit per unit of AUM (bps) and cost-to-income** | Operating profit (PBT **excluding** other/treasury income) ÷ average AUM in bps — the Indian convention — plus the developed-market equivalent, cost-to-income ratio. | India: 25–40 bps operating profit on AUM is strong; <15 bps is subscale. Cost/income 40–55% for a good traditional manager; >70% is subscale or over-distributed. Alt managers: FRE margin 35–60%, best-in-class ~55–60%. | Isolates operating leverage and scale economics from market movements, and separates the fee franchise from returns on the firm's own investment book. Those two earnings streams deserve completely different multiples and must never be capitalised together. |
|
||||
| **FRE, DE and permanent-capital share** *(alternative managers)* | FRE = recurring management fees − fee-related expenses, excluding all performance income. DE = FRE + realised performance fees + realised principal investment income, less taxes and interest. Permanent-capital share = % of FPAUM in perpetual or long-dated (>8-year, non-redeemable) vehicles. | FRE at 55–75% of DE indicates earnings are not carry-dependent. Permanent/long-dated capital >50% of FPAUM is a strong structural positive. FRE growth of 10–20% p.a. is the benchmark. | GAAP net income here is noise. FRE is the annuity the market capitalises at 20–30x; carry is capitalised at far less. Because the split determines the multiple, management has every incentive to reclassify items into FRE — so audit the definition, not just the number. |
|
||||
| **Accrued carry, DPI and realisation rate** *(alternative managers)* | Net accrued performance receivable per share; gross vs net accrued carry after clawback and comp-sharing; DPI (distributions to paid-in) and MOIC / net IRR by vintage; % of funds above their preferred return (typically an 8% hurdle). | Net accrued carry is typically worth 10–25% of market cap and should be haircut 25–40% for realisation and timing risk. >75–80% of FPAUM in funds above hurdle is healthy. DPI >1.0x by year 6–7 of a vintage indicates real cash returns. | Accrued carry is an unrealised, reversible, manager-marked asset that is routinely valued in SOTP as if it were cash. Vintages that never cross the hurdle write it to zero, with clawback on top. DPI is the only honest test that paper marks convert to cash. |
|
||||
| **Investment performance and asset stickiness** | % of AUM in funds beating benchmark or above peer median over 3 and 5 years; redemption rate; India: monthly SIP inflow, SIP AUM as % of equity AUM, share of equity AUM held >24 months. Institutional: top-5 clients as % of revenue. | >60% of AUM above benchmark/median on 3- and 5-year windows. India: SIP AUM >35–45% of equity AUM with rising monthly flow; individual (vs institutional) AUM >50%. Top-5 client concentration <20% of revenue. | Performance drives flows with a 2–3 year lag, so today's performance table is next year's revenue. Sticky retail SIP money survives drawdowns; institutional and corporate liquid money leaves in a week. Best single operational predictor of flow durability. |
|
||||
| **Related-party exposure, minority leakage and promoter pledge** | RPTs (sales, purchases, ICDs, loans, guarantees) as % of revenue and net worth; corporate guarantees and contingent liabilities for group companies vs net worth; NCI share of consolidated profit vs NCI share of consolidated equity; promoter shares pledged as % of promoter holding; any circular cross-holdings. | RPTs excluding normal-course operations <5% of revenue; guarantees + contingent liabilities <25–30% of net worth; promoter pledge 0% (>10% is a serious flag in India); no circular cross-holdings. | In group structures value leaks sideways rather than being lost operationally: below-market intra-group pricing, ICDs to promoter vehicles, guarantees for weak affiliates, dilutive rights issues. **NCI profit share materially below NCI equity share** means minorities sit in the good businesses while the parent absorbs the losses. Circular holdings double-count NAV and make SOTP upside illusory. |
|
||||
| **Free float, buyback record and payout policy** | Promoter/founder holding and free float; buybacks executed and the discount to NAV at which they were done; dividend payout as % of dividends *received* (the pass-through ratio). | Free float >25–30%; a stated policy of passing through received dividends; buybacks executed only at a material discount to NAV. | These are the only mechanisms by which a discount actually narrows. A holdco with cash, a 60% discount and no buyback in a decade is telling you the discount is a governance fact, not a mispricing. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
**Default method: sum-of-the-parts NAV. Consolidated multiples are sanity checks only.**
|
||||
|
||||
### Holding companies and conglomerates — the SOTP build
|
||||
|
||||
1. **Listed stakes at market price.** Apply a block/illiquidity discount (10–20%) where the stake exceeds several months of trading volume or is strategically unsellable.
|
||||
2. **Unlisted operating subsidiaries at segment-appropriate multiples.** EV/EBITDA for capital-intensive assets (cement, power, telecom infra: roughly 7–12x); EV/EBIT or P/E for asset-light services; **P/B calibrated to ROE** for lending and insurance arms (high-quality Indian NBFCs 2–4x P/B, banks 1.5–3x; insurers on embedded value); EV/Sales or GMV multiples only for genuinely early-stage assets. Never one blended multiple across dissimilar segments.
|
||||
3. **Real estate, land banks and treasury at appraised or market value**, not book.
|
||||
4. **Deduct holdco standalone net debt** (never consolidated net debt), pension deficits and group guarantees likely to be called.
|
||||
5. **Deduct the capitalised PV of holdco running costs** (annual cost ÷ discount rate).
|
||||
6. **Deduct latent tax on unrealised gains.** In India, LTCG on listed equity plus surcharge, and the full corporate rate on unlisted asset sales. Ignoring this is the single most common overstatement of holdco NAV.
|
||||
7. **Apply a holding-company discount** to the resulting NAV. Calibrate from the company's own 5–10 year discount band and from peers with similar liquidity, governance and upstreaming — not from a textbook number.
|
||||
|
||||
**What widens the discount:** illiquid or unlisted-heavy portfolio, no buyback, thin free float, tax leakage on any monetisation, high running costs, poor NAV compounding, promoter entrenchment, complex multi-layer structures.
|
||||
**What narrows it:** buybacks below NAV, a generous pass-through dividend policy, a listed and liquid portfolio, demonstrated NAV outperformance, simplification or a stated monetisation path.
|
||||
|
||||
**Model the catalyst, not just the gap.** Buyback authorisation, demerger or scheme of arrangement, listing of an unlisted sub, delisting or open offer, change in regulatory status (e.g. RBI CIC classification), promoter succession, or index inclusion. Absent a credible catalyst, assume the discount is permanent and underwrite only the NAV compounding plus dividend yield. This is the discipline that separates a genuine holdco idea from a decade-long value trap.
|
||||
|
||||
**Operating conglomerates of the Berkshire type** are better valued two-column: investments per share **plus** a capitalised multiple (roughly 9–12x pre-tax) on operating earnings, or on adjusted P/B (~1.2–1.6x). For diversified conglomerates, build segment EV with segment-specific multiples, allocate net debt to the segments that carry it, then apply a **conglomerate discount of 10–25%** where there is real cross-subsidy or capital misallocation — or a **premium** where the parent demonstrably allocates capital better than the market would.
|
||||
|
||||
### Traditional asset managers (AMCs, wealth, PMS)
|
||||
|
||||
- **P/E on core earnings** — PAT excluding other/treasury income — cross-checked against **EV/AUM** and **market cap / AUM**.
|
||||
- Indian AMCs are conventionally quoted as a **percentage of QAAUM**: roughly 3–7% of AUM depending on equity mix and growth, with 25–40x P/E for franchise leaders and 12–20x for subscale players. Developed-market traditional managers trade at 8–15x P/E and 1–3% of AUM, reflecting terminal-decline fears from passives.
|
||||
- **Always strip net cash and the investment book out of market cap** before computing the operating P/E. Indian AMCs typically carry 15–25% of market cap in liquid investments; including it makes the franchise look more expensive than it is.
|
||||
- A DCF on fee streams is legitimate but must model **yield compression explicitly** — assume 2–4% annual blended yield decline unless mix is genuinely shifting toward equity and alternatives.
|
||||
|
||||
### Alternative asset managers
|
||||
|
||||
Strict SOTP:
|
||||
- **(a) FRE capitalised at 18–30x after tax**, with the multiple set by permanent-capital share, flow durability and FRE margin.
|
||||
- **(b) Net accrued carried interest at a 25–40% haircut** for realisation, timing and clawback risk.
|
||||
- **(c) Expected future carry** as a separate low-multiple DCF — never bundled into the FRE multiple.
|
||||
- **(d) Balance-sheet / principal investments at or below carrying value.**
|
||||
- Cross-check with **P/DE of 15–25x**. Ignore GAAP P/E entirely, and **de-consolidate funds, CLOs and VIEs** before any leverage analysis.
|
||||
- For hybrids with insurance balance sheets, value **spread-related earnings separately at a much lower multiple (8–12x)** than fee-related earnings — the market is paying for an annuity book, not a fee franchise.
|
||||
|
||||
### What NOT to use
|
||||
|
||||
Consolidated EV/EBITDA for any group containing a financial subsidiary; consolidated P/E for holdcos; consolidated ROCE; consolidated net debt in a holdco solvency assessment; GAAP P/E for alternative managers; peer-average multiples across conglomerates with different segment mixes; and P/B compared across holdcos without normalising the carrying basis of investments.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
Do not put these in one peer table. The sub-sectors below have different value drivers, different multiples and different failure modes.
|
||||
|
||||
**1. Pure investment holdcos / promoter vehicles.** Compare only against holdcos with (a) similar portfolio liquidity — listed-heavy vs unlisted-heavy, (b) similar governance and free float, (c) similar tax leakage on monetisation, and (d) similar holdco leverage. An Indian family investment company holding decades-old listed stakes at cost is not comparable to a European family holdco that fair-values, buys back stock and publishes NAV monthly, even if both are "holdcos". The comparable statistic is the **discount band**, not P/E or P/B.
|
||||
|
||||
**2. Operating conglomerates.** Comparability requires similar **segment mix and similar capital intensity**. Never compare an industrial-plus-financial-services conglomerate to a pure-industrial one; the financial sub makes consolidated EV, D/E and EBITDA incomparable by construction. Where mix differs, do not compare multiples at all — compare segment-level ROCE and incremental ROIC, and compare the SOTP-implied conglomerate discount.
|
||||
|
||||
**3. Traditional AMCs.** Split by (a) equity/hybrid share of AUM — a liquid-heavy AMC is a different business at 8–15 bps than an equity-heavy one at 60–75 bps; (b) distribution model — captive bank/parent channel vs open-architecture vs direct/digital; (c) scale — top-5 by AUM enjoy real operating leverage that mid-table players do not; (d) regulatory regime, since TER caps are jurisdiction-specific. Never mix an Indian AMC (SEBI TER slabs, SIP-driven retail annuity) with a US traditional manager facing structural passive outflows.
|
||||
|
||||
**4. Alternative managers.** Split by (a) strategy mix — PE vs credit vs real assets vs infra have different fee rates, hurdle structures and duration; (b) permanent vs finite-life capital; (c) FRE-driven vs carry-driven earnings; (d) whether an insurance/annuity balance sheet is attached. A credit manager with 90% permanent capital and 65% FRE/DE is a different security from an opportunistic PE firm whose earnings are carry.
|
||||
|
||||
**5. Wealth managers, brokers and platforms** are a separate set again — they earn on client assets without taking manufacturing risk, have different regulatory capital, and should not be benchmarked on AMC bps.
|
||||
|
||||
Cross-cutting rule: never build a peer set on market cap or index membership alone. In this sector the accounting treatment of stakes, the liquidity of the portfolio and the fee-earning mix determine comparability — nothing else does.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Structure and leakage**
|
||||
- **Circular or cross-holdings** between group entities (A owns B, B owns A) that double-count NAV. Headline SOTP upside is arithmetic fiction until the loop is eliminated.
|
||||
- **Holdco standalone debt rising while dividends received are flat** — the parent is servicing itself with borrowings or asset sales. Check specifically whether the dividend to shareholders is funded from borrowings; that is a classic late-stage holdco pattern.
|
||||
- **Double leverage above ~1.3x** — invisible in consolidated D/E, and the first thing that breaks in a downturn.
|
||||
- **Consolidated net cash claimed while holdco standalone cash is near zero** — the cash is trapped inside partly-owned or regulated subsidiaries and is unavailable for debt service, buybacks or dividends.
|
||||
- **Minority-interest asymmetry** — NCI's profit share far below its equity share. Also watch subsidiary rights issues priced to dilute minorities or the listed parent.
|
||||
- **Holdco expenses pushed down to operating subsidiaries**, or brand/royalty/management fees charged by an unlisted promoter entity to listed subsidiaries — legal, but a real transfer of value away from the listed shareholder.
|
||||
- **Promoter pledges, ICDs to promoter vehicles, guarantees for weak affiliates, non-arm's-length RPTs.** Contingent liabilities plus guarantees exceeding net worth is a solvency-level warning in a group structure.
|
||||
|
||||
**Accounting and disclosure**
|
||||
- **Earnings driven by Level 3 fair-value gains** on unquoted investments marked on internal DCFs or manager marks, with no third-party transaction to corroborate them. Track the cumulative gap between carrying marks and realised exit values.
|
||||
- **Frequent restructuring** — schemes of arrangement, demergers, mergers of loss-making group entities into profitable listed ones, re-segmentation of reported segments. Each one resets the historical record. A shrinking disclosed segment count or a swelling "Others" segment is deliberate.
|
||||
- **NAV quoted gross of tax and gross of holdco costs**, with no deduction for capital-gains leakage on latent gains — the most common way holdco "upside" is overstated, typically by 15–25%.
|
||||
- **Auditor resignation or qualification, especially at unlisted subsidiaries**; group audits where "other auditors" certify >20–30% of consolidated assets; delayed subsidiary filings; unavailable standalone accounts for key subs.
|
||||
- **Fund / CLO / VIE consolidation** grossing up an alternative manager's balance sheet — apparent leverage and total assets that have nothing to do with the manager's own risk.
|
||||
|
||||
**Capital allocation**
|
||||
- **Conglomerate cross-subsidy** — a mature cash cow funding years of losses in a promoter's new venture (new energy, telecom, retail, EV) with no stated ROIC hurdle, no ring-fencing and no timeline to breakeven. Look for group capex rising while segment incremental ROIC falls.
|
||||
- **Huge cash and listed investments at a 60%+ discount with no buyback, no special dividend and no monetisation in a decade.** That is a governance signal, not a mispricing. Rising promoter stake toward the 75% ceiling without an open offer, or years of unexplained capital hoarding, means minorities will never see the value.
|
||||
|
||||
**Asset-manager specific**
|
||||
- **AUM growth driven by market appreciation or by low-yield liquid/debt flows** — headline AUM up, blended bps down, revenue flat. Also check for **AUM definition inflation**: including advisory-only, non-fee-paying, uncalled commitments, or double-counted fund-of-fund assets.
|
||||
- **FRE/DE definition drift** — reclassifying fee-related performance revenues, transaction and monitoring fees, or netting placement costs into FRE; excluding equity-based compensation from DE. These are non-GAAP and company-defined, so **the definition change is the signal**.
|
||||
- **Accrued carry that grows for years without converting** — rising net accrued carry with flat or falling DPI means paper marks. Vintages that drop below the hurdle write it all off, with clawback exposure on top.
|
||||
- **Client, mandate or channel concentration** — a single anchor mandate, captive parent/insurance flows, or one distributor bank driving most net sales.
|
||||
- **Key-man and performance decay** — CIO or star PM exit; top-quartile AUM share falling below 50% on 3-year windows; the flagship underperforming while the firm launches new schemes to disguise net outflows (gross sales strong, net flows negative).
|
||||
- **India-specific:** SEBI TER slab cuts, migration to direct plans, side-pocketing of stressed debt paper, and credit events in debt schemes — a debt-scheme wind-up can destroy franchise value overnight. A rising share of low-rated credit paper in debt schemes is an unpriced tail risk. Watch B30 incentive-driven flows that reverse when the clawback period ends.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Discounts are pro-cyclical, and that is the whole game.** NAV discounts narrow in bull markets (when NAV is also high) and widen violently in drawdowns, so the holdco shareholder takes leveraged exposure to market direction. Buying a holdco at a historically narrow discount near a market peak stacks two mean-reverting variables against you. Conversely, the best risk-reward is a wide discount *plus* a visible catalyst *plus* a portfolio of businesses whose earnings are near a cyclical trough — but at least one of those three must be present or the position is dead money.
|
||||
|
||||
**Asset managers are levered beta with a lag.** Revenue = AUM × yield, and AUM moves with markets, so an AMC's earnings fall with the index and its multiple de-rates at the same time — a double hit. But flows lag performance by 2–3 years in both directions, so a good performance record earned during a drawdown pays for the next up-cycle. Model the flow response to a 30% market decline explicitly: how much AUM is sticky SIP/permanent capital, and how much is institutional money that leaves in a week?
|
||||
|
||||
**Secular threats.**
|
||||
- *Fee compression and passive substitution.* Structural and one-directional in developed markets; in India it is regulator-driven (TER slabs that tighten as scheme AUM grows, so scale itself compresses yield) plus direct-plan migration. Passive share is still low in India but rising fast. Any model assuming flat blended bps for a decade is wrong.
|
||||
- *Private markets consolidation.* Fee-paying AUM is concentrating in a handful of large multi-strategy alternative managers with permanent capital; sub-scale managers face a fundraising cliff as LPs consolidate relationships.
|
||||
- *The private-credit and insurance-annuity convergence* changes the risk profile of alternative managers materially: spread earnings carry credit and duration risk that fee earnings never did, and deserve a much lower multiple.
|
||||
- *Conglomerate de-rating.* Global capital markets have structurally penalised diversification since the 1990s; investors can diversify more cheaply than a company can. A conglomerate must now justify itself with demonstrated allocation skill, not with "synergies".
|
||||
|
||||
**Regulation is a first-order valuation variable here, not a footnote.**
|
||||
- India: SEBI's TER caps and slab structure directly set AMC revenue yield; SEBI regulates AIF and PMS structures; RBI regulates **Core Investment Companies** (registration threshold, the double-leverage test, and limits on the number of layers in a group); the Companies Act restricts layers of subsidiaries; IRDAI and RBI gate dividend upstreaming from insurance and lending subs; RPT approval rules under LODR tightened materially.
|
||||
- Global: SEC registration for advisers, the Investment Company Act 40-Act constraints, Volcker-type limits on bank-affiliated managers, AIFMD and MiFID II (which unbundled research payments and compressed fees) in Europe, and UK/EU value-for-money assessments that ratchet fees down.
|
||||
|
||||
**Where holdcos structurally persist.** In India, wide discounts have proved durable for decades because monetisation triggers full capital-gains tax, floats are thin, promoters have no intention of collapsing the structure, and the holdco often exists to hold control rather than to generate shareholder returns. Do not underwrite discount convergence in such names without an identified, dated, mechanically credible catalyst.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
**Accounting and filings.** India: Ind AS (converged with IFRS), standalone **and** consolidated statements both filed — **always read the standalone for holdco solvency and the consolidated for economics**. Segment disclosure under Ind AS 108 is the raw material for conglomerate analysis; check for re-segmentation year to year. CARO reporting, the auditor's report on subsidiaries ("other auditors"), and the related-party note in the annual report carry most of the governance signal. Concall transcripts and investor presentations often disclose SOTP inputs, QAAUM splits and SIP data that never appear in the financials. Amounts are in crore/lakh — normalise before any cross-border comparison.
|
||||
US/global: 10-K and 10-Q on EDGAR, US GAAP or IFRS; alternative managers disclose FRE, DE, FPAUM, accrued carry and fund-level performance in a supplemental non-GAAP section — read the reconciliation tables, not the headline. Segment reporting under ASC 280 is generally more granular than Indian practice.
|
||||
|
||||
**Holdco discounts.** India 40–75% is normal and durable; Europe 20–40%; well-governed, buyback-active developed-market holdcos 5–30%. The difference is not investor irrationality — it is tax leakage on monetisation, free float, buyback culture and promoter intent.
|
||||
|
||||
**Promoter/founder holding.** India-specific and load-bearing: promoter holding %, the 75% maximum public-shareholding ceiling, pledged shares (disclosed quarterly), and inter-se transfers. A promoter creeping toward 75% without an open offer, or persistent pledging, changes the governance read entirely. There is no equivalent disclosure regime in most developed markets, where dual-class share structures play a similar role and must be checked separately.
|
||||
|
||||
**Regulatory perimeter.** India's **CIC** regime under RBI is unique: a company whose assets are >90% investments in group companies, with >60% in equity of group companies, must register as a CIC and faces the double-leverage test and layer limits. Check whether the holdco is a registered CIC or an NBFC-ICC — it changes leverage capacity and dividend flexibility. In the US, watch instead for inadvertent Investment Company Act status.
|
||||
|
||||
**Dividend taxation and upstreaming.** Post-FY21 India taxes dividends in the shareholder's hands, which mechanically penalises multi-layer holdco structures; Section 80M relief applies only where a domestic company redistributes dividends received. This tax cascade is a genuine economic reason Indian holdco discounts are wide, and it must be modelled, not hand-waved. In the US, the dividends-received deduction and participation exemptions in Europe mitigate the cascade substantially.
|
||||
|
||||
**Asset managers.** India: SEBI-mandated slab-based TER falling as scheme AUM rises; monthly AMFI industry AUM and QAAUM data; the SIP book as a structural retail annuity with no direct developed-market equivalent; B30 incentives for smaller-city flows; direct plans mandated since 2013. Disclosure of QAAUM by scheme category is public and monthly — use it, and cross-check the company's claimed market share against AMFI data. US/Europe: fee disclosure through the prospectus and Form ADV; flow data via industry aggregators; heavy passive substitution and continuous fee-war pressure that Indian AMCs have so far felt less acutely.
|
||||
|
||||
**Latent capital-gains tax.** India levies LTCG on listed equity plus surcharge and full corporate rate on unlisted asset sales — this must be deducted from NAV. Many developed-market holdco jurisdictions offer participation exemptions on the sale of qualifying stakes, which is a large part of why their discounts are structurally narrower. Never apply an Indian tax haircut to a European holdco or vice versa.
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Classify every material stake by accounting treatment (consolidated / equity method / FVTPL) before computing any ratio; note which ratios that invalidates.
|
||||
- [ ] Build a tax-adjusted SOTP NAV per share: listed at market (with block discount), unlisted at segment multiples, minus **holdco standalone** net debt, minus capitalised holdco costs, minus latent capital-gains tax.
|
||||
- [ ] Plot the current discount against the company's own 5–10 year discount band, not against a textbook number.
|
||||
- [ ] Name the catalyst that closes the discount, with a date and a mechanism. If there is none, underwrite only NAV compounding plus dividend yield.
|
||||
- [ ] Compute look-through earnings and look-through P/E; check the implied discount reconciles with the NAV discount.
|
||||
- [ ] Compute holdco standalone cash-flow cover from the **standalone** accounts; flag anything below 1.2x.
|
||||
- [ ] Compute holdco LTV and double leverage; flag LTV >30% or double leverage >1.3x.
|
||||
- [ ] Measure portfolio liquidity (% of NAV listed and freely marketable) and top-asset concentration.
|
||||
- [ ] Compute 5- and 10-year NAV-per-share total return vs the relevant total-return index; this is the capital-allocation verdict.
|
||||
- [ ] Compute the holdco running cost ratio and capitalise it — that is a permanent NAV deduction.
|
||||
- [ ] For conglomerates: segment ROCE, incremental ROIC, and the share of group capital employed earning below WACC.
|
||||
- [ ] Check for circular cross-holdings and eliminate the loop before quoting SOTP upside.
|
||||
- [ ] Compare NCI's share of consolidated profit against NCI's share of consolidated equity; asymmetry means minorities own the good assets.
|
||||
- [ ] Scan RPTs, ICDs, corporate guarantees, contingent liabilities vs net worth, and promoter pledge (India).
|
||||
- [ ] For managers: split AUM growth into net flows vs market appreciation; never accept headline AUM growth.
|
||||
- [ ] For managers: track net revenue yield in bps by asset class and its multi-year trend; model yield compression explicitly.
|
||||
- [ ] For managers: strip treasury/investment income and net cash out before computing an operating P/E or bps-on-AUM.
|
||||
- [ ] For alternative managers: separate FRE from carry, check the FRE/DE ratio and permanent-capital share, and audit FRE/DE definition changes year to year.
|
||||
- [ ] For alternative managers: compare accrued carry growth against DPI; de-consolidate funds/CLOs/VIEs before any leverage work.
|
||||
- [ ] Check performance persistence (% AUM above benchmark on 3- and 5-year windows) and stickiness (India: SIP AUM share; global: institutional concentration).
|
||||
- [ ] Read the auditor's report for qualifications, resignations, and the share of consolidated assets certified by "other auditors".
|
||||
- [ ] Check for re-segmentation, demergers and schemes over 5 years; rebuild a like-for-like history before trusting any trend.
|
||||
- [ ] Confirm the peer set shares accounting treatment, portfolio liquidity and fee/segment mix — not just market cap or index membership.
|
||||
|
|
@ -0,0 +1,198 @@
|
|||
# Infrastructure, EPC, capital goods and defence — sector playbook
|
||||
|
||||
Use this when: the company builds, engineers or equips physical assets to order — EPC and civil contractors, roads/water/urban-infra developers, T&D and railway/metro specialists, industrial and process capital-goods makers, electrical equipment, machinery, defence and shipbuilding PSUs and private primes, and their global analogues (E&C services firms, concession operators, industrial OEMs, defence primes).
|
||||
|
||||
This sector breaks a generic checklist at the definitional level, not the benchmark level. Revenue and margin are not observations — they are outputs of management's estimate of cost-to-complete under percentage-of-completion accounting, trued up years later. Most Indian infra groups are two incompatible businesses stapled together (an asset-light contracting arm and a set of 15–30 year concession SPVs), so every consolidated ratio describes a company that does not exist. And the binding constraint on growth is usually not balance-sheet debt but bank-guarantee headroom, which never appears in D/E. Analyse this sector as: **order book quality → working capital → cash conversion → guarantee headroom**, with margin percentage treated as the least reliable number on the page.
|
||||
|
||||
All ranges below are **indicative only**. They move with the capex cycle, contract mix, client type, commodity regime and country. A company's own 5–10 year history and its closest sub-sector peers override every absolute band in this file.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Four structural reasons, then the metric-by-metric damage.
|
||||
|
||||
**(1) Revenue and margin are accounting estimates, not facts.** Under Ind AS 115 / IFRS 15 (and ASC 606) over-time recognition — usually cost-to-cost input method — revenue and margin are derived from management's estimate of total contract cost-to-complete. A 200bps "margin improvement" can be a spreadsheet change rather than an operating event. Reported OPM is an *opinion* that gets corrected years later, often through an onerous-contract provision. Treat any margin move that is not corroborated by cash collection as unproven.
|
||||
|
||||
**(2) Margin is not comparable across companies.** Reported OPM is a function of contract structure, not efficiency: item-rate vs lump-sum turnkey (LSTK); how much client-supplied free-issue material (steel, cement, cable) sits inside the scope; how much of the work is subcontracted pass-through; whether price-variation/escalation clauses exist. A contractor with 40% pass-through content shows 6% OPM on identical economics to a peer showing 12%. Developed markets solve this explicitly — Fluor, AECOM, WSP, Stantec report **Net Service Revenue** (revenue net of pass-through subcontractor and procured cost) and compute margin on NSR. Indian companies rarely disclose the split, so raw OPM comparisons across large diversified EPC, T&D, roads and water contractors are close to meaningless without a scope-mix adjustment. **EBITDA per unit of capital employed and cash conversion beat margin percentage.**
|
||||
|
||||
**(3) Consolidated ROCE and D/E blend two different businesses.** The EPC arm may earn 20–25% ROCE; a HAM/BOT SPV earns a contracted 12–16% equity IRR back-ended over 20 years with near-zero accounting return in years 1–5. The blended figure describes no real business. Split into **core/standalone EPC ROCE** (EBIT of contracting ÷ [net working capital + net fixed assets used in EPC], *excluding* investments in and loans to SPVs) and **asset-level project/equity IRR**. The same split breaks D/E: SPV debt is non-recourse and self-liquidating against a contracted annuity; parent recourse debt is not. A 2.0x consolidated D/E can be materially safer than a 0.8x one. Equity-accounted JVs — very common in EPC consortia and defence offset structures — keep both revenue and capital entirely off the face of the statements.
|
||||
|
||||
**(4) D/E and net debt understate true leverage by design.** EPC runs on **non-fund-based limits**: performance bank guarantees, advance BGs against mobilisation advances, retention BGs, LCs. These routinely run 1.5–3x fund-based debt, never appear in D/E, and convert instantly into funded debt on invocation. Add customer mobilisation advances (interest-free customer financing), acceptances / channel finance / supply-chain finance parked in trade payables instead of borrowings, and corporate guarantees issued to SPVs. Interest during construction is capitalised, so interest coverage is flattered too.
|
||||
|
||||
Metric by metric:
|
||||
|
||||
- **OPM / EBITDA margin** — an estimate, and non-comparable across contract structures (above). Never rank contractors on it.
|
||||
- **ROCE** — arithmetically valid but economically meaningless on a consolidated infra group. Recompute on core EPC capital only.
|
||||
- **EV/EBITDA** — usable for concession assets and product capital goods; wrong for the consolidated group, and wrong for E&C services where acquisition intangible amortisation should *not* be added back (use EV/EBITA there).
|
||||
- **D/E and net debt/EBITDA** — systematically understated; blind to BGs, LCs, corporate guarantees, acceptances and mobilisation advances. Compute recourse and non-recourse separately, then add a third line for off-balance-sheet contingent exposure.
|
||||
- **FCF** — structurally negative for a *healthy growing* contractor, because every new order consumes working capital before it produces cash. Positive FCF frequently signals a shrinking order book, not quality. Screening on FCF here selects for decline. Use cumulative CFO/EBITDA instead.
|
||||
- **Current ratio** — inflated by contract assets and retention money that may never convert to cash, and distorted by contract liabilities (mobilisation advances) that are customer financing, not a normal payable. It says almost nothing about liquidity; BG headroom does.
|
||||
- **P/E** — near-useless. Earnings are lumpy and cycle-dependent; a single arbitration award or claim recognition can be 30–60% of PAT; loss years from onerous contracts are common; and trailing P/E looks cheapest at peak-cycle margin. This is the classic value trap that caught investors in 2007–08 and again in 2018.
|
||||
- **DSO on trade receivables** — understates the true cycle by 50–100%, because the largest receivable buckets are **contract assets (unbilled revenue)** and **retention money**, which sit outside trade receivables.
|
||||
- **P/B** — meaningless for asset-light EPC (book value is mostly stranded working capital), but the *primary* anchor for concession assets. Same ratio, opposite validity, inside one consolidated entity.
|
||||
- **Revenue growth comparability** — for HAM projects the financial-asset model makes construction revenue and "finance income" behave differently from a toll asset's revenue. Headline revenue and EBITDA can fall while economics improve. Growth rates are not comparable across contract types.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are indicative and sub-sector-specific; judge intra-segment and against the company's own history.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
| --- | --- | --- | --- |
|
||||
| **Order book (backlog) and OB/TTM revenue** | Unexecuted value of signed contracts ÷ trailing-twelve-month revenue = years of revenue visibility. Disclosed in DM as backlog or **RUPO / remaining performance obligations** (ASC 606, IFRS 15), often split into ≤12 months and beyond. | Indian EPC 2.5–3.5x TTM revenue (~30–42 months). Below 2.0x = revenue risk inside 12 months. Above 4.5x = execution-bandwidth or working-capital constraint, or a padded book. DM E&C runs leaner at 1.2–2.5x (shorter, services-heavy contracts). Defence order books run 5–10x+ on multi-year platform programmes — do not compare across. | The single best leading indicator; revenue is a lagging, accounting-derived output. But backlog is disclosed at *contract value*, not at margin, so it is only as good as its quality. |
|
||||
| **Order inflow growth and book-to-bill** | New orders awarded in the period ÷ revenue recognised in the same period. Track on a rolling 4-quarter basis to strip lumpiness. | >1.0x sustained; >1.2x in an upcycle. Two consecutive years below 0.9x means the backlog is being consumed and revenue will roll over. | Book-to-bill turns before revenue, before margin and before the stock. It also exposes who holds pricing discipline in a hot bidding market (inflow dips) versus who buys revenue at bad prices. |
|
||||
| **Order book quality and mix** | Decompose the backlog: (a) fixed-price LSTK vs item-rate/cost-plus; (b) % carrying price-escalation/price-variation clauses; (c) government vs private vs export client; (d) concentration — top 5 clients and top 5 projects as % of backlog; (e) **slow-moving / non-moving orders** — awarded but no appointed date, no financial closure, no right-of-way, or stayed by litigation; (f) vertical mix (roads, water, T&D, buildings, urban, oil & gas, defence) with their differing margin and working-capital profiles. | Slow-moving <10% of backlog and explicitly disclosed. Single project <10–15% of backlog. Meaningful escalation-clause share in a commodity-inflation environment. Diversification across ≥3 verticals. | Two identical backlogs can have completely different economics. Fixed-price without escalation transfers commodity and wage risk to the contractor; a road order without right-of-way or appointed date is a liability, not an asset. Companies rarely volunteer this — mine concall transcripts and the annual report. |
|
||||
| **Net working capital days (correctly defined)** | (Trade receivables + contract assets/unbilled + retention money + inventory − trade payables − acceptances − contract liabilities/mobilisation advances) ÷ revenue × 365. **Never use plain debtor days.** | Best-in-class Indian EPC 60–100 days; acceptable 100–130; stress zone >150 and rising. Contractors working for central agencies (NHAI, PGCIL, Railways) sit lower; state-PWD, irrigation and municipal-water exposure runs 180–300 days. Product capital goods often run near zero or negative. | This *is* the sector's return driver: working-capital days × revenue ≈ capital employed, so core ROCE is essentially a function of this number. A 30-day deterioration on a growing top line can consume an entire year's profit in cash. State-government working capital is the single most common cause of Indian infra blow-ups. |
|
||||
| **Unbilled revenue (contract assets) as % of revenue, and its growth vs revenue growth** | Work recognised under POC but not yet invoiced, as a share of annual revenue; tracked against revenue growth itself. | Typically 15–30% of revenue for Indian EPC. The test is directional: unbilled should grow no faster than revenue. Unbilled growing ~2x revenue growth for two consecutive years is a hard warning. | Unbilled is the standard vehicle for aggressive POC recognition and for parking unapproved variation orders and claims. It is profit the client has not yet agreed to. When it converts to a write-off it hits equity directly. |
|
||||
| **Cash conversion: cumulative CFO ÷ cumulative EBITDA over 3–5 years** | Sum CFO over a rolling 3–5 year window ÷ sum of EBITDA over the same window. Single-year figures are noise here. | >60–70% cumulative for a growing contractor; >80% for a mature one. Below 40% over five years while PAT compounds is a strong signal that reported profit is not economic. | The most reliable lie-detector for POC accounting: margin is an estimate, cash is not. Essentially every major Indian infra distress case showed years of PAT growth alongside structurally weak CFO/EBITDA before it broke. |
|
||||
| **Total leverage including non-fund-based exposure** | Three numbers, not one: (a) standalone/recourse net debt ÷ standalone EBITDA; (b) consolidated net debt ÷ EBITDA with SPV non-recourse debt shown separately; (c) outstanding BGs + LCs + corporate guarantees as a multiple of net worth, and as % of sanctioned non-fund limits utilised. | Recourse net debt/EBITDA <2.0x (<1.5x comfortable, >3.0x stressed). Recourse net debt/net worth <0.5x for a pure EPC. Non-fund-based outstanding at 1.5–3.0x fund-based debt is normal; **utilisation of sanctioned non-fund limits above ~85% is a hidden growth cap** — the company cannot bid new work without a fresh sanction. | The binding constraint on a contractor is usually BG headroom, not balance-sheet debt: every bid needs an EMD and performance BG. Groups have failed with "low" D/E because BGs were invoked. This line also captures acceptances/supply-chain-finance dressing that moves debt into payables. |
|
||||
| **Core EPC ROCE vs consolidated ROCE, and capital locked in subsidiaries** | EBIT of the contracting business ÷ (net working capital + net fixed assets used in EPC), excluding investments in and loans to concession SPVs. Separately: investments + loans + guarantees to subsidiaries as % of consolidated net worth, plus **pending equity commitment** on won HAM/BOT/transmission projects. | Core EPC ROCE >18–20% for a good contractor; very large diversified players do 15–18% on a much bigger base. Capital locked in concessions ideally <30–40% of net worth for a company marketed as an EPC play. Pending equity commitment should be fundable from 2–3 years of internal accruals without dilution. | This is the fork in the road for the whole sector. EPC is high-return, capital-light and cyclical; concessions are low-return, capital-hungry and bond-like. Blending them destroys the analysis and historically destroyed the companies — the classic failure mode is a good contractor bidding aggressively for BOT work so its own construction arm gets the job, then drowning in SPV equity calls. |
|
||||
| **Claims, arbitration and variation-order exposure** | Claims filed / awards received but under challenge; amounts already recognised in the books (inside unbilled revenue or "other current assets"), as % of net worth and % of PAT. India: NHAI conciliation-committee status, awards under Arbitration Act s.34/s.37 challenge, and amounts released against BG under the 2016 government scheme (75% of award). DM: unapproved change orders and claims disclosed in the 10-K. | Recognised claim assets <10–15% of net worth. Any year where claim/arbitration settlements contribute >20–25% of PAT should be treated as non-recurring and stripped from the earnings base. | Claim cycles run 5–12 years through arbitration and appeals, with realisation frequently 30–60% of the filed amount. Companies capitalise claims and recognise income long before cash, then quietly write them off. It is also the easiest place to manufacture a good quarter. |
|
||||
| **Receivables ageing and retention money** | Trade receivables by ageing bucket (>180 days, >1 year, >3 years) from the **Schedule III ageing schedule** (mandatory in India since FY22), plus retention money held by clients as a separate line and as % of revenue. | Receivables >365 days <10% of gross receivables and not growing. Retention typically 5–10% of contract value, released on expiry of the defect-liability period (usually 12–24 months post completion). | The ageing schedule is one of the few pieces of hard, non-estimated data in an EPC balance sheet. A fat >3-year bucket that never moves is a write-off queue. Retention is real money, but only released if the project is actually completed and defects closed — so it doubles as an execution-quality proxy. |
|
||||
| **Bid pipeline, hit ratio and L1 position** | Value of tenders bid; win rate (hit ratio); value where the company is lowest bidder (L1) but the award letter has not been issued; tender-to-award conversion time; and the addressable tendering pipeline of key clients (NHAI/MoRTH awarding targets, PGCIL/TBCB transmission tenders, Jal Jeevan Mission, metro and railway capex, MoD acquisition pipeline). | Hit ratio ~10–20% is normal and healthy. L1 pipeline should be disclosed and convert within 3–6 months. A sharply rising hit ratio usually means cheap bidding, not better capability. | The only forward indicator ahead of order inflow, and the clearest read on pricing discipline. A contractor whose hit ratio jumps from 12% to 35% in a hot market has almost certainly bought backlog that becomes a margin problem 24–36 months later. |
|
||||
| **Pre-qualification capability and single-project execution size** | The largest single project the company is technically and financially pre-qualified to bid — a function of net worth, turnover, BG limits and completed-project credentials — plus its blacklisting/debarment record with government agencies and multilaterals. | A rising single-project PQ threshold over time *is* the structural growth story. Any active debarment by NHAI, a state PWD, PGCIL, Railways, MoD or the World Bank is disqualifying for the affected segment. | This is the sector's real moat and it is entirely non-financial. Large-ticket work (metros, tunnels, marine, nuclear, HV transmission, refinery LSTK, defence platforms) has far fewer qualified bidders and structurally better margins than commoditised roads and buildings, where anyone with modest net worth can bid. Loss of PQ status kills a business faster than leverage does. |
|
||||
| **Concession-asset KPIs (BOT / HAM / toll / transmission / airport)** | Asset-level operating and financial metrics: toll traffic growth and WPI-linked rate revision; HAM annuity receipts plus interest at bank rate + 3% on the 60% deferred portion; O&M and major-maintenance cost per lane-km; project DSCR; **residual concession life**; project IRR vs equity IRR; PCOD/COD dates vs schedule. | Minimum DSCR ~1.2x, average 1.3–1.5x. HAM equity IRR contracted around 13–16% pre-refinancing, often 16–20% post-refinancing after COD. Mature-stretch toll traffic growth ~1.0–1.5x real GDP growth. | These are finite-life, contractually defined cash flows and must be monitored as project finance, not as a corporate. Residual concession life is the most important single number — a 25-year asset with 6 years left is a depleting bond, not a growth asset. Post-COD refinancing (200–300bps once construction risk is gone) is the biggest value lever; InvIT monetisation is the standard exit. |
|
||||
| **Product capital goods: aftermarket share, utilisation, operating leverage** | For equipment OEMs rather than contractors: share of revenue from spares, service, retrofits and AMCs; plant capacity utilisation; incremental/decremental EBITDA margin per unit of revenue change; export share; and the sign of working capital (many run negative on customer advances). | Aftermarket/service 20–40% of revenue for a high-quality franchise; incremental EBITDA margin 20–30% in an upcycle. Negative or near-zero working-capital days is the hallmark of pricing power. | Product capital goods and EPC contracting are routinely lumped into one "sector" and must not be. Product companies have brand, installed-base annuity and pricing power; contractors have a balance sheet and a tender. Aftermarket share is what separates a 40x-multiple franchise from a 12x-multiple contractor. |
|
||||
| **Defence-specific: order pipeline quality, indigenisation and nomination share** | Split backlog into signed contracts vs AoN/RFP-stage pipeline (India: Acceptance of Necessity is *not* an order). Track indigenous content %, share of revenue from nominated vs competitively tendered orders, export share, offset obligations outstanding, and LD exposure on delayed platform deliveries. | Signed-order backlog is what counts; treat AoN pipeline as optionality only. Rising export share and rising nominated share both improve durability. Any programme slipping >2 years should be re-underwritten. | Defence revenue is politically and budget-driven with multi-year lags between announcement and cash. Nominated orders to PSUs carry lower price risk but come with tight cost-audit scrutiny; competitively tendered private orders carry both price and LD risk. Backlog-to-revenue looks spectacular here purely because programme tenors are long — it is not a quality signal on its own. |
|
||||
| **Execution throughput and physical progress** | Revenue per employee, revenue per unit of gross block or owned equipment fleet, and — where disclosed — physical progress (lane-km, ckt-km, MW, tonnes fabricated) vs POC percentage claimed. | Directional only; the diagnostic is POC percentage running ahead of physical progress or ahead of billing. | The cleanest non-accounting cross-check available. If accounting completion outruns physical completion, revenue is being pulled forward. Also flags contractors adding backlog faster than they add execution capacity — equipment, people and site management are the real bottlenecks. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
**Sum-of-the-parts (SOTP) is the default, not an optional refinement.** This is the core Indian-market convention and the main departure from a generic checklist. A single consolidated multiple applied to an infra group is almost always wrong, because it prices a capital-light cyclical services business and a finite-life annuity asset with the same number.
|
||||
|
||||
Standard SOTP build-up:
|
||||
|
||||
1. **Core EPC business** — EV/EBITDA of roughly 7–12x, or P/E of 12–20x on standalone/core earnings, using **mid-cycle rather than peak margin**. The multiple is justified by order-book visibility, working-capital discipline and segment mix, not by growth alone. Names with >2.5x book-to-revenue, sub-100-day working capital and clean cash conversion earn the top of the band; state-government-exposed contractors on 200-day cycles trade at 6–10x P/E and deserve to.
|
||||
2. **Concession / BOT / HAM / transmission SPVs** — DCF or NPV of free cash flow to equity over the **remaining** concession life, discounted at cost of equity (roughly 12–15% in India). Terminal value must be zero or the residual transfer value only. A common street shortcut is P/BV on invested equity: 0.8–1.2x for operational HAM/annuity assets, 1.0–1.5x for de-risked toll assets with proven traffic, and below 1.0x (often 0.3–0.6x) for under-construction or traffic-disappointing assets. **Never apply a P/E to a concession** — the asset amortises to zero by design.
|
||||
3. **Real estate / land bank, listed investments, InvIT and subsidiary stakes** at market or NAV, with a holding-company discount of 20–30% where relevant.
|
||||
4. **Less net *recourse* debt at the parent.** SPV non-recourse debt is already embedded inside the SPV equity value — deducting it again double-counts.
|
||||
|
||||
**Why EV/EBITDA for assets and earnings multiples for services.** Operating infrastructure assets are capital-intensive with heavy D&A and different leverage, so EV/EBITDA neutralises capital structure and depreciation policy. The EPC arm is asset-light and its "capital" is working capital, so earnings-based multiples and core ROCE are more informative there.
|
||||
|
||||
**Developed-market conventions differ.**
|
||||
|
||||
- **E&C services firms** (AECOM, Jacobs, WSP, Stantec, Fluor, Quanta) are valued on **EV/EBITA** — not EBITDA, because acquisition intangible amortisation is deliberately included for serial acquirers — at roughly 8–14x, and on P/E on adjusted EPS at 15–25x. Margins and multiples are computed on **Net Service Revenue**, excluding pass-through subcontractor cost.
|
||||
- **Backlog multiples** (EV / backlog, typically 0.2–0.6x) are a cross-check only, never primary — backlog is at contract value, not gross profit.
|
||||
- **Regulated infrastructure** (transmission, water, regulated-till airports) is valued on **Regulated Asset Base**: EV/RAB, where 1.0x means the market pays exactly the allowed asset base and any premium is a bet on beating the allowed return or on RAB growth. Applies to UK/EU utilities, Indian TBCB transmission and regulated airports.
|
||||
- **Toll roads and yield assets** globally trade on EV/EBITDA (10–16x for concession operators) plus DCF on remaining life.
|
||||
- **Defence primes** are valued on P/E and EV/EBITDA with a visibility premium (global primes historically ~15–22x earnings; Indian defence PSUs have re-rated far above that on order-book and indigenisation narratives). Free cash flow conversion and the signed-vs-pipeline split matter more than backlog headline.
|
||||
|
||||
**India-specific instruments.** InvITs (transmission and highway vehicles, including NHAI's sponsored trust) are valued on **distribution yield versus the 10-year G-Sec spread** (typically 250–450bps), on NDCF (net distributable cash flow) per unit, DPU growth, and P/NAV — the same logic as FFO/AFFO and cap rates for REITs. This also gives you the right way to value a developer's mature assets: **at the price a yield vehicle would pay, not at book.**
|
||||
|
||||
**Multiples to avoid.** P/B on an asset-light EPC (book is mostly stranded working capital); trailing P/E at cycle peak; EV/Sales (revenue is a POC estimate and includes pass-through); and any consolidated DCF that assumes perpetual-growth terminal value while a large share of assets have contractually finite lives.
|
||||
|
||||
**Cross-checks worth running.** Replacement-cost and per-unit metrics (EV per lane-km, per ckt-km, per MW, per MTPA of installed capacity) for asset owners; and **market cap ÷ order book** as a sanity screen — a contractor trading at 1.5x its order book on 6% margins is pricing in a decade of flawless execution.
|
||||
|
||||
**Product capital goods are valued completely differently.** Quality Indian capital-goods franchises with MNC parentage and high aftermarket share have long traded at 40–70x earnings against 8–25x for global peers, driven by scarcity value, negative working capital, cash-rich balance sheets and domestic-capex-cycle positioning. Do not benchmark these against EPC contractors, and do not assume the Indian premium is available on a developed-market listing of the same parent.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
The commonest analytical error in this sector is a peer table that mixes business models. Build the peer set on **contract structure and client type**, not on the exchange's sector label.
|
||||
|
||||
Splits that must not be mixed:
|
||||
|
||||
- **Contractor vs concession owner vs product OEM.** Three different return profiles, capital intensities and valuation frameworks. A company that is all three requires three separate peer sets, one per segment, reassembled in SOTP.
|
||||
- **Vertical.** Roads, water/irrigation, T&D and transmission, railways/metro, buildings and factories, urban infra, oil & gas and refinery LSTK, marine and dredging, tunnelling, defence. Margins, working-capital cycles, competitive intensity and PQ barriers differ by a factor of two or more across these.
|
||||
- **Client type.** Central agencies (NHAI, PGCIL, Railways, NTPC, MoD) vs state departments (PWD, irrigation, municipal bodies) vs private capex vs export/EPC-abroad. This single variable often explains more of the working-capital and ROCE difference between two "road contractors" than anything about their operations.
|
||||
- **Contract structure.** LSTK/fixed-price vs item-rate vs cost-plus vs EPC-with-escalation. Also the pass-through content, which mechanically sets the margin optics.
|
||||
- **Scale and PQ tier.** A contractor qualified for a single project of a few hundred crore competes in a fundamentally different, more commoditised market than one qualified for multi-thousand-crore tunnels or HV transmission. Do not put them in one table.
|
||||
- **Defence PSU vs private defence.** Nominated-order PSUs with cost-audit pricing are not comparable to private primes winning competitive tenders, and neither is comparable to a defence-adjacent components supplier.
|
||||
|
||||
Normalisation steps before any cross-company comparison:
|
||||
|
||||
1. **Rebuild margin on a comparable revenue base.** Where disclosed, strip pass-through/free-issue material to get an NSR-equivalent. Where not disclosed, do not compare margin at all — compare EBITDA per unit of core capital employed and cash conversion instead.
|
||||
2. **Use standalone/core numbers, not consolidated**, for the contracting comparison; handle SPVs separately.
|
||||
3. **Match the point in the order-execution cycle.** A company one year into a large new backlog and one in the final year of an old one show different margins for reasons unrelated to quality.
|
||||
4. **Compare working-capital days on the full definition** (contract assets + retention included), or the comparison is worthless.
|
||||
5. **Global comparisons:** compare Indian EPC to global E&C services only on cash conversion, book-to-bill and ROCE — never on margin, since NSR-based DM margins are structurally higher on a smaller revenue base.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
Ordered roughly by how reliably each precedes trouble.
|
||||
|
||||
1. **Unbilled revenue / contract assets growing materially faster than revenue for two or more consecutive years.** The single most common vehicle for aggressive POC recognition and for capitalising unapproved variation orders and claims.
|
||||
2. **Cumulative CFO below 40–50% of cumulative EBITDA over 3–5 years while reported PAT compounds.** The gap is where the accounting is.
|
||||
3. **Margin improvement driven by a "change in estimate" of total contract cost-to-complete**, with no corresponding improvement in collections or working-capital days. Look for the change-in-estimate disclosure, and for POC percentage jumping ahead of physical progress or billing.
|
||||
4. **PAT propped by claims, arbitration settlements, interest on delayed payments, land sales, asset-monetisation gains or other income.** Strip these out and check whether core EPC EBIT is actually growing.
|
||||
5. **Order book padded with LOIs, MOUs, framework agreements, in-principle approvals, AoN-stage defence pipeline, or L1 positions not yet awarded**; failure to disclose slow-moving orders (no appointed date, no financial closure, no right-of-way, stayed by court); silent cancellations appearing only as an unexplained backlog reduction.
|
||||
6. **Hit ratio spiking while new-order margins fall** — buying backlog to sustain a growth narrative. The damage surfaces 24–36 months later as onerous-contract provisions, by which time the stock has usually re-rated *upward* on order-inflow headlines.
|
||||
7. **Acceptances, channel finance, vendor finance or supply-chain finance parked in trade payables rather than borrowings.** Detect via a sudden jump in payable days combined with an implied interest rate (finance cost ÷ average reported debt) far above the company's actual borrowing rate.
|
||||
8. **BG and LC outstanding rising much faster than revenue; non-fund-based limit utilisation above ~85%; corporate guarantees to SPVs growing** — or, most seriously, an actual **BG invocation or LD levy** by a client.
|
||||
9. **Investments, loans and advances to subsidiaries and "other current assets" ballooning without explanation**; parent EPC margins booked on construction of the group's own captive BOT/HAM SPVs and not properly eliminated on consolidation — profit manufactured against the group's own balance sheet.
|
||||
10. **Related-party subcontracting to promoter-owned or promoter-connected entities**, and unusual related-party purchases of materials or equipment hire — the classic siphoning route in Indian infra.
|
||||
11. **Promoter share pledge rising, promoter stake falling, repeated dilutive QIPs or preferential issues used to fund working capital rather than growth capex**, and reliance on short-term debt to finance long-cycle project working capital (asset-liability mismatch).
|
||||
12. **Receivables >365 days and >3 years buckets growing and never converting** in the Schedule III ageing schedule; large retention outstanding on projects completed years ago (defects never closed, or the client disputes completion).
|
||||
13. **Auditor resignation, auditor change without credible reason, qualified opinion, or an Emphasis of Matter on recoverability** of receivables, claims, unbilled revenue or SPV investments. Repeated CFO turnover belongs in the same bucket.
|
||||
14. **Working-capital days improving sharply only at 31 March and reversing in Q1** — year-end window dressing via bill discounting, factoring or short-dated collection pushes. Compare the March-quarter balance sheet with the September half-year balance sheet.
|
||||
15. **Migration from asset-light EPC into owning concessions, real estate or unrelated verticals**, especially bidding aggressively for BOT projects primarily to feed the in-house construction arm. This exact pattern preceded the destruction of an entire generation of Indian infra names in the 2008–2018 cycle.
|
||||
16. **Heavy state-government, municipal or irrigation exposure without a matching working-capital buffer.** Payment cycles routinely run 12–24 months and are budget-dependent, unlike central agencies.
|
||||
17. **Aggressive capitalisation** — interest during construction, pre-operative expenses and even O&M costs capitalised into concession intangibles; delaying declaration of COD to keep capitalising and defer depreciation.
|
||||
18. **Fixed-price LSTK backlog with no escalation clause entering a commodity or wage inflation cycle**, with no disclosed hedging or back-to-back supplier lock-in.
|
||||
19. **Debarment or blacklisting** by NHAI, a state PWD, Railways, PGCIL, MoD, a multilateral lender, or (in DM) suspension/debarment from federal contracting. This removes pre-qualification and can be existential even for a profitable company.
|
||||
20. **Contingent liabilities section growing faster than the balance sheet** — disputed tax and duty demands, counter-claims by clients, guarantees. In this sector the contingent-liability note is often more informative than the balance sheet itself.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Where you are in the cycle changes which metrics to trust.** The sector's cycle is: government/private capex announcement → tendering → order inflow → execution ramp → margin realisation → working-capital strain → payment/claims settlement. Order inflow leads reported revenue by roughly 12–24 months and reported margin by 24–36 months. At the top of the cycle, margin is peak, trailing P/E is lowest, competition for orders is fiercest and bid discipline is weakest — so cheap trailing multiples at peak margin are the sector's characteristic value trap. At the bottom, backlog is thin, balance sheets are repaired and the surviving contractors emerge with better pricing power because weaker bidders have been eliminated.
|
||||
|
||||
**Order-inflow is politically and fiscally driven in India.** Central capex allocations, election cycles (award activity typically slows into a general election and accelerates after), state fiscal stress, and specific programme funding (highway awarding targets, Jal Jeevan Mission, metro sanctions, TBCB transmission tendering, defence capital acquisition budget) all move the addressable pipeline more than any company-level factor. Track the client's awarding pipeline, not just the company's order book.
|
||||
|
||||
**Structural shifts to weigh.**
|
||||
|
||||
- **Model migration in roads:** BOT-toll → annuity → HAM → back toward BOT-toll for select stretches, plus asset monetisation into InvITs. Each shift changes how much equity a contractor must sink per rupee of construction revenue. A contractor that avoided BOT in 2010–14 survived; the model risk is real, not theoretical.
|
||||
- **Commodity and wage inflation** is the fastest way to destroy a fixed-price backlog. Check escalation-clause coverage before every inflation cycle, and check the *lag* structure of the escalation index versus actual input costs.
|
||||
- **Energy transition and grid capex** is a durable multi-year driver for T&D, transmission EPC, cabling, switchgear and renewables-linked balance-of-plant, and simultaneously a terminal threat to thermal-power BTG and coal-linked equipment franchises.
|
||||
- **Import substitution / indigenisation and PLI** shift value toward domestic equipment makers and defence suppliers, but the earnings arrive with long qualification lags and often depend on policy that can be reversed.
|
||||
- **Labour availability, land acquisition and environmental clearance** are the recurring physical bottlenecks in India; right-of-way delay is the most common cause of a good order becoming a bad one.
|
||||
- **Regulation and arbitration regime.** In India, changes to the Arbitration and Conciliation Act, the conciliation-committee mechanism and the government scheme releasing 75% of awards against BG materially change claim-realisation timelines and therefore the value of claim assets on the balance sheet. In DM, watch federal infrastructure funding cycles, Buy-America-type content rules and the suspension/debarment regime.
|
||||
- **Consolidation and PQ inflation.** Larger tender sizes and stricter pre-qualification steadily push work toward bigger balance sheets. This is a structural tailwind for scale players and a structural squeeze on the mid-tier — and it is invisible in any financial ratio.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India (NSE/BSE, Ind AS) | US / global (10-K, GAAP/IFRS) |
|
||||
| --- | --- | --- |
|
||||
| Revenue standard | Ind AS 115, over-time recognition, usually cost-to-cost. Contract assets/liabilities presented separately. | ASC 606 / IFRS 15, same principle. **RUPO / remaining performance obligations** disclosed with a time-band split — a genuinely useful disclosure Indian filers rarely match. |
|
||||
| Pass-through disclosure | Rarely disclosed; margins reported on gross revenue including free-issue and subcontract pass-through. | **Net Service Revenue** widely reported by E&C services firms; margins and multiples computed on NSR. |
|
||||
| Units and scale | Crore and lakh. Order book usually quoted in Rs crore; convert consistently before any cross-border comparison. | Millions/billions of USD or EUR. |
|
||||
| Concession structures | BOT-toll, annuity, **HAM** (40% construction grant + 60% deferred annuity with interest at bank rate + 3%), TOT, TBCB transmission, airport concessions. NHAI/MoRTH/PGCIL are the dominant counterparties. | PPP/P3, availability payments, DBFOM, regulated-asset-base frameworks in UK/EU; US toll concessions are comparatively rare. |
|
||||
| Ownership and governance | **Promoter holding** and **promoter pledge** are first-order signals; check quarterly shareholding pattern. Related-party subcontracting is a known siphoning route. | Dispersed ownership; the analogue signals are insider transactions, related-party disclosures in the proxy, and auditor changes via 8-K. |
|
||||
| Audit disclosures | **CARO** annexure (fixed-asset verification, loans to related parties, statutory dues, fund diversion, whistle-blower matters), Ind AS ageing schedules under Schedule III, and Key Audit Matters — POC estimation and claim recoverability are almost always a KAM. | Critical Audit Matters in the audit report; ICFR attestation; SEC comment letters on revenue-recognition estimates. |
|
||||
| Management communication | **Quarterly concall transcripts** are indispensable — order book quality, slow-moving orders, L1 pipeline, BG utilisation and claim status are usually disclosed only verbally there. Investor presentations often carry backlog splits absent from the annual report. | Earnings calls plus much richer written segment disclosure; backlog, book-to-bill and NSR margins are typically in the press release itself. |
|
||||
| Contingent liabilities | Extensive disputed tax/duty demands and client counter-claims in the notes; often larger than net worth. Read this note every year. | Legal proceedings and commitments disclosed in 10-K Item 3 and the notes; generally tighter and more quantified. |
|
||||
| Yield vehicles | **InvITs** (SEBI-regulated) are the standard monetisation route; valued on distribution yield vs 10-year G-Sec, NDCF/unit, DPU growth, P/NAV. | REIT/YieldCo analogues; infrastructure funds and direct pension/sovereign-fund buyers set the private-market clearing price. |
|
||||
| Defence | MoD acquisition process (AoN → RFP → trials → contract) with very long lags; defence PSUs get nominated orders; indigenisation content rules and offset obligations. | DoD programme-of-record structure, multi-year procurement, FAR/DFARS cost accounting, and the federal suspension/debarment regime. |
|
||||
| Multiples | Product capital goods carry a large domestic scarcity premium; contractors trade at low single-to-mid-teens earnings multiples. | Product OEMs and E&C services trade in tighter, more globally arbitraged bands; no equivalent scarcity premium. |
|
||||
|
||||
## Checklist
|
||||
|
||||
- Split the company into contracting, concessions and products before computing a single ratio; never analyse the consolidated blend.
|
||||
- Pull order book, order inflow, book-to-bill and OB/TTM revenue for at least 8 quarters; check whether backlog growth is real or definitional.
|
||||
- Decompose backlog by vertical, client type, contract structure, escalation-clause coverage and top-5 project concentration; quantify slow-moving/non-moving orders.
|
||||
- Recompute working-capital days on the full definition (receivables + contract assets + retention + inventory − payables − acceptances − contract liabilities). Ignore plain debtor days.
|
||||
- Chart unbilled revenue growth against revenue growth over 5 years; flag two consecutive years of unbilled outrunning revenue.
|
||||
- Compute cumulative CFO ÷ cumulative EBITDA over 3 and 5 years. Below 40–50% while PAT compounds = stop and do forensic work.
|
||||
- Build the three-line leverage picture: recourse net debt/EBITDA, consolidated with SPV debt shown separately, and BG+LC+corporate guarantees vs net worth. Check non-fund-limit utilisation for a hidden growth cap.
|
||||
- Compute core EPC ROCE excluding SPV investments and loans; separately quantify capital locked in subsidiaries and pending equity commitments on won projects.
|
||||
- Quantify recognised claim and arbitration assets as % of net worth and % of PAT; strip settlement income out of the earnings base.
|
||||
- Read the Schedule III receivables ageing schedule; check whether the >1 year and >3 year buckets are converting or accumulating. (India)
|
||||
- Check retention money outstanding against projects completed more than two years ago.
|
||||
- Read the last four concall transcripts specifically for BG utilisation, slow-moving orders, L1 pipeline, hit ratio and claim status.
|
||||
- Compare the March-quarter balance sheet with the September half-year balance sheet for year-end working-capital window dressing.
|
||||
- Check promoter pledge, promoter stake trend, and the last three equity raises — were they for growth capex or to plug working capital? (India)
|
||||
- Scan CARO, Key Audit Matters, auditor changes and the contingent-liability note; check for Emphasis of Matter on receivables, claims or SPV recoverability.
|
||||
- Search for related-party subcontracting, equipment hire and material purchases from promoter-connected entities.
|
||||
- Check debarment/blacklisting status with every major client agency and multilateral lender.
|
||||
- For each concession asset: residual concession life, DSCR, COD status, project vs equity IRR, and refinancing/InvIT monetisation potential.
|
||||
- For product capital-goods names: aftermarket revenue share, working-capital sign, incremental EBITDA margin and capacity utilisation — and value them on a completely separate framework from contractors.
|
||||
- For defence names: separate signed backlog from AoN/RFP pipeline; check programme slippage, LD exposure and nominated-vs-tendered mix.
|
||||
- Value via SOTP: mid-cycle EPC multiple + concession DCF over remaining life + investments at NAV − net recourse debt. Never a single consolidated multiple.
|
||||
- Sanity-check with market cap ÷ order book and per-unit replacement metrics before concluding anything on valuation.
|
||||
|
|
@ -0,0 +1,182 @@
|
|||
# Insurance brokers, TPAs and distribution — sector playbook
|
||||
|
||||
Use this when: the company **places, distributes or administers** insurance but does not underwrite it — retail commercial and personal-lines brokers, employee-benefit consultants, reinsurance brokers, wholesale brokers, MGAs/MGUs/coverholders, third-party administrators (TPA), claims and health-benefit administrators, insurance marketing firms, corporate agents, PoSP aggregator platforms and online insurance distributors.
|
||||
|
||||
**This is not an insurer. Do not route it to `insurance.md`.** A broker takes **no underwriting risk**, holds **no float**, and therefore has **no combined ratio, no solvency ratio, no reserve development, no persistency, no claims ratio, no embedded value and no VNB**. Those metrics do not exist for this company; if a data provider supplies one, it has mis-classified the entity. What exists instead is a commission-and-fee business with negligible fixed capital, high incremental margins and a working-capital profile dominated by money that belongs to other people. Economically this is a **high-margin professional-services roll-up** that happens to be paid as a percentage of somebody else's premium — closer to an asset manager or a staffing/consulting compounder than to a carrier.
|
||||
|
||||
Two facts govern everything below. First, revenue is a *percentage of premium*, so the broker's top line rides the underwriting cycle without taking any of its risk — a soft P&C market shrinks revenue with zero loss of clients or volume. Second, most listed players in this space are serial acquirers, so reported growth, reported margin, reported capital returns and reported book value are all artefacts of acquisition accounting until you separate the organic business from the bought one.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Unlike banks and insurers, most generic ratios are *computable* here — which is precisely the trap. They compute, they look plausible, and several of them are systematically wrong in a direction that flatters or punishes the wrong companies.
|
||||
|
||||
**Headline revenue growth — computable and near-worthless on its own.** A roll-up's reported growth is organic + acquired + FX + fiduciary investment income + disposals, four of which say nothing about the business. Never quote total revenue growth without the organic decomposition; if the company does not disclose organic growth on a consistent basis, say so and treat growth as unverified.
|
||||
|
||||
**"Revenue" itself is not one thing.** Some brokers report **net revenue** (commission and fees retained), others report gross billings or gross written premium handled, and wholesalers/MGAs vary in whether they gross up amounts paid away to sub-brokers and producers. Under Ind-AS 115 / ASC 606 the broker is an *agent*, not a principal, so the premium collected is not revenue — but the agent/principal call on sub-broker arrangements still differs across companies. Confirm the base before comparing any margin, because a gross-revenue reporter will show a structurally lower margin on identical economics.
|
||||
|
||||
**OPM / GAAP operating margin — mis-signed against acquirers.** Amortisation of acquired customer relationships and non-compete intangibles is a very large, entirely non-cash charge for a roll-up and zero for an organically grown peer. GAAP EBIT margin therefore ranks the acquirer below the organic operator on identical cash economics. The sector's own convention is **EBITDAC** (see below); use it, and also look at the GAAP number, but never compare the two forms across peers.
|
||||
|
||||
**EV/EBITDA — the right family of multiple, but both terms are usually built wrong.** Enterprise value must **add** deferred consideration and earnout/contingent-consideration liabilities (these are debt-like obligations to former owners, often several percent of market cap and frequently omitted by screeners) and must **not** net off fiduciary cash. Fiduciary cash is premium held in trust for insurers and clients; it is legally not the company's money and cannot repay debt. Netting it produces a fictitious low net-debt figure and a fictitious low EV. Screener EV for this sector is wrong far more often than it is right — rebuild it.
|
||||
|
||||
**D/E and equity-based leverage — broken at both ends.** After a decade of debt-funded acquisition, book equity is mostly goodwill, and many roll-ups run *negative tangible net worth*. D/E is then either meaningless or literally negative. The binding constraint is cash-flow leverage: **net debt / EBITDAC**, with earnouts included and covenant definitions read directly from the credit agreement (they usually permit generous "run-rate synergy" add-backs that make covenant leverage look 0.5–1.5x lower than the honest number).
|
||||
|
||||
**ROCE / ROE — distorted in opposite directions by the same fact.** Capital employed for an acquisitive broker is overwhelmingly goodwill from past deals, so ROCE measures the price paid for past books, not the return on the operating business. For an organically grown broker, capital employed is near zero or negative and ROCE explodes to a meaningless number. Neither reading is comparable. Use **return on tangible invested capital measured against cumulative acquisition spend** as the real test of whether the roll-up creates value.
|
||||
|
||||
**Current ratio, working capital, receivable and payable days — contaminated and undefined.** The balance sheet is grossed up by fiduciary assets and an almost exactly offsetting fiduciary liability, which pins the current ratio near 1.0x by construction regardless of financial health. Premiums receivable from clients and payable to insurers are pass-through items, not trade working capital; DSO computed on them measures the insurance settlement calendar, not the company. Compute working-capital metrics on own-account receivables (fee billings) only, or not at all.
|
||||
|
||||
**Free cash flow — genuinely meaningful here, unlike in banks and insurers, but with two traps.** Capex is typically 1–2% of revenue, so FCF should track EBITDAC closely; a persistent gap is the single most informative anomaly in this sector. Trap one: fiduciary balances swing operating cash flow with premium seasonality and rate moves, so use FCF before fiduciary movements. Trap two: earnout payments are split between operating and financing cash flow under both IFRS and US GAAP (the portion above acquisition-date fair value goes to operating), so acquisition cost leaks into "operating" cash flow in ways that vary by company.
|
||||
|
||||
**P/E — usable but two-headed.** Reported GAAP EPS is depressed by intangible amortisation and distorted by fair-value remeasurement of earnout liabilities (a *gain* when acquired businesses underperform their targets — an earnings tailwind produced by bad news). The sector quotes "adjusted" or "cash" EPS adding back amortisation; that is directionally right but must be interrogated, because customer relationships genuinely do churn and retaining them costs real money.
|
||||
|
||||
**P/B and book value — meaningless, and this is the exact reverse of the underwriter case.** For a carrier, book value is economic capital and the primary valuation anchor. For a broker, there are no reserves, no investment portfolio and no regulatory capital worth speaking of; the assets are client relationships, producer teams, binding authorities and data. Book value is an accounting residue of deal prices. Do not compute P/B; do not treat negative tangible equity as distress by itself.
|
||||
|
||||
**Anything imported from `insurance.md` — undefined.** Combined ratio, loss ratio, solvency/RBC ratio, reserve triangles, persistency, VNB margin, embedded value, float, investment leverage. State explicitly in the output that these do not apply. The one exception: for an **MGA/MGU with delegated underwriting authority**, the *carrier's* loss ratio on the delegated book is not the MGA's P&L but is the key leading indicator of whether the binder gets renewed — track it as a business-continuity metric, not a profitability metric.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, sub-sector, point in the pricing cycle, interest-rate environment and period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set and against the company's own 5–10 year record overrides every absolute band below.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Organic revenue growth** | Total revenue growth excluding acquisitions and disposals (typically excluded for the first 12 months of ownership), excluding FX, and — for the honest version — excluding fiduciary investment income. Best practice is to reconcile: reported growth = organic + M&A + FX + fiduciary income + other. | Soft market 2–5%; hard market 7–12%; sustained 6–8%+ through a full cycle is best-in-class. Below system premium-rate growth is share loss. | **The single most watched number in the sector**, and the one management has most incentive to shape. It is also the only figure that separates a genuine franchise from a purchasing programme. Definitions are not standardised: check whether acquired revenue is folded into the organic base after 12 months (standard) or earlier; whether "same-store" excludes lost accounts; whether large one-off placements, book-of-business transfers between subsidiaries or the annualisation of a mid-year acquisition are counted; and whether the definition changed. A definition change in a weak quarter is a governance flag, not an accounting detail. |
|
||||
| **Revenue mix: commission vs fee vs contingent/supplemental** | Split net revenue into base commission (% of premium, paid by insurer), client fees (fixed or hourly, paid by the client, common in large-account and benefits consulting), contingent/supplemental commissions, and fiduciary investment income. | Retail commercial: 60–80% commission. Large-account and benefits consulting can be 40–60% fee. Fee-heavy mix is more defensive; commission-heavy mix is more cycle-levered. | Determines cycle sensitivity, which is the whole game here. Commission scales with premium **rate**, so a fee-based consultant keeps revenue flat through a soft market while a commission-based broker loses 5–10% of revenue without losing a single client. Fee revenue is also higher quality (client-negotiated, disclosed, transparency-proof) but usually lower margin because it is people-delivered. A shift from commission to fee is often a mix effect of moving upmarket, not a deterioration — check which. |
|
||||
| **Contingent and supplemental commissions** | Profit-sharing paid by insurers based on the volume, growth and **loss experience** of the book placed, plus fixed-rate "supplementals" agreed in advance. Express as % of total revenue and as % of EBITDAC. | 3–8% of revenue for a typical retail broker; higher for wholesale and MGA models. High conversion to profit (near-100% incremental margin). | Disproportionately important because it is almost pure margin — a company where contingents are 6% of revenue may be earning 15–20% of EBITDAC from them. But it is the lowest-quality revenue line: it depends on the *carrier's* loss experience, so it collapses after a catastrophe year or an adverse loss trend, arrives lumpily (often concentrated in one quarter), and carries a permanent conflict-of-interest and regulatory-disclosure risk. Strip it out and re-run organic growth and margin without it. Rising contingents masking flat base commission is a classic quality-of-earnings problem. |
|
||||
| **EBITDAC margin** | Earnings Before Interest, Tax, Depreciation, Amortisation and **Change in estimated acquisition earn-out payables**. The "C" is the industry convention: it removes the non-cash fair-value remeasurement of contingent consideration, which otherwise makes operating profit move when acquired businesses beat or miss their earnout targets. Most companies also report "adjusted EBITDAC" after further add-backs. | Global large-cap retail brokers 25–33%; strong mid-cap retail 20–28%; wholesale/MGA 30–40% (fewer service obligations, higher revenue per head); reinsurance broking 25–35%; TPAs and benefit administrators 10–20%. | This is the sector's replacement for OPM and the denominator of nearly every valuation multiple used here, so getting the definition right decides the answer. Understand *why* the convention exists — without the "C", a company whose acquisitions are failing books an earnout write-back as operating income. Then police the gap between EBITDAC and **adjusted** EBITDAC: transaction costs, "integration costs" that recur every year, restructuring, and run-rate synergies not yet earned. Recurring add-backs are operating costs. Margin should expand slowly with scale; a sharp jump usually means mix (a wholesale or MGA acquisition) rather than efficiency. |
|
||||
| **Compensation ratio** | Employee compensation and benefits (including producer commissions, share-based pay and incentive accruals) / net revenue. | Retail broking 50–60%; wholesale/MGA 40–50%; benefits consulting 55–65%. Stability matters more than level. | This is a people business; comp is 55–70% of the entire cost base, so the comp ratio *is* the margin story. It also reveals the bargaining balance between the firm and its producers: a falling comp ratio can mean scale and better back-office leverage, or it can mean the firm is underpaying producers who will leave with their books. Read against producer retention. Check share-based compensation separately — excluding it from "adjusted" margin while issuing it every year overstates profitability. |
|
||||
| **Fiduciary investment income and fiduciary asset balance** | Interest earned on premiums held in trust between client collection and remittance to the insurer. Track the average fiduciary asset balance, the realised yield, and this income as % of revenue and % of EBITDAC. | Balance is a function of premium volume and settlement terms. Income can move from ~1% of revenue at zero rates to 5–8%+ at high short rates, and drops close to 100% to EBITDAC. | The purest rate-sensitivity in the business and a frequent source of analytical error. It is not float — the broker holds it briefly, cannot invest it in risk assets, and in most regimes must keep it segregated in trust. It carries almost no cost, so it converts to profit at nearly 100% and can single-handedly manufacture a margin expansion story in a hiking cycle and reverse it in a cutting cycle. Best-practice disclosure separates it from organic revenue; if the company does not, do it yourself and restate. Also check where the balances sit — bank counterparty concentration on fiduciary trust accounts is a real, under-discussed risk. |
|
||||
| **Client retention rate** | Revenue retained from the prior-year client base, measured on revenue not client count. Distinguish gross retention (before new business, before rate) from net revenue retention (including rate, exposure and cross-sell on retained clients). | Commercial P&C 90–95%; large-account and benefits 92–96%; personal lines 85–92%; MGA program business more volatile. Below ~88% on commercial needs an explanation. | Retention is the compounding engine: at 95% retention a broker keeps the same book for two decades and every new placement is additive; at 85% it is on a treadmill. Because renewal commission requires almost no incremental work, retained revenue carries far higher incremental margin than new business. Retention is also the direct read on whether an acquisition worked — books bought from a departing founder frequently leak 10–20% over three years, which shows up nowhere in "organic growth" if the acquired unit is excluded from the base. |
|
||||
| **Producer productivity, headcount and recruitment** | Revenue per producer; the vintage curve (producers typically take 3–5 years to become net contributors); validated vs unvalidated producer counts; annual producer hires, departures and lift-outs of teams from competitors; non-solicit/non-compete enforceability by jurisdiction. | Producer count growing with revenue; a rising share of validated producers; low involuntary and voluntary attrition among top-decile producers. | The book of business walks out of the door on two legs. Producer economics are the leading indicator of organic growth two to three years ahead: a firm that stops hiring saves money now and prints weak organic growth later, which is a favourite pre-sale cosmetic. Conversely, heavy hiring depresses near-term margin for the right reason. Team lift-outs (in either direction) and the litigation that accompanies them are the sector's most visible competitive event — track both sides. In the US, state-level non-compete enforceability materially changes book-portability risk. |
|
||||
| **Revenue per employee** | Net revenue / average total headcount. Compare only within the same market and sub-sector — the absolute figure is not comparable between a US broker and an Indian one. | Rises with mix toward wholesale/MGA and large accounts; falls with mix toward claims administration, TPA work and high-touch personal lines. Track the 5-year trend. | The cleanest single proxy for operating leverage in a people business, and the one that shows whether technology and offshoring spend is actually working. It is also the honest test of a "digital distribution" claim: a platform that genuinely automates placement should show revenue per employee climbing materially; one that has simply bought a call centre will not. Watch for offshore/GCC headcount shifting the ratio for cost reasons rather than productivity reasons. |
|
||||
| **Free cash flow conversion** | (Operating cash flow before fiduciary movements − capex) / EBITDAC. Also compute cash EPS conversion and check the split of earnout payments between operating and financing cash flow. | 70–90% of EBITDAC for a healthy broker; capex 1–2% of revenue. Persistent conversion below ~60% needs a cause. | Because capex is trivial and there is no inventory or genuine trade working capital, an honest broker's EBITDAC should turn into cash almost immediately. A sustained gap is therefore diagnostic rather than incidental: the usual causes are capitalised commissions or capitalised software, earnout payments buried in operating cash flow, growing own-account receivables from disputed fees, cash interest on acquisition debt exceeding the picture EBITDAC paints, or add-backs that are actually cash costs. This is the metric that catches an over-adjusted EBITDAC. |
|
||||
| **M&A programme economics** | Deals per year, annualised revenue acquired, total consideration, implied EV/EBITDA paid, share of consideration in earnouts and rollover equity, earnout liabilities on the balance sheet as % of market cap, and the retention of acquired books at 24 and 36 months. | Tuck-ins historically 6–12x EBITDA versus a listed acquirer at 12–20x; earnouts 15–35% of consideration. Both ends move with credit conditions and PE competition. | The entire equity story of most listed names in this sector is **multiple arbitrage**: buy at 9x, consolidate into a business rated 16x, and EPS rises by arithmetic alone with no operational improvement whatsoever. That is real value but it is finite, mechanical and reverses instantly if the buying multiple rises or the rating falls — so it must be *scored separately from operating quality*, never blended into "growth". The diagnostic question is whether acquired books retain and grow after year two. Also watch the direction of purchase multiples: paying up late in a cycle for books whose commissions are inflated by hard-market rates is buying peak earnings at a peak multiple. |
|
||||
| **Leverage: net debt / EBITDAC** | Net debt **including** deferred and contingent consideration, finance leases and any seller notes, **excluding** fiduciary cash from the cash offset. Compare to the covenant definition in the credit agreement, which is usually more permissive. | Listed acquisitive brokers commonly 2.5–4.5x; PE-owned roll-ups 5.5–7.5x and higher. Above ~5x with organic growth below 4% is a fragile combination. | Serial acquisition funded with debt is the standard model here and moderate leverage is not distress — but leverage is what converts a soft-market revenue decline into an equity problem. Because revenue falls in a soft market with no volume loss and the cost base is largely fixed producer comp, EBITDAC is more operationally geared than the top line suggests. Model a 10% revenue decline through to covenant headroom. Also check the maturity wall, floating-rate share (many roll-ups are heavily floating and were rescued on the revenue line by the same rates that raised their interest cost), and whether earnouts fall due in the same window. |
|
||||
| **Goodwill and intangibles vs tangible net worth; ROTIC** | Goodwill + acquired intangibles as % of total assets and of equity; tangible net worth; and return on tangible invested capital = post-tax EBITA / cumulative cash spent on acquisitions plus organic tangible capital. | Goodwill + intangibles of 60–80% of assets is normal, not alarming. Negative tangible equity is common and not by itself a warning. ROTIC comfortably above WACC and *rising* is the test. | Because P/B is meaningless here, the balance sheet's only real analytical use is to answer one question: did the money spent on acquisitions earn a return? ROTIC against cumulative deal spend is the discipline that a roll-up's own adjusted EPS bridge is designed to avoid. Also track goodwill by cash-generating unit and the headroom disclosed in the impairment note — impairment is the sector's delayed admission that a book was overpaid for or has run off. |
|
||||
| **Premium rate exposure: organic growth decomposition** | Split organic growth into (a) premium **rate** change on renewed business, (b) **exposure units** — insured values, payroll, headcount, vehicle count, revenue of the client, (c) **net new business** won minus lost, and (d) commission-rate change. Benchmark (a) against a published commercial P&C rate index for the relevant market and lines. | In a hard market, rate can be most of reported organic growth; in a soft market it is negative and net new business must carry everything. | This is the decomposition that tells you whether you are looking at a good business or a good market, and it is the reason a broker must never be judged on organic growth in isolation. A broker printing 9% organic growth while market rates are up 10% is losing share; one printing 4% while rates are down 3% is winning. Exposure-unit growth also makes brokers a structural inflation beneficiary — nominal wage and property-value inflation raises insured values and therefore commission with no new clients. Commission-rate change is the silent line: carriers cut commission percentages when their own margins compress. |
|
||||
| **Wholesale / MGA / MGU-specific: delegated authority and carrier concentration** | Share of revenue from binding authority and program business; number of capacity providers and top-3 carrier concentration; contract length and termination notice on each binder; the *carrier's* loss ratio on the delegated book; share of revenue from E&S (excess & surplus / non-admitted) lines. | Top-3 capacity concentration below ~50% of delegated revenue is comfortable; binder terms of 3+ years with limited termination rights are stronger than annual rolling ones. Carrier loss ratio on the program at or below the carrier's target. | A wholesale broker or MGA is a fundamentally different business from a retail broker and must never be blended into the same peer set. It earns higher margin and higher commission rates because it takes on underwriting selection, pricing and sometimes claims handling as a delegated service — but its revenue depends on a small number of carriers continuing to lend it their balance sheet. If the delegated book runs a poor loss ratio, capacity is withdrawn and the revenue line disappears in a single renewal cycle, regardless of client retention. E&S exposure also makes the model *more* cyclical, not less: E&S volume surges when standard markets contract and drains back when they reopen. |
|
||||
| **TPA / benefits administration: lives, claims and contract concentration** | Lives or members administered; claims processed per period; fee basis (per-employee-per-month, per-claim, or % of premium); revenue per life; contract terms and renewal dates; top-5 client/carrier concentration; auto-adjudication rate and claims turnaround time; service-level penalties. | Client concentration above ~20% from one carrier or scheme is a material risk. Auto-adjudication rate rising; turnaround and grievance ratios improving. | TPAs and health-benefit administrators are a **contract services** business, not a broking business: revenue is per-life or per-claim, margins are structurally lower (10–20%), and the customer is often the insurer or a self-funded employer rather than a retail client. Their existential risk is not the pricing cycle but **in-sourcing** — insurers repeatedly decide to bring claims administration back in house, and a single contract loss can remove a double-digit share of revenue with 90 days' notice. Operational quality metrics (auto-adjudication, turnaround, grievance and repudiation-related complaints) are the leading indicator of contract renewal and, in India, of regulatory attention. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
This is an asset-light, cash-generative, low-capex services business. Cash-flow-based and earnings-based methods work; balance-sheet methods do not.
|
||||
|
||||
**Primary — EV/EBITDAC (and EV/adjusted EBITDA).** The sector's own currency, and the multiple at which the businesses actually change hands in private M&A, which gives it an external validation the public multiple alone does not have. Build both sides properly: EV = market cap + gross debt + deferred and contingent consideration + finance leases − **own** cash, with fiduciary cash excluded from the cash offset. If the company reports both EBITDAC and adjusted EBITDAC, value on the less-adjusted figure and show the difference. Indicative ranges: global large-cap brokers have historically commanded high-teens to low-twenties EV/EBITDA in strong markets, mid-cap consolidators low-to-mid teens, TPAs and administration businesses high single digits to low teens — but these are cycle- and rate-dependent and must be re-anchored to the current peer set.
|
||||
|
||||
**Primary — P/E on a defined earnings figure, computed twice.** Compute GAAP P/E and adjusted/cash P/E (adding back acquisition-intangible amortisation and earnout remeasurement) and present both. Then take a view on the add-back: amortisation of customer relationships is non-cash, but if acquired books shrink and must be replaced with more acquisitions, the amortisation is proxying for a real, recurring cost of maintaining revenue. The test is empirical — check whether acquired books grow organically at 24–36 months. If they do, the add-back is fair; if they run off, cash EPS is overstating durable earnings.
|
||||
|
||||
**Primary — free cash flow yield and a DCF.** Because capex is trivial and working capital is largely pass-through, this is one of the few financial-sector-adjacent businesses where a straightforward FCFF or FCFE DCF is legitimate and informative. Model it explicitly with organic growth and acquisition spend separated: forecast organic revenue growth, EBITDAC margin, cash tax, cash interest and maintenance capex, then treat acquisition consideration (including earnout payments) as a **separate, explicit investing line** with its own return assumption. Never fold acquisitions into a single blended growth rate — that assumes free, infinite, constant-multiple deal supply, which is the sector's standard forecasting error.
|
||||
|
||||
**Sum-of-the-parts where the mix is genuinely mixed.** Retail broking, wholesale/MGA, reinsurance broking and TPA/administration deserve different multiples because they have different margins, different cycle sensitivity and different customer-concentration risk. A group that is 70% retail and 30% administration should not be valued on one blended multiple.
|
||||
|
||||
**Cross-checks.** EV/revenue is a useful sanity check *only within a tight sub-sector* given the high and fairly narrow margin band. Private-market transaction multiples for comparable books (widely reported in broker M&A commentary) anchor whether the public multiple is stretched. A reverse-valuation test is particularly powerful here: solve for the organic growth rate and the annual acquired-revenue run rate implied by today's price, then ask whether the deal pipeline and balance-sheet capacity can actually supply it.
|
||||
|
||||
**Do not use:**
|
||||
- **Price-to-book and price-to-tangible-book.** No reserves, no investment portfolio, no regulatory capital base; book value is a residue of deal prices and is frequently negative on a tangible basis. This is the exact inverse of the underwriter case in `insurance.md`, where book value *is* the valuation anchor — and the single most common analytical error made with these companies.
|
||||
- Any insurer metric: embedded value, P/EV, VNB multiple, price-to-GWP, combined ratio, solvency ratio.
|
||||
- ROCE-based valuation screens, for the reasons in the section above.
|
||||
- A blended growth-based PEG on total (organic + acquired) growth.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares the **revenue model, cycle exposure and regulatory regime** — not merely the label "insurance". Mixing across these lines produces confidently wrong conclusions.
|
||||
|
||||
**Splits that must never be mixed:**
|
||||
|
||||
- **Brokers/intermediaries vs insurers.** Non-negotiable, and the reason this playbook exists. An intermediary and a carrier share a customer and nothing else — no risk, no reserves, no capital regime, opposite balance-sheet logic, opposite valuation anchor.
|
||||
- **Retail broking vs wholesale / MGA / MGU.** Different margin structure (wholesale is materially higher), different customer (the retail broker is the wholesaler's client), different risk (carrier capacity withdrawal vs client attrition), different cyclicality (E&S flow is counter-cyclical to standard-market capacity).
|
||||
- **Commercial P&C broking vs employee benefits vs personal lines vs reinsurance broking.** Fee/commission mix, retention, cycle sensitivity and regulatory exposure all differ. Reinsurance broking is a small-client-count, very high revenue-per-head, relationship-concentrated business that behaves nothing like retail.
|
||||
- **Brokers vs TPAs and claims/benefit administrators.** Fee-per-life or fee-per-claim contract services with 10–20% margins, in-sourcing risk and client concentration — not a commission business. Never blend the two into a single margin comparison.
|
||||
- **Serial acquirers vs organic-only operators.** Their reported growth, margin, EPS, capital returns and balance sheets are constructed differently. Compare them only on **organic growth, EBITDAC margin and FCF conversion**, never on GAAP EBIT margin, ROCE, P/B or reported EPS growth.
|
||||
- **Listed intermediaries vs PE-owned consolidators.** PE-owned platforms run 5.5–7.5x leverage with aggressive covenant add-backs and often disclose only under bond documentation. Their EBITDA definitions are usually not comparable to a listed peer's.
|
||||
- **India: IRDAI-licensed brokers vs corporate agents vs web aggregators vs insurance marketing firms vs PoSP-led platforms.** These are separate licence categories with different permitted activities, different tie-up limits and different commission economics (see below).
|
||||
- **Digital-first distribution platforms vs traditional brokers.** A platform carrying heavy customer-acquisition marketing spend, negative EBITDA in growth phase and a take rate on low-ticket retail policies is closer to a consumer-internet business than to a commercial broker; consider whether `exchanges-payments.md` or `it-saas.md` unit-economics logic (CAC payback, cohort retention, contribution margin) should be run alongside this playbook.
|
||||
|
||||
**Also align:** market and pricing cycle (a US broker and an Indian broker are at different points of a different P&C cycle); accounting regime (Ind-AS vs IFRS vs US GAAP, and whether revenue is reported gross or net); fiscal year (India April–March); interest-rate environment, because fiduciary income is a large and non-comparable margin component across rate regimes; and size band, since scale drives comp ratio, carrier leverage and access to national accounts.
|
||||
|
||||
Aim for 5–8 peers. State the basis explicitly, and benchmark every metric twice — against peers *and* against the company's own multi-year record.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **The organic growth definition changes, or stops being disclosed.** The most important number in the sector is also the least standardised. Watch for acquired revenue entering the organic base early, "same-store" definitions that quietly exclude lost accounts, mid-year acquisitions annualised into the base, book transfers between subsidiaries counted as new business, and fiduciary investment income left inside organic revenue during a hiking cycle. A definition change coinciding with a slowdown is a governance flag.
|
||||
- **Growth entirely from M&A while organic decelerates.** The classic roll-up decay pattern: as the base grows, each tuck-in moves the needle less, so deal size and purchase multiples rise, leverage rises with them, and the arbitrage narrows. Chart organic growth and acquired revenue separately over five years; if organic is trending toward zero, the equity story is a financing structure, not a business.
|
||||
- **Acquired book run-off hidden by the exclusion window.** Books bought from a retiring founder commonly leak clients once the earnout period ends and the seller's non-compete expires. Because acquired revenue sits outside the organic base for 12 months and inside it thereafter, the leakage shows up as mysteriously weak organic growth two to three years after a deal-heavy period. Ask for retention of acquired books at 24 and 36 months.
|
||||
- **Earnout accounting used as an earnings lever.** A downward remeasurement of contingent consideration is a P&L *gain* generated by an acquisition **failing**. The EBITDAC convention exists to strip it out — verify it actually has been, both in the operating line and in adjusted EPS.
|
||||
- **Adjusted EBITDAC add-backs that recur.** "Integration costs", "transaction costs", restructuring and "one-off" legal charges appearing every year for five years are operating costs. Track the cumulative gap between GAAP operating profit and adjusted EBITDAC; the FCF conversion metric is the referee.
|
||||
- **Margin expansion sourced from fiduciary investment income or contingents rather than operations.** Both drop nearly 100% to profit and both are outside management's control. Restate margin excluding them before concluding anything about efficiency. The corollary risk is symmetric and under-appreciated: a rate-cutting cycle removes this margin with no operational cause.
|
||||
- **Contingent commissions rising as a share of revenue.** Higher dependence on carrier profit-sharing means earnings quality is deteriorating and a single bad catastrophe or loss-trend year will take it away. It also raises conflict-of-interest and disclosure risk — this is the exact practice that produced the major US broker contingent-commission enforcement actions of the mid-2000s and led to years of disclosure reform.
|
||||
- **Producer attrition, team lift-outs and litigation.** Departure of top producers, a wave of poaching suits, or a sharp fall in unvalidated-producer hiring all precede organic weakness by two to three years. So does an abnormally falling comp ratio.
|
||||
- **Carrier concentration and binder loss (wholesale/MGA).** Loss of a capacity provider, non-renewal of a binding authority, or deterioration in the loss ratio on a delegated program can remove a revenue block instantly. Read the capacity-provider disclosure and the program renewal calendar.
|
||||
- **Client or carrier concentration and in-sourcing risk (TPA).** A single insurer or large self-funded scheme worth a double-digit share of revenue, on a short-notice contract, is an existential dependency. Insurers periodically bring claims administration in house.
|
||||
- **Fiduciary funds handling.** Any indication of commingling client/insurer money with own funds, delayed remittance to insurers, use of fiduciary balances to fund operations, or a regulatory finding on trust-account segregation is a first-order integrity flag — it is the intermediary equivalent of a bank misusing depositor money, and it is how brokers actually fail.
|
||||
- **Leverage plus soft market.** Net debt/EBITDAC above ~5x (including earnouts) with organic growth below 4% and a floating-rate debt stack is the configuration that turns a normal cyclical revenue decline into a restructuring. Test covenant headroom against a 10% revenue fall.
|
||||
- **Goodwill impairment, or conspicuously thin headroom in the impairment note.** The delayed acknowledgement that books were overpaid for. Read the CGU-level disclosure, not the group total.
|
||||
- **Revenue recognition timing.** Under IFRS 15 / ASC 606 placement commission is generally recognised when the policy is bound rather than spread over the policy period, which front-loads revenue and amplifies seasonality around major renewal dates. Watch for policy changes, for estimates of variable consideration (contingents accrued in advance), and for aggressive accrual of profit-sharing not yet confirmed by the carrier.
|
||||
- **Capitalised commissions and capitalised software** growing faster than revenue — the most common cause of an EBITDAC-to-cash gap.
|
||||
- **Regulatory and conduct exposure.** Commission-disclosure regimes, remuneration transparency rules, mis-selling and claims-handling penalties, and — in India — IRDAI inspection findings, licence-renewal conditions, and the periodic scrutiny of payouts routed through non-broking entities or group companies to sidestep commission and expense limits.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The P&C pricing cycle is the sector's exogenous driver, and it moves revenue without moving volume.** Commission is a percentage of premium, so a hard market — rising rates after catastrophe losses, adverse reserve development or capital withdrawal — lifts broker revenue with essentially zero incremental cost, and a soft market compresses it with zero client loss. This is the most important sentence in this playbook after the "not an insurer" warning: **you cannot read a broker's revenue decline as commercial failure, or a revenue surge as commercial success, without the rate index.** Always decompose organic growth into rate, exposure and net new business, and always state where the local P&C market is in its cycle.
|
||||
|
||||
**Exposure units make brokers a structural inflation beneficiary.** Premiums scale with insured values, payrolls, headcount, fleet size and client revenue. Nominal inflation raises all of them, so commission rises with no new business at all. This is why brokers have historically compounded through inflationary periods that damaged most services businesses — and why real, volume-driven growth must be isolated before crediting management.
|
||||
|
||||
**Interest rates enter through fiduciary income, not through underwriting.** A rate cycle changes broker margin directly and quickly, with essentially no lag and no operational cause. A cutting cycle removes a margin tailwind that a hiking cycle handed over.
|
||||
|
||||
**Capital-cycle interaction with wholesale/MGA.** When carriers retrench, business flows to E&S and delegated-authority markets, benefiting wholesalers and MGAs; when capacity returns, it flows back to standard markets. So the wholesale sub-sector is counter-cyclical to standard-market capacity while still being levered to overall rate levels — a two-factor exposure that retail brokers do not have.
|
||||
|
||||
**Consolidation is the defining structural feature.** Insurance distribution is one of the most fragmented professional-services markets in the world, and private-equity capital has been an aggressive competing bidder for the same tuck-ins that listed consolidators buy. That competition sets purchase multiples, which sets the arbitrage, which sets the acquirers' incremental returns. Track the direction of private-market multiples as a sector-level input.
|
||||
|
||||
**Structural threats to score explicitly.** Carrier direct-to-consumer distribution in personal lines and small commercial, where the broker's advisory value-add is weakest. Commission-rate compression as carriers manage their own expense ratios. Regulatory transparency initiatives that expose remuneration to clients. Automation of low-touch placement and quote comparison. And in the other direction, structural supports: rising insurance penetration in emerging markets, growing complexity in cyber, climate, D&O and specialty lines where advice is genuinely valued, and the shift of employers to self-funded benefit structures that need administrators.
|
||||
|
||||
**For TPAs specifically, the cycle is contractual, not pricing-driven.** Their risk is the periodic decision by insurers to in-source claims, and their opportunity is regulatory or technological complexity that makes outsourcing cheaper. Model them on contract renewal dates and lives administered, not on premium rates.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India | US / global |
|
||||
|---|---|---|
|
||||
| Regulator and licence categories | IRDAI. Distinct registrations with distinct rules: **direct broker** (life / general / composite), **reinsurance broker**, **composite broker** — under the IRDAI (Insurance Brokers) Regulations, 2018, with minimum capital requirements scaled by category (broadly ₹75 lakh direct, ₹4 crore reinsurance, ₹5 crore composite) and net-worth maintenance obligations. Separately: **corporate agents**, **web aggregators**, **insurance marketing firms**, **motor insurance service providers (MISP)** and **point-of-sales persons (PoSP)**. Licences are periodically renewed and can be conditioned or suspended | US: state-by-state producer and surplus-lines licensing, no single federal regulator; NAIC model rules. UK: FCA authorisation, with client-money (CASS 5) rules governing premium trust accounts. EU: IDD (Insurance Distribution Directive) with demands-and-needs and remuneration-disclosure requirements |
|
||||
| Broker vs agent distinction | Legally central. A **broker represents the client** and may place with any insurer; a **corporate agent represents the insurer** and may tie up with a limited number of insurers per line (broadly up to three each in life, general and health under the open-architecture rules). This single distinction determines the revenue model, the conflict-of-interest profile and the competitive set | The retail/wholesale/MGA distinction matters more than broker/agent; independent agents and captive agents coexist, and MGAs hold delegated underwriting authority under binding agreements |
|
||||
| Commission regulation | Historically product-level commission caps. The **Expenses of Management (EOM) regulations effective FY2024** replaced product-wise commission caps with an overall board-approved EOM ceiling at the insurer level, giving insurers flexibility on what they pay intermediaries within that limit — a material change to the sector's revenue mechanics and a live source of channel-by-channel commission repricing | Commission rates are market-determined; disclosure regimes (US state rules post the mid-2000s contingent-commission settlements, UK/EU under IDD) govern transparency rather than level |
|
||||
| Bancassurance | A dominant channel, particularly for life. Banks act as **corporate agents**, distributing for a small number of tied insurers — frequently a group insurance company — which raises persistent mis-selling and captive-distribution concerns and has drawn both IRDAI and RBI attention. Bancassurance economics compete directly with independent broking for the same premium pool, so treat it as part of the competitive analysis for any Indian distributor | Bank distribution exists but is a smaller share of the market in the US; more significant in parts of Europe and Asia |
|
||||
| Digital distribution | Web aggregators are a licensed category; several online platforms have converted to full **direct broker** licences to widen permitted activity. **Bima Sugam**, the IRDAI-sponsored electronic insurance marketplace, is a structural disintermediation and margin question for every online distributor — model it as a scenario, not a certainty. PoSP networks are the standard way digital brokers scale low-ticket distribution | Online comparison and digital MGA models are unlicensed-category-free but subject to state producer licensing; no central state-sponsored marketplace equivalent |
|
||||
| TPAs | Licensed under the IRDAI (Third Party Administrators – Health Services) Regulations, 2016; paid a percentage of premium or a per-claim/per-life fee. Structural pressure from insurers building in-house health claims capability, and from regulator focus on claims turnaround, repudiation and grievance metrics | Health-benefit administration is dominated by ASO (administrative services only) arrangements for self-funded employers, plus pharmacy benefit and specialty administrators; PEPM fee structures are the norm |
|
||||
| Listed universe and disclosure | Thin and skewed toward online distribution; most traditional brokers and TPAs are unlisted, promoter-owned or PE-owned, so peer sets are hard to build and often require unlisted or cross-border comparables — say so explicitly. Ind-AS 115 governs agent-vs-principal revenue presentation. Reporting in ₹ crore/lakh, April–March fiscal year, quarterly results plus concall. Check promoter holding and pledge, related-party flows to group insurers or group distribution entities, and CARO qualifications | Deep listed universe across global, national and specialist brokers. 10-K/10-Q on EDGAR; organic growth, EBITDAC and adjusted EPS are standard non-GAAP disclosures with mandated reconciliations — read the reconciliation tables, not the headline |
|
||||
| Taxes and other | GST at 18% on broking commission and services; TDS obligations on commission payouts; sub-broker/PoSP payouts are a large pass-through cost line to check for gross-vs-net presentation | Sales tax generally not applicable to commissions; surplus-lines taxes and stamping fees apply in the US E&S market and are collected by the wholesaler |
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Confirm the company takes **no underwriting risk** — if it does on any material book, route that part to `insurance.md` and analyse separately.
|
||||
- [ ] State explicitly in the report that combined ratio, solvency ratio, reserve development, persistency, claims ratio, float, embedded value and VNB do not exist for this company.
|
||||
- [ ] Delete P/B, P/TBV, ROCE and receivable/payable-day metrics; explain why book value is not an anchor for an asset-light intermediary.
|
||||
- [ ] Establish whether revenue is reported gross or net, and whether sub-broker/PoSP payouts are grossed up, before comparing any margin.
|
||||
- [ ] Get organic revenue growth, read the company's **definition** of it, check whether the definition has changed, and reconcile reported growth = organic + M&A + FX + fiduciary income.
|
||||
- [ ] Decompose organic growth into premium **rate**, **exposure units** and **net new business**; benchmark rate against a market P&C rate index and state where the cycle is.
|
||||
- [ ] Split revenue into base commission, client fees, contingent/supplemental commissions and fiduciary investment income; restate growth and margin excluding the last two.
|
||||
- [ ] Compute EBITDAC margin; then compute the gap to **adjusted** EBITDAC and list every add-back, flagging anything that recurs annually.
|
||||
- [ ] Track fiduciary asset balance, realised yield and fiduciary income as % of EBITDAC; model the effect of a 200 bps rate move in each direction.
|
||||
- [ ] Check client retention (revenue-weighted), and separately the retention of acquired books at 24 and 36 months.
|
||||
- [ ] Review producer economics: revenue per producer, validated vs unvalidated mix, hiring, attrition, lift-outs and litigation; check the comp ratio trend.
|
||||
- [ ] Compute revenue per employee over five years as the operating-leverage and automation test.
|
||||
- [ ] Rebuild EV from scratch: add deferred and contingent consideration, **exclude fiduciary cash** from the cash offset. Never use a screener's EV here.
|
||||
- [ ] Compute net debt / EBITDAC including earnouts, compare to the covenant definition, and stress a 10% revenue decline against covenant headroom.
|
||||
- [ ] Score the M&A programme separately from operating quality: deals, revenue acquired, multiples paid, earnout share, and ROTIC on cumulative acquisition spend.
|
||||
- [ ] Reconcile EBITDAC to free cash flow; investigate any conversion below ~60–70% (capitalised commissions/software, earnouts in operating cash flow, cash add-backs).
|
||||
- [ ] Present GAAP and adjusted EPS side by side and take an explicit view on whether the intangible-amortisation add-back is economically justified.
|
||||
- [ ] Value on EV/EBITDAC, P/E on defined earnings, and an explicit DCF with acquisition spend modelled as a separate investing line — never a single blended growth rate.
|
||||
- [ ] Wholesale/MGA: check capacity-provider concentration, binder terms and renewal calendar, and the carrier's loss ratio on delegated programs.
|
||||
- [ ] TPA/administration: check lives and claims administered, fee basis, top-5 contract concentration, renewal dates, and in-sourcing risk.
|
||||
- [ ] Test fiduciary-funds integrity: segregation, remittance timing, any regulatory finding on trust accounts, bank counterparty concentration.
|
||||
- [ ] India: identify the exact IRDAI licence category (direct/reinsurance/composite broker, corporate agent, web aggregator, IMF, PoSP-led) and its permitted activities and tie-up limits.
|
||||
- [ ] India: assess EOM-regulation-driven commission repricing, bancassurance competition, Bima Sugam disintermediation risk, and related-party flows to group insurers or group distribution entities.
|
||||
- [ ] Peer set: same sub-sector (retail / wholesale-MGA / reinsurance / TPA), same market and rate environment, same acquisitive-vs-organic profile, same revenue presentation — stated explicitly.
|
||||
- [ ] Benchmark every metric twice: against the peer set and against the company's own 5–10 year history. No conclusion from a single metric.
|
||||
176
finance/skills/stock-analysis/references/sectors/insurance.md
Normal file
176
finance/skills/stock-analysis/references/sectors/insurance.md
Normal file
|
|
@ -0,0 +1,176 @@
|
|||
# Insurance (life, general/P&C, health) — sector playbook
|
||||
|
||||
Use this when: the company underwrites risk on its own balance sheet — a life insurer, a general/P&C carrier, a standalone health insurer, a reinsurer, or a holding company whose main assets are insurance subsidiaries.
|
||||
|
||||
Insurers sell a promise today and discover the cost of goods sold years later, and they fund themselves with other people's money (float). That single fact breaks almost every ratio in the generic screening set: the largest expense is a management estimate, the largest liability is neither debt nor equity, and profit for a growing life insurer is legitimately negative for years. Underwrite the reserves and the capital, not the income statement. If the company only distributes or administers insurance — brokers, web aggregators, TPAs, InsurTech MGAs — it carries no underwriting risk and should be analysed as a capital-light services business, not with this playbook.
|
||||
|
||||
## Contents
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
**"Revenue" is not one number, and growth is not a virtue.** Gross written premium (GWP), net written premium (NWP), net earned premium (NEP) and — under IFRS 17 — "insurance revenue" (which strips out investment components and deposit elements) are four different figures for the same company. Indian life insurers headline New Business Premium and APE (Annualised Premium Equivalent = regular premium + 10% of single premium), not revenue. Comparing "sales growth" across insurers without knowing the base is meaningless. Worse, premium growth is trivially manufactured by underpricing: this is the one industry where you can grow 40% next quarter by promising to pay out more than you charge, and the bill arrives three to five years later. Treat unexplained above-market growth as a risk flag, not a quality signal.
|
||||
|
||||
**OPM / EBITDA / EBIT are undefined or nonsensical.** There is no gross margin, because the dominant cost — incurred claims — is an actuarial estimate management sets. Interest is not a financing add-back: investment income and interest credited to policyholders are core operating revenue. D&A is trivial. No practitioner quotes EBITDA for a carrier. The correct analogue of operating margin is the **combined ratio** for P&C/health and **VNB margin** (plus CSM release under IFRS 17) for life.
|
||||
|
||||
**ROCE and "capital employed" are undefined.** Seventy to ninety percent of an insurer's balance sheet is policyholder liabilities — float and reserves — which are neither debt nor equity and are not capital the firm employs at a cost. Any ROCE computed off total assets or off liabilities-plus-equity is arithmetic noise. Use operating ROE (ex-AOCI, ex-realized gains) and operating RoEV instead.
|
||||
|
||||
**Debt/Equity is the wrong leverage measure.** Real leverage here is regulatory and actuarial. Use three measures together: financial leverage (debt + hybrids / total capital, comfortable below ~25–30%), **solvency ratio** (IRDAI minimum 150%; Solvency II SCR coverage; US NAIC RBC), and **underwriting leverage** (NWP/equity). A carrier with zero debt can be dangerously levered on under-priced reserves.
|
||||
|
||||
**FCF is misleading in both directions.** A fast-growing life insurer consumes cash — new business strain means acquisition costs and reserve set-up are paid upfront while profit emerges over 15–30 years — so healthy growth looks like cash burn. Conversely a shrinking or under-reserved insurer throws off cash. And operating cash is not distributable: it belongs to policyholders and is trapped by solvency rules. The only genuinely free cash is **remittances from regulated subsidiaries to the holding company**, which require regulator sign-off. Model that, not FCF.
|
||||
|
||||
**Working-capital metrics do not exist.** Current ratio, inventory and receivable turnover, cash conversion cycle, capex intensity and asset turnover have no meaning. Do not compute them; do not let a screener's "poor current ratio" flag influence the conclusion.
|
||||
|
||||
**P/E is distorted, especially for life.** Under Indian GAAP / IFRS 4, accounting profit is back-ended, so a fast-growing life insurer reports depressed or negative earnings precisely when it is creating the most value. Under IFRS 17, reported profit is largely the CSM release — an output of management assumptions. Even for P&C, headline EPS blends realized capital gains and prior-year reserve movements that have nothing to do with this year's underwriting. Use operating EPS, defined explicitly.
|
||||
|
||||
**Book value and ROE need adjustment.** IFRS 4 / Indian GAAP book value ignores the value of in-force business, which is why Embedded Value exists. Reported equity swings with AOCI / fair-value moves on the bond book as rates move, so P/B and ROE change for reasons unrelated to performance — hence "book value ex-AOCI" and "operating ROE ex-AOCI" are the industry standards. In the other direction, held-to-maturity classification can hide large unrealized bond losses that are economically real.
|
||||
|
||||
**Consolidated composites are un-valuable on any single multiple.** Groups that blend life, general, health, asset management and lending (Indian financial conglomerates; global multi-line insurers) mix businesses with different capital intensity, different earnings emergence and different correct multiples. Sum-of-the-parts is mandatory.
|
||||
|
||||
---
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
All ranges are **indicative only**. They vary by market, line of business, cycle stage and accounting regime, and they shift over time. A peer-relative and own-history comparison always overrides an absolute band: an Indian general insurer at 103% combined is strong, while the same number in US commercial specialty is mediocre.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Combined ratio** (general/P&C, health) | Incurred claims ratio + expense ratio (commission + operating expenses), on net earned premium. Note the definition used: Indian general insurers often quote a version *including* policyholders' investment income; US/European carriers quote the pure underwriting number and split ex-cat and accident-year vs calendar-year. | Developed-market P&C 90–97% good, sub-90% best-in-class. India general insurance sector routinely 100–115%; sustainably below ~102–103% is strong. Standalone health 95–100%. | The cleanest single measure of whether pricing risk works. It replaces operating margin outright. Above 100% the insurer survives only if float and investment yield cover the gap — a rate-cycle bet, not a moat. |
|
||||
| **Loss ratio, accident-year vs calendar-year** | Incurred claims / NEP. Calendar-year includes movements on prior-year reserves; accident-year (best: current accident year ex-cat) isolates this year's underwriting. IRDAI publishes incurred claims ratios by insurer and line. | Indicative India: motor OD 60–70%, motor TP 70–90%, commercial property 50–65%, retail health 65–75%, group health frequently 90–110% (loss-leader). Life claims are judged against actuarial mortality/morbidity assumptions, not a fixed ratio. | Calendar-year loss ratios can be flattered indefinitely by releasing prior reserves. Only the accident-year ex-cat number tells you whether this year's price covers this year's risk. |
|
||||
| **Expense ratio, Expense of Management (EOM), commission ratio** | Operating expenses + commissions as a % of premium. India has a hard regulatory version: IRDAI (Expenses of Management) Regulations cap *total* EOM rather than capping commission line by line. | India: EOM caps broadly ~30% of GWP for general insurers and ~30–35% for life depending on vintage and mix; running 3–5 points under the cap is a real cost advantage. Developed P&C 25–33%; direct writers 20–25%; broker-distributed specialty 35%+. | Distribution cost is the durable differentiator in a commoditised product, and it is where regulatory shocks land (e.g. India's Sept-2025 removal of GST on individual life and health premiums eliminated input tax credit, structurally raising net expense burden). |
|
||||
| **Prior-year reserve development** | Change in the estimated ultimate cost of claims from earlier accident years, booked in the current P&L. Favourable = release; adverse = strengthening. Read loss-development triangles (US Schedule P and 10-K triangles; IFRS 17 claims development tables). Indian disclosure is thinner — use IBNR-to-total-reserve trends and the appointed actuary's certificate. | Modest, consistent favourable development of 1–3% of opening net reserves signals prudence. Sustained >5% is suspicious. Any adverse development in long-tail casualty/liability/motor-TP is a serious signal. | The single largest earnings-management lever in P&C. A one-point reserve change can swing EPS 10–20%. Chronic releases funding a deteriorating book is the classic pre-blowup pattern. |
|
||||
| **Float, investment yield and cost of float** | Float ≈ reserves + unearned premium − recoverables/DAC. Cost of float = underwriting loss / average float (negative means you are paid to hold other people's money). Track investment leverage (investments/equity), book yield and new-money yield. | P&C float/equity 2–4x typical; life far higher. Cost of float ≤0 (i.e. combined ≤100%). New-money yield vs book yield tells you the direction of future investment income. | This is the economic engine generic metrics miss entirely. Two insurers with identical ROE can be completely different in quality: one earns it from underwriting and cheap float, the other from taking investment risk with leverage. |
|
||||
| **Solvency / regulatory capital adequacy** | Available over required solvency margin (India), SCR coverage (Solvency II), RBC ratio (US NAIC). Interrogate the composition: how much is subordinated debt, deferred tax assets, or value-of-in-force rather than hard equity. | India: IRDAI minimum 150%; comfortable 180–220%. Solvency II: minimum 100%, management targets typically 150–200%. US: RBC well above 300–400% of authorised control level (200% triggers company action). | Solvency, not D/E, sets how fast the insurer can grow and whether it can pay dividends. Drift toward the floor forces a capital raise (dilution), a quota-share treaty, or growth switched off. |
|
||||
| **VNB and VNB margin** (life) | VNB = present value of future profits from policies sold this year, net of cost of capital. VNB margin = VNB / APE, where APE = regular premium + 10% of single premium. | India 20–28% is the current listed-player band (protection and non-par guaranteed carry 40–80%; ULIPs typically 10–15%). Developed markets structurally lower and annuity/protection dependent. VNB growth should broadly match or beat APE growth. | The life-sector substitute for revenue and operating profit combined: economic value created this year, which reported accounting profit will not show for a decade. Assumption-driven — always check what moved in persistency, mortality and expense assumptions. |
|
||||
| **Embedded Value, operating RoEV, EV movement analysis** (life) | EV = adjusted net worth + PV of in-force. India uses Indian Embedded Value (market-consistent); Europe MCEV/EEV. Operating RoEV = (unwind + VNB + operating variances) / opening EV, before economic variance. | India: operating RoEV 15–20% strong, low-teens average. Operating variances should be small and consistent, not the main growth driver. | EV is the denominator for life valuation, and its credibility lives entirely in the movement analysis. Growth from unwind + VNB is real; growth from "change in operating assumptions" or "model refinements" is management writing its own scorecard. |
|
||||
| **Persistency (13/25/37/49/61 month) and surrender/lapse ratio** (life; renewal retention for retail health) | % of policies or premium still in force after n months. IRDAI mandates disclosure at 13/25/37/49/61 months on both premium and policy-count bases — the premium basis usually flatters; read both. | India 13th month: 85–90%+ good on premium basis, <80% weak. 61st month: >55–60% good, <45% poor. Developed protection books: 4–8% annual lapse. Retail health renewal retention 85–90%+. | The operational KPI that validates or destroys VNB, which assumes policyholders keep paying. Falling 13th-month persistency alongside rising reported VNB margin means the margin is fiction and mis-selling is likely. Surrenders also crystallise losses on new-business strain already spent. |
|
||||
| **Product mix and distribution-channel mix** | Life: APE split by par, non-par guaranteed, ULIP, protection, annuity, group; channel split by bancassurance, agency, direct, brokers, online. General: motor OD/TP, retail vs group health, commercial, crop. | No single bancassurance partner above ~40–50% of APE (India is actively debating a cap). Protection + annuity above 15–20% of APE supports margin. Proprietary/agency above ~30% indicates distribution independence. | Margin, capital intensity and persistency are all mix-driven, so mix explains most of any change in reported VNB margin or combined ratio. Channel mix is a franchise-risk metric: an insurer dependent on one parent bank's branches does not own its distribution, and a partnership renegotiation reprices the whole equity. |
|
||||
| **Claims settlement ratio, repudiation rate, TAT, grievance ratio** | % of claims settled by count and by amount, % repudiated, average settlement turnaround, complaints per 10,000 policies. Published by IRDAI in its annual report and by NAIC/state DOIs and the FCA equivalents abroad. | India life individual death-claim settlement 98%+ expected, <97% poor. Health repudiation above ~10–12% invites regulatory scrutiny. Grievance ratio should be low and falling versus peers. | Leading indicator of both future growth (brand, renewals) and hidden profitability. Suspiciously low loss ratio plus high repudiation and complaints means profit is being earned by not paying claims — which reverses via regulation, ombudsman rulings and lost renewals. |
|
||||
| **Reinsurance dependence: cession, retention, recoverables** | Ceded premium / GWP; net retention; reinsurance recoverables as % of shareholders' equity; counterparty credit quality and concentration. India: note mandatory obligatory cession to GIC Re and the order of preference for cession. | Recoverables above ~50% of equity is a credit/concentration concern. Any sudden jump in cession — especially quota share — needs a full explanation. | Reinsurance both protects and flatters. Heavy quota-share cession releases capital, lifts the solvency ratio and books ceding commission upfront — better optics, worse economics. Recoverables are unsecured credit exposure that becomes real exactly when a catastrophe hits. |
|
||||
| **Catastrophe exposure: PML, accumulations, cat load** | Net-of-reinsurance probable maximum loss at 1-in-100 and 1-in-250 return periods as % of equity; cat programme attachment, limit and reinstatements; the cat load built into the combined ratio. | Net 1-in-250 PML above ~15–20% of equity for a single peril/region is aggressive. Actual cat losses should average close to the budgeted load across a cycle. | P&C earnings are not normally distributed. A carrier can look superb for six years and lose a third of book value in one event. Insurers that habitually report "ex-catastrophe" combined ratios are excluding a recurring cost of doing business. |
|
||||
| **ALM duration gap, asset quality, unrealized position** | Asset vs liability duration; credit-quality distribution (share below investment grade, share in Level 3 / private credit / real estate); cumulative unrealized gains/losses as % of equity, *including* amounts in held-to-maturity that are never marked. | Duration gap near zero for annuity/guaranteed books. Below-investment-grade under ~5–10% of portfolio. HTM unrealized losses under ~20–25% of equity. | Life insurers with long guarantees are effectively short a very long-dated rate option; India's shortage of ultra-long assets makes the non-par guaranteed book a genuine ALM risk. A carrier stretching for yield in illiquid credit is converting underwriting weakness into hidden investment risk. |
|
||||
| **Operating ROE (ex-AOCI, ex-realized gains) and underwriting leverage** | ROE on operating earnings — excluding realized gains, AOCI/mark-to-market swings and one-off reserve items — paired with NWP / shareholders' equity. | P&C operating ROE 12–15% through the cycle is good; 15%+ excellent and rare. Underwriting leverage 1.0–1.5x normal; above ~2.0x is aggressive and stresses solvency in a bad year. | Operating ROE against cost of equity is the direct input to the justified P/B, which is how P&C insurers are actually valued. Underwriting leverage tells you how much of that ROE comes from writing more premium per unit of capital rather than from better underwriting. |
|
||||
| **Health-specific: MLR, PMPM cost trend vs pricing trend, lives covered** | Medical loss ratio (claims / premium, US ACA definition includes quality-improvement spend); per-member-per-month claim cost and its year-on-year trend versus the premium rate increase filed; membership by segment with retention/attrition. India: retail vs group vs government-scheme lives, plus cashless ratio and network hospital count. | US ACA floors: 80% individual/small group, 85% large group and Medicare Advantage — below the floor triggers rebates, so an "efficient" MLR is capped by law. India retail health loss ratio 65–75%; group health often 90%+. Pricing trend should lead cost trend by 50–150 bps when medical inflation is rising. | Health is a spread business on medical inflation. The whole P&L turns on whether next year's price was set above next year's medical cost trend — a forecast made 6–18 months before the risk is borne. A widening gap between PMPM cost trend and filed rate increases is the earliest warning of a bad year, well before the loss ratio moves. |
|
||||
|
||||
Supplementary operational reads that rarely appear in screeners but change conclusions: for US managed care, Medicare Advantage **star ratings** (they drive bonus payments and are effectively a multi-year revenue annuity) and **risk-adjustment** model changes; for Indian health, the **claims paid without deduction** ratio and TPA versus in-house claim handling; for life everywhere, **new-business strain** as a percentage of capital and the resulting capital-generation self-sufficiency.
|
||||
|
||||
---
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
Insurers are valued on capital and the present value of the profits that will be released from that capital. **Never EV/EBITDA. Never an FCF-based DCF.**
|
||||
|
||||
**General / P&C (developed and India)**
|
||||
- Primary: **price to book, or better, price to tangible book excluding AOCI**, anchored to sustainable operating ROE via the justified-multiple relation `P/B ≈ (ROE − g) / (COE − g)`. A carrier earning 10% ROE against a 10–11% cost of equity is worth roughly 1x book; sustained 15–18% operating ROE with sub-95% combined ratios supports 2–4x book. Adjust reported book for suspected reserve deficiency or redundancy — **reserve-adjusted book is the real denominator**.
|
||||
- Secondary: **P/E on operating EPS**, explicitly excluding realized gains and prior-year development. Roughly 10–16x for diversified P&C; higher for specialty franchises with a durable underwriting edge. Indian general and standalone health insurers trade at premium P/E and P/B on growth runway and low insurance penetration, not on superior combined ratios — state that explicitly rather than concluding they are "expensive versus global peers".
|
||||
- Reinsurers and property-cat writers: closer to 1.0–1.5x tangible book with mean-reverting P/E, because earnings are event-driven and a single year proves nothing.
|
||||
|
||||
**Life**
|
||||
- India and most of emerging Asia: **P/EV** is the standard (Indian listed life insurers have historically spanned roughly 1.5–3.5x IEV, compressing toward the ~1.7–2.5x area more recently). Because EV captures only the existing book, the market pays for future new business through the **appraisal value**: `Appraisal Value = EV + (VNB multiple × current-year VNB)`. Back out the implied multiple as `(Market cap − EV) / VNB`; roughly 10–25x is the observed band and it is the cleanest way to read what growth expectation is embedded in the price. Cross-check operating RoEV against the P/EV paid — the same logic as ROE versus P/B.
|
||||
- Developed markets under IFRS 17: the emerging convention is **price to (adjusted book value + CSM net of tax)**, plus multiples on the CSM stock and on new-business CSM, since the CSM is the stock of unearned future profit. Many European insurers now guide on Solvency II own-funds and free-capital generation rather than EV, valued on P/(BV+CSM) plus dividend / cash-remittance yield.
|
||||
- Tie-breaker and the fundamentally correct method for any insurer: a **distributable-earnings (free-surplus) model** — project statutory profits, subtract the increase in required regulatory capital, discount the surplus actually distributable at the cost of equity. In practice a two- or three-stage dividend discount model. It is the only DCF variant that respects the capital constraint.
|
||||
|
||||
**Composites and holding companies.** Sum-of-the-parts is mandatory: life on P/EV or appraisal value, general on P/B against its own ROE, health on P/E, asset management on % of AUM or P/E, lending on P/B — then apply a holding-company discount (commonly 20–40% in India for financial conglomerates and for bank/NBFC parents of listed insurance subsidiaries). Never apply one blended multiple to consolidated group numbers.
|
||||
|
||||
**Do not use, and say why if a screener offers them:** EV/EBITDA (EBITDA undefined), EV/Sales (enterprise value is meaningless when debt-like liabilities are policyholder funds), FCF yield (new-business strain inverts the sign), PEG on reported EPS, and any DCF of operating cash flow.
|
||||
|
||||
**Cross-checks that beat any single multiple:** growth in book value per share plus dividends over 5–10 years for P&C; growth in EV per share (or EV + dividends) for life; cumulative cash remitted from subsidiaries to the holding company versus cumulative reported profit. These compound measures cut through single-year accounting noise.
|
||||
|
||||
---
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares **line of business, tail length, regulatory regime and accounting basis**. Get any of those wrong and the ratios are not measuring the same thing.
|
||||
|
||||
Splits that must never be mixed:
|
||||
- **Life vs general vs health vs reinsurance.** Different metrics entirely (VNB/EV vs combined ratio vs MLR vs event-driven book value). Never rank them in one table.
|
||||
- **Carriers vs brokers, aggregators, TPAs and MGAs.** Brokers and TPAs take no underwriting risk, are capital-light with recurring commission revenue, and *are* correctly valued on EV/EBITDA (typically 15–25x) and P/E. Putting a broker in a carrier peer set makes every carrier look capital-inefficient and every broker look expensive.
|
||||
- **Long-tail vs short-tail P&C.** Casualty, liability and motor third-party pay out over 5–15 years and carry huge reserve estimation risk; property, motor OD and travel settle within a year. Reserve development means completely different things in each.
|
||||
- **Life product mix.** A protection/annuity-led writer, a ULIP-led writer and a par-savings-led writer have structurally different margins, capital intensity and rate sensitivity. Compare VNB margin only after normalising for mix, or compare mix-adjusted margin trends instead of levels.
|
||||
- **Retail vs group vs government-scheme health.** Retail health is a renewal annuity with 65–75% loss ratios; group health is often written near or below cost to win corporate relationships; government schemes (India: PMFBY crop, PMJAY-linked business, state schemes) carry political pricing and slow state receivables.
|
||||
- **Accounting regime.** IFRS 17 versus IFRS 4 versus Indian GAAP (IRDAI-prescribed formats) versus US GAAP post-LDTI versus US statutory. Book value, revenue and profit are not comparable across these without adjustment. India has deferred Ind AS 117; until it lands, Indian insurers' reported numbers are not directly comparable to IFRS 17 filers.
|
||||
- **Regulatory regime and capital standard.** Solvency ratio under IRDAI's factor-based rules, Solvency II's risk-based SCR and US RBC are not the same scale — 200% means different things in each.
|
||||
- **Listed subsidiary vs group parent.** Compare the Indian listed life arm against other listed life arms, not against the promoter bank or the conglomerate parent.
|
||||
|
||||
Practical construction: 4–8 peers from the same sub-sector and market, plus 2–3 developed-market benchmarks *only* to frame what best-in-class underwriting looks like — never to conclude that an Indian carrier is over- or under-valued on an absolute multiple, since growth runway and penetration differ by an order of magnitude.
|
||||
|
||||
---
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Reserve releases carrying earnings.** Calendar-year combined comfortably below 100% while the current-accident-year ex-cat loss ratio deteriorates. Check the development triangle for the newest accident years being set at optimistic initial loss picks, and for IBNR shrinking as a share of total reserves.
|
||||
- **Premium growth far above market in a soft (falling-price) market, with a better-than-peer reported loss ratio.** The loss surfaces three to five years later. Highest-risk version: long-tail casualty, liability and motor third-party.
|
||||
- **Reinsurance as financial engineering.** A large new quota-share that lifts solvency and books ceding commission upfront; finite/structured covers with limited real risk transfer; retrocession into related-party or offshore captives; recoverables ballooning past ~50% of equity with concentrated or weakly rated counterparties.
|
||||
- **EV or VNB growth driven by assumption changes rather than new business.** Read the EV movement analysis. If "change in operating assumptions", "modelling refinements" or a lower risk-discount rate is doing the work — while persistency assumptions are being *raised* — the reported margin is an accounting choice. Unaudited EV, a change of actuarial consultant, or a switch of EV methodology are amplifiers.
|
||||
- **Persistency contradicting reported margins.** Falling 13th-month persistency, or 61st-month below ~45%, alongside record VNB margins. Usually means mis-selling, single-premium or short-pay churn, and future negative persistency variances.
|
||||
- **Low-quality APE/premium growth.** Single-premium and group fund-management business inflating headline premium; ULIP-led growth in a rising market that reverses when markets fall; unusually large March-quarter loading (India); growth concentrated in one bancassurance partner whose contract is up for renegotiation.
|
||||
- **Solvency drifting toward the floor** (below ~170% in India, below ~140% SCR coverage in Europe, RBC heading toward 250%), or solvency maintained by repeated subordinated-debt issuance and quota-share treaties rather than by internal capital generation. This precedes dilution or a growth stop.
|
||||
- **Chronic adjusted metrics.** Habitually presenting the combined ratio "ex-catastrophe", "ex-COVID", "ex-one-offs", or including policyholder investment income to get under 100%. Catastrophes are a recurring cost, not an exception.
|
||||
- **Reaching for yield.** Rising allocation to below-investment-grade credit, private/illiquid credit, commercial real estate, structured or Level 3 assets, or affiliate and promoter-group securities; or a large unrealized loss parked in held-to-maturity so it never touches book value while duration is mismatched against liabilities.
|
||||
- **Long-dated guarantees without matching assets.** Life insurers writing heavy non-par guaranteed or annuity volumes without ultra-long assets — acute in India given limited supply of very long bonds and a shallow derivatives market. Attractive VNB margins there are compensation for uncompensated rate and longevity risk.
|
||||
- **Profit sustained by not paying claims.** Falling loss ratio alongside rising repudiation, lengthening settlement turnaround and a rising grievance ratio. It reverses through regulation, ombudsman rulings and lost renewals.
|
||||
- **India line-specific landmines.** Crop insurance (PMFBY) volatility with large slow-paying state-government receivables; motor third-party pricing set by regulation rather than by the insurer; group health written below cost to win mandates; aged "premium due from agents/intermediaries" that is effectively unrecognised bad debt.
|
||||
- **DAC and CSM aggression.** Pre-IFRS 17, aggressive deferred acquisition cost capitalisation and amortisation; under IFRS 17, a CSM that keeps growing on assumption unlocks while cash generation and dividend remittances stagnate. The reliable cross-check: cash actually remitted from operating subsidiaries to the holding company versus reported group profit. Years of rising earnings without rising remittances means the profit is not real yet.
|
||||
- **Governance and structure signals.** Frequent auditor or appointed-actuary changes; restatement of reserves or EV; related-party investments and reinsurance; commission structures pinned at the EOM cap; regulatory penalties for mis-selling or expense-cap breaches.
|
||||
|
||||
---
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The underwriting cycle dominates P&C returns.** Capital floods in after profitable years, prices soften, terms loosen, and reserves set in soft years prove deficient; a large loss event or reserve blow-up destroys capital, prices harden, and the best underwriting years are written into hard markets. Establish where you are before extrapolating any combined ratio. Rate-change disclosures (US carriers publish renewal rate change; Indian insurers disclose far less) and industry capacity commentary are the tell. The corollary: a carrier growing fastest at the bottom of the cycle is usually buying business, and one shrinking in a soft market is often the better underwriter.
|
||||
|
||||
**Interest rates drive life more than anything management does.** Rising rates lift new-money yields, improve annuity and non-par guaranteed economics and raise VNB, but hit reported book value through mark-to-market; falling rates do the reverse and can make long guarantees written at high rates ruinous. Distinguish operating RoEV from economic variance in every EV walk.
|
||||
|
||||
**Health runs on the medical-cost trend cycle,** not the underwriting cycle: utilisation rebounds, provider price negotiations, new high-cost therapies (obesity and specialty drugs are the current driver globally), and — in the US — Medicare Advantage rate notices, risk-model recalibration and star-rating changes. Pricing is filed months ahead of the risk period, so a trend surprise cannot be repriced until the next cycle.
|
||||
|
||||
**Structural growth versus structural threat.** India's under-penetration is real: insurance penetration and protection gaps remain far below developed markets, and the regulator's stated ambition of broad insurance access supports multi-decade volume growth — which is why Indian carriers trade above global multiples. Against that: distribution disruption (online, aggregators, embedded insurance) compresses commissions but also disintermediates incumbent agency franchises; telematics, AI underwriting and claims automation reward scale and data; climate change is systematically re-pricing property-cat and making some geographies uninsurable; and social/legal inflation is lengthening the tail in casualty lines.
|
||||
|
||||
**Regulation is a first-order earnings driver, not background.** In India: IRDAI's EOM caps, surrender-value regulations that raised early-exit payouts and pressured non-par margins, motor TP tariff decisions, the composite-licence and 100% FDI proposals, Bima Sugam-style distribution platforms, and the Sept-2025 GST exemption on individual life and health premiums (which removed input tax credit and raised net expense burden). Globally: IFRS 17 adoption, Solvency II reviews, US LDTI, ACA MLR floors and rebates, and state rate-approval regimes that can deny needed increases. Any of these can move a whole sub-sector's margin by hundreds of basis points independent of company quality — attribute margin moves to regulation before crediting management.
|
||||
|
||||
---
|
||||
|
||||
## India vs global notes
|
||||
|
||||
**Regulators and filings.** India: IRDAI is the single regulator; listed insurers file quarterly **public disclosures in prescribed L-forms (life) and NL-forms (general)** covering premium, claims, expenses, solvency, persistency, and the analytical ratios — these are richer than the annual report for ratio work. The IRDAI Annual Report and Handbook on Indian Insurance Statistics give sector and per-insurer incurred claims ratios, settlement ratios and grievance data. Amounts are in crore/lakh — normalise before comparing globally. US: 10-K and 10-Q on EDGAR plus **NAIC statutory filings (Schedule P triangles, RBC)**, which often reveal more about reserves than GAAP. Europe/UK: IFRS 17 accounts plus the **Solvency and Financial Condition Report (SFCR)** for capital detail.
|
||||
|
||||
**Accounting basis (the biggest comparability trap).** India still reports on IRDAI-prescribed formats under Indian GAAP with Ind AS 117 deferred; developed markets are on IFRS 17 (CSM, insurance revenue, no premium line as revenue) or US GAAP post-LDTI (annual assumption review, market-risk-benefit fair valuation). Because of that, "revenue", "profit" and "book value" for an Indian insurer and an IFRS 17 filer are not the same constructs. India also retains **Embedded Value as the primary life yardstick**, whereas Europe has largely moved to CSM and Solvency II own-funds generation.
|
||||
|
||||
**Life reporting conventions.** India headlines APE, New Business Premium, VNB, VNB margin, IEV, operating RoEV and 13th/61st-month persistency — check the definitions in the investor presentation, since APE treatment of group and single premium varies. Developed markets emphasise new-business CSM, sales by product, lapse rates and free-capital generation.
|
||||
|
||||
**Capital standards.** IRDAI runs a factor-based required solvency margin with a 150% minimum (with a risk-based capital regime long under discussion); Europe runs the risk-based SCR; the US runs RBC against the authorised control level. Do not compare the headline percentages across regimes — compare each against its own regime's action levels and peer norms.
|
||||
|
||||
**India-specific structural features to check.** Mandatory obligatory cession to GIC Re and the cession order of preference; the EOM cap regime; motor third-party premiums set by the regulator; PMFBY crop insurance with state-government receivables; bancassurance dominance and the concentration risk that creates; promoter/parent bank shareholding and related-party distribution economics; and CARO/auditor observations plus concall commentary as an under-used source on receivables, reinsurance arrangements and reserving philosophy. Indian disclosure of **loss-development triangles is far thinner** than US Schedule P — compensate with IBNR-to-reserve trends, the appointed actuary's certificate, and line-level incurred claims ratios from IRDAI data.
|
||||
|
||||
**Valuation convention divergence.** India/emerging Asia: P/EV and implied VNB multiple for life, P/B and P/E for general and health, with premium multiples justified by penetration runway. Developed markets: P/(BV + CSM), P/TBV ex-AOCI, dividend and buyback capacity from remittances. Applying the developed-market multiple set to an Indian insurer (or vice versa) is the most common valuation error in this sector.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Identify the sub-sector first — life, general/P&C, standalone health, reinsurer, composite, or non-carrier (broker/TPA/aggregator) — and load the right metric set.
|
||||
- [ ] Suppress every generic ratio that is undefined here: OPM, EBITDA, EV/EBITDA, ROCE, current ratio, inventory/receivable turnover, FCF yield, asset turnover. Say why in the output rather than reporting them as weaknesses.
|
||||
- [ ] State which premium base the company headlines (GWP / NWP / NEP / insurance revenue / APE / NBP) before quoting any growth number.
|
||||
- [ ] P&C/health: compute combined ratio and split it into loss and expense; then isolate **current-accident-year ex-cat** loss ratio.
|
||||
- [ ] Quantify prior-year reserve development as % of opening net reserves for at least 5 years; check triangles or IBNR-to-reserve trends.
|
||||
- [ ] Life: compute VNB, VNB margin, APE growth, operating RoEV, and read the full **EV movement analysis** — separate unwind + VNB from assumption changes.
|
||||
- [ ] Life: pull 13th- and 61st-month persistency on both premium and policy-count bases; test them against the VNB margin trend for contradiction.
|
||||
- [ ] Health: compare PMPM cost trend with filed/achieved pricing trend, and check MLR against regulatory floors and membership retention.
|
||||
- [ ] Check solvency (IRDAI / SCR / RBC) level, trend and composition; note reliance on sub-debt or quota share.
|
||||
- [ ] Check reinsurance: cession ratio trend, recoverables vs equity, counterparty concentration, any new quota-share treaty.
|
||||
- [ ] Check the asset side: duration gap, below-investment-grade and Level 3 share, HTM unrealized losses vs equity, related-party holdings.
|
||||
- [ ] Compute operating ROE ex-AOCI and ex-realized gains, plus NWP/equity underwriting leverage.
|
||||
- [ ] Read the operational KPIs — claims settlement ratio, repudiation, TAT, grievance ratio, product and channel mix, bancassurance concentration.
|
||||
- [ ] Value with the right tool: P/TBV ex-AOCI anchored to operating ROE for P&C; P/EV plus implied VNB multiple for Indian life; P/(BV+CSM) for IFRS 17 filers; SOTP with a holding-company discount for composites; free-surplus DDM as tie-breaker.
|
||||
- [ ] Cross-check with 5–10 year book-value-per-share-plus-dividends (P&C) or EV-per-share (life) compounding, and with subsidiary cash remittances versus reported profit.
|
||||
- [ ] Build the peer set within sub-sector, tail length, accounting regime and market; never mix carriers with brokers or life with general.
|
||||
- [ ] Place the company in the cycle (P&C pricing, rate environment for life, medical trend for health) and name the live regulatory changes before extrapolating any margin.
|
||||
- [ ] Treat every healthy range above as indicative — conclude on peer-relative and own-history comparison, and say which one drove the call.
|
||||
176
finance/skills/stock-analysis/references/sectors/it-saas.md
Normal file
176
finance/skills/stock-analysis/references/sectors/it-saas.md
Normal file
|
|
@ -0,0 +1,176 @@
|
|||
# IT services, software, SaaS and internet platforms — sector playbook
|
||||
|
||||
Use this when: the company earns most of its revenue from software licences, subscriptions, cloud/platform services, IT outsourcing, systems integration, engineering/R&D services, BPM, or internet marketplace/ad monetisation — including Indian tier-1 and mid-cap IT, global SaaS, and product companies whose balance sheet is essentially cash plus goodwill.
|
||||
|
||||
This is the sector where the generic ratio set fails hardest. The assets that produce the earnings — code, brand, customer relationships, trained engineers — are expensed as incurred and never appear on the balance sheet, so every ratio with capital, book value or assets in the denominator is an accounting artefact rather than an economic measure. At the same time, the largest true cost at many software firms (stock-based compensation) is excluded from the numbers management asks you to use. Your job is to replace the balance-sheet lens with a contract-and-cohort lens: retention, contracted backlog, unit economics of customer acquisition, and — on the services side — utilisation, pyramid and pricing. Almost everything that predicts the next two years is disclosed outside the financial statements.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
**ROCE / ROIC / ROA / asset turnover — near-meaningless, and polluted in both directions.** The value-creating assets are expensed (R&D, S&M, salaries), so capital employed is a fictional denominator. Indian tier-1 IT posts 40-60%+ ROCE and US software firms post triple-digit ROIC not because they are ten times better operators than a good manufacturer, but because the denominator is structurally understated. That same denominator is then distorted the other way by (i) large net cash piles — Indian IT often holds 15-25% of market cap in cash, which drags reported ROCE *down* — and (ii) acquisition goodwill, which at software roll-ups swamps genuine operating capital. Comparing ROCE across two software firms compares accounting policies, not economics. If you use it at all, compute ROCE ex-cash and ex-goodwill, and only within the sector.
|
||||
|
||||
**D/E, interest cover, current ratio — non-diagnostic and often inverted.** Most quality names are net cash: D/E is ~0 and interest cover is infinite or undefined, so leverage screens produce no ranking information. Worse, the largest "liability" on a SaaS balance sheet — deferred revenue / contract liabilities — is cash already collected for services not yet delivered. It is a sign of *strength* that mechanically worsens the current ratio and D/E. A leverage screen will rank a healthy, fast-growing SaaS company as more indebted than a stagnant one. Ind AS 116 / ASC 842 lease liabilities further inflate "debt" for firms with large campus footprints without representing financial risk. Where leverage genuinely matters — PE-backed software, take-private LBOs, roll-ups, Indian mid-caps funding acquisitions — the right measure is net debt / EBITDA read against *recurring* revenue and contracted backlog, never D/E.
|
||||
|
||||
**P/B — unusable.** Book equity here is cash + goodwill + receivables. Sustained buybacks can drive book equity negative (a recurring feature of mature US software), making P/B negative or absurdly large. It carries zero information about earning power.
|
||||
|
||||
**P/E — misleading in both directions, but not uniformly.** For growth SaaS, GAAP EPS is depressed or negative *by design*: essentially 100% of customer-acquisition cost is expensed in year 0 while the revenue it buys is recognised rateably over 3-10 years. A company can be loss-making and creating enormous value; another can be profitable simply because it stopped growing. GAAP EPS is further crushed by non-cash SBC and acquired-intangible amortisation, while "non-GAAP EPS" adds back SBC, which is a real economic cost. GAAP P/E is therefore too high, non-GAAP P/E too low, and neither is comparable across companies with different growth rates. For Indian IT services the opposite holds: these are genuinely profitable, cash-generative annuity businesses and forward P/E *is* the primary tool — but read against currency, deal cycle and pyramid position, never as an absolute.
|
||||
|
||||
**OPM / EBITDA margin — a level without growth context tells you nothing.** A 5% margin at 40% growth is worth far more than a 25% margin at 4% growth; the growth company is *choosing* to spend the margin. Rule of 40 exists precisely to fix this. EBITDA is additionally a poor proxy for software cash economics because (i) it excludes SBC, often the single largest true cost (15-25% of revenue at many US SaaS names), (ii) capex is trivial so EBITDA ≈ EBIT and the metric adds nothing over EBIT, and (iii) firms capitalising internal software development (ASC 350-40 / IAS 38) shift opex into capex and inflate EBITDA versus peers who expense the identical activity. For Indian IT, reported OPM differences across tier-1 names reflect onsite-offshore mix, subcontractor usage, utilisation and hedging — not intrinsic efficiency.
|
||||
|
||||
**FCF — a billing-terms artefact, not a profitability measure (in SaaS).** A company that shifts customers to annual-upfront billing produces a step-up in FCF with zero change in economics; one that concedes monthly billing to win deals shows FCF deterioration while performing fine. Negative-working-capital models can produce FCF > net income for years. And "adjusted FCF" that ignores SBC-funded payroll overstates cash generation: the honest number is FCF less SBC, or FCF with the buyback spend needed to hold share count flat treated as an operating cost. Conversely, for Indian IT, FCF/PAT conversion is a valid and important quality test — one of the few generic metrics that survives intact.
|
||||
|
||||
**Inventory turns, working-capital cycle, fixed-asset turnover, capex/sales — not applicable.** No inventory; capex is typically 2-4% of revenue. Replace with DSO computed *including unbilled revenue / contract assets*, and for SaaS with DSO plus the deferred-revenue trend.
|
||||
|
||||
**Dividend yield / payout — ranks lifecycle, not quality.** Indian large-cap IT returns 80-100% of FCF via dividends and buybacks (yields 2-4%); US SaaS pays nothing and often has a *negative* net buyback yield after dilution. Comparing them on payout is comparing where they sit in the corporate lifecycle.
|
||||
|
||||
**Headline revenue growth — not comparable as reported.** Indian IT must be read in constant currency and ex-acquisitions (reported USD growth swings 200-400bps on cross-currency alone). Global software must be read organically, because roll-ups buy growth. Any "total revenue growth" that blends subscription, professional services and hardware/pass-through resale can hide subscription deceleration entirely.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
All ranges below are **indicative only**. They shift with market (India vs US), sub-sector, cycle phase and reporting period. A company's own 3-5 year trend and its position versus a tight peer set override any absolute band in this table.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Net Revenue Retention (NRR / NDR) | Current-period revenue from the cohort of customers present 12 months ago ÷ that cohort's revenue then. Captures churn, downgrades, price rises, seat expansion, cross-sell; excludes all new logos. | Enterprise SaaS 115-130% (best-in-class >130%); SMB/PLG 100-115%; usage-based models can exceed 130%. <100% means the installed base is shrinking. A fall from >120% to <105% over four quarters is a structural break, not noise. | The single highest-explanatory-power variable in SaaS multiple regressions. It measures whether the product is embedded in the customer's workflow. At 125% NRR a company grows a quarter annually without selling to a single new customer. It also sets LTV, and therefore how much CAC is rational. |
|
||||
| Gross Revenue Retention (GRR) and logo churn | Retention *before* any upsell: fraction of last year's revenue base surviving churn and downgrades. Logo churn is the same in customer counts. | Enterprise/mission-critical GRR 90-95%+ (best 95-98%), annual logo churn <5-8%. SMB GRR 80-88%, monthly logo churn <1.5-2%. Enterprise GRR below 85% signals a nice-to-have product. | GRR is the ceiling on business quality and the truest read on switching costs. 125% NRR built on 85% GRR plus 40 points of upsell into a few whales is far more fragile than 115% NRR on 96% GRR — the first breaks the moment budget scrutiny arrives. Firms that report NRR but refuse GRR are telling you something. |
|
||||
| Rule of 40 (and its composition) | YoY revenue growth % + FCF margin % (or EBIT margin — state which, and be consistent across the peer set). | >40 is the benchmark, >50 elite, 30-40 acceptable at scale, <30 sustained is a value trap absent a credible margin path. Indian IT equivalent bar ≈ 10-12% cc growth + 20-26% EBIT margin, i.e. 32-38. | Stops you penalising a firm for deliberately spending margin to compound revenue, and stops you rewarding one that manufactured margin by starving R&D and S&M. Composition matters more than the score: 40 growth + 5 margin is worth far more than 5 growth + 40 margin. A deteriorating Rule of 40 driven by growth deceleration is the most reliable precursor of multiple compression. |
|
||||
| CAC payback / LTV:CAC / Magic Number | CAC payback = S&M spend ÷ (next-period net new ARR × subscription gross margin), in months. Magic Number = annualised change in quarterly revenue ÷ prior-quarter S&M. LTV:CAC = (ARPA × GM ÷ churn) ÷ CAC. | CAC payback <12m excellent, 12-18 healthy, 18-24 acceptable for enterprise with high GRR, >24-30 broken. Magic Number >0.75 = scale spend, <0.5 = stop. LTV:CAC >3x; <1x destroys value per customer won. | This is the actual capital-allocation decision inside the business. Because S&M is expensed but buys a multi-year asset, the income statement cannot tell you whether growth spend is investment or waste — these ratios can. Deteriorating CAC payback while growth still looks fine is the earliest sign of saturation or competitive pressure, typically 2-4 quarters ahead of a growth collapse. |
|
||||
| Subscription gross margin (split from services GM) | GM on recurring software revenue only, after hosting/cloud cost, support, third-party licence fees and capitalised-software amortisation — reported separately from professional-services GM. Services equivalent: gross margin before SG&A. | Pure SaaS subscription GM 75-85%; infrastructure- or inference-heavy 60-72%; <65% needs explanation. Professional services GM 0-20%, often negative — fine if small. Blended >70%. Indian IT gross margin 30-36%; EBIT 20-26% tier-1, 14-19% mid-cap. | Sets the marginal economics and the LTV ceiling. Blended margin hides mix: a company whose growth is increasingly professional services and pass-through resale is degrading in quality while headline revenue looks fine. In the AI era this is the metric to watch hardest — GPU/inference cost is compressing subscription GM, and a 10-point GM decline destroys the unit economics that justified the multiple. |
|
||||
| SBC % of revenue and net diluted share count growth | Total SBC ÷ revenue; YoY change in fully diluted shares after buybacks; cash spent on buybacks purely to offset dilution. | US SaaS: <10-12% of revenue at scale is good, 15-20% high, >25% is a transfer of ownership to employees. Net dilution <1-2% p.a. Indian IT: typically <1-2% of revenue — a genuine structural advantage. | The sector's defining accounting distortion. Non-GAAP EPS, "adjusted EBITDA" and "adjusted FCF" all add SBC back, yet it is real compensation that either dilutes you or forces cash buybacks. A firm with 20% SBC/revenue and a 25% adjusted FCF margin has roughly zero economic FCF margin. Always recompute FCF − SBC and treat dilution-offsetting buybacks as opex, not return of capital. |
|
||||
| Billings, RPO and cRPO growth | Billings ≈ revenue + change in deferred revenue. RPO = total contracted revenue not yet recognised; cRPO = the portion due within 12 months. Track each growth rate against reported revenue growth. | cRPO growth at or slightly above revenue growth in a healthy company. Book-to-bill / TCV-to-revenue >1.0x, 1.1-1.3x indicating a strong services deal cycle. RPO ÷ annual revenue of 1.5-3x typical for enterprise SaaS. | Revenue is a lagging indicator — the rateable release of contracts signed earlier. cRPO and billings turn 2-3 quarters before revenue. Use cRPO, not total RPO: total RPO can be inflated by one 7-year mega-deal or a bulk renewal, masking a collapse in near-term demand. Decelerating cRPO with steady revenue is the classic pre-derating setup. |
|
||||
| Constant-currency organic growth (with the full bridge) | Reported growth = organic cc growth + inorganic + FX. Strip FX translation and any revenue acquired in the last 12 months. | Indian tier-1: 8-12% cc in an upcycle, 4-7% mid-cycle, 0-3% a downturn; mid-caps need 12-18% cc to justify a premium. Enterprise SaaS at $1bn+ scale: 15-25% strong; <10% means value it as a mature software company. | Reported growth swings hundreds of basis points on cross-currency alone, and roll-ups routinely mask organic deceleration with M&A. The bridge is where managements hide the story. Note the INR asymmetry: rupee depreciation flatters Indian IT margins and INR EPS even when the underlying dollar business is shrinking — never judge Indian IT on INR revenue growth. |
|
||||
| Utilisation (ex-trainees) and offshore mix | Billable ÷ available hours for delivery staff, disclosed both including and excluding trainees; share of effort and of revenue delivered offshore vs onsite. | Utilisation ex-trainees 82-86% is the effective ceiling; above ~87% signals no bench and future delivery/attrition risk. Offshore effort mix 72-78%, offshore revenue mix 50-55%. Roughly 100bps of utilisation ≈ 25-30bps of EBIT margin. | In a people business, margin is manufactured from utilisation, pyramid (fresher share), offshore mix, pricing and subcontractor cost — nothing else. Knowing which lever produced a beat tells you whether it repeats: a beat from utilisation at 87% is borrowed from next year; one from offshore mix or pricing is durable. Utilisation also falls *before* revenue when the pipeline dries up. |
|
||||
| Attrition (LTM voluntary) and headcount vs revenue | LTM voluntary attrition in delivery staff; quarterly net adds and fresher hiring, compared against cc revenue growth. | Indian IT normalised attrition 12-15%; >18-20% is a wage-cost and delivery-quality crisis; <11% often signals a weak external job market and therefore weak demand. Headcount growth ≈ cc revenue growth minus 2-4% productivity. | Attrition is simultaneously a cost signal (backfill at market wages, more subcontracting), a delivery-risk signal (escalations, fixed-price overruns) and a demand signal. Divergence is equally diagnostic: revenue up on flat headcount means utilisation/pricing gains that eventually exhaust; headcount outrunning revenue means pyramid deterioration and margin pressure ahead. Most exposed metric to GenAI disruption of the linear people-to-revenue model. |
|
||||
| Revenue per employee (and its trend) | Annual USD revenue ÷ average headcount, tracked over 3-5 years. | Indian tier-1 $50,000-62,000, with 2-4% annual improvement a good outcome. Accenture and Western peers $95,000-120,000 (different onsite mix). Product SaaS at scale $250,000-450,000+; best-in-class PLG >$500,000. | The cleanest cross-check on both the AI/non-linearity thesis and pricing power. If a services firm claims automation, platform IP and outcome-based pricing, revenue per employee must rise; flat for five years means the "non-linear revenue" story is marketing. For software it is the operating-leverage proxy that ROCE cannot provide in an asset-light model. |
|
||||
| Deal TCV, book-to-bill, client concentration, account ladder | Quarterly TCV split net-new vs renewal; book-to-bill; top-5/top-10 client revenue share; count of clients >$1m / $50m / $100m. SaaS equivalents: customers >$100k ARR and >$1m ARR and their growth. | Book-to-bill >1.0x, ideally 1.1-1.3x. Top-10 concentration <22-28% for large IT services; any single client >10% of revenue is a material risk. Growth in $1m+ accounts should outpace total customer-count growth. | TCV is the forward order book; the net-new vs renewal split separates real share gain from defensive re-signing. The account ladder shows whether the company is moving upmarket into stickier, higher-NRR relationships or drifting into churn-prone SMB. Concentration risk is acute here: one client's insourcing decision, bankruptcy or vendor consolidation can remove several points of growth overnight. |
|
||||
| DSO including unbilled revenue / contract assets | DSO computed on receivables **plus** unbilled revenue (contract assets), not receivables alone. Track the unbilled component separately as a % of revenue. | Indian IT 65-78 days including unbilled is normal; >85 days, or a 10-day YoY rise, warrants investigation. SaaS 45-70 days depending on billing seasonality (Q4-heavy billers spike). Unbilled should be stable as a % of revenue. | In percentage-of-completion fixed-price contracts — a growing share of IT services revenue — unbilled revenue is where aggressive recognition lives: revenue booked for work not yet invoiced or client-accepted. Unbilled growing materially faster than revenue is the single most common accounting warning in Indian IT. It also flags client financial stress and pricing concessions dressed as payment-term extensions. |
|
||||
| R&D % of revenue (software) / subcontractor cost % (services), plus FCF/PAT conversion | Software: R&D ÷ revenue and the capitalised share of it. Services: subcontracting/contractor cost ÷ revenue. Both: FCF ÷ net income. | SaaS R&D 15-25% of revenue at scale; a drop below 12% while claiming product leadership is harvesting. Capitalised software should be a small, stable share of R&D. Services subcontractor cost 6-9%; >11-12% compresses margin. FCF/PAT >85-90% for Indian IT; >100% for SaaS with upfront billing (recompute after SBC). | R&D intensity is the reinvestment rate that sustains the moat, and the expensed-vs-capitalised split is where reported margins are manufactured. Subcontractor cost makes an Indian IT capacity constraint visible — it spikes when demand outruns hiring or niche skills (cloud, AI, SAP) are unavailable in-house. Cash conversion is the honest cross-check that reported profits are real. |
|
||||
| Pricing and duration signals (secondary but decisive) | Realised price per seat / per unit of consumption; average contract duration; discount depth at renewal; share of multi-year and of usage-based contracts. | Flat-to-rising realised pricing is healthy; persistent discounting to hold logos is not. Lengthening duration with deepening discounts is a demand tell, not a strength. | Retention can be bought. NRR that holds only because renewals are discounted 15-20% shows up here long before it shows up in NRR. In IT services, rate-card compression and vendor consolidation rebids are the same phenomenon. |
|
||||
|
||||
### If the company is an internet platform or marketplace
|
||||
|
||||
Platform/marketplace names sit in this sector but need three additional metrics, because "revenue" for them is a net take on someone else's gross flow and is not comparable to subscription revenue.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| GMV / gross bookings and take rate | Gross transaction value flowing through the platform; take rate = net revenue ÷ GMV. Check whether revenue is reported gross (principal) or net (agent) under Ind AS 115 / ASC 606. | Take rate varies enormously by category — marketplaces 8-20%, payments 1-3%, food/mobility 15-25%. What matters is the *trend* and whether it is rising through pricing or through mix into higher-take ancillary services (ads, logistics, credit). | Gross-vs-net presentation changes reported revenue by an order of magnitude with zero economic difference, which makes cross-company EV/revenue meaningless unless you normalise to GMV or gross profit. Take-rate expansion without merchant churn is real pricing power; take-rate expansion with rising incentive spend is not. |
|
||||
| Contribution margin per transaction / per cohort, after incentives | Net revenue less directly attributable variable cost *and* all customer/merchant incentives, discounts and cashbacks — not the version that classifies incentives as marketing. | Positive and improving with scale. Negative contribution margin at scale means growth destroys value. | Incentives are frequently booked as a revenue reduction in one company and as S&M in another, which flips both revenue and margin optics. Recompute on a consistent basis before comparing. This is the marketplace analogue of subscription gross margin. |
|
||||
| Engagement and cohort repeat behaviour | MAU/DAU and the DAU/MAU ratio; transactions per active user per year; cohort retention curves by signup month; share of GMV from cohorts older than 24 months. | Flat-to-rising transactions per user and cohort curves that flatten rather than decay to zero. Older cohorts should contribute a rising absolute GMV share. | User counts can be bought with incentives; cohort behaviour cannot. A platform whose newer cohorts monetise worse than older ones is buying growth from a shrinking-quality funnel, and reported user growth will mask it for 4-6 quarters. |
|
||||
|
||||
### When a metric is not disclosed
|
||||
|
||||
Do not silently drop it. Either (a) proxy it and label the proxy — deferred-revenue growth as a billings proxy, S&M ÷ net new ARR as a rough CAC payback, headcount disclosures from annual reports where quarterly data is absent — or (b) record the absence as a finding. Non-disclosure of NRR, GRR or net-new TCV in a company whose peers all disclose them is itself evidence, and should reduce your confidence in the thesis rather than being treated as neutral.
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
There is no single sector multiple. The right tool depends on where the company sits on the growth/profitability curve, and the sector splits into two genuinely different valuation regimes.
|
||||
|
||||
**1. High-growth SaaS (growth >20%, GAAP-unprofitable or thin-margin): EV/NTM revenue, growth-adjusted.** Earnings multiples are undefined or absurd, so the market prices forward revenue. Use EV (market cap + debt − cash; note that convertible-funded cash balances are common) over *next-twelve-month* revenue, not trailing. The multiple is not a number to compare naively — it is the output of a cross-sectional regression whose dominant explanatory variables are forward growth, NRR and Rule of 40. Practical method: fit EV/NTM revenue against Rule of 40 (or against growth, with NRR and gross margin as secondary terms) across the peer set and ask whether the stock sits above or below the line. A crude but useful normaliser is EV/NTM revenue ÷ NTM growth %. Absolute levels are regime-dependent — public SaaS median EV/NTM revenue has ranged from roughly 4x in the 2022-23 trough to above 12x at the 2021 peak, with high-growth/high-NRR names at 2-3x the median. Only *relative* positioning is stable across regimes; never anchor on a multiple level from a different regime.
|
||||
|
||||
**2. EV/gross profit — the better cross-sectional comparator.** Because subscription gross margins range from ~60% (infrastructure- or inference-heavy) to ~85% (pure application software), EV/revenue systematically overvalues low-margin businesses. EV/gross profit normalises this and is the right multiple when comparing an AI-native company carrying GPU cost of goods against a classic 80%-margin vendor. It is becoming the preferred metric as AI COGS reshapes the sector.
|
||||
|
||||
**3. EV/ARR and EV/cRPO — for the recurring core.** Where reported revenue blends subscription, professional services and pass-through hardware, value the recurring base on EV/ARR and treat services at a low multiple (1-2x revenue) or as a cost centre. EV/cRPO is the sharpest tool late in a cycle because contracted backlog is harder to manipulate than recognised revenue. EV/ARR is also the standard currency in private and M&A comps, which makes it the bridge for take-private scenarios.
|
||||
|
||||
**4. Mature software and Indian IT services: forward P/E, FCF yield, DCF.** Once growth falls below ~15% and margins normalise, the sector reverts to conventional earnings valuation. For Indian IT this is the primary framework from the start — these are structurally profitable, capital-light, negative-working-capital annuity businesses with 80-100% payout. Indian convention is forward P/E on 1-year-forward EPS: tier-1 has historically traded around 20-28x forward with the highest-quality names at a premium and laggards at a discount; quality mid-caps have commanded 30-45x forward on faster growth. Cross-check with PEG and with FCF yield plus buyback yield (Indian IT total shareholder yield typically 3-5%). Important mechanical point: EV/EBITDA looks artificially cheap for Indian IT because of the large net cash pile — always state whether you are on an EV or equity basis, and prefer valuing operations ex-cash and adding cash back at (or below) book, since idle cash earning treasury yields deserves no operating multiple.
|
||||
|
||||
**5. DCF and cohort valuation — unusually credible here.** Because revenue is contracted and retention is measurable, SaaS cash flows are more forecastable than in most sectors. Decompose: value the existing customer base as an annuity decaying at the GRR rate and growing at the expansion rate, then value future customer acquisition separately using CAC-payback economics. This tells you how much of the market cap is embedded in customers already won versus customers yet to be acquired — often 40-60% of a high-growth SaaS valuation is the latter, which is precisely where the risk sits. In any DCF or FCF-yield exercise, treat SBC as a cash cost (deduct it, or model share-count growth explicitly). The most common valuation error in this sector is discounting SBC-adjusted cash flows to an unadjusted share count.
|
||||
|
||||
**6. What not to use.** P/B — book value is cash plus goodwill and can be negative after buybacks. EV/EBITDA — capex is negligible so EBITDA ≈ EBIT and it adds nothing, while rewarding firms that capitalise software development. Replacement cost, NAV and asset-based methods do not apply. Dividend discount models apply only to mature Indian IT and legacy licence software. Trailing P/E on GAAP earnings for a growth SaaS name is not a conservative choice — it is a meaningless one.
|
||||
|
||||
**7. Cross-checks before you commit to a fair value.** Compare the implied terminal EBIT margin against a genuinely mature comparable (the 25-30% zone that scaled software and Indian tier-1 IT actually achieve) rather than an aspirational one. Sanity-check implied revenue against a realistic TAM and market share. Stress-test NRR: a 10-point NRR decline compounds through the model and typically justifies a 25-40% cut to fair value on its own — run it before you write the target. And check that the FX assumption embedded in an Indian IT model is not doing the work that operations should be doing.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable here shares **revenue model, growth stage, gross-margin structure and end-market**, not merely the "technology" label. Mixing these produces conclusions that are artefacts of the peer set.
|
||||
|
||||
Splits that must not be mixed:
|
||||
|
||||
- **Product software vs IT services.** Different gross margins (75-85% vs 30-36%), different scaling laws (marginal cost near zero vs linear headcount), different valuation regimes. Never put a SaaS vendor and an outsourcing firm in the same multiple table.
|
||||
- **Recurring subscription vs perpetual-licence-plus-maintenance vs consumption/usage-based.** Usage-based revenue is genuinely more volatile and re-rates faster in a downturn; licence revenue is lumpy and front-loaded. Their NRR figures are not comparable definitions.
|
||||
- **Enterprise vs SMB vs PLG/self-serve.** GRR bands differ by 10+ points, CAC payback and sales-motion economics differ entirely, and SMB churn is macro-sensitive in a way enterprise churn is not.
|
||||
- **Indian tier-1 vs Indian mid-cap vs global SI (Accenture-type) vs captive/GCC-exposed ER&D.** Different growth, margin, client-size and revenue-per-employee bands, and different currency exposure.
|
||||
- **Vertical/domain concentration.** BFSI-heavy, healthcare-heavy, retail-heavy and hi-tech-heavy books behave differently across a cycle; a hi-tech-concentrated services firm in a client capex freeze is not comparable to a BFSI-led peer in a rate-driven spending cycle.
|
||||
- **Growth stage.** A 35%-growth name and a 6%-growth name are in different regimes even with identical products. Bucket by growth first, then compare.
|
||||
- **Organic vs roll-up.** Serial acquirers carry goodwill, purchase-accounting effects and perpetual "one-off" charges. Compare them to each other, and always on organic cc growth.
|
||||
- **AI-native / inference-heavy vs classic application software.** Different COGS structure; use EV/gross profit, not EV/revenue, when they must sit in one table.
|
||||
|
||||
Also normalise before comparing: put every peer on the same currency basis (cc where possible), the same margin definition (EBIT or FCF, stated), the same Rule of 40 formulation, and the same fiscal-year alignment — Indian companies report April-March, many US software companies use January or June year-ends, and a raw calendar comparison in a fast-moving cycle mis-ranks them.
|
||||
|
||||
Aim for 5-8 tight comparables. If you cannot find them, say so and widen to a global set explicitly rather than silently comparing across sub-sectors.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **SBC excluded from every headline number.** Non-GAAP EPS, "adjusted EBITDA" and "adjusted FCF" all add back stock comp while the company spends most of its FCF on buybacks that merely hold share count flat. Test: compute FCF − SBC, and check net diluted share count over 3-5 years. If shares are up 3-5% p.a. despite large buybacks, the reported "cash generation" is largely being paid to employees, not owners.
|
||||
- **Unbilled revenue / contract assets growing materially faster than revenue.** The classic fixed-price and Indian IT warning: percentage-of-completion revenue for work not yet invoiced or client-accepted. Watch DSO-including-unbilled creeping up 8-15 days, especially alongside a margin beat — it usually means revenue was pulled forward or a client is in distress.
|
||||
- **cRPO or billings decelerating while reported revenue holds up.** Revenue is backlog burning off; cRPO is the truth. Related tell: management stops guiding on billings, shifts emphasis from cRPO to total RPO, or headlines an RPO number inflated by one long-duration mega-deal or bulk renewal.
|
||||
- **Metric disappearance or redefinition.** A company that disclosed NRR, GRR, customers above $100k ARR, CAC payback or attrition every quarter for years and then quietly stops, changes the definition, or moves to annual disclosure "for consistency". This is the most reliable qualitative red flag in the sector and it almost always precedes a bad print. Equally: ARR redefined to include non-recurring services, usage estimates, "committed ARR", or partner/reseller bookings.
|
||||
- **Rising capitalisation of internal software development.** Check capitalised software on the balance sheet and the capitalised share of total R&D. Higher capitalisation shifts cash costs out of opex, flatters margins and EBITDA, and defers the hit into amortisation. Margins improving while capitalised software jumps is not improvement.
|
||||
- **Acquired growth presented as organic.** Serial roll-ups obscure a decaying core — demand the organic cc bridge. Corroborating signals: ballooning goodwill and acquired-intangible amortisation excluded from adjusted profit, purchase-accounting deferred-revenue haircuts that flatter subsequent growth, and integration/restructuring charges recurring every single year (i.e. they are operating costs).
|
||||
- **NRR propped up by a few accounts while GRR erodes.** If enterprise GRR drifts toward the mid-80s while NRR still looks fine, the base is churning and being papered over with upsell into whales. Cross-check net customer adds: adding revenue while losing logos means the runway is shortening.
|
||||
- **Margin beats from non-repeatable levers.** In IT services: utilisation pushed above ~87% (no bench, delivery risk, future attrition), a sharp cut in fresher hiring, a one-off drop in subcontractor cost, or FX/hedging gains presented as operating performance. In SaaS: a large cut to R&D or S&M that props up the Rule of 40 while growth quietly decelerates — margin harvested from the future.
|
||||
- **Cash flow flattered by working-capital and billing manoeuvres.** Aggressive discounting to convert customers to multi-year upfront prepay (borrowing FCF from future years), receivables factoring or supply-chain finance, stretched payables, lengthening the amortisation period on capitalised sales commissions (ASC 606 contract cost assets) to lift reported margin, and channel/reseller stuffing at quarter-end. One spectacular FCF quarter with flat billings deserves suspicion.
|
||||
- **Concentration risk being waved away.** A top client above 10% of revenue, top-10 above 30%, or heavy exposure to one stressed vertical. In services, also watch a mega-deal won on rebadging/transition terms that is margin-dilutive for 2-3 years but announced as record TCV.
|
||||
- **Headcount and revenue diverging in the wrong direction.** Revenue flat-to-up while headcount falls sharply can be genuine automation, but is more often a one-time utilisation-and-pyramid squeeze that cannot repeat. The reverse — headcount growing well ahead of revenue — signals pyramid deterioration, bench build-up and margin compression 2-3 quarters out. Treat unquantified "AI-led productivity" claims sceptically unless revenue per employee is actually rising.
|
||||
- **TCV and bookings disclosure games.** TCV bundling renewals, extensions and rebadged headcount without a net-new split; TCV including optional or contingent scope; a changed duration convention. A record TCV quarter with no book-to-bill and no net-new split is a marketing number.
|
||||
- **Governance and personnel tells, unusually predictive here.** CFO or auditor turnover (especially Indian mid-cap IT), whistleblower complaints on revenue recognition, restated segment reporting, promoter pledging, related-party transactions with promoter-linked entities, revenue routed through associates or opaque subsidiaries, option repricing after a share-price fall, and heavy insider selling into a rally.
|
||||
- **AI-era specific.** Subscription gross margin compression from inference/GPU cost attributed vaguely to "mix"; "AI ARR" or "AI pipeline" figures disclosed without definition or without appearing in reported revenue; and, on the services side, silence about the deflationary risk GenAI poses to time-and-materials, headcount-linked pricing. Also check the contractual-obligations note for large committed cloud/GPU purchase commitments — these are debt-like fixed costs sitting on an otherwise asset-light balance sheet.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The demand cycle is a client-budget cycle, and it is observable early.** Enterprise IT spending tracks corporate profit expectations and rate levels with a 2-3 quarter lag. The order in which it shows up is consistent: discretionary/transformation spend is cut first (project ramp-downs, deferred starts), then pricing pressure and vendor consolidation rebids, then headcount and utilisation, and only then reported revenue. Cost-takeout and vendor-consolidation deals actually *increase* in a downturn — large multi-year outsourcing TCV can hit records while organic growth is collapsing, because the deals are long-duration, margin-dilutive in the transition years, and often involve rebadging client staff. Read a record-TCV headline against net-new TCV and near-term revenue, never in isolation.
|
||||
|
||||
**Where in the cycle matters differently by sub-sector.** Consumption/usage-based software de-rates fastest into a downturn (customers throttle usage within the quarter) and recovers fastest. Seat-based enterprise subscription lags in both directions because contracts are annual. SMB-exposed SaaS carries credit-like churn risk in a recession. IT services sits between: revenue is annuity-like, but discretionary project work is the swing factor and margin is levered to utilisation.
|
||||
|
||||
**Structural threats to underwrite explicitly.** (i) GenAI as a deflationary force on headcount-linked pricing — if a services firm's price per unit of output falls faster than its cost per unit, revenue shrinks even as it wins share; revenue per employee is the check. (ii) GenAI as a moat threat in software — thin application layers over a general-purpose model, seat-based pricing under pressure as agents replace seats, and vendors' own COGS rising with inference. (iii) Captive/GCC insourcing by large clients, which removes both revenue and the best delivery talent. (iv) Cloud-vendor platform encroachment on point-solution SaaS categories. (v) Consolidation of vendor rosters, which is good for scale players and lethal for tier-3.
|
||||
|
||||
**Currency and rates.** Indian IT earns in USD/EUR/GBP and pays largely in INR: rupee depreciation flatters INR margins and EPS while cross-currency (EUR/GBP/AUD vs USD) moves reported USD growth by hundreds of basis points. Hedge books smooth this with a 2-4 quarter lag, so an FX-driven margin beat is a timing effect, not performance. For unprofitable global SaaS, the discount rate is the dominant valuation variable — a duration asset whose value sits mostly in terminal years re-rates violently with long rates, independent of operations.
|
||||
|
||||
**Regulation and policy.** Data localisation and cross-border transfer rules (GDPR, India's DPDP Act, sectoral rules in BFSI and healthcare) raise delivery cost and can force in-country capacity. Visa and immigration policy in the US/UK affects onsite cost and mix for Indian IT. Antitrust and platform regulation bear on internet/marketplace names (app-store rules, self-preferencing, ad-tech). AI-specific regulation (EU AI Act and analogues) creates compliance cost and, for some vendors, a moat. Public-sector and BFSI clients add procurement-cycle and audit risk. Cyber-incident materiality disclosure rules mean a breach is now a reportable, quantifiable event — check for prior incidents and the associated contractual liabilities.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
**Reporting and filings.** India: Ind AS, quarterly results filed with NSE/BSE within 45 days, figures in ₹ crore/lakh, mandatory quarterly earnings calls and investor presentations at large caps (the concall is where utilisation, attrition, offshore mix, client-count buckets and TCV are actually disclosed — the financial statements alone will not give you the operating KPIs). Annual report includes MD&A, CARO 2020 auditor reporting, and the auditor's report on internal financial controls. US/global: 10-K/10-Q on EDGAR, GAAP with a reconciled non-GAAP section, 8-K for material events, and the shareholder letter / supplemental metrics deck where NRR, RPO, cRPO and customer cohorts live.
|
||||
|
||||
**Disclosure asymmetries to expect.** Indian IT discloses operating KPIs generously (utilisation, attrition, offshore/onsite, client buckets, TCV) but rarely NRR/GRR in SaaS form. US SaaS discloses retention and RPO but almost never utilisation or attrition. Do not conclude a metric is absent because it is absent from the financials — check the concall transcript (India) or the supplemental metrics deck / prepared remarks (US) first.
|
||||
|
||||
**India-specific items to check.** Promoter holding and any pledging; promoter-group related-party transactions; CARO qualifications; RPT approvals and the audit committee's composition; ESOP pools at mid-caps (small vs US peers but rising); dividend and buyback policy (many large caps run explicit capital-return policies returning 80-100% of FCF); SEBI LODR disclosures on material events; and — for mid-caps — auditor changes, which have historically been an early warning.
|
||||
|
||||
**Accounting and convention differences that change the numbers.** Ind AS 115 and ASC 606 are converged on revenue recognition, so percentage-of-completion and contract-asset treatment are broadly comparable — but the *disclosure granularity* differs, and Indian firms often report unbilled revenue within trade receivables notes rather than as a headline. Ind AS 116 and ASC 842 both put leases on the balance sheet; strip them before any leverage comparison. Hedge accounting under Ind AS 109 pushes forward-contract gains through OCI and the P&L on different lines across companies — read the hedge note before attributing a margin move to operations. SBC is expensed under both frameworks, but the *magnitude* differs by an order of magnitude between Indian IT and US SaaS, which is why non-GAAP and GAAP converge in India and diverge sharply in the US.
|
||||
|
||||
**Valuation convention.** India quotes forward P/E on 1-year-forward EPS as the default and discusses growth in cc USD terms; the US quotes EV/NTM revenue for growth software and non-GAAP EPS for mature software. When comparing, convert explicitly and state the basis. Note also that Indian IT's large net cash makes EV-based multiples look optically cheap versus equity-based ones — pick one and be consistent across the peer table.
|
||||
|
||||
**Ownership and index effects.** Indian IT has large FII ownership and is index-heavy, so it carries flow-driven volatility unrelated to fundamentals; US SaaS is exposed to index/ETF and factor rotation between growth and value. Neither changes intrinsic value, but both explain multiple moves you should not attribute to operations.
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Classify the company first: product software / SaaS, IT services, or platform — and its growth bucket. Everything downstream depends on this.
|
||||
- [ ] Discard ROCE, ROA, P/B, D/E, current ratio and EV/EBITDA as primary metrics; if used at all, state the adjustment (ex-cash, ex-goodwill, ex-lease) explicitly.
|
||||
- [ ] Pull NRR and GRR together. NRR without GRR is unreadable. Note if GRR is undisclosed.
|
||||
- [ ] Compute Rule of 40 and, more importantly, its composition (growth vs margin). Track its 8-quarter trend.
|
||||
- [ ] Check cRPO and billings growth against revenue growth. Divergence is a leading indicator; use cRPO, not total RPO.
|
||||
- [ ] Build the growth bridge: reported = organic cc + inorganic + FX. Never quote reported growth without it.
|
||||
- [ ] Recompute FCF − SBC and net diluted share count over 3-5 years. Treat dilution-offsetting buybacks as an operating cost.
|
||||
- [ ] Split subscription gross margin from services gross margin; check the trend for inference/GPU cost creep.
|
||||
- [ ] Compute CAC payback and Magic Number; a deteriorating trend leads a growth collapse by 2-4 quarters.
|
||||
- [ ] For services: utilisation ex-trainees, offshore mix, attrition, subcontractor cost, headcount vs revenue, revenue per employee. Identify which lever drove any margin change and whether it repeats.
|
||||
- [ ] Compute DSO *including unbilled revenue* and track the unbilled share of revenue. Rising unbilled alongside a margin beat is the top accounting warning here.
|
||||
- [ ] Check client concentration (top-1 >10%, top-10 >30%) and vertical concentration against the current macro stress point.
|
||||
- [ ] For platforms/marketplaces: normalise gross-vs-net revenue presentation, compute take rate and post-incentive contribution margin, and check cohort monetisation by vintage.
|
||||
- [ ] Check capitalised software as a share of R&D and whether it is rising; check capitalised commission amortisation periods.
|
||||
- [ ] Compare against 5-8 true comparables matched on revenue model, growth stage, gross-margin structure and end-market; state the peer set and why.
|
||||
- [ ] Value with the regime-appropriate tool: EV/NTM revenue (growth-adjusted) or EV/gross profit for growth SaaS; EV/ARR or EV/cRPO for mixed-revenue firms; forward P/E, FCF+buyback yield and DCF for mature software and Indian IT.
|
||||
- [ ] In any DCF, treat SBC as a cash cost and model share count explicitly; decompose value into existing-cohort annuity vs future acquisition.
|
||||
- [ ] Stress-test a 10-point NRR decline and an adverse FX move before writing a fair value.
|
||||
- [ ] Scan the KPI history for metrics that were discontinued, redefined, or moved to annual disclosure.
|
||||
- [ ] India: check promoter pledging, RPTs, CARO qualifications, auditor/CFO changes, and read the concall for operating KPIs absent from the financials.
|
||||
- [ ] State explicitly which conclusions rest on management-defined, unaudited metrics (ARR, TCV, pipeline, "AI ARR") and how much of the thesis breaks if those definitions change.
|
||||
|
|
@ -0,0 +1,219 @@
|
|||
# Metals, mining and commodity producers — sector playbook
|
||||
|
||||
Use this when: the company digs, processes, smelts or refines a physically traded commodity and takes the price the market gives it — iron ore, coal, copper, zinc, lead, aluminium, gold, silver, nickel, lithium, bauxite, alumina, integrated and secondary steel, ferro-alloys, sponge iron, and the mining-adjacent explorers and developers that have reserves but no earnings.
|
||||
|
||||
Two assumptions underneath the generic ratio checklist both fail here, and they fail in the same direction. First, the company does not set its selling price: the price is exogenous, identical for every competitor, and moves several hundred percent across a cycle. Second, the asset base is not a going concern of indefinite life — every tonne sold is inventory liquidation from a finite orebody, and the mine eventually stops and must be closed at the owner's cost. The consequence is that almost every standard ratio is not merely noisy here but *inverted*: it looks best at the top of the cycle and worst at the bottom, which is precisely backwards. Your job is to replace price-contaminated financial ratios with unit economics (cost per tonne against the global cost curve), physicals (grade, strip, recovery, volume) and through-cycle normalisation.
|
||||
|
||||
## Contents
|
||||
|
||||
1. [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
2. [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
3. [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
4. [Peer set construction](#peer-set-construction)
|
||||
5. [Sector-specific red flags](#sector-specific-red-flags)
|
||||
6. [Cycle and structural context](#cycle-and-structural-context)
|
||||
7. [India vs global notes](#india-vs-global-notes)
|
||||
8. [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Work through these before you quote any standard ratio. In most cases the correct action is to suppress the metric or replace it with the through-cycle version, not to caveat it.
|
||||
|
||||
**P/E — actively inverted, and the single most dangerous number in the sector.** Earnings peak when the commodity peaks, so the stock screens cheapest (3–5x) at exactly the moment the cycle is about to roll, and screens expensive or loss-making (negative, or 40x+) at the trough when the risk-reward is best. Screening for "low P/E in metals" is a reliable mechanical method of buying the top. The correct read is the opposite of the generic one: **high or negative P/E at a cyclical trough is a potential entry; a mid-single-digit P/E on peak earnings is a warning.** Only normalised, mid-cycle EPS makes a P/E interpretable at all.
|
||||
|
||||
**OPM / EBITDA margin — a commodity-price artifact, not a measure of management.** A fourth-quartile-cost miner prints 40% margins at peak prices; a first-quartile miner prints 15% at the trough. Margin tells you where the *price* is, not how good the business is. Ranking peers on OPM in this sector ranks them on when you happened to look. Replace it entirely with **unit cash cost versus the global cost curve** and **EBITDA per tonne against the company's own history**.
|
||||
|
||||
**ROCE — doubly distorted, and anti-comparable across peers.** Self-discovered reserves are carried at near-zero (exploration expensed or written down); acquired reserves are carried at full purchase price. Two geologically identical mines can therefore show 40% and 8% ROCE purely because one was found and one was bought. Add fully-depreciated legacy assets flattering the denominator, and a just-commissioned greenfield with capitalised capex and no output crushing it, and the raw number carries almost no information. Compute ROCE on **mid-cycle EBIT** and ideally against **replacement cost of installed capacity**, not book.
|
||||
|
||||
**D/E and net debt/EBITDA — procyclical, and they lie in the same direction as P/E.** 0.8x net debt/EBITDA at the peak becomes 5x on *identical debt* when the price halves. Leverage looks most reassuring exactly when the risk is highest. Test leverage against **trough EBITDA**, and make sure the "debt" figure includes leases, acceptances/bill discounting, perpetual and hybrid instruments, mine-closure and rehabilitation provisions (ARO), and — India-specific — the discounted value of committed auction-premium and DMF obligations.
|
||||
|
||||
**Revenue growth — meaningless as reported.** Revenue is price × volume, and price moves far more than volume. A miner can post +40% revenue with *falling* production. Never report revenue growth in this sector without decomposing it; only **saleable volume growth** is a real KPI, and only realised-price-vs-benchmark explains the rest.
|
||||
|
||||
**FCF — the easiest number in the sector to manufacture.** Capex is lumpy and splits three ways: sustaining, capitalised waste stripping, and growth. A company that defers waste stripping, fleet rebuilds, furnace relines and tailings-dam spend prints excellent free cash flow for two or three years while quietly liquidating the orebody and accumulating risk. Split reported capex into sustaining vs growth, compare sustaining capex to DD&A and to life-of-mine average stripping, and only then treat FCF as a quality signal.
|
||||
|
||||
**D&A comparability is broken, which breaks EBIT, OPM and P/E together.** Units-of-production versus straight-line depreciation, and different assumed mine lives, change reported EBIT between otherwise identical peers with no cash difference at all. This is *why* the sector talks in EBITDA and unit cash costs rather than operating profit — use the sector's own language rather than forcing EBIT-based ratios onto it.
|
||||
|
||||
**P/B and book value — unstable and not a floor.** Serial impairments, revaluation of acquired reserves, and full-cost versus successful-efforts treatment of exploration make book value a residue of past accounting choices rather than a measure of asset value. A "low P/B" in metals frequently means the impairments have not been taken yet. Use EV per tonne of capacity against greenfield replacement cost instead — that is the real asset-value floor.
|
||||
|
||||
**Current ratio, inventory turns and working-capital rules — contaminated.** Inventory revaluation gains and losses run through cost of sales, so turns move with price rather than efficiency. Concentrate sales are provisionally priced: the final price is set on a quotational period one to four months after shipment, so a quarter's receivables and EBITDA carry marks that reverse next quarter with zero operational change. Do not read working-capital deterioration as distress without first stripping revaluation and provisional-pricing effects.
|
||||
|
||||
**DCF with a perpetual-growth terminal value is simply wrong for a mine.** Reserves deplete; the asset stops. A Gordon-growth terminal value assumes the opposite of the defining fact about the business. The correct model is a **finite life-of-mine NPV with an explicit closure cost at the end**. (For processors and recyclers with no orebody — rolled aluminium, EAF steel, secondary refiners — a going-concern DCF is defensible; for a mine it is not.)
|
||||
|
||||
**Trailing dividend yield — a peak-cycle mirage.** Most majors now run base-plus-variable payout policies explicitly designed to distribute windfalls. A trailing yield of 10–12% is therefore a signal that you are near the top, not that you have found an income stock. Value the **base** dividend as the sustainable component and treat the variable component as a cyclical windfall.
|
||||
|
||||
**"Consistency" screens systematically select the wrong companies.** Filters for 10-year EPS CAGR, no loss-making years, stable margins and steadily rising book value reject essentially every good miner (they all have loss years) and select the ones whose numbers were flattered by a peak. If your framework contains such a screen, disable it for this sector rather than applying it and noting an exception.
|
||||
|
||||
**India-specific blind spots in generic checklists.** A large share of the cost structure is statutory and non-negotiable — royalty, DMF, NMET, GST compensation cess on coal, and auction premiums that can exceed 100% of the IBM-notified average sale price. None of this appears in any standard ratio, yet it can consume half of gross revenue. Separately, many Indian producers do not publish JORC/NI 43-101/SK-1300-compliant reserves at all, so the reserve-based metrics that developed-market analysis leans on must be reconstructed from lease documents, approved Mine Plans and IBM filings, or flagged as unavailable.
|
||||
|
||||
---
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges below are **indicative only**. They vary by commodity, market, jurisdiction, cycle position and reporting period, and several are quoted in nominal dollars that drift with inflation. A company's own 10-year history and its direct sub-sector peers at the *same point in the cycle* always override any absolute band quoted here.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Unit cash cost and position on the global cost curve** (C1; AISC for precious metals) | C1 = mining + processing + on-site G&A + freight, net of by-product credits, per unit of saleable output. AISC (World Gold Council definition) = C1 + sustaining capex + sustaining stripping + royalties + corporate G&A + reclamation accretion. What matters is the **quartile** on the global cost curve (Wood Mackenzie / CRU / AME), not the absolute number. | First or second quartile; ideally first. Reference points: copper C1 below ~$1.60/lb (first quartile ~$1.00–1.25/lb); gold AISC below ~$1,400/oz against a global average of roughly $1,450–1,600/oz; iron ore C1 of $18–30/t for the seaborne majors; large Indian zinc producers guiding cost of production ex-royalty near $1,000–1,100/t against LME $2,600–3,000/t. Above the 75th percentile is a survival question, not a valuation question. | Price is exogenous and identical for everyone, so the only durable competitive advantage in this sector is being low on the cost curve. Cost position determines who still makes money in the trough (when high-cost tonnes shut and set the marginal price), who survives without a rescue rights issue, and who compounds. **This metric replaces operating profit margin entirely.** |
|
||||
| **EBITDA per tonne / per ounce (unit spread)** | EBITDA ÷ saleable volume *sold*, tracked by product and by asset. For processors also track the conversion spread separately: HRC price minus roughly 1.6t iron ore plus 0.7t coking coal; LME aluminium minus ~1.9t alumina, ~0.4t carbon and ~14 MWh of power. | Indian flat steel: mid-cycle roughly Rs 9,000–12,000/t; below Rs 6,000/t is stress; above Rs 18,000–20,000/t is an unsustainable peak. Global integrated steel $100–150/t mid-cycle. Indian primary aluminium $700–900/t mid-cycle, $1,100/t+ at peak. Rolled-products converters ~$500–550/t of shipments and largely spread-agnostic. | Normalises out price and volume mix and isolates operating performance, which reported margin cannot. It is the unit in which the sector guides, forecasts and values, and the input to mid-cycle EV/EBITDA. A company whose EBITDA/t consistently exceeds peers *at the same realised price* has real operating advantage (integration, scale, energy, yield); one whose EBITDA/t is only high when prices are high has none. |
|
||||
| **Reserve life (R/P), resource life and reserve replacement ratio** | Proved + probable reserves ÷ current annual production = years of mine life; the measured/indicated/inferred resource behind it; and reserve replacement ratio = reserves added ÷ reserves depleted, on a rolling 3-year basis. Always check the reporting code: JORC (Australia), NI 43-101 (Canada), SK-1300 (US, mandatory since 2021), PERC (Europe) versus India's UNFC/IMIC 2019 framework, which is far less consistently applied. | Core assets: reserve life above 15–20 years. Below 8–10 years the company must find or buy reserves under time pressure — where value is destroyed. Replacement ratio above 100% on a 3-year average. India: captive leases run to 2030/2050/2070 depending on MMDR vintage — check the **actual expiry date**, not the geology. | A miner is a wasting asset. Short reserve life converts an apparently profitable business into a forced acquirer at the top of the cycle. Long life plus in-house replacement is what separates a compounding franchise from a run-off. Watch restatements: reserves can be "added" by raising the assumed long-term price or lowering the cut-off grade — an accounting event, not a discovery. |
|
||||
| **Head grade vs reserve grade, strip ratio, metallurgical recovery** | Grade = metal content per tonne of ore (g/t Au, % Cu, % Fe, % Zn). Strip ratio = waste tonnes moved per tonne of ore. Recovery = % of contained metal actually recovered in the plant. Compare mined grade and strip against the **life-of-mine (LoM) plan averages** in the technical report. | Mined grade at or below reserve grade, and strip ratio at or above LoM average, is normal and healthy. Grade materially above reserve grade, or strip materially below LoM average, for several consecutive periods is the classic high-grading / deferred-stripping pattern. Recovery stable or improving; a 2–3 point recovery decline is a real earnings event. | These are the physical drivers of everything downstream. Falling grade means more tonnes must be moved, crushed and processed for the same metal, raising unit cost mechanically regardless of management effort — the structural headwind in global copper and gold. Conversely, mining above reserve grade flatters today's cost and cash flow while stealing from future years. **No financial metric reveals this; only the physicals do.** |
|
||||
| **Saleable production volume, sales vs production, capacity utilisation** | Volume actually *sold* (not produced), the gap between production and sales (stockpile build/draw), and utilisation of installed smelter, refinery, blast-furnace and mill capacity. Track debottlenecking-led volume growth and the ramp curve of new capacity against guidance. | Steel/alumina/refinery utilisation above 85–90%; below 75–80% fixed-cost absorption collapses. Sales should track production closely; a persistent finished-stock build is a demand problem or an evacuation/logistics problem. New projects should reach design capacity within 4–6 quarters. | Volume is the only part of revenue management actually controls. In a fixed-cost-heavy business incremental tonnes carry very high contribution margin, so a 5% volume miss can cost 15–20% of EBITDA. Serial volume guidance misses are the most reliable early indicator of orebody, equipment or permitting problems, and the number on which the market re-rates. |
|
||||
| **Realised price versus benchmark (realisation discount / NSR)** | Achieved price per tonne or ounce against the relevant benchmark (LME/COMEX, Platts 62% Fe CFR China, HRC import parity, Newcastle/API coal indices), plus the reason for the gap: product mix, grade and impurity penalties (silica, alumina, phosphorus, moisture), treatment and refining charges (TC/RC) on concentrate, freight, provisional-pricing marks, and contract vs spot vs e-auction mix. | The gap should be **stable and explainable**. Widening discounts signal deteriorating ore quality or product mix. India: the large coal producer's realisation blends FSA notified price with e-auction volumes that can clear 40–100%+ above notified price — the auction share is a major swing factor. Indian steel NSR should track import parity within a narrow band. | Two producers quoting the same benchmark can realise materially different revenue per tonne. Persistent widening of the discount is a silent margin leak that no headline cost metric shows, and provisional pricing can flip a quarter's reported EBITDA in either direction with no operational change. |
|
||||
| **Sustaining capex per unit, and sustaining capex vs DD&A** | Capital required to keep current production and safety standards intact — mine development, capitalised stripping under IFRIC 20, tailings dams, fleet rebuilds, furnace relines — separated from growth capex, expressed per tonne/ounce and compared with DD&A and the LoM plan. | Over a full cycle sustaining capex should be broadly in line with DD&A. Gold roughly $150–300/oz. Integrated steel roughly $25–45 per tonne of capacity per year, plus relines every 15–20 years. Sustaining capex below 60–70% of DD&A for multiple years is deferred maintenance dressed up as free cash flow. | The easiest lever for flattering short-term FCF and the one causing the most permanent damage — and, for tailings dams, catastrophic risk. Splitting sustaining from growth is also what makes FCF interpretable at all: growth capex is optional and can be stopped; sustaining capex cannot. |
|
||||
| **All-in cash break-even commodity price** | The commodity price at which the company generates zero free cash flow after cash costs, royalties and levies, sustaining capex, interest and cash tax. Express per tonne/ounce and compare with spot and with the consensus long-run/incentive price. | Spot at least 30–40% above all-in break-even for a comfortable balance sheet. A producer whose break-even sits within 10% of spot has no cushion. Also compare break-even with the marginal industry cost (≈90th percentile of the cost curve), which anchors the long-run floor price. | Converts the entire income statement into the one number that matters in a downturn: at what price does this company stop self-funding and start drawing debt? Far more decision-useful than interest coverage or D/E, and it lets you size downside directly from a price deck. |
|
||||
| **Through-cycle leverage: net debt / mid-cycle EBITDA and / trough EBITDA** | Net debt — including leases, acceptances, perpetual and hybrid instruments, discounted closure/rehabilitation provisions, and in India the NPV of committed auction-premium and DMF liabilities — tested against normalised mid-cycle EBITDA *and* a modelled trough EBITDA. Plus gearing = net debt / (net debt + equity). | Diversified majors run net cash to 0.5x mid-cycle and gearing under 20–25%. Indian integrated steel up to 2.0–2.5x mid-cycle is workable given growth capex; above 3.5x mid-cycle is dangerous. Real test: **net debt / trough EBITDA under 4–5x, and no refinancing wall inside 24 months.** | Almost every permanent capital loss in this sector is a leverage event, not an operating event — debt taken on at the peak against peak EBITDA, then refinanced dilutively at the trough. Reported net debt/EBITDA is most reassuring exactly when risk is highest, so only the mid-cycle and trough versions carry information. |
|
||||
| **Raw-material integration ratio (captive ore, coking coal, bauxite, power)** | Share of key input requirements met from own mines or captive power. Indian steel: captive iron ore and coking coal percentages. Aluminium: captive bauxite, alumina and captive coal-based power (~14 MWh per tonne of aluminium). | Indian integrated steel spans near-100% captive iron ore with 20–25% coking coal at one end to roughly 40–50% iron ore and minimal coking coal at the other. Each ~10 percentage points of iron-ore integration is worth roughly Rs 500–900/t of EBITDA at normal ore prices. For aluminium, captive bauxite plus captive power is the difference between first- and third-quartile cost. | Integration converts a price-taking converter into a structurally low-cost producer and is the main reason Indian producers' EBITDA/t diverges so widely. It also changes cycle behaviour: an unintegrated converter is squeezed from both ends, while an integrated producer captures the mining margin. Verify integration is real and long-dated (lease expiry, evacuation approvals), not a signed MoU. |
|
||||
| **Energy and power cost per unit, and specific consumption** | Energy cost per tonne plus physical intensity: MWh per tonne of aluminium, GJ or kg of coke per tonne of hot metal (coke rate / fuel rate), diesel per BCM moved. Plus source mix — captive thermal, linkage coal, e-auction coal, imported coal, grid, renewables / round-the-clock PPAs. | Aluminium smelting 13.5–15 MWh/t (below 14 is efficient). Blast-furnace fuel rate 480–520 kg/thm. Energy is typically 30–40% of aluminium cash cost and 20–30% of mining cost, so a 10% energy move is a first-order earnings event. | The largest controllable cost line in smelting and a very large one in mining, and the axis on which decarbonisation capex, carbon pricing (EU CBAM phasing in on steel and aluminium from 2026) and coal-linkage policy will play out. Producers with captive coal and cheap renewables PPAs have a durable edge; smelters exposed to spot power do not. |
|
||||
| **Royalty, cess and total government take as % of revenue** (especially India) | All statutory levies as a share of revenue: royalty (India: iron ore 15% ad valorem, coal 14%, plus bauxite and zinc rates), District Mineral Foundation (10–30% of royalty), NMET (2% of royalty), GST compensation cess on coal (Rs 400/t), and the auction premium bid as a % of IBM average sale price for post-2015 blocks. Globally: state royalties, resource-rent taxes, export duties. | For an Indian post-2015 auctioned iron ore block with a 100–150% premium bid, total government take can exceed 45–60% of gross revenue — such a block is uneconomic at low ore prices. Legacy/captive royalty-only leases are dramatically better. Developed-market take is typically 5–15% of revenue plus corporate tax. | The most under-modelled cost in Indian mining, and it is **fixed regardless of the price cycle**, which massively amplifies downside operating leverage. Companies that won auctions with aggressive premium bids bought volume, not value. This line alone explains large permanent EBITDA/t divergence between peers mining the same ore. |
|
||||
| **Mid-cycle ROCE, measured against replacement cost** | EBIT at normalised mid-cycle commodity prices ÷ capital employed, ideally adjusted so capital employed reflects the replacement cost of installed capacity rather than a mix of near-zero self-discovered reserves and marked-up acquired reserves. | Above 15% at mid-cycle prices is a high-quality asset base; 8–12% is average; below the cost of capital at mid-cycle means the business destroys value across a full cycle no matter how good the peak year looks. Benchmark against the ~8–10% real WACC used for base-metal projects. | Answers whether the company earns its cost of capital through a full cycle rather than in one good year. The replacement-cost adjustment removes the distortion that makes acquirers look permanently bad and old fully-depreciated assets look permanently brilliant. It is also a discipline test: managements that report and are paid on mid-cycle ROCE historically avoid peak-cycle M&A. |
|
||||
| **FCF yield at spot AND at mid-cycle, with price sensitivity** | Operating cash flow less sustaining capex, interest, tax and leases ÷ market cap or EV — computed **twice**, once at spot and once at a normalised long-run price deck. Add explicit sensitivity: EBITDA and EPS impact per $10/t change in the ore or metal price, per Rs 1 change in USD/INR. | Mid-cycle FCF yield of 6–10% on EV is attractive. A **spot** FCF yield of 15–25% is almost always a cycle-peak signal, not a value signal. Sensitivity should be in the annual report; if it is not, build it. | This is the discipline that stops you buying the peak. The spot-versus-mid-cycle gap tells you how much current cash flow is price windfall versus structural. The sensitivity table tells you the true equity risk: for a levered producer a 20% price fall can erase 60–80% of EBITDA and all of the free cash flow. |
|
||||
| **Rehabilitation / closure provisions and tailings risk profile** | The balance-sheet ARO provision for mine closure, tailings and land rehab; the discount rate and cost-inflation assumption used; the funding status (cash-backed vs unfunded); and the physical inventory of tailings dams by construction type (upstream vs downstream/centreline), consequence classification, and independent GISTM conformance. | Provisions should grow with disturbed area and be funded or covered by dedicated reserve accounts where jurisdictions require it (Australia, Canada, Brazil). Upstream-construction dams in high-consequence locations are a distinct, material risk and are now banned in Brazil. Look for a stated GISTM conformance date and an independent tailings review board. | Closure liabilities are debt in disguise: unfunded, long-dated, inflation-linked, and easily understated with a high discount rate or a stale cost estimate. Tailings failures have destroyed more shareholder value in single events than most commodity downturns, and post-failure liabilities are effectively uncapped. |
|
||||
| **By-product credit dependence and co-product mix** | Share of C1 cost offset by by-product credits (silver and gold in zinc/lead, molybdenum and gold in copper, cobalt in nickel), and whether the company nets credits against cost or uses co-product accounting. | Know the number. A "first-quartile" cost position that depends on 30–50% of cost being offset by a by-product is a leveraged bet on *two* commodities, not one. Prefer co-product presentation for comparability. | By-product netting is the most common way a mid-cost mine is presented as a low-cost mine. When the by-product price falls, the headline cash cost jumps with no operational change — and peers using co-product accounting will look artificially worse. |
|
||||
| **Safety and social licence: fatalities, LTIFR, community/permit status** | Fatalities and lost-time injury frequency rate per million hours, plus the status of forest and environmental clearances, community consent, and litigation. | Zero fatalities is the only acceptable target; a rising LTIFR or a fatality cluster is a leading indicator of deferred maintenance and production pressure. | Safety performance is the cleanest available proxy for operational discipline, and it is causally linked to the cost-cutting that precedes both accidents and production misses. Loss of social licence — protest, blockade, permit revocation — has stopped large producing mines outright and is not priced in any financial ratio. |
|
||||
|
||||
**Sourcing notes.** Globally: reserves, grade, strip, LoM plans and unit costs are in the technical report (NI 43-101 / SK-1300 / JORC) and the annual production report, not the financial statements; US filers must give reserves and cost detail in the 10-K under SK-1300. In India: production and realisation come from the monthly/quarterly volume release and the concall; royalty, DMF and auction-premium detail from the annual report notes, lease documents and IBM filings; capitalised stripping from the fixed-asset and accounting-policy notes. If reserve disclosure is absent (common in India), say so explicitly rather than substituting resource figures of unknown confidence.
|
||||
|
||||
---
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
The sector is valued on **mid-cycle cash flow, asset value and replacement cost — never on trailing earnings multiples.** Present the answer as a range across a bear/mid/bull commodity price deck with explicit EBITDA and FCF sensitivity per unit price move. A single point-estimate target price in this sector is close to meaningless.
|
||||
|
||||
**1. EV/EBITDA on normalised mid-cycle EBITDA — the primary working multiple.** It strips out the D&A distortion (units-of-production vs straight-line, acquired vs self-discovered reserves) and the very different leverage structures. Indicative anchors: diversified majors 4.5–6.0x mid-cycle; Indian integrated steel 6–7x (a structural growth premium over global steel at 4–5x); gold producers 6–9x; thermal coal 3–4x because of terminal-value risk. **The multiple must contract as you move up the cycle** — paying 6x on peak EBITDA is paying 12x on mid-cycle. If you find yourself applying a constant multiple to a rising EBITDA estimate, you have built a momentum model, not a valuation.
|
||||
|
||||
**2. P/NAV — the standard method in developed markets**, especially Canada and Australia for precious and base metals. Build an explicit life-of-mine DCF from the technical report: annual tonnes and grade, recovery, unit costs, sustaining and expansion capex, taxes and royalties, and closure cost at the end — with **no perpetual-growth terminal value**, because the asset simply stops. Discount at roughly 5% real for gold, 8–10% real for base metals and bulks, and 12–15%+ where jurisdiction or terminal-demand risk is severe. Then add corporate items and net debt. Benchmarks: producing majors 0.9–1.3x NAV, single-asset producers 0.5–0.8x, developers and juniors 0.3–0.6x. Above 1.5x you are paying for exploration optionality or for a commodity price above your deck — say which.
|
||||
|
||||
**3. EV per tonne of installed capacity / price-to-replacement-cost — the cycle-trough anchor**, particularly for processors. Greenfield integrated steel replacement cost is roughly $900–1,200 per tonne globally and roughly $550–800 per tonne for brownfield expansion in India. Buying well below replacement cost is the classic deep-value entry; paying a premium to it is only justified where the asset is captive-ore-integrated and genuinely cannot be replicated (mining leases are no longer freely available in India post-auction).
|
||||
|
||||
**4. EV per unit of reserve or resource** — EV per reserve ounce of gold, per pound of contained copper, per tonne of contained iron ore. Very rough and highly sensitive to grade and jurisdiction, but it is the only tool for pre-production explorers and developers with no earnings, and it is useful for cross-sectional screening.
|
||||
|
||||
**5. Sum-of-the-parts — essential for diversified and holding structures.** Value each commodity stream on its own appropriate multiple, then subtract a holding-company discount (typically 20–40% where a listed parent's main asset is a stake in a listed subsidiary). Typical structures requiring SOTP: a parent holding a listed zinc subsidiary plus aluminium, power and other unlisted assets; an aluminium producer whose downstream rolled-products arm should be valued on $/t of shipments rather than on the upstream multiple; an Indian steel producer whose domestic business deserves Indian multiples while a loss-making European business deserves a heavy discount or negative value.
|
||||
|
||||
**6. Mid-cycle EPS × a mid-cycle P/E** is a legitimate cross-check — but only with normalised EPS, never trailing.
|
||||
|
||||
**7. For dividend-oriented names**, model the base-plus-variable policy explicitly. Value the **base** dividend as the sustainable component and treat the variable component (historically taking total payout to 50–60%+ of underlying earnings in good years) as a windfall that should not be capitalised.
|
||||
|
||||
**What NOT to use:** trailing P/E; P/B as a value screen; DCF with a Gordon-growth terminal value for any depleting asset; EV/EBITDA on spot or peak EBITDA; trailing dividend yield; PEG; and any multiple applied uniformly across sub-sectors with different cost structures and terminal-demand risk.
|
||||
|
||||
**Developed-market vs India convention.** DM analysts lead with P/NAV and published long-term price decks because technical-report disclosure is mandatory and audited. In India, JORC/IMIC-standard reserve disclosure is patchy and LoM plans are rarely public, so P/NAV is seldom used outside a couple of large zinc and coal names. The practical Indian toolkit is: **mid-cycle EV/EBITDA + EBITDA per tonne × capacity + EV per tonne of capacity against greenfield replacement cost**, with an SOTP overlay for conglomerates and an explicit deduction for auction-premium-burdened leases.
|
||||
|
||||
---
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable here shares **cost-curve position, commodity, integration level and jurisdiction** — not merely the label "metals". Compare at the same point in the cycle, or normalise both sides to mid-cycle first.
|
||||
|
||||
**Splits that must not be mixed:**
|
||||
|
||||
- **Miner vs processor vs converter.** A pure iron-ore miner earns the mining margin and has a cost curve; an EAF steel mini-mill converts scrap and earns a spread; a rolled-products aluminium converter earns a fixed conversion margin per tonne and is largely metal-price-agnostic. Their margins, capital intensity and cyclicality are structurally different. Putting them in one table produces nonsense.
|
||||
- **Integrated vs unintegrated.** An integrated steel producer with captive ore and a merchant converter buying ore at spot are different businesses with opposite cycle behaviour. Never compare their EBITDA/t without stating integration percentages.
|
||||
- **Bulk vs base vs precious vs battery metals.** Iron ore and coal are freight- and quality-driven with China-concentrated demand; base metals are LME-priced with global inventories; gold is a monetary asset priced off real rates rather than industrial demand; lithium, cobalt and rare earths are thin, policy-driven markets with immature price discovery. Cost-curve logic applies to all, but valuation multiples and demand drivers do not transfer.
|
||||
- **Producer vs developer vs explorer.** Producers are valued on cash flow; developers on risked NAV with a discount for financing and permitting risk; explorers on EV per resource unit and optionality. Applying a producer multiple to a developer, or vice versa, is a category error.
|
||||
- **Diversified vs single-asset.** Diversification is worth a real premium because it smooths the cycle and spreads geotechnical and political risk. A single-asset producer must trade at a discount to NAV; do not treat that discount as an opportunity without underwriting the single-asset risk.
|
||||
- **Jurisdiction tiers.** Australia/Canada/US/Chile-tier stability versus DRC, Indonesia, West Africa, Zambia and parts of Latin America. Jurisdiction shows up in the discount rate (5 points or more) and in the willingness of financiers to fund the next expansion — it is not a footnote.
|
||||
- **Thermal coal vs met coal.** Thermal carries terminal-demand and financing risk and trades at 3–4x; metallurgical coal is tied to blast-furnace steel and has a longer runway. They are not interchangeable.
|
||||
- **India-specific:** post-2015 auctioned leases versus legacy/captive royalty-only leases are economically different assets even for the same ore body. State-owned producers with administered pricing, government stake sales, and social obligations do not compare cleanly to private peers.
|
||||
|
||||
**Practical rule:** if you cannot state each peer's cost-curve quartile, integration percentage, reserve life and jurisdiction, you do not yet have a peer set — you have a list of tickers.
|
||||
|
||||
---
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Capital allocation at the top of the cycle**
|
||||
- Large debt-funded acquisitions or greenfield sanctions announced near a cycle peak. This is the sector's single most reliable value-destruction pattern — the 2007 mega-deals and the 2011–12 Indian capex wave both produced a decade of deleveraging. Watch for management describing peak prices as a "new structural floor" or a "structural shift in the cost curve".
|
||||
- Buybacks, special dividends or upstreaming to a parent funded at the top while net debt is rising. In Indian promoter structures, watch specifically for a cash-rich listed subsidiary funding an unlisted parent via inter-corporate deposits, loans, or outsized "brand fee" and management-service charges.
|
||||
- Aggressive auction-premium bids on Indian mineral blocks (at or above 100–150% of IBM notified average sale price). These convert a mine into a fixed-cost liability that is loss-making at low commodity prices. Check the premium percentage on **every block** before valuing the volume it adds.
|
||||
|
||||
**Borrowing from the future (invisible in financial ratios)**
|
||||
- Capitalised waste stripping running well above the LoM average strip ratio (IFRIC 20): shifting operating cost into capex flatters unit cash cost and EBITDA today and guarantees higher costs later. Compare the capitalised stripping charge to the disclosed LoM strip every period.
|
||||
- High-grading — mining materially above reserve grade to boost near-term output. Shortens mine life, raises future unit costs, and is invisible in every financial ratio. Detect it only by comparing mined grade to reserve grade across several quarters.
|
||||
- Sustaining capex persistently below DD&A while free cash flow and dividends are showcased. Deferred relines, fleet rebuilds, mine development and tailings spend are borrowed cash flow, repaid later with interest.
|
||||
- Reserve restatements achieved by raising the assumed long-run price or lowering the cut-off grade rather than by drilling. Reserves added by a spreadsheet assumption reverse when prices normalise, and typically trigger impairments.
|
||||
|
||||
**Disclosure and definitional games**
|
||||
- Changing the cost metric definition: switching between C1, "cash cost", "total cost" and AISC; changing by-product credit treatment (netting versus co-product); or dropping AISC disclosure entirely once it deteriorates.
|
||||
- Extending assumed mine life, or switching depreciation from units-of-production to straight-line, to reduce the DD&A charge — a pure accounting boost to EBIT and EPS with no cash effect.
|
||||
- Serial "exceptional" and "one-off" items — impairments, restructuring, closure charges — appearing in most years. In this sector recurring impairments are the operating model of a bad asset base, not exceptions. Always look at reported earnings over a full cycle, not just underlying.
|
||||
- Inventory revaluation gains and provisional-pricing (quotational-period) marks presented as operating performance. Both reverse, and both can swing a quarter's EBITDA by 15–25% with zero change in the business.
|
||||
- Guidance or investor decks extrapolating peak EBITDA/t into forward years, or quoting enterprise value against spot-price EBITDA. Ask for the mid-cycle number; **if management cannot produce one, that is itself the finding.**
|
||||
|
||||
**Balance sheet and financing**
|
||||
- A debt maturity wall inside the next 18–24 months while spot sits near or below the company's all-in cash break-even. This is the precise setup for a heavily dilutive equity raise at the bottom.
|
||||
- Understated rehabilitation and closure provisions — a high discount rate, a stale cost estimate, no inflation escalation, or wholly unfunded obligations. Compare provision per tonne of disturbed ground against peers in the same jurisdiction.
|
||||
- Hedging that has become speculative: large fixed-price forward sales locked in near the lows, or unhedged provisional pricing and currency exposure described as a "natural hedge". Read the derivative note, not the commentary.
|
||||
|
||||
**Operations, risk concentration and governance**
|
||||
- Volume guidance missed repeatedly, or a new project ramping far slower than the feasibility study assumed. Serial volume misses almost always mean an orebody, metallurgy or evacuation problem management has not yet acknowledged.
|
||||
- Widening realisation discount to benchmark (impurity penalties, falling Fe or Cu content, deteriorating product mix, rising TC/RCs) that is not explained in the MD&A — a silent, permanent margin leak.
|
||||
- Upstream-construction tailings dams in high-consequence locations, absent or delayed GISTM conformance, or no independent tailings review board. Low probability, uncapped severity, and no financial metric will surface it.
|
||||
- Single-asset, single-commodity, single-jurisdiction exposure combined with leverage. Any one is manageable; all four together mean one geotechnical, permitting or political event is terminal.
|
||||
- Concentrated regulatory and jurisdictional risk with no mitigation: expiring mining leases, pending forest/environmental clearance (Stage-I vs Stage-II), NGT or Supreme Court proceedings, retrospective demands (the Odisha excess-production demands under the Common Cause judgment), state-level mining bans of the kind seen in Goa and Karnataka, and resource nationalism (Indonesian export bans, DRC, Chile, Mexico lithium, Panama).
|
||||
- **India:** promoter share pledging, and related-party off-take, marketing or logistics agreements routing product to promoter-linked entities at below-market realisations.
|
||||
|
||||
---
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Where you are in the cycle changes which metrics are informative.** At the peak: leverage ratios, margins and P/E are all flattering and should be discounted; focus on capital-allocation discipline, the spot-vs-mid-cycle FCF gap, and whether management is sanctioning capex. At the trough: earnings-based metrics are useless; focus on cost-curve position, all-in break-even versus spot, liquidity and maturity profile, and EV per tonne of capacity against replacement cost. State explicitly in your output where you believe the cycle is and on what evidence — inventory levels (LME/SHFE/port stocks), the shape of the cost curve, incentive price versus spot, and industry capex intentions.
|
||||
|
||||
**The supply-side clock is long and that is the whole game.** A greenfield copper or iron ore project takes 7–15 years from discovery to first production and is subject to permitting risk throughout. This is why underinvestment during a trough sets up the next upcycle, and why capex announced at a peak reliably arrives into a glut. Track industry-wide capex and project pipelines, not just the company's.
|
||||
|
||||
**Structural cost inflation from declining grades.** Global copper and gold head grades have trended down for decades; the same tonnage of metal requires more material moved, more energy and more water. This raises the whole cost curve over time and supports higher long-run incentive prices — but it also means a company merely holding unit cost flat in real terms is outperforming.
|
||||
|
||||
**Demand concentration and the China factor.** Roughly half of global consumption of several base metals and bulks is China-linked. Chinese property, infrastructure and export-steel policy therefore drive iron ore, met coal and copper demand more than any Western macro variable. Chinese steel export volumes directly compress margins in India, South-East Asia and Europe. Model the demand side with that concentration explicit.
|
||||
|
||||
**Energy transition — a two-sided structural force.** Copper, aluminium, lithium, nickel and rare earths gain demand from electrification, grid build-out and storage; thermal coal faces terminal-demand and financing risk (hence its 3–4x multiple); blast-furnace steel faces decarbonisation capex it cannot fully pass through. Do not apply a single "commodities" narrative across the sector.
|
||||
|
||||
**Carbon and trade regulation.** EU CBAM phases in on steel, aluminium and cement from 2026, taxing the embedded carbon of imports and directly disadvantaging blast-furnace and coal-power-based producers selling into Europe. Scope 1 and 2 intensity per tonne is therefore becoming a cost variable, not an ESG footnote. Anti-dumping duties, safeguard measures and export taxes (including India's episodic export duties on iron ore and steel) can reprice a company's economics with weeks of notice.
|
||||
|
||||
**Scrap, recycling and secondary supply.** EAF and secondary-refining capacity grows as scrap pools mature, capping long-run prices and shifting the cost curve. A high-cost primary producer facing a growing secondary alternative has a structural, not cyclical, problem.
|
||||
|
||||
**Regulatory architecture (India).** The MMDR Act and its amendments moved India from discretionary allotment to auctions, creating a permanent economic split between legacy captive leases and post-2015 auctioned blocks. Forest and environmental clearance (Stage-I in principle, Stage-II final), state pollution board consents, evacuation infrastructure (railway sidings, conveyor corridors) and gram-sabha consent under FRA/PESA are all binding constraints on stated capacity. Treat announced capacity without clearances as an option, not an asset.
|
||||
|
||||
---
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India (NSE/BSE, Ind AS) | US / global (10-K, GAAP/IFRS, EDGAR/ASX/TSX) |
|
||||
|---|---|---|
|
||||
| Reserve disclosure | UNFC / IMIC 2019; patchy, rarely audited, LoM plans usually not public. Reconstruct from lease documents, approved Mine Plans and IBM filings — or state that it is unavailable. | Mandatory and standardised: SK-1300 (US, since 2021), NI 43-101 (Canada), JORC (Australia), PERC (Europe). Technical reports are public, signed by a qualified/competent person, and are the primary input to NAV. |
|
||||
| Government take | Royalty (iron ore 15% ad valorem, coal 14%), DMF (10–30% of royalty), NMET (2%), GST compensation cess on coal (Rs 400/t), plus auction premium on post-2015 blocks that can exceed 100% of IBM ASP. Can exceed 45–60% of gross revenue on an aggressively bid block. | State/provincial royalties, resource-rent taxes (e.g. Australia), free-carry and state participation in some jurisdictions. Typically 5–15% of revenue plus corporate tax. |
|
||||
| Pricing conventions | Steel quoted in Rs/tonne on import parity; coal on FSA notified price plus e-auction premium; iron ore on IBM notified average sale price for royalty and on domestic/seaborne benchmarks for sales. Figures in crore/lakh — convert consistently and state the unit. | LME/COMEX/SHFE for base and precious metals; Platts/Argus 62% Fe CFR China for iron ore; Newcastle/API indices for coal; USD per tonne, pound or ounce. |
|
||||
| Currency | Most commodity prices are dollar-linked while a large part of the cost base is rupee-denominated, so INR depreciation is usually EBITDA-accretive for exporters and import-competing producers — but it inflates USD-denominated debt. Model both legs. | Local-currency cost base against USD revenue is the same structure in Australia, Brazil, South Africa and Chile — the AUD/BRL/ZAR/CLP effect is a standard part of cost-curve analysis. |
|
||||
| Ownership and governance | Promoter and government holding matter: check pledge levels, related-party off-take and marketing arrangements, brand/management fees to unlisted parents, and minority protection in listed subsidiaries. PSU miners carry administered pricing, disinvestment overhang and social obligations. | Widely held; the governance issues are different — dual-class structures, state golden shares in some jurisdictions, and controlling-family stakes in a few majors. |
|
||||
| Disclosure venues | Concall transcripts and quarterly investor presentations carry volume, realisation, cost and integration detail that never appears in the financials. Annual report notes carry royalty, DMF, stripping policy and closure provisions. CARO reporting flags statutory dues and related-party issues. | 10-K MD&A and segment notes, quarterly production reports, technical reports on SEDAR/ASX/EDGAR, and reserve tables under SK-1300. Sell-side publishes explicit commodity price decks. |
|
||||
| Valuation practice | Mid-cycle EV/EBITDA, EBITDA/t × capacity, EV per tonne of capacity against replacement cost, SOTP for conglomerates. P/NAV used for only a handful of names. | P/NAV leads, especially in Canada/Australia; EV/EBITDA on consensus deck as cross-check; EV per reserve unit for developers. |
|
||||
| Accounting detail | Ind AS mirrors IFRS, including IFRIC 20 on stripping and IFRS 16 leases. Watch for capitalisation policy differences on exploration and on pre-production revenue. | IFRS filers similar. **US GAAP differs**: no IFRIC 20 equivalent (US practice generally expenses post-production stripping), different impairment reversal rules (IFRS permits reversal, US GAAP does not), and successful-efforts vs full-cost choices. Do not compare capitalised-stripping-adjusted cost between a US GAAP and an IFRS filer without adjusting. |
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] State where you believe the commodity is in its cycle, and on what evidence — do not quote a single ratio before doing this.
|
||||
- [ ] Suppress trailing P/E, or report it only alongside mid-cycle normalised EPS; never call a 4x peak-earnings P/E cheap.
|
||||
- [ ] Replace OPM with unit cash cost (C1 / AISC) and the company's **quartile on the global cost curve**.
|
||||
- [ ] Compute EBITDA per tonne/ounce by product and compare to the company's own 10-year mean and to peers at the same realised price.
|
||||
- [ ] Decompose revenue growth into price and **saleable volume**; report volume growth separately.
|
||||
- [ ] Check reserve life (R/P), 3-year reserve replacement ratio, and whether reserves were added by drilling or by assumption changes.
|
||||
- [ ] Compare mined grade to reserve grade and current strip ratio to LoM average across several periods — this is the high-grading test.
|
||||
- [ ] Split capex into sustaining vs growth; check sustaining capex against DD&A and against capitalised stripping.
|
||||
- [ ] Compute all-in cash break-even price and compare with spot and with the 90th-percentile marginal industry cost.
|
||||
- [ ] Test leverage against **trough** EBITDA, not trailing; include leases, hybrids, ARO and (India) auction-premium/DMF commitments in net debt.
|
||||
- [ ] Map the debt maturity profile against the break-even price — flag any wall inside 24 months.
|
||||
- [ ] Quantify integration (captive ore, coal, bauxite, power) and verify it is long-dated and cleared, not an MoU.
|
||||
- [ ] Compute total government take as % of revenue; for Indian post-2015 blocks, pull the auction premium % on every block.
|
||||
- [ ] Check realised price versus benchmark and explain any widening discount.
|
||||
- [ ] Compute FCF yield at spot **and** at mid-cycle; build the EBITDA sensitivity per unit price and per unit FX move.
|
||||
- [ ] Compute mid-cycle ROCE and compare with the ~8–10% real WACC used for base-metal projects.
|
||||
- [ ] Review closure/rehab provisions (discount rate, escalation, funding) and the tailings inventory with GISTM status.
|
||||
- [ ] Check by-product credit dependence and whether cost is presented net or on a co-product basis.
|
||||
- [ ] Value on mid-cycle EV/EBITDA and, where technical reports exist, a finite life-of-mine NAV with **no perpetual terminal value**.
|
||||
- [ ] Cross-check against EV per tonne of installed capacity versus greenfield/brownfield replacement cost.
|
||||
- [ ] Apply SOTP with an explicit holding-company discount for diversified or holding structures.
|
||||
- [ ] Build the peer set on cost quartile, commodity, integration and jurisdiction — never on the "metals" label alone.
|
||||
- [ ] Scan for peak-cycle M&A or greenfield sanction, definitional changes to cost metrics, and serial "exceptionals".
|
||||
- [ ] India: check promoter pledge, related-party off-take/marketing, lease expiry dates, and clearance status (Stage-I vs Stage-II).
|
||||
- [ ] Present the conclusion as a bear/mid/bull range across a price deck, not as a single target price.
|
||||
|
|
@ -0,0 +1,194 @@
|
|||
# Mortgage REITs, BDCs, equipment lessors and specialty finance — sector playbook
|
||||
|
||||
Use this when: the company's economic engine is a **leveraged portfolio of financial assets or leased hardware**, not an operating business — US agency and hybrid mortgage REITs (mREITs), commercial mortgage REITs, business development companies and listed private-credit vehicles, listed credit funds and CLO equity vehicles, aircraft/container/railcar/energy-equipment lessors, and Indian equipment-rental, leasing and asset-financing companies that sit outside the conventional NBFC lending frame.
|
||||
|
||||
These businesses are routinely mis-routed, and the mis-route is catastrophic rather than merely imprecise. A mortgage REIT has the word "REIT" in its name and owns **no buildings** — occupancy, WALE, same-store NOI, AFFO, cap-rate spread and rent reversion are not "less relevant" here, they are undefined. It is a levered agency/non-agency MBS book funded overnight in the repo market. A BDC looks like an asset manager but is a levered senior-loan portfolio with a mark-to-model NAV. An equipment lessor looks like an industrial but earns a spread between funding cost and lease yield, plus a residual-value bet.
|
||||
|
||||
Three facts govern everything below. **Borrowings are the raw material**, so every enterprise-value construct is meaningless. **Reported earnings are dominated by marks and hedges**, so P/E is noise and book value is the anchor. And **the dividend is usually the reason the stock is owned**, so dividend coverage by a properly defined economic earnings measure — not by GAAP EPS — is the central analytical question.
|
||||
|
||||
**Routing:** if the entity originates and holds whole loans on its own balance sheet as its main business (NBFC, HFC, gold-loan, MFI, consumer lender), use `references/sectors/nbfc.md`. If it takes deposits, use `references/sectors/banks.md`. If it owns and leases **real property** and collects rent, use `references/sectors/realestate-reit.md`. If it manages third-party capital for fees rather than deploying its own balance sheet, use `references/sectors/holdco-assetmgr.md`.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Do not compute these. If a screener hands them to you, report them as inapplicable rather than reporting them with a caveat — a printed number gets used.
|
||||
|
||||
**Every equity-REIT metric, for a mortgage REIT — undefined, and the most damaging error in this playbook's scope.** Occupancy, WALE / WAULT, same-store NOI, rent per square foot, releasing spreads, cap rate, NAV-per-square-foot, development pipeline, AFFO and even FFO have no referent: there is no property, no tenant, no lease and no depreciation of a building. FFO exists to add back depreciation on appreciating real assets; an mREIT holds securities carried at fair value with no meaningful depreciation, so an "AFFO" figure computed for one is a fabricated number. A commercial mortgage REIT lends *against* buildings — the buildings are collateral inside someone else's balance sheet, and cap-rate movement matters only through loan-to-value and loss severity, never as a valuation multiple applied to this company.
|
||||
|
||||
**EV, EV/EBITDA, EV/Sales, net debt, Debt/EBITDA — undefined and never used.** Enterprise value assumes debt is financing you can strip out to see the operating asset underneath. Here the borrowings *buy the assets that generate the return*: repo funds the MBS, the credit facility funds the loan portfolio, the ABS funds the fleet. Subtracting "net cash" removes the liquidity buffer that determines survival; adding debt to market cap double-counts the asset side. For lessors specifically, EV/EBITDA is superficially computable and therefore especially dangerous — EBITDA excludes both depreciation (the actual consumption of the leased asset) and interest (the actual cost of the raw material), which between them are most of the cost base. A lessor's "EBITDA margin" of 80–90% is an accounting artefact, not a moat.
|
||||
|
||||
**D/E, gearing and interest coverage — mis-signed.** Agency mREITs run 6–9x debt/equity **by design**, and a well-run one deleveraging to 4x may be signalling stress, not prudence. Hybrid and credit mREITs run 1–4x; BDCs are capped near 2:1 by statute in the US; lessors run 2–4x. A generic "D/E above 2 is risky" screen rejects the entire sector's healthiest names and passes the impaired ones. Interest coverage is nearly meaningless when interest expense is the cost of goods sold — though for lessors and BDCs a fixed-charge coverage or asset-coverage ratio *does* bind contractually, so read the covenant, not the textbook.
|
||||
|
||||
**OPM, gross margin, EBITDA margin, ROCE, asset turnover — meaningless.** There is no COGS and no unit of output. "Capital employed" would include every repo line. Asset turnover collapses to portfolio yield, which is measured directly and better. For a BDC, "revenue" is total investment income, which is just yield × assets — a margin on it tells you only the fee and leverage structure.
|
||||
|
||||
**Free cash flow and FCF yield — noise, and frequently inverted.** Cash flow is dominated by portfolio purchases, paydowns, repo rollovers and fleet capex. A growing lessor buying equipment shows deeply negative FCF; a shrinking one liquidating its fleet shows strongly positive FCF at the exact moment its earning base is disappearing. Operating and financing flows cannot be cleanly separated, so no FCFF/WACC model can be built.
|
||||
|
||||
**P/E on reported EPS — noise, and often perversely signed.** GAAP net income for an mREIT includes unrealised marks on securities and on hedges, which frequently move in opposite directions and can swamp the actual spread income; a quarter with a large derivative gain can show enormous "EPS" while book value fell. BDC GAAP EPS mixes net investment income with unrealised depreciation. Use net interest spread / EAD / distributable earnings for mREITs, NII for BDCs, and always cross-read against book value change.
|
||||
|
||||
**Current ratio, quick ratio, working capital, inventory and receivable days, cash conversion cycle — undefined.** These balance sheets are portfolios, not classified current/non-current in any economically meaningful way. Liquidity here means unencumbered assets, undrawn facilities and days of margin-call capacity.
|
||||
|
||||
**Dividend yield read as a quality signal — inverted.** A 15%+ headline yield in this sector is a market forecast of a dividend cut and/or book-value erosion, not a bargain. Yield is an output of price falling, and price falls here almost always because book value fell or coverage broke.
|
||||
|
||||
**"Growth in AUM/portfolio" as an unqualified positive — inverted.** Portfolio growth funded by issuing equity **below** book value or NAV is per-share value destruction dressed as scale. Always convert to per-share terms.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, sub-sector, rate and credit cycle, and by period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set and against the company's own 5–10 year history overrides every absolute band below. Metrics marked (M) are mortgage-REIT, (B) BDC/private credit, (L) lessor; unmarked ones apply across all three.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Book value per share (BVPS) / NAV per share** | (M) Shareholders' equity less preferred liquidation preference, ÷ common shares. (B) Net assets ÷ shares, struck quarterly by the board using ASC 820 fair value. (L) Book equity per share, plus a separate estimate of fleet market value vs carrying value. | Not a level — a *trajectory*. Flat-to-rising BVPS across a full rate cycle is the mark of a well-hedged mREIT; a 30–50% multi-year decline is common among the weak ones. | This is the entire foundation. It is the denominator of the primary multiple, the base for economic return, and the thing that is silently destroyed while the dividend keeps being paid. Always adjust for share issuance and buybacks — aggregate equity growth from serial ATM issuance conceals falling BVPS. |
|
||||
| **Economic return on book value** | (Change in BVPS over the period + dividends declared per share) ÷ opening BVPS, annualised. The sector's single most important number. | Roughly 8–14% through a cycle for an agency mREIT; a negative economic return in any year where credit did not blow up means the hedge or leverage decision failed. | Dividends paid out of returned capital are not income. A company can pay a 14% yield while book falls 18% — the shareholder's economic return is negative and the "yield" was a partial liquidation. This metric is the only honest way to score management, and it is the correct thing to rank on, never dividend yield. |
|
||||
| **Net interest spread and net interest margin (M)** | Weighted average asset yield − weighted average cost of funds (including the effect of interest-rate swaps). NIM = net interest income ÷ average interest-earning assets. | Agency spread roughly 1.0–2.0%; NIM on levered equity is spread × leverage plus unlevered yield. Direction and *composition* matter more than level. | The engine. A widening spread driven by cheaper repo is durable; one driven by buying lower-coupon, longer-duration paper is a duration bet in disguise. Always check whether swap costs are inside the reported spread or presented below it — presentation differs across companies and is a common comparability trap. |
|
||||
| **Leverage: debt/equity and economic leverage (M, B, L)** | (M) Repo + other borrowings ÷ total equity; *economic* leverage adds the notional of TBA dollar-roll positions, which are off-balance-sheet long exposure. (B) Debt ÷ net assets, against the statutory cap. (L) Net debt ÷ tangible equity, plus off-balance-sheet lease commitments. | Agency mREIT 6–9x; hybrid/credit mREIT 1–4x; BDC 0.9–1.25x typical against a 2.0x US regulatory ceiling; lessors 2–4x. | Leverage is the business model, but it is also the mechanism of ruin. Compare *economic* leverage, not stated: a company at 6x stated and 8.5x economic via TBAs is not comparable to a peer at 6x with no TBA book. A BDC operating at 1.5x+ has little room before a mark-driven covenant breach forces asset sales into a falling market. |
|
||||
| **Funding profile: repo mix, tenor and haircuts (M)** | % of borrowings in repo, weighted average days to maturity, number and concentration of counterparties, haircut by collateral type (agency vs non-agency vs whole loan), and unencumbered assets as % of equity. | Agency haircuts typically 3–5%; non-agency and credit collateral 15–30%+. Weighted average repo tenor of 30–90 days is normal; concentration in the top 3 counterparties well under half the book. | This is how mREITs die — not from credit, but overnight. Repo is short-dated and haircuts widen exactly when marks fall, so a price decline triggers margin calls, forced sales, further price declines. Every mREIT failure in March 2020 followed this sequence, and the ones that survived were the ones with unencumbered liquidity and agency-only collateral. |
|
||||
| **Duration gap and convexity (M)** | Asset duration − liability-plus-hedge duration, in years. Read with the disclosed rate-shock table (BVPS change for ±25/50/100 bps). | Duration gap typically within ±1.0 year; a ±100 bp shock moving book value more than 8–12% signals an unhedged rate bet. | Tells you how much of the equity is a bet on rates rather than on spread capture. Negative convexity is the specific curse of MBS: when rates fall, borrowers refinance and the asset shortens; when rates rise, prepayments stop and the asset extends — the portfolio lengthens exactly when duration is most painful. |
|
||||
| **Hedge ratio and hedge composition (M)** | Notional of interest-rate hedges ÷ repo and other rate-sensitive borrowings; split into swaps, futures, swaptions, TBA shorts. | 70–100% is typical for a fully hedged agency book. Sudden moves in this ratio are management taking a view. | A falling hedge ratio into a hiking cycle is the classic setup for book-value destruction. Also check *what* is hedged: hedging the funding leg does nothing about spread widening, which is a separate and often larger risk. Post-LIBOR, most books are SOFR-based — confirm the transition is complete and basis risk is disclosed. |
|
||||
| **Prepayment speed (CPR) and extension risk (M)** | Constant prepayment rate, annualised % of principal prepaying. Read with weighted average coupon, loan age, and the premium/discount to par at which assets are carried. | Highly regime-dependent: single-digit CPR in a high-rate, out-of-the-money regime; 20–40%+ in a refi wave. What matters is CPR *versus what the carrying premium assumes*. | Premium-priced MBS amortise faster than expected when CPR spikes, destroying yield and book value; discount-priced MBS suffer when CPR collapses and the expected pull-to-par is deferred. Specified pools and loan-balance stories exist precisely to buy prepayment protection — check whether the company is paying up for it and whether the protection is actually delivering. |
|
||||
| **Agency vs credit exposure (M)** | % of portfolio in agency (Fannie/Freddie/Ginnie-guaranteed) vs non-agency RMBS/CMBS, credit risk transfer, whole loans, mezzanine and bridge loans. For commercial mREITs: loan-to-value distribution, watchlist/risk-rated 4–5 loans, CECL reserve as % of loans, and office concentration. | Agency-only books have essentially no credit risk and pure rate/spread/prepay risk. Credit books need loss estimates. Watchlist loans <5% of the book and not rising. | These are two entirely different businesses sharing a label. An agency book's risk is duration and repo; a credit book's risk is default and severity, with far lower leverage and far wider funding haircuts. Never place them in the same peer scatter. |
|
||||
| **Dividend coverage by economic earnings** | (M) Earnings available for distribution (EAD) / distributable earnings / "core EPS" ÷ dividend per share — *and* recompute it yourself, since these are non-GAAP measures the company defines. (B) Net investment income per share ÷ dividend per share. | Coverage ≥1.0x sustained; 0.9–1.0x is a warning; below 0.9x for two or more quarters usually precedes a cut. | The dividend is the thesis for most holders of these securities, and it is the last thing management cuts. Scrutinise the non-GAAP bridge: excluding "realised losses on terminated swaps" or capitalising origination costs can turn uncovered into covered. Check whether the payout is being funded by return of capital — the tax character disclosed on the US Form 1099-DIV or in the annual distribution statement tells you directly. |
|
||||
| **Non-accruals (B)** | Investments on non-accrual, expressed both at **cost** and at **fair value**, as % of the portfolio. Always take both. | Under 1–2% at fair value is clean; above 3–4% at cost, or a widening cost-vs-fair-value gap, indicates real deterioration. | The core asset-quality metric for private credit. The gap between the two measures is itself the signal: non-accruals at 5% of cost but 2% of fair value means the marks have already absorbed roughly 60% severity. A company quoting only the fair-value number is presenting the flattering half. |
|
||||
| **PIK income as % of total investment income (B)** | Payment-in-kind interest (accrued, not received in cash) ÷ total investment income. Track the trend and split "structural" PIK (agreed at origination) from "amendment" PIK (granted to a struggling borrower). | Below 5–8% is normal; above 10–15% and rising is a serious quality tell. | The highest-signal quality metric in private credit. PIK is income you have booked but not collected; a borrower converted to PIK is a borrower that cannot pay cash. It flatters NII and therefore dividend coverage while the underlying credit degrades, and it typically appears one to three quarters before non-accruals rise. |
|
||||
| **Portfolio yield vs cost of debt, and first-lien mix (B)** | Weighted average yield on debt investments at cost and at fair value; weighted average interest rate on borrowings; % first-lien senior secured; % unitranche; % equity and junior positions; average EBITDA of portfolio companies; weighted average interest coverage of borrowers. | Spread of 400–700 bps over cost of debt typical. First lien >70–80% for a conservatively positioned BDC. Borrower interest coverage below ~1.5x across a large share of the book is a stress signal. | Yield without a corresponding funding cost tells you nothing about earnings power. A rising portfolio yield that comes from moving down the capital structure or into smaller borrowers is rented, not earned. Borrower-level interest coverage is the closest thing to a leading indicator of the next non-accrual wave. |
|
||||
| **Fee structure and external management drag (B, M)** | Base management fee as % of gross (not net) assets, incentive fee rate and hurdle, whether there is a total-return hurdle with a lookback, and fee waivers with expiry dates. Express total fees as % of average net assets and as % of gross investment income. | Base 1.0–1.5% of gross assets, incentive 15–20% over a ~6–8% hurdle, is the common shape. Total fee load above ~3% of net assets is a heavy drag. | Externally managed vehicles have a structural conflict: a fee on *gross* assets rewards raising and levering capital regardless of per-share returns. This is the mechanism behind dilutive issuance below NAV. A fee waiver supporting current dividend coverage is a temporary subsidy with a known expiry — model the cliff. |
|
||||
| **Spillover / undistributed taxable income (B, M)** | Taxable income earned but not yet distributed, per share. Disclosed by US RICs and REITs. | One to two quarters of dividends of spillover is a healthy cushion. Falling spillover with flat dividends means the buffer is being spent. | The shock absorber that lets a vehicle maintain its dividend through a weak quarter. Its depletion is an early, quantitative warning of a cut — visible before coverage formally breaks. |
|
||||
| **Fleet age, utilisation and lease yield (L)** | Average fleet age vs economic life; **time utilisation** (units on hire ÷ units available) and **dollar utilisation** (rental revenue ÷ original equipment cost); lease yield = lease revenue ÷ net book value of equipment on lease; average remaining lease term. | Time utilisation 85–95% strong for aircraft/containers, 65–80% typical for general equipment rental; dollar utilisation trends matter more than the absolute. Fleet age well inside economic life. | Time utilisation tells you whether the assets are working; dollar utilisation tells you whether they are working *at a price*. The two diverge exactly when pricing is deteriorating but management keeps units on hire by cutting rates — high time utilisation with falling dollar utilisation is the classic pre-downturn configuration. An ageing fleet is deferred capex and a future residual-value problem. |
|
||||
| **Residual value realisation and gain/loss on disposal (L)** | Proceeds on sale of off-lease equipment vs net book value, as a %, tracked over 3–5 years; disposal gains as % of pre-tax profit; the depreciation policy's assumed residual and useful life vs peers. | Disposal gains a modest and stable share of profit — persistently above ~20–25% of pre-tax profit means earnings depend on selling the fleet. | The lessor's central hidden bet. Optimistic residual assumptions understate depreciation and overstate current profit for years before the truth arrives at disposal. Consistent gains on sale mean the fleet is conservatively depreciated (a hidden reserve); losses mean the book is overstated and impairments are coming. Changes to useful-life or residual assumptions are a first-order earnings-quality event — always find the note. |
|
||||
| **Funding cost, mix and maturity ladder (L, B)** | Weighted average cost of debt; split secured/ABS vs unsecured bonds vs bank revolver; fixed vs floating; debt maturities by year against lease cash inflows; % of assets encumbered. | Debt maturity profile matched to lease term; a large unencumbered asset pool; no single year holding an outsized share of maturities. | Borrowing short to lease long is the sector's recurring failure mode. An asset–liability maturity mismatch converts a funding-market closure into an insolvency. Rising encumbrance means the unsecured lenders are being structurally subordinated — usually the first visible sign of funding stress. |
|
||||
| **Credit losses on lessees / receivables (L)** | Provision for doubtful lease receivables ÷ average lease receivables; ageing of receivables; concentration of the top 5–10 lessees; exposure to lessees in a single sector or country. | Loss rates in the low tens of basis points for investment-grade lessee books; higher for SME rental. Top-10 lessee concentration well under half of revenue. | A lessor is a lender whose collateral it already owns — which helps on severity but not on the earnings hole from an unexpected off-lease unit. Lessee concentration turns one airline or one shipping-line failure into a capital event, and repossession across jurisdictions is slow and expensive. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
Value the **equity directly, against the asset base it owns**. Every enterprise-value method is structurally inapplicable, and every earnings multiple applied to mark-driven profit is noise.
|
||||
|
||||
**Primary for mREITs and BDCs — price-to-book / price-to-NAV, regressed against sustainable ROE.** These are portfolios of financial assets carried close to fair value, so book value is a genuine estimate of what the equity owns, not a historic-cost relic. The multiple is not a free parameter — it follows the same warranted-multiple logic used for banks:
|
||||
|
||||
> **Justified P/B = (sustainable ROE − g) ÷ (COE − g)**
|
||||
|
||||
In practice, run a cross-sectional scatter of P/B against economic return on equity (mREITs) or against NII return on NAV net of fees (BDCs) across a tight peer set, and explain the residual with hedge discipline, funding quality, non-accrual history, fee load and management track record. A persistent discount to book is usually the market pricing (a) future book erosion, (b) the fee drag of external management, or (c) disbelief in the marks — decide which before calling it cheap.
|
||||
|
||||
**Adjusted book value.** For credit mREITs and BDCs, reported book contains marks you may not accept. Re-strike NAV by: haircutting level-3 assets to observable proxies where they exist; applying your own severity to non-accruals and watchlist loans; deducting the capitalised value of any fee-waiver subsidy; and deducting preferred stock at liquidation preference, not carrying value. Two vehicles at 0.85x reported NAV can be at 0.80x and 1.05x adjusted.
|
||||
|
||||
**Mark observability is a valuation input, not a footnote.** Agency MBS are level 1/2 with deep, screen-quoted markets — the book value is close to a fact. Non-agency, whole loans, bridge loans and BDC private credit are level 3, valued by model or by a third-party valuation firm engaged by the manager. Report the level-1/2/3 split explicitly and apply a wider valuation range to level-3-heavy books. A vehicle whose marks barely moved through a quarter when public credit spreads widened 100 bps is telling you the marks are stale, not that the portfolio is resilient.
|
||||
|
||||
**Dividend discount models — appropriate here, with care.** These are pass-through vehicles by construction (US REITs and RICs must distribute the large majority of taxable income), so a DDM is one of the few cash-flow models that genuinely fits. Use a *sustainable* dividend — coverage-adjusted, with the fee waiver removed and PIK income excluded — not the trailing declared one.
|
||||
|
||||
**Lessors — NAV / replacement-value based.** Build a fleet NAV: independent appraised or market value of the equipment by type and vintage, less net debt, less lease-liability and maintenance obligations, plus the value of the contracted lease book. Cross-check against price-to-tangible book, and against the private-market transaction values for comparable assets (aircraft and container sale-leaseback pricing is observable). Replacement cost matters because new-build cost sets the ceiling on lease rates: when equipment prices rise, an existing fleet is worth more and lease rates follow. For lessors with a genuine operating-services business bolted on, value that separately on operating metrics and sum the parts.
|
||||
|
||||
**Cross-checks.** Economic return on book over 3, 5 and 10 years versus the sector — the cleanest management scorecard available. Dividend coverage by EAD or NII. Implied credit loss: solve for the cumulative portfolio loss rate the current price implies and test it against the vehicle's own worst historical experience. For lessors, implied residual value: solve for the disposal proceeds assumption embedded in today's price.
|
||||
|
||||
**Do not use:** EV/EBITDA, EV/Sales, EV/EBIT, net debt or Debt/EBITDA, FCF yield, any WACC-discounted enterprise cash-flow model, P/E on reported GAAP EPS, PEG, and — for mortgage REITs — FFO, AFFO, cap rates, NOI multiples or any per-square-foot measure.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares the **asset class, funding model, leverage regime and management structure**. The label "REIT", "credit fund" or "leasing company" is not a peer set.
|
||||
|
||||
**Splits that must never be mixed:**
|
||||
|
||||
- **Mortgage REITs vs equity REITs.** Different assets, different risks, different metrics, different multiples. This is the primary mis-route this playbook exists to prevent. They share only a tax regime.
|
||||
- **Agency mREITs vs credit/hybrid mREITs vs commercial mREITs.** Agency: 6–9x leverage, no credit risk, rate and prepayment risk. Credit/hybrid: 1–4x, real default risk, wider haircuts. Commercial: originating balance-sheet loans against buildings, CECL reserving, office and construction concentration. Three distinct businesses; a common P/B scatter across them is meaningless.
|
||||
- **BDCs vs equity/venture asset managers vs banks.** A BDC deploys its own balance sheet; a manager earns fees on other people's capital and belongs in `holdco-assetmgr.md`.
|
||||
- **Internally vs externally managed vehicles.** The fee drag is worth a large and persistent multiple gap. Never explain that gap away as "cheapness".
|
||||
- **Upper-middle-market vs lower-middle-market BDCs.** Borrower EBITDA size drives loss severity, covenant quality and yield; a $100m-EBITDA-borrower book and a $15m one have different loss distributions at the same stated yield.
|
||||
- **First-lien senior-secured BDCs vs junior/mezzanine/CLO-equity vehicles.** Same wrapper, opposite position in the waterfall.
|
||||
- **Long-lived asset lessors (aircraft, rail, containers, marine) vs short-cycle rental (general equipment, construction, industrial tools).** Long-lived: 10–25 year assets, contracted lease terms, residual bets over decades, capital-markets funded. Short-cycle: 3–8 year assets, day/week rate exposure, utilisation-driven, priced off construction activity. Different volatility, different multiples.
|
||||
- **Operating lessors vs finance lessors.** An operating lessor holds residual risk on its balance sheet; a finance lessor has effectively made a loan and belongs closer to `nbfc.md`. The accounting differs (Ind-AS 116 / IFRS 16 / ASC 842) and so does the risk.
|
||||
- **Listed BDC vs non-traded/perpetual private BDC.** Non-traded vehicles have different fee structures, redemption gates and NAV-striking processes; their marks are not disciplined by a traded price.
|
||||
|
||||
**Also align:** rate and credit regime (a 2021 comparison against a 2024 one compares different worlds); accounting regime (US GAAP with CECL vs IFRS 9 vs Ind-AS); fiscal year end; leverage policy as *stated by management*, not just as observed; hedging philosophy; and size, since scale drives repo access, unsecured bond market access and funding cost directly.
|
||||
|
||||
Aim for 5–8 peers. State the basis explicitly, and benchmark every metric twice — against peers *and* against the company's own record through at least one full rate or credit cycle.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Dividend maintained while book value per share erodes.** The defining pathology of the sector. A stable dividend and a falling BVPS means capital is being returned and called income. Compute economic return on book: if it is below the dividend yield, the payout is partially a liquidation.
|
||||
- **Equity issued below book value or NAV.** Immediately and permanently dilutive to BVPS, and the standard behaviour of externally managed vehicles paid on gross assets. Check every ATM programme and follow-on against the prevailing P/B. US BDCs generally require shareholder approval to issue below NAV — watch for that proposal appearing on the proxy, it is a statement about management's intent.
|
||||
- **Rising PIK share of investment income (BDC).** Booked but uncollected. Separate amendment PIK from structural PIK; a jump in amendment PIK is borrowers being restructured quietly. It flatters NII and dividend coverage precisely while credit deteriorates.
|
||||
- **Non-accruals disclosed only at fair value, or the definition changing.** Demand both cost and fair-value measures. A widening gap is severity already taken; a narrowing gap with rising cost-basis non-accruals is marks that have not caught up.
|
||||
- **Restructurings that reset the clock.** Amend-and-extend, covenant holidays, converting cash interest to PIK, or moving a loan into a joint venture or unconsolidated vehicle so it leaves the non-accrual line. The private-credit analogue of bank evergreening.
|
||||
- **Non-GAAP earnings definitions that change, or that exclude recurring items.** "Distributable earnings", "core EPS" and "earnings available for distribution" are company-defined. If the definition changed in the period where coverage would otherwise have broken, that is the finding. Rebuild it yourself from the income statement every time.
|
||||
- **Falling hedge ratio, lengthening duration gap, or a hedge book concentrated in short-dated instruments rolled quarterly.** Management taking an undisclosed rate view with shareholder book value. The disclosed rate-shock table is the check.
|
||||
- **Repo concentration, shortening tenor, or rising haircuts.** Fewer counterparties, more overnight funding, more encumbered assets, shrinking unrestricted cash. This is the pre-margin-call configuration; it develops over weeks, not years.
|
||||
- **Leverage rising into a spread-widening environment.** Buying more of an asset whose price is falling, funded by borrowings whose haircuts are rising, is how forced sellers are created.
|
||||
- **Level-3 marks that do not move when observable markets do.** Compare the reported mark trajectory against public credit indices or agency MBS spreads. Stale marks are a solvency question, not a presentation quibble.
|
||||
- **Third-party valuation coverage narrowed.** BDCs disclose what proportion of the portfolio was reviewed by an independent valuation firm. A falling proportion, or a change of valuation provider, deserves an explanation.
|
||||
- **Fee waivers supporting dividend coverage, with a stated expiry.** Model the post-waiver quarter explicitly. Also watch incentive fees accrued on unrealised gains that later reverse without clawback.
|
||||
- **Realised losses persistently exceeding unrealised write-ups (BDC).** The marks were optimistic and are being validated downward at exit. Track cumulative realised vs unrealised over 5 years — this is the single best test of whether a manager's NAV is honest.
|
||||
- **Lessor: depreciation policy changes, extended useful lives, raised residual assumptions.** Boosts current profit and defers a loss to disposal. Also watch for impairments concentrated in one "clean-up" year.
|
||||
- **Lessor: disposal gains carrying an outsized share of pre-tax profit,** or a fleet being sold faster than it is replaced. Earnings from shrinking the earning base.
|
||||
- **Lessor: high time utilisation with falling dollar utilisation,** or lease renewals repeatedly at rates below expiring ones. Volume held by price concession.
|
||||
- **Concentration.** Top-5 lessee, top-5 borrower or top-3 repo counterparty concentration. In this sector one counterparty failure is a capital event, not a bad quarter.
|
||||
- **Related-party and affiliate transactions.** Assets bought from or sold to an affiliate of the external manager, co-investments alongside manager-affiliated funds, or servicing paid to a related entity. Read the related-party note in full, every year.
|
||||
- **A structurally wide discount to book that never closes.** Often correct: the market is saying it does not believe the NAV, or that the fee load consumes the return. Do not treat persistent 0.6–0.7x P/B as automatic upside without identifying what would change.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Rates drive mREITs; credit drives BDCs; capex and asset prices drive lessors.** Get the dominant driver right before scoring anything else.
|
||||
|
||||
**The rate cycle.** Rising short rates lift repo cost immediately while asset yields reprice slowly, compressing spread; the hedge book is what determines whether book value survives. Curve shape matters directly — an inverted curve is structurally hostile to a borrow-short-lend-long model, and steepening is the sector's classic recovery trade. Falling rates trigger refinancing waves: premium MBS prepay away and reinvestment happens at lower yields, so a rate cut is not unambiguously good news. Spread widening independent of rates (2020, 2022) hits book value even in a fully rate-hedged agency book, which is why spread duration must be tracked separately from rate duration.
|
||||
|
||||
**The credit cycle.** Private credit deteriorates with a long lag and in a specific sequence: borrower interest coverage falls, then amendment PIK rises, then watchlist ratings migrate, then non-accruals appear, then realised losses print. By the time non-accruals are visible the underwriting decision was made two to four years earlier. Floating-rate BDC books gain yield when rates rise but simultaneously squeeze borrower coverage — the yield benefit and the credit damage arrive from the same event, and analysts routinely score only the first.
|
||||
|
||||
**The equipment cycle.** Utilisation and lease rates are pro-cyclical and track construction, freight, air traffic or industrial capex. New-build supply is the swing variable and has long lead times, so gluts persist. Residual values are correlated with new equipment prices, so an inflationary period lifts used values and flatters disposal gains — a transient benefit that reverses. Sale-leaseback volume is a useful read on how tight financing conditions are for the lessee industry.
|
||||
|
||||
**Funding-market access is the survival variable in all three.** These vehicles cannot function without continuous access to repo, ABS, revolvers or unsecured bonds. Every crisis in this sector — 2008, March 2020, the 2022 UK LDI episode's second-order effects — was a funding event that became a solvency event through forced selling. Score unencumbered liquidity, undrawn committed facilities and the maturity ladder as risk metrics of first order.
|
||||
|
||||
**Structural shifts to weigh explicitly.** Private credit's decade-long expansion has compressed spreads and loosened documentation (covenant-lite is now the norm in the upper middle market), so today's yields are being earned on weaker structures than a decade ago — the loss experience of the last cycle is not a good guide. Non-traded perpetual BDCs have absorbed enormous retail inflows, changing both competition for deals and redemption dynamics. Bank retrenchment under Basel III endgame keeps pushing assets toward non-bank balance sheets. For mREITs, the Fed's balance-sheet trajectory sets agency MBS spreads directly. For lessors, fleet electrification and emissions rules create a new class of technological obsolescence risk in residual values.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
The mortgage-REIT and BDC structures are essentially **absent from India**; the lessor and specialty-finance families are present but sit inside a different regulatory frame. Do not assume an Indian analogue exists — check the actual structure first.
|
||||
|
||||
| Dimension | India | US / global |
|
||||
|---|---|---|
|
||||
| Mortgage REIT equivalent | No listed mREIT structure. Indian REIT regulations (SEBI REIT Regulations, 2014) require at least 80% of value in **completed, rent-generating property** — a mortgage-securities vehicle cannot qualify. The closest analogues are HFCs, NBFC-MFIs and securitisation vehicles under RBI rules, which route to `nbfc.md`. RMBS is nascent; NHB refinance and direct assignment / PTC pools dominate | US mREITs elect REIT status under the Internal Revenue Code, distribute ≥90% of taxable income, file 10-K/10-Q with the SEC, and disclose repo, haircuts, duration gap and CPR in quantitative detail |
|
||||
| BDC equivalent | No BDC regime. Private credit reaches borrowers through Category II AIFs, NBFC-ICCs, ARCs and special-situation funds — mostly unlisted, so NAV, non-accruals and PIK disclosure are far thinner. Where a listed vehicle exists, treat it as an NBFC with a concentrated book | BDCs are regulated under the Investment Company Act of 1940, taxed as RICs, statutorily capped near 2:1 leverage (150% asset coverage after the 2018 change), must value the portfolio at fair value quarterly under board oversight, and file detailed schedules of investments naming every position |
|
||||
| Lessor / rental regime | Equipment financing largely through NBFC-AFCs (asset finance companies) under RBI scale-based regulation; growing construction-equipment and industrial rental, and a large aircraft-leasing push through **GIFT City IFSC** with IFSCA as regulator and tax incentives. Ind-AS 116 governs lease accounting | Aircraft, container, railcar and general-equipment lessors under IFRS 16 / ASC 842; Ireland and Singapore are the traditional aircraft-leasing hubs; appraised fleet values from recognised appraisers are a market standard |
|
||||
| Accounting | Ind-AS (IFRS-converged): Ind-AS 109 for ECL on financial assets, Ind-AS 116 for leases, Ind-AS 113 fair-value hierarchy. RBI provisioning norms run alongside Ind-AS for NBFCs, and the higher of the two applies via an impairment reserve | US GAAP with CECL for loans; ASC 820 fair-value hierarchy; fair-value option common in mREITs; IFRS 9 ECL elsewhere |
|
||||
| Regulators | RBI (NBFCs, securitisation, ARC), SEBI (REITs/InvITs, AIFs, listing and disclosure), IFSCA (GIFT City leasing and finance) | SEC (registration, 10-K, proxy, closed-end fund rules), Fed/FHFA (agency MBS market structure), FINRA for distribution |
|
||||
| Units and reporting | ₹ crore and lakh; fiscal year April–March; quarterly results plus investor presentation and concall — the concall is often the only source for utilisation, lease-rate and residual commentary | $ millions; calendar year common; 10-K/10-Q plus supplemental packages containing CPR, duration, haircuts, schedule of investments, non-accrual and PIK detail |
|
||||
| Ownership | Promoter holding, pledged-share disclosure and group-company exposure are central governance checks; related-party lending within a promoter group is a recurring failure mode | Widely held; the external manager relationship (and its ownership) is the equivalent governance focus |
|
||||
| Distribution rules | InvITs/REITs must distribute ≥90% of net distributable cash flows (SEBI); NBFCs have no such mandate and dividends are subject to RBI's dividend-payout criteria linked to CRAR and NPA levels | US REITs ≥90% of taxable income; RICs (including BDCs) ≥90% to avoid entity-level tax, with a separate 4% excise-tax calculation that drives spillover management |
|
||||
|
||||
**India-specific checks:** for an Indian leasing or asset-finance company, confirm whether it is an NBFC-AFC under RBI scale-based regulation (and therefore subject to RBI provisioning norms, CRAR requirements and dividend-payout eligibility criteria), or a pure operating-lease company outside it — the constraint set differs entirely. Check the Ind-AS 109 impairment reserve reconciliation. For GIFT City aircraft-leasing entities, understand which tax exemption is being relied on and its sunset date, because a large part of the reported return may be a time-limited fiscal benefit rather than operating economics.
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Confirm the family: mortgage REIT, BDC/private credit, or lessor — and confirm it is *not* an equity REIT, a deposit-taker or a fee-based asset manager. Route away if so.
|
||||
- [ ] For any mortgage REIT, state explicitly in the report that occupancy, WALE, same-store NOI, cap rates, FFO and AFFO are inapplicable, and why.
|
||||
- [ ] Delete EV/EBITDA, net debt, D/E-as-risk-score, ROCE, FCF yield, current ratio and reported P/E from the analysis; say why.
|
||||
- [ ] Compute economic return on book: (change in BVPS + dividends per share) ÷ opening BVPS, for each of the last 5–10 years.
|
||||
- [ ] Track BVPS/NAV per share, not aggregate equity; check every equity issuance against the prevailing P/B or P/NAV.
|
||||
- [ ] Rebuild dividend coverage yourself: EAD or core EPS (mREIT) / NII per share (BDC) ÷ dividend per share. Compare to the company's own non-GAAP definition and note any change to that definition.
|
||||
- [ ] Check the tax character of distributions — how much is return of capital?
|
||||
- [ ] mREIT: measure stated *and* economic leverage (include TBA notional); read the disclosed ±100 bp rate-shock table; compute the duration gap and hedge ratio.
|
||||
- [ ] mREIT: map repo tenor, counterparty concentration, haircuts by collateral type, and unencumbered assets as % of equity.
|
||||
- [ ] mREIT: check CPR against the portfolio's carrying premium/discount; assess extension risk and prepayment protection actually delivered.
|
||||
- [ ] mREIT: split agency vs credit exposure and never compare across that line.
|
||||
- [ ] BDC: take non-accruals at **both** cost and fair value; track the gap and the trend.
|
||||
- [ ] BDC: compute PIK as % of total investment income; split structural from amendment PIK.
|
||||
- [ ] BDC: check first-lien share, borrower EBITDA size, borrower interest coverage, portfolio yield vs cost of debt, and leverage against the statutory cap.
|
||||
- [ ] BDC: compare cumulative realised losses against cumulative unrealised write-ups over 5 years.
|
||||
- [ ] BDC/mREIT: quantify the fee load as % of net assets; identify any fee waiver and model its expiry; check internal vs external management.
|
||||
- [ ] Check spillover / undistributed taxable income and whether it is being depleted.
|
||||
- [ ] Report the level-1/2/3 fair-value split and test whether level-3 marks moved with observable markets.
|
||||
- [ ] Lessor: fleet size, age vs economic life, time utilisation *and* dollar utilisation, lease yield, average remaining lease term.
|
||||
- [ ] Lessor: 3–5 year history of disposal proceeds vs net book value; disposal gains as % of pre-tax profit; any change to useful life or residual assumptions.
|
||||
- [ ] Lessor: split maintenance capex from growth capex; confirm the fleet is being replaced, not run down.
|
||||
- [ ] Lessor: operating vs finance lease mix and the accounting treatment; lessee concentration and credit loss experience.
|
||||
- [ ] All: map the debt maturity ladder against asset cash flows; check encumbrance, undrawn committed facilities and unsecured market access.
|
||||
- [ ] Value on P/B vs sustainable ROE (mREIT, BDC) or fleet NAV / replacement value (lessor); re-strike an adjusted book with your own marks.
|
||||
- [ ] Run a DDM on a *sustainable* dividend, and a reverse test: what loss rate or residual value does today's price imply?
|
||||
- [ ] State where in the rate, credit and equipment cycle this sits, and what funding-market conditions are assumed.
|
||||
- [ ] Peer set: same asset family, leverage regime, capital-structure seniority, management structure and accounting regime — stated explicitly.
|
||||
- [ ] India: confirm the regulatory wrapper (NBFC-AFC under RBI, AIF under SEBI, IFSC entity under IFSCA) and whether any reported return is a time-limited tax benefit.
|
||||
178
finance/skills/stock-analysis/references/sectors/nbfc.md
Normal file
178
finance/skills/stock-analysis/references/sectors/nbfc.md
Normal file
|
|
@ -0,0 +1,178 @@
|
|||
# NBFCs, housing finance and non-bank lenders — sector playbook
|
||||
|
||||
Use this when: the company earns most of its income by lending its own balance sheet — NBFCs, HFCs, gold-loan and microfinance lenders, vehicle and CV financiers, LAP/SME lenders, consumer and fintech lenders, US/EU specialty finance, consumer and mortgage originators, BDCs and thrifts.
|
||||
|
||||
A lender's balance sheet *is* its product line. Money is the raw material, interest expense is cost of goods, and the loan book is inventory that can silently rot for 12–24 months before it shows up in any reported ratio. That single fact breaks the generic industrial ratio set at the definitional level — not at the "different benchmark" level — and it means the two things that actually kill lenders (funding and credit) are both largely invisible in the P&L until they are terminal. Analyse this sector as: margin (NIM) minus credit cost, on a funding base that must not run, on capital that must fund growth.
|
||||
|
||||
All ranges below are **indicative only**. They shift with the rate cycle, product mix, regulatory regime and country. A lender's own 5–10 year history and its closest sub-sector peers override every absolute band in this file.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Do not compute the following for a lender. If a screener or data provider hands them to you, discard them explicitly and say why.
|
||||
|
||||
**OPM / EBITDA margin / EV-EBITDA / EV-Sales — undefined in economic substance.** EBITDA adds back interest expense. For a lender, interest expense is the cost of raw material: money bought wholesale, sold retail. Adding it back produces a number with no meaning, and any "operating margin" computed on gross interest income is an artefact of leverage rather than efficiency. Equally, Enterprise Value is undefined: debt is operating float, not a claim to be netted against equity value. Never compute EV, net debt or EV/Sales for a lender. The correct analogue of gross margin is **Net Interest Margin**; of operating margin, **pre-provision operating profit / assets**.
|
||||
|
||||
**Debt/Equity — a regulatory input, not a risk signal, and often inverted.** NBFCs typically run 4–7x, HFCs 7–11x, banks higher still. A D/E screen mechanically rejects the entire sector. Worse, the sign is unreliable: 9x leverage on a well-provisioned prime mortgage book can be far safer than 3x on an unsecured book with no collateral and 100% LGD. The real solvency measures are risk-weighted and regulator-defined — **CRAR, Tier 1, CET1**, plus a simple leverage backstop where the regulator imposes one.
|
||||
|
||||
**Free cash flow and DCF-on-FCFF — structurally negative and sign-inverted.** Under Ind AS 109 / IFRS 9 presentation, loan disbursements sit in *operating* cash flow. A fast-growing, perfectly healthy lender therefore reports hugely negative CFO and negative FCF every single year, while a shrinking, dying lender reports strongly positive FCF as the book runs off. Screening for positive FCF in this sector selects for terminal decline. Equity value must be built from **FCFE, dividend discount, or residual-income/excess-return** models, where "investment" is the regulatory capital consumed by growth.
|
||||
|
||||
**ROCE — a trap, especially on Indian screeners.** Screener-style ROCE = EBIT / (equity + borrowings) collapses, for a lender, to approximately the **gross yield on assets**. A gold-loan or microfinance NBFC yielding 20% shows a spectacular "ROCE" that says nothing about profitability after funding cost, opex and credit cost. It systematically ranks the highest-risk lenders highest. Use **ROA and DuPont-decomposed ROE** only.
|
||||
|
||||
**Working-capital metrics — no counterparties exist.** Current ratio, cash conversion cycle, inventory turnover, debtor days, asset turnover and capex/sales have no meaning on a lender's balance sheet. Interest coverage is also meaningless — interest is revenue-side, not a fixed charge to be covered. What replaces working capital entirely is the **ALM maturity bucket table**.
|
||||
|
||||
**"Sales" / revenue growth — the wrong top line.** Reported revenue is gross interest income, which rises with both book size *and* portfolio risk. A lender can double revenue by migrating from 9% prime home loans to 24% unsecured personal loans while destroying value. Use **NII, NIM, and risk-adjusted NIM (NIM minus credit cost)** as the real revenue lines.
|
||||
|
||||
**P/E — defined, but pro-cyclical and dangerous.** Reported PAT for a lender is a policy variable: it is whatever remains after a discretionary provisioning decision (ECL staging, PD/LGD assumptions, management overlays). Credit cost is near zero at the top of a cycle, so lenders look statistically cheapest on trailing P/E precisely when the loss cycle is about to turn. Trailing-P/E screens systematically buy the top. Anchor on **book value and sustainable ROE** instead.
|
||||
|
||||
**Depreciation, capex intensity, gross block, fixed-asset turnover — irrelevant.** This is an asset-light but capital-*consuming* business. The true "capex" is regulatory capital absorbed per unit of AUM growth, and it never appears in the capex line.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are indicative and product-specific; judge intra-segment and against the company's own history.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
| --- | --- | --- | --- |
|
||||
| **Net Interest Margin & Spread** | NIM = NII / average interest-earning assets (or avg AUM). Spread = yield on advances − cost of funds. NIM exceeds spread because part of the book is funded by free equity. Best used as risk-adjusted NIM = NIM − credit cost. | Prime housing 2.5–3.5%; affordable housing 5–7%; LAP/SME 5–7%; vehicle & CV 6–8%; gold 11–14%; microfinance 11–13%; unsecured consumer 12–18%. Spread ≥3% (HFC) / ≥5% (diversified NBFC) is comfortable. DM specialty consumer 8–10% net yield; US mortgage originators far thinner. | The sector's gross margin. At 5–10x leverage a 50bp NIM compression can wipe out a third of ROE. Rising NIM in a *falling*-rate environment usually means the lender moved down the credit curve — the bill arrives as credit cost 12–24 months later. Always decompose NIM change into yield vs cost-of-funds. |
|
||||
| **Cost of funds & funding mix** | Weighted-average interest cost on borrowings, plus liability composition: bank term loans, NCDs/bonds, CP, ECB, securitisation/direct assignment, public deposits, NHB refinance (India), warehouse lines/ABS/conduits (DM). Compare *incremental* cost of new borrowing vs blended average. | CP under 10–15% of borrowings (hard convention in India post-IL&FS). No single source above ~50–60%. AA+/AAA is the practical threshold for cheap wholesale funding; a slide to A adds roughly 150–300bps. For deposit-takers, retail deposits >30–40% with >70% renewal is a real franchise. | Largest expense line and the primary competitive advantage — the sector's pecking order is decided by who borrows cheapest. Also the main contagion channel: funding is a confidence good, so a downgrade or a peer default raises marginal cost and shuts rollover at the same moment. Incremental vs blended tells you where margin is heading. |
|
||||
| **ALM gap & liquidity buffer** | Cumulative inflow−outflow mismatch per maturity bucket (1–30d, 1–2m, up to 1y) as % of outflows; plus LCR and on-balance-sheet liquid assets + undrawn committed lines as % of the next 3–6 months of debt repayments. | No negative cumulative gap in any bucket up to one year is the gold standard; regulatory tolerance is roughly −10% to −20% in short buckets. LCR ≥100% (RBI-mandated, phased, for middle/upper-layer NBFCs). Buffer covering 3–6 months of debt servicing with zero new borrowing. | Every large failure here is a liquidity failure *before* it is a solvency failure — IL&FS, DHFL, and in DM Northern Rock and Greensill all reported adequate capital at the point they died. Borrowing short to lend long is a duration bet invisible in the P&L until it kills the company. The single most under-analysed number by generalists. |
|
||||
| **CRAR / Tier 1 & growth runway** | Regulatory capital as % of risk-weighted assets, split Tier 1 (core equity) / Tier 2 (sub debt, eligible provisions). Pair with runway: years of planned AUM growth the current Tier 1 supports before dilution. | India: RBI minimum 15% CRAR with 10% Tier 1 for NBFC-ICC and HFCs; comfortable is 18–22%+ Tier 1 for a fast grower. DM bank-like lenders 11–15% CET1; US BDC leverage capped ~2:1. Tier 1 below ~13–14% while growing 25%+ implies a raise within 12–18 months. | Growth is only monetisable if it is fundable. Any lender growing faster than ROE × (1 − payout) must issue equity, and issuance below book permanently destroys per-share value. Capital adequacy is also the regulator's kill switch: a breach triggers lending restrictions and forced deleveraging. |
|
||||
| **ROA and DuPont-decomposed ROE** | ROA = PAT / avg total assets; ROE = ROA × (avg assets / avg equity). Full bridge: NII/assets + fees/assets − opex/assets − credit cost/assets − tax = ROA. | Diversified NBFC ROA 2.5–4%; prime HFC 1.6–2.2%; gold/MFI 4–6% in good years; vehicle 2–3%. ROE 15–18% respectable, 20%+ franchise-quality. DM prime mortgage ROA 0.8–1.5%, ROTE 10–14%. Sub-12% ROE against a 12–14% Indian COE is value destruction. | ROA is the only leverage-neutral read on underwriting and operating quality; ROE alone can be manufactured by gearing up. The DuPont bridge tells you *why* returns moved and whether that driver is durable. An 18% ROE built on 3.5% ROA / 5x leverage and one built on 1.5% ROA / 12x leverage are entirely different risk propositions. |
|
||||
| **Credit cost** | (ECL impairment charge + write-offs net of recoveries) / avg loans, in bps. Show reported-year *and* through-cycle average spanning at least one full downturn. | Prime housing 10–40bps; LAP/SME 60–120bps; vehicle/CV 150–250bps; used-vehicle & consumer durables 200–350bps; MFI 150–300bps normalised but 600–1200bps in a state crisis; gold 20–80bps. US subprime auto / near-prime consumer 500–900bps net charge-offs, priced accordingly. | The most manipulable and most decisive line in the sector. High-yield lending is not more profitable if losses scale faster than spread — only risk-adjusted NIM matters. Because ECL is model-driven with overlays, reported credit cost embeds discretion: compare cumulative provisions to actual gross write-offs over 3–5 years to detect chronic under-reserving. |
|
||||
| **GNPA / NNPA / Stage 3 & PCR** | GNPA % of gross advances (Stage 3 under Ind AS); NNPA net of provisions; PCR = Stage 3 provisions / gross Stage 3. Solvency-adjusted version: NNPA as % of net worth. Track Stage 2 separately. | Secured retail NBFC GNPA <3%, NNPA <1.5%, PCR 40–60% (collateral justifies lower coverage). Unsecured/consumer PCR 70–100%. Prime housing GNPA <1.5%. NNPA/net worth >15–20% is a warning; >30% means book value is materially overstated. | Direct input to adjusted book value, the sector's valuation anchor. Low GNPA with low PCR is worse than higher GNPA with high PCR — the former merely defers the loss. Stage 2 (30–89 DPD / significant increase in credit risk) is the feeder pipeline into Stage 3 and the earliest audited number that shows the cycle turning. |
|
||||
| **True loss rate: GNPA + write-offs + ARC sales + restructured** | Reconstructed stressed book = reported GNPA + cumulative technical/prudential write-offs (2–3 yrs) + loans sold to ARCs net of cash received (security receipts still on book) + restructured/OTR + scheme-based deferrals, as % of the book. | No absolute benchmark — the test is the *gap* versus headline GNPA. Write-offs >30–40% of opening GNPA in a year, or a stressed pool >2x reported GNPA, warrants forensic work. Recoveries from written-off accounts below 10–15% mean the write-offs were real losses, not hygiene. | Reported GNPA is a stock whose *outflow* management controls. Aggressive write-offs remove NPAs from the numerator with no recovery, so a lender can show falling GNPA while destroying capital. Only cumulative loss on the book as originated is honest — which is why vintage analysis is the professional standard. |
|
||||
| **Vintage / static-pool loss curves & early delinquency** | Losses by origination cohort (FY23 vs FY24 vs FY25 book) at fixed seasoning — 6, 12, 24 months on book. Leading indicators: collection efficiency %, NACH/cheque bounce rate on first presentation, 1+ DPD, 30+ DPD, and bucket-to-bucket roll rates. | Collection efficiency (current-month billing only) >98% secured retail, >97–98% MFI. Bounce rates flat or falling; a 300–500bp rise leads GNPA by 2–3 quarters. Roll-forward 30-60 → 60-90 under 30–40% for a lender with functioning collections. | In a fast-growing book, headline GNPA is suppressed by denominator inflation: new loans have not had time to default, so a book growing 50% can show falling GNPA while every cohort deteriorates. Vintage curves are the only real-time view of underwriting quality. Always pin down the collection-efficiency definition. |
|
||||
| **AUM growth, mix, on-book vs off-book** | AUM growth split by product, geography and ticket size; disbursement growth; and the split between on-balance-sheet loans and off-book AUM (securitisation, direct assignment, co-lending, managed pools). | Sustainable ≈1.5–2x nominal system credit growth (India: roughly 20–30%). Above 40–50% for multiple years in a new product or geography is the classic pre-blowup signature. Off-book above 25–30% of total, or growing much faster than on-book, requires knowing who holds first loss. | Growth in lending is trivially easy to buy by lowering standards, and the cost arrives with a 12–24 month lag. Mix shift matters more than the headline: a shift from secured vehicle finance to unsecured personal loans changes the risk profile completely while AUM growth looks steady. Co-lending and FLDG/DLG structures can leave economic risk with the originator off balance sheet. |
|
||||
| **Cost-to-income & opex/AUM (+ productivity)** | Opex (ex-interest, ex-credit cost) / net total income (NII + fees); and opex as bps of avg AUM. Complement with AUM per branch, AUM per employee, disbursements per branch, customers per field officer, and branch vintage curves. | Prime HFC 15–25% C/I (most efficient model in the sector); diversified retail NBFC 30–40%; gold 35–45% (branch- and cash-heavy); MFI 40–55% (field-force intensive). Opex/AUM 1.5–2.5% secured retail, 5–8% MFI. C/I should fall as branches season. | Distribution cost per rupee lent is the second durable advantage after cost of funds, and it decides whether small-ticket high-yield lending is actually profitable. Flat C/I through an expansion means branches are not maturing — growth is being bought where the lender has no underwriting or collections edge. Check whether DSA/sourcing commissions are expensed or capitalised into EIR. |
|
||||
| **Underwriting parameters: LTV, FOIR, ticket size, borrower mix** | LTV at origination and current; FOIR/IIR (fixed-obligation- or instalment-to-income); average ticket size and trend; salaried vs self-employed; new-to-credit share; bureau score bands; share of balance-transfer and top-up loans; average tenor. | Housing LTV 65–75% at origination (RBI risk weights step up above 75–80%; DM prime conforming 80% with mortgage insurance above). Gold capped at 75% LTV by RBI. Retail FOIR under 50–55%. Rising self-employed share, ticket size outrunning inflation, or climbing NTC share are risk-migration signals. | The only forward-looking inputs available *before* losses appear. Collateral coverage sets loss-given-default: a 60% LTV mortgage has near-zero LGD, an unsecured personal loan ~100%. Rising ticket size is the most common quiet way to take more risk while every reported ratio stays flat. In gold, slipping LTV discipline or delayed auctions turns a low-risk product into an unhedged commodity bet. |
|
||||
| **Fee / other income mix and its quality** | Non-interest income as % of total, split into recurring (servicing, processing fees amortised through EIR, insurance/cross-sell commission, BC/collection fees) vs one-off or front-loaded (gain on direct assignment/derecognition, upfront EIS, fair-value gains, one-time recoveries). | 10–20% of total income from genuinely recurring fees is healthy diversification. Upfront assignment/derecognition gains above 10–15% of PBT — or rising as a share of PBT — is a quality-of-earnings problem. Fair-value gains on unlisted or illiquid investments should be immaterial for a pure lender. | Under Ind AS 109 / IFRS 9, direct assignment lets a lender book the entire future excess interest spread as an upfront gain at sale — converting several years of margin into one quarter of profit and flattering ROA and ROE. Sustaining it requires ever-larger assignments: a treadmill. Strip these gains and recompute ROA before any peer comparison. |
|
||||
| **Concentration: product, geography, borrower, funding** | Share of AUM in top product, top state/region, top-20 borrowers (critical for wholesale/developer/infra books); share of borrowings from the largest single lender or instrument. DM: add channel concentration (broker vs direct) and warehouse-line counterparty concentration. | Top state under 25–30% of AUM; top-20 borrowers under 15–20% of net worth on wholesale books; no funding counterparty above 15–20%. Retail granularity — no borrower above ~1% of net worth — is the strongest structural protection available. | Lending losses are correlated, not independent, and they cluster by geography and product. Indian microfinance has proved this repeatedly (Andhra Pradesh 2010, demonetisation 2016, Assam 2019, Karnataka 2025) — one state ordinance can destroy repayment culture overnight. Wholesale lenders fail differently: chunky bullet-repayment exposures make the book a concentrated equity-like bet dressed as loans. |
|
||||
| **Book value per share growth & dilution history** | BVPS CAGR over 5–10 years, alongside share-count growth and the price-to-book at which each equity raise was done. Compare BVPS growth to ROE × (1 − payout). | BVPS compounding close to sustainable ROE, with share count growing modestly and raises done above book. Repeated raises below book, or BVPS growth materially below ROE, is the tell. | This is the sector's true compounding measure, and it silently nets out the dilution that headline AUM and PAT growth hide. A lender that grows AUM 30% by issuing equity at 0.8x book is shrinking per-share value while every growth headline looks excellent. |
|
||||
| **Restructured / modified book and forbearance stock** | Loans restructured, rescheduled, under OTR schemes, moratorium extensions, or (DM) TDRs / loan modifications, plus the provision held against them and their subsequent slippage rate. | Ideally negligible in a normal year. Post-crisis, watch the *slippage rate* out of the restructured pool — 20–30%+ re-defaulting is normal and should already be provided for. | Restructuring is loss deferral with regulatory blessing. The pool's re-default rate is the cleanest evidence of whether the original stress was liquidity or solvency, and it flows straight into adjusted book value. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
**Primary method — Price to Adjusted Book, anchored to sustainable ROE.**
|
||||
|
||||
The canonical relationship is **P/B = (ROE − g) / (COE − g)**. Book value here is the productive asset base — unlike an industrial, where book is sunk cost — and returns are earned directly on it, so the multiple is a function of how far sustainable ROE exceeds cost of equity. A lender earning 12% ROE against a 13% COE should trade *below* 1x book no matter how fast it grows, because growth at sub-COE returns destroys value and forces dilutive issuance. A 22% ROE franchise with a genuine low-cost funding moat can rationally sustain 4–6x book.
|
||||
|
||||
Use **adjusted** book (P/ABV), not reported. Deduct: net NPAs not covered by provisions; the uncovered portion of restructured and ARC-sold exposures (including security receipts carried at inflated values); goodwill and intangibles; deferred tax assets that depend on future profits materialising; capitalised sourcing costs. In DM this is framed as **Price/Tangible Book Value paired with ROTE** — the standard for US and European consumer and mortgage lenders.
|
||||
|
||||
Indicative 1-year-forward P/ABV bands (India): high-ROE, high-growth, low-credit-cost franchises 3.5–6x; solid secured retail lenders 2–3x; average diversified NBFCs 1.5–2.5x; prime HFCs 1.5–3x; gold-loan lenders 2–3x; sub-scale, high-credit-cost or governance-impaired names below 1x. DM specialty consumer and near-prime auto typically 0.8–1.6x TBV; prime mortgage originators often below book because ROTE sits near COE.
|
||||
|
||||
**Secondary methods.**
|
||||
|
||||
- **P/E on normalised credit cost.** Never use trailing P/E raw. Rebuild EPS with a through-cycle credit-cost assumption drawn from at least one full downturn, then apply a multiple. This corrects the classic error of buying at 8x peak-cycle earnings just before losses normalise. Indicative Indian bands: 12–18x for average quality, 25–40x for compounders with cycle-tested underwriting.
|
||||
- **Residual income / excess return.** Theoretically cleanest: value = current book + PV of (ROE − COE) × book, projected with explicit capital consumption for growth. It sidesteps the FCFF problem entirely and makes the ROE-vs-COE spread the explicit driver.
|
||||
- **FCFE / dividend discount.** FCFE = earnings − equity capital absorbed by RWA growth. This is the correct DCF for a lender. DDM works well for mature, low-growth, high-payout DM lenders.
|
||||
- **P/AUM (or EV/AUM in DM deal contexts).** Cross-check and the standard M&A benchmark, especially for microfinance, gold-loan and affordable-housing platforms where the franchise is the distribution network. Indian precedent transactions have spanned roughly 1.5–3.5x book or 20–45% of AUM depending on ROA. Useful for loss-making or early-stage lenders where P/E is undefined, but it ignores asset quality completely — never standalone.
|
||||
- **Sum-of-the-parts for holding structures.** Many Indian NBFC groups hold stakes in AMCs, insurance, broking or housing subsidiaries valued on entirely different conventions (AUM multiples for AMCs, embedded-value multiples for life insurance). Value each on its own basis and apply a holding-company discount — historically 20–50% in India.
|
||||
|
||||
**Do not use:** DCF on FCFF, EV/EBITDA, EV/Sales, EV/EBIT, ROCE-based screens, or any multiple with EV in the numerator. Debt is an operating input, so EV is undefined; and CFO is structurally negative for a growing lender. Any EV/EBITDA quoted for an NBFC is a data-provider artefact — say so and discard it.
|
||||
|
||||
**Sensitivity discipline.** At 6–10x leverage, a 25bp move in NIM or a 50bp move in credit cost swings ROE by 200–400bps, which can move justified P/B by a full turn. Always present valuation as a NIM × credit-cost grid, never a point estimate. State the COE you assumed (India: 12–14% is the usual working range; DM lenders 9–11%) because the whole framework hinges on it.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable in this sector shares **asset class, funding profile and regulatory regime** — not merely the "NBFC" label. Get this wrong and every conclusion inverts, because yield, credit cost, opex and leverage all differ by 3–5x across sub-sectors.
|
||||
|
||||
Do not mix these:
|
||||
|
||||
- **Prime housing finance** (2.5–3.5% NIM, 10–40bps credit cost, 8–11x leverage, 15–25% C/I) with **affordable housing** (5–7% NIM, higher opex, different customer). They are different businesses sharing a regulator.
|
||||
- **Secured retail** (vehicle, gold, LAP, mortgage) with **unsecured consumer / personal / digital lending**. LGD differs by an order of magnitude, so identical GNPA means completely different capital consumption.
|
||||
- **Retail granular books** with **wholesale / developer / infrastructure lenders**. Retail fails gradually and statistically; wholesale fails in discrete, lumpy, correlated events. Loss distributions are not comparable and neither are the valuation multiples they deserve.
|
||||
- **Microfinance** with anything else. Unsecured, joint-liability, politically exposed, geographically clustered, with regulatory rate and multiple-lending caps. It has its own cycle.
|
||||
- **Gold loans** with other secured lenders. Short tenor, liquid collateral, auction-driven recovery, LTV capped by regulation, and an embedded gold-price sensitivity that no other product carries.
|
||||
- **Deposit-taking (NBFC-D / thrifts / banks)** with **wholesale-funded NBFCs**. Deposit franchises have structurally cheaper, stickier funding and heavier regulation. Comparing their cost of funds and their multiples is meaningless.
|
||||
- **Captive / OEM-linked financiers** with independent lenders — their sourcing cost, credit selection and growth are governed by the parent's product cycle.
|
||||
- **Balance-sheet lenders** with **originate-to-distribute / fee-based platforms and fintech marketplaces**. The latter carry little credit risk and should be valued on earnings or revenue multiples, not book. Be alert to hybrids that claim to be asset-light while retaining FLDG.
|
||||
|
||||
Also align: stage of growth (a 40%-growing lender consuming capital vs a mature payer), country and rate cycle, accounting regime (Ind AS/IFRS 9 ECL vs older incurred-loss regimes vs US CECL), and — in India — listed vs unlisted and bank-promoted vs standalone, since parentage materially changes cost of funds.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Growth far above system** — AUM compounding 40–50%+ for multiple years, especially in a new product or geography. Rapid growth mechanically suppresses GNPA through denominator inflation and defers loss recognition 12–24 months. Cross-check with vintage curves: if each successive cohort shows worse 12-month-on-book losses while headline GNPA falls, the ratio is lying.
|
||||
- **Evergreening and disguised restructuring** — top-up loans to borrowers approaching delinquency, refinancing a borrower to clear their own arrears, LAP taken to repay another loan, or interest capitalised into principal on developer exposures so a non-paying loan never stamps a DPD. Tell-tales: a large "interest accrued but not due" balance, non-cash income rising as a share of interest income, bullet/balloon structures on real-estate loans.
|
||||
- **Related-party, promoter-group or shell-entity lending** — inter-corporate deposits, unsecured loans to entities with no operating business, exposures to the promoter's other ventures. This was the mechanism in both the IL&FS and DHFL failures. Read the related-party note and the largest-exposures list, not the press release.
|
||||
- **Aggressive write-off policy masking asset quality** — write-offs above 30–40% of opening GNPA, or falling GNPA ratio alongside rising absolute write-offs. Recompute GNPA adding back three years of cumulative write-offs. Likewise, ARC sales where consideration is mostly security receipts retained on book simply defer recognition.
|
||||
- **Upfront income via direct assignment / securitisation** — booking the entire future excess interest spread as a gain on derecognition. Front-loads years of margin into one quarter and, once started, must be repeated at increasing scale. Above 10–15% of PBT, restate earnings without it before valuing.
|
||||
- **ECL model discretion** — sudden cuts to PD/LGD assumptions, release of COVID-era or other management overlays into profit, unexplained Stage 2 → Stage 1 migration, or PCR falling while Stage 2 rises. Visible in the ECL note of the annual report, not the investor deck.
|
||||
- **Funding fragility** — CP above ~15% of borrowings, negative cumulative ALM gap in sub-one-year buckets, dependence on a single bank or instrument, or rollover reliance to fund long-tenor assets. Watch the traded spread on the company's own NCDs versus similarly rated peers: the bond market prices distress before the equity market does.
|
||||
- **Rating downgrade, negative outlook, or promoter share pledge** — here a downgrade is not a lagging indicator, it is a *causal event* that raises funding cost and can shut market access outright. High promoter pledge adds forced-selling risk that feeds back into funding confidence.
|
||||
- **Governance and reporting signals** — auditor resignation or qualification, repeated CFO or CRO departures, delayed or restated results, whistle-blower complaints, or a widening gap between standalone and consolidated performance. In lending, governance failure and credit failure are the same event.
|
||||
- **Concentration and single-event exposure** — one state above ~30% of AUM, wholesale top-20 borrowers above 15–20% of net worth, or a single-product model with no counter-cyclical ballast.
|
||||
- **Off-balance-sheet risk retention** — co-lending or partnership structures where the NBFC provides first-loss default guarantees (FLDG/DLG) or holds the junior tranche of its own securitisations. AUM growth looks capital-light while economic risk is fully retained. RBI caps DLG at 5% of the portfolio in digital-lending arrangements; check the disclosed retained first loss.
|
||||
- **Collection-efficiency definition games** — including recoveries of prior-period arrears in the numerator, which can print above 100% while the current book deteriorates. Insist on current-month-billing-only efficiency and cross-check against bounce rates and 30+ DPD.
|
||||
- **Risk migration hidden inside stable ratios** — rising average ticket size, rising LTV, rising self-employed or new-to-credit share, lengthening tenors to keep EMIs affordable, or a shift toward balance-transfer and top-up volume. Each raises loss frequency or severity while leaving current-period ratios untouched.
|
||||
- **Borrowing or deposit rates materially above peers** — a lender paying up for retail deposits or wholesale funds is either being priced for risk by the market or funding an asset book whose yield cannot be sustained. A classic late-stage signal in both Indian NBFC-D and DM thrift/specialty failures.
|
||||
- **Regulatory overhang and supervisory action** — scale-based-regulation reclassification, risk-weight increases (e.g. the November 2023 move to 125% on unsecured consumer credit and on bank lending to NBFCs), gold-loan LTV and auction-norm tightening, digital-lending guidelines, or business-restriction orders against a specific entity. Regulation changes unit economics overnight and is a first-order valuation input, not a footnote.
|
||||
- **Low effective tax rate or building deferred tax assets** — often loss carry-forwards or aggressive provisioning timing differences. Reduce adjusted book by DTAs that depend on future profits materialising.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Where you are in the credit cycle dominates everything else.** The cycle runs: cheap and abundant funding → competition for growth → underwriting standards loosen → yields compress or lenders migrate to riskier products → a rate or liquidity shock → funding cost spikes and rollover tightens → losses surface 12–24 months after origination → capital erodes → forced deleveraging and consolidation. Reported earnings look *best* just before the turn, because credit cost is at its trough and growth at its peak. Ask explicitly: is this book seasoned, and did this management team run this book through a full downturn?
|
||||
|
||||
**Rate cycle mechanics.** Asset repricing lags liability repricing in most Indian NBFC structures (fixed-rate vehicle, gold, MFI and personal loans funded by floating or short-tenor borrowings), so **rising rates compress NIM first and only later flow into loan pricing**. Falling rates do the reverse and can flatter NIM for 2–3 quarters. Separately, floating-rate mortgage books repriced to an external benchmark (India: repo-linked) transmit rate changes faster on the asset side than fixed-book lenders. Model the repricing gap, not just the direction of rates.
|
||||
|
||||
**Liquidity events, not slow decay, are how lenders die.** The 2018 IL&FS default froze the Indian NBFC wholesale funding market and killed institutions that were reporting healthy capital days earlier. Northern Rock and Greensill are the DM analogues. Any lender whose survival depends on continuous access to wholesale markets carries an option written against a tail event that is not in its cost of funds.
|
||||
|
||||
**Structural and competitive threats.** Bank competition in prime segments compresses HFC and vehicle-finance spreads structurally — banks fund cheaper and can always take the prime customer. Balance-transfer/refinance activity in mortgages erodes portfolio yield and shortens effective duration. Digital and fintech origination has collapsed customer acquisition cost in unsecured lending but also compressed underwriting time and made adverse selection faster. Account aggregators, credit bureaus and UPI-linked data are steadily commoditising the informational edge that used to justify high yields. Ask what the durable advantage is: cost of funds, distribution reach, collections infrastructure, or proprietary underwriting data — and whether it survives digitisation.
|
||||
|
||||
**Regulatory direction.** In India, RBI's scale-based regulation (Base/Middle/Upper/Top layers) progressively imposes bank-like norms — LCR, CRAR, board composition, NPA recognition, listing requirements for upper-layer entities — on larger NBFCs. Direction of travel is convergence toward bank regulation, which raises compliance cost and lowers steady-state ROE for the largest players. Globally, regulatory arbitrage between banks and non-banks is the sector's founding rationale and it periodically closes: assume any regulatory gap that a lender's economics depend on will eventually narrow.
|
||||
|
||||
**Counter-cyclical positioning.** The best entry points historically follow forced deleveraging, when survivors with capital and funding access buy books cheaply and market share consolidates. The worst are at cycle peaks when trailing P/E looks lowest. Let the credit-cost gap versus through-cycle norms, not the P/E, tell you where you are.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
**India (NSE/BSE, Ind AS).**
|
||||
- Regulators split by entity: **RBI** for NBFCs and (since 2019) HFCs, with **NHB** retaining supervision and refinance functions for housing finance. Deposit-taking entities (NBFC-D) face tighter rules than NBFC-ND.
|
||||
- **Scale-based regulation** classifies NBFCs into Base, Middle, Upper and Top layers, with rising capital, governance, disclosure and listing obligations. Check which layer the company sits in — it determines the regulatory trajectory.
|
||||
- **RBI November 2021 daily-stamping circular**: NPA upgrade only after full clearance of all arrears. GNPA reported before and after this change is not comparable; do not draw trend conclusions across that boundary.
|
||||
- **Ind AS 109 ECL** with three-stage classification. RBI additionally requires disclosure of the **gap between Ind AS provisions and IRACP norms**; if IRACP exceeds ECL, the shortfall goes to an impairment reserve. Read that reconciliation — it is a direct check on ECL aggressiveness.
|
||||
- Numbers in **crore/lakh**; AUM often quoted including off-book. Always confirm whether AUM is on-book, on+off-book, or includes co-lending partner share.
|
||||
- **Promoter holding and pledge** are first-order: check pledge percentage in the shareholding pattern. Bank- or corporate-promoted NBFCs enjoy materially lower cost of funds than standalone peers.
|
||||
- **CARO** reporting includes specific clauses on loans granted, related-party transactions, defaults in repayment of borrowings, and (for NBFCs) whether the entity conducted registered activities without a valid RBI registration. Read the CARO annexure and the auditor's key audit matters — ECL is almost always a KAM for a lender.
|
||||
- **Concalls and investor decks** disclose collection efficiency, bounce rates, Stage 2, product-wise AUM and cost of funds that are not in the financials. Use them, but restate collection efficiency to a current-month-billing basis.
|
||||
- **Priority sector lending** creates a structural market: banks buy PSL-eligible portfolios (MFI, small-ticket housing, agri) via securitisation/assignment, which is why assignment income is so prevalent in Indian NBFC P&Ls.
|
||||
- Rating agencies (CRISIL, ICRA, CARE, India Ratings) publish detailed rationales with ALM and liquidity commentary — often the most informative public document on a mid-size NBFC.
|
||||
|
||||
**US / global (10-K, EDGAR, GAAP/IFRS).**
|
||||
- **US GAAP uses CECL** (lifetime expected loss on day one) rather than IFRS 9's three-stage model, so allowance levels and the timing of provisioning differ materially. Do not compare coverage ratios across the two regimes without adjustment.
|
||||
- Terminology maps: GNPA → **non-performing / non-accrual loans**; credit cost → **provision for credit losses**; write-offs → **net charge-offs (NCOs)**; restructured → **TDRs / modified loans**; PCR → **allowance coverage**; ROE → **ROTE**; P/ABV → **P/TBV**.
|
||||
- **Delinquency and net charge-off disclosure is far richer in the US**: 10-Ks and 10-Qs give delinquency buckets, NCO rates, and often vintage tables (ASU 2016-13 requires gross write-offs by origination year) — the vintage analysis you must reconstruct manually in India is frequently disclosed directly.
|
||||
- Funding conventions differ: **warehouse lines, ABS term deals, revolving conduits and deposit funding** replace CP/NCD/bank-term-loan mixes. Watch advance rates and covenants on warehouse facilities — a covenant breach can be as fatal as a downgrade in India.
|
||||
- Capital rules: **Basel III CET1 stacks** for bank-like lenders; **BDCs** are governed by a simple 2:1 asset-coverage leverage cap rather than risk weights; **mortgage REITs** are valued on book and dividend, with entirely different accounting.
|
||||
- **Prime US mortgage lenders often trade below book** because ROTE sits near COE — that is rational, not a bargain. Judge it by the ROE-vs-COE spread, not the absolute multiple.
|
||||
- Consumer-protection regulators (CFPB in the US, FCA in the UK) can impose product-level pricing and collection restrictions that change unit economics as abruptly as RBI action does in India.
|
||||
|
||||
## Checklist
|
||||
|
||||
- Reject EV/EBITDA, EV/Sales, ROCE, FCF, current ratio and D/E outright; state that they are undefined or inverted for a lender.
|
||||
- Compute NIM, spread and **risk-adjusted NIM (NIM − credit cost)**; decompose any NIM change into yield vs cost of funds.
|
||||
- Build the DuPont bridge from ROA to ROE and identify which driver moved and whether it is durable.
|
||||
- Compare **incremental** cost of funds with the blended average; check CP share, single-source concentration, rating, and rating outlook.
|
||||
- Read the ALM bucket table; flag any negative cumulative gap inside one year and check the liquidity buffer against 3–6 months of debt servicing.
|
||||
- Check CRAR/Tier 1 (or CET1) against the minimum, then compute the growth runway to the next equity raise and the P/B at which prior raises were done.
|
||||
- Reconstruct the true loss rate: GNPA + 3-year cumulative write-offs + ARC/SR exposure + restructured pool; compare to headline GNPA.
|
||||
- Check PCR against product type and compute NNPA as a % of net worth.
|
||||
- Pull Stage 2 assets, bounce rates, collection efficiency (current-month billing only) and 30+ DPD roll rates as the leading indicators.
|
||||
- Build or demand vintage/static-pool loss curves by origination cohort; never judge a fast-growing book on headline GNPA.
|
||||
- Separate on-book from off-book AUM and identify who holds first loss (FLDG/DLG, junior tranches, co-lending share).
|
||||
- Strip upfront assignment/derecognition gains and fair-value gains from PBT; recompute ROA and ROE without them.
|
||||
- Test for risk migration: ticket size, LTV, tenor, self-employed and new-to-credit share, top-up and balance-transfer volume.
|
||||
- Check concentration by state, product, top-20 borrowers and funding counterparty.
|
||||
- Read the related-party note, the ECL note, CARO/KAM (India) or the credit-quality and vintage tables (10-K), not just the investor deck.
|
||||
- Value on **P/adjusted book vs sustainable ROE** using P/B = (ROE − g)/(COE − g); cross-check with residual income and normalised-credit-cost P/E; use P/AUM only as a sanity check.
|
||||
- Present the valuation as a NIM × credit-cost sensitivity grid and state the assumed cost of equity.
|
||||
- Locate the position in the credit cycle and ask whether this management has been tested through a full downturn.
|
||||
- Confirm the peer set shares asset class, funding profile, regulatory regime and accounting basis; never blend HFC, MFI, gold, wholesale and unsecured lenders in one table.
|
||||
183
finance/skills/stock-analysis/references/sectors/oil-gas.md
Normal file
183
finance/skills/stock-analysis/references/sectors/oil-gas.md
Normal file
|
|
@ -0,0 +1,183 @@
|
|||
# Oil and gas — sector playbook
|
||||
|
||||
Use this when: the company's earnings are driven by hydrocarbon prices, refining or marketing spreads, or regulated gas throughput — Indian upstream (ONGC, Oil India, Vedanta's Cairn segment), OMCs and refiners (IOC, BPCL, HPCL, MRPL, CPCL, RIL's O2C), gas transmission and city gas distribution (GAIL, GSPL, IGL, MGL, Gujarat Gas, Adani Total Gas, Petronet LNG), and global integrateds, independent E&Ps, pure refiners, LNG players and oilfield service names.
|
||||
|
||||
Three facts govern everything below. The company is a **price taker** — revenue is a market price it does not set multiplied by a volume it can only partly control. Upstream assets are **depleting** — production without reserve replacement is liquidation reported as profit. And the accounting is **non-comparable** — successful-efforts vs full-cost, LIFO vs weighted-average inventory, and unit-of-production DD&A mean two companies with identical physical operations report materially different earnings. Every generic ratio breaks on at least one of these. Express margin in physical units ($/bbl, ₹/litre, $/boe, ₹/scm), value on cash flow and asset value rather than earnings, and normalise to mid-cycle before applying any multiple.
|
||||
|
||||
If the name is a **regulated gas transmission or city gas distribution** business, treat it as infrastructure with a volume ramp, not as a commodity producer — the relevant logic is regulated-asset-base returns and EBITDA per scm, and it is a category error to screen it alongside an E&P. Sections below flag where CGD/transmission diverges.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
**OPM, net margin and revenue growth — near-meaningless.** Revenue is price × volume, not a business decision. A 40% revenue jump can coincide with falling production. For refiners and marketers, revenue is a pass-through of feedstock plus excise and duties: an Indian OMC's topline includes excise duty and road cess, so a 3% "OPM" and a 9% "OPM" can represent the identical physical margin at two different crude prices. Worse, upstream margins and refining margins are **inversely correlated** — a blended "energy OPM" benchmark averages two opposing signals into noise. Always restate margin per physical unit: $/bbl GRM, ₹/litre marketing margin, $/boe netback, ₹/scm for CGD.
|
||||
|
||||
**P/E — inverted and actively dangerous.** Cyclicals print their *lowest* P/E at the peak (peak earnings, imminent mean reversion) and their highest or a negative P/E at the trough. Screening for "low P/E" in this sector systematically buys the top of the cycle. Trailing EPS carries essentially no information about mid-cycle earning power.
|
||||
|
||||
**EPS — not comparable across companies, by construction.** Successful-efforts vs full-cost accounting for E&P produces materially different DD&A, capitalised exploration and net income for identical physical operations. Full-cost companies take ceiling-test write-downs when prices fall; successful-efforts companies expense dry holes as incurred. DD&A is unit-of-production based, so it moves with reserve revisions rather than with economics — a positive reserve revision lowers DD&A per barrel and raises EPS without anything happening in the field.
|
||||
|
||||
**Reported refining margin — polluted by inventory accounting.** US refiners commonly use LIFO, which insulates reported margins. Ind AS and IFRS prohibit LIFO, so Indian and European refiners book large inventory *gains* when crude rises and losses when it falls. Reported GRM must be split into core (current-cost) GRM and inventory gain/loss before any cross-border or year-on-year comparison. Comparing an Indian refiner's reported GRM against a US LIFO refiner's unadjusted is a standing error.
|
||||
|
||||
**D/E and interest coverage — understate true leverage.** Asset retirement / decommissioning obligations, long-term take-or-pay LNG and pipeline capacity commitments, rig and FPSO charters, prepaid offtake and volumetric production payments, and reserve-based lending covenants are all economically debt-like and sit outside a simple D/E. Interest is capitalised during multi-year refinery and petrochemical construction, flattering coverage. Indian OMCs fund seasonal crude swings with buyer's credit and letters of credit, so quarter-end short-term debt can be a fraction of average debt through the quarter. Use net debt / mid-cycle EBITDA, gearing, debt per boe of 1P, and net debt *including* ARO instead.
|
||||
|
||||
**ROCE — distorted in both directions, and perversely by write-downs.** Historic-cost legacy fields (a field discovered fifty years ago and long since depreciated) show inflated ROCE; recently acquired or newly commissioned assets carried at fair value show depressed ROCE for reasons unrelated to quality. A full-cost ceiling-test write-down shrinks the capital base and mechanically raises next year's ROCE — a punishment that reads as an improvement. And a single-year ROCE is uninformative without knowing where in the cycle it sits.
|
||||
|
||||
**FCF — can be manufactured by liquidating the asset.** Reserves deplete, so upstream cash flow is partly return *of* capital. A producer that cuts capex below maintenance level prints spectacular FCF for two or three years while its reserve life shrinks. FCF is only interpretable alongside reserve replacement ratio and reserve life. The inverse also holds: deeply negative FCF at a trough from counter-cyclical capex can be the most value-creating thing management does.
|
||||
|
||||
**P/B and book value — close to irrelevant upstream.** Reserves are carried at historical finding cost, not value; the gap between book equity and NAV runs to multiples in either direction. Book value has residual use only as a cyclical band indicator (own 10–15 year P/B range), and mainly for refiners where book at least reflects real physical plant.
|
||||
|
||||
**Current ratio, inventory days, cash conversion cycle — polluted.** Compulsory strategic and pipeline stock, 30–60 day crude voyages, and the price effect on inventory value all distort them. Inventory days can fall simply because crude got dearer.
|
||||
|
||||
**India-specific breakages.** (a) Retail petrol and diesel pricing is *de jure* deregulated but *de facto* administered — in FY23 OMCs absorbed large marketing losses through the crude spike, so earnings reflected government policy, not management. (b) LPG under-recoveries and subsidy receivables shift between years depending on budget compensation. (c) The SAED windfall levy (July 2022 to December 2024) capped domestic crude realisations and taxed diesel/ATF exports, breaking the historic Brent-to-domestic-EPS link. (d) APM/administered gas pricing under the Kirit Parikh formula (a percentage of the Indian crude basket, with a floor and ceiling) caps upstream gas realisation regardless of Henry Hub or JKM. (e) Cross-holdings — the OMCs hold listed stakes in each other and in ONGC, GAIL and Petronet LNG — make consolidated P/E meaningless without SOTP and a holdco discount. (f) PSU dividend policy is a function of the government's fiscal position, so dividend yield is not evidence of capital discipline.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, sub-sector, cycle position and period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set at the *same price deck*, and against the company's own 5–10 year history, overrides every absolute band below. Metrics marked (U) are upstream, (D) downstream/refining-marketing, (G) gas/CGD.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Reserve Replacement Ratio (RRR), organic, 3-yr average** (U) | Proved (1P) reserves added via extensions, discoveries and revisions ÷ production for the year. Strip acquisitions for organic RRR; use a 3-year rolling average because single years are lumpy. Exclude price-driven revisions — those are not barrels found. | >100% sustained; >120% for a genuine growth story; <80% for three consecutive years signals liquidation. | The upstream equivalent of revenue sustainability. A producer that does not replace what it produces is converting a reserve base into cash and calling it profit. This is the single check that tells you whether reported FCF is earnings or self-liquidation. |
|
||||
| **Reserve Life Index (R/P) and reserve quality mix** (U) | 1P (and separately 2P) reserves ÷ current annual production = years of runway. Read alongside proved developed vs proved undeveloped (PUD) split, and oil vs gas mix. | Integrated majors 8–13 yrs; conventional international E&P 10–15; US shale 6–9; Indian PSU upstream historically ~8–12 on 1P. PUD above ~40% of 1P is aggressive; SEC rules require PUDs to be drilled within five years. | Sets the runway and, with the PUD share, tells you how much of the reserve base still needs capital before it produces a barrel. A long R/P built of undeveloped gas in a stranded basin is worth far less per boe than a short R/P of developed, pipeline-connected oil. |
|
||||
| **F&D cost per boe and recycle ratio** (U) | (Exploration + development capex) ÷ reserves added, 3-year rolling. All-in adds acquisitions and unproved property spend. Recycle ratio = netback per boe ÷ F&D per boe. | F&D $8–15/boe for competitive conventional and good-rock shale. Recycle ratio >1.5x, ideally >2x. | F&D is the true cost of goods sold for a producer, and the recycle ratio is the cleanest measure of whether the company creates or destroys value per barrel. A company can look profitable on the income statement while replacing barrels at a cost above what it sells them for. |
|
||||
| **Cash lifting cost and all-in cash cost per boe** (U) | Lifting cost per boe, then the fuller stack: lifting + royalty + cess/production taxes + transport + cash G&A. India: royalty, OID cess (₹/tonne) and NCCD materially raise the all-in figure. | Best-in-class Middle East and legacy onshore <$10/boe; majors $6–12/boe lifting and $20–30/boe all-in cash cost; deepwater and mature offshore higher. Should not drift up faster than inflation, ex price effects. | Cost position determines who survives the trough and who issues equity at the bottom. It is the only durable competitive advantage available in a commodity business — and it is completely invisible in OPM. |
|
||||
| **Netback per boe and FCF breakeven oil price** (U) | Netback = realised price − royalty − production taxes − opex − transport, per boe. FCF breakeven = the Brent price at which operating cash flow covers maintenance capex, and separately at which it also covers the dividend. | Organic FCF breakeven including dividend below $40–50/bbl Brent for a resilient major; below $35–40 is strong. Post-dividend breakeven above ~$70 is a fragile balance sheet in disguise. | Converts the entire cost and capital structure into one number denominated in the only variable that matters. It answers directly: at what price does this company start borrowing to pay you? |
|
||||
| **Realisation vs benchmark (differential capture)** (U) | Realised $/bbl and $/mmbtu against Brent/WTI/Dubai and against any administered price, as a discount or premium. Include crude quality, location basis, marketing arrangements, and any windfall levy or price cap. | Discount should be stable and explicable by quality and logistics. India: check gas realisation against the APM ceiling, and whether new/deepwater/HPHT fields qualify for the higher free-market price. | Two producers with identical costs can have very different economics purely through differentials and fiscal capture. In India this is decisive — the APM ceiling and the 2022–24 windfall levy severed the Brent-to-realisation link, so modelling Indian upstream off Brent alone gives the wrong answer. |
|
||||
| **Production growth and base decline rate** (U) | boe/d output growth split organic vs acquired, plus the underlying annual decline of the existing base before new wells — the maintenance treadmill. | Conventional base decline 4–8%/yr; US shale base decline 25–40%, with first-year well declines of 60–70%. Maintenance capex should be disclosed and reconcilable to flat production. | Decline rate determines how much of capex is running to stand still. A shale producer with 35% base decline and a "growth" budget may be spending 80% of it on maintenance. For PSU upstream that has struggled to hold volumes flat despite rising capex, that *is* the story — not the reported profit. |
|
||||
| **GRM: reported, core (ex-inventory), and premium over benchmark** (D) | Product revenue − crude and feedstock cost, per barrel of throughput. Decompose into current-cost/core GRM and inventory gain or loss. Benchmark: Singapore complex for Indian and Asian refiners, NWE for Europe, USGC 3-2-1 crack for the US. | Mid-cycle Singapore complex GRM roughly $4–7/bbl. A complex refiner should sustain a $2–5/bbl premium over benchmark; the most complex Indian private refining has historically run a mid-to-high single-digit premium. | GRM is the entire refining P&L in one number, and the premium over benchmark is the only part attributable to management — configuration, crude sourcing, product slate, yield optimisation. The benchmark is the weather; the premium is the skill. A GRM that beats only because crude rose during the quarter is an inventory gain, not a business. |
|
||||
| **Nelson Complexity Index and crude slate flexibility** (D) | Secondary conversion capability (cokers, hydrocrackers, FCC, hydrotreaters) relative to simple distillation, plus achieved share of heavy/sour and discounted crude, and distillate yield. | Simple hydroskimming 3–6; typical Indian PSU refineries 8–12; the most complex refining complexes globally run in the mid-to-high teens and above. Heavy/sour share above 60–70% with strong distillate yield indicates real conversion capability. | Complexity is the structural moat in refining: it lets a refiner buy the cheapest, dirtiest barrel and still sell high-value distillates, earning a premium GRM in every environment and staying cash-positive when simple refiners go negative. Since 2022 it also determined who could process discounted Russian Urals. |
|
||||
| **Utilisation / capacity factor and fuel-and-loss** (D) | Throughput as % of nameplate capacity; energy consumed plus processing losses as % of throughput; turnaround schedule and unplanned outage days. | >90% healthy; Indian refiners frequently run 100–110% of nameplate via debottlenecking. Fuel & loss 6–9% depending on complexity — a rising trend signals ageing units. Below 80% in a non-turnaround quarter needs an explanation. | Refining is a high fixed-cost business, so at the margin utilisation drives unit economics more than headline crack. Utilisation also flags reliability problems and deferred maintenance, which surface as an earnings surprise one or two quarters later. |
|
||||
| **Marketing margin per litre and throughput per outlet** (D) | Gross marketing margin in ₹/litre on petrol and diesel (net realisation − refinery gate / import parity price − transport − dealer commission), plus market share, volume growth vs industry, throughput per retail outlet (KL/month), and network count. | Normalised gross marketing margin roughly ₹3.0–4.0/litre through the cycle; below ~₹1.5 implies the marketer is absorbing losses. Throughput per outlet materially above industry average signals network quality rather than network size. | For the Indian OMCs the marketing segment often contributes more mid-cycle EBITDA than refining and is far less volatile — except when policy intervenes. Tracking ₹/litre against crude tells you immediately whether the company is being used as a price-stabilisation instrument, which is the dominant risk in Indian downstream. |
|
||||
| **Unit EBITDA by segment and segment split** | Normalised EBITDA per boe (U), per tonne of throughput (D), per scm (G), with consolidated EBITDA explicitly split into upstream, refining, marketing, petrochemicals, gas transmission and trading. | No universal level. The test is stability of the unit figure versus peers at the same price deck, and whether disclosure is granular enough to model at all. India CGD: EBITDA of roughly ₹5–8/scm has been the working band. | Integrated companies are natural hedges — upstream and refining margins move inversely — so consolidated numbers hide everything. Collapsing refining and petrochemicals into one reported segment is a live example: less granularity means you can no longer see which leg is carrying the result. |
|
||||
| **Net debt / mid-cycle EBITDA, gearing, debt per boe of 1P** | Leverage against *normalised* EBITDA at a mid-cycle deck, not trailing. Gearing = net debt ÷ (net debt + equity). Debt per boe = (net debt + ARO + leases) ÷ 1P reserves. | Net debt / mid-cycle EBITDA below 1.5–2.0x; gearing 20–25% is the majors' stated target band; debt including ARO below roughly $4–6 per boe of 1P for a conventional producer. | Trailing EBITDA at a peak makes every energy balance sheet look pristine and at a trough makes every one look distressed. Mid-cycle normalisation and debt-per-barrel are the only leverage measures that survive the cycle — and debt-per-boe is what reserve-based lenders actually underwrite against. |
|
||||
| **Reinvestment rate and maintenance vs growth capex** | Capex ÷ cash flow from operations, with maintenance capex (the spend needed to hold production and refinery reliability flat) explicitly separated from growth and energy-transition capex. | Below 60–70% of CFO through the cycle for a shareholder-return model; sustained above 100% means external funding. Capex persistently below DD&A for three or more years is under-investment. | This is where energy companies destroy value most reliably: pro-cyclical capex at the peak, starvation at the trough. It is also the test of the FCF story — high FCF with capex below maintenance level is a temporary accounting artefact, not a durable cash yield. |
|
||||
| **Carbon intensity, methane intensity and ARO** | Scope 1+2 emissions per boe produced or per tonne refined; methane intensity of gas production; flaring rate; and the undiscounted *and* discounted asset retirement obligation with its assumed discount rate and retirement timing. | Upstream Scope 1+2 of roughly 15–20 kgCO2e/boe is upper quartile; methane intensity below 0.20%; routine flaring approaching zero. Compare ARO against market decommissioning cost estimates for the same water depth and asset vintage. | In developed markets this is a direct cost-of-capital and cost-of-operation input (EU ETS, CBAM, methane rules, lender and insurer exclusions), not a reporting nicety. ARO is real, senior, unavoidable cash that most screens ignore entirely — for a mature offshore portfolio it can rival net debt in size, and a small change in the discount rate moves it materially. |
|
||||
| **Regulated tariff, RAB and volume ramp** (G) | For transmission: approved capital base, PNGRB tariff order, achieved vs approved utilisation, and tariff review cycle. For CGD: geographical areas won, minimum work programme commitments, CNG stations and domestic PNG connections added, volume/day by segment, and exclusivity expiry dates. | Utilisation of transmission capacity trending toward the level assumed in the tariff order; CGD volume CAGR in the low-to-mid teens during the ramp; capex funded within operating cash flow after the initial build. | These businesses earn a regulated or quasi-regulated return on an approved asset base, so value accrues through volume ramp and capex execution, not through the oil cycle. Marketing-exclusivity expiry and network-exclusivity expiry are the two dates that change the competitive structure of a CGD; both are knowable years in advance and are routinely under-modelled. |
|
||||
| **Hedge book and forward sales position** | Percentage of next 12–24 months' production hedged, instrument type (swaps, collars, three-ways), average floor and ceiling, and whether realised hedge gains/losses sit inside or outside headline margin. | Levered producers typically hedge 40–70% of near-term production; an unhedged, highly levered producer is a directional bet, not a business. | Hedging determines whether the balance sheet survives a 40% price drop, and it is a common site of margin flattery — hedge gains booked inside EBITDA make a high-cost producer look low-cost for exactly as long as the hedge lasts. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
Because earnings are cyclical and accounting is non-comparable, this sector is valued on **cash flow, asset value and normalised mid-cycle earnings** — essentially never on trailing P/E.
|
||||
|
||||
**Normalise the denominator first.** Before any multiple, build EBITDA / DACF at a mid-cycle deck — for example $65–75 Brent, $5–6/bbl Singapore complex GRM, ~₹3.5/litre normalised marketing margin — and apply the multiple to *that*. Applying a "cheap" multiple to peak earnings is the classic energy value trap and the most common single error in the sector.
|
||||
|
||||
**Cash-flow multiples (the working tools).**
|
||||
- **EV/DACF** is the standard upstream multiple. DACF = cash flow from operations before working capital + after-tax interest expense. It neutralises differences in leverage and in the tax shield, making a levered and an unlevered producer comparable. Typical 3–6x; below ~3.5x on mid-cycle assumptions is historically cheap, above 7x demands growth or premium rock.
|
||||
- **EV/EBITDAX** (EBITDA before exploration expense) exists specifically to neutralise successful-efforts vs full-cost, since exploration cost is expensed under one and capitalised under the other. Typical 3–6x for E&P, 4–7x for refiners, 7–10x for regulated gas transmission and CGD, which are annuity-like.
|
||||
- **P/CF** is preferred to P/E throughout the sector because it steps around DD&A, which is unit-of-production based and moves with reserve revisions rather than economics.
|
||||
|
||||
**Asset-based valuation (the anchor).**
|
||||
- **NAV / DCF of the production profile** is the primary upstream method: discount after-tax free cash flow field by field over the producing life at 10% nominal (the PV-10 convention embedded in SEC disclosure) or 8–12% by risk; add risked or unrisked value for probable/possible reserves and exploration acreage; subtract net debt, ARO and corporate G&A.
|
||||
- Watch the convention: the **SEC standardised measure is PV-10 on 1P at trailing 12-month average prices** — a disclosure convention, not a valuation. Canadian and Australian practice quotes NPV10 pre-tax on 2P. Always rerun at strip or at your own deck before using either.
|
||||
- **P/NAV** is the resulting yardstick: integrated majors and large caps typically 0.9–1.2x NAV; single-asset and junior E&Ps 0.4–0.7x, reflecting funding and execution risk. A persistent sub-0.5x for a producing, funded company usually signals a governance, fiscal-regime or decommissioning problem rather than an opportunity.
|
||||
- **Transaction/screening comparables:** EV per boe of 2P reserves, and EV per flowing barrel ($ per boe/d of production). Both need adjusting for reserve life, oil/gas mix and fiscal regime, but they frame transaction value fast.
|
||||
- **Replacement-cost benchmarks downstream:** EV per barrel/day of refining capacity against greenfield build cost (far higher in developed markets than in India or the Gulf), EV per *complexity-barrel* (capacity × Nelson index) to give credit for conversion, and EV per retail outlet or per tonne of marketing throughput.
|
||||
|
||||
**Normalised and cycle-aware earnings.**
|
||||
- **Mid-cycle P/E** on normalised margins is legitimate; trailing P/E is not. The operating rule is inverted — a high or negative P/E at trough conditions is often the entry point, and a low P/E at peak margins is often the exit.
|
||||
- **P/B against the company's own 10–15 year band** works as a crude cycle-position indicator, most usefully for refiners where book reflects real physical plant.
|
||||
- **FCF yield stated at a specified crude price** ("X% FCF yield at $70 Brent") is the standard framing for the majors and large US independents, because it makes the price assumption explicit rather than burying it inside a trailing multiple. Quote at two or three prices, not one.
|
||||
|
||||
**Indian conventions that differ.**
|
||||
- **SOTP is effectively mandatory for the Indian integrateds.** The OMCs each hold large listed stakes (upstream, gas transmission, LNG regas), conventionally valued at market with a 20–40% holdco discount, plus pipelines valued separately on EV/EBITDA, plus refining and marketing on segment EV/EBITDA. Consolidated P/E on these names is close to meaningless.
|
||||
- **Conglomerate energy names are pure SOTP:** O2C on EV/EBITDA, telecom on EV/EBITDA or per subscriber, retail on EV/EBITDA or EV/sales, upstream on DCF, and new-energy build-out largely at invested capital until it generates cash.
|
||||
- **Regulated gas is valued on regulated-return logic, not the oil cycle.** PNGRB sets transmission tariffs to deliver a post-tax return on capital employed (12% for natural gas pipelines, 14% for petroleum product pipelines) on an approved asset base, so RAB-style DCF plus steady EV/EBITDA and P/E apply. CGD is valued on EBITDA per scm, volume growth and P/E — infrastructure with a ramp.
|
||||
- **Indian upstream must explicitly model the APM gas price formula ceiling and any windfall levy regime,** and should carry a governance/policy discount for PSU capital allocation. Standard practice: value the standalone E&P on DCF or EV/EBITDA, then add listed investments separately at a discount.
|
||||
- **Disinvestment/privatisation optionality and government shareholding** create event-driven gaps no multiple captures. Treat as a separate scenario, not as a haircut baked into the base multiple.
|
||||
|
||||
**Do not use:** trailing P/E on its own, PEG, EV/Sales (revenue is a pass-through of feedstock and duties), P/B as a level judgement upstream, or any cross-company EPS comparison that ignores successful-efforts vs full-cost and LIFO vs weighted-average.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares **sub-sector, fiscal regime, asset quality and price exposure** — not merely the label "energy". Mixing across these lines produces confidently wrong conclusions, and the correlation structure makes it worse: upstream and refining margins move in *opposite* directions, so a mixed peer set averages a signal against its own inverse.
|
||||
|
||||
**Splits that must not be mixed:**
|
||||
|
||||
- **Upstream vs refining vs marketing vs gas transmission/CGD vs oilfield services.** Four different business models, four different valuation frameworks. A CGD utility and an E&P do not belong in the same table under any circumstance.
|
||||
- **Integrated vs pure-play.** Integrateds are internally hedged, so their consolidated volatility is structurally lower and their multiple structurally different. Compare integrated to integrated, and compare *segments* to pure-plays.
|
||||
- **Conventional vs shale vs deepwater vs oil sands.** Base decline of 4–8% vs 25–40% changes the meaning of every capex, FCF and growth number. Capital intensity, cycle time and breakeven differ by more than the differences between many separate sectors.
|
||||
- **Oil-weighted vs gas-weighted producers.** Different price benchmarks (Brent/WTI vs Henry Hub/JKM/TTF/APM), different transport economics, different demand cycles. Convert to boe only for scale, never for valuation.
|
||||
- **Simple vs complex refiners.** A hydroskimmer at Nelson 4 and a deep-conversion refinery at Nelson 12+ have structurally different margins in the same crack environment. Benchmark complexity-adjusted.
|
||||
- **PSU vs private (India) and NOC vs IOC (global).** State-controlled companies carry policy-driven pricing, forced acquisitions, government dividend demands and appointment-driven governance. A PSU at 5x EV/EBITDA is not "cheap versus" a private peer at 8x — the gap is largely a governance and policy discount, and it is usually justified.
|
||||
- **Fiscal regime.** Royalty/tax regimes, production sharing contracts with cost recovery, and service contracts distribute upside completely differently at high prices. Two identical fields under different PSCs have different equity value.
|
||||
- **Regulated vs merchant gas.** PNGRB-tariffed transmission and a merchant LNG trading book have almost nothing in common.
|
||||
|
||||
**Also align:** the **price deck** (comparing a company's FY at $95 Brent against a peer's at $70 is a comparison of years, not companies — restate to a common deck or a common period); accounting regime (successful-efforts vs full-cost, LIFO vs weighted-average, US GAAP vs IFRS vs Ind-AS); reserve reporting standard (SEC 1P at trailing-12-month prices vs SPE-PRMS 2P at forecast prices — these are not the same barrels); fiscal year end (Indian April–March vs calendar); and hedging posture.
|
||||
|
||||
Aim for 5–8 peers. State the basis explicitly, and benchmark every metric twice — against peers at a common deck, and against the company's own full-cycle history including its last trough.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Reserve replacement below 100% for three consecutive years**, or a reserve base held up mainly by positive *price* revisions and PUD bookings rather than by the drill bit. Check whether additions came from extensions and discoveries or from revisions, and whether PUDs are rebooked year after year without being drilled — the SEC five-year rule exists precisely because of this abuse.
|
||||
- **Reported GRM with no core / ex-inventory breakdown**, or a quarter where the entire beat is an inventory gain from rising crude. The mirror image is equally telling: a refiner that never discloses inventory *losses* in a falling-crude quarter is disclosing selectively.
|
||||
- **Capex persistently below DD&A while the company markets a high FCF yield.** This is harvesting the asset; the reserve life index will confirm it. Related: a dividend or buyback funded by asset sales, hybrid issuance or incremental debt rather than by operating cash flow, especially near a price peak.
|
||||
- **Aggressive capitalisation.** Capitalising dry holes or unsuccessful exploration under a loose "successful efforts" reading; capitalising workover and maintenance spend; or switching accounting policy between successful-efforts and full-cost. A large full-cost ceiling-test write-down is itself a flag, and the post-write-down jump in ROCE and asset turnover is an artefact, not an improvement.
|
||||
- **Under-provisioned or opaque ARO.** A discount rate quietly raised to shrink the liability, retirement dates pushed further out, or an ARO small relative to peers with comparable water depth and vintage. For mature offshore portfolios this is the largest hidden claim on equity.
|
||||
- **Off-balance-sheet and quasi-debt commitments outside D/E:** long-term take-or-pay LNG and pipeline capacity commitments, FPSO and drilling-rig charters, prepaid offtake and volumetric production payments, and — India — heavy reliance on buyer's credit and LCs that make quarter-end short-term debt look far lower than average debt through the quarter.
|
||||
- **A trading arm that never loses money**, or opaque related-party crude sourcing and product placement. Trading profits with no disclosed VaR, no volume-versus-margin decomposition and no losing quarters are a classic site of smoothing and, occasionally, of fraud.
|
||||
- **Hedging problems in either direction:** an unhedged, highly levered producer at a price peak; or a producer that locked in large volumes at trough prices and books the resulting derivative gains *inside* EBITDA. Check where realised hedge gains and losses sit, and how much of next year's production is already sold forward.
|
||||
- **Project cost overruns and stagnant CWIP.** Refinery expansions, cokers and crackers routinely run over budget and late. A capital-work-in-progress balance that grows for years without commissioning is capital earning nothing — and it flatters current ROCE by sitting outside the denominator in some presentations while depressing future returns.
|
||||
- **India — government policy masquerading as an earnings trend.** Marketing margins suppressed ahead of elections or during crude spikes; price hikes deferred without compensation; LPG under-recoveries not booked while awaiting a budget subsidy; ballooning subsidy receivables from the government. The inverse error is equally common: extrapolating a windfall-margin period as a structural re-rating.
|
||||
- **India — fiscal-regime shocks and levies.** SAED windfall tax on domestic crude and on diesel/ATF exports (July 2022 to December 2024), OID cess, NCCD, and the APM gas ceiling. Any model that runs Indian upstream off Brent alone, without ceiling and levy mechanics, will be systematically wrong in a predictable direction.
|
||||
- **PSU capital-allocation flags:** forced acquisitions of other state entities funded with debt, large dividends and buybacks paid to the government while the company simultaneously borrows for capex, and cross-holdings used as a fiscal instrument. These are governance costs justifying a discount, not a bargain narrative.
|
||||
- **Reduced segment granularity or definitional change.** Collapsing refining and petrochemicals into a single segment, redefining GRM, changing the comparison benchmark, or restating a "normalised" margin without reconciliation. Loss of disclosure almost always precedes deterioration in the leg that got hidden.
|
||||
- **Concentration and contract risk:** single field, single refinery or single-basin exposure; a PSC nearing expiry with uncertain extension terms; cost-recovery disputes with the regulator (Indian DGH disputes have run for years); non-operated interests where the company cannot control capex timing; and resource-nationalism or fiscal-terms risk in the host country.
|
||||
- **Working capital and cash-conversion breakdown:** receivable days rising against state distributors or government entities, an inventory build not explained by price, and operating cash flow persistently lagging EBITDA. In gas distribution and marketing, receivables from state-owned counterparties are a recurring and under-priced credit exposure.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Locate the cycle before writing a single conclusion.** State explicitly where the current price deck sits relative to the last 10 years, and whether reported margins are above, at, or below mid-cycle. Every metric above changes meaning with that answer. The classic trap sequence is: peak prices → peak EPS → low trailing P/E → screen flags "cheap" → mean reversion. The inverse — negative EPS and no P/E at the trough — is frequently the entry point. Cross-check with own-history P/B band, inventory levels, and rig-count or refinery-margin trends.
|
||||
|
||||
**Supply-side drivers to check each time.** OPEC+ spare capacity and quota discipline (spare capacity is the shock absorber; when it is thin, prices are convex to any disruption); US shale response elasticity, which has fallen since operators shifted to capital discipline and shareholder returns; and multi-year underinvestment in long-cycle conventional supply, which tightens supply with a lag of five to ten years.
|
||||
|
||||
**Refining is a capacity cycle, not a price cycle.** Cracks are set by the balance between global capacity and demand. Closures in developed markets, new mega-capacity in Asia and the Middle East, and the timing of turnarounds drive margins far more than crude direction. Complexity and location determine which refiners survive the down leg — simple refiners in high-cost jurisdictions go cash-negative first and close permanently, which itself sets up the next up leg.
|
||||
|
||||
**Sanctions, war and trade reroutes create differentials, not just prices.** Since 2022, the discounted-crude opportunity rewarded refiners with the complexity and the freedom to process heavy sour barrels. Differential capture became a bigger earnings driver than the flat price for several Asian refiners. Treat differentials as a distinct, separately-modelled line, not as noise around a benchmark.
|
||||
|
||||
**Secular demand threats, sequenced by timing.** Gasoline demand faces EV penetration first (developed markets already past peak in several); diesel and jet are more durable because heavy transport and aviation electrify slowly; petrochemical feedstock demand is the longest-lived leg, which is why refiners are pushing crude-to-chemicals. Gas is the transition fuel with a long runway in Asia — Indian gas demand is policy-supported toward a higher share of the primary energy mix — but LNG price spikes destroy demand in price-sensitive markets, which is why volume ramps in CGD depend on gas being *cheap enough against liquid fuel alternatives*, not just available.
|
||||
|
||||
**Terminal value is the hard part.** For upstream, the depleting asset base means a conventional perpetuity growth assumption is wrong; run the DCF to reserve exhaustion plus a risked exploration value instead. For refining, ask whether the asset is a survivor or a closure candidate in 15 years, and let that drive the terminal assumption. For CGD and transmission, terminal value depends on regulatory continuity and exclusivity renewal, which is a policy question, not a financial one.
|
||||
|
||||
**Regulation as a cost of capital input.** EU ETS and CBAM, methane regulation, lender and insurer exclusion policies, and disclosure regimes (TCFD/ISSB) all feed into discount rates and access to capital in developed markets — a European or US major faces a genuinely higher cost of capital for long-cycle oil projects than it did a decade ago. In India the binding constraints are different: PNGRB tariff orders, DGH cost-recovery, the APM formula, and administered retail pricing. Model the regime you are actually in.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
- **Disclosure.** India: Ind-AS financials, Schedule III format, figures in crore/lakh, quarterly results plus a concall and investor presentation where GRM and marketing margin are usually disclosed. Annual report includes CARO (fixed-asset verification, loans to related parties, statutory dues, CWIP), related-party disclosures, and promoter/government shareholding. US/global: 10-K on EDGAR, with the **SEC Subpart 1200 reserve disclosures** — proved reserves, standardised measure (PV-10), reserve roll-forward by category and a third-party reserve auditor's report. There is no Indian equivalent of that reserve schedule at the same granularity, so Indian upstream reserve analysis leans on DGH data, annual report disclosures and management guidance.
|
||||
- **Reserve standards.** SEC = 1P (proved), priced at trailing 12-month average, PUDs must be drilled within five years. Canada (NI 51-101) and Australia/UK practice commonly report 2P under SPE-PRMS at forecast prices. Never compare an SEC 1P number against a PRMS 2P number without restating.
|
||||
- **Inventory accounting.** US GAAP permits LIFO and most large US refiners use it; Ind-AS and IFRS prohibit it, so Indian and European refiners report weighted-average-cost inventory with large gains and losses flowing through GRM. This single difference makes headline GRMs non-comparable across the two blocks.
|
||||
- **Pricing regimes.** India: retail petrol/diesel nominally deregulated but administered in practice; LPG subsidised with under-recovery and budget-compensation timing risk; domestic gas priced under the APM/Kirit Parikh formula with floor and ceiling, and a separate higher price band for HPHT/deepwater/new fields. Global: merchant pricing off Brent/WTI/Dubai and Henry Hub/TTF/JKM, with long-term LNG contracts often oil-indexed at a slope to Brent.
|
||||
- **Regulators.** India: PNGRB (pipeline and CGD tariffs, exclusivity, authorisation), DGH (upstream, PSC administration and cost recovery), MoPNG (policy and PSU control), SEBI/exchanges (disclosure), plus state VAT on fuels alongside central excise — note that petroleum products remain outside GST, which is why the tax stack is visible in OMC revenue. Global: SEC (reserve and disclosure rules), EPA/BOEM and equivalents, EU ETS and CBAM, host-country petroleum ministries and NOC partners.
|
||||
- **Ownership and governance.** India: government promoter holding in the PSUs, with disinvestment optionality and periodic government-driven dividend, buyback and acquisition decisions; cross-holdings among the energy PSUs. Monitor pledge, promoter changes and related-party transactions as standard. Global: dispersed institutional ownership with activist pressure typically pushing toward shareholder returns and away from growth capex — the opposite direction from the Indian PSU pressure toward strategic capex.
|
||||
- **Units and conventions.** India: crore/lakh, ₹/litre for marketing, ₹/scm for CGD, MMSCMD for gas volumes, MMTPA for refinery capacity, ₹/tonne for OID cess. Global: $/bbl, $/mmbtu, boe/d, bcf, MMTPA for LNG, barrels/day for refining. Standardise units *before* computing anything, and state the FX and conversion assumptions (a boe conversion of 6 mcf per barrel is an energy convention, not a value convention — gas-weighted producers look artificially large on a boe basis).
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] State where the current price deck sits versus the 10-year range, and whether reported margins are above, at, or below mid-cycle — before any other conclusion.
|
||||
- [ ] Refuse to report OPM, trailing P/E or EV/Sales as signals; restate margin per physical unit ($/bbl, ₹/litre, $/boe, ₹/scm).
|
||||
- [ ] Identify the sub-sector (upstream / refining / marketing / gas transmission / CGD / integrated / services) and use only that sub-sector's framework.
|
||||
- [ ] Upstream: check 3-year organic reserve replacement, reserve life, PUD share, and whether additions came from the drill bit or from price revisions.
|
||||
- [ ] Upstream: compute F&D per boe and the recycle ratio (netback ÷ F&D); below ~1.5x the company is not creating value per barrel.
|
||||
- [ ] Upstream: compute all-in cash cost per boe and the FCF breakeven Brent price including the dividend.
|
||||
- [ ] Upstream: check realisation vs benchmark, and in India apply the APM ceiling and any windfall levy explicitly — never model off Brent alone.
|
||||
- [ ] Upstream: separate base decline and maintenance capex from growth capex before believing any growth narrative.
|
||||
- [ ] Refining: split reported GRM into core and inventory gain/loss; benchmark the *premium* over Singapore/NWE/USGC, not the absolute.
|
||||
- [ ] Refining: check Nelson complexity, heavy/sour slate share, utilisation and fuel-and-loss trend.
|
||||
- [ ] Marketing: track ₹/litre gross margin against crude to detect policy absorption; check throughput per outlet, not just outlet count.
|
||||
- [ ] Gas/CGD: use RAB and tariff-order logic, EBITDA per scm and volume ramp — never oil-cycle logic; note exclusivity expiry dates.
|
||||
- [ ] Identify the accounting regime: successful-efforts vs full-cost, LIFO vs weighted-average, Ind-AS vs IFRS vs US GAAP — and say so before comparing EPS or GRM.
|
||||
- [ ] Compute net debt / *mid-cycle* EBITDA, gearing and debt per boe of 1P; add ARO, leases, charters and take-or-pay commitments to debt.
|
||||
- [ ] Check reinvestment rate and whether capex is below DD&A or below maintenance level while an FCF yield is being marketed.
|
||||
- [ ] Value on EV/DACF, EV/EBITDAX, P/CF and NAV/PV-10 at your own deck; state FCF yield at two or three named crude prices.
|
||||
- [ ] Use SOTP for any Indian integrated or conglomerate energy name, with a stated holdco discount on listed stakes.
|
||||
- [ ] Build the peer set within sub-sector, fiscal regime and price exposure, restated to a common price deck; never blend upstream and refining.
|
||||
- [ ] Scan for the flatter list: inventory-gain-driven beats, PUD rebooking, ARO discount-rate changes, trading profits without losing quarters, hedge gains inside EBITDA, stagnant CWIP, reduced segment granularity.
|
||||
- [ ] For PSUs, quantify the policy and governance discount explicitly rather than treating the low multiple as an opportunity.
|
||||
- [ ] Test the terminal assumption: for upstream run to reserve exhaustion plus risked exploration; for refining ask survivor-or-closure at 15 years; for CGD ask regulatory continuity.
|
||||
|
|
@ -0,0 +1,183 @@
|
|||
# Staffing, consulting, advertising and professional services — sector playbook
|
||||
|
||||
Use this when: the company sells human time, judgement or attention rather than a product — temporary and permanent recruitment, flexi-staffing and payrolling, IT and management consulting, engineering and design services, advertising and media agencies, market research, and outsourced business services such as facilities management, security manpower, testing/inspection/certification and contact-centre operations.
|
||||
|
||||
The defining fact is that the productive asset walks out of the building every evening and can resign in the morning. Capital employed is trivial or negative, so ROCE and ROIC print at 40–300% and rank nothing; the binding constraints are headcount, utilisation and bill rate, and the entire margin question reduces to whether the spread between what the client pays for an hour and what the worker is paid for that hour is widening or narrowing. Reported revenue is also unreliable as a scale measure here in a way it is not in most sectors: in staffing it includes pass-through wage cost, and in media it can include client money that never belonged to the agency. Work on **gross profit / net revenue** as the top line, and on **conversion of gross profit into operating profit** as the margin.
|
||||
|
||||
If the company owns delivery outcomes with offshore leverage, fixed-price transformation contracts, licensed IP or subscription revenue — Indian tier-1 IT, global SI, SaaS, technology-led BPM — use `references/sectors/it-saas.md`. The two look adjacent and are not: an IT staffing firm bills a markup on a head with no delivery responsibility, while an IT services firm owns the outcome. Applying the offshore-mix, backlog and NRR framework to a staffing company, or EV/gross profit to a services exporter, produces confident nonsense in both directions.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
**ROCE / ROIC / return on assets / asset turnover — spectacular, and empty.** A staffing branch needs desks, phones and a receivables facility; a consulting practice needs laptops. Capital employed is a rounding error against gross profit, so the ratio prints 50–300% for a mediocre operator and can be *negative or undefined* where negative working capital exceeds the fixed asset base (common in agencies holding media payables). Worse, the denominator is then dominated by whatever is unrelated to operations: acquisition goodwill at roll-ups (which mechanically *depresses* ROCE for the firm that paid cash for a good business), net cash piles, and IFRS 16 / Ind-AS 116 right-of-use office assets. Ranking two people businesses on ROCE ranks their acquisition history and lease footprint, nothing else. If capital returns must be discussed at all, discuss **gross profit per employee** and **cash conversion**, which are the economically equivalent questions in a model where the "capital" is payroll.
|
||||
|
||||
**OPM / EBITDA margin on reported revenue — mis-signed, and mostly a mix statistic.** In staffing, revenue includes the contractor's own pay, statutory on-costs and any pass-through. A blue-collar temp business at 12% gross margin cannot mathematically print more than ~4% operating margin; a permanent-placement business at ~100% gross margin prints 20%+. Neither number says which is better run. Margin on revenue therefore *falls* when temp volumes grow faster than perm — a mix change, often a share gain, read by a generic screen as deterioration. The sector's own margin metric is the **conversion ratio: operating profit (EBITA) ÷ gross profit**, and it must be used in place of OPM throughout.
|
||||
|
||||
**Revenue itself is not comparable across companies.** Advertising agencies do not earn billings; billings are the client's media money passing through. Principal-versus-agent determination under Ind-AS 115 / IFRS 15 / ASC 606 decides whether pass-through media, print production, talent fees and third-party costs are grossed into revenue or netted out — and the answer changes reported "revenue" by a multiple with zero change in economics. US holding companies and Indian agencies report on different conventions, and a firm that shifts media buying from agency to **principal** (inventory bought on its own book and resold) grosses up revenue overnight. Never build a growth series, an EV/Sales multiple or a market-share estimate on the top line until you have confirmed the basis.
|
||||
|
||||
**Free cash flow — inverted in staffing, seasonal and window-dressable in agencies.** Staffing pays contractors weekly or fortnightly and collects from clients in 45–75 days, so growth consumes cash and contraction releases it. A staffing firm in a violent downturn posts its best-ever FCF as the receivable book unwinds; the same firm in a strong recovery posts weak FCF while creating value. Agencies run structurally *negative* working capital because media payables exceed receivables, which makes year-end net cash a function of payment timing rather than earnings — always use **average net debt** (many disclose it; if not, model intra-year peaks) and treat a large year-end cash balance as unavailable to shareholders. In both cases, FCF is a working-capital signal first and a profitability signal second.
|
||||
|
||||
**D/E, net debt and current ratio — distorted at both ends.** Balance sheets are small, so modest absolute debt produces alarming-looking ratios, while receivables and payables gross-ups from pass-through costs swamp the current ratio in agencies and outsourcers. More importantly, the real obligations sit off the standard leverage screen: **deferred consideration and earn-outs** on acquired agencies and boutiques, **put options held by minority shareholders** of subsidiary agencies (a contractual cash obligation, frequently excluded from screened net debt), pension deficits at old-line professional services firms, and IFRS 16 lease liabilities on large office estates that are a genuine operating cost, not financing.
|
||||
|
||||
**EV/EBITDA post-IFRS 16 — overstated and non-comparable.** Office rent is a real, recurring, unavoidable cost in a business whose only other cost is payroll. Capitalising it moves 3–8% of gross profit out of EBITDA. Compare on EBITDA-after-leases (EBITDAaL) or on EBITA, and confirm every peer is on the same basis and the same standard-adoption date.
|
||||
|
||||
**P/E on reported EPS — the classic cyclical trap, in both directions.** Because the cost base is semi-fixed (recruiters and consultants cannot be hired and fired at the speed of demand), **drop-through** of a gross-profit decline to operating profit runs 50–70%. A 20% fall in gross profit can halve or eliminate EPS. P/E is therefore lowest at the peak — when perm fees and utilisation are maxed — and infinite or negative at the trough, which is often the correct time to buy. Normalise to mid-cycle before applying any multiple.
|
||||
|
||||
**P/B and book value — no information.** Book equity is acquisition goodwill plus receivables less buybacks; serial acquirers of people businesses have large intangible balances backed by staff who can leave, and mature agencies have driven tangible book negative. Impairment tests here are a lagging confirmation of a client loss you should already have found in the organic growth bridge.
|
||||
|
||||
**Inventory, fixed-asset turnover, capex/sales — not applicable.** No inventory; maintenance capex is typically 0.5–2% of revenue. Depreciation ex-leases is trivial, so EBITDA ≈ EBITA ≈ EBIT and EBITDA adds nothing except the lease distortion.
|
||||
|
||||
**Headline growth as an unqualified positive — inverted twice.** First, acquired growth is bought, not earned, and this sector consolidates constantly. Second, revenue growth achieved by taking on payrolling, MSP pass-through or low-markup volume *dilutes gross profit margin* and can raise revenue while gross profit is flat. Growth must be stated as **organic, constant-currency, gross-profit (or net-revenue) growth** or it is not a fact.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by sub-sector, geography, wage regime, cycle phase and reporting period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set and against the company's own 5–10 year record — including its last full downturn — overrides every absolute band below.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Gross profit / net fee income (the real top line)** | Revenue less the direct cost of the people billed (contractor pay, statutory on-costs) and less pass-through third-party costs. UK/European staffing calls it **net fee income (NFI)**; agencies call it **net revenue** or revenue-less-pass-through. Rebuild it consistently for every peer. | Staffing GP margin: blue-collar/industrial temp 10–16%, professional/IT temp 18–28%, blended 15–25%; perm placement ~100%. Agencies: net revenue typically 15–25% of billings, but the ratio is convention-dependent. | This is the only number that measures the company's own economic activity. Everything above it belongs to the worker or the media owner. Growth, margin, per-head productivity and valuation must all be computed on this line. A company that talks about revenue growth while gross profit is flat is growing its pass-through, not its business. |
|
||||
| **Conversion ratio (EBITA ÷ gross profit)** | Operating profit before amortisation of acquired intangibles and before exceptionals ÷ gross profit. Compute on a lease-consistent basis across peers. | Staffing 10–18% mid-cycle, >20–25% at a cyclical peak with high perm mix, 0–5% or negative at the trough. Consulting 12–20%. Agencies (operating margin on net revenue) 13–18% for large groups. Judge against the company's own last two cycles. | The sector's true margin, and immune to the temp/perm and principal/agent mix distortions that destroy OPM. It answers the only operating question that exists here: how much of the spread the firm captures survives its own SG&A. A conversion ratio at an all-time high late in an upcycle is peak earnings, not a re-rated business. |
|
||||
| **Utilisation (billable hours ÷ available hours)** | For delivery staff only, stated on a defined available-hours base, and disclosed both including and excluding trainees/bench. Track alongside average billable headcount. | Strategy/management consulting 60–75%; IT and implementation consulting 75–85%; engineering/testing services 80–88%. Above ~88% means no bench and imminent delivery and attrition risk. | Utilisation is the volume lever and the earliest demand signal in consulting — it falls a quarter or two before revenue, because staff are hired to a forecast. Roughly 100 bps of utilisation converts to a meaningful chunk of EBIT margin in a business where payroll is 60–70% of net revenue. A margin beat produced by pushing utilisation to a record is borrowed from next year's attrition. |
|
||||
| **Realisation rate (billed ÷ standard rate)** | Fees actually invoiced and collected ÷ fees at standard rate card for hours worked. Equivalently, the discount and write-off leakage between timesheet and invoice. | 85–95% healthy; a persistent slide below ~80% signals pricing indiscipline, scope overruns being absorbed, or a rate card that no longer clears the market. | Utilisation can be held up by billing work cheaply — realisation is where that shows. Rising utilisation with falling realisation is a demand problem being disguised as a capacity success. Also the first place fixed-price overruns appear, since unbilled effort is written off here before it reaches the margin line. |
|
||||
| **Pyramid ratio / leverage** | Billable staff per partner or per senior manager; share of headcount by grade; average cost per billable head; in Indian delivery models, fresher share of headcount. | Depends entirely on the model: strategy houses run flat pyramids, implementation and engineering practices run steep ones. Track the *direction* — a flattening pyramid at constant pricing is structural margin loss. | The pyramid is the profit engine: juniors are billed at a multiple of cost, seniors are not. Margin can be manufactured for two or three years by hiring cheaper and pushing leverage, and that is a different quality of earnings from a rate rise. A pyramid that flattens because juniors left, or because clients refuse to pay for inexperienced staff, is the mechanism behind most consulting margin decay. |
|
||||
| **Bench cost and time-to-deploy** | Non-billable delivery payroll ÷ net revenue; average days between a consultant rolling off a project and rolling on to the next; share of headcount on bench beyond 30/60 days. | Bench cost low single-digit % of net revenue in a normal market; deployment gaps rising sharply is a leading indicator of a utilisation and then margin fall. | Bench is committed cost against uncertain revenue — the closest thing to inventory in this sector, and it spoils. Companies frequently hide it by reclassifying benched staff to "internal initiatives", "investment projects" or capitalised platform work; check whether internal-project headcount grew when utilisation fell. |
|
||||
| **Attrition (voluntary, LTM) and replacement cost** | Voluntary attrition of billable staff, split regretted vs unregretted and by grade. Replacement cost = recruitment fee + onboarding + lost productivity ramp, conventionally estimated at 50–150% of annual salary for professional staff. | Consulting 12–20% is typical; >25% is a delivery-quality and cost crisis. Very *low* attrition often signals a weak external job market, i.e. weak demand — read it with hiring. | This is the depreciation schedule of the only asset. High attrition means backfilling at market wages (spread compression), more subcontracting, project escalations and lost client relationships. Senior attrition matters disproportionately: partners and practice heads leave with the client and often with the team. |
|
||||
| **Bill rate, pay rate and the pay-bill spread** | Average client bill rate per hour/day and average worker pay rate, tracked separately, with the spread in both absolute currency and percentage terms. Never rely on the percentage alone. | Spread stable-to-widening in real terms is the whole thesis. A stable % spread on a rising pay rate is *absolute* margin growth; a stable % on a falling pay rate is decline. | Wage inflation is passed on as a higher bill rate at a constant percentage markup, which mechanically raises gross profit per head — flattering "growth" that is pure inflation. Splitting the two separates volume, price and inflation. It is also where client procurement pressure first becomes visible, months before it reaches the margin. |
|
||||
| **Contractors on assignment / billable headcount** | Number of temps or contractors out on assignment at period-end and average during the period (staffing); average billable delivery headcount (consulting); average full-time equivalents on contract (outsourcing). Track weekly or monthly where disclosed. | Direction and inflection matter, not the level. Compare growth in heads on assignment against growth in gross profit to isolate mix and rate. | The physical unit of production. Gross profit = heads × hours × spread; decomposing it tells you whether growth came from volume, hours (a real risk in a slowdown, as clients cut overtime before cutting heads) or rate. Heads-on-assignment inflects before revenue and before any accounting number. |
|
||||
| **Permanent placement mix and perm fee** | Perm placement revenue as % of gross profit; average fee per placement (typically 15–25% of first-year salary); placements made per consultant per month. | Perm is often 15–35% of a diversified staffing firm's gross profit, and materially more of its profit. | Perm is the highest-margin, most cyclical and most information-rich line in the sector: it is ~100% gross margin, so its decline drops through to EBIT almost one-for-one, and it is the first thing corporate clients stop buying and the first thing they resume. A staffing firm's profit cycle is largely the perm cycle amplified by operating leverage. |
|
||||
| **Fill rate and order-to-fill time** | Orders filled ÷ orders received (or vacancies taken); median days from requisition to placement/start; interview-to-placement conversion. | Fill rate 55–80% depending on skill scarcity and whether the firm accepts speculative orders; order-to-fill trending down. | The operational quality of the recruiting engine, and the leading indicator inside a leading indicator. Rising orders taken with a falling fill rate means either a labour shortage (bill rates about to rise) or an eroding candidate database. Falling orders taken is the cleanest early read on client demand and turns before placements. |
|
||||
| **Client concentration, retention and contract tenure** | Top-5 / top-10 clients as % of gross profit (not revenue); annual client retention %; contract renewal/rebid win rate; average remaining contract tenure for outsourced services; average client relationship age for agencies. | Top-10 below ~20–25% of gross profit for a diversified firm; any single client >8–10% is a material risk. FM/security/outsourcing renewal rates 90–95%+; agency top-20 client tenure often measured in decades, which cuts both ways. | Revenue here is a relationship, not a contract — often terminable on 30–90 days' notice in advertising, and rebid every 3–5 years in outsourcing. A single account loss can remove several points of growth in a quarter with no warning in the financials. Compute concentration on gross profit, since a low-margin pass-through account overstates its own importance on revenue. |
|
||||
| **Organic, constant-currency net revenue / gross profit growth (with the full bridge)** | Reported growth = organic + acquisitions/disposals + FX + (for agencies) pass-through and principal-accounting effects. Demand the bridge; rebuild it if not given. | Agencies: 0–4% organic in a normal market, >5% strong, negative organic with positive reported growth is the standard warning configuration. Staffing: swings from +20% to −25% across a cycle — the level is meaningless without cycle position. | This is where managements hide. Roll-ups mask organic decline with acquisitions; agencies have flexible definitions of "organic" that sometimes absorb pass-through and same-store adjustments. Also check whether "organic" includes revenue from businesses acquired 13 months ago at their inflated pre-deal run rate. |
|
||||
| **Backlog, bookings and book-to-bill** | Signed but undelivered fees; new bookings/TCV in the period; book-to-bill = bookings ÷ revenue; backlog expressed as months of revenue. Split project vs retainer/managed-service, and fixed-price vs time-and-materials. | Consulting book-to-bill >1.0x, 1.1–1.3x in an upcycle; backlog cover of 3–9 months typical. Retainer/annuity share above ~50% materially reduces cyclicality. | The only forward-looking number in a sector with no order book in the industrial sense. Bookings turn 2–3 quarters before revenue. The fixed-price share carries the estimation risk: percentage-of-completion accounting on fixed-price work is where optimistic cost-to-complete assumptions live, and where a delivery problem becomes a sudden write-off rather than a gradual margin slide. |
|
||||
| **Wage-inflation pass-through coverage** | Share of contracted revenue with explicit indexation (CPI, wage-index or statutory-minimum-wage pass-through clauses); the reset frequency and lag in months; historical realised pass-through vs actual wage inflation. | Contracted outsourcing: aim for majority coverage with ≤6–12 month lag. Staffing: markup-based pricing passes wages through mechanically but only on *new* assignments — legacy assignments reprice at renewal. | The central margin question in the entire sector. Where pricing is a percentage markup, wage inflation is neutral-to-positive; where pricing is a fixed rate per head or per site on a multi-year contract, wage inflation is a direct hit to the spread and cannot be recovered until rebid. Statutory minimum-wage rises are the acute case: cost rises on a legislated date whether or not the contract allows recovery. |
|
||||
| **Gross profit per employee, and cash conversion** | Gross profit ÷ average *internal* headcount (recruiters, consultants, support) — not contractors on assignment. Cash conversion = operating cash flow ÷ EBITA, and DSO including unbilled/contract assets. | GP per internal head should rise in real terms across a cycle. Staffing DSO 45–75 days; consulting DSO including unbilled 60–90 days. Cash conversion >90% of EBITA through a full cycle. | Productivity per internal head is the operating-leverage measure that ROCE cannot provide, and it exposes whether technology and AI investment is doing anything. Cash conversion is the honesty check on revenue recognition — unbilled/contract assets growing faster than revenue in a consulting firm is the same warning it is in IT services: work recognised but not yet accepted or invoiced. |
|
||||
|
||||
### Family-specific additions
|
||||
|
||||
**Staffing.** Split gross profit into temp and perm, and temp further into professional and industrial. Track heads on assignment weekly where disclosed, average assignment length, temp-to-perm conversion income, and the share of gross profit from MSP/RPO/VMS programmes (large, sticky, low-margin) versus direct branch recruitment (small, high-margin, cyclical). Watch employment-tax and worker-classification exposure (UK IR35, US federal/state independent-contractor tests, EU Agency Workers Directive equal-treatment after a qualifying period). Note the sub-sectors with their own cycles: healthcare/nurse staffing (driven by clinical shortages and rate spikes, not GDP), education, and government/defence contracting.
|
||||
|
||||
**IT and management consulting.** Beyond utilisation, realisation and pyramid: partner/practice-head tenure, revenue per partner, share of revenue from the top practice and top industry vertical, subcontractor cost as % of net revenue (spikes when demand outruns hiring), and the fixed-price share of backlog with the associated cost-to-complete provisioning. Distinguish transformation projects (discretionary, cut first, high margin) from run/managed services (annuity, resilient, lower margin). A book that has drifted from project to run is more defensive and worth a lower multiple, not a higher one.
|
||||
|
||||
**Advertising and marketing agencies.** State plainly in any report that **billings are not revenue**. Then: organic net revenue growth, staff cost ÷ net revenue (typically 60–68%; the single biggest lever), new business wins and losses net, media versus creative versus data/technology/CX mix, share of media bought as principal, and the payables/receivables float. Principal media buying converts an agency fee into a trading spread — higher headline revenue, undisclosed margin, and a genuine inventory and transparency risk; the industry-wide advertiser scrutiny of media rebates and non-transparent principal trading is the reference case, and it never fully went away. Check whether client contracts are 30–90 day terminable and how many of the top-20 relationships are up for statutory review.
|
||||
|
||||
**Other professional and business services (security, facilities management, TIC, outsourced customer operations).** Contract tenure and the maturity ladder of the contract book, renewal and rebid win rates, revenue under contract for the next 12/24 months, site or seat counts, revenue per site/seat/FTE, wage-indexation clause coverage, statutory minimum-wage and social-security exposure by geography, and mobilisation cost on contract wins (upfront cash out, recovered over the term — a real drag on FCF during a growth phase). TIC businesses are the exception in this family: they carry laboratory capex and accreditation moats, so asset-based returns are *not* meaningless there, and margins are structurally higher (15–25% EBIT).
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
Value the **enterprise on normalised mid-cycle profit**, and never capitalise the profit the company is earning today unless you have established where in the cycle today sits.
|
||||
|
||||
**Primary — EV/EBITA on normalised earnings.** Use EBITA, not EBITDA: amortisation of acquired intangibles should be excluded (it is an artefact of deal accounting), but depreciation and lease costs should not be, because office estates are a real recurring cost. Confirm every peer is on the same lease standard and the same treatment. Normalisation means resetting the conversion ratio to the company's own mid-cycle level, not the current one — a staffing firm at a 22% conversion ratio in a hot labour market and one at 4% in a recession may be identical businesses. Indicative: staffing 7–11x mid-cycle EV/EBITA, consulting 9–14x, agencies 7–11x on net revenue-based EBITA, contracted outsourcing 8–12x. All cycle- and market-dependent.
|
||||
|
||||
**Staffing — EV/gross profit is the sector-standard cross-check, and the only comparable revenue multiple.** Because revenue includes contractor pay, EV/Sales compares temp/perm mix rather than value. EV/gross profit removes that entirely. Indicative 0.8–2.0x, with the position inside that range set almost mechanically by the mid-cycle conversion ratio and the perm share — a firm converting 18% of gross profit at the mid-cycle deserves roughly double the EV/GP of one converting 9%. Sense-check the implied EV/EBITA against it.
|
||||
|
||||
**Agencies — EV/net revenue and EV/EBITDA on net revenue.** Indicative EV/net revenue 1.2–2.5x, EV/EBITDA 6–10x for the large groups, higher for genuinely growing digital/data-led independents. Two adjustments are non-negotiable: add **deferred consideration, earn-outs and the fair value of minority put options** to enterprise value, and use **average** rather than year-end net debt, because the media float makes the balance-sheet date unrepresentative.
|
||||
|
||||
**P/E on normalised cycle earnings.** Legitimate here, unlike in banks, because these are genuinely simple P&Ls — but only after mid-cycle normalisation. The practical method is to compute mid-cycle gross profit (trend line through the last two full cycles), apply the mid-cycle conversion ratio, tax it, and apply a mid-cycle multiple. Reported trough P/E of 40x and peak P/E of 8x can describe the same fair value.
|
||||
|
||||
**Free cash flow yield and DCF — usable, with two corrections.** Capex is trivial and cash conversion is high, so DCF is more tractable here than in most sectors. But (i) model working capital explicitly as a function of gross profit growth — it is the difference between a cash-generative and a cash-consumptive year in staffing, and it flips sign across the cycle — and (ii) build the forecast off mid-cycle margins, since terminal value dominates and a terminal margin set at the current peak is the standard way DCFs in this sector produce absurd answers. For contracted outsourcing with long tenure and high renewal rates, a contract-by-contract run-off plus renewal-probability model is materially better than a growth-rate DCF.
|
||||
|
||||
**Cross-checks.** EV per billable head or per consultant against transaction comparables; the implied mid-cycle conversion ratio and implied organic growth solved backwards out of today's price (then ask whether the company has ever achieved them); and dividend/buyback sustainability against average, not year-end, net debt.
|
||||
|
||||
**Do not use:** EV/Sales or P/S for staffing and for agencies reporting on a principal or grossed-up basis; P/B and any book-value-anchored method; ROCE- or ROIC-based screens and quality scores; EV/EBITDA compared across firms on different lease standards; PEG on reported EPS at either end of the cycle; and replacement-cost or asset-based methods, which have no meaning when the assets are employed under a resignation clause.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares the **revenue model, the top-line convention, the geography's labour regime and the cycle position** — not the label "human capital" or "professional services".
|
||||
|
||||
**Splits that must never be mixed:**
|
||||
|
||||
- **Staffing vs consulting vs agencies vs outsourced services.** Four different economic models. Staffing sells heads at a markup; consulting sells outcomes at a pyramid margin; agencies sell attention and take a fee on someone else's money; outsourcing sells a contracted service at a fixed price with wage risk retained. Their margins, cycles, working capital and multiples do not overlap.
|
||||
- **Within staffing: perm-heavy vs temp-heavy, and professional vs industrial.** A firm with 35% of gross profit from perm has roughly double the earnings cyclicality of a temp-only industrial firm at the same size. Also separate branch-led recruitment from MSP/RPO/VMS programme businesses — different margins, different stickiness, different capital intensity.
|
||||
- **Within consulting: strategy vs implementation vs engineering/R&D vs regulated-adjacent (audit/tax/risk).** Different pyramid shapes, different discretionary exposure, different pricing power.
|
||||
- **Within agencies: holding companies vs independents vs performance/digital specialists vs martech.** And within holdcos, never compare across different principal-vs-agent revenue conventions without restating.
|
||||
- **Contracted outsourcing vs discretionary services.** Revenue visibility of 12–36 months versus 30–90 days is the single biggest driver of the multiple in this family.
|
||||
- **Geography, because the labour regime changes the economics.** US at-will employment gives high margin volatility and fast cost adjustment; Continental European employment protection dampens both the upswing and the downswing and changes the trough conversion ratio structurally; Japan has its own dispatch-labour rules; the UK carries IR35 and agency-worker equal-treatment. India's flexi-staffing is a different business again (see below).
|
||||
- **Cycle position.** Comparing a firm in a market at the top of its labour cycle with one at the bottom, on current-year multiples, is the most common error made in this sector. Compare mid-cycle to mid-cycle.
|
||||
|
||||
**Also align:** the top-line basis (gross profit / net fee income / net revenue, restated identically for all peers); lease standard and adoption date; fiscal year end; whether amortisation of acquired intangibles is in or out of the "adjusted" figure; and organic-growth definitions. Aim for 5–8 peers, state the basis explicitly, and benchmark every metric twice — against peers and against the company's own record through its last full downturn.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Revenue growing while gross profit is flat.** Volume taken at negligible markup — payrolling, MSP pass-through, principal media, low-margin master-vendor deals. It buys scale headlines and no profit, and it permanently dilutes the reported margin, which management then explains away as "mix" every year.
|
||||
- **Conversion ratio at an all-time high, presented as structural improvement.** Late-cycle perm fees and peak utilisation are not a re-rating; they are the thing that reverses. Ask what the conversion ratio was in the last two troughs.
|
||||
- **Cost taken out of the front line to defend margin while gross profit falls.** Cutting recruiters, business development or junior consultants protects this year's EBIT and mortgages the recovery — the firm cannot fill orders when demand returns. Track sales/recruiter headcount against gross profit; a firm cutting producers faster than gross profit is falling is managing to a number.
|
||||
- **Serial "adjusted" earnings.** Restructuring charges every single year, acquisition and integration costs treated as exceptional at a company whose growth strategy *is* acquisition, and amortisation of acquired intangibles added back at a firm that must keep buying teams to replace ones that left. Compute a 5-year total of "exceptionals" against 5-year cumulative reported EBITA.
|
||||
- **Acquisitions masking organic decline.** Demand the organic bridge, check the definition, and check whether acquired businesses are lapped at their pre-deal run rate. Also watch earn-out structures: an earn-out expiring is a well-documented trigger for founder departure and revenue decline in acquired agencies and boutiques.
|
||||
- **Unbilled revenue / contract assets growing faster than revenue in consulting.** Fixed-price percentage-of-completion recognition with optimistic cost-to-complete estimates. A step-change in unbilled, or a lengthening gap between recognition and invoicing, precedes write-offs.
|
||||
- **Bench disguised as investment.** A jump in "internal projects", "platform development", capitalised software or "training investment" headcount at exactly the moment utilisation falls. Reconcile total delivery headcount to billable headcount every period.
|
||||
- **Withdrawal of a previously given operating disclosure.** Companies here voluntarily publish heads on assignment, perm placement counts, utilisation, organic growth by discipline or net new business. A firm that quietly stops disclosing one it used to give is telling you the number turned.
|
||||
- **Agency-specific:** a shift toward principal media buying without margin disclosure; client-money and float being described as balance-sheet strength; "net new business" reported as wins without netting losses; a top client entering statutory media review; late or vague disclosure of an account loss; and organic growth definitions that flex between years.
|
||||
- **Key-person and team-lift risk.** Departure of a practice head, creative leader or desk manager, typically followed by a team and then the clients. Check non-compete enforceability by jurisdiction (unenforceable or narrowly enforced in several US states), partner/senior tenure, and how much of gross profit sits with the top 10 producers.
|
||||
- **Worker-classification and employment-tax exposure.** Contractors reclassified as employees creates retrospective tax, social-security and benefit liabilities that dwarf annual profit. Read the contingent liabilities note for statutory wage, provident fund, social-security and misclassification claims — this is the sector's equivalent of a credit event.
|
||||
- **Wage inflation without pass-through.** Multi-year fixed-rate contracts signed in a low-inflation period, statutory minimum-wage increases, or a rebid won on price that assumed flat wages. The margin damage arrives on a legislated date and lasts until renewal.
|
||||
- **Client concentration measured on revenue rather than gross profit**, and a single client, sector or government framework agreement carrying a disproportionate share of profit.
|
||||
- **Receivables quality.** Rising DSO, factoring or receivables-financing programmes introduced quietly (which flatter reported cash conversion and net debt), concentration of receivables in one distressed client, or extended payment terms conceded to hold an account — a price cut recorded as a working-capital movement.
|
||||
- **Goodwill that never impairs** at a roll-up whose acquired businesses are visibly shrinking, alongside an accounting policy of long or indefinite intangible lives on customer relationships that churn.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Staffing is a leading macro indicator, and knowing that is half of using it.** Temporary employment is one of the cleanest early cyclical series available — clients add and cut flexible labour before they touch permanent headcount. Within the sector, **permanent placement turns first at both ends**: perm fees are pure discretionary spend and collapse two to three quarters ahead of the broader economy, and resume ahead of it. The sequence to watch is: orders/vacancies taken → fill rates and perm placements → contractors on assignment → temp gross profit → reported revenue. Because perm is ~100% gross margin and the cost base is semi-fixed, drop-through of a gross-profit decline to EBIT of 50–70% is normal, which is why peak-to-trough EPS declines of 50%+ are routine and why the reported P/E is at its most misleading at both extremes.
|
||||
|
||||
**Consulting lags staffing modestly and asymmetrically.** Backlog cushions the first two or three quarters of a downturn, then discretionary transformation work is cancelled or deferred while run/managed services persist. On the recovery, bookings turn before revenue by a similar lag. Cost-reduction and restructuring practices are counter-cyclical and partially offset — check the practice mix before assuming a uniform cycle.
|
||||
|
||||
**Advertising tracks nominal GDP with a beta above one.** Ad spend is a discretionary corporate budget cut early and restored late, and agencies sit one step further from the money than media owners. Event-driven boosts (elections, major sporting cycles) accrue mostly to media owners, not agencies. Currency matters disproportionately, since the large groups earn across dozens of currencies with costs in the same places.
|
||||
|
||||
**Contracted outsourcing, security and facilities management are the defensive corner** — low cyclicality, high renewal, but low margin and permanent exposure to wage regulation. The risk here is not demand; it is a minimum-wage increase, a social-security rate change or an aggressive rebid.
|
||||
|
||||
**Structural pressures to score explicitly, not to wave at:**
|
||||
|
||||
- **Generative AI on the entry-level pyramid.** The economics of consulting, research, creative production and outsourced customer operations depend on billing junior hours at a multiple of junior cost. Anything that automates first-draft research, deck production, code scaffolding, creative variants or tier-1 support attacks the widest part of the pyramid. Test the claim empirically: if a firm says AI is making it more productive, gross profit per internal head must rise. Flat for five years means the story is marketing.
|
||||
- **In-housing.** Advertisers have moved media planning, creative production and data operations in-house; corporates have built internal consulting and internal recruitment functions. This removes fee pools permanently rather than cyclically.
|
||||
- **Platform self-serve.** Automated buying on the large ad platforms and retail media networks compresses the media planning and buying fee pool; the agency response has been data, technology, commerce and CX services, which carry different margins and different competitors (consultancies, SIs, martech vendors).
|
||||
- **Procurement professionalisation in staffing.** MSP/VMS programmes, direct sourcing, talent marketplaces and freelancer platforms all compress markups and disintermediate the branch. Large, stable, low-margin programme revenue displacing small, cyclical, high-margin direct revenue is a genuine change in business quality that shows up first as gross margin dilution.
|
||||
- **Regulatory drift toward reclassifying flexible labour as employment** across most major markets. This is the sector's tail risk.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India | US / global |
|
||||
|---|---|---|
|
||||
| Sector composition | Dominated by **general (blue-collar) flexi-staffing** and **IT staffing**, plus facilities management, security manpower and a fast-growing GCC-support ecosystem. Listed advertising and management consulting pure-plays are few; agency businesses are often subsidiaries of global groups | Deep listed universe across staffing, consulting, agency holding companies, TIC and outsourced services, with long multi-cycle histories |
|
||||
| Top-line convention | Ind-AS 115 principal/agent determination; most Indian staffing firms report gross billings as revenue with associate salary cost below it. **Gross margin is far thinner than Western peers** — general staffing often mid-single-digit % of revenue, IT staffing low-to-high teens — so net margins of 1–3% are structurally normal, not distress | UK/European staffing headline **net fee income**; US staffing reports revenue and gross profit prominently; agency holdcos report revenue with pass-through costs disclosed, conventions changed materially post-ASC 606 |
|
||||
| Labour regulation (India-specific) | Contract Labour (Regulation and Abolition) Act 1970 and state rules; the four Labour Codes (Wages, Industrial Relations, Social Security, OSH) and their staged implementation; EPFO and ESIC contributions; state-wise minimum wages revised on a fixed cycle; Shops and Establishments Acts state by state; principal-employer liability for statutory dues, which makes compliance itself a competitive moat for large organised players | US: federal/state independent-contractor tests (including California's ABC test), joint-employer doctrine, at-will employment. UK: IR35 off-payroll rules and Agency Workers Regulations equal treatment after a qualifying period. EU: Agency Work Directive and strong dismissal protection |
|
||||
| Tax and working capital (India-specific) | GST at the standard rate on the **full billing including wages passed through**, creating a large input-credit and working-capital drag; TDS under s.194C/194J; PF/ESI deposit timing. Formalisation and GST have been a structural share gain for organised staffing over the unorganised market | Sales tax generally not applied to staffing wages in the same grossed-up way; payroll taxes are the equivalent cash-timing item |
|
||||
| IT staffing vs IT services (India-specific) | Distinct businesses that screens routinely merge. Staffing bills a markup on a deployed head, carries no delivery risk, has no offshore pyramid, no fixed-price exposure and no backlog in the services sense. **Do not** apply utilisation-and-offshore-mix, NRR, TCV or FCF/PAT frameworks from `it-saas.md`; **do not** apply EV/gross profit to an IT services exporter. The GCC (global capability centre) build-out is a demand driver for IT staffing, contract-to-hire and facilities services simultaneously | The equivalent split is contract IT staffing vs systems integration; the same warning applies but the gross margin gap is narrower |
|
||||
| Disclosure practice | Quarterly results under SEBI LODR; associates/headcount deployed, client counts and segment splits are **voluntary** and disclosure quality varies widely — read the investor presentation and concall, which are often the only source of operating KPIs. ₹ crore/lakh; April–March fiscal year; promoter holding and pledge disclosure matter; related-party note for group manpower contracts | 10-K/10-Q on EDGAR with segment and often weekly/monthly operating data; UK/European annual reports disclose NFI by discipline and geography; earnings calls give perm/temp splits and heads on assignment |
|
||||
| Regulator / oversight | SEBI for disclosure; labour ministries (central and state) for compliance; EPFO/ESIC; the Advertising Standards Council of India (self-regulatory) for advertising content | SEC; Department of Labor and state agencies; FTC for advertising practices; industry bodies for media audit and transparency standards |
|
||||
| Valuation convention | Multiples usually quoted on P/E and EV/EBITDA of reported (grossed-up) numbers — recompute EV/gross profit before comparing an Indian staffing firm with a global one, or the Indian firm will look absurdly expensive on EV/Sales-adjacent measures | EV/gross profit and EV/EBITA are the working staffing conventions; EV/net revenue for agencies |
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Confirm the family: staffing, consulting, agency, or contracted business services — and confirm it is not an IT services/BPM company that belongs in `it-saas.md`.
|
||||
- [ ] Delete ROCE, ROIC, ROA, asset turnover, P/B and EV/Sales from the analysis, and say in the report why they are inapplicable.
|
||||
- [ ] Rebuild the top line as gross profit / net fee income / net revenue, on an identical basis for every peer, and do all growth and margin work on that line.
|
||||
- [ ] Replace OPM with the conversion ratio (EBITA ÷ gross profit) and compare it to the company's own last two cycle peaks and troughs.
|
||||
- [ ] Decompose gross profit into heads × hours × spread; state which of the three produced the growth.
|
||||
- [ ] Split bill rate and pay rate separately — establish how much of "growth" is simply wage inflation passed through at a constant markup.
|
||||
- [ ] Staffing: split temp vs perm gross profit, get perm as % of gross profit, and estimate the drop-through if perm falls 30%.
|
||||
- [ ] Staffing: check contractors on assignment, orders taken, fill rate and order-to-fill trend — the earliest demand signals available.
|
||||
- [ ] Consulting: check utilisation (ex-trainees), realisation, pyramid shape, bench cost, subcontractor cost and the fixed-price share of backlog.
|
||||
- [ ] Consulting: check unbilled revenue / contract assets against revenue growth, and DSO including unbilled.
|
||||
- [ ] Agencies: state explicitly that billings are not revenue; get organic constant-currency net revenue growth with the full bridge; check staff cost ÷ net revenue.
|
||||
- [ ] Agencies: check principal vs agency media buying, use average (not year-end) net debt, and add earn-outs, deferred consideration and minority put options to enterprise value.
|
||||
- [ ] Outsourced services: check contract tenure ladder, renewal/rebid win rates, revenue under contract for 12/24 months, mobilisation cash cost, and wage-indexation clause coverage with its lag.
|
||||
- [ ] Quantify wage-inflation pass-through: what share of the book reprices automatically, what share only at rebid, and what statutory wage changes are scheduled.
|
||||
- [ ] Compute attrition (voluntary, by grade), estimate replacement cost, and identify key-person and team-lift risk in the top producers.
|
||||
- [ ] Compute client concentration on **gross profit**, not revenue, and check contract termination notice periods.
|
||||
- [ ] Build the organic growth bridge: organic + M&A + FX + pass-through/principal effects; interrogate the company's definition of "organic".
|
||||
- [ ] Total five years of "exceptional" and restructuring charges against five years of reported EBITA.
|
||||
- [ ] Normalise to mid-cycle gross profit and mid-cycle conversion ratio *before* applying any multiple; state explicitly where in the labour/ad cycle this sits.
|
||||
- [ ] Value on EV/EBITA (mid-cycle) and EV/gross profit (staffing) or EV/net revenue (agencies); model working capital as a function of gross-profit growth in any DCF.
|
||||
- [ ] Check whether reported cash conversion is helped by factoring or receivables financing, and whether DSO is drifting.
|
||||
- [ ] Score the structural threats explicitly — AI on the junior pyramid, in-housing, platform self-serve, MSP/VMS markup compression — and test the productivity claim against gross profit per internal head over five years.
|
||||
- [ ] India: check GST working-capital drag, EPF/ESI and minimum-wage exposure, Labour Code implementation status, contract-labour compliance and the contingent liabilities note for statutory claims.
|
||||
- [ ] Peer set: same family, same sub-model, same top-line convention, same labour regime, same lease standard, same cycle position — stated explicitly.
|
||||
|
|
@ -0,0 +1,215 @@
|
|||
# Pharma, biotech, CDMO, hospitals and diagnostics — sector playbook
|
||||
|
||||
Use this when: the company under analysis makes drugs or drug intermediates (formulations, API, biosimilars), does contract development or manufacturing (CDMO/CRAMS), runs clinical-stage R&D without product revenue, or delivers care (hospitals, single-specialty chains, diagnostics labs, medical devices distribution).
|
||||
|
||||
This is not one sector — it is at least five businesses with incompatible economics filed under one GICS heading, and the generic ratio set misreads all of them. The assets that produce the cash are patents, trial data, plant compliance status, prescriber loyalty and consultant relationships, and almost none of them appear on the balance sheet unless somebody bought them. Two consequences dominate everything below: **capital-employed and margin ratios are non-comparable by construction**, and **the single largest source of permanent value destruction in this sector — a regulatory action on a manufacturing site — has zero representation in any financial ratio.** Identify the sub-sector before you compute anything; a metric that is decisive for a hospital chain is noise for a biotech.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
**OPM is inverted by R&D accounting.** R&D is expensed as incurred (US GAAP ASC 730 mandates it; IAS 38 / Ind AS 38 permit only narrow development-cost capitalisation after technical feasibility). So the P&L charges the full cost of future revenue today and credits none of the asset. A company cutting R&D from 9% to 4% of sales prints +500bps of OPM and screens as "improving quality" while liquidating its 2030 revenue. Never compare OPM across pharma names without normalising for R&D intensity *and* for business mix — a branded-formulations rupee, a US-generic rupee, an API rupee and a CDMO rupee carry structurally different gross margins.
|
||||
|
||||
**ROCE and ROE are non-comparable by construction.** Build a pipeline organically and you expensed everything: capital employed is tiny and ROCE looks spectacular. Buy the identical pipeline and you carry goodwill plus acquired intangibles: ROCE looks poor and reported EPS is crushed by non-cash amortisation. Same economics, opposite scores. Hospitals sit at the far end — structurally low asset turns, and every new unit depresses ROCE for three to five years, so low ROCE during expansion is not evidence of poor quality. Only mature-unit or steady-state ROCE is informative there.
|
||||
|
||||
**P/E is undefined or distorted.** For clinical-stage biotech it is permanently undefined — negative EPS is the business model, not a problem. For commercial pharma it is distorted by intangible amortisation, IPR&D impairments, litigation settlements (opioid, talc, antitrust/price-fixing), remediation costs and lumpy upfront/milestone licensing income. Hence the market's use of "core"/"adjusted" EPS — which is itself the sector's primary earnings-management lever, so you must audit the bridge rather than accept the adjusted number.
|
||||
|
||||
**D/E and interest cover mislead at both ends.** Biotech is usually net cash; the binding constraint is runway versus burn, not leverage, and a "conservative" balance sheet with 9 months of cash is a distressed one. For hospitals, Ind AS 116 / IFRS 16 converted property rent into a lease liability plus depreciation and interest — inflating EBITDA and gearing overnight with zero economic change. An asset-light lease/O&M operator and an owned-real-estate operator are not comparable on EBITDA margin *or* D/E without an EBITDAR (pre-rent) restatement.
|
||||
|
||||
**FCF is a false negative for growth providers and CDMOs.** All the capex is front-loaded growth capex; a hospital chain adding beds, a diagnostics network adding labs, or a CDMO building a block two to three years ahead of revenue shows its worst FCF precisely when it is compounding fastest. Separate maintenance from growth capex before FCF carries any information.
|
||||
|
||||
**Reported revenue growth is not a clean signal.** In US generics the base portfolio erodes on price every single year, so flat revenue can conceal strong launches, while a single 180-day first-to-file exclusivity can add hundreds of basis points of margin that disappear on a known calendar date. And US "net revenue" is an estimate, not a fact: gross list price minus a 30–70% gross-to-net accrual for chargebacks, rebates, Medicaid/340B and returns.
|
||||
|
||||
**P/B and dividend yield are close to irrelevant.** Book value captures neither the patent estate, the approved-and-inspected plant, the prescriber franchise, nor the clinical talent. Where book value *is* large it usually means acquisitions — i.e. the least organic version of the same business.
|
||||
|
||||
**The current ratio tells you almost nothing.** Pharma structurally carries 90–150 days of inventory for legitimate reasons (batch stability testing, regulatory hold, long API lead times), so a "healthy" current ratio may just be slow-moving stock approaching expiry; hospitals and labs run negative working capital, so a low current ratio is normal and healthy.
|
||||
|
||||
---
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
All ranges below are **indicative only**. They shift with market, cycle, sub-sector and accounting period. A company's own 5–10 year history and its true peer set override every absolute band here — if a range disagrees with a well-constructed peer median, trust the peers.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **R&D intensity and productivity** | R&D as % of sales, split by type (innovative NCE/biologic vs ANDA/bioequivalence vs biosimilar); plus approvals and launches per unit of cumulative R&D over rolling 5–10 years, and peak sales or eNPV generated per rupee/dollar spent. Track trend, not level. | India plain-vanilla generics/API 4–7%; India complex generics/specialty 8–12%; global innovator 18–25% (some >30%); CDMO 3–5%; hospitals/diagnostics <1%. A US-facing generic player sustaining <5% is starving its pipeline. | R&D hits the P&L now and pays back in 3–7 years, so cutting it is the fastest way to manufacture margin and EPS that a screen reads as quality. **High OPM plus falling R&D intensity is usually a wind-down, not an edge.** A margin dip caused by a step-up in complex-generic or biosimilar spend is often the best signal in the file. |
|
||||
| **Regulatory compliance scorecard** (USFDA / EU GMP / WHO-GMP) | Per-site inspection classification (NAI / VAI / OAI), count and *severity* of Form 483 observations, warning letters, import alerts, consent decrees, EIR received or not. Critically: % of consolidated revenue, % of EBITDA and % of pending ANDAs tied to each affected site. | Zero OAI sites, zero open warning letters, zero import alerts. 483s limited to a few procedural observations, closed with an EIR within ~6 months. | The highest-impact operational KPI in Indian pharma and invisible to every financial ratio. An import alert halts that plant's US shipments **and freezes all pending approvals filed from it**, typically 2–4 years — converting a growth asset into a cost centre overnight. History (Ranbaxy, Wockhardt, Sun Halol, Lupin Goa, Divi's, Intas) says remediation takes longer and costs more than guided. Read the FDA inspection classification database and warning-letter list directly; never rely on the press release. Any site under import alert contributing >5% of revenue is a material impairment event. |
|
||||
| **Data-integrity vs procedural 483 split** | Classify each observation: procedural/documentation vs data integrity (deleted or re-run chromatograms, unofficial "trial" testing, shredded records, shared logins, disabled audit trails). | Zero data-integrity observations. | Procedural findings are a process failure; data-integrity findings are a *culture* failure and imply everything else filed from that site is suspect. They take years, not quarters, to clear and often spread to sister sites. Treat one data-integrity observation as more serious than twenty procedural ones. |
|
||||
| **ANDA/DMF pipeline with complexity mix** | Cumulative and annual ANDA filings; final vs tentative vs pending approvals; DMF filings; Para IV challenges and first-to-file 180-day exclusivities; share of filings that are complex (injectables, inhalation, ophthalmics, transdermals, peptides, depot/long-acting, 505(b)(2), biosimilars) vs plain oral solids; median filing-to-approval time. | Mid/large-cap Indian US-facing player: 10–20 filings/year, 80–150 cumulative pending, 25%+ in complex categories. Approval-to-launch *conversion* matters more than gross filing count. | Revenue two to four years out is mechanically a function of what is filed today — the only genuine forward indicator for a generics business. But mix decides the economics: a plain oral solid meets 8–12 competitors and double-digit annual erosion; a complex injectable or inhaler may meet 1–3 and hold price for years. A filing count without a complexity breakdown is a vanity metric. |
|
||||
| **Base price erosion and the revenue bridge** | Decompose reported growth: base price erosion + base volume + new launches + one-off exclusivities + FX + acquisitions. Demand it geography by geography. | US generics: −3% to −7% p.a. is normalised; −8% to −12% signals a commoditised portfolio or consortium pressure; positive base pricing is almost always shortage-driven and non-repeatable. India branded: +3% to +6% price/mix, capped on NLEM products by the annual WPI-linked DPCO revision. | Reported growth nets two large opposing forces. A company can print +10% while its base decays −12% — meaning it must launch harder every year just to stand still, a treadmill a P/E multiple should not capitalise as growth. Only the bridge separates a durable franchise from a launch-dependent one. |
|
||||
| **Revenue concentration and LOE exposure** | % of revenue *and* of EBITDA from the largest product, top five, and from limited-competition/exclusivity opportunities; % of revenue facing patent expiry, exclusivity loss or a known new entrant within 1, 3 and 5 years. Providers: % revenue from top three units/labs and largest payer. | Top product <10–15% of sales and <20% of EBITDA; 5-year LOE exposure <20–25% of revenue; no single hospital unit >20–25% of chain EBITDA. | Exclusivity profits are a wasting asset with a known expiry date, and at 60–90% incremental margins they can be 200–400bps of consolidated OPM (the gRevlimid windfall across several Indian names is the textbook case). **Applying a normal multiple to peak-exclusivity earnings is the most common single valuation error in this sector.** For innovators, the patent cliff *is* the terminal-value question. |
|
||||
| **Gross-to-net deductions and accrual adequacy** | Chargebacks, commercial and Medicaid rebates, 340B, returns, shelf-stock adjustments, copay assistance, failure-to-supply penalties, as % of gross sales; balance-sheet accrual as a multiple of one quarter's deductions; size of prior-period true-ups credited to current revenue. | US branded 45–70% of list; US generics ~30–55%. Accrual coverage stable or rising; prior-period true-ups immaterial (<1–2% of net revenue) and netting out over time rather than always favourable. | Reported US net revenue is a management estimate. Under-accruing rebates and chargebacks flatters revenue and gross margin with almost no immediate detectability, then reverses years later as an "exceptional" charge. Disclosure sits in the 10-K/20-F or the US subsidiary accounts — not in Indian standalone results. Go looking for it. |
|
||||
| **Cash runway vs net operating burn** (clinical-stage biotech) | (cash + equivalents + short-term marketable securities − near-term debt) ÷ average quarterly net cash used in operations, in months; mapped against the next value-inflecting readout and the next financing need. List committed milestone receipts, undrawn facilities and any ATM shelf separately. | >24 months comfortable; 18–24 adequate; <12 means a dilutive raise or distressed partnership is imminent almost regardless of the science. Guidance should fund *past* the next Phase II/III readout, not into it. | P/E, ROCE, D/E and FCF are undefined here; runway versus catalyst timing is the actual solvency model. A company forced to finance before a readout raises on the market's terms and dilutes holders at the worst possible price. Runway also determines management's negotiating leverage in any licensing deal. |
|
||||
| **Risk-adjusted pipeline and catalyst calendar** | Assets by phase, indication, modality and mechanism novelty, weighted by historical probability of success; dated catalysts (interim analyses, topline readouts, PDUFA/EMA/CDSCO decisions, partnering deadlines); bottom-up peak sales = eligible population × diagnosis rate × treatment rate × realistic net price after GTN × penetration × duration of therapy. | Base rates: Phase I to approval ~7–10% (oncology ~5–6%, rare/haematology 15–25%); Phase II→III ~30% (the real filter); Phase III→filing ~55–60%; filed→approved ~85–90%. Premium for validated mechanisms; discount for first-in-class novel targets. | This *is* the balance sheet for a biotech and none of it is capitalised. Two companies with identical financial statements can differ tenfold in value purely on phase mix, mechanism validation and catalyst proximity. A single-asset, single-mechanism company is a binary instrument, not a compounding business — size and value it as such. |
|
||||
| **Occupancy, ARPOB and ALOS** (hospitals — read as a triangle) | Occupancy = occupied bed-days / operational bed-days. ARPOB = average revenue per occupied bed per day. ALOS = average length of stay. Split mature units (>3–4 yrs) from ramping units, and by specialty. Diagnostics analogue: test volume growth, revenue per patient and per test, B2C vs B2B mix, same-store growth. | India mature units 65–75% occupancy (sustained >75% = capacity-constrained, capex due); blended chain 55–70%. Metro ARPOB broadly Rs 45,000–80,000/day growing 6–10%. ALOS ~3–4 days and structurally falling. US: occupancy 60–70%, revenue per adjusted admission in place of ARPOB. | Hospital revenue is arithmetically beds × occupancy × ARPOB × 365 — no income-statement ratio explains a hospital; these three do. They also trade off: falling ALOS raises throughput and ARPOB while mechanically depressing occupancy, so a genuinely improving chain can look stagnant on occupancy alone. Rising ARPOB from case-mix upgrade (oncology, cardiac, neuro, transplants) is high quality; rising ARPOB with falling footfalls is price-led and fragile. |
|
||||
| **Mature-unit margin, capex per bed, new-unit breakeven** | EBITDA margin split mature vs ramping; capex per bed for greenfield vs brownfield vs asset-light O&M/lease; months from commissioning to EBITDA breakeven, to PAT breakeven, to target ROCE. State everything consistently pre- or post-Ind AS 116/IFRS 16. | India mature units 22–30% EBITDA margin, blended chain 18–24%. Greenfield ~Rs 0.8–1.5 crore/bed in metros, Rs 0.4–0.7 crore brownfield; EBITDA breakeven 12–24 months; mature ROCE >15–18% by year 4–5. Asset-light O&M carries lower margin but far higher ROCE — compare on ROCE, not margin. | A chain in expansion always shows depressed consolidated margins, negative FCF and weak ROCE, which tells you nothing either way. Mature-unit economics and the shape of the ramp curve decide whether the capex compounds or destroys capital. **A lengthening breakeven period across successive cohorts is the earliest reliable sign of over-expansion.** |
|
||||
| **Payer mix and days in AR** | Revenue by cash/self-pay, private insurance/TPA, corporate/PSU, and government schemes (PM-JAY, CGHS, ECHS, state schemes in India; Medicare, Medicaid, commercial in the US); DSO/days in AR; disallowance rate; bad-debt / uncompensated-care provision. | India: DSO 40–70 days healthy; scheme-heavy chains run 90+. Scheme tariffs typically realise 15–35% below cash/insurance rates. US: days in AR 40–55; commercial mix drives margin; watch bad debt and charity care as separate lines. | Two hospitals with identical occupancy can have completely different profitability and cash conversion purely on payer mix. Filling beds with low-tariff scheme volume flatters occupancy and revenue growth while diluting ARPOB, stretching receivables and consuming working capital — a very common way a growing provider quietly stops generating cash. Payer concentration also creates tariff-negotiation risk no leverage ratio captures. |
|
||||
| **Field-force productivity and therapy mix** (India branded formulations) | Revenue per medical representative (MR) per month; MR headcount growth vs domestic sales growth; chronic vs acute mix; top-10 brand contribution; secondary (IQVIA/AWACS retail offtake) growth vs primary (billing) growth; % of domestic portfolio under DPCO/NLEM. | Rs 5–9 lakh revenue per MR per month for efficient players (top quartile higher); chronic mix >45–50% preferred; NLEM exposure ideally <20% of domestic sales; secondary growth tracking primary within ~200bps over four quarters. | Domestic branded formulations are the highest-quality, highest-multiple, most annuity-like part of an Indian pharma company — prescriber loyalty, not patents, is the moat. Primary persistently outrunning secondary means the channel is being stuffed and a correction quarter is coming. Chronic therapies (cardiac, diabetes, CNS, respiratory) compound with patient longevity; acute is seasonal and switch-prone. NLEM exposure caps pricing power by regulation regardless of competitive position. |
|
||||
| **CDMO capacity, utilisation and molecule-stage mix** | Installed reaction/fermentation capacity (KL or litres); utilisation %; revenue share from commercial-stage vs clinical-stage molecules; innovator vs generic customers; top-5 customer concentration; disclosed order book or committed capacity; raw-material pass-through terms. | Utilisation 70–85% (sustained >85% means expansion capex is overdue); commercial-molecule share >50% for stability; top customer <20–25% of revenue; order book covering >1x NTM revenue. | CDMO earnings look erratic on a P/E view because one molecule's phase transition, a customer's clinical failure, or a single destocking cycle moves revenue sharply. Margins cannot explain that volatility; stage mix and utilisation can. Capex must lead revenue by 2–3 years, so a weak FCF year is often the setup for the next growth phase. Concentration risk here is far more dangerous than leverage. |
|
||||
| **Working capital cycle and cash conversion** | Inventory days split RM/WIP/FG; receivable days by geography; payable days; core NWC as % of sales; CFO/EBITDA; FCF after separating maintenance from growth capex. | Pharma inventory 90–150 days is structurally normal. Receivables 60–90 days in emerging markets, 60–100 in the US given buying-consortium terms. Core NWC 25–40% of sales. CFO/EBITDA sustained >70%; providers and diagnostics >85% given negative working capital. | Working capital is where channel stuffing, disputed emerging-market receivables and expiring inventory hide. Inventory risk here is unusually severe: product becomes worthless at expiry or the day a competitor launches, and provisioning policy is discretionary. **A widening EBITDA-to-CFO gap sustained over four to six quarters is the most reliable early warning that reported profits are not real.** |
|
||||
| **Earnings-quality bridge: reported → core** | Full reconciliation: amortisation of acquired intangibles, IPR&D impairment, litigation/settlement charges, remediation, restructuring, upfront and milestone licensing income, forex and treasury "other income", PLI and export incentives, and any development cost capitalised under Ind AS 38 / IAS 38. | Acquired-intangible amortisation of 5–15% of revenue is normal for acquisitive pharma and legitimately added back if disclosed consistently. Capitalised development cost near zero, or clearly disclosed with amortisation starting at launch. Other income a small single-digit % of PBT. **Any "exceptional" appearing three years running is an operating cost.** | Reported P/E is nearly meaningless for acquisitive pharma, so the market uses core EPS — and that same adjustment mechanism is the sector's primary earnings-management lever. Your job is to decide which add-backs reflect genuine non-cash purchase accounting and which are recurring costs relabelled. A rising "intangibles under development" balance with no launches is a direct quality-of-earnings hit. |
|
||||
|
||||
---
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
There is no single method. **The sub-sector dictates the tool**, and using the wrong one produces confident nonsense.
|
||||
|
||||
### Clinical-stage biotech (no product revenue)
|
||||
Risk-adjusted NPV (rNPV/eNPV), built asset by asset. For each programme: bottom-up epidemiology peak sales, net of gross-to-net, × cumulative probability of success from the current phase, discounted at 10–14% (higher for single-asset or first-in-class), with the patent/exclusivity cliff modelled explicitly and revenue collapsing to near zero after LOE — **no perpetuity**. Sum the assets, subtract PV of unallocated G&A and expected future financing dilution, add net cash. Cross-checks used in practice: EV/cash (to find negative-EV situations), EV per programme, price-to-risk-adjusted-peak-sales (0.5–2x), and comparable licensing-deal economics (upfront + milestones + royalty %). **Do not use** P/E, EV/EBITDA, P/B, or a DCF with terminal growth — all are inapplicable.
|
||||
|
||||
### Commercial innovator pharma
|
||||
P/E on core EPS (adding back acquired-intangible amortisation), EV/EBITDA, and a DCF that models the in-line portfolio to LOE *plus* a separately risk-adjusted pipeline — effectively a sum-of-the-parts of a melting ice cube plus an option. Terminal growth must be low (0–2%) because patents expire; this is precisely why large-cap pharma structurally trades at a discount to other high-margin businesses, and mistaking that discount for cheapness is a classic error. Developed-market ranges have historically run ~10–16x core EPS and ~8–13x EV/EBITDA, with the multiple driven almost entirely by 5-year LOE exposure and pipeline depth. US IRA Medicare price negotiation and EU international reference pricing now sit inside the terminal-value assumption, not outside it.
|
||||
|
||||
### Generics and Indian pharma
|
||||
Consolidated P/E remains the headline convention (quality Indian names have historically traded ~22–35x forward core EPS, mid-caps 15–22x), but the real work is a **sum-of-the-parts by segment**, because segments deserve very different multiples. Indicative, historical, and cycle-dependent:
|
||||
|
||||
| Segment | Indicative EV/EBITDA | Why |
|
||||
|---|---|---|
|
||||
| India branded formulations | 25–35x | Annuity-like, prescriber moat, price/mix pricing power |
|
||||
| CDMO / CRAMS | 20–35x | Long contracts, high switching costs, innovator stickiness |
|
||||
| Complex generics / specialty | 15–25x | Limited competition, defensible for years |
|
||||
| API | 10–15x | Cyclical, China-price exposed, commoditising |
|
||||
| Emerging markets / RoW | 10–15x | Fragmented, FX-exposed, distributor-dependent |
|
||||
| US plain generics | 7–12x | Price-erosion treadmill, binary FDA risk, 3-consortium buyer power |
|
||||
|
||||
Always strip one-off exclusivity profits out of the base before applying any multiple, and haircut or separately value plants under regulatory action. Prefer EV/EBITDA over P/E where acquisition amortisation is large. P/B and dividend yield are close to useless.
|
||||
|
||||
### Hospitals and providers
|
||||
EV/EBITDA is primary, stated consistently pre- or post-Ind AS 116/IFRS 16. Historically the convention was **EV/EBITDAR** (rent-adjusted) precisely so owned-property and leased operators could be compared — that logic still applies, so restate to a rent-inclusive basis before comparing an asset-light operator to an owner. Because ramping units depress consolidated numbers, the more accurate approach is a unit-level DCF or a two-part valuation: mature units on a full multiple, plus new units carried at or below invested capital until they cross breakeven. Cross-checks: EV per operational bed, EV per *mature* bed, and replacement cost (which also captures the land, licence and clinical-talent barrier to entry). Indian listed chains have traded roughly 18–30x EV/EBITDA (premium names higher); large US for-profit operators far lower, ~7–10x — reflecting payer-mix and reimbursement risk, not lower quality. **P/E is poor here** because heavy depreciation on new units distorts it for years. Diagnostics chains: EV/EBITDA (India historically 25–40x, compressing as competition and online-aggregator pricing intensify), supported by same-store growth and revenue per patient. Healthcare real estate in REIT structures: FFO/AFFO and cap rates, never EBITDA multiples.
|
||||
|
||||
### Cross-cutting rules
|
||||
- Capitalise compliance risk explicitly: a plant under warning letter should be valued at a discount or excluded from the base entirely.
|
||||
- Treat regulated-price exposure (DPCO/NLEM in India, IRA and reference pricing abroad) as a **permanent margin cap**, not a cyclical headwind.
|
||||
- Never apply a peak-cycle multiple to peak-exclusivity earnings — that error compounds two mistakes in the same number.
|
||||
- For a mixed group, valuing on consolidated EBITDA alone will systematically misprice it; the segment mix *is* the valuation.
|
||||
|
||||
---
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares **business model, end-market regulator, and stage of capex cycle** — not merely the word "pharma".
|
||||
|
||||
Splits that must never be mixed in one peer set:
|
||||
- **Innovator vs generic vs API vs CDMO vs provider.** Different revenue durability, different capital intensity, different multiples. A CDMO compared to a generics maker on EV/EBITDA is meaningless.
|
||||
- **US-exposed vs India-domestic-only.** FDA binary risk, price erosion and litigation exposure are present in one and absent in the other. A domestic-branded pure play deserves a structurally higher multiple.
|
||||
- **Clinical-stage vs commercial biotech.** Once there is product revenue, the entire valuation framework changes.
|
||||
- **Owned-real-estate vs leased vs O&M hospitals.** Compare only on EBITDAR and ROCE, never on EBITDA margin or D/E.
|
||||
- **Mature-network vs expansion-phase providers.** A chain with 80% mature beds and one with 40% are at different points on the same curve; compare mature-unit metrics, not consolidated ones.
|
||||
- **B2C vs B2B diagnostics.** B2B/reference-lab revenue carries lower margin and worse receivables; a blended margin comparison is misleading.
|
||||
- **Acquisitive vs organic pharma.** Any ROCE, ROE or reported-EPS comparison across this line is invalid without normalising for goodwill and acquired-intangible amortisation.
|
||||
|
||||
Also normalise for: R&D intensity (or restate margins at a common R&D%), one-off exclusivity contribution in the base year, IFRS 16 treatment, and geographic revenue mix. Peer sets here are usually small — three to six genuine comparables beats fifteen loosely related tickers, and where no clean peer exists, the company's own 5–10 year history becomes the primary benchmark.
|
||||
|
||||
---
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Regulatory and compliance**
|
||||
- Any open USFDA warning letter, OAI classification, import alert or consent decree — and specifically 483 observations citing data integrity (deleted or re-run chromatograms, unofficial "trial" testing, shredded records, shared logins). Data-integrity findings signal culture, not process, and take years to clear.
|
||||
- Management downplaying or delaying disclosure of an inspection outcome, or describing an OAI as "procedural". Cross-check the FDA's own inspection classification database, not the press release.
|
||||
- Segment or operational disclosure *deteriorating*: geography detail withdrawn, ARPOB or occupancy no longer reported, ANDA filing counts dropped. Reduced disclosure almost always precedes bad numbers in this sector.
|
||||
|
||||
**Growth quality**
|
||||
- Growth built on a one-time exclusivity (a Para IV 180-day window, a competitor's supply failure) presented or modelled as the new base — and the multiple applied to that inflated EBITDA.
|
||||
- Reported revenue growing while base price erosion accelerates, i.e. an ever-larger share of revenue from launches. A launch treadmill needs a bigger launch every year just to stand still.
|
||||
- Licensing upfronts and milestones recognised as revenue and left inside the growth narrative, creating a base that cannot repeat.
|
||||
- Customer concentration in US generics: three buying consortia control roughly 90% of US generic purchasing, so a contract loss is a step-change, not a gradual decline. Similarly a CDMO with one innovator customer above ~25% of revenue.
|
||||
|
||||
**Accounting and earnings quality**
|
||||
- R&D intensity falling for two or more consecutive years while OPM expands, especially at a US-generics-dependent company. That is margin harvested from the future.
|
||||
- Rising "intangible assets under development" or capitalised development cost under Ind AS 38 / IAS 38 with no corresponding launches — legal, disclosed, and a direct transfer of expense from P&L to balance sheet.
|
||||
- Inventory days and receivable days rising faster than sales, particularly in the US or in emerging-market distributor businesses — the classic channel-stuffing signature. In India, compare primary billing growth with IQVIA/AWACS secondary offtake.
|
||||
- CFO/EBITDA persistently below ~60–70%, or a widening EBITDA-to-cash gap sustained four-plus quarters despite clean reported profits.
|
||||
- Favourable prior-period gross-to-net or rebate accrual reversals boosting current revenue; or a shrinking rebate/chargeback accrual relative to gross sales. Under-accrual is the most detection-resistant revenue inflator in US pharma.
|
||||
- "Adjusted EBITDA" or "core EPS" excluding the same categories every year — litigation, remediation, restructuring, impairment.
|
||||
- Heavy dependence on "other income" (forex, treasury, export/PLI incentives) to hit PBT; unhedged or undisclosed forex debt and derivative positions at exporters.
|
||||
|
||||
**Governance and legal**
|
||||
- Large or growing off-balance-sheet contingencies: opioid, talc, antitrust/price-fixing, product liability, DOJ False Claims Act and upcoding investigations, state AG actions. Read the contingencies note *before* the ratios.
|
||||
- Related-party structures: promoter-owned distribution, marketing or C&F entities; sale-and-leaseback of hospital property into promoter vehicles; low-substance overseas subsidiaries; unexplained loans and advances to related entities.
|
||||
- Auditor resignation or qualification, delayed filings, restatement, repeated CFO or company-secretary churn, or a change in the group's US subsidiary auditor. In this sector these have repeatedly preceded regulatory and accounting blow-ups.
|
||||
|
||||
**Biotech-specific**
|
||||
- Undisclosed pipeline pruning (assets quietly vanishing from the corporate deck), mid-trial changes to the primary endpoint or statistical analysis plan, claims built on open-label or single-arm data with cross-trial comparisons, subgroup-rescue after a missed primary, and insider selling or a 10b5-1 plan initiated shortly before a readout.
|
||||
- Financing distress signals: an active ATM programme, going-concern qualification, reverse stock split, royalty-monetisation or revenue-interest financing (economically debt, not always presented as such), and runway ending before the next catalyst.
|
||||
|
||||
**Provider-specific**
|
||||
- Occupancy improving only on low-tariff government-scheme volume, with flat or falling ARPOB and lengthening receivables. Also gross-billing revenue recognition before discounts and disallowances, and under-provisioning for scheme disallowances and bad debt.
|
||||
- Departure of high-revenue consultants or a whole specialty team — the asset walks out of the building, and it shows up in ARPOB and case mix two to three quarters later. Rising doctor payout as % of revenue signals loss of bargaining power.
|
||||
- Aggressive capitalisation of pre-operative and pre-commissioning expenses; lengthening breakeven across successive new-unit cohorts; owned, leased and O&M units blended into one margin without disclosure.
|
||||
|
||||
---
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Pharma is not economically cyclical, but it is intensely *policy* and *product* cyclical.** Demand is inelastic — volumes barely move with GDP — so the cycles that matter are: the patent cycle (LOE waves), the US generic pricing cycle (consolidation of buying consortia in the mid-2010s triggered a multi-year erosion shock from which the industry never fully recovered), the API cycle (China supply and pricing, plus the post-2020 destocking and restocking swings), and the CDMO cycle (biotech funding → clinical activity → order books, with a 2–3 year lag).
|
||||
|
||||
**Where to check you are in the cycle:** US price erosion running better than −5% is usually a shortage-driven upswing that will normalise; API prices near cycle highs invite Chinese capacity back; CDMO order books track biotech funding two years earlier — a funding winter shows up in CDMO revenue with a delay, so a strong current order book from a weak funding period is worth interrogating.
|
||||
|
||||
**Structural threats to underwrite explicitly:**
|
||||
- **US IRA Medicare price negotiation** and the small-molecule/biologic timing asymmetry — a permanent margin and terminal-value issue for innovators, and a change to the economics of which modalities get funded.
|
||||
- **Biosimilars** eroding the historically safest innovator revenue, and interchangeability rules accelerating substitution.
|
||||
- **China+1 and PLI** re-shoring API and key starting material capacity to India — a genuine multi-year tailwind for Indian API and CDMO, but one that also invites capacity oversupply.
|
||||
- **GLP-1s** reallocating an enormous share of global pharma spend and, over time, plausibly reducing volumes in adjacent chronic categories (cardiac, diabetes complications, some orthopaedics and bariatrics) — model second-order effects, not just direct participation.
|
||||
- **Payer consolidation and PBM reform** in the US; **PM-JAY expansion and tariff-setting** in India, which raises volume while capping realisation.
|
||||
- **Diagnostics disruption**: online aggregators and hospital-captive labs compressing pricing in a business that historically enjoyed 25–30% margins.
|
||||
- **Regulatory tightening**: revised Schedule M and stricter CDSCO enforcement in India raising the compliance-capex floor for smaller manufacturers, which consolidates the industry toward larger players.
|
||||
|
||||
**Provider structural context:** the constraint is beds, clinicians and land, not demand. Insurance penetration, medical tourism and case-mix upgrade drive the long-run compounding; the binding risks are tariff regulation (scheme rates, any price capping on procedures, stent and knee-implant style price caps recurring), clinician cost inflation, and over-expansion into low-density micro-markets.
|
||||
|
||||
---
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India (NSE/BSE, Ind-AS) | US / global (10-K, 20-F, GAAP/IFRS) |
|
||||
|---|---|---|
|
||||
| Primary filings | Annual report, quarterly results, investor presentation, **earnings concall transcript** (often the only place ARPOB, occupancy, ANDA filings, price erosion and segment splits are disclosed), stock-exchange announcements | 10-K / 10-Q / 8-K / 20-F on **EDGAR**; proxy (DEF 14A); segment and product-level revenue disclosure is mandated and far richer |
|
||||
| Units | Rs crore / lakh; convert consistently — 1 crore = 10 million | USD millions |
|
||||
| R&D disclosure | Often a single P&L line; the innovative/ANDA split usually only appears in the concall or presentation. Development-cost capitalisation permitted under Ind AS 38 — always check "intangibles under development" | ASC 730 mandates expensing; disclosure by programme is voluntary but common for innovators |
|
||||
| Regulator (product) | CDSCO, DCGI; state FDAs for licensing; revised Schedule M for GMP | USFDA (CDER/CBER), EMA, MHRA, PMDA; **the FDA inspection classification database and warning-letter list are public — use them** |
|
||||
| Price control | **DPCO / NLEM**: ceiling prices on scheduled formulations, annual WPI-linked revision; NPPA enforcement and retrospective demands | IRA Medicare negotiation, 340B, Medicaid rebates, EU international reference pricing |
|
||||
| Ownership | **Promoter holding** and pledge disclosure are central; check pledge %, promoter entities in the distribution chain, and inter-corporate deposits | Institutional and insider ownership; Form 4 insider transactions and 10b5-1 plans are highly informative pre-catalyst |
|
||||
| Audit and governance | **CARO** reporting (related-party transactions, loans and advances, statutory dues, inventory verification), auditor's report qualifications, SEBI LODR related-party approvals | SOX 404 internal-control opinion, critical audit matters, audit-committee independence |
|
||||
| Provider metrics | ARPOB, occupancy, ALOS, bed count, doctor payout %, payer mix including PM-JAY/CGHS/ECHS | Revenue per adjusted admission, adjusted admissions, case mix index, same-facility volumes, bad debt and charity care as separate lines |
|
||||
| Domestic sales tracking | **IQVIA / AWACS secondary sales data** — independent check on primary billing; no equivalent is normally needed elsewhere | IQVIA scripts (TRx/NRx) for branded products; channel data via distributors |
|
||||
| Leases | Ind AS 116 (aligned to IFRS 16) since FY20 — pre-FY20 EBITDA is not comparable to post | IFRS 16 / ASC 842; US GAAP retains an operating-lease split, so US EBITDA is *not* directly comparable to IFRS 16 EBITDA for lease-heavy operators |
|
||||
| Typical multiples | Structurally higher than global peers for domestic-branded and CDMO franchises; whole sector re-rates and de-rates on FDA news flow | Lower headline multiples for both innovators (patent cliff) and providers (payer risk) |
|
||||
|
||||
Two India-specific traps worth naming: **standalone vs consolidated** — the US business usually sits in overseas subsidiaries, so standalone numbers can look pristine while consolidated tells the real story (and the GTN accruals only exist in the subsidiary accounts); and **"other income"** from export incentives, PLI and forex, which in some years is a large share of PBT and is not operating profit.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Classify the sub-sector first (innovator / generic / API / CDMO / clinical-stage biotech / hospital / diagnostics) and pick the metric and valuation frame accordingly.
|
||||
- [ ] Pull the FDA inspection classification and warning-letter databases yourself for every manufacturing site; map each affected site to % of revenue, % of EBITDA and % of pending ANDAs.
|
||||
- [ ] Separate data-integrity 483 observations from procedural ones; treat the former as a culture problem measured in years.
|
||||
- [ ] Compute R&D intensity by type and its 5-year trend before looking at OPM; flag any margin expansion accompanied by falling R&D.
|
||||
- [ ] Rebuild the revenue bridge: base price erosion + base volume + launches + exclusivities + FX + M&A, by geography.
|
||||
- [ ] Strip one-off exclusivity and licensing-milestone profits out of the earnings base before applying any multiple.
|
||||
- [ ] Check top-product and top-5 concentration on **EBITDA**, not just revenue; quantify 1/3/5-year LOE exposure.
|
||||
- [ ] For US-facing names, find gross-to-net deductions and the accrual trend in the 10-K/20-F or subsidiary accounts; check prior-period true-ups.
|
||||
- [ ] Reconcile reported EPS to core EPS line by line; reclassify any "exceptional" recurring three years running as an operating cost.
|
||||
- [ ] Check "intangible assets under development" and capitalised development cost against actual launches.
|
||||
- [ ] Compare CFO/EBITDA and the EBITDA-to-cash gap over 4–8 quarters; split maintenance from growth capex before judging FCF.
|
||||
- [ ] India domestic: compare primary billing growth with IQVIA/AWACS secondary offtake; check chronic mix, revenue per MR, NLEM exposure.
|
||||
- [ ] Biotech: compute months of runway vs the next catalyst date; check for ATM, going-concern language, royalty financing and pipeline assets that quietly disappeared.
|
||||
- [ ] Biotech: build PoS-weighted eNPV asset by asset with an explicit LOE cliff and no perpetuity; add expected financing dilution.
|
||||
- [ ] Hospitals: read occupancy, ARPOB and ALOS together; split mature from ramping units; check payer mix, DSO and disallowance provisioning.
|
||||
- [ ] Hospitals: track new-unit breakeven period across successive cohorts; restate to EBITDAR before comparing owned, leased and O&M operators.
|
||||
- [ ] CDMO: check utilisation, commercial vs clinical molecule mix, top-5 customer concentration and order-book coverage.
|
||||
- [ ] Build a sum-of-the-parts by segment rather than valuing consolidated EBITDA on one multiple; discount or exclude plants under regulatory action.
|
||||
- [ ] Read the contingencies note, CARO observations and related-party disclosures before finalising any view.
|
||||
- [ ] Verify the peer set shares business model, end-market regulator and capex-cycle stage; where no clean peer exists, benchmark against the company's own 5–10 year history.
|
||||
254
finance/skills/stock-analysis/references/sectors/rail-freight.md
Normal file
254
finance/skills/stock-analysis/references/sectors/rail-freight.md
Normal file
|
|
@ -0,0 +1,254 @@
|
|||
# Railroads and rail freight networks — sector playbook
|
||||
|
||||
Use this when: the company owns or operates a freight rail network or earns its margin from moving freight over one — US and Canadian Class I railroads, Mexican and other national freight carriers, short lines and regional holding companies, and in India the listed rail-linked logistics operators (container train operators, private freight terminal and multimodal players) that run over Indian Railways infrastructure.
|
||||
|
||||
A railroad is not a transport company with trucks that happen to run on steel. It is a capital-intensive network utility with duopoly geography, a common carrier obligation, real pricing power, and a maintenance burden that never stops and is only partly visible in the depreciation line. The economics are closer to a regulated pipeline or a tower network than to a trucking or dry-bulk shipping business, and analysing it with a trucking cyclicality framework produces confident nonsense in both directions — it under-rates the pricing durability and under-states the capital intensity.
|
||||
|
||||
Two facts govern everything below. First, the sector's own efficiency metric — the **operating ratio** — is inverted relative to every margin metric in the generic toolkit: lower is better, and a falling OR is only good news if the network is still being fed. Second, a railroad can manufacture years of margin and free cash flow simply by under-spending on track, ties, ballast, bridges and locomotives, and the damage shows up in service metrics long before it shows up in the P&L. Most of this playbook is about telling genuine efficiency apart from deferred maintenance.
|
||||
|
||||
If the company builds rail infrastructure, rolling stock or signalling rather than operating a network (wagon and coach manufacturers, EPC contractors, RVNL/IRCON-type entities), it is a capital goods / infrastructure EPC business — use the relevant playbook, not this one. If it leases rolling stock and funds itself as a financier (IRFC-type entities), route to `references/sectors/nbfc.md`.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Most generic ratios are computable here, unlike in banking. The problem is that several are *mis-scaled*, one is *inverted by convention*, and the two that matter most — FCF and ROCE — are the easiest in the entire market to flatter. Report the sector's own metric alongside, or instead of, each of these.
|
||||
|
||||
**OPM / EBITDA margin — computable, but the wrong convention and the wrong denominator discipline.** The sector speaks in **operating ratio = operating expenses / operating revenue**, so OR ≈ 100% − OPM. Report OR. Two reasons this is not merely cosmetic: (a) every peer, every management guidance statement and every historical series is stated in OR, so converting to OPM breaks comparability with the company's own record; (b) OR moves mechanically with **fuel surcharge revenue**, which inflates both revenue and expense — a rising diesel price worsens OR arithmetically while dollar profit is unchanged or better. Always ask for OR ex-fuel-surcharge, and for the adjusted OR excluding restructuring, land sales and casualty items. EBITDA margin is worse than useless here: depreciation is a real, large, recurring economic cost of consuming a physical network, typically running to a high-single-digit to low-teens percentage of revenue. A railroad that "generates EBITDA" while its rail is wearing out has generated nothing.
|
||||
|
||||
**ROCE / ROIC on reported book — structurally overstated, sometimes grossly.** The capital employed denominator is historical-cost track, grading, tunnels, bridges and land, much of it laid down decades or a century ago and, in the case of land and grading, never depreciated and never revalued. Replacement cost of a mainline network is a large multiple of its carrying value. A railroad showing 14% ROCE on book may be earning materially less on the capital it would take to recreate the asset. This matters analytically in one direction: it makes ROCE useless for cross-sector ranking and useful only against the company's own history and direct peers with similar network vintage. It also means a *newly built* corridor will show a punishingly low ROCE for a decade against an old network's high one, with no difference in operating quality.
|
||||
|
||||
**Free cash flow and FCF yield — the single most manipulable number in the sector.** Capex is huge (structurally mid-to-high teens as a percentage of revenue, often more) and the great majority of it is *sustaining*, not growth. Because track renewal can be slipped a year or three without an immediate revenue consequence, "record free cash flow" is frequently just a capex holiday. FCF yield is informative **only after** you have separately identified maintenance capex — from the capex programme disclosure, from track miles of rail and ties installed, from the capex/depreciation ratio, and from the fleet age — and re-run FCF at a normalised sustaining level. Treat a headline FCF yield computed on reported capex as unverified.
|
||||
|
||||
**D/E, net debt/EBITDA and interest coverage — mis-signed if read against a generic band.** Stable, contracted-ish, inflation-linked cash flows over hard, mortgageable assets support far more leverage than an industrial average. Investment-grade Class I railroads run sustained net debt/EBITDA in the low-to-mid 2x range by design, much of it raised to fund buybacks, and this is a deliberate capital structure rather than distress. The signal to look for is not the level but the *use*: leverage rising while capex/revenue falls is a warning; leverage rising to fund network expansion at returns above WACC is not.
|
||||
|
||||
**Current ratio, quick ratio, working capital and inventory days — near-irrelevant.** A railroad carries essentially no saleable inventory (materials and supplies are track components and fuel), bills customers on short terms, and routinely runs a current ratio below 1 with committed revolver backup. Reading that as a liquidity problem is a category error. The real liquidity question is commercial paper access and revolver headroom in a downturn, not the ratio.
|
||||
|
||||
**Operating lease and equipment-rent treatment — check before comparing anything.** Locomotives, cars and terminals may be owned, leased or hired from other carriers (car hire and equipment rents flow through operating expense and therefore straight into OR). A carrier that leases heavily reports a worse OR and a lighter balance sheet than an identical one that owns, and lease capitalisation rules differ across accounting regimes and vintages. Normalise for lease and equipment-rent intensity before any cross-carrier OR or ROIC comparison.
|
||||
|
||||
**Asset turnover — structurally low, and not comparable to anything else in transport.** Revenue to gross assets in the 0.2–0.4x region is normal. A trucking company at 1.5x looks "more efficient" and is simply a different business: it rents the road from the taxpayer. Never rank a railroad against a trucker, a 3PL or a freight forwarder on turnover, margin or capital intensity.
|
||||
|
||||
**P/B — understates by construction.** Book equity reflects historical-cost infrastructure net of decades of depreciation, less large cumulative buybacks. P/B of 4–6x can be perfectly consistent with the stock trading below replacement value of the network. Use replacement value directly instead (see valuation).
|
||||
|
||||
**Revenue growth as an unqualified positive — must be decomposed before use.** Reported revenue change = volume × mix × core price × fuel surcharge × FX. A quarter of "8% revenue growth" that is 6 points fuel surcharge is a margin-neutral, value-neutral event. Conversely, revenue *falling* because coal volumes rolled off while core price rose 4% can be a strengthening franchise. Always decompose.
|
||||
|
||||
**EV/EBITDA used alone — misses the capital intensity that defines the sector.** Two railroads at the same EV/EBITDA can have completely different capex/revenue and therefore completely different owner earnings. Pair it with EV/EBIT and with EV/(EBITDA − maintenance capex).
|
||||
|
||||
**Depreciation itself needs reading, not accepting.** Railroads depreciate long-lived track assets over very long lives, often on group or composite methods, and the capitalise-versus-expense boundary for rail grinding, tie replacement, ballast cleaning and locomotive rebuilds is a genuine accounting choice that moves operating ratio by real amounts. A carrier that capitalises more of its renewal work reports a better OR and a worse capex line than one that expenses it, with identical physical activity. Check the property accounting policy note and the depreciation study history before comparing OR across carriers or across an accounting-policy change.
|
||||
|
||||
**ROE — flattered twice over, and not the metric to lead with.** Book equity is depressed by historical-cost accounting on the asset side and by years of buybacks on the liability side, so ROE can be spectacular at a company earning only a modest return on the capital genuinely at work. Some large networks have driven book equity down far enough that ROE ceases to mean anything at all. Use ROIC against WACC and treat ROE as a by-product of the capital structure.
|
||||
|
||||
**EPS growth taken at face value — check the share count first.** Sustained buybacks funded partly by leverage are standard capital allocation in this sector. EPS can compound for years while operating income, volume and network quality are flat. Report operating income growth, revenue ton-mile growth and per-share growth separately so the reader can see which is which.
|
||||
|
||||
**Dividend yield and payout ratio — read against FCF at normalised capex, not against EPS.** A payout ratio that looks conservative on earnings can be unaffordable once sustaining capex is set at an honest level, particularly for a carrier that has been deferring renewal.
|
||||
|
||||
**EV/Sales and PEG — no analytical content here.** Revenue per unit of enterprise value varies with commodity mix and length of haul rather than with quality, and PEG on reported EPS rewards exactly the buyback-and-defer pattern this playbook is designed to detect.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, network geography, commodity mix, gauge and electrification, regulatory regime, cycle stage and period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set and against the company's own 5–10 year history overrides every absolute band below. Bands quoted for "Class I" refer to large North American mainline freight railroads and do not transfer to short lines, Indian operators or state systems.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Operating ratio (OR), adjusted and ex-fuel** | Operating expenses / operating revenue, in percent. Compute three versions: reported, adjusted (excluding restructuring, land/asset sale gains, casualty and legal charges), and ex-fuel-surcharge (strip surcharge revenue and fuel expense from both sides). | Class I best-in-class 55–60%; 60–65% good; 65–72% average-to-improving; >75% sub-scale or structurally disadvantaged. Short lines 70–82%. State systems carrying a passenger cross-subsidy can sit near or above 95%. | The sector's defining efficiency metric, and the number management is compensated on — which is exactly why it must be interrogated. Lower is better. A 100 bps improvement on a large network is very large in absolute profit, so OR trajectory drives the multiple more than absolute margin does. But OR improves for good reasons (longer trains, better asset utilisation, higher price) and bad ones (deferred maintenance, shedding low-margin but network-feeding volume, one-off land gains in the revenue line). Never accept an OR improvement without attributing it. |
|
||||
| **Volume: revenue ton-miles (RTM) / net tonne-kilometres (NTK), and carloads / units** | RTM = tons of revenue freight × miles hauled. Carloads (and intermodal units) count shipments. Track both plus **gross ton-miles (GTM)**, which includes locomotive and car weight and is the correct denominator for productivity and fuel metrics. India: NTKM and originating tonnage; container operators report TEUs and rakes. | Judge against industrial production, the company's own history and rail-served market growth — not an absolute band. Volume shrinking while price rises is normal in secular-decline commodities and not automatically bad. | Volume and price are the two revenue drivers and they behave completely differently. Carloads tell you shipment count (drives cost — crews, switching, terminal work); RTM/NTK tells you the work performed (drives revenue and fuel). A network moving fewer carloads at longer length of haul can grow revenue while cost falls. Divergence between carload growth and RTM growth is a mix signal you must explain before scoring anything else. |
|
||||
| **Commodity mix and coal exposure** | Revenue and volume split by: intermodal, coal, grain/agricultural, chemicals and petroleum, automotive, metals/minerals, aggregates and construction, forest products. Compute coal as % of revenue *and* % of operating profit — coal is usually higher-margin than its revenue share implies. | Coal below ~10–12% of revenue is a structurally lower-risk mix for a US network today; above 20% requires an explicit run-off model. Intermodal above ~40% of volume means truck-competitive pricing dominates the revenue line. | The single largest determinant of both cyclicality and pricing power. Each commodity has a different competitive alternative: coal has almost none (captive utilities), so it carries high rates and high margin but is in secular decline; intermodal competes directly with truckload, so its price is capped by diesel-and-driver economics; grain is weather- and export-driven and lumpy; autos and chemicals track industrial cycles. Two railroads with identical OR and identical volume growth can have entirely different forward economics purely on mix. |
|
||||
| **Revenue per carload / per RTM, and core pricing** | Revenue per carload = freight revenue / carloads. Decompose the change into mix, length of haul, fuel surcharge and **core price**. Core pricing is the rate change excluding fuel and mix — compare it to a rail-specific cost inflation index (in the US, the STB's Rail Cost Adjustment Factor family; elsewhere, wage plus materials inflation). | Core pricing sustained 100–250 bps above rail cost inflation is the signature of genuine network pricing power. At or below rail inflation over several years means the moat is being competed or regulated away. | This is the moat test, and it is the most important single line of the analysis. A network with duopoly geography and captive shippers can price above its own cost inflation year after year; a network that has to match truck economics cannot. Note the asymmetry: revenue per carload can rise purely on longer haul or a shift to denser commodities, which is mix, not power. Insist on the company's own core-price disclosure and sanity-check it against revenue-per-unit trends by commodity. |
|
||||
| **Train velocity and terminal dwell** | Average train speed (mph or kph, system-wide, excluding time in terminals) and average terminal dwell (hours a car spends in a yard between movements). In the US these are filed weekly with the STB and published by the AAR; elsewhere, dig them out of investor presentations. | Class I system velocity roughly 20–26 mph in fluid conditions; terminal dwell roughly 20–28 hours. Direction and volatility matter far more than the level, which is geography-dependent. | The two headline fluidity metrics, and the earliest observable evidence of whether an OR improvement is real. A network running faster with shorter dwell is genuinely more productive: the same physical assets do more work. A network whose OR improved while velocity fell and dwell rose has bought margin with service, and will pay it back in lost volume, customer complaints, regulatory attention and eventually a costly recovery programme. Read these two metrics *before* you read the margin. |
|
||||
| **Car miles per day, cars online, trip plan compliance** | Car miles per day = total car miles / (cars online × days). Cars online = active cars on the system. Trip plan compliance = % of shipments delivered within the published plan, reported for intermodal and manifest separately. | Car miles per day rising over time is the productivity signal; cars online falling *while volume holds* is genuine asset release. Trip plan compliance in the 70–90% band is typical; a sustained fall below the company's own norm is a service failure. | These distinguish the two ways of shrinking cars online. Good: better velocity means each car does more work, so fewer are needed — car miles per day rises. Bad: volume left the network, so cars are idle or stored — car miles per day is flat or falling while cars online falls. Both look identical in a headline "we removed 15,000 cars" slide. Trip plan compliance is the customer's view of the same network and is what shippers testify about to regulators. |
|
||||
| **Train length, train starts and crew productivity** | Average train length (feet or cars), total train starts, GTMs per employee, and crew starts per thousand GTM. Also locomotive count in service vs stored, and horsepower per trailing ton. | GTMs per employee rising steadily is the core productivity series. Train length increases are real productivity up to the point where they exceed siding lengths and terminal capacity. | Running fewer, longer trains is the primary lever behind modern rail margin improvement, and it is genuine — one crew, fewer locomotives, more freight. But it has a hard physical limit and a service cost: very long trains cannot fit passing sidings, block crossings, take longer to build and break, and increase the chance a single failure strands a large amount of freight. Train length rising while trip plan compliance falls is the trade-off going the wrong way. |
|
||||
| **Fuel efficiency and fuel surcharge mechanics** | Gallons (or litres) of diesel per thousand GTM. Separately: the fuel surcharge programme — index used (highway diesel or WTI), trigger threshold, and the lag between the price move and the billed surcharge (commonly around two months). | Class I roughly 1.0–1.2 gallons per thousand GTM, improving slowly with new locomotives, distributed power and idle-reduction. Rail is several times more fuel-efficient per ton-mile than truck — that gap is the structural competitive advantage. | Fuel is one of the largest single expense lines, and the surcharge lag creates a mechanical margin swing that has nothing to do with performance: when diesel rises fast, the surcharge under-recovers and margin dips; when it falls fast, the railroad over-recovers and margin looks great. Analysts routinely mistake this for operating improvement or deterioration. Always separate the *efficiency* trend (gallons per GTM, a real long-term productivity and ESG lever) from the *recovery* effect (timing noise). |
|
||||
| **Labour cost and agreement exposure** | Compensation and benefits as % of revenue and as % of operating expense; headcount vs volume; average headcount cost; and the status of collective agreements — expiry dates, national bargaining rounds, arbitration or government-imposed settlements, crew-consist rules. | Labour typically the largest or second-largest expense, often roughly a quarter to a third of operating expense. Headcount falling faster than volume over a multi-year period is productivity; headcount cut below the level needed to recover from a demand upturn is a future cost. | Rail labour is heavily unionised, agreements are multi-year, and in some jurisdictions strikes are governed by special statutes (the US Railway Labor Act, with Congressional intervention as a live possibility; Canadian federal mediation and back-to-work legislation). The cost is therefore lumpy and partly outside management control: a national settlement can reset the wage base in one step, and back-pay accruals distort a quarter. Crew-consist and one-person-crew rules are a multi-hundred-basis-point OR question decided in bargaining and regulation, not by management. |
|
||||
| **Capex as % of revenue, and the maintenance vs growth split** | Total capex / revenue; capex / depreciation; and the disclosed split between maintenance-of-way and infrastructure replacement (rail, ties, ballast, bridges, signals) versus growth and productivity projects (new sidings, terminals, capacity, locomotives). Cross-check with physical disclosure: track miles of rail replaced, ties installed, average locomotive and car fleet age. | Structurally high: mid-to-high teens as % of revenue is the normal running rate for a mainline network, and can exceed 20% during a capacity or regulatory-driven programme. Capex / depreciation sustained near or below 1.0x for several years is a deferral flag. | This is where the sector's most important judgement sits. Maintenance capex is very large and largely irreducible — the network physically degrades under load whether or not the market is good. Management has wide discretion over *timing*, which converts into reported FCF. The physical disclosures are the honest check: ties and rail installed per year, and fleet age, cannot be spun the way a capex budget can. A company cutting rail and tie programmes while celebrating record FCF is borrowing from its own future, and the repayment comes as slow orders, derailment risk and a step-up in spend three to five years later. |
|
||||
| **ROIC vs WACC across a full cycle** | NOPAT / (net debt + equity), or the company's own defined ROIC — check the definition, since treatments of operating leases, deferred tax and goodwill differ. Compare to an estimated WACC and track the spread over at least one full freight cycle. | A mature Class I network earning a sustained few hundred basis points above WACC is a genuinely good business; ROIC in the low-to-mid teens against a high-single-digit WACC is the modern benchmark. Peak-year ROIC alone proves nothing. | The real test of whether the network creates value, and the only metric that simultaneously captures pricing power, cost control and the capital intensity that OR alone ignores. It is also the metric regulators watch: in the US the STB makes an annual **revenue adequacy** determination, and railroads earning persistently above their cost of capital face greater regulatory pressure on rates. That makes ROIC a two-edged number here — high is good for shareholders and increases regulatory risk, which is a genuinely sector-specific dynamic worth stating in the report. |
|
||||
| **Free cash flow after honest sustaining capex; FCF conversion** | Operating cash flow − *normalised maintenance* capex. Then FCF conversion = FCF / net income, and cash return to shareholders (dividends + buybacks) vs FCF. | Conversion near or modestly above 1.0x on a steady-state network is credible. Conversion well above that for several years, alongside falling capex/revenue, is deferral rather than performance. Distributions persistently exceeding FCF are being debt-funded — say so. | FCF is the number the equity story is usually told in, and the number most easily manufactured here. Recomputing it at normalised sustaining capex is the core act of diligence in this sector. Also check whether buybacks are funded from cash generation or from incremental leverage; both are legitimate, but only one is repeatable. |
|
||||
| **Incremental margin / operating leverage** | Change in operating income / change in revenue, year over year, ideally ex-fuel and ex-one-offs. | Roughly 50–65% incremental margin on volume growth in a fluid network is typical; decremental margins on the way down are usually gentler because a large share of cost is fixed but a meaningful share (crews, fuel, car hire) is variable. | Quantifies the network effect. A high incremental margin tells you the next ton over an existing network is very profitable — which is why volume defence matters more than it looks, and why shedding "low-margin" traffic under a margin programme can be value-destructive if that traffic was contributing above its variable cost and feeding density. |
|
||||
| **Service metrics and regulatory exposure** | Filed/published performance data (velocity, dwell, cars held, first-mile/last-mile service, missed switches), customer complaints and formal proceedings, rate case activity, demurrage and accessorial revenue as % of total, and safety data — derailments and accident rates per million train miles. | Demurrage/accessorial income should be a small, stable share of revenue. Accident rate flat-to-improving. Any formal regulatory service proceeding is a material event. | Service quality is the leading indicator of both volume and regulation. Deteriorating fluidity brings shipper complaints, regulator hearings, emergency service orders and, historically, structural rule changes (rate relief, switching access) that permanently reduce pricing power. A jump in demurrage and accessorial revenue often means the *railroad's own* congestion is being billed to customers — flattering revenue while the underlying network worsens, and reliably attracting regulatory attention. |
|
||||
| **Land, right-of-way and non-freight income** | Acreage and route miles owned vs leased; trackage and haulage rights granted or received; real estate, fibre/telecom easement, pipeline crossing and lease income; land sale gains in the P&L. | Non-freight income small and consistent; land sale gains should be excluded from adjusted OR and from any run-rate earnings. | The right-of-way is an irreplaceable asset — contiguous corridors through built-up land cannot be assembled again at any realistic cost, which is the ultimate source of the duopoly. It also carries optional value (easements, data conduit, redevelopment) that never appears at fair value on the balance sheet. But land gains dropped into the revenue or other-income line flatter OR and earnings; strip them, then value the optionality separately if it is material. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
Railroads are enterprise-value businesses with real debt, real assets and long-lived cash flows. Unlike financials, the whole EV toolkit applies — but every multiple must be read against the OR trajectory, the ROIC-WACC spread and the honesty of the capex line, or it is just a number.
|
||||
|
||||
**Primary — EV/EBITDA and EV/EBIT, read against operating ratio trajectory and ROIC.** Class I railroads have historically traded in a broad EV/EBITDA band around the low-to-mid teens, with the position inside that band determined almost entirely by (a) where OR is versus where the market believes it can get to, and (b) whether ROIC exceeds WACC and is widening. A railroad at 68% OR trading at a discount is not cheap if there is no credible plan to get to 60%; a railroad at 58% OR is not expensive if the improvement is real and price is still compounding above rail inflation. Always carry **EV/EBIT alongside EV/EBITDA**, because depreciation here is a genuine economic cost and the D&A gap between an old, heavily depreciated network and a recently rebuilt one is large.
|
||||
|
||||
**Capital-intensity-adjusted multiple.** Compute **EV / (EBITDA − normalised maintenance capex)**. This is the honest version of the cash multiple and it is where capex deferral gets caught: a company whose EV/EBITDA looks cheap and whose capex-adjusted multiple looks expensive is under-investing. Do this before quoting any FCF yield.
|
||||
|
||||
**DCF with an explicit, separately-stated maintenance capex line.** The right structure for a network: model volume by commodity (with coal on an explicit decline path), core price separately from fuel surcharge, OR trajectory with an argued endpoint, and **maintenance capex as its own line that does not fall when the model wants free cash flow**. Long asset lives and stable demand make a DCF more reliable here than in most cyclicals, provided the terminal-year capex is at least depreciation and realistically above it. Sensitivity on core price versus rail cost inflation is the most informative sensitivity in the model.
|
||||
|
||||
**Replacement value of the network.** Estimate what it would cost to rebuild the route structure — right-of-way acquisition, grading, tunnels and bridges, track, signalling, yards and terminals — and compare to EV. For dense corridors through developed land the answer is usually "you could not, at any price," which is the quantitative expression of the moat and a hard floor under long-run value. Use it as a cross-check and a downside anchor, never as a target price: replacement value says nothing about whether current returns justify the asset.
|
||||
|
||||
**FCF yield — only after maintenance capex is honestly identified.** State explicitly in the report what sustaining capex you assumed, how you derived it (capex/depreciation history, physical renewal disclosures, fleet age, management's own maintenance-vs-growth split) and what the yield would be at that level versus at reported capex. A FCF yield quoted off a deferral year is a number that will not repeat.
|
||||
|
||||
**P/E — usable, but cycle- and OR-aware.** Rail earnings are cyclical on volume and mechanically noisy on fuel surcharge lag. Normalise: mid-cycle volume, core price at trend, fuel surcharge neutral, no land gains. A trough-volume P/E looks high and a peak-volume P/E looks low; both mislead in the usual direction.
|
||||
|
||||
**Sum-of-the-parts where the entity is mixed.** Many rail-linked companies are not pure networks: an operator may combine rail haulage, terminals and warehouses, a coastal shipping arm, a trucking fleet and a 3PL contract-logistics business, each with different capital intensity and different multiples. Value the rail-linked network business on its own metrics, the asset-light logistics arm on a services multiple, and terminals/real estate on an asset or yield basis. Reporting one blended EV/EBITDA across that mix is one of the most common errors in this sector, particularly in India.
|
||||
|
||||
**Scenario the operating ratio explicitly.** Because a single point of OR on a large network is a very large absolute profit number, the valuation is far more sensitive to the OR endpoint than to volume assumptions. Build three cases — OR holds, OR improves by the amount management guides, OR reverts because the improvement was service-funded — and show what each does to equity value. If the bull case requires an OR the network has never achieved and the fluidity metrics are deteriorating, say so in one sentence rather than burying it in a sensitivity grid.
|
||||
|
||||
**Control and M&A value.** Rail transactions are priced on network fit — the value of a contiguous corridor to an adjacent owner, of a short line to the Class I it feeds, of a terminal to an operator that already controls the lane — rather than on standalone multiples. Merger approval is a genuine gating risk in North America, where the competitive standard is demanding and conditions can include granting access to the very corridors that create the moat. Do not capitalise an unapproved merger's synergies.
|
||||
|
||||
**Cost of capital deserves more care than usual.** Long asset lives, high fixed costs and a duopoly position argue for a lower equity risk premium than the industrial average; regulatory exposure to rate and access rules argues the other way, and the effect is asymmetric because regulation bites hardest exactly when returns are highest. For cross-border networks, model each country's cash flows and discount rate separately rather than blending — a network spanning several currencies and regulatory regimes is not one asset.
|
||||
|
||||
**Cross-checks.** EV per route mile / per track kilometre against comparable transactions; EV per carload or per TEU of annual throughput; dividend and buyback sustainability against FCF at normalised capex; and a reverse-valuation test — solve for the OR and the core-price spread implied by today's price, then ask whether the network's own history and fluidity metrics support it.
|
||||
|
||||
**Do not use:** P/B as a primary method (book value bears no relation to network worth); EBITDA multiples quoted without a capex adjustment; FCF yield on reported capex; trucking or shipping sector multiples as a benchmark; or any comparison of margin, asset turnover or capital intensity against asset-light freight brokers and forwarders.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares the *asset model, regulatory regime, geography and commodity mix* — not the word "rail". The commonest error in the sector is comparing an operator that runs trains on someone else's tracks with a railroad that owns the tracks.
|
||||
|
||||
**Splits that must never be mixed:**
|
||||
|
||||
- **Infrastructure-owning railroads vs train operators running on third-party track.** The first owns the right-of-way, bears the maintenance capex and captures the network rent; the second buys haulage and is a margin-taker with a fraction of the capital intensity, a completely different OR, and no pricing moat. This is the single split that matters most, and it is exactly the line between a US Class I and a listed Indian container train operator.
|
||||
- **Class I mainline railroads vs short lines and regional holding companies.** Short lines run higher operating ratios, feed the Class I networks, have far shorter hauls, and are often valued on acquisition-roll-up logic rather than network economics.
|
||||
- **Freight-only vs mixed freight-and-passenger networks.** A network carrying a socially-priced passenger obligation has policy-set tariffs, a cross-subsidy running through the freight rate, and an operating ratio that is not comparable to a commercial freight carrier's at any level.
|
||||
- **Commodity-mix cohorts.** A coal-and-bulk-heavy network, an intermodal-heavy network and a chemicals/manifest-heavy network face different pricing regimes, different cyclicality and different asset needs. Match the mix before comparing OR.
|
||||
- **Regulatory regimes.** US STB-regulated, Canadian, Mexican, EU open-access (where track and operations are legally separated and multiple operators compete on the same infrastructure), Indian state-monopoly-with-private-participation. Open-access markets have structurally lower operator margins and no geographic duopoly — never benchmark them against a vertically-integrated North American network.
|
||||
- **Networks with different length of haul and density.** A long-haul, low-density transcontinental network and a short-haul, high-density regional network have structurally different revenue per carload, crew cost per ton-mile and terminal intensity. Length of haul alone can explain most of an apparent revenue-per-unit gap.
|
||||
- **Rail operators vs the rail supply chain.** Wagon and locomotive manufacturers, signalling and EPC contractors, wagon-leasing financiers and rolling-stock lessors are different sectors with different playbooks. Their fortunes correlate with rail capex, not rail freight economics.
|
||||
- **Pure networks vs diversified logistics groups.** If rail is under roughly half of EBITDA, it is a logistics company with a rail arm; do the SOTP and compare the segments separately.
|
||||
|
||||
**Also align:** fiscal year end (Indian companies April–March, most North American railroads calendar); accounting regime (Ind-AS vs US GAAP vs IFRS — lease treatment and capitalisation policies for track renewal differ, and capitalise-vs-expense choices on rail grinding, ties and rebuilds move OR by real amounts); gauge, electrification and double-stacking capability, which cap the productivity ceiling; network density and average length of haul; and the degree of vertical integration into terminals and last-mile trucking.
|
||||
|
||||
**Build the peer comparison on operating metrics first, financials second.** Velocity, dwell, car miles per day, GTMs per employee, gallons per thousand GTM and capex per route mile are more comparable across networks than margins are, because they are physical. Two carriers with the same OR and very different fuel efficiency or crew productivity are not equally good businesses — one has better price or mix hiding worse operations. Rank on the physical metrics, then explain the financial gap.
|
||||
|
||||
**Two comparisons that are always wrong and are made constantly:**
|
||||
|
||||
- **Railroad versus trucking company.** A trucker rents its right-of-way from the taxpayer, turns its asset base several times faster, has near-zero barriers to entry, and no pricing power beyond the spot market. Comparing margin, asset turnover, capex intensity or ROCE across the two says nothing. They meet only at the competitive boundary — truckload rates cap intermodal pricing — and that is a demand relationship, not a valuation comparison.
|
||||
- **Railroad versus dry-bulk or container shipping.** Shipping is a global, near-commodity, order-book-driven business where capacity can be added by anyone with a shipyard slot and returns are destroyed by newbuild cycles. A rail network cannot be replicated at all. Rail cyclicality is industrial-demand cyclicality; shipping cyclicality is supply cyclicality. The frameworks share almost nothing.
|
||||
|
||||
Aim for 4–8 peers. There are very few large listed railroads globally, so a thin peer set is normal — when it is, lean harder on the company's own 5–10 year history and say so explicitly in the report. Where the peer set has to cross regulatory regimes to reach a usable size, benchmark operating metrics (velocity, fuel efficiency, GTMs per employee) rather than margins and multiples, and state the limitation.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Operating ratio improving while velocity falls, dwell rises and trip plan compliance deteriorates.** The defining failure mode of the sector. Margin has been taken out of service quality, and the bill arrives as lost volume, regulatory intervention and an expensive recovery. Always read fluidity metrics in the same breath as OR.
|
||||
- **Capex falling as a percentage of revenue, or capex/depreciation drifting below ~1.0x, while FCF hits records.** Deferred maintenance dressed as cash generation. Corroborate with physical disclosures: rail miles and ties installed, bridge programme, average locomotive and car fleet age. A shrinking renewal programme on a network with flat volume is a three-to-five-year problem being created today.
|
||||
- **Headcount and locomotive cuts that leave no surge capacity.** Furloughing crews and storing locomotives improves OR immediately and looks like discipline — until volume returns and the network cannot absorb it, producing a service meltdown, emergency hiring at premium cost, and customer defection to truck. This has happened repeatedly and is the classic PSR over-shoot.
|
||||
- **Yard, siding or line closures presented purely as cost savings.** Closing a hump yard, lifting a siding or embargoing a branch permanently removes optionality and capacity that cannot be cheaply restored, and it is irreversible in a way headcount is not. Ask what the closed asset was doing and what happens to that traffic when volume recovers.
|
||||
- **Volume shed deliberately to improve the ratio.** Walking away from low-rate but density-feeding traffic raises OR arithmetically and can lower absolute profit and long-run network value. Check whether revenue per carload rose because price rose or because the cheap freight was pushed off. Ask what the incremental margin on the departed traffic actually was.
|
||||
- **Shifting equipment off balance sheet to flatter capital metrics.** Selling and leasing back locomotives or cars raises ROIC and cuts capex while raising equipment rents inside the operating ratio. It is a financing decision dressed as an operating one; reverse it before comparing to peers.
|
||||
- **Rising demurrage, storage and accessorial revenue.** Frequently a symptom of the railroad's own congestion being billed to shippers. It flatters revenue and OR while the network deteriorates, and it is a reliable precursor to complaints and regulatory scrutiny.
|
||||
- **Revenue growth that is mostly fuel surcharge.** Decompose every reported growth number into volume, mix, core price and fuel. Surcharge-driven growth is margin-neutral at best and OR-dilutive arithmetically.
|
||||
- **Core pricing at or below rail cost inflation for several years.** The moat is eroding — either to truck competition, to a resurgent competing route, or to regulatory pressure. This is the quietest of the red flags and the most consequential.
|
||||
- **Concentration in a single commodity, single customer or single corridor.** A coal-heavy network facing utility retirements, a grain network exposed to one export programme, an automotive-heavy corridor exposed to one manufacturer's plant decisions. Concentration converts a customer-level event into a network-level one.
|
||||
- **Slow orders rising, or the disclosure of them disappearing.** Slow orders — speed restrictions imposed on sections of track pending repair — are the most direct physical evidence of deferred maintenance. They lengthen transit times, consume crew hours and compound congestion. Where disclosed, track the trend; where not disclosed, treat velocity deterioration on a stable volume base as the proxy.
|
||||
- **Fleet age rising while capex falls.** An ageing locomotive fleet consumes more fuel per GTM, fails more often (each failure stranding a whole train), and eventually forces a bunched replacement cycle at a time not of management's choosing. Same logic for the car fleet and for bridges.
|
||||
- **Safety and derailment trend deterioration.** Beyond the human and environmental cost, a serious incident triggers regulatory response, litigation, remediation cost, insurance repricing and reputational damage with shippers and legislators, and is often the visible consequence of the deferred maintenance the numbers were hiding.
|
||||
- **Buybacks funded by leverage while the network under-invests.** Leverage rising, capex falling, EPS rising on a shrinking share count — an arithmetic improvement in per-share metrics with no improvement in the business. Track capex/revenue and net debt/EBITDA on the same chart as EPS.
|
||||
- **Adjusted OR carrying persistent "one-off" adjustments.** Restructuring charges every year, recurring land sale gains booked above the operating line, casualty reserve releases. Recompute OR on a clean, consistent basis over five years.
|
||||
- **Regulatory escalation.** Rate case losses, an adverse reciprocal switching or open-access rule, a revenue adequacy finding used against the carrier, service-related emergency orders, or a merger condition imposing open access on a corridor. Each permanently changes the pricing equation; none of them appears in this year's ratios.
|
||||
- **Management incentives tied predominantly to operating ratio.** Directly encourages the deferral and volume-shedding behaviours above. Read the remuneration disclosure and check whether service, safety and volume metrics carry real weight.
|
||||
- **A change in capitalisation policy, depreciation lives or a new depreciation study, arriving alongside an OR improvement.** Moving renewal spend from expense to capex, or extending asset lives, improves OR and earnings with no change in the physical railroad. Check the accounting policy note whenever a step-change in margin has no corresponding step-change in an operating metric.
|
||||
- **Withdrawal or redefinition of a previously disclosed operating metric.** A carrier that stops publishing trip plan compliance, changes how velocity is measured, or moves to a "new methodology" for dwell in the same period the number turns is telling you something. Rebuild the series on the old definition where possible.
|
||||
- **Growth capex justified by volume that has not been contracted.** New terminals, sidings and capacity projects should have identifiable committed volume or a specific bottleneck behind them. Speculative capacity on a network with flat volume earns a return below WACC for a very long time.
|
||||
- **Pension, casualty and environmental liabilities under-reserved.** Long-lived unionised networks carry large legacy obligations — personal injury and occupational claims, environmental remediation on old yards and rights-of-way, and defined-benefit pensions. These sit off the operating ratio and surface as cash calls. Check the reserve trend and the discount-rate assumption.
|
||||
- **Contract structure hiding the pricing story.** Long-term contracts repricing on a lagged index look like stability until the index turns; a large share of revenue coming up for renewal in one year is a concentrated repricing event. Ask what proportion of the book reprices when, and on what index.
|
||||
- **Interchange and haulage disputes with connecting carriers.** A network dependent on a competitor's terminal, bridge or trackage rights for a major lane has a cost and service exposure it does not control. Check trackage-rights agreements and their renewal terms.
|
||||
- **A "one-time" service recovery programme that recurs.** Recovery cost booked as unusual in consecutive years means the network is running at or beyond capacity as a normal state, not suffering an event.
|
||||
- **India-specific — dependence on a policy-set haulage rate.** For operators running over Indian Railways, a haulage charge revision, an empty-flow or terminal-access policy change, or a diesel/electric traction cost pass-through decision can reset the entire margin structure in one notification, with no warning in the financials.
|
||||
- **Customer countervailing power building.** Large shippers responding to poor service by building private fleets, signing trucking capacity, relocating plants off-rail or lobbying for access remedies. Each is a permanent, not cyclical, loss of pricing power, and each is visible in trade press and regulatory filings long before it appears in volume.
|
||||
- **India-specific — terminal and land economics carrying the earnings.** If a rail-linked operator's profit increasingly comes from terminal handling, warehousing or land monetisation rather than from freight movement, it is becoming a real-estate and infrastructure business. That may be fine, but it must be valued as one, and the rail volume story should stop being the headline.
|
||||
- **India-specific — EXIM concentration and empty running.** A container train operator whose volume is concentrated on one port pair, or whose empty-running ratio is deteriorating, is carrying a cost problem that revenue per TEU alone will not reveal.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The freight cycle is industrial, not consumer.** Volumes track industrial production, housing starts, auto builds, agricultural harvests and export programmes rather than retail sentiment, and intermodal tracks the container import cycle with a port-to-inland lag. Because a large share of cost is fixed, profit is more cyclical than volume, and OR worsens on the way down before management can adjust crew and locomotive levels. Judge a network by its through-cycle OR and ROIC, never by a peak or trough year.
|
||||
|
||||
**Seasonality and weather are real operating variables, not noise to be smoothed.** Winter operations on northern networks reduce train length (air brake limitations in extreme cold), slow velocity and raise cost; spring flooding, hurricanes and wildfires close corridors outright; the grain harvest and export programme concentrate demand into specific quarters. A quarter-on-quarter OR deterioration in a severe winter is not a franchise event. Conversely, a mild year flatters the comparison. Always compare like quarters and check what the weather did.
|
||||
|
||||
**Service recovery has its own cycle, and it is expensive.** Once a network goes fluid-to-congested, recovery requires hiring and training crews (a months-long lead time), returning stored locomotives to service, and temporarily running the railroad less efficiently to clear backlogs. Cost rises before volume returns, so OR worsens for several quarters after the demand recovery has begun. Analysts who read that as structural deterioration sell the recovery; analysts who read a congestion-driven revenue spike as strength buy the peak.
|
||||
|
||||
**Coal is in structural decline and must be modelled as run-off, not cycle.** Utility retirements, gas substitution and renewables have permanently reduced domestic thermal coal volumes in developed markets; export metallurgical and thermal coal is more durable but price- and trade-policy-dependent. Coal's disproportionate contribution to operating profit means its decline compresses margin faster than it compresses revenue. Do not model a coal recovery into a terminal value.
|
||||
|
||||
**Intermodal is the growth vector and the truck-competitive one.** Rail's structural fuel efficiency per ton-mile gives it a large cost advantage over trucking on long hauls, which is why intermodal has taken share for decades. But its price ceiling is set by truckload economics: when truck capacity is abundant and spot rates collapse, intermodal loses both price and share; when trucking is tight or driver supply is constrained, intermodal price and volume both rise. Model intermodal against the truck cycle, not against GDP. Service reliability is the binding constraint on further share gain — shippers pay for predictability, and a network with poor trip plan compliance cannot convert truck freight regardless of price.
|
||||
|
||||
**Density is the network effect, and it is the reason volume defence matters.** A rail network's cost per ton-mile falls with traffic density on a corridor: the same track, signalling, crew base and terminal absorb more freight. That is why the incremental margin is high, why losing a lane to truck is worse than the revenue loss suggests, and why a network that has thinned its traffic to improve a ratio has quietly raised its own unit cost. Density also explains why the strongest corridors are almost impossible to attack — a challenger would need volume to be cost-competitive and needs to be cost-competitive to win volume.
|
||||
|
||||
**Network effects and duopoly geography are the moat.** Freight rail in North America is effectively a set of regional duopolies with interchange between them; most large shippers have access to one or two railroads, and only a minority are genuinely dual-served. This geography — not brand, technology or scale in the ordinary sense — is what produces sustained above-inflation pricing. It is also why the regulatory question is always about *access*: reciprocal switching, trackage rights and merger conditions all attack pricing power by manufacturing a second option for captive shippers.
|
||||
|
||||
**Land and right-of-way are irreplaceable and under-stated.** Contiguous corridors through developed land cannot be reassembled. That is simultaneously the source of the moat, the floor under asset value, and the reason regulators treat railroads as quasi-utilities rather than ordinary competitors.
|
||||
|
||||
**Precision scheduled railroading (PSR) — the central operating debate.** PSR runs freight on fixed schedules with longer, less frequent trains, points-based operation rather than hub-and-spoke switching, and aggressive removal of cars, locomotives, yards and headcount. Applied well it delivered large, durable OR improvements and genuinely faster asset cycles. Applied dogmatically it removed the buffer capacity that absorbs demand surges and weather, degraded first-mile/last-mile service, pushed customers to truck, and drew regulatory intervention. When analysing a PSR programme, ask three questions: did velocity and car miles per day improve alongside the OR (real productivity) or deteriorate (extraction); did volume grow or shrink over the same period; and did capex per route mile hold. Margin gains that pass all three are structural. Margin gains that fail them are a loan.
|
||||
|
||||
**The common carrier obligation is an asymmetry worth naming.** Where it applies, a railroad must provide service on reasonable request over its lines — it cannot simply refuse unattractive freight the way a trucker can decline a load. That obligation is the political price of the franchise, it constrains how far a margin programme can go in shedding traffic, and it is the hook through which regulators intervene when service fails. A margin story that depends on walking away from customers is running against a legal duty as well as against network density.
|
||||
|
||||
**Regulatory posture moves with service quality.** The historical pattern is consistent: deregulation and consolidation produce a period of strong pricing and returns; service failures and shipper complaints then produce regulatory push-back on access and rates. Always check what is currently in flight at the regulator before extrapolating today's core pricing.
|
||||
|
||||
**Safety and labour rulemaking is a slow-moving cost variable with step changes.** Crew-size mandates, hours-of-service rules, train-length and inspection requirements, hazardous-materials routing and signalling mandates all arrive through rulemaking rather than negotiation, and each can reset the cost base or the productivity ceiling in one step. They tend to tighten after high-profile incidents, which is precisely when a carrier with a deteriorating safety record is least able to absorb them. Check what is in the rulemaking pipeline before extrapolating a productivity trend that depends on crew or train-length flexibility.
|
||||
|
||||
**Consolidation is nearly complete in North America and only partly begun elsewhere.** Decades of merger activity have left a small number of very large networks, each with regional pre-eminence and interchange dependence on the others. Further large combinations face a demanding competitive standard and conditions designed to preserve or create shipper choice, which caps the upside from consolidation-driven pricing. Short-line roll-ups remain a live source of value, but the economics there are acquisition-multiple arbitrage and feeder-traffic capture, not network rent.
|
||||
|
||||
**Inflation is broadly a friend, with a lag.** Rail contracts and tariffs commonly escalate on cost indices, the asset base is already built at historical cost, and the replacement cost of competing capacity rises with inflation — so a network with genuine pricing power passes cost through and widens the gap to a truck alternative whose driver and equipment costs rise faster. The lag is the risk: labour settlements and fuel move before indexed rate increases catch up, so a rapid inflation acceleration compresses margin for several quarters before it helps.
|
||||
|
||||
**Longer-term structural questions to score explicitly:** decarbonisation (rail is the low-emission long-haul mode, a genuine tailwind, offset by exposure to fossil freight); battery and hydrogen locomotives and their capex implications; autonomous trucking as a potential long-run threat to intermodal's cost advantage; nearshoring and shifting trade lanes redrawing which corridors matter; and, in India, the modal-share reversal that dedicated freight corridors are explicitly designed to achieve.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
The structural difference is fundamental and must be stated at the top of any Indian rail analysis: **there is no listed Indian equivalent of a Class I railroad.** The network is owned and operated by the state. Listed Indian companies participate in rail freight as *users* of that network, not owners of it, so almost none of the network-rent economics above transfers directly to them.
|
||||
|
||||
| Dimension | India | US / global |
|
||||
|---|---|---|
|
||||
| Who owns the network | Indian Railways, a departmental undertaking under the Ministry of Railways — a vertically integrated state monopoly over track, signalling, traction and most rolling stock. Not listed, not investable directly. Its own operating ratio is published in the Railway Budget documents and has historically hovered near or above the mid-90s, because freight tariffs cross-subsidise below-cost passenger fares | Investor-owned Class I railroads own their right-of-way, track and terminals outright, are freight-only, and are among the most profitable large transport assets in the world |
|
||||
| How listed companies participate | Container train operators licensed to run container rakes over IR track (categories by geography, since the 2006 liberalisation), private freight terminals and inland container depots, wagon investment and leasing schemes (general-purpose wagon investment, liberalised wagon investment, private freight terminal policies), automobile freight train operators, and multimodal/3PL groups with a rail arm | Direct ownership of the network; short lines and regionals feed the Class I system under interchange agreements |
|
||||
| The economics of a listed Indian rail-linked operator | Buys **haulage** from Indian Railways at policy-set rates and resells door-to-door service. Owns rakes, containers, terminals and trucks, not track. Therefore: far lower capital intensity than a Class I, no right-of-way moat, no core pricing power over the underlying haul, margin squeezed between IR haulage revisions and customer rates, and a business that is fundamentally a **terminal, asset-utilisation and multimodal margin business** — closer to a logistics operator than a railroad. Never apply a Class I operating ratio, capex/revenue or ROIC framework to it | Network rent, common carrier obligation, captive shipper pricing, regulated rate reasonableness, enormous sustaining capex |
|
||||
| Key operating metrics for Indian operators | TEUs and rakes handled; EXIM vs domestic mix; realisation and margin **per TEU**; empty running ratio (both directions); rake turnaround days; double-stacking share (constrained by overhead electrification on many routes); terminal throughput and land bank; haulage cost as % of revenue; port-pair concentration | RTM/GTM, carloads, OR, velocity, dwell, core pricing, gallons per thousand GTM, capex/revenue |
|
||||
| Dedicated freight corridors (India-specific) | The Eastern and Western DFCs are purpose-built high-axle-load freight-only corridors intended to raise average freight speed, allow double-stack containers and longer/heavier trains, and reverse rail's declining share of national freight (the rail modal coefficient has fallen over decades to well under a third). Their commissioning changes transit times, cost per TEU and route economics for private operators — model this as a structural shift, not a cyclical one, and check corridor-by-corridor which of an operator's lanes actually benefit | No direct analogue; capacity comes from incremental double-tracking, siding extensions and terminal investment on existing corridors |
|
||||
| Regulator / policy | Ministry of Railways sets freight tariffs, haulage charges, terminal access policy and wagon scheme terms administratively — policy risk arrives as a circular, not a proceeding. No independent economic rail regulator with tariff-setting power comparable to the STB. SEBI governs disclosure for the listed operators | US STB: common carrier obligation, rate reasonableness proceedings (stand-alone cost and simplified tests, with a revenue-to-variable-cost threshold before jurisdiction attaches), annual revenue adequacy determination, reciprocal switching rules, merger review with a competition-enhancing standard. Canada has interswitching and maximum grain revenue entitlement; the EU mandates infrastructure/operations separation and open access |
|
||||
| Accounting and reporting | Ind-AS; ₹ crore and lakh; fiscal year April–March; quarterly results with investor presentation and concall. Promoter holding matters, and several rail-linked entities have government promoters, which brings policy alignment and policy risk simultaneously. Operating KPIs are disclosed less consistently than in North America — build the series from concalls and presentations | 10-K / 10-Q on EDGAR under US GAAP; calendar year; weekly carload and performance data filed with the STB and published by the AAR, giving near-real-time volume and service visibility that has no Indian equivalent |
|
||||
| Valuation convention | EV/EBITDA and P/E on the operator, with lease and terminal assets examined explicitly; SOTP where rail, trucking, warehousing and freight forwarding coexist; land and terminal real estate valued separately. Replacement-value-of-network logic does **not** apply — the operator does not own the network | EV/EBITDA and EV/EBIT against OR trajectory and ROIC; DCF with explicit maintenance capex; replacement value of the network as a downside anchor |
|
||||
|
||||
**One further India-specific caution.** Because the listed operators sit downstream of a state monopoly, their earnings quality depends on a policy relationship rather than on a contractual or regulated one. There is no rate case to bring and no independent tribunal to appeal a haulage revision to. That argues for a lower terminal multiple than the operating metrics alone would suggest, and for explicit scenario work on haulage cost per TEU. Equally, the same relationship can deliver step-change benefits — corridor commissioning, wagon scheme liberalisation, terminal policy easing — that no financial model would have forecast from history. Score policy in both directions rather than assuming continuity.
|
||||
|
||||
**Also note (India):** rail-linked capital goods and EPC companies (wagon and coach builders, track and signalling contractors, project execution arms) move with the government's rail capex budget, not with freight volumes, and belong in a different playbook. Rolling-stock financing entities are lenders, not operators. Passenger-side listed entities (ticketing, catering, tourism) share a name and almost nothing else with freight economics — do not put them in a rail freight peer set. Wagon-leasing and wagon-investment scheme participants earn a haulage rebate or assured-rake economics rather than freight margin, so their return profile is closer to a lease yield than to an operating business, and the analysis should say which of the two the company actually is. Where a group spans several of these — operator, terminal owner, wagon investor, road fleet — insist on segment disclosure before writing any consolidated multiple.
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Establish first whether the company **owns the network** or runs trains on someone else's — the entire framework depends on the answer.
|
||||
- [ ] Confirm the entity is a freight network or operator, not a rail EPC, rolling-stock manufacturer, lessor or passenger-services company — route elsewhere if so.
|
||||
- [ ] Build the physical operating-metric comparison before the financial one; explain any margin gap the physical metrics do not support.
|
||||
- [ ] Check slow orders, locomotive and car fleet age, and bridge programme status as direct evidence on maintenance adequacy.
|
||||
- [ ] Identify interchange, trackage-rights and terminal dependencies on connecting carriers, and their renewal terms.
|
||||
- [ ] Model each country's cash flows and discount rate separately for a cross-border network.
|
||||
- [ ] Report operating ratio, not OPM; compute reported, adjusted and ex-fuel-surcharge versions over at least five years.
|
||||
- [ ] Decompose revenue change into volume, mix, length of haul, core price and fuel surcharge before scoring growth.
|
||||
- [ ] Compare core price growth to rail cost inflation over 3–5 years — this is the moat test.
|
||||
- [ ] Pull the commodity mix; compute coal as % of revenue and % of profit; model coal as secular run-off.
|
||||
- [ ] Read velocity, terminal dwell, car miles per day and trip plan compliance *before* reading the margin; check whether OR improvement was accompanied by better or worse fluidity.
|
||||
- [ ] Check train length, train starts, GTMs per employee and locomotives in service vs stored — is productivity real, or is capacity simply gone?
|
||||
- [ ] Separate fuel *efficiency* (gallons per thousand GTM) from fuel *surcharge recovery lag*; strip the timing effect from margin commentary.
|
||||
- [ ] Normalise for owned-versus-leased equipment and car hire/equipment rents before any cross-carrier OR or ROIC comparison.
|
||||
- [ ] Compute capex as % of revenue and capex/depreciation; find the maintenance-vs-growth split and corroborate with rail miles, ties installed and fleet age.
|
||||
- [ ] Re-run FCF at a normalised sustaining capex level and state the assumption explicitly; never quote FCF yield off reported capex alone.
|
||||
- [ ] Compute ROIC and compare to WACC across a full cycle, not a single year; note the regulatory implication of persistently high returns.
|
||||
- [ ] Compute EV/EBITDA, EV/EBIT and EV/(EBITDA − maintenance capex); read all three against the OR trajectory.
|
||||
- [ ] Check incremental margin on volume growth and ask what the shed traffic's contribution margin actually was.
|
||||
- [ ] Check whether buybacks and dividends are funded by cash generation or by rising leverage while capex falls.
|
||||
- [ ] Review safety and derailment trends, service complaints, demurrage/accessorial revenue share, and any live regulatory proceeding.
|
||||
- [ ] Check the safety and labour rulemaking pipeline for anything that resets crew size, train length, inspection or hours-of-service economics.
|
||||
- [ ] Confirm intermodal assumptions against the truckload cycle, not against GDP.
|
||||
- [ ] Read the remuneration disclosure: is management paid on OR alone, or also on service, safety and volume?
|
||||
- [ ] List any yard, siding or line closures and state what capacity and optionality was permanently removed.
|
||||
- [ ] Strip land sale gains, restructuring and casualty items; rebuild a clean five-year OR and earnings series.
|
||||
- [ ] Check whether the common carrier obligation applies and whether the margin plan is compatible with it.
|
||||
- [ ] Look for evidence of customer countervailing action — private fleets, modal shift, access lobbying — in trade press and regulatory filings.
|
||||
- [ ] India: identify haulage-charge dependence, EXIM vs domestic mix, realisation per TEU, empty running ratio, rake turnaround, double-stacking eligibility and DFC exposure by lane.
|
||||
- [ ] India: confirm the entity is a freight operator, not a rail capital goods, EPC, leasing/finance or passenger-services company — route elsewhere if so.
|
||||
- [ ] Peer set: same asset model, regulatory regime, geography, commodity mix and consolidation basis — stated explicitly; where the peer set is thin, lean on own-history and say so.
|
||||
- [ ] Read the property accounting and depreciation policy notes; flag any capitalisation-policy or asset-life change coinciding with a margin improvement.
|
||||
- [ ] Separate operating income growth, volume growth and EPS growth in the report so buyback-driven per-share growth is visible.
|
||||
- [ ] Check legacy liabilities — pension, personal injury/casualty, environmental remediation on yards and rights-of-way — and their reserve trends.
|
||||
- [ ] Ask what share of the revenue book reprices in the next 12 months, on what index, and what happens if that index turns.
|
||||
- [ ] Adjust quarter comparisons for weather and harvest seasonality before calling a trend.
|
||||
- [ ] Scenario the operating ratio explicitly (holds / guided improvement / service-funded reversion) and show the equity value impact of each.
|
||||
- [ ] Never benchmark against trucking, shipping or asset-light forwarders on margin, turnover or capital intensity — state this in the report if a screener has done it for you.
|
||||
- [ ] State where in the freight and truck cycle this sits, and what regulatory change is in flight.
|
||||
|
|
@ -0,0 +1,234 @@
|
|||
# Real estate developers, REITs and InvITs — sector playbook
|
||||
|
||||
Use this when: the company's primary business is creating, owning or monetising real property or long-life infrastructure concessions — Indian listed residential and commercial developers, Indian REITs and InvITs, US equity REITs and REOCs filing on EDGAR, European/Asian property companies under IAS 40, and homebuilders and land-banking companies anywhere.
|
||||
|
||||
Three facts govern everything below. Reported profit is an accounting artefact — depreciation on appreciating buildings, valuer opinions booked as income, and revenue recognised on projects sold three to five years ago. The balance sheet is carried at the wrong basis — historic-cost land understates developer equity, fair-value marks inflate REIT equity. And negative free cash flow is frequently the bullish signal, because a developer buying land looks identical on the cash-flow statement to a developer bleeding out. Replace the generic ratio set entirely; do not adjust it.
|
||||
|
||||
The three sub-sectors here share a physical asset class but almost nothing else analytically. **Developers** are serial project underwriters with lumpy, backward-looking accounting. **REITs** are stabilised rent-collecting vehicles judged on cash distribution per unit. **InvITs** are finite-life concession portfolios where the headline yield is partly return of capital. Never apply one framework to another, and never put them in the same peer table.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
If a screener hands you these, state that they are inapplicable rather than reporting them with a caveat. A reported number gets used downstream.
|
||||
|
||||
**P/E and EPS — close to meaningless, in four separate ways.**
|
||||
|
||||
1. *REIT depreciation.* IFRS/Ind-AS and US GAAP force straight-line depreciation on buildings that in practice hold or appreciate in value. A stabilised office REIT can report near-zero or negative EPS while generating large and growing cash distributions. This single distortion is the entire reason NAREIT invented FFO.
|
||||
2. *Fair-value accounting.* Under IAS 40's fair-value model (common in Europe, UK, Singapore, Hong Kong), unrealised revaluation gains run through the P&L. "Profit" is a valuer's opinion, not cash — earnings can double in a year with zero change in rent, and collapse the next with zero change in occupancy.
|
||||
3. *Ind-AS 115 for Indian developers.* From FY19, percentage-of-completion was replaced by completion-based recognition. Reported revenue reflects projects **sold three to five years ago** and has almost no relationship to current sales momentum. Two identical developers can show wildly different EPS purely on hand-over timing.
|
||||
4. *InvIT amortisation.* Toll-concession intangibles amortised under Appendix A/D to Ind-AS 115 routinely push consolidated InvIT results to a loss while the trust pays a 9–13% cash yield.
|
||||
|
||||
**OPM / EBITDA margin — not a measure of operating skill for developers.** Cost of sales carries land at historical acquisition cost. A 45% gross margin usually means land bought a decade ago in a different price cycle; a 22% margin may mean freshly acquired land at market. Margins are also structurally different by model: outright-purchase development books full revenue and full cost, joint-development agreements (JDA) and development-management (DM) mandates book only the developer's revenue share, and plotted development carries far higher margins than high-rise. Worse, interest is capitalised into inventory and released through cost of sales, so "EBITDA margin" silently varies with the financing structure. Cross-company and cross-period OPM comparison here is close to noise.
|
||||
|
||||
**D/E and Net debt/EBITDA — misleading in both directions.** Developer equity is understated because land sits at historic cost, so D/E is *overstated*. IFRS fair-value REIT equity is inflated by revaluations, so D/E is *understated* and moves with valuer assumptions rather than with borrowing. Developer gross debt also needs customer advances treated separately — they are pre-sold cash, not creditors, and under RERA 70% is escrowed and legally ring-fenced. EBITDA is lumpy and completion-driven, so Net debt/EBITDA oscillates violently for a business whose cash flows are actually quite forecastable at project level. For REITs and InvITs the correct denominators are asset value and cash flow: **LTV and DSCR**, never equity or EBITDA.
|
||||
|
||||
**ROCE / ROE — structurally wrong.** Capital employed includes land and work-in-progress that will not generate revenue for three to seven years. A developer in an aggressive land-buying phase shows collapsing ROCE precisely when it is creating the most value; a developer liquidating old inventory shows excellent ROCE while its business shrinks. For REITs, ROE is depressed by non-cash depreciation and, under fair-value accounting, the denominator is marked to market, so ROE mechanically compresses in a bull market.
|
||||
|
||||
**FCF and cash-conversion — inverted.** A developer's operating cash flow is negative when it buys land and launches (growth) and positive when it stops investing (decline). Negative FCF is often a launch cycle, not distress. Interest paid is partly capitalised, and its classification between operating and financing differs across companies, so headline OCF is not comparable without normalisation.
|
||||
|
||||
**Working-capital ratios — undefined in spirit.** Inventory (land, WIP, unsold finished units) turns in years yet is classified current. Inventory turnover, current ratio and the cash-conversion cycle flag every developer on earth as distressed. Debtor days are meaningless because most receivables are construction-linked and unbilled.
|
||||
|
||||
**Dividend payout ratio — undefined or nonsensical.** REIT/InvIT distributions come out of net distributable cash flow, not accounting profit. In India they flow up from SPVs as a mix of interest, dividend and repayment of capital, each taxed differently in the unitholder's hands. Payout on EPS is routinely above 100% or negative. The correct denominators are **AFFO** (developed markets) and **NDCF** (SEBI regime).
|
||||
|
||||
**P/B — unusable for developers, tautological for REITs.** Developer book carries land at historic cost, so P/B of 3x may be cheap. Fair-value REIT book equals appraised NAV roughly by construction, so P/B just restates price/NAV. Use the mandatory independent valuation's NAV per unit, not accounting book value.
|
||||
|
||||
**Interest coverage — understates the true burden.** P&L finance cost excludes capitalised interest. Use cash interest paid from the cash-flow statement, or DSCR at the asset/SPV level.
|
||||
|
||||
**Revenue and PAT growth — lagging indicators for developers.** Pre-sales (bookings) and collections lead reported revenue by several years. Ranking developers on revenue or PAT growth systematically buys the previous cycle's winners at the top of the current one.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, sub-sector, asset class, cycle stage and period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set and against the company's own history overrides every absolute band below. Metrics marked **[D]** apply to developers, **[R]** to REITs and rental portfolios, **[I]** to InvITs; several apply across.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Pre-sales / bookings — value, area and realisation per sq ft [D]** | Value of units sold in the period, both gross **and net of cancellations**; area sold in msf; implied realisation = value ÷ area. This is the true top line, preceding Ind-AS 115 revenue by 3–5 years. | Sustained double-digit YoY growth in a normal cycle; cancellations under ~5–7% of gross bookings; realisation per sq ft rising at or above construction-cost inflation. | The only forward-looking demand signal. Reported revenue tells you about the market of 3–5 years ago. Decompose growth: value growth driven by *area* (cheaper geographies, plotted land) is a structurally different and lower-quality business from growth driven by *realisation*. |
|
||||
| **Collections and collection efficiency [D]** | Cash actually received from customers under construction-linked or time-linked plans, expressed against pre-sales value. Pair with operating cash flow before land payments and interest. | Collections roughly 75–90% of pre-sales value over a rolling 4–8 quarter window; persistently below ~65% suggests subvention/deferred-payment schemes or execution slippage. | Bookings can be manufactured with soft payment schemes; cash cannot. A widening pre-sales-to-collections gap is the earliest reliable warning of channel stuffing, construction delay or a coming cancellation wave. |
|
||||
| **Operating cash surplus and net debt / operating surplus [D]** | Collections − construction spend − overheads − approval costs − cash interest, *before* new land investment. Then net debt (excluding RERA-escrowed advances) over that surplus. | India large caps post-2020: net D/E 0.0–0.5x and net debt / annual operating surplus below ~2.5x. Net D/E above 1.0x *with* negative operating surplus is the classic pre-distress profile. | Real estate defaults are cash-flow-timing events, not P&L events. This pairing is what separates good negative FCF (investing in land) from fatal negative FCF (funding overheads and interest with new borrowing). |
|
||||
| **Business development: GDV added and land cost as % of GDV [D]** | Gross development value of projects added in the period (outright, JDA or DM), the land-plus-approval cost as a % of that GDV, and the owned-land vs asset-light JDA split. | India: land + approvals ~20–30% of GDV for a viable project; below ~20% is strong; above ~35% usually destroys project margin. Pipeline replacement should at least match annual pre-sales. | A developer is a serial underwriter. Land bought at the wrong percentage of GDV locks in poor returns for a decade regardless of management quality. A developer selling faster than it replenishes is liquidating, not compounding. |
|
||||
| **Unsold inventory overhang and ready-inventory value [D]** | Unsold saleable area ÷ trailing sales run-rate, expressed in months; split between under-construction and completed (ready) stock. | India: 15–24 months healthy; above 30–36 months signals oversupply. Ready unsold inventory should be a low single-digit % of portfolio value. | Completed unsold stock carries maintenance, property tax and full interest with no offsetting construction-linked collections — the single largest destroyer of developer returns. Overhang also predicts pricing power: low overhang raises prices, high overhang discounts. |
|
||||
| **Project-level cash margin and embedded surplus [D]** | Expected cash surplus per project (sales value − land − construction − approvals − marketing − interest), aggregated across ongoing and planned pipeline and discounted. Effectively the order-book economics. | India residential: 25–35% project-level cash margin on new underwriting is typical; 18–22% signals thin underwriting. Compare aggregate embedded surplus to current market cap. | Replaces company-level OPM, which is contaminated by historic land cost and completion timing. It is also the direct input to NAV, the primary valuation method for developers. |
|
||||
| **FFO and AFFO **per unit**, and AFFO payout ratio [R]** | FFO (NAREIT) = net income + real-estate D&A − gains (+ losses) on property sales. AFFO further deducts recurring maintenance capex, tenant improvements, leasing commissions and the straight-line rent adjustment. | AFFO payout 70–90% for developed-market REITs (below 70% is growth-retaining, above 95–100% unsustainable). FFO/AFFO per unit growth 3–6% p.a. in developed markets; higher in an Indian office upcycle. | The direct replacement for EPS. Always per unit — externally managed REITs grow *total* FFO by issuing units while per-unit FFO stagnates or falls. AFFO is the honest number because it charges for the capex needed just to keep rents where they are. |
|
||||
| **NDCF, DPU and distribution composition [R][I]** | The SEBI-mandated cash construct: cash generated at each SPV, adjusted per the SEBI NDCF framework, upstreamed as interest, dividend and repayment of capital/loans. DPU = distribution per unit. | SEBI requires ≥90% of NDCF distributed at least semi-annually (Indian practice is quarterly). Look for DPU growth of 4–8% p.a. and a stable or falling share of "repayment of capital". | NDCF is the Indian analogue of AFFO but regulator-defined, so it is genuinely comparable across trusts. Composition matters twice: a rising capital-repayment share means the yield is partly your own money returning and the asset base is depleting, and the post-tax yield differs materially from the headline. |
|
||||
| **Same-store / same-property NOI growth [R]** | NOI (rental + recovery income − property-level opex, before corporate overhead, interest and depreciation) growth for assets owned and stabilised through both comparable periods. | 2–4% p.a. developed markets in a normal cycle; mid-to-high single digits for Indian Grade-A offices given contractual ~15% escalations every 3 years (~4.7% annualised) plus re-letting mark-to-market. | Strips out growth bought with acquisitions and unit issuance. Aggregate NOI growth flatters serial acquirers; same-store NOI is what a private buyer would underwrite. |
|
||||
| **Occupancy, committed occupancy, WALE and the lock-in expiry ladder [R]** | Physical vs committed occupancy (including signed-not-occupied); weighted average lease expiry in years; the schedule of both lease expiries **and lock-in expiries** by year; tenant and sector concentration. | Indian Grade-A office: 85–95% committed occupancy, WALE 6–9 years, no tenant above ~8–10% of gross rentals, no single year above ~15–20% of expiries. Retail: 95%+ occupancy, occupancy cost ratio 12–18% of tenant sales. | The lease book *is* the REIT's cash-flow contract. WALE alone is deceptive: Indian leases run 9–15 years but with a 3–5 year lock-in and a tenant exit option thereafter, so the **lock-in ladder, not the lease ladder**, is the real risk schedule. |
|
||||
| **Mark-to-market gap and realised re-leasing spread [R]** | Contracted in-place rent per sq ft vs prevailing market rent for comparable space; plus the rent spread actually achieved on renewals and re-lettings in the period. | Positive MTM of 10–25% is a healthy embedded growth reserve. Negative spread means rent was over-marked or the micro-market turned. Realised re-leasing spreads should roughly track the stated MTM. | The best measure of organic future growth not yet in the numbers — and a truth test on the valuer. If stated MTM upside never converts into realised spreads, the appraisal and therefore the NAV are overstated. |
|
||||
| **LTV, DSCR/ICR, cost and maturity profile of debt [R][I]** | Net debt ÷ independently appraised gross asset value; debt service coverage; weighted average cost of debt; % fixed-rate; maturity ladder; SPV-level cash traps. | SEBI caps consolidated REIT/InvIT borrowings at 49% of asset value, with conditions biting above 25% (InvITs need AAA and unitholder approval to go beyond 49%, up to 70%). Prudent Indian REITs run 20–30%; US/EU REITs 30–40%. DSCR >1.8–2.0x, ICR >3x, majority fixed-rate, no single year above ~20–25% of maturities. | LTV is correct because the collateral is an appraised, income-producing asset, not equity book value. The regulatory caps are hard constraints: a trust drifting toward 49% loses acquisition flexibility and may be forced to issue units at a discount. Bullet maturities plus floating-rate exposure is how yield vehicles blow up in a tightening cycle. |
|
||||
| **Maintenance capex, TI and leasing costs as % of NOI [R]** | Recurring capital spend needed to hold current rent-earning capacity: base-building capex, tenant fit-out contributions, leasing commissions, free-rent periods. | ~10–20% of NOI for offices over a cycle; lower for industrial/warehousing, higher for older Grade-B stock and retail re-tenanting. Consistently under 5% of NOI is almost certainly deferral or capitalisation. | The line most often understated to inflate AFFO and make the distribution look covered. Chronic under-spend surfaces years later as falling occupancy and negative re-leasing spreads — the asset is being harvested, not managed. |
|
||||
| **Development pipeline: under-construction area, pre-leasing %, yield-on-cost vs cap rate [R]** | Size of on-balance-sheet development (large in Indian REITs), proportion pre-leased, stabilised NOI yield on total development cost, and the spread over the cap rate at which completed assets trade. | Development spread of 150–300 bps over market cap rate justifies the risk. Under-construction area 10–20% of portfolio is manageable; above 30% makes the vehicle part developer. Pre-leasing above 50% before topping out is comforting. | Development is where REIT value is created or destroyed, and it is funded partly by withholding distributions. A thin or negative development spread means unitholders take construction and leasing risk for no premium — better to buy the finished asset. |
|
||||
| **InvIT asset KPIs: volume/availability, residual life, MMR funding [I]** | Roads: toll traffic growth (PCU), WPI-linked toll escalation, annuity/HAM receipts, funded status of the major maintenance reserve. Transmission: line availability (tariff is availability-linked, no volume risk) and counterparty receivable days. All: weighted average residual concession life. | Transmission availability 98–99%+ (incentives kick in around there); road traffic growth 4–7% p.a. plus WPI escalation; MMR fully funded against the concession's periodic overlay cycle; weighted residual life 15+ years — treat under 10 years as a wasting asset. | InvIT assets are finite-life. A 13% yield on a road with 8 years of concession left is largely return of capital, not income. Residual life, volume risk (toll) vs no volume risk (annuity/HAM/transmission), and honestly funded major maintenance separate a real income stream from a liquidation schedule dressed as a dividend. |
|
||||
| **NAV per unit, premium/discount to NAV, implied cap rate [D][R][I]** | GAV from the mandatory independent valuation (SEBI: full valuation at least annually, half-yearly updates) less net debt, per unit; market price relative to it; implied cap rate = stabilised NOI ÷ (market cap + net debt). | Developed-market REITs oscillate between roughly a 20% discount and 20% premium. A persistent discount above ~25% means either the market thinks valuations are stale or there is a governance/leverage problem. Compare implied cap rate to actual transactions — Indian Grade-A office roughly 7.5–8.5%; US office far wider than industrial. | The anchor valuation for the sector and the arbitrage check. If the market implies a cap rate far above private transactions, the vehicle should be selling assets and buying back units; if far below, issuing units and acquiring. Management's behaviour against that signal is a direct capital-allocation test. |
|
||||
| **Per-unit / per-share discipline and dilution history [D][R][I]** | Track pre-sales per share, FFO per unit, DPU and NAV per unit across every equity raise, QIP, institutional placement and sponsor infusion, with the price/NAV at which each was done. | Per-unit metrics compounding at least as fast as aggregate metrics; no material issuance below NAV. | Growth funded by unit issuance is the standard illusion in this sector. Aggregate NOI, FFO and DPU can all rise while the existing unitholder is worse off. Issuing below NAV to buy assets above the implied cap rate is direct value transfer. |
|
||||
| **Contingent liabilities, JV/associate debt and corporate guarantees [D]** | Project debt in equity-accounted JVs and associates, guarantees given to lenders of SPVs and JDA partners, and litigation/title contingencies — from the notes, not the face of the balance sheet. | Guarantees and JV debt should be small relative to consolidated net worth; disclose and add them to net debt when they are not. | Consolidated D/E for developers routinely omits the leverage that actually sinks them. Equity-method JVs hide project debt; guarantees convert to real obligations exactly when the cycle turns. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
There is no single multiple. Three sub-sectors, three frameworks, and P/E belongs to none of them.
|
||||
|
||||
### Developers — NAV / sum-of-the-parts is primary
|
||||
|
||||
Build bottom-up, project by project:
|
||||
|
||||
1. Forecast each **ongoing project's** remaining cash flows: remaining collections less remaining construction, approvals, marketing, tax and interest.
|
||||
2. Do the same for the **planned pipeline** on assumed launch dates, haircut for approval risk.
|
||||
3. Discount at a project-appropriate rate — India roughly 12–15% real; developed markets WACC or 8–12% depending on risk.
|
||||
4. Value the **unlaunched land bank** at either a per-acre market rate or a heavily discounted NPV. Land under MOU/LOI or without approvals gets a severe haircut or zero.
|
||||
5. Add the **capitalised value of annuity/rental assets** at an appropriate cap rate.
|
||||
6. Subtract **net debt** and the **NPV of corporate overheads**.
|
||||
|
||||
That is NAV. Indian listed developers have historically traded between roughly 0.6x NAV at cycle troughs and 1.5–2.0x at peaks. The premium is justified by brand, execution speed and business-development capability — NAV assumes only one turn of the land, whereas a developer that reliably converts fresh land into 25%+ margin projects compounds. Judge the premium against evidence of that conversion, not against reputation.
|
||||
|
||||
**Secondary cross-checks:** EV / GDV of the pipeline; market cap / annual pre-sales (Indian large caps have traded roughly 2–5x); price per sq ft of embedded saleable area vs physical market prices; EV / embedded EBITDA; replacement cost and land value per acre for land-heavy legacy names.
|
||||
|
||||
**Do not use:** P/B (historic-cost land). P/E is defensible only where revenue recognition has stabilised and the mix is annuity-heavy, and even then cross-check against NAV.
|
||||
|
||||
### REITs — FFO/AFFO multiples, cap rates and NAV, in that order
|
||||
|
||||
The working multiples are **P/FFO and P/AFFO** (developed markets: office historically 12–18x FFO, industrial and data centres far higher, with wide dispersion by property type and cycle) and EV/EBITDA. Above both sits the **cap rate framework**: value = stabilised NOI ÷ cap rate, with the cap rate taken from actual private transactions in the same micro-market and asset grade.
|
||||
|
||||
Then compute the **implied cap rate** from the market price and compare it to the private-market cap rate. That gap is the entire public-versus-private arbitrage and the single best sanity check on whether the appraised NAV is credible. Finally, build NAV = (portfolio NOI capitalised + development at cost or risk-adjusted value + cash) − net debt, and assess the premium/discount.
|
||||
|
||||
**For Indian REITs the practical framework is yield-based.** Distribution yield versus the 10-year G-sec: Indian REITs have generally been underwritten to a spread of roughly 150–300 bps over the 10-year. Two refinements are essential. First, a large part of the distribution is tax-advantaged or tax-deferred (the capital-repayment component), so compare **post-tax** yields, not headline yields. Second, add expected DPU growth — contractual ~15%/3-year escalations, plus mark-to-market, plus committed development — to get an expected total return. The rigorous version is a discounted-NDCF or dividend-discount model over ten years with a terminal cap rate.
|
||||
|
||||
### InvITs — total-return DCF on a finite-life asset, never headline yield
|
||||
|
||||
Because road and many other InvIT assets have finite concession lives, discount the DPU stream over the residual concession life with little or no terminal value and solve for the **unitholder IRR**. A 12% headline yield on a road with nine years of residual life may be a 7% economic return once you recognise that part of the distribution is return of capital.
|
||||
|
||||
Compare that IRR to the G-sec plus an equity risk premium of roughly 400–600 bps for toll assets (volume risk) and 250–400 bps for annuity/HAM and transmission assets (availability-based, no volume risk). Perpetual-style InvITs with reinvestment mandates and acquisition pipelines can carry a partial terminal value — but only where the sponsor has a credible ROFO pipeline **and** a demonstrated record of per-unit-accretive acquisitions.
|
||||
|
||||
### Cross-cutting rules
|
||||
|
||||
- **Always value per unit / per share, never in aggregate.** Growth funded by unit issuance is the standard illusion in this sector.
|
||||
- **Test every acquisition for DPU/AFFO-per-unit accretion after financing cost**, not for NOI accretion.
|
||||
- **Compare the entity's own cap rate assumptions with observable transactions.** When rates move and stated cap rates do not, the NAV is stale and everything derived from it is wrong.
|
||||
- **For developers, judge the cycle explicitly.** Returns are dominated by where you sit in the price/inventory cycle. Low overhang + low leverage + a replenishing pipeline at a low land-to-GDV ratio matters more than any single multiple.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares the **cash-flow shape and the accounting regime**, not merely the SIC/NIC code. Never mix across these splits:
|
||||
|
||||
- **Sub-sector.** Developers, REITs and InvITs are three different businesses. A developer with a growing annuity portfolio is a hybrid — split it in the SOTP and compare each leg to its own peer set.
|
||||
- **Asset class within REITs.** Office, retail malls, industrial/warehousing, data centres, hotels, healthcare, residential/multifamily, self-storage and net-lease trade at materially different cap rates, growth rates and capex intensity. A 12x FFO office REIT is not cheap relative to a 25x industrial REIT.
|
||||
- **Residential vs commercial vs plotted development.** Plotted development has far higher margins, minimal construction risk and fast cash cycles; high-rise residential is the opposite. Commercial-for-lease is a capital-consuming annuity business masquerading as development.
|
||||
- **Business model within developers.** Outright land purchase vs JDA/JV vs pure development management. Reported revenue and margin are not comparable across them — normalise to GDV, pre-sales and project cash margin.
|
||||
- **Geography and micro-market.** Real estate is local. An MMR/NCR/Bengaluru/Hyderabad developer faces different absorption, approval regimes and price cycles. In the US, sunbelt vs coastal, and state-level rent regulation, dominate outcomes.
|
||||
- **Accounting regime.** IAS 40 fair-value REITs are not comparable to US GAAP historic-cost REITs on any equity-side metric; compare on FFO/AFFO, NOI and cap rates instead. Ind-AS 115 completion-based developer revenue is not comparable to pre-FY19 percentage-of-completion figures — a developer's own history breaks at that transition.
|
||||
- **Management structure.** Externally managed vehicles (fee on AUM or GAV) have structurally worse incentives than internally managed ones. Adjust the multiple, and never compare per-unit growth records across the two without noting it.
|
||||
- **Concession type for InvITs.** Toll (volume risk), annuity (no volume risk), HAM (hybrid), and transmission (availability-linked) are different risk assets. Also split by weighted residual life — a 20-year portfolio and an 8-year portfolio at the same yield are not comparable at all.
|
||||
- **Consolidation basis.** Some developers consolidate JV projects, others equity-account them. Restate to a consistent basis (usually economic-interest share of GDV, debt and surplus) before ranking.
|
||||
- **Cycle position.** Comparing an Indian developer's current metrics to its FY13–FY19 downturn history is valid and useful; comparing it to a US homebuilder in a different rate cycle is not.
|
||||
|
||||
State the peer set and the exclusions explicitly in the output. If fewer than three genuine comparables exist, say so and lean harder on absolute NAV and cap-rate analysis.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Demand and bookings quality [D]**
|
||||
|
||||
- **Pre-sales growing while collections stagnate.** The gap almost always resolves through cancellations, construction delay or subvention, never through a cash catch-up.
|
||||
- **Bookings propped up by 10:90, no-EMI-till-possession, subvention or assured-return schemes.** These are financing offers booked as demand; they convert to cancellations when possession slips.
|
||||
- **Only gross bookings disclosed**, with cancellations netted quietly or not at all. A cancellation rate rising above ~7–8% of gross bookings is a leading indicator of a downgrade cycle.
|
||||
- **Area growth without value growth**, or mix shifting to lower-realisation geographies and asset classes while headline growth looks intact — a volume story dressed as a pricing story.
|
||||
- **One-time gains presented as run-rate:** land parcel sales, plotted-development windfalls, FSI/TDR monetisation and "other income" bulking up a weak core quarter.
|
||||
|
||||
**Accounting and disclosure**
|
||||
|
||||
- **Interest capitalised into inventory:** P&L finance cost far below cash interest paid in the cash-flow statement. This simultaneously inflates gross margin and flatters interest coverage.
|
||||
- **Fair-value revaluation gains driving profit (IAS 40).** Check whether the valuer is genuinely independent and rotated, and whether cap rate assumptions moved when the bond market moved. Cap rates held flat through a 200 bps rate rise is a valuation that has not been marked.
|
||||
- **Company-defined "adjusted" or "normalised" FFO** with a bespoke, drifting definition, or "one-off" exclusions that recur every quarter. Insist on the NAREIT FFO bridge and, in India, the SEBI NDCF reconciliation.
|
||||
- **Growing gap between accounting rental income and cash rent.** Straight-lining of stepped rents, rent-free periods and lease incentives inflates NOI on assets that are not yet paying.
|
||||
- **Land bank quoted at full GDV** when the land is under MOU/LOI only, lacks approvals, carries title or litigation issues, or sits in a market where the developer has never sold. GDV without approvals is a press release, not an asset.
|
||||
- **Stalled projects carried for years with no inventory write-down**, rising RERA complaints, and repeated delivery deferrals.
|
||||
|
||||
**Distribution sustainability [R][I]**
|
||||
|
||||
- **Distribution not covered by AFFO/NDCF** — funded instead by new debt, asset sales, sponsor support, or a rising "repayment of capital" component. A steadily rising capital-repayment share of DPU means flat underlying performance being masked while the asset base depletes.
|
||||
- **Suspiciously low maintenance capex, TI and leasing commissions relative to NOI**, or reclassification of recurring capex as "growth/enhancement capex" to lift AFFO. Deferred capex surfaces years later as occupancy loss.
|
||||
- **Long headline WALE masking a near-term lock-in expiry cliff** (India), a single year with 20%+ of leases expiring, or one tenant/one sector above ~10–15% of gross rentals.
|
||||
|
||||
**Balance sheet and structure**
|
||||
|
||||
- **Leverage drifting toward the SEBI 49% cap or covenant limits**, heavy floating-rate exposure, bullet maturities clustered in one or two years, refinancing needed into a tightening rate environment. Check SPV-level cash traps and whether covenants restrict upstreaming to the trust.
|
||||
- **Off-balance-sheet leverage:** JVs and associates on the equity method with project debt and corporate guarantees invisible in consolidated D/E. Read the contingent-liability and guarantee notes in full.
|
||||
- **Reliance on continuous equity raises** (QIPs, promoter infusion, institutional placements) to fund negative operating cash flow. Check pre-sales *per share*, not just pre-sales.
|
||||
- **Fungibility of customer money** — advances from one project funding land or interest for another. In India, verify RERA 70% escrow compliance project by project; escrow breaches precede insolvency.
|
||||
|
||||
**Governance and related party**
|
||||
|
||||
- **Sponsor conflicts:** assets acquired from the sponsor at or above independent valuation, ROFO pipelines with no price discipline, and management fees based on AUM or GAV rather than per-unit performance — all reward dilutive empire-building.
|
||||
- **Total FFO/NOI/DPU rising while per-unit FFO/DPU is flat or falling**, with equity issued below NAV to buy assets above the implied cap rate.
|
||||
- **Promoter share pledging, frequent auditor or CFO changes, multi-layered SPV/holding structures**, and land held in promoter-owned entities transacted with the listed company.
|
||||
|
||||
**InvIT-specific**
|
||||
|
||||
- Consultant traffic forecasts persistently above actuals; under-provisioned major maintenance reserve ahead of a periodic overlay; short residual concession life presented as a high perpetual yield; stretched receivables from NHAI, discoms or any single counterparty.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The cycle dominates everything.** Residential real estate runs a long inventory-and-price cycle — typically 7–10 years — and returns are determined far more by entry point in that cycle than by company selection. The sequence is reliable: absorption improves → overhang falls → prices firm → developers bid aggressively for land → land-to-GDV ratios deteriorate → supply arrives → overhang rises → prices stall → leveraged developers fail → consolidation. India's FY13–FY19 downturn (compounded by demonetisation, RERA and GST) followed by the post-2020 upcycle is the canonical recent example: the surviving listed developers gained share precisely because unorganised and leveraged players could not access funding. Locate the company in that sequence explicitly before applying any multiple. Buying developers on trailing earnings growth at the top of the cycle is the most common way this sector destroys capital.
|
||||
|
||||
**Rates are the sector's single biggest exogenous driver, and they hit twice.** On the demand side, mortgage rates set affordability and absorption. On the valuation side, cap rates move with the risk-free rate — a 100 bps cap rate expansion cuts asset value by roughly 12–13% at an 8% cap rate, and because REITs are levered, the equity impact is multiples of that. Any REIT thesis must state what cap rate is assumed and stress it. For InvITs, the DPU is contractual but the discount rate is not; unit prices move inversely with the G-sec almost mechanically.
|
||||
|
||||
**Structural threats to score explicitly.**
|
||||
- *Office:* hybrid and remote work have permanently reduced space per employee in developed markets, hollowing out older Grade-B stock while Grade-A stays tight. India's office demand is driven by global capability centres and offshoring, which is a different — and so far more resilient — demand engine than domestic white-collar headcount, but it concentrates tenant risk in a handful of sectors and in the outsourcing decision itself.
|
||||
- *Retail:* e-commerce penetration continues to compress marginal mall economics; judge malls on tenant sales per sq ft and occupancy cost ratio, not on occupancy.
|
||||
- *Industrial/warehousing:* the structural winner of the same shift, but cap rates have already compressed to reflect that.
|
||||
- *Residential:* affordability ceilings, urban land availability and construction-cost inflation cap volume growth; demographic tailwinds in India (household formation, urbanisation, falling household size) are genuine but slow.
|
||||
|
||||
**Regulation is a first-order value driver.** India: RERA (registration, project-wise 70% escrow, delivery penalties, complaint disclosure — it structurally favoured large organised developers), GST on under-construction property versus none on ready inventory (which distorts buyer behaviour toward completed stock), stamp duty changes at state level (temporary cuts have visibly pulled demand forward), FSI/TDR and development-control regulation, land-title uncertainty and litigation, environmental and approval timelines, and the SEBI REIT/InvIT regulations including leverage caps, mandatory valuation frequency, minimum distribution and the small-and-medium REIT framework. Globally: zoning and entitlement regimes, rent control (a live equity risk for US multifamily in several states), building-decarbonisation mandates (a real capex liability for older European and US office stock), and the REIT tax regime itself — REIT status is conditional on asset, income and distribution tests, and losing it is catastrophic.
|
||||
|
||||
**Liquidity and funding regime.** This sector is the most credit-sensitive in the market. Developer distress historically follows a funding-channel closure rather than a demand collapse — the Indian NBFC/HFC funding freeze after 2018 is the reference case, qualitatively: developers dependent on wholesale construction finance failed while those with pre-sales-funded cash cycles gained share. Always ask which funding channel this company depends on, and what happens if it closes.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India | US / global |
|
||||
|---|---|---|
|
||||
| Regulator / framework | SEBI (REIT Regulations 2014, InvIT Regulations 2014, plus the SM REIT framework); RERA at state level for developers; NHAI/state concessioning authorities for road InvITs | SEC (10-K/10-Q on EDGAR); REIT status under IRC — 75% asset and income tests, 90% taxable income distribution requirement; EPRA guidance in Europe; SGX/HKEX regimes in Asia |
|
||||
| Accounting | Ind-AS. Ind-AS 115 completion-based revenue for developers (from FY19 — breaks the historic series). Ind-AS 40 investment property is **cost model only** — no fair-value P&L gains, unlike IFRS. Concession intangibles amortised under Appendix A/D to Ind-AS 115 | US GAAP: historic cost, no revaluation, so FFO is essential. IFRS/IAS 40 elsewhere: fair-value model common, revaluation gains through P&L, which is why European REITs report EPRA earnings and EPRA NTA alongside statutory |
|
||||
| Distribution construct | **NDCF**, defined by SEBI — ≥90% distributed at least semi-annually (quarterly in practice). Distribution splits into interest, dividend and repayment of capital, each taxed differently in the unitholder's hands | **FFO/AFFO**, NAREIT-defined but not mandatory; company-adjusted variants proliferate. US REIT distributions are ordinary income, capital gain and return of capital for tax |
|
||||
| Leverage rules | SEBI hard cap: 49% of asset value consolidated, with conditions above 25%; InvITs can go to 70% with AAA rating and unitholder approval. Prudent Indian REITs run 20–30% | No statutory cap; discipline comes from covenants, rating agencies and unsecured bond markets. US/EU REITs typically 30–40% LTV; net debt/EBITDA is a common rating-agency metric here |
|
||||
| Valuation disclosure | Mandatory **independent valuation at least annually with half-yearly updates**; valuer rotation rules; NAV per unit published | Appraisals not mandatory for US REITs; NAV is analyst-estimated from cap rates. IFRS jurisdictions publish balance-sheet fair values, so NAV is more directly observable but valuer-dependent |
|
||||
| Developer disclosure | Pre-sales, collections, area sold and business development are disclosed in quarterly investor presentations and the **concall** — treat the concall Q&A as a primary source for cancellations, launch timing and land pipeline. RERA portals give project-level registration, timelines and complaints. CARO 2020 reporting covers title deeds, loans to related parties and default in repayment | Homebuilders disclose net new orders, backlog, cancellation rate, community count and gross margin in the 10-Q/10-K; REITs publish a supplemental package with property-level NOI, lease expiry schedules, same-store metrics and an FFO/AFFO bridge — always read the supplemental, not just the 10-K |
|
||||
| Lease conventions | Typically 9–15 year leases with 3–5 year lock-ins and a tenant exit option; ~15% escalation every 3 years; rents quoted per sq ft per **month**; security deposits of 6–12 months are a material cash item | US office leases 5–10 years with annual escalations of 2–3% or CPI-linked; rents quoted per sq ft per **year**; triple-net vs gross leases change the NOI definition — check which before comparing margins |
|
||||
| Units and reporting | ₹ crore/lakh; msf for area; fiscal year April–March; per sq ft on carpet/saleable/chargeable area — **confirm which**, because saleable-to-carpet ratios differ by 20–35% and quietly change every per-sq-ft metric | $ millions; square feet; calendar year typical; rentable vs usable area with a load factor — same trap, different vocabulary |
|
||||
| Ownership and governance | Promoter holding is central; check pledging, promoter-owned land entities and related-party transactions. REITs/InvITs have a sponsor, a trustee and a manager — sponsor lock-in and ROFO arrangements matter | Widely held; internal vs external management is the key governance axis; UPREIT/OP-unit structures create tax-driven lock-ins for insiders that can block asset sales |
|
||||
| Taxation of the vehicle | REIT/InvIT is a pass-through; SPV dividends, interest and capital repayment are taxed differently in the unitholder's hands — compute a **post-tax** yield before comparing to a G-sec or a bank deposit | US REITs avoid entity-level tax if the distribution and asset tests are met; unitholders taxed on distributions; foreign investors face withholding and FIRPTA considerations |
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Classify first: developer, REIT, InvIT or hybrid — and if hybrid, split it and value each leg separately.
|
||||
- [ ] Delete P/E, OPM, ROCE, D/E, P/B, current ratio, inventory turnover and FCF from the analysis, and state in the report why each is inapplicable here.
|
||||
- [ ] Developer: pull pre-sales (gross **and** net of cancellations), area, realisation per sq ft, and decompose value growth into area vs price.
|
||||
- [ ] Developer: compute collections ÷ pre-sales over a rolling 4–8 quarters; investigate any persistent gap.
|
||||
- [ ] Developer: compute operating cash surplus before land spend, and net debt ÷ that surplus, excluding RERA-escrowed advances from net debt.
|
||||
- [ ] Developer: check GDV added vs annual pre-sales (is the pipeline replenishing?) and land+approval cost as % of GDV.
|
||||
- [ ] Developer: months of unsold overhang, split under-construction vs ready; value ready unsold stock separately.
|
||||
- [ ] Developer: build project-level NAV bottom-up; value land bank separately with an approval-status haircut; subtract net debt and NPV of overheads.
|
||||
- [ ] Developer: reconcile P&L finance cost against cash interest paid; quantify capitalised interest.
|
||||
- [ ] REIT: compute FFO and AFFO **per unit** from the NAREIT bridge; check AFFO payout coverage of the distribution.
|
||||
- [ ] REIT: same-store NOI growth, not aggregate NOI; strip acquisition-driven growth.
|
||||
- [ ] REIT: occupancy vs committed occupancy, WALE, and the **lock-in** expiry ladder plus tenant/sector concentration.
|
||||
- [ ] REIT: MTM gap vs realised re-leasing spreads — do the claimed upsides actually convert?
|
||||
- [ ] REIT: maintenance capex + TI + leasing costs as % of NOI; flag anything under ~5% as deferral or reclassification.
|
||||
- [ ] REIT: LTV vs the SEBI 49% cap (India) or covenant limits, DSCR/ICR, fixed vs floating mix, maturity ladder, SPV cash traps.
|
||||
- [ ] REIT/InvIT: NDCF reconciliation and the composition of DPU — flag a rising repayment-of-capital share.
|
||||
- [ ] InvIT: weighted residual concession life, volume risk vs availability risk, MMR funding status, counterparty receivable days.
|
||||
- [ ] InvIT: model DPU over residual life with little/no terminal value and solve for unitholder IRR; never quote the headline yield alone.
|
||||
- [ ] Compute the implied cap rate from market price and compare it to observable private-market transaction cap rates.
|
||||
- [ ] Check whether stated cap rate assumptions moved when the bond market moved; if not, treat the NAV as stale.
|
||||
- [ ] Test the last three acquisitions for per-unit AFFO/DPU accretion after financing cost, and the price paid vs independent valuation (sponsor deals especially).
|
||||
- [ ] Track per-unit/per-share metrics across every equity raise; flag issuance below NAV.
|
||||
- [ ] Read the contingent-liability, guarantee and related-party notes; add JV project debt and guarantees to economic net debt.
|
||||
- [ ] India: check RERA project registrations, delivery timelines, complaints and 70% escrow compliance; read CARO on title deeds and defaults; read the concall Q&A.
|
||||
- [ ] Confirm the area basis (carpet/saleable/chargeable, or rentable vs usable) before using any per-sq-ft figure.
|
||||
- [ ] State where in the price/inventory cycle and the rate cycle this sits, and what regulatory change is in flight.
|
||||
- [ ] Peer set: same sub-sector, asset class, geography, accounting regime, management structure and consolidation basis — stated explicitly, with exclusions named.
|
||||
|
|
@ -0,0 +1,218 @@
|
|||
# Retail chains, e-commerce, marketplaces and quick commerce — sector playbook
|
||||
|
||||
Use this when: the company sells goods to end consumers through a store estate, a website/app, or a third-party platform — supermarkets and hypermarkets, value and specialty apparel chains, department stores, jewellery and electronics retail, horizontal and vertical marketplaces, 1P inventory-led e-commerce, food delivery, quick commerce and dark-store networks, and omni-channel hybrids of these.
|
||||
|
||||
This sector breaks the generic checklist more comprehensively than almost any other, because two accounting standards (IFRS 15 / Ind AS 115 on principal-vs-agent, and IFRS 16 / Ind AS 116 on leases) and one structural feature (negative working capital) between them corrupt revenue, margin, leverage, returns and free cash flow simultaneously. On top of that, the generic list contains **no operating KPI at all** — nothing that separates growth from opening stores versus growth from existing stores, or growth from more users versus more spend per user. Your job is to normalise everything to a comparable unit (GMV, or gross profit), rebuild unit economics from the notes, and judge the business on like-for-like and cohort behaviour rather than on the consolidated P&L.
|
||||
|
||||
## Contents
|
||||
|
||||
1. [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
2. [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
3. [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
4. [Peer set construction](#peer-set-construction)
|
||||
5. [Sector-specific red flags](#sector-specific-red-flags)
|
||||
6. [Cycle and structural context](#cycle-and-structural-context)
|
||||
7. [India vs global notes](#india-vs-global-notes)
|
||||
8. [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Work through all seven before quoting any standard ratio. In most cases the correct action is to restate the metric onto a common basis, or suppress it entirely — not to caveat it.
|
||||
|
||||
**Revenue is not a comparable unit, so every revenue-derived ratio is arithmetically broken.** Under IFRS 15 / Ind AS 115 a **principal** (1P, inventory-led: a supermarket chain, an own-stock beauty e-tailer) books the full customer ticket as revenue. An **agent** (3P marketplace, food delivery, most horizontal platforms) books only its commission. The same ₹100 of consumer spend becomes ₹100 of revenue for one and ₹18 for the other. Consequently a 4% operating margin at a grocer (earned on gross sales) is a far better business than a 4% margin at a marketplace (earned on net commission), and OPM, EV/Sales and revenue-growth comparisons across the two models are meaningless unless normalised to GMV or to gross profit. Worse, companies **flip** between principal and agent treatment for parts of their business, generating optical revenue growth or collapse with zero economic change. Never compare margins across 1P and 3P without stating the basis.
|
||||
|
||||
**IFRS 16 / Ind AS 116 destroys EBITDA, D/E and ROCE comparability.** Retail is a leasehold industry. Since FY20 (India) / 2019 (IFRS; US GAAP ASC 842 for lessee balance sheets), rent is split into right-of-use depreciation plus lease interest. Three consequences: EBITDA margins for leased retailers jumped roughly 300–800bps overnight with no trading improvement; lease liabilities inflate reported "debt", so leased apparel and department-store chains routinely print D/E of 1–3x that is almost entirely rent; and ROU assets inflate capital employed, so ROCE fell. Pre-FY20 and post-FY20 EBITDA margin, D/E and ROCE series **are not the same metric**. A "D/E < 1" screen mechanically rejects every leased-store retailer and mechanically passes owned-property retailers regardless of economics — the exact opposite of the intended signal.
|
||||
|
||||
**FCF and working-capital signals are inverted.** Grocery, quick commerce and marketplaces run structurally negative working capital: the customer pays instantly, the supplier is paid in 45–90 days. Growth therefore *generates* cash — "float" — so FCF looks superb precisely while the business is consuming economic capital, and FCF **collapses when growth stops** even though profitability is unchanged. Standard FCF also ignores lease payments, a real contractual rent-like outflow that IFRS 16 parks in financing activities, making leased retailers look far more cash-generative than owned ones. Always compute FCF **after** lease payments, and model the working-capital unwind at lower growth.
|
||||
|
||||
**Current ratio and liquidity rules are inverted for the same reason.** A well-run grocer or quick-commerce operator should have a current ratio below 1.0 — that is supplier float, not distress. A "current ratio > 1.5" rule rewards the retailer that finances its own inventory and penalises the one with channel power. Judge liquidity on the cash conversion cycle trend, undrawn facilities and lease-adjusted fixed-charge cover instead.
|
||||
|
||||
**ROCE is gameable in both directions.** Franchise-led and asset-light formats (brand licensors, franchise apparel) show 40%+ ROCE on almost no capital, while post-IPO platforms sitting on very large idle cash balances show depressed ROCE that says nothing about the operating business. Owned-property retailers look permanently capital-inefficient versus leased peers doing the identical trade. Compute ROCE on **operating capital excluding surplus cash**, on a lease-consistent basis, and pair it with **return on incremental capital** (new-store payback) — average ROCE tells you about yesterday's estate, not about the rollout that the multiple is paying for.
|
||||
|
||||
**P/E and P/B are frequently undefined or irrelevant.** Most scaled platforms were loss-making for a decade, so P/E is negative or a meaningless four-digit number through the crossover year and mean-reverts violently for two years afterward. P/B fails because the assets that matter — brand, customer cohorts, seller network, delivery density, private-label IP, catchment locations — are unbooked, while accumulated losses can push book equity toward zero or negative. Conversely, Indian retail P/Es of 60–120x are not "expensive" in isolation: they price a decade-long store-rollout runway that a static P/E cannot express. Judge the multiple against the implied store count and density, not against the market.
|
||||
|
||||
**EV/EBITDA is usable but is the single most common site of a basis error.** The unforgivable and extremely frequent mistake is mixing bases: adding lease liabilities into enterprise value while using a pre-IFRS 16 EBITDA (double-counting rent), or comparing a post-IFRS 16 multiple against a pre-FY20 historical average. Pick one basis, state it, and apply it to every peer.
|
||||
|
||||
**The generic list has no operating KPIs, and seasonality makes the ones it has misleading.** A retailer can post 25% revenue growth with negative like-for-like sales, falling sales density and lengthening store payback — the checklist sees only the 25%. Add Q3 festive/holiday concentration (30–40% of annual profit for Indian apparel, gifting and jewellery retail; similar for Western Q4) and annualising a single quarter is actively misleading. TTM and LFL are mandatory, never optional. Finally, Indian new-age platforms headline an "Adjusted EBITDA" that excludes ESOP charges running 3–8% of revenue — a real, recurring, dilutive shareholder cost that the generic ratios silently absorb.
|
||||
|
||||
---
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, format, cycle and reporting period, and post-IFRS 16 versus pre-IFRS 16 basis changes several of them materially. A company's own multi-year history and its direct sub-format peers always override any absolute band below.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| Like-for-like / same-store sales growth (LFL, SSSG), decomposed | Sales growth from stores open the full comparable prior period, excluding openings, closures, currency and acquisitions. Decompose into footfall/transactions × conversion × average basket value × items per basket. Check whether online and click-and-collect sit inside the LFL base — most Indian retailers include them, which flatters it. | Developed markets 2–5% grocery, 3–6% specialty. India 6–12% for a healthy format; best-in-class value formats have run 15–25% in expansion phases. Below food/CPI inflation = real volume decline. Negative for 2+ consecutive quarters is structural. | The single most important retail metric and it is absent from the generic list. Total revenue growth can be manufactured indefinitely by opening stores at declining returns; LFL isolates whether the existing asset base is getting healthier. Volume-led LFL is high quality; price-led LFL during inflation reverses. Falling footfall masked by a rising ticket is the classic pre-decline signature. |
|
||||
| Sales density — revenue per sq ft, per store, per dark store | Annualised revenue ÷ average carpet/retail area. Track the level, the trend, and the **gap between mature-store and new-store density**. Analogues: GMV per dark store per day (quick commerce), sales per checkout (grocery), GMV per active seller (marketplace). | India: best-in-class value grocery ~₹32,000–36,000/sqft/yr; value apparel ~₹10,000–14,000; department stores ~₹9,000–12,000. US: mass-market big-box ~$500–700/sqft, warehouse clubs $1,000–1,500+. Quick commerce: a dark store generally needs ~₹8–10 lakh/day GMV to be contribution-positive. | Density determines whether rent, staff and inventory can be absorbed at all. A retailer whose density falls as it expands is buying growth by moving into weaker catchments or cannibalising itself. It is the cleanest early evidence that the rollout runway — which is what a 70x P/E is paying for — is exhausted. |
|
||||
| Occupancy cost ratio (rent + CAM + property tax as % of sales) | Post-Ind AS 116/IFRS 16 you must **reconstruct** this from the lease note: ROU depreciation + lease interest, or the undiscounted lease commitment schedule. Also record the fixed vs revenue-share split and the escalation clause (India: typically ~5% p.a., or ~15% every 3 years). | Grocery/value retail 2–5% of sales; apparel/specialty 8–12%; mall-based department stores 12–16%. Above ~15–18% the format is structurally fragile. Revenue-share leases (Indian malls, commonly 12–18% of sales) are far safer in a downturn than fixed rent. | Rent is the retailer's operating leverage and its main route to insolvency: a 200bps rise in occupancy ratio can erase the entire EBIT of a specialty retailer. Ind AS 116 removed it from the P&L, which is precisely why the generic checklist misses it. High-fixed-rent, low-density formats break first when LFL turns. |
|
||||
| GMV / GOV / NMV growth and take rate | GMV = gross value transacted. Take rate = platform net revenue (commission + fulfilment + ads + payments) ÷ GMV. Decompose take rate into commission / logistics / advertising / other — each has a different margin and a different ceiling. Pin the definition: gross or net of cancellations, returns, discounts, delivery fee and taxes. | Blended take rates: large global auction/horizontal marketplaces ~13–14%; craft/curated marketplaces ~20%+; large 3P ecosystems ~45–50% of 3P GMV all-in but ~15–20% commission-only; Indian horizontals 5–12%; deliberately low-take social commerce 4–6%; Indian food delivery ~19–22% of GOV; quick commerce ~15–18%. | GMV is the true scale variable and reported revenue is not comparable across models — take rate is the bridge between them. Take-rate expansion is the primary margin lever and a direct measure of pricing power over sellers. But a rising take rate alongside decelerating GMV or seller churn is fee extraction, not monetisation. **GMV is not revenue** and must never be substituted into a revenue ratio. |
|
||||
| Contribution margin per order (₹/$ per order and % of GMV) | Net revenue per order less **all** variable costs: last-mile/rider payouts, packaging, payment gateway and COD handling, customer discounts and cashbacks, returns and RTO cost, customer support, variable warehouse cost — before corporate overhead, technology and brand marketing. Show mature versus new cities/cohorts separately. | Indian food delivery ~7–8% of GOV (₹35–45/order) at maturity. Quick commerce: mature dark stores ~4–6% of GMV, blended often 1–3% during expansion. 1P e-commerce 8–15% of GMV. Must be positive **and rising with density**, not merely with discount withdrawal. | This is the metric that says whether the business model works at all, and no generic ratio captures it. A platform can post improving consolidated EBITDA purely by throttling growth spend while unit economics stagnate. Widening contribution margin is the only evidence that scale creates genuine cost advantage. Rebuild it yourself — companies quietly exclude rider incentives, platform fees or discount spend to manufacture positivity. |
|
||||
| Cohort retention, repeat share, transacting users and frequency | % of an acquisition cohort still transacting in year 2/3/4, and that cohort's GMV versus its year-1 GMV (net revenue retention). Alongside: monthly/annual transacting users (MTU/ATU), orders per user, and repeat customers' share of orders. Decompose GMV growth as users × frequency × AOV. | Repeat customers should drive >70–80% of orders at a mature platform. Year-3 cohort GMV of 60–100%+ of year-1 is strong (best-in-class cohorts spend *more* over time). Frequency: Indian food delivery ~3–4 orders/month for a core user; quick commerce ~3–5/month; fashion e-commerce ~3–5/year. Watch for the retention curve **flattening**, not just its level. | Retention is the asset. A platform with 40% year-2 retention must replace half its base annually with paid acquisition, permanently capping margins regardless of scale. Cohort curves also reveal bought growth: rising new-user counts with steepening cohort decay means progressively worse customers. This is where terminal value actually comes from, and it is invisible in P/E and ROCE. |
|
||||
| CAC, CAC payback, LTV:CAC and discount intensity | CAC = performance marketing + first-order discounts/cashbacks/referral spend ÷ new customers. Payback = CAC ÷ monthly contribution per customer. Discount intensity = total customer discounts and promotions as % of GMV, **whether booked as a revenue reduction or as marketing expense**. | LTV:CAC > 3x; payback < 12 months (< 6 months excellent for high-frequency models). Sustainable platforms discount 2–5% of GMV; 10%+ signals demand that does not exist at true prices. Scaled Indian platforms should trend below 5–6% of GMV on ad + promo combined. | With minimal switching costs, acquisition economics *are* the business model. The accounting trap: platform-funded discounts can be booked as a revenue reduction (correct when paid to the customer) or as marketing expense — the latter simultaneously inflates revenue, gross margin and apparent take rate. Reconstruct discount spend from the notes and re-net it against GMV. |
|
||||
| Gross margin (on a restated COGS definition) and private-label mix | State explicitly what sits in COGS — logistics, fulfilment, warehousing, shrinkage and last-mile are inside COGS for some filers and in opex for others. Alongside: own-brand sales as % of total and the margin spread over national brands. | Grocery 14–18% (deep-value formats deliberately ~14–15% to drive density); value apparel 30–40%; department stores/branded fashion 45–55%; marketplace net-revenue gross margin 60–80%. Private label: 15–25% is good for a grocer (European hard discounters >70%); own brand typically carries 500–1,500bps more margin. | Private label is the main structural margin lever in retail — it converts scale into margin without raising prices and defends against a marketplace commoditising your assortment. But cross-check rising GM against LFL: margin expansion with decelerating volume is harvesting, not compounding. Restate all peers onto one COGS definition before comparing. |
|
||||
| Inventory turns, shrinkage, markdowns and ageing profile | COGS ÷ average inventory; days inventory outstanding; shrinkage (theft, damage, expiry) as % of sales; markdown as % of gross sales; and the ageing note (% over 90/180/365 days) plus the provisioning policy. | Grocery/FMCG retail 10–14x turns (~26–36 days). Value apparel 3–4x (90–120 days). Branded/department fashion 2.5–3.5x (100–150 days). Shrinkage <0.5% is best-in-class grocery, 1–2% acceptable, >2% is process failure. Markdowns should be stable as % of sales. | Inventory is where retail fraud and retail failure both live. Rising days-inventory with flat sales is the most reliable single predictor of a future margin shock, because unsold stock must eventually be marked down or written off. The ageing bucket and the year-on-year provisioning **rate** are more informative than the turns ratio; quiet policy changes here are a governance signal. |
|
||||
| Cash conversion cycle, negative working capital and supplier float | Days inventory + days receivable − days payable. Decompose: is negative WC driven by genuine inventory efficiency, or purely by stretching payables? Cross-check against supply-chain finance / reverse factoring / channel financing, which converts trade payables into economic bank debt. | Grocery/quick commerce −10 to −40 days; large 1P e-commerce around −30. Some deep-value grocers run slightly *positive* by design, paying suppliers fast for cash discounts — that is a strategy, not weakness. Apparel retail +30 to +90 days. Marketplaces strongly negative. | Negative working capital is the retail float: it makes growth self-funding and is a genuine competitive asset — but it inverts the FCF signal, looking strongest during expansion and cratering when growth stalls. Model the unwind. Reverse factoring is the most common way retailers keep real debt off the debt line; check the cash-flow classification and the auditor's note. A 15–20 day jump in payable days without a stated procurement change is not efficiency. |
|
||||
| Return rate, RTO and COD mix | Returns as % of gross orders/GMV (post-delivery), plus RTO — orders refused or undeliverable and shipped back, a distinctly Indian problem driven by cash-on-delivery. Track COD share of orders and the cost of the reverse leg (typically full forward logistics plus refurbishment or write-off). | Fashion e-commerce 25–40% returns in developed markets, 20–30% in India. Electronics/grocery 2–8%. RTO healthy <5% of orders; >10% is economically ruinous. Indian COD share has fallen from ~60% to ~20–30% with UPI; a **rising** COD share is a negative mix signal. | A returned fashion order can cost 1.5–2x the contribution it would have earned, so a 5pp rise in return rate flips a category from profitable to loss-making with no change in reported revenue. Returns provisioning is soft: revenue is recognised net of expected returns, so an understated return assumption directly inflates current revenue and profit. GMV reported gross of returns overstates true scale by a quarter or more in fashion. |
|
||||
| Fulfilment and last-mile cost per order (and % of GMV) | Warehousing, packing, line-haul, last-mile and rider/partner payouts, per order and as % of GMV. Track against order density (orders per sq km per day) and average delivery distance/time. | Large global 1P: fulfilment + shipping ~15–17% of revenue. Indian food delivery: cost per delivery ₹55–70, of which the platform bears ₹20–30 after customer delivery fees. Quick commerce ₹35–50/order at maturity. Should fall 10–20% a year in a scaling network. | This is where the theoretical scale economies of e-commerce either materialise or do not. Delivery cost is a function of **route density, not company size** — which is why national scale does not guarantee profitability while local density does. Cost per order falling as GMV grows is empirical proof of a moat; flat cost per order means a linear-cost logistics operator wearing a technology multiple. |
|
||||
| Advertising and ancillary monetisation (% of GMV, % of gross profit) | Seller/brand advertising and sponsored listings, subscription and loyalty fees, fulfilment services sold to sellers, payments and seller lending — separated from core commission. Track ad take rate and ads as % of total gross profit. | Ad take rate: largest global 3P ecosystem ~5–6% of GMV; craft marketplaces ~2%; Indian marketplaces 1.5–3.5% and rising; Indian food delivery ~1–2% of GOV. Ads carry 70–95% incremental margin. Subscription members should show 2–3x the frequency and AOV of non-members. | For every scaled marketplace, advertising rather than commission is the profit engine — at the largest platforms the ad business alone exceeds the operating profit of the entire retail segment. The path from breakeven to a 15–25% EBITDA margin is almost entirely an ad-monetisation story, so this drives the terminal margin in any DCF. Counterweight: rising ad load degrades organic relevance, so monitor ad take rate against conversion and repeat rate together. |
|
||||
| New-store / dark-store payback, capex per store, mature-store EBITDA, maturity mix | Capital to open a store (fit-out + initial inventory + pre-opening) ÷ annual store-level cash EBITDA. Alongside: store-level EBITDA margin by vintage (year 1, year 2, mature), % of the estate still immature, net additions and the closure rate. | India large-format grocery: ₹15–30 crore per **owned** store (payback ~5–6 years) versus ₹3–6 crore leased; value apparel ₹1–2 crore with 2–3 year payback. Quick-commerce dark store ₹40–60 lakh, target payback 12–24 months. Mature store-level EBITDA 8–12% grocery, 18–25% apparel. Closure rate >3–4% of the estate annually signals format failure. | Return on **incremental** capital, not average ROCE, determines whether a rollout creates value: a company earning 25% ROCE overall while opening stores at 8% incremental returns is destroying value while screening beautifully. The maturity mix also explains reported margins mechanically — fast openers always show depressed consolidated margins, so mature-cohort economics are the only honest steady-state read. Refusal to disclose store-vintage economics is itself informative. |
|
||||
| Lease-adjusted leverage and fixed-charge coverage (EBITDAR), plus pre-Ind AS 116 EBITDA | (Net debt + lease liabilities) / post-IFRS 16 EBITDA, **or** the older convention (net debt + 8× annual rent) / EBITDAR. Fixed-charge cover = EBITDAR / (interest + rent). Also restate EBITDA pre-Ind AS 116 (rent back in opex) and compute FCF after lease payments. | Lease-adjusted net debt/EBITDAR < 3.0x comfortable, 3.0–4.0x manageable, >4.5x fragile. Fixed-charge cover > 2.0x healthy, < 1.5x distress. Rating agencies, Indian ones included, use the 8×-rent capitalisation convention. | Retail insolvencies are almost always rent insolvencies, and generic D/E either misses rent entirely (pre-2019 accounting, or US GAAP operating-lease presentation) or counts it as debt without adding rent back to EBITDA. Pre-Ind AS 116 EBITDA is also the only way to compare an Indian retailer against its own pre-FY20 history. |
|
||||
| ESOP charge as % of revenue and diluted-share bridge (India new-age; global tech-retail) | Share-based payment expense from the P&L note as % of revenue, plus outstanding options/RSUs as % of share capital and the 3-year dilution trend. | Indian new-age platforms commonly 3–8% of revenue at listing, should fall toward 1–2% within 3–4 years. Outstanding pool often 5–10% of share capital. | Companies headline "Adjusted EBITDA" excluding it. It is a recurring, cash-equivalent, shareholder-borne cost and a direct transfer of value. Always add it back into the earnings base before applying any multiple, and model the dilution separately in per-share terms. |
|
||||
|
||||
Sourcing notes: in India, LFL, sales density, store count by format, GMV/GOV, take rate, contribution margin and dark-store cohorts appear in the **quarterly investor presentation and concall transcript**, not in the Ind AS financials — read the transcript and the shareholder letter. Lease and inventory-ageing detail lives in the notes to accounts and the CARO annexure. In the US, segment revenue, fulfilment cost lines and lease maturity schedules are in the 10-K; store counts, square footage and comparable-sales definitions are in the MD&A and the 8-K earnings release; the comparable-sales *definition* is footnoted and changes are disclosed there.
|
||||
|
||||
---
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
No single multiple works across this sector. Pick the method from the sub-model, and state the basis explicitly every time.
|
||||
|
||||
### A) Mature physical retail (grocery, value apparel, department stores, jewellery, electronics)
|
||||
|
||||
**Primary: EV/EBITDA, with absolute basis consistency.** Either (i) post-IFRS 16 — EV includes lease liabilities in net debt and EBITDA is post-IFRS 16 (typically 8–14x in developed markets, 25–45x for premium Indian compounders); or (ii) lease-adjusted — EV = market cap + net debt + 8× annual rent, over EBITDAR. **Never mix the two.** Secondary: EV/Sales as a sanity check (0.3–1.0x developed grocery, 2–5x high-growth Indian retail) and P/E for genuinely mature, low-growth names. Indian sell-side convention is to present "EV/EBITDA pre-Ind AS 116" alongside reported specifically to preserve comparability with pre-FY20 history — replicate that.
|
||||
|
||||
**DCF is the honest workhorse for Indian retail**, because headline P/Es of 60–130x are pricing a decade-long rollout runway that no static multiple expresses. Build it bottom-up: store additions × sales density × mature store EBITDA margin × incremental capex per store, with an explicit **terminal store count**. Then invert: at today's price, what store count and density are implied, and are they physically plausible given catchment arithmetic and competitor estates?
|
||||
|
||||
**Property adjustment (opco/propco).** Where the retailer owns its real estate — some Indian large-format grocers own the large majority of their stores, as do several US big-box chains — split it: value the operating business on EV/EBITDAR with a **market rent charged**, then add the property at a cap rate. Without this, owned-store retailers look permanently and misleadingly capital-inefficient against leased peers.
|
||||
|
||||
### B) Marketplaces and platforms (3P e-commerce, food delivery, horizontals, social commerce)
|
||||
|
||||
Because reported revenue is a net number and near-term EBITDA is small or negative, climb the ladder: **EV/GMV (or EV/GOV) → EV/Net Revenue → EV/Gross Profit → EV/Contribution Profit → EV/EBITDA once real.** EV/GMV benchmarks: 0.3–0.8x for low-take-rate horizontals, 1.5–3.0x for high-take-rate, high-frequency platforms — but EV/GMV is only interpretable **paired with the take rate**, since EV/GMV = EV/Revenue × take rate. **EV/Gross Profit or EV/Contribution Profit is the most defensible near-term multiple**, because it normalises away the 1P-versus-3P revenue-recognition distortion entirely; this is the single most useful comparability fix in the sector.
|
||||
|
||||
The primary method remains a **steady-state-margin DCF** structured as: GMV growth → take rate → contribution margin → mature EBITDA margin → reinvestment. Every metric in the table above feeds one link of that chain. Terminal margins you must be able to defend: 15–25% of net revenue for a scaled marketplace, 4–8% of GMV for food delivery, 2–5% of GMV for quick commerce.
|
||||
|
||||
**Cohort/LTV valuation** is the rigorous alternative for high-frequency models: value = NPV of existing cohorts (observed retention × contribution per cohort) + option value on future cohorts. It is the only method that makes an unprofitable, fast-growing platform valuable for a defensible reason rather than a narrative one.
|
||||
|
||||
### C) Indian new-age platforms — SOTP is the market convention
|
||||
|
||||
Listed Indian internet/retail platforms are almost universally valued **sum-of-the-parts**, because segments have wildly different economics and maturity: a food-delivery segment on DCF or EV/EBITDA, a quick-commerce segment on EV/GOV, a B2B supplies arm on EV/Sales, a going-out/ticketing arm on EV/Revenue — less a holding-company discount, **plus net cash added separately**. Post-IPO cash piles are large; never let them dilute the operating multiple, and never let treasury "other income" flatter consolidated PAT. Beauty/fashion platforms split naturally into a high-margin near-profitable vertical (EV/EBITDA) and a loss-making one (EV/GMV). Do the segment split yourself even where the company reports consolidated.
|
||||
|
||||
**Critical Indian adjustment:** restate "Adjusted EBITDA" to **include ESOP cost** before applying any multiple, and model option-pool dilution separately in the per-share bridge.
|
||||
|
||||
### D) 1P inventory-led e-commerce
|
||||
|
||||
EV/Sales and EV/Gross Profit near term; EV/EBITDA at maturity. These are economically retailers with a distribution overlay — benchmark their gross margin, inventory turns and contribution margin against **physical retail** peers, not against asset-light marketplaces.
|
||||
|
||||
### What not to use
|
||||
|
||||
- **P/B** — brand, cohorts and network are unbooked and accumulated losses distort equity. Exception: property-heavy retailers, where book at least anchors to land.
|
||||
- **Trailing P/E through the loss-to-profit crossover** — mathematically unstable and economically uninformative.
|
||||
- **EV/Sales compared across 1P and 3P** — the denominators are different quantities.
|
||||
- **Any multiple applied to GMV as if GMV were revenue.**
|
||||
- **Post-IFRS 16 EV against pre-IFRS 16 EBITDA**, in either direction.
|
||||
|
||||
Always close by inverting the valuation: what mature EBITDA margin, terminal store count, or terminal GMV share does today's price require — and has any comparable company anywhere ever achieved it?
|
||||
|
||||
---
|
||||
|
||||
## Peer set construction
|
||||
|
||||
The defining rule: **peers must share a revenue-recognition model, a lease posture and a maturity stage.** Violating any one of the three makes the comparison arithmetic, not analysis.
|
||||
|
||||
Split on these axes, and never blend across them:
|
||||
|
||||
- **Principal (1P) vs agent (3P)** — the hard boundary. A 1P grocer and a 3P marketplace cannot be compared on margin, EV/Sales or revenue growth. If you must span them, convert both to EV/Gross Profit or EV/GMV.
|
||||
- **Format and basket** — grocery/food (high frequency, low ticket, low GM), value apparel (low ticket, high GM, high turns), department stores and premium fashion (high ticket, high GM, low turns), jewellery (very high ticket, gold-price-linked, hallmarking and making-charge economics), electronics (low GM, financing-driven). Sales density, occupancy ratio and inventory turns differ by multiples across these.
|
||||
- **Owned vs leased property** — until you have run the opco/propco adjustment and charged market rent, an owner and a lessee are not comparable on ROCE, EBITDA margin or D/E.
|
||||
- **Franchise/FOFO vs company-owned (COCO)** — franchised chains book wholesale revenue at lower margin on almost no capital; company-owned chains book retail revenue at higher margin on real capital. ROCE and OPM are non-comparable; compare **system-wide sales** and store-level economics instead.
|
||||
- **Delivery model** — food delivery, quick commerce (10–30 min, dark stores, owned inventory), scheduled e-grocery, and horizontal e-commerce have entirely different cost curves, frequencies and AOVs. Quick commerce is *inventory-led* even when the parent is a marketplace; treat it as 1P.
|
||||
- **Maturity stage** — a chain with 40% of its estate under two years old will always show worse consolidated margins than an identical mature chain. Compare mature-cohort economics, or explicitly adjust for the maturity mix.
|
||||
- **Geography and density** — delivery economics are set by population density and labour cost. Indian quick commerce, US same-day and European e-grocery are not the same industry. Also split by urban tier: metro-only formats and tier-2/3 formats have different rent, wage and basket structures.
|
||||
|
||||
Practical construction rules: use **TTM** figures, never annualised quarters, because of festive/holiday concentration. Restate every peer onto a single lease basis and a single COGS definition before tabling anything. Where an Indian conglomerate houses retail inside a larger listed entity, use the **segment disclosure** and compare segment-level EBIT and capital employed, never the consolidated entity. For diversified platforms, build peer sets segment-by-segment, matching each segment to its own comparables.
|
||||
|
||||
---
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
Ordered roughly by how often they precede a de-rating.
|
||||
|
||||
1. **GMV/NMV/GOV definition changes or silent redefinition.** Switching between GMV, NMV and GOV, or including cancelled, returned and RTO orders in headline GMV. In fashion this can overstate true transacted value by 25–40%. Any mid-series definition change, or a quiet footnote change to inclusions, is a deliberate flattering of growth until proven otherwise.
|
||||
2. **Principal-vs-agent (gross-vs-net) revenue-recognition flips.** Optical revenue growth or collapse with zero economic change. The giveaway is revenue growth diverging sharply from gross profit growth or from GMV growth.
|
||||
3. **Customer discounts booked as marketing expense rather than as a revenue reduction.** This inflates revenue, gross margin and apparent take rate simultaneously. Reconstruct discount spend from the notes and re-net it against GMV; discounts above ~5–8% of GMV suggest demand that does not exist at real prices.
|
||||
4. **"Adjusted EBITDA" excluding ESOP, and ESOP rising as a share of revenue.** Endemic among Indian new-age platforms at 3–8% of revenue. Watch equally for "one-off" restructuring, store-closure or inventory-write-down adjustments that recur every single year.
|
||||
5. **IFRS 16 / Ind AS 116 EBITDA flattery.** Headline EBITDA growth driven by the lease standard rather than trading; or a company presenting lease-inflated EBITDA against a pre-IFRS 16 enterprise value; or comparing post-FY20 D/E and ROCE with the pre-FY20 series as though they were the same metric.
|
||||
6. **Strong total revenue growth while LFL is flat or negative** — growth entirely from new openings. Paired with falling sales per sq ft as the estate expands, this means new stores are entering weaker catchments or cannibalising existing ones, and the runway justifying the multiple is already spent.
|
||||
7. **Stretching supplier payment terms to manufacture FCF, and undisclosed reverse factoring / supply-chain finance / channel financing** that keeps economically debt-like obligations inside trade payables. Check the cash-flow-statement classification, the payables ageing and any auditor comment. A 15–25 day jump in payable days without a stated procurement change is not efficiency.
|
||||
8. **Inventory building ahead of an inevitable markdown.** Days-inventory rising while sales are flat; deterioration in the >90/>180 day ageing buckets; quiet loosening of the provisioning policy; or recognising shrinkage only at the annual physical count so the first three quarters look clean.
|
||||
9. **Channel stuffing into franchisees, dealers or distributors** — common in Indian franchise-led apparel and footwear. Primary sales (to the franchisee) are booked as revenue while secondary sales (to the consumer) stagnate. Demand secondary-sales and franchisee-inventory disclosure; a widening primary–secondary gap plus rising related-party receivable days is the signature.
|
||||
10. **Contribution margin defined to exclude real variable costs** — rider incentives, platform fees paid out, packaging, gateway charges, reverse-logistics on returns. Companies reach "contribution positive" by moving a cost line into corporate overhead. Rebuild the number from the segment notes yourself.
|
||||
11. **Take-rate expansion from unilateral fee hikes rather than value delivered** — visible as rising take rate with decelerating GMV, falling active-seller counts, or seller agitation and regulatory noise. In India, add the overhang on marketplace fees, deep-discounting under FDI rules and platform-neutrality scrutiny, any of which can reset take rates abruptly.
|
||||
12. **Disclosure withdrawal or metric-switching in cohort and user data** — dropping monthly transacting users for annual, redefining a cohort, moving from "orders" to "transactions", or ceasing to publish retention curves. Companies stop disclosing a metric precisely when it turns. Treat removal of a previously reported KPI as a negative disclosure event in its own right.
|
||||
13. **Marketing cut sharply to hit an EBITDA-breakeven promise while GMV growth decelerates in the same quarters** — harvesting rather than building. Genuine operating leverage shows margin improvement *with* sustained growth; artificial improvement shows margin up and growth down together.
|
||||
14. **Rising returns and RTO with inadequate provisioning, and a rising COD mix.** Revenue is booked net of expected returns, so an understated return assumption inflates current profit and creates a future reversal. High COD plus rising RTO can make an entire category structurally loss-making while GMV still looks healthy.
|
||||
15. **Lease sweeteners flattering early store economics** — sale-and-leaseback gains, rent-free periods, landlord fit-out contributions, step-up leases. Reported occupancy cost is artificially low in years 1–3 and steps up later. Also check whether gains on property disposals or store closures sit inside operating profit rather than below the line.
|
||||
16. **Quick-commerce / dark-store specific:** reporting dark-store **count** as the growth metric while blending immature and mature stores to hide per-store economics; or claiming store-level profitability on a definition excluding central warehousing, line-haul and rider fixed costs. Demand mature-cohort economics and orders-per-store-per-day by vintage.
|
||||
17. **Aggressive capitalisation** — of customer acquisition or content costs, software and technology development, pre-opening store expenses, or last-mile assets. Cross-check the gap between reported EBITDA and (operating cash flow − capex); a persistently widening gap at a company reporting improving "adjusted" profitability is the classic signature.
|
||||
18. **Treasury income presented as core earnings.** A large post-IPO cash pile generating other income that turns consolidated PAT positive while the operating business still burns cash. Strip other income out and read operating EBIT; a company earning more from treasury than from operations is not yet a business.
|
||||
19. **Gift-card and loyalty-point breakage, and deferred-revenue release from subscriptions**, used to smooth or manufacture quarterly profit — a low-visibility lever with material year-end effects.
|
||||
20. **Governance and concentration warnings** — CFO or auditor churn (especially at Indian new-age names), heavy related-party transactions with promoter-owned suppliers, logistics arms or franchisees, GMV concentrated in a few sellers or a single category, and continuous large promoter or pre-IPO-investor selling into strength.
|
||||
|
||||
---
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**Where you are in the cycle changes which metric leads.** Retail is a levered play on real disposable income. In a consumption upcycle, LFL runs ahead of inflation, footfall grows, markdowns fall and operating leverage flatters margins; in a downturn, ticket holds up (price/mix) while footfall falls first — which is why the footfall-vs-ticket decomposition is the earliest cycle read available. Watch **trade-down**: value formats and private label gain share in downturns while premium and department stores lose it, so the same macro is a tailwind for one peer group and a headwind for another. Never treat a sector-wide LFL number as a company signal without this split.
|
||||
|
||||
**Inflation cuts both ways.** Moderate food inflation *helps* grocers' reported LFL and absorbs fixed costs; sharp inflation compresses basket volumes and shifts mix to essentials. Deflation is the harder regime — LFL turns negative on unchanged volumes and operating leverage runs in reverse. Always separate price-led from volume-led LFL before calling a trend.
|
||||
|
||||
**Rent and wage cycles set the floor on fragility.** Occupancy ratios are agreed years in advance with 5% escalations, but sales are not. A retailer that signed leases at peak rents and then sees flat LFL will breach fixed-charge cover before it breaches any P&L covenant. In India, minimum-wage revisions and rising gig-worker payouts feed directly into quick-commerce and delivery unit economics.
|
||||
|
||||
**Secular threats to physical retail:** marketplace commoditisation of assortment (the reason private label matters), quick-commerce cannibalisation of top-up grocery baskets and of general trade, mall traffic decline in weaker catchments, and format obsolescence (large-box department stores globally). Test any physical retailer for what proportion of its basket is genuinely defensible against 10-minute delivery.
|
||||
|
||||
**Secular threats to platforms:** customer-acquisition cost inflation as ad auctions mature; regulatory resets to take rates and to gig-worker classification; the shift of discovery to social and AI-mediated interfaces, which can disintermediate a marketplace's own search; and brands going direct (D2C) to reclaim margin. The counterweight is advertising monetisation and logistics density, which is why those two metrics dominate the terminal-value case.
|
||||
|
||||
**Regulation — India specifically.** FDI policy distinguishes single-brand from multi-brand retail and restricts e-commerce marketplaces from owning inventory or influencing prices, which is why the marketplace/1P structuring is often legally driven rather than economically driven. Press Note 2 style restrictions, deep-discounting scrutiny, platform-neutrality and seller-exclusivity issues, CCI investigations, ONDC as a policy attempt to unbundle discovery from fulfilment, and gig-worker social-security proposals are all live take-rate and cost risks. GST rate changes shift ticket sizes; the e-commerce TCS/TDS regime affects seller cash flows. **Globally:** antitrust and self-preferencing actions against large platforms, DSA/DMA-type obligations in the EU, state-level gig-worker classification rules in the US, and de minimis import thresholds that determine whether cross-border ultra-low-price players are viable.
|
||||
|
||||
**Seasonality is structural, not noise.** Indian apparel, gifting, jewellery and electronics concentrate 30–40% of annual profit in the festive quarter (Q3, Oct–Dec, around Navratri/Durga Puja/Diwali, with a wedding-season tail); Western retail concentrates in Q4 holiday. Never annualise a quarter, always compare year-on-year on the same quarter, and check whether a festive-date shift moved sales between quarters before reading a "collapse" or a "surge".
|
||||
|
||||
---
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India (NSE/BSE, Ind AS) | US / global (10-K, US GAAP / IFRS) |
|
||||
|---|---|---|
|
||||
| Units and reporting | ₹ crore/lakh; quarterly results plus a detailed investor deck and concall; annual report with notes, CARO annexure and related-party schedules | $ millions; 10-Q/10-K on EDGAR; 8-K earnings release; store counts and comparable-sales definitions in MD&A |
|
||||
| Lease accounting | Ind AS 116 from FY20 — all leases on balance sheet; rent vanishes from opex | IFRS 16 from 2019 (all leases on balance sheet); **US GAAP ASC 842 keeps operating-lease expense as a single opex line in the income statement** while still recognising the ROU asset and liability — so US EBITDA margins were *not* restated the way IFRS/Ind AS ones were. This is a major cross-border comparability trap |
|
||||
| Where KPIs live | LFL, sales density, store count, GMV, take rate and contribution margin are in the investor presentation and concall transcript, not the financials | Comparable sales, square footage, segment revenue and fulfilment costs are in the 10-K/8-K itself; GMV and take rate in shareholder letters and supplemental decks |
|
||||
| Ownership | Promoter holding, pledge disclosure, promoter-affiliated suppliers and logistics arms; SEBI related-party rules; look at promoter and pre-IPO investor selling | Dispersed ownership; dual-class structures common at founder-led platforms; insider sales via Form 4 and 10b5-1 plans |
|
||||
| Audit and controls | CARO 2020 reporting on inventory verification, related-party loans and undisclosed income; auditor resignations are a strong governance flag | SOX 404 internal-control opinion; material weakness disclosures; auditor changes on Form 8-K Item 4.01 |
|
||||
| Non-GAAP conventions | "Adjusted EBITDA" almost always excludes ESOP; pre-Ind AS 116 EBITDA commonly presented alongside reported; "Adjusted EBITDA as % of GOV" is the food-delivery/quick-commerce convention | Non-GAAP reconciliations mandated by Reg G; SBC exclusion is also common and equally objectionable; "free cash flow" definitions vary widely on lease and finance-lease treatment |
|
||||
| Payments and returns | COD and RTO are material, distinctly Indian cost lines; UPI has collapsed COD share; card/EMI penetration lower | Card-dominant; RTO negligible; returns cost concentrated in apparel; "returnless refunds" now common at scale |
|
||||
| Regulation | FDI rules on multi-brand retail and marketplace inventory ownership; deep-discounting and platform-neutrality scrutiny; CCI; ONDC; gig-worker social-security proposals; GST and e-commerce TCS | Antitrust/self-preferencing actions; EU DMA/DSA; state gig-worker classification; de minimis import thresholds; FTC rules on subscriptions and pricing disclosure |
|
||||
| Valuation convention | High absolute P/E and EV/EBITDA for quality retail; SOTP with net cash added separately for new-age platforms; sell-side presents pre- and post-Ind AS 116 multiples in parallel | EV/EBITDA and EV/Sales dominant; SOTP used for conglomerate platforms (retail vs cloud vs ads); property adjustments common for owned-real-estate big-box |
|
||||
| Real estate | Mall revenue-share leases common (12–18% of sales); some large grocers own the majority of their stores, making opco/propco essential | Predominantly leased in specialty; owned real estate significant in big-box and warehouse clubs; sale-leaseback activity is a recurring earnings-quality issue |
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Classify the business: 1P principal, 3P agent, hybrid, franchise, or quick-commerce inventory-led — and state it before quoting any margin.
|
||||
- [ ] Normalise everything to GMV/GOV or gross profit before comparing across models; never treat GMV as revenue.
|
||||
- [ ] Pin the GMV definition (returns, cancellations, RTO, delivery fee, taxes) and check it has not changed mid-series.
|
||||
- [ ] State your lease basis (post-IFRS 16 or lease-adjusted 8× rent) and apply it identically to EV, EBITDA, D/E and ROCE for every peer.
|
||||
- [ ] Restate EBITDA pre-Ind AS 116 to compare an Indian retailer against its own pre-FY20 history.
|
||||
- [ ] Compute FCF **after** lease payments; model the negative-working-capital unwind at lower growth.
|
||||
- [ ] Get LFL/SSSG on a TTM basis and decompose it into footfall × conversion × ticket × items.
|
||||
- [ ] Compare mature-store versus new-store sales density; if density falls as the estate grows, the runway is closing.
|
||||
- [ ] Rebuild the occupancy cost ratio from the lease note; flag anything above ~15% of sales for a specialty format.
|
||||
- [ ] Rebuild contribution margin per order yourself from the notes, including rider incentives, discounts, gateway and reverse-logistics costs.
|
||||
- [ ] Check take rate alongside GMV growth and active-seller counts — rising take rate with falling GMV is extraction.
|
||||
- [ ] Reconstruct discount spend as % of GMV regardless of where it is booked, and re-net it against revenue and take rate.
|
||||
- [ ] Read the cohort/retention disclosure; treat any withdrawn or redefined KPI as a negative event.
|
||||
- [ ] Test whether fulfilment cost per order is falling with volume — flat cost per order means no density moat.
|
||||
- [ ] Size advertising and ancillary monetisation as % of gross profit; it usually is the terminal margin story.
|
||||
- [ ] Get new-store/dark-store payback, capex per store and mature-cohort store EBITDA; compute return on **incremental** capital.
|
||||
- [ ] Read the inventory ageing note and provisioning policy; rising days-inventory on flat sales predicts a markdown.
|
||||
- [ ] Check payable days, reverse factoring / channel financing and the cash-flow classification before crediting negative working capital.
|
||||
- [ ] Add ESOP charges back into EBITDA and model option-pool dilution per share.
|
||||
- [ ] Strip treasury/other income out of consolidated profit and read operating EBIT alone.
|
||||
- [ ] For franchise-led chains, demand secondary sales and franchisee inventory; watch the primary–secondary gap.
|
||||
- [ ] Run lease-adjusted net debt/EBITDAR and fixed-charge cover; retail failures are rent failures.
|
||||
- [ ] For owned-property retailers, run an opco/propco split with market rent charged before judging ROCE.
|
||||
- [ ] Use TTM, never annualised quarters — festive/holiday concentration makes single-quarter annualisation misleading.
|
||||
- [ ] For Indian new-age platforms, value SOTP by segment and add net cash separately.
|
||||
- [ ] Invert the valuation: what terminal margin, store count or GMV share does the price require, and has anyone ever achieved it?
|
||||
|
|
@ -0,0 +1,205 @@
|
|||
# Semiconductors, foundries, fabless designers, equipment and capital-intensive hardware — sector playbook
|
||||
|
||||
Use this when: the company designs, manufactures, packages, tests, or supplies the tools and materials for integrated circuits — pure-play foundries, fabless designers, IDMs, memory makers, OSAT/ATMP assembly-test houses, wafer-fab-equipment (WFE) vendors, EDA and IP licensors, semiconductor materials suppliers, and the capital-intensive hardware businesses (photonics, power modules, advanced packaging substrates) that share their economics.
|
||||
|
||||
Three facts break the generic checklist here, and they compound. First, this is a **fixed-cost manufacturing business layered on a physics roadmap**: the same fab prints 55% gross margin at 95% utilisation and negative margin at 60%, with no change in management quality, product or price discipline. Second, **spending precedes revenue by two to four years** — a fab sanctioned today depreciates for a decade against demand nobody can forecast — so cash flow and returns look worst exactly when a company is investing into a genuine upcycle. Third, the industry runs a violent **inventory cycle stacked on top of a capex cycle**, and demand seen by a chip supplier is the second derivative of end demand: a 5% dip in device sales produces a 30% collapse in orders once the channel destocks. Your job is to separate cycle from franchise, distinguish the depreciation schedule from the business, and to read operational KPIs — utilisation, yield, node mix, channel inventory, book-to-bill — that no financial ratio contains.
|
||||
|
||||
## Contents
|
||||
|
||||
1. [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
2. [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
3. [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
4. [Peer set construction](#peer-set-construction)
|
||||
5. [Sector-specific red flags](#sector-specific-red-flags)
|
||||
6. [Cycle and structural context](#cycle-and-structural-context)
|
||||
7. [India vs global notes](#india-vs-global-notes)
|
||||
8. [Checklist](#checklist)
|
||||
|
||||
---
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Work through these before quoting any standard ratio. In most cases the correct action is to suppress the metric, or to replace it with the cycle-normalised or business-model-specific version — not to print it with a footnote.
|
||||
|
||||
**P/E — inverted across the cycle, and the single most common way to buy the top.** Semiconductor earnings are extraordinarily operationally geared: a 20% revenue decline can take EPS down 60–80% because depreciation, fab fixed costs and R&D are all committed. So the stock screens at 6–9x on peak earnings just as the correction begins, and at 40x, 80x or a loss at the trough when risk-reward is best. For memory, foundry and WFE this inversion is near-total. **Treat a mid-single-digit P/E on record earnings as a warning, not a valuation.** Only mid-cycle normalised EPS makes a P/E interpretable, and for memory it barely does even then. Mature-node analog and microcontroller businesses, and EDA/IP licensors, are the exceptions where trailing P/E carries real information.
|
||||
|
||||
**OPM and gross margin — largely a utilisation and depreciation artifact, not a measure of pricing power.** Fab operating leverage is brutal: incremental gross margin on marginal wafers is often 70–90% because the fab is already paid for. A foundry at 95% utilisation and one at 65% utilisation with identical technology, cost discipline and pricing will print margins 20+ points apart. Comparing OPM across a foundry, a fabless designer (no fab depreciation, but full R&D and third-party wafer cost), an OSAT (thin margin, high asset turns) and an EDA vendor is a category error — the numbers are not measuring the same thing. Decompose margin into **utilisation, node/product mix, yield, ASP and depreciation load** before attributing any of it to management.
|
||||
|
||||
**EV/EBITDA — actively misleading for anyone who owns a fab, and the most dangerous multiple in the sector.** EBITDA adds back depreciation, but for a foundry, memory maker or IDM, depreciation *is* the business: capacity physically obsoletes on a node cadence and must be rebuilt continuously. A leading-edge fab running 15–35% of revenue as capex year after year converts a "6x EV/EBITDA" into something closer to fair or expensive on any cash measure. Use **EV/(EBITDA − maintenance capex)**, EV/EBIT, or EV/FCF with a normalised capex assumption. EV/EBITDA is defensible for fabless designers and EDA companies, where D&A is small and mostly acquisition-related.
|
||||
|
||||
**FCF — correctly signed for fabless, mis-signed for anyone building capacity.** A foundry sanctioning two fabs into a genuine structural upcycle will show deeply negative FCF for three years; that is the investment thesis executing, not distress. Conversely, a fab owner harvesting — cutting capex below depreciation, skipping the node transition — prints beautiful FCF for two or three years while its competitive position erodes irreversibly, because you cannot re-enter a node you skipped. **Always split capex into maintenance/technology-upgrade versus greenfield capacity, compare capex to depreciation, and treat capex < D&A for multiple years at a leading-edge manufacturer as a red flag rather than a quality signal.** For fabless firms, FCF is a clean and central metric — there is no fab to hide behind.
|
||||
|
||||
**ROCE / ROIC — distorted by the depreciation cycle in both directions, and non-comparable across models.** A fully depreciated 200mm mature-node fab shows spectacular ROCE on a near-zero denominator; a just-commissioned 300mm fab shows negative ROCE while capital sits in CWIP producing nothing. Neither number describes the economics. Compound this with government capex subsidies (which under some regimes net off the asset's carrying value, permanently inflating measured returns), acquisition goodwill on the fabless side, and capitalised versus expensed development. Compute ROIC on **mid-cycle EBIT** and, for manufacturers, sanity-check against **replacement cost of installed capacity** rather than net book. For fabless designers, ROCE is nearly meaningless — the real capital is expensed R&D, so invested capital is understated and returns look absurdly high.
|
||||
|
||||
**P/B — near-useless for fabless, genuinely informative for manufacturers.** A fabless designer's principal asset is a decade of expensed R&D, an IP library and a customer socket base, none of which is on the balance sheet; P/B of 15–25x says nothing. For memory makers and foundries, however, book value approximates replaceable physical capacity, and **P/B has historically been one of the more reliable cycle-timing tools** — troughs cluster near or below 1x for memory, peaks well above.
|
||||
|
||||
**D/E and net debt/EBITDA — procyclical and structurally incomplete.** Leverage looks safe on peak EBITDA and terrifying on identical debt at the trough; always test against **trough EBITDA**. More importantly, the reported debt figure routinely misses the real obligations: multi-year take-or-pay wafer supply agreements, customer capacity prepayments received (a liability, and sometimes a disguised financing), equipment purchase commitments already placed with 12–18 month lead times, operating leases on tools and buildings, and non-cancellable long-term materials contracts. Read the commitments and contingencies note before forming a leverage view.
|
||||
|
||||
**Current ratio and working-capital rules — contaminated by prepayments and deliberate inventory build.** Customer prepayments (common in shortages) sit in current liabilities and crush the current ratio while representing the opposite of stress. Equipment vendors carry huge customer deposits and deferred revenue for the same reason. Meanwhile a company can *strategically* build inventory ahead of a ramp or in anticipation of export restrictions — the ratio deteriorates, the business is fine. Never read the current ratio here without reading the composition.
|
||||
|
||||
**Revenue growth as reported — often measures channel behaviour, not demand.** Most broad-based analog, MCU and discrete suppliers sell into distributors and recognise revenue on **sell-in** (shipment to distributor) or **sell-through** (distributor's onward sale), and firms change convention. A quarter of "growth" can be pure channel fill, and a quarter of collapse can be pure destocking with end demand flat. Reconcile reported revenue against distributor weeks-of-inventory and, where disclosed, sell-through, before attributing growth to demand.
|
||||
|
||||
**Non-GAAP EPS — the sector's standard presentation, and it excludes real costs.** Fabless and EDA companies routinely exclude stock-based compensation (which can run 10–25% of revenue and is a genuine, recurring, dilutive expense) and acquisition-related intangible amortisation (real for a serial acquirer). Use GAAP as the base; if you use non-GAAP, add SBC back and track **net dilution after buybacks** — many buyback programmes are simply funding dilution, not returning capital.
|
||||
|
||||
**Backlog and "design win pipeline" — quoted as if contracted, frequently not.** Semiconductor backlog is often cancellable, and during shortages customers double- and triple-order across suppliers, inflating backlog with phantom demand that vanishes without a single cancellation notice. A design win is an *option* on revenue, not revenue: it converts 12–36 months later, at volumes the customer controls, and can be lost at the next platform refresh.
|
||||
|
||||
---
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges below are **indicative only**. They vary by sub-sector, node, geography, cycle position and reporting period, and several are conventions that drift. A company's own history across a full cycle, and its direct sub-sector peers at the *same point in the cycle*, always override any absolute band quoted here.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Fab utilisation rate** | Actual wafer starts ÷ installed capacity, ideally by fab and node. Rarely disclosed directly outside foundries and Japanese/Taiwanese IDMs; infer from wafer shipments vs stated capacity, from gross margin bridges in the concall, or from management's qualitative "loadings" commentary. | Above 90% is a tight, profitable market; 80–90% workable; below 70–75% typically means gross margin compression of 10+ points and is the classic downcycle signature. Mature-node specialty fabs often run structurally lower. | The single largest short-run driver of margin for anyone who owns a fab, and it is an *operational* variable no financial ratio contains. Utilisation explains most quarter-to-quarter margin surprise; attributing that surprise to pricing or cost control is almost always wrong. |
|
||||
| **Capex intensity** | Capex ÷ revenue, split into (a) maintenance and technology upgrade, (b) greenfield capacity, (c) advanced packaging. Compare with D&A. | Leading-edge foundry/memory: 30–45% at the top of an investment cycle, high-teens to 25% mid-cycle. Mature-node/specialty: 10–15%. OSAT: 15–25%. Fabless: 1–3%. Equipment/EDA: 2–5%. **Capex sustained below D&A at a leading-edge manufacturer is under-investment, not efficiency.** | Determines both future capacity (revenue) and future depreciation (cost), on a 2–4 year lag. It is the sector's core capital-allocation decision and the main destroyer of returns: capacity sanctioned at the top arrives at the trough. Track the *ratio to depreciation* over five years — that is the harvesting-vs-investing test. |
|
||||
| **Depreciation as % of revenue, and depreciation policy** | D&A ÷ revenue; plus the assumed useful life of fab equipment disclosed in the accounting policy note. | Foundry/memory: 20–35% of revenue. Fabless: below 5% ex-acquisition amortisation. Equipment lives of 5 years are conservative; extensions to 6, 7 or 8 years should be flagged and quantified. | Depreciation is the largest fixed cost in a fab and it front-loads: a new fab is loss-making for 4–8 quarters purely on depreciation before yields mature. Extending useful life is a legitimate accounting choice for mature-node tools and a classic earnings-flattering lever at the leading edge — **always quantify the EPS effect of any life extension and restate to the prior policy.** |
|
||||
| **Wafer starts per month (WSPM), on 300mm-equivalent basis** | Installed capacity in 8-inch or 12-inch equivalents; convert (one 300mm wafer ≈ 2.25x the area of a 200mm). Track capacity growth vs shipment growth. | Judge against the company's own trajectory and announced fab ramps rather than an absolute. Capacity growing materially faster than shipments for more than 2–3 quarters presages a utilisation and margin problem. | The physical unit of the industry. Capacity is added in indivisible fab-sized lumps with 24–36 month lead times, which is *why* the industry over- and under-shoots. Revenue forecasts that are not reconcilable to wafer capacity are unanchored. |
|
||||
| **Blended wafer ASP / revenue per wafer** | Wafer revenue ÷ wafers shipped (12-inch equivalent). Decompose into node mix and price. | Rising blended ASP driven by *mix* toward advanced nodes is healthy; rising ASP purely from price during a shortage is a reversal risk. Flat volumes with falling ASP is the destocking signature. | Separates genuine technology migration from cyclical pricing. A foundry whose ASP rises only because it raised prices in a shortage will give it all back; one whose ASP rises because 3nm replaced 7nm has moved up the value chain permanently. |
|
||||
| **Revenue by process node (advanced-node mix)** | % of wafer revenue from ≤7nm, ≤5nm, ≤3nm (leading edge) vs 16/28nm (mainstream) vs ≥40nm (mature/specialty). Disclosed by foundries; inferable for IDMs. | For a leading-edge foundry, a rising and majority share from the two newest nodes. For a specialty player, node mix is irrelevant — judge on BCD/BiCMOS/SiC/GaN/RF/power differentiation instead. | The node roadmap *is* the competitive position at the leading edge. Only two or three players can fund each successive node; falling behind by one node is usually terminal for the merchant business because the leading customers migrate and do not come back. Conversely, mature-node economics are about differentiation and fab depreciation status, not nanometres — do not penalise a specialty fab for lacking 3nm. |
|
||||
| **Yield / defect density (D0) and yield-ramp trajectory** | Defect density per cm²; or good die per wafer ÷ gross die per wafer. Rarely disclosed numerically — infer from gross margin trajectory during a ramp, from management's "yield is ahead of/behind plan" language, and from customer commentary. | A new node typically starts at 30–60% yield and reaches mature yield (often 80–90%+ for moderate die sizes) over 4–8 quarters. Faster-than-plan ramps show up as gross margin beating guidance during a ramp quarter. | Yield determines cost per good die and therefore whether a node is profitable at all. A node that ramps slowly burns depreciation against low output, and yield problems are the most common cause of a manufacturer losing a socket to a competitor mid-generation. **Large die (GPUs, HBM-attached logic) are disproportionately yield-sensitive — defect probability scales with die area.** |
|
||||
| **Cost per good die** | (Wafer cost + test + packaging) ÷ (gross die per wafer × yield). Gross die per wafer falls with die area; yield falls faster. | Judge as a trend within a product family and against the prior node. **Node shrinks no longer reliably reduce cost per transistor** — below ~7nm, wafer cost inflation (EUV, multi-patterning, mask sets) has largely offset density gains for many designs. | This is the real unit economic, and it is why the industry pivoted to chiplets and advanced packaging. A company whose roadmap assumes classical cost-per-transistor scaling is planning on an economics that stopped holding. Also explains why mature nodes remain highly profitable rather than obsolete. |
|
||||
| **Inventory days — own and channel (the full pipeline)** | Own DOI = inventory ÷ COGS × 365, split into raw/WIP/finished goods. Plus **distributor weeks of inventory** and, where available, sell-in vs sell-through gap. Add customer inventory commentary. | Own DOI: fabless 60–100 days; IDM/analog 90–130 days (they run deliberately high to serve long product lifecycles); foundry 60–90. Distributor: 7–9 weeks is normal, 12+ weeks is a correction in progress. | **This is the single best early-warning indicator in the sector.** Inventory accumulates in three places — supplier, distributor, customer — and a correction is the simultaneous drain of all three. Rising own FG inventory plus rising channel weeks plus flat end demand is the canonical pre-correction setup, and it precedes the revenue decline by one to three quarters. Rising *raw and WIP* inventory ahead of a disclosed ramp is a different and benign signal. |
|
||||
| **Book-to-bill and WFE spend trajectory** (equipment and materials) | Orders booked ÷ revenue billed in the period; plus disclosed backlog and its coverage in months; plus the industry WFE spend forecast (SEMI, and the majors' own guidance). | Above 1.0 sustained = expansion; below 0.9 for two or more quarters = contraction underway. Backlog coverage of 6–12 months is normal for WFE. | Equipment revenue is the derivative of foundry/memory capex, which is itself the derivative of chip demand — so WFE amplitude is the largest in the value chain (peak-to-trough swings of 30–40% in a normal cycle). Book-to-bill turns before revenue and is the cleanest leading indicator available. Discount backlog for cancellability and for push-outs, which is how customers actually cut without cancelling. |
|
||||
| **R&D intensity** | R&D ÷ revenue. For fabless, also R&D per major design win and mask-set/tape-out cost exposure. | Fabless logic/compute: 20–35%. Analog/mixed-signal: 12–18%. Foundry: 7–9%. Memory: 8–12%. OSAT: 3–6%. EDA/IP: 30–40%. **Falling R&D intensity in a downturn at a leading-edge player is a solvency-driven decision with multi-year consequences.** | R&D is the true capex of a fabless company and is fully expensed, which is why its ROCE is meaningless and its book value is fictional. Node economics make this a scale business: a leading-edge SoC tape-out can cost tens to hundreds of millions of dollars before a single unit ships, so sub-scale players cannot participate at all. Track R&D in absolute currency through the cycle, not just as a ratio — the ratio rises in a downturn on falling revenue while spending is actually being cut. |
|
||||
| **Customer concentration** | Revenue from top-1 and top-5 customers. US filers must disclose any customer above 10% of revenue (ASC 280); Ind-AS 108 requires equivalent disclosure. Also check end-market concentration behind the direct customer. | Top-5 above 50%, or any single customer above 20%, is a structural risk that should affect the discount rate, not just be noted. Foundries and OSATs routinely exceed this and are still investable — but only where the customer is captive to the technology. | Sockets are large, few, and multi-year. Losing one designed-in flagship socket can remove 15–30% of revenue in a single product cycle with no warning in the financials until it happens. Concentration cuts both ways: a customer that cannot switch (because of process, IP or packaging lock-in) is a moat; a customer that dual-sources or is building its own silicon is a countdown. |
|
||||
| **Design wins and socket longevity** | Number and value of design wins; the design-win-to-revenue lag; expected product lifecycle; and share of revenue from products older than 5 years. | Design-win-to-revenue lag: consumer 9–18 months, industrial 2–3 years, automotive 3–5 years. Automotive/industrial sockets then run 7–15 years; consumer sockets 12–24 months. | Determines the persistence of revenue and therefore the multiple. An automotive analog supplier with 10-year sockets and 30-year-old parts still shipping deserves a completely different valuation from a consumer SoC vendor re-competing for its entire revenue base every 18 months. **Check the vintage of the revenue base, not just the growth rate.** |
|
||||
| **Free cash flow after capex, through a full cycle** | FCF = CFO − capex, averaged over a complete 4–5 year cycle and separately at the peak and trough. | Fabless: 20–35% FCF margin mid-cycle. Leading-edge manufacturers: positive on a cycle average but frequently negative for 2–3 consecutive years during a build. Memory: negative at trough is normal. | The only capital-allocation test that survives the depreciation and utilisation distortions. Single-year FCF is nearly uninterpretable here; **cycle-average FCF versus cycle-average capex tells you whether the business actually earns its cost of capital or merely converts shareholder money into fabs.** Several historically respected manufacturers have never cleared this bar. |
|
||||
| **Government incentives and effective net capex** | Grants, investment tax credits and subsidised loans received or committed, and their accounting treatment (netted against the asset's cost vs recognised as deferred income and released to P&L). | Announced support of 25–50% of project cost is now common globally. What matters is cash received vs announced, and the clawback/milestone conditions. | Subsidies materially change project IRR and can permanently distort reported ROCE — netting a grant off the asset both lowers the denominator and lowers future depreciation, flattering returns for a decade. **Restate returns on gross, pre-subsidy capital cost to compare a subsidised project with an unsubsidised peer.** Also check whether subsidy receipt is conditional on volumes, employment or milestones the company may miss. |
|
||||
| **Export-control and geographic revenue exposure** | Revenue and capacity by country of end use; share of revenue requiring export licences; share of manufacturing concentrated in a single geography. | Not a range — a mapping. Flag any single-country manufacturing above ~60% of capacity, and any restricted-market revenue above ~15–20%. | Regulatory action can remove a revenue line at a stroke with no commercial warning, and has repeatedly done so. Geographic concentration of leading-edge capacity is an unhedgeable tail risk that belongs in the discount rate or in an explicit scenario, not in a footnote. |
|
||||
|
||||
---
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
**Start by placing the cycle, then choose the method.** Never quote a multiple before stating where you believe the silicon cycle, the memory cycle and the WFE cycle are — they are related but not synchronous, and the answer changes which method is valid.
|
||||
|
||||
**Fabless designers (logic, SoC, analog, RF, connectivity).** Cash-generative, asset-light, R&D-driven. Use **EV/Sales cross-checked against a growth-and-margin frame** (the classic anchor: a rough sum of revenue growth % and FCF margin %, compared across the peer set), **EV/FCF**, and **P/E on mid-cycle EPS**. A DCF is defensible with an explicit cycle in the forecast years — never straight-line a peak year into perpetuity. Always value on **GAAP** earnings or add SBC back; and use fully diluted share count including unvested awards.
|
||||
|
||||
**Pure-play foundries and IDMs with fabs.** Use **EV/EBIT** or **EV/(EBITDA − maintenance capex)**, **P/B against ROE** (book value here is real, replaceable capacity), and **EV per 12-inch-equivalent wafer of installed capacity against greenfield replacement cost** — a leading-edge fab's build cost is a genuine valuation floor and a barrier-to-entry measure at once. A DCF works only if capex is modelled as permanently high and cyclical, with explicit node transitions; the terminal value must assume continuing reinvestment at roughly depreciation-plus, not a harvest.
|
||||
|
||||
**Memory (DRAM, NAND, HBM).** The most commodity-like sub-sector: undifferentiated bits, price set by supply/demand balance, oligopoly discipline that periodically breaks. Value on **P/B through the cycle** (troughs historically near or below 1x book, peaks well above) and on **mid-cycle EPS**, never on trailing P/E, which is fully inverted. Model bit supply growth versus bit demand growth explicitly — that ratio, not any financial metric, sets the price. HBM is a partial exception: it is capacity-constrained, contracted ahead, and behaves more like a specialty logic product, so segment it out.
|
||||
|
||||
**Wafer fab equipment and materials.** Revenue is the derivative of customer capex, so amplitude is the highest in the chain. Value on **mid-cycle EPS × a through-cycle multiple**, and cross-check with **EV/Sales against normalised WFE spend**. Give explicit credit for the **installed-base / service and spares revenue**, which is recurring, high-margin and far less cyclical than tool sales — valuing it at the same multiple as tool revenue undervalues the better business. **Do not extrapolate a peak-capex year.**
|
||||
|
||||
**OSAT / ATMP (assembly, test, packaging).** Capital-intensive, thinner margin, closer to contract manufacturing. Use **EV/EBITDA net of maintenance capex**, ROCE against WACC, and capacity utilisation. Advanced packaging (2.5D/3D, CoWoS-class, fan-out, chiplet integration) commands genuinely better economics than commodity wire-bond and must be segmented separately.
|
||||
|
||||
**EDA and semiconductor IP licensors.** These are software/royalty businesses wearing a semiconductor label. Value them as such: **recurring revenue, backlog/RPO, net revenue retention, Rule-of-40 style frames, EV/FCF, DCF on royalty streams.** They are the least cyclical link in the chain because design activity continues through a downturn.
|
||||
|
||||
**What NOT to use.** Trailing P/E for anything cyclical here (inverted). Trailing EV/EBITDA for a fab owner (ignores the mandatory reinvestment that *is* the cost structure). PEG on a cyclical peak (the "G" is a cycle, not a trend). Dividend discount models (payouts are residual and subordinate to capex). Book-value screens for fabless firms (the assets are expensed). Perpetual-growth DCF terminal values without explicit ongoing capex at or above depreciation. And do not use a single point estimate at all — **present bear/mid/bull across a cycle scenario**, because the honest uncertainty here is a range, not a number.
|
||||
|
||||
---
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares **business model, position on the node/technology curve, end market, and cycle exposure**. The word "semiconductor" is not a peer set — it spans businesses with 3% capex intensity and 40% capex intensity.
|
||||
|
||||
**Splits that must never be mixed:**
|
||||
|
||||
- **Fabless vs foundry vs IDM vs OSAT vs equipment vs EDA/IP vs materials vs distributor.** Different capital intensity, different margin structure, different position in the cycle, different multiples. Mixing them makes every ratio comparison meaningless.
|
||||
- **Leading edge vs mature/specialty node.** A ≤5nm foundry and a 180nm BCD/power specialty fab are in different industries. The first competes on R&D scale and roadmap; the second on differentiated process, fully depreciated tools and customer stickiness.
|
||||
- **Logic vs memory vs analog/mixed-signal vs discrete/power vs sensors.** Memory is a commodity with a bit-price cycle; analog is a long-tail catalogue business with 10-year sockets and structurally high, stable margins; compute logic is a winner-take-most design race.
|
||||
- **End market: AI/datacentre vs smartphone vs PC vs automotive vs industrial vs consumer.** These cycles are not synchronised and have diverged sharply — one can be at a record while another is in a deep correction. A "semis peer group" spanning both produces an average that describes nobody.
|
||||
- **Silicon vs compound semiconductors (SiC, GaN, GaAs, InP).** Different substrates, different cost curves, different maturity, and a different competitive dynamic (substrate supply, not lithography).
|
||||
- **Merchant vs captive.** A company selling into the open market is not comparable to one whose output is largely consumed by an affiliate or a single anchor customer at negotiated transfer prices.
|
||||
|
||||
**Additional dimensions to hold constant:** geography of manufacturing (subsidy regime, labour and utility cost, export-control exposure), stage of ramp (a company mid-fab-ramp is not comparable to one at steady state), and subsidy treatment (compare returns pre-subsidy).
|
||||
|
||||
**Cycle synchronisation is mandatory.** Comparing a company reporting a trough quarter with one reporting a peak quarter produces a conclusion about calendars, not businesses. If the peer set is not at the same cycle point, normalise everything to mid-cycle before comparing.
|
||||
|
||||
---
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Channel stuffing and the sell-in/sell-through gap.** Revenue recognised on shipment to distributors while distributor inventory weeks climb is borrowed revenue that reverses violently. Watch for: distributor weeks rising while revenue grows; a change in revenue recognition convention; extended payment terms or expanded return/price-protection rights; and receivables growing materially faster than revenue. This is the most common way a semiconductor company delays admitting a correction.
|
||||
|
||||
**Depreciation-life extensions and reclassification.** Extending fab equipment life from 5 to 6+ years, or moving tools between asset classes, lifts EPS with zero cash effect. Legitimate for genuinely long-lived mature-node tools; a warning sign at the leading edge. Quantify the EPS impact and restate.
|
||||
|
||||
**Capex falling below depreciation for multiple years at a manufacturer.** Reads as excellent FCF and is usually a decision to skip or delay a node. It is close to irreversible — re-entering a node you sat out requires both capital and a customer base that has already migrated.
|
||||
|
||||
**Capitalising costs that should be expensed.** Pre-production fab costs, ramp-up losses, and development spend capitalised into CWIP or intangibles; also watch for prolonged accumulation in capital work-in-progress without transfer to fixed assets, which defers depreciation. Under Ind-AS 38 / IAS 38, development capitalisation is permitted on criteria; check whether a peer group expenses the same spend.
|
||||
|
||||
**Non-GAAP that excludes recurring items.** SBC, acquisition amortisation, "ramp-up costs", "restructuring" that recurs annually, and inventory write-downs that later reverse into margin as the written-down stock is sold (which inflates a future quarter's gross margin — a real and recurring pattern worth checking after any large write-down).
|
||||
|
||||
**Backlog and order-book inflation.** Double-ordering across suppliers during shortages, non-cancellable-in-name-only agreements, and "long-term supply agreements" or customer prepayments presented as demand certainty. Ask what happens to the LTA if the customer's end demand halves — usually it is renegotiated.
|
||||
|
||||
**Design-win language substituting for revenue.** Companies late in a socket cycle emphasise pipeline, wins and "engagements" precisely when converting revenue is weakening. Check the lag: if wins announced three years ago have not become revenue, they will not.
|
||||
|
||||
**Single-socket dependency being quietly lost.** The signals are subtle and lead the financials: a customer announcing in-house silicon, a competitor's win at the same customer, declining share of a customer's bill of materials, or the supplier moving from sole- to dual-source. None of this appears in the accounts until the revenue is gone.
|
||||
|
||||
**Yield problems disguised as mix.** Gross margin missing guidance during a ramp, attributed to "product mix", when the real cause is a slow yield curve on a new node. Cross-check with customer commentary and with whether the ramp schedule slipped.
|
||||
|
||||
**Government-grant dependency and clawbacks.** A project whose IRR only works with subsidy, milestone conditions that may be missed, grants announced but not received, and grant accounting that flatters ROCE. Check the cash flow statement for actual receipts against announced amounts.
|
||||
|
||||
**Inventory write-down asymmetry.** Large write-downs at the trough (understating cost) followed by sale of that inventory at zero cost basis (overstating recovery margins). Normalise gross margin across both periods.
|
||||
|
||||
**India-specific.** Companies re-badging themselves as "semiconductor" plays with no fab, no ATMP line and no chip revenue — verify the actual revenue mix and whether an announced MoU has converted into a signed agreement, a land allotment, disbursed incentive, and equipment orders. Also check promoter pledge, related-party technology-licence and royalty payments to an overseas partner, CARO comments on capital advances and CWIP, and whether announced capacity is a policy application or a funded project.
|
||||
|
||||
---
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The silicon cycle.** Historically 3–4 years peak to peak, driven by the mismatch between capacity added in 24–36 month lumps and demand that moves continuously. The classical sequence: lead times extend → customers over-order and build safety stock → suppliers read the double-ordering as demand and add capacity → end demand normalises → channel destocks → shipments fall far below consumption → utilisation and margins collapse → capex is cut → the next shortage. **Lead times and distributor inventory weeks turn before revenue; revenue turns before earnings; earnings turn before the multiple re-rates.** Know which of these you are looking at.
|
||||
|
||||
**The inventory correction specifically.** Corrections are amplification events, not demand events. Because the channel holds several weeks of stock and customers hold their own, a modest slowdown in end demand produces a disproportionate collapse in supplier shipments while the pipeline drains, then a disproportionate snap-back when it refills. **Do not model a correction as a demand forecast** — model the pipeline. The reliable trough signal is inventory days normalising across supplier, distributor and customer simultaneously, plus lead times bottoming, not an improvement in reported earnings.
|
||||
|
||||
**The WFE cycle rides on top and swings harder.** Equipment orders are the derivative of customer capex plans, so a 15% cut in foundry capex can mean a 30%+ decline in tool orders, and the reverse on the way up. Book-to-bill is the leading indicator. Service and installed-base revenue is the shock absorber.
|
||||
|
||||
**Memory runs its own cycle.** Bit supply growth (from both new fabs and node migration, which yields more bits from the same wafers) against bit demand growth sets price, and price moves multiples in both directions. Oligopoly discipline moderates the amplitude but has broken repeatedly.
|
||||
|
||||
**Structural: node economics have changed.** Cost per transistor no longer falls reliably with each shrink; EUV tools, multi-patterning, mask sets and design costs have risen faster than density gains for many designs. The industry response — chiplets, 2.5D/3D advanced packaging, heterogeneous integration — moves value toward packaging and toward whoever controls the interconnect. Consequence: **advanced packaging capacity is now a genuine bottleneck and a valuation driver in its own right**, and mature nodes remain highly profitable rather than obsolete.
|
||||
|
||||
**Structural: customer disintermediation.** Large end-customers (hyperscalers, handset and auto OEMs) increasingly design their own silicon and buy foundry capacity directly. This is good for foundries and packaging, bad for merchant chip vendors selling into those same accounts. Check whether a company's largest customer is also a prospective competitor.
|
||||
|
||||
**Structural: AI demand concentration.** A large share of recent industry growth is concentrated in datacentre accelerators, HBM and the advanced packaging and networking around them, funded by a small number of buyers. That concentration is both the growth story and the principal risk: a capex pause at a handful of customers propagates through the entire leading-edge chain. Treat it as a scenario, not a trend line.
|
||||
|
||||
**Regulation and geopolitics.** Export controls on advanced compute, lithography tools and, increasingly, on manufacturing equipment and design software, are now a first-order determinant of addressable market and can change without commercial warning. Entity-list additions, licence requirements, foreign direct product rules, outbound investment screening and tariffs all bear directly on revenue. Simultaneously, large subsidy programmes (US, EU, Japan, Korea, China, India) are deliberately building duplicative capacity, which is supportive for equipment vendors and a medium-term oversupply risk for manufacturers, especially at mature nodes. **Geographic concentration of leading-edge capacity in a single strait-adjacent region is an unhedgeable tail risk** — handle it explicitly in scenarios rather than by ignoring it.
|
||||
|
||||
---
|
||||
|
||||
## India vs global notes
|
||||
|
||||
**The listed universe is different from the global one — check what the company actually does.** India currently has no operating leading-edge logic fab. The listed "semiconductor" exposure is overwhelmingly: chip *design services* and VLSI engineering (people businesses, valued like IT services — headcount, utilisation, billing rate, attrition, not wafer economics), EMS and PCB assembly (contract manufacturing economics), power/discrete and packaging aspirants, and equipment/materials suppliers. **Apply the design-services or EMS frame to those, not this one.** Reserve this playbook for genuine fab, ATMP/OSAT and semiconductor-materials businesses.
|
||||
|
||||
**Policy framework (India-specific).** The India Semiconductor Mission provides fiscal support of up to 50% of project cost for fabs, display fabs, compound-semiconductor/ATMP/OSAT units, with state governments layering additional support; the Design Linked Incentive scheme supports design companies on a smaller scale. For any company citing these: verify approval status, the actual disbursement schedule, milestone and employment conditions, clawback provisions, and how much has been received in cash versus announced. An approval is not a fab.
|
||||
|
||||
**Accounting (Ind-AS).** Government grants follow **Ind-AS 20** — an entity may present a capital grant either as deferred income released to P&L over the asset's life or as a deduction from the asset's carrying amount. The second materially inflates reported ROCE for a decade. **Identify the policy and restate to gross cost for comparability with global peers.** Development-cost capitalisation under Ind-AS 38 mirrors IAS 38; check it against peer treatment. Leases under Ind-AS 116 bring tool and building leases on balance sheet. Watch capital work-in-progress ageing disclosures (Schedule III requires a CWIP ageing and completion schedule) — prolonged CWIP with slipping completion dates is a direct read on project execution.
|
||||
|
||||
**Disclosure gaps (India).** Indian filings rarely disclose fab utilisation, wafer starts, yield, node mix, book-to-bill or channel inventory. You will often have to reconstruct these from the concall transcript, the annual report's management discussion, capacity tables in the directors' report, and industry sources. **If a KPI is unavailable, say so explicitly rather than substituting a financial ratio for it.** Concalls are the richest source of operational commentary; read the Q&A, not just the prepared remarks.
|
||||
|
||||
**India-specific governance items.** Promoter holding and pledge levels; related-party transactions, especially technology licences, royalty and off-take arrangements with an overseas technology partner (common in Indian fab and ATMP joint ventures — check whether the royalty is arm's-length and whether it scales with volume); CARO 2020 reporting on capital advances, loans to related parties and use of borrowed funds; and the gap between announced MoUs and signed, funded, land-allotted, equipment-ordered projects. Figures are in crore/lakh — normalise before any cross-border comparison, and state the INR/USD rate used.
|
||||
|
||||
**Global filings (US/EU/Asia).** US 10-K/10-Q under GAAP via EDGAR: expect segment reporting (ASC 280) including disclosure of any customer above 10% of revenue, extensive risk factors on export controls and concentration, and detailed commitments notes covering purchase obligations and capacity agreements. Taiwanese, Korean and Japanese manufacturers disclose **monthly revenue**, which is the highest-frequency real-time cycle indicator available anywhere in the sector — use it. Foundries and equipment makers also disclose capacity, utilisation commentary, node-mix revenue splits and capex guidance in quarterly decks that have no Indian equivalent. IFRS filers under IAS 20 face the same grant-presentation choice as Ind-AS filers; check it the same way.
|
||||
|
||||
---
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] State where the silicon, memory and WFE cycles each are, and on what evidence, before quoting a single multiple.
|
||||
- [ ] Classify the business model precisely — fabless / foundry / IDM / OSAT / equipment / EDA-IP / materials / design services — and apply the right frame.
|
||||
- [ ] Suppress trailing P/E for cyclical sub-sectors, or show it only next to mid-cycle normalised EPS.
|
||||
- [ ] Do not use EV/EBITDA for any company that owns a fab; use EV/EBIT or EV/(EBITDA − maintenance capex).
|
||||
- [ ] Decompose gross margin into utilisation, node/product mix, yield, ASP and depreciation load before attributing it to management.
|
||||
- [ ] Find or infer fab utilisation; flag anything below ~75% as a margin event in progress.
|
||||
- [ ] Compute capex ÷ revenue and capex ÷ D&A over five years; flag capex below depreciation at a leading-edge manufacturer.
|
||||
- [ ] Split capex into maintenance/upgrade versus greenfield capacity versus advanced packaging.
|
||||
- [ ] Read the depreciation policy note; quantify and restate any useful-life extension.
|
||||
- [ ] Track wafer starts / installed capacity against shipment growth; capacity outrunning shipments presages a utilisation problem.
|
||||
- [ ] Compute blended wafer ASP and separate mix-driven gains from shortage pricing.
|
||||
- [ ] Check advanced-node revenue mix and roadmap credibility; for specialty fabs, judge differentiation instead of nanometres.
|
||||
- [ ] Look for yield-ramp evidence in gross margin bridges and ramp-quarter guidance misses.
|
||||
- [ ] Compute own inventory days split by raw/WIP/FG, and obtain distributor weeks of inventory and the sell-in/sell-through convention.
|
||||
- [ ] For equipment and materials names, get book-to-bill, backlog coverage, push-out commentary and installed-base/service revenue share.
|
||||
- [ ] Track R&D in absolute currency through the cycle, not only as a percentage of revenue.
|
||||
- [ ] Identify top-1 and top-5 customer concentration and assess switching cost and in-house-silicon risk at each.
|
||||
- [ ] Establish design-win-to-revenue lag, socket life and the share of revenue from products older than five years.
|
||||
- [ ] Compute cycle-average FCF versus cycle-average capex — the real test of whether the business earns its cost of capital.
|
||||
- [ ] Use GAAP earnings; add SBC back to any non-GAAP figure and check net dilution after buybacks.
|
||||
- [ ] Identify all government grants, their accounting treatment, cash actually received, and clawback conditions; restate ROCE pre-subsidy.
|
||||
- [ ] Map revenue and manufacturing capacity by geography; quantify export-control-restricted revenue explicitly.
|
||||
- [ ] Read commitments and contingencies for take-or-pay wafer agreements, equipment purchase orders and customer prepayments before forming a leverage view.
|
||||
- [ ] Test leverage against trough EBITDA, not trailing.
|
||||
- [ ] Build the peer set on business model, node position, end market and cycle point — never on the "semiconductor" label.
|
||||
- [ ] India: verify the company actually has fab/ATMP revenue rather than an MoU; check ISM/DLI disbursement status, Ind-AS 20 grant presentation, CWIP ageing, promoter pledge and related-party royalty terms.
|
||||
- [ ] Global: use monthly revenue disclosures from Taiwanese/Korean/Japanese filers as the highest-frequency cycle read available.
|
||||
- [ ] Present the conclusion as bear/mid/bull across a cycle scenario, not as a single target price.
|
||||
|
|
@ -0,0 +1,176 @@
|
|||
# Shipping and logistics — sector playbook
|
||||
|
||||
Use this when: the company owns, operates or brokers the physical movement of goods — crude and product tankers, dry bulk, container liners and container tonnage providers, gas carriers (LNG/LPG), offshore support vessels, ports and terminals, and land-side logistics (freight forwarding, express parcel, contract logistics, rail container operation, warehousing). India: Great Eastern Shipping, Shipping Corporation of India, Seamec, Adani Ports, JSW Infrastructure, Gujarat Pipavav, Concor, Allcargo, TCI, TCI Express, Blue Dart, Delhivery, Mahindra Logistics, Gateway Distriparks, Aegis Logistics. Global: Frontline, DHT, International Seaways, Scorpio, Torm, Hafnia, Star Bulk, Golden Ocean, Genco, Maersk, Hapag-Lloyd, ZIM, Danaos, Costamare, Global Ship Lease, Flex LNG, BW LPG, DP World, ICTSI, DSV, Kuehne+Nagel, Expeditors, C.H. Robinson, GXO, UPS, FedEx.
|
||||
|
||||
Four facts govern everything below. Freight rates are a **volatile spot price** the company does not set, so a single year's earnings carries almost no information about earning power. Ships and terminals are **long-lived, tradeable, finite-life assets** whose market value moves with the rate cycle, so book equity and reported profit both diverge violently from economic value. Supply is **known three years in advance** (the orderbook) while demand is not, which makes this one of the few sectors where the forward supply curve is observable and therefore the dominant analytical edge. And the reporting conventions differ so much across sub-sectors — voyage-charter gross revenue, forwarder pass-through revenue, tonnage-tax near-zero tax rates, concession intangibles — that headline margins and P/E are not comparable even between two companies in the same index.
|
||||
|
||||
Decide the sub-sector before anything else. An **asset-owning spot shipowner**, a **charter-backed tonnage provider**, a **liner operator**, a **port concessionaire** and an **asset-light freight forwarder** are five different businesses that happen to share the word "logistics". Applying one sub-sector's metric set to another is the most common category error here, and sections below flag where they diverge.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
**OPM and revenue growth — undefined across sub-sectors, and mis-signed within them.** Under a **voyage charter** the owner pays bunkers, port charges and canal dues out of freight, so reported revenue rises and falls with the *fuel price* with no change in economics; under a **time charter** the charterer pays them and revenue is a clean daily hire. The same vessel earning the same money reports revenue that differs by 40–60% depending on charter type, and OPM differs by more. A **freight forwarder** books gross freight billed to the customer as revenue and purchased transportation as cost, so a world-class forwarder runs a 3–5% "OPM" on gross revenue and a 30%+ margin on net revenue — the two look like different industries and are the same company. Never rank shipping or forwarding names on OPM. Restate to **TCE per day** for shipowners, **net revenue / gross profit** for forwarders, and **EBITDA per TEU or per tonne** for terminals.
|
||||
|
||||
**P/E — inverted and actively dangerous, twice over.** First, the normal cyclical inversion: freight cyclicals print their lowest P/E at the peak on peak earnings and a negative P/E at the trough, so a low-P/E screen systematically buys the top. Second, and specific to shipping, reported net income is contaminated by **gains on vessel sales** and, under IFRS and Ind-AS, by **impairment reversals** — both of which are asset-value events, not operating results, and both of which arrive precisely when the cycle has already turned up. A shipowner can report record EPS in a year of mediocre TCE purely by selling two old ships bought at the trough.
|
||||
|
||||
**EV/EBITDA — structurally understates the cost of the business.** EBITDA for a shipowner excludes three real, mandatory, cash costs: **drydocking and special survey capex** (every 2.5 and 5 years, typically 15–30 off-hire days and a seven-figure bill per vessel, higher with a ballast water treatment retrofit), **debt amortisation** on asset-backed loans that must be repaid on a bank schedule regardless of the cycle, and the fact that the asset itself is **consumed over 20–25 years** to a scrap value. A 2.5x EV/EBITDA at a rate peak is not cheap; it is a warning that the market has correctly identified the earnings as non-recurring. IFRS 16 compounds the problem: since 2019 charter-in commitments sit on balance sheet, inflating both EV and EBITDA, so pre- and post-2019 multiples are not comparable, and a liner that charters in half its fleet is not comparable to one that owns it.
|
||||
|
||||
**D/E and P/B — measured against the wrong number.** Book equity is historic cost less depreciation. A fleet bought at the 2016–17 trough may be worth two or three times book; a fleet ordered at a 2007–08 or 2021–22 peak may be worth half. Both the numerator and the denominator of D/E are therefore fiction. The lender does not care about D/E either — asset-backed shipping loans are covenanted on **loan-to-value against broker market values** and on minimum liquidity, and it is an LTV breach, not a D/E ratio, that triggers a cash sweep or forced sale. Use net LTV on market values and cash breakeven per day.
|
||||
|
||||
**ROCE and ROE — flattered by the same accounting that destroys P/B.** A trough-bought fleet sitting at low historic cost generates a spectacular ROCE at a rate peak that says nothing about the return on capital an investor would earn buying at today's asset prices. Worse, a prior impairment shrinks the capital base and mechanically raises subsequent ROCE — the write-down reads as an improvement. Measure return on capital **across a full cycle** (7–10 years of cumulative operating cash flow against average gross assets) or against **current market value of the fleet**, never on a single year.
|
||||
|
||||
**FCF — lumpy to the point of meaninglessness in any single year.** Newbuild instalments (typically 20/20/20/40 or heavily back-ended to delivery) land in blocks; vessel sales generate large positive swings; drydock schedules cluster. A shipowner can print enormous FCF for two years simply by not renewing its fleet, which is asset liquidation reported as cash generation. Read FCF only alongside fleet age, orderbook commitments and remaining drydock schedule.
|
||||
|
||||
**Current ratio and working capital metrics — near-useless.** Vessels and terminals are non-current by construction, so the current ratio is almost always below 1 for a healthy shipowner and tells you nothing. The real liquidity question is: does cash plus undrawn facilities cover the next twelve months of **debt amortisation + newbuild instalments + scheduled drydocks** at a *trough* TCE assumption. For forwarders the opposite distortion applies — receivables and payables are enormous relative to net revenue, so a forwarder's balance sheet swells and shrinks with freight rates without any change in the business.
|
||||
|
||||
**Depreciation policy is a discretionary earnings lever.** Useful life (25 vs 30 years) and assumed residual scrap value (a per-lightweight-tonne assumption) are both management estimates, and both move EPS materially without any economic change. Always read the accounting policy note and normalise before comparing EPS or P/E across shipowners.
|
||||
|
||||
**Tax rates are not comparable.** Most shipowning is under a **tonnage tax** regime (India Sections 115V–115VP of the Income Tax Act; also Greece, Norway, UK, Singapore) where tax is a notional charge on net tonnage, not on profit — effective tax rates near zero. Logistics and port companies pay full corporate tax. Comparing a shipowner's P/E to a logistics company's P/E without adjusting for a 25–30 percentage-point tax differential is a standing error; compare on EV/EBITDA or on post-tax cash flow.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by vessel class, sub-sector, geography, cycle position and period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set at the *same point in the cycle*, and against the company's own 7–10 year history, overrides every absolute band below. Metrics marked (S) apply to shipowners, (P) to ports and terminals, (L) to land-side logistics.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **TCE per day, by vessel class** (S) | (Voyage revenue − voyage expenses: bunkers, port charges, canal dues, brokerage) ÷ revenue-earning days. Report separately for each class (VLCC, Suezmax, Aframax/LR2, MR, Capesize, Kamsarmax, Ultramax, Handysize, each container size band, LNG, VLGC). Compare against the Baltic route benchmarks (BDI/BCI/BPI/BSI, TD3C, TC2) and against peers' same-class TCE for the same quarter. | Class-specific and cycle-specific. Indicatively: mid-cycle VLCC roughly $30–40k/day, Capesize $20–25k/day, MR product $18–25k/day — with troughs below opex and peaks at multiples of these. The test is *relative*: a persistent discount to the class benchmark or to peers signals inferior commercial management, an older or less fuel-efficient ship, or poor positioning. | This is the entire revenue line of a shipowner reduced to one comparable number, and it is the only figure that neutralises voyage-vs-time-charter reporting and bunker price movement. Nothing else about a shipowner can be interpreted until TCE is on the table. |
|
||||
| **Cash breakeven TCE per day** (S) | Daily vessel opex + G&A per vessel-day + net interest + scheduled debt amortisation + drydock/special-survey accrual, all per operating day. Compute per vessel class and for the fleet. | Depends on leverage and age. Indicatively a modern, moderately levered bulker $10–14k/day and a VLCC $22–28k/day; a low-leverage owner can be $5–8k/day lower. The critical fact is the **gap between breakeven and mid-cycle TCE** — the wider, the more cycles the company survives. | This is the survival number. Everything about the equity — whether it can pay a dividend, whether it must issue shares at the bottom, whether the banks take control — follows from where breakeven sits relative to the spot rate. Two owners of identical ships can have opposite outcomes in the same market purely on breakeven. |
|
||||
| **Daily vessel operating expense (opex) per ship-day** (S) | Crew wages, lubricants, stores and spares, insurance (H&M and P&I), routine repairs and maintenance, management fee — excluding voyage costs, drydock capex, depreciation and finance costs. Per ship per calendar day. | Indicatively Handysize/Supramax $5,500–7,000; Capesize $6,500–8,000; MR $7,000–8,000; VLCC $8,000–10,000; LNG carrier $15,000–20,000. Should be flat to modestly inflationary; a step-up signals an ageing fleet, deferred maintenance catching up, or crew-cost inflation. | This is the only cost line genuinely under management control, and it is where scale and in-house technical management earn their keep. It is also a quality tell: an opex materially *below* peers on an old fleet usually means deferred maintenance, which surfaces later as off-hire and detentions. |
|
||||
| **Fleet utilisation, off-hire and drydock days** (S) | Revenue-earning days ÷ available calendar days. Split scheduled off-hire (drydock, special survey, retrofit) from unscheduled (breakdown, detention, waiting for employment). | Ex-drydock utilisation above 98–99%; total commercial utilisation typically 95%+ for a well-run fleet. Special survey every 5 years plus an intermediate at 2.5, indicatively 15–30 off-hire days each. | Off-hire is revenue lost at zero marginal saving on opex, so it flows straight through to the bottom line. Rising *unscheduled* off-hire is the earliest hard evidence of a deteriorating fleet, and it precedes the maintenance capex it implies by several quarters. Drydock scheduling also explains quarter-on-quarter earnings swings that have nothing to do with the market. |
|
||||
| **Fleet age, composition and eco/compliance profile** (S) | Average age weighted by dwt/TEU; age distribution (not just the mean); vessel class mix; share of "eco" fuel-efficient designs vs first-generation tonnage; scrubber-fitted share; dual-fuel capability; ice class or other niche specification. | Fleet average age below the world-fleet class average is a competitive position; above 15 years for a bulker or tanker means rising opex, worse CII ratings and approaching scrap. Beware the average — a fleet averaging 10 years may be five 2-year-old and five 18-year-old ships, which is a completely different asset. | Age drives opex, fuel consumption, charterer acceptance (oil majors vet tankers and increasingly refuse older tonnage), residual value and the size of the compliance capex bill. Composition determines *which* cycle you are exposed to; a "diversified" owner is often exposed to two cycles badly rather than one well. |
|
||||
| **Orderbook-to-fleet ratio (sector) and own newbuild commitments** (S) | Sector: total tonnage on order ÷ existing fleet, in dwt or TEU, for the specific vessel class — from Clarksons/broker data, not company disclosure. Company: contracted newbuildings, yard, delivery dates, contract price, and remaining instalments as a share of liquidity and market cap. | Sector orderbook below ~10% of fleet is supportive; 15–20% is a caution; above 25–30% for a class points to a multi-year oversupply. Historic extremes have approached 50%+ of fleet, which produced a decade-long hangover. | This is the single highest-information number in the sector and the reason shipping is analysable at all: because ships take 2–3 years to build, supply for the next three years is already known while demand is not. Company-level, ordering at peak newbuild prices is the classic mechanism by which shipowners destroy the cash the cycle just handed them. |
|
||||
| **Net fleet supply growth vs ton-mile demand growth** (S) | Deliveries − demolitions ± conversions, as % of existing fleet, for the specific class; against estimated ton-mile demand growth (tonnes × average voyage distance), not tonnage demand. Add slippage (non-delivery) and any effective supply absorbed by congestion, slow steaming or sanctions-trade inefficiency. | Demand growth exceeding supply growth is the necessary condition for a rate upcycle; the size of the gap sets its violence. Because utilisation is convex, a 2-percentage-point gap can double or halve rates. | Freight rates are set by the marginal ton of capacity, so small supply-demand gaps produce enormous rate moves. Ton-miles, not tonnes, is the correct demand unit — route lengthening (Cape of Good Hope routing instead of Suez, Russian crude to Asia instead of Europe, Panama Canal draught restrictions) creates real demand without a single extra tonne shipped. |
|
||||
| **Scrapping / demolition rate and scrap economics** (S) | Demolition tonnage as % of fleet, average age at scrapping, and the prevailing demolition price ($/lightweight tonne at Alang, Chattogram, Gadani) against the vessel's carrying value. Check whether the company recycles under Hong Kong Convention / EU Ship Recycling Regulation approved yards. | Steady-state fleet renewal requires roughly 2–3% p.a. demolition; typical scrapping age 20–25 years and falling for tonnage that cannot meet efficiency rules. Demolition surges when TCE sits below opex for a sustained period. | Scrapping is the only mechanism that removes supply, and it is the mechanism by which a trough ends. It also sets the floor under vessel values — a ship is never worth less than its steel. For the company, scrap price versus book value tells you whether the oldest ships are a hidden asset or a pending impairment. |
|
||||
| **NAV per share and price-to-NAV** (S) | Broker market value of each vessel (Clarksons, VesselsValue, Baltic panel; charter-free and, separately, charter-attached) + other assets + cash − all debt including finance leases, sale-and-leaseback obligations and newbuild commitments, ÷ shares outstanding. | Indicatively 0.5–0.7x NAV at troughs, ~1.0x mid-cycle, above 1.2–1.3x in froth. But see the valuation section: NAV is itself cyclical, so a low P/NAV at a rate peak is a trap, not a discount. | Ships are a liquid, marked-to-market asset class with an observable secondhand price, which makes NAV far more meaningful here than in almost any other sector — and makes book value correspondingly useless. P/NAV is the sector's core relative-value tool, provided you know where NAV sits in its own cycle. |
|
||||
| **Net loan-to-value and liquidity vs 12-month obligations** (S) | Net debt (including finance leases, sale-and-leaseback and any Japanese operating lease with a purchase option) ÷ market value of the fleet. Separately: cash + undrawn facilities ÷ next 12 months of amortisation + newbuild instalments + drydock spend, stress-tested at trough TCE. | Net LTV below 40–50% is comfortable; above 65–70% is a covenant and refinancing risk regardless of current earnings. Liquidity should cover 12 months of obligations at a *trough* rate assumption, not the current one. | Shipping equity is wiped out by leverage in a downturn, not by operating losses. LTV covenants tighten automatically when vessel values fall — exactly when cash flow falls too — so leverage and asset values are correlated in the worst possible direction. This is the pair of numbers that separates a cyclical opportunity from a zero. |
|
||||
| **Charter cover: fixed days, rate and duration** (S) | % of the next 12 and 24 months' available days already fixed on time charter or COA, the average fixed rate, remaining duration, and counterparty identity and credit. Compare fixed rate against current spot and against cash breakeven. | No universal "right" level — it is a stated strategy, not a virtue. Judge it by: does contracted revenue cover cash breakeven (downside protected), and was the cover taken at a good point in the cycle? High cover fixed at a trough is value destruction; high cover fixed near a peak is skill. | Charter cover converts a commodity bet into a bond with a residual, and determines how much of the next upcycle the shareholder actually captures. A company presenting "high contract coverage" as unambiguous quality is telling you nothing until you know the rate. Counterparty matters too — a fixed charter is worth only as much as the charterer's balance sheet, as multiple liner failures have demonstrated. |
|
||||
| **Operating leverage: EBITDA sensitivity per $1,000/day of TCE** (S) | Annual EBITDA change from a $1,000/day move in TCE = $1,000 × operating days × spot-exposed fleet share. Express as a % of current market cap. | Report it as computed, not against a band. For a highly spot-exposed owner, $1,000/day can be several percent of market cap in annual EBITDA — this is the number that explains the equity's volatility. | It reframes the entire investment case in the only variable that matters and makes cross-company comparison honest. Two owners with the same fleet can have three-fold different sensitivity purely through charter cover and leverage. It is also the fastest sanity check on a broker's target price. |
|
||||
| **Environmental compliance position and cost per day** (S) | CII rating distribution across the fleet (A–E), EEXI compliance status and any engine power limitation, ballast water treatment retrofit status and remaining cost, EU ETS allowance cost and FuelEU Maritime penalty exposure per voyage day for EU-touching trades, and whether these are contractually passed to charterers. | Fleet skewed to CII A–C with a credible path to hold ratings as thresholds tighten annually. Retrofit and allowance costs should be quantified by the company; a company that cannot quantify them has not modelled them. | Environmental rules are now a direct cash cost and, more importantly, a *supply-side* mechanism: slower steaming to hold a CII rating removes effective capacity, and non-compliant tonnage becomes uncharterable before it becomes unscrappable. The pass-through clause is the crux — whether the owner or charterer bears ETS and FuelEU cost decides whose margin moves. |
|
||||
| **Terminal throughput, realisation and EBITDA per unit** (P) | Cargo volume in TEU (containers) and MMT (bulk/liquid), split by cargo type; revenue per TEU / per tonne; EBITDA per TEU / per tonne; capacity utilisation against rated capacity; berth productivity (moves per crane-hour, vessel turnaround time). | Terminal EBITDA margins are structurally high — indicatively 45–65%, and higher for large Indian port operators. Utilisation above 70–80% supports pricing; sustained above 90% means capacity constraint and capex. Realisation per TEU should be stable or rising in real terms. | Ports are fixed-cost infrastructure, so incremental volume drops through at very high margin and the operating leverage runs both ways. Realisation per unit separates genuine pricing power from volume bought with discounts — a common way terminal operators flatter growth. Cargo mix matters more than total volume: liquid and specialised cargo typically earn multiples of the per-tonne margin of bulk coal. |
|
||||
| **Remaining concession life, revenue share and minimum guarantees** (P) | Years remaining on each concession, renewal terms and probability, royalty or revenue-share percentage payable to the port authority (and its escalation), minimum guaranteed throughput commitments and any shortfall penalties, and the handover condition of assets at expiry. | Weighted-average remaining concession life well above the asset depreciation period; revenue share that does not escalate faster than realisation. A concession with under 10 years remaining and no renewal clarity is a melting ice cube regardless of current EBITDA. | A concession is a finite-life asset with a terminal value of approximately zero, so a perpetuity-based valuation or an EV/EBITDA multiple borrowed from freehold infrastructure overstates it. Escalating revenue share is a silent margin compressor that does not appear until it bites, and minimum guaranteed throughput turns a volume shortfall into a fixed cash outflow. |
|
||||
| **Logistics network density and cost per shipment** (L) | Cost per shipment or per parcel (total network cost ÷ shipments), revenue per shipment (yield), shipments per route or per hub, drop density (deliveries per stop or per km), first-attempt delivery rate, linehaul load factor / vehicle fill, warehouse occupancy and revenue per sq ft, and sortation automation share. | Cost per shipment should fall as volume grows — that *is* the business model. Yield per shipment falling faster than cost per shipment is the failure mode. Load factors above 85–90% and first-attempt delivery above 90% indicate a mature network. | Land logistics economics are almost entirely a density problem: the same truck, hub and route serving more shipments has structurally lower unit cost, which is why the largest network in a lane usually has the best margin and why sub-scale entrants cannot price their way in. This pair of numbers, not OPM, tells you whether a logistics company is compounding an advantage or buying volume. |
|
||||
| **Net revenue (gross profit) and conversion ratio** (L) | For forwarders and brokers: net revenue = gross revenue − purchased transportation. Conversion ratio = EBIT ÷ net revenue. Track net revenue *per shipment* and volume in TEU/tonnes separately from gross revenue. | Forwarder net revenue margin indicatively 20–30% of gross; conversion ratio 25–40%, with best-in-class asset-light operators materially higher. Asset-heavy contract logistics and trucking run lower conversion but on a larger asset base. | Gross revenue for a forwarder is a pass-through that inflates and deflates with freight rates — it can double in a rate spike with no change in volume or profit. Net revenue is the real topline and the only basis on which forwarders can be compared to each other or across time. Conversion ratio is the cleanest measure of forwarder productivity and the metric management is usually judged on internally. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
The governing rule: **never apply a multiple to trailing earnings**. Normalise to mid-cycle, or value the assets directly.
|
||||
|
||||
**Asset-owning shipowners — NAV is the anchor, mid-cycle EV/EBITDA the cross-check.**
|
||||
- **P/NAV** is the primary tool. Build NAV from broker charter-free vessel values, add contracted charter value separately where a ship is fixed above or below market, subtract *all* debt-like items including sale-and-leaseback and remaining newbuild instalments.
|
||||
- The critical subtlety: **NAV is itself cyclical**, because vessel values track rates. Buying at 0.5x NAV at a rate peak can lose more money than buying at 1.1x NAV at a trough, because the NAV halves. Always state where vessel values sit relative to (a) newbuilding parity, (b) their own 10-year range, and (c) scrap value. Buying near scrap-adjusted asset values with a low orderbook is the sector's highest-probability setup; buying a "discount to NAV" when values are at decade highs is not.
|
||||
- **EV/EBITDA on normalised mid-cycle TCE**, not trailing. Indicatively 4–7x mid-cycle for tankers and dry bulk; a 2–3x on peak earnings is a signal of unsustainability, not value. Add back nothing for drydock — treat it as capex that must be funded.
|
||||
- **NAV-adjusted DCF** for a fleet with meaningful charter cover: discount contracted cash flows at a low rate (it is a credit exposure), then value residual open days at mid-cycle TCE and terminate at the scrap value on the vessel's expected demolition date. Never use a perpetuity growth model on a ship.
|
||||
- **Replacement cost / newbuild parity**: compare implied value per dwt or per TEU in the share price against current newbuilding prices. When the equity market values ships far below the cost of building them, no rational owner orders — which is itself the mechanism that ends the downcycle.
|
||||
- **Do not use**: trailing P/E, P/B, EV/Sales, or dividend yield as a valuation input. Variable-dividend spot owners pay out peak-cycle cash; that "yield" is partly return of capital and disappears entirely at the trough.
|
||||
|
||||
**Charter-backed tonnage providers (container lessors, long-term LNG/LPG charters)** are contract businesses, not spot cyclicals. Value on **contracted revenue backlog** (total contracted EBITDA, weighted average remaining charter duration, counterparty credit) plus a residual value for the vessel at charter expiry, discounted. EV/EBITDA is defensible here because EBITDA is contracted. The two risks to price are counterparty default and re-chartering risk at expiry — not the spot rate.
|
||||
|
||||
**Liner operators (container lines)** are the most extreme cyclicals in the sector: fixed-cost networks with alliance-determined capacity, capable of swinging from a 50%+ EBIT margin to a loss within four quarters. Value on **mid-cycle EBIT with an explicit assumption about freight rate normalisation**, cross-checked against net cash — several liners have traded below net cash after a peak, which is the market pricing the cash burn to come. Do not annualise a spike quarter.
|
||||
|
||||
**Ports and terminals** are infrastructure with a finite life. Use **DCF over the remaining concession term with a terminal value at or near zero** (or the contractual handover compensation), and **EV/EBITDA** as a cross-check — indicatively 10–16x for long-dated, well-located concessions, lower where concession life is short or cargo is single-commodity. **EV per TEU of installed capacity** is a useful sanity check against greenfield build cost. Do not use a perpetuity DCF, and do not apply a listed-utility multiple to a 12-year concession.
|
||||
|
||||
**Land logistics** is a service business and tolerates conventional multiples better than shipping does, with adjustments. Asset-light forwarders and brokers: **EV/net revenue (gross profit)** and **EV/EBIT**, never EV/gross revenue. Express parcel and contract logistics: **EV/EBITDA** and **EV/EBIT** with lease obligations fully in EV (post-IFRS 16 EBITDA is not comparable to pre-2019). P/E is usable for mature, full-tax logistics names but not for anything with a freight-rate-linked revenue line. For loss-making network builders, value on a path to target cost-per-shipment at a stated volume — and demand that management state that volume.
|
||||
|
||||
**Cross-sub-sector**: never compare P/E across a tonnage-tax shipowner and a full-tax logistics company. Move to EV/EBITDA or post-tax free cash flow.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable in this sector shares **the same asset, the same contract structure, and the same cycle**. Get any one wrong and the comparison is noise.
|
||||
|
||||
- **Split by vessel class, not by "shipping".** VLCCs, MRs, Capesizes and Handysizes have different demand drivers (crude trade vs refined product arbitrage vs iron ore and coal vs minor bulks), different orderbooks and different rate cycles. A crude tanker and a dry bulk carrier have repeatedly moved in opposite directions in the same year.
|
||||
- **Split tankers into crude and product.** Product tanker demand is driven by refinery dislocation and arbitrage, which can be strong precisely when crude tanker demand is weak.
|
||||
- **Never mix spot-exposed owners with charter-backed owners.** They have different betas, different valuation methods and different downside. A blended "container shipping" peer set containing both a liner operator and a tonnage provider is analytically meaningless.
|
||||
- **Never mix asset-owners with asset-light forwarders or brokers.** Different capital intensity, different margin denominators, different cycle sensitivity (forwarders often earn *more* in a rate spike on spread, then normalise).
|
||||
- **Ports: split gateway from transhipment, and landlord from operator.** A transhipment hub is exposed to alliance routing decisions and can lose half its volume to a competing hub; a gateway serves captive hinterland demand. A landlord port earning lease and royalty income is a different risk profile from an operator running cranes and labour.
|
||||
- **Land logistics: split express parcel, contract logistics/warehousing, freight forwarding, full-truckload/less-than-truckload trucking, and rail container operation.** Margin structures range from low-single-digit to mid-teens with no read-across.
|
||||
- **Adjust for tax regime before any earnings-based comparison.** Tonnage tax vs full corporate tax is a 25–30 point difference in effective rate.
|
||||
- **Adjust for fleet age and specification.** A 5-year-old eco fleet and a 15-year-old non-eco fleet in the same class are not comparables on TCE, opex or asset value.
|
||||
- **Adjust for corporate structure.** Many US-listed shipowners are Marshall Islands entities with an affiliated, founder-owned technical and commercial manager, a controlling shareholder, and dual-class or preferred structures. Their reported G&A is not comparable to an internally managed peer's, and minority shareholders' claim on cash flow differs.
|
||||
- **India-specific**: Great Eastern Shipping combines shipping with an offshore services segment (Greatship) on a different cycle — segment-split it before comparing to a pure shipowner. Concor's economics are dominated by the administered rail haulage charge paid to Indian Railways and by land licence fees, which are policy variables, not management variables — it is not comparable to a road-based 3PL.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Gains on vessel sales inside operating income or EBITDA.** Asset trading is a legitimate part of shipowning, but it is a balance-sheet event and must be reported separately. A company that runs disposal gains through EBITDA and then presents an EV/EBITDA multiple is overstating recurring earning power. Check the cash flow statement for proceeds from vessel sales against reported "operating" profit.
|
||||
|
||||
**Depreciation policy changes.** An extension of useful life from 25 to 30 years, or an increase in assumed residual scrap value per lightweight tonne, raises EPS immediately with no economic change. Read the estimates note every year; a change in either, especially in a weak year, is a deliberate earnings action.
|
||||
|
||||
**Impairment reversals (IFRS and Ind-AS only).** US GAAP prohibits reversing a vessel impairment; IFRS permits it. An IFRS shipowner can report a large profit swing purely from writing assets back up as vessel values recover. This is not earnings — strip it and note that peer comparison across accounting frameworks is broken by it.
|
||||
|
||||
**Related-party everything.** Vessels purchased from or sold to entities controlled by the founder; technical and commercial management fees paid to an affiliated manager; charters with affiliated operators; newbuild contracts placed through a related intermediary. This is endemic in listed shipping. Read the related-party note in full and ask whether an arms-length buyer would have paid that price.
|
||||
|
||||
**Equity issuance at the top and dilution at the bottom.** At-the-market programmes that quietly issue shares whenever the price rallies; a reverse split to maintain a listing followed by fresh dilution. Track shares outstanding over 5–10 years against NAV per share — a company whose fleet grew and whose NAV per share did not has transferred value from shareholders to itself.
|
||||
|
||||
**Ordering newbuilds at peak prices.** The defining capital-cycle error. High rates lift asset prices, cash-rich owners order, yards deliver three years later into a weaker market. Check newbuild contract prices against the historic newbuild price range, and against the mid-cycle TCE required to earn a return on them.
|
||||
|
||||
**Off-balance-sheet and quasi-debt structures.** Sale-and-leaseback with Chinese leasing houses, Japanese operating leases with purchase options, bareboat charters with balloon obligations, and non-consolidated JVs holding vessels and their debt. All are economically debt; all can leave headline net debt looking modest while true LTV is 70%+. Reconcile fleet count to balance-sheet vessels and investigate the gap.
|
||||
|
||||
**Backlog that is not what it seems.** Charter backlog presented at gross contracted revenue with no deduction for opex; charters to a counterparty in financial distress; charters with early-termination or rate-adjustment clauses; a backlog whose weighted average duration is dominated by one long contract while everything else rolls off next year. Ask for backlog EBITDA, by counterparty, by year.
|
||||
|
||||
**Deferred maintenance and drydock timing.** Pushing a special survey into the next financial year lifts current-year utilisation and earnings and creates a bill and off-hire later. A fleet with an unusually light drydock schedule this year and a heavy one next year is not a margin improvement.
|
||||
|
||||
**Ports: throughput bought with price, and captive group cargo.** Volume growth alongside falling realisation per TEU or per tonne is discounting, not share gain. Where the terminal's parent or group companies are also its largest cargo owners, a large share of "third-party validated" volume is intra-group — check concentration and the pricing of related-party cargo. Also watch aggressive capitalisation and long amortisation of concession intangibles, minimum guaranteed throughput shortfalls, and escalating revenue-share terms that compress margin on a fixed schedule.
|
||||
|
||||
**Logistics: gross revenue growth that is freight-rate inflation.** A forwarder's revenue doubling in a rate spike is not growth; volume in TEU or tonnes and net revenue per shipment tell you what actually happened. Also watch capitalised network build costs, rising unbilled revenue, growing receivables from franchise or pickup partners, and yield per shipment declining while volume grows — the standard signature of buying share below cost.
|
||||
|
||||
**India-specific.** Promoter share pledging, especially in port and infrastructure groups where the pledged security is itself cyclical. Large intra-group receivables, loans and guarantees to unlisted promoter entities — read the Ind-AS 24 related-party note and the LODR Regulation 23 disclosures, not the press release. Auditor resignations or qualifications, and CARO 2020 clauses on related-party compliance and utilisation of borrowings. Also check whether a concession is held in a subsidiary with minority partners, so consolidated EBITDA overstates the parent's economic share.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The capital cycle is the sector's master narrative.** High rates generate cash and lift secondhand and newbuild asset prices; owners order; yards deliver 2–3 years later; supply overshoots; rates collapse below cash breakeven; ordering stops; the fleet ages; demolition exceeds delivery; supply tightens; the cycle restarts. This has repeated for over a century. The analytically decisive point is the **asymmetry of information about supply and demand**: the orderbook tells you supply three years out with high confidence, while demand is unforecastable. Therefore anchor the thesis on supply, and treat demand forecasts as scenario inputs rather than conclusions.
|
||||
|
||||
**Where you are in the cycle changes which metrics matter.** Near a trough — asset values near scrap-adjusted floors, orderbook low, demolition high, owners loss-making — the questions are balance-sheet survival (LTV, liquidity vs 12-month obligations, cash breakeven) and asset value downside. Near a peak — record TCE, asset values at decade highs, orderbook rising, owners announcing newbuilds and special dividends — the questions are capital allocation discipline and how much of the reported earnings is non-recurring. A "cheap" 3x EV/EBITDA and 40% dividend yield at a peak is the market pricing the mean reversion, not a mispricing.
|
||||
|
||||
**Effective supply is not the same as nominal supply.** Port congestion, slow steaming (increasingly driven by CII compliance), canal restrictions, sanctions-driven inefficiency in a parallel "shadow" tanker fleet, and route lengthening all absorb capacity without changing the fleet count. Conversely, congestion unwinding releases a wave of effective supply and can crush rates without a single delivery. Always separate nominal fleet growth from effective capacity.
|
||||
|
||||
**Route length is a demand variable.** Red Sea avoidance routing Asia–Europe traffic around the Cape of Good Hope materially lengthens voyages; Russian crude and product flows redirected to Asia lengthened tanker ton-miles substantially; Panama Canal draught restrictions reroute and lengthen. These are demand shocks created by geopolitics, they can reverse abruptly, and a thesis resting on them should say so explicitly.
|
||||
|
||||
**Regulation is now a supply mechanism, not just a cost.** The sulphur cap changed fuel economics and created a scrubber-fitted vs non-scrubber spread. Ballast water treatment retrofit costs pushed marginal old tonnage to scrap. EEXI and the annually tightening CII regime force speed reduction, which removes effective capacity from the oldest, least efficient ships first. The EU Emissions Trading System now covers maritime emissions on EU-touching voyages on a phased basis, and FuelEU Maritime imposes GHG intensity limits with penalties. A global IMO framework for greenhouse gas pricing and fuel intensity has been under negotiation with its adoption timetable repeatedly contested — **verify the current status and phase-in dates before modelling; do not assume the position as of any prior date still holds.** The investable consequence is fuel-choice risk: an owner ordering a conventional-fuel ship today may own a stranded asset, and an owner ordering the wrong alternative fuel (LNG vs methanol vs ammonia) may own an expensive one.
|
||||
|
||||
**Secular demand questions by sub-sector.** Dry bulk is levered to Chinese steel and construction, and to the substitution of iron ore sources by voyage distance. Crude tankers face a long-dated but real transition risk from oil demand plateauing, partly offset by trade-route lengthening. Product tankers benefit from refinery capacity moving away from consumption centres. Containers face nearshoring and friendshoring pressure on trade intensity, and periodic alliance restructuring that reshuffles port volumes. LNG shipping is levered to a large liquefaction capacity build-out with its own delivery timing risk. Ports and land logistics are levered to trade volume, e-commerce penetration and warehousing demand, which are structurally growing but cyclically exposed.
|
||||
|
||||
**Shipyard capacity is the current governor on supply.** Yard consolidation reduced global newbuilding capacity, berth slots have been in demand from LNG, container and offshore orders, and newbuild prices have consequently stayed high with long delivery lead times. High newbuild prices and distant delivery dates restrain ordering, which is supportive for incumbent owners — and this constraint is what a supply thesis should be built on, verified against current yard orderbooks.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
**Reporting and disclosure.** India: Ind-AS, quarterly results with limited review, figures in ₹ crore/lakh, mandatory earnings calls and investor presentations for larger names, promoter shareholding and pledge disclosed quarterly, CARO 2020 auditor reporting, related-party disclosure under Ind-AS 24 and SEBI LODR Regulation 23. Global: 10-K/10-Q for domestic US filers on EDGAR; **most US-listed shipowners are foreign private issuers filing 20-F annually** (Marshall Islands, Greek, Norwegian or Singapore domiciled), often under IFRS, with quarterly reporting voluntary rather than mandatory. This asymmetry matters: an Indian shipowner gives you four datapoints a year and a call; a Marshall Islands 20-F filer may give you one audited set plus press releases.
|
||||
|
||||
**Tax.** India operates a **tonnage tax regime under Sections 115V–115VP** of the Income Tax Act — an optional, long-lock-in scheme taxing notional tonnage income rather than actual profit, with conditions including a minimum transfer to a reserve for fleet acquisition and a training requirement. Effective tax rates for qualifying shipping income are consequently very low. Indian logistics and port companies pay full corporate tax (with MAT considerations where relevant). Global equivalents: Greek, Norwegian, UK, Singapore and Cyprus tonnage regimes; several US-listed owners are effectively untaxed by domicile. Never compare P/E across these without adjustment.
|
||||
|
||||
**Regulators and policy (India).** Directorate General of Shipping (safety, flag, seafarers) and the Ministry of Ports, Shipping and Waterways. Major ports were historically tariff-regulated by TAMP; the **Major Port Authorities Act, 2021** gave major port authorities greater tariff autonomy, while non-major ports sit under state maritime boards (Gujarat Maritime Board and equivalents) with materially more pricing freedom — this is a structural reason non-major private ports have earned higher realisations. Policy programmes (Sagarmala, Maritime India Vision, National Logistics Policy, PM Gati Shakti, dedicated freight corridors) drive capex and modal-shift assumptions that appear in company guidance; treat them as directional, not contractual. Cabotage rules and Indian-flag right of first refusal affect coastal trade competitiveness.
|
||||
|
||||
**Currency and functional currency.** Shipping revenue is overwhelmingly USD-denominated worldwide. An Indian shipowner reporting in INR with USD revenue and USD asset-backed debt has a partial natural hedge but a translation effect on reported earnings and book value. Check the functional currency disclosure — a company whose functional currency is USD but presentation currency is INR will show FX noise that is not economic.
|
||||
|
||||
**Data sources and benchmarks.** Rates and asset values come from brokers and indices, not from companies: Baltic Exchange (BDI, BCI, BPI, BSI, and tanker routes such as TD3C and TC2), Clarksons for newbuild/secondhand values and orderbooks, VesselsValue, and for containers the SCFI, Drewry WCI, Xeneta and Harpex charter indices. Indian port throughput data is published by the Indian Ports Association and by state maritime boards. Always cross-check a company's claimed TCE against the relevant benchmark for the same period.
|
||||
|
||||
**Structural differences to remember.** Indian listed shipping is small and PSU-influenced (Shipping Corporation of India is a disinvestment candidate with the attendant policy overhang); Indian port and logistics listings are large and group-controlled, so governance and intra-group exposure carry more weight than fleet analysis. Conversely, global listed shipping is dominated by controlled, externally managed, low-float vehicles where related-party terms and dilution history matter more than the sector cycle in determining what a minority shareholder actually earns.
|
||||
|
||||
## Checklist
|
||||
|
||||
- Identify the sub-sector first (spot shipowner / charter-backed tonnage / liner / port concession / asset-light logistics) and discard metrics that do not apply.
|
||||
- Restate the topline: TCE per day per vessel class for shipowners; net revenue (gross profit) for forwarders; EBITDA per TEU or per tonne for terminals. Never rank on OPM.
|
||||
- Compute cash breakeven per day (opex + G&A + interest + amortisation + drydock accrual) and state the gap to current and mid-cycle TCE.
|
||||
- Pull the sector orderbook-to-fleet ratio for the specific vessel class from broker data, and the company's own newbuild commitments and remaining instalments.
|
||||
- Compare net fleet supply growth against ton-mile (not tonne) demand growth, and note anything absorbing effective supply — congestion, slow steaming, route lengthening, sanctions.
|
||||
- Build NAV from broker charter-free vessel values less all debt-like items; compute P/NAV and state where vessel values sit versus newbuild parity, their 10-year range, and scrap.
|
||||
- Compute net LTV on market values and test 12-month liquidity against amortisation, newbuild instalments and drydocks at a *trough* rate assumption.
|
||||
- Quantify charter cover: % of next 12 and 24 months fixed, at what rate versus breakeven, for how long, with which counterparty.
|
||||
- Read the depreciation policy note for useful life and residual value; check for any change, and strip vessel sale gains and IFRS impairment reversals from reported earnings.
|
||||
- Read the related-party note in full: manager fees, vessel purchases from affiliates, group cargo, intra-group receivables and guarantees.
|
||||
- Reconcile fleet count to balance-sheet vessels; hunt sale-and-leaseback, bareboat balloons, Japanese operating leases and non-consolidated JV debt.
|
||||
- Check fleet age distribution (not average), eco/scrubber/dual-fuel mix, CII rating spread, and the quantified EU ETS / FuelEU / retrofit cost per day and who bears it.
|
||||
- For ports: remaining concession life, revenue share and escalation, minimum guaranteed throughput, realisation per TEU/tonne trend, cargo concentration and related-party volume share.
|
||||
- For land logistics: cost per shipment versus yield per shipment over 3–5 years, load factor, drop density, and volume in units — not gross revenue growth.
|
||||
- Track shares outstanding and NAV per share over 5–10 years to see whether growth accrued to shareholders or diluted them.
|
||||
- Value on P/NAV and mid-cycle EV/EBITDA (shipowners), backlog DCF (charter-backed), concession-term DCF with near-zero terminal value (ports), EV/net revenue and EV/EBIT (forwarders). Never on trailing P/E, P/B, EV/gross sales, or peak dividend yield.
|
||||
- Adjust for tonnage tax versus full corporate tax before any earnings-based cross-comparison.
|
||||
- State explicitly where in the cycle the analysis sits, and what has to be true about supply — not demand — for the thesis to work.
|
||||
|
|
@ -0,0 +1,202 @@
|
|||
# Telecom, towers, broadcasting, media and OTT — sector playbook
|
||||
|
||||
Use this when: the company sells connectivity or audience attention — mobile and fixed-line operators, tower and fibre infrastructure vehicles and InvITs, cable/DTH distribution, TV broadcasters, radio, print, film production and exhibition, music/IP libraries, and streaming (SVOD/AVOD) platforms.
|
||||
|
||||
These are licence-gated, capital- or content-intensive subscription and advertising businesses in which almost every line of a generic screener is driven by accounting policy, regulation or the position in the investment cycle rather than by underlying economics. Telecom is an invest-then-harvest business where the return profile is structurally awful for four to six years after each technology cycle and then jumps; media is a business where the single largest cost — content — flows through the P&L on a schedule management chooses. In both, the operational KPIs (ARPU, churn, active-subscriber ratio, tenancy, ratings share, paid subs) lead the financials by two to four quarters, so they carry more information than the current income statement. Nothing in this sector can be analysed on a consolidated basis: a group containing mobile, towers, DTH, broadcast and a cash-burning OTT arm must be pulled apart before a single ratio is computed.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Do not report any of the following without the correction stated alongside. Several of them do not merely add noise — they invert.
|
||||
|
||||
**P/E and EPS — near-useless, frequently undefined.** Telecom carries enormous non-cash depreciation and amortisation: network assets on 10–25 year lives, plus spectrum amortised over the 20-year licence term. An operator can be strongly cash-generative and still post accounting losses for years; several large listed telcos have done exactly that through a 4G/5G build. Media is worse, because content and film libraries are amortised on management-chosen curves, making EPS a policy output rather than an observation. A consolidated media P/E also blends a profitable linear broadcast business with a streaming arm that is loss-making *by design* during scale-up. Negative or violently volatile EPS makes P/E undefined, and where it is defined it usually ranks the cycle rather than the business.
|
||||
|
||||
**OPM / EBITDA margin — not comparable across companies or across time.** Since IFRS 16 / Ind AS 116 (FY20 in India), tower and fibre lease rentals moved out of opex and into depreciation and lease interest, inflating reported telecom EBITDA margins by roughly 800–1,200 bps with zero change in cash flow. The perverse consequence: an operator that sold its towers and leased them back now reports a *higher* margin than one that owns them, despite identical or worse economics. Any cross-company or pre/post-2019 margin comparison is invalid unless computed on **EBITDAaL** (EBITDA after lease costs), now the standard European reporting convention. Mix compounds the problem — an integrated telco with handset/device sales, wholesale carriage or DTH is structurally lower-margin than a pure mobile play, with no difference in quality.
|
||||
|
||||
**Revenue is not clean either (India-specific).** Reported revenue is gross revenue, while licence fee (8% of AGR including USOF) and spectrum usage charge are levied on **Adjusted Gross Revenue** — a regulatory cost wedge of roughly 8–11% of service revenue with no developed-market equivalent. Comparing an Indian telco's margin to a US or EU carrier's without adjusting for this compares regulatory regimes.
|
||||
|
||||
**ROCE / ROE — distorted at both ends, and pro-cyclical in the wrong direction.** The denominator includes spectrum (an intangible with no standalone earning power), right-of-use lease assets, and in media large acquisition goodwill. The numerator is depressed during multi-year build-outs. Because the sector is invest-then-harvest, trailing ROCE is structurally poor for years after each technology cycle and then steps up — so screening on trailing ROCE systematically buys the top of the cycle and sells the bottom. Where accumulated losses have driven book equity negative, ROE is not low; it is mathematically meaningless.
|
||||
|
||||
**D/E — misleading in both numerator and denominator.** Book equity is corrupted by accumulated losses, revaluations and past capitalisation of forex differences. More importantly, headline borrowings routinely exclude the largest real obligations: deferred spectrum payment liabilities to the government, AGR dues, lease liabilities and vendor/supply-chain financing. Replace D/E entirely with **fully-loaded net debt / EBITDAaL** rebuilt from the notes.
|
||||
|
||||
**FCF — swings from deeply negative to strongly positive with no change in business quality.** Network capex is lumpy and spectrum auctions are episodic. You must separate maintenance capex from growth capex, and treat spectrum outlays as a distinct quasi-regulatory item rather than as capex. Use **(EBITDAaL − capex) / EBITDAaL** as the operating cash conversion measure and keep spectrum on its own line.
|
||||
|
||||
**Current ratio — inverted.** Prepaid telecom runs structurally negative working capital because customers pay in advance. A current ratio well below 1.0 is normal and is a sign of a good business model, not distress. The same is true of subscription media with annual prepayment.
|
||||
|
||||
**Asset turnover, inventory turnover and P/B — meaningless for the asset-light half of the sector.** For a broadcaster, music label or production house, the real asset — the IP library, the ratings franchise, talent relationships — is either fully amortised or was never capitalised. P/B on such a company measures acquisition history. Conversely, telecom asset turnover of 0.3–0.6x is normal for the second-most capital-intensive sector in the market and reads as "inefficiency" to a generic screen.
|
||||
|
||||
**Dividend payout and yield — invert across the capex cycle.** Telcos suspend or cut dividends during spectrum and technology-build years and pay out heavily in harvest years, so the yield signal is highest exactly when the reinvestment need is lowest and vice versa. Do not treat a suspended dividend during a 5G build as a quality signal in either direction.
|
||||
|
||||
**Any consolidated ratio on a group.** Mobile, towers, DTH, enterprise/data-centre, broadcast, exhibition and OTT have different margins, different capital intensity, different cyclicality and different multiples. Analyse and value them separately or do not analyse them at all.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges below are **indicative only**. They vary by market, market structure (number of competitors), regulatory regime, technology cycle and reporting period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set, against regulator-published industry data (TRAI in India, FCC/Ofcom/BEREC elsewhere) and against the company's own eight-to-twenty-quarter history overrides every absolute band here.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **ARPU and its trend/composition** | Service revenue ÷ average subscribers, monthly. Split prepaid/postpaid, mobile/fixed, consumer/enterprise. Check every quarter for definitional changes (inclusion or exclusion of interconnect, device, or enterprise revenue). | India ₹180–250/month post the 2024 tariff repair, with management ambition materially higher; US postpaid $45–55; Western Europe €10–16. **Direction matters more than level** — sustained 8–12% YoY ARPU growth is the entire Indian telecom thesis. | In a saturated market with 85–100% SIM penetration, subscriber growth is over and essentially all incremental EBITDA comes from ARPU. Incremental revenue on an already-built network drops through at 70–85%, making ARPU the highest-operating-leverage variable in the model. It is also the cleanest read on whether oligopoly pricing discipline is holding. |
|
||||
| **Monthly churn rate** | Disconnections per month as % of average base. Split prepaid vs postpaid and, where disclosed, voluntary vs involuntary. | India prepaid 2.0–3.5%/month normal, >4% signals distress; postpaid (India/US) 0.8–1.2%; FTTH/broadband 1.0–1.5%; pay-TV/DTH 1.5–2.5%; standalone SVOD 3–6%. | Churn sets subscriber lifetime (≈1/churn) and therefore acquisition payback. At 2% monthly churn a subscriber lasts ~50 months; at 4%, ~25 months — halving lifetime value while acquisition spend is unchanged. Rising churn alongside rising ARPU tells you a tariff hike is being rejected. Never read the two separately. |
|
||||
| **Active subscriber ratio (VLR %) and quality of net adds** | Visitor Location Register subscribers — those actually active on the network — as % of reported subscribers. **Published monthly by TRAI in India, per operator per circle.** Elsewhere, use the reported-subs vs revenue-generating-units gap. | India 90%+ is strong; the strongest operators run 96–100%, weak ones 80–88%. Watch the trend at least as much as the level. | Reported subscriber counts are the most gameable number in telecom — inactive SIMs, multi-SIM users and dealer-loaded connections inflate the base and mechanically depress ARPU. VLR% is an independent, regulator-published cross-check on whether headline net adds are real paying customers. India is the only major market with this disclosure; use it aggressively. |
|
||||
| **Revenue market share vs subscriber market share (RMS vs SMS)** | Share of industry AGR/service revenue versus share of industry subscribers, by circle. TRAI publishes circle-level AGR quarterly in India. | RMS > SMS indicates a premium subscriber mix; the leading Indian incumbent runs several hundred bps of RMS above its SMS. A widening RMS–SMS gap marks a share gainer in value rather than volume. | Subscriber share rewards whoever gives away the most; revenue share is the only share that converts into profit. With ~80% fixed costs, the operator gaining RMS compounds a margin advantage. Circle-level RMS also reveals where an operator has genuine network density versus where it is subscale and structurally loss-making. |
|
||||
| **Capex intensity, split maintenance / growth / spectrum** | Cash capex ÷ revenue, with spectrum payments broken out separately (spectrum is a licence cost, not network capex). | Steady-state telecom 13–18% of revenue; active 5G or FTTH build 22–30%; sustained above 30% means the business is not self-funding. Media/broadcast 3–6% — in media, **content spend replaces capex** and should be measured instead. | Determines whether EBITDA ever becomes shareholder cash. Two telcos with identical EBITDA margins are worth very different amounts if one needs 15% of revenue to stand still and the other 28%. Capex intensity is also where earnings management hides (see red flags on capitalised opex). |
|
||||
| **EBITDAaL margin (EBITDA after lease costs)** | EBITDA less right-of-use depreciation and lease interest — i.e. the pre-IFRS 16 / Ind AS 116 economic margin. Most European operators and Indian sell-side models publish it; if not disclosed, rebuild it from the lease note. | Indian mobile: 40–48% reported EBITDA ≈ 33–40% EBITDAaL. Developed-market mobile 30–38% EBITDAaL. Towercos 55–70% (a different business). Cable/broadband 40–50%. | The only margin comparable across operators with different tower-ownership structures and across the IFRS 16 boundary. It also keeps EV/EBITDA honest — if you use reported post-IFRS-16 EBITDA you must add lease liabilities to EV, and mixing the two conventions is the single most common valuation error in the sector today. |
|
||||
| **Fully-loaded net debt / EBITDAaL** | Net debt **including** deferred spectrum liabilities to the government, AGR dues, lease liabilities, vendor/supply-chain financing, and any perpetual or hybrid instruments — divided by EBITDAaL for consistency. | Below 2.5x comfortable; 2.5–3.5x manageable for a stable incumbent with contracted cash flows; above 4x is a solvency question, not a valuation question. Towercos and infra vehicles sustain 4–6x on contracted revenue. | Telecom failures are always leverage failures, never demand failures: the assets are long-lived and revenue is sticky, so what kills operators is a maturity wall meeting a spectrum auction. Deferred spectrum and AGR dues are legally senior government obligations with hard moratorium expiry dates; excluding them understates leverage by turns, not decimals. |
|
||||
| **Operating FCF conversion: (EBITDAaL − capex) / EBITDAaL** | Share of operating profit surviving the network reinvestment requirement, before interest, tax and spectrum. | Mature developed telco 45–60%. Indian telco mid-5G-cycle 20–40%, rising above 50% as the build completes. Persistently below 20% excluding growth capex means the business is a treadmill. | Replaces FCF yield in a sector where reported FCF is dominated by lumpy spectrum. It answers the only question that matters for a capital-intensive business: after paying to keep the network competitive, is anything left? It is also the input to EV/OpFCF, the primary developed-market telecom multiple. |
|
||||
| **Data usage per subscriber and network/plan mix** | GB per user per month; % of base on 4G/5G; postpaid share of base; fixed-broadband attach or converged-household share. | India 25–33 GB/user/month, the highest globally, growing 15–20% YoY; developed markets 15–25 GB. Postpaid mix: India 5–8%, US 55–70%, Europe 40–60%. 5G handset share above 30–40% of the base is typically where monetisation begins. | Data growth is the demand driver that eventually forces either capacity capex or tariff increases — the tension between the two *is* the telecom investment cycle. Postpaid and 5G mix are the leading indicators of ARPU: moving a prepaid user to postpaid roughly doubles ARPU and cuts churn by more than half, raising revenue and lowering acquisition cost simultaneously. |
|
||||
| **Subscriber acquisition cost and payback months** | Gross SAC (handset subsidy + dealer commission + activation + marketing) ÷ gross adds; payback = SAC ÷ (ARPU × contribution margin). Cross-check against whether SAC is expensed or capitalised. | Payback under 12 months is strong; 12–24 months acceptable for postpaid/FTTH with low churn; beyond 24 months the model depends on churn staying low, which it rarely does. | Ties churn and ARPU into a single return-on-marketing test. It is also the item most often quietly capitalised — if SAC moves to the balance sheet, EBITDA rises with no change in cash. Compare SAC × gross adds against the reported selling and marketing line to detect this. |
|
||||
| **Homes passed, homes connected, penetration of homes passed** | Premises the fibre/cable network can serve, premises actually taking service, and the ratio. Also track cost per home passed and per home connected. | Penetration of homes passed: 30–40% is roughly breakeven, 45–60% a good return, below 25% after three years means the build was mis-targeted. Indian FTTH ARPU ₹500–700 against build cost of ₹8,000–15,000 per home passed requires high take-up. | Fixed-line economics are entirely a penetration story: the cost is incurred when the street is passed and the incremental cost of connecting a home is small. Returns are hyper-sensitive to take-up, not to ARPU. Companies love to disclose homes passed (an input they control) and stay vague about homes connected (the output that determines returns). |
|
||||
| **Tower tenancy ratio, EBITDA per tower, contract structure** | Tenants per tower; cash EBITDA per tower per month; plus weighted-average remaining contract life, escalators, exit penalties and tenant concentration. | Tenancy 1.7–2.2x India, 2.0–2.5x US towercos; below 1.5x the asset is uneconomic. Each incremental tenant carries roughly 90% incremental margin. Contracted revenue backlog of 5+ years is the norm. | A tower is a fixed-cost asset whose entire profitability is the tenancy ratio — the second and third tenants are almost pure profit. Tenancy trend also tells you whether operators are consolidating networks (bad) or densifying for 5G (good). Tenant concentration is a counterparty risk no financial ratio captures: a towerco leaning on a financially stressed anchor tenant faces write-offs and forced renegotiation, not a tenancy problem. |
|
||||
| **Content cost as % of revenue, and the amortisation policy** | Cash content/programming spend vs the P&L content amortisation charge, plus the disclosed amortisation curve (accelerated vs straight-line) and assumed library life. | Indian general-entertainment broadcasters 30–40% of revenue; sports-rights businesses 60–90%+ and structurally lower-margin; global streamers 45–60%. Cash spend and amortisation should be roughly neutral over a full cycle. | Content is the media equivalent of capex, but unlike capex it flows through the P&L on a schedule management chooses — making the cash-spend vs amortisation gap the single largest lever on reported media profit. Comparing two broadcasters on EBITDA margin without comparing amortisation policy compares accounting policies, not businesses. |
|
||||
| **Revenue mix: advertising vs subscription; ad growth vs nominal GDP** | Split of media revenue between cyclical advertising and recurring subscription/carriage; ratio of ad revenue growth to nominal GDP growth over 5+ years. | Advertising grows 1.0–1.3x nominal GDP over a cycle but falls 15–30% in a downturn. Subscription share above 50% materially de-risks the model. Indian TV broadcasters have historically run 60–75% advertising; print 65–75% advertising plus circulation. | Advertising has near-100% operating leverage in both directions and two-to-three times the cyclical amplitude of GDP, so an ad-heavy media company must be valued on mid-cycle earnings, never trailing. In India the subscription line is additionally regulated — TRAI's New Tariff Order capped channel pricing and bouquet discounts, structurally compressing it, a policy risk with no developed-market analogue. |
|
||||
| **Viewership/ratings share and ad-rate realisation (CPM/GRP)** | Share of TV and digital viewership by genre and language (BARC in India, Nielsen in the US), plus effective CPM or rate per GRP achieved. Track over 8+ quarters. | Genre leadership matters far more than aggregate share: the #1 channel in a genre commands a 20–40% ad-rate premium over #2, and #3 onwards is often loss-making. Stable-to-rising share in core genres is the requirement. | Media is winner-takes-most at the genre level — advertisers buy reach, so ratings share converts non-linearly into revenue share. A broadcaster losing ratings reports flat revenue for two to three quarters because rate cards lag, then falls off a cliff. Ratings are the leading indicator the financials will not show for a year. |
|
||||
| **Streaming/OTT unit economics** | **Paying** subscribers (not MAU, registered users or downloads), monthly ARPU, annual content spend ÷ average paying subs, and segment contribution margin after content and marketing. | Content cost per paying sub must trend below roughly half of annual ARPU for the model to work. Scaled global streamers run content near 45% of revenue; Indian SVOD ARPU of ₹50–150/month against globally-priced content is why most of it is structurally loss-making. Contribution margin should turn positive within 4–5 years of launch. | Streaming inverts media economics: content cost is fixed and global, revenue is per-subscriber and local, so the business only works above a scale threshold — below it, losses grow *with* subscribers. Companies substitute MAU and engagement metrics for paid subs precisely when paid conversion is failing. Insist on the paying number, the ARPU and the segment margin, and check the OTT arm is not buried inside a profitable broadcast segment. |
|
||||
| **Spectrum holdings, expiry schedule and cost per MHz** | MHz held by band and circle/market, weighted-average remaining licence life, deferred payment schedule and moratorium expiry dates, and price paid per MHz per capita versus recent auction clearing prices. | No material expiry inside 3 years without a disclosed, funded renewal plan. Sub-1GHz (700/850/900 MHz) coverage spectrum is worth a multiple of mid-band per MHz because it determines rural and in-building coverage economics. | Spectrum is the sector's recurring solvency event and its main source of value destruction — auction-inflated prices are how operators end up earning below cost of capital for a decade. Spectrum depth also determines capex: an operator short of mid-band spectrum must build more sites for the same capacity, permanently raising capex intensity. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
Value at the **enterprise level, on cash-flow-based multiples, with a fully-loaded EV** — and normalise to mid-cycle. Trailing numbers value the peak of the ad cycle or the trough of the capex cycle.
|
||||
|
||||
**EV/EBITDA (on EBITDAaL) is the anchor for telecom**, for the same reason it is for utilities: enormous depreciation makes earnings meaningless, capital structures vary wildly, and enterprise value is the only level at which spectrum-heavy, debt-laden and debt-free operators are comparable. Two disciplines are non-negotiable:
|
||||
|
||||
1. Use **EBITDAaL**, or if you use reported post-IFRS-16 EBITDA, **add lease liabilities into EV**. Mixing the two is the most common valuation error in the sector.
|
||||
2. Build a fully-loaded EV: market cap + net debt + **deferred spectrum liabilities + AGR dues** + lease liabilities + minorities − market value of listed stakes.
|
||||
|
||||
Indicative multiple ranges (they move with rates and cycle; treat as orientation, not targets): developed-market incumbents 5–7x EV/EBITDAaL, US carriers 6–8x, Indian telcos 9–13x (a growth premium reflecting the ARPU-repair thesis and a consolidated three-plus-one market structure), towercos 10–15x, Indian broadcasters 10–16x, print 4–7x, exhibition 7–10x on EV/EBITDAaL.
|
||||
|
||||
**EV/OpFCF — EV ÷ (EBITDAaL − capex) — is the sharper telecom multiple** and the one European specialists actually trade on, because it penalises operators whose EBITDA is expensive to maintain. Anything cheap on EV/EBITDA but expensive on EV/OpFCF is a capex trap; run both, always.
|
||||
|
||||
**DCF is more defensible here than in almost any other sector and should be the primary intrinsic method.** Subscriber revenue is contractually recurring and highly predictable, asset lives are long, and terminal value is genuinely reachable. Model it as a **subscriber build** — subs × ARPU, with churn, capex intensity and an explicit spectrum renewal schedule — rather than as percentage-of-revenue assumptions. Discount at a WACC reflecting actual leverage, and separately test whether **spectrum-inclusive ROIC exceeds WACC**: the sector's long-run failure mode is earning below the cost of capital on auction-inflated spectrum, and a DCF that ignores the next auction is a DCF of a business that will not exist.
|
||||
|
||||
**Sum-of-the-parts is mandatory wherever the entity is not a single-market mobile operator.** Indian structures make this unavoidable — an integrated incumbent may combine India mobile, a separately listed African business, a stake in a listed towerco, an enterprise/data-centre arm, a DTH business and a partly-owned regional subsidiary, each on its own multiple. The largest Indian mobile business exists only inside a diversified conglomerate and must be valued at an implied EV/EBITDA within a group SOTP. Media conglomerates similarly need broadcast, films, music IP and OTT valued on different bases.
|
||||
|
||||
**Value loss-making OTT arms separately and honestly** — on EV/Sales against a credible path to contribution margin, or on LTV/CAC, or as a *negative* (a quantified cash drain with option value). Folding a structurally loss-making streaming business into a group EBITDA multiple either destroys the multiple or hides the burn; both are wrong.
|
||||
|
||||
**EV per subscriber and EV per MHz (or MHz-pop) are the replacement-cost / transaction benchmarks.** Use them for distressed or loss-making operators where every earnings-based multiple is undefined. They set a floor and are how sector M&A is actually priced. **EV per tower and EV per tenancy** do the same for infrastructure; **EV per screen** for exhibition; **EV per home passed** for fibre.
|
||||
|
||||
**Infrastructure vehicles — towers, fibre InvITs, data centres — are valued on yield, closer to REIT convention than to telecom convention:** distribution or AFFO yield, and EV/EBITDA benchmarked as a spread over the risk-free rate. In India these increasingly sit in InvIT structures where the operative test is distribution yield versus the 10-year G-sec spread, plus a line-by-line read of the NDCF bridge.
|
||||
|
||||
**Media splits by sub-sector:**
|
||||
- *Mature, low-capex, high-payout broadcasters* — the one corner of this sector where **P/E and dividend yield genuinely work**, provided you have checked content amortisation policy and related-party content sourcing first.
|
||||
- *Content and IP owners (music, film libraries)* — library NPV plus a slate DCF; the back catalogue is an annuity, the new slate is a portfolio of options.
|
||||
- *Streaming and digital-first media* — EV/Sales against a path to contribution margin, or LTV/CAC. Current earnings are negative by design.
|
||||
- *Exhibition* — EV/EBITDAaL and EV per screen; IFRS 16 lease liabilities dominate the balance sheet and must be in EV.
|
||||
- *Print* — value the cash and property separately from the declining operating business; a low P/E on a structurally shrinking circulation base is not cheapness.
|
||||
|
||||
**What NOT to use:** P/E on any loss-making or heavily-amortising telco; P/B on asset-light media; reported EV/EBITDA without a lease convention decision; EV/EBITDA on an entity with a large loss-making segment inside the consolidated EBITDA; dividend yield on a telco mid-capex-cycle; trailing multiples on any advertising-exposed business.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
Compare like with like or do not compare. The sub-sector splits below must **never** be mixed in a single peer table.
|
||||
|
||||
- **Mobile operator vs integrated telco vs pure fixed/cable.** Device and handset revenue, wholesale carriage and DTH all dilute margin without diluting quality. Where possible compare on service revenue only, excluding equipment.
|
||||
- **Telecom operator vs towerco vs fibre InvIT vs data centre.** These are three different asset classes: an operator is an operating business with technology risk; a towerco is a contracted-cash-flow annuity valued like infrastructure; an InvIT is a yield instrument. Their EBITDA margins (40% vs 60%+ vs 90%) and their multiples are not comparable in either direction.
|
||||
- **Market structure is part of the peer definition.** A three-player market with tariff discipline and a five-or-six-player market with a price war are different industries. Never benchmark an operator in a consolidating market against one in a fragmenting one.
|
||||
- **Position in the market matters more than country.** A #1/#2 operator with scale and RMS above SMS has structurally different economics from a subscale #3/#4 operator, which is usually loss-making at the circle/regional level regardless of national reporting. Compare leaders to leaders.
|
||||
- **Lease convention and reporting standard.** Verify every peer is on the same EBITDA definition (pre- or post-IFRS 16). Pre-FY20 Indian data is pre-Ind AS 116 and is not comparable to post-FY20 without restatement.
|
||||
- **Regulatory-cost regime.** Indian operators bear licence fee and SUC on AGR; most developed markets do not. Adjust before comparing margins across borders.
|
||||
- **Media: split by revenue model and genre.** Ad-led general entertainment, subscription-led niche/sports, regional-language broadcasters, print, radio, music IP, film production, exhibition and OTT are separate peer sets. A regional-language broadcaster with genre leadership and a national broadcaster with fragmented share are not comparables even at similar revenue.
|
||||
- **Sports-rights businesses are their own category.** Content cost at 60–90% of revenue, cliff-edge rights renewal risk, and lumpy multi-year amortisation make them non-comparable with general entertainment.
|
||||
- **Streaming: split by ownership.** A standalone SVOD, a studio-owned streamer subsidised by a library, and a telco-bundled OTT have completely different acquisition costs and churn. Bundled OTT subs are not equivalent to directly-acquired paying subs.
|
||||
- **Own history is the strongest peer.** For a company whose market structure has changed (a merger, an entrant exiting, a tariff repair), pre-change history may be a worse comparator than current peers. Say which you are using and why.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
**Leverage and obligations**
|
||||
- Headline "net debt" that excludes deferred spectrum payment obligations, AGR dues, lease liabilities or vendor financing. Indian operators have historically presented debt ex-spectrum; these are legally senior government dues with hard moratorium expiry dates. Always rebuild leverage yourself from the notes.
|
||||
- Tower/fibre sale-and-leaseback or InvIT monetisation presented as **deleveraging**. Cash debt falls, lease liabilities rise, and an owned asset has become a permanent rental obligation, often at a worse economic cost. Check total obligations, not reported borrowings.
|
||||
- Spectrum or licence expiry inside two to three years with no disclosed funding plan, or management calling a renewal auction "manageable" without quantifying it. Spectrum is the sector's recurring solvency event.
|
||||
- Negative net worth sustained only by promoter or government support, or by conversion of dues into equity. At that point conventional ratios are undefined and the work is a solvency-and-dilution analysis, not a valuation.
|
||||
|
||||
**Subscriber and revenue quality**
|
||||
- Rising subscriber base with a falling VLR/active ratio, or a quiet change in the definition of "subscriber" (moving from a 30-day to a 90-day activity window). This is the sector's most common cosmetic fix: it flatters net adds and deflates ARPU simultaneously.
|
||||
- ARPU "growth" delivered by shedding low-value subscribers rather than by pricing. Read ARPU alongside **absolute service revenue** — if ARPU rises while service revenue is flat or falling, the base is shrinking and the improvement is arithmetic, not commercial.
|
||||
- Growing gross adds alongside rising churn — churning the same customers through the front and back door inflates reported adds while acquisition cost is expensed repeatedly. Read gross adds, net adds and churn together, never in isolation.
|
||||
- Registered users, downloads, MAU or "reach" substituted for paying subscribers and audited circulation, precisely when paid conversion is deteriorating.
|
||||
|
||||
**Accounting**
|
||||
- A step-up in capitalised network costs, capitalised interest, or capitalised subscriber acquisition costs (handset subsidies, dealer commissions). Moving opex into capex lifts EBITDA immediately and defers the charge into depreciation years later. Watch for capex rising while network deployment metrics (sites added, km of fibre laid) do not.
|
||||
- Lengthening content amortisation lives, or switching from an accelerated to a straight-line curve. Also watch cash content spend running persistently far above the P&L amortisation charge — the library is either being built or the charge is understated, and only the impairment test will eventually tell you which.
|
||||
- Presenting post-IFRS 16 / Ind AS 116 EBITDA alongside peers' pre-standard figures, or celebrating margin expansion in the adoption year. The 800–1,200 bps uplift is pure accounting.
|
||||
- "Other income", treasury and investment gains, spectrum trading gains, or asset disposal profits carrying the reported profit line. Strip to core operating cash generation.
|
||||
- Receivable days above 100–120 in media — government advertising receivables in print, agency receivables in broadcast — and "unbilled revenue" growing faster than revenue.
|
||||
- Revenue recognised from barter, ad-for-equity or advertising-for-stake deals, common among media houses with startup clients. Non-cash revenue booked at full margin that reverses when the counterparty fails.
|
||||
|
||||
**Segment and governance (India-weighted)**
|
||||
- A loss-making OTT/digital business consolidated into a profitable broadcast segment with no separate segment disclosure. Insist on segment-level EBITDA; the **absence** of the disclosure is itself the signal.
|
||||
- Related-party content sourcing — film, music or programming rights bought from promoter-owned production houses without a demonstrated arm's-length test. Check group loans and advances to promoter entities buried in "other non-current assets"; the mid-cycle collapse of a large Indian media group followed exactly this pattern.
|
||||
- High or rising promoter share pledging in Indian media and telecom holding structures, which converts a business problem into a forced-selling problem.
|
||||
- Concentration risk in infrastructure: a towerco or fibre company with a large revenue share from a financially stressed anchor tenant. The real risk is receivable write-offs and contract renegotiation, not tenancy trends.
|
||||
|
||||
**Leading indicators of trouble**
|
||||
- Ratings/viewership share declining while revenue holds up. Rate cards lag ratings by two to three quarters, so financials look fine right until they do not. Treat BARC/Nielsen share loss as a leading indicator that **overrides** current earnings.
|
||||
- Regulatory changes treated as one-offs when they are structural resets: TRAI's New Tariff Order on channel pricing, AGR definition changes, licence-fee or USOF revisions, must-carry and carriage-fee rules.
|
||||
- Capex guidance cut sharply in a competitive market. It buys short-term FCF and cash flow at the cost of network quality, which shows up as churn 18–24 months later.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The telecom capex cycle drives everything.** Each generation (3G, 4G, 5G, next) follows the same arc: spectrum auction → heavy build with collapsing ROCE and negative FCF → coverage parity, price war and consolidation → tariff repair and margin expansion → harvest with high FCF and dividends → next auction. Where a company sits on that arc determines which metrics are informative. In the build phase, ignore ROCE, P/E and FCF and focus on capex efficiency, net debt trajectory and funding cover. In the harvest phase, ignore the flattering trailing multiples and ask when the next auction is and what it will cost.
|
||||
|
||||
**Consolidation is the value event.** Telecom margins are a function of the number of credible competitors. Markets going from five-plus players to three tend to see ARPU repair and multiple expansion; markets where a well-funded entrant appears see the reverse, sometimes for a decade. Track competitor count, competitor funding capacity, and whether the weakest player is being kept alive by government forbearance — a subscale competitor unable to invest but unable to exit is the worst structure for the whole industry.
|
||||
|
||||
**Structural threats to media are not cyclical.** Linear TV viewing and print circulation are in secular decline in most markets; advertising is migrating to a small number of global digital platforms that capture the majority of incremental ad spend. Do not model a broadcaster's ad revenue as merely cyclical without testing whether the audience base itself is eroding. Cord-cutting in developed markets, and the shift from pay-TV to bundled OTT in India, permanently compress carriage and subscription revenue for distributors.
|
||||
|
||||
**Telecom's own structural threats:** OTT messaging and voice destroyed the voice and SMS revenue lines a decade ago and the sector has been repricing data ever since; satellite direct-to-device and fixed wireless access are the current edge cases. Net-neutrality regimes prevent operators capturing application-layer value, which is why telecom persistently earns less than the ecosystem it enables.
|
||||
|
||||
**Regulation is a primary earnings variable, not a footnote.** Spectrum auction design and reserve prices; licence fee and revenue-share definitions; interconnect/termination rates; the New Tariff Order in India; must-carry and carriage rules; content and broadcasting ownership caps; data-protection and content-takedown regimes; and merger approval thresholds. Any of these can reset the revenue base permanently. Read the current consultation papers, not just the enacted rules — the regulator's direction of travel is usually visible a year ahead.
|
||||
|
||||
**Rates matter more than for most sectors.** These are long-duration, highly leveraged, yield-held assets. Rising rates hit valuation twice: through the discount rate on very long cash flows and through refinancing cost on structurally high debt. Infrastructure vehicles and InvITs trade explicitly on a spread to the sovereign.
|
||||
|
||||
**Content cost inflation is the media cycle.** Sports rights and premium content costs ratchet up with each renewal while advertising is cyclical, so media margin compression is often a rights-renewal event rather than a demand event. Check the renewal calendar for every material rights contract.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
**Regulators and disclosure.** India: TRAI (tariffs, subscriber and AGR data, New Tariff Order for broadcasting), DoT (licences, spectrum, AGR assessment), MIB (broadcasting and content), and BARC for TV ratings. TRAI publishes monthly subscriber and VLR data and quarterly performance indicator reports with circle-level AGR — a level of independent operational disclosure no other major market provides. Use it as the primary cross-check on company-reported subscribers, ARPU and market share. Globally: FCC and Nielsen in the US, Ofcom in the UK, BEREC/national regulators in the EU, with disclosure in 10-K/10-Q (EDGAR) or annual reports and much less granular regulator-published operating data.
|
||||
|
||||
**India-specific cost and liability structure (no developed-market analogue).**
|
||||
- **AGR / licence fee:** 8% of Adjusted Gross Revenue including USOF, plus spectrum usage charges. This is a revenue-share tax on the top line.
|
||||
- **AGR dues:** the Supreme Court's ruling on the definition of AGR created large retrospective liabilities with defined instalment schedules. These are senior government dues and belong in net debt.
|
||||
- **Deferred spectrum payments:** auction purchases are paid over 16–20 years after a moratorium. Headline "net debt" often excludes them; you must add them back, with the moratorium expiry date noted as a cliff.
|
||||
- **New Tariff Order (broadcasting):** TRAI caps on channel à-la-carte pricing and bouquet discounting structurally compressed broadcaster subscription revenue and reset the distributor–broadcaster split. There is no US or EU equivalent.
|
||||
|
||||
**Accounting.** Ind AS 116 mirrors IFRS 16 (mandatory FY20 in India), so Indian pre-FY20 EBITDA is not comparable to post-FY20. US GAAP retains an operating-lease P&L charge for ASC 842 operating leases, so US carriers' reported EBITDA is *already* closer to EBITDAaL than an IFRS peer's — a direct cross-border comparability trap. Content amortisation policy is disclosed under ASC 926 for US film/TV entities with useful specificity; Indian disclosure is typically thinner, so read the significant-accounting-policies note and the concall Q&A.
|
||||
|
||||
**Units and conventions.** Indian filings use crore and lakh; ARPU is quoted monthly in rupees, while US carriers quote monthly ARPU/ARPA in dollars and European operators often quote it excluding VAT. India reports subscribers by **circle** (22 licensed service areas) — circle-level economics vary enormously and a national average conceals subscale, loss-making circles. Indian quarterly reporting is not required to include full segment cash flows; use the annual report, CARO reporting on related-party and pledge disclosures, and the earnings call transcript, where operational KPIs (churn, VLR, 5G rollout, content spend) are usually disclosed only verbally.
|
||||
|
||||
**Ownership and governance.** Indian telecom and media are promoter-controlled; check promoter holding, pledge percentage, and the structure of holding companies between the promoter and the listed entity. FDI in telecom is permitted to 100% (with security-clearance conditions) and broadcasting has sector-specific caps; a change in foreign ownership rules is a live corporate-action variable. Related-party content transactions are the dominant Indian media governance risk — check the RPT schedule and the audit committee's approval language, not just the aggregate number.
|
||||
|
||||
**Market maturity.** India runs the world's highest data usage per user at among the world's lowest ARPUs, so the investment case is a price-repair thesis with enormous operating leverage. Developed markets run the reverse: high ARPU, saturated demand, and the investment case is cost efficiency, convergence bundling and capital return. Do not import a target multiple or a healthy-range band across that divide without stating the adjustment.
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Identify sub-sector precisely (mobile / integrated / fixed / tower / InvIT / broadcast / print / music-IP / exhibition / OTT) and refuse consolidated ratios on multi-segment groups.
|
||||
- [ ] Recompute EBITDAaL; state the lease convention used and confirm every peer is on the same one.
|
||||
- [ ] Rebuild net debt fully loaded: borrowings + deferred spectrum + AGR dues + lease liabilities + vendor financing + hybrids; compute net debt/EBITDAaL.
|
||||
- [ ] Pull ARPU and absolute service revenue together — confirm ARPU growth is pricing, not base shrinkage.
|
||||
- [ ] Read churn and ARPU jointly; compute implied subscriber life (1/churn) and acquisition payback.
|
||||
- [ ] For India, cross-check reported subscribers against TRAI VLR % and circle-level RMS vs SMS.
|
||||
- [ ] Split capex into maintenance, growth and spectrum; compute capex/revenue and (EBITDAaL − capex)/EBITDAaL.
|
||||
- [ ] Map the spectrum expiry and deferred-payment schedule for the next five years, with the funding plan.
|
||||
- [ ] For fixed/fibre, get homes connected, not just homes passed; compute penetration of homes passed.
|
||||
- [ ] For towers, get tenancy ratio, contracted backlog, escalators and tenant concentration; assess anchor-tenant credit.
|
||||
- [ ] For media, compare cash content spend against the P&L amortisation charge and read the amortisation policy note for changes.
|
||||
- [ ] Split media revenue into advertising vs subscription; value ad-exposed earnings on mid-cycle, never trailing.
|
||||
- [ ] Check genre-level ratings share over 8+ quarters; treat share loss as overriding current revenue.
|
||||
- [ ] For OTT, demand paying subs, ARPU, content cost per paying sub and segment contribution margin — reject MAU substitutes.
|
||||
- [ ] Confirm the loss-making digital arm is separately disclosed; absence of segment disclosure is itself a flag.
|
||||
- [ ] Test for capitalised opex: capex rising without matching network build metrics; SAC moving to the balance sheet.
|
||||
- [ ] Value on EV/EBITDAaL **and** EV/OpFCF; investigate any gap between the two.
|
||||
- [ ] Run a subscriber-build DCF with explicit churn, capex intensity and spectrum renewal; test spectrum-inclusive ROIC vs WACC.
|
||||
- [ ] Build an SOTP for any group with listed stakes, towers, DTH, enterprise or OTT; value infra vehicles on distribution yield vs the sovereign.
|
||||
- [ ] India: check promoter pledge, related-party content sourcing, group loans in "other non-current assets", and the concall for KPIs absent from the filings.
|
||||
- [ ] State the market structure (number of credible competitors, direction of consolidation) and where the company sits in the capex cycle before quoting any multiple.
|
||||
|
|
@ -0,0 +1,192 @@
|
|||
# Power generation, transmission and regulated utilities — sector playbook
|
||||
|
||||
Use this when: the company earns money by generating, transmitting, distributing or trading electricity (or gas/water under an analogous regulated regime) — Indian gencos, transcos, discoms, renewable IPPs, power InvITs, US regulated and multi-utility holdcos, UK/EU RAB-regulated networks, and merchant generators anywhere.
|
||||
|
||||
The defining fact is that price is not set by competition. It is set by a regulator's formula or by a long-term PPA, and the asset base itself — not sales, not margin — is the earnings engine. Earnings equal rate base times allowed return; growth equals rate-base growth; risk equals counterparty and regulator behaviour. That inverts or voids most of the generic ratio set, and it means a diversified utility containing regulated networks, contracted renewables and merchant thermal must be pulled apart before any number is computed on it.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
A generic OPM / ROCE / D-E / P-E / FCF checklist does not merely add noise here — it mis-ranks the sector almost systematically, and several of its signals point the wrong way. Do not report these without the correction stated alongside.
|
||||
|
||||
**OPM / EBITDA margin — an artefact of fuel pass-through accounting, not efficiency.** A distribution utility books the full retail tariff as revenue and power-purchase cost as expense, so 4–10% margins are structurally normal. A regulated transmission company or a solar IPP has almost no variable cost and prints 85–92% EBITDA margins. A coal genco on a fuel-pass-through PPA books fuel in both revenue and cost, so its margin *mechanically falls when coal prices rise* even though profit is unchanged. Margin here measures business mix, not operating quality. The only comparable margin is on **net revenue** (revenue less fuel and purchased power), or better, **EBITDA per unit sold** (₹/kWh, $/MWh).
|
||||
|
||||
**Revenue growth — meaningless.** Top line moves with fuel prices, fuel-surcharge true-ups (FPPPA/FAC in India, deferred fuel balances in the US) and pass-through of purchased power. A discom can grow revenue 25% while selling fewer units. The real growth variables are **units sold (MU/TWh), customers, MW commissioned and rate base**.
|
||||
|
||||
**ROCE — converges to the allowed return by construction, so it discriminates poorly and often perversely.** Under CERC/SERC norms an Indian regulated genco or transco earns a formula return (15.5% post-tax RoE on 30% notional equity, plus normative O&M, depreciation and interest); in the US an allowed ROE of roughly 9–10.5%, in the UK/EU a WACC-based RAB return, does the same. ROCE far *above* the allowed return usually means old, fully-depreciated assets — a shrinking earnings base, not a moat — or large merchant exposure. ROCE far *below* may simply reflect a big CWIP block that legally earns nothing until commissioning. Always recompute excluding CWIP, and split regulated from merchant.
|
||||
|
||||
**D/E — rejects the entire sector.** Regulated networks are financed to 55–65% gearing on RAB *precisely because* the cash flows are contracted; project-financed generation SPVs are built 70:30 or 75:25 debt:equity by regulatory design. A "D/E < 1" filter eliminates essentially every listed transmission utility, most IPPs and every InvIT. Replace it with rating-agency cash-flow ratios (FFO/Debt, FFO interest cover), Debt/RAB, and a recourse-vs-non-recourse split.
|
||||
|
||||
**Free cash flow — structurally negative during rate-base growth, and that is a buy signal.** A utility is *supposed* to spend more than depreciation; value is created by earning the allowed return on new capex. Positive FCF often means under-investment and a shrinking future earnings base. Reported FCF also does not separate maintenance from growth capex. Use FFO, FFO less maintenance capex, and capex/depreciation instead.
|
||||
|
||||
**P/E — corrupted by non-cash and timing items unique to this sector.** Regulatory deferral account balances (Ind AS 114) and US-style regulatory assets/liabilities; prior-period true-ups and arrears landing in a single quarter; late-payment surcharge income; capitalised interest during construction (IDC); in India, capitalisation of exchange differences on long-term borrowings under the Ind AS 21 D13AA exemption; IFRS 9 mark-to-market on merchant hedges; deferred tax and MAT credits; and book gains on asset drop-downs into sponsored InvITs/YieldCos. Two identical plants can report very different EPS.
|
||||
|
||||
**P/B — usable, but only with a translation layer.** The economically relevant capital is the regulator's rate base / RAB, not Ind-AS or IFRS net block. Assets funded by consumer contributions and government grants (sitting as deferred revenue), disallowed capex, and revaluation differences all break the link. P/B remains a core utility tool — but read against *earned* ROE and against RAB, never alone.
|
||||
|
||||
**Current ratio, receivable days and working-capital screens — wrong, especially in India.** Receivables from state discoms are a political variable; 90–250 days DSO is common and does not by itself indicate a bad operator. Conversely a sudden fall in receivables may just be a one-off government bailout or securitisation scheme, not an operating improvement.
|
||||
|
||||
**Interest cover and asset turnover — structurally punished.** EBIT interest cover is distorted by IDC capitalisation (interest that never hits the P&L). Asset turnover of 0.2–0.4x is normal for the most capital-intensive sector in the market; a generic screen reads it as inefficiency.
|
||||
|
||||
**Payout-ratio screens — misfire in the opposite direction.** A 50–80% payout is normal and healthy for a regulated utility. The "low payout = reinvestment quality" heuristic does not apply; here, low payout with weak rate-base growth is simply cash trapped.
|
||||
|
||||
**Any consolidated ratio on a diversified utility — misleading by construction.** Regulated networks, contracted renewables and merchant thermal carry different risk, different cost of capital and different multiples. Analyse and value them separately or do not analyse them at all.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market, technology, regulatory regime, control period and point in the cycle, and any of them can be wrong for a specific asset in a specific year. Comparison against a tight peer set, against the *regulator's own normative level*, and against the company's own 5–10 year history overrides every absolute band below.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Regulated Asset Base (RAB) / rate base growth** | The regulator-approved capital on which a return is allowed, and its CAGR. India: practical proxy is approved gross block plus CWIP capitalisation admitted in the current control period (CERC/SERC tariff orders). UK/EU: published RAV/RAB. US: rate base per the last rate case. | DM regulated networks 5–8% p.a. real; Indian transmission/distribution 8–14% nominal gross-block growth *with capitalisation actually approved*. Below nominal GDP growth = a shrinking earnings engine. | Earnings = rate base × allowed return, so rate-base growth is essentially the entire organic EPS algorithm — and far more predictable than sales or margin. It also reveals whether reported capex is converting into earning assets or piling up in CWIP. |
|
||||
| **Allowed ROE vs earned ROE (the under-earning gap)** | The return the regulator permits versus what is actually earned on regulated equity, plus the *reasons* for the gap: regulatory lag, disallowed capex, cost over-runs, incentive/penalty outcomes, under-recovery of fixed cost. | US allowed ROE typically 9.0–10.5%, earned within 50–100 bps of allowed is good, >150 bps under-earning is a flag. India: CERC norm 15.5% post-tax RoE on 30% notional equity for central generation/transmission; SERC distribution 14–16%. Chronic realisation below 80% of allowed = weak regulator or weak operator. | This single spread explains most of the valuation dispersion between regulated utilities. A reliable full-earner deserves ~1.2–1.6x book; a chronic under-earner deserves a discount to book regardless of what its P/E looks like. |
|
||||
| **Availability (NAF) vs PLF vs CUF** | For regulated thermal: declared availability, which drives fixed-cost (capacity charge) recovery — distinct from PLF, which only drives variable-cost recovery. For renewables: Capacity Utilisation Factor / load factor. Compare to the regulator's normative level, not to zero. | Indian coal under CERC norms: 85% NAF for full fixed-cost recovery, incentive above; >88–90% is strong. All-India thermal PLF ~65–70%; a plant >80% is good. Solar CUF 19–25% (single-axis tracking to 26–28%); onshore wind 25–35%; offshore wind 45–55%; hydro 30–45%; nuclear >85%. | In a capacity-payment regime, availability — not generation — pays the fixed costs and the equity return. A plant at 45% PLF can be fully profitable at 90% availability. Sustained availability below the norm is direct, unrecoverable erosion of the allowed return. For renewables, CUF *is* the revenue line and is the number most often over-promised in project models. |
|
||||
| **AT&C losses and collection efficiency** | Distribution: 1 − (billing efficiency × collection efficiency), capturing technical line losses plus theft, non-billing and non-collection. DM analogue: T&D loss plus bad-debt/uncollected revenue. | Best-in-class Indian private discoms and licensed franchises 6–9%; RDSS national target 12–15%; weak state discoms 20–35%+. DM T&D losses 4–7% with ~99% collection efficiency. | The cleanest single measure of distribution operating quality, and of whether privatisation/franchise value has actually been created. Every 100 bps of AT&C reduction drops almost entirely to EBITDA. It is also what regulators reward with incentive tariffs, and what determines whether a discom can pay its gencos. |
|
||||
| **ACS–ARR gap** | Average Cost of Supply per unit less Average Revenue Realised per unit (₹/kWh) — the structural cash loss per unit sold. Largely an Indian construct; DM analogue is the revenue-requirement shortfall or deferred fuel balance. | Zero or negative. All-India has run roughly ₹0.30–0.50/kWh; weak states ₹1.0–1.5/kWh. Any positive gap not funded by an explicit, budgeted state subsidy is unsustainable. | Root cause of the entire Indian power receivable chain. A genco or transco selling into wide-gap states shows good P&L revenue and terrible cash conversion. It is also the best forward indicator of tariff shocks, PPA renegotiation attempts and payment default. |
|
||||
| **Station heat rate, specific fuel consumption, auxiliary consumption** | Thermal efficiency (kcal/kWh, or Btu/kWh), specific coal/oil consumption (kg/kWh, ml/kWh), and in-house consumption as a share of gross generation — each measured **against the regulator's normative level**. | Indian supercritical coal normative SHR ~2,375–2,450 kcal/kWh (subcritical ~2,450–2,500); auxiliary consumption norm 5.25–6.5% coal, ~1–2% gas/CCGT. US/EU CCGT 6,400–7,000 Btu/kWh (50–60% net efficiency). Beating the norm is where real operating alpha appears. | Under cost-plus tariffs, performance versus norm is retained by (or charged to) the company — the only genuine efficiency lever a regulated genco has, and completely invisible in OPM because fuel is pass-through. For merchant plants, heat rate sets merit-order position and therefore dispatch hours. |
|
||||
| **Variable cost per unit / merit-order position; spark and dark spreads** | Fuel plus variable O&M per kWh, benchmarked against the market clearing price (IEX DAM/RTM in India) or against the clean spark spread (gas margin after fuel and carbon) and dark spread (coal equivalent) in DM. | Indian pithead coal variable cost ₹1.7–2.6/kWh vs imported-coal plants ₹4–7/kWh; IEX DAM typically ₹3–6/kWh with scarcity spikes. Bottom-quartile variable cost in the national merit order = near-certain dispatch. | The single determinant of a merchant plant's earnings, and of a regulated plant's PLF (hence incentive income). Two plants with identical capacity and identical D/E can have opposite economics purely on fuel logistics — pithead vs imported, linkage vs e-auction, FSA coverage. |
|
||||
| **Contracted vs merchant mix, weighted-average PPA tenor, hedge ratio** | Share of capacity (MW) *and* of EBITDA under long-term PPAs vs short-term/merchant; weighted-average remaining PPA life; counterparty credit quality; for merchant fleets the forward hedge ratio by year. | Investment-grade IPPs: >80–85% of capacity contracted with >10 years weighted-average remaining life. Merchant fleets: 85–100% hedged for the next 12 months, 50–70% year 2, 25–40% year 3. Under 5 years average PPA life with no re-contracting visibility is a cliff. | This sets the cost of capital and the multiple: contracted cash flows are bond-like (10–13x EV/EBITDA), merchant cash flows commodity-like (5–8x). It is also the most obscured number in consolidated reporting — rolling one-year "short-term PPAs" get described as contracted. |
|
||||
| **FFO/Debt, FFO interest cover, Net Debt/EBITDA, Debt/RAB** | Rating-agency cash-flow leverage, adjusted for hybrids/perpetuals, leases, pension and decommissioning provisions, with debt split between recourse (holdco) and non-recourse (project SPV). | Regulated networks: FFO/Debt 13–20% for BBB (>18–20% for A), FFO interest cover 3.0–4.5x, Net Debt/EBITDA 4.5–6.0x, Debt/RAB 55–70%. Merchant generation: Net Debt/EBITDA below 3.5–4.0x, FFO/Debt above 25–30%. Indian IPPs: under 5x for contracted, under 3.5x for merchant-exposed. | Replaces D/E entirely — utilities are financed against cash-flow stability, not equity book. Downgrades are valuation events here, because the whole model rests on continuous access to cheap long-dated debt; a fall below investment grade can make the growth plan uneconomic overnight. |
|
||||
| **Receivable days by counterparty, and the regulatory asset / deferral account balance** | DSO split by counterparty state/utility, overdues above 60 and 90 days, plus the balance-sheet stock of "regulatory assets" / Ind AS 114 regulatory deferral account balances — costs recognised in P&L but not yet admitted into tariff. | Indian gencos/transcos: 45–90 days healthy, above 150 days signals a weak counterparty book. Regulatory assets should be small and amortising on an approved, dated schedule; a balance exceeding 6–12 months of revenue is serious impairment risk. | This is where earnings quality lives. Profit is booked on accrual against a state counterparty that may not pay for years, and the regulatory asset is effectively an unsecured, unrecognised receivable on a *future regulator*. Rising regulatory assets alongside rising PAT is the classic sector accounting trap. |
|
||||
| **Capex/depreciation, capitalisation rate, CWIP ageing** | Capex ÷ depreciation (growth intensity); the share of the year's capex actually capitalised and admitted into rate base; and the ageing of CWIP — how long each project has sat accruing IDC. | Capex/depreciation 1.3–2.0x indicates healthy rate-base growth; below 1.0x means shrinkage. CWIP under ~15–25% of gross block for a mature utility, turning over within the project cycle; individual line items older than 4–5 years are usually stranded. | Capex is the growth engine only if the regulator admits it. Aged CWIP is capital earning nothing while interest is capitalised into the asset — flattering the P&L — and is the most common precursor to a large impairment or a disallowance of cost over-runs. |
|
||||
| **EBITDA per unit sold and cost per unit delivered** | EBITDA ÷ units generated/sold (₹/kWh, $/MWh); separately, O&M + employee + other opex per unit, per customer, per circuit-km or per MW. | Highly technology-specific: Indian regulated coal roughly ₹1.2–1.8/kWh EBITDA; solar ₹2.5–3.5/kWh; transmission better measured per ckt-km or per MVA. Judge trend and peer-relative, not level. Fixed O&M should track the regulator's escalation index (~4–6% p.a. in India), not exceed it. | Strips out fuel and purchased-power pass-through — exactly what OPM fails to do — and makes a discom, a genco and a transco comparable on unit economics. Opex per unit versus the normative allowance is where a regulated operator either keeps or loses the efficiency gain. |
|
||||
| **Emissions intensity, compliance capex, remaining thermal asset life** | gCO₂/kWh; SOx/NOx/PM compliance status (FGD, SCR, ESP upgrades); carbon cost exposure (EU/UK ETS, US state programmes); remaining useful life of thermal assets versus the depreciation schedule *and* versus PPA tenor. | EU/UK integrated utilities largely below 200–300 gCO₂/kWh; Indian coal-heavy gencos near 900–1,000 gCO₂/kWh. Indian FGD has cost roughly ₹0.4–0.6 crore/MW and adds ~₹0.25–0.50/kWh to tariff. Flag thermal assets with 25+ years of book life left but a PPA ending within 10. | Drives mandatory capex (which may or may not be tariff-recoverable) and terminal-value risk. A coal plant depreciated over 40 years in a market decarbonising in 15 carries an unrecognised impairment. In DM, carbon cost is a direct hit to the dark spread and to dispatch order. |
|
||||
| **Under-construction pipeline: MW by contracting stage** | Forward capacity split into (a) awarded, no PPA/PSA signed, (b) PPA signed, no financial closure, (c) under construction and financed — with the winning tariff and assumed equity IRR on each tranche. | For an Indian renewable IPP only the PPA+PSA-signed, financially-closed portion is meaningful. Target project equity IRR 13–16% India, 8–12% DM; a bid tariff implying sub-10% equity IRR at realistic CUF is value-destructive growth. Award-to-commissioning should be 18–24 months. | The gap between "MW awarded" and "MW earning" is the most systematically over-marketed number in the sector — multi-GW of Indian central and state auction awards have sat stranded for years without a signed power sale agreement. It is also the capital-discipline test: winning volume at uneconomic tariffs grows rate base while shrinking value. |
|
||||
| **Grid and network operating KPIs** | Distribution/transmission reliability: SAIDI/SAIFI (or India's outage-hours and RDSS reliability metrics), transmission system availability against the CERC norm, transformer failure rate, circuit-km and MVA added, connections/customers added, and curtailment hours suffered by must-run renewables. | Indian transmission availability norm ~98–99% for full incentive; DM SAIDI targets are set explicitly by the regulator with penalty/reward attached. Rising curtailment above a few percent of generation is a direct revenue loss unless deemed-generation is contractually payable *and* actually paid. | These are the KPIs the regulator pays or penalises on, so they translate mechanically into allowed revenue. Reliability deterioration also precedes regulatory intervention, licence-condition disputes and consumer-facing political pressure — usually before it appears in the accounts. |
|
||||
| **Distribution / dividend coverage from FFO less maintenance capex** | Dividend (or InvIT/YieldCo distribution) tested against FFO minus maintenance capex, not against EPS; plus the share of distribution that is return *of* capital. | Payout 50–80% of EPS is normal in DM; coverage on FFO-less-maintenance-capex above 1.0x on a multi-year basis. For InvITs/YieldCos, examine the NDCF bridge line by line. | Utilities are held as yield instruments, so a distribution cut is a de-rating event, not a rounding error. EPS-based coverage hides the fact that depreciation understates true asset replacement cost in an inflationary capex environment, and that some distributions are simply returning the unitholder's own capital. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
Utilities are valued as **regulated capital stocks and contracted cash-flow streams**, not as earnings multiples. A diversified utility must be valued sum-of-the-parts; a single blended P/E on such an entity is close to meaningless.
|
||||
|
||||
**1. EV/RAB (or P/RAB) — primary for regulated networks.** The tool of choice for UK/EU transmission and distribution, and increasingly for Indian transmission and InvIT-held networks. You pay a premium or discount to the regulator-approved capital base depending on whether the company can out-earn its allowed return, beat its totex allowance and grow the RAB. Typical range 1.0–1.4x. Above ~1.4x embeds aggressive outperformance or aggressive growth; below 1.0x implies the market expects disallowance or chronic under-earning. It works because the regulator has effectively fixed both the numerator (allowed return) and the denominator (capital).
|
||||
|
||||
**2. P/B read against earned ROE — the standard cross-check** for US regulated utilities and Indian regulated PSUs. Justified P/B ≈ (earned ROE − g) / (Ke − g). Because allowed ROE is administratively set and stable, P/B is a far more stable and comparable anchor than P/E. A utility earning its allowed 15.5% RoE against a ~12% cost of equity supports a meaningful premium to book; one earning 9% against the same Ke should trade below book. US regulated utilities have historically traded 1.6–2.2x book; Indian regulated PSUs 1.0–2.5x depending on the growth and payout cycle.
|
||||
|
||||
**3. Long-horizon DCF, modelled control period by control period.** This is one of the few sectors where a 10–20 year explicit DCF is genuinely defensible, because the tariff formula, PPA tenor and asset life are contractually known. Model each regulatory period separately — allowed return, capex allowance, incentive/penalty, true-ups — and take terminal value off **closing RAB**, not a perpetuity growth rate. For contracted IPPs, model to PPA expiry with an explicit and conservative re-contracting or residual-value assumption; never a full-value perpetuity beyond the contract.
|
||||
|
||||
**4. DDM and dividend yield versus the sovereign bond.** Utilities are yield instruments and trade on the spread of dividend yield over the 10-year government bond; a widening spread is often the cleanest valuation signal in the sector. Test coverage against FFO less maintenance capex, not EPS.
|
||||
|
||||
**5. EV/EBITDA in preference to P/E**, because it neutralises capital structure, the enormous depreciation charge and differing tax positions (MAT, deferred tax, accelerated depreciation on renewables). Indicative bands: regulated networks 9–13x; contracted renewables 9–12x; contracted thermal 6–9x; merchant generation 4–7x on **mid-cycle** spreads. Always adjust EBITDA for capitalised interest and capitalised O&M, strip late-payment surcharge and other income, and neutralise regulatory deferral account movements.
|
||||
|
||||
**6. EV/MW and EV/kW as a replacement-cost sanity check.** India: greenfield coal roughly ₹8–9.5 crore/MW, solar ₹3.5–4.5 crore/MW, onshore wind ₹6–7.5 crore/MW, hydro ₹8–14 crore/MW; transmission per ckt-km or per MVA. US/EU: CCGT roughly $800–1,200/kW, utility-scale solar $900–1,300/kWac, onshore wind $1,300–1,700/kW, battery storage $250–400/kWh. Buying operating capacity materially below replacement cost is the classic entry signal in merchant power; paying well above it requires a demonstrable contract or grid-position advantage.
|
||||
|
||||
**7. Project-level equity IRR / NPV build-up for renewable and contracted IPPs, then aggregated.** Value each asset as discounted contracted cash flow to PPA end plus residual, net of project debt; add corporate overhead as a negative. This is how sponsors and lenders themselves underwrite, and it exposes auctions won at uneconomic tariffs that a consolidated EV/EBITDA hides completely.
|
||||
|
||||
**8. CAFD / NDCF yield for YieldCos and InvITs.** Indian power InvITs are valued on Net Distributable Cash Flow yield (typically 9–12%) and on NAV per unit versus market price, with careful attention to whether distributions are return *of* capital rather than return *on* capital, and to the residual asset life behind the yield. DM YieldCos are valued on CAFD yield plus DPS growth guidance.
|
||||
|
||||
**9. Merchant generation — value the fleet as a strip of spread options, not a stable EBITDA multiple.** Run mid-cycle and stressed spark/dark/clean-spark spreads through the plant's actual heat rate and dispatch profile; add explicit value for capacity-market payments and ancillary services; haircut for hedge roll-off. Merchant EBITDA must never be capitalised at a peak-of-cycle multiple — that is how power cycles are lost.
|
||||
|
||||
**Practical output for a diversified utility:** a sum-of-the-parts — regulated transmission at RAB or P/B, regulated distribution at P/B against earned RoE, contracted renewables at project DCF or EV/MW, merchant thermal at a low mid-cycle EV/EBITDA, and any manufacturing/EPC/mining arm on its own sector basis — less holdco net debt, less contingent liabilities, less a holdco discount (typically 15–25%).
|
||||
|
||||
**Do not use:** consolidated P/E on a mixed-asset utility; EV/Sales (revenue is a pass-through artefact); PEG; FCF yield on reported FCF; a perpetuity-growth terminal value on a contracted asset with a finite PPA; or peak-spread EV/EBITDA on merchant capacity.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares the **regulatory regime, contracting structure and technology** — not merely the label "power". Mixing across these lines produces confidently wrong conclusions, because the multiple is a function of who bears price and volume risk.
|
||||
|
||||
**Splits that must not be mixed:**
|
||||
|
||||
- **Regulated network vs contracted generation vs merchant generation.** Different risk, different cost of capital, different multiple band. This is the primary split and it overrides every other similarity.
|
||||
- **Generation vs transmission vs distribution.** Structurally different margin optics (85–92% vs 4–10% EBITDA margin), different KPI sets, different regulatory instruments. Never place a discom and a transco on the same margin chart.
|
||||
- **Cost-plus regulated vs competitively-bid (TBCB/auction) assets, even inside the same company.** A cost-plus transmission line earns a formula return with true-ups; a TBCB line earns whatever the winning bid implied and carries the cost over-run risk itself.
|
||||
- **Fuel type and fuel logistics.** Pithead coal, imported coal, domestic-linkage coal, gas/CCGT, hydro, nuclear, solar, wind, and storage have different variable costs, dispatch positions, capex per MW and terminal-value risk. A pithead and an imported-coal plant are not comparables.
|
||||
- **Counterparty quality.** A genco selling to financially sound discoms or to central agencies is not comparable to one selling into states with a wide ACS–ARR gap and a renegotiation history, even at identical tariffs.
|
||||
- **State-owned/PSU vs private.** Different cost of debt, different capital allocation incentives, government dividend and disinvestment overhangs, and different willingness to bid aggressively.
|
||||
- **Corporate utility vs InvIT/YieldCo.** Yield vehicles have no retained growth, different tax treatment, an external sponsor/manager and a distribution-yield valuation basis. Do not put them in a P/E or P/B scatter with operating companies.
|
||||
- **Consolidated vs standalone.** For groups with EPC, manufacturing, mining or trading arms, compare standalone regulated entities to each other and handle the rest in the SOTP.
|
||||
|
||||
**Also align:** regulatory jurisdiction and control-period stage (a company one year into a new control period faces a different lag from one at the end); accounting regime (Ind-AS 114 regulatory deferral accounts vs US GAAP ASC 980 regulatory assets vs IFRS without a regulatory-account standard — these are not comparable line items); fiscal year end (India April–March, most DM calendar); asset vintage (a fully-depreciated fleet flatters ROCE and depresses future rate base); and growth stage (a company mid-build will show weak ROCE and negative FCF for structural, not quality, reasons).
|
||||
|
||||
Aim for 5–8 peers. State the basis explicitly, and benchmark every operational metric **twice** — against peers, and against the regulator's normative level, which is the standard the company is actually paid against.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Rising regulatory asset / Ind AS 114 deferral balance alongside rising reported PAT.** Costs are being recognised in the P&L against a tariff recovery the regulator has not yet approved. The sector's single most common earnings-quality trap; multiple Indian discoms have carried regulatory assets exceeding a full year of revenue. Ask: is there a dated, approved amortisation schedule, and has the regulator ever disallowed part of it?
|
||||
- **Aggressive interest and overhead capitalisation.** A jump in the capitalisation rate, capitalised IDC growing faster than CWIP, employee cost and O&M capitalised into projects, or (India-specific) use of the Ind AS 21 D13AA exemption to capitalise forex losses on long-term borrowings into fixed assets instead of the P&L. Each flatters EPS and inflates the asset base simultaneously.
|
||||
- **Aged, static CWIP.** Projects sitting 4+ years while IDC accrues, with no commissioning date. Stranded capital dressed up as growth; it ends in impairment or in a regulator refusing to admit the cost over-run into rate base.
|
||||
- **Extension of asset useful life or a change in depreciation policy** — particularly stretching coal plant life to 30–40 years in a decarbonising market, or departing from the CERC depreciation schedule. Boosts EPS immediately and disguises stranded-asset risk.
|
||||
- **Discom receivables managed by financing rather than collection.** Heavy use of late-payment-surcharge instalment schemes, receivable factoring or securitisation, bill discounting, or trade-receivable sales that move overdues off balance sheet and into "improved" operating cash flow. Check gross receivables and the >90-day ageing bucket, not just DSO.
|
||||
- **Disputed or provisional tariff income booked as revenue.** Compensatory-tariff claims, change-in-law claims, carrying-cost claims and arbitration awards recognised while under appeal. Indian appellate history (APTEL and the Supreme Court) is full of reversals of exactly these.
|
||||
- **PPA cliff and renegotiation risk.** A large share of capacity with PPAs expiring within 5 years and no re-contracting visibility; or exposure to states with a record of attempting retrospective tariff renegotiation. Also watch capacity awarded by central or state agencies with no downstream power sale agreement signed — it may never generate revenue.
|
||||
- **Merchant exposure disguised as contracted.** Rolling one-year "short-term PPAs" presented as long-term contracting, a hedge book with a near-term maturity wall, or PPA counterparties that are trading intermediaries rather than end discoms. Read the hedge ratio *by year*, not the headline contracted percentage.
|
||||
- **Related-party fuel, EPC or O&M contracts.** Fuel imported through a group trading arm, EPC awarded to a promoter entity, O&M priced above the regulator's norm. Benchmark fuel cost per unit and capex per MW against listed peers — a persistent unexplained premium is the tell, and over-invoicing allegations against Indian coal importers are the cautionary case.
|
||||
- **Persistent under-recovery of fixed cost.** Availability below the normative level (below 85% NAF in India), frequent forced outages, or heavy partial-load operation. This permanently erodes the allowed return and is often buried in "other expenses" or a prior-period line.
|
||||
- **Asset drop-downs into a sponsor-controlled InvIT or YieldCo at valuations generating large book gains.** The gain is recycled related-party value, not operating performance, and it can leave the listed sponsor holding the residual, harder-to-monetise assets.
|
||||
- **Leverage that is not what it appears.** Hybrid or perpetual instruments counted as equity; non-recourse SPV debt carrying an undisclosed parent guarantee or sponsor support undertaking; large contingent liabilities relative to net worth. Reconstruct leverage on a fully-recourse basis before applying any coverage test.
|
||||
- **Growth funded by repeated equity dilution, or by winning auctions at uneconomic tariffs.** Aggressive low bids in solar/wind or transmission auctions grow reported MW and rate base while destroying equity value. Test each win against realistic CUF, cost of debt and equipment cost.
|
||||
- **Under-provisioned long-tail obligations.** Ash pond and mine reclamation, nuclear decommissioning funds, pension deficits — and the discount rate used on each. A 50 bps discount-rate change can move the reported liability materially and is a common quiet lever.
|
||||
- **EBITDA quality contamination.** Late-payment surcharge income, treasury income on surplus cash, one-off insurance recoveries, government grant amortisation and consumer-contribution amortisation sitting inside "operating" EBITDA. Rebuild EBITDA from units sold × unit economics and compare.
|
||||
- **Promoter share pledging and holdco leverage (India), plus a widening gap between consolidated and standalone cash flow.** Dividends may not be reaching the listed entity from the SPVs where the cash actually sits — project-finance covenants create dividend traps, and consolidated EBITDA can be structurally unavailable to the parent.
|
||||
- **Regulatory relationship deterioration.** Delayed or unfiled ARR/true-up petitions, repeated disallowances, tariff orders issued years late, a state commission operating without full quorum, or a state failing to release budgeted subsidy on time. The regulator is the counterparty; its behaviour is a fundamental, not a footnote.
|
||||
- **Resource shortfall hidden behind "deemed generation" claims (hydro and renewables).** Poor hydrology, low wind years, soiling and degradation above the modelled 0.5–0.7% p.a. for solar, or grid curtailment despite must-run status. Compare actual generation against P50/P90 estimates over 3–5 years, never one good year.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**There are two different cycles, and which one applies depends on the asset.** Regulated networks run on the **regulatory cycle** — the control period. Returns are reset every 3–5 years (CERC control periods in India, RIIO price controls in the UK, rate cases in the US), and the reset is the single largest scheduled valuation event a network faces. Early in a period, outperformance against the totex/opex allowance is retained; late in a period, the regulator has seen the outperformance and claws it into the next allowance. Always know where in the control period a company sits, and what the draft determination looks like.
|
||||
|
||||
**Merchant generation runs on the classic capacity cycle**, and it is brutal in both directions: high spreads attract capacity additions, additions crush spreads for years, low returns stop investment, reserve margins tighten, spreads spike again. The reliable rule is that merchant EBITDA at the top of the cycle should never be capitalised at a normal multiple, and merchant assets bought below replacement cost at the bottom are where the sector's largest returns have historically been made. Reserve margin and the forward capacity-addition pipeline are the leading indicators.
|
||||
|
||||
**Rate cycle matters twice over.** Utilities are long-duration bond proxies, so the equity de-rates when the sovereign yield rises — the dividend-yield-to-bond spread is the practical gauge. Separately, rising rates raise the cost of the debt that funds rate-base growth, and there is a lag before the regulator resets the allowed return to compensate; that lag is a real earnings hit for a company mid-build. Check the fixed/floating debt mix and the maturity wall.
|
||||
|
||||
**The secular structure is changing faster than the accounting.** Score these explicitly:
|
||||
|
||||
- **Decarbonisation and stranded assets.** Coal fleets carrying decades of remaining book life in markets targeting steep emissions cuts hold unrecognised impairment. Terminal value, not near-term EPS, is where this shows up.
|
||||
- **Renewable cost deflation and auction competition** have compressed IPP returns; a portfolio built at old tariffs is a different asset from a pipeline being bid today.
|
||||
- **Intermittency, storage and firming.** As renewable penetration rises, the value shifts from energy to **firm, dispatchable and flexible** capacity — storage, hydro, gas peakers, and ancillary services. Capacity markets, firm-and-dispatchable (FDRE) tenders and round-the-clock contracts are the commercial response. A pure-solar IPP faces curtailment and price-cannibalisation risk that its historical CUF does not capture.
|
||||
- **Demand growth returning after two decades of stagnation in DM**, driven by data centres, electrification of transport and heat, and industrial electrification. This is a genuine change to the rate-base growth algorithm and the first real volume story utilities have had in a generation — but check whether the load is *contracted* and who pays for the network reinforcement.
|
||||
- **Grid constraint as the binding scarcity.** Transmission and interconnection queues, not generation capex, are increasingly the bottleneck — which is structurally favourable for transmission RAB growth.
|
||||
- **Distributed generation, rooftop solar and open access** erode the discom's most profitable industrial and commercial customers, worsening cross-subsidy economics and the ACS–ARR gap. In India, open access and captive generation removing high-tariff C&I load is a direct threat to distribution licensee earnings.
|
||||
|
||||
**Regulation is the business model, not a constraint on it.** In India: the Electricity Act 2003 framework, CERC and state SERC tariff regulations, the current control period's norms, RDSS conditionality and distribution privatisation/franchising, the late-payment-surcharge rules that forced discom payment discipline, RPO and carbon-credit obligations, and coal linkage and pricing policy. In the US: state PUC rate cases, FERC for transmission and wholesale markets, allowed-ROE trends, and formula-rate mechanisms. In the UK/EU: RIIO price controls, RAB indexation to inflation, and the ETS. A change in any of these repriced the sector before it appeared in any financial statement.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India | US / UK / EU |
|
||||
|---|---|---|
|
||||
| Regulator | CERC (central generation, interstate transmission, interstate trading); state SERCs (distribution, intra-state); APTEL as appellate body, then Supreme Court. Ministry of Power and state governments set policy and subsidy | US: state PUCs for retail rates, FERC for transmission and wholesale markets. UK: Ofgem (RIIO). EU: national regulators plus ACER. Independence and predictability generally higher |
|
||||
| Return mechanism | Cost-plus with normative parameters: 15.5% post-tax RoE on a 30:70 notional equity:debt structure, normative O&M, availability-linked fixed-cost recovery, incentives for beating heat rate/availability norms. Increasingly displaced by competitive bidding (TBCB for transmission, reverse auctions for renewables) | US: rate cases setting allowed ROE (~9–10.5%) and equity ratio, with formula rates and trackers. UK/EU: RAB × allowed WACC with totex incentive sharing and RAB inflation indexation |
|
||||
| Reporting | Ind-AS; Ind AS 114 permits regulatory deferral account balances presented as separate line items; ₹ crore/lakh; FY April–March; quarterly results, investor presentation and **analyst concall** — treat concall Q&A as a primary source on PPA status, receivables and capitalisation | 10-K/10-Q on EDGAR under US GAAP with ASC 980 regulatory assets/liabilities; UK/EU annual report under IFRS, which has no equivalent regulatory-asset standard, so RAB reconciliations sit in the regulatory accounts, not the IFRS statements |
|
||||
| Counterparty risk | The dominant risk. State discoms are the buyers; ACS–ARR gaps, delayed subsidy release and long receivables are structural. Watch state-level payment data and any securitisation/bailout scheme | Largely absent for regulated utilities; DM merchant generators face market rather than counterparty risk. Credit risk sits in offtaker rating for contracted PPAs |
|
||||
| Ownership and governance | Central PSUs, state utilities and private groups coexist; promoter holding, promoter share pledging, and government disinvestment overhangs matter. CARO reporting, related-party disclosures and auditor observations are the standard India-specific governance reads | Widely held; regulated utilities are typically single-jurisdiction operating companies under a holdco. Governance risk is more about capital allocation and M&A than promoter conduct |
|
||||
| Yield vehicles | InvITs (power transmission and renewables) with SEBI-mandated NDCF distribution, external manager/sponsor structure, and unit-level yield valuation | YieldCos and listed infrastructure funds; MLP-like structures in some markets; distribution based on CAFD |
|
||||
| Fuel and inputs | Coal linkage/FSA vs e-auction vs imported coal drives the entire variable-cost dispersion; gas availability limited; hydro subject to monsoon and state royalty/free-power obligations | Gas-dominated marginal pricing in the US, with carbon cost embedded in EU/UK dispatch; coal largely retiring in DM |
|
||||
| Carbon | RPO obligations, carbon credit trading scheme in development, no broad economy-wide carbon price yet | EU ETS and UK ETS are a direct, quantified cost in the dark/clean-spark spread; US state and regional programmes plus tax-credit regimes (ITC/PTC and transferability) that materially change renewable project economics |
|
||||
| Typical leverage convention | Project SPVs at 70:30 or 75:25 debt:equity by regulatory design; holdco recourse debt often separate and less visible | Networks geared 55–65% of RAB; rating agencies drive the target, and the rating is managed as a policy variable |
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Classify every material business into regulated network / contracted generation / merchant generation / trading / EPC-manufacturing before computing anything.
|
||||
- [ ] Refuse to report consolidated OPM, ROCE, D/E and FCF for a mixed-asset utility; state why in the report.
|
||||
- [ ] Recompute margin on **net revenue** (ex fuel and purchased power) and as **EBITDA per unit sold**.
|
||||
- [ ] Identify the regulatory regime, the current control period, its start and end, and what the next reset is expected to do.
|
||||
- [ ] Establish rate base / RAB and its multi-year growth; check how much capex was actually **admitted** into it.
|
||||
- [ ] Compute allowed ROE vs earned ROE on regulated equity, and explain every basis point of the gap.
|
||||
- [ ] Pull the operational KPIs against the **norm**: availability/NAF, PLF, CUF, heat rate, auxiliary consumption, AT&C losses, transmission availability, SAIDI/SAIFI.
|
||||
- [ ] For distribution: AT&C losses, collection efficiency, ACS–ARR gap, and whether subsidy is budgeted and released.
|
||||
- [ ] Map contracted vs merchant mix by MW and by EBITDA, weighted-average PPA life, counterparty by name, and hedge ratio year by year.
|
||||
- [ ] Replace D/E with FFO/Debt, FFO interest cover, Net Debt/EBITDA and Debt/RAB; split recourse from non-recourse and re-add hybrids treated as equity.
|
||||
- [ ] Check receivable days by counterparty and the >90-day ageing bucket; test whether any DSO improvement came from factoring, securitisation or a bailout scheme.
|
||||
- [ ] Read the regulatory deferral account / regulatory asset note in full: balance, trend vs PAT, approved amortisation schedule, disallowance history.
|
||||
- [ ] Age the CWIP, check the capitalisation rate and capitalised IDC, and flag anything sitting 4+ years.
|
||||
- [ ] Compute capex/depreciation; negative FCF with capex/depreciation of 1.3–2.0x is a growth signal, not distress — say so explicitly.
|
||||
- [ ] Rebuild EBITDA excluding late-payment surcharge, other income, grant and consumer-contribution amortisation, and regulatory-account movements.
|
||||
- [ ] Check depreciation policy and asset-life assumptions against PPA tenor and decarbonisation timelines; quantify stranded-asset exposure.
|
||||
- [ ] Verify the pipeline stage by stage — awarded / PPA+PSA signed / financially closed / under construction — and back out the implied equity IRR on recent wins.
|
||||
- [ ] For merchant capacity, run mid-cycle and stressed spreads through the actual heat rate; never capitalise peak-cycle EBITDA.
|
||||
- [ ] Value sum-of-the-parts: RAB or P/B for regulated, project DCF or EV/MW for contracted, low mid-cycle EV/EBITDA for merchant; deduct holdco debt, contingent liabilities and a holdco discount.
|
||||
- [ ] Cross-check with EV/MW against replacement cost, and dividend yield against the 10-year sovereign.
|
||||
- [ ] Test distribution coverage on FFO less maintenance capex; for InvITs/YieldCos, decompose NDCF and identify return of capital.
|
||||
- [ ] India: read the CARO report, related-party note (fuel, EPC, O&M), promoter pledge disclosure, contingent liabilities, and the latest tariff order and true-up petition status.
|
||||
- [ ] Check long-tail provisions — ash pond, mine reclamation, decommissioning, pension — and the discount rates applied.
|
||||
- [ ] Compare actual renewable/hydro generation to P50/P90 over 3–5 years; quantify curtailment and whether deemed generation was actually paid.
|
||||
- [ ] Peer set: same regulatory regime, sub-sector, contracting structure, technology and consolidation basis — stated explicitly, 5–8 names.
|
||||
|
|
@ -0,0 +1,182 @@
|
|||
# Waste management, environmental and water treatment services — sector playbook
|
||||
|
||||
Use this when: the company collects, transfers, processes or disposes of solid, hazardous, medical or industrial waste; owns or operates landfills, transfer stations, incinerators/waste-to-energy plants or material recovery facilities; recycles packaging, plastics, e-waste or metals under producer-responsibility mandates; or operates water and wastewater treatment assets under municipal contracts or concessions. Also route here for environmental remediation and industrial-cleaning services.
|
||||
|
||||
This is a route-density and permitted-asset business, not a manufacturing business. Two things determine almost all of the economics: how many stops a truck can service in a day within a given geography, and whether the tonnes that truck collects go into a hole in the ground the company owns. Everything else — price escalators, recycling commodity prices, fleet efficiency — is second order. The moat is a permit that a competitor cannot obtain at any price, and the offsetting cost is a liability that outlives the asset by thirty years and sits mostly outside reported debt.
|
||||
|
||||
The single most common analytical failure here is aggregation. A national EBITDA margin and one consolidated EV/EBITDA multiple describe a company that does not exist: these businesses are won or lost market by market, and a group average blends a dense metro franchise earning 40% margins with sub-scale rural routes losing money. Never accept a company-level margin without asking which markets produce it.
|
||||
|
||||
Two adjacent business models must be routed elsewhere. **Pollution-control and water-treatment equipment makers** (scrubbers, ESPs, membranes, pumps, filtration skids, ZLD systems) are industrial capital-goods businesses — order book, execution, working capital, customer capex cycle — and belong in `references/sectors/infra-capitalgoods.md`, not here; the fact that the end use is environmental changes nothing about their economics. **Regulated water utilities** with a rate base and an allowed return belong in `references/sectors/utilities-power.md`. **Waste-to-energy plants selling power under a PPA** are IPPs first and waste companies second — value the power contract with `utilities-power.md` and use this file only for the tipping-fee side.
|
||||
|
||||
## Contents
|
||||
|
||||
- [Why the generic ratio set fails here](#why-the-generic-ratio-set-fails-here)
|
||||
- [The metrics that actually matter](#the-metrics-that-actually-matter)
|
||||
- [How to value companies in this sector](#how-to-value-companies-in-this-sector)
|
||||
- [Peer set construction](#peer-set-construction)
|
||||
- [Sector-specific red flags](#sector-specific-red-flags)
|
||||
- [Cycle and structural context](#cycle-and-structural-context)
|
||||
- [India vs global notes](#india-vs-global-notes)
|
||||
- [Checklist](#checklist)
|
||||
|
||||
## Why the generic ratio set fails here
|
||||
|
||||
Most generic ratios are computable here — that is the trap. They produce numbers that look sensible and mean the wrong thing.
|
||||
|
||||
**Consolidated OPM / EBITDA margin — an average of structurally different businesses, and of structurally different geographies.** Collection, transfer, disposal and recycling have margins that differ by 20–40 percentage points by design. A company that shifts mix toward disposal shows "margin expansion" with no operational improvement; a company that wins a large low-margin municipal collection contract shows "margin compression" while adding value. Worse, the same line of business earns completely different margins in different markets: a landfill with 60% of the local disposal market and a two-hour haul radius with no competing permitted site is a different asset from an identical landfill with three competitors. Demand the line-of-business split and, where disclosed, the market-level or region-level commentary. If neither exists, say the consolidated margin is uninterpretable rather than reporting it.
|
||||
|
||||
**EV/EBITDA as normally computed — systematically understates the price paid.** Closure, post-closure and environmental remediation obligations are contractually mandated, non-discretionary, cash-settled and long-dated. They are debt. They sit in provisions, not borrowings, so standard screeners exclude them from enterprise value. Add them. On a landfill-heavy operator this adjustment can move EV by a mid-to-high single-digit percentage, and it moves it most for exactly the companies with the oldest, most depleted asset bases — the ones a naive screen flags as cheap.
|
||||
|
||||
**D/E and net debt/EBITDA — mis-scaled in both directions.** High leverage is normal and appropriate: contracted, recession-resistant cash flows support it. But reported net debt omits AROs, remediation reserves, and any unfunded portion of financial assurance obligations. A company at 2.8x reported net debt/EBITDA can be at 3.4x on an honest measure. Compute both and use the adjusted number.
|
||||
|
||||
**FCF and FCF yield — routinely overstated, and the overstatement is deliberate in some disclosures.** Landfill cell development capex is not growth capex. It is the cost of producing the airspace you are about to sell — economically it is cost of goods sold, paid years in advance and capitalised. A company that classifies development capex as "growth" and reports FCF after maintenance capex only is reporting a number that can never be realised, because the spend recurs for as long as the landfill operates. Reconstruct FCF as operating cash flow minus fleet/container/equipment replacement capex minus landfill development capex; only genuinely new sites, new markets and new processing plants are growth.
|
||||
|
||||
**EBIT, D&A and therefore P/E — estimate-driven.** Landfill airspace is amortised on units-of-consumption: cost per tonne = capitalised plus estimated future development cost divided by estimated total remaining airspace. Raising the airspace estimate lowers the amortisation rate and lifts EBIT with no change in cash or operations. Add roll-up amortisation of acquired customer relationships, periodic remediation charges, ARO revisions and impairments, and reported EPS becomes one of the least comparable numbers in the sector. EBITDA is more comparable than EBIT here — but only because it hides the estimate, not because the estimate does not matter.
|
||||
|
||||
**ROCE / ROIC — broken by vintage and by goodwill.** A landfill permitted in 1985 and long since depreciated shows a spectacular return on a book value that bears no relation to what the permit is worth. The identical asset acquired last year, carried at fair value plus goodwill, shows a mediocre one. In a serial acquirer, group ROCE mostly measures acquisition vintage. Use ROIC only pre-goodwill and only against the company's own history, or replace it with cash return on the replacement value of the asset base.
|
||||
|
||||
**P/B — meaningless.** The core asset is a permit. Permits obtained organically carry essentially no book value; permits acquired carry an arbitrary purchase-accounting value. Book value is the sum of a depreciated fleet, historical-cost land and acquisition goodwill.
|
||||
|
||||
**Current ratio and working capital — inverted.** Subscription collection is billed in advance, so negative working capital is the healthy state. A rising current ratio usually means receivables are stretching — in India, that it is not being paid by a municipal body.
|
||||
|
||||
**Headline revenue growth — uninformative until decomposed.** Revenue growth is the sum of core price, fuel and environmental surcharges, volume, recycled-commodity price, recycled-commodity volume, acquisitions, divestitures and FX. These have entirely different quality and persistence. Eight percent growth from core price is a franchise; eight percent from a cardboard price spike reverses.
|
||||
|
||||
**Order book / order-to-revenue ratios — do not apply** to services operators, however common they are in the sector's own presentations for the EPC and equipment arms. If order book is the main disclosure, you are looking at a capital-goods business and should re-route.
|
||||
|
||||
## The metrics that actually matter
|
||||
|
||||
Ranges are **indicative only**. They vary by market density, sub-sector, regulatory regime, commodity cycle and period, and any of them can be wrong for a specific company in a specific year. Comparison against a tight peer set and against the company's own 5–10 year history overrides every absolute band below.
|
||||
|
||||
| Metric | Definition / how to compute | Indicative healthy range | Why it matters |
|
||||
|---|---|---|---|
|
||||
| **Route density** | Serviced stops (or lifts) per route-day; stops per hour on route; revenue per route-day; miles driven per stop; population or commercial-establishment density in the served postcodes. Where not disclosed, proxy with revenue per truck and revenue per employee by region. | Residential 700–1,200 stops per route-day in dense suburban geography; commercial 15–25 lifts per hour; miles per stop falling year over year. | The core economic driver of the entire sector. Truck, driver, fuel and depot cost are fixed for the day; the incremental stop on an existing route drops through at close to 100% margin. This is why a 30% local share earns nothing and a 55% local share earns 40% margins on the same price. It is also why national margin is meaningless: density is a local variable. Two operators with identical prices and identical fleets earn completely different returns if one has twice the stops per mile. |
|
||||
| **Internalisation rate** | Tonnes collected that are disposed into the company's own landfills or routed through its own transfer stations, as a % of total tonnes collected. Report separately by region. | Integrated operators 60–80%; above 80% is very strong; below 40% means the largest single cost is set by a competitor. | Disposal is where the margin lives. If a third party owns the only permitted landfill in the haul radius, it captures the spread and can raise your gate rate at will — your collection business is then a low-return logistics operation with a supplier that is also your competitor. Vertical integration, not scale, is what converts route density into profit. Falling internalisation after an acquisition means the acquired volume was bought without the disposal to serve it. |
|
||||
| **Remaining permitted airspace and remaining life** | Remaining permitted airspace (cubic yards or tonnes) plus, separately, "probable expansion" airspace not yet permitted. Divide by annual disposal volume for years of remaining life, by site and weighted for the group. | 20–40 years of weighted average life is strong; under 10 years without a filed and progressing expansion application is a value cliff. Probable-expansion airspace above ~20–25% of reported total deserves scrutiny. | Airspace is depleting inventory that cannot be restocked without a permit that may take 5–10 years and may simply be refused. A landfill with 8 years left is a wasting asset whose cash flows terminate and then invert into closure spending; a perpetuity growth assumption on it is nonsense. Track remaining life every year: if it falls faster than one year per year, the company is consuming its franchise. |
|
||||
| **Permitting position and barrier to entry** | Number of permitted sites in each served market and who owns them; status of pending expansion and new-site applications; time since the last greenfield MSW landfill was permitted in that jurisdiction; local opposition, litigation and appeals. | Qualitative. The strongest position is a market where no new permit has been granted in 20+ years and the company owns the only site inside the economic haul radius. | This is the actual moat, and it is political rather than economic. Capital cannot replicate it — a competitor with unlimited money still cannot site a landfill next to yours. It is also the moat's fragility: the same political process can deny an expansion, impose host-community fees, or cap daily tonnage. Read the permit and litigation disclosures, not just the financials. |
|
||||
| **Line-of-business mix and EBITDA margin by line** | Revenue and EBITDA split across collection (residential / commercial / industrial-roll-off), transfer, disposal, recycling/MRF, and other (special waste, remediation, energy). Compute margin on each and track mix shift. | Indicative: collection 25–32%; transfer 25–35%; landfill/disposal 35–50%+; recycling anywhere from negative to 25% depending on commodity and contract form; residential collection typically the weakest line. | The only way to know whether group margin moved because operations improved or because mix shifted. It also tells you where the earnings are exposed: a company with 25% of EBITDA from recycling has a commodity book inside a utility-like wrapper. Mix explains most cross-company margin differences before any judgement about management quality is warranted. |
|
||||
| **Core price vs volume, and price above cost inflation** | Core price = same-store yield excluding fuel and environmental surcharges, excluding recycled-commodity price, excluding acquisitions. Report alongside volume change and against the company's own cash cost inflation (labour, fuel, third-party disposal, maintenance). | Core price 3–6% in a normal environment, higher in inflationary periods. The test that matters: core price minus cash cost inflation positive and stable. Volume flat to modestly negative is acceptable if price is holding. | This sector compounds on price, not volume. Underlying tonnage grows roughly with population and GDP at low amplitude, so the entire value creation is the ability to raise price faster than cost every year without losing customers — which is only possible where the permit and the density make switching expensive. A company reporting good revenue with decelerating core price is renting growth from surcharges, commodity or M&A. |
|
||||
| **Contract structure: franchise / exclusive / contracted vs open market** | % of revenue under exclusive municipal franchise, non-exclusive municipal contract, long-term commercial contract, or open-market (subscription/spot). Weighted average remaining contract life; escalator basis (CPI, a trash-and-water-specific CPI sub-index, fixed %, cost pass-through); renewal and retention rates; re-bid calendar. | Long-dated contracted/franchise revenue 40–70% of the book is a strong, defensible position. Weighted average remaining life 5+ years. Municipal contract retention above 90% at re-bid. | Determines both the durability and the ceiling of pricing. Exclusive franchises give guaranteed density — the single best margin structure in the sector — but cap price to a formula and expose the whole block to a single re-bid date. Open-market commercial gives pricing freedom and higher margins but churns. Check what index the escalator uses: a contract escalating on headline CPI while the cost base is 55% driver wages compresses in a tight labour market, and the mismatch is invisible until it has run for three years. |
|
||||
| **Customer churn and retention (open-market commercial)** | Net churn = lost revenue from cancellations and price-downs, less recovered, as % of opening recurring revenue. Split defection to competitors vs business closures. | Net churn below 8–10% a year on a commercial book. Rising churn concurrent with above-market price increases is the classic warning that price has run ahead of the moat. | Price and churn are a single decision, not two metrics. Any company can post strong core price for two years by pushing rates; the question is what happens to the route density that made the margin possible. Churn is the check on whether pricing power is real or borrowed. |
|
||||
| **Closure, post-closure and remediation liabilities** | Recorded ARO / provision for closure and post-closure; the **undiscounted** total; the discount rate and inflation rate used; the accretion charge; remediation reserves separately; Superfund/CERCLA PRP site count and allocation share; expressed also per remaining tonne of airspace. Sensitivity to a 100 bp change in discount rate. | Judge the disclosure quality first. Recorded liability materially below the undiscounted figure is arithmetically normal; a rising discount rate assumption or a shrinking liability against a growing site base is not. | This is the long-dated debt that funds the asset. It is discretionary in accounting but not in cash: closure spending is mandated, post-closure monitoring typically runs 30 years or more after a site stops accepting waste, and remediation is joint and several under CERCLA-type regimes. Management sets the discount rate, the inflation rate, the assumed closure date and the assumed post-closure period — four levers, all of which move the liability without moving reality. Always add the liability to EV and check the assumption trail year over year. |
|
||||
| **Capex intensity and its split** | Total capex / revenue; then split into (a) maintenance — fleet replacement, containers, plant overhaul, (b) landfill cell development, cost per cubic yard of airspace developed, (c) growth — new sites, new markets, new processing capacity. Also fleet age and replacement cadence. | Total capex 9–13% of revenue for an integrated operator. Maintenance alone typically 5–8%. Development capex should track disposal volume; a sharp drop is deferral, not efficiency. | Determines whether the reported cash flow is real. Development capex is the cost of the tonnes you will sell and must be deducted before any FCF claim. Maintenance capex is deferrable for two or three years, which is exactly how a company facing a bad quarter manufactures cash flow — and the deferral shows up later as a rising average fleet age and a maintenance-cost spike. |
|
||||
| **Free cash flow conversion (honest basis)** | (Operating cash flow − maintenance capex − landfill development capex) / EBITDA, and the same over revenue. Reconcile to the company's own FCF definition and state the difference. | Integrated solid waste: FCF/EBITDA 40–55%, FCF/revenue 10–15%. Concession-heavy and build-phase businesses will be negative and that is structural, not a defect. | The sector's real claim to quality is cash conversion, and it is the number most often overstated. If the company's definition and yours differ by more than a couple of points of revenue, find out which capex line is being reclassified and report both. |
|
||||
| **Recycling commodity exposure and contract form** | Tonnes processed; revenue per tonne by commodity (OCC, mixed paper, aluminium, PET, HDPE); % of inbound tonnes on fee-for-service / processing-fee contracts vs revenue-share or floor-price contracts; contamination and residual rate; the disclosed EBITDA sensitivity to a fixed move in the commodity basket. | Fee-for-service share above 70–80% of processed tonnes is a materially de-risked model. Residual/contamination rate below 15–20%. | Contract structure decides who owns the commodity cycle. Under a processing-fee model the customer pays a fixed rate per tonne and takes the commodity risk; under a revenue-share model the operator does. The same physical recycling business is a stable service annuity or a leveraged commodity bet depending purely on paperwork. Companies rarely re-paper contracts toward fee-for-service while prices are high — the incentive runs the wrong way, which is why the exposure surfaces at the bottom of the cycle. |
|
||||
| **Landfill gas, renewable energy and environmental credits** | Installed gas-to-energy or RNG capacity; volumes sold; revenue and EBITDA from RINs, LCFS credits, RECs, carbon credits or Indian equivalents; % of group EBITDA; the price assumption embedded in guidance. | Treat any line above ~5–8% of EBITDA as a separately valued, policy-dependent stream, not core. | These are genuine cash flows on assets the company already owns, and the incremental margin is very high — but the price is set by regulation, not by a market with supply and demand fundamentals you can forecast. Credit regimes have been repriced by administrative decisions repeatedly. Value at a lower multiple than collection and disposal, and never let a credit-price spike be presented as operating improvement. |
|
||||
| **Special waste and event-driven volumes** | Share of landfill tonnes and revenue from contaminated soil, remediation projects, industrial clean-outs, disaster debris, one-off construction and demolition. | Ideally identified and quantified. Sustained above ~10–15% of disposal volume needs a separate persistence judgement. | The highest-margin tonnes and the least repeatable. A hurricane, a large remediation project or a single plant demolition can add several points to disposal volume for four quarters and then vanish. Companies book it in the ordinary run rate; the next year's "volume decline" is then blamed on the economy. Strip it before extrapolating. |
|
||||
| **Safety and regulatory compliance record** | TRIR / lost-time injury frequency rate, DART rate, preventable vehicle accidents per million miles; notices of violation, consent decrees, penalties, permit suspensions; odour, leachate and groundwater complaints; in India, CPCB/SPCB directions, closure notices and NGT orders and environmental compensation levied. | TRIR trending down and below the sector average; zero material consent decrees; no repeat violations at the same site. | This is a licence-to-operate metric, not an ESG decoration. A serious incident or a pattern of violations can cost a permit renewal or an expansion approval, which is the whole asset. It is also the cleanest available proxy for operational discipline in a business with thousands of vehicle movements a day — safety records and maintenance discipline degrade together, and both degrade before the financials do. Driver turnover belongs alongside: above ~25–30% a year it drives accidents, overtime and route inefficiency simultaneously. |
|
||||
| **Water/wastewater operating KPIs (where applicable)** | Contracted treatment capacity (MLD or MGD); plants under O&M and under concession; plant availability/uptime; effluent quality compliance against consent conditions; non-revenue water reduction where contracted; receivable days from municipal counterparties; concession residual life. | Availability above 95–98% and compliance at or near 100% of tested parameters — penalties and annuity deductions are tied to these. Municipal receivable days are the number to watch, not margin. | For contract operators the technical KPIs determine whether the annuity or O&M fee is paid in full, since deductions are formulaic. But the binding risk is counterparty: an operator can hit every technical target and still fail because the urban local body cannot pay. Model collection, not just billing. |
|
||||
|
||||
## How to value companies in this sector
|
||||
|
||||
**Primary — EV/EBITDA with environmental liabilities added to enterprise value.** Use EBITDA rather than earnings because D&A is estimate-driven (airspace amortisation rates, acquired-intangible amortisation) and capital structures differ. But the standard EV is wrong here. Construct:
|
||||
|
||||
> **Adjusted EV = market cap + net debt + closure/post-closure liability + remediation reserves + unfunded financial assurance + pension deficit + minorities − equity-accounted stakes at value**
|
||||
|
||||
Use the recorded liability as the minimum; where the discount rate looks aggressive relative to peers or to the market rate on comparable-duration debt, re-discount the undiscounted disclosure yourself and use that. State which you used. Indicative multiples: high-quality integrated solid waste in developed markets 11–15x adjusted EV/EBITDA; non-integrated collection-only 6–9x; hazardous and specialty waste 8–12x; recycling-led lower and cycle-dependent; Indian concession-based operators 6–10x. Indicative only, and the spread within each band is explained mostly by internalisation rate and contracted-revenue share.
|
||||
|
||||
**Co-anchor — FCF yield on honest maintenance capex.** Because these are cash-compounding businesses with modest growth, FCF yield is often more decision-useful than the multiple. Compute FCF after maintenance *and* landfill development capex, as defined above, and compare to the company's own definition. A gap between the two definitions of more than a couple of points of revenue is itself a finding. Cross-check FCF yield against the ten-year government bond in the same currency; the sector's claim to a premium multiple is a bond-like, inflation-linked cash stream, so that spread is the real question.
|
||||
|
||||
**Asset-based — value per unit of airspace and per tonne of annual capacity.** Permits cannot be reproduced, so private-market transaction evidence in currency per remaining cubic yard (or tonne) of permitted airspace, and per tonne of annual disposal or collection volume, gives a replacement-value floor that is genuinely informative — unusual for a services business. Useful for cross-checking a roll-up's acquisition prices against public trading multiples, and for judging whether an old, nearly depleted asset base is being valued as though it were perpetual.
|
||||
|
||||
**DCF — the correct primary method for a single landfill or a concession, and a useful discipline for the group.** Model a landfill explicitly as a depleting asset: volume over remaining permitted life, gate rate escalating at contracted or historical rates, then the closure spend and 30-plus years of post-closure monitoring as explicit negative cash flows after the site stops accepting waste. Never apply a perpetuity growth rate to a landfill with a finite airspace estimate — that single error is responsible for a large share of the sector's mis-valuations. For concessions, model to the end of the concession term with a terminal value equal to the contractual residual or transfer value, which is frequently zero.
|
||||
|
||||
**Concession and annuity structures — value the contract, not the company.** For Indian MSW, waste-to-energy and hybrid-annuity wastewater projects, build a project-level equity cash-flow model over the concession term and solve for equity IRR against cost of equity, then sum SPVs and deduct holdco debt and costs. The logic is identical to a HAM road; cross-reference `references/sectors/infra-capitalgoods.md`. The critical input is not tariff but collection probability from the municipal counterparty.
|
||||
|
||||
**Sum-of-the-parts — the default for anything mixed.** A group with solid waste services, a hazardous-waste business, an environmental-remediation consultancy, a waste-to-energy IPP and an equipment-manufacturing arm must be valued piece by piece on each piece's own convention. A single blended multiple across those is arithmetic without meaning.
|
||||
|
||||
**Do not use:** unadjusted EV/EBITDA (understates by excluding closure and remediation obligations); P/B (permits carry no meaningful book value; goodwill dominates in roll-ups); standalone P/E (distorted by amortisation policy, ARO revisions, remediation charges and divestiture gains); EV/Sales across companies with different line-of-business mix or different gross-vs-net revenue recognition; DDM; and any single national multiple applied to a company whose market positions are heterogeneous — decompose or state the limitation.
|
||||
|
||||
## Peer set construction
|
||||
|
||||
A valid comparable shares *degree of vertical integration, waste stream, contract structure and regulatory regime*. Label similarity is worthless: "waste management" spans a landfill monopoly and an asset-light broker.
|
||||
|
||||
**Splits that must never be mixed:**
|
||||
|
||||
- **Integrated (owns disposal) vs collection-only vs pure disposal vs brokers.** Integrated operators earn the disposal margin; collection-only companies pay it away; pure landfill/transfer companies have higher margins and shorter effective asset lives; brokers gross up revenue for third-party disposal they never touch and show low single-digit margins on inflated revenue. Their EBITDA margins are not on the same scale and should never appear in one table.
|
||||
- **Municipal solid waste vs hazardous/industrial (RCRA Subtitle C or Indian HOWM Rules) vs medical/biomedical vs E&P and radioactive waste.** Different permitting difficulty, different pricing power, and completely different liability tails. Hazardous waste commands higher margins precisely because the permit and the liability are heavier.
|
||||
- **Waste services vs waste-to-energy IPPs vs equipment manufacturers.** WtE profit is largely a power tariff or PPA (`utilities-power.md`); equipment is order-book capital goods (`infra-capitalgoods.md`). Both are routinely bundled into "environmental services" indices and both destroy a peer set.
|
||||
- **Landfill-led markets vs incineration-led markets.** In much of northern Europe and Japan, landfilling is effectively prohibited or heavily taxed; airspace is irrelevant and the moat is incinerator permits plus district-heating offtake. Comparing a US or Indian landfill operator to a European WtE operator on EV/EBITDA compares two different assets.
|
||||
- **Franchise/contract-heavy vs open-market commercial-heavy.** Different growth ceilings, different pricing mechanics, different re-bid risk profiles.
|
||||
- **Recycling-exposed on revenue-share vs fee-for-service.** One is a commodity business; the other is a service annuity.
|
||||
- **Water: regulated utilities vs contract O&M operators vs EPC builders vs technology/product companies.** Four different playbooks behind one word.
|
||||
- **India-specific: concession/BOT SPV operators vs asset-owning private operators vs EPC contractors to municipal bodies.** Under Ind-AS service concession accounting the first group's reported revenue and margin are an artefact of the accounting model chosen, not of operations — see the India section.
|
||||
|
||||
**Also align:** market density (a metro-focused operator and a rural one are not comparable regardless of size); accounting regime (ARO discount rates, airspace estimation practice and remediation-reserve conventions differ enough between US GAAP, IFRS and Ind-AS to make margins and multiples non-comparable without adjustment); fiscal year; the share of revenue from acquisitions in the last three years; and revenue recognition gross vs net of third-party disposal.
|
||||
|
||||
Aim for 4–8 peers. State the basis in the report, and benchmark every metric twice — against peers and against the company's own 5–10 year record.
|
||||
|
||||
## Sector-specific red flags
|
||||
|
||||
- **Core price decelerating while headline revenue holds up on surcharges, commodity or acquisitions.** The franchise is the price spread; everything else is borrowed. Decompose the revenue bridge every quarter and judge on core price minus cash cost inflation.
|
||||
- **A change in the total airspace estimate that lowers the amortisation rate.** Margin improves, cash does not. Any restatement of estimated total airspace, assumed final elevation or assumed compaction density should be found and quantified before crediting a margin gain.
|
||||
- **Rising share of "probable expansion" airspace in reported remaining life**, or a weighted average remaining life that falls faster than one year per year. The reported life is being propped up by permits not yet granted.
|
||||
- **An expansion permit denied, appealed, or conditioned with a daily-tonnage cap or host-community fee.** This is a direct hit to the asset's cash flows and often to its remaining life; it rarely appears in guidance until the following year.
|
||||
- **ARO assumption drift.** A rising discount rate, a lowered inflation assumption, a pushed-out assumed closure date, or a shortened post-closure period — each shrinks the recorded liability with no change in obligation. Track the four assumptions in a table across five years. A liability that falls while the site base grows needs a written explanation.
|
||||
- **Remediation reserves recorded at the low end of a range, and reserve releases running through income.** Where the accounting permits the low end of a range when no point estimate is better supported, the low end is what gets booked. A company reporting environmental "gains" from reserve releases is recognising a benefit it has not banked.
|
||||
- **Superfund / PRP exposure growing quietly.** New site designations, a rising allocation share, or co-PRPs becoming insolvent — joint and several liability means the solvent party pays. Read the legal proceedings and environmental matters notes in full, every year.
|
||||
- **Roll-up arithmetic.** Revenue growth carried by acquisitions while same-store volume is flat or negative, goodwill and acquired intangibles rising faster than EBITDA, and pre-goodwill ROIC drifting down. Tuck-ins bought at 5–8x by a company trading at 13x create value; the question is whether the pipeline of dense, integrable targets still exists or whether the company has started buying volume it cannot internalise.
|
||||
- **Falling internalisation rate after acquisitions.** Volume bought without the disposal to serve it. The acquired revenue arrives at a fraction of the assumed margin, and the shortfall is usually described as "integration timing".
|
||||
- **FCF flattered by capex reclassification or deferral.** Development capex labelled growth; maintenance capex postponed; a rising average fleet age and rising per-truck maintenance cost are the tells that follow.
|
||||
- **Special waste, disaster-debris or large one-off remediation volumes carried into the run rate.** Quantify and strip before extrapolating.
|
||||
- **Recycling contracts left on revenue-share while commodity prices are high**, or a company describing a commodity-price windfall as an operational turnaround. Ask what the same book earns at trough commodity prices.
|
||||
- **Environmental-credit income (RINs, LCFS, RECs, carbon) growing as a share of EBITDA and valued at the group multiple.** Policy-set prices are not operating income of the same quality.
|
||||
- **Municipal contract losses at re-bid, or a large block of franchise revenue re-bidding in one year.** Check the re-bid calendar. Also check for contracts won at aggressive prices to build density that never arrived — those show up as a market with persistent sub-scale margins.
|
||||
- **Deteriorating safety and compliance metrics.** Rising TRIR, repeat notices of violation at one site, a consent decree, a spike in odour or groundwater complaints, or driver turnover above ~30%. These precede permit trouble and margin trouble in that order.
|
||||
- **PFAS and emerging-contaminant exposure not addressed.** Leachate treatment costs, potential retrospective liability at landfills and remediation sites, and insurance exclusions. A company that has not quantified its position is deferring a known and growing cost.
|
||||
- **India — receivables from urban local bodies stretching, or a tipping-fee revision pending with the authority for more than a year.** Revenue recognised is not revenue collected. Also: SPV-level debt invisible in standalone accounts, promoter-affiliated EPC contracts inside a concession, and concession disputes or termination notices disclosed only in the notes.
|
||||
- **Financial assurance backed by parent guarantees or self-insurance rather than bonds, letters of credit or funded trusts.** If closure and post-closure obligations are self-assured, the obligation and the credit risk sit in the same place.
|
||||
|
||||
## Cycle and structural context
|
||||
|
||||
**The volume cycle is real but shallow; the price cycle is what matters.** Municipal solid waste tonnage falls only modestly in a recession — households and offices keep generating waste — which is the basis of the sector's defensive reputation. But the cyclical components are much sharper: construction and demolition debris, industrial and manufacturing waste, roll-off pulls per container, and special waste all track construction and industrial activity closely and can fall by double digits. A company with heavy C&D and industrial exposure is not the defensive business the sector average implies. Judge cyclicality by mix, not by label.
|
||||
|
||||
**Cost cycles pass through with a lag, and the lag is the earnings volatility.** Diesel surcharges reset monthly or quarterly against an index, so a fuel spike compresses margin for a quarter or two and then normalises — do not extrapolate either direction. Labour is the harder problem: driver and technician shortages are structural in developed markets, wage inflation has repeatedly outrun the CPI indices embedded in municipal contracts, and turnover carries a compounding cost in accidents, overtime and lost route efficiency.
|
||||
|
||||
**The recycling commodity cycle repriced the industry once and can again.** The 2018 Chinese import restrictions collapsed mixed-paper and mixed-plastic values and pushed the industry from revenue-share toward fee-for-service processing contracts — a structural improvement in earnings quality that is only as durable as the discipline to keep repapering contracts through the next price upswing. Track the fee-for-service share; it drifts.
|
||||
|
||||
**Regulation is the growth engine and the cost driver simultaneously.** Landfill diversion targets, methane control rules on landfill gas, extended producer responsibility shifting packaging and e-waste costs onto producers, landfill taxes, and carbon pricing all create revenue pools for processors while raising compliance costs for disposal. PFAS is the live structural risk in developed markets: leachate treatment obligations, possible retrospective liability, and insurance market withdrawal. Score what is in flight in the specific jurisdiction before extrapolating margins.
|
||||
|
||||
**Consolidation is the sector's default corporate strategy, because permits are the moat and permits are acquired rather than built.** The arithmetic of buying tuck-ins at mid-single-digit multiples into a business trading at low-double-digits is genuinely value-creating while dense, adjacent targets remain. It exhausts. The late stage looks like acquisitions further from existing routes, lower internalisation, rising goodwill and flat organic margins.
|
||||
|
||||
**India is at a different point on the same curve.** The business is transitioning from informal, largely uncontracted collection toward formal, contracted municipal systems under the Solid Waste Management Rules, with a very long runway and a genuine structural growth story — but the sector's economics are dominated by concession terms and by the credit quality of urban local bodies rather than by route density and landfill ownership, because sanitary landfill airspace ownership by private operators is comparatively rare and processing/WtE/EPR-driven models are more common. Read the concession, not the industry.
|
||||
|
||||
## India vs global notes
|
||||
|
||||
| Dimension | India | US / global |
|
||||
|---|---|---|
|
||||
| Regulators and rules | CPCB and state pollution control boards; consent to establish / consent to operate under the Water Act 1974 and Air Act 1981; Solid Waste Management Rules 2016; Hazardous and Other Wastes (Management and Transboundary Movement) Rules 2016; Plastic Waste Management Rules and E-Waste Management Rules 2022 and Battery Waste Rules 2022 with EPR targets and tradable EPR certificates; Bio-Medical Waste Rules 2016; the National Green Tribunal as an active adjudicator imposing environmental compensation | US: EPA under RCRA Subtitle D (MSW) and Subtitle C (hazardous), CERCLA/Superfund for legacy contamination, Clean Air Act NSPS/EG rules on landfill gas, state environmental agencies issuing the actual permits. EU: Landfill Directive, Waste Framework Directive and the waste hierarchy, national EPR schemes |
|
||||
| Typical business structure | Concession-heavy. A 15–30 year concession from an urban local body or state agency, held in an SPV, for collection and transportation, processing, waste-to-energy, or an integrated MSW facility. Wastewater increasingly on hybrid annuity (part construction payment, part performance-linked annuity, e.g. under Namami Gange), plus large EPC pipelines under AMRUT and Jal Jeevan Mission | Asset ownership. Companies own landfills, transfer stations and MRFs outright and hold perpetual-until-revoked operating permits; municipal work is a contract layered on owned disposal, not the asset itself |
|
||||
| Revenue mechanics | Tipping fee per tonne escalated by a contractual formula (often WPI/CPI-linked), plus power sale under a PPA for WtE, plus RDF/compost/recyclate sales, plus viability gap funding or capital grants. Counterparty is a municipal body with weak finances — collection risk, not demand risk, is the central issue | Gate rate per tonne set commercially, collection priced per lift or per subscription, municipal franchises priced by tender with index escalators. Counterparty risk is minimal; pricing power is the variable |
|
||||
| Environmental liability accounting | Ind-AS 37 provisions for closure and post-closure; disclosure is far thinner than the US ARO rollforward, and the discount rate, inflation assumption and post-closure period are often not separately stated. Expect to estimate. There is no Superfund analogue; legacy dumpsite remediation is largely government-funded (a revenue opportunity for operators) rather than a retrospective corporate liability, with "polluter pays" applied case-by-case through NGT environmental compensation | US: ASC 410-20 asset retirement obligations discounted at a credit-adjusted risk-free rate with accretion charged to operating cost, plus ASC 410-30 environmental remediation liabilities — commonly recorded at the low end of an estimated range. A full ARO rollforward, remaining airspace, remaining life and site counts are standard 10-K disclosure. IFRS uses IAS 37 with a current market discount rate, so recorded amounts are not directly comparable to US GAAP |
|
||||
| Accounting trap to check first | **Service concession accounting (Ind-AS 115 / Appendix D).** Whether a concession is accounted for under the financial-asset model (an annuity receivable) or the intangible-asset model (a right to charge users) changes reported revenue, EBITDA margin and ROCE completely. Under the intangible model, construction revenue is recognised during the build phase with a thin margin, inflating revenue and depressing margin, then collapsing when construction ends — the identical distortion seen in HAM road developers. Identify the model before comparing any margin | Straightforward operating-company accounting. The main comparability issues are airspace estimation, ARO assumptions and acquired-intangible amortisation policy |
|
||||
| Disclosure available | Annual report with segment note under Ind-AS 108, concession-wise disclosure that varies from good to nil, quarterly results and concall. Airspace, remaining life, route counts, internalisation and safety metrics are rarely disclosed — you will often have to reason from capacity in TPD/MLD and from tender documents. CARO qualifications and the related-party note matter, particularly for EPC awards to promoter entities | 10-K with line-of-business revenue and EBITDA, internalisation rate, remaining permitted and expansion airspace, average remaining site life, core price / volume / surcharge / commodity revenue bridge, ARO rollforward, TRIR, and fleet composition. The revenue bridge and internalisation disclosure are the two most valuable items and are essentially standard |
|
||||
| Units and conventions | ₹ crore and lakh; capacity in TPD (tonnes per day) for waste and MLD (million litres per day) for water; fiscal year April–March; SEBI listing-obligation disclosures; promoter holding and pledge are material | $ millions; tonnes or short tons, cubic yards of airspace, MGD for water; calendar fiscal year typical; SEC filings on EDGAR; widely held ownership |
|
||||
| Financing and assurance | Project finance at SPV level, often with a lender-mandated escrow over concession receipts; financial assurance for closure is weakly enforced in practice — treat that as risk, not as a saving | Financial assurance for closure and post-closure is mandatory via surety bonds, letters of credit or funded trusts; check the form, the cost and whether any portion is self-assured on the parent balance sheet |
|
||||
|
||||
## Checklist
|
||||
|
||||
- [ ] Confirm the business model: services operator, concession SPV, WtE IPP, or equipment maker — re-route equipment to `infra-capitalgoods.md`, WtE power economics to `utilities-power.md`, regulated water to `utilities-power.md`.
|
||||
- [ ] Refuse to report a consolidated EBITDA margin without the line-of-business split; state that a national margin is uninterpretable if the split is unavailable.
|
||||
- [ ] Build the revenue bridge: core price, surcharges, volume, recycled-commodity price and volume, acquisitions, divestitures, FX. Judge on core price.
|
||||
- [ ] Compute core price minus the company's own cash cost inflation. That spread is the franchise.
|
||||
- [ ] Establish route density by region — stops or lifts per route-day, revenue per truck, miles per stop — and say which markets produce the group margin.
|
||||
- [ ] Compute the internalisation rate and track it against acquisitions; falling internalisation after M&A is volume bought without disposal.
|
||||
- [ ] Pull remaining permitted airspace, probable-expansion airspace, and weighted average remaining life by site; check whether life is falling faster than one year per year.
|
||||
- [ ] Check every pending expansion or new-site permit, its status, opposition and conditions. The permit is the moat.
|
||||
- [ ] Test whether the airspace estimate changed, and quantify the effect on the amortisation rate before crediting any margin gain.
|
||||
- [ ] Tabulate the ARO assumptions across five years: discount rate, inflation rate, assumed closure date, post-closure period. Compare recorded vs undiscounted.
|
||||
- [ ] Read the environmental matters and legal proceedings notes in full: remediation reserves, range low-end recording, PRP site count and allocation share, PFAS exposure.
|
||||
- [ ] Add closure, post-closure, remediation and unfunded assurance obligations to enterprise value before computing any EV/EBITDA.
|
||||
- [ ] Rebuild FCF after maintenance capex *and* landfill development capex; reconcile to the company's definition and report both.
|
||||
- [ ] Split capex into maintenance / development / growth; check fleet age and per-truck maintenance cost for deferral.
|
||||
- [ ] Map contract structure: franchise, contracted and open-market shares, weighted average remaining life, escalator index vs actual cost base, and the re-bid calendar.
|
||||
- [ ] Check commercial churn against the price increases taken — pricing power that raises churn is borrowed.
|
||||
- [ ] Quantify recycling exposure and the fee-for-service vs revenue-share split; ask what the book earns at trough commodity prices.
|
||||
- [ ] Separate landfill gas, RNG and environmental-credit EBITDA and value it at a lower, policy-risk-adjusted multiple.
|
||||
- [ ] Identify and strip special waste, disaster debris and one-off remediation volumes before extrapolating.
|
||||
- [ ] Review safety and compliance: TRIR, DART, vehicle accidents, notices of violation, consent decrees, driver turnover; treat these as licence-to-operate metrics.
|
||||
- [ ] For a landfill or concession, build an explicit finite-life DCF including closure and 30-year post-closure outflows. Never apply perpetuity growth to finite airspace.
|
||||
- [ ] India: identify the service-concession accounting model (financial asset vs intangible) before comparing any margin or ROCE.
|
||||
- [ ] India: check municipal receivable days, tipping-fee revision status, SPV-level debt, concession disputes, CPCB/SPCB directions and NGT orders, EPR obligations and certificate revenues.
|
||||
- [ ] Peer set: same integration level, waste stream, contract structure, market density and accounting regime — stated explicitly, 4–8 names.
|
||||
- [ ] Benchmark every metric twice: against peers and against the company's own 5–10 year history.
|
||||
1608
finance/skills/stock-analysis/scripts/benchmarks.json
Normal file
1608
finance/skills/stock-analysis/scripts/benchmarks.json
Normal file
File diff suppressed because it is too large
Load diff
1121
finance/skills/stock-analysis/scripts/lint_report.py
Normal file
1121
finance/skills/stock-analysis/scripts/lint_report.py
Normal file
File diff suppressed because it is too large
Load diff
2690
finance/skills/stock-analysis/scripts/ratios.py
Normal file
2690
finance/skills/stock-analysis/scripts/ratios.py
Normal file
File diff suppressed because it is too large
Load diff
2072
finance/skills/stock-analysis/scripts/score.py
Normal file
2072
finance/skills/stock-analysis/scripts/score.py
Normal file
File diff suppressed because it is too large
Load diff
893
finance/skills/stock-analysis/scripts/valuation.py
Normal file
893
finance/skills/stock-analysis/scripts/valuation.py
Normal file
|
|
@ -0,0 +1,893 @@
|
|||
#!/usr/bin/env python3
|
||||
"""valuation.py -- Stage-6 valuation calculator for the stock-analysis skill.
|
||||
|
||||
Purpose
|
||||
-------
|
||||
`references/06-valuation.md` calls the reverse-DCF "the most useful single
|
||||
output" of a valuation, yet Stage 6 was the one place the skill still did all
|
||||
its arithmetic by hand -- EV bridges, trailing multiples, the reverse-DCF
|
||||
implied-growth solve, a forward DCF, and a probability-weighted scenario table.
|
||||
Hand arithmetic is where false precision and slips creep in. This script does
|
||||
the mechanical parts consistently, the same way `ratios.py` and `score.py` do,
|
||||
so the analyst spends judgement on the *inputs and interpretation*, not on
|
||||
compounding a cash-flow series in their head.
|
||||
|
||||
It computes nothing it was not given and asserts nothing about whether the
|
||||
inputs are right. It is a calculator with guard-rails, not an oracle: every
|
||||
output is only as good as the assumptions fed in, and the reverse-DCF is
|
||||
deliberately framed as "what growth does today's price imply?" -- a testable
|
||||
question, not a target price.
|
||||
|
||||
Standard library only. Python 3.8+. No network, no third-party packages.
|
||||
|
||||
--------------------------------------------------------------------------------
|
||||
WHAT IT PRODUCES
|
||||
--------------------------------------------------------------------------------
|
||||
Each section runs only if its input block is present.
|
||||
|
||||
ev_bridge Enterprise value from the bridge: market cap + debt + minority
|
||||
+ preferred - cash (+ leases / - associate investments if given).
|
||||
multiples Trailing valuation multiples from EV / market cap and the P&L:
|
||||
P/E, EV/EBITDA, EV/EBIT, EV/Sales, P/B, P/FCF, FCF yield,
|
||||
earnings yield, dividend yield.
|
||||
reverse_dcf The market-implied stage-1 growth: the constant FCF growth rate,
|
||||
held for N years then fading to terminal growth, that a 2-stage
|
||||
FCFF model needs to reproduce today's EV. The headline question.
|
||||
dcf A forward 2-stage FCFF value per share from your own growth,
|
||||
fade, terminal-growth, WACC and net-debt assumptions.
|
||||
scenarios A probability-weighted value per share across bear/base/bull rows,
|
||||
each priced by whatever inputs it carries (value, EPS x exit P/E,
|
||||
EBITDA x EV/EBITDA, or a small DCF), plus upside vs the price.
|
||||
|
||||
--------------------------------------------------------------------------------
|
||||
INPUT SCHEMA (JSON object; every block optional)
|
||||
--------------------------------------------------------------------------------
|
||||
company, ticker, as_of, currency, units -- labels only.
|
||||
market: {price, shares_out, market_cap, as_of}
|
||||
market_cap is used if given, else price * shares_out.
|
||||
ev_bridge: {market_cap, total_debt, cash, minority_interest, preferred,
|
||||
lease_liabilities (added), associate_investments (subtracted)}
|
||||
financials: {ebitda, ebit, pat, sales, book_value_equity, fcf, dividends}
|
||||
trailing figures for the multiples panel.
|
||||
reverse_dcf:{base_fcf, wacc, stage1_years, terminal_growth, ev (optional -
|
||||
defaults to the ev_bridge result)}
|
||||
dcf: {base_fcf, stage1_growth, stage1_years, fade_years,
|
||||
terminal_growth, wacc, net_debt, minority, shares_out}
|
||||
scenarios: [{label, prob, ...pricing inputs...}, ...]
|
||||
pricing inputs, first match wins:
|
||||
value_per_share
|
||||
eps + exit_pe
|
||||
ebitda + ev_ebitda (+ net_debt, minority, shares_out)
|
||||
base_fcf + stage1_growth (+ the dcf fields; unstated fields fall
|
||||
back to the top-level dcf block)
|
||||
|
||||
RATES. wacc, growth and terminal_growth may be given as decimals (0.12) or as
|
||||
percents (12); any magnitude above 1.5 is read as a percent and divided by 100.
|
||||
A Gordon terminal requires wacc > terminal_growth -- otherwise the model is
|
||||
infinite/negative and the run FAILS with a clear message.
|
||||
|
||||
--------------------------------------------------------------------------------
|
||||
USAGE
|
||||
--------------------------------------------------------------------------------
|
||||
python valuation.py inputs.json # readable report
|
||||
python valuation.py inputs.json --json # machine-readable
|
||||
python valuation.py --template # annotated blank input
|
||||
python valuation.py --example # run the built-in example
|
||||
python valuation.py --example --json
|
||||
|
||||
Exit code: 0 on a clean run, 1 on an invalid assumption (e.g. terminal growth
|
||||
>= WACC), 2 on unusable input (bad path / bad JSON).
|
||||
"""
|
||||
|
||||
from __future__ import annotations
|
||||
|
||||
import argparse
|
||||
import json
|
||||
import re
|
||||
import sys
|
||||
from typing import Any, Dict, List, Optional, Sequence, Tuple
|
||||
|
||||
SCRIPT = "valuation.py"
|
||||
|
||||
# A rate given as a percent (12) rather than a decimal (0.12) is a common slip;
|
||||
# anything larger than this is interpreted as a percent and divided by 100.
|
||||
_RATE_AS_PERCENT_ABOVE = 1.5
|
||||
|
||||
# Interpretive guard-rails (warnings only -- judgement, not hard rules).
|
||||
_TERMINAL_GROWTH_HIGH = 0.05 # terminal growth above ~nominal long-run GDP.
|
||||
_WACC_LOW = 0.06 # a suspiciously low discount rate.
|
||||
_WACC_HIGH = 0.20 # a suspiciously high one.
|
||||
_IMPLIED_GROWTH_DEMANDING = 0.15 # implied stage-1 growth the market rarely sustains.
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Loading and coercion
|
||||
# --------------------------------------------------------------------------- #
|
||||
def strip_line_comments(text: str) -> str:
|
||||
"""Drop whole-line `//` comments so an annotated template loads as JSON."""
|
||||
return "\n".join(
|
||||
line for line in text.splitlines() if not line.lstrip().startswith("//")
|
||||
)
|
||||
|
||||
|
||||
def load_input(path: str) -> Dict[str, Any]:
|
||||
"""Read and parse the input file, raising ValueError with a clear message."""
|
||||
try:
|
||||
with open(path, "r", encoding="utf-8-sig") as handle:
|
||||
raw = handle.read()
|
||||
except FileNotFoundError:
|
||||
raise ValueError("cannot read %r: no such file" % path)
|
||||
except OSError as err:
|
||||
raise ValueError("cannot read %r: %s" % (path, err.strerror or err))
|
||||
try:
|
||||
doc = json.loads(strip_line_comments(raw))
|
||||
except json.JSONDecodeError as err:
|
||||
raise ValueError(
|
||||
"%s is not valid JSON: %s (line %d, column %d)"
|
||||
% (path, err.msg, err.lineno, err.colno)
|
||||
)
|
||||
if not isinstance(doc, dict):
|
||||
raise ValueError(
|
||||
"%s must contain a JSON object at the top level, got %s"
|
||||
% (path, type(doc).__name__)
|
||||
)
|
||||
return doc
|
||||
|
||||
|
||||
def num(value: Any) -> Optional[float]:
|
||||
"""Coerce a value to float, or return None. Accepts '1,23,456' and '₹ 59,500'."""
|
||||
if isinstance(value, bool):
|
||||
return None
|
||||
if isinstance(value, (int, float)):
|
||||
return float(value)
|
||||
if isinstance(value, str):
|
||||
cleaned = re.sub(r"[,\s₹$£€¥%]", "", value)
|
||||
try:
|
||||
return float(cleaned)
|
||||
except ValueError:
|
||||
return None
|
||||
return None
|
||||
|
||||
|
||||
def rate(value: Any) -> Optional[float]:
|
||||
"""Coerce to a decimal rate; a magnitude above 1.5 is read as a percent."""
|
||||
n = num(value)
|
||||
if n is None:
|
||||
return None
|
||||
return n / 100.0 if abs(n) > _RATE_AS_PERCENT_ABOVE else n
|
||||
|
||||
|
||||
def get(block: Any, key: str) -> Optional[float]:
|
||||
"""Fetch and numify block[key], tolerating a missing block."""
|
||||
if not isinstance(block, dict):
|
||||
return None
|
||||
return num(block.get(key))
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Formatting
|
||||
# --------------------------------------------------------------------------- #
|
||||
def fmt_money(x: Optional[float]) -> str:
|
||||
"""Format a currency amount with thousands separators, or n/a."""
|
||||
if x is None:
|
||||
return "n/a"
|
||||
if x == int(x):
|
||||
return "{:,}".format(int(x))
|
||||
return "{:,.1f}".format(x)
|
||||
|
||||
|
||||
def fmt_x(x: Optional[float]) -> str:
|
||||
"""Format a multiple like 21.7x, or n/a."""
|
||||
return "n/a" if x is None else "%.1fx" % x
|
||||
|
||||
|
||||
def fmt_pct(x: Optional[float]) -> str:
|
||||
"""Format a decimal rate as a percentage, or n/a."""
|
||||
return "n/a" if x is None else "%.1f%%" % (x * 100.0)
|
||||
|
||||
|
||||
def _div(a: Optional[float], b: Optional[float]) -> Optional[float]:
|
||||
"""Safe division: None if either side is missing or the denominator is ~0."""
|
||||
if a is None or b is None or abs(b) < 1e-12:
|
||||
return None
|
||||
return a / b
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Result / finding model
|
||||
# --------------------------------------------------------------------------- #
|
||||
class Note:
|
||||
"""A warning or error surfaced during a valuation run."""
|
||||
|
||||
def __init__(self, severity: str, message: str) -> None:
|
||||
self.severity = severity # "error" | "warn"
|
||||
self.message = message
|
||||
|
||||
def to_dict(self) -> Dict[str, str]:
|
||||
return {"severity": self.severity, "message": self.message}
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Market cap resolution
|
||||
# --------------------------------------------------------------------------- #
|
||||
def resolve_market_cap(doc: Dict[str, Any]) -> Optional[float]:
|
||||
"""Market cap from ev_bridge, else market.market_cap, else price*shares."""
|
||||
mc = get(doc.get("ev_bridge"), "market_cap")
|
||||
if mc is not None:
|
||||
return mc
|
||||
market = doc.get("market")
|
||||
mc = get(market, "market_cap")
|
||||
if mc is not None:
|
||||
return mc
|
||||
price = get(market, "price")
|
||||
shares = get(market, "shares_out")
|
||||
if price is not None and shares is not None:
|
||||
return price * shares
|
||||
return None
|
||||
|
||||
|
||||
def resolve_price(doc: Dict[str, Any]) -> Optional[float]:
|
||||
"""Current price per share, if given."""
|
||||
return get(doc.get("market"), "price")
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# EV bridge
|
||||
# --------------------------------------------------------------------------- #
|
||||
def compute_ev_bridge(doc: Dict[str, Any]) -> Optional[Dict[str, Any]]:
|
||||
"""Enterprise value from its components, returning the bridge and the total."""
|
||||
block = doc.get("ev_bridge")
|
||||
if not isinstance(block, dict):
|
||||
return None
|
||||
mc = resolve_market_cap(doc)
|
||||
if mc is None:
|
||||
return None
|
||||
debt = get(block, "total_debt") or 0.0
|
||||
minority = get(block, "minority_interest") or 0.0
|
||||
preferred = get(block, "preferred") or 0.0
|
||||
cash = get(block, "cash") or 0.0
|
||||
leases = get(block, "lease_liabilities") or 0.0
|
||||
assoc = get(block, "associate_investments") or 0.0
|
||||
ev = mc + debt + minority + preferred + leases - cash - assoc
|
||||
net_debt = debt + leases - cash
|
||||
rows = [
|
||||
("Market cap", mc),
|
||||
("+ Total debt", debt),
|
||||
("+ Lease liabilities", leases) if leases else None,
|
||||
("+ Minority interest", minority) if minority else None,
|
||||
("+ Preferred", preferred) if preferred else None,
|
||||
("- Cash & equivalents", -cash),
|
||||
("- Investments in associates", -assoc) if assoc else None,
|
||||
("= Enterprise value", ev),
|
||||
]
|
||||
return {
|
||||
"market_cap": mc,
|
||||
"enterprise_value": ev,
|
||||
"net_debt": net_debt,
|
||||
"rows": [r for r in rows if r is not None],
|
||||
}
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Trailing multiples
|
||||
# --------------------------------------------------------------------------- #
|
||||
def compute_multiples(doc: Dict[str, Any], ev: Optional[float],
|
||||
market_cap: Optional[float]) -> Optional[Dict[str, Any]]:
|
||||
"""Trailing valuation multiples from EV / market cap and the P&L block."""
|
||||
fin = doc.get("financials")
|
||||
if not isinstance(fin, dict) or (ev is None and market_cap is None):
|
||||
return None
|
||||
ebitda = get(fin, "ebitda")
|
||||
ebit = get(fin, "ebit")
|
||||
pat = get(fin, "pat")
|
||||
sales = get(fin, "sales")
|
||||
book = get(fin, "book_value_equity")
|
||||
fcf = get(fin, "fcf")
|
||||
dividends = get(fin, "dividends")
|
||||
out = {
|
||||
"pe": _div(market_cap, pat),
|
||||
"ev_ebitda": _div(ev, ebitda),
|
||||
"ev_ebit": _div(ev, ebit),
|
||||
"ev_sales": _div(ev, sales),
|
||||
"pb": _div(market_cap, book),
|
||||
"p_fcf": _div(market_cap, fcf),
|
||||
"fcf_yield": _div(fcf, market_cap),
|
||||
"earnings_yield": _div(pat, market_cap),
|
||||
"dividend_yield": _div(dividends, market_cap),
|
||||
}
|
||||
return out
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# DCF core (shared by forward DCF and scenarios)
|
||||
# --------------------------------------------------------------------------- #
|
||||
def _ev_from_growth(base: float, g: float, wacc: float, years: int,
|
||||
term_g: float) -> float:
|
||||
"""PV of a constant-growth stage plus Gordon terminal (FCFF), for one g."""
|
||||
pv = 0.0
|
||||
fcf = base
|
||||
for t in range(1, years + 1):
|
||||
fcf = base * (1.0 + g) ** t
|
||||
pv += fcf / (1.0 + wacc) ** t
|
||||
fcf_n = base * (1.0 + g) ** years
|
||||
tv = fcf_n * (1.0 + term_g) / (wacc - term_g)
|
||||
pv += tv / (1.0 + wacc) ** years
|
||||
return pv
|
||||
|
||||
|
||||
def solve_implied_growth(target_ev: float, base: float, wacc: float,
|
||||
years: int, term_g: float) -> Tuple[str, float]:
|
||||
"""Bisection-solve the stage-1 growth that reproduces target_ev.
|
||||
|
||||
EV is monotone increasing in g, so bisection is exact and robust. Returns a
|
||||
status: 'ok' with the growth; 'below'/'above' if the target sits outside the
|
||||
range the model can produce between -95% and +200% growth (a signal the price
|
||||
is unreachable under these terminal/WACC assumptions, which is itself
|
||||
informative).
|
||||
"""
|
||||
lo, hi = -0.95, 2.0
|
||||
f_lo = _ev_from_growth(base, lo, wacc, years, term_g) - target_ev
|
||||
f_hi = _ev_from_growth(base, hi, wacc, years, term_g) - target_ev
|
||||
if f_lo > 0:
|
||||
return "below", lo
|
||||
if f_hi < 0:
|
||||
return "above", hi
|
||||
for _ in range(200):
|
||||
mid = (lo + hi) / 2.0
|
||||
f_mid = _ev_from_growth(base, mid, wacc, years, term_g) - target_ev
|
||||
if abs(f_mid) < 1e-6 * max(1.0, abs(target_ev)):
|
||||
return "ok", mid
|
||||
if f_mid < 0:
|
||||
lo = mid
|
||||
else:
|
||||
hi = mid
|
||||
return "ok", (lo + hi) / 2.0
|
||||
|
||||
|
||||
def forward_dcf(base: float, g1: float, n1: int, fade_years: int, term_g: float,
|
||||
wacc: float, net_debt: float, minority: float,
|
||||
shares: Optional[float]) -> Dict[str, Any]:
|
||||
"""A 2-stage (constant then linear-fade) FCFF DCF -> EV, equity, per share."""
|
||||
pv_explicit = 0.0
|
||||
fcf = base
|
||||
year = 0
|
||||
for _ in range(max(0, n1)):
|
||||
year += 1
|
||||
fcf = fcf * (1.0 + g1)
|
||||
pv_explicit += fcf / (1.0 + wacc) ** year
|
||||
for k in range(1, max(0, fade_years) + 1):
|
||||
year += 1
|
||||
g = g1 + (term_g - g1) * (k / fade_years) if fade_years else term_g
|
||||
fcf = fcf * (1.0 + g)
|
||||
pv_explicit += fcf / (1.0 + wacc) ** year
|
||||
if year == 0: # no explicit years: value the terminal off the base directly.
|
||||
year = 1
|
||||
fcf = base * (1.0 + term_g)
|
||||
tv = fcf * (1.0 + term_g) / (wacc - term_g)
|
||||
pv_terminal = tv / (1.0 + wacc) ** year
|
||||
ev = pv_explicit + pv_terminal
|
||||
equity = ev - net_debt - minority
|
||||
per_share = _div(equity, shares)
|
||||
return {
|
||||
"enterprise_value": ev,
|
||||
"equity_value": equity,
|
||||
"per_share": per_share,
|
||||
"pv_explicit": pv_explicit,
|
||||
"pv_terminal": pv_terminal,
|
||||
"terminal_pct_of_ev": _div(pv_terminal, ev),
|
||||
}
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Reverse DCF
|
||||
# --------------------------------------------------------------------------- #
|
||||
def compute_reverse_dcf(doc: Dict[str, Any], ev_bridge: Optional[Dict[str, Any]],
|
||||
notes: List[Note]) -> Optional[Dict[str, Any]]:
|
||||
"""Solve for the market-implied stage-1 growth, given price-derived EV."""
|
||||
block = doc.get("reverse_dcf")
|
||||
if not isinstance(block, dict):
|
||||
return None
|
||||
base = get(block, "base_fcf")
|
||||
wacc = rate(block.get("wacc"))
|
||||
years = get(block, "stage1_years")
|
||||
term_g = rate(block.get("terminal_growth"))
|
||||
target_ev = get(block, "ev")
|
||||
if target_ev is None and ev_bridge is not None:
|
||||
target_ev = ev_bridge.get("enterprise_value")
|
||||
missing = [k for k, v in (("base_fcf", base), ("wacc", wacc),
|
||||
("stage1_years", years), ("terminal_growth", term_g),
|
||||
("ev", target_ev)) if v is None]
|
||||
if missing:
|
||||
notes.append(Note("warn", "reverse_dcf skipped: missing %s."
|
||||
% ", ".join(missing)))
|
||||
return None
|
||||
years = int(years)
|
||||
if wacc <= term_g:
|
||||
notes.append(Note("error",
|
||||
"reverse_dcf: WACC (%.1f%%) must exceed terminal growth "
|
||||
"(%.1f%%); the Gordon terminal is otherwise infinite."
|
||||
% (wacc * 100, term_g * 100)))
|
||||
return None
|
||||
if base <= 0:
|
||||
notes.append(Note("warn",
|
||||
"reverse_dcf skipped: base FCF is non-positive, so an "
|
||||
"implied-growth solve is not meaningful. Anchor on "
|
||||
"EV/EBITDA or normalise FCF first."))
|
||||
return None
|
||||
status, g = solve_implied_growth(target_ev, base, wacc, years, term_g)
|
||||
result = {
|
||||
"target_ev": target_ev, "base_fcf": base, "wacc": wacc,
|
||||
"stage1_years": years, "terminal_growth": term_g,
|
||||
"implied_growth": g, "status": status,
|
||||
}
|
||||
if status == "ok" and g >= _IMPLIED_GROWTH_DEMANDING:
|
||||
notes.append(Note("warn",
|
||||
"Market implies ~%.1f%% FCF growth for %d years -- "
|
||||
"demanding; check it against what this company (and its "
|
||||
"industry) has actually delivered."
|
||||
% (g * 100, years)))
|
||||
if status == "above":
|
||||
notes.append(Note("warn",
|
||||
"Even 200%% growth for %d years cannot reproduce today's "
|
||||
"EV under these WACC/terminal assumptions -- the price "
|
||||
"embeds more than this model can express; revisit the "
|
||||
"assumptions or the base FCF." % years))
|
||||
if status == "below":
|
||||
notes.append(Note("warn",
|
||||
"Today's EV is below the model's value even at deeply "
|
||||
"negative growth -- the market is pricing in decline or "
|
||||
"distress relative to these assumptions."))
|
||||
return result
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Forward DCF
|
||||
# --------------------------------------------------------------------------- #
|
||||
def compute_forward_dcf(doc: Dict[str, Any], notes: List[Note]
|
||||
) -> Optional[Dict[str, Any]]:
|
||||
"""A forward 2-stage FCFF DCF from the analyst's own assumptions."""
|
||||
block = doc.get("dcf")
|
||||
if not isinstance(block, dict):
|
||||
return None
|
||||
base = get(block, "base_fcf")
|
||||
g1 = rate(block.get("stage1_growth"))
|
||||
n1 = get(block, "stage1_years")
|
||||
fade = get(block, "fade_years") or 0.0
|
||||
term_g = rate(block.get("terminal_growth"))
|
||||
wacc = rate(block.get("wacc"))
|
||||
net_debt = get(block, "net_debt") or 0.0
|
||||
minority = get(block, "minority") or 0.0
|
||||
shares = get(block, "shares_out")
|
||||
missing = [k for k, v in (("base_fcf", base), ("stage1_growth", g1),
|
||||
("stage1_years", n1), ("terminal_growth", term_g),
|
||||
("wacc", wacc)) if v is None]
|
||||
if missing:
|
||||
notes.append(Note("warn", "dcf skipped: missing %s." % ", ".join(missing)))
|
||||
return None
|
||||
if wacc <= term_g:
|
||||
notes.append(Note("error",
|
||||
"dcf: WACC (%.1f%%) must exceed terminal growth (%.1f%%)."
|
||||
% (wacc * 100, term_g * 100)))
|
||||
return None
|
||||
res = forward_dcf(base, g1, int(n1), int(fade), term_g, wacc,
|
||||
net_debt, minority, shares)
|
||||
res.update({"base_fcf": base, "stage1_growth": g1, "stage1_years": int(n1),
|
||||
"fade_years": int(fade), "terminal_growth": term_g, "wacc": wacc,
|
||||
"net_debt": net_debt})
|
||||
price = resolve_price(doc)
|
||||
if price is not None and res.get("per_share"):
|
||||
res["upside_vs_price"] = _div(res["per_share"] - price, price)
|
||||
if res.get("terminal_pct_of_ev") and res["terminal_pct_of_ev"] > 0.75:
|
||||
notes.append(Note("warn",
|
||||
"dcf: %.0f%% of value sits in the terminal -- the answer "
|
||||
"is an assumption about perpetuity, not the explicit "
|
||||
"forecast." % (res["terminal_pct_of_ev"] * 100)))
|
||||
return res
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Scenarios
|
||||
# --------------------------------------------------------------------------- #
|
||||
def scenario_value(row: Dict[str, Any], doc: Dict[str, Any],
|
||||
notes: List[Note]) -> Optional[float]:
|
||||
"""Value one scenario row by the first pricing method whose inputs are present."""
|
||||
label = row.get("label", "(scenario)")
|
||||
# 1) value per share stated directly.
|
||||
v = get(row, "value_per_share")
|
||||
if v is not None:
|
||||
return v
|
||||
# 2) EPS x exit P/E.
|
||||
eps, pe = get(row, "eps"), get(row, "exit_pe")
|
||||
if eps is not None and pe is not None:
|
||||
return eps * pe
|
||||
# 3) EBITDA x EV/EBITDA -> equity -> per share.
|
||||
ebitda, mult = get(row, "ebitda"), get(row, "ev_ebitda")
|
||||
if ebitda is not None and mult is not None:
|
||||
ev = ebitda * mult
|
||||
net_debt = get(row, "net_debt")
|
||||
if net_debt is None:
|
||||
net_debt = get(doc.get("dcf"), "net_debt") or 0.0
|
||||
minority = get(row, "minority") or 0.0
|
||||
shares = get(row, "shares_out") or get(doc.get("dcf"), "shares_out") \
|
||||
or get(doc.get("market"), "shares_out")
|
||||
return _div(ev - net_debt - minority, shares)
|
||||
# 4) a small DCF, falling back to the top-level dcf block for unstated fields.
|
||||
base = get(row, "base_fcf")
|
||||
g1 = rate(row.get("stage1_growth"))
|
||||
if base is not None and g1 is not None:
|
||||
d = doc.get("dcf") if isinstance(doc.get("dcf"), dict) else {}
|
||||
n1 = get(row, "stage1_years") or get(d, "stage1_years") or 10
|
||||
fade = get(row, "fade_years") or get(d, "fade_years") or 0
|
||||
term_g = rate(row.get("terminal_growth")) or rate(d.get("terminal_growth"))
|
||||
wacc = rate(row.get("wacc")) or rate(d.get("wacc"))
|
||||
net_debt = get(row, "net_debt")
|
||||
if net_debt is None:
|
||||
net_debt = get(d, "net_debt") or 0.0
|
||||
minority = get(row, "minority") or 0.0
|
||||
shares = get(row, "shares_out") or get(d, "shares_out") \
|
||||
or get(doc.get("market"), "shares_out")
|
||||
if None in (term_g, wacc) or shares is None:
|
||||
notes.append(Note("warn", "scenario '%s': DCF inputs incomplete." % label))
|
||||
return None
|
||||
if wacc <= term_g:
|
||||
notes.append(Note("error", "scenario '%s': WACC must exceed terminal "
|
||||
"growth." % label))
|
||||
return None
|
||||
res = forward_dcf(base, g1, int(n1), int(fade), term_g, wacc,
|
||||
net_debt, minority, shares)
|
||||
return res.get("per_share")
|
||||
notes.append(Note("warn", "scenario '%s': no usable pricing inputs "
|
||||
"(value_per_share, eps+exit_pe, ebitda+ev_ebitda, or "
|
||||
"base_fcf+stage1_growth)." % label))
|
||||
return None
|
||||
|
||||
|
||||
def compute_scenarios(doc: Dict[str, Any], notes: List[Note]
|
||||
) -> Optional[Dict[str, Any]]:
|
||||
"""Value each scenario, weight by probability, compare to the current price."""
|
||||
rows = doc.get("scenarios")
|
||||
if not isinstance(rows, list) or not rows:
|
||||
return None
|
||||
price = resolve_price(doc)
|
||||
out_rows: List[Dict[str, Any]] = []
|
||||
weighted = 0.0
|
||||
prob_sum = 0.0
|
||||
have_all = True
|
||||
for row in rows:
|
||||
if not isinstance(row, dict):
|
||||
continue
|
||||
label = row.get("label", "(scenario)")
|
||||
prob = get(row, "prob")
|
||||
value = scenario_value(row, doc, notes)
|
||||
if prob is not None:
|
||||
prob_sum += prob
|
||||
if value is None or prob is None:
|
||||
have_all = False
|
||||
else:
|
||||
weighted += prob * value
|
||||
out_rows.append({
|
||||
"label": label, "prob": prob, "value_per_share": value,
|
||||
"upside_vs_price": _div(value - price, price)
|
||||
if (value is not None and price is not None) else None,
|
||||
})
|
||||
if abs(prob_sum - 1.0) > 0.02:
|
||||
notes.append(Note("warn", "scenario probabilities sum to %.2f, not 1.00."
|
||||
% prob_sum))
|
||||
result = {
|
||||
"rows": out_rows,
|
||||
"prob_sum": prob_sum,
|
||||
"weighted_value": weighted if have_all else None,
|
||||
"weighted_upside": _div(weighted - price, price)
|
||||
if (have_all and price is not None) else None,
|
||||
"price": price,
|
||||
}
|
||||
return result
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Assumption guard-rails (warnings)
|
||||
# --------------------------------------------------------------------------- #
|
||||
def check_assumptions(doc: Dict[str, Any], notes: List[Note]) -> None:
|
||||
"""Flag aggressive or implausible discount-rate / terminal-growth inputs."""
|
||||
for block_name in ("reverse_dcf", "dcf"):
|
||||
block = doc.get(block_name)
|
||||
if not isinstance(block, dict):
|
||||
continue
|
||||
wacc = rate(block.get("wacc"))
|
||||
term_g = rate(block.get("terminal_growth"))
|
||||
if wacc is not None and not (_WACC_LOW <= wacc <= _WACC_HIGH):
|
||||
notes.append(Note("warn", "%s: WACC of %.1f%% is outside the usual "
|
||||
"6-20%% band -- state how it was derived (risk-free "
|
||||
"rate + its date, ERP, beta)."
|
||||
% (block_name, wacc * 100)))
|
||||
if term_g is not None and term_g > _TERMINAL_GROWTH_HIGH:
|
||||
notes.append(Note("warn", "%s: terminal growth of %.1f%% exceeds "
|
||||
"~nominal long-run GDP; a business cannot outgrow the "
|
||||
"economy forever." % (block_name, term_g * 100)))
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Orchestration
|
||||
# --------------------------------------------------------------------------- #
|
||||
def run(doc: Dict[str, Any]) -> Dict[str, Any]:
|
||||
"""Run every section whose inputs are present; collect results and notes."""
|
||||
notes: List[Note] = []
|
||||
check_assumptions(doc, notes)
|
||||
ev_bridge = compute_ev_bridge(doc)
|
||||
market_cap = resolve_market_cap(doc)
|
||||
ev = ev_bridge.get("enterprise_value") if ev_bridge else \
|
||||
get(doc.get("reverse_dcf"), "ev")
|
||||
multiples = compute_multiples(doc, ev, market_cap)
|
||||
reverse = compute_reverse_dcf(doc, ev_bridge, notes)
|
||||
dcf = compute_forward_dcf(doc, notes)
|
||||
scenarios = compute_scenarios(doc, notes)
|
||||
return {
|
||||
"company": doc.get("company"),
|
||||
"ticker": doc.get("ticker"),
|
||||
"as_of": doc.get("as_of"),
|
||||
"currency": doc.get("currency"),
|
||||
"units": doc.get("units"),
|
||||
"market_cap": market_cap,
|
||||
"ev_bridge": ev_bridge,
|
||||
"multiples": multiples,
|
||||
"reverse_dcf": reverse,
|
||||
"dcf": dcf,
|
||||
"scenarios": scenarios,
|
||||
"notes": notes,
|
||||
}
|
||||
|
||||
|
||||
def has_error(notes: Sequence[Note]) -> bool:
|
||||
"""True if any note is an error (invalid assumption)."""
|
||||
return any(n.severity == "error" for n in notes)
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Rendering
|
||||
# --------------------------------------------------------------------------- #
|
||||
def render_text(res: Dict[str, Any]) -> str:
|
||||
"""Render the human-readable valuation report."""
|
||||
cur = res.get("currency") or ""
|
||||
units = res.get("units") or ""
|
||||
unit_tag = ("%s %s" % (cur, units)).strip() or "(units unstated)"
|
||||
lines: List[str] = []
|
||||
lines.append("=" * 72)
|
||||
lines.append("VALUATION -- %s%s" % (
|
||||
res.get("company") or "(company not stated)",
|
||||
" [%s]" % res["ticker"] if res.get("ticker") else ""))
|
||||
lines.append("=" * 72)
|
||||
lines.append("As of : %s Amounts in: %s (multiples/rates are unitless)"
|
||||
% (res.get("as_of") or "(not stated)", unit_tag))
|
||||
lines.append("Outputs are estimates -- only as sound as the assumptions below.")
|
||||
|
||||
ev_bridge = res.get("ev_bridge")
|
||||
if ev_bridge:
|
||||
lines.append("")
|
||||
lines.append("-" * 72)
|
||||
lines.append("EV BRIDGE (%s)" % unit_tag)
|
||||
lines.append("-" * 72)
|
||||
for label, val in ev_bridge["rows"]:
|
||||
lines.append(" %-32s %14s" % (label, fmt_money(val)))
|
||||
lines.append(" %-32s %14s" % ("(net debt)", fmt_money(ev_bridge["net_debt"])))
|
||||
|
||||
mult = res.get("multiples")
|
||||
if mult:
|
||||
lines.append("")
|
||||
lines.append("-" * 72)
|
||||
lines.append("TRAILING MULTIPLES")
|
||||
lines.append("-" * 72)
|
||||
pairs = [
|
||||
("P/E", fmt_x(mult["pe"])), ("EV/EBITDA", fmt_x(mult["ev_ebitda"])),
|
||||
("EV/EBIT", fmt_x(mult["ev_ebit"])), ("EV/Sales", fmt_x(mult["ev_sales"])),
|
||||
("P/B", fmt_x(mult["pb"])), ("P/FCF", fmt_x(mult["p_fcf"])),
|
||||
("FCF yield", fmt_pct(mult["fcf_yield"])),
|
||||
("Earnings yield", fmt_pct(mult["earnings_yield"])),
|
||||
("Dividend yield", fmt_pct(mult["dividend_yield"])),
|
||||
]
|
||||
for i in range(0, len(pairs), 3):
|
||||
chunk = pairs[i:i + 3]
|
||||
lines.append(" " + "".join("%-14s %-9s" % (k, v) for k, v in chunk))
|
||||
|
||||
rev = res.get("reverse_dcf")
|
||||
if rev:
|
||||
lines.append("")
|
||||
lines.append("-" * 72)
|
||||
lines.append("REVERSE DCF -- what growth is priced in?")
|
||||
lines.append("-" * 72)
|
||||
lines.append(" Anchor EV : %s %s" % (fmt_money(rev["target_ev"]), unit_tag))
|
||||
lines.append(" Base FCF : %s %s" % (fmt_money(rev["base_fcf"]), unit_tag))
|
||||
lines.append(" WACC / terminal g: %s / %s"
|
||||
% (fmt_pct(rev["wacc"]), fmt_pct(rev["terminal_growth"])))
|
||||
lines.append(" Stage-1 horizon : %d years" % rev["stage1_years"])
|
||||
if rev["status"] == "ok":
|
||||
lines.append(" => IMPLIED stage-1 FCF growth: %s per year" %
|
||||
fmt_pct(rev["implied_growth"]))
|
||||
lines.append(" i.e. today's price already assumes ~%s FCF growth "
|
||||
"for %d years, fading to %s."
|
||||
% (fmt_pct(rev["implied_growth"]), rev["stage1_years"],
|
||||
fmt_pct(rev["terminal_growth"])))
|
||||
elif rev["status"] == "above":
|
||||
lines.append(" => price implies MORE than +200%%/yr growth is needed "
|
||||
"-- unreachable under these assumptions.")
|
||||
else:
|
||||
lines.append(" => price sits below the model even at deeply negative "
|
||||
"growth -- decline/distress is priced in.")
|
||||
|
||||
dcf = res.get("dcf")
|
||||
if dcf:
|
||||
lines.append("")
|
||||
lines.append("-" * 72)
|
||||
lines.append("FORWARD DCF (your assumptions)")
|
||||
lines.append("-" * 72)
|
||||
lines.append(" Base FCF %s | g1 %s for %dy | fade %dy | term g %s | WACC %s"
|
||||
% (fmt_money(dcf["base_fcf"]), fmt_pct(dcf["stage1_growth"]),
|
||||
dcf["stage1_years"], dcf["fade_years"],
|
||||
fmt_pct(dcf["terminal_growth"]), fmt_pct(dcf["wacc"])))
|
||||
lines.append(" Enterprise value : %s %s" % (fmt_money(dcf["enterprise_value"]), unit_tag))
|
||||
lines.append(" Equity value : %s %s" % (fmt_money(dcf["equity_value"]), unit_tag))
|
||||
lines.append(" Value per share : %s" % fmt_money(dcf["per_share"]))
|
||||
lines.append(" Terminal %% of EV : %s" % fmt_pct(dcf["terminal_pct_of_ev"]))
|
||||
if dcf.get("upside_vs_price") is not None:
|
||||
lines.append(" Upside vs price : %s" % fmt_pct(dcf["upside_vs_price"]))
|
||||
|
||||
scen = res.get("scenarios")
|
||||
if scen:
|
||||
lines.append("")
|
||||
lines.append("-" * 72)
|
||||
lines.append("SCENARIOS")
|
||||
lines.append("-" * 72)
|
||||
lines.append(" %-14s %6s %16s %12s" % ("Scenario", "Prob", "Value/share", "vs price"))
|
||||
for row in scen["rows"]:
|
||||
lines.append(" %-14s %6s %16s %12s" % (
|
||||
row["label"],
|
||||
fmt_pct(row["prob"]) if row["prob"] is not None else "n/a",
|
||||
fmt_money(row["value_per_share"]),
|
||||
fmt_pct(row["upside_vs_price"]) if row["upside_vs_price"] is not None else "n/a"))
|
||||
if scen["weighted_value"] is not None:
|
||||
lines.append(" %-14s %6s %16s %12s" % (
|
||||
"Prob-weighted", fmt_pct(scen["prob_sum"]),
|
||||
fmt_money(scen["weighted_value"]),
|
||||
fmt_pct(scen["weighted_upside"]) if scen["weighted_upside"] is not None else "n/a"))
|
||||
|
||||
notes = res.get("notes") or []
|
||||
errors = [n for n in notes if n.severity == "error"]
|
||||
warns = [n for n in notes if n.severity == "warn"]
|
||||
lines.append("")
|
||||
lines.append("-" * 72)
|
||||
if errors:
|
||||
lines.append("ERRORS -- %d (invalid assumptions; results above may be omitted)"
|
||||
% len(errors))
|
||||
for n in errors:
|
||||
lines.append(" [error] %s" % n.message)
|
||||
if warns:
|
||||
lines.append("WARNINGS -- %d" % len(warns))
|
||||
for n in warns:
|
||||
lines.append(" [warn] %s" % n.message)
|
||||
if not notes:
|
||||
lines.append("No assumption warnings.")
|
||||
return "\n".join(lines)
|
||||
|
||||
|
||||
def render_json(res: Dict[str, Any]) -> str:
|
||||
"""Render the machine-readable result."""
|
||||
payload = dict(res)
|
||||
payload["notes"] = [n.to_dict() for n in res.get("notes", [])]
|
||||
return json.dumps(payload, indent=2, ensure_ascii=False, default=str)
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# Template and example
|
||||
# --------------------------------------------------------------------------- #
|
||||
TEMPLATE = """\
|
||||
// Valuation input template for the stock-analysis skill.
|
||||
// Fill in only the blocks you need; each section runs if its block is present.
|
||||
// Rates may be decimals (0.12) or percents (12). Whole-line // comments are
|
||||
// stripped by the loader. Then run: python valuation.py this_file.json
|
||||
{
|
||||
"company": "",
|
||||
"ticker": "",
|
||||
"as_of": "YYYY-MM-DD",
|
||||
"currency": "INR",
|
||||
"units": "crore",
|
||||
"market": {"price": 0, "shares_out": 0, "market_cap": 0, "as_of": "YYYY-MM-DD"},
|
||||
"ev_bridge": {
|
||||
"market_cap": 0, "total_debt": 0, "cash": 0,
|
||||
"minority_interest": 0, "preferred": 0,
|
||||
"lease_liabilities": 0, "associate_investments": 0
|
||||
},
|
||||
"financials": {
|
||||
"ebitda": 0, "ebit": 0, "pat": 0, "sales": 0,
|
||||
"book_value_equity": 0, "fcf": 0, "dividends": 0
|
||||
},
|
||||
"reverse_dcf": {"base_fcf": 0, "wacc": 0.12, "stage1_years": 10, "terminal_growth": 0.04},
|
||||
"dcf": {
|
||||
"base_fcf": 0, "stage1_growth": 0.15, "stage1_years": 10, "fade_years": 5,
|
||||
"terminal_growth": 0.04, "wacc": 0.12, "net_debt": 0, "minority": 0, "shares_out": 0
|
||||
},
|
||||
"scenarios": [
|
||||
{"label": "Bear", "prob": 0.30, "eps": 0, "exit_pe": 0},
|
||||
{"label": "Base", "prob": 0.45, "eps": 0, "exit_pe": 0},
|
||||
{"label": "Bull", "prob": 0.25, "eps": 0, "exit_pe": 0}
|
||||
]
|
||||
}
|
||||
"""
|
||||
|
||||
|
||||
def example_document() -> Dict[str, Any]:
|
||||
"""A filled example (a fictional distributor) exercising every section."""
|
||||
return {
|
||||
"company": "Illustrative Distribution Co (fictional)",
|
||||
"ticker": "NSE:ILLUSDEMO",
|
||||
"as_of": "2026-08-02",
|
||||
"currency": "INR", "units": "crore",
|
||||
"market": {"price": 1240.0, "shares_out": 4.36, "market_cap": 5406.0,
|
||||
"as_of": "2026-07-15"},
|
||||
"ev_bridge": {"market_cap": 5406.0, "total_debt": 677.0, "cash": 327.0,
|
||||
"minority_interest": 60.0, "preferred": 0.0},
|
||||
"financials": {"ebitda": 266.0, "ebit": 220.0, "pat": 115.0,
|
||||
"sales": 6591.0, "book_value_equity": 1688.0,
|
||||
"fcf": 60.0, "dividends": 0.0},
|
||||
"reverse_dcf": {"base_fcf": 90.0, "wacc": 0.125, "stage1_years": 10,
|
||||
"terminal_growth": 0.04},
|
||||
"dcf": {"base_fcf": 90.0, "stage1_growth": 0.20, "stage1_years": 7,
|
||||
"fade_years": 5, "terminal_growth": 0.04, "wacc": 0.125,
|
||||
"net_debt": 410.0, "minority": 0.0, "shares_out": 4.36},
|
||||
"scenarios": [
|
||||
{"label": "Bear", "prob": 0.30, "eps": 31.0, "exit_pe": 25.0},
|
||||
{"label": "Base", "prob": 0.45, "eps": 34.0, "exit_pe": 33.0},
|
||||
{"label": "Bull", "prob": 0.25, "eps": 36.0, "exit_pe": 40.0},
|
||||
],
|
||||
}
|
||||
|
||||
|
||||
# --------------------------------------------------------------------------- #
|
||||
# CLI
|
||||
# --------------------------------------------------------------------------- #
|
||||
def build_parser() -> argparse.ArgumentParser:
|
||||
"""Construct the command-line argument parser."""
|
||||
parser = argparse.ArgumentParser(
|
||||
prog=SCRIPT,
|
||||
description="Stage-6 valuation calculator: EV bridge, trailing multiples, "
|
||||
"reverse-DCF implied growth, forward 2-stage DCF, and a "
|
||||
"probability-weighted scenario table.",
|
||||
formatter_class=argparse.RawDescriptionHelpFormatter,
|
||||
)
|
||||
parser.add_argument("input", nargs="?", help="path to the valuation input JSON")
|
||||
parser.add_argument("--json", dest="as_json", action="store_true",
|
||||
help="emit results as JSON instead of a text report")
|
||||
parser.add_argument("--template", action="store_true",
|
||||
help="print an annotated blank input file and exit")
|
||||
parser.add_argument("--example", action="store_true",
|
||||
help="run the built-in fictional example")
|
||||
return parser
|
||||
|
||||
|
||||
def main(argv: Optional[Sequence[str]] = None) -> int:
|
||||
"""Entry point. Returns 0 clean, 1 invalid assumption, 2 bad input."""
|
||||
parser = build_parser()
|
||||
args = parser.parse_args(argv)
|
||||
|
||||
if args.template:
|
||||
sys.stdout.write(TEMPLATE)
|
||||
return 0
|
||||
if args.example:
|
||||
doc = example_document()
|
||||
else:
|
||||
if not args.input:
|
||||
parser.error("a valuation JSON file is required (or --template / --example)")
|
||||
try:
|
||||
doc = load_input(args.input)
|
||||
except ValueError as err:
|
||||
sys.stderr.write("%s: %s\n" % (SCRIPT, err))
|
||||
return 2
|
||||
|
||||
res = run(doc)
|
||||
if args.as_json:
|
||||
sys.stdout.write(render_json(res) + "\n")
|
||||
else:
|
||||
sys.stdout.write(render_text(res) + "\n")
|
||||
return 1 if has_error(res["notes"]) else 0
|
||||
|
||||
|
||||
if __name__ == "__main__":
|
||||
sys.exit(main())
|
||||
1663
finance/skills/stock-analysis/scripts/verify_data.py
Normal file
1663
finance/skills/stock-analysis/scripts/verify_data.py
Normal file
File diff suppressed because it is too large
Load diff
Loading…
Add table
Reference in a new issue